<SEC-DOCUMENT>0000059478-22-000068.txt : 20220223
<SEC-HEADER>0000059478-22-000068.hdr.sgml : 20220223
<ACCEPTANCE-DATETIME>20220223110057
ACCESSION NUMBER:		0000059478-22-000068
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		143
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220223
DATE AS OF CHANGE:		20220223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		22661479

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lly-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9fcc0128-8cb1-4f14-a312-a98ab5e27206,g:b055a216-cbe3-42fc-b7bd-1f3a75142c02,d:1a85401413cf428bb86d28ee6b337a59--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:lly="http://www.lilly.com/20211231" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF8yLTEtMS0xLTM2MDk4_e316f2b2-4063-42b9-977a-a851e954c00f">true</ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF8zLTEtMS0xLTM2MDk4_f0d53db8-6f49-449f-8044-90b55f399e34">false</ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF80LTEtMS0xLTM2MDk4_fbaf8e9b-103a-4f75-817a-ce9aeb7bdc01">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF81LTEtMS0xLTM2MDk4_65ed4c20-dad1-4ea9-8b76-c3f9fe69887d">2021</ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF82LTEtMS0xLTM2MDk4_99f5a310-af60-4598-b549-914fd96f9847">FY</ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF83LTEtMS0xLTM2MDk4_9461a90a-b15d-4718-a9c9-2f59a3bfd30e">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="i828c4fd6a50342c5a0296de836f61ccf_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDA_50a976ec-2fe9-4481-a965-701914495450">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i86faebb6ff9045eba6433aa67924475e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i49de5751f19b463f82f0525d37e01c83_D20191201-20191231" name="lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTcvZnJhZzpkMzQxYTIxYzA4MzQ0MDQ4YWRmMmUwZTBiOTRkZThlMS90ZXh0cmVnaW9uOmQzNDFhMjFjMDgzNDQwNDhhZGYyZTBlMGI5NGRlOGUxXzI1OQ_d3bff026-8cb3-4cdd-9cc7-13ef9a84de20">P21D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib999762467224e169f22d930370a98cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id219efe1b1d547adb5713a0601859853_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5badd592a21c4a338eed272300758c16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822be716a0774b71a20856f8866c402a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333cc430d5f24f45a3a99e2e1060db9c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id1a06f9ea4dd4dcabf049aeb8fab3e59_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib5593b99da6745cb9b411b2031bc3e15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350adfc8d85547d9a3c4e39ba5c1a2fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11a42da50f242f2a8b81a0a0173884f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ef7ac05a14478b89f3032c4251b7ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4663754a3a444cb9830c13af3caf35bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18a38bac34cb4ca8800ba1a18314f494_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica0f6e15b180491b9202fefd783ba908_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49b2b7f42884738a47622d8db6c8d71_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f2ebcb04234bb78d53e95c789a7b18_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386013c272b445c8b61ea4782a574cd9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da9dd99174a476bbcf317f5a6d40e2f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f786d93b75241c98d9db2267b3c5983_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d195254fb024cf89d97aaed06aee2a4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb85a614be34013a6354f3d76b46357_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia85d124a50b14e73af531af45079e36c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73859b7dcd34e62805fa367251b795b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c5a45e3bbf4d98a9b6fa76889230d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib74aad145fd948ae9241828f24c78548_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e3201d8c6744198aed86ef435de4ee7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442a597afbe14853a841ac8d37aa9e20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad901c3559244039c17a109cdaa8bf4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b908b0dc9bf437c83b6a218c5c17f88_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e50a9ab65b4a50b58927a520657bd2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed8c31b73e04315b4155a37149b9553_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f4e379653645eb9685399ff3793535_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76aeae647cb549b29344d42e8dcaf22e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844c6baec2a24ddfb0175699e7c9dc89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a1f40609cb46c88a55f8a58cc0d213_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a5b8a498064844963780b1fa864865_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2e8d9c52ce423296c40435172ba45f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59cb920c729498ca310e03243606c6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1cc336a64ff4c18b6d2f64e83fb7ca5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6461da26ed149deab96c87d5cfef978_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6224d7ff3d6b43fb824c0b8619fad9b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15da3dd702544a0897dc45c712757909_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075446bdf9684175b09f4719c83305db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5960a9f72a304f2d91d83b22d8017bcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39610d1c5d9d46bc880d62462c72fd8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8449ae740dff423f9a21a63ae89c9c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0bae0b2bc940ec8f928a12995eb037_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25abdb96f76b4a36b8f4b2e517289462_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0ee22589c346b4ba844a54471306b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa5fbd37ece44598769646bdacd67e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2161fbcc13a94af3a14765cc6ce775d6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ba1030bd04458783b9caf2f17c3b41_I20190311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">lly:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i99ba0120ed084c1da3c0cb9a06a3535c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595bde8d325b4f8cbe525ae5a8cc043a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bbc4ab2a1ab4437a863acf75b60865b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e084561da84353a68fc13b0b1f1065_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78db9bb959f4a65b59c065a865101de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768c5436d8e0411f87860a079a65368a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66a9d0bc8c447a7854e1d121fdd3fd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447315375734437a83fd432f1d82adc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b153236a1d746dc8a5d74cfd7f107eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d45ee2631a0458287be066c530c6943_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb03da6839043d3aa73f8b83497cb73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2dc431125a344f3a63a4412d26d8a50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a79ebd44a14e7d82fceef0898c5849_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b94e10336ae4cbb8c40c7c7092d7840_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2cff9b89ea946558f2bb3511379631b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8113e64d76f847a682da0b64b7063dbe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed77f1070fa4a9ea80eb29d531c5ba2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cd4eb0f13b417caac242fba3efbbb7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd89b253c657495cbf93efa71c826c3c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29dffcb1c75e447186d0449682c8fa4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3938017a09480e9b6c89ec4a92190a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id826775b3fff46ea93386f9abf618ef5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i894124740513476f9e7e298369f85ae6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61882a82645e44f0a5cd7626f0f4dfad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f18bbf764ba4e309b4033e323311922_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1ace1a30ff430eaa6398df95d6adaa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ba46a0dc564f5784eafb2834664c13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib713ca7d34c54a46bedf84120eebdddb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbd7358f9a44cc88fca6a40a7f752fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cd2cb43377431bbd784ed4ddbb902d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id79b2564a4684bfa9b4e8e9903612823_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6229ebed99384ddbb1c1e41cca2e59c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a64281a74ce486b8871c0204881291e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4531e2c9cdf04fb883d1a76bcdaa75e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba5f87a65a34af5bfab01d9bc64e2a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8386db744f4affa13508c19b5df3ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcb37f86b5bf4fc1b82f022c4ace7930_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d1e272d16d4280b14162a8a5ae7248_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f67b8b79d7454aa2e6e8e2b5d56679_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a59b1db34b94c5b98790e3b0b011098_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90bb2847aa5f47228628aa3e17c89913_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7e8500d4804c3c92d4e3b21e6f0979_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cde1cb13d724c348cf0aa37a2ee59fb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab22f8425aa742719232da9a982b98dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa9d24bc7c349259210cb5ddc15b20d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40488cc77fe48a9983b2d76229a1dcd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf934f62efbd4bdc9ad148a1e8d39475_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if84b38b1fbdf4b4baafbe6846c60b875_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e50f47eeaad4777a025c7b8314d19ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c03a2130e8e4b15b3e45e071937aca3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b3bf965c6b4aedbc71cd1b54cc2247_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b8fc33095f47ce91f0fb991ada922c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab862c66ad8f40b58f51d2e670bc2d65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe81546f9364a4d9ebf816f2afe77ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c49328469d94560909e62a300fb15cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5845ce666250472aacd23b84c3e4c403_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4abe14ed7d746c2a4d0112b075ac9cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4df3bf3464b489caa60ad6df0783bbe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5174aeaa35294f1097a209bd1b7845b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icceb1eff5cdd4984b54eff367696ca4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64371009fdca47a9bea3857741540621_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc100215d1f4fa9816b460de125dfa8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243440aa810243239953f41351bdcf24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3a7bc030e446fb82edf9a7f6f92844_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia101d6eca8f243bb98e9561330ac20b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122fb9e7cbb34242a643302cb8dac50c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec68387645db4b4f92d21db543507a42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa12801a6f24c04b0786f055da95eda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7b63b2d4824ebd8b98d1a3e0bec191_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49adc5d81365456dacca8f1348186c71_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4404efba44734e41af51f0f6e510b480_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7197e9a2124fe299c14e4eaaecce76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c95be326e745df83b5161e9b90eb8b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54524c6278e14aeba0959cc606b06515_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib118e8524e0a4034a5733e9334f28db0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e0f9785fd343efa0193891217b008a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79c5294ee4f4ef681fd908091186ae4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef513531c7049ef9396372c3a862b18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i279a034c277f4a1ab4e300b899b21d54_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2570b2af4dc0432b9372301788fad363_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3338ad8173349e988242ec0e6f04e1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ffe64f002d641c6a9b980be3ed01dcc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17e3c0297594484b5fc11d78d43ee29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d777c538b14159ac60b1362f07fb22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if890ac36822f469d8ddea5dfd470c95c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id361aece11434b678eaf1e55548add4a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifabd8a9ea7f3489f96d642962db788ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2245dfc68e249d0a3b540ce6711b4d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7abf976b41e94d6abcc6e5fdc45e8040_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098a3086a33e473685588ae2026e5f1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1126ae549787451f9bb5e56ec4579eac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia458924680af4b66841795f4b0921155_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee79c787a98549fbb814a8a2d8423bbf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c16c6e39bc54a20a076eddb68a38dc3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df57ca285b34436ad72599838d20b63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd23ae2c169427ea701232617ba23e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c6dd0e87a04241b80ae67b85eaac34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia145809c4057498dbea07cefe5b3af5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a4f3931810408b8426d88ab25f2543_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7563fab9a921489c8c33ab7ddf46db30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d2921396f2408f81b37c768c975994_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c6d36f572740b5958ea1e5a869f0e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b26b6ce6fb747bbb9e0775792261b89_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aeb1d3ab83b4f499609731a48e300dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786023411d90417782c4325faf5d0199_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb4acbcaa7a4e1d9a4bf8429bc4c60f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea541b5215c48e7be8cfa4c03730bb4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76285bcbd8264a4d88f79ec61700d427_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690e96d0ed8f4be1b474dfd0143fec7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78854061d9a4a8094725b7186b33c24_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566b619706fc4300afef9a4b18065698_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9c8432ad704f298370bae297a97816_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948ab3ff4ae849d798539c9be859e02d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ad9e5e91ec46c58d5c3d879543ad79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ddfd937e21f452faab9486fd44a1792_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12a0757fc294a8a9f3e7f4e96ad2b79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a6e3cb90de4b7fbc1a26ec8413acad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8356524214f4293839013dae33b408e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c4fc8c4be9466483d1f9c47e96410f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7951f7fd96467c823ac40837825eac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa237d56f2a04c60baf2abac03b59800_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e4b2fc062e409eb90fc22b3ecac117_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85af31eff3fd4bcfbe2f8093e081a909_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec77e9a200a45bcb3e18647fab83ba0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047fada9bd1a4eed91bd54b125f10f2b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i905d5bb1f6a644aa9480da295c712847_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e35fbd704c46248a24dedd85300ea9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa7c39af28c4bc5993971a70aa09d60_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f4f924f3ad4797bf23e88d55c7d012_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9109389a244076841dca316010ff8c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca2f0cae6db46e1969f249939f14190_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d55d846ec5c43f0859bff0869b8d85d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib62fbafb830b45f18b06599b0a020555_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2370ca55475d4c2392256a9363409c09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73989eaa96b4c098c63cf6dfabe07da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba680c3a60c4c94b757bfbbdffadfcd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib446da6700c5431bb4dfa20d113e3796_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c8904967084c20a526f2bea52ae9d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476342288dcd4c35aab4ebcef726722f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c18e45789f14afab755bf84d42ee66f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f55af49432141a9a5b2a16fc58b0038_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e993b0bc60d4c04b3d713bcaf91ff26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id444acee0b204bdc95711361bd992be1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf1f9d51d284edaa1b7ef76c6479ef9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070feb5d9c28438b8531680d930b657a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9628b9ed2749ddae9bef49cb39bb99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702fa5c2e0c34c519b69e8801bee2eea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc40e99c9fe5483eb7a04d9734858a85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c20349b02348d9bb87dc176d930352_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55d7bb83bed4b79933fb93ad8dc8ce2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61dcb4e367e49e69e147967d3466245_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c3070f248e45bfb4c8b53127810450_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027e829cf3a94fdb838086c03633207d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926e2ce8db484a19b6686864f7dce2d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16730972cec04bc9b31ee8293f90b16f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad2157f26744eac8a277f68ec6e9f75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93492794bd9d4ade882f1194e9f5d0c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86210214b8d04600afad8c88d79dd48b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657903dac3a84f118dfd3c2d2d0b4f45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925c14ebf59d401e90944a793809c61c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6718cacc2a5a484ea0fe4ebcd8d0f0a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3108d4822f4200ba775774e2c6d17b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81bc73f6221746d8bf84498f9556f8ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2d4950c43e4823b068eca9c847caf9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2d91be0889414c97992735d48a782e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e5b3258a5645c4b9f053f742b53b7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3650248e7a546aba24f1190e20ee44c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib423ef1778dc4914ac8a36e61d82d79e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec20cacccc854ae999285ef6ae4bf265_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9166c1982686472cb2be38f81d2bdc5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i099a16e9db4d42d3ad065da66bb72352_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0929e27d1f44afae4a0ec0efbc7d3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a0bf62c9bad4a789c15447bb315106d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b796c46dd2848e0bcfe542ee2f9ea37_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6126155439840c494a0d59a4c901ef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15079d32a6af431cbe2362c300da4d30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8495e35a20ac4d5fa299dbb1a540308e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2101347099ea4c55aa493f4b7e3e75f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9fdd9cfde64d12a304f9907a75d463_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8243736e267647a7a63b74278bfe227c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69102089b51742579ff9ad41273b6e5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3630db9f3642a0bf1262ba09e339ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e4d52b72a54afba956fc68e8d09cb9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034bec2524a34f378ecb3ac05b076873_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364bef469c6b409eb2e05dec7fa48bec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a1ac288cb249769f4020a76446066e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc25daef9774ec8ba96201a6d17c48f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id884085efd444ed5a42695f06ab42933_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25b2eb90e2f49aaa97ed46e09ddedc5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fec7ee5a58242fcbbf477d186e1a542_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ed3edf12174b94967056072504bcad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c8ab2aa0454112b333a7f6f112c62e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e0bdec56134029ae9680e3db1ec79b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e356ee1b9d440e875c1efc62a80b33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52fa75e3f5284c179ee6b4ab5243be53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad81ef38f2d4e57bd00e5dd2c0a168f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8591d057cc4eec92033c36fb05fd49_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0df35c8a12146d0bcdb02fe162f2cb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74307f9a9f5f43698c550cd45a1c8b8c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib51a0dd6c879443684c594e3c15c31cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65921f0a4824d3b8e3297260e7cb19d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c951e01e904d87b87e2c491d7f9dcd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04193007085b41a38db99637f0c0d6af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d224ea9b86e4818acc1bd5468570078_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164330216f6841af817f8d04691a5b0b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13e5ce657124ce698dc637219f87ea0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7e25f558c047e4ac74c9e031a5a865_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028aeea4c2e64264850f271d8ffb0481_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd215bb90d2941cb94a58ff2fd939bbe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf899c4538e4ec6b299cfa3908d15fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f3427b27d748f5ba11f0d766ffe5d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb2e32e1ad2454892693138d44916ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id558c6364b764995aa2b6842b75cf8db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96cf3dcfa7cc4f1396ca4bc3f3f3bf8d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636eda8cc422414eae95184d5ae5708b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="i4d886a39796d42f5809576721f051d0f_I20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98abec6e97245e78d9fc27b845e6067_D20210122-20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-22</xbrli:startDate><xbrli:endDate>2021-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia99148e294d448a3b8022b7ab548973c_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef95a45c6244b97901afb132b2e8ede_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8e1b30058b460e98b4ea10699f32c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800aa827b6e345e58b4aa9e11e49e882_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65135fb98c54b32b997c038034eab2f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:SelpercatinibLOXO292Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id02a7381a3be4e38890430d12e20673b_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i600f4904f99849f2ad5f229699acc149_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:SelpercatinibLOXO292Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d716a1f4534165962c18f76f7af45c_D20190215-20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-15</xbrli:startDate><xbrli:endDate>2019-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9950f4e9a0354b2fa627384fb3ed7958_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2670d0faa7f348ceb8cb0477e2bbd7ec_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d1e0d5a52d4681bade2958b5aa1a4c_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6feddb3904ec46578edf8428b7b289a5_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20656f42f67e4b3ca3072208a9060499_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MiNATherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec4ebbe67054429582ac383c3ca59a99_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProtomerTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f63838d417e4d52a843ed3cdc791134_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:KumquatBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe5e5a2099d4c20964ac1055881f0e0_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:LyciaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625c2c9631a44ce4add09fd63dbb08e4_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProQRTherapeuticsNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb6a0e595d94643bec576021c87b042_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:QILURegorTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia358c590fff34220b7173f72a36ae251_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:FoghornTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a67f18c7ea48ea95d82f120474b9f0_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:EntosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb6fc6a416848fea9d309fc8093b580_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fc657efa784f17b8ef30a51ea8a755_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie824a9d4024d4da5b3b95622f0f82015_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8c7a108f87404bad726fa03ba1f4b3_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba7dfdc0b6a4b679a897b2cc2ae3a36_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:EvoxTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib187355b4ba34c879321b64031638699_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c3dbabca1c4ca8b1462ca74374ab69_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:DisarmTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14514c12fe4a4a7eac789632d8162634_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:FochonPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc045dfe17704aa1bf6a4e76fc728f04_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65311cc8393345fda909ba57dd56598f_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ImmuNextInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64076c56e50481bbcc81b0f17931613_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AvidityBiosciencesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d547a0ec4c74b6b9cc9b20749c49656_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:CentrexionTherapeuticsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ed8956b9f74476a74b29069c13a878_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ffbfb3b6be4f91b268691cc52236e2_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f10220b2a3487cad57915da408086c_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9afc4eaa56b444c8eefdac063ce4a28_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="medicine"><xbrli:measure>lly:medicine</xbrli:measure></xbrli:unit><xbrli:context id="i8a5d6173c0cd4f7ab337f6b352f5a84c_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f8e0aa5a644441a2554b382567027e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fafa3bd40547eda95f4f50a6dbab51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ebe26c48d94c40a9b534da5ed3e8d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853d77493c24496b99d5233e605a2605_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c6112bfb3344d99c577b0fc24fd405_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa9ef0f44c884bf695c4900d1d6d8b9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied98305e265a49d9bdc89506cb9d5cd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136e92857ae343079e9fdebb19210eb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399d8f462fc045509a0e309187f2f20c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9c6636c6e8b4149a436c5c7f6ae3d8f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486722122165416c854ef981a6e4ff97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb15db3b22d7456aa9d475cfe3645e22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d89303e28444753a87b86f2491e9dfd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8434b474adc4712945fa8b15221a062_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c1f715e391472e9c4295cbc73dfcc5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc1b15a414543789a445369b1f1c319_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie508b8edff5e4d49ac5daeb3e44ee7d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa8514e03e541bab9bb427c8c8e408d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b90b30620c4805b8c68b6df7e498b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id33d1a73df7248168e83573873688d81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f74e83d5644e2c8fbb2e5c78bfd650_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ffacbc5450e4178843413354209aaed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb740f8f8fb49248e01e2ab80d6ae9d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249d33d5a06a4082a59829e958e69da7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48acf53cf4c149ba854e91d6ea82b05a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a83cd101f14432a8f149d6a0e602f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a3812ca43742f1ae973a2b31a04adc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief25801843e9467799271bdda2e99bd9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e413d56e5d84f349849637c0f978d4b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e4260516b4243cab0755138b1cb1e20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a4b9d553f8498a8d8c5c1b0148aee5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ae01d552e14307ade61a2e8ce4818f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ec11f13ec44ec886a4d089e6954497_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd825e2456741c6b9498e5c19f301ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cba64a30364790b8eb1eb2ae66c5e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45283f4c7fdc40bf9a23a33c5df93208_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf2be9f580f44fd8e954526bb36e7f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e72a7d25b8a40b99e28b009e54e5649_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7bd696f56304ea8940548378684aacd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponInitiationOfPhaseITrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7efe9a1356e9485983eeb603c301d153_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e71ae8b5064232b5cf8e0340ad9913_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f34fc75a9044519a55f0a841ded99b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ic28ad2006eb14d37878a695f14e7352c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20261b7a34e44eef9f687c2383ca625d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i6fe06c36179f415f8d86b66fba575560_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ia33be6c87c2c473f9a400403f197ba1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf59c02dd99c40c1952252de92c7253e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62bec06499364dfeacd40d1298f61c82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cb727e20f143faa3e3a38b9dfff0c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacadc29206d84c3fa7fd83b205a66414_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cf07612b294643a8bc48b8588f1f8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7edcbbba5dfc46c38e6a76c687dd5837_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6411281e97d94731863b39b1923f21a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc442230d5c4382b155b07c92135617_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3963f62afd047ba88fb5cbe40c1d155_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de4d107e8a743a9aaf08d126d7c581c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8aad08f18b4154898d2ecd801df8d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0f3057dc4a4dd1ab06ea189bd4a2fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3cc7a81d924d63acfe2aeb96bbdd40_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1125c3d05584e4488d02c8aa1c758e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172c281918af4f27986511aa04ee513f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4ac65858f54342b86be7fc605a4ffe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b70f245d0994606a77553c858e70e2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf867828fd8402cab098ff96e91c5b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231f5158b0a54e01b77ad8a5c7af7e1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea923d9282a47d6b6affe9918bcfb47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdf591423b44978b57ec5e6980efa0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e3b85955b94cd59588c3c75b0d84c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2733925e7174df2a7294f9cc18f29d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d907c6902548ad9042a61cf12bc57c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1034a9c1ab4a439abf5f9b58a0013acc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c7e5f9100c44eb48c6a8b02af879981_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i242bd07c45d542379d0e0d769eb01235_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f207cd4c10c40c58e5e98e94e0977fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01d3d2786ef48c7b3a9a7abc2347162_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca22a25490746b2a01afb869b9c9451_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cacf599a2654a73aeb964f7e22ed6fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd392ae258dd4c8682df0b88169ff443_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9309322cbf4299ba4880f01282b66d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c1fe3ce37c429a96afdfe79afa5af8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id782339ced69430ea75a51f82b17fa9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5366462e14a747678162a92e578671fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873a6f3b952448949d4f521a40683c05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af1d3d2625a408dbe57ea38651c828d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77f19b3dbbc4c1d80c04d076b72b774_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2626088ca7db42dd977c6aebdf6b049b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5386daa8d43b4f8fbff09fb65341a6f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d69d72b4fd4b7b89d28f60a414253c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ffc73d6c5b44b9afdbee59fdd53fd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i167566322d3e4bad868eb0f8ff25fb59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a69147b72c429dbae1a73cd1a2182c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f41fed5a2748dd899cdc2d6df25422_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac07bef7ae3f4c03ab806ac0355474b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdffc1192c114929a5c33da248552b55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc6a1a7f28f40fb9514b1428d9518a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4d104ab06043e094df62100f0da340_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66fc52f2565b4f23a7e7a380898faab8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908a1e69c3d14ca19b78ad94abf18315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if243f863e61d40228ccaf6b6475f9534_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d669a981bf145e98752c8ae97287ef1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814218cfc2834473ba1512b07052cb1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id88d4e701c504e9b93b9007e768400d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a0e6c24bfd5491e8a07010acbd5b7a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde117f5d3be4373957394d16191ee0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f07bbac3664847aaeae5a2475a657f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e1eb7cb09f94a6c988ce5500bf74a37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc632f8e72b402d89710b5655c6a876_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306e14d7ddca4e21b4794cb488fce5b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9895d0dae6d7445ea42921b93f0a9c68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c09ae807e54da4a01d2cfc00bd5e06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e05a36b4b8c46ab99d9337d3cd3d4f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3af9bc2dbbf14e6d8e3d8e05279f0cbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30bf5e4d039481f8d19ae86d4a50d87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8cf31dd8d64f55aa42897b097ff8bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88230f75c60c479dbd0b6cf91c9e74fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia445641f8593463bbe60fb23e89ff376_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5fca9cdf5874c528fd7153bb23cf79e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031c8be8676a417ca167ea02c5249ecb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf98252eb304398b10e2fa6fa205edb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fe70f0bb1ff48bbb5988ae3b9d281fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief06bdf136c6446e86155ffb29485c04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ac021a9eb94f3c991cd84f64525cc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa29f9114014c86920bd9c97e83e197_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316934550e024acbbd6325dc2c36d8a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ee87f534b7486eb812b3019d90f10e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie004b16f34fb49528fc900ea4eb9ab5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd5c0e714b6457c9291715287cdcb10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887f5d8d558444408da6b729be6176e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i167ec5deb3594dfea6abdbaeb717e48e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1675ab4c41749a9a192e7bb01d5570c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e36489b4fd04ec19524988a99361ff3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95497ef3752c49bea81162355fe898f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id804f4973bed4a98bead10d90e4a5ec4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4f48f77a9304c3d928d59f5cda4e8cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574e8be0dcbe46febe19bb311f0b3e9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia594156723e841d78c3dd942261e75ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcfab070c414ee789784a20354c6b69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8628ddde09c14992bc17930fcf88de35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a22aba314ec4e5b8758419c0aced782_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia193b0c52b7842c9af258c8e25683106_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4f335ad729d456583d5537025bce75c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf7334b5c1440cd914d71e8eb5158ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64ce11134d3479a80fbee093c8eeb0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia33787997401459d96a225f2f2ddfdaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d528edb81f432ea8b0d77df211e863_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic46f810428ec41a0854465f3dd3eeb28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if288edb5c28645d78092d94621a6e314_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie426e3b515ca4c32966ac2238ae9f29d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb03dc979e1948809868f9121af92653_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b512c10faf4454e92e2820bdebb03cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb330dcd0a3d42cc853a2009b99f4554_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344dc72ffe804d559e7ecfd187252c52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6319d8f9aaa3462cbc841393e3484980_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc78c865a114757a146a87ed649467d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a588f349f449d29c4cd500d935548a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9df1bc022c4981908c34ce7da7d7c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2efecde667454dafa903f13553e58c5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf529e3651a448988c0e69800bad62e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f60e90823904e52907d87d841e42ffc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d818676d44496c9f05bbd23d02b4e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i827063ec6d8b47cc8ef73cadbb5e308c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26af35be2884e2e8476d92958017ea6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd801c4ac2b4ba5929965024c9495c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b14338524644f794041da64329d7ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6f2f073c974e75b0df61d368ef3198_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a8dbbb22358480a9d1227dd77b3d9c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i591b41c97ee542518e6b5bf5504d3133_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice0f72bd70654124b4ddbe68456882ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a1d18f3f5f4e94a780c2d35119942e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd739cb8ecf4fce97d2650748700a73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e3a34c12fe45458f64b1588317741a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ba73fdaaa94d918532bf88e602aea4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e862569cb8e4d77b08bc51be4980e34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee4fbb4cad946a0b316ae9a0d5c2f7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03be72af30a547c281fc637c8b272953_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de4ea09bc4b4318aa35ba040cbaddd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734334d67c56497ea2fe5de69c592773_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8795f816d3e4ca2aaba6e653e468c06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf0573899a39469e83be2b20e0eb8b87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda2686ddc2d4cd0b6656354b98930b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2859719f266a46efb30de54c44c9888d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17438a4e988240c58930bd2fca58fe5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc3c2c66d9e4d0da075849aa425fa7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2746f9d419c14a098e97957fdfe7641a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b77e24600d447186fdb36b48034cda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i103492ff7b1c4667ac257e9154cd5beb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30df961528f4463793f7905786bea152_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643183966d6848f3b666d367edf73743_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70569b8f4108449c84afeaf1c43a3dbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a291d5a17ef4657b4a29f981d818719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14bc637594d43eba77368fce832327f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e070cb04b247668d999c7e61d52938_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6d03e2ed8d4d58992474db5137bc29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b03d00bc65a4499823bf2ae6673dc24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1690d7f6c7cf4875b045a1c058aacdff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4526f1f10b794ec991819ce33cc96cab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237291a28a7343ae877503eaf0fa41a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d5a9e0154c43b2b5d3386c1d0b0538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe2d1bbead584d8e8b7d3a56191796b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f78d8a998c493b824d37739f09cee9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b6f347e0f6d4d7688e6ede323ba93ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec315121c623474c92f184ce17dafae2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f76462cfe94c048d2e8e07abc8ac06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ba7848623e4295a4d08297c9dcfc05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c838ae6a6741a289a916ea6b2a18f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fb983303214a0fab76fb48ca842390_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ebf2c8591c4a65a69ef2a0f9a1c023_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2e86153cfd4c15b9467efd88051085_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62613c2b0b0949e8a36439ddee87c7d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9a7f6d784f4d7b8b53c4631c9e75eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d10b06674c46a98dd32098076c5e36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffde3a7d917c478db3902cc934826508_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3392ad7d22c4bf7b9a4a1c59ed94a0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c20187921d4be8beea2d674ea20464_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia914bdc1f6a941bea69658cc92f5058b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a2be087dc94b038c7c193e1cce0685_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf95a7cf14e94274ab9c3f3de25a81aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic901be7c5ce4440f886d70a9f0528564_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8afdee24674791bca30cb8d138a90d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10a9d80e8d1486caea9af7c720bf668_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba53f9f1da64ce78f2027435c7eeb45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45fa035c9b02420dafaa115085c6e8f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9383a6db72eb499a9b97a5c2952db425_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie531ec456aac40d486f50a514ec2ebe5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9815b1af955c480e81629936863a716d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a9323f52794ceeaceff691b1800d6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3a57eb5302145278ada333579227b74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i757bec4b105a4991afb95cd0de81960c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828c4fd6a50342c5a0296de836f61ccf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1549f6338d244929cd807e3277907a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c486aeafe64057905b3c05060eedc7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4a476458934d3d96c4cac37450ee31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86faebb6ff9045eba6433aa67924475e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib85d997efea3485690a6a131ac2e8edb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46d6fa65cff4aa58bb12b8d03b24b7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e4a32babb7454bbabcc34a329041d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33be57ca2aa9408c95b321d324369f80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifafdd7dbd10c49a3ae14d232fa79500b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9497e574157241008a6608086202bffd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca73150a1e34797a7531629fc846e9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3edfd436e4164d2f80725061a45ac456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf0dcd71d534c529a1afa8977dd40ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c09aa7a84a1474780ee33c2cf2dc8e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e573d0614c4b0dafebc560bf1e985c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2550d98cc4814022b18b1a19bba41105_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i726ef58174614df18141c66c144a35ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfdc5e7be96a48c89529e9addbc8ad7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e2941af15b4d969e19eddd03468386_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e0725e0711473c9cc3cffd0a7eedf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26698e02933442c83d95b1cd9eee56d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154de6e52643472eac6dcdf2abeed4ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07da3333727b4428aad7bfefccb6d377_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dfd1e097624c6488862d5324309a2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93730e7e82dc4832803e374edfe8ead2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75deddf561c0493e8e46b607e2749a0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bd23b8192c4011a4b88d56642b3f8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if60345d16c5f4360a5db3ba0799c8e53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5686e91f0d54967a085ff54595dcd73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3de88e24648844a59b518e653fed8863_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeef731d794a4687b24f3700ad5eb752_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef2c7899afb4acea061037c69340c76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eaacf39e2ea44ed8c2e4582391bdcb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21429821125945baa4970226531ad503_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie460a9111eb84d4a80874905c816ec62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b1d20b9535421399292eaeb2e1404d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb82f7d9a12471bb259d4ecd5857cf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddfc74445594fbfaaea12c6240ebc86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2102d6980fea4c88a7c3bd4a75c97991_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b59c5814594a1298d4215076efeee8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4662c8bc38545fb8b2d9cb09707ea95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e119752ce84afebbd0e53e707424ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa8f1a49264490990fa783782542124_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d037b9981404553a0d4424d89b04955_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f18ee96f0b945dea57a5126d8ac86e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad3157951114b79b6573431cb911415_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia474b21ab0f644219eba3b34a8113881_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa96c35099cd409caaa67bff540585fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c29dcff71ec45a593556dfe25bd76e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a94c884519b4702b3f5dc1c813be663_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69442670727945548dd575b353aadf52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c0e225dc9f24b699d469b030eab3e0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a35afa117740c1980f3bb027fc8dd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6648301f7e343c8b1397283a5da0166_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a776f2958104fed92c610952957426f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i231000e09f2d43bb84cd04cf8c324914_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a00f397c444157b4b4d73e2eea183b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f29fc3788e4afabc141f44cf4cd192_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2fca1966da41f8adc01f317059c621_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bfe7750c7f43cfbb99996103ae776d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72baca3e465440cdae1136e4d7206b9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8af2d2c452d42a8b7cd8f16e4ebd74b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36aea259f0b34f19ba983964d19353fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4361ba8f6e1e4492a8664a509357866c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i935c853cb5344480a0fde97d3a5bbf26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd87a02ecce94de892c2873f98f3488e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c6d753d735746cd823811c9493f0574_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849ed38906ec4ff5b38dd57dffe8ecf1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1eff0e4f1e846f2890a8d5f2938a568_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a5deea4c6d48b7a2eafbede3b86af1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b466072109461f818c9dc82d5550bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77673fc123d84b82ac7de1c624dc395f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id057083c27874cbd98e27c582abf0489_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03f60cda085426697bf93f5635d81c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2170ade6674e849351094a6814a792_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2f9c7572f84dd09b8fc2143f1c7713_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87692d02cc64457990db62efd471306d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d63bfbf5dc1474eb7e49de284e9b9bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib618046f71cd4612a921448bdebdc46a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec709b7886f4f2cb0cfba7f68baeac3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f7f06fe81f4197af8d197ea94e6fad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ecd2cf284544f3a2b8a03785d285bc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841cd3e00f484488bd7b6b817257e859_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf79b1977acf44dfb438b2b46b217354_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i551b1c26feb64783b8cdff78bf43afdc_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a28246e7f384385969289659ed183cd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2874fde88d0443708940891c7b27e2c3_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4501b277cafa4a86baa5a206571b8208_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3a4dd737f64e34a0e898318bacdb1f_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a543f8c48547aa9e78a63f01f33c83_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2ba1b9c9854a9488d1f797845e5637_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1dff00d32cb4ba2b10f010cbd418d9e_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88fafea838de4336a9206daa5e470df6_D20200801-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDueMay2050AndSeptember2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a25b1bbb8494f0cbd38976a0a587f00_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b13e3f15a94aa09c71215b3ab2d172_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae5dc6dd3d94739aca17ae8276b5801_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a86269df3d466591806fc6e81d3051_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e3b9057af3454595d19c23e9d0f7bd_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ade2425c63414ea6978d8687390db3_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709f676fc9614b42b1b0311c076d8dc4_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11cc64930a449558e5ae1a4c19b6806_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982bcc21bc3a40c48ddab9f94be23c67_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019EuroDenominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2998c6421144a5959f9da4218d7f13_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0d0d5ad7314fd8aba39a1931772306_D20191101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f666283299a422782250b8f89a2f761_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id13727de8f3441d299f77635f64f9362_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41718151ae0142b0a3f6ffa452de44fb_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60cdef46f66424db1dd39767e60ddd8_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019YenDenominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id842f1546f35423585d05e7ce66b80c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b33128ceba4b25a2ac485bd4f78d97_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica452a7bd83c44088dffeaca9fe9e6e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5abc04db6b73450ab221929c47623631_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1522d5872545dc9d89fb44d73b59ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294da3bef2c24972816679da2293ee28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5bfe01bbc4845fa8a1d24e9e0d98eb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51954a83d3fc4e158da2a14d11be3b67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b72858f1e1a4cbea5c56de4e31319a8_D20210101-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie76506d8813f4a7fa6b07b99e9f4ddbb_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368ce9c4630f4059918b97512f0fc80f_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b37dec9dc524596b81869a5a184313c_D20210501-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1c1179afa04c4888ffdac81ad4e1bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:CarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibefae15cacca4b6fb80885f8b7f6034d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationin6YearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca9c900f5ba4830a421d9f973e97825_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationIn12To18YearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7ea2349e0e4231b618eb04ea877890_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64908cb8d2bc48e58b3df38be9554dc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fcde25a10741c89da748954342eb63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a0a2d94ade4455b3533cea592bf9d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationwithin5yearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7929b7916024d43ad8c5746cb69f8db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expiration5to20YearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7227f8a46eda4c649d9047310a103ffd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0a88d32df74c0cb0fcdd7915d26f3a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff79519d513f4f68bf15f66911ffa849_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icddb724942ed473c88a3646e8ec26fcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f87d43e733a4aae95d03ad94fe423bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f092b15cc046d898a11dda527a6927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd80bbb97874a039463577583da19c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99352080eaa64b8aa55bab4783a9052b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4622c6482f3d45069c12df64c7dd78b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968dbf693bb54261a0cad1975a0f50cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41cc8775b020470392c03bca0264fe6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i673f610f07dd4af7a79e6fae5b2a77f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764e26f54c2b4e88b9f325ce95d6d91a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78fcffa5fcb4363b925527a37fdd04d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7cb49a7d1f0485eb5048fc42c817807_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51c7d73826fb4c3ea998d99f0cab890a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1338ebe78ec64e74910cb8e168f15f3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12cb2759a4414f6a87de7960536796f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a59bd989ed047e89cfeadb49552c829_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4ea41679f04d40a1f04042e79615f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913594ad00c9409d8b93872f5b5fbb98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bdaefce21c9475cb128cd1bec0b2b54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b14f14bed9450fbcce11d6df4b26a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603f1e71c9ed4e7b8d938450da375dbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d5edaf21db341aaa94c8e50e73bb216_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a706cd4ae4a48b185995bdd2f78fd3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78fc7d44d8cd48aea3c78cadc0049519_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b8bd8f7cd5b4670a3e7ff6635118b75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f83daf4fca54e40bbaab49dd09cc5a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31478b67a9a7415d8e22de1ce680a740_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5636680a6e4e4350b3fad57180768fbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e43baf9dd8e4024aaad2773c4f843c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d32acfe18e3466fa5910b344222cd82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede2b770f3c64ba68bc39044be90f109_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f7db50ad1c415288b9ea85aa6709fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a91711f8ddc4cb89e215732b94181ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7aa0c503f5488795d936ac19312dad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa35aec973a9495d8cfb4d1860d7f186_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5278164416d440878ce7f8241506dad2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30503f9548ef49748f6c47f41c46b9fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i692d2c7285d94749b0594132364bf602_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e6e217adbf4a0bb420bbb79525b195_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230a704d2f5740a0b69a5d2fe32aea0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd8a47a67cb40659b5f2400ba2e2a97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4af7abd8884c829ce2cf89b4eeb4a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0db00ed934147a0b1454ebbfb9605e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91ba6b55fdf460aa45150043f7993d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9090de42c1e1431d880e89e365433af9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9162ecb9fcdc4a8a88c76c029e0ec77f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b11998c76c4e07837a915345cd5625_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f60d47dcdc4aea9e98cfeaa8959089_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae4fe3ccc0a24e18ae11dc80ffeca0f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4e6aa2e94d4863a9d4c4d40db622ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ada8f6f4d09490b91888fc53f19799a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8ba6c16b8a4854afcda9d5176c4082_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fef9519e5cf4d83bb440f5dd2dff978_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e10b3bce8240ed99c41e92c2c7c166_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b60c7852e34d32bfb74a52b2d6c8ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626717f8b3604479aa9d86b960ead4df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93e68a551ac24824aab0b50cf96ac505_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd41dfa5131b4ed8a3c4edff4cccd882_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dfb78e31d4e43a48f83b015b72c519d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96d870bd1a8c432ebcf9c58cce764986_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866e79b40fc84b748948629cdaf16e9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a07c54e28594ef985fae75cee518345_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f183c3cbbd4fda982cfd4dd42bb6ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e533a36459c459998922edcc7dc2e06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3685410209c4742a6877711165cde44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244b201723df412384c2a82e49dddb47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie223fdbc588545c7aa7794612858f25e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44600c684d24718a1f3801f118c80eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a5f9dbd52e49c9964b39f2bb6a3117_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a1acd17d36146009b635e6ac8876b00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia121cc72798a41b99b32667d68124755_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ddd772d1a82411e9d52cfd46b93391b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bf0bc4572794f0bbc6996cb82ce99da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4a130b58aa4fc787b2559b8e658309_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c2688876344ae09d2527a2174d8cfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d399445e4a24b55856d4967cfbb5abd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ff171bf7ca484fb1a1179c3b99e72a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38811147de6a4ae49619b0c6fb50b5fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49b9ae457524259bb341c9357a21cb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109ad29c5c0843d19c3fb35636897f6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c48fc80fbd4c02894b634f68421b19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923f6a0606ca4c659014e936327d763e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ebd34478dc44aa94bd2cd5d0ae09b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4dbe652b11144049f9f252b2a082929_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i126ac11b05304e3480af55e56aab89f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c1c1e97cbfa4338851f65cd304431ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15d1d4659da48ea849e744343f5a3d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab573539a9a94f85bad389b1d078779b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f296c7bb394430981a1fb8d6838282a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002c38a65f454861808977f397fda65d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd94f2c6bb2e4e2fa5ffb39664bdf21d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dad2404b29349fb8450d5b39364906f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27235dedb8194dfe8ed6a11ba255ac26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b97858557449bcbd42057fb05bf2b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica4dad88d4f64153b1ec36fb80920aa3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16f68bc36bd4ad9878079914f8e282b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b81a674c8349d5805272c34a30b9fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2f3b2cbe4349ca9de603412aa190c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe2b2b2f8174da2975d92a5e46521b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4caf2d660c4b4484538e8cbb90b925_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492309902f57471882356fb89a26bd66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db00e44884e4324921fffe1db888357_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7920ff7437c4431394c58ae1b77ea77d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a76d7e24404d87b2fb139a19273f9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i920509e109ff475b8bc9e2c46f33d0be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab5f50dc04544153acdb845c6d785a71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd270e9d09cb49339a3220d22dd73473_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90078976fc1443fe9588fd6b5904ab69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5677ed160204f11beec751a2ccee116_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b36d1b515614e75986f6da15379aabd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9670f5b2d1b401bae5142ec826f2a84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedb4afcb9df4c4e8e4622bdceece6d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1fedf4fa6a74d72b7aff18d5cad5971_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3027fdae9ac423dad98aa4717b2d250_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i904066c648bf4a7891d0c09bd32f935a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if37beb85aa5242baa69698b7f1ac5a62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dab754da4cd430a946579d76e7a4235_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c886b62fb994e6b8d799a1e75d54ba5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c687db083a348319e2e8ddb46c0e62c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c04b7697ad04751a168650303409b1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4204c5315adc45d48e818bbe9a8ba906_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4986843a114a4fa8abd7bb677f0a6e09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1852094aef8a41098d0642f072f681a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id971a9a8b7eb4b6c844ae83861fff3d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05c9d92ee39418698a8b85febf6ef92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a265af7c90b4248bcc3b03e1b75d45e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376b64ff0bcc4868b48f64179cccef38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28a3ca1d4022458f96a8a99957fa07fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d1d1c1c3ed4109a81ec41ff3971fe1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22e780cae244f9ab866e47a503bb04e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1c7cdebbee4183a6490b6aa660776c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098c8e062f114cf895dfab6de7e2a153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05001400e56b4185b37c3c340b3cb549_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f54761004c14a0fbeed714f829c9a9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab1592b5b5a4ea5803c843fa59ea969_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief12a02bce14452ab3abe51ad1dbdb96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8303f3b61154040a4ed58939d6a8db7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9dbef9e3cee42a6aba4ec399d8d2392_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b9c108036e4a95a83b7d094eaefd7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a011bb0a6704772865e32f9508fda79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90317e246984c68baa7aec717e1b700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a9ee8915a1448aa53821d3de24626e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77dcf7055a13436793411bbc50581e33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54aba7ea557147118c52c20b184223c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4bfc6afcf347469c09d2fffbd3b3ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d6e9fb0a8e41d7a79bcebc0f396ca9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286bdb1bdb4a4e99b3a1228c6f203ff6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e85922b83894b11b8b77f4c73af1fcd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2ff10cc6de4d44b3171363fb8d3314_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443731e8b90e4ff1b5ede21f5cedfd96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45319fdcff414b46b8cee3c8ecc98372_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2d59c1620642d784d6b10e9f31a7a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50063c31ba9749efa23653ec53ec7046_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id966a267adc34a0ba8ffaf9925c61ef2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f8eaf7e5d4c4ea48272ed7d73c53069_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id872ed9c15ae4df9bd2ff63acfe92e0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7e2a5a735740298384d7b6e050d5aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c132cf90104d488c23e6ca6eb8098f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4113c6d6bab42948b9ff02ab6f74741_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e88ac2258ee4936ad5dc86525cd9442_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670f1a97ccbf41da8154342d4d6523b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3ae3cf49674f30ade8c18fa107c77b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257e5842c7554e4caa669c0ffca933f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cfd8a609414a0db58349eb5ea9a5fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0f0411d0c340e5a80b9de1a90ac71a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fcea8bc696240ccb6279f2fa8f961ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717d2780362b4ed5a803d5d092fc68de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89af2a8588fb43c7a9f34777a2e4a820_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a8292117714ce7b0efadd7981b2635_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie331a6b7526d4646ba4c0c78741cf4a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica375fb13ab44116bd7cec8010c65295_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc92d20b166347aba8996743e2f94f5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154ab60f7f874167b0110415b0bb6bcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82568bb9dcf84a24a49d7b60fa84c30e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9537a27ef3aa4c4c9ab9cf72607bf998_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1425cdedc7949b0b143bc6ff55254ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80391b34e15c469b9897032dcc29bcae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie906d9e82b62417aae23edf6f663034e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0008b840b33b4978b52d9f21ad80d88b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i062da986ad0544f289a0f7f67fb3d529_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c8c08e195b457581bae02f1a1a1ed6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic671a63b2541465ebb7421a6e68854b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9a8b2e771d41f990fd1f9ea5be38a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ee2af27ade4a0d8bc08bef2fff9cfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75775f4e3d5407da9f8fd41bc619cc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4d0bb3ce4b4cd7a9e3ffbc447cb4a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3fdb269b554706bad0f7c0db4c4650_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c8f217fe0234a80a11ef720e8b0c5be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf725fef3924b1ca90629c2fbfd82be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e73d975a09b4b51b349b6589f7f2026_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2345619fcf84c878d4d255125aff795_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f2b6878a0d4219bec7cca02fca3f31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id081a7188b3f482cadd9f20bf9235396_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a933ecf8154d50959fd7b679fa2059_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c80776c9e5d478fb71a447f058f5795_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf9330f1044b4da28b7e3b56aee502c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fa9acd89db451e96eec95ad09cf9c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd7cd72ddc74159a112e5175ba27aab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1884086160c4545b61f9deb3369c36a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3c2d07882344e098b3ebd363334c5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e1bafb60044816a73bd73702d87ead_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6128315f59094f028caf8bb50fc29382_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1472d9c0614d2792d02449a8430661_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f512b891abe4e69bc22f07f86783f45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8f4700075e46e181eeffde2392ca23_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="idaebf92d82564ada897eaa69c56f337c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2467803c679342dea9a3819f8bbf7baf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ib12387763bcb4249a0acbacdd6def054_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b71fdf7d6d451ea94e93caa29ecafe_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f4e6781ac7b44e984cc9a7e9559b57d_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0462964f7244546aefa834caa5190c4_I20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac210e833f7b4de39ab853cd87ad843d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf373b574e5c43eeb34e1e1ca9dc68c7_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i58d4f95ec17a42b1a27bfd827f5f8a06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i329ac6196728431792b5fc0adace7b76_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie857e2c012a4416d91e56a0f10db62fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95acadd05dab463fa98262e3b7d9a30c_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f2181a9b6d4e6ab309b180381eac2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d637cc5246347c6a23d9f91a36fba87_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1eda23144b47d083c10338438ad3c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2521580e2ede416981af3b0b347ee8f3_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4899ed067c4d2c9996df4ef5abba7e_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09447c7b9f54599a8f05f81d771fab0_D20090301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78be52744324235b791e091239d55c9_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506357620067488b978ab8ff85c80057_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>lly:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i0fe8d453b4a64bcd91db0e517126df58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie428c3da402741de9dc989224e4a1931_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce97af02d724dd5a6b2d83575df05d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="i9f0a8d43e1354331a472dc5baeceebd0_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="iea9d1b8804f84d8d9335353484110e31_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3712c098015042f9b63839407eed2efb_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec2ece19688425e9036c61b5348541e_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id79706b98b434731856afd46cac0b247_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0eaa187336948399c69ed01819ea277_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeabe64521a64f398e690da708946fca_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>lly:claim</xbrli:measure></xbrli:unit><xbrli:context id="i49de5751f19b463f82f0525d37e01c83_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:AlimtaPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8b2889ec6e4963b72ebda5ec3e0226_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70389d1a8dce4373ba9770278325d644_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7efe1f182bf74c749bcde3ee035a8288_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f70fcf53724eacba2dff838d3080f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51cd7b473ca14dc78773ea45b5740f8b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0475e54cb8944cbbf6fd301a3970da7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8db92bbdad41589e45f909109c9432_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc77c9789cc449891871245cbbdd250_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda565e24c4e4030b83ae8ca958f008f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d1710cee29438bb4194f2e32033a79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7432a131a0fb49ff89baca4d230f866c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900912a3de074ff99d6a423f98a6bd4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14978ed722694c18a3fc2706b4ca82f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164180694aa747c791f72edab93ae1a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa4777312b864b708203b734b774366c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c0f201926f4948bca2dbe17676cc5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c0eb69cf624cc4b293df7b97c976e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6183f5a5c9455dbf2c516793377cd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c9273e754e42ff817a718c1ba70d7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic435e2ecf0a9408aaba2f2109d4c1db2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf58fefc745a46b9862d5a41ca2b485c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554c64bad97a42be803841abd88811cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie990d35793244c81978b349a80a82099_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bf6f4a94b544a686ef51fbf1c8c304_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2772b8591a3a435d806d664e42747e10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18d0b0c520347f3b7f49fd16cebe265_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d26295f837471e92a911cbfa5f09ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7a7a2ccbdd490e9438393be18ea12f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33da3a3872a4c1a8a126e0502034dad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibebbd5414c314196b2e7f72291cfad2b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i456c6ad8d4564976aef8554ffb59ccb7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4452a2c88c941349af1c9b68847bcb5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b8a5e3c0f84e68afcd481209c5d2e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65892dc9a2954d38b4ead8cdfcd6ba81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d96de74d5a4264aaa3443af2d2593f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd3bf1571cf4ded9e6e79654afd40d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6958d74700da422a8372afeee6138499_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb264b12ab0a49edae53a6a459216f4d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabad7b42145343838527d4f8737a08dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie225690e6f6c43e7bf1510e4c46c7696_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8379681ef59448d18a9ce97f8241d61a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4cdbdd02bc04cdf82cfd0ecb1e7506a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4e3d75ed7a447f964c2076c2654b6d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bd38897fbf84ba6886a357f48aa2eaf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08bfe6219e8843de84f18681cf0d0cbf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080cb1f6c4c54fada36e6a66c670db4b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf4d129e0b547c78a08a57ac046797d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa4547d667b4859a0ef3510f8201e3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16a788a1f3b4a209b13227afbf2188f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4726fae6a954ef28f20a75d12754243_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e2a870edf2467790f0a84a2d627f6c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc78576f75247428a588a52665c4852_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb9aa249e034756b9c8db5d7fecdf51_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecabf182d17143a49900323bf9cdddde_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c2697f3892040f38f4824aa3f7f6f6a_D20190311-20190311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-11</xbrli:startDate><xbrli:endDate>2019-03-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1a85401413cf428bb86d28ee6b337a59_4"></div><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">United States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities and Exchange Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgw_4428cc0f-cd87-499a-81d9-12718e1b7218">10-K</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Annual report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">for the fiscal year ended <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yMDE_8561bf7d-b968-402f-9ee3-11848d290ab5"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yMDE_d522a18a-e62a-4eeb-9299-6afffda02ce9">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg0_3c99796a-cd14-4415-b34b-2d2519bded77">001-06351</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yMzc_d46d5a0d-91cb-4b55-8cb3-0150bf2b4c2d">ELI LILLY AND COMPANY</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.432%"><tr><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6NDU2MDNjZjA5MzJlNGI3MGI4NmMyZmE2M2M2MWQ3Y2IvdGFibGVyYW5nZTo0NTYwM2NmMDkzMmU0YjcwYjg2YzJmYTYzYzYxZDdjYl8wLTItMS0xLTM2MDk4_bb38eb09-5993-4faf-9726-b90c3d327a7c">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6NDU2MDNjZjA5MzJlNGI3MGI4NmMyZmE2M2M2MWQ3Y2IvdGFibGVyYW5nZTo0NTYwM2NmMDkzMmU0YjcwYjg2YzJmYTYzYzYxZDdjYl8wLTUtMS0xLTM2MDk4_3de46c3e-2c6c-4c46-8997-f00564290242">35-0470950</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgx_e3455463-56a4-4c71-9392-9f63005f4a4b">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgy_c6b70c08-2fb9-43ec-bb68-2bb66f8b3de1">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg3_acb105da-94e0-43bd-936a-623faf7440db">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg5_1c79ac83-c8fb-44ff-b925-8bab2f5f1681">46285</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code (<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF80NTY_a9aa84b0-b3b5-4ba0-8ee5-0f977321013e">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg4_4bd20f5b-ce2c-482b-b937-dd40303f0497">276-2000</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib999762467224e169f22d930370a98cc_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xLTAtMS0xLTM2MDk4_e3699240-2a25-46b3-90c1-c6afa0910b4b">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib999762467224e169f22d930370a98cc_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xLTEtMS0xLTM2MDk4_9e4434fb-c8fe-45de-b2fd-2b4b7f215e85">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib999762467224e169f22d930370a98cc_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xLTItMS0xLTM2MDk4_5551320f-c62c-4706-b002-bcb69fb548ae">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8yLTAtMS0xLTM2MDk4_d76822a4-b490-47f7-8192-6fb32f8ed3bd">1.000% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8yLTEtMS0xLTM2MDk4_13b5b791-4032-453a-8ccf-851060b70327">LLY22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8yLTItMS0xLTM2MDk4_6544ffb3-371b-4062-9058-86c89321004f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8zLTAtMS0xLTM2MDk4_ff2cb2d5-30fd-43b6-b2dc-47a7428d1c3f">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8zLTEtMS0xLTM2MDk4_56ebe9da-cdee-49bb-8044-063c173d5955">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8zLTItMS0xLTM2MDk4_2caa25cd-9c4e-4ab4-a4f4-5ae8ed60534e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF80LTAtMS0xLTM2MDk4_be2ee041-46e6-4d0e-99a1-5b9a1df1c874">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF80LTEtMS0xLTM2MDk4_5c54ad91-915c-4349-91ce-2e7313d6966a">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF80LTItMS0xLTM2MDk4_66662b98-303d-4003-8b77-f4d6c1afd8e2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id219efe1b1d547adb5713a0601859853_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF81LTAtMS0xLTM2MDk4_aaa8bf20-21ab-4044-aaba-7be01059ac6e">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id219efe1b1d547adb5713a0601859853_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF81LTEtMS0xLTM2MDk4_c579c998-db0d-4ff1-a232-d6e8db9fbac7">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id219efe1b1d547adb5713a0601859853_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF81LTItMS0xLTM2MDk4_7e0b46cf-0277-4b7d-9c42-e5c490d33bce">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5badd592a21c4a338eed272300758c16_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF82LTAtMS0xLTM2MDk4_23b179dc-6307-4a86-a320-372577f00ddf">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5badd592a21c4a338eed272300758c16_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF82LTEtMS0xLTM2MDk4_0b1c5e21-715e-4446-93e3-85c2b2ad7e9f">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5badd592a21c4a338eed272300758c16_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF82LTItMS0xLTM2MDk4_259e5e68-97a9-409d-ab95-3d4d42d303bd">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTAtMS0xLTg1MTY2_07b5846c-98da-4401-b40c-7a7eef4215d3">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTEtMS0xLTg1MTY2_9c44e37a-253e-4051-97ee-a1355bf262fe">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTItMS0xLTg1MTY2_502051c6-6176-47a5-97c3-a894c9ec011a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTAtMS0xLTM2MDk4_0c1ead68-ffb8-4b14-b04a-bfc4d379cb1a">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTEtMS0xLTM2MDk4_3202eff6-b042-4530-9578-125d95f1123c">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTItMS0xLTM2MDk4_4dec5099-3ad9-4471-aa75-4678524035e0">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF85LTAtMS0xLTg1MTY5_fa98c14f-079c-496b-85fa-241b1cda4426">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF85LTEtMS0xLTg1MTY5_7ad06af4-902c-4b9a-b862-a17cd4c3f49e">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF85LTItMS0xLTg1MTY5_469a6ad1-8332-41c7-bfa7-2953c124be78">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i822be716a0774b71a20856f8866c402a_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF84LTAtMS0xLTM2MDk4_8fe9b277-1ad7-418b-8a1c-d8fc4fce2aa3">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i822be716a0774b71a20856f8866c402a_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF84LTEtMS0xLTM2MDk4_ac96a1ea-d3a8-4e20-8e42-d27da5e5828d">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i822be716a0774b71a20856f8866c402a_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF84LTItMS0xLTM2MDk4_65d27e48-2b9a-4188-8c1a-7993bd3745d8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMS0wLTEtMS04NTE3Mw_0de78b51-3140-4cd9-a8d2-8c9df12b3cd0">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMS0xLTEtMS04NTE3Mw_2420096a-af3d-45b5-befb-12cb604f2d33">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMS0yLTEtMS04NTE3Mw_ad587919-2f0f-4536-8f8f-33d7e27ec9ea">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMi0wLTEtMS04NTE3Mw_55c0da52-d45c-4676-8068-9065222c6dbf">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMi0xLTEtMS04NTE3Mw_db8f21e1-a1c7-4509-89ea-e4a177fdeac4">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMi0yLTEtMS04NTE3Mw_dbda52a1-0ba5-47f8-b421-c5edf609e8f1">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDkw_c0a93b3d-24c1-4b3d-8679-138d7b9d8b81">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Exchange Act. Yes&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgz_b9fd407a-5398-4a61-8072-116e18f1a864">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDkx_122ce800-9ef3-4d06-a1c9-8e8da1308bb5">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDky_8e6fbf07-0150-4eca-9e65-e5670d5fefe3">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MDZhMTYxOWUxNzA3NDU2Zjk0MmFjM2U4ODhkZmE5YTQvdGFibGVyYW5nZTowNmExNjE5ZTE3MDc0NTZmOTQyYWMzZTg4OGRmYTlhNF8wLTAtMS0xLTM2MDk4_cd3e54cb-93ae-40fb-a0dd-e6d0bef91c48">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MDZhMTYxOWUxNzA3NDU2Zjk0MmFjM2U4ODhkZmE5YTQvdGFibGVyYW5nZTowNmExNjE5ZTE3MDc0NTZmOTQyYWMzZTg4OGRmYTlhNF8xLTctMS0xLTM2MDk4_945ed3b0-d9b7-4fe4-9126-5a107e8f5ef0">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MDZhMTYxOWUxNzA3NDU2Zjk0MmFjM2U4ODhkZmE5YTQvdGFibGVyYW5nZTowNmExNjE5ZTE3MDc0NTZmOTQyYWMzZTg4OGRmYTlhNF8yLTctMS0xLTM2MDk4_1dd57e93-633e-4595-b84d-e35924715e7a">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg1_645f973d-6134-4e21-a15a-bfb998a5486c">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Yes  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg2_7d43fda4-9d57-4ac3-9f5c-c06dd8d4a2ea">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Aggregate market value of the common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of the last business day of the Registrant's most recently completed second fiscal quarter: approximately $<ix:nonFraction unitRef="usd" contextRef="i333cc430d5f24f45a3a99e2e1060db9c_I20210630" decimals="-6" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yODYz_235bf960-80b1-4713-93e7-6cdeaa8c052e">193,649,000,000</ix:nonFraction>.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of shares of common stock outstanding as of February&#160;18, 2022: <ix:nonFraction unitRef="shares" contextRef="id1a06f9ea4dd4dcabf049aeb8fab3e59_I20220218" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yOTIy_57f6881d-1404-4a2d-973d-56c4969c904f">952,347,126</ix:nonFraction></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDkz_a5812c85-3d39-4f80-b208-a9d2f1a0e236" escape="true">Portions of the Registrant's Proxy Statement for the 2022 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.</ix:nonNumeric></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2021 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_16">Part I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_19">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_19">Business</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_22">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_25">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_28">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_28">Properties</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_28">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_31">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_31">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_34">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_34">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_37">Part II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_40">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_40">Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_40">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_46">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_46">[Reserved]</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_46">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_52">Item 7.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_52">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_52">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_79">Item 7A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_79">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_82">Item 8.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_82">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_82">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_181">Item 9.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_181">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_181">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_184">Item 9A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_184">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_184">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_187">Item 9B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_187">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_187">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_1934">Item 9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_1934">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_1934">118</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_190">Part III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_193">Item 10.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_193">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_193">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_196">Item 11.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_196">Executive Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_196">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_199">Item 12.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_199">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_199">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_205">Item 13.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_205">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_205">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_208">Item 14.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_208">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_208">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_211">Item 15.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_211">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_211">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_214">Item 16.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_214">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1a85401413cf428bb86d28ee6b337a59_214">123</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under "Business," "Risk Factors," and "Management's Discussion and Analysis of Results of Operations and Financial Condition" includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "intend," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact and outcome of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">devaluations in foreign currency exchange rates, changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">asset impairments and restructuring charges;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance problems or government investigations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should also carefully read the factors described under Item 1A, "Risk Factors" in this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause our actual results to differ from those expressed in forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Item 1A, "Risk Factors" to be a complete statement of all potential risks and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Annual Report and are expressly qualified in their entirety by the risk factors and cautionary statements included in this Annual Report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part I</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_19"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment&#8212;human pharmaceutical products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and 7 other countries. Our products are sold in approximately 120 countries.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diabetes products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog Mix 75/25,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog U-100,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog U-200,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog Mix 50/50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">insulin lispro,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">insulin lispro protamine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> insulin lispro mix 75/25, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human insulin analogs for the treatment of diabetes. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Humulin 70/30, Humulin N, Humulin R, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humulin U-500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human insulins of recombinant DNA origin for the treatment of diabetes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; and to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults with heart failure and reduced ejection fraction.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the first-line treatment, in combination with two other agents, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations; for the first-line treatment, in combination with another agent, of advanced non-squamous NSCLC; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent for the treatment of malignant pleural mesothelioma.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for use as monotherapy or in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma; in combination with another agent as a second-line treatment of metastatic NSCLC; in combination with another agent as a second-line treatment of metastatic colorectal cancer; as a monotherapy as a second-line treatment of hepatocellular carcinoma; and in combination with another agent as a first-line treatment of adult patients with metastatic NSCLC with activating epidermal growth factor receptor mutations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, indicated both as monotherapy and in combination with another agent for the treatment of certain types of colorectal cancers; and as monotherapy, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of metastatic NSCLC in adult patients; for the treatment of advanced metastatic medullary thyroid cancer who require systemic therapy in adult and pediatric patients; and for the treatment of advanced metastatic thyroid cancer in adult and pediatric patients who require systemic therapy and are radioactive iodin-refractory.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Innovent Biologics, Inc., for the treatment of relapsed or refractory classic Hodgkin's lymphoma and for the first-line treatment of non-squamous NSCLC in combination with Alimta and another agent in China.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer and in combination with endocrine therapy for treatment of HR+, HER2-, node positive, early breast cancer at high risk of recurrence and a Ki-67 score at least 20%, as determined by a U.S. Food and Drug Administration (FDA) approved test.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunology products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Incyte Corporation, for the treatment of adults with moderately-to-severely active rheumatoid arthritis and for moderate to severe atopic dermatitis. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Baricitinib</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted Emergency Use Authorization (EUA) in 2021 for the treatment of COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adults and pediatric patients aged 6 years or older with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuroscience products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for migraine prevention and the treatment of episodic cluster headache in adults.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other therapies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Bamlanivimab </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> etesevimab</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, administered together, for the treatment of mild-to-moderate COVID-19 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in adults and pediatric patients from birth to 12 years old with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death (EUA granted in 2021). In January 2022, the FDA revised the EUA for bamlanivimab and etesevimab administered together to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to this combination treatment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Bebtelovimab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older and weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate (EUA granted in 2022).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of erectile dysfunction and benign prostatic hyperplasia.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Distribution</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell most of our products worldwide. We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our major products in the U.S. through sales representatives who engage with physicians and other health care professionals. We also educate healthcare providers about our products in various other ways, including promoting in online health care channels, distributing literature and samples of certain products to physicians, and exhibiting at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels with information about our major products. We supplement our employee sales force with contract sales organizations to leverage our resources and reach additional patients in need.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. We enter into arrangements with these organizations providing for discounts or rebates on our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. In 2021, 2020, and 2019, three wholesale distributors in the U.S.&#8212;McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc.&#8212;each accounted for between 15 percent and 20 percent of our consolidated revenue. No other customer accounted for more than 10&#160;percent of our consolidated revenue in any of these years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., we promote our products to healthcare providers primarily through sales representatives and other health care channels. While the products we market vary from country to country, diabetes products constitute the largest single group of our consolidated revenue. Distribution patterns for our products also vary from country to country. In most countries in which we operate, we maintain our own sales organizations, but in some smaller countries we market our products through third-party distributors, some of which we have engaged through distribution and promotion arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are marketed in arrangements with other pharmaceutical companies.  For example, we and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Trajenta, Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jardiance, Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XR, and Basaglar. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Item 8, "Financial Statements and Supplementary Data - Note 4, Collaborations and Other Arrangements."</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products compete globally with many other pharmaceutical products in highly competitive markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important competitive factors include effectiveness, safety, and ease of use; formulary placement, price, and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products, processes, modalities, and uses. Most new products that we introduce must compete with other branded, biosimilar, or generic products already on the market or that are later developed by competitors. When competitors introduce new products or delivery systems with therapeutic or cost advantages, including by developing new modalities, our products become subject to decreased sales, progressive price reductions, or both. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our long-term competitive success depends on discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment. There can be no assurance that our efforts will result in commercially successful products, and it is possible that our products will be, or will become, uncompetitive from time to time as a result of products developed by our competitors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Pharmaceuticals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the biggest competitive challenges we face is from generic pharmaceuticals. In the U.S. and Europe, the regulatory approval process for pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product. As a result, generic manufacturers generally invest far fewer resources than we do in research and development and can price their products significantly lower than our branded products. Accordingly, when a branded non-biologic pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product, which can cause us to lose a significant portion of the product's revenue in a very short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, public and private payers typically encourage the use of generics as alternatives to brand-name drugs in their healthcare programs. Laws in the U.S. generally allow, and in many cases require, pharmacists to substitute generic drugs that have been rated under government procedures to be essentially equivalent to a brand-name drug. Where substitution is mandatory, it must be made unless the prescribing physician expressly forbids it. In many countries outside the U.S., intellectual property protection is weak, and we must compete with generic or counterfeit versions of our products relatively shortly after launch. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products and potential new medicines in our clinical-stage pipeline are biologics. In the U.S., the FDA regulates biologics under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, and implementing regulations. Competition for Lilly's biologics may be affected by the approval of follow-on biologics, also known as biosimilars. A biosimilar is a subsequent version of an approved innovator biologic that, due to its analytical and clinical similarity to the innovator biologic, may be approved based on an abbreviated data package that relies in part on the full testing required of the innovator biologic. Approval by the FDA ultimately depends on many factors, including a showing that the biosimilar is "highly similar" to the original product and has no clinically meaningful differences from the original product in terms of safety, purity, and potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, most governments have developed abbreviated regulatory pathways to approve biosimilars as follow-ons to innovator-developed biologics, including the Biologics Price Competition and Innovation Act of 2009 (the BPCIA) in the U.S. A number of biosimilars have been licensed under the BPCIA and in Europe. The patent and regulatory exclusivity for the existing innovator biologic generally must expire in a given market before biosimilars may enter that market. However, in the U.S., the product exclusivity period under the BPCIA could be affected by recent government proposals and litigation. See "- Patents, Trademarks, and Other Intellectual Property Rights." In addition, the extent to which a biosimilar, once approved, will be substituted for the innovator biologic in a way that is similar to traditional generic substitution for non-biologic products is not yet entirely clear, and will depend on a number of regulatory and marketplace factors that are still developing. In the U.S., currently only a biosimilar product that is determined to be "interchangeable" by the FDA will be considered substitutable for the original biologic product without the intervention of the health care provider who prescribed the original biologic product. To prove that a biosimilar product is interchangeable, the applicant must demonstrate that the product can be expected to produce the same clinical results as the original biologic product in any given patient, and if the product is administered more than once in a patient, that safety risks and potential for diminished efficacy of alternating or switching between the use of the interchangeable biosimilar biologic product and the original biologic product is no greater than the risk of using the original biologic product without switching. The FDA has begun to issue "interchangeable" designations for biosimilar products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars may present both competitive challenges and opportunities. For example, a competitor company has developed a version of insulin lispro that competes with our product Humalog. On the other hand, in collaboration with Boehringer Ingelheim, we developed Basaglar, an insulin glargine product, which has the same amino acid sequence as a product currently marketed by a competitor and has launched as a follow-on biologic in the U.S., and as a biosimilar in Europe and Japan. However, in March 2020, the FDA began regulating all of our insulin products as "biologics" rather than "drugs." Based on FDA draft guidance, this change may lessen the amount of data required for competitor biosimilar products to enter the market, some of which could be designated as interchangeable and therefore substituted for our insulin products at U.S. pharmacies. For example, in June 2020, the FDA approved a New Drug Application (NDA) for Semglee, a follow-on insulin glargine product that competes with Basaglar in the U.S., and, in July 2021, Semglee received additional FDA approval as a biosimilar that is interchangeable to its reference insulin glargine product. The FDA's interpretation of important aspects of the laws regulating biosimilars continues to evolve and, therefore, the impact of these laws on our business remains subject to substantial uncertainty.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Private Sector Dynamics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. private sector, consolidation and integration among healthcare providers significantly affects the competitive marketplace for pharmaceuticals. Health plans, managed care organizations, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer) to control costs by negotiating discounted prices in exchange for formulary inclusion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles. Consequently, pharmaceutical companies face increased pressure in pricing and usage negotiation, and compete fiercely for formulary placement, not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates. As payers and pharmaceutical companies continue to negotiate formulary placement and pricing, value-based agreements, where pricing is based on achievement (or not) of specified outcomes, are another tool that may become increasingly prevalent. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. We expect these downward pricing pressures will continue to negatively affect our consolidated results of operations. In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans and higher co-insurance or co-pays. For additional information on pricing and reimbursement for our pharmaceutical products, see "- Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access - U.S."</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks, and Other Intellectual Property Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines. We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes. In addition, as discussed below, for some products we have effective intellectual property protection in the form of data protection under pharmaceutical regulatory laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent protection anticipated to be of most relevance to pharmaceuticals is provided by national patents claiming the active ingredient (the compound patent), particularly those in major markets such as the U.S., major European countries, and Japan. These patents may be issued based upon the filing of international patent applications, usually filed under the Patent Cooperation Treaty (PCT). Patent applications covering compounds are generally filed during the Discovery Phase of the drug discovery process, which is described in the "Research and Development" section below. In general, national patents in each relevant country are available for a period of 20 years from the filing date of the PCT application, which is often years prior to the launch of a commercial product. Further patent term adjustments and restorations may extend the original patent term:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent term adjustment is a statutory right available to all U.S. patent applicants to provide relief in the event that a patent grant is delayed during examination by the United States Patent and Trademark Office (USPTO).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent term restoration is a statutory right provided to U.S. patent holders that claim inventions subject to review by the FDA. To make up for a portion of the time invested in clinical trials and the FDA review process, a single patent for a pharmaceutical product may be eligible for patent term restoration. Patent term restoration is limited by a formula and cannot be calculated until product approval due to uncertainty about the duration of clinical trials and the time it takes the FDA to review an application. There is a five-year cap on any restoration, and no patent's expiration date may be extended beyond 14 years from FDA approval. Some countries outside the U.S. similarly offer forms of patent term restoration for patents claiming inventions subject to a local review by a regulatory agency. For example, Supplementary Protection Certificates are available to extend the life of a European patent up to an additional five years (subject to a 15-year cap from European Medicines Agency (EMA) approval). Also, in Japan, South Korea, and Australia, patent terms can be extended up to five years, depending on the length of regulatory review and other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of effective patent protection for pharmaceuticals, especially for non-biologic products, typically results in the loss of effective market exclusivity for the product, which often results in severe and rapid decline in revenues for the product. However, in some cases the innovator company may retain exclusivity despite approval of the generic, biosimilar, or other follow-on versions of a new medicine beyond the expiration of the compound patent through manufacturing trade secrets, later-expiring patents on manufacturing processes, methods of use or formulations, or data protection that may be available under pharmaceutical regulatory laws. Changes to the laws and regulations governing these protections could result in earlier loss of effective market exclusivity. The primary forms of data protection are as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory authorities in major markets generally grant data package protection for a period of years following new drug approvals in recognition of the substantial investment required to complete clinical trials. Data package protection prohibits other manufacturers from submitting regulatory applications for marketing approval in reliance on the innovator company's regulatory submission data for the drug. The base period of data package protection depends on the country. For example, the period is generally five years in the U.S. (12 years for new biologics as described below), effectively 10 years in Europe, and eight years in Japan. The period begins on the date of product approval and runs concurrently with the patent term for any relevant patent.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the BPCIA, the FDA has the authority to approve biosimilars. A competitor seeking approval of a biosimilar must file an application to show its molecule is highly similar to an approved innovator biologic and include a certain amount of safety and efficacy data that the FDA will consider on a case-by-case basis. Under the data protection provisions of this law, the FDA cannot approve a biosimilar application until 12 years after initial marketing approval of the innovator biologic, subject to certain conditions. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the U.S., the FDA has the authority to grant additional data protection for approved drugs where the sponsor conducts specified testing in pediatric or adolescent populations within a specified time period. If granted, this "pediatric exclusivity" provides an additional six months of exclusivity, which is added to the term of data protection and, for products other than biologics, to the term of any relevant patents, to the extent these protections have not already expired. While the term of the pediatric exclusivity attaches to the term of any relevant patent, pediatric exclusivity is a regulatory exclusivity&#8212;i.e., a bar to generic or biosimilar approval, not a patent right.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the U.S. orphan drug law, a specific use of a drug or biologic can receive "orphan" designation if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or affecting more than 200,000&#160;people but not reasonably expected to recover its development and marketing costs through U.S. sales. Among other benefits, orphan designation entitles the particular use of the drug to seven years of market exclusivity, meaning that the FDA cannot (with limited exceptions) approve another marketing application for the same drug for the same indication until expiration of the seven-year period. Unlike pediatric exclusivity, the orphan exclusivity period is independent of and runs in parallel with any applicable patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the major markets, the adequacy and effectiveness of intellectual property protection for pharmaceuticals varies widely, and in a number of these markets we are unable to patent our products or to enforce the patents we receive for our products. Under the Trade-Related Aspects of Intellectual Property Agreement (TRIPs) administered by the World Trade Organization, more than 140 countries have agreed to provide non-discriminatory protection for most pharmaceutical inventions and to assure that adequate and effective rights are available to patent owners. Certain developing countries limit protection for biopharmaceutical products under their interpretation of "flexibilities" allowed under the agreement. Thus, some types of patents, such as those on new uses of compounds or new forms of molecules, are not available in certain developing countries. Further, many developing countries, and some developed countries, do not provide effective data package protection even though it is specified in TRIPs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property Portfolio</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider intellectual property protection for certain products, processes, uses, and formulations&#8212;particularly with respect to those products discussed below&#8212;to be important to our operations. In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, devices, or uses that extend exclusivity beyond the dates shown below. For approved products, dates include, where applicable, pending or granted patent term extensions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most relevant U.S. patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alimta is protected by pediatric exclusivity (2022). See Item 8, "Financial Statements and Supplementary Data - Note 16, Contingencies," for information regarding our settlement agreement with Eagle Pharmaceuticals, Inc. and its impact on our exclusivity for Alimta.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Baqsimi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by data protection (2022).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza is protected by a compound patent and biologics data protection (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality is protected by a compound patent (2033) and biologics data protection (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance, and the related combination product Glyxambi, is protected by a compound patent (2028). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant is protected by a compound patent (2032). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo is protected by a compound patent (2037) and by data protection (2025).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by a compound patent (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz is protected by a compound patent (2030) and by biologics data protection (2028).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio is protected by a compound patent (2031) and by data protection (2022).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., important patent protection or data protection includes: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Baqsimi is protected by data protection in Japan (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza is protected by a compound patent (2028) and by data protection (2024) in major European countries, and by a compound patent (2026) and by data protection (2023) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality is protected by a compound patent (2033) and by data protection (2028) in major European countries, and by a compound patent (2035) and by data protection (2029) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance is protected by a compound patent in major European countries (2029) and Japan (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant is protected by a compound patent (2032) and by data protection (2027) in major European countries, and by a compound patent (2033) and by data protection (2025) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo is protected by a compound patent (2037) and by data protection (2031) in major European countries, and by a compound patent (2038) and by data protection (2029) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow is protected by a compound patent (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and by data protection (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz is protected by a compound patent (2031) and data protection (2027) in major European countries and a compound patent (2030) and data protection (2024) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicity is protected by a compound patent (2029) and by data protection (2024) in major European countries and by a compound patent (2029) and by data protection (2023) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio is protected by a compound patent (2033) and data protection (2028) in major European countries and by a compound patent (2034) and data protection (2026) in Japan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following product candidates are currently under regulatory review. Upon approval, we expect relevant compound patent and data protections to apply:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have commenced a rolling submission in the U.S. for donanemab for the treatment of Alzheimer's disease.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have commenced a rolling submission in the U.S. for pirtobrutinib (LOXO-305) for the treatment of mantle cell lymphoma.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow has been submitted for regulatory review in certain major European countries for the acute treatment of migraine.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tirzepatide has been submitted for regulatory review in the U.S., in Japan, and in certain major European countries as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, we sell all of our major products under trademarks consisting of our product names, logos, and unique product appearances (e.g., the appearance of our Trulicity autoinjector) which we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms. Trademark protection typically extends beyond the patent and data protection for a product. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Licenses and Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our major products are not subject to significant license and collaboration agreements. For information on our license and collaboration agreements, see Item 8, "Financial Statements and Supplementary Data - Note 4, Collaborations and Other Arrangements." </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Challenges </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, authorizes the FDA to approve generic versions of innovative pharmaceuticals (other than biologics, which are discussed below in more detail) when the generic manufacturer has not conducted safety and efficacy studies but files an Abbreviated New Drug Application (ANDA). In an ANDA, the generic manufacturer must demonstrate only "pharmaceutical equivalence" and "bioequivalence" between the generic version and the NDA-approved drug&#8212;not safety and efficacy. Establishing pharmaceutical equivalence and bioequivalence is generally straightforward and inexpensive for the generic company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent a patent challenge, the FDA cannot approve an ANDA until after certain of the innovator's patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA alleging that one or more or all of the patents listed in the innovator's NDA are invalid or not infringed. This allegation is commonly known as a "Paragraph IV certification." If the innovator responds by filing suit against the generic manufacturer, the FDA is then prohibited from approving the generic company's application for a 30-month period (which can be shortened or extended by the trial court judge hearing the patent challenge). If one or more of the NDA-listed patents are challenged, the first filer(s) of a Paragraph IV certification may be entitled to a 180-day period of market exclusivity over all other generic manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers use Paragraph IV certifications extensively to challenge patents on innovative pharmaceuticals. In addition, generic companies have shown willingness to launch "at risk," i.e., after receiving ANDA approval but before final resolution of their patent challenge.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, the FDA cannot approve an application for a biosimilar product until data protection expires, 12 years after initial marketing approval of the innovator biologic, and an application may not be submitted until four years following the date the innovator biologic was first approved. However, the BPCIA does provide a mechanism for a competitor to challenge the validity of an innovator's patents as early as four years after initial marketing approval of the innovator biologic. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA as well as courts. Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration. Further, in the U.S., the increased likelihood of generic and biosimilar challenges to innovators' intellectual property has increased the risk of loss of innovators' market exclusivity. See also "- Competition - Biosimilars." In addition, there is a procedure in U.S. patent law, known as inter partes review (IPR), which allows any member of the public to file a petition with the USPTO seeking the review of any issued U.S. patent for validity. IPRs are conducted before Administrative Patent Judges in the USPTO using a lower standard of proof than used in federal district court. In addition, the challenged patents are not accorded the presumption of validity as they are in federal district court. Generic drug companies and even some investment firms have engaged in the IPR process in attempts to invalidate our patents. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators. We expect additional changes to the Patent Trial and Appeal Board (PTAB), including potentially to the policy to discretionarily deny an otherwise meritorious petition for IPR in light of a concurrent district court proceeding. See "Risk Factors&#8212;Risks Related to Our Business&#8212;Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the legal doctrines and processes by which pharmaceutical patents can be challenged vary widely. In recent years, we have experienced an increase in patent challenges from generic manufacturers in many countries outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on administrative challenges and litigation involving our intellectual property rights, see Item 8, "Financial Statements and Supplementary Data - Note 16, Contingencies." </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation of Our Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are regulated extensively by numerous national, state, and local agencies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation of Products </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy process of laboratory and clinical testing, data analysis, manufacturing development, and regulatory review necessary for governmental approvals of our products is extremely costly and can significantly delay product introductions and revenue generation. In addition, our operations are subject to complex federal, state, local, and foreign laws and regulations concerning relationships with healthcare providers and suppliers, the environment, occupational health and safety, data privacy, and other matters. Evolving regulatory priorities have intensified governmental scrutiny of our operations, including with respect to current Good Manufacturing Practices (cGMP), quality assurance, and similar regulations. Compliance with the laws and regulations affecting the manufacture and sale of current products and the discovery, development, and introduction of new products will continue to require substantial effort, expense, and capital investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular importance to our business is regulation by the FDA in the U.S. Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act, the FDA has jurisdiction over all of our products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, our products remain subject to regulation by various agencies in connection with labeling, import, export, storage, recordkeeping, advertising, promotion, and safety reporting. We conduct extensive post-marketing surveillance of the safety of the products we sell. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after a product reaches the market. The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA extensively regulates all aspects of manufacturing quality for pharmaceuticals under its cGMP regulations. Outside the U.S., our products and operations are subject to similar regulatory requirements, notably by the EMA in Europe, the Ministry of Health, Labor and Welfare in Japan, and the National Medical Products Administration in China. Specific regulatory requirements vary from country to country. Regulatory requirements and approval processes outside the U.S. may differ from those in the U.S. and may involve additional costs, uncertainties, and risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make substantial investments of capital and operating expenses to implement comprehensive, company-wide quality systems and controls in our manufacturing, product development, and process development operations in an effort to maintain sustained compliance with cGMP and similar regulations. However, in the event we fail to adhere to these requirements, we become subject to potential government investigations, regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals, and reputational harm, any of which would adversely affect our business. Certain of our products are manufactured by third parties, and their failure to comply with these regulations could adversely affect us, including through failure to supply product to us or delays in new product approvals. Any determination by the FDA or other regulatory authorities of manufacturing or other deficiencies could adversely affect our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a variety of federal, state, local, and foreign environmental, health and safety, and other laws and regulations that may affect our research, development or production efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Use Authorizations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secretary of Health and Human Services may authorize unapproved medical products to be manufactured, marketed, and sold in the context of an actual or potential emergency that has been designated by the government. After an emergency has been announced, the Secretary of Health and Human Services may authorize EUAs for the use of specific products based on criteria established by statute, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA is subject to additional conditions and restrictions, such as the obligation to provide fact sheets for healthcare providers administering the product and those to whom it is administered, adverse event monitoring and reporting, and recordkeeping and reporting requirements by product manufacturers. The FDA may also establish additional discretionary conditions of authorization that the FDA deems necessary or appropriate to protect the public health, including conditions related to product distribution, product administration and data collection and analysis concerning the safety and effectiveness of the product. In issuing an EUA, the FDA considers the totality of available scientific evidence regarding quality, safety and efficacy, including the known and potential risks of such products and the adequacy and availability of approved alternatives, among other factors. An EUA is not a substitute for obtaining FDA approval, licensure, or clearance for use of a product. An EUA terminates when the emergency determination underlying the EUA terminates, and EUAs can be revoked under other circumstances, the timing of which may occur unexpectedly or be difficult to predict.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the emergency use of medical products is subject to regulatory processes and requirements that differ from those in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has been designated as a national emergency in the U.S. On the basis of such determination, the Secretary of Health and Human Services declared that circumstances exist justifying the authorization of emergency use of drugs and biologics during the COVID-19 pandemic. The FDA has granted EUAs for bamlanivimab and etesevimab administered together, baricitinib, and bebtelovimab, and similar actions have been taken by other regulators in certain jurisdictions outside the U.S. However, the FDA has revised, and may in the future revise, any EUA for our COVID-19 antibodies in response to the prevalence of variants against which our antibodies have varying degrees of efficacy. For example, in January 2022, the FDA revised the EUA for bamlanivimab and etesevimab administered together to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible to this combination treatment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to various other U.S. federal and state laws, as well as analogous foreign laws and regulations, including the federal anti-kickback statute, the False Claims Act, and state laws governing kickbacks, false claims, unfair trade practices, and consumer protection. These laws are administered by, among others, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services, the Federal Trade Commission, the Office of Personnel Management, and state attorneys general. Over the past several years, state, federal, and foreign governments, agencies, and other regulatory bodies have increased their oversight, enforcement activities, and coordination with respect to pharmaceutical companies, which has resulted in intensified scrutiny, corporate criminal sanctions, and substantial civil settlements in the pharmaceutical industry. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Office of Inspector General of the U.S. Department of Health and Human Services and the Centers for Medicare &amp; Medicaid Services (CMS) issued final rules expanding and modifying existing, and adding new, regulatory "safe harbors" and exceptions, respectively, under the anti-kickback statute and the Ethics in Patient Referrals Act. We are currently evaluating the impact, if any, these regulatory amendments will have upon becoming effective on our consolidated results of operations, liquidity, and financial position, which is uncertain at this time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits certain individuals and entities, including U.S. publicly traded companies, from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage. The FCPA also imposes specific recordkeeping and internal controls requirements on U.S. publicly traded companies. As noted above, outside the U.S., our business is heavily regulated and therefore involves significant interaction with foreign officials. Additionally, in many countries outside the U.S., healthcare providers who prescribe pharmaceuticals are employed by the government and purchasers of pharmaceuticals are government entities; therefore, our interactions with these prescribers and purchasers are subject to regulation under the FCPA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the U.S. application and enforcement of the FCPA, the various jurisdictions in which we operate and supply our products have laws and regulations aimed at preventing and penalizing corrupt and anticompetitive behavior. In recent years, several jurisdictions have enhanced their laws and regulations in this area, increased their enforcement activities, and/or increased the level of cross-border coordination and information sharing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and could in the future become subject to administrative and legal proceedings and actions, which could include claims for civil penalties (including treble damages under the False Claims Act), criminal sanctions, and administrative remedies, including exclusion from U.S. federal and other health care programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a variety of federal, state, local, and foreign environmental, health and safety, and other laws and regulations that may affect our research, development or production efforts. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be considerable public and government scrutiny of pharmaceutical pricing, and measures to address the perceived high cost of pharmaceuticals are being considered at various levels of state and federal government. In addition, U.S. government action to reduce federal spending on entitlement programs, including Medicare and Medicaid, may affect payment for our products or services associated with the provision of our products. Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, or private payers could also adversely impact our business and financial results. For example, in January 2022, the CMS proposed a national coverage determination (NCD) decision memorandum stating that the proposed NCD would cover FDA approved monoclonal antibodies that target amyloid for the treatment of Alzheimer's disease for people with Medicare only if they are enrolled in qualifying clinical trials (the Alzheimer&#8217;s Monoclonal Antibody NCD). If finalized in its current form, the proposed Alzheimer&#8217;s Monoclonal Antibody NCD would result in reduced coverage for, and negatively impact, our product candidate donanemab, and may negatively impact our business and financial results. The regulatory priorities of the current U.S. presidential administration could further intensify these efforts, which could have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we are required to provide rebates to the federal government and respective state governments on their purchases of our pharmaceuticals under various federal and state healthcare programs, including state Medicaid and Medicaid Managed Care programs (minimum of 23.1 percent plus adjustments for price increases over time) and discounts to private entities who treat patients in certain types of health care facilities intended to serve low-income and uninsured patients (known as 340B facilities). No rebates are required at this time in the Medicare Part B (physician and hospital outpatient) program where reimbursement is set on an "average sales price plus 4.3 percent" formula. Additionally, an annual fee is imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs. Since 2019, the Bipartisan Budget Act has required manufacturers of brand-name drugs, biologics, and biosimilars to provide a discount of 70 percent of the cost of branded prescription drugs for Medicare Part D participants who are in the "doughnut hole" (the coverage gap in Medicare prescription drug coverage).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are also negotiated in the private sector. We pay rebates to private payers that provide prescription drug benefits to seniors covered by Medicare and to private payers that provide prescription drug benefits to their customers. These rebates are affected by the introduction of competitive products and generics in the same class. Our approach to the rebates we offer to private payers that provide prescription drug benefits to seniors covered by Medicare may be impacted by the 2020 regulatory amendments to the anti-kickback statute's discount safe harbor, which have currently been stayed until at least January 1, 2026. Pending legislation could repeal the amendments to the discount safe harbor. Accordingly, their impact on our business is uncertain at this time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, public and private payers are increasingly restricting access to pharmaceuticals based on assessments of comparative effectiveness and value, including through the establishment of formal health technology assessment processes. In addition, third-party organizations, including professional associations, academic institutions, and non-profit entities associated with payers, are conducting and publishing comparative effectiveness and cost/benefit analyses on medicines, the impact of which are uncertain at this time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most international markets, we operate in an environment of government-mandated cost-containment programs, which may include price controls, international reference pricing (to other countries' prices), discounts and rebates, therapeutic reference pricing (to other, often generic, pharmaceutical choices), restrictions on physician prescription levels, and mandatory generic substitution. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative, regulatory, or payer developments. However, in general we expect to see continued focus on regulating pricing resulting in additional state, federal, and international legislative and regulatory developments that could have further negative effects on pricing and reimbursement for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access" for additional information regarding recent legislative, administrative, and other pricing initiatives and their impact on our results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to research and development dates back more than 140 years. We invest heavily in research and development because we believe it is critical to our long-term competitiveness. At the end of 2021, we employed approximately 8,100 people in pharmaceutical research and development activities, including a substantial number of physicians, scientists holding graduate or postgraduate degrees, and highly skilled technical personnel. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal pharmaceutical research focuses primarily on the areas of diabetes, immunology, neuroscience, and oncology. During the past two years, we have also focused on researching and developing potential treatments for COVID-19. In addition to discovering and developing new medicines, we seek to expand the value of existing products through new uses, formulations, and therapeutic approaches that provide additional value to patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies. We use the services of physicians, hospitals, medical schools, and other research organizations worldwide to conduct clinical trials to establish the safety and effectiveness of our medicines. We also invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including, among others, licensing arrangements, co-development agreements, co-promotion arrangements, joint ventures, acquisitions, and equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical development is time-consuming, expensive, and risky. Very few of the candidates discovered by researchers ultimately become approved medicines. The process from discovery to regulatory approval can take over a decade. Candidates can fail at any stage of the process, and even late-stage candidates sometimes fail to receive regulatory approval or achieve commercial success. The following describes in more detail the research and development process for pharmaceutical products:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phases of New Drug Development</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">Discovery Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discovery phase, scientists identify, design, and synthesize promising candidates by analyzing their effect on biological targets thought to play a role in disease. Targets are often unproven and only candidates that have the desired effect on the target and meet other design criteria move to the next phase of development, which includes the initiation of studies in animals to support regulatory and safety requirements for clinical research in humans. The discovery phase can take years and the probability of any one candidate becoming a medicine is extremely low.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Early Development Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early development includes initial testing for safety and efficacy and early analyses of manufacturing requirements. Safety testing is initially performed in laboratory tests and animals, as necessary. In general, the first human tests (often referred to as Phase I) are conducted in small groups of subjects to assess safety and evaluate the potential dosing range. Subsequently, larger populations of patients are studied (Phase II) to identify initial signs of efficacy while continuing to assess safety. In parallel, scientists work to identify safe, effective, and economical manufacturing processes. Long-term animal studies continue to test for potential safety issues. Of the candidates that enter the early development phase, approximately 10 percent move to the late development phase. The early development phase varies but can take several years to complete.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Late Development Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Late phase development projects (typically Phase III) have met initial safety requirements and shown initial evidence of efficacy in earlier studies. As a result, these candidates generally have a higher likelihood of success and trials include larger patient populations to demonstrate safety and efficacy in the disease. These studies are designed to demonstrate the benefit and risk of the potential new medicine and may be compared to competitive therapies, placebo, or both. Phase III studies are generally conducted globally and are designed to support regulatory filings for marketing approval. The duration of Phase III testing varies by disease and may take two to four years.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Submission Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a potential new medicine is submitted to regulatory agencies, the time to final marketing approval can vary from several months to several years, depending on the disease state, the strength and complexity of available data, the degree of unmet need, and the time required for the regulatory agency(ies) to evaluate the submission, which can depend on prioritization by regulators and other factors. There is no guarantee that a potential medicine will receive marketing approval, or that decisions on marketing approvals or indications will be consistent across geographic areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our investments in research, both internally and in collaboration with others, have resulted in a robust pipeline of potential new medicines and new treatment indications in all stages of development. We currently have approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 new medicine </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase. See Item 7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - Late-Stage Pipeline," for more information on certain of our product candidates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials and Product Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw or intermediate materials primarily from only one source. We generally seek to maintain sufficient inventory to supply the market until an alternative source of supply could be implemented, in the event one of these suppliers was unable to provide the materials or product. However, various developments from time to time lead to interruption or shortages in supply until we establish new sources or, in some cases, implement alternative processes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue comes from products produced in our own facilities. Our principal active ingredient manufacturing occurs at sites we own in the U.S., including Puerto Rico, and Ireland. Finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at a number of sites throughout the world. We utilize third parties for certain active ingredient manufacturing and finishing operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that is intended to allow us to meet substantially all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain a stable supply of our products, we use a variety of techniques including comprehensive quality systems, inventory management, and back-up sites.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, developments such as unplanned plant shutdowns, manufacturing or quality assurance difficulties at one of our facilities or contracted facilities, failure or refusal of a supplier or contract manufacturer to supply contracted quantities, increases in demand on a supplier, or difficulties in predicting or variability in demand for our products, from time to time lead to interruption or higher costs in the supply of certain products or product shortages. Further, global transportation and logistics challenges, as well as tight labor markets, have caused, and in the future may cause, delays in, and/or increase costs related to, distribution of our medicines, the construction or acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements. For more information on the additional risks we face in connection with any difficulties, disruptions, and shortages in the manufacturing, distribution, and sale of our products, see "Risk Factors - Risks Related to Our Business - Manufacturing and supply chain difficulties, disruptions, or shortages could lead to product supply problems."</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the strain on global transportation, logistics, and labor markets caused by the COVID-19 pandemic and an increase in overall demand in our industry for certain materials have had, and may continue to have, a number of impacts on our business, including increased costs to provide a consistent supply of our medicines where they are needed and disruptions in the supply of our medicines. For more information, see Item 1A, "Risk Factors - Risks Related to Our Business - The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business and operations. We are currently unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat will adversely impact our business and operations in the future." and Item 7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - COVID-19 Pandemic."</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Assurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in great measure on customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness. Product quality arises from a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, distribution, and dissemination of information about our medicines. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality of production processes involves strict control of ingredients, equipment, facilities, manufacturing methods, packaging materials, and labeling. We perform tests at various stages of production processes and on the final product in an effort to ensure that the product meets all applicable regulatory requirements and our internal standards. These tests may involve chemical and physical chemical analyses, microbiological testing, testing in animals, or a combination thereof. Additional assurance of quality is provided by quality assurance groups that audit and monitor all aspects of quality related to pharmaceutical manufacturing procedures and systems in company operations and at third-party suppliers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Company</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding our current executive officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of office for each executive officer expires on the date of the annual meeting of the board of directors, to be held on May 2, 2022 in connection with the company's annual meeting of shareholders, or on the date his or her successor is chosen and qualified. No director or executive officer has a "family relationship" with any other director or executive officer of the company, as that term is defined for purposes of this disclosure requirement. There is no understanding between any executive officer or director and any other person pursuant to which the executive officer was selected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.597%"><tr><td style="width:1.0%"></td><td style="width:16.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Titles and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">David A. Ricks</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer (CEO) (since 2017). Previously, Mr. Ricks held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 25 years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anat Ashkenazi </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (since 2021). Previously, Ms. Ashkenazi held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 20 years of service with Lilly. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stephen F. Fry</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President, Human Resources and Diversity (since 2011). Previously, Mr. Fry held various leadership roles with Lilly, including vice president, human resources. Mr. Fry has 34 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anat Hakim</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Secretary (since 2020). Prior to joining Lilly, Ms. Hakim was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has two years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Edgardo Hernandez</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and President, Manufacturing Operations (since 2021). Previously, Mr. Hernandez held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patrik Jonsson</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and President, Lilly Immunology, Lilly USA, and Chief Customer Officer (since 2021). Previously, Mr. Jonsson held various leadership roles with Lilly, including senior vice president and president, Lilly USA, and chief customer officer, senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 31 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael B. Mason </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and President, Lilly Diabetes (since 2020). Previously, Mr. Mason held various leadership roles with Lilly, including senior vice president, connected care and insulins and vice president of U.S. Diabetes. Mr. Mason has 32 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johna L. Norton</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Global Quality (since 2017). Previously, Ms. Norton held various leadership roles with Lilly, including vice president, global quality assurance API manufacturing and product research and development. Ms. Norton has 31 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leigh Ann Pusey</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Corporate Affairs and Communications (since 2017). Prior to joining Lilly, Ms. Pusey was president and chief executive officer of the American Insurance Association from 2009 to 2017. Ms. Pusey has four years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diogo Rau</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and Chief Information and Digital Officer (since 2021). Prior to joining Lilly, Mr. Rau was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey &amp; Company.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Daniel M. Skovronsky, M.D., Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories (since 2021). Previously, Dr. Skovronsky held various leadership roles with Lilly, including senior vice president, chief scientific officer, and president, Lilly Research Laboratories, and senior vice president, clinical and product development. Dr. Skovronsky has 11 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jacob Van Naarden</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, CEO Loxo Oncology at Lilly, and President, Lilly Oncology (since 2021). Previously, Mr. Van Naarden served as Chief Executive Officer-Loxo Oncology at Lilly, and Chief Operating Officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has three years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alonzo Weems</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer (since 2021). Previously, Mr. Weems held various leadership roles with Lilly, including vice president and deputy general counsel for corporate legal functions, general counsel for Lilly USA, and general counsel for biomedicines and diabetes. Mr. Weems has </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anne E. White</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President and President, Lilly Neuroscience (since 2021). Previously, Ms. White held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development. Ms. White has 26 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ilya Yuffa</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President and President, Lilly International (since 2021). Previously, Mr. Yuffa held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer since 2014. Mr. Yuffa has 25 years of service with Lilly.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core values&#8212;integrity, excellence, and respect for people&#8212;shape our approach to attracting, retaining, engaging, and developing a highly skilled and ethical workforce, which is critical to executing our strategy. We believe the strength of our workforce significantly contributes to our financial performance and enables us to make life better for people around the world. For instance, most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We believe that fostering a positive culture that values the contributions of our talented colleagues helps drive our success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to creating a safe, supportive, ethical, and rewarding work environment through strategic focus on our human capital management process, fairness and nondiscrimination in our employment practices, robust training and development opportunities, and competitive pay and benefits. We believe our dedication to promoting diversity, equity, and inclusion (DEI) within our company reflects our values and is a key driver of business success and growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly conduct anonymous employee surveys to seek feedback from our workforce on a variety of topics. These results are reviewed and analyzed by our leaders in order to implement changes to our policies and benefits designed to improve our employees' well-being. As a result of our efforts, we believe that we have a highly performing, cohesive workforce and that our employee relations are good.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2021, we employed approximately 35,000 people, including approximately 19,600 employees outside the U.S. Our employees include approximately 8,100 people engaged in research and development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy and Oversight</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build diverse and inclusive teams, our CEO and executive committee set expectations for inclusive leadership and hold leaders accountable for achieving results. Because dedication to human capital management is also a core component of our corporate governance, our board of directors regularly engages with management and facilitates a system of reporting designed to monitor human capital management initiatives and progress as part of the overarching framework that guides how we attract, retain, engage, and develop a workforce that aligns with our values and mission. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to fairness and nondiscrimination in our employment practices, and we deeply value diverse backgrounds, skills, and global perspectives. To fulfill our purpose, we believe we must look at challenges from multiple viewpoints and understand the diverse experiences of the patients who depend on us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that fostering DEI begins with understanding. For example, our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Journeys </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research has yielded important insights about the experiences of women, Black/African American, Latinx, Asian, and LGBTQ+ employees at Lilly. The results of this research are reviewed by our senior leadership, and we deploy actions and activities in response to these insights to improve our workplace and corporate culture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, as part of our DEI and community initiatives, Lilly and the Lilly Foundation launched the Racial Justice Commitment and pledged $25 million and 25,000 volunteer hours over five years to help decrease the burden of racial injustice and its effects on communities of color. The Racial Justice Commitment aims to drive change across five areas: internal people development, health equity, social impact, diversity partners, and family sustaining jobs, through the use of financial and people resources. In 2021, we made progress in these efforts, including through the development of two apprenticeship programs at Lilly for individuals without college degrees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017, we have committed to increasing the number of women, Black/African American, Latinx, and Asian populations in leadership roles, and we actively monitor our progress. From the end of 2017 through the end of 2021, we increased the percentage of women in management globally from 41 percent to 48 percent. For minority group members (MGM) in the U.S. over the same period, we increased management representation from 16 percent to 24 percent. Across all levels of our workforce, from the end of 2017 through the end of 2021, we have seen increased representation for MGMs in the U.S. and women globally. Our focus on DEI is also evident at our executive committee and board of directors. Five of 15 current members (approximately 33 percent) of our executive committee (which includes our CEO) are women and two are MGM. In addition, as of the filing of this report, the company's 13-member board of directors includes four women and six members who are MGMs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts in DEI and workplace benefits have garnered numerous recognitions, including, in 2021, Top 50 Companies for Diversity by DiversityInc., America's Best Employers for Diversity by Forbes, America's Most JUST Companies and Forbes JUST 100 by Forbes and JUST Capital, Perfect Score on the Human Rights Campaign Foundation Corporate Equality Index, World's Most Ethical Companies by Ethisphere, Leading Disability Employer by the National Organization on Disability, Top Employers by Science Magazine, and 100 Best Companies, Top Companies for Executive Women, Best Companies for Dads, and Best Companies for Multicultural Women by Working Mother Magazine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe talent begins with the hiring process. We therefore require hiring managers to consider a diverse pool of candidates and we strive to provide a diverse panel of interviewers for open positions. We believe that hiring in this way helps ensure that people from all backgrounds have equal opportunity to advance their careers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer training to enable our employees to perform their duties in our highly regulated industry. We also strive to cultivate a culture that promotes ongoing learning by encouraging employees to seek further education and growth experiences, helping them build rewarding careers. We have introduced online programming to facilitate access to our learning and development offerings. Many training courses are designed to improve accessibility for people with disabilities and other unique needs. Across Lilly, we are working to design learning experiences to be more inclusive and effective. In addition, we have implemented tools and resources and improved our talent programs and processes to provide broad access to information and transparency regarding career development and advancement at Lilly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we launched </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discover</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a 12-month new employee onboarding program with multiple touchpoints designed to foster integration into the Lilly culture, to accelerate learning in their new roles and to create connections to further a sense of belonging at Lilly. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discover</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was shaped in part by external benchmarking, feedback from employees, and learnings from onboarding remotely during the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee resource groups (ERGs) are another important component of developing talent at Lilly. We currently have 11 ERGs representing groups including women, MGMs, LGBTQ+ individuals, veterans, and people with disabilities. ERGs offer our diverse workforce opportunities to build relationships, engage with senior leaders, advance our caring community, and offer unique insights and perspectives to improve our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have continued our efforts to create an inclusive workplace with the goal of ensuring that all employees feel safe to speak up and share their ideas at work. Our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Make it Safe to Thrive </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">education and awareness program is designed to help employees and leaders understand how individual psychological safety can be created and enhanced and includes live and online training and a monthly video series.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly is committed to fostering a culture of diversity and respect in the workplace&#8212;an environment free of discrimination, harassment, or retaliation of any kind. In 2022, as part of our annual review of The Red Book (Lilly's comprehensive code of business conduct applicable to our board and all employees worldwide) and related policies and procedures, we revised the Global Conduct in the Workplace procedure to continue to help ensure that we maintain a respectful, safe, inclusive, and professional workplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Health and Safety</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to foster a healthy, vibrant work environment, which includes keeping our employees safe. We seek to create a companywide culture where best-in-class safety practices are consistently followed. To do this, we assess and continuously attempt to improve our companywide safety performance to promote the well-being of employees and to help safeguard communities where we operate. As the COVID-19 pandemic has evolved, we have taken various measures to protect and support the health and safety of our employees globally, including instituting travel restrictions and work-from-home arrangements, offering onsite testing and vaccination options where possible, and instituting safety precautions such as masking, social distancing, and enhanced cleaning practices. To support employee well-being in the U.S., we also enhanced local benefits related to health care, childcare, and time off. We believe this holistic approach and dedication to safety helps us be our best as we deliver on our company purpose to improve lives around the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Available on Our Website</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company website is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">www.lilly.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the information accessible on or through our website is incorporated into this Annual Report on Form 10-K. We make available through the website, free of charge, our company filings with the SEC as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. These include our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents. The link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paper copies of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that are filed with the SEC are available without charge upon written request to:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c/o General Counsel and Secretary</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Corporate Center</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana 46285</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Governance portion of our website includes our corporate governance guidelines, board of directors and committee information (including committee charters), and our articles of incorporation and bylaws. The link to our corporate governance information is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">lilly.com/leadership/governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">22</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information contained in this Annual Report on Form 10-K, the following risk factors should be considered carefully in evaluating our company. It is possible that our business, financial condition, liquidity, cash flows, or results of operations could be materially adversely affected by any of these risks. Certain of these risks could also adversely affect the company's reputation. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could also adversely affect our business and reputation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business and operations. We are currently unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat will adversely impact our business and operations in the future.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to burden healthcare systems worldwide. The focus of resources on COVID-19, widespread protective measures implemented to control the spread of COVID-19, and the resulting strain on global transportation, manufacturing, and labor markets have negatively impacted development, manufacturing, supply, distribution, and sales of our medicines.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although in-person interactions with healthcare professionals have largely resumed, we continue to see a lack of "normal" access and fewer in-person interactions by patients and our employees with healthcare professionals. As the COVID-19 pandemic continues to develop, we may decide to halt such in-person interactions in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strain on global transportation, logistics, and labor markets caused by the COVID-19 pandemic and an increase in overall demand in our industry for certain materials resulting in changed buying patterns and constrained supply have had, and may continue to have, a number of impacts on our business, including increased costs to provide a consistent supply of our medicines where they are needed and disruptions and shortages in the supply of our medicines. These factors may negatively affect our results of operations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks and uncertainties related to our COVID-19 therapies, including heightened regulatory scrutiny of our manufacturing practices, quality assurance, and similar regulations, restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. In addition, expedited authorization processes have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available may call into question the safety or effectiveness of our COVID-19 therapies. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures such as vaccines, coupled with the unpredictable nature of pandemics, have and could further negatively impact or eliminate demand for our COVID-19 therapies. We also expect that additional revenue from the sale of bamlanivimab and etesevimab after the first quarter of 2022 will be limited. Mutations or the spread of other variants of the coronavirus have in some cases impacted the effectiveness of our COVID-19 therapies, and may further render our therapies more or less effective or ineffective. Furthermore, the FDA has revised, and may in the future revise, any EUA for our COVID-19 therapies in response to the prevalence of variants against which our therapies have varying degrees of efficacy. These and other risks related to COVID-19 could affect other aspects of our business or intensify other risks inherent in our business, including potentially resulting in delays or denials in the approval or launch of other products or indications.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It remains difficult to reasonably assess or predict the full extent of the ongoing impact of the COVID-19 pandemic on us. The degree to which the COVID-19 pandemic continues to affect us will depend on developments that are highly uncertain and beyond our knowledge or control, including, but not limited to, the duration and severity of the pandemic, the actions taken to reduce its transmission, including widespread availability and efficacy of vaccines, the introduction and spread of new variants of the coronavirus that may be resistant to currently approved vaccines, the continuation of existing or implementation of new government restrictions and the speed with which, and extent to which, more stable economic and operating conditions resume. Should the COVID-19 pandemic, or any future pandemic, epidemic, or similar public health threat, and any associated supply chain disruption, labor </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market impact, recession, or depression continue for a prolonged period, these risks could be exacerbated, causing further impact on our business and operations in the future.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will soon lose intellectual property protection or are displaced by competing products or therapies.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products, and business development activities to enhance our product pipeline. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products and indications.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot state with certainty when or whether our products now under development will be approved or launched; whether, if initially granted, such approval will be maintained; whether we will be able to develop, license, or otherwise acquire additional product candidates or products; or whether our products, once launched, will be commercially successful. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must maintain a continuous flow of successful new products and successful new indications or brand extensions for existing products, both through our internal efforts and our business development activities, sufficient both to cover our substantial research and development costs and to replace revenues that are lost as profitable products lose intellectual property exclusivity or are displaced by competing products or therapies. Failure to do so in the short-term or long-term would have a material adverse effect on our business, results of operations, cash flows, and financial position.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in various forms of business development activities to enhance our product pipeline, including licensing arrangements, co-development agreements, co-promotion arrangements, joint ventures, acquisitions, and equity investments. There are substantial risks associated with identifying successful business development targets and consummating related transactions. Increased focus on business combinations in our industry, including by the Federal Trade Commission, and heightened competition for attractive targets has and could continue to delay, jeopardize or increase the costs of our business development activities. In addition, failures or difficulties in integrating or retaining new personnel or the operations of the businesses, products, or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing, distribution, and general business operations and procedures) may affect our ability to realize the expected benefits of business development transactions and may result in our incurrence of substantial asset impairment or restructuring charges. We also may fail to generate the expected revenue and pipeline enhancement from business development activities due to developments outside our control, including unsuccessful clinical trials, issues related to the quality, integrity, or broad applicability of data, regulatory impediments, and commercialization challenges. Accordingly, business development transactions may not be completed in a timely manner (if at all), may not result in successful commercialization of any product, and may give rise to legal proceedings or regulatory scrutiny.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1, "Business - Research and Development - Phases of New Drug Development" and Item 7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - Late-Stage Pipeline," for more details about our current product pipeline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or soon will lose effective intellectual property protection for a number of our products, which has resulted and is likely to continue to result in rapid and severe declines in revenues.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products, including Alimta and Forteo, have recently lost, or soon will lose, significant patent protection and/or data protection in the U.S. as well as in key jurisdictions outside the U.S. We have faced, and remain exposed to, generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item&#160;7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters," and Item 1, "Business - Patents, Trademarks, and Other Intellectual Property Rights," for more details. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market. Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering pharmaceutical products. As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act. The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain. However, if our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win provides limited precedential value at the PTAB and no precedential value in federal district court, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. In addition, intellectual property protection in certain jurisdictions outside the U.S. is weak and we face additional risks to our intellectual property rights, including competition with generic or counterfeit versions of our products relatively shortly after launch. See Item 1, "Business - </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents, Trademarks, and Other Intellectual Property Rights," and Item 8, "Financial Statements and Supplementary Data - Note 16: Contingencies," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We and our products face intense competition from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with a large number of multinational pharmaceutical companies, biotechnology companies, and generic pharmaceutical companies and, in many cases, our products compete against the leading products of one or more of our competitors. To compete successfully, we must continue to deliver to the market innovative, cost-effective products that meet important medical needs. Our product revenues can be adversely affected by the introduction by competitors of branded products that are perceived as superior by the marketplace, by generic or biosimilar versions of our branded products, and by generic or biosimilar versions of other products in the same therapeutic class as our branded products. Our revenues can also be adversely affected by treatment innovations that eliminate or minimize the need for treatment with our drugs.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, recent health authority guidelines and legislative proposals could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars. In the U.S., the FDA has begun issuing "interchangeability" designations for biosimilar products, which could &#8211; subject to state law requirements &#8211; enable pharmacies to substitute biosimilars for innovator biological products. Given the importance of biologic products to our clinical-stage pipeline, such regulation could have a material adverse effect on our business. See Item 1, "Business - Competition" and "Business - Research and Development," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on our ability to attract, engage, and retain highly qualified and skilled personnel in order to compete effectively. To continue to commercialize our products, and advance the research, development, and commercialization of additional modalities and product candidates, we may need to expand our workforce, including in the areas of manufacturing, clinical trials management, regulatory affairs, and sales and marketing, both in and outside the U.S. We continue to face intense competition for qualified individuals from numerous multinational pharmaceutical companies, biotechnology companies, academic and other research institutions, as well as employers near our manufacturing and other facilities, which has and may continue to increase our labor costs. Our ability to attract and retain talent in our increasingly competitive environment may be further complicated by evolving employment trends arising from the COVID-19 pandemic, including vaccination mandates, increased preferences for remote, alternative, or flexible work arrangements, and other factors. Our failure to compete effectively for talent could negatively affect sales of our current and any future approved products, and could result in material financial, legal, commercial, or reputational harm to our business.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could each result in material harm to our business and reputation.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A great deal of confidential information owned by us or our business partners or other third parties is stored in our information systems, networks, and facilities or those of third parties. This includes valuable trade secrets and intellectual property, clinical trial information, corporate strategic plans, marketing plans, customer information, and personally identifiable information, such as employee and patient information (collectively, confidential information). We also rely, to a large extent, on the efficient and uninterrupted operation of complex information technology systems, infrastructure, and hardware (together, IT systems), some of which are within our control and some of which are within the control of third parties, to accumulate, process, store, and transmit large amounts of confidential information and other data. We are subject to a variety of continuously evolving and developing laws and regulations around the world related to privacy, data protection, and data security. Maintaining the security, confidentiality, integrity and availability of our IT systems and confidential information is vital to our business. Our failure, or the failure of our third party service providers, to protect and maintain the security, confidentiality, integrity, and availability of our (or their) IT systems and our confidential information and other data could significantly harm our reputation as well as result in significant costs, including those related to fines, litigation, and obligations to comply with applicable data breach laws.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT systems are vulnerable to system inadequacies, operating failures, service interruptions or failures, security breaches, malicious intrusions, or cyber-attacks from a variety of sources. Cyber-attacks are growing in their frequency, sophistication, and intensity, and are becoming increasingly difficult to detect, mitigate, or prevent. Cyber-attacks come in many forms, including the deployment of harmful malware, exploitation of vulnerabilities (including those of third-party software or systems), denial-of-service attacks, the use of social engineering, and other means to compromise the confidentiality, integrity and availability of our IT systems, confidential information, and other data. Breaches resulting in the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure or use of confidential information, or the unauthorized access to, disruption of, or interference with our IT systems, products and services, can occur in a variety of ways, including but not limited to, negligent or wrongful conduct by employees or others with permitted access to our systems and information, or wrongful conduct by hackers, competitors, certain governments or nation-states, or other current or former company personnel. Our third-party partners, including third-party providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third parties with whom we may share data, face similar risks, which could affect us directly or indirectly. The healthcare industry has been and continues to be a target for cyber-attacks, and the number of threats has only increased over time. Numerous federal agencies that monitor and regulate internet and cyber-crime have issued guidance, alerts and directives warning of software vulnerabilities that require immediate patching, malicious actors targeting healthcare related systems and nation-state sponsored hacking designed to steal valuable information.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages. Unauthorized disclosure of personally identifiable information could expose us to significant sanctions for violations of data privacy laws and regulations around the world and could damage public trust in our company. In addition, IT system security in jurisdictions outside the U.S. is weaker and may result in additional costs, uncertainties, and risks. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, system inadequacies, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, cyber-attacks, and the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure or use of confidential information have not had a material impact on our consolidated results of operations. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption or breach of our IT systems. We continue to implement measures in an effort to protect, detect, respond to, and minimize or prevent these risks and to enhance the resiliency of our IT systems; however, these measures may not be successful and we may fail to detect or remediate security breaches, malicious intrusions, cyber-attacks, or other compromises of our systems. Any of these events could result in material financial, legal, commercial, or reputational harm to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Significant economic downturns or international trade and other global disruptions or disputes could adversely affect our business and operating results.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While pharmaceuticals have generally been less sensitive to overall economic cycles, prolonged economic slowdowns could lead to decreased utilization of our products, affecting our sales volume. Declining tax revenues attributable to economic downturns increase the pressure on governments to reduce health care spending, leading to increasing government efforts to control drug prices and utilization. Additionally, some customers, including governments or other entities reliant upon government funding, may be unable to pay for our products in a timely manner. Also, if our customers, suppliers, or collaboration partners experience financial difficulties, we could experience slower customer collections, greater bad debt expense, and performance defaults by suppliers or collaboration partners. Similarly, in the event of a significant economic downturn, we could have difficulty accessing credit markets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant portions of our business are conducted in Europe, including the United Kingdom, in Asia, including China, and in other international geographies. Trade and other global disputes and interruptions in international relationships, including related to tariffs, trade protection measures, import or export licensing requirements, the imposition of trade sanctions or similar restrictions by the U.S. or other governments, unrest or war, as well as pandemic diseases, such as COVID-19, affect our ability to do business. For example, tensions between the U.S. and China have led to a series of tariffs and sanctions being imposed by the U.S. on imports from China mainland, as well as other business restrictions. These and similar events could adversely affect us, or our business partners or customers.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical products can develop unexpected safety or efficacy concerns, which could have a material adverse effect on our revenues, income, and reputation.&#160;</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. After approval, the products are used for longer periods of time by much larger numbers of patients. Accordingly, we and others (including regulatory agencies and private payers) collect extensive information on the efficacy and safety of our marketed products by continuously monitoring the use of our products in the marketplace. In addition, we or others may conduct post-marketing clinical studies on efficacy and safety of our marketed products. New safety or efficacy data from both market surveillance and post-marketing clinical studies may result in product label changes or other measures that could reduce the product's market acceptance and result in declining sales. Serious safety or efficacy issues that arise after product approval have, and could in the future, result in voluntary or mandatory product recalls or withdrawals from the market. Safety issues have, and could in the future, result in costly product liability claims. See also " - The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business and operations. We are currently unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat will adversely impact our business and operations in the future."</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We face litigation and investigations related to our products, how we price our products, and how we commercialize our products; we could face large numbers of claims in the future, which could adversely affect our business, and we are self-insured for such matters. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a substantial number of product liability claims involving various current and historical products, litigation and investigations related to how we commercialize and/or how we price our products, including relating to our 340B drug pricing program, as well as contractual disputes. See Item&#160;8, "Financial Statements and Supplementary Data - Note 16, Contingencies" for more information on our current product liability litigation, as well as pricing litigation, investigations, and inquiries. Because of the nature of pharmaceutical products, we are and could in the future become subject to large numbers of product liability claims for our previous, current, or future products, or to further litigation or investigations, including related to pricing or other commercial practices. Such matters could affect our results of operations or require us to recognize substantial charges to resolve and, if involving marketed products, could adversely affect sales of the product. Due to a very restrictive market for liability insurance, we are self-insured for litigation liability losses for all our currently marketed products, as well as for litigation or investigations related to our pricing practices or other similar matters. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing and supply chain difficulties, disruptions, or shortages could lead to product supply problems.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical manufacturing is complex and highly regulated. Manufacturing or quality assurance difficulties at our facilities or contracted facilities, the failure or refusal of a supplier or contract manufacturer to supply contracted quantities, or increases in demand on a supplier could result in delays and disruptions in the manufacturing, distribution, and sale of our products and/or product shortages, leading to lost revenue. Further, global transportation and logistics challenges, as well as tight labor markets, have caused, and in the future may cause, delays in, and/or increase costs related to, distribution of our medicines, the construction or other acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements. Such difficulties, disruptions, or challenges could result from quality, oversight, or regulatory compliance problems; natural disasters or pandemic disease; equipment, mechanical, data, or information technology system vulnerabilities, such as system inadequacies, inadequate controls or procedures, operating failures, service interruptions or failures, security breaches, malicious intrusions, or cyber-attacks from a variety of sources; labor shortages; contractual disputes with our suppliers and contract manufacturers; or inability to obtain single-source or other raw or intermediate materials. In addition, difficulties in predicting or variability in demand for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and indications and the very long lead times necessary for the expansion and regulatory qualification of pharmaceutical manufacturing capacity from time to time result in difficulty meeting demand for, or disruptions, shortages, and higher costs in the supply of, our products. See Item 1, "Business - Raw Materials and Product Supply," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Reliance on third-party relationships and outsourcing arrangements could adversely affect our business. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties, including suppliers, distributors, alliances, and collaborations with other pharmaceutical and biotechnology companies, and third-party service providers, for selected aspects of product and clinical development, manufacturing, commercialization, hosting of, and support for, information technology systems, product distribution, and certain financial transactional processes. As examples, we outsource the day-to-day management and oversight of some of our clinical trials to contract research organizations and the distribution of our products through logistics providers.&#160;Outsourcing these functions involves the risk that the third parties may not perform to our standards or legal requirements; may not produce reliable results; may not perform in a timely manner; may not maintain the confidentiality, integrity, and availability of confidential and proprietary information relating to us, our clinical trial subjects, or patients; may experience disruption or fail to perform due to information technology system vulnerabilities, breaches, cyber-attacks, or inadequate controls or procedures; may be unable to satisfy their commitments to us in which case we may not be able to achieve acceptable alternative sourcing; or may fail to perform at all. The foregoing risks may be heightened in jurisdictions outside the U.S., where we may face additional costs, uncertainties, and risks. Failure of these third parties to meet their contractual, regulatory, confidentiality, privacy, security, or other obligations to us, our clinical trial subjects, and our patients could have a material adverse effect on our business. </span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our reputation or business.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private payers continue to take aggressive steps to control their expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, our medicines. These pressures could continue to negatively affect our future revenues and net income. Governments and private payers worldwide have intensified their scrutiny of, and actions intended to address, pricing, reimbursement, and access to pharmaceutical products. Additional policies, regulations, legislation, or enforcement, including as a result of the regulatory priorities of the current U.S. presidential administration and other regulatory authorities worldwide, could adversely impact our business and revenue. For example, pending legislation in the U.S. could result in government negotiation of the price of some of our medicines, including insulin. Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, or private payers, such as the recently proposed Alzheimer&#8217;s Monoclonal Antibody NCD, may adversely impact our business and financial results. However, we cannot predict the likelihood, nature, or extent of current and future health care reform efforts. We also may continue to experience potential additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more details, see Item 1, "Business - Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access," Item&#160;7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access," and Item 8, "Financial Statements and Supplementary Data - Note 16: Contingencies."</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Changes in foreign currency rates, interest rate risks, or inflation could materially affect our results of operations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, interest rate risk from our exposure to floating and variable interest rates, and inflation risk from existing and expected rates of inflation in the U.S. and other jurisdictions. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates, interest rates, and inflation can have a material impact, either positive or negative, on our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations. Further, in the event of an extreme devaluation of local currency, the price of our products could become unsustainable in the relevant market. In addition, the discontinuation, modification, or other reform of the London Interbank Offered Rate (LIBOR), or the replacement of LIBOR with a different reference rate, could increase our interest expense, decrease our cash flows, and/or require us to amend certain of our existing agreements. See Item 7, "Management's Discussion and Analysis - Financial Condition and Liquidity" and Item 8, "Financial Statements and Supplementary Data - Note 1: Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard" for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Changes in tax laws or exposure to additional tax liabilities could increase our income taxes and decrease our net income.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and numerous foreign jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events. Changes in tax laws, regulations, administrative practices, principles, and interpretations, as well as events that differ from our expectations, have affected and may adversely affect our effective tax rates, cash flows, and/or and results of operations. For example, in December 2017, the U.S. enacted tax reform legislation significantly revising U.S. tax laws, and a number of other countries are also actively considering or enacting tax changes. Significant uncertainty currently exists regarding proposed tax policies of the current U.S. presidential administration and Congress, including modifications to certain aspects of the 2017 tax law. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions, which could unfavorably impact our results of operations. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Cooperation and Development and the European Commission could influence tax laws in countries in which we operate. Modifications to key elements of the current U.S. or international tax framework could have a significant impact on our effective tax rate, results of operations, and cash flows. See Item 7, "Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Tax Matters" and Item 8, "Financial Statements and Supplementary Data - Note 14: Income Taxes," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Regulatory compliance problems could be damaging to the company.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to extensive regulation. Many companies, including us, have been subject to claims related to these practices asserted by federal, state, and foreign governmental authorities, private payers, and consumers. These claims have resulted in substantial expense and other significant consequences to us. We are and could in the future become subject to such investigations, the outcomes of which could include criminal charges and fines, penalties, or other monetary or non-monetary remedies, including exclusion from U.S. federal and other health care programs. Such investigations have intensified and may continue to intensify as a result of the regulatory priorities of the current U.S. presidential administration and other regulatory authorities worldwide. In addition, regulatory issues concerning compliance with cGMP, quality assurance, and similar regulations (and comparable foreign regulations) for our products can lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products or supplemental approvals of current products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. Regulatory compliance and processes in jurisdictions outside the U.S. may also be less predictable and result in additional costs, uncertainties, and risks. See Item 1, "Business - Government Regulation of Our Operations," for more details. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">30</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_28"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal domestic and international executive offices are located in Indianapolis. At December&#160;31, 2021, we owned 9 production and distribution sites in the United States (U.S.), including Puerto Rico. Together with the corporate administrative offices, these facilities contain an aggregate of approximately 8.1 million square feet of floor area dedicated to production, distribution, and administration. Major production sites include Indianapolis, Indiana; Carolina, Puerto Rico; and Branchburg, New Jersey.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own production and distribution sites in 7 countries outside the U.S., containing an aggregate of approximately 4.7&#160;million square feet of floor area. Major production sites include facilities in Ireland, France, Spain, Italy, and China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our research and development facilities contain an aggregate of approximately 4.4 million square feet of floor area, primarily consisting of owned facilities located in Indianapolis and smaller leased sites primarily in San Diego, California; San Francisco, California; and New York, New York. Outside the U.S., we own a small research and development facility in Spain and lease a small site in Singapore.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that none of our properties is subject to any encumbrance, easement, or other restriction that would detract materially from its value or impair its use in the operation of the business. The buildings we own are of varying ages and in good condition.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_31"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. Information pertaining to legal proceedings is described in Item 8, "Financial Statements and Supplementary Data - Note 16: Contingencies," and incorporated by reference herein. </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_34"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">31</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part II</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_40"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related stockholder matters is described in Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" and Item 12, "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters." This information is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 18, 2022, there were approximately 20,641 holders of record of our common stock based on information provided by EQ Shareowner Services, our transfer agent. Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the fourth quarter ended December&#160;31, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(in&#160;thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid<br/>per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate&#160;Dollar&#160;Value<br/>of&#160;Shares&#160;that&#160;May&#160;Yet&#160;Be<br/>Purchased Under the<br/>Plans or Programs<br/>(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2021</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.70&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 46pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 46pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,889.1</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.70&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 46pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,750.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, we repurchased the remaining $500.0 million of shares available under the $8.00 billion share repurchase program authorized in June 2018 and $250.0 million of shares available under the $5.00 billion share repurchase program authorized in May 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">32</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE GRAPH</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the return on Lilly stock with that of the Standard&#160;&amp; Poor's (S&amp;P) 500 Stock Index and our peer group for the years 2017 through 2021. The graph assumes that, on the last business day of 2016, a person invested $100 each in Lilly stock, the S&amp;P 500 Stock Index, and the peer group's collective common stock. The graph measures total shareholder return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are immediately reinvested in that company's stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Value of $100 Invested on Last Business Day of 2016 Comparison of Five-Year Cumulative Total Shareholder Return Among Lilly, S&amp;P 500 Stock Index, and Peer Group</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span><br/></span></div><div style="text-align:center"><img src="lly-20211231_g1.jpg" alt="lly-20211231_g1.jpg" style="height:434px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.598%"><tr><td style="width:1.0%"></td><td style="width:16.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lilly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peer&#160;Group</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P&#160;500</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-16</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-18</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.50&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.85&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.49&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-20</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.93&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.47&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.35&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">We constructed the peer group as the industry index for this graph. It is comprised of the following companies in the pharmaceutical and biotechnology industries: AbbVie Inc.; Amgen Inc.; AstraZeneca PLC; Biogen Inc.; Bristol-Myers Squibb Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson&#160;&amp; Johnson; Merck&#160;&amp; Co., Inc.; Novartis AG.; Novo Nordisk A/S; Pfizer Inc.; Roche Holding AG; Sanofi S.A.; and Takeda Pharmaceutical Company Limited. The peer group used for performance benchmarking aligns with the peer group used for executive compensation purposes for 2021 other than our peer group for performance benchmarking excludes Allergan plc, Celgene Corporation, and Shire plc as they were acquired in 2020, 2019 and 2019, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">33</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_52"></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Management's Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with Item 8, "Financial Statements and Supplementary Data." Certain statements in this Item 7 constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item&#160;1A, "Risk Factors," may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have focused on maintaining a supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin. As part of our response to the COVID-19 pandemic, and at the request of the United States (U.S.) and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUA) for bamlanivimab and etesevimab administered together for higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19 and for baricitinib for treatment with or without remdesivir in hospitalized COVID-19 patients. In the third quarter of 2021, the FDA expanded the EUA for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection. We expect that additional revenue from the sale of bamlanivimab and etesevimab after the first quarter of 2022 will be limited. In February 2022, the FDA granted an EUA for bebtelovimab for certain high-risk patients who have been recently diagnosed with mild-to-moderate COVID-19. We have agreed with the U.S. government to supply up to 600,000 doses of bebtelovimab no later than March 31, 2022 for at least $720 million with an option of 500,000 additional doses no later than July 31, 2022. The FDA has revised, and may in the future revise, any EUA for our COVID-19 therapies in response to the prevalence of variants against which our therapies have varying degrees of efficacy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has, and may continue to, adversely impact our business and operations. The focus of resources on COVID-19, widespread protective measures implemented to control the spread of COVID-19, and the resulting strain on global transportation, manufacturing, and labor markets have negatively impacted development, manufacturing, supply, distribution, and sales of our medicines. In addition to decreases in new prescriptions, changes in payer segment mix, and the increased use of patient affordability programs in the U.S., we have experienced, and may continue to experience if the COVID-19 pandemic undergoes resurgent or more severe waves, decreased demand as a result of lack of "normal" access and fewer in-person interactions by patients and our employees with healthcare professionals. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks and uncertainties related to our COVID-19 therapies, including heightened regulatory scrutiny of our manufacturing practices, quality assurance, and similar regulations, restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures such as vaccines, coupled with the unpredictable nature of pandemics, have and could further negatively impact or eliminate demand for our COVID-19 therapies. Mutations or the spread of other variants of the coronavirus have in some cases impacted the effectiveness of our COVID-19 therapies, and may further render our therapies more or less effective or ineffective. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strain on global transportation, logistics, and labor markets caused by the COVID-19 pandemic and an increase in overall demand in our industry for certain materials resulting in changed buying patterns and constrained supply have had, and may continue to have, a number of impacts on our business, including increased costs to provide a consistent supply of our medicines where they are needed and potential disruptions in the supply of our medications. These factors may negatively affect our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It remains difficult to reasonably assess or predict the full extent of the ongoing impact of the COVID-19 pandemic on us. The degree to which the COVID-19 pandemic continues to affect us will depend on developments that are highly uncertain and beyond our knowledge or control. We are currently unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact our business and operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A, "Risk Factors" for additional information on risk factors that could impact our business and operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:54.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.697%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,005.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,457.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,206.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">874.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">201.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,171.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,155.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,229.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,581.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,193.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased in 2021 driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. Operating expenses, defined as the sum of research and development and marketing, selling, and administrative expenses, increased in 2021, driven primarily by higher development expenses for late-stage assets. The decreases in net income and EPS in 2021 were driven primarily by reduction in other-net, (income) expense and higher operating expenses, partially offset by higher gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items affect comparisons of our 2021 and 2020 financial results:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales (See Note 6 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $339.7&#160;million. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired In-Process Research and Development (IPR&amp;D) (Note 3 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $874.9 million related to business development transactions. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $316.1 million primarily related to an impairment of a contract-based intangible asset from our acquisition of Loxo Oncology, Inc. (Loxo), an intangible asset impairment resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (Note 18 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a debt extinguishment loss of $405.2 million related to the repurchase of debt. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $176.9 million of net investment gains on equity securities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2020 </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (Note 3 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $660.4 million related to business development transactions. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $131.2 million primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (Note 18 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $1.44 billion of net investment gains on equity securities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certain new molecular entities (NMEs) are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review in the U.S., Europe, or Japan. The following table reflects the status of certain NMEs, including certain other developments since our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COVID-19 Antibodies</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bebtelovimab (LY-CoV1404)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA granted EUA for certain high-risk patients recently diagnosed with mild-to-moderate COVID-19 in February 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. using a priority review voucher and in Europe and Japan in 2021. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GGG Tri-Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GLP-1R NPA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in 2021 that Phase III trials met primary and all key secondary endpoints. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's Disease</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in 2021 that Phase III trials met primary and all key secondary endpoints. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-2 Conjugate</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ulcerative colitis</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PD-1 MAB Agonist</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatoid arthritis</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neuroscience</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submission initiated </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Initiated a rolling submission in the U.S. for accelerated approval in 2021. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epiregulin/TGF&#945; MAB</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in the Prevail acquisition in 2021. Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O-glc-NAcase</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the fourth quarter of 2021.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 Antagonist</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In February 2022, the Oncologic Drugs Advisory Committee recommended that the FDA require additional clinical trials prior to a final regulatory decision.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib (LOXO-305)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submission initiated</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated a rolling submission in the U.S. for accelerated approval in the fourth quarter of 2021. Phase II and Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell malignancies</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imlunestrant</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER+HER2- metastatic breast cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Almirall, S.A. in Europe. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Innovent Biologics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">38</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_1893"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products for use in the indication described are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review in the U.S., Europe, or Japan. The following table reflects the status of certain NILEX products, including certain other developments since our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td></tr><tr style="height:75pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in the U.S. and Europe in 2021 and in Japan in January 2022. The FDA granted priority review for adults with heart failure independent of left ventricular ejection fraction.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing. </span></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. and the FDA granted priority review in January 2022.</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in U.S., Europe and Japan in 2021.</span></div></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in January 2022 that, based on top-line efficacy results from Phase III trials,  we discontinued development.</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+, HER2- Adjuvant breast cancer </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in the U.S. and Japan in the fourth quarter of 2021. </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></div></td></tr><tr style="height:45pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+, HER2+ Adjuvant breast cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discontinued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in January 2022 that we will discontinue the Phase III trial in response to the changing treatment landscape and global enrollment challenges.</span></div></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products and indications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage research and development spending across our portfolio of potential new medicines. A delay in, or termination of, any one project will not necessarily cause a significant change in our total research and development spending. Due to the risks and uncertainties involved in the research and development process, we cannot reliably estimate the nature, timing, and costs of the efforts necessary to complete the development of our research and development projects, nor can we reliably estimate the future potential revenue that will be generated from any successful research and development project. Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated research and development expense. While we do accumulate certain research and development costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms. Therefore, we do not have sufficiently reliable data to report on total research and development costs by project, by preclinical versus clinical spend, or by therapeutic category. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, our vitamin regimen patents for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired worldwide. Following the loss of patent exclusivity in major European countries and Japan, we faced, and remain exposed to, generic competition which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. In the U.S., we expect pediatric data exclusivity to provide us with protection through May 2022. However, we and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending U.S. patent litigation, allowing Eagle a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition in the U.S. following the loss of exclusivity will cause a rapid and severe decline in revenue and will have a material adverse effect on our consolidated results of operations and cash flows. See Note 16 to the consolidated financial statements for a more detailed account of the legal proceedings currently pending regarding, among others, our Alimta patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor has similar version of insulin lispro in the U.S. and in certain European markets. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that may continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our formulation and use patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired in major markets. We expect further decline in revenue as a result of the entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulatory data and patent exclusivity for Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in Japan. Beginning in mid-2021, we have faced, and remain exposed to, generic competition which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could adversely impact our future consolidated results of operations and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate, as well as worldwide cost containment efforts by governmental authorities. Such measures may include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In addition, consolidation of private payors in the U.S. has significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price concessions and pharmacy reimbursement rates. Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, or private payers, such as the recently proposed Alzheimer&#8217;s Monoclonal Antibody national coverage determination, may adversely impact our business and financial results. We expect that these actions may intensify and could particularly affect certain products, such as insulin, as governments manage and emerge from the COVID-19 pandemic, which could adversely affect our business. In addition, we are engaged in litigation and investigations related to our 340B program that, if resolved adversely to us, could negatively impact our business and consolidated results of operations. It is not currently possible to predict the overall potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts worldwide. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations and our industry, including with respect to current Good Manufacturing Practices, quality assurance, and similar regulations, and increased focus on business combinations in our industry. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products or supplemental approvals of current products pending resolution of the issues, impediments to the completion of business combinations, and reputational harm, any of which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1, "Business - Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access" and Note 16 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations have affected and may affect our effective tax rate, results of operations, and cash flows. In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contains a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. While this provision of the 2017 Tax Act is expected to have an immaterial impact on our consolidated results of operations, if it is not deferred or repealed by Congress, we expect that the implementation of this provision will increase our cash payments of income taxes by up to $1.50 billion in 2022 and subsequently decrease our cash payments of income taxes moderately over the five-year amortization period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and countries around the world are actively considering and enacting tax law changes. Tax proposals introduced by Congress and the U.S. presidential administration contain significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions, which could adversely impact our future consolidated results of operations and cash flows. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We opportunistically invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including acquisitions, collaborations, investments, and licensing arrangements. We view our business development activity as a way to enhance our pipeline and strengthen our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira, Inc. for a purchase price of $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). In 2021, we sold the rights to Qbrexza. See Note 5 to the consolidated financial statements for additional information regarding the sale of the rights to Qbrexza. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib, an oral RET inhibitor, and LOXO-305 (pirtobrutinib), an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated financial statements for additional information regarding our recent acquisitions.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">42</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results&#8212;2021 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,811.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,507.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S the increase in volume in 2021 was primarily driven by COVID-19 antibodies, Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. the increase in volume in 2021 was primarily driven by Trulicity, Olumiant, COVID-19 antibodies, Verzenio, and Taltz. The decrease in realized prices outside the U.S. was primarily driven by the price impact of the updated National Reimbursement Drug List formulary for certain products, largely Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in China.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity in 2021 compared with 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:35.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside&#160;U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,914.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,557.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,471.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,068.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,320.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,132.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,453.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,978.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,239.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,542.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">670.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,212.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">827.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,061.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">807.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">683.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,490.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">834.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">515.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,349.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">832.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">389.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,222.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">791.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,115.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,033.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">588.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">892.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">441.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">801.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">707.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">718.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">542.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">581.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">577.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">481.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">548.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(5)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">780.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,327.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,811.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,507.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased 28 percent in the U.S., driven by increased demand. Revenue outside the U.S. increased 26 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 11 percent in the U.S., primarily driven by lower realized prices. Humalog's lower realized prices in the U.S. in 2021 were driven by higher contracted rebates and discounts and increased utilization in more highly-rebated government segments, partially offset by lower utilization in the 340B segment. Revenue outside the U.S. decreased 1 percent, driven by decreased volume and, to a lesser extent, lower realized prices, largely offset by the favorable impact of foreign exchange rates. Included in the revenue of Humalog in the U.S. are our own insulin lispro authorized generics. While it is difficult to estimate the severity of the impact of similar insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some price decline and loss of market share to continue over time.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies, treatments for mild to moderate COVID-19 for higher-risk patients and for post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection, was $1.98&#160;billion in the U.S. during the year ended December 31, 2021. Revenue outside the U.S. was $261.4&#160;million during the year ended December 31, 2021. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the unpredictable nature of pandemics, have and could further negatively impact or eliminate demand for these COVID-19 antibodies. The FDA has revised, and may in the future revise, any EUA for our COVID-19 antibodies in response to the prevalence of variants against which our antibodies have varying degrees of efficacy. We expect that additional revenue from the sale of bamlanivimab and etesevimab after the first quarter of 2022 will be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, increased 20 percent in the U.S., driven by increased demand, partially offset by lower realized prices due to increased rebates to gain commercial access. Revenue outside the U.S. increased 34 percent, primarily driven by increased volume. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, decreased 2 percent in the U.S., driven by decreased volume, partially offset by higher realized prices. Revenue outside the U.S. decreased 22 percent, primarily driven by decreased volume due to the entry of generic competition in certain markets and, to a lesser extent, lower realized prices, partially offset by the favorable impact of foreign exchange rates. Following the loss of exclusivity in major European countries and Japan in June 2021, we faced, and remain exposed to, generic competition which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. In the U.S., we expect the limited entry of generic competition starting February 2022 and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition following the loss of exclusivity in the U.S. will cause a rapid and severe decline in revenue. See "Executive Overview - Other Matters- Patent Matters" for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure and reduced ejection fraction, increased 30 percent in the U.S., primarily driven by increased demand. Revenue outside the U.S. increased 28 percent, primarily driven by increased volume. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer and high risk early breast cancer, increased 35 percent in the U.S., driven by increased demand. Revenue outside the U.S. increased 75 percent, driven by increased volume.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humulin, an injectable human insulin for the treatment of diabetes, decreased 4 percent in the U.S., driven by decreased demand and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 1 percent, driven by decreased volume, largely offset by higher realized prices and the favorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Olumiant, a treatment for adults with moderately-to-severely active rheumatoid arthritis, moderate to severe atopic dermatitis, and of baricitinib, a treatment, with or without remdesivir, of hospitalized patients with COVID-19, increased $260.3&#160;million in the U.S., driven by increased volume and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased 38 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. Increased volume worldwide was partially driven by utilization of Olumiant for the treatment of hospitalized patients with COVID-19.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Cyramza, a treatment for various cancers, decreased 6 percent in the U.S., driven by decreased demand, partially offset by higher realized prices. Revenue outside the U.S. increased 4 percent, driven by increased volume, partially offset by lower realized prices. </span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue was 74.2 percent in 2021, a decrease of 3.5 percentage points compared with 2020, driven by higher sales of COVID-19 antibodies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased 15 percent to $7.03 billion in 2021, primarily driven by higher development expenses for late-stage assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses increased 5 percent to $6.43 billion in 2021, primarily due to increased marketing costs to continue to drive growth for certain products, investment in preparation for new launches, and lower marketing activities in 2020 as a result of pandemic-related spending reductions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D charges of $874.9 million and $660.4 million in 2021 and 2020, respectively, related to business development transactions. See Note 3 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $316.1 million in 2021. The charges were primarily related to an impairment of a contract-based intangible asset from our acquisition of Loxo, an intangible asset impairment resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. In 2020, we recognized $131.2 million of asset impairment, restructuring, and other special charges primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8212;net, (income) expense was expense of $201.6 million in 2021 compared to income of $1.17 billion in 2020, primarily driven by lower net investment gains on equity securities and a debt extinguishment loss of $405.2 million related to the repurchase of debt.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate was 9.3 percent in 2021, compared with an effective tax rate of 14.3 percent in 2020, primarily driven by the tax impacts of acquired IPR&amp;D charges, lower net investment gains on equity securities, as well as a net discrete tax benefit. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results&#8212;2020 </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our results of operations pertaining to 2020 and 2019 see Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">46</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND LIQUIDITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements, which include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">working capital requirements, including related to employee payroll, clinical trials, manufacturing materials, and taxes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital expenditures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share repurchases and dividends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repayment of outstanding short-term and long-term borrowings; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contributions to our defined benefit pension and retiree health benefit plans;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">milestone and royalty payments; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential business development activities, including acquisitions, collaborations, investments, and licensing arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management continuously evaluates our liquidity and capital resources, including our access to external capital, to ensure we can adequately and efficiently finance our capital requirements. As of December 31, 2021, our material cash requirements primarily related to purchases of goods and services to produce our products and conduct our operations, capital equipment expenditures, dividends, repayment of outstanding borrowings, milestone and royalty payments, the remaining obligations for the one-time repatriation transition tax (also known as the 'Toll Tax') from the 2017 Tax Act, leases, unfunded commitments to invest in venture capital funds, and retirement benefits (see Notes 11, 4, 14, 10, 7, and 15 to the consolidated financial statements). We anticipate our cash requirements related to ordinary course purchases of goods and services and capital equipment expenditures will be consistent with our past levels relative to revenues. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the 2017 Tax Act contains a provision that requires us to capitalize and amortize research and development expenses for tax purposes, whereas previously we could fully deduct these expenses in the year incurred. While this provision of the 2017 Tax Act is expected to have an immaterial impact on our consolidated results of operations, if it is not deferred or repealed by Congress, we expect that the implementation of this provision will increase our cash payments of income taxes by up to $1.50 billion in 2022 and subsequently decrease our cash payments of income taxes moderately over the five-year amortization period. See "Results of Operations - Executive Overview - Other Matters -Tax Matters" for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to invest more than $1 billion over several years in a new facility in Concord, North Carolina to manufacture parenteral (injectable) products and devices. We plan to invest more than 400 million euros over several years in a new facility in Limerick, Ireland to expand our manufacturing network for biologic active ingredients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents increased to $3.82 billion as of December&#160;31, 2021, compared with $3.66 billion at December&#160;31, 2020. Net cash provided by operating activities was $7.26 billion in 2021, compared with $6.50&#160;billion in 2020. Refer to the consolidated statements of cash flows for additional information on the significant sources and uses of cash for the years ended December&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $3.30 billion and $2.99 billion as of December&#160;31, 2021 and 2020, respectively. See Note 7 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions. This acquisition was funded primarily through cash on hand. See Note 3 to the consolidated financial statements for additional information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total debt was $16.88 billion, an increase of $289.4 million compared with $16.60&#160;billion at December&#160;31, 2020. In September 2021, we issued euro-denominated notes consisting of &#8364;500.0 million of 1.125 percent fixed-rate notes due in September 2051 and &#8364;700.0 million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;250.0 million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91 billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50 billion. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. In addition, in September 2021, we issued euro-denominated notes consisting of &#8364;600.0 million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives. See Note 11 to the consolidated financial statements for additional information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had a total of $5.26 billion of unused committed bank credit facilities, $5.00&#160;billion of which is available to support our commercial paper program. See Note 11 to the consolidated financial statements for additional information. We believe that amounts accessible through existing commercial paper markets should be adequate to fund any short-term borrowing needs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consecutive year, we distributed dividends to our shareholders. Dividends of $3.40 per share and $2.96 per share were paid in 2021 and 2020, respectively. In the fourth quarter of 2021, effective for the dividend to be paid in the first quarter of 2022, the quarterly dividend was increased to $0.98 per share, resulting in an indicated annual rate for 2022 of $3.92 per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures of $1.31 billion during 2021, compared to $1.39 billion in 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we repurchased $1.00 billion of shares, which completed our $8.00 billion share repurchase program authorized in June 2018. Additionally, our board authorized a $5.00 billion share repurchase program in May 2021. In 2021, we repurchased $250.0 million of shares under the $5.00 billion share repurchase program. As of December 31, 2021, we had $4.75 billion remaining under the $5.00 billion share repurchase program. See Note 13 to the consolidated financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Results of Operations - Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; and various international government funding levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates, currency values, and fair values of equity securities. These fluctuations can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of this risk management program is to limit the impact on earnings of fluctuations in interest and currency exchange rates. All derivative activities are for purposes other than trading.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. As of December 31, 2021, substantially all of our total long-term debt carries interest at a fixed rate. We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. Based on our overall interest rate exposure at December&#160;31, 2021 and 2020, including derivatives and other interest rate risk-sensitive instruments, a hypothetical 10 percent change in interest rates applied to the fair value of the instruments as of December&#160;31, 2021 and 2020, respectively, would not have a material impact on earnings, cash flows, or fair values of interest rate risk-sensitive instruments over a one-year period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We&#160;may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates (primarily the euro, the Japanese yen, and Chinese yuan). Our corporate risk-management policy outlines the minimum and maximum hedge coverage of such exposures. Gains and losses on these derivative contracts offset, in part, the impact of currency fluctuations on the existing assets and liabilities. We periodically analyze the fair values of the outstanding foreign currency derivative contracts to determine their sensitivity to changes in foreign exchange rates. A hypothetical 10 percent change in exchange rates (primarily against the U.S. dollar) applied to the fair values of our outstanding foreign currency derivative contracts as of December&#160;31, 2021 and 2020, would not have a material impact on earnings, cash flows, or financial position over a one-year period. This sensitivity analysis does not consider the impact that hypothetical changes in exchange rates would have on the underlying foreign currency denominated transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value risk exposure relates primarily to our public equity investments and to equity investments that do not have readily determinable fair values. As of December 31, 2021 and 2020, our carrying values of these investments were $1.83 billion and $2.04 billion, respectively. A hypothetical 20 percent change in fair value of the equity instruments would have impacted other-net, (income) expense by $365.6 million and $407.6 million as of December 31, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product (e.g., approval for marketing by the appropriate regulatory agency or upon the achievement of certain sales levels). If required by the arrangement, we may make royalty payments based upon a percentage of the sales of the product in the event that regulatory approval for marketing is obtained. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individually, these arrangements are generally not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate expense or aggregate milestone payments made could be material to our results of operations or cash flows, respectively, in that period. See Note 4 to the consolidated financial statements for additional information. These arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves milestone objectives. We also note that, from a business perspective, we view these payments as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flows from sales of products.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">49</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPLICATION OF CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements in accordance with accounting principles generally accepted in the U.S., we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and consequently actual results could differ from those estimates. For any given individual estimate or assumption we make, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. We believe that, given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position, or liquidity for the periods presented in this report. Our most critical accounting estimates have been discussed with our audit committee and are described below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition and Sales Return, Rebate, and Discount Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. For product sales to customers, provisions for returns, rebates and discounts are established in the same period the related product sales are recognized. To determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates. The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the consolidated financial statements for further information on revenue recognition and sales return, rebate, and discount accruals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Our rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet. As of December&#160;31, 2021, a 5 percent change in our consolidated sales return, rebate, and discount liability would have led to an approximate $366 million effect on our income before income taxes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of our consolidated sales return, rebate, and discount liability resulting from sales of our products in the U.S. was approximately 90 percent as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a roll-forward of our most significant U.S. sales return, rebate, and discount liability balances, including managed care, Medicare, Medicaid, chargeback, and patient assistance programs:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:75.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales return, rebate, and discount liabilities, beginning of year</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,400.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,635.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of net sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,106.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,668.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,344.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,903.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales return, rebate, and discount liabilities, end of year</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,161.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments of the estimates for these returns, rebates, and discounts to actual results were less than 1 percent of consolidated revenue for each of the years presented.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Liabilities and Other Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation liabilities and other contingencies are, by their nature, uncertain and based upon complex judgments and probabilities. The factors we consider in developing our litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nature and the number of other similar current and past matters, the nature of the product and the current assessment of the science subject to the litigation, as applicable, and the likelihood of settlement and current state of settlement discussions, if any. In addition, we accrue for certain liability claims incurred, but not filed, to the extent we can formulate a reasonable estimate of their costs based primarily on historical claims experience and data regarding product usage. We accrue legal defense costs expected to be incurred in connection with significant liability contingencies when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibility of and length of time for collection. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently marketed products. In addition to insurance coverage, we consider any third-party indemnification to which we are entitled or under which we are obligated. With respect to our third-party indemnification rights, these considerations include the nature of the indemnification, the financial condition of the indemnifying party, and the possibility of and length of time for collection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether acquisitions or licensing transactions should be accounted for as a business combination or as an asset acquisition, we make certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the acquired set of activities and assets meets the definition of a business, assets acquired and liabilities assumed are required to be recorded at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an acquisition of assets and, therefore, any acquired IPR&amp;D that does not have an alternative future use is charged to expense at the acquisition date, and goodwill is not recorded. See Note 3 to the consolidated financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as estimated asset lives, can materially affect our consolidated results of operations. The fair values of intangible assets, including acquired IPR&amp;D, are determined using information available near the acquisition date based on estimates and assumptions that are deemed reasonable by management. Significant estimates and assumptions include, but are not limited to, probability of technical success, revenue growth and discount rate. Depending on the facts and circumstances, we may deem it necessary to engage an independent valuation expert to assist in valuing significant assets and liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets are primarily determined using an "income method," as described in Note 8 to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of any contingent consideration liability that results from a business combination is primarily determined using a discounted cash flow analysis, as described in Note 7 to the consolidated financial statements. Estimating the fair value of contingent consideration requires the use of significant estimates and judgments, including, but not limited to, probability of technical success and the discount rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, a 5 percent change in the contingent consideration liability would result in a change in income before income taxes of $3.5 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Indefinite-Lived and Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable. We identify impairment by comparing the projected undiscounted cash flows to be generated by the asset (or asset group) to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several methods may be used to determine the estimated fair value of acquired IPR&amp;D, all of which require multiple assumptions. We utilize the "income method," as described in Note 8 to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired IPR&amp;D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in "Results of Operations - Executive Overview - Late-Stage Pipeline." The nature of the pharmaceutical business is high-risk and requires that we invest in a large number of projects to maintain a successful portfolio of approved products. As such, it is likely that some acquired IPR&amp;D assets will become impaired in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates of future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management's judgment. Actual results could vary materially from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefits Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, expected return on plan assets, and retirement age. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 15 to the consolidated financial statements for additional information regarding our retirement benefits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates. In evaluating the expected return on plan assets, we consider many factors, with a primary analysis of current and projected market conditions, asset returns and asset allocations (approximately 75 percent of which are growth investments), and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the discount rates and expected return on plan assets of other companies, where applicable. In evaluating our expected retirement age assumption, we consider the retirement ages of our past employees eligible for pension and medical benefits together with our expectations of future retirement ages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we determine the fair value of the plan assets in our defined benefit pension and retiree health benefit plans. Approximately 38 percent of our plan assets are in hedge funds and private equity-like investment funds (collectively, alternative assets). We value these alternative investments using significant unobservable inputs or using the net asset value reported by the counterparty, adjusted as necessary. Inputs include underlying net asset values, discounted cash flows valuations, comparable market valuations, and adjustments for currency, credit, liquidity and other risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the 2021 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $21.6 million. If the 2021 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $31.5 million. If our assumption regarding the 2021 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affected by $51.1 million. The U.S. plans, including Puerto Rico, represent approximately 80 percent of each of the total projected benefit obligation and total plan assets at December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to the fair value of plan assets are not recognized in pension and retiree health benefit expense in the year that the adjustments occur. Such changes are deferred, along with other actuarial gains and losses, and are amortized into expense over the expected remaining service life of employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare and file tax returns based upon our interpretation of tax laws and regulations, and we record estimates based upon these interpretations. Our tax returns are routinely subject to examination by taxing authorities, which could result in future tax, interest, and penalty assessments. Inherent uncertainties exist in estimates of many tax positions due to changes in tax law resulting from legislation and regulation as concluded through the various jurisdictions' tax court systems. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. The amount of unrecognized tax benefits is adjusted for changes in facts and circumstances. For example, adjustments could result from changes to existing tax law, the issuance of regulations by taxing authorities, new information obtained during a tax examination, or resolution of a tax examination. We believe our estimates for uncertain tax positions are appropriate and sufficient to pay assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses, tax credits, and other tax carryforwards and carrybacks in certain taxing jurisdictions. In evaluating whether we would more likely than not recover these deferred tax assets, we have not assumed future taxable income in the jurisdictions associated with these carryforwards where history does not support such an assumption. Implementation of tax planning strategies to recover these deferred tax assets or to generate future taxable income in these jurisdictions could lead to the reversal of all or a portion of these valuation allowances and a reduction of income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, a 5 percent change in the amount of uncertain tax positions and the valuation allowance would result in a change in net income of $84.9 million and $43.8 million, respectively.</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL AND REGULATORY MATTERS </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings can be found in Note 16 to the consolidated financial statements and is incorporated here by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">53</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can find quantitative and qualitative disclosures about market risk (e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest rate risk) at Item&#160;7, "Management's Discussion and Analysis - Financial Condition and Liquidity." That information is incorporated by reference herein.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">54</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Financial Statements and Supplementary Data</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_85"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:37.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions and shares in thousands, except per-share data)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMS00LTEtMS0zNjA5OA_2f6b4858-3c12-4b09-b54e-ff8f1aab6e96">28,318.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMS02LTEtMS0zNjA5OA_d0159511-328d-4c54-8062-b6f7e55124cc">24,539.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMS04LTEtMS0zNjA5OA_189b6c5a-946f-46ce-a1a9-3754e7ed26ab">22,319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMy00LTEtMS0zNjA5OA_93f03b0c-8624-4d3c-a4c6-ce060a990d60">7,312.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMy02LTEtMS0zNjA5OA_72f1356c-16f3-46f8-ade3-12f569dc74a4">5,483.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMy04LTEtMS0zNjA5OA_3452ec99-c1f2-4a15-9046-3c696338e3b2">4,721.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNC00LTEtMS0zNjA5OA_dffe095b-189e-4847-a474-b61d8d4ff3ae">7,025.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNC02LTEtMS0zNjA5OA_87e81b3c-958f-40cf-8212-93ad3061216d">6,085.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNC04LTEtMS0zNjA5OA_08b5dce8-cdcd-429e-a5f1-93e2791dd7a9">5,595.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNS00LTEtMS0zNjA5OA_b1abd1be-3b54-40bd-8140-8204debb5885">6,431.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNS02LTEtMS0zNjA5OA_92e16706-ec7c-413b-8f0f-cf095b45b3f0">6,121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNS04LTEtMS0zNjA5OA_75bf68f7-1f4c-4b54-8001-2659de60f573">6,213.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNi00LTEtMS0zNjA5OA_600f65c8-df53-4de2-9768-87bd5a501e49">874.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNi02LTEtMS0zNjA5OA_3b1fb55f-4b90-4539-9972-fccaa9afbb37">660.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNi04LTEtMS0zNjA5OA_719233dd-4803-476a-8e4c-95e1850e4e8e">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges <br/>(Note 5)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNy00LTEtMS0zNjA5OA_dfce4b27-d82e-46f5-bb9e-608325fe306b">316.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNy02LTEtMS0zNjA5OA_01132e42-10c9-424e-be35-fa3b546879be">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNy04LTEtMS0zNjA5OA_93fcca7a-078d-49a2-bf98-37d107a4031c">575.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense (Note 18)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOC00LTEtMS0zNjA5OA_4a103795-4690-45c8-b7e6-6cfccefe011e">201.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOC02LTEtMS0zNjA5OA_b7c7a090-809f-49dd-afc9-18f9ab61da68">1,171.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOC04LTEtMS0zNjA5OA_4beb65c6-e454-4f1f-b169-b0302f5631d4">291.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOS00LTEtMS0zNjA5OA_175e8b71-b258-46b3-bb0a-44013038c642">22,162.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOS02LTEtMS0zNjA5OA_78cd0b03-1715-4bad-b029-e8ed09618ff9">17,309.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOS04LTEtMS0zNjA5OA_2dd90eb3-2df5-43cb-981a-2727ae09312d">17,053.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTAtNC0xLTEtMzYwOTg_a00ba516-f26f-4da5-8f68-b98da62829e5">6,155.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTAtNi0xLTEtMzYwOTg_8845dad0-3969-4a1b-b57d-7eaa2880e066">7,229.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTAtOC0xLTEtMzYwOTg_dd6aae4c-5f74-49b1-9ea3-a3280a46fddc">5,265.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 14)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTEtNC0xLTEtMzYwOTg_c2d480b9-4326-4ba6-ade4-8f6e3da5b8d7">573.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTEtNi0xLTEtMzYwOTg_2199eab7-98ad-47b6-8da3-2d081b145112">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTEtOC0xLTEtMzYwOTg_03336bcf-c3ac-4449-b39b-54aea2eccd86">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTItNC0xLTEtMzYwOTg_a971d431-d92d-4d16-84c3-48e7a115e5f4">5,581.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTItNi0xLTEtMzYwOTg_f7de0f60-63db-4a38-8e3c-cd1ebdf4c278">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTItOC0xLTEtMzYwOTg_0ac679ce-5b40-4d26-95eb-3639e6faebaa">4,637.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations (Note 19)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTMtNC0xLTEtMzYwOTg_0219fb5f-a7c1-4515-8e2e-34c5cfbff98f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTMtNi0xLTEtMzYwOTg_2b8c7a5d-caa7-440d-86e3-d0fe13d8cdb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTMtOC0xLTEtMzYwOTg_0efe270a-a610-4729-adda-d22ba6718e44">3,680.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTQtNC0xLTEtMzYwOTg_9ca74bff-4f12-4430-966b-fc2e088715cb">5,581.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTQtNi0xLTEtMzYwOTg_89c3c5e8-67eb-4fa6-abbe-91965cf69cc5">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTQtOC0xLTEtMzYwOTg_28294dc5-36f0-45a0-8974-70bdff925ff8">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from continuing operations - basic</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTctNC0xLTEtMzYwOTg_18349996-b3c7-4664-9a0b-5367bc75c52a">6.15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTctNi0xLTEtMzYwOTg_dca4dafe-1655-4d25-a80e-4290ab3b9eac">6.82</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTctOC0xLTEtMzYwOTg_62a3be15-bc89-453b-b820-1dbd057d5a41">4.98</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from discontinued operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTgtNC0xLTEtMzYwOTg_8ae66d9f-41e1-42c7-8c61-5bfcff445d8c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTgtNi0xLTEtMzYwOTg_c2b85f1a-9a93-4b90-9543-964559daedd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTgtOC0xLTEtMzYwOTg_317e000e-97a6-4ddc-b5e1-454c1fe6ca52">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - basic</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTktNC0xLTEtMzYwOTg_21fb8791-cf7a-4c3d-9c0c-f4bbd1802f56">6.15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTktNi0xLTEtMzYwOTg_3ce68b7b-c473-4c2d-94bc-508080a9b229">6.82</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTktOC0xLTEtMzYwOTg_0591d6b7-8fa8-40e8-8651-c2e309a7eafc">8.93</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from continuing operations - diluted</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjEtNC0xLTEtMzYwOTg_88cf8192-7751-4c5d-8268-a4c00f3fffcc">6.12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjEtNi0xLTEtMzYwOTg_63eef34e-c0f1-46bf-af3c-af5e9bc7740b">6.79</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjEtOC0xLTEtMzYwOTg_90854680-30b6-4302-9ea4-c43c839b14d8">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from discontinued operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjItNC0xLTEtMzYwOTg_fea9606c-3a09-4bdb-81a3-961f5c4fc01f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjItNi0xLTEtMzYwOTg_1405120f-7c3e-40b8-a1c9-aade2b650bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjItOC0xLTEtMzYwOTg_2dffaaa0-6c15-4f7f-a029-182460cf6be6">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjMtNC0xLTEtMzYwOTg_65b0ab03-fa00-4fec-9a54-6a3d2dea0332">6.12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjMtNi0xLTEtMzYwOTg_87c970ea-cc2b-4714-a194-c269a90a62db">6.79</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjMtOC0xLTEtMzYwOTg_aef53688-f717-43c4-9745-8941b0a64dc2">8.89</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjYtNC0xLTEtMzYwOTg_9416ddba-f508-44e4-9cfc-c36b3123e39b">906,963</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjYtNi0xLTEtMzYwOTg_0f10c486-617d-47d7-87fe-30e187a65d5e">907,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjYtOC0xLTEtMzYwOTg_836676b6-d346-4866-aaa5-bf621107e5c7">931,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjctNC0xLTEtMzYwOTg_61d6b9cf-8038-417a-a636-02ca26893a59">911,681</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjctNi0xLTEtMzYwOTg_e0c1ba4d-4a0a-42b5-8ee2-c9451cd3ca32">912,505</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjctOC0xLTEtMzYwOTg_fc95c3bc-14b3-4af3-886a-bb0677ab69c4">935,684</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">55</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMS00LTEtMS0zNjA5OA_a064a5ef-5803-4249-a3b0-439b556ce7bb">5,581.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMS02LTEtMS0zNjA5OA_5c796367-3c44-48d4-998f-71298d479ccb">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMS04LTEtMS0zNjA5OA_f315e93e-2d6a-41bd-8617-ad8cb4058643">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation gains (losses)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMy00LTEtMS0zNjA5OA_35b90ba7-cb94-4605-b873-5d26b0e6fcec">13.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMy02LTEtMS0zNjA5OA_c8f316b0-e268-47bf-96a2-ca602f442915">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMy04LTEtMS0zNjA5OA_762c4cfb-715c-4202-8524-72e1b97f7926">89.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains (losses) on securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNC00LTEtMS0zNjA5OA_2ba8863f-a51f-418c-b521-2f47578fac2f">15.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNC02LTEtMS0zNjA5OA_d245ede0-eaea-405f-865f-ffc91ee2053b">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNC04LTEtMS0zNjA5OA_dd94bb48-7511-4f27-9cd9-473439f36ebe">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in defined benefit pension and retiree health benefit plans (Note 15)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNS00LTEtMS0zNjA5OA_c09dddf7-4b8f-4272-bbf0-ac0717b3091f">2,699.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNS02LTEtMS0zNjA5OA_f93df287-c1ff-4851-9d24-04272978b6f1">157.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNS04LTEtMS0zNjA5OA_7df109e5-12b7-4af1-a734-8156a3751f31">970.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in effective portion of cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNi00LTEtMS0zNjA5OA_967ee535-7784-4323-8fa3-48ff9b23c295">151.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNi02LTEtMS0zNjA5OA_236585e5-69a7-4e2c-a81d-f279d8e4b3a8">152.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNi04LTEtMS0zNjA5OA_05aa4bbd-a229-4d8f-b3ac-c96ecb257333">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) from continuing operations before income taxes</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNy00LTEtMS0zNjA5OA_c78821a5-834c-49e5-8ac0-8d657fe31a17">2,848.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNy02LTEtMS0zNjA5OA_69c23f9e-43c9-4a48-9fa5-42910df3aa19">173.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNy04LTEtMS0zNjA5OA_11ce8d91-85b3-4956-999b-278f6b605ebb">991.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOC00LTEtMS0zNjA5OA_0a189ccf-bb59-4a80-93d0-2f73ade6ae52">695.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOC02LTEtMS0zNjA5OA_c3a44ebe-1e6f-48d8-8430-f0b3c14371f2">200.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOC04LTEtMS0zNjA5OA_a05efdff-feb8-42f6-8e8b-3a6afb1cd31a">151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) from continuing operations, net of tax (Note 17)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5593b99da6745cb9b411b2031bc3e15_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOS00LTEtMS0zNjA5OA_18333278-bf08-4121-9a8e-1505778fa824">2,153.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350adfc8d85547d9a3c4e39ba5c1a2fc_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOS02LTEtMS0zNjA5OA_d0b31f91-5eb4-4942-8868-6284be918f30">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id11a42da50f242f2a8b81a0a0173884f_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOS04LTEtMS0zNjA5OA_669807bf-7214-43e7-944e-33589288cb11">840.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income from discontinued operations, net of tax (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ef7ac05a14478b89f3032c4251b7ea_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTAtNC0xLTEtMzYwOTg_08ae4b7f-50c3-4892-9dc1-60907bdcf12d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4663754a3a444cb9830c13af3caf35bb_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTAtNi0xLTEtMzYwOTg_86e681aa-c209-4584-9879-e9a9c83c64fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18a38bac34cb4ca8800ba1a18314f494_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTAtOC0xLTEtMzYwOTg_77c33c72-a32b-473f-b349-aa9f92c8074d">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax (Note 17)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTEtNC0xLTEtMzYwOTg_2a3176f5-e0ef-4be9-b5ea-fd0f65d17277">2,153.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTEtNi0xLTEtMzYwOTg_f3f5bd09-3b6b-4399-be58-89f657c35488">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTEtOC0xLTEtMzYwOTg_3bea0885-1677-4c82-b139-fc5b8f468a4f">783.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTItNC0xLTEtMzYwOTg_6621bb25-93e8-4ea1-8a55-ef0ece292b00">7,735.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTItNi0xLTEtMzYwOTg_4ccaee39-9aaf-4fab-9741-68e7aa30f163">6,220.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTItOC0xLTEtMzYwOTg_f27439a4-0883-48f1-ac8c-3c6ea3cb5c06">7,535.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">56</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions, shares in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 7)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMy00LTEtMS0zNjA5OA_c785657a-a445-4f72-b935-1ebfb96748f6">3,818.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMy02LTEtMS0zNjA5OA_d386f271-59f3-4ee6-99c5-ed60611a8aff">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNC00LTEtMS0zNjA5OA_92c52679-a223-47d7-b007-d697c5b4f8b6">90.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNC02LTEtMS0zNjA5OA_8d55acaa-3bbe-4ffe-b1f4-f0e68cde007c">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS0wLTEtMS0zNjA5OC90ZXh0cmVnaW9uOjAyZGUyZjQ3ZThjYTQ1OTc4YzJiN2IzZjcyYWI4N2ZhXzQ3_08404094-9094-4d60-a9e3-ae7fe8f5df36">22.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and $<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS0wLTEtMS0zNjA5OC90ZXh0cmVnaW9uOjAyZGUyZjQ3ZThjYTQ1OTc4YzJiN2IzZjcyYWI4N2ZhXzYx_0732bea4-2e7e-4495-bd28-1b574165753a">25.9</ix:nonFraction> (2020)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS00LTEtMS0zNjA5OA_a0b1db77-5825-4744-a9c7-e0b6a8366b6d">6,672.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS02LTEtMS0zNjA5OA_3aebca66-b8e4-4350-a8a8-495a6f33012b">5,875.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNi00LTEtMS0zNjA5OA_1afb888e-7d0c-47be-a768-89f61dfefd49">1,454.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNi02LTEtMS0zNjA5OA_2c1eff7c-8d2a-4125-9d72-44c67129ba02">1,053.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 6)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNy00LTEtMS0zNjA5OA_b5f45dca-8555-490c-8f49-2d93ef08e9a1">3,886.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNy02LTEtMS0zNjA5OA_0268bf3f-3ba5-411a-ab55-76983b023115">3,980.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfOC00LTEtMS0zNjA5OA_5f4a25ca-47ec-4b8e-908f-2da7123ffa02">2,530.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfOC02LTEtMS0zNjA5OA_a59c3d6c-8bff-4db8-91c5-20ee8319ce7b">2,871.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTAtNC0xLTEtMzYwOTg_2547a693-13b0-4a4a-8ca2-1e593e2318fa">18,452.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTAtNi0xLTEtMzYwOTg_104dcd2b-4149-4860-a16a-dfb71573b686">17,462.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTEtNC0xLTEtMzYwOTg_9a1ec573-4a16-459e-8835-3ebe9d4461ed">3,212.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTEtNi0xLTEtMzYwOTg_1b570f9f-77c5-4b0b-957f-8bfd865735f3">2,966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 8)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTItNC0xLTEtMzYwOTg_a6b6708a-bce3-455c-b533-c2c05f78f5d9">3,892.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTItNi0xLTEtMzYwOTg_68a20bb9-c2e9-491f-948e-0733867945c6">3,766.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTMtNC0xLTEtMzYwOTg_43f5aa3a-7bd2-4243-8424-d5f7f7b10336">7,691.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTMtNi0xLTEtMzYwOTg_c0fcb7b4-93b4-4369-aa62-693af26d73b6">7,450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (Note 14)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTQtNC0xLTEtMzYwOTg_2f9d75bf-cf11-4f88-9501-e69ccf30d286">2,489.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTQtNi0xLTEtMzYwOTg_d21b2730-137d-4386-a06b-976e1a32a8e3">2,830.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTUtNC0xLTEtMzYwOTg_f1890466-5f82-4999-9856-c7f219ebcba1">8,985.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTUtNi0xLTEtMzYwOTg_dced8d05-9e93-4223-a892-15c4d41ba0c3">8,681.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTctNC0xLTEtMzYwOTg_006527f0-d7f8-41c1-975d-e9b2c062886b">4,082.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTctNi0xLTEtMzYwOTg_470a358b-9121-47c8-804e-e0937a462291">3,475.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTktNC0xLTEtMzYwOTg_f51f2a02-68ae-48ff-b3d8-743c86eab273">48,806.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTktNi0xLTEtMzYwOTg_855d5cf1-7871-4478-944a-42ea9c1dc354">46,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt (Note 11)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjItNC0xLTEtMzYwOTg_ad120af0-0b38-4502-b784-01351238b665">1,538.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjItNi0xLTEtMzYwOTg_086d427d-33fc-436b-be55-e8f8f34a2734">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjMtNC0xLTEtMzYwOTg_e76b145d-e5d2-4818-be08-eacbd0147df7">1,670.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjMtNi0xLTEtMzYwOTg_da5e14e4-5988-4beb-8579-8b054a54eb1d">1,606.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjQtNC0xLTEtMzYwOTg_be1b2f15-3693-4ede-bb7a-dc89a05b4784">958.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjQtNi0xLTEtMzYwOTg_136728b3-373e-48e8-b22a-15aa7b54ce2e">997.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjUtNC0xLTEtMzYwOTg_fe980c7a-9d64-4a29-9ae9-e49347f50ef4">6,845.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjUtNi0xLTEtMzYwOTg_4261cc29-3d64-41ce-bc2c-ebd5b4e31b9d">5,853.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjYtNC0xLTEtMzYwOTg_b4a422a9-d914-4fbf-9116-04e814e12ebc">885.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjYtNi0xLTEtMzYwOTg_95076fe3-2aba-4e67-a54b-52ceb710f885">770.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjctNC0xLTEtMzYwOTg_5ce7aec6-e0bb-4ce1-8c5d-92ce03730dea">126.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjctNi0xLTEtMzYwOTg_e184e9d1-2c3f-480c-bcbb-0f8cdcdb902e">495.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjgtNC0xLTEtMzYwOTg_61eee2dc-1815-4270-832d-6265a633a3c1">3,027.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjgtNi0xLTEtMzYwOTg_553d314b-51ca-4f35-9142-5552877cdf3a">2,750.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzAtNC0xLTEtMzYwOTg_e1584477-5834-4241-a456-22a814d7ce01">15,052.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzAtNi0xLTEtMzYwOTg_9358681f-b795-4418-be4a-f6bfac90c8e4">12,481.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzItNC0xLTEtMzYwOTg_f5282aef-f0f8-451c-9c81-d50a0e03f9de">15,346.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzItNi0xLTEtMzYwOTg_a2ba9ba2-9c07-403f-bb02-c0abb7299e0e">16,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 15)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzMtNC0xLTEtMzYwOTg_34904b7f-3573-420c-9158-17694473ba21">1,954.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzMtNi0xLTEtMzYwOTg_4e1f5830-436b-4eb2-aaad-633c035934ae">4,094.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzQtNC0xLTEtMzYwOTg_be7ddb0b-91a5-4b06-8227-48b552333786">3,920.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzQtNi0xLTEtMzYwOTg_d4c35dd4-fd42-4794-8b27-0d6c7fce32e3">3,837.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities (Note 14)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNC0xLTEtNjExMTQ_4b596070-ee1e-4841-8fa4-11101c56b004">1,733.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNi0xLTEtNjExMTc_f99c5e51-1a4b-48b4-84ef-84a24a1745cf">2,099.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNC0xLTEtMzYwOTg_fae6028c-8b07-4cc6-88bc-d9a719623bcb">1,644.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNi0xLTEtMzYwOTg_72a70790-2d31-4568-a8b7-95539b2274a0">1,707.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzgtNC0xLTEtMzYwOTg_408cc0aa-40cc-49bf-be68-4d088b83b8e7">24,598.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzgtNi0xLTEtMzYwOTg_0235ebef-7f8a-4aa1-b0b1-22fd87d2158e">28,326.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 16)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzktNC0xLTEtMzYwOTg_8b8d8bb6-7c4d-48ad-b117-2851032cfa1b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzktNi0xLTEtMzYwOTg_c3964bbd-4164-4fff-99b3-9dfc92e87f2f"></ix:nonFraction></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;no par value<br/>   Authorized shares: <ix:nonFraction unitRef="shares" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV81Mg_d01b82ae-b11c-47fd-bc67-259206d53fc4"><ix:nonFraction unitRef="shares" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV81Mg_f67e200c-98c7-4349-a7ae-2a9b8549e93b">3,200,000</ix:nonFraction></ix:nonFraction><br/>   Issued shares: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV83Mw_d8de427f-f303-49ac-b584-fa6b4cb375f5">954,116</ix:nonFraction> (2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and <ix:nonFraction unitRef="shares" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV84Nw_0c258676-1fe5-417e-964b-f1bba2882773">957,077</ix:nonFraction> (2020)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtNC0xLTEtMzYwOTg_8ef85419-be93-4fd2-8332-61f251b46111">596.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtNi0xLTEtMzYwOTg_aeaf363a-46fd-4d6b-bf13-6008b720e05d">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDItNC0xLTEtMzYwOTg_9e86f992-4423-4542-bde0-b83041476aef">6,833.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDItNi0xLTEtMzYwOTg_f280791f-53e7-4e80-a2ed-d8098c3652da">6,778.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDMtNC0xLTEtMzYwOTg_b280cc66-9eaf-495a-b93e-c09235f28dee">8,958.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDMtNi0xLTEtMzYwOTg_9be5adbb-fa77-467a-9a86-c692a70b590f">7,830.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDQtNC0xLTEtMzYwOTg_5ca2b732-7bb7-4cce-96a1-1e137a5d7f2d">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDQtNi0xLTEtMzYwOTg_5ebf123a-96f9-4875-9262-c18ee98ef9a2">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDUtNC0xLTEtMzYwOTg_4f55fdcd-fe4a-47da-9152-ad964cf49e6c">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDUtNi0xLTEtMzYwOTg_683ffd55-6190-428e-87e3-14daa8e511c4">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDYtNC0xLTEtMzYwOTg_5746a773-4d11-405c-884c-4144774884aa">52.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDYtNi0xLTEtMzYwOTg_0cd6c885-c77b-459d-9f73-12661c9afdd7">55.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDctNC0xLTEtMzYwOTg_94fc7d9a-a48d-4c7e-8d65-0e70b0a527b9">8,979.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDctNi0xLTEtMzYwOTg_feb7074e-b156-4770-a3f4-821e4077b3ed">5,641.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDgtNC0xLTEtMzYwOTg_5288005d-1081-4547-9cb2-8a066f0813c6">175.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDgtNi0xLTEtMzYwOTg_5dbc7113-e6a6-4c78-a942-6e1f1c2dc42d">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDktNC0xLTEtMzYwOTg_8f1534b6-7965-4835-92be-0c85612062ff">9,154.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDktNi0xLTEtMzYwOTg_f863b454-4677-432d-b375-df16322f849c">5,825.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNTAtNC0xLTEtMzYwOTg_7de9d405-81fe-4b64-9a26-7c8fa964a5ae">48,806.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNTAtNi0xLTEtMzYwOTg_107f93a4-c923-4986-a891-4cef46424fb6">46,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">57</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Shareholders' Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions, shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interest</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib49b2b7f42884738a47622d8db6c8d71_I20181231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xLTEtMS0zNjA5OA_91e0e90b-b2ce-428b-b015-561d4fc58bb5">1,057,639</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49b2b7f42884738a47622d8db6c8d71_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0zLTEtMS0zNjA5OA_e5f8944b-1ec3-42d5-9f2a-daae951a92d6">661.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f2ebcb04234bb78d53e95c789a7b18_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy01LTEtMS0zNjA5OA_045fe533-fa8a-44c4-b4f7-1fb2c07c5290">6,583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386013c272b445c8b61ea4782a574cd9_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy03LTEtMS0zNjA5OA_c5a6c4cb-0b36-458d-806a-12c9371d8695">11,395.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da9dd99174a476bbcf317f5a6d40e2f_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy05LTEtMS0zNjA5OA_f4e01c52-fb69-4936-b12d-49caf1224323">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f786d93b75241c98d9db2267b3c5983_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xMS0xLTEtMzYwOTg_40f9ced5-4211-4c2c-a92d-d7cbe5011079">5,729.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d195254fb024cf89d97aaed06aee2a4_I20181231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xMy0xLTEtMzYwOTg_b6995842-bfbd-4860-a9d8-e8974e5ffc20">604</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d195254fb024cf89d97aaed06aee2a4_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xNS0xLTEtMzYwOTg_7dcbe2f1-a003-486b-a686-92c2bd2d7c17">69.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb85a614be34013a6354f3d76b46357_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xNy0xLTEtMzYwOTg_6613c979-2738-4279-b74b-0d6fb3499db4">1,080.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNC03LTEtMS0zNjA5OA_fba86ce4-7b7f-44c7-94a3-8a31f95cff58">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNC0xNy0xLTEtMzYwOTg_116f7ff3-76b8-4d47-b4e1-c72c31f7e7f3">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia85d124a50b14e73af531af45079e36c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNS0xMS0xLTEtMzYwOTg_5dd094d0-f908-4dd6-9d22-db127bc5c6b5">794.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNS0xNy0xLTEtMzYwOTg_fd6c9342-361a-4c9b-9cd6-fd18108f118e">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNi0wLTEtMS0zNjA5OC90ZXh0cmVnaW9uOjc3NjkzYTRmODllYTRjM2ViZWIzN2NiMWUxMjIyYzhlXzc2OTY1ODEzOTQ0ODE_c02fe7d4-b4a3-4cf7-bdf3-dfdad726b43a">2.68</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNi03LTEtMS0zNjA5OA_dc4bc245-4925-44b6-9817-750750186611">2,430.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0xLTEtMS0zNjA5OA_fd13a471-1e90-4a18-a0ba-373e158aab55">102,640</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0zLTEtMS0zNjA5OA_674ed41c-0c32-4a9b-8ebd-783f42790bdf">64.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy03LTEtMS0zNjA5OA_44a89f35-900a-4b47-abb7-aad97926fb39">12,363.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0xMy0xLTEtMzYwOTg_8ec82693-b4ff-420d-8330-cc84a66f256d">102,640</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0xNS0xLTEtMzYwOTg_e0ef78b3-6ad6-48d7-b12f-4e96a9824276">12,427.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOC0xMy0xLTEtMzYwOTg_a9043e24-1123-4487-bf83-0faf1cf33452">37,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOC0xNS0xLTEtMzYwOTg_4184d0bd-b129-4313-a39b-3e9b98acbf24">4,400.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0xLTEtMS0zNjA5OA_06872b50-3707-4cce-bb8c-f63a477a60e0">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0zLTEtMS0zNjA5OA_5cf2a3a0-c58e-41b4-b239-8c0df97f521f">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id73859b7dcd34e62805fa367251b795b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS01LTEtMS0zNjA5OA_aff8a076-1793-44ac-9dc9-315c470924f1">210.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0xMy0xLTEtMzYwOTg_194afbf7-94a4-4163-bd75-ad33c1a9fd95">74</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0xNS0xLTEtMzYwOTg_456da579-79a7-46ee-b64c-3d77cfe839c5">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73859b7dcd34e62805fa367251b795b_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTAtNS0xLTEtMzYwOTg_361866e8-0661-469b-9e59-c357bb294b29">312.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition of common stock in exchange offer</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-3" name="lly:StockAcquiredDuringPeriodSharesExchangeOffer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTEtMTMtMS0xLTQxODIw_0d5f0629-6398-429d-9a34-efd230987d0f">65,001</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231" decimals="-5" name="lly:StockAcquiredDuringPeriodValueExchangeOffer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTEtMTUtMS0xLTQxODMz_e00b6ea1-66dc-4fdb-b932-75c1e4e69e34">8,027.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deconsolidation of Elanco</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="lly:ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTItMTctMS0xLTM2MDk4_2d729844-fb78-471c-a03b-4839486eb6ab">1,028.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTMtMTctMS0xLTM2MDk4_fbee7ecd-ec6b-45cd-8ea9-d8d6420ec567">8.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27c5a45e3bbf4d98a9b6fa76889230d0_I20191231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMS0xLTEtMzYwOTg_94d261f3-3595-4a42-be0d-655733046d80">958,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c5a45e3bbf4d98a9b6fa76889230d0_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMy0xLTEtMzYwOTg_4c60e665-1c84-4c3a-92e8-7b93db446000">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74aad145fd948ae9241828f24c78548_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtNS0xLTEtMzYwOTg_7b38dd60-7e01-4a4e-9365-f589dd3b4c11">6,685.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3201d8c6744198aed86ef435de4ee7_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtNy0xLTEtMzYwOTg_f9c07f01-ffaa-4534-9840-a74f0d8b1d22">4,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i442a597afbe14853a841ac8d37aa9e20_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtOS0xLTEtMzYwOTg_af48d418-08b1-4555-8078-81fc10a0df5f">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ad901c3559244039c17a109cdaa8bf4_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTEtMS0xLTM2MDk4_07867320-aabb-430e-a561-d4cb873f1772">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b908b0dc9bf437c83b6a218c5c17f88_I20191231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTMtMS0xLTM2MDk4_22e33b6e-d0b8-4719-9c5d-f8760a0c65c5">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b908b0dc9bf437c83b6a218c5c17f88_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTUtMS0xLTM2MDk4_1ec65a62-780a-4a51-bff8-5245213d8683">60.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e50a9ab65b4a50b58927a520657bd2_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTctMS0xLTM2MDk4_1c042bb9-a1da-4dfe-8bd9-bb2da5a1682c">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTUtNy0xLTEtMzYwOTg_c6dca2ba-b2a1-4443-88e0-ebdefe39ce1b">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTUtMTctMS0xLTM2MDk4_72ec3a2f-ff66-45ab-bc75-5dd7a14900ba">126.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed8c31b73e04315b4155a37149b9553_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTYtMTEtMS0xLTM2MDk4_4dface74-8064-40cb-adc5-c234d9e8f3cc">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTYtMTctMS0xLTM2MDk4_28f4a1c9-7012-4e37-9123-468e49a30869"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTctMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjpiNzk0OTYzN2I5MjU0NmNmODVhOWE2ZGRhYjA1NDNkNF83Njk2NTgxMzk0NDgx_cfa34860-5131-4841-921e-af1e6eff1f39">3.07</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTctNy0xLTEtMzYwOTg_2447f6f7-f198-4e94-9d1e-4e1b6f20c168">2,786.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMS0xLTEtMzYwOTg_13b6d76e-69f1-4355-8d04-8eb1ed318bbc">3,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMy0xLTEtMzYwOTg_511231d4-19c1-454f-bc46-5b112a15d7ed">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtNy0xLTEtMzYwOTg_8f5d440e-1713-45f8-a509-56121e693516">497.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMTMtMS0xLTM2MDk4_fb8dd9a4-e5d6-43b7-af9a-df1017c80d8d">3,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMTUtMS0xLTM2MDk4_6b15b8b0-e37f-430c-a6f7-07c31d9ccd4d">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTktMTMtMS0xLTM2MDk4_04952cff-b9c4-4b3f-9c6d-d1de8c1d954d">3,627</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTktMTUtMS0xLTM2MDk4_a5dba540-9a28-45c0-9ab7-e491646a6fdc">500.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMS0xLTEtMzYwOTg_725ad3cf-e810-4678-ac41-442878f95361">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMy0xLTEtMzYwOTg_feba0acc-77bb-4937-a07d-63676590722d">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtNS0xLTEtMzYwOTg_d9cd7336-72b4-441a-8507-2856494e6c40">212.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMTMtMS0xLTM2MDk4_d5913793-8b65-4dc8-b53b-bf8bb82b3c3e">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMTUtMS0xLTM2MDk4_1a930324-3ff1-42fb-90e4-71f433fb379a">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjEtNS0xLTEtMzYwOTg_7d51dacd-957c-4ba6-ac6d-1314cefb52a2">308.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjQtNS0xLTEtMzYwOTg_1a2f0234-733b-4433-ae4f-73f985df134d">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjQtMTctMS0xLTM2MDk4_dfccd75d-66cf-4511-8906-5dd752d5040c">35.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76aeae647cb549b29344d42e8dcaf22e_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMS0xLTEtMzYwOTg_b4b3b9f5-e111-4aae-937f-b15265976a1c">957,077</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76aeae647cb549b29344d42e8dcaf22e_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMy0xLTEtMzYwOTg_9b08bdf5-d64b-41fe-9e2c-aeff0c09d033">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844c6baec2a24ddfb0175699e7c9dc89_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtNS0xLTEtMzYwOTg_e8d7512f-6319-4980-b3b9-6def6e34311d">6,778.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a1f40609cb46c88a55f8a58cc0d213_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtNy0xLTEtMzYwOTg_f74456f1-cb89-4235-bd10-3626ce84dd53">7,830.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a5b8a498064844963780b1fa864865_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtOS0xLTEtMzYwOTg_2ef36c87-edb1-46f0-9e5e-1ad0cc8d4892">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee2e8d9c52ce423296c40435172ba45f_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTEtMS0xLTM2MDk4_6224992b-b504-48f7-baf3-e8941d151ae1">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic59cb920c729498ca310e03243606c6a_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTMtMS0xLTM2MDk4_9f938671-d361-4cf6-96ff-647f5c84f12f">487</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic59cb920c729498ca310e03243606c6a_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTUtMS0xLTM2MDk4_c8a25912-6103-4eac-9419-04e13e7ffe76">55.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cc336a64ff4c18b6d2f64e83fb7ca5_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTctMS0xLTM2MDk4_33ee561c-f545-4f10-972e-39a97be7e6fe">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjYtNy0xLTEtMzYwOTg_ac50741f-313a-4b47-94c8-01241316a5b7">5,581.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjYtMTctMS0xLTM2MDk4_89e74151-67da-4c53-85d5-2238050c91ab">3.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6224d7ff3d6b43fb824c0b8619fad9b4_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjctMTEtMS0xLTM2MDk4_59a11ce3-f87e-4594-b00a-a0d7ed777d77">2,153.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjctMTctMS0xLTM2MDk4_c920f750-0eec-4cb3-b25b-dd23741f2be8"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjgtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjozNDIwN2Q5NzhhZDk0MGQ5OWI5YzgyNDJkNjZiOWJlNV83Njk2NTgxMzk0NDgx_f6f31a67-7220-41b8-90e4-008cdbc69007">3.53</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjgtNy0xLTEtMzYwOTg_f80ca892-12b8-4588-a345-85a866344322">3,201.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMS0xLTEtMzYwOTg_16ddc55c-86e8-49d6-b113-ac76fa6a1a64">5,412</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMy0xLTEtMzYwOTg_764c1346-1564-485d-8cc3-47288f2384f8">3.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktNy0xLTEtMzYwOTg_b2504977-40f9-49b3-968a-0abf0a1f0b43">1,246.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMTMtMS0xLTM2MDk4_17411d1e-22d3-470b-a4e5-5f202b9141b5">5,412</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMTUtMS0xLTM2MDk4_3067fdb0-d169-4508-811e-575c6803469e">1,250.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzAtMTMtMS0xLTM2MDk4_c47070e9-6834-40f7-ac02-b4a3af3aa409">5,412</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzAtMTUtMS0xLTM2MDk4_65e160ce-6c5d-4ca9-ac3c-9ebf54c3a2ad">1,250.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMS0xLTEtMzYwOTg_e633ce28-2879-4652-92d7-a7c01702aa50">2,451</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMy0xLTEtMzYwOTg_7e0f02f3-2db3-47b7-a2ab-d23cc1a8eb9e">1.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15da3dd702544a0897dc45c712757909_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtNS0xLTEtMzYwOTg_80a2d499-638e-43d7-96f0-c870571ea3fa">287.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMTMtMS0xLTM2MDk4_eb0d4a55-1149-4170-ab2a-d4a0ab0bcac6">24</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMTUtMS0xLTM2MDk4_0b1b162d-776b-4322-b736-5e8dadb836fc">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15da3dd702544a0897dc45c712757909_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzItNS0xLTEtMzYwOTg_4ac2f3dc-c507-4819-a3b5-5d80975c834a">342.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzUtNy0xLTEtNDE5ODU_698b43c7-3d02-4cf1-9b52-3613e960871d">5.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzUtMTctMS0xLTM2MDk4_a726d25b-7356-4902-808e-d802a776fa7f">11.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i075446bdf9684175b09f4719c83305db_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMS0xLTEtMzYwOTg_826b5864-de8d-49f4-94d1-93c65d7f5941">954,116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075446bdf9684175b09f4719c83305db_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMy0xLTEtMzYwOTg_aae769fa-65ea-4d3e-9200-e42575c18885">596.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5960a9f72a304f2d91d83b22d8017bcc_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtNS0xLTEtMzYwOTg_ec28db14-6117-4e5d-b394-d97474e35387">6,833.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39610d1c5d9d46bc880d62462c72fd8e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtNy0xLTEtMzYwOTg_30ba8e18-ee84-452f-9adc-53bd36689993">8,958.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8449ae740dff423f9a21a63ae89c9c0f_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtOS0xLTEtMzYwOTg_b1c7c383-1158-417f-8204-77981de5c71f">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a0bae0b2bc940ec8f928a12995eb037_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTEtMS0xLTM2MDk4_9ad8ccf3-f969-448e-a503-01d01fd3f15f">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25abdb96f76b4a36b8f4b2e517289462_I20211231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTMtMS0xLTM2MDk4_57abdb11-11de-4669-839b-1ba954821138">463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25abdb96f76b4a36b8f4b2e517289462_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTUtMS0xLTM2MDk4_57e71cf9-8a6f-4c93-a6ef-644cadba52b6">52.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0ee22589c346b4ba844a54471306b4_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTctMS0xLTM2MDk4_a92cf04a-0a5f-4344-bd54-d2c9dea6e130">175.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">58</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"></td><td style="width:40.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMi00LTEtMS0zNjA5OA_a064a5ef-5803-4249-a3b0-439b556ce7bb">5,581.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMi02LTEtMS0zNjA5OA_5c796367-3c44-48d4-998f-71298d479ccb">6,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMi04LTEtMS0zNjA5OA_f315e93e-2d6a-41bd-8617-ad8cb4058643">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to disposition of Elanco (Note 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNC00LTEtMS0zNjA5OA_3a748cda-d867-463f-a369-eccb4c99e9c0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNC02LTEtMS0zNjA5OA_4f51ed51-f01a-46d4-8774-4fc2371e8889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNC04LTEtMS0zNjA5OA_711e3155-d49f-4a76-be0a-d3c01f9fa8fb">3,680.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNS00LTEtMS0zNjA5OA_e3db80da-9aaf-425d-a05a-c67c7c77bcfe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNS02LTEtMS0zNjA5OA_97e1817f-a543-4b54-b22c-5d2497bb89f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNS04LTEtMS0zNjA5OA_68bc8df3-53be-4e59-8ac8-d40f63b5a676">309.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNi00LTEtMS0zNjA5OA_ac714d32-8b97-4281-ba13-d4e06ad175a2">1,547.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNi02LTEtMS0zNjA5OA_489ae14e-9aab-4321-abd0-b7137a84cde3">1,323.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNi04LTEtMS0zNjA5OA_e18d4b61-fba6-4c2a-805c-661d10146141">1,232.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy00LTEtMS04NTI3Mg_94677957-c376-4223-85ac-1429c4377a64">405.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy02LTEtMS04NTI3Mg_da86af03-f415-478d-9bc0-fdd6f1d0e0c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy04LTEtMS04NTI3Mg_447cd1bd-18dd-4336-9abf-cda17cd11171">252.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy00LTEtMS0zNjA5OA_5adc4333-5361-4f73-86df-daea4b8af846">802.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy02LTEtMS0zNjA5OA_691d0bde-3912-48a2-b34a-5c1c495b3bee">134.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy04LTEtMS0zNjA5OA_a6419dfe-6dcf-4fde-aeac-be8cd0cc53ce">62.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOC00LTEtMS0zNjA5OA_6867446c-14a2-4795-a787-fbb5f3d2463d">342.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOC02LTEtMS0zNjA5OA_07e6bbe3-fa31-449a-8882-d7b28841751c">308.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOC04LTEtMS0zNjA5OA_576d5fa9-d71d-4189-be5a-4e21661bcc12">312.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOS00LTEtMS0zNjA5OA_518f95b6-afdf-4190-9808-a0af16ad5454">178.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOS02LTEtMS0zNjA5OA_4ffc864f-2e5a-4bb3-b258-6cbe8fb8a51d">1,438.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOS04LTEtMS0zNjA5OA_8d746745-e3ea-4bae-8a19-1422ed578207">403.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTAtNC0xLTEtMzYwOTg_76fc6429-fb84-407e-a6c6-e70476bafbce">874.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTAtNi0xLTEtMzYwOTg_dde86e1f-1dfe-4eb1-9fb2-4de15ebe8fbb">660.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTAtOC0xLTEtMzYwOTg_5a42b9fa-3d35-4ebd-90a3-bb4bde515150">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTEtNC0xLTEtMzYwOTg_aef20b70-ea86-44fc-a12d-9862a5a4440e">511.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTEtNi0xLTEtMzYwOTg_2a9a6b21-efa7-45e4-a7e9-c78c6f88a2c7">333.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTEtOC0xLTEtMzYwOTg_af18db97-853e-43e4-9407-4ba3f1d118d1">499.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTMtNC0xLTEtMzYwOTg_aa932607-f0ae-4e33-89cf-ac7c9fa79126">1,278.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTMtNi0xLTEtMzYwOTg_7e23d35b-a00a-44e8-b4ef-19c19fe8f9c7">1,350.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTMtOC0xLTEtMzYwOTg_e7cd689e-fb29-4b14-9b85-9f42aa334589">127.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTQtNC0xLTEtMzYwOTg_bff79d63-43aa-4c99-84c1-4b3e0c8fb4b6">235.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTQtNi0xLTEtMzYwOTg_7d84b8f9-a21f-400e-9d1b-59b3826648c9">533.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTQtOC0xLTEtMzYwOTg_7e03d37b-073e-4785-92cc-f8455386bac9">258.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTUtNC0xLTEtMzYwOTg_e4a58bc6-70dd-4ebf-8beb-f272462726d1">1,515.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTUtNi0xLTEtMzYwOTg_d0525a6d-7db0-4d92-8e80-e3ac94e2a496">457.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTUtOC0xLTEtMzYwOTg_062a1343-5f85-4324-a8c7-bd212be809bc">602.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable&#8212;increase (decrease)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTYtNC0xLTEtMzYwOTg_8ad5308d-0c11-4276-abce-0add61cd7768">359.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTYtNi0xLTEtMzYwOTg_f997917f-45e2-4b11-a9d1-a88f235c4547">322.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTYtOC0xLTEtMzYwOTg_b3f4bf1a-0cf9-4796-94bc-520a11c72fe2">221.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities&#8212;increase (decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTctNC0xLTEtMzYwOTg_3e81056a-ae9b-416f-bb91-61082b708583">664.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTctNi0xLTEtMzYwOTg_55e8e1cc-d110-4de4-b4f9-c4c27c373d46">1,271.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTctOC0xLTEtMzYwOTg_0108a826-d5b2-4e92-85ab-c1ea3df761ac">477.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTgtNC0xLTEtMzYwOTg_fabcab39-6af9-4306-8df1-cc67b538a150">7,260.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTgtNi0xLTEtMzYwOTg_b4fa0558-8411-4d18-9965-14d10ff5beb9">6,499.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTgtOC0xLTEtMzYwOTg_792f9c45-ed0e-45e6-b1b0-120c28079d00">4,836.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjAtNC0xLTEtMzYwOTg_83cd7b1d-2d1c-4140-9d9e-7920a70b2f99">1,309.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjAtNi0xLTEtMzYwOTg_9d1304a8-5281-4484-8cca-512485d7ddbe">1,387.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjAtOC0xLTEtMzYwOTg_6775a46c-603e-488a-a90a-ef2bc9cedf3d">1,033.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjEtNC0xLTEtMzYwOTg_86731175-fa3d-42e0-a9f4-0594816acfe7">47.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjEtNi0xLTEtMzYwOTg_ad9ace9f-ab77-44de-a3ae-9df839c946a9">129.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjEtOC0xLTEtMzYwOTg_e42fef64-767a-45ea-a12b-c3e4d87933b2">136.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjItNC0xLTEtMzYwOTg_18c24744-c0c6-4dc8-871b-6fdc7560f978">83.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjItNi0xLTEtMzYwOTg_8444794e-d707-421a-bd5e-7b9fb46b990f">11.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjItOC0xLTEtMzYwOTg_f1f2bb5f-6357-42e1-8336-26d13bfc3ecb">42.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjMtNC0xLTEtMzYwOTg_6fd44347-79c8-449c-bbd4-2b3dabd7ba5d">800.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjMtNi0xLTEtMzYwOTg_4fae9ec8-7551-4ae1-bdee-b91891ebea36">757.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjMtOC0xLTEtMzYwOTg_c7d8f9fc-cf4d-4f1d-aa47-e00b0b644516">609.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjQtNC0xLTEtMzYwOTg_53dbf9ac-7bd4-4543-8dab-c62077d9656f">929.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjQtNi0xLTEtMzYwOTg_7e572a74-9eae-43ac-91cd-fb4ce9876693">358.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjQtOC0xLTEtMzYwOTg_32dfcc7c-80f2-4517-bbf2-2b96b42c74d3">247.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjUtNC0xLTEtMzYwOTg_0bc32afe-7edf-4214-bf6b-7206b4fea643">563.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjUtNi0xLTEtMzYwOTg_52364d58-e614-4275-815b-002e149f79d2">641.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjUtOC0xLTEtMzYwOTg_ea165013-f8eb-4549-9110-78ebd96ee35d">319.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjYtNC0xLTEtMzYwOTg_2f11ef27-3c5d-4bc2-a3e5-a0f70401170c">747.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjYtNi0xLTEtMzYwOTg_7b12a14c-ff64-4ca9-852a-6b7a7ade8a04">849.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjYtOC0xLTEtMzYwOTg_60b73a0e-ac75-47bb-9af4-fc2953b7c886">6,917.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash distributed to Elanco upon disposition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjctNC0xLTEtMzYwOTg_6b74535b-8d66-4e84-a487-c1de1eb373a3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjctNi0xLTEtMzYwOTg_17f84ffe-59ce-4751-a455-d65926430632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:CashDivestedFromDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjctOC0xLTEtMzYwOTg_271b1dc9-0bcb-42cd-9764-5162bcccf8dc">374.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for sale of antibiotic business in China</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjgtNC0xLTEtMzYwOTg_20a8a578-73a6-4a6e-bcf1-fc453dd15625">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjgtNi0xLTEtMzYwOTg_e6eb8142-c84d-4bf1-8b66-649155bd84e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjgtOC0xLTEtMzYwOTg_5149e949-cd78-4535-b6df-e452f3865920">354.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjktNC0xLTEtMzYwOTg_eb63e2e2-74ef-4a30-af01-9b0100aed8de">24.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjktNi0xLTEtMzYwOTg_e1317e79-274b-46e1-b31c-e8013b46472c">102.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjktOC0xLTEtMzYwOTg_4079d1b7-6936-4b6d-b6ca-8f6cb1b46862">248.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzAtNC0xLTEtMzYwOTg_f26191db-6857-43c3-967a-57267a3b19f1">2,762.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzAtNi0xLTEtMzYwOTg_99954367-d476-4afd-83c9-d3762ec03e19">2,258.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzAtOC0xLTEtMzYwOTg_87763083-a45e-4cb9-9261-6cc36d438dd2">8,082.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzItNC0xLTEtMzYwOTg_5e23a1f1-3091-42ee-850b-a6000ffb517f">3,086.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzItNi0xLTEtMzYwOTg_01cddf44-f0ef-4682-af42-b31475f9a7f3">2,687.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzItOC0xLTEtMzYwOTg_05903be1-c2ba-4aa5-9848-83616d0c0560">2,409.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzMtNC0xLTEtMzYwOTg_7d2009d6-d3c4-4fec-9e9a-ba3e23f6537f">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzMtNi0xLTEtMzYwOTg_c4c9ccd9-9e85-4e54-8d88-af99def796be">1,494.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzMtOC0xLTEtMzYwOTg_5bc5ac25-c95d-4353-95c6-13eb3b09ea79">995.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzQtNC0xLTEtMzYwOTg_e61411fe-19fe-4917-9da5-4900bb7462b4">2,410.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzQtNi0xLTEtMzYwOTg_27c7069a-c829-466b-854e-b190d9d6f7ae">2,062.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzQtOC0xLTEtMzYwOTg_8a6becad-62fb-4d9a-a8a1-2e10c11bbb52">6,556.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzUtNC0xLTEtMzYwOTg_4d3cb1ce-20c2-4260-b351-51bc2a884397">1,905.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzUtNi0xLTEtMzYwOTg_b759faf4-16b1-43ac-a387-83898c4cbdd6">276.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzUtOC0xLTEtMzYwOTg_a60347e8-566c-4cee-bf1c-91d385665ea4">2,866.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzYtNC0xLTEtMzYwOTg_22b1a60b-ebbf-46d5-a610-3cc40f74ddfe">1,250.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzYtNi0xLTEtMzYwOTg_b459d312-69da-4516-8705-a2d80da2edc9">500.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzYtOC0xLTEtMzYwOTg_c0cc33a3-c798-499d-8c4b-3fe9b0bc698a">4,400.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzgtNC0xLTEtMzYwOTg_0eed52de-3fc7-4e95-8360-8e5acd33b9c6">295.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzgtNi0xLTEtMzYwOTg_954b283e-6025-428c-8920-74c3cdd090c8">241.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzgtOC0xLTEtMzYwOTg_c0ca0bb0-e694-4f42-87a3-9b5179e6ffb9">200.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Financing Activities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzktNC0xLTEtMzYwOTg_96ffdccf-6001-4286-86df-af2955d35d17">4,131.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzktNi0xLTEtMzYwOTg_0e52510d-9a53-446e-a1a5-d5961223fed9">3,137.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzktOC0xLTEtMzYwOTg_4ecbf66a-8499-4565-b1a9-3e70548c9503">2,324.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDAtNC0xLTEtMzYwOTg_fbc98cf7-314c-445e-81a3-f95135cbdc01">205.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDAtNi0xLTEtMzYwOTg_7173bfe6-8404-4ff9-8c70-bbc3afbdbe69">216.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDAtOC0xLTEtMzYwOTg_aa7c7261-81b7-4650-a647-bee2b4230351">89.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDEtNC0xLTEtMzYwOTg_0a000cc3-6e75-45a1-8add-ae9eeda1ac71">161.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDEtNi0xLTEtMzYwOTg_81efa0a8-32b9-41db-bd93-63aa532fa01e">1,319.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDEtOC0xLTEtMzYwOTg_b8eaf80d-8b0b-4a3f-b62e-96ebda03b51d">5,660.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year (2019 includes $<ix:nonFraction unitRef="usd" contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjowYWNhNjExNTUxNWM0MTk1YmI0MDIzMjE2ZjFiZmJlOV82MQ_e47da504-bc19-4b11-8115-d3091448dfed">677.5</ix:nonFraction> of discontinued operations)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItNC0xLTEtMzYwOTg_f95e5502-051a-415b-8321-c939ecb67542">3,657.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItNi0xLTEtMzYwOTg_d44ab462-da34-483a-b1ce-71daa3108942">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2161fbcc13a94af3a14765cc6ce775d6_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItOC0xLTEtMzYwOTg_cadaf098-6c97-43e0-b8e3-c15dba05b590">7,998.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at End of Year</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDMtNC0xLTEtMzYwOTg_16e3bced-850d-4b00-ab7c-ecb8ffb64672">3,818.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDMtNi0xLTEtMzYwOTg_ca7578f0-624a-4738-ae79-d93b91fae959">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDMtOC0xLTEtMzYwOTg_74121cdd-5315-4baf-a1cd-58d0814b85b9">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">59</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;1:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MDg_88ee945e-a959-4f43-84e4-1dc852a4149e" continuedAt="ie3a752203a084105bebe297baad8e3d2" escape="true">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard</ix:nonNumeric></span></div><ix:continuation id="ie3a752203a084105bebe297baad8e3d2" continuedAt="i185a769d54b3402794c1fad65e7ea2e5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining <ix:nonFraction unitRef="number" contextRef="ie9ba1030bd04458783b9caf2f17c3b41_I20190311" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzE2NzQ_be812c18-fdba-48bf-a6b6-23564bb8c024">80.2</ix:nonFraction> percent ownership of Elanco Animal Health Incorporated (Elanco) common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MDA_e4139798-d2a7-4612-9b46-3a6bda094379" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development costs, which are expensed as incurred.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense includes the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MTU_84c901fd-6fed-44c0-8a1f-c5017b2cee36" continuedAt="i8ea3cb9473db4be69892e384de5c08b6" escape="true">Earnings Per Share (EPS)</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ea3cb9473db4be69892e384de5c08b6">We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i185a769d54b3402794c1fad65e7ea2e5" continuedAt="i9d3a12a83a1543e48d3b0500b6a58589"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg3OTc_356d792c-bbab-4c52-a10c-5071185b1fe4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MTk_19e64d0f-03d9-4291-9ddc-285ee4f2deb9" continuedAt="i97330f876845459c9c15c6d470cb226a" escape="true">Advertising Expenses</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i97330f876845459c9c15c6d470cb226a">Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.</ix:continuation> Advertising expenses, comprised primarily of television, radio, print media, and Internet advertising, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2MDQ_fce93b7d-82ab-4319-89f8-5d9171f24cfa">1.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2MDg_13854916-29a0-473d-99e3-0cb61172be07">1.1</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2MTY_01c6ed46-2e49-4f14-b178-4c4d0977e0b5">1.1</ix:nonFraction> billion in 2021, 2020, and 2019, respectively, which was less than <ix:nonFraction unitRef="number" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="lly:AdvertisingExpensePercentageOfRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2Nzg_39ec4ce5-c3ee-4f68-a3b8-7a726f2980f5"><ix:nonFraction unitRef="number" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="lly:AdvertisingExpensePercentageOfRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2Nzg_cde85914-f1eb-427f-a61f-39bbc65acc33"><ix:nonFraction unitRef="number" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="lly:AdvertisingExpensePercentageOfRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2Nzg_da07c667-0f60-4b53-814e-7c31171c9ddb">5</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of revenue each year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MTM_3b9e9419-c589-45ab-974d-007f36081e22" continuedAt="i1dd7e2e49b274f559977d0b2a6243afe" escape="true">Implementation of New Financial Accounting Standard</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><ix:continuation id="i9d3a12a83a1543e48d3b0500b6a58589" continuedAt="ib3a72a594c004d3cbbece7b5a019370f"><ix:continuation id="i1dd7e2e49b274f559977d0b2a6243afe" continuedAt="i5d6d94ecf3a64893bf9205e1b861bce6"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform, </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib3a72a594c004d3cbbece7b5a019370f"><ix:continuation id="i5d6d94ecf3a64893bf9205e1b861bce6">provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard can be adopted immediately and is applicable to contracts entered into before January 1, 2023. We do not expect the transition from the use of LIBOR to an alternative reference rate to have a material impact to our consolidated statements of operations or balance sheets at the initial transition.</ix:continuation></ix:continuation> </span></div><div id="i1a85401413cf428bb86d28ee6b337a59_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;2:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODM5_c994e3c6-c96d-4ea5-9af6-bd33b4d7046e" continuedAt="i57804360cd454cf5b9147a5bbac4567c" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i57804360cd454cf5b9147a5bbac4567c" continuedAt="i336f9c7216c2441199d22669f0ac356a"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODI5_1dc34034-7357-42dd-941d-1c946ae6d9bc" continuedAt="i0c455afdeabe4fc6ac19d25c1685ec57" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ba0120ed084c1da3c0cb9a06a3535c_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzEtMS0xLTEtMzYwOTg_ee4358e8-ddde-4680-b764-691e43edcb75">25,957.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595bde8d325b4f8cbe525ae5a8cc043a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzEtMy0xLTEtMzYwOTg_cfeb36cd-84f6-4ace-ad12-14bdc7615aec">22,694.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc4ab2a1ab4437a863acf75b60865b_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzEtNS0xLTEtMzYwOTg_3ce40e11-c6b1-44c4-8e53-62e8eb827f8d">20,377.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e084561da84353a68fc13b0b1f1065_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzItMS0xLTEtMzYwOTg_db5ddf1e-6388-45e9-a7a5-a7138099119e">2,360.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78db9bb959f4a65b59c065a865101de_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzItMy0xLTEtMzYwOTg_658295a9-3072-43b8-b251-43a9f2e5acb8">1,845.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768c5436d8e0411f87860a079a65368a_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzItNS0xLTEtMzYwOTg_2fda8d72-2615-4628-a566-85d122bb601f">1,942.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzMtMS0xLTEtMzYwOTg_abb2093f-aea0-4653-ba77-190bbd28232b">28,318.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzMtMy0xLTEtMzYwOTg_0d43956e-3026-428f-a68f-39efb012af5d">24,539.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzMtNS0xLTEtMzYwOTg_d03f1c18-fa87-4492-b726-2fa236768e3a">22,319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="if66a9d0bc8c447a7854e1d121fdd3fd9_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzIyOA_77826cbf-8212-4103-9a51-09a9f056b55b">175.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i447315375734437a83fd432f1d82adc3_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzIzMg_37aa5559-5304-4eaf-8939-13a9f864eab9">135.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i8b153236a1d746dc8a5d74cfd7f107eb_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI0MA_cb50aaca-5d81-48dc-a82e-ef247bd7f5da">301.5</ix:nonFraction> million during the years ended December 31, 2021, 2020, and 2019, respectively.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i336f9c7216c2441199d22669f0ac356a" continuedAt="i4aa7bf6edf2749f0826ecf65074aa701"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:RevenuefromContractPaymentTermMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzE0ODI_c55a6d0b-c54e-4bbc-b96f-b06bf45ac3a6">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:RevenuefromContractPaymentTermMaximum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODE2_b3c24c49-52d5-45f5-ad82-ad7094f63f95">70</ix:nonNumeric> days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzE3NDk_44b74601-350e-478e-86f8-03ad7380e976">one year</ix:nonNumeric> or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December&#160;31, 2021, 2020, and 2019, our three largest wholesalers each accounted for between <ix:nonFraction unitRef="number" contextRef="i2d45ee2631a0458287be066c530c6943_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI2OTk_1c58574e-7591-4a51-b582-8743fff89b68"><ix:nonFraction unitRef="number" contextRef="i4cb03da6839043d3aa73f8b83497cb73_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI2OTk_239760d1-e16f-4bd7-903d-6438c145df62"><ix:nonFraction unitRef="number" contextRef="ie2dc431125a344f3a63a4412d26d8a50_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI2OTk_ff5b45ca-5ffc-40ae-b226-415bfd6d4f58">15</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i52a79ebd44a14e7d82fceef0898c5849_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3MDY_4113e22e-2955-400b-9507-7a5d844c9dfd"><ix:nonFraction unitRef="number" contextRef="i4b94e10336ae4cbb8c40c7c7092d7840_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3MDY_4549500d-0971-4028-9f93-3151bf55dd84"><ix:nonFraction unitRef="number" contextRef="ie2cff9b89ea946558f2bb3511379631b_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3MDY_f1e97063-9678-4c3f-9b48-c08009b295a9">20</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of consolidated revenue. Further, they each accounted for between <ix:nonFraction unitRef="number" contextRef="i8113e64d76f847a682da0b64b7063dbe_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3NzU_4aa02ed8-8972-4ab5-af41-1ac80f391c5f"><ix:nonFraction unitRef="number" contextRef="i9ed77f1070fa4a9ea80eb29d531c5ba2_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3NzU_aa08497d-5f02-48a8-b50a-dd1fdc51aa75">18</ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="if7cd4eb0f13b417caac242fba3efbbb7_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3ODI_5473a5d5-ffc6-4cbf-b54f-e877b9825f6c"><ix:nonFraction unitRef="number" contextRef="idd89b253c657495cbf93efa71c826c3c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3ODI_ec7ed4da-9b90-4999-a5ff-1b513e7cff02">28</ix:nonFraction></ix:nonFraction> percent of accounts receivable as of December&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. The following describe the most significant of these judgments:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:RevenuePerformanceObligationSalesRebatePaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzQ4MTI_c44ce60e-caad-4b0f-a71d-de4f49b71ceb">six months</ix:nonNumeric> later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i4aa7bf6edf2749f0826ecf65074aa701" continuedAt="i1fff549db86640cebaa9b9ee09455cff"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Returns - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzU3NjA_d175cb35-c3aa-46a9-8970-18221ed89903">24</ix:nonNumeric> months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzc4MTE_387e27d9-3877-4ded-b779-4cf70ca35402">one month</ix:nonNumeric> or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual U.S. product returns have been less than <ix:nonFraction unitRef="number" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzg0OTA_1edf31d0-18fe-46f3-8012-b02eb0352b45"><ix:nonFraction unitRef="number" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzg0OTA_dd66df47-d8e6-444c-8d95-b743e5270414"><ix:nonFraction unitRef="number" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzg0OTA_e3581415-e89c-4ca6-8cb2-e5adbbe287ef">2</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record adjustments to revenue as a result of changes in estimates, for the judgments described above, for our most significant U.S. sales returns, rebates and discounts liability balances. Such adjustments for products shipped in previous periods resulted in approximately <ix:nonFraction unitRef="number" contextRef="i29dffcb1c75e447186d0449682c8fa4f_D20200101-20201231" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzkwMzQ_70f00547-7f69-4928-82cd-e03d3e2dc4e0"><ix:nonFraction unitRef="number" contextRef="iba3938017a09480e9b6c89ec4a92190a_D20210101-20211231" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzkwMzQ_71b6d9c7-7ecc-4690-9b18-e56b6d1158cf"><ix:nonFraction unitRef="number" contextRef="id826775b3fff46ea93386f9abf618ef5_D20190101-20191231" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzkwMzQ_e26ce411-6321-42db-918e-d261fc7627fc">2</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent or less increase to U.S revenue during each of the years ended December 31, 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Other Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i1fff549db86640cebaa9b9ee09455cff" continuedAt="ic77a3ea8907744c98b792ed1e30a0940"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODE3_bf71109c-0673-4fb4-8f02-ec91d4c7ec20" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTpjNDY2ZDM0ODMxYWE0OTYyOTA5MWJiNWZhMjFmNGQ4Yy90YWJsZXJhbmdlOmM0NjZkMzQ4MzFhYTQ5NjI5MDkxYmI1ZmEyMWY0ZDhjXzEtMS0xLTEtMzYwOTg_7eb71144-7e72-49e2-b8ab-e966ffb5d66c">262.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTpjNDY2ZDM0ODMxYWE0OTYyOTA5MWJiNWZhMjFmNGQ4Yy90YWJsZXJhbmdlOmM0NjZkMzQ4MzFhYTQ5NjI5MDkxYmI1ZmEyMWY0ZDhjXzEtMy0xLTEtMzYwOTg_e639413e-86c6-4422-ac36-35ee0d1f4d82">276.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities balances disclosed above as of December&#160;31, 2021 and 2020 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ic77a3ea8907744c98b792ed1e30a0940" continuedAt="i45eeac14a0414e2e8c3316eccfb24fa5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:continuation id="i0c455afdeabe4fc6ac19d25c1685ec57" continuedAt="iaf7721bd6eaf44979b770d283abd517c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894124740513476f9e7e298369f85ae6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtMy0xLTEtMzYwOTg_6d13b9c5-1a53-4fe7-84e1-d50f9686554e">4,914.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61882a82645e44f0a5cd7626f0f4dfad_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtNS0xLTEtMzYwOTg_56769034-85e4-4032-b52c-c128fcd9f9f0">3,835.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f18bbf764ba4e309b4033e323311922_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtNy0xLTEtMzYwOTg_0ed1bf03-acb7-4547-9bd9-95ebef810a03">3,155.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1ace1a30ff430eaa6398df95d6adaa_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtOS0xLTEtMzYwOTg_e2c6c01c-ef23-43e6-a167-50310363f263">1,557.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ba46a0dc564f5784eafb2834664c13_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtMTEtMS0xLTM2MDk4_4959504d-baa1-445d-bb2c-74f768bb77e2">1,232.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib713ca7d34c54a46bedf84120eebdddb_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtMTMtMS0xLTM2MDk4_f2abb794-ff99-4536-8ac1-53a56e6335a0">972.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bbd7358f9a44cc88fca6a40a7f752fb_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctMy0xLTEtMzYwOTg_7c1adf9b-66cf-4e2c-939e-7fc1d67c4e13">1,320.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cd2cb43377431bbd784ed4ddbb902d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctNS0xLTEtMzYwOTg_5f2e7063-7072-4b6a-92f0-e73227eb3755">1,485.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79b2564a4684bfa9b4e8e9903612823_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctNy0xLTEtMzYwOTg_ea0c11cb-8a57-41a9-a968-da825467b01b">1,669.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6229ebed99384ddbb1c1e41cca2e59c8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctOS0xLTEtMzYwOTg_ceb737bf-7284-4e33-b3d8-1501ee9fb807">1,132.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a64281a74ce486b8871c0204881291e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctMTEtMS0xLTM2MDk4_3cff7c48-d451-4967-b993-f50880b928f4">1,140.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4531e2c9cdf04fb883d1a76bcdaa75e7_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctMTMtMS0xLTM2MDk4_0d995b08-2120-4231-9d93-96fb48968ed3">1,151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba5f87a65a34af5bfab01d9bc64e2a9_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMy0xLTEtNzEzMzg_909ddc7c-ae69-4fc0-9c86-4691eb94668b">807.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8386db744f4affa13508c19b5df3ea_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNS0xLTEtNzEzMzg_1d143bcd-5e1f-4c1d-8f9f-2c2812609a02">620.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb37f86b5bf4fc1b82f022c4ace7930_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNy0xLTEtNzEzMzg_47d14b51-2eb6-4846-9125-05948f0cfd9a">565.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d1e272d16d4280b14162a8a5ae7248_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtOS0xLTEtNzEzMzg_2b1597e0-4b9a-4514-a01e-b45cefd19429">683.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f67b8b79d7454aa2e6e8e2b5d56679_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTEtMS0xLTcxMzM4_8369b738-db9c-4b0d-95f4-240da5b011b6">533.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a59b1db34b94c5b98790e3b0b011098_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTMtMS0xLTcxMzM4_4eb2d630-8b38-4d2e-85aa-e38a2352685d">378.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90bb2847aa5f47228628aa3e17c89913_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMy0xLTEtMzYwOTg_f38368f4-e03d-4961-a849-9828edb4e05e">832.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b7e8500d4804c3c92d4e3b21e6f0979_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNS0xLTEtMzYwOTg_29ec8ea9-3638-4856-bcf7-c3ab470f1dd6">866.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde1cb13d724c348cf0aa37a2ee59fb_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNy0xLTEtMzYwOTg_02ddc49d-bacf-4c08-8d2b-2ab6b3e11e69">879.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab22f8425aa742719232da9a982b98dc_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtOS0xLTEtMzYwOTg_9deb2d73-d749-43d7-bb20-d1b140abd288">389.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa9d24bc7c349259210cb5ddc15b20d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTEtMS0xLTM2MDk4_78b3ff1b-aae7-40e4-9cab-ece49feb5a5e">393.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib40488cc77fe48a9983b2d76229a1dcd_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTMtMS0xLTM2MDk4_e1cf2bed-4f95-4b48-b77f-5dfe49097a8f">410.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf934f62efbd4bdc9ad148a1e8d39475_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTMtMS0xLTM2MDk4_acd5068c-70fc-4d6e-bfd1-509a27c0eca6">588.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84b38b1fbdf4b4baafbe6846c60b875_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTUtMS0xLTM2MDk4_aea461b4-86d1-4b0f-b6bb-11f183ecdec3">842.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e50f47eeaad4777a025c7b8314d19ca_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTctMS0xLTM2MDk4_53fefc21-a297-4702-b24a-fd79e2996c7c">876.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c03a2130e8e4b15b3e45e071937aca3_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTktMS0xLTM2MDk4_27361b82-581d-485c-a384-43da21ac0968">304.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b3bf965c6b4aedbc71cd1b54cc2247_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTExLTEtMS0zNjA5OA_568f2877-93fd-4d9d-ba20-72b20bf26432">282.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b8fc33095f47ce91f0fb991ada922c_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTEzLTEtMS0zNjA5OA_85050470-4bb8-4031-9fe3-39510b904ba0">236.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab862c66ad8f40b58f51d2e670bc2d65_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTMtMS0xLTM2MDk4_b8ec0c71-ff7f-456d-9291-afec88b5ea90">82.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe81546f9364a4d9ebf816f2afe77ba_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTUtMS0xLTM2MDk4_1d95701f-94a1-4d29-bff6-30322e5e90b9">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c49328469d94560909e62a300fb15cc_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTctMS0xLTM2MDk4_c4e0b93c-14fc-43f2-9f55-d3732b13710f">224.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5845ce666250472aacd23b84c3e4c403_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTktMS0xLTM2MDk4_01f36de5-9c6a-4509-8adf-9d71e3d82317">290.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4abe14ed7d746c2a4d0112b075ac9cc_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTExLTEtMS0zNjA5OA_a619640c-d9dc-4a41-b3c8-92b2f04f0cf1">263.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4df3bf3464b489caa60ad6df0783bbe_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTEzLTEtMS0zNjA5OA_0c857383-5b00-49b1-8b9a-22969e199acc">365.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5174aeaa35294f1097a209bd1b7845b6_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTMtMS0xLTM2MDk4_d9bb9d95-9daa-4718-a9bd-901bd371a396">173.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icceb1eff5cdd4984b54eff367696ca4e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTUtMS0xLTM2MDk4_c3601b21-1bf7-45b5-8f46-a0975d9612e1">162.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64371009fdca47a9bea3857741540621_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTctMS0xLTM2MDk4_de32145a-9bf0-4b8f-a183-d585dd865427">158.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc100215d1f4fa9816b460de125dfa8_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTktMS0xLTM2MDk4_cd2acbfa-d114-4085-895a-3682b2070da7">111.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243440aa810243239953f41351bdcf24_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTExLTEtMS0zNjA5OA_07adc992-6ad4-4b00-8fff-3825766e346e">81.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3a7bc030e446fb82edf9a7f6f92844_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTEzLTEtMS0zNjA5OA_3e4b9f17-6348-46b2-a250-460d0318cc19">88.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia101d6eca8f243bb98e9561330ac20b5_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTMtMS0xLTM2MDk4_18832992-5c0c-4559-b802-69a77b3b5801">8,719.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122fb9e7cbb34242a643302cb8dac50c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTUtMS0xLTM2MDk4_fe8aa2d1-de6f-47bc-b4a7-29a13602e988">7,909.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec68387645db4b4f92d21db543507a42_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTctMS0xLTM2MDk4_3741b091-85da-4a7e-97d2-c1b3f1826cc4">7,529.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa12801a6f24c04b0786f055da95eda_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTktMS0xLTM2MDk4_998e7454-9b8e-4be3-b251-d19669df3cda">4,468.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7b63b2d4824ebd8b98d1a3e0bec191_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTExLTEtMS0zNjA5OA_1c1fc7cc-6e48-483a-98f7-a8bc3fb34295">3,925.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49adc5d81365456dacca8f1348186c71_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTEzLTEtMS0zNjA5OA_7166d717-895a-4b77-9305-ed20b3ba7dc4">3,602.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4404efba44734e41af51f0f6e510b480_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTMtMS0xLTM2MDk4_2a822dbf-c235-4942-8662-b01eb134784a">1,233.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba7197e9a2124fe299c14e4eaaecce76_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTUtMS0xLTM2MDk4_11eea74e-080a-49b9-b1df-59afc94b045f">1,265.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c95be326e745df83b5161e9b90eb8b_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTctMS0xLTM2MDk4_56026ff2-b759-42fa-a70f-c67ec0288c46">1,219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54524c6278e14aeba0959cc606b06515_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTktMS0xLTM2MDk4_ae62af01-ecd5-48cd-98d3-1c96fa2fc833">827.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib118e8524e0a4034a5733e9334f28db0_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTExLTEtMS0zNjA5OA_67544414-edee-45ee-a068-e3bb01a86c0e">1,064.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e0f9785fd343efa0193891217b008a_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTEzLTEtMS0zNjA5OA_4f04fb94-bebb-4ea5-b026-9ca30ce8aaec">896.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c5294ee4f4ef681fd908091186ae4_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTMtMS0xLTcxMzQ3_40dd202a-f445-4bcc-abd9-a61900c3e8cc">834.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef513531c7049ef9396372c3a862b18_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTUtMS0xLTcxMzQ3_79077636-18ee-4a6c-a98e-50a9492fac12">618.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279a034c277f4a1ab4e300b899b21d54_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTctMS0xLTcxMzQ3_5e97201b-7f0b-49ba-912b-6528398554b3">454.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2570b2af4dc0432b9372301788fad363_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTktMS0xLTcxMzQ3_45c73b5a-53c9-42d9-9499-1f61b0fe1c86">515.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3338ad8173349e988242ec0e6f04e1e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTExLTEtMS03MTM0Nw_edd63a71-70b7-4ba2-8488-bfb933aff083">294.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffe64f002d641c6a9b980be3ed01dcc_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTEzLTEtMS03MTM0Nw_8b9fd1c2-b6a9-47cb-8002-1b267ae5dabe">124.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17e3c0297594484b5fc11d78d43ee29_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTMtMS0xLTM2MDk4_5ad2df00-99e1-4196-a792-819def96c95a">358.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d777c538b14159ac60b1362f07fb22_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTUtMS0xLTM2MDk4_615cc2b6-5d2c-4b69-ab37-c72cca349043">381.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if890ac36822f469d8ddea5dfd470c95c_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTctMS0xLTM2MDk4_fad52308-c5d2-435e-bac8-9acce15f36d7">335.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id361aece11434b678eaf1e55548add4a_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTktMS0xLTM2MDk4_fd53bc7b-5ec7-4e89-9679-371cc9cf8171">674.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabd8a9ea7f3489f96d642962db788ef_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTExLTEtMS0zNjA5OA_d41ffb2b-658b-4c74-abf4-fe6e18bc164f">650.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2245dfc68e249d0a3b540ce6711b4d8_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTEzLTEtMS0zNjA5OA_e8e07755-76c2-448d-a8dc-e57d5988ce0a">589.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7abf976b41e94d6abcc6e5fdc45e8040_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTMtMS0xLTM2MDk4_14967e64-bfe3-4b56-bbe3-8150d0b34118">481.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098a3086a33e473685588ae2026e5f1c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTUtMS0xLTM2MDk4_a3220491-1d6a-466b-9e9e-4cbfd498a2aa">480.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1126ae549787451f9bb5e56ec4579eac_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTctMS0xLTM2MDk4_db4bd14b-8066-466a-b65e-95cc922d592d">487.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia458924680af4b66841795f4b0921155_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTktMS0xLTM2MDk4_e9fe1013-c402-413c-acce-deb4f4dcf74f">66.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee79c787a98549fbb814a8a2d8423bbf_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTExLTEtMS0zNjA5OA_af3408a4-63c9-46b4-852c-14d0857beb5b">56.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c16c6e39bc54a20a076eddb68a38dc3_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTEzLTEtMS0zNjA5OA_c90d51ee-23db-4f3b-b569-a941a7825f07">55.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df57ca285b34436ad72599838d20b63_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTMtMS0xLTY0Mzc0_e6775145-90f6-40ec-bffd-93d035badf76">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd23ae2c169427ea701232617ba23e9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTUtMS0xLTY1NTQ3_a3581052-584c-4e6e-951c-8bcca73cb708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c6dd0e87a04241b80ae67b85eaac34_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTctMS0xLTY1NTUz_238a462d-a91c-4487-9c64-b2200e314f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia145809c4057498dbea07cefe5b3af5a_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTktMS0xLTY0Mzgw_aea058d5-5256-46b3-909d-622018e992ad">418.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a4f3931810408b8426d88ab25f2543_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTExLTEtMS02NTU1OQ_b5f828a1-e668-4f19-9931-2afba9db5e82">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7563fab9a921489c8c33ab7ddf46db30_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTEzLTEtMS02NTU2Ng_46a341ad-31d6-4e34-808e-32a2dd24131a">134.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d2921396f2408f81b37c768c975994_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTMtMS0xLTM2MDk4_40c86c15-af42-48ce-8611-ef44a4600eba">120.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c6d36f572740b5958ea1e5a869f0e2_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTUtMS0xLTM2MDk4_820bf29a-c332-4039-b4c0-d0a3644ca809">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b26b6ce6fb747bbb9e0775792261b89_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTctMS0xLTM2MDk4_7cfc17e9-eab9-4880-8ceb-47f0a786ea47">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aeb1d3ab83b4f499609731a48e300dd_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTktMS0xLTM2MDk4_f36347da-f3b6-474c-a2e0-bb199a2f202b">210.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786023411d90417782c4325faf5d0199_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTExLTEtMS0zNjA5OA_65bb3023-14c5-48ad-8a94-95231c614f59">152.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb4acbcaa7a4e1d9a4bf8429bc4c60f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTEzLTEtMS0zNjA5OA_aaa6141d-a2d3-40bc-b7aa-3a279922b485">205.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea541b5215c48e7be8cfa4c03730bb4_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTMtMS0xLTM2MDk4_8e1bebc4-dbba-4bb3-a48b-043c87ddd5d9">3,028.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76285bcbd8264a4d88f79ec61700d427_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTUtMS0xLTM2MDk4_1e61ee6e-34d0-483f-bf09-8ffae3f6bb02">2,792.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690e96d0ed8f4be1b474dfd0143fec7f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTctMS0xLTM2MDk4_0383cc45-0707-4ea0-b921-953f9495b769">2,608.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78854061d9a4a8094725b7186b33c24_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTktMS0xLTM2MDk4_77519c0a-3271-4792-9a8c-463c130c1499">2,712.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566b619706fc4300afef9a4b18065698_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTExLTEtMS0zNjA5OA_2f2193c3-c4e0-4193-a4d8-84bf6122bee4">2,527.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9c8432ad704f298370bae297a97816_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTEzLTEtMS0zNjA5OA_c30d314f-603b-44a7-b0f5-486f991167c7">2,005.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948ab3ff4ae849d798539c9be859e02d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTMtMS0xLTM2MDk4_d7db212c-8e20-40d3-a269-cfa994c82ff0">1,542.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ad9e5e91ec46c58d5c3d879543ad79_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTUtMS0xLTM2MDk4_900f5ba1-7c07-479c-b6e2-84d6c13bbb13">1,288.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddfd937e21f452faab9486fd44a1792_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTctMS0xLTM2MDk4_952fec7c-5a85-40ca-84a4-995db6cf12e9">1,016.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12a0757fc294a8a9f3e7f4e96ad2b79_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTktMS0xLTM2MDk4_c0545e27-ec9c-4284-97e7-8f3b3d74deae">670.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a6e3cb90de4b7fbc1a26ec8413acad_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTExLTEtMS0zNjA5OA_53a99f17-8811-40e2-a740-70ba9e3b6084">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8356524214f4293839013dae33b408e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTEzLTEtMS0zNjA5OA_7c53c87f-7938-4dda-8cd2-a1745654c48b">349.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c4fc8c4be9466483d1f9c47e96410f_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTMtMS0xLTM2MDk4_f8dc86dc-9ab0-4757-bf0a-0d19f432b9d1">324.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7951f7fd96467c823ac40837825eac_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTUtMS0xLTM2MDk4_16df1184-163d-4dc3-8d29-a64b573d5639">63.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa237d56f2a04c60baf2abac03b59800_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTctMS0xLTM2MDk4_fc325547-382b-446f-959d-94540f03d0b5">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e4b2fc062e409eb90fc22b3ecac117_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTktMS0xLTM2MDk4_afea76d6-7c79-456a-a4d7-872ab5e879f4">791.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85af31eff3fd4bcfbe2f8093e081a909_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTExLTEtMS0zNjA5OA_9c2aa6b5-7acb-445f-bd65-002b5a7983d0">575.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec77e9a200a45bcb3e18647fab83ba0_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTEzLTEtMS0zNjA5OA_3a2b6e06-240a-4c20-967b-25b32417cc16">384.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047fada9bd1a4eed91bd54b125f10f2b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTMtMS0xLTM2MDk4_5ee35e83-aa1d-4d21-b7b7-4cd9abb3cfa6">15.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905d5bb1f6a644aa9480da295c712847_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTUtMS0xLTM2MDk4_903c0926-1fcb-4fa3-baa2-8ae2bdc33d52">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e35fbd704c46248a24dedd85300ea9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTctMS0xLTM2MDk4_63502cee-0d8f-4880-8e15-76baca3dbb72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa7c39af28c4bc5993971a70aa09d60_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTktMS0xLTM2MDk4_83d817a3-43d1-4532-9f25-5f3d6fa88523">17.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f4f924f3ad4797bf23e88d55c7d012_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTExLTEtMS0zNjA5OA_5886a249-2e8f-4064-b491-3f200cf8fa83">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9109389a244076841dca316010ff8c_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTEzLTEtMS0zNjA5OA_86ebcce0-59e2-4ab2-a7de-db840ea1f604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca2f0cae6db46e1969f249939f14190_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTMtMS0xLTM2MDk4_b017e9d9-5924-4695-b6c8-ec8c34247107">1,881.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d55d846ec5c43f0859bff0869b8d85d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTUtMS0xLTM2MDk4_8f6bec3e-953e-4525-847a-3d6abae3c941">1,372.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib62fbafb830b45f18b06599b0a020555_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTctMS0xLTM2MDk4_86ccb4ba-7eb2-4956-8813-cba33d4565d9">1,059.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2370ca55475d4c2392256a9363409c09_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTktMS0xLTM2MDk4_f3e992b7-57bd-4126-a9af-6738f243ea97">1,479.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73989eaa96b4c098c63cf6dfabe07da_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTExLTEtMS0zNjA5OA_ec861698-1139-4fe6-8e2d-200df6119f91">1,089.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba680c3a60c4c94b757bfbbdffadfcd_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTEzLTEtMS0zNjA5OA_3e258393-5343-490f-8798-cabd09f1bd59">734.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib446da6700c5431bb4dfa20d113e3796_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTMtMS0xLTM2MDk4_e79dcfec-2478-4607-922a-4a72bcd5a164">38.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c8904967084c20a526f2bea52ae9d1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTUtMS0xLTM2MDk4_f11689d6-7e25-4115-8955-6fbe2f07ee53">42.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476342288dcd4c35aab4ebcef726722f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTctMS0xLTM2MDk4_11f58634-43fd-444c-b872-b525ac0b0d54">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c18e45789f14afab755bf84d42ee66f_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTktMS0xLTM2MDk4_c9025687-5570-4afd-a0fc-4d460f9d83ff">542.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f55af49432141a9a5b2a16fc58b0038_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTExLTEtMS0zNjA5OA_9c2db3fc-ec79-47f6-ac92-10282703a26c">725.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e993b0bc60d4c04b3d713bcaf91ff26_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTEzLTEtMS0zNjA5OA_c359fd6e-d2df-417c-a9db-acca3c465cfb">675.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id444acee0b204bdc95711361bd992be1_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTMtMS0xLTcxMzYy_01105ca5-80e2-47e2-a051-f58621aed59a">434.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf1f9d51d284edaa1b7ef76c6479ef9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTUtMS0xLTcxMzYy_3d5b25b2-85cb-4c3a-83d0-26ff7f029af0">325.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070feb5d9c28438b8531680d930b657a_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTctMS0xLTcxMzYy_d4a95a68-d320-4304-89aa-d658861473be">154.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9628b9ed2749ddae9bef49cb39bb99_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTktMS0xLTcxMzYy_fc6c8d1f-21ca-4e2b-a0c4-6b680e4cc02b">142.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702fa5c2e0c34c519b69e8801bee2eea_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTExLTEtMS03MTM2Mg_49cc2290-38ea-4f4f-b360-170107f54507">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc40e99c9fe5483eb7a04d9734858a85_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTEzLTEtMS03MTM2Mg_253403dd-59dd-4057-88dc-e4438fe8d832">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c20349b02348d9bb87dc176d930352_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTMtMS0xLTM2MDk4_4d4c2131-74df-492d-b66f-a197a9e07e4c">39.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55d7bb83bed4b79933fb93ad8dc8ce2_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTUtMS0xLTM2MDk4_8319a61b-4fd4-4a97-bc1e-4b4eb125f65d">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61dcb4e367e49e69e147967d3466245_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTctMS0xLTM2MDk4_ba17e7e5-d507-461e-b234-3740e4cfbe47">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c3070f248e45bfb4c8b53127810450_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTktMS0xLTM2MDk4_495031cd-96f7-4742-b6cc-85d5d1131b24">390.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027e829cf3a94fdb838086c03633207d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTExLTEtMS0zNjA5OA_10fc477d-8174-404b-b189-aaf658e7e283">360.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926e2ce8db484a19b6686864f7dce2d8_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTEzLTEtMS0zNjA5OA_ce5ee6b5-561a-4988-a079-4ab0b7551126">377.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16730972cec04bc9b31ee8293f90b16f_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTMtMS0xLTM2MDk4_5fc78b4b-f09d-4db5-b23e-6ad27e55f0ca">102.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad2157f26744eac8a277f68ec6e9f75_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTUtMS0xLTM2MDk4_09763793-66f8-404c-997d-8ac3236698b1">73.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93492794bd9d4ade882f1194e9f5d0c6_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTctMS0xLTM2MDk4_4a713193-9781-48de-86db-25c1762134be">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86210214b8d04600afad8c88d79dd48b_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTktMS0xLTM2MDk4_86cb4e78-65b7-4ba2-99bc-c4d008524a3f">207.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657903dac3a84f118dfd3c2d2d0b4f45_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTExLTEtMS0zNjA5OA_0b27f454-3a7e-4c58-9f85-4082f0a1ed23">220.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925c14ebf59d401e90944a793809c61c_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTEzLTEtMS0zNjA5OA_aca4dfc4-c6a2-468f-9e3e-3f31f5d6b53b">305.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6718cacc2a5a484ea0fe4ebcd8d0f0a1_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTMtMS0xLTM2MDk4_57efc918-3fce-4bb5-a6eb-0a0dd35b7547">614.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3108d4822f4200ba775774e2c6d17b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTUtMS0xLTM2MDk4_5946707c-be97-4cca-8d2c-15079a6edf89">487.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bc73f6221746d8bf84498f9556f8ed_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTctMS0xLTM2MDk4_0a310384-a864-4c75-8a92-a319632bca98">356.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2d4950c43e4823b068eca9c847caf9_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTktMS0xLTM2MDk4_8d2adf4f-f970-473d-87e0-6177e5a1cd2b">1,283.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2d91be0889414c97992735d48a782e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTExLTEtMS0zNjA5OA_ec1442fe-de65-49ac-bf18-b96251075e6a">1,344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e5b3258a5645c4b9f053f742b53b7e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTEzLTEtMS0zNjA5OA_c54fe1b0-b000-48da-ab0f-5fe09662ffb9">1,366.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3650248e7a546aba24f1190e20ee44c_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTMtMS0xLTcxMzc0_0fe95bc6-1ca6-4013-8a39-589d076d27fa">1,978.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib423ef1778dc4914ac8a36e61d82d79e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTUtMS0xLTcxMzc0_c8227bf4-ed3d-4951-835f-0c5ccdde3668">850.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec20cacccc854ae999285ef6ae4bf265_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTctMS0xLTcxMzc0_df4a03cd-360d-4edd-ba0d-da20c269ce7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9166c1982686472cb2be38f81d2bdc5e_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTktMS0xLTcxMzc0_9f5d8287-03b1-4817-ae89-cc7152404d4b">261.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099a16e9db4d42d3ad065da66bb72352_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTExLTEtMS03MTM3NA_05875ec8-150e-417b-baa8-59a7350ee17c">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0929e27d1f44afae4a0ec0efbc7d3f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTEzLTEtMS03MTM3NA_306756ce-ca65-45c6-adc0-ce71604ec6ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0bf62c9bad4a789c15447bb315106d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTMtMS0xLTM2MDk4_e46a1cc5-027a-4aaf-978d-8c29e8786e6e">441.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b796c46dd2848e0bcfe542ee2f9ea37_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTUtMS0xLTM2MDk4_4d952ddd-5ef2-4f08-847e-676f7a154483">510.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6126155439840c494a0d59a4c901ef6_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTctMS0xLTM2MDk4_1711a164-7e7f-48a2-893f-d65777499c48">645.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15079d32a6af431cbe2362c300da4d30_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTktMS0xLTM2MDk4_00dfb368-9bfc-4746-8fbe-95cde257e065">360.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8495e35a20ac4d5fa299dbb1a540308e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTExLTEtMS0zNjA5OA_ec7049ef-2e4a-47aa-93f6-8046ca49b0fd">536.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2101347099ea4c55aa493f4b7e3e75f2_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTEzLTEtMS0zNjA5OA_90d25f94-f3f6-48a2-b676-66e94659745d">759.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9fdd9cfde64d12a304f9907a75d463_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTMtMS0xLTM2MDk4_98aa355d-acfc-4935-846c-7a0c487ba480">10.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8243736e267647a7a63b74278bfe227c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTUtMS0xLTM2MDk4_b6cb7b88-2579-4c63-b720-55c32ee2f254">61.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69102089b51742579ff9ad41273b6e5d_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTctMS0xLTM2MDk4_0ad84edf-0da3-4c4b-826e-7c6b73511da9">231.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3630db9f3642a0bf1262ba09e339ee_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTktMS0xLTM2MDk4_ac845cde-cad2-4eab-b9e1-747bc7511c26">707.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e4d52b72a54afba956fc68e8d09cb9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTExLTEtMS0zNjA5OA_7bd69e0f-2113-47e2-8227-6365f3f6151f">545.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034bec2524a34f378ecb3ac05b076873_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTEzLTEtMS0zNjA5OA_0107e6af-d325-4af8-97e3-908645f17d48">658.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364bef469c6b409eb2e05dec7fa48bec_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTMtMS0xLTM2MDk4_18e8b23b-8d2d-41ee-83ab-af895578e58c">136.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a1ac288cb249769f4020a76446066e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTUtMS0xLTM2MDk4_273bd448-40ed-476b-b952-8ac829c5f834">246.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc25daef9774ec8ba96201a6d17c48f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTctMS0xLTM2MDk4_9a2721b9-4461-4c17-9bc0-9ab772781d6d">291.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id884085efd444ed5a42695f06ab42933_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTktMS0xLTM2MDk4_85d66b0b-c600-4c28-868d-1f12b627f833">233.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25b2eb90e2f49aaa97ed46e09ddedc5_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTExLTEtMS0zNjA5OA_d089c401-d19f-4257-ab26-3f9a1b6302df">321.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fec7ee5a58242fcbbf477d186e1a542_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTEzLTEtMS0zNjA5OA_ab8afc95-1aef-4c99-b38d-59c3963cd364">469.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ed3edf12174b94967056072504bcad_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTMtMS0xLTM2MDk4_801d85f4-3d6f-413e-a214-1b040e182056">2,566.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c8ab2aa0454112b333a7f6f112c62e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTUtMS0xLTM2MDk4_dd896edb-7db7-4b87-b6d3-fdbdd1a2568e">1,668.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e0bdec56134029ae9680e3db1ec79b_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTctMS0xLTM2MDk4_4e3245ec-a71b-4644-99fc-9968cab4672f">1,169.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e356ee1b9d440e875c1efc62a80b33_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTktMS0xLTM2MDk4_6a9c9d6c-2814-4cd1-99c3-2d5c47fb723b">1,563.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52fa75e3f5284c179ee6b4ab5243be53_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTExLTEtMS0zNjA5OA_71ccdeac-c44c-4f5e-9e65-f0ea1386706f">1,424.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad81ef38f2d4e57bd00e5dd2c0a168f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTEzLTEtMS0zNjA5OA_022a8b26-c4eb-49a7-8ab9-3a7e0d27ee57">1,887.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8591d057cc4eec92033c36fb05fd49_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTMtMS0xLTM2MDk4_a8496c01-0866-4d07-918a-2355617a4403">16,811.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0df35c8a12146d0bcdb02fe162f2cb8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTUtMS0xLTM2MDk4_e1db797f-7690-4e3c-a56a-3d1205e39442">14,229.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74307f9a9f5f43698c550cd45a1c8b8c_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTctMS0xLTM2MDk4_cb52dbb8-c7e3-4aaa-b0e8-7c7aa33ca9e8">12,722.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib51a0dd6c879443684c594e3c15c31cd_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTktMS0xLTM2MDk4_2c1a2c95-1de7-4ec2-9ee6-ea77c072df44">11,507.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65921f0a4824d3b8e3297260e7cb19d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTExLTEtMS0zNjA5OA_db8085a1-fd48-4f77-9a34-bad34693be3d">10,310.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c951e01e904d87b87e2c491d7f9dcd_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTEzLTEtMS0zNjA5OA_c92b658b-0b7b-4ec9-8de8-c9c8c5f986c7">9,596.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations. </span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i45eeac14a0414e2e8c3316eccfb24fa5"><ix:continuation id="iaf7721bd6eaf44979b770d283abd517c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:38.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8591d057cc4eec92033c36fb05fd49_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzMtNC0xLTEtMzYwOTg_c79439d1-938c-4607-9390-82bd231c7541">16,811.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0df35c8a12146d0bcdb02fe162f2cb8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzMtNi0xLTEtMzYwOTg_89771b13-d713-4fcc-86fd-a3a7fa5f6380">14,229.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74307f9a9f5f43698c550cd45a1c8b8c_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzMtOC0xLTEtMzYwOTg_407a17bb-8915-446d-9a94-65eefd98c86c">12,722.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04193007085b41a38db99637f0c0d6af_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzQtNC0xLTEtMzYwOTg_23b9688a-da4e-42e7-93ce-b358362d1764">4,776.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d224ea9b86e4818acc1bd5468570078_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzQtNi0xLTEtMzYwOTg_29cccf9b-045a-487b-855e-c86c4b931dd5">4,187.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164330216f6841af817f8d04691a5b0b_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzQtOC0xLTEtMzYwOTg_53d8a64f-355b-47d7-b54c-fd076aabb029">3,765.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13e5ce657124ce698dc637219f87ea0_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzUtNC0xLTEtMzYwOTg_b5f07b89-732f-49f5-bfe2-b83c6d3e85e4">2,367.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7e25f558c047e4ac74c9e031a5a865_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzUtNi0xLTEtMzYwOTg_fcecd08d-e97d-46f2-8ec3-e1484da30563">2,583.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028aeea4c2e64264850f271d8ffb0481_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzUtOC0xLTEtMzYwOTg_4ae4f967-3df8-4dc1-af0a-f452c5b26218">2,547.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd215bb90d2941cb94a58ff2fd939bbe_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzYtNC0xLTEtMzYwOTg_10f96403-36b0-4421-891d-4bf7b1e697fc">1,661.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf899c4538e4ec6b299cfa3908d15fe_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzYtNi0xLTEtMzYwOTg_c632f525-68d3-4aec-a167-1bfb892200b1">1,116.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f3427b27d748f5ba11f0d766ffe5d3_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzYtOC0xLTEtMzYwOTg_a8f9c32e-a786-4998-9ef4-066227449207">939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb2e32e1ad2454892693138d44916ad_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzctNC0xLTEtMzYwOTg_e85f119a-4f59-47d7-8dfe-3d37e0021052">2,702.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id558c6364b764995aa2b6842b75cf8db_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzctNi0xLTEtMzYwOTg_e3969f8d-b184-4627-b7e4-b4751b1acaa9">2,422.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96cf3dcfa7cc4f1396ca4bc3f3f3bf8d_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzctOC0xLTEtMzYwOTg_091162a6-5ffd-4511-99c9-c654aef2b696">2,344.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzgtNC0xLTEtMzYwOTg_86f6abcc-ef7e-4d33-8729-6c4d9d86ed1e">28,318.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzgtNi0xLTEtMzYwOTg_b7ba1b3c-db99-4b0f-928f-a73d4fdc21ba">24,539.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzgtOC0xLTEtMzYwOTg_7ac73087-1559-49eb-814c-2716e3828ff8">22,319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="padding-left:9pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwMDEw_82280466-9b5f-49fd-967e-6f42e8859ec5" continuedAt="i9cbbbc15e97549a6958c5285a52c8584" escape="true"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwMDEw_e7b6866f-2683-49c4-88a5-cd0721208e08" continuedAt="ib987e68786cd4ec088338847040230f5" escape="true">Acquisitions and Divestiture</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i9cbbbc15e97549a6958c5285a52c8584" continuedAt="i83289c58e1824a43b66e53c31264bf79"><ix:continuation id="ib987e68786cd4ec088338847040230f5" continuedAt="icebe8fa9b3e641f7bc6ea10eda5f9bfb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzk5OTY_6f945ef9-d0e4-4c20-a012-bf171d5b55b7" continuedAt="i8bff402c2de04b0ca77e8a28d6759890" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. <ix:continuation id="i8bff402c2de04b0ca77e8a28d6759890">Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use.</ix:continuation> For the years ended December&#160;31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEyNTQ_1ca061c8-a1b8-413c-a5be-46fa588f3edc">874.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEyNTg_cdde136a-75df-422f-8c6f-2dafd0f3bd0f">660.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEyNjY_8098eae9-0875-4c12-81ea-b576cb585e1c">239.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDAyNTI_68e203bc-2564-4a39-97c1-5fd26ecee3d5">22.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i636eda8cc422414eae95184d5ae5708b_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDAyOTQ_6f8872fc-2237-4708-b09b-8f86e6eed957">747.4</ix:nonFraction> million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="i636eda8cc422414eae95184d5ae5708b_D20210101-20210131" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDAzMzQ_566bfdbb-3ab5-41ce-b259-b46e5f5da745">one</ix:nonFraction> non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDA0NDk_b0f86ca8-c9d0-4a80-8f94-865c4c831843">4.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDA1MDU_cc6d0cc3-eaaa-4de8-b33d-150b723b5a5c">160</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonFraction unitRef="usdPerShare" contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDA5MjM_95a6eb31-fcb0-4f33-a508-4bb63bbf1815">8.3</ix:nonFraction> cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i83289c58e1824a43b66e53c31264bf79" continuedAt="i36c510004760468ca276e7b1d02aff1d"><ix:continuation id="icebe8fa9b3e641f7bc6ea10eda5f9bfb" continuedAt="i1742b86c91a04541b138d4303fdb733e"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzI3NDg3NzkwOTQyMTc_f462eefb-14fb-4662-9673-0bc79bdf8e3a" continuedAt="i031741dcd96b48ed8f4193f03d6573be" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzEtMS0xLTEtNDI0ODM_7ef41d79-d977-4bc5-b037-eee8bd438b82">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzItMS0xLTEtNDI0ODM_2edca7b0-0a2a-47d0-ac98-63fa53bfd951">824.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzMtMS0xLTEtNDI0ODM_2b3edf95-0324-48a2-87ff-057d580e861f">126.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzQtMS0xLTEtNDI0ODM_c049a6c2-243f-49ca-be68-8cd06954e8af">106.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzUtMS0xLTEtNDI0ODM_4ca8bb4c-1676-4e9f-a62d-a2afb77ecd99">31.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzYtMS0xLTEtNDI0ODM_12ae728d-6120-4c90-9ae8-0135e0887689">903.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98abec6e97245e78d9fc27b845e6067_D20210122-20210122" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzgtMS0xLTEtNDI0ODM_44d308a4-8ce2-49d1-a6b4-2ce246f78e0d">90.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d886a39796d42f5809576721f051d0f_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzktMS0xLTEtNDI0ODM_c29be1b2-0886-4ea3-9a6a-071410a5c223">65.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98abec6e97245e78d9fc27b845e6067_D20210122-20210122" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzEwLTEtMS0xLTg1MzYx_4841a279-3700-4a13-ada0-2956cbd6fe6b">747.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the year ended December 31, 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="ia99148e294d448a3b8022b7ab548973c_D20200201-20200229" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzE0NDU_a8bac373-e4a7-46b5-aca1-1444e8964aac">849.3</ix:nonFraction> million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $<ix:nonFraction unitRef="usd" contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIxMDE_75d001c1-0f33-4d01-b195-62ed5dae6282">86.8</ix:nonFraction> million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229" decimals="-7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIxMjY_c88498b2-f3fb-49dd-8588-468c8f2f15e3">1.20</ix:nonFraction> billion primarily related to lebrikizumab, deferred income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIxOTk_a0253aa5-056d-4900-ac06-d5510906977a">49.5</ix:nonFraction> million, and long-term debt of $<ix:nonFraction unitRef="usd" contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIyMjU_fe6a3c12-a3e5-472f-a015-373ca6c44aaa">375.5</ix:nonFraction> million. After the acquisition, we repaid $<ix:nonFraction unitRef="usd" contextRef="i0e8e1b30058b460e98b4ea10699f32c6_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIyNjI_a3a39e94-c420-4215-9d40-7f5a034dbeb0">276.2</ix:nonFraction>&#160;million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Loxo Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired all shares of Loxo for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i800aa827b6e345e58b4aa9e11e49e882_D20190201-20190228" decimals="-7" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzI5OTA_cd1f4bf7-4bc5-4e98-85bf-1bef549ab472">6.92</ix:nonFraction> billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i36c510004760468ca276e7b1d02aff1d" continuedAt="i9ac833366e054953834ae109456b452b"><ix:continuation id="i1742b86c91a04541b138d4303fdb733e" continuedAt="i0b689cd66bfe4cf0a51fed87d76f195f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $<ix:nonFraction unitRef="usd" contextRef="id65135fb98c54b32b997c038034eab2f_I20190630" decimals="-7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzM2OTc_56c2ba59-7ef8-4751-aa11-16478564f58f">4.60</ix:nonFraction>&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><ix:continuation id="i031741dcd96b48ed8f4193f03d6573be"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzEtMS0xLTEtMzYwOTg_555c677b-bc6e-421c-a302-cfafbc4a625a">4,670.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzItMS0xLTEtMzYwOTg_5ad8673c-c06a-44f5-a757-0a71d69efc01">980.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzMtMS0xLTEtMzYwOTg_d1cfb97c-5a99-4754-a929-4d1850853955">1,032.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzQtMS0xLTEtMzYwOTg_4018705c-bd36-4d53-ba38-f7edd361f946">26.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzUtMS0xLTEtMzYwOTg_5e2b57f9-9c9a-4f15-90d7-f66a6be0c214">4,590.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzYtMS0xLTEtMzYwOTg_a8ade55a-91c7-4aac-b1b0-7ee457897c7d">2,326.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02a7381a3be4e38890430d12e20673b_I20190215" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzctMS0xLTEtMzYwOTg_a8b4d8a4-7fdb-4dcd-8465-84a575d4e213">6,917.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i600f4904f99849f2ad5f229699acc149_I20190215" decimals="-7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzQwODU_8733a7bd-5fc2-42ae-bd67-f8f9ab79a819">4.60</ix:nonFraction> billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately <ix:nonNumeric contextRef="id7d716a1f4534165962c18f76f7af45c_D20190215-20190215" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzQzODM_b7d883e0-4a10-448e-b644-3eee75b60e60">12</ix:nonNumeric> years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzk5OTA_9246e1dc-9b4a-4d15-8efe-d95e7e6d5513" continuedAt="i03361a33a27840e99f527c4fa8eb6922" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9950f4e9a0354b2fa627384fb3ed7958_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEtNi0xLTEtMzYwOTg_9477d216-c63a-4c2b-8fd0-e1392b17784b">107.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2670d0faa7f348ceb8cb0477e2bbd7ec_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzItNi0xLTEtMzYwOTg_64e966c3-1c96-4b04-93f1-00473adf6c55">46.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d1e0d5a52d4681bade2958b5aa1a4c_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzMtNi0xLTEtMzYwOTg_8f4e13fe-9aea-419a-b6e9-fa7ebbb49e32">20.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6feddb3904ec46578edf8428b7b289a5_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzQtNi0xLTEtMzYwOTg_3403e4f1-924b-4d7c-b8b2-c641ada34001">125.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20656f42f67e4b3ca3072208a9060499_D20210501-20210531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzUtNi0xLTEtMzYwOTg_d7e0dcd5-8b3c-43e7-a200-5c4fde05c71b">25.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec4ebbe67054429582ac383c3ca59a99_D20210701-20210731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzYtNi0xLTEtMzYwOTg_605791ee-c59f-44d9-ab2e-a813c4fc5cdc">57.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><ix:continuation id="i9ac833366e054953834ae109456b452b" continuedAt="iac43cbeae13c49668d5b623e701edfc6"><ix:continuation id="i0b689cd66bfe4cf0a51fed87d76f195f" continuedAt="i17cae7f45b5b4ebbac0b4d4f2f6912dd"><ix:continuation id="i03361a33a27840e99f527c4fa8eb6922" continuedAt="iaad630ec1b6746aab693245afa777535"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f63838d417e4d52a843ed3cdc791134_D20210701-20210731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzctNi0xLTEtMzYwOTg_06df1840-7bd0-4848-b5a0-6117956bb191">55.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe5e5a2099d4c20964ac1055881f0e0_D20210801-20210831" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzgtNi0xLTEtNDI2NDk_17eca403-b02b-4d2d-8d5d-94973c49af5d">35.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625c2c9631a44ce4add09fd63dbb08e4_D20210901-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzgtNi0xLTEtMzYwOTg_ecb35293-2f0a-412a-97aa-faf6bf9939ff">26.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QILU Regor Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for metabolic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb6a0e595d94643bec576021c87b042_D20211201-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEwLTYtMS0xLTg1Mzg5_e61b46b9-6748-436a-ab69-53bc1841129a">30.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia358c590fff34220b7173f72a36ae251_D20211201-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzExLTYtMS0xLTg1Mzg5_05b7703a-4943-4e6e-ad80-64640aa679b2">316.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entos Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a67f18c7ea48ea95d82f120474b9f0_D20211201-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzExLTYtMS0xLTY4Mjgx_06fb0400-2523-4cf3-bd11-1d8fd05fca6a">30.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb6fc6a416848fea9d309fc8093b580_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEwLTYtMS0xLTM2MDk4_ec398e5f-363a-43a2-9d8b-1810c4a94541">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fc657efa784f17b8ef30a51ea8a755_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzExLTYtMS0xLTM2MDk4_a2ba33a2-3adb-4852-8f00-7af38fa9effd">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie824a9d4024d4da5b3b95622f0f82015_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEyLTYtMS0xLTM2MDk4_2d0598ed-752b-4a4f-b64d-a7271490a5c0">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8c7a108f87404bad726fa03ba1f4b3_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEzLTYtMS0xLTQyNTU0_dee1725b-d51f-40b1-818f-a3aa9a419b73">174.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba7dfdc0b6a4b679a897b2cc2ae3a36_D20200601-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE0LTYtMS0xLTQyNTU3_e8c65637-b84c-4040-9993-5cf06b2df27d">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib187355b4ba34c879321b64031638699_D20201001-20201031" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE1LTYtMS0xLTQyNTYw_f7d7df8a-c2fe-4224-8eb6-9565e5030874">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c3dbabca1c4ca8b1462ca74374ab69_D20201001-20201031" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE2LTYtMS0xLTQyNTYz_38a1df59-1cac-4082-87b1-d950bd079c46">126.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14514c12fe4a4a7eac789632d8162634_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEzLTYtMS0xLTM2MDk4_341d996b-484f-47c9-a7b6-00e57b7cd376">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iac43cbeae13c49668d5b623e701edfc6" continuedAt="i9f2f1f95881d4899a6514c58f3e0f999"><ix:continuation id="i17cae7f45b5b4ebbac0b4d4f2f6912dd" continuedAt="id9b89afa73fc4bfd9e9f22f4ed260f84"><ix:continuation id="iaad630ec1b6746aab693245afa777535"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.718%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc045dfe17704aa1bf6a4e76fc728f04_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE1LTYtMS0xLTM2MDk4_b60e1419-eea4-411b-af2f-632258f56bfa">127.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65311cc8393345fda909ba57dd56598f_D20190301-20190331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE2LTYtMS0xLTM2MDk4_79f792a3-4112-419b-8174-f2270ba98b4f">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64076c56e50481bbcc81b0f17931613_D20190401-20190430" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE3LTYtMS0xLTM2MDk4_528dbe65-5cc1-4a6e-890f-50962382d635">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d547a0ec4c74b6b9cc9b20749c49656_D20190701-20190731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE4LTYtMS0xLTM2MDk4_1daab156-df47-4323-8130-dff028fb2d8b">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="i86ed8956b9f74476a74b29069c13a878_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzU1Mzk_43347cdd-fa77-4b53-a4c5-02c28f4a5210">25.0</ix:nonFraction>&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $<ix:nonFraction unitRef="usd" contextRef="i15ffbfb3b6be4f91b268691cc52236e2_D20190101-20190131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzU2MzM_56e67f2f-be4a-481d-9e6f-db213765985f">96.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $<ix:nonFraction unitRef="usd" contextRef="ie1f10220b2a3487cad57915da408086c_D20190901-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzU2OTU_d8078b12-485b-4315-a91c-5dc379e423d4">30.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture</span></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f2f1f95881d4899a6514c58f3e0f999"><ix:continuation id="id9b89afa73fc4bfd9e9f22f4ed260f84">In October 2019, we completed a transaction in which we sold the rights in China for <ix:nonFraction unitRef="medicine" contextRef="if9afc4eaa56b444c8eefdac063ce4a28_D20191001-20191031" decimals="INF" name="lly:NumberOfMedicinesRightsToSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzYyNDI_3b9a6bdc-95bb-433e-a63e-62a1ca28d2a9">two</ix:nonFraction> legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="if9afc4eaa56b444c8eefdac063ce4a28_D20191001-20191031" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzY0NTM_cbf25c02-198f-4974-8df5-da6f86f7e7d0">354.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a5d6173c0cd4f7ab337f6b352f5a84c_I20191031" decimals="-5" name="lly:DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzY0NjA_cb0babab-22f8-49f4-8242-c23fc6d0afd1">40.3</ix:nonFraction> million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="ia3f8e0aa5a644441a2554b382567027e_D20191001-20191231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzY1OTQ_895eec64-e283-4ba6-a4b3-2f635b6a1458">309.8</ix:nonFraction> million in other&#8212;net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</ix:continuation></ix:continuation> </span></div><div id="i1a85401413cf428bb86d28ee6b337a59_115"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;4:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEzMzM1_9a05e989-3f6e-4a03-bc7e-3531b195a716" continuedAt="i7e4ff8ce08144ec2b868e3d08564bae5" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="i7e4ff8ce08144ec2b868e3d08564bae5" continuedAt="i234b1e9a4aff467bbd6d82d4900a487b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto, as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i234b1e9a4aff467bbd6d82d4900a487b" continuedAt="ia0168b59205b4494b4de2853b810933a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta and Basaglar in the U.S, Europe and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. These milestones are being amortized through their respective term under the collaboration which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) any supplementary protection certificates or extensions thereto. <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEzMzU4_1fb60269-1767-4213-b6e8-2bafe93e423a" continuedAt="ifb6f37b2a6354fab8d5b1027dd7f661d" escape="true">The table below summarizes the net milestones capitalized (deferred) at December 31 for the compounds included in this collaboration: </ix:nonNumeric></span></div><ix:continuation id="ifb6f37b2a6354fab8d5b1027dd7f661d" continuedAt="i020aced53ce747c7ab7adf95d143e0ed"><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.216%"><tr><td style="width:1.0%"></td><td style="width:59.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8fafa3bd40547eda95f4f50a6dbab51_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzItMS0xLTEtNjg1Njc_0faa60d4-c503-4988-a546-32c031646cba">136.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebe26c48d94c40a9b534da5ed3e8d8_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzItMi0xLTEtMzYwOTg_349200b6-2d4a-4687-abad-cc7b6b3f4680">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853d77493c24496b99d5233e605a2605_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzMtMS0xLTEtNjg1NTQ_918edf71-eb6a-4338-9511-6e39afc81a52">88.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c6112bfb3344d99c577b0fc24fd405_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzMtMi0xLTEtNDI3NDQ_1e812965-bc67-4d4c-8ebe-29fc4ab86d60">114.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa9ef0f44c884bf695c4900d1d6d8b9a_I20211231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzQtMS0xLTEtNjg1NzU_93f71402-6ca7-4ab2-a0ec-4bcdb27a6efa">149.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied98305e265a49d9bdc89506cb9d5cd6_I20201231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzMtMi0xLTEtMzYwOTg_022a465b-9362-4e03-a763-ad84686df7b7">168.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2019, in the most significant markets, we and Boehringer Ingelheim shared equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We recorded our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We recorded our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we recorded our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company was entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments may have resulted in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may have been reduced by any performance payments we made related to these products. Similarly, performance payments we may have received related to Basaglar effectively reduced Boehringer Ingelheim's share of the gross margin, which reduced our cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, we and Boehringer Ingelheim modernized the alliance. For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><ix:continuation id="i020aced53ce747c7ab7adf95d143e0ed" continuedAt="ia6e27f1d59f04df8b575701b2eb45c7d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136e92857ae343079e9fdebb19210eb1_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzItMS0xLTEtMzYwOTg_01017acd-ea80-4e59-b8d8-0f8cea9d0fe8">1,490.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399d8f462fc045509a0e309187f2f20c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzItMy0xLTEtMzYwOTg_a843246e-9f20-4ea3-9678-a3ab90f782a7">1,153.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c6636c6e8b4149a436c5c7f6ae3d8f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzItNS0xLTEtMzYwOTg_3d50f42d-cf4f-42ee-ba04-623069760d89">944.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486722122165416c854ef981a6e4ff97_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMS0xLTEtNDI3ODE_e541f512-34a8-453e-9b47-7200e24cfc39">892.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb15db3b22d7456aa9d475cfe3645e22_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMy0xLTEtNDI3Nzg_50df9222-893d-42fb-9000-9935891cec95">1,124.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d89303e28444753a87b86f2491e9dfd_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtNS0xLTEtNDI3ODQ_6b86da31-bb06-4f56-879c-b67e59bb2268">1,112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8434b474adc4712945fa8b15221a062_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMS0xLTEtMzYwOTg_fb2dd6eb-e5c5-43dc-be86-ab79615c196f">372.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c1f715e391472e9c4295cbc73dfcc5_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMy0xLTEtMzYwOTg_6b77112a-2813-4d3c-8161-49daadcdd914">358.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc1b15a414543789a445369b1f1c319_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtNS0xLTEtMzYwOTg_c1f03e0c-54d2-4582-8b2d-4565d049f91c">590.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ia0168b59205b4494b4de2853b810933a" continuedAt="i41d04da8b2684a73aff904f86d8a847f"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="ie508b8edff5e4d49ac5daeb3e44ee7d3_D20210101-20211231" decimals="2" name="lly:CollaborativeArrangementRightsAndObligationsPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzYxNzA_d35b5d68-7048-43c7-841a-00f7aa3d1842">20</ix:nonFraction> percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i8fa8514e03e541bab9bb427c8c8e408d_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzQzOTgwNDY1MzkxMjc_221e32ef-e417-4f0f-b0d2-9f8cf25a7fdf">260.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i05b90b30620c4805b8c68b6df7e498b5_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzY3Mjg_54c24bd9-abed-4ab5-a091-6033b93cb4ce">210.0</ix:nonFraction> million were capitalized as intangible assets as of December 31, 2021 and 2020, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="id33d1a73df7248168e83573873688d81_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzcwODg_203f0d80-fe3d-42fa-beb3-a8fea7108cf5">100.0</ix:nonFraction>&#160;million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i60f74e83d5644e2c8fbb2e5c78bfd650_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzcyMjQ_dae2e2f1-a57f-4988-a912-984ad490e5eb">100.0</ix:nonFraction>&#160;million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to an EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="ia6e27f1d59f04df8b575701b2eb45c7d" continuedAt="iba29e191b5e944f0ba5307387c05b5ae">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-top:11pt;text-align:center"><ix:continuation id="iba29e191b5e944f0ba5307387c05b5ae" continuedAt="id547bad2e81244f484e8521339b256a4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffacbc5450e4178843413354209aaed_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplNDFhOWVhNjhhNTQ0MmYyOWUyOTllZGQ2OWY0Njc1Ni90YWJsZXJhbmdlOmU0MWE5ZWE2OGE1NDQyZjI5ZTI5OWVkZDY5ZjQ2NzU2XzEtMS0xLTEtMzYwOTg_2d00d0fa-6bd9-4f28-bbcc-1c3c9180a219">1,115.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb740f8f8fb49248e01e2ab80d6ae9d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplNDFhOWVhNjhhNTQ0MmYyOWUyOTllZGQ2OWY0Njc1Ni90YWJsZXJhbmdlOmU0MWE5ZWE2OGE1NDQyZjI5ZTI5OWVkZDY5ZjQ2NzU2XzEtMy0xLTEtMzYwOTg_a4917510-53e0-404e-828c-3abee49f1097">638.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249d33d5a06a4082a59829e958e69da7_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplNDFhOWVhNjhhNTQ0MmYyOWUyOTllZGQ2OWY0Njc1Ni90YWJsZXJhbmdlOmU0MWE5ZWE2OGE1NDQyZjI5ZTI5OWVkZDY5ZjQ2NzU2XzEtNS0xLTEtMzYwOTg_7772597b-7e2e-4c0d-b395-e93a239a8b22">426.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also had the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of sales-based milestones in 2021, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i48acf53cf4c149ba854e91d6ea82b05a_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzI3NDg3NzkxMDc5MjY_0b3dde24-7132-4cd7-8b0d-485093c232a3">195.0</ix:nonFraction>&#160;million were capitalized as intangible assets and are being amortized to cost of sales over the estimated useful life of etesevimab. During the year ended December 31, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="if1a83cd101f14432a8f149d6a0e602f8_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzI3NDg3NzkxMDc5NDI_3a4f85fc-bed3-4119-9594-4f90926ddaff">50.0</ix:nonFraction>&#160;million of research and development expenses related to development milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized $<ix:nonFraction unitRef="usd" contextRef="ic9a3812ca43742f1ae973a2b31a04adc_D20210101-20211231" decimals="-7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzE2NDkyNjc0NjM0OTM_0d3cafe4-aeed-4bb9-a2b8-84da9a00e3cb">2.24</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ief25801843e9467799271bdda2e99bd9_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzE2NDkyNjc0NjM2NDY_2d838093-8b3f-4ad1-b283-bf8a0dd49cb1">871.2</ix:nonFraction>&#160;million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December&#160;31, 2021 and 2020, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i41d04da8b2684a73aff904f86d8a847f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we plan to pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a regulatory approval for Tyvyt in China in 2021, we capitalized a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i5e413d56e5d84f349849637c0f978d4b_I20210630" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzcxNDY4MjU2MTkwNjE_7fd3c807-8f94-479d-b088-9c2385135542">40.0</ix:nonFraction>&#160;million as an intangible asset which is being amortized to cost of sales through the term of the collaboration. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Innovent is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i4e4260516b4243cab0755138b1cb1e20_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwMzE1_118da4d7-3608-46a7-8f72-28663eada047">825.0</ix:nonFraction> million for geographies outside of China and up to $<ix:nonFraction unitRef="usd" contextRef="i96a4b9d553f8498a8d8c5c1b0148aee5_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwMzYx_32b251c2-4580-4833-bc96-5d9ec22efcfc">195.0</ix:nonFraction> million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. <ix:continuation id="id547bad2e81244f484e8521339b256a4" continuedAt="i1fcdf2f93c5f4e928a54cbaacc8f1fbc">The following table summarizes our revenue recognized in China with respect to Tyvyt: </ix:continuation></span></div><div style="margin-top:11pt;text-align:center"><ix:continuation id="i1fcdf2f93c5f4e928a54cbaacc8f1fbc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ae01d552e14307ade61a2e8ce4818f_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTo0MGRhYmM1Mzc4OTk0ZDFhYjZiNmMyMDgyODAxODM0OS90YWJsZXJhbmdlOjQwZGFiYzUzNzg5OTRkMWFiNmI2YzIwODI4MDE4MzQ5XzItNS0xLTEtNDMwODE_cac46780-05ab-4386-a7de-a74de795693f">418.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ec11f13ec44ec886a4d089e6954497_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTo0MGRhYmM1Mzc4OTk0ZDFhYjZiNmMyMDgyODAxODM0OS90YWJsZXJhbmdlOjQwZGFiYzUzNzg5OTRkMWFiNmI2YzIwODI4MDE4MzQ5XzItNy0xLTEtNDMwODE_ec111761-e28c-4928-85fe-52851a728a20">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd825e2456741c6b9498e5c19f301ed_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTo0MGRhYmM1Mzc4OTk0ZDFhYjZiNmMyMDgyODAxODM0OS90YWJsZXJhbmdlOjQwZGFiYzUzNzg5OTRkMWFiNmI2YzIwODI4MDE4MzQ5XzEtMy0xLTEtNjg3OTQ_5425c907-f0e2-4231-b632-5014576a13f2">134.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2021, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i42cba64a30364790b8eb1eb2ae66c5e1_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyMDUw_7063d8a7-963d-4c58-91ee-4e4e028e275e">180.0</ix:nonFraction> million of payments from us contingent upon the achievement of success-based regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i45283f4c7fdc40bf9a23a33c5df93208_I20211231" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyMTU1_aa2c871e-aa1f-43ed-836d-85c52cf5c6f1">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2021, we are eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="icaf2be9f580f44fd8e954526bb36e7f2_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyODEx_aad61345-3d0e-4f9c-b3d9-92a9dcfda7dd">85.0</ix:nonFraction> million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i2e72a7d25b8a40b99e28b009e54e5649_I20211231" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyOTA5_f166a5b6-0bbf-4270-8e0f-97d6deb83d3e">1.25</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. As of December&#160;31, 2021 and 2020, contract liabilities were not material. During the twelve months ended December&#160;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Petra</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. Our more significant, near term milestones include a development milestone of approximately $<ix:nonFraction unitRef="usd" contextRef="ie7bd696f56304ea8940548378684aacd_I20211231" decimals="-6" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwOTk1MTE2NTU0MzA_dbcc66b0-9597-4f41-aaeb-e8753733c2ee">205</ix:nonFraction>&#160;million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $<ix:nonFraction unitRef="usd" contextRef="i7efe9a1356e9485983eeb603c301d153_I20211231" decimals="-6" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwOTk1MTE2NTU1NDM_2a01489e-f87d-430c-8119-f8043639ded3">164</ix:nonFraction>&#160;million in 2023 contingent upon achieving clinical proof of concept.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">73</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzEwNzA_f0c591a7-3a0a-49b6-9348-358e1ed987df" continuedAt="ic77fabe60b964a1bb9d5437acb41273e" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonNumeric></span></div><ix:continuation id="ic77fabe60b964a1bb9d5437acb41273e" continuedAt="i0fcf42a44ccb4cb7a93661c9448a91ac"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzEwNjQ_3b4e5122-14a7-4a5c-a3f3-43d760d6caaf" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzEtMS0xLTEtMzYwOTg_8eea55fe-b56b-41a9-9ea0-2d20e0079ded">13.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzEtMy0xLTEtMzYwOTg_a6dbbdbe-1945-4400-9c77-35e7226251d6">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzEtNS0xLTEtMzYwOTg_f30a6708-15ac-4d5d-beab-d8942d913008">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzMtMS0xLTEtMzYwOTg_653db8dc-f09e-4530-bc64-c905c0cc4f94">303.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzMtMy0xLTEtMzYwOTg_b86f2b53-b9be-4ae3-96df-0fa681be8833">20.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzMtNS0xLTEtMzYwOTg_bd071071-c544-4e3e-b943-7ba701a2190f">497.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzQtMS0xLTEtMzYwOTg_92c62eda-0587-4a49-9eac-ff439bbfc426">316.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzQtMy0xLTEtMzYwOTg_fd3f5846-fd89-430b-8b87-ffbb39d60790">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzQtNS0xLTEtMzYwOTg_29d04535-3fb1-473c-8b1a-c01f6c2ada73">575.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance costs recognized during the years ended December 31, 2020 and 2019 were incurred as a result of actions taken worldwide to reduce our cost structure. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzExNTQ0ODcyMDk1NDY2_7049f8c1-a112-4280-95a1-eb19c2d61db1">128.0</ix:nonFraction> million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo. Additionally, we recognized $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzExNTQ0ODcyMDk1NDQ1_4b0edd23-e2b6-446a-8256-8dc83005fedf">108.1</ix:nonFraction> million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0fcf42a44ccb4cb7a93661c9448a91ac">Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $<ix:nonFraction unitRef="usd" contextRef="i76e71ae8b5064232b5cf8e0340ad9913_D20190101-20191231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzYzMw_a6695e17-dfb3-4578-a6c1-5e1d4113b938">400.7</ix:nonFraction> million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards.</ix:continuation> </span></div><div id="i1a85401413cf428bb86d28ee6b337a59_121"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;6:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzYwMQ_65a0a216-4742-47cd-b6bd-43330f17a754" continuedAt="idcbbdfe935d148af8b03178b7de9d542" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="idcbbdfe935d148af8b03178b7de9d542" continuedAt="ia925931f5a234061b79258fc05d85ea3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzYwOA_f4f863e5-6dca-46df-aa1f-5cb550926013" escape="true">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</ix:nonNumeric> Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzYxNw_49a06a33-6952-4a48-bc20-a8020794b03a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzEtMS0xLTEtMzYwOTg_aa760040-7970-48a0-a980-4501c4211976">761.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzEtMy0xLTEtMzYwOTg_9d86b5f9-9980-4553-8acd-a6c508cc98c8">758.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzItMS0xLTEtMzYwOTg_235d3f17-ef76-4e06-973b-1dca018a27ef">2,372.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzItMy0xLTEtMzYwOTg_93ed2781-102b-44b1-aab6-b4ee377764dc">2,535.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzMtMS0xLTEtMzYwOTg_1f5af9e9-eb15-4e84-bb74-d91e329ae6c8">717.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzMtMy0xLTEtMzYwOTg_d8002b63-7b2a-4160-92fa-6c400816880c">651.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzQtMS0xLTEtMzYwOTg_30469f51-5d52-4b5b-baeb-4604aaab36db">3,851.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzQtMy0xLTEtMzYwOTg_2a3f94b7-f0c6-4446-ae82-f56a5cd59f1d">3,945.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" sign="-" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzUtMS0xLTEtMzYwOTg_a99a687a-925d-41a0-b9fe-e269d8ba8b50">34.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" sign="-" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzUtMy0xLTEtMzYwOTg_7eec3a12-037e-4ee1-a8b0-f43cc8cc90f8">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzYtMS0xLTEtMzYwOTg_7b181697-c13d-4fef-abce-8bed77341b9d">3,886.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzYtMy0xLTEtMzYwOTg_ad470dc3-7ac8-46e1-a494-84447062ce7d">3,980.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzUzOA_ea15a25a-11f2-4b00-a61c-f5e896fedd0d">1.36</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-7" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzU0NQ_1b79d523-8c6f-4db0-8cee-98e8c21bd202">1.21</ix:nonFraction> billion of total inventories at December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia925931f5a234061b79258fc05d85ea3" continuedAt="i3f81734685da46feb93c494f00215c2a">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzExNTQ0ODcyMDkzMTA0_3cf167cd-de01-4a93-a969-ee1e4ac9ef62">339.7</ix:nonFraction>&#160;million during the year ended December 31, 2021 in cost of sales in our consolidated statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments,</ix:continuation></span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3f81734685da46feb93c494f00215c2a"> including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">74</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTYz_2d499527-a87d-44db-92cd-47982ec19f6d" continuedAt="id84c20c0ee5d44a58b53d5442cfcef4f" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="id84c20c0ee5d44a58b53d5442cfcef4f" continuedAt="i3874350d6b0a46c08c5da08bf5daa63c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTMw_7ddbd1c9-d737-4a0e-b5a6-96ca549ab1d5" escape="true">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTM3_4649f05e-a483-4f3c-9242-cbf3db1757f9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTA4_e01fb2e6-a2c8-4dc5-80b3-b8c0bb35c972" continuedAt="i6ac86a7155f44d86921c769e3a2a0633" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ac86a7155f44d86921c769e3a2a0633" continuedAt="icaba6d1a66794bd48e27f01cf1666d26">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.</ix:continuation> Forward contracts generally have maturities not exceeding <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQyMjQ_ab33b0ca-3e18-48c0-bdf7-507dd0caac64">12</ix:nonNumeric> months. At December&#160;31, 2021, we had outstanding foreign currency forward commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i04f34fc75a9044519a55f0a841ded99b_I20211231" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzMTA_9a4b7226-4129-443a-b9f5-2ef3782e4891">4.43</ix:nonFraction> billion U.S. dollars and sell <ix:nonFraction unitRef="eur" contextRef="i04f34fc75a9044519a55f0a841ded99b_I20211231" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzMzU_f2a4883e-d6aa-4e40-b67c-23857c7cc562">3.92</ix:nonFraction> billion euro; commitments to purchase <ix:nonFraction unitRef="eur" contextRef="ic28ad2006eb14d37878a695f14e7352c_I20211231" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzNjg_80746a0a-afd9-4111-ba12-58e79b60b11d">3.84</ix:nonFraction>&#160;billion euro and sell <ix:nonFraction unitRef="usd" contextRef="ic28ad2006eb14d37878a695f14e7352c_I20211231" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzODU_68aba537-6868-4706-8c09-d23817fccefd">4.37</ix:nonFraction>&#160;billion U.S. dollars; commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i20261b7a34e44eef9f687c2383ca625d_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ0MjY_06550ac8-3531-492a-b3af-9756e337492a">159.2</ix:nonFraction>&#160;million U.S. dollars and sell <ix:nonFraction unitRef="jpy" contextRef="i20261b7a34e44eef9f687c2383ca625d_I20211231" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ0NTE_758b89d1-27ef-4930-80c7-aae67e351ad8">18.26</ix:nonFraction> billion Japanese yen, and commitments to purchase <ix:nonFraction unitRef="gbp" contextRef="i6fe06c36179f415f8d86b66fba575560_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ0OTY_82570ed0-960b-4005-8077-383be247c691">223.0</ix:nonFraction> million British pounds and sell <ix:nonFraction unitRef="usd" contextRef="i6fe06c36179f415f8d86b66fba575560_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ1MjM_45659656-9bab-4ba4-bd15-ae88ed9985fd">296.0</ix:nonFraction> million U.S. dollars, which all have settlement dates within <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ1NjQ_72bba9bf-ea28-47af-91dd-4dcfd1f8ff84">180</ix:nonNumeric> days.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i3874350d6b0a46c08c5da08bf5daa63c" continuedAt="i225f052465674ce0ba6a0eb4edcc4e6d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="ia33be6c87c2c473f9a400403f197ba1f_I20211231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ3NTk_597c1ef7-fedd-48ae-86f4-23dd04dbf157">7.90</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ibf59c02dd99c40c1952252de92c7253e_I20201231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ3NjY_ec6b6ffe-7018-4b52-b25e-b9b486a900d4">6.02</ix:nonFraction>&#160;billion as of December&#160;31, 2021 and 2020, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ4MTA_99bf1e2b-5688-49da-8a62-0182fc47bf1d">5.79</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ4MTc_3eb38886-84e2-4578-b097-8ef6a01caa3f">4.50</ix:nonFraction>&#160;billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December&#160;31, 2021 and 2020, respectively. At December&#160;31, 2021, we had outstanding cross currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i62bec06499364dfeacd40d1298f61c82_I20211231" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzUwNTk_4ebc9d3d-7d4c-479e-bcbb-29979c0e57ba">1.02</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="ic6cb727e20f143faa3e3a38b9dfff0c3_I20211231" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzUwOTY_2836ebc7-c6fa-4e41-9f3b-30a5d949af6b">1.00</ix:nonFraction>&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icaba6d1a66794bd48e27f01cf1666d26" continuedAt="i607ce4871ebf4a1b94cc6c4c828b8983">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i607ce4871ebf4a1b94cc6c4c828b8983" continuedAt="i37202b8b9b4a41b88a320115c96c3aa1">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.</ix:continuation> At December&#160;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="2" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzY4Njk_5b223b63-4676-41a4-a223-0dee630a0eb6">13</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i37202b8b9b4a41b88a320115c96c3aa1">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</ix:continuation> As of December&#160;31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="iacadc29206d84c3fa7fd83b205a66414_I20211231" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzc1Nzg_f48d6b2c-5487-4be0-99d5-8b7107e56af5">1.75</ix:nonFraction>&#160;billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTc0_0a9bddce-8207-41fc-a86b-e6129c1d92f9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13cf07612b294643a8bc48b8588f1f8d_D20210101-20211231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzItMS0xLTEtMzYwOTg_e399b6d3-9e6f-490a-b3e2-2ce83a60e741">78.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7edcbbba5dfc46c38e6a76c687dd5837_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzItMy0xLTEtMzYwOTg_9a218302-ee52-43d3-b0e4-e88ce3381dcd">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6411281e97d94731863b39b1923f21a0_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzItNS0xLTEtMzYwOTg_f9a34b4c-6a30-4e94-aa4c-cb4027c296da">112.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc442230d5c4382b155b07c92135617_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzMtMS0xLTEtMzYwOTg_0fdb75e1-43a6-4595-99ff-d9bcc772392c">78.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3963f62afd047ba88fb5cbe40c1d155_D20200101-20201231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzMtMy0xLTEtMzYwOTg_eb671c6e-f1de-4568-93cc-97fa00e6a75a">86.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8de4d107e8a743a9aaf08d126d7c581c_D20190101-20191231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzMtNS0xLTEtMzYwOTg_48a193d0-b4d6-45ec-888e-14cff5ae0e1a">112.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc442230d5c4382b155b07c92135617_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzUtMS0xLTEtMzYwOTg_f5e70f54-9e68-474f-ac9f-e8712a1ff24d">16.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3963f62afd047ba88fb5cbe40c1d155_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzUtMy0xLTEtMzYwOTg_cdb249e7-ff13-4fcc-b873-8106c6176be1">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de4d107e8a743a9aaf08d126d7c581c_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzUtNS0xLTEtMzYwOTg_843d5ec9-c13f-4203-834f-12c8dfba3a36">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8aad08f18b4154898d2ecd801df8d1_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzYtMS0xLTEtMzYwOTg_00871951-7262-44df-a4d4-61dbb6ebf7ac">41.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e0f3057dc4a4dd1ab06ea189bd4a2fa_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzYtMy0xLTEtMzYwOTg_c940b9c3-e434-40a8-8728-8f3eee69de84">102.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c3cc7a81d924d63acfe2aeb96bbdd40_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzYtNS0xLTEtMzYwOTg_e7f22fe6-ca56-4149-89cd-2986caab2e9f">17.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1125c3d05584e4488d02c8aa1c758e9_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzctMS0xLTEtMzYwOTg_404907b5-5ef2-4081-a9f9-259a3c400661">204.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i172c281918af4f27986511aa04ee513f_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzctMy0xLTEtMzYwOTg_bae4ad90-d94e-43e4-8dbc-ec8b9861e17d">123.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4ac65858f54342b86be7fc605a4ffe_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzctNS0xLTEtMzYwOTg_32c59a1d-792c-4a14-acc0-30f58a67c82f">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzgtMS0xLTEtMzYwOTg_8532b679-3e4c-4db7-af32-a39d96de985e">263.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzgtMy0xLTEtMzYwOTg_8283cd0d-87ba-4524-a270-b6c25e8a3933">209.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzgtNS0xLTEtMzYwOTg_26c65b78-b8c0-4582-ac3b-427a39d7e2c3">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i225f052465674ce0ba6a0eb4edcc4e6d" continuedAt="ic36889cb2fd74facac6729f2c3de7c62"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDk5_45054e8b-a499-4c17-add6-2b4dabfb44d6" escape="true"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDk5_c91c5558-01af-41f4-8ee7-b8de5eeeeba9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b70f245d0994606a77553c858e70e2d_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzItMS0xLTEtMzYwOTg_cba464a9-ce82-45e6-b82b-eea21ab916c7">435.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf867828fd8402cab098ff96e91c5b4_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzItMy0xLTEtMzYwOTg_b4492c3e-1865-4b58-a928-c72b5dedf420">404.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231f5158b0a54e01b77ad8a5c7af7e1a_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzItNS0xLTEtMzYwOTg_65615bf8-f007-4955-9731-097ca7d70288">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea923d9282a47d6b6affe9918bcfb47_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzMtMS0xLTEtMzYwOTg_bcf43e7c-26aa-43d6-b521-a5582ff50758">213.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdf591423b44978b57ec5e6980efa0a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzMtMy0xLTEtMzYwOTg_7a3a9c10-b4d9-4b3f-bc46-ab9990fb6a08">207.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e3b85955b94cd59588c3c75b0d84c6_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzMtNS0xLTEtMzYwOTg_96ea8a73-cdd0-44d0-83c4-5d95fdbb568e">47.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2733925e7174df2a7294f9cc18f29d0_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzYtMS0xLTEtMzYwOTg_7e3b6915-3481-47b3-ad86-42f669bdb07d">97.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48d907c6902548ad9042a61cf12bc57c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzYtMy0xLTEtMzYwOTg_9a6fd370-f024-4b19-831b-c5ae7aab4264">110.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1034a9c1ab4a439abf5f9b58a0013acc_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzYtNS0xLTEtMzYwOTg_629f7d56-f9a9-4868-a186-d0ab635f5b02">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea923d9282a47d6b6affe9918bcfb47_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzctMS0xLTEtMzYwOTg_6025ea90-678f-4490-91b5-2f06bde82858">42.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccdf591423b44978b57ec5e6980efa0a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzctMy0xLTEtMzYwOTg_89dac576-e423-4412-85de-9ecad7f1f6e3">53.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87e3b85955b94cd59588c3c75b0d84c6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzctNS0xLTEtMzYwOTg_4d084783-4855-42bf-81fe-ac73ca0cc299">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12 months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzgzMjc_bfc7e511-135c-4067-b571-887cd70cef5c">16.5</ix:nonFraction> million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the years ended December&#160;31, 2021, 2020, and 2019, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ic36889cb2fd74facac6729f2c3de7c62" continuedAt="i7bb4c1c4839342ca8b778537ecccff15"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTEz_e1798ecb-ca58-42d3-be8d-c36c21739907" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtMS0xLTEtMzYwOTg_8b71d884-37d6-47a0-930b-bbd82cef9e8b">2,379.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242bd07c45d542379d0e0d769eb01235_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtMy0xLTEtMzYwOTg_3dfff4e9-c191-481d-b259-97ae22596086">2,379.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f207cd4c10c40c58e5e98e94e0977fe_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtNS0xLTEtMzYwOTg_ff466a6c-3e25-4438-9b9a-48c51842fc14">2,361.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01d3d2786ef48c7b3a9a7abc2347162_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtNy0xLTEtMzYwOTg_dbc65f0a-01ad-4ad1-8061-1f8ffb45722a">18.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca22a25490746b2a01afb869b9c9451_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtOS0xLTEtMzYwOTg_eedc1a2d-249d-415a-989c-ee10316e8a7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cacf599a2654a73aeb964f7e22ed6fb_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtMTEtMS0xLTM2MDk4_006cf3fc-7859-4eb5-8fcc-4fd6c00f6918">2,379.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd392ae258dd4c8682df0b88169ff443_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtMS0xLTEtMzYwOTg_68f7c03b-ea8e-4cd6-94b7-62bca4dc8ae3">25.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9309322cbf4299ba4880f01282b66d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtMy0xLTEtMzYwOTg_017eea14-bba7-404c-9ddb-8e1a85bccc98">25.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c1fe3ce37c429a96afdfe79afa5af8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtNS0xLTEtMzYwOTg_7463ea52-1bf0-45b3-a520-5ea9dbca4be8">25.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id782339ced69430ea75a51f82b17fa9e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtNy0xLTEtMzYwOTg_5309397e-04e5-42c8-89dc-9b0c8c85aff1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366462e14a747678162a92e578671fc_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtOS0xLTEtMzYwOTg_f6bb7e54-1b02-4bf5-85de-78d410f7d419">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873a6f3b952448949d4f521a40683c05_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtMTEtMS0xLTM2MDk4_1de66f0b-77d5-4d15-8019-6b7e46c8d6ef">25.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af1d3d2625a408dbe57ea38651c828d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtMS0xLTEtMzYwOTg_2b85cb3a-d514-4e49-84df-4aa99211874b">43.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77f19b3dbbc4c1d80c04d076b72b774_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtMy0xLTEtMzYwOTg_857b9c52-a00a-49eb-b041-b6d38f79c786">43.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2626088ca7db42dd977c6aebdf6b049b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtNS0xLTEtMzYwOTg_972794d3-f64f-49c6-977c-40eaffe40399">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5386daa8d43b4f8fbff09fb65341a6f2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtNy0xLTEtMzYwOTg_b645c99f-3d1b-4364-beb2-92576a6e1e3f">43.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d69d72b4fd4b7b89d28f60a414253c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtOS0xLTEtMzYwOTg_af53201b-6da6-4981-8eaf-2f27bec44e8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1ffc73d6c5b44b9afdbee59fdd53fd4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtMTEtMS0xLTM2MDk4_33e03330-064c-4e8f-94ab-6c828b7f4a18">43.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167566322d3e4bad868eb0f8ff25fb59_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMS0xLTEtODQ5MzM_d7355d5c-ec45-4b72-8e58-860725be4a91">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a69147b72c429dbae1a73cd1a2182c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMy0xLTEtODQ5NDE_1d72a628-35db-42bd-a3a1-39bb154bcb1c">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f41fed5a2748dd899cdc2d6df25422_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNS0xLTEtODQ5NDk_d9551cea-81f6-48a8-811b-54366b36bcbc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac07bef7ae3f4c03ab806ac0355474b8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNy0xLTEtODQ5NTc_726c1983-8647-434b-ae6d-291ac555dd51">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdffc1192c114929a5c33da248552b55_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctOS0xLTEtODQ5Nzk_8adc6b3d-1f4c-493e-ace7-382e4b78c724">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc6a1a7f28f40fb9514b1428d9518a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMTEtMS0xLTg0OTg3_b7d607ad-208a-4a20-924d-4eee604dc6b7">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4d104ab06043e094df62100f0da340_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMS0xLTEtMzYwOTg_10a9444e-e835-4821-a310-a3c849e8f9ac">6.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fc52f2565b4f23a7e7a380898faab8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMy0xLTEtMzYwOTg_409db513-34d7-4d3f-a6b2-5eaf46cb2431">6.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908a1e69c3d14ca19b78ad94abf18315_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNS0xLTEtMzYwOTg_524288e9-8650-4e33-a017-ae10d544e928">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if243f863e61d40228ccaf6b6475f9534_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNy0xLTEtMzYwOTg_fd025085-68a9-43e9-901f-98b127b85dd2">6.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d669a981bf145e98752c8ae97287ef1_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctOS0xLTEtMzYwOTg_42247870-f5b2-4dae-931a-83753a3415c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814218cfc2834473ba1512b07052cb1d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMTEtMS0xLTM2MDk4_96b682d2-3482-48bd-bde0-d301d3863298">6.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88d4e701c504e9b93b9007e768400d8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtMS0xLTEtMzYwOTg_de031d33-5e83-45f6-9f78-36c2f850ea3d">14.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0e6c24bfd5491e8a07010acbd5b7a7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtMy0xLTEtMzYwOTg_2c6a9ed2-6e4e-4725-9cfd-8178d6738370">14.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde117f5d3be4373957394d16191ee0b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtNS0xLTEtMzYwOTg_4b1d465f-5092-4bdd-9cf9-ce98636d09c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f07bbac3664847aaeae5a2475a657f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtNy0xLTEtMzYwOTg_d66ccbec-2faf-4022-9962-da7abf75ea1c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1eb7cb09f94a6c988ce5500bf74a37_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtOS0xLTEtMzYwOTg_c2a3636f-fae8-497d-9c0c-e04f09ba40e8">14.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc632f8e72b402d89710b5655c6a876_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtMTEtMS0xLTM2MDk4_3131c728-939e-4247-ab77-43517d734bb1">14.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEwLTEtMS0xLTM2MDk4_7eeac32a-83a5-46ab-9cfd-80705bcc98f6">90.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd392ae258dd4c8682df0b88169ff443_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTEtMS0xLTM2MDk4_365ff496-ec2e-47c5-a477-d06ec8e089db">137.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9309322cbf4299ba4880f01282b66d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTMtMS0xLTM2MDk4_5ba33991-634a-4d41-b14b-05b154b3c576">136.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c1fe3ce37c429a96afdfe79afa5af8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTUtMS0xLTM2MDk4_f1079e69-8d30-4135-838f-139f6c0402b4">137.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id782339ced69430ea75a51f82b17fa9e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTctMS0xLTM2MDk4_99c048e3-64d0-42d8-aaf8-b56d3fd92d3d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366462e14a747678162a92e578671fc_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTktMS0xLTM2MDk4_e428de92-6b2f-47a9-9647-60da79fd43df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873a6f3b952448949d4f521a40683c05_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTExLTEtMS0zNjA5OA_c42f6c5e-648c-4ff2-bfd3-23fbfa43c5f2">137.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af1d3d2625a408dbe57ea38651c828d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTEtMS0xLTM2MDk4_f756eb66-3641-48ba-9fbb-f9f1e6fcdc60">235.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77f19b3dbbc4c1d80c04d076b72b774_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTMtMS0xLTM2MDk4_d0e7bfd6-ee28-42e0-ba38-0ad58dcf22da">232.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2626088ca7db42dd977c6aebdf6b049b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTUtMS0xLTM2MDk4_96836dc1-adf0-4a3f-821e-052774fdafba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5386daa8d43b4f8fbff09fb65341a6f2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTctMS0xLTM2MDk4_b8de8a18-0ae6-46cd-a7c5-2c4b8d85e043">235.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d69d72b4fd4b7b89d28f60a414253c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTktMS0xLTM2MDk4_59928fbb-73a6-4a9c-a780-49c5e7c8f6e1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1ffc73d6c5b44b9afdbee59fdd53fd4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTExLTEtMS0zNjA5OA_4e0341ac-8a9a-4372-986c-c1ed67e6c3e2">235.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167566322d3e4bad868eb0f8ff25fb59_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTEtMS0xLTM2MDk4_37bb24d2-5734-419b-bd48-4fcd4fc7b134">109.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a69147b72c429dbae1a73cd1a2182c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTMtMS0xLTM2MDk4_a35ddc92-b181-4cf1-8121-473a4344be48">108.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f41fed5a2748dd899cdc2d6df25422_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTUtMS0xLTM2MDk4_51f221c7-c037-499a-9d64-bee309aeb819">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac07bef7ae3f4c03ab806ac0355474b8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTctMS0xLTM2MDk4_d0a1269a-8a43-489b-a25d-6d95e5b42780">109.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdffc1192c114929a5c33da248552b55_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTktMS0xLTM2MDk4_ff9f9691-23cd-4f6d-86d9-2a0bd5893a10">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc6a1a7f28f40fb9514b1428d9518a0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTExLTEtMS0zNjA5OA_6a18ba7f-949a-4c3f-9432-ac612dda9422">109.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4d104ab06043e094df62100f0da340_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTEtMS0xLTM2MDk4_4077d677-db76-4877-9aad-c0bc7c1de4ff">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fc52f2565b4f23a7e7a380898faab8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTMtMS0xLTM2MDk4_2d638a02-8a7d-421d-889d-ec6e8ab00586">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908a1e69c3d14ca19b78ad94abf18315_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTUtMS0xLTM2MDk4_838a51b7-46cf-45a7-839b-5fa83408e8ba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if243f863e61d40228ccaf6b6475f9534_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTctMS0xLTM2MDk4_8509cbc5-16cf-4fb2-98ee-e48ce6831685">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d669a981bf145e98752c8ae97287ef1_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTktMS0xLTM2MDk4_4cf94ad7-12f6-4064-be63-4e357d32f526">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814218cfc2834473ba1512b07052cb1d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTExLTEtMS0zNjA5OA_0a531ed4-8132-4f3a-b4ff-76dbd61e015d">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306e14d7ddca4e21b4794cb488fce5b8_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTEtMS0xLTM2MDk4_98d7f38e-6e78-4e44-81ac-560b1da82d35">108.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9895d0dae6d7445ea42921b93f0a9c68_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTMtMS0xLTM2MDk4_82d7cf74-e690-4c8f-91b5-5e096e22b771">22.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c09ae807e54da4a01d2cfc00bd5e06_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTUtMS0xLTM2MDk4_10ef9dbb-2a36-4820-a6e9-ce55e92df7b4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05a36b4b8c46ab99d9337d3cd3d4f8_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTctMS0xLTM2MDk4_7fd2fea8-b823-4a69-af5d-438565f6208f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af9bc2dbbf14e6d8e3d8e05279f0cbd_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTktMS0xLTM2MDk4_7dfc1a3e-6aff-4be9-8fba-b9deac59c73e">108.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30bf5e4d039481f8d19ae86d4a50d87_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTExLTEtMS0zNjA5OA_a842f636-4d75-4446-a748-295d236fa116">108.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8cf31dd8d64f55aa42897b097ff8bc_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTEtMS0xLTM2MDk4_220b3780-58e8-49b6-99f5-25d9114af229">1,279.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88230f75c60c479dbd0b6cf91c9e74fb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTMtMS0xLTM2MDk4_eeb5f66c-0e2d-479a-9228-d223df7b3721">487.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia445641f8593463bbe60fb23e89ff376_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTUtMS0xLTM2MDk4_06edfd45-b06d-4889-85b6-c8ea21f99c13">1,279.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fca9cdf5874c528fd7153bb23cf79e_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTctMS0xLTM2MDk4_fed2e29b-f221-4158-8786-8ace44a7ef23">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c8be8676a417ca167ea02c5249ecb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTktMS0xLTM2MDk4_04774fe0-caf0-4eb4-a98f-71717097c6b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf98252eb304398b10e2fa6fa205edb_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTExLTEtMS0zNjA5OA_5a62eeca-ca3f-42af-bab6-7ec89b98cd6d">1,279.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE4LTEtMS0xLTM2MDk4_67361666-c93c-40fe-884b-3001cde32ce4">548.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe70f0bb1ff48bbb5988ae3b9d281fe_I20211231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE5LTEtMS0xLTM2MDk4_64991fff-1422-439b-be97-b8a02e9a27c3">771.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIwLTEtMS0xLTM2MDk4_ee63fa4c-6672-4cdc-833a-549c38da38f2">3,212.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTEtMS0xLTM2MDk4_e7b72bfc-7f01-4219-81f2-d81159bf361a">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ac021a9eb94f3c991cd84f64525cc3_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTMtMS0xLTM2MDk4_e385376a-c370-4c35-a585-ba3ec07024ac">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa29f9114014c86920bd9c97e83e197_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTUtMS0xLTM2MDk4_b02f3d13-7fdf-4852-a1a7-4871e3f22e46">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316934550e024acbbd6325dc2c36d8a5_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTctMS0xLTM2MDk4_398d1fa1-a9f2-4d96-8078-5e02f9d19a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ee87f534b7486eb812b3019d90f10e_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTktMS0xLTM2MDk4_ab1756e4-b7f0-4d98-a0f2-cb8cbd207d2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004b16f34fb49528fc900ea4eb9ab5f_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTExLTEtMS0zNjA5OA_b046a52f-bbba-4a8c-bea4-cb5ead1b795a">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd5c0e714b6457c9291715287cdcb10_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTEtMS0xLTM2MDk4_9ae33e3c-86f7-42cc-9d01-fffedd72ca0e">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887f5d8d558444408da6b729be6176e3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTMtMS0xLTM2MDk4_d75f2296-4fd4-4759-b843-cdba1a4d348b">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ec5deb3594dfea6abdbaeb717e48e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTUtMS0xLTM2MDk4_ffd1ba18-3924-4d6a-b990-04728aadf810">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1675ab4c41749a9a192e7bb01d5570c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTctMS0xLTM2MDk4_35a8f16a-ae53-4817-8020-5d44636d14b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e36489b4fd04ec19524988a99361ff3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTktMS0xLTM2MDk4_563cee55-1744-4df9-ad2b-3687852f27a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95497ef3752c49bea81162355fe898f6_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTExLTEtMS0zNjA5OA_e7b1e3b7-5e51-4cb4-b003-71e428720642">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id804f4973bed4a98bead10d90e4a5ec4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTEtMS0xLTM2MDk4_5becd78e-80b2-4115-82bc-11155f40188e">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f48f77a9304c3d928d59f5cda4e8cd_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTMtMS0xLTM2MDk4_f4af5b2b-bb79-4be4-bc01-4535f732e2e7">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574e8be0dcbe46febe19bb311f0b3e9d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTUtMS0xLTM2MDk4_eee3f72c-73e0-40a2-81f8-655f66da4e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia594156723e841d78c3dd942261e75ca_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTctMS0xLTM2MDk4_a8a35128-dc46-411c-b485-4061c75a7c3e">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfcfab070c414ee789784a20354c6b69_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTktMS0xLTM2MDk4_5d9017ef-532b-401b-a3a2-88ebd95bc5e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8628ddde09c14992bc17930fcf88de35_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTExLTEtMS0zNjA5OA_ac3019a5-6453-4a4c-bb0a-218a57ae49f4">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a22aba314ec4e5b8758419c0aced782_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTEtMS0xLTM2MDk4_6ca18702-c92a-41bc-8ec4-0a6767317991">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia193b0c52b7842c9af258c8e25683106_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTMtMS0xLTM2MDk4_877a7b39-912e-4b66-9355-9a6bf2db2ad2">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f335ad729d456583d5537025bce75c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTUtMS0xLTM2MDk4_fb114b36-43b6-42aa-ba2a-4f16ac717d51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf7334b5c1440cd914d71e8eb5158ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTctMS0xLTM2MDk4_921c63cf-2e32-4f6f-8bc4-9204b735b9e7">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64ce11134d3479a80fbee093c8eeb0b_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTktMS0xLTM2MDk4_d0c63f55-c39b-4052-8f68-b6664e397cde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33787997401459d96a225f2f2ddfdaf_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTExLTEtMS0zNjA5OA_bde6be94-63f2-4c85-adf6-305de8dc6740">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d528edb81f432ea8b0d77df211e863_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTEtMS0xLTM2MDk4_a77e459c-0260-44bd-9b2c-4ca2de055637">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46f810428ec41a0854465f3dd3eeb28_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTMtMS0xLTM2MDk4_a02a3831-120c-4882-b2aa-ff862f7ea925">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if288edb5c28645d78092d94621a6e314_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTUtMS0xLTM2MDk4_b1865c92-c078-44ca-8d6f-6c3537091a9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie426e3b515ca4c32966ac2238ae9f29d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTctMS0xLTM2MDk4_e29bda9b-1a67-4d70-80df-5b3cf3fcdc51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb03dc979e1948809868f9121af92653_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTktMS0xLTM2MDk4_16868774-b3e1-4e6f-b71b-9a64cf507379">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b512c10faf4454e92e2820bdebb03cb_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTExLTEtMS0zNjA5OA_3f706d0d-74fb-4e70-a876-15f347845f93">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMwLTEtMS0xLTM2MDk4_74250a44-3832-4bdc-ab34-16e0d87ab04a">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd5c0e714b6457c9291715287cdcb10_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTEtMS0xLTM2MDk4_96e1a36b-4190-4b45-ac8a-f3627da255db">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887f5d8d558444408da6b729be6176e3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTMtMS0xLTM2MDk4_d0251b15-b450-4970-92ad-7e6880554ea7">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167ec5deb3594dfea6abdbaeb717e48e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTUtMS0xLTM2MDk4_c7d84ada-3270-4bad-986f-762fb8d650a0">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1675ab4c41749a9a192e7bb01d5570c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTctMS0xLTM2MDk4_a46eee0f-24ad-4831-b8f2-2aebb3710659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e36489b4fd04ec19524988a99361ff3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTktMS0xLTM2MDk4_c7d40c97-a578-4842-9dee-84d7e19cd9b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95497ef3752c49bea81162355fe898f6_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTExLTEtMS0zNjA5OA_108eddcc-345c-4e16-9e9d-ec7f2ff453eb">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id804f4973bed4a98bead10d90e4a5ec4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTEtMS0xLTM2MDk4_17195649-c38a-4c55-b582-8b0dd3c8e414">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f48f77a9304c3d928d59f5cda4e8cd_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTMtMS0xLTM2MDk4_b55969f6-dcfc-4a08-b83f-1527dc44748e">126.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574e8be0dcbe46febe19bb311f0b3e9d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTUtMS0xLTM2MDk4_e144b948-5033-42ee-af48-baadd1152641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia594156723e841d78c3dd942261e75ca_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTctMS0xLTM2MDk4_f18cbf10-b220-4d7d-a871-6776ddb77f88">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfcfab070c414ee789784a20354c6b69_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTktMS0xLTM2MDk4_a845ae94-dcfd-442b-a4a8-493fa6f11c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8628ddde09c14992bc17930fcf88de35_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTExLTEtMS0zNjA5OA_e5d906f9-cf22-4b2c-83ba-abdd6294003f">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb330dcd0a3d42cc853a2009b99f4554_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTEtMS0xLTM2MDk4_4f91b7af-b2ad-4294-900d-78a7e5afc87e">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344dc72ffe804d559e7ecfd187252c52_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTMtMS0xLTM2MDk4_4f186e3d-a24d-4c6a-b9a0-afd53d90ba9c">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6319d8f9aaa3462cbc841393e3484980_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTUtMS0xLTM2MDk4_6d1e7852-be4c-4ac0-a76b-c0bb03511869">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc78c865a114757a146a87ed649467d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTctMS0xLTM2MDk4_d4908944-ba34-478f-88ed-a6fbe2b4a151">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a588f349f449d29c4cd500d935548a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTktMS0xLTM2MDk4_ef51e7bc-4e9e-4e4d-b79a-4da8f8662d70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9df1bc022c4981908c34ce7da7d7c9_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTExLTEtMS0zNjA5OA_fe15b3d8-f54a-4e64-a580-27cb7f56fb52">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a22aba314ec4e5b8758419c0aced782_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTEtMS0xLTM2MDk4_dd6e4635-13bb-4fb6-9d01-854690972ac2">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia193b0c52b7842c9af258c8e25683106_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTMtMS0xLTM2MDk4_51822ed2-6f94-4dfa-ac0c-4c1c0208150c">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f335ad729d456583d5537025bce75c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTUtMS0xLTM2MDk4_4db6b501-b04a-4313-85e4-e7e675e7159a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf7334b5c1440cd914d71e8eb5158ac_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTctMS0xLTM2MDk4_0e11d854-5dff-4e7d-af2c-3904eef447a7">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64ce11134d3479a80fbee093c8eeb0b_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTktMS0xLTM2MDk4_6b5b545f-2c2f-4962-8656-07552e0c8692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33787997401459d96a225f2f2ddfdaf_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTExLTEtMS0zNjA5OA_f895f2f3-be3d-4d13-a0ed-a8ae18fb08fb">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efecde667454dafa903f13553e58c5a_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTEtMS0xLTM2MDk4_0390390b-cd43-477d-8101-4ef9d02c2608">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf529e3651a448988c0e69800bad62e_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTMtMS0xLTM2MDk4_842e6e5f-2dbc-4e72-bf3a-54c97c912c44">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f60e90823904e52907d87d841e42ffc_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTUtMS0xLTM2MDk4_971e8fe7-9c40-4650-aebf-dc0789b52db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d818676d44496c9f05bbd23d02b4e2_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTctMS0xLTM2MDk4_bde72a9e-38e7-49e9-9e35-65ec01a1cd62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i827063ec6d8b47cc8ef73cadbb5e308c_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTktMS0xLTM2MDk4_69c0b8a8-509f-43c7-b5d0-7b7bec484803">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26af35be2884e2e8476d92958017ea6_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTExLTEtMS0zNjA5OA_7815a318-5fab-4c58-90cf-5dc2ae8fa968">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd801c4ac2b4ba5929965024c9495c7_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTEtMS0xLTM2MDk4_5a167203-29ad-4936-bdc1-78f54aa42b9c">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b14338524644f794041da64329d7ed_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTMtMS0xLTM2MDk4_65ad7c38-8e5d-4921-aae7-ed27bd55d2fc">311.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6f2f073c974e75b0df61d368ef3198_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTUtMS0xLTM2MDk4_db76dc64-0783-44ce-9444-4506a0739ebc">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8dbbb22358480a9d1227dd77b3d9c7_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTctMS0xLTM2MDk4_19d47b8c-3edc-4089-bb20-0d5635eea68e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591b41c97ee542518e6b5bf5504d3133_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTktMS0xLTM2MDk4_f6e28b48-c790-453b-ab8e-2d38df431bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0f72bd70654124b4ddbe68456882ba_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTExLTEtMS0zNjA5OA_350fda93-d06e-4773-bfde-e6fa2a4340aa">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM4LTEtMS0xLTM2MDk4_c6306c73-5f23-495f-b2fb-668ca4b5742b">373.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a1d18f3f5f4e94a780c2d35119942e_I20201231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM5LTEtMS0xLTM2MDk4_a2f4dd1e-c66e-4fab-8173-15aaa930da36">471.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzQwLTEtMS0xLTM2MDk4_d4d23521-6db7-4237-b34f-c1ab414a717a">2,966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:11pt;text-align:center"><ix:continuation id="i7bb4c1c4839342ca8b778537ecccff15" continuedAt="ib4d8705d0d424a808cfe520ebaf17fe9"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDcw_11d6de28-70f2-4e2b-a89c-e37f0579465c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctMS0xLTEtMzYwOTg_dbd23875-9615-4ec4-ab84-3557ce00579f">16,884.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f207cd4c10c40c58e5e98e94e0977fe_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctMy0xLTEtMzYwOTg_19bd90b7-f6aa-48b8-9203-779043001c1a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic01d3d2786ef48c7b3a9a7abc2347162_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctNS0xLTEtMzYwOTg_ce8e28a8-98df-463d-9baa-ad3167800fab">18,157.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca22a25490746b2a01afb869b9c9451_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctNy0xLTEtMzYwOTg_732994ec-bdf8-4a6a-b4b5-556a125e0de9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cacf599a2654a73aeb964f7e22ed6fb_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctOS0xLTEtMzYwOTg_ef07fbce-7cee-403c-846f-852b17f3d55b">18,157.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtMS0xLTEtMzYwOTg_464c4952-327d-4746-8750-de8d51dbfb35">16,595.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa29f9114014c86920bd9c97e83e197_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtMy0xLTEtMzYwOTg_a6851bac-d590-4da7-b6f9-5a74e4c27520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i316934550e024acbbd6325dc2c36d8a5_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtNS0xLTEtMzYwOTg_ecd7c1ef-d301-4197-9e79-7af1b823108b">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ee87f534b7486eb812b3019d90f10e_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtNy0xLTEtMzYwOTg_798e4cb0-2cee-4861-b351-5749d006c80c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie004b16f34fb49528fc900ea4eb9ab5f_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtOS0xLTEtMzYwOTg_df090aed-58d5-4e55-a191-375ac5c5998b">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><ix:continuation id="ib4d8705d0d424a808cfe520ebaf17fe9" continuedAt="i7c787b862c174380aff84e3a3e95e12c"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTY5_6ec892b7-9ccb-4d15-a2e7-f48be31e8fa0" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd739cb8ecf4fce97d2650748700a73_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtMS0xLTEtMzYwOTg_1b1351c8-9b0c-4aa5-adc6-62ecd60c353d">4.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtMy0xLTEtMzYwOTg_a57b543b-5917-4af2-9c67-1683cd68f8e3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e3a34c12fe45458f64b1588317741a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtNS0xLTEtMzYwOTg_1387e175-cbc0-49ea-a2d5-aa4dca5fd3e4">4.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ba73fdaaa94d918532bf88e602aea4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtNy0xLTEtMzYwOTg_2c4a0ab3-68d2-4b41-9842-0bafb965abf6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtOS0xLTEtMzYwOTg_e4cde581-49b6-43d3-89fc-471860a40cc5">4.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd739cb8ecf4fce97d2650748700a73_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtMS0xLTEtMzYwOTg_ef16d031-ecae-430c-adcd-b28742077522">78.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtMy0xLTEtMzYwOTg_2736ba66-d8b1-46b7-a5da-77dbae6d76c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e3a34c12fe45458f64b1588317741a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtNS0xLTEtMzYwOTg_29280e45-57c0-465b-8d2f-eaa74048c7c4">78.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ba73fdaaa94d918532bf88e602aea4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtNy0xLTEtMzYwOTg_b5449374-08d9-4640-a5a4-eefd36e9108c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtOS0xLTEtMzYwOTg_867b21ae-cc14-4d08-b795-303ad6750d73">78.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfd739cb8ecf4fce97d2650748700a73_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctMS0xLTEtODUzNTE_a008c051-bd82-45dd-8a47-ac301dc125cd">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctMy0xLTEtODUzNjU_c4a84f62-6ee3-4f25-a86e-a1f1d3ac6b19">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45e3a34c12fe45458f64b1588317741a_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctNS0xLTEtODUzNzM_615ca43e-c5c7-4db6-b7f3-9c9dc4cb819c">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ba73fdaaa94d918532bf88e602aea4_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctNy0xLTEtODUzODM_ce4880e6-6646-4131-aec6-962e4d46cfc6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctOS0xLTEtODUzOTM_a53bf99c-e8b0-47c2-badc-48fbc222cb87">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e862569cb8e4d77b08bc51be4980e34_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktMS0xLTEtMzYwOTg_d8045674-1897-4c3e-a912-1ea2eabe9797">49.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee4fbb4cad946a0b316ae9a0d5c2f7f_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktMy0xLTEtMzYwOTg_5aec66f0-d471-404d-a48f-762595df46cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03be72af30a547c281fc637c8b272953_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktNS0xLTEtMzYwOTg_acbb793a-8d61-4e67-8be5-ce507f219ace">49.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4ea09bc4b4318aa35ba040cbaddd4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktNy0xLTEtMzYwOTg_b56c651f-1e20-4be3-abdf-5fbe2bb7d401">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734334d67c56497ea2fe5de69c592773_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktOS0xLTEtMzYwOTg_c4c10ac4-ebf6-4c8b-a89f-28baf8f209cc">49.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e862569cb8e4d77b08bc51be4980e34_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTEtMS0xLTM2MDk4_1c079672-98be-4832-8f0c-25d587702646">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee4fbb4cad946a0b316ae9a0d5c2f7f_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTMtMS0xLTM2MDk4_e739018c-ab3a-4910-bad1-e67c7c16f847">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03be72af30a547c281fc637c8b272953_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTUtMS0xLTM2MDk4_280fe966-0d83-48f7-8f40-2e366e8c3198">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de4ea09bc4b4318aa35ba040cbaddd4_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTctMS0xLTM2MDk4_aeacb1a2-f33b-49d8-96cd-decd12583ae5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i734334d67c56497ea2fe5de69c592773_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTktMS0xLTM2MDk4_2e2c4c2a-d61d-4086-98d6-c9bbbc3afbc4">31.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8795f816d3e4ca2aaba6e653e468c06_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTEtMS0xLTM2MDk4_3bd517a9-9aa2-4c3d-a304-882ac6888946">31.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf0573899a39469e83be2b20e0eb8b87_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTMtMS0xLTM2MDk4_553c7f6f-76aa-42b1-b16c-9dae9ce8d1e5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda2686ddc2d4cd0b6656354b98930b5_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTUtMS0xLTM2MDk4_877db820-f23e-447f-bdf5-466f98b21e72">31.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2859719f266a46efb30de54c44c9888d_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTctMS0xLTM2MDk4_9805fb37-0314-4345-8e7e-15a67816ded8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17438a4e988240c58930bd2fca58fe5e_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTktMS0xLTM2MDk4_865641db-68f8-4ea2-88ad-63ddff3caa2a">31.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8795f816d3e4ca2aaba6e653e468c06_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTEtMS0xLTM2MDk4_711fa734-223d-4134-9c6c-8fd4631b833e">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf0573899a39469e83be2b20e0eb8b87_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTMtMS0xLTM2MDk4_011095e4-685b-42b0-b387-0b0f952e80ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibda2686ddc2d4cd0b6656354b98930b5_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTUtMS0xLTM2MDk4_ada61cb7-7ad9-4ccd-8a17-d342ef5dea7e">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2859719f266a46efb30de54c44c9888d_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTctMS0xLTM2MDk4_c0a65ef0-9857-472c-905a-27933fa9d679">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17438a4e988240c58930bd2fca58fe5e_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTktMS0xLTM2MDk4_15e717e9-ba2b-4878-a085-d484c861084a">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc3c2c66d9e4d0da075849aa425fa7a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTEtMS0xLTM2MDk4_2ed0faf1-f296-4ad6-b822-cb9283374e7e">33.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2746f9d419c14a098e97957fdfe7641a_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTMtMS0xLTM2MDk4_704c3521-2ff6-49bf-97f7-6f53042dad71">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b77e24600d447186fdb36b48034cda_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTUtMS0xLTM2MDk4_8f781826-030c-4979-8149-0e26ee2a52ca">33.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103492ff7b1c4667ac257e9154cd5beb_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTctMS0xLTM2MDk4_29eadd74-c99a-472c-89e5-e412100f6b38">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df961528f4463793f7905786bea152_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTktMS0xLTM2MDk4_d6118eeb-805d-4f70-8569-dd753de51e6f">33.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bc3c2c66d9e4d0da075849aa425fa7a_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTEtMS0xLTM2MDk4_db754db1-89c1-4b01-9234-830e50ce03d9">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2746f9d419c14a098e97957fdfe7641a_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTMtMS0xLTM2MDk4_67c775f0-8a37-47cc-bcf9-97560df6edad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b77e24600d447186fdb36b48034cda_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTUtMS0xLTM2MDk4_90d48601-83b4-4f16-9dd2-98e13870d634">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103492ff7b1c4667ac257e9154cd5beb_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTctMS0xLTM2MDk4_c83fd10f-60b8-441e-a300-ac1be3f00e90">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df961528f4463793f7905786bea152_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTktMS0xLTM2MDk4_19bb0186-e4af-4ddd-a076-7114987ba24e">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643183966d6848f3b666d367edf73743_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTEtMS0xLTM2MDk4_4bd08447-2d5b-4eeb-8f08-a50a71c7d321">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70569b8f4108449c84afeaf1c43a3dbb_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTMtMS0xLTM2MDk4_14f536ac-e15e-4d69-beea-19bfe835a6e3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a291d5a17ef4657b4a29f981d818719_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTUtMS0xLTM2MDk4_510fc84d-5db6-4bf2-9bea-fb297d574212">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14bc637594d43eba77368fce832327f_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTctMS0xLTM2MDk4_9c2ff7cd-a4c6-4505-b2b0-f3c9f001331a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e070cb04b247668d999c7e61d52938_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTktMS0xLTM2MDk4_8c8ffd83-4522-42ce-b2e1-464a838ba2ce">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i643183966d6848f3b666d367edf73743_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTEtMS0xLTM2MDk4_e19a4e88-1447-494d-a5b5-b034fe49d9fd">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70569b8f4108449c84afeaf1c43a3dbb_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTMtMS0xLTM2MDk4_453a7ea3-32dc-44c5-949e-9505cc04380b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a291d5a17ef4657b4a29f981d818719_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTUtMS0xLTM2MDk4_58a28299-a9c3-48fe-b3f1-ff05d0a60940">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14bc637594d43eba77368fce832327f_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTctMS0xLTM2MDk4_c1561278-3fdf-435d-990b-0b326e160a8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60e070cb04b247668d999c7e61d52938_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTktMS0xLTM2MDk4_395077e3-f7f8-4b90-95e5-5a1822240934">35.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i643183966d6848f3b666d367edf73743_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTEtMS0xLTM2MDk4_3888a5a6-18a1-458c-a735-3f9c4286279f">70.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70569b8f4108449c84afeaf1c43a3dbb_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTMtMS0xLTM2MDk4_dab4a837-577d-4d61-b013-800167f35e16">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a291d5a17ef4657b4a29f981d818719_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTUtMS0xLTM2MDk4_c9655c01-125e-4c9d-97fd-ca4653277c93">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id14bc637594d43eba77368fce832327f_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTctMS0xLTM2MDk4_daf64b0a-2d3a-4653-8fbf-201d20ee9ea5">70.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60e070cb04b247668d999c7e61d52938_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTktMS0xLTM2MDk4_104b9516-8d91-4fbf-ab90-177c21f3283f">70.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6d03e2ed8d4d58992474db5137bc29_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTEtMS0xLTM2MDk4_efeabb54-e50d-4624-8b28-d0ab9747011e">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b03d00bc65a4499823bf2ae6673dc24_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTMtMS0xLTM2MDk4_696e2cd4-9c86-4eb2-aedc-2a5fcc977f22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1690d7f6c7cf4875b045a1c058aacdff_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTUtMS0xLTM2MDk4_d83446d5-faa6-4ab8-992b-2acc929e8894">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4526f1f10b794ec991819ce33cc96cab_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTctMS0xLTM2MDk4_4cdb06b8-19dc-41c5-9285-6d5fdbbb1b73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237291a28a7343ae877503eaf0fa41a9_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTktMS0xLTM2MDk4_7c1dba99-d108-4e75-b97f-c30ab5b1e6c2">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d5a9e0154c43b2b5d3386c1d0b0538_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTEtMS0xLTM2MDk4_f79e4727-1d34-4a41-b154-c5cf87e43a3a">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2d1bbead584d8e8b7d3a56191796b9_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTMtMS0xLTM2MDk4_479f2efc-48d2-45f1-af1b-6f18930af640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f78d8a998c493b824d37739f09cee9_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTUtMS0xLTM2MDk4_3289047a-94cd-4405-ae1a-9d1dd787069a">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6f347e0f6d4d7688e6ede323ba93ed_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTctMS0xLTM2MDk4_45f08a15-4ba5-4ba3-b71e-6f56092a4e77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec315121c623474c92f184ce17dafae2_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTktMS0xLTM2MDk4_db997aaf-3ae0-4214-8876-17a0e21bf6e1">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d5a9e0154c43b2b5d3386c1d0b0538_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM3LTEtMS0xLTQ0NTI1_210748cd-dc8b-4a23-a225-5d719c861757">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe2d1bbead584d8e8b7d3a56191796b9_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM4LTMtMS0xLTg3Mzcz_3efe218d-7da9-45f0-88b6-3f06bb5d18a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2f78d8a998c493b824d37739f09cee9_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM3LTUtMS0xLTQ0NTQw_8a7f8c8e-b742-4c40-a97c-a5497a052e3e">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6f347e0f6d4d7688e6ede323ba93ed_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM4LTctMS0xLTg3Mzcz_7655e946-caa7-4a36-94a2-0570b3a822dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec315121c623474c92f184ce17dafae2_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM3LTktMS0xLTQ0NTUy_97b3bbc8-1a8c-41bb-a3c6-29500f210689">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70f76462cfe94c048d2e8e07abc8ac06_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTEtMS0xLTM2MDk4_e5b906bf-b4b0-4ba3-9eb9-48465544ed80">92.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ba7848623e4295a4d08297c9dcfc05_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTMtMS0xLTM2MDk4_8132bc47-229f-4e8b-8a10-a6657df0a03c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93c838ae6a6741a289a916ea6b2a18f9_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTUtMS0xLTM2MDk4_041e6136-e6ae-41df-ab8c-d4c3d8e8e7b1">92.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fb983303214a0fab76fb48ca842390_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTctMS0xLTM2MDk4_2f37de92-d1dd-431e-920b-0f55f466b30c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ebf2c8591c4a65a69ef2a0f9a1c023_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTktMS0xLTM2MDk4_88a3058b-b94a-46b1-a9b8-ad7f1fd12f85">92.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70f76462cfe94c048d2e8e07abc8ac06_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTEtMS0xLTM2MDk4_80ed8554-e6e2-4be7-a356-1df5f754a616">97.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ba7848623e4295a4d08297c9dcfc05_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTMtMS0xLTM2MDk4_f90669f5-9e52-447d-8861-8615efe85e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93c838ae6a6741a289a916ea6b2a18f9_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTUtMS0xLTM2MDk4_77c44b45-7c11-4ac3-a1e5-27e4b8fe55e6">97.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fb983303214a0fab76fb48ca842390_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTctMS0xLTM2MDk4_95e817aa-893e-4dac-9464-95d429f7fba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ebf2c8591c4a65a69ef2a0f9a1c023_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTktMS0xLTM2MDk4_1eaff941-e74f-4585-a217-cfe46f858f7b">97.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2e86153cfd4c15b9467efd88051085_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTEtMS0xLTM2MDk4_adfb925f-6b89-4fd3-8ee9-3da96744002b">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62613c2b0b0949e8a36439ddee87c7d2_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTMtMS0xLTM2MDk4_50078baa-a0b9-4ffc-a40b-27cb76d19374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida9a7f6d784f4d7b8b53c4631c9e75eb_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTUtMS0xLTM2MDk4_062c1ef2-b32e-453d-ad95-0289cb6a643d">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d10b06674c46a98dd32098076c5e36_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTctMS0xLTM2MDk4_46f712f2-d54a-429c-b099-33b11ac6b6f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffde3a7d917c478db3902cc934826508_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTktMS0xLTM2MDk4_8a6d80b6-d4d5-4ec4-984d-91202f83c793">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3392ad7d22c4bf7b9a4a1c59ed94a0d_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTEtMS0xLTM2MDk4_0c93445e-66fc-4a64-8219-094d4098e4ab">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c20187921d4be8beea2d674ea20464_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTMtMS0xLTM2MDk4_91605c70-2edd-40aa-a403-747a94303ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia914bdc1f6a941bea69658cc92f5058b_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTUtMS0xLTM2MDk4_33364078-add1-4e7a-9b1b-1b091ec39ad1">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a2be087dc94b038c7c193e1cce0685_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTctMS0xLTM2MDk4_0ae31574-d4ce-40fc-a664-f0e181902ef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf95a7cf14e94274ab9c3f3de25a81aa_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTktMS0xLTM2MDk4_c4f2ee2d-4d4b-42e4-8ce8-88721f089372">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic901be7c5ce4440f886d70a9f0528564_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTEtMS0xLTM2MDk4_1a9959bc-f247-47d7-a01a-6ba6b8f1a8b0">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8afdee24674791bca30cb8d138a90d_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTMtMS0xLTM2MDk4_bcda2439-2a51-41cd-8155-780652100695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10a9d80e8d1486caea9af7c720bf668_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTUtMS0xLTM2MDk4_9234b341-cdba-42d8-9bdb-37079195ffdb">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba53f9f1da64ce78f2027435c7eeb45_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTctMS0xLTM2MDk4_fb15478c-394b-4a4e-b973-dd8ffb98046c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45fa035c9b02420dafaa115085c6e8f6_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTktMS0xLTM2MDk4_5ab417fe-606a-40e8-b374-54bda3ef7cf7">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic901be7c5ce4440f886d70a9f0528564_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTEtMS0xLTM2MDk4_5e1b5a2d-5833-4fd4-a458-d15cec8d9200">15.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8afdee24674791bca30cb8d138a90d_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTMtMS0xLTM2MDk4_836532ee-4a9c-4e83-89b3-b19deaae35f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic10a9d80e8d1486caea9af7c720bf668_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTUtMS0xLTM2MDk4_3bc05510-77da-473c-b4b2-89c817f7bcd1">15.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba53f9f1da64ce78f2027435c7eeb45_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTctMS0xLTM2MDk4_b09b356d-91ed-4eac-ac73-afb41005ce05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45fa035c9b02420dafaa115085c6e8f6_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTktMS0xLTM2MDk4_d6abfa41-0f35-4226-8dbc-0b9563ea1299">15.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i7c787b862c174380aff84e3a3e95e12c" continuedAt="i9e5155b21f9e40e6b2592490ae0398fb"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwMzI3_4e47c1b9-fc8d-4462-b413-159194d511c2">828</ix:nonFraction>&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be invested over a period of up to <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNDQ2_e43912db-f05a-4426-bc04-d82514a488cd">10</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTQ3_f9dd5275-ca5d-4d43-9fc0-2d2fe3514d01" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:42.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5      Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10    Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItMS0xLTEtMzYwOTg_b2dbe182-9763-4179-b53d-c5aab8956560">581.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItMy0xLTEtMzYwOTg_e9bc9dab-f7ff-49ee-8611-56bba9ae4cea">75.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItNS0xLTEtMzYwOTg_a5917f3b-8e50-4bd9-9861-b3146eb16e0b">216.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItNy0xLTEtMzYwOTg_4b0d2f76-fbee-4a01-8bd4-f6ff16eb48cf">126.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItOS0xLTEtMzYwOTg_6a10028c-8a60-4af1-aafd-9b27329d250d">162.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated statements of operations for equity securities were $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNjc0_c4b8f519-16e3-4d7a-9b48-01206f18d4ac">176.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-7" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNjc4_b3bbdf2e-9801-4912-b87e-faad18ae9bb5">1.44</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNjg1_6eb89d94-b918-4d2d-a5c7-0b62d3b0550c">401.2</ix:nonFraction>&#160;million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. The net gains/losses recognized for the years ended December 31, 2021, 2020, and 2019 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2021, 2020, and 2019 were not material.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDg0_3a9e527e-3429-43c5-b35a-5d807b75f48f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzEtMS0xLTEtMzYwOTg_52881071-a397-4d8f-b877-cbefa25d5412">9.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzEtMy0xLTEtMzYwOTg_290aa402-919c-4b8b-81ae-0eb24ace6d63">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzItMS0xLTEtMzYwOTg_c336c417-a104-4f03-b318-37d77af5f64e">5.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzItMy0xLTEtMzYwOTg_508c7bd6-9bf9-4836-9b82-507d57318a36">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzMtMS0xLTEtMzYwOTg_bd23c6c0-0ec6-4769-9ff2-99e16ddf85a8">250.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzMtMy0xLTEtMzYwOTg_867d21fb-f3eb-4166-9671-631f990d82b9">348.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzQtMS0xLTEtMzYwOTg_89b57ccf-57d7-4fe1-baf0-7f85fbc96469">290.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzQtMy0xLTEtMzYwOTg_36c964fd-e7bd-4bf3-931f-8a27ede78e2b">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2021, 2020, and 2019.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i9e5155b21f9e40e6b2592490ae0398fb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEyNTI1_80105f93-4322-4666-b53d-e78509f61e58">97</ix:nonFraction> percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTIx_1cdc0227-84e7-4030-8635-7b18688c8e16" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzEtMS0xLTEtMzYwOTg_f27257de-8ce4-4e1d-87a2-df7afe223ff4">174.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzEtMy0xLTEtMzYwOTg_5f6d35b4-e7b2-4fad-837a-1ffe8b7a3402">264.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzEtNS0xLTEtMzYwOTg_7126fd98-6c3c-4bf4-a115-c7382daeff0c">431.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzItMS0xLTEtMzYwOTg_50a8c3b2-fb1f-4e1f-8283-988079bcc620">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzItMy0xLTEtMzYwOTg_182a0e36-d218-4f1f-877d-b44f6b1991ba">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzItNS0xLTEtMzYwOTg_227a77eb-c935-4b79-b695-58d194e161e6">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzMtMS0xLTEtMzYwOTg_c448744b-60a1-4542-bd62-ff95f86b08f1">1.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzMtMy0xLTEtMzYwOTg_c698a662-3125-470d-8d71-6b3b02b0ded3">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzMtNS0xLTEtMzYwOTg_4d0bd96e-ada4-4085-ab1d-433b61fe7710">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEzODE3_69d6e49d-f82d-4d47-b405-1e50dbd35a94">550.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEzODI0_a85e50f5-58db-4a53-9f37-e7655a7ba5e7">754.9</ix:nonFraction> million&#160;of accounts receivable as of December&#160;31, 2021 and 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2021, 2020, and 2019 were not material.</span></div></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_127"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;8: <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1ODI_358b9e90-4c7f-4df2-9479-bdba1d33d643" continuedAt="i434d3fd8b2d147a0b005199dac5950a3" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><ix:continuation id="i434d3fd8b2d147a0b005199dac5950a3" continuedAt="i7bb2c61357354e279454fadf4a857ee1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1NTQ_fcfebfba-e544-458c-8939-0b0f90f78a68" continuedAt="i85ce34a01acd498ab8df508e7bdf4f09" escape="true">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.</ix:nonNumeric> The changes in goodwill during 2021 and 2020 were primarily related to our acquisitions of Prevail and Dermira, respectively. See Note 3 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzgzNA_210b56ad-f18a-42ee-8285-b80e647e58e8"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzgzNA_3482346c-e862-461d-a0a8-ac91b6613101"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzgzNA_8ac94439-55cb-417f-8898-0a57f0db4fee">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2021, 2020, and 2019.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i7bb2c61357354e279454fadf4a857ee1" continuedAt="i2047d6149fcf464baacb4ccfc52f4dc0"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1NTA_03a974f4-14f0-4a69-a3cb-31108618e207" escape="true"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1ODY_9287ada1-29c7-465a-9ea0-3c4a2e6858bf" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:26.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9383a6db72eb499a9b97a5c2952db425_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtMS0xLTEtMzYwOTg_6d6d549b-3b91-4c79-9880-0988b2540879">7,987.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9383a6db72eb499a9b97a5c2952db425_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtMy0xLTEtMzYwOTg_6859c350-7eb1-40ee-8801-999384c6c6e3">2,229.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9383a6db72eb499a9b97a5c2952db425_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtNS0xLTEtMzYwOTg_677735e9-c9e8-4194-9b94-194e54580ca0">5,758.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie531ec456aac40d486f50a514ec2ebe5_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtNy0xLTEtMzYwOTg_5a8318de-732b-48f6-8392-5e35796ab257">7,984.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie531ec456aac40d486f50a514ec2ebe5_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtOS0xLTEtMzYwOTg_b022a9c8-dc76-483a-b26b-5e17a20ffcc4">1,659.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie531ec456aac40d486f50a514ec2ebe5_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtMTEtMS0xLTM2MDk4_02687a10-47b4-48ed-9de3-e6dd80b417d6">6,324.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9815b1af955c480e81629936863a716d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtMS0xLTEtMzYwOTg_5e772b51-0969-4acf-b853-52585baaff59">69.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9815b1af955c480e81629936863a716d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtMy0xLTEtMzYwOTg_562f2a4f-055d-4f34-bd62-ab23548ff2c7">60.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9815b1af955c480e81629936863a716d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtNS0xLTEtMzYwOTg_418e41af-a562-4431-8ad3-d3f2933fced1">8.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a9323f52794ceeaceff691b1800d6f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtNy0xLTEtMzYwOTg_0d6aa1f3-2da7-44c5-8437-28aeae878eb6">92.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a9323f52794ceeaceff691b1800d6f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtOS0xLTEtMzYwOTg_1a5784ea-c75b-4a85-bcb6-ee36b4de127f">68.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a9323f52794ceeaceff691b1800d6f_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtMTEtMS0xLTM2MDk4_e16e8365-2d6b-483b-902c-9caceca97675">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtMS0xLTEtMzYwOTg_04f59002-4737-412c-9999-50049f57e8da">8,056.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtMy0xLTEtMzYwOTg_6fe53300-2683-4625-b0cb-4dbd5d0d0ab6">2,289.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtNS0xLTEtMzYwOTg_da1f935e-1127-4f22-935f-90fc2a171366">5,766.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtNy0xLTEtMzYwOTg_b1810054-3f1e-43d8-a60f-420de5818a93">8,076.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtOS0xLTEtMzYwOTg_18b37e41-67af-4f18-8ced-c8a448c46bc5">1,727.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtMTEtMS0xLTM2MDk4_9ab3c556-9eb5-4615-956b-d0b9436e19c2">6,349.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a57eb5302145278ada333579227b74_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctMS0xLTEtMzYwOTg_71662aac-b87a-4623-b64a-1bc6c1593e56">1,925.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a57eb5302145278ada333579227b74_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctNS0xLTEtMzYwOTg_ed4137a8-5242-420b-96e5-b607b3777aed">1,925.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757bec4b105a4991afb95cd0de81960c_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctNy0xLTEtMzYwOTg_5e7f8fc4-1f11-4286-b489-d4b928ca5f9e">1,101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757bec4b105a4991afb95cd0de81960c_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctMTEtMS0xLTM2MDk4_d82f7b1c-b58b-4295-b794-acf153e6afb7">1,101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtMS0xLTEtMzYwOTg_d271105a-d2c7-40c3-896e-38a50d96fedf">9,981.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtMy0xLTEtMzYwOTg_8619ca75-dd8d-4445-bb5f-7e0d0d043856">2,289.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtNS0xLTEtMzYwOTg_011646ae-615e-4e2d-98ab-809a04b88e7b">7,691.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtNy0xLTEtMzYwOTg_48ddd2e2-eb13-44d7-99c7-da1feccdef13">9,177.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtOS0xLTEtMzYwOTg_b4d6723f-9c14-4ddf-82e6-6c40e20491bf">1,727.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtMTEtMS0xLTM2MDk4_52ac1966-1f9f-42d4-805a-22ccbcea98e2">7,450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. <ix:continuation id="i85ce34a01acd498ab8df508e7bdf4f09" continuedAt="ie69b5e52f2d94d009732a5faf8b46cee">For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of the fair values of acquired IPR&amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. <ix:continuation id="ie69b5e52f2d94d009732a5faf8b46cee" continuedAt="i7293aaa99262408ea17f55e35a91dcbc">The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;D projects that had no alternative future use. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7293aaa99262408ea17f55e35a91dcbc" continuedAt="i60b216bd989f4bd984cfb5d74f4a5de6">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in marketed products in 2021 primarily related to the sale of rights to Qbrexza in 2021 as well as the impairment of a Phase I molecule related to a contract-based intangible. See Note 5 for additional information. These decreases were more than offset by the recognition of several milestones related to the COVID-19 therapies that occurred in 2021. The increase in the acquired IPR&amp;D in 2021 is due to the acquisition of Prevail. See Note 3 for additional information regarding intangible assets acquired in a recent business combination and Note 4 for additional information regarding capitalized milestone payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I<ix:continuation id="i60b216bd989f4bd984cfb5d74f4a5de6">ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i2047d6149fcf464baacb4ccfc52f4dc0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDA_50a976ec-2fe9-4481-a965-701914495450">one</span> to <ix:nonNumeric contextRef="id1549f6338d244929cd807e3277907a7_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDY_ccb2a177-9fba-4bd0-b7d5-c3ee9421accb">20</ix:nonNumeric> years. As of December&#160;31, 2021, the remaining weighted-average amortization period for finite-lived intangible assets was approximately <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUxMjQ_2febeb18-5909-49f9-9a2a-067f127f1b26">14</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1ODE_1ac3a383-ec98-40d1-9846-0755bef7ee05" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTphMjg5YjQ2ZTRhOGU0Nzk3YThlYTgzMDExMGM3MWVlNC90YWJsZXJhbmdlOmEyODliNDZlNGE4ZTQ3OTdhOGVhODMwMTEwYzcxZWU0XzEtMS0xLTEtMzYwOTg_0b7a2252-71f2-4a46-a123-6e755e6290f8">628.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTphMjg5YjQ2ZTRhOGU0Nzk3YThlYTgzMDExMGM3MWVlNC90YWJsZXJhbmdlOmEyODliNDZlNGE4ZTQ3OTdhOGVhODMwMTEwYzcxZWU0XzEtMy0xLTEtMzYwOTg_6690ca52-64ad-4c2f-a9b7-c0bdc1d6e296">428.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTphMjg5YjQ2ZTRhOGU0Nzk3YThlYTgzMDExMGM3MWVlNC90YWJsZXJhbmdlOmEyODliNDZlNGE4ZTQ3OTdhOGVhODMwMTEwYzcxZWU0XzEtNS0xLTEtMzYwOTg_f6f0c6c9-4693-4030-a5f0-a4c735dd279d">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1NDQ_cc0a253b-5b6f-47fe-be65-cb09214bfc3f" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2021 is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:49.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtMS0xLTEtMzYwOTg_2d693b69-d00c-48c1-af66-e85975eb4e0d">570.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtMy0xLTEtMzYwOTg_cfcdea51-1bf6-41c6-944f-b9b5aaea67f1">483.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtNS0xLTEtMzYwOTg_c10fa555-86ed-43ea-9337-1719fb04b7b2">433.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtNy0xLTEtMzYwOTg_4a3744fb-dd6c-49a1-afd9-fb7ab6cbb72f">417.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtOS0xLTEtMzYwOTg_c4c041b9-979f-432b-984b-00d66959f092">408.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:4pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_130"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9: <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMDQ_3dda055f-00cb-47f0-8ea0-cbc5cd58e6ee" continuedAt="i30db38ed603d40ab8bb68ff58ca98e38" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i30db38ed603d40ab8bb68ff58ca98e38" continuedAt="i9b3bb9c34d2745ce8088aa1f3dd37961"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMjg_0a70aeb9-91aa-4b26-be17-5061e7aef55c" escape="true">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (<ix:nonNumeric contextRef="ia3c486aeafe64057905b3c05060eedc7_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI0NQ_58c65805-1f47-4e23-944a-62d9bd6080c0">12</ix:nonNumeric> to <ix:nonNumeric contextRef="iba4a476458934d3d96c4cac37450ee31_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI1MQ_c1cc413b-7bb3-46da-8f0f-2ac68e0feb58">50</ix:nonNumeric> years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25">three</span> to <ix:nonNumeric contextRef="ib85d997efea3485690a6a131ac2e8edb_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3OA_f8c802bb-a195-4d5a-8a0b-c16412938667">25</ix:nonNumeric> years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMjk_e5365d6d-e17a-4b6a-aea8-103f26665125" continuedAt="idc3fe5fcfade42e5a1485bb9b5af0bff" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzEtMS0xLTEtMzYwOTg_b1484a9b-b393-4044-8402-4131649ba0f9">258.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzEtMy0xLTEtMzYwOTg_add6db52-1094-4004-8719-ff6792c708ef">226.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzItMS0xLTEtMzYwOTg_e2363015-25ff-44dc-bd7b-d5511a100510">7,588.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzItMy0xLTEtMzYwOTg_6ffcb065-afd4-4ef4-a6d2-5a715dcb6120">7,326.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzMtMS0xLTEtMzYwOTg_c28c3e0c-57fd-4406-9992-3502bb4e377f">8,937.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzMtMy0xLTEtMzYwOTg_0df47a96-d288-4e79-811c-83b64366dd7a">8,560.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzUtMS0xLTEtMzYwOTg_f4ed9a58-f66e-4ad1-a2eb-d3046b3e822d">2,177.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzUtMy0xLTEtMzYwOTg_7eba83d1-f70c-4626-bafc-3f625a61ca1c">2,138.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzYtMS0xLTEtMzYwOTg_5ef68895-ad00-4c3a-a6ca-2817b51b9f39">18,961.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzYtMy0xLTEtMzYwOTg_4b73c629-ce60-4b79-990a-d150d112a485">18,252.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzctMS0xLTEtMzYwOTg_0c19996d-5b86-40e6-a963-260e829bdd0c">9,976.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzctMy0xLTEtMzYwOTg_d725f3bf-2981-49cd-9f41-1b4933b68e3b">9,570.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzgtMS0xLTEtMzYwOTg_dd0907f3-7972-4cfe-a3cb-8d27e9d313f9">8,985.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzgtMy0xLTEtMzYwOTg_967ca337-d0d9-4cb1-9a3f-5c5f16fe5fff">8,681.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:4pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i9b3bb9c34d2745ce8088aa1f3dd37961"><ix:continuation id="idc3fe5fcfade42e5a1485bb9b5af0bff"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:69.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo4NDlkMmQxOGY4MTY0YjIyODkyYWVlZGVhMDI4MDYyMS90YWJsZXJhbmdlOjg0OWQyZDE4ZjgxNjRiMjI4OTJhZWVkZWEwMjgwNjIxXzEtMS0xLTEtMzYwOTg_d2f7b535-8246-4217-a678-e391a108e995">787.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo4NDlkMmQxOGY4MTY0YjIyODkyYWVlZGVhMDI4MDYyMS90YWJsZXJhbmdlOjg0OWQyZDE4ZjgxNjRiMjI4OTJhZWVkZWEwMjgwNjIxXzEtMy0xLTEtMzYwOTg_1bb3f6be-76c7-46d7-a818-29eb90facc7a">765.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo4NDlkMmQxOGY4MTY0YjIyODkyYWVlZGVhMDI4MDYyMS90YWJsZXJhbmdlOjg0OWQyZDE4ZjgxNjRiMjI4OTJhZWVkZWEwMjgwNjIxXzEtNS0xLTEtMzYwOTg_c9b41e08-3169-4d89-b020-8b7b3533efa7">814.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest costs were not material for the years ended December&#160;31, 2021, 2020, and 2019. </span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMTU_4ea198a2-c103-44dd-85b7-ebe4dafa9082" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:38.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46d6fa65cff4aa58bb12b8d03b24b7f_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzMtNC0xLTEtMzYwOTg_f0c28297-34bd-4c18-ba7c-93f5855bcf55">6,620.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e4a32babb7454bbabcc34a329041d4_I20201231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzMtNi0xLTEtMzYwOTg_7e6886ee-43c9-4098-8619-4728e733e543">6,113.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33be57ca2aa9408c95b321d324369f80_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzQtNC0xLTEtMzYwOTg_74b46021-bf8e-4ad3-ab93-6547f2639713">1,702.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifafdd7dbd10c49a3ae14d232fa79500b_I20201231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzQtNi0xLTEtMzYwOTg_a7c30fdc-3f8c-4a17-9340-cfe2a029bc45">1,786.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9497e574157241008a6608086202bffd_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzUtNC0xLTEtMzYwOTg_45dfdcc7-9d87-4609-bca8-f3f245ac25a4">1,691.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca73150a1e34797a7531629fc846e9d_I20201231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzUtNi0xLTEtMzYwOTg_d5083cdc-b570-433c-b6c5-7b7ef1bb4e76">1,747.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzYtNC0xLTEtMzYwOTg_a23fae8f-f1f3-48ab-90ed-74521d1a705d">10,013.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzYtNi0xLTEtMzYwOTg_a6d95fd2-8b96-4b0c-bf11-fa3b850f4b96">9,648.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div></ix:nonNumeric></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_133"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MTA_04aa283a-2179-4cd1-ba76-ede3b9b15077" continuedAt="ie2ec526295364ec6aa2f131fa4398296" escape="true"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MTE_5801bf07-9530-4e11-b5a3-c459e49cecbf" continuedAt="ia5daaccc4c7c4264a4f9fc53288dbca6" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ie2ec526295364ec6aa2f131fa4398296" continuedAt="i9276028f9d914cabbd1880c800d2670a"><ix:continuation id="ia5daaccc4c7c4264a4f9fc53288dbca6" continuedAt="id4e06846e1ba411d93ec64186a835dfd"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:LesseeLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzEwOQ_eb85f30e-7710-486b-b1dc-e8a0a8a4a4c5">14</ix:nonNumeric> years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzE1Mjg_8847798c-04f7-400b-af8a-cb644a00dc30">159.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0Xzc2OTY1ODEzOTc3NzE_e7771309-497a-476b-aa20-01a60cf7c917">154.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0Xzc2OTY1ODEzOTc3MzA_d84ffc8c-9cf1-417c-8c48-7ddd75fd67a5">172.8</ix:nonFraction> million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2021, 2020, and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2021, 2020, and 2019.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i9276028f9d914cabbd1880c800d2670a"><ix:continuation id="id4e06846e1ba411d93ec64186a835dfd"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MTI_7c748e60-b868-4208-a168-09594db1c100" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.801%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.950%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzEtMi0xLTEtMzYwOTg_3bed232a-5480-4a45-87d5-5ce8dcba1177">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzEtMy0xLTEtMzYwOTg_4da36a51-e5a7-450b-baf8-1eb051a1795e">7</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzItMi0xLTEtMzYwOTg_627292ab-d734-45f7-ac42-4b4c6e051700">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzItMy0xLTEtMzYwOTg_4139d270-2126-4cf2-acc9-dfafe95cd722">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzEtMi0xLTEtMzYwOTg_aa50091e-9796-4380-80fe-9b4a98584aff">156.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzEtMy0xLTEtMzYwOTg_d4276345-f9c2-4967-98d8-5a77cc966b81">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzEtNC0xLTEtNjUwOTg_cfdcd99c-0b2f-4a75-890c-e475fee198c5">153.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzItMi0xLTEtMzYwOTg_d5f4c01d-f1dc-4c00-ab67-a4eb6be86425">163.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzItMy0xLTEtMzYwOTg_5c206754-6136-481e-9c70-51c0cf7b172e">136.7</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzItNC0xLTEtNjUxMDQ_0f6f73e2-6cbb-49b9-8751-ef1f32fbde5a">81.2</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MDk_a1712258-bfcb-4b6d-aefd-526a5a5c6b4b" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzEtMS0xLTEtMzYwOTg_e98bad78-afc7-41e1-a3cd-f597b235b068">148.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzItMS0xLTEtMzYwOTg_3f73a8f4-3158-4e88-94dc-adcabe4603f6">117.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzMtMS0xLTEtMzYwOTg_3bc145e7-bfd1-47db-b3c7-8a5a6a4d9a34">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzQtMS0xLTEtMzYwOTg_864b511a-5954-44fc-bc2a-07ed50c6f4e5">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzUtMS0xLTEtMzYwOTg_2012bbac-9c37-4f02-872b-43dbcb504235">64.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzYtMS0xLTEtMzYwOTg_1e8d4427-06bc-4679-b252-7718fefbbb15">270.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzctMS0xLTEtMzYwOTg_eca84d70-3aba-44d2-b008-5b7c1e7e35bf">775.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzgtMS0xLTEtMzYwOTg_dc7895fa-ce5e-4dad-be40-f44d1e524b56">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMS0xLTEtMzYwOTg_ed2f2ec6-7308-4b0b-bf7c-11087126a049">685.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_139"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwNzU_130dd784-1d58-4b3d-afab-df3a9d23ed1e" continuedAt="id23b3b229f1e484b95ba908531ca01a7" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="id23b3b229f1e484b95ba908531ca01a7" continuedAt="i69ef474c51f449a7a0346882b167a9ae"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwODE_98f8227c-a331-4c9a-9f46-7a925359e6e2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzItMS0xLTEtMzYwOTg_8998e6d1-0581-4b9d-ab17-a395c527f8f2">16,741.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzItMy0xLTEtMzYwOTg_7197e12d-24d1-40d0-97cc-71cf30615b42">16,348.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:OtherNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzMtMS0xLTEtMzYwOTg_23b6a293-3d86-4d11-9a53-5448e4edfb65">10.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:OtherNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzMtMy0xLTEtMzYwOTg_d6dd63ca-9cac-4085-89ce-774889189290">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzQtMS0xLTEtMzYwOTg_b0539674-59e6-4b00-99dd-b7ce698672a5">84.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzQtMy0xLTEtMzYwOTg_e35338fa-a7eb-4e0e-9671-e2d3c701de9d">89.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:LongTermDebtFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzUtMS0xLTEtMzYwOTg_be0082f6-cba8-47ca-a30f-d01cf456213b">216.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:LongTermDebtFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzUtMy0xLTEtMzYwOTg_4cc25a7e-990d-4fde-85e4-610582bac123">320.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzYtMS0xLTEtMzYwOTg_5b311013-638a-439d-a32a-a549fad22daa">16,884.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzYtMy0xLTEtMzYwOTg_e64d0623-3396-4743-962f-a4f92fe04797">16,595.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzctMS0xLTEtMzYwOTg_0c187ade-239a-4d44-988f-56482f307641">1,538.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzctMy0xLTEtMzYwOTg_9909e67d-6a15-4091-8a7f-c1cb9a7ba914">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzgtMS0xLTEtMzYwOTg_e0e64f10-65f5-4831-9554-36e6b842351a">15,346.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzgtMy0xLTEtMzYwOTg_2fa2ad7a-8107-4ae9-bcc4-6034f94cf969">16,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:4pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i69ef474c51f449a7a0346882b167a9ae" continuedAt="ibbee9f1d0a084729870de310c701bdf4"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwNTY_c5989739-3a7f-41d6-8924-32bb2c4c88bd" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.179%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i3edfd436e4164d2f80725061a45ac456_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo4MmQzZjI2ZThhOTA0NGY4OGUwNjc2OTkxYjRlMWM4MF80_20e699b4-f78e-4a00-b774-cf362f636ff0">2.35</ix:nonFraction>% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3edfd436e4164d2f80725061a45ac456_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEtMS0xLTEtMzYwOTg_371c6a06-302a-4f68-a262-ea08670e25e0">750.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf0dcd71d534c529a1afa8977dd40ff_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEtMy0xLTEtMzYwOTg_eb372b19-480b-4cb7-a3ed-a4d885595180">750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i4c09aa7a84a1474780ee33c2cf2dc8e2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzItMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjpiOTFkM2Y3ZDA4YTU0OGY2OWFkYzBmOGNkNzU0YzBlMV80_9c04b8a0-9370-4bb3-8eae-fb9b3d5a57ee">3.00</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c09aa7a84a1474780ee33c2cf2dc8e2_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzItMS0xLTEtMzYwOTg_4d7eaf10-b50b-4859-885a-2760b6591fcd">99.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e573d0614c4b0dafebc560bf1e985c_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzItMy0xLTEtMzYwOTg_587bce9d-854e-4034-a52c-433e1e56f0d1">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i2550d98cc4814022b18b1a19bba41105_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo1ZWFhNWVmNzU3ZGI0YzAyYjc1ODg0MzViZDEwZGRhZl80_fc701c12-2cc5-44cc-8b7f-4e09faa74118">1.00</ix:nonFraction>% euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2550d98cc4814022b18b1a19bba41105_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMtMS0xLTEtMzYwOTg_3ae3b3b7-7ef2-4a8f-98ec-8049bea555b2">678.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i726ef58174614df18141c66c144a35ac_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMtMy0xLTEtMzYwOTg_bd1396cf-81d7-4e5f-842a-e2c201dc367b">737.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="idfdc5e7be96a48c89529e9addbc8ad7e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzQtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjpiZjM1MzY3YmVhZGE0ZWNkODRlYzU0OTY0Mjc4MmE2N180_03a62c9f-954e-4715-b662-c461441e575d">0.15</ix:nonFraction>% Swiss franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idfdc5e7be96a48c89529e9addbc8ad7e_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzQtMS0xLTEtMzYwOTg_9859da0f-c56d-447d-b791-6e1bec979a6e">654.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i92e2941af15b4d969e19eddd03468386_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzQtMy0xLTEtMzYwOTg_3931e9d9-74f9-4c68-a53d-26ca0351cbfd">679.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia6e0725e0711473c9cc3cffd0a7eedf8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzUtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo0NGZkN2YyZjE5YTk0NGZlOTFiMzM1Y2RlMDI1N2ZlYl80_796ef9fa-2d68-4a15-a162-7f260e77de7d">7.125</ix:nonFraction>% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia6e0725e0711473c9cc3cffd0a7eedf8_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzUtMS0xLTEtMzYwOTg_55ee09f1-7ad9-4e2e-a06e-cf350468cd50">217.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if26698e02933442c83d95b1cd9eee56d_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzUtMy0xLTEtMzYwOTg_abe0e1dc-b135-4f19-ab78-b9b468ff3ea6">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i154de6e52643472eac6dcdf2abeed4ed_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzYtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjplOWYzNTI3MTlmMjU0MWJhOGRiNzJhYTc2YzQxYWIxNF80_e1cb5c9d-2567-46a6-b7f7-00401e0575d8">2.75</ix:nonFraction>% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154de6e52643472eac6dcdf2abeed4ed_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzYtMS0xLTEtMzYwOTg_cd6e75b0-b5ba-4444-bec8-5c53249c7ec3">560.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i07da3333727b4428aad7bfefccb6d377_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzYtMy0xLTEtMzYwOTg_3b11bb16-145e-42d2-b6d1-793ad37ab7a4">560.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i67dfd1e097624c6488862d5324309a2b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzctMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjplNjgxYWVhZjc3NTM0NTJlODI5NTI1NDU4MzQwZDQ3YV80_f59cd359-9882-4e96-8bb6-dad383fd4274">1.625</ix:nonFraction>% euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i67dfd1e097624c6488862d5324309a2b_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzctMS0xLTEtMzYwOTg_79017192-317d-482b-99ca-6bf8674ba023">847.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i93730e7e82dc4832803e374edfe8ead2_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzctMy0xLTEtMzYwOTg_edcdc278-ab32-462b-bd2d-0d1d4316e409">922.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i75deddf561c0493e8e46b607e2749a0a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzgtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjozY2EzZTZiODAyYzA0OWJkOTk3YjFlZTkzYWE3YmVhM180_115ee838-0f8a-4ed0-b0aa-ecda78a9cedf">5.5</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i75deddf561c0493e8e46b607e2749a0a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzgtMS0xLTEtMzYwOTg_0eff1171-cd1c-4ea5-85b9-697d744802ac">364.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i48bd23b8192c4011a4b88d56642b3f8a_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzgtMy0xLTEtMzYwOTg_f3ece1c6-cc5e-457b-825b-9049ecdab498">377.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="if60345d16c5f4360a5db3ba0799c8e53_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzktMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo2NGZiZmI3ZDQzY2M0OGRlOWUzYTllOTk0YTM2ZWQ0Zl80_2e030777-0465-488c-8c1d-8522a3374d85">3.1</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if60345d16c5f4360a5db3ba0799c8e53_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzktMS0xLTEtMzYwOTg_d9513f10-7c6a-4e33-86da-feae9a05e4ec">401.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if5686e91f0d54967a085ff54595dcd73_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzktMy0xLTEtMzYwOTg_7678c829-108c-4371-89b3-94a8a2a8431a">401.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i3de88e24648844a59b518e653fed8863_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEwLTAtMS0xLTM2MDk4L3RleHRyZWdpb246M2ViMTlhNjRjNWI0NDgwNzlhNmIxMzU0Y2IwZjEwNGZfNA_d96d8081-974a-4e12-bf9b-2cebfb05856f">0.45</ix:nonFraction>% Swiss franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3de88e24648844a59b518e653fed8863_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEwLTEtMS0xLTM2MDk4_0e6f7328-cc11-4937-8067-ec5e251c99b9">436.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ifeef731d794a4687b24f3700ad5eb752_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEwLTMtMS0xLTM2MDk4_bd8d2073-b974-44ce-856d-829c18c5e09f">453.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0ef2c7899afb4acea061037c69340c76_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzExLTAtMS0xLTM2MDk4L3RleHRyZWdpb246Njc3N2U5MDk3YzU5NGJiNDk2ZjU1MGI1ZWZmN2RiNzVfNA_ecdfe0aa-4611-46db-80a1-d1707e069762">3.375</ix:nonFraction>% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0ef2c7899afb4acea061037c69340c76_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzExLTEtMS0xLTM2MDk4_30dd9faf-1b6a-4bc7-baa4-f667a1fc1897">930.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9eaacf39e2ea44ed8c2e4582391bdcb8_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzExLTMtMS0xLTM2MDk4_0ab46dbc-a091-453a-8761-4fc74381f6a5">1,150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i21429821125945baa4970226531ad503_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEyLTAtMS0xLTM2MDk4L3RleHRyZWdpb246OTMyYjc2YjEzZDM0NGE5OWIzYzU2YTIyMmEzMTE0MTBfNA_3edaa05f-f2ad-4f2b-bdda-9252ed84beab">0.42</ix:nonFraction>% Japanese yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i21429821125945baa4970226531ad503_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEyLTEtMS0xLTM2MDk4_d81d7f21-c990-476e-b7bb-11b8a6d76794">199.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie460a9111eb84d4a80874905c816ec62_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEyLTMtMS0xLTM2MDk4_7350481a-1d45-4dc7-91d8-76264e67eb5d">222.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i80b1d20b9535421399292eaeb2e1404d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEzLTAtMS0xLTM2MDk4L3RleHRyZWdpb246OWQwNGQ4Yjk4ZGQxNGU3Y2FmMzM1MjJjZDExYTljYzBfNA_2e492906-5522-4416-a370-97ddca0cfb38">2.125</ix:nonFraction>% euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i80b1d20b9535421399292eaeb2e1404d_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEzLTEtMS0xLTM2MDk4_2df0d7ff-8c36-4102-b2af-504f5bd6fd32">847.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1eb82f7d9a12471bb259d4ecd5857cf6_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEzLTMtMS0xLTM2MDk4_135e6496-6da4-4639-b7a6-6d6a01aa9d7c">922.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i6ddfc74445594fbfaaea12c6240ebc86_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE0LTAtMS0xLTM2MDk4L3RleHRyZWdpb246OWNmMjJkMjE1M2ZmNDI5OWE5Y2MzNWQwZGQwYTA1ZmNfNA_402486a8-18ad-4a7f-a115-413414fdf8bb">0.625</ix:nonFraction>% euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6ddfc74445594fbfaaea12c6240ebc86_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE0LTEtMS0xLTM2MDk4_5fd2f096-bf21-46c3-ab9d-19b355f5cf1d">678.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2102d6980fea4c88a7c3bd4a75c97991_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE0LTMtMS0xLTM2MDk4_0b6eb76e-6eb8-44c6-995a-ad82a29d35e2">737.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia4b59c5814594a1298d4215076efeee8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTAtMS0xLTc3MTE0L3RleHRyZWdpb246MTg1ODg5MjVjMzQyNGQ0YzkwYmY3MzdmZWUzYTgxMGVfNzY5NjU4MTM5NDQ3OA_dc3ec8d4-fdd2-4419-b1d9-7da63668499b">0.50</ix:nonFraction>% euro denominated notes due 2033</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia4b59c5814594a1298d4215076efeee8_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTEtMS0xLTc3MTI1_38424e56-3c23-4853-87cf-12f0e4e78602">678.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic4662c8bc38545fb8b2d9cb09707ea95_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTMtMS0xLTc3MTMz_2fe464a1-06fd-465f-85fd-3a8d30f39390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i69e119752ce84afebbd0e53e707424ea_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZGY5ZjIwYzc5YzQ2NDM2OWFkZWJlZDk0OGI4YjUyNzJfNA_cddbd0e8-5cfd-4fb2-a99d-5d75070ff089">0.56</ix:nonFraction>% Japanese yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i69e119752ce84afebbd0e53e707424ea_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTEtMS0xLTM2MDk4_97982662-8bc4-42b3-b3b4-7dfd8b4edca1">80.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iffa8f1a49264490990fa783782542124_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTMtMS0xLTM2MDk4_ae818d38-b147-4156-8fc1-663127dcdaed">90.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i3d037b9981404553a0d4424d89b04955_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE2LTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZGExYmNlNmI2NGY2NDY2ZDg4YTZkMzY0OTZhYmE2YjNfNA_c0587041-b362-4c2d-bfb2-1a09b56fc4ac">6.77</ix:nonFraction>% notes due 2036</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3d037b9981404553a0d4424d89b04955_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE2LTEtMS0xLTM2MDk4_6f6eea18-2c43-4f86-ae69-c2f2f91ef94c">158.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0f18ee96f0b945dea57a5126d8ac86e5_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE2LTMtMS0xLTM2MDk4_0edbe95a-a3cd-45e5-b2b9-3088e333ed68">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i1ad3157951114b79b6573431cb911415_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE3LTAtMS0xLTM2MDk4L3RleHRyZWdpb246MWZhNDFkOWQ0ODJlNDIyMDg5ZTkwODkwN2ViMDg4M2NfNA_c5300cbd-1275-4fbb-9725-078e4939f21f">5.55</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1ad3157951114b79b6573431cb911415_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE3LTEtMS0xLTM2MDk4_0b2900be-7195-4855-9781-222f1c4556f0">444.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia474b21ab0f644219eba3b34a8113881_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE3LTMtMS0xLTM2MDk4_3fbe9030-2612-4348-861e-5f8ca1731c20">476.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="iaa96c35099cd409caaa67bff540585fa_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE4LTAtMS0xLTM2MDk4L3RleHRyZWdpb246NDE2OTM5Mjg1ODliNGNkOTgwNmJkYzZmODgyM2U2MzBfNA_d000478a-9d6d-4658-8c28-db6930d8a6b4">5.95</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iaa96c35099cd409caaa67bff540585fa_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE4LTEtMS0xLTM2MDk4_6e2630b8-c57c-42eb-90ba-26c2f2114e14">266.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c29dcff71ec45a593556dfe25bd76e0_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE4LTMtMS0xLTM2MDk4_5a83fc51-39ec-4214-86d3-2e5f32985c09">284.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i4a94c884519b4702b3f5dc1c813be663_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE5LTAtMS0xLTM2MDk4L3RleHRyZWdpb246MDRhNTBhY2Q0N2Y2NGJlN2E2NGQwNzI3YTM0ODRlNDNfNA_d6d5e45a-0d05-45c0-880a-a801804b958e">3.875</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a94c884519b4702b3f5dc1c813be663_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE5LTEtMS0xLTM2MDk4_5fdc011b-2d16-4229-be31-c8a87b3572b2">240.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i69442670727945548dd575b353aadf52_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE5LTMtMS0xLTM2MDk4_5b7cbe6d-c32f-46f5-b75f-2c6324e4f7a2">360.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i9c0e225dc9f24b699d469b030eab3e0f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTAtMS0xLTc3MTUyL3RleHRyZWdpb246YzBmNGM0OWFmNmY1NGYwNGE5ODdlMWU1MTJhNDNjNWNfNzY5NjU4MTM5NDQ4OQ_ce7cb319-44cb-469e-b634-e235232be93a">1.625</ix:nonFraction>% British pound denominated notes due 2043</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9c0e225dc9f24b699d469b030eab3e0f_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTEtMS0xLTc3MTUy_058e44d2-dff6-4f1f-aff8-bc134b58189a">337.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ib9a35afa117740c1980f3bb027fc8dd0_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTMtMS0xLTc3MTc5_30761cd6-ec22-42ab-aff0-e9cbd32316a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie6648301f7e343c8b1397283a5da0166_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIwLTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZjNkZjI1YWQ2NzY3NDQ2NjlmMWM1ZjdlYzE1ODU1MGFfNA_5ef944e0-ae89-4b39-a1c0-86fb19b64119">4.65</ix:nonFraction>% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie6648301f7e343c8b1397283a5da0166_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIwLTEtMS0xLTM2MDk4_96fa8331-9cd9-4e3d-8b04-a5c76b28b000">38.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2a776f2958104fed92c610952957426f_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIwLTMtMS0xLTM2MDk4_0593b177-27ce-4191-a077-17579726f791">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i231000e09f2d43bb84cd04cf8c324914_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTAtMS0xLTM2MDk4L3RleHRyZWdpb246NjQ5OTdjZmMyZmM1NDc2ZWI5MmEwMzlkMmQ0YjkxZWJfNA_da66cd0f-18ee-4b5c-8401-2c173d9e8519">3.7</ix:nonFraction>% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i231000e09f2d43bb84cd04cf8c324914_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTEtMS0xLTM2MDk4_55bfe914-3d06-48af-9002-75ac375a0a7a">386.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i68a00f397c444157b4b4d73e2eea183b_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTMtMS0xLTM2MDk4_126375de-6089-4b02-8f1e-4dd5182adf0b">412.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i06f29fc3788e4afabc141f44cf4cd192_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIyLTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZDdiMmZiMmExZTM4NGViYjljMmUzNzI2MjM0MTIxMWZfNA_d1f19807-22e9-4f10-ba64-e79056a149d2">3.95</ix:nonFraction>% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i06f29fc3788e4afabc141f44cf4cd192_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIyLTEtMS0xLTM2MDk4_de78d676-73bc-4025-ac82-43d4c1121bb7">347.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4f2fca1966da41f8adc01f317059c621_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIyLTMtMS0xLTM2MDk4_2e5ad84b-5acd-468b-b387-236eccdfbadd">436.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i18bfe7750c7f43cfbb99996103ae776d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIzLTAtMS0xLTM2MDk4L3RleHRyZWdpb246MmUxZDYwMTY1ZGI4NGM2MGE2MTlhNDE0N2RmODhlNDBfNA_00b0e87e-2188-40fd-b105-e8ffd644dc84">3.95</ix:nonFraction>% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i18bfe7750c7f43cfbb99996103ae776d_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIzLTEtMS0xLTM2MDk4_7c7c4340-9c5f-4a74-94d6-1b64847dfb13">958.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i72baca3e465440cdae1136e4d7206b9e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIzLTMtMS0xLTM2MDk4_4269610b-664f-4bfd-acf2-84813b52a5b8">1,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ib8af2d2c452d42a8b7cd8f16e4ebd74b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI0LTAtMS0xLTM2MDk4L3RleHRyZWdpb246NWM4OGM2ZGJjMmI2NDgyOGJlMzI2ZTE1MjRjYTVkYjZfNzY5NjU4MTM5NDQ3OA_153a1dbe-2294-4a4b-bada-2198d1950cf9">1.70</ix:nonFraction>% euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ib8af2d2c452d42a8b7cd8f16e4ebd74b_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI0LTEtMS0xLTM2MDk4_7cd2adbc-89c9-404a-88fd-b10b1ada81de">1,130.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i36aea259f0b34f19ba983964d19353fb_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI0LTMtMS0xLTM2MDk4_10250d68-9aba-4554-b617-4319d319fa92">1,229.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i4361ba8f6e1e4492a8664a509357866c_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI1LTAtMS0xLTM2MDk4L3RleHRyZWdpb246Yjk1ZGNhN2JhZjY3NDJlNjg4ODFjYzhmZTBhNWMwNGJfNA_bd4cd7b4-41d4-4581-bcab-25f81baa96ef">0.97</ix:nonFraction>% Japanese yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4361ba8f6e1e4492a8664a509357866c_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI1LTEtMS0xLTM2MDk4_dd8ef064-081c-48f4-9c67-2de347c923f9">66.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i935c853cb5344480a0fde97d3a5bbf26_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI1LTMtMS0xLTM2MDk4_fe25100d-14c0-430a-bada-b9fb530b7534">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="icd87a02ecce94de892c2873f98f3488e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI2LTAtMS0xLTM2MDk4L3RleHRyZWdpb246YzE1NzAxNDc4NWRiNDBkYjlmYWZhZDQ0YTlkYjg2NDlfNA_982baab6-0d25-4d90-b33f-d3d74083c7b2">2.25</ix:nonFraction>% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="icd87a02ecce94de892c2873f98f3488e_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI2LTEtMS0xLTM2MDk4_14baa796-bbfa-4a57-be6a-ddc5deb322c5">1,250.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6d753d735746cd823811c9493f0574_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI2LTMtMS0xLTM2MDk4_cf9a9960-dbe9-44b9-be45-08a84cbbfc7b">1,250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i849ed38906ec4ff5b38dd57dffe8ecf1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTAtMS0xLTc3MTYwL3RleHRyZWdpb246NTcxZGI5YWFkMGZiNDA3MDg4NTI1NDllMGU0MDAwZjFfNzY5NjU4MTM5NDQ4MA_eb58cd5d-b24c-404a-96cf-ba8024538d1b">1.125</ix:nonFraction>% euro denominated notes due 2051</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i849ed38906ec4ff5b38dd57dffe8ecf1_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTEtMS0xLTc3MTYw_048f5bfb-812e-407a-81ea-a41a66feabd7">565.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ib1eff0e4f1e846f2890a8d5f2938a568_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTMtMS0xLTc3MTg4_33f34fd6-8f6d-4bfa-bb4c-dbddd92f28f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i13a5deea4c6d48b7a2eafbede3b86af1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI4LTAtMS0xLTM2MDk4L3RleHRyZWdpb246MDNjZGUzZWM1YTU3NDFmYmE0NWFjMzAwZTVjODI2MzJfNA_842b983e-5677-4f54-8e73-ded51a4c32ad">4.15</ix:nonFraction>% notes due 2059</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i13a5deea4c6d48b7a2eafbede3b86af1_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI4LTEtMS0xLTM2MDk4_35640c60-400a-4eb8-bed3-a729e9132867">591.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i51b466072109461f818c9dc82d5550bc_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI4LTMtMS0xLTM2MDk4_61a8ea72-71e5-415c-8d06-22cc7f76790a">1,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i77673fc123d84b82ac7de1c624dc395f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI5LTAtMS0xLTM2MDk4L3RleHRyZWdpb246OGM3NDZmY2MzMWE0NDI2YWE4Y2MyMjg3ZTE1MjllYThfNzY5NjU4MTM5NDQ2MQ_a7b13c06-fb1d-48c5-8300-70dbb25897f6">2.50</ix:nonFraction>% notes due 2060</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i77673fc123d84b82ac7de1c624dc395f_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI5LTEtMS0xLTM2MDk4_2964159a-9551-4308-b4d7-9d575f70dfd2">850.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id057083c27874cbd98e27c582abf0489_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI5LTMtMS0xLTM2MDk4_ea155a5e-8969-4c07-8439-c881e06cb20e">850.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="if03f60cda085426697bf93f5635d81c0_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMzLTAtMS0xLTc3MTY5L3RleHRyZWdpb246ODgwMDg4NzM3MzY5NGQwMmFkM2E4ZWYxNTJkNzg5ZTVfNzY5NjU4MTM5NDQ4MA_67d35128-788e-4d6b-9478-34bc8a33b895">1.375</ix:nonFraction>% euro denominated notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if03f60cda085426697bf93f5635d81c0_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMzLTEtMS0xLTc3MTY5_fde6769d-4779-44c4-99fe-d225012d98a6">791.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9f2170ade6674e849351094a6814a792_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMzLTMtMS0xLTc3MTk2_2d92860d-e267-4707-a006-b0c9cd558a77">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTEtMS0xLTM2MDk4_8414799b-75cd-4ce7-8314-7faf7676c102">105.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTMtMS0xLTM2MDk4_0331602d-9f29-4028-a032-fc0f7c0b6544">76.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMxLTEtMS0xLTM2MDk4_ce523505-df2e-41fb-87fc-b097eab6d1e0">16,741.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMxLTMtMS0xLTM2MDk4_950e4fac-078b-4840-b09e-ca88fe15d72f">16,348.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had a total of $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzM4Ng_9f9dd9a9-db47-4df3-9f79-2c3b91d2d2b4">5.26</ix:nonFraction> billion of unused committed bank credit facilities, which consisted primarily of a $<ix:nonFraction unitRef="usd" contextRef="iea2f9c7572f84dd09b8fc2143f1c7713_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQ2NA_9884340d-a00f-4f53-8ef6-9c5188197667">3.00</ix:nonFraction> billion credit facility that expires in December 2026 and a $<ix:nonFraction unitRef="usd" contextRef="i87692d02cc64457990db62efd471306d_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzUxOQ_9d66f86d-3cec-440b-8523-fd6f0f4de450">2.00</ix:nonFraction>&#160;billion <ix:nonNumeric contextRef="i0d63bfbf5dc1474eb7e49de284e9b9bd_D20210101-20211231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzUyMg_a94289a0-8cff-45fc-a203-65e51cb0eee5">364</ix:nonNumeric>-day facility that expires in November 2022, both of which are available to support our commercial paper program. We have not drawn against the $<ix:nonFraction unitRef="usd" contextRef="iea2f9c7572f84dd09b8fc2143f1c7713_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzY2OA_9884340d-a00f-4f53-8ef6-9c5188197667">3.00</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i87692d02cc64457990db62efd471306d_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzY3NQ_9d66f86d-3cec-440b-8523-fd6f0f4de450">2.00</ix:nonFraction> billion facilities as of December&#160;31, 2021. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2021 and 2020 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ibbee9f1d0a084729870de310c701bdf4" continuedAt="i8deb27948bf44daf9f082ce22000b558"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="ib618046f71cd4612a921448bdebdc46a_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzE5OTY_1e7b7d3a-9002-42ba-85e0-cfc611a72636">600.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="ib618046f71cd4612a921448bdebdc46a_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIwMDM_9b406ef4-ae3c-4b0d-8bb3-03594e20279d">0.50</ix:nonFraction> percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="iaec709b7886f4f2cb0cfba7f68baeac3_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzMzM_68bc4aae-0a8b-46ef-b67a-e6aa8c649ab8">500.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="iaec709b7886f4f2cb0cfba7f68baeac3_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzNDA_03309689-b359-4b6f-adf5-5d210f80b8ac">1.125</ix:nonFraction> percent fixed-rate notes due in September 2051 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i89f7f06fe81f4197af8d197ea94e6fad_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzODc_2b73cc15-c65d-40b6-931c-c8f2489076e3">700.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i89f7f06fe81f4197af8d197ea94e6fad_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzOTQ_a7c5407e-e958-462c-9976-b788082d1224">1.375</ix:nonFraction> percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;<ix:nonFraction unitRef="gbp" contextRef="i07ecd2cf284544f3a2b8a03785d285bc_I20210930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI1MjM_12aeabcb-4957-4795-846a-63b86cf250b3">250.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i07ecd2cf284544f3a2b8a03785d285bc_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI1MzA_d3729480-0fd8-4578-b9b0-2d8dcc5e4d30">1.625</ix:nonFraction> percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $<ix:nonFraction unitRef="usd" contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930" decimals="-7" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI2MTc_9207cd74-5e98-4705-863f-4339d56cefe0">1.91</ix:nonFraction>&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930" decimals="-7" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI3ODQ_db86fc5a-e5f4-4967-9bbe-6ac18ce9a7a5">1.50</ix:nonFraction>&#160;billion, resulting in a debt extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI4MzI_32f1967c-d242-4081-bde4-b616b80b9cad">405.2</ix:nonFraction>&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930" decimals="-7" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI5OTg_db86fc5a-e5f4-4967-9bbe-6ac18ce9a7a5">1.50</ix:nonFraction>&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $<ix:nonFraction unitRef="usd" contextRef="i841cd3e00f484488bd7b6b817257e859_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxMTE_2156c3f5-a68c-4cec-acd9-0346f250d0ae">541.8</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="iaf79b1977acf44dfb438b2b46b217354_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxMTg_5881843e-bbbc-4190-aaeb-9f23c78c9800">3.95</ix:nonFraction> percent notes due 2049, $<ix:nonFraction unitRef="usd" contextRef="i551b1c26feb64783b8cdff78bf43afdc_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxMzg_e707ecda-90e7-4f9a-be66-ec0d1e01c213">408.7</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i6a28246e7f384385969289659ed183cd_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxNDU_173b0059-fa31-4be9-8bad-e02d93ed44ec">4.15</ix:nonFraction> percent notes due 2059, and $<ix:nonFraction unitRef="usd" contextRef="i2874fde88d0443708940891c7b27e2c3_D20210901-20210930" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxNjk_a8fbaa9e-5dbb-4be6-8f77-ce117337514a">219.4</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i4501b277cafa4a86baa5a206571b8208_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxNzY_e0d41102-cf4f-480a-b20e-78f5bde1ff93">3.375</ix:nonFraction> percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i8d3a4dd737f64e34a0e898318bacdb1f_I20200531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2Xzk5NQ_cfffd20f-a314-4279-af52-4685c8c5bfac">1.00</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i8d3a4dd737f64e34a0e898318bacdb1f_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwMDE_dc590781-ec0f-41d7-b294-7ceb270202e2">2.25</ix:nonFraction> percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="i89a543f8c48547aa9e78a63f01f33c83_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzExMjk_c9a2f0cc-4ccd-4bfb-898a-9e6f13df5ab5">988.6</ix:nonFraction> million for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="i9c2ba1b9c9854a9488d1f797845e5637_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEyNDg_c99b64cb-1e06-4830-bc36-1d8169f77217">850.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i9c2ba1b9c9854a9488d1f797845e5637_I20200831" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEyNTQ_f9ee41cf-e945-48a5-b64e-d810c7183248">2.50</ix:nonFraction> percent fixed-rate notes due in September 2060 and an additional $<ix:nonFraction unitRef="usd" contextRef="ic1dff00d32cb4ba2b10f010cbd418d9e_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEzMTQ_7f83e37b-399a-436c-a6f2-f0769c2b016c">250.0</ix:nonFraction> million of our <ix:nonFraction unitRef="number" contextRef="ic1dff00d32cb4ba2b10f010cbd418d9e_I20200831" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEzMjQ_8ed9e8b3-99df-4b5d-bc1b-9ebb7245715c">2.25</ix:nonFraction> percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="i88fafea838de4336a9206daa5e470df6_D20200801-20200930" decimals="-7" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzE0NTI_7c06a4c7-19eb-4da3-810d-ab81514d4a0d">1.07</ix:nonFraction> billion for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $<ix:nonFraction unitRef="usd" contextRef="i7a25b1bbb8494f0cbd38976a0a587f00_I20190228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4MTE_a64f26b7-9abd-42fa-b5b5-47ac872aa5f1">1.15</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i7a25b1bbb8494f0cbd38976a0a587f00_I20190228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4MjU_7f02fb58-9cf2-44eb-9ca4-b6487015f7e2">3.375</ix:nonFraction> percent fixed-rate notes due in March 2029, $<ix:nonFraction unitRef="usd" contextRef="id3b13e3f15a94aa09c71215b3ab2d172_I20190228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4ODA_aed29dc1-4f5e-4434-b3ea-0990d3479c9c">850.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="id3b13e3f15a94aa09c71215b3ab2d172_I20190228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4OTU_1ec5afe1-26a1-43ef-b904-e722a43e2bab">3.875</ix:nonFraction> percent fixed-rate notes due in March 2039, $<ix:nonFraction unitRef="usd" contextRef="i5ae5dc6dd3d94739aca17ae8276b5801_I20190228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4NjU_d32c9ab2-4681-433d-80af-2c88e543f1fc">1.50</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i5ae5dc6dd3d94739aca17ae8276b5801_I20190228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4NDY_1fd7fc46-59cb-4022-8f26-a221b873f2c4">3.95</ix:nonFraction> percent fixed-rate notes due in March 2049, and $<ix:nonFraction unitRef="usd" contextRef="if2a86269df3d466591806fc6e81d3051_I20190228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5MTU_ecfc6d38-f8ae-4ed6-bc0b-30303ea9882b">1.00</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="if2a86269df3d466591806fc6e81d3051_I20190228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5Mjk_09bbcca9-2321-4cd5-a071-0df59a57011b">4.15</ix:nonFraction> percent fixed-rate notes due in March 2059, with interest to be paid semi-annually. We used the net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i21e3b9057af3454595d19c23e9d0f7bd_D20190201-20190228" decimals="-7" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5NDg_0b966bd5-652e-4867-bd1a-8529eea7f7a2">4.45</ix:nonFraction>&#160;billion from the offering to repay commercial paper that was issued in connection with the acquisition of Loxo and for general corporate purposes.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="i80ade2425c63414ea6978d8687390db3_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwMzk_145926be-57b3-4717-a5fd-4a24a7c5fa8d">600.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i80ade2425c63414ea6978d8687390db3_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwNDU_9f035ad3-c7b0-4620-99c0-f3ac7ed84145">0.625</ix:nonFraction> percent fixed-notes due November 2031 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i709f676fc9614b42b1b0311c076d8dc4_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwOTE_dbef1360-6122-4f03-b929-a815cbc8c44c">1.00</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i709f676fc9614b42b1b0311c076d8dc4_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwOTc_a9892c70-8ac4-4500-9383-c342fddde4f9">1.70</ix:nonFraction> percent fixed-rate notes due in November 2049 with interest to be paid annually. We paid $<ix:nonFraction unitRef="usd" contextRef="ie11cc64930a449558e5ae1a4c19b6806_D20191101-20191130" decimals="-7" sign="-" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIxODk_17f6bdfc-4057-4411-b08c-7158f36967aa">2.27</ix:nonFraction> billion, comprised of $<ix:nonFraction unitRef="usd" contextRef="i982bcc21bc3a40c48ddab9f94be23c67_D20191101-20191130" decimals="-7" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIyMDY_7f84263d-8e61-4c7a-88c9-72bdbc2ce61e">1.75</ix:nonFraction> billion of net cash proceeds from the offering and proceeds from commercial paper, to purchase and redeem certain higher interest rate U.S. dollar denominated notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i8a2998c6421144a5959f9da4218d7f13_I20191130" decimals="-7" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI0MDQ_3cd39f84-ed6d-4bda-915e-40110703d8d8">2.00</ix:nonFraction> billion and a net carrying value of $<ix:nonFraction unitRef="usd" contextRef="i8a2998c6421144a5959f9da4218d7f13_I20191130" decimals="-7" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI0MzU_b04f188c-ac1b-4990-8d14-d92b4b06ae13">2.01</ix:nonFraction>&#160;billion, resulting in a debt extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="i7f0d0d5ad7314fd8aba39a1931772306_D20191101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI0ODI_bdc299ca-e8c5-4e23-9409-cd89cb2f3439">252.5</ix:nonFraction> million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued Japanese Yen-denominated notes consisting of &#165;<ix:nonFraction unitRef="jpy" contextRef="i5f666283299a422782250b8f89a2f761_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5OTQ_721415fd-5a8d-4f2b-9a4e-5bc111faad68">22.92</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i5f666283299a422782250b8f89a2f761_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwMDg_16e66480-0241-456e-b71d-431ef1f2b79e">0.42</ix:nonFraction> percent fixed-rate notes due in November 2029, &#165;<ix:nonFraction unitRef="jpy" contextRef="id13727de8f3441d299f77635f64f9362_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNDE_7f83c0c5-66d9-4b6d-b54e-c1ef49e098e6">9.28</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="id13727de8f3441d299f77635f64f9362_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNTQ_0dd0e658-cb8b-4739-a8be-ecfde0d92c81">0.56</ix:nonFraction> percent fixed-rate notes due in November 2034, and &#165;<ix:nonFraction unitRef="jpy" contextRef="i41718151ae0142b0a3f6ffa452de44fb_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwMjc_9a3ea866-fc46-45cf-b91a-807f7cf29212">7.64</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="i41718151ae0142b0a3f6ffa452de44fb_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNzQ_70c5fb82-e62e-4558-a5ea-dc378bf8863c">0.97</ix:nonFraction> percent fixed-rate notes due in November 2049, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="id60cdef46f66424db1dd39767e60ddd8_D20191101-20191130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNzY_42523ce3-0ef7-41ad-a748-bf9d4dfbce58">356.6</ix:nonFraction>&#160;million for general corporate purposes, including the repayment of outstanding commercial paper.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwODI_993f441a-cf6a-4f7c-8cf0-ad097852f129" escape="true"><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:49.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtMS0xLTEtMzYwOTg_b53049ce-e42c-40e9-83f6-2be3f22f25a6">1,531.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtMy0xLTEtMzYwOTg_540471b6-f9ec-46a5-a8d9-8b043301e288">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtNS0xLTEtMzYwOTg_dbc29fdf-6c77-4683-a934-5484d6ad11e2">657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtNy0xLTEtMzYwOTg_1d28cf0b-443a-4e78-85a1-bca1ec82d6a2">778.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtOS0xLTEtMzYwOTg_10bc7d4f-36c5-440f-9227-7f1bd2bfbe28">847.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have converted approximately <ix:nonFraction unitRef="number" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="2" name="lly:DescriptionOfDerivativeActivityVolumePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzMxODQ_92bf97c3-87b1-4611-a450-7a31804ec790">13</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2021 and 2020, including the effects of interest rate swaps for hedged debt obligations, were <ix:nonFraction unitRef="number" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzM0NzQ_b17d995c-1aec-49c9-8cdc-4c7f54d82ec7">2.27</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzM0ODE_4e359766-1c5c-4962-a00c-282f18902cd9">2.61</ix:nonFraction> percent, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i8deb27948bf44daf9f082ce22000b558"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwODM_cd1ac5b5-fca2-4578-b93e-ae0847d96892" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToxNDBiZjkzODE1NzA0MWUyYjA0MDAzNjVhNjg3NDEzOS90YWJsZXJhbmdlOjE0MGJmOTM4MTU3MDQxZTJiMDQwMDM2NWE2ODc0MTM5XzEtMS0xLTEtMzYwOTg_b404eb66-fde2-4155-8a5d-f9cc759bf841">338.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToxNDBiZjkzODE1NzA0MWUyYjA0MDAzNjVhNjg3NDEzOS90YWJsZXJhbmdlOjE0MGJmOTM4MTU3MDQxZTJiMDQwMDM2NWE2ODc0MTM5XzEtMy0xLTEtMzYwOTg_01a9134f-b7cd-4489-bf27-c1084a2afdab">345.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToxNDBiZjkzODE1NzA0MWUyYjA0MDAzNjVhNjg3NDEzOS90YWJsZXJhbmdlOjE0MGJmOTM4MTU3MDQxZTJiMDQwMDM2NWE2ODc0MTM5XzEtNS0xLTEtMzYwOTg_82bdae4e-98bd-495d-b7a3-cb95890086d3">305.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_142"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MzM_7fd2a0a9-01f3-4972-8d1e-be9d2d637155" continuedAt="ib4acdc13a44d4bcf9dd6b65717b8a8d5" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ib4acdc13a44d4bcf9dd6b65717b8a8d5" continuedAt="id915b4b95557488eb9cdf5ef864ce63b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTI_5aaad746-6be5-49f6-91ee-980b63bfda22" escape="true">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MjY_8041fc35-a222-417f-8cb4-a3c32e117861" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzEtMS0xLTEtMzYwOTg_e7ad8d6a-d10a-4453-a8c6-960b7a23e2eb">342.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzEtMy0xLTEtMzYwOTg_970d7f5b-0835-4ad5-b6ac-133dc8b506ad">308.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzEtNS0xLTEtMzYwOTg_4706adb6-5e32-41ee-b204-d3abee487850">306.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzItMS0xLTEtMzYwOTg_475f0bd0-79e3-4985-bc96-128b4480bbf3">72.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzItMy0xLTEtMzYwOTg_398272fe-914a-4a73-8610-fc6642fde3d5">64.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzItNS0xLTEtMzYwOTg_7347e02a-3cff-4ec2-a922-40566585ad89">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than <ix:nonFraction unitRef="shares" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzY5Ng_16b9ca79-dfdf-4241-adc4-4af56430d855">50.6</ix:nonFraction> million additional shares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a <ix:nonNumeric contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTM_592a566a-80f5-4071-9bad-67fe4f60013d">two-year</ix:nonNumeric> period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2021, 2020, and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzEyMTk_77fd34eb-4eca-4663-8e65-7a486f0c9685">198.57</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="id842f1546f35423585d05e7ce66b80c2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzEyMjM_cd76cb3b-36fe-4f8e-823d-cb60e9c83caa">137.33</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic4b33128ceba4b25a2ac485bd4f78d97_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzEyMzE_317000ed-7e5c-42f0-8b8a-ed8fc30063bb">112.09</ix:nonFraction>, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately <ix:nonFraction unitRef="shares" contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE0MDk_f6692f70-1e8d-41bc-96c5-894400b0d680">0.7</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="id842f1546f35423585d05e7ce66b80c2_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE0MjA_64766abc-a9e8-44fa-94ad-8123437f5973">1.1</ix:nonFraction> million shares, and <ix:nonFraction unitRef="shares" contextRef="ic4b33128ceba4b25a2ac485bd4f78d97_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE0MzU_569e96ba-7a92-465f-bc7a-4c51fdf0c31b">1.2</ix:nonFraction>&#160;million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE1MjQ_0a48c408-aaa7-4e99-b318-4f692ab369f4">0.7</ix:nonFraction> million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested PAs was $<ix:nonFraction unitRef="usd" contextRef="ica452a7bd83c44088dffeaca9fe9e6e3_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE2NTc_57cadc92-893a-40da-878c-9f62a85e0f11">66.1</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE3NDk_d6ad94ff-11c3-4adc-8694-f8a360391652">12</ix:nonNumeric> months.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id915b4b95557488eb9cdf5ef864ce63b" continuedAt="i6aa451749cc442219e08dafb9a401eae"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the <ix:nonNumeric contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1NDM_7517a5ad-2fc1-40fd-9c7c-b74bc07ee541">three-year</ix:nonNumeric> vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTQ_47256d61-98de-42f8-80d6-6288d1ea0314" continuedAt="i64db81a0d69e4a4f8989a1925acefc0c" escape="true">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2021, 2020, and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI4MTg_0fc4372f-51c1-4c86-80b4-45eecadd000c">230.19</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI4MjI_ef5205f8-6335-4f22-9afb-8988b146dc5c">139.14</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI4MzA_2ab21b62-ae44-4e5e-8f44-1855c618d3f1">95.01</ix:nonFraction>, respectively, determined using the following assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:11pt"><ix:continuation id="i64db81a0d69e4a4f8989a1925acefc0c" continuedAt="i7cdf1d4324c04ead83d215f703297668"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzEtMS0xLTEtMzYwOTg_0bbb20a7-c312-4c34-9549-1a6505b8c6e2">2.50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzEtMy0xLTEtMzYwOTg_5a235ac8-29ab-4f2d-962f-fdfcf598ef3d">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzEtNS0xLTEtMzYwOTg_27dd4d3f-fd8e-4921-9a4f-53337c842556">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzItMS0xLTEtMzYwOTg_56364485-b59b-42ca-a660-bffb9876776f">0.19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzItMy0xLTEtMzYwOTg_3a068bde-0506-42d3-9db3-3cb796cbce79">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzItNS0xLTEtMzYwOTg_d484ea6a-e86f-42df-96a9-ad8ab0e38c78">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzMtMS0xLTEtMzYwOTg_9ea6371a-1814-4a87-96d5-133e8a389051">31.42</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzMtMy0xLTEtMzYwOTg_eab3a753-0cf3-49d9-89f5-6c4dde260b68">20.90</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzMtNS0xLTEtMzYwOTg_99e1140b-52de-4ebd-ab20-95b3363827f5">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, approximately <ix:nonFraction unitRef="shares" contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI5MzQ_56b85b93-9f9d-4bc7-9c56-a8e60b4adfbd">1.0</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI5NDU_de0b10ce-708f-4234-bfaf-e8707d62ed10">0.8</ix:nonFraction> million shares, and <ix:nonFraction unitRef="shares" contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI5NjA_bd7352ae-50a0-450b-9368-3902c9538177">1.0</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzMwNDk_72ade34c-b03d-4f78-9016-0858b7d42bfb">0.5</ix:nonFraction>&#160;million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested SVAs was $<ix:nonFraction unitRef="usd" contextRef="icd1522d5872545dc9d89fb44d73b59ae_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzMxODM_e5879e74-1a9a-4d15-b1c4-9c266e7e091e">47.0</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzMyNzU_e058d1c1-061d-4e2b-8b70-db180d7c21b5">21</ix:nonNumeric> months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relative Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we granted RVAs to officers and management that are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the <ix:nonNumeric contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MzA_f2aaf8ac-e7a3-48d7-a09c-5731e3241044">three-year</ix:nonNumeric> vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. <ix:continuation id="i7cdf1d4324c04ead83d215f703297668" continuedAt="i38c2d96ff7734a209f77bbb096f28dba">The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQzNTk_7ada5ec9-c18e-4cbf-a27f-7dc2e18fea3a">286.71</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzc2OTY1ODE0MDAwNzc_57104d17-8719-433e-8152-1b4e433ab418">179.90</ix:nonFraction>, respectively, determined using the following assumptions:</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:11pt"><ix:continuation id="i38c2d96ff7734a209f77bbb096f28dba"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzEtMS0xLTEtMzYwOTg_a5c9f3b9-e760-4d8d-96f3-707e8fade5bc">2.50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzEtMi0xLTEtODU1Nzg_40880b98-71a5-4ea3-add4-6274dbc1d928">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzItMS0xLTEtMzYwOTg_6b851133-4913-4042-8701-894408c0b246">0.19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzItMi0xLTEtODU1Nzg_e4591053-e354-43ad-ae8c-9da68d63ecc6">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzMtMS0xLTEtMzYwOTg_2553b8c8-3feb-4d4c-911e-1be6bf853292">30.95</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzMtMi0xLTEtODU1Nzg_3aec7bf0-0509-4e12-88e8-ae1f8e49e7a7">19.89</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested RVAs was $<ix:nonFraction unitRef="usd" contextRef="ic5bfe01bbc4845fa8a1d24e9e0d98eb6_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ1MDA_6bce32b0-6764-496d-941d-cd725984c96f">18.6</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ1OTI_03a45eaf-fbe4-41fd-b597-ca18db410c38">21</ix:nonNumeric> months.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6aa451749cc442219e08dafb9a401eae"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically <ix:nonNumeric contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ4Nzg_9679f80d-c5c4-4655-8f82-333e0b1a9719">three years</ix:nonNumeric>. The fair values of RSU awards granted during the years ended December&#160;31, 2021, 2020, and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ5NjM_5e5a77c3-3f09-457f-81bc-fdbc37889498">196.30</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ5Njc_f50e9e40-59ee-40b5-996b-78ce888ca2f9">135.42</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ5NzU_a4782adc-61c0-4162-bdb9-d71a7aeb720e">108.43</ix:nonFraction>, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, <ix:nonFraction unitRef="shares" contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxMzA_156a8315-9f93-4126-a357-9f9a6833f786">0.7</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxMzQ_3569264b-c41c-45db-9ff5-173f71a5e01b">1.1</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxNDI_25d79252-4b7a-452a-939f-83582f11971e">1.5</ix:nonFraction> million shares were granted and approximately <ix:nonFraction unitRef="shares" contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxODM_25a9a39d-b7a0-49eb-85ae-4ae8fbab52cb">0.6</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxODc_5edfbd82-46c6-494e-8ae7-99b13df99ab5">0.6</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxOTU_6fc62380-493e-4987-9ae9-80da340dce04">0.8</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231" decimals="-5" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUyODQ_be7226fc-3062-4fb1-8f76-bf60502ded6f">0.9</ix:nonFraction> million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="i51954a83d3fc4e158da2a14d11be3b67_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU0MTg_acf67640-c7b4-4f47-927c-a944f77c0649">161.4</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTA_7841c9ee-0260-4601-a867-2d0017247b4c">25</ix:nonNumeric> months.</span></div></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_145"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzk4Nw_7d2e1da6-339f-48b4-9d6c-22dc262171e1" continuedAt="i289d2a7bf86d4914a7ff9e8b078e896c" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i289d2a7bf86d4914a7ff9e8b078e896c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020, and 2019, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-7" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NjI2_e5d4ab04-8a25-483d-94e3-42deed6e195b">1.25</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzc3_a2c53ec6-1e32-45ac-a3e1-093575478a75">500.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-7" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzg0_b07dd692-de54-4127-93c8-0d07051e4601">4.40</ix:nonFraction> billion, respectively, of shares associated with our share repurchase programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i0b72858f1e1a4cbea5c56de4e31319a8_D20210101-20210430" decimals="-7" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NjQ4_d4867302-97d7-4ae8-8ffc-3a08d9e3e6e0">1.00</ix:nonFraction> billion of shares, which completed our $<ix:nonFraction unitRef="usd" contextRef="ie76506d8813f4a7fa6b07b99e9f4ddbb_I20180630" decimals="-7" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzg3OTYwOTMwMjQ3NzY_f6da495a-6c3c-470b-ad5b-b5f7a559fb8d">8.00</ix:nonFraction> billion share repurchase program authorized in June 2018. Additionally, our board authorized a $<ix:nonFraction unitRef="usd" contextRef="i368ce9c4630f4059918b97512f0fc80f_I20210531" decimals="-7" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0Njkw_3fe0023a-5b89-40be-83e1-d559dcd91bc1">5.00</ix:nonFraction> billion share repurchase program in May 2021. In 2021, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i4b37dec9dc524596b81869a5a184313c_D20210501-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NzQx_310e9709-9186-4e6f-a347-cf85434ed67f">250.0</ix:nonFraction> million of shares under the $<ix:nonFraction unitRef="usd" contextRef="i368ce9c4630f4059918b97512f0fc80f_I20210531" decimals="-7" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NzEw_3fe0023a-5b89-40be-83e1-d559dcd91bc1">5.00</ix:nonFraction> billion share repurchase program. As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NzY2_c774d88a-5d11-4711-a9f5-fb5c0beff755">4.75</ix:nonFraction> billion remaining under the $<ix:nonFraction unitRef="usd" contextRef="i368ce9c4630f4059918b97512f0fc80f_I20210531" decimals="-7" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzYwNDczMTM5NTcxNTg_3fe0023a-5b89-40be-83e1-d559dcd91bc1">5.00</ix:nonFraction> billion share repurchase program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzI3NQ_fb36504c-61ff-4a08-aa17-6ee5066adf42">5.0</ix:nonFraction> million authorized shares of preferred stock. As of December&#160;31, 2021 and 2020, <ix:nonFraction unitRef="shares" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzMzMw_8064073e-2adc-4dcc-b7ae-8b46294f7bab"><ix:nonFraction unitRef="shares" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzMzMw_8e1043a4-8214-4f46-a4ab-7b29ef80c666">no</ix:nonFraction></ix:nonFraction> preferred stock was issued.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee benefit trust that held <ix:nonFraction unitRef="shares" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrustShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzQwOA_0e7e2950-302a-4e8e-b295-2ef817c132e9"><ix:nonFraction unitRef="shares" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrustShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzQwOA_1cabc412-7846-4027-9ff3-58af4a91ea14">50.0</ix:nonFraction></ix:nonFraction> million shares of our common stock at both December&#160;31, 2021 and 2020, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzYxNQ_5e4b3307-19c5-4973-9de4-d67336d7a05c"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-7" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzYxNQ_ea1457be-58f2-4e35-b3c9-807d93c90cd0">3.01</ix:nonFraction></ix:nonFraction>&#160;billion at both December&#160;31, 2021 and 2020, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2021, 2020, and 2019.</span></div></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_148"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;14:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMzE_0413e464-2e95-4eee-8f69-014079fc9add" continuedAt="ief84c76d5ff349a8902e826352042566" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ief84c76d5ff349a8902e826352042566" continuedAt="i8b5a1e541f7440858146f81dc4b77c6a"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNDU_7ed070e1-df56-4cd0-aaa9-afbccc94c54b" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i8b5a1e541f7440858146f81dc4b77c6a" continuedAt="i2c245fd63b034658b18e626dc0e21cbc"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNjM_c1095f95-80f0-401c-b289-c80c3c499e9e" continuedAt="i956c2dc72e9b48dc94dbc76da4593a22" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzItMS0xLTEtMzYwOTg_96ce5361-735f-47a9-abd4-c1f6ad68e5dc">938.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzItMy0xLTEtMzYwOTg_20ca5ce0-b025-4ec1-967f-7e013f5bd043">567.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzItNS0xLTEtMzYwOTg_2af5b36a-2a5c-4fe3-8680-d6963e2226b9">280.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzMtMS0xLTEtMzYwOTg_7e88c779-68c2-4101-8575-366cc1a5d317">466.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzMtMy0xLTEtMzYwOTg_7dd4d43e-f9ab-432a-8e22-1d6b2468c8ad">650.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzMtNS0xLTEtMzYwOTg_b0badba9-fde1-4b1d-9912-bbd490ea6868">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzQtMS0xLTEtMzYwOTg_0083da6b-6f80-49d5-8710-90ff608c2261">28.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzQtMy0xLTEtMzYwOTg_78db3861-c97e-4948-8a47-d2f45769e5b2">47.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzQtNS0xLTEtMzYwOTg_5c6e67bb-c959-4e8d-8773-775e3958a046">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzUtMS0xLTEtMzYwOTg_3688c54b-4852-4b3f-ac18-5c5131c1ac9d">1,376.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzUtMy0xLTEtMzYwOTg_d4efa742-3d11-43a8-8c85-2d05467d15ec">1,170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzUtNS0xLTEtMzYwOTg_e14090bf-a635-44fd-9e45-011c8c46cf3a">565.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzctMS0xLTEtMzYwOTg_c4564095-f926-408c-b18a-7b3191dbbf61">977.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzctMy0xLTEtMzYwOTg_4a98cb6e-df6d-4471-b68f-89f80e3f605b">97.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzctNS0xLTEtMzYwOTg_b130cf34-834e-485a-ac64-55cac9986bea">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzgtMS0xLTEtMzYwOTg_f22ebc39-44a7-49f7-a06a-cc742a3f3ef9">174.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzgtMy0xLTEtMzYwOTg_dea801ed-fd77-4652-9e75-8f9ba3194514">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzgtNS0xLTEtMzYwOTg_8971291c-4440-4a89-8980-85760f7c2ce7">24.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzktMS0xLTEtMzYwOTg_a414ba36-9516-4ca4-86b6-00aa37e2887c">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzktMy0xLTEtMzYwOTg_453ddba4-0def-4e2a-921f-08408d38eccc">20.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzktNS0xLTEtMzYwOTg_fb48ee9d-0708-4367-b710-a36a0e41e832">54.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzEwLTEtMS0xLTM2MDk4_37f33593-4e88-4c1a-98ec-0ea1fff0dd4c">802.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzEwLTMtMS0xLTM2MDk4_4e2a47c2-c4f9-41bd-b8a6-e7f319e48196">134.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzEwLTUtMS0xLTM2MDk4_80442353-2b7c-4714-952c-9f4a557cee81">62.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzExLTEtMS0xLTM2MDk4_93c9574b-e4dd-4bb8-8e7a-11b10ad611b6">573.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzExLTMtMS0xLTM2MDk4_2740af60-4ea5-4366-b030-1bc13b84a53f">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzExLTUtMS0xLTM2MDk4_68609ea4-1bfd-4773-acbf-e90d70fc3445">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i956c2dc72e9b48dc94dbc76da4593a22" continuedAt="ieabdeb556a154bd79a8c4872e8a12ff3">(1)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ieabdeb556a154bd79a8c4872e8a12ff3"> The 2021, 2020, and 2019 current tax expense includes $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2Xzc2OTY1ODE0MDQwODE_9d70fb73-5e6d-4c23-acc2-3313ffc73e83">64.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzE1ODM_414cd480-8b2e-4d89-84d6-8c9e2e453e12">144.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzE1OTA_0733ca02-e9a7-4f67-bf89-4ca8d7e7f990">153.1</ix:nonFraction> million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards.</ix:continuation> </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNzk_d41aae1d-615f-4abd-bd72-a2644433f0ea" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzItMS0xLTEtMzYwOTg_1b035e80-0830-4129-81df-27fb1e79f9f8">2,347.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzItMy0xLTEtMzYwOTg_fefed61e-6179-4edd-beda-9a7e95098ee8">2,560.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzMtMS0xLTEtMzYwOTg_4bd6dedf-be32-4f94-9dc1-10d88c840146">634.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzMtMy0xLTEtMzYwOTg_84277d72-0d0d-47c2-ad8d-eb47374e11fd">1,045.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzQtMS0xLTEtMzYwOTg_c17f7755-5ab0-4061-90de-bad80153385a">463.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzQtMy0xLTEtMzYwOTg_96227f5f-b348-41ec-87c1-8c0de51e92b5">523.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and other tax carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzUtMS0xLTEtMzYwOTg_da998ebc-d756-4a1e-a897-f179909a2e38">645.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzUtMy0xLTEtMzYwOTg_c2ed3e01-a841-4036-830a-83284390b5a5">488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:DeferredTaxAssetsSalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzYtMS0xLTEtMzYwOTg_b2b9a1b9-1022-48e0-935a-0cf0ce0bf6fe">832.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:DeferredTaxAssetsSalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzYtMy0xLTEtMzYwOTg_0e87d798-c1e4-4d62-b733-dad88ed65801">461.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:DeferredTaxAssetsCorrectiveTaxAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzctMS0xLTEtMzYwOTg_ece77bbc-7d8d-47b2-becf-5c897ead8a54">560.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:DeferredTaxAssetsCorrectiveTaxAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzctMy0xLTEtMzYwOTg_1998fa1f-4426-4e6b-b320-acec634e890b">404.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:DeferredTaxAssetsForeignTaxRedeterminations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzgtMS0xLTEtMzYwOTg_e346c3cc-8843-45c1-bbfd-ee3727e74c4d">274.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:DeferredTaxAssetsForeignTaxRedeterminations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzgtMy0xLTEtMzYwOTg_57a2b640-0a1c-4012-bd00-ac36c6e6b193">242.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzktMS0xLTEtMzYwOTg_73172ddf-1f40-48e8-a588-ac79a2a056f9">150.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="lly:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzktMy0xLTEtMzYwOTg_d534bc18-0c32-486b-85dc-c241d03c0032">150.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEwLTEtMS0xLTM2MDk4_5b2c6bf6-a566-4b6c-8f4b-a2dd68a5549c">275.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEwLTMtMS0xLTM2MDk4_3e38cd9a-cc66-4711-9378-9a5c92b96514">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzExLTEtMS0xLTM2MDk4_18bff183-7d0c-4a6f-9f56-6d4ec548d829">477.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzExLTMtMS0xLTM2MDk4_2ddd1ebe-f312-43db-97d5-2d91ab2e9b9d">605.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEyLTEtMS0xLTM2MDk4_1ed46cb4-b127-442b-a5d0-2ae977be31db">6,662.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEyLTMtMS0xLTM2MDk4_5b64d06f-6d56-4034-9d99-dbeca8bc2138">6,618.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEzLTEtMS0xLTM2MDk4_044ffa42-85ba-4649-a60d-ee429532c3b4">875.6</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEzLTMtMS0xLTM2MDk4_536681c7-fb02-4e54-8cb9-979b3dea6cfa">816.3</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE0LTEtMS0xLTM2MDk4_74cc116c-dab8-48f3-a19d-a14a2066abc0">5,786.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE0LTMtMS0xLTM2MDk4_fa694401-68c8-4ecb-a2e7-9ba7458a5764">5,801.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE2LTEtMS0xLTM2MDk4_cf874699-5379-4a19-8d2d-535aa4115c7b">1,583.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE2LTMtMS0xLTM2MDk4_3cbf17cc-9f43-4925-868b-5a211a0dc785">1,905.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE3LTEtMS0xLTM2MDk4_adbe89af-f60d-4acf-bb31-23d4753f5478">1,516.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE3LTMtMS0xLTM2MDk4_edc36d21-7e73-4896-800e-6db9a6b17cac">1,465.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE4LTEtMS0xLTM2MDk4_c41193c8-2272-4d5d-968a-98260a3022a0">596.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE4LTMtMS0xLTM2MDk4_c696fc4d-4e97-4aa4-a3fe-1daab1da9c16">623.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE5LTEtMS0xLTM2MDk4_1324bc25-d49a-4fe1-9e83-3208d019763a">560.6</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE5LTMtMS0xLTM2MDk4_6b855712-2450-487f-8f57-a7c0e4c4b905">410.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIwLTEtMS0xLTM2MDk4_04ac0d08-7b18-4b6f-9d29-f2f7f3c62dc0">338.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIwLTMtMS0xLTM2MDk4_2bdbf4db-b466-40c1-85c7-8506c42f54d0">315.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIxLTEtMS0xLTM2MDk4_443d8eab-6a49-4152-a19c-b6d12f2bb2c0">303.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIxLTMtMS0xLTM2MDk4_cf5b8f65-2512-400e-9f00-21509b4ed3ce">216.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIyLTEtMS0xLTM2MDk4_07b1bbfd-2ce6-4754-ab6a-02fe7ecd14ff">132.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIyLTMtMS0xLTM2MDk4_4b9e28b6-540c-49b0-9226-06811444f240">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIzLTEtMS0xLTM2MDk4_dd91cb55-303d-4b96-95b1-103f197859b3">5,030.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIzLTMtMS0xLTM2MDk4_53f03966-a617-4a75-a094-aecd48e961da">5,071.2</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzI0LTEtMS0xLTM2MDk4_4e8d950b-0875-4ab2-88d9-0c13eb69d4e4">755.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzI0LTMtMS0xLTM2MDk4_92786260-b0a3-4954-b17b-7a71bd9de081">730.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i2c245fd63b034658b18e626dc0e21cbc" continuedAt="i7784fd686a2b46ba971cc3300579d57d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, based on filed tax returns we have tax credit carryforwards and carrybacks of $<ix:nonFraction unitRef="usd" contextRef="ifc1c1179afa04c4888ffdac81ad4e1bb_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzIzMTg_6da9c9bb-fb69-4ad2-80f1-553acb366d5d">859.9</ix:nonFraction>&#160;million available to reduce future income taxes; $<ix:nonFraction unitRef="usd" contextRef="ibefae15cacca4b6fb80885f8b7f6034d_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzIzNjI_d128c212-bedd-4884-bb3c-d6bf483cba38">148.8</ix:nonFraction> million, if unused, will expire by 2026, and $<ix:nonFraction unitRef="usd" contextRef="i7ca9c900f5ba4830a421d9f973e97825_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI0MDA_549b169f-1a64-46eb-97ab-1765ce5703e8">21.5</ix:nonFraction>&#160;million, if unused, will expire between 2030 and 2040. The remaining portion of the tax credit carryforwards is related to federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="i7a7ea2349e0e4231b618eb04ea877890_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI1Mzc_40f8510e-e1fb-46a4-9fa0-9953ebc74fc6">76.2</ix:nonFraction> million, international tax credits of $<ix:nonFraction unitRef="usd" contextRef="i64908cb8d2bc48e58b3df38be9554dc3_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI1NzA_69fb8f12-a1d6-444b-b4f0-4063a0f1c30b">115.3</ix:nonFraction>&#160;million, and state tax credits of $<ix:nonFraction unitRef="usd" contextRef="id3fcde25a10741c89da748954342eb63_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI1OTk_a0104c9d-149e-4406-a7ff-9d3f915f68b1">498.1</ix:nonFraction> million, all of which are fully reserved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="ifc1c1179afa04c4888ffdac81ad4e1bb_I20211231" decimals="-7" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI3ODA_085db38d-5be4-4380-843b-5f459caca366">2.21</ix:nonFraction> billion: $<ix:nonFraction unitRef="usd" contextRef="i27a0a2d94ade4455b3533cea592bf9d7_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI3ODQ_522510c6-9f87-4df7-8472-87a7d350c3ca">832.6</ix:nonFraction> million will expire by 2026; $<ix:nonFraction unitRef="usd" contextRef="ic7929b7916024d43ad8c5746cb69f8db_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI4MDY_7a6771fb-7b6a-4fd7-8a61-38d4fa5ebe05">818.2</ix:nonFraction>&#160;million will expire between 2027 and 2041; and $<ix:nonFraction unitRef="usd" contextRef="i7227f8a46eda4c649d9047310a103ffd_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI4NDQ_105b7253-b6aa-4b83-9860-87fac700a267">561.5</ix:nonFraction> million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $<ix:nonFraction unitRef="usd" contextRef="id3fcde25a10741c89da748954342eb63_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMwOTY_02b68762-30bb-4791-bc6d-a22208b477ba">230.0</ix:nonFraction>&#160;million are fully reserved as of December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and Puerto Rican companies contributed approximately <ix:nonFraction unitRef="number" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMyMDU_3f878cca-9947-4a91-8c3c-ac29e19c1505">28</ix:nonFraction> percent, <ix:nonFraction unitRef="number" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="2" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMyMDk_92214bf2-0fd1-4b8c-890f-ae98461d42fd">39</ix:nonFraction> percent, and <ix:nonFraction unitRef="number" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="2" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMyMTc_438b83a8-ad11-46b0-9193-66f68a67cc87">44</ix:nonFraction> percent for the years ended December&#160;31, 2021, 2020, and 2019, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2021 and December 31, 2020, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNDg_5d818bd4-50a3-4d0c-aa64-461717bdb856" continuedAt="ie42c4f38e3d740edab0676df105b5035" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo2ZDQ1MzcyMjIyNDE0MWMxOWE3ZmRkYWNkNjZiNzI5Mi90YWJsZXJhbmdlOjZkNDUzNzIyMjI0MTQxYzE5YTdmZGRhY2Q2NmI3MjkyXzEtMS0xLTEtMzYwOTg_2b34423f-6cb8-49e1-85f3-c2f95209bedd">1,598.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo2ZDQ1MzcyMjIyNDE0MWMxOWE3ZmRkYWNkNjZiNzI5Mi90YWJsZXJhbmdlOjZkNDUzNzIyMjI0MTQxYzE5YTdmZGRhY2Q2NmI3MjkyXzEtMy0xLTEtMzYwOTg_c2b33972-3b2e-4a29-a7d9-16ca4cae2124">954.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo2ZDQ1MzcyMjIyNDE0MWMxOWE3ZmRkYWNkNjZiNzI5Mi90YWJsZXJhbmdlOjZkNDUzNzIyMjI0MTQxYzE5YTdmZGRhY2Q2NmI3MjkyXzEtNS0xLTEtMzYwOTg_7f32ff37-a586-4a99-9d0b-cb8fbb9c73cb">1,180.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. <ix:continuation id="ie42c4f38e3d740edab0676df105b5035" continuedAt="id6de20054cc845d6b3e5dcbc4695f05b">Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2021 are as follows:</ix:continuation></span></div><div style="margin-top:6pt"><ix:continuation id="id6de20054cc845d6b3e5dcbc4695f05b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years </span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtMS0xLTEtMzYwOTg_15da671f-ca0f-4724-8a53-bc7d0de4e5e8">2,149.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtMi0xLTEtMzYwOTg_e1f5a1b1-df3b-4790-bf79-eda35307c54e">253.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtMy0xLTEtMzYwOTg_c44cad36-5aaf-4219-ac68-18c80bbc5f72">1,109.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtNC0xLTEtMzYwOTg_952afe54-7c7c-4076-9391-1e296bcfd890">785.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additional noncurrent income tax payables of $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzcxNDY4MjU1OTA2OTI_0aab1fc4-4924-4cd8-a7f0-7220811c89b5">2.02</ix:nonFraction>&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. </span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMjk_c45d1953-8ca1-4f2d-9c47-8bcef5091cdf" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzEtMS0xLTEtMzYwOTg_b3581d4e-11cd-4b30-b392-7d9c7a53528f">1,292.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzEtMy0xLTEtMzYwOTg_2de0bd11-7cba-49f9-b37c-100db265a79f">1,518.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzEtNS0xLTEtMzYwOTg_b5c618b4-4ef6-496a-80a9-1c55d6dfe9e8">1,105.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzMtMS0xLTEtMzYwOTg_0b04c0ec-6183-4345-96ce-66815d9f8735">458.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzMtMy0xLTEtMzYwOTg_94236f2c-fcf1-4857-8f7f-b13b7b6138cb">297.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzMtNS0xLTEtMzYwOTg_3c83ba30-402a-4b25-a9e9-31c2f77ea057">242.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzQtMS0xLTEtMzYwOTg_89acdbd3-b722-4d29-9d35-c3fbc1213c2c">100.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzQtMy0xLTEtMzYwOTg_25ff16c5-64dd-4707-a45b-eaf9db85fc71">97.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzQtNS0xLTEtMzYwOTg_ef1e33b9-e820-4763-8498-923bda8ccf7e">108.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzUtMS0xLTEtMzYwOTg_a4500acb-f7b1-4d9d-8cb8-6391a6f8f525">86.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzUtMy0xLTEtMzYwOTg_024dbf33-355b-4b50-9927-a614812e36d0">71.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzUtNS0xLTEtMzYwOTg_5da222e8-828a-41b4-9975-d2d46449697d">15.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzctMS0xLTEtMzYwOTg_9aaa1052-98cc-467c-b9cc-520a4bce5116">73.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzctMy0xLTEtMzYwOTg_8fdbd63e-8eec-440b-b648-40ddffdf8b1b">15.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzctNS0xLTEtMzYwOTg_a3485ea8-4693-4f4e-925d-2ec68f8b8308">111.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzgtMS0xLTEtMzYwOTg_b6f294e3-da22-4c55-916c-25d568aec85a">573.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzgtMy0xLTEtMzYwOTg_553c9817-b0f8-4ed8-9c14-a0d43ec98d1c">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzgtNS0xLTEtMzYwOTg_1f4cd09d-9c7f-44c8-9fb3-4774e3a96067">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i7784fd686a2b46ba971cc3300579d57d"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMzM_42598c65-788f-4f88-8ac5-b8c91896097f" continuedAt="ia05819001d2845fda16cfdbd5e31d350" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzEtMS0xLTEtMzYwOTg_cb93a9d3-5f8a-4679-9877-bd35615ac9d2">2,551.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzEtMy0xLTEtMzYwOTg_cd92a97b-85f6-4592-a932-a044abb781d8">2,108.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2161fbcc13a94af3a14765cc6ce775d6_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzEtNS0xLTEtMzYwOTg_bbeb55f6-c0dd-4b1f-8106-50ac3d04438a">2,034.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzItMS0xLTEtMzYwOTg_816ed780-60b3-4c95-90f1-832b75266c1e">310.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzItMy0xLTEtMzYwOTg_290c7f2c-26d0-461a-b231-c23ce8eacc8c">225.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzItNS0xLTEtMzYwOTg_dd1b5a91-3990-4fe0-94a6-97ddf99174c2">187.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzMtMS0xLTEtMzYwOTg_1dc66e70-428b-4521-80a5-ed2a8136fd91">98.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzMtMy0xLTEtMzYwOTg_0c20257c-5b6b-4990-9faf-f98168e3ed0c">310.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzMtNS0xLTEtMzYwOTg_40f73a9d-6418-4788-9233-6a60378e417e">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzQtMS0xLTEtMzYwOTg_161e3f6a-6f9a-46e1-975d-f838140600bb">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzQtMy0xLTEtMzYwOTg_5f952f3f-a3c0-4d8e-802b-de97ba7114e4">52.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzQtNS0xLTEtMzYwOTg_b85934ef-3b2f-4f3f-9cc0-4e2c793cbfdd">100.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzUtMS0xLTEtMzYwOTg_c202e473-4f2e-4ea0-abe7-187b2f29464b">38.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzUtMy0xLTEtMzYwOTg_0ed34c41-c454-41ae-9471-7674ad20a743">72.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzUtNS0xLTEtMzYwOTg_981df580-a462-4f7b-9bcc-50dd02b2a1d9">260.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzYtMS0xLTEtMzYwOTg_e765b5cf-b398-482e-b770-c9699e499f77">49.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzYtMy0xLTEtMzYwOTg_93b41e8d-9d35-4c39-89c5-35a86b098eb4">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzYtNS0xLTEtMzYwOTg_b8fc3540-9080-49a7-88a6-71ca362f4be7">161.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzctMS0xLTEtMzYwOTg_5f701e03-11c8-463f-963a-cb17dcb8786d">66.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzctMy0xLTEtMzYwOTg_d9950b5b-970f-4039-91bc-e0c7c38050cf">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzctNS0xLTEtMzYwOTg_e4a97d47-b19a-47cc-99bf-1fd9b9fb9658">16.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzgtMS0xLTEtMzYwOTg_7e365d8c-1164-4019-98ed-54671d01a73c">2,798.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzgtMy0xLTEtMzYwOTg_3e8a8e02-5b09-4fa4-a94b-acf15ac5e025">2,551.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzgtNS0xLTEtMzYwOTg_eca49140-feb6-4bb0-9cb8-822f0ac6460a">2,108.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-7" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzUyMjg_03988c4a-fd59-4bb1-b493-a350993d9d75">1.70</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-7" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzUyMzU_b831902f-38a7-436d-8f4a-4950c763753c">1.67</ix:nonFraction> billion at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months. For tax years 2013-2015, all matters were effectively settled in 2019. As a result, our gross uncertain tax positions were reduced by approximately $<ix:nonFraction unitRef="usd" contextRef="i6f0a88d32df74c0cb0fcdd7915d26f3a_I20200630" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzU4ODc_88813c03-6c8b-44d3-b43c-2c4e8045dce1">200</ix:nonFraction>&#160;million, we made a cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="iff79519d513f4f68bf15f66911ffa849_D20200401-20200630" decimals="-6" name="lly:PaymentsForIncomeTaxSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzU5MzE_38aa9be1-da3a-4b1a-b1ce-002f779b4337">125</ix:nonFraction> million, and our consolidated results were benefited by an immaterial reduction in tax expense. </span></div><ix:continuation id="ia05819001d2845fda16cfdbd5e31d350"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTowY2QwZGM1NDAxZDE0YmZlOWNlMDUzMmI0MzFkZWZiZC90YWJsZXJhbmdlOjBjZDBkYzU0MDFkMTRiZmU5Y2UwNTMyYjQzMWRlZmJkXzEtMS0xLTEtMzYwOTg_0590c5be-11a2-40ef-8293-b5148c04a620">20.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTowY2QwZGM1NDAxZDE0YmZlOWNlMDUzMmI0MzFkZWZiZC90YWJsZXJhbmdlOjBjZDBkYzU0MDFkMTRiZmU5Y2UwNTMyYjQzMWRlZmJkXzEtMy0xLTEtMzYwOTg_262fa834-889c-4072-a379-e41ff49be509">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTowY2QwZGM1NDAxZDE0YmZlOWNlMDUzMmI0MzFkZWZiZC90YWJsZXJhbmdlOjBjZDBkYzU0MDFkMTRiZmU5Y2UwNTMyYjQzMWRlZmJkXzEtNS0xLTEtMzYwOTg_b64e5ae1-d520-424e-9ca1-dd79c9af582f">26.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, our accruals for the payment of interest and penalties totaled $<ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMDA_4397d22d-65ac-444d-b914-9a6906d80301">220.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMDc_5f27965f-9e64-4c66-8712-c270f7c797cd">196.7</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">94</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzgx_29615f1e-7a51-4e9d-a680-af6ce51062bf" continuedAt="idc49b1567aa941f7a733c948379cd798" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="idc49b1567aa941f7a733c948379cd798" continuedAt="i15b7e4a93a294a08aa7d0edc494dd451"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzQ4_92b762ff-4f69-4c43-b695-67eec539dc94" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtMS0xLTEtMzYwOTg_820a6f65-41c3-40b4-b836-e109866a9863">18,225.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtMy0xLTEtMzYwOTg_08a14d38-aae2-4784-9b00-6ea8584833f2">16,251.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtNS0xLTEtMzYwOTg_ab816b50-8c28-44c7-a63a-94bc89297ac3">1,753.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd80bbb97874a039463577583da19c4_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtNy0xLTEtMzYwOTg_ab0295dd-6c41-45f1-92d2-92516cdccdc1">1,601.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtMS0xLTEtMzYwOTg_605845f8-dc33-45dd-8104-e8b697e525ca">369.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtMy0xLTEtMzYwOTg_60ea9be4-9f7f-4dce-a9d1-d2d0c0e7724d">325.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtNS0xLTEtMzYwOTg_0429a983-69fc-4fdc-8cf0-ccf3126efb72">49.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtNy0xLTEtMzYwOTg_74fac149-95d7-4ab6-88e0-ef6848630da0">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtMS0xLTEtMzYwOTg_0b76dd0f-3db4-494c-8fb1-aebcf33aeae7">337.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtMy0xLTEtMzYwOTg_fd084e0e-c1ab-43ac-a3f3-877ebe0073fc">425.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtNS0xLTEtMzYwOTg_06b301ae-b237-499a-a782-e9c93da6c9b2">32.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtNy0xLTEtMzYwOTg_b06cf40d-7336-416d-90b6-61943a876575">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtMS0xLTEtMzYwOTg_8b90e59b-713c-446f-b83f-f61153da041a">564.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtMy0xLTEtMzYwOTg_db167d20-c2b2-4a3e-a4de-f748cc7f9bbc">1,563.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtNS0xLTEtMzYwOTg_beceb83a-f4bf-498c-8f43-2ad44e2d800a">86.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtNy0xLTEtMzYwOTg_25c0efc2-e6b2-453f-8052-03a1028d457f">142.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctMS0xLTEtMzYwOTg_5eb80016-f533-4f59-8d7a-83861eb271e4">630.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctMy0xLTEtMzYwOTg_5027075b-ca65-4bb0-ba35-8f1a07eaba77">587.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctNS0xLTEtMzYwOTg_e50d7a6d-6e6f-41df-9a90-e698dab1b967">79.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctNy0xLTEtMzYwOTg_4d6afcbb-6e55-4332-8366-d039d4df046d">75.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktMS0xLTEtMzYwOTg_fd26185b-eab0-4cb0-bf6e-9ebef874ce0d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktMy0xLTEtMzYwOTg_d811767f-ff94-4c70-8d67-977623bfa20b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktNS0xLTEtMzYwOTg_0c7881e3-6cdb-4c1c-a568-f0c679163bc6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktNy0xLTEtMzYwOTg_bd188ecf-cf81-4ca6-ab65-7b7c712ea2bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTEtMS0xLTM2MDk4_f1bce172-4a8c-4d3f-a8ad-44cdb27c64a7">173.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTMtMS0xLTM2MDk4_5ae2cf1f-e5a0-449b-9bd0-80d41db5999b">245.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTUtMS0xLTM2MDk4_949d132a-69ff-4ddc-95e1-29c8bbff38ea">6.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTctMS0xLTM2MDk4_743c6d54-8e38-465e-b9d1-871e0c28f783">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTEtMS0xLTM2MDk4_ae373dcd-f7f5-4c6e-8b19-b0889d29429a">17,565.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTMtMS0xLTM2MDk4_9d83d118-b45b-4286-a8dc-0c02b046335f">18,225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTUtMS0xLTM2MDk4_5f0cb63a-c3c2-4641-b694-10310089f8f8">1,663.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTctMS0xLTM2MDk4_b81bfcf3-088d-40c0-95e7-3542242a8644">1,753.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDI3_8124ec18-4239-465a-ae07-986d983236a3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtMS0xLTEtMzYwOTg_1b2f36bd-998e-4e45-a919-87d00e25413a">14,579.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtMy0xLTEtMzYwOTg_63f8bd3b-9cc2-407a-a38f-04354a092a8f">12,858.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtNS0xLTEtMzYwOTg_b068ba71-35bb-4800-91e7-f665fe924b0e">3,227.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd80bbb97874a039463577583da19c4_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtNy0xLTEtMzYwOTg_55cd5cb3-b478-4675-b35a-c960a8f7b7a3">2,768.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItMS0xLTEtMzYwOTg_f1a58075-a707-417f-b83a-edb1dd6d0d14">2,458.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItMy0xLTEtMzYwOTg_78cb17e2-bbb7-420f-ac7a-f60050197cd2">1,802.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItNS0xLTEtMzYwOTg_e54d5879-4ab8-4190-99d2-25c6f7b2e608">202.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItNy0xLTEtMzYwOTg_78c8a465-25ce-4570-b1ae-c2430498af99">539.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtMS0xLTEtMzYwOTg_ef8b48aa-0244-4ef1-9926-f57115b4e36f">131.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtMy0xLTEtMzYwOTg_84b05180-c4a0-4379-a858-7d3626085bd8">318.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtNS0xLTEtMzYwOTg_51fb6741-d4e8-4e12-8ce6-988b7903f729">11.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtNy0xLTEtMzYwOTg_fafba15f-747b-4b74-a920-533f80f378b4">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtMS0xLTEtMzYwOTg_ace3df89-f5c2-40a2-b02e-db2b32edbf49">630.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtMy0xLTEtMzYwOTg_e2a2ba40-d5c2-4abe-8cf6-883d05005e03">587.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtNS0xLTEtMzYwOTg_7da5cab7-a296-4a43-ac80-84cab0306cef">79.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtNy0xLTEtMzYwOTg_adb712fb-ff51-452e-86a4-755fa274a978">75.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtMS0xLTEtMzYwOTg_db8b0cc8-5fc9-4ddb-9cef-2088b9b1bb62">122.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtMy0xLTEtMzYwOTg_f76d5812-0a0f-469b-928a-ccb7c6f4add6">187.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtNS0xLTEtMzYwOTg_d8e3b6b0-1f84-444e-90ae-315a55be3f62">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtNy0xLTEtMzYwOTg_fefc52f7-d70b-4e1c-8835-81d02b2c70f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtMS0xLTEtMzYwOTg_9c809b23-a6b6-481a-9e96-416871ece78a">16,416.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtMy0xLTEtMzYwOTg_aa4cfe89-45f1-4acc-b53e-13710dfd1f33">14,579.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtNS0xLTEtMzYwOTg_abca3f1b-3446-4569-937a-8f2edbe62347">3,361.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtNy0xLTEtMzYwOTg_6d84e45c-e397-44fc-8754-57f70f92911c">3,227.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDIw_bf74edf5-9f86-43ca-9df5-a24b7f9e71c8" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtMS0xLTEtMzYwOTg_71fbd14d-9075-4b9d-9dff-ad8371077631">1,149.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtMy0xLTEtMzYwOTg_979de631-36aa-40bd-85c0-5b8bdb2a74ea">3,646.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtNS0xLTEtMzYwOTg_34f53465-fbe0-4aca-a1d8-8fa3ff545d34">1,697.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtNy0xLTEtMzYwOTg_3fc99abf-75d9-4d65-afd3-dc63b4edb4e0">1,473.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtMS0xLTEtMzYwOTg_fc6ea856-d53d-487c-ac34-3f607c10d35d">3,908.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtMy0xLTEtMzYwOTg_94ec2bf6-cf3d-455b-a4f3-97482a685e28">6,515.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtNS0xLTEtMzYwOTg_1dfe51e8-032d-48a1-84de-0ec3bf82af71">497.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtNy0xLTEtMzYwOTg_b26e39a7-308d-451b-9a3d-b0cfc799019a">349.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItMS0xLTEtMzYwOTg_a7b12604-74ae-427d-ae5b-0a1669eb9d25">11.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItMy0xLTEtMzYwOTg_7726226b-ef34-4fca-bb01-3ab871606d6e">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItNS0xLTEtMzYwOTg_ae79a697-5e16-4a0e-ba65-1129d188501a">117.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItNy0xLTEtMzYwOTg_46178404-03c4-4d38-974c-13227e86af67">177.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtMS0xLTEtMzYwOTg_4a0c870c-edaa-4043-afa3-a803a3b3a722">2,770.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtMy0xLTEtMzYwOTg_bd5ac25c-b15c-4bab-a772-ba9dc143f7b3">2,884.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtNS0xLTEtMzYwOTg_a843aeeb-b276-4efd-b879-eb743eb50b62">1,082.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtNy0xLTEtMzYwOTg_67af63d9-1d77-4fd8-9cf4-29541ae7b52c">946.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzEz_03493948-a606-4206-b4bd-7604ea1a427f" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtMS0xLTEtMzYwOTg_ae7c6462-41c1-48c1-b4e0-5ca1b9288d36">668.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtMy0xLTEtMzYwOTg_0380943a-62b1-4f31-a814-dd0299ff770b">299.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtNS0xLTEtMzYwOTg_c48636b7-9ae6-4162-9a96-6bab338e8e9a">1,910.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtNy0xLTEtMzYwOTg_96360a76-ca92-4c57-a265-896c7c463b33">1,697.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItMS0xLTEtMzYwOTg_3b183628-9827-4dca-a38a-822a40562ae1">68.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItMy0xLTEtMzYwOTg_ec07e48e-8990-4f2d-a321-54cfbdc29d1e">67.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItNS0xLTEtMzYwOTg_0f2ed45c-a94c-4256-a0d2-aa669f973bf5">7.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItNy0xLTEtMzYwOTg_c332f283-8034-444c-a54c-48d5fb3312f2">7.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtMS0xLTEtMzYwOTg_71611946-0ec1-49b5-bb8c-bbbffab92777">1,749.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtMy0xLTEtMzYwOTg_8333c9b6-cafe-4e47-b0f1-724fc180a7de">3,878.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtNS0xLTEtMzYwOTg_914b3df1-8e6a-4531-a64a-ed60c88491f2">204.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtNy0xLTEtMzYwOTg_a403b360-ff98-4dcb-9eb1-409a55e956a2">216.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtMS0xLTEtMzYwOTg_02820799-952d-4a44-8d30-2a96af82356a">3,919.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtMy0xLTEtMzYwOTg_3ceeab87-ec78-4f22-8ea8-e84e9f215bc9">6,530.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtNS0xLTEtMzYwOTg_28a70fb2-dcb7-497d-a1ad-dd686eb6c532">614.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtNy0xLTEtMzYwOTg_61b11d24-8eb0-4325-89e3-8b2662c4a334">526.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtMS0xLTEtMzYwOTg_49c94d2f-3bc9-40c7-9ea6-ffb348441cd8">2,770.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtMy0xLTEtMzYwOTg_82d51313-9493-4c41-83ec-74aaedc9ecf9">2,884.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtNS0xLTEtMzYwOTg_d8083ab5-75dd-4ca8-a1e9-08fa4b83b701">1,082.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtNy0xLTEtMzYwOTg_946a8028-27dd-4987-9d4b-15ed0ad25ec4">946.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><ix:continuation id="i15b7e4a93a294a08aa7d0edc494dd451" continuedAt="i2a427bdcf7bb437e8cd3041ca9d392ac"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM0MDg0ODYwNDc2MjU2_0510a535-40fd-47e6-b977-833fb559d880">750.4</ix:nonFraction>&#160;million decrease in benefit obligation in 2021 was driven primarily by an increase in the discount rate. The $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-7" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzE0ODA_8f2a3252-cbb8-403b-af7d-f9233e80bdc4">2.13</ix:nonFraction>&#160;billion increase in the benefit obligation in 2020 was driven by a decrease in the discount rate.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzgz_9e36c983-8f72-436b-9811-87548db5a55f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItMS0xLTEtMzYwOTg_2102911f-2dda-4fb1-9634-6b4465506d15">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItMy0xLTEtMzYwOTg_6ed22668-7418-4ae7-a313-93c90294ef4e">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItNS0xLTEtMzYwOTg_207f22dd-cc20-42c1-b9f5-30b9d3d0ea30">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItNy0xLTEtMzYwOTg_c3275a96-0938-4310-a290-7510e2718faa">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItOS0xLTEtMzYwOTg_037093f3-5822-4e25-b175-43e8d1570dfb">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fd80bbb97874a039463577583da19c4_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItMTEtMS0xLTM2MDk4_33ec5cc0-a149-4df9-9fdd-47a80ef6c54c">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtMS0xLTEtMzYwOTg_3f4c0466-177b-4c63-8192-bb48a9976691">2.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtMy0xLTEtMzYwOTg_fbbb5fa8-e1cf-4a68-af78-425234003904">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtNS0xLTEtMzYwOTg_c1e39720-bd29-46e6-8fe8-787889d77061">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtNy0xLTEtMzYwOTg_734e4c97-3015-4cb5-ad80-007154742974">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtOS0xLTEtMzYwOTg_f63d4065-2c9a-4971-9873-235e1524fd5c">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtMTEtMS0xLTM2MDk4_ef2a54a9-2319-4489-ac9d-d41739a75588">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzQtMS0xLTEtMzYwOTg_a3cbfb1b-09ba-4db8-814e-7b44abece92f">3.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzQtMy0xLTEtMzYwOTg_0d9715e3-d4d3-4590-b175-faad0f369abd">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzQtNS0xLTEtMzYwOTg_6c2f139c-ddc1-40b8-b2e6-9ad0fdd7fe42">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzUtMS0xLTEtMzYwOTg_8e634ea1-ddb9-4561-85c3-94b351f0ade0">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzUtMy0xLTEtMzYwOTg_c3f64818-f09b-4529-90dd-59e4e2b281a1">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzUtNS0xLTEtMzYwOTg_1ea4d285-6e67-4f97-80f8-c1ccb58b8885">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtMS0xLTEtMzYwOTg_31d4552e-71eb-42e8-8327-d7f1a6c1c105">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtMy0xLTEtMzYwOTg_2f9c26d3-f170-4c4a-bfac-08e86c8f706d">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtNS0xLTEtMzYwOTg_c0cbee36-2fab-4276-b2d0-455510ddf07c">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtNy0xLTEtMzYwOTg_50e4fa13-cad0-4e1d-9e89-9657533927dc">5.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtOS0xLTEtMzYwOTg_e27d75bd-b3f9-4201-a30c-03322f1cb6cd">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtMTEtMS0xLTM2MDk4_af7e4f1b-214f-4e52-a053-9d14ed269d94">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzI0_cbb3ae6e-d514-4b44-bd37-3c4c57cc083e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtMS0xLTEtMzYwOTg_3314aee8-b86c-4655-ba6c-29778243ca69">631.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtMy0xLTEtMzYwOTg_dc48915f-22ba-4260-bd92-7837cd75edb7">641.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtNS0xLTEtMzYwOTg_aea64740-ac1a-4e72-a6d0-e244586bc92c">669.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtNy0xLTEtMzYwOTg_c17aa179-7b7f-405b-9aeb-88172cffff7d">686.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtOS0xLTEtMzYwOTg_700d9d47-1630-497a-8775-965301023d75">707.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtMTEtMS0xLTM2MDk4_b6a30449-0a9e-4e0e-bdf5-f6777b9701ca">3,919.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItMS0xLTEtMzYwOTg_67ffa697-d3b7-4c36-a8eb-3f81ae01a8ea">89.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItMy0xLTEtMzYwOTg_49b8ba53-5e23-49c7-bf2b-0ecd7395ecc4">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItNS0xLTEtMzYwOTg_9648d4f4-fd2c-4cee-b2da-0bbf37feb8f7">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItNy0xLTEtMzYwOTg_930cbb4e-7f67-4fde-a3b9-63c3d8b99590">93.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItOS0xLTEtMzYwOTg_f7ac388a-5c30-4f14-a7ea-d31e81866ca6">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItMTEtMS0xLTM2MDk4_ba2b3085-03a5-4143-87f7-540a9703fb01">477.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDIz_d223db18-a2fc-4f9d-b4e5-3989427757a7" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzEtMS0xLTEtMzYwOTg_13c63b25-24ba-4daf-ae66-615f7d886f55">3,360.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzEtMy0xLTEtMzYwOTg_e9fd3051-fa22-4241-9d4c-55b889a05069">15,770.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzItMS0xLTEtMzYwOTg_398b7853-be87-4172-ad6d-68778fd0e991">1,542.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzItMy0xLTEtMzYwOTg_2e91c4fe-1148-4615-92b1-7ba7cb96c7b0">11,824.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzg0_75a78f45-e592-4b6b-a891-d09b2abbb240" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItMS0xLTEtMzYwOTg_8301ca0f-991b-403c-bfa4-a01c739013df">2,532.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItMy0xLTEtMzYwOTg_f367df91-ae62-4e22-ad07-4ac8a9abddd6">14,682.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItNS0xLTEtMzYwOTg_781c9e09-b584-47b2-93e0-1a1d60f64a21">212.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItNy0xLTEtMzYwOTg_3bbc2ed2-8f3a-4c8b-8800-0db6eaf2ac9d">223.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtMS0xLTEtMzYwOTg_d5958d10-b6bc-4077-a433-b8d0d045fe44">973.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtMy0xLTEtMzYwOTg_dd9ba72d-2fe6-4d93-9d5f-a020e961a5c3">11,824.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtNS0xLTEtMzYwOTg_f795095a-b821-4f62-a60a-4b9585340bf5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtNy0xLTEtMzYwOTg_8abe2f88-9980-465e-924a-df38d9f6da18">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total accumulated benefit obligation for our defined benefit pension plans was $<ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-7" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzMyNzA_5b490bf6-2138-4d4e-a107-f20607f149f2">16.44</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-7" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzMyNzc_2db87658-0bfe-4301-8a97-9d86273ed47a">17.03</ix:nonFraction>&#160;billion at December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i2a427bdcf7bb437e8cd3041ca9d392ac" continuedAt="i7b7104cd681740f6aa6e8892e4cc3831"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzM0_83fb0948-ba87-4b25-a6b9-57533579b285" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtMS0xLTEtMzYwOTg_057684dc-14cc-445b-9080-24da7dd8c637">369.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtMy0xLTEtMzYwOTg_236d3a2d-372f-42bf-899d-53f8ef0bf85b">325.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtNS0xLTEtMzYwOTg_99e3dc91-0354-4220-9c8d-5d734eb6243b">250.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtNy0xLTEtMzYwOTg_e1680e48-db14-4b5a-aab8-8d54502a0dd1">49.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtOS0xLTEtMzYwOTg_6f1ae7e8-d565-4f32-ba0f-b9ee52a3520e">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtMTEtMS0xLTM2MDk4_60d4cca5-9f9d-49ae-8cc3-6dc27fd9fb9f">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtMS0xLTEtMzYwOTg_9f607502-6587-4b52-9dac-d1f609d8b7ad">337.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtMy0xLTEtMzYwOTg_83f1005c-cfdc-4e98-908f-299a8e2eaebe">425.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtNS0xLTEtMzYwOTg_1813a6b8-6b93-47db-8336-78a8c2880a69">486.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtNy0xLTEtMzYwOTg_aa914e73-14de-43aa-88fe-c1dd1e70ae84">32.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtOS0xLTEtMzYwOTg_2d2cb9cf-9d64-4937-aad9-ac67f15ac88e">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtMTEtMS0xLTM2MDk4_aef6c320-3960-4365-95e5-9ca35065138c">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtMS0xLTEtMzYwOTg_9e367a0b-79eb-4c6f-a969-9319d1bf50ec">949.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtMy0xLTEtMzYwOTg_387366cc-1cd9-4b93-bc83-be5c1c72ebf2">901.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtNS0xLTEtMzYwOTg_33706b23-9790-498c-aab6-c972a9181b53">839.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtNy0xLTEtMzYwOTg_dad9284a-5df1-46c9-8186-42dc5c6714e4">146.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtOS0xLTEtMzYwOTg_cd3c7937-87ae-489b-a042-56f5c3f4c6bb">158.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtMTEtMS0xLTM2MDk4_e593f05b-717c-4b4c-ad5e-b60a01be7b87">144.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtMS0xLTEtMzYwOTg_7dd6c289-1c57-4de3-aee3-052cbfa14f76">4.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtMy0xLTEtMzYwOTg_9cd2ff18-efbf-43d7-9821-ac5cd1105d0f">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtNS0xLTEtMzYwOTg_371712b8-ca2f-44fc-bc61-c70755bfc72a">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtNy0xLTEtMzYwOTg_bd999046-a7d3-42b0-b06a-cf457346b789">59.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtOS0xLTEtMzYwOTg_579a1630-d022-4a67-8da3-42bceef0f0a4">59.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtMTEtMS0xLTM2MDk4_48677d20-0d24-4103-827e-e587683d3a01">62.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctMS0xLTEtMzYwOTg_13097c8b-19e6-4d4a-8934-58647ee917c9">487.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctMy0xLTEtMzYwOTg_2d127e62-1cf8-4a2a-9243-4545ba570e88">396.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctNS0xLTEtMzYwOTg_c22039c1-591d-4b9b-812a-45d4da1e6ec8">284.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctNy0xLTEtMzYwOTg_60450550-7aad-4770-bfeb-32bccb2bebe1">3.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctOS0xLTEtMzYwOTg_877f5aa0-e87c-4f01-b597-b1bc696648be">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctMTEtMS0xLTM2MDk4_359a45b0-9155-46c5-9792-5091ab202444">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtMS0xLTEtMzYwOTg_ab55a35c-e1ed-40c6-ab95-4b40bb2e6b12">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtMy0xLTEtMzYwOTg_087dd47d-9cea-44b3-a1fb-6ed8910dc455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtNS0xLTEtMzYwOTg_9c571ef7-5469-4b7c-88ba-716c9a21a087">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtNy0xLTEtMzYwOTg_84cadd56-8920-48bd-8117-2b9502714f35">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtOS0xLTEtMzYwOTg_bd201c1f-8a76-4791-9b01-5138285f51d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtMTEtMS0xLTM2MDk4_012b36de-8199-422c-a28c-7a9745260249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTEtMS0xLTM2MDk4_1eebffb2-5194-4134-8738-1d211d986eec">249.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTMtMS0xLTM2MDk4_186e5804-1082-430b-a3d6-96efb78d9a0d">250.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTUtMS0xLTM2MDk4_e102dd37-1222-45a2-bc0d-28e2f43a3e6f">190.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTctMS0xLTM2MDk4_607588fc-f47c-4fb0-a2c5-0bf74e28c360">120.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTktMS0xLTM2MDk4_e6c6beda-538d-4c65-be79-de479ad38c6c">136.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTExLTEtMS0zNjA5OA_3f30b2f1-0b29-497d-839b-fe4d1f4b80d5">111.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzg4_380d0abb-f53c-4796-a760-9489e01bbc33" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, and 2019:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItMS0xLTEtMzYwOTg_0a110182-07ee-4fc7-9854-9be446bbe05a">2,072.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItMy0xLTEtMzYwOTg_8f13c2f3-5194-4fc7-881b-23c4a935cbe5">663.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItNS0xLTEtMzYwOTg_55c073e8-0d13-4be6-90d9-794dfc18ec8f">1,461.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItNy0xLTEtMzYwOTg_76464467-d753-4c3a-a0e1-df5f46b60cb5">142.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItOS0xLTEtMzYwOTg_074eba3e-f791-412d-9c75-367eb708a1a2">238.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItMTEtMS0xLTM2MDk4_62205767-92a6-48a3-bd93-a6215ab370df">246.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtMS0xLTEtMzYwOTg_d069a845-b1fe-44d5-8f1f-489686752a76">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtMy0xLTEtMzYwOTg_a20e6859-a09d-4ae0-b3f3-9890afb3acc7">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtNS0xLTEtMzYwOTg_9160f660-1fa8-42f7-a1ce-e6d0374a3f38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtNy0xLTEtMzYwOTg_254d917a-77b3-4836-acdc-7f1b6bbc4178">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtOS0xLTEtMzYwOTg_b92dce56-bc30-41e3-8333-f3f6904a2f8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtMTEtMS0xLTM2MDk4_7fb9cc0c-2f8e-41d5-ba71-3639c139be9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtMS0xLTEtMzYwOTg_dfc51e88-6e6f-4f3c-867d-545741c982e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtMy0xLTEtMzYwOTg_4dee4cba-d3f9-485e-80e4-eb53d5328678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtNS0xLTEtMzYwOTg_2956b16c-0136-41a3-9f4d-8b1352cd9c66">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtNy0xLTEtMzYwOTg_c4066ded-33d6-4465-aef3-75eba6c45756">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtOS0xLTEtMzYwOTg_eb2bbdf7-2f30-416e-a899-4e11e52eb5b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtMTEtMS0xLTM2MDk4_e544fb3c-c12a-4de1-89b8-2b95e8388420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtMS0xLTEtMzYwOTg_9ec1e43c-de5f-4948-9b3e-6eb61ce77da7">4.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtMy0xLTEtMzYwOTg_74d251ca-62ae-4a11-a2ed-19e0ca8eb446">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtNS0xLTEtMzYwOTg_a05d4534-c85c-4637-b817-909b2902d19f">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtNy0xLTEtMzYwOTg_01d51f35-bdde-4e98-a449-5e930f34f43c">59.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtOS0xLTEtMzYwOTg_851491f7-4460-47a8-9cdf-759b8e25d7bb">59.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtMTEtMS0xLTM2MDk4_2d5dc73c-8acc-4993-a060-a7dd1d76cfdf">62.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial (gain) loss included in net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtMS0xLTEtMzYwOTg_3474d115-9d2b-4ea1-991f-62990f283993">487.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtMy0xLTEtMzYwOTg_9bfbe002-e2ac-4fff-b0c1-fbd537a5e354">396.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtNS0xLTEtMzYwOTg_4e4eef92-1015-464b-8759-914e6835ddf3">284.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtNy0xLTEtMzYwOTg_7d20de1f-da62-4631-b9c5-1469dc72b406">3.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtOS0xLTEtMzYwOTg_0067174b-960d-4293-bcc9-d628be2aa3c5">3.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtMTEtMS0xLTM2MDk4_901c13f9-86fb-45d5-9052-ebf91825602f">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctMS0xLTEtMzYwOTg_f5a47889-b615-4f66-b067-bf4a8d23fcf9">47.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctMy0xLTEtMzYwOTg_1482ef1d-73cf-493f-9cb5-7eb91ef858be">71.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctNS0xLTEtMzYwOTg_a5e83935-774a-47b0-be07-a3e21d9a73b6">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctNy0xLTEtMzYwOTg_99746818-0100-4eb3-bc89-adfd5d7f0ecd">1.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctOS0xLTEtMzYwOTg_29b9fbee-9d8a-43f3-8aa3-a1e54717d2e0">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctMTEtMS0xLTM2MDk4_2d7750f6-d1fe-4255-9460-640c76b195ac">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtMS0xLTEtMzYwOTg_3d84b571-17bf-4a05-90b5-82918417f0e1">2,611.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtMy0xLTEtMzYwOTg_abdf66f8-720d-46e1-a880-9408fb5b65aa">335.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtNS0xLTEtMzYwOTg_a6decb57-88f4-4410-afd0-ca112b7a72fc">1,158.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtNy0xLTEtMzYwOTg_32fe5a96-831e-4c60-899e-6e0b46a28315">88.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtOS0xLTEtMzYwOTg_ac3ef7b0-5169-4a3b-ad25-3c67fae91962">178.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtMTEtMS0xLTM2MDk4_c070d1af-f16c-423a-88fb-9d55d024c0fa">188.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM4ODA_75efb26a-650b-4130-9aa9-87944d1a8a0c">167.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM4ODQ_a56d9aff-33b2-45ba-8402-ecbc0f6002c3">164.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM4OTI_95315920-8d53-4d2c-a3db-b09c4bd27558">145.2</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2021, 2020, and 2019 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit Plan Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately <ix:nonFraction unitRef="number" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="2" name="lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzQ0MzE_177d5ca4-6812-45e0-a5ac-6e3d959cad4a">80</ix:nonFraction> percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i7b7104cd681740f6aa6e8892e4cc3831" continuedAt="i57f604a51e5a4144b37faf8760bca75f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately <ix:nonFraction unitRef="number" contextRef="i968dbf693bb54261a0cad1975a0f50cb_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzYxMjY_c5cb8082-0ab3-45d3-b6f1-6755b27b0adb">75</ix:nonFraction> percent growth investments and <ix:nonFraction unitRef="number" contextRef="i41cc8775b020470392c03bca0264fe6d_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzYxNTI_121dd39f-04c9-49b0-ab9b-93af1cd825c8">25</ix:nonFraction> percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i57f604a51e5a4144b37faf8760bca75f" continuedAt="i6fdff5f4077240c49158886891572e55"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDA5_c9d754e4-82c8-4de9-b2b0-126c4c795bb2" continuedAt="i22511b80675642058d35c7e0ce00a180" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673f610f07dd4af7a79e6fae5b2a77f2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtMS0xLTEtMzYwOTg_298f3249-d4e3-4565-994c-adcac701c0c4">1,325.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i764e26f54c2b4e88b9f325ce95d6d91a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtMy0xLTEtMzYwOTg_1c35f83a-d1c9-44bb-9413-4d1db8cf2a05">430.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78fcffa5fcb4363b925527a37fdd04d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtNS0xLTEtMzYwOTg_07962594-2a4a-4e25-aa26-abfdf6e9864a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7cb49a7d1f0485eb5048fc42c817807_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtNy0xLTEtMzYwOTg_3218bf01-b0e2-4793-a26b-7a7850182ff1">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c7d73826fb4c3ea998d99f0cab890a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtOS0xLTEtMzYwOTg_b583efcb-6470-4af4-99b5-3a5cb54e5859">893.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1338ebe78ec64e74910cb8e168f15f3c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtMS0xLTEtMzYwOTg_486a10c0-3a86-45db-a140-aa1a974f9c24">2,722.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12cb2759a4414f6a87de7960536796f0_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtMy0xLTEtMzYwOTg_30b3f97e-e63d-420e-9b3e-be6b30285b92">815.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59bd989ed047e89cfeadb49552c829_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtNS0xLTEtMzYwOTg_1737f01f-9617-4186-9020-b5b33ee19daf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4ea41679f04d40a1f04042e79615f7_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtNy0xLTEtMzYwOTg_dbe96a33-320f-4820-97a5-cbf48b7e8585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913594ad00c9409d8b93872f5b5fbb98_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtOS0xLTEtMzYwOTg_dc3a7064-e860-4b59-9fe8-ad8b9e252e8b">1,907.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdaefce21c9475cb128cd1bec0b2b54_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctMS0xLTEtMzYwOTg_19fe0e8f-7ed6-443c-a530-c0e73d7f9548">4,496.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b14f14bed9450fbcce11d6df4b26a8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctMy0xLTEtMzYwOTg_a1e810aa-8592-4db5-ac81-01cb4b5fb972">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603f1e71c9ed4e7b8d938450da375dbd_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctNS0xLTEtMzYwOTg_961691a9-eb74-4ff5-9727-cf40a05cc135">3,356.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d5edaf21db341aaa94c8e50e73bb216_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctNy0xLTEtMzYwOTg_ac6a3d5f-a8e9-4eff-bad1-3e4b3c16a4c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a706cd4ae4a48b185995bdd2f78fd3c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctOS0xLTEtMzYwOTg_24457064-929c-42f2-8e35-7f9fbbdaa2bd">1,136.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78fc7d44d8cd48aea3c78cadc0049519_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtMS0xLTEtMzYwOTg_aabbe2df-44fc-48c6-bede-89db1e74f816">1,376.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8bd8f7cd5b4670a3e7ff6635118b75_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtMy0xLTEtMzYwOTg_07e26b3c-e460-4f2b-bd33-47f88c3309e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f83daf4fca54e40bbaab49dd09cc5a6_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtNS0xLTEtMzYwOTg_5f78c8b7-df5c-41ff-a7d8-18db9cf6c330">1,376.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31478b67a9a7415d8e22de1ce680a740_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtNy0xLTEtMzYwOTg_baef05eb-fa5e-41bd-91e0-d096dd10c436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5636680a6e4e4350b3fad57180768fbe_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtOS0xLTEtMzYwOTg_90902115-61e2-435e-bcb4-eed6120aa7b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e43baf9dd8e4024aaad2773c4f843c2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktMS0xLTEtMzYwOTg_c5f91409-41d3-4713-8dde-9b2ba285fef1">611.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d32acfe18e3466fa5910b344222cd82_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktMy0xLTEtMzYwOTg_dae8bbbf-f63a-4e46-bdfc-e4027a0671fb">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede2b770f3c64ba68bc39044be90f109_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktNS0xLTEtMzYwOTg_8eedf1e9-6b2f-40fb-9764-3666160d0c7c">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f7db50ad1c415288b9ea85aa6709fc_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktNy0xLTEtMzYwOTg_14a4f55f-6ec5-4aed-ae75-b96530fe1821">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a91711f8ddc4cb89e215732b94181ef_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktOS0xLTEtMzYwOTg_f5101df8-5ae9-44d4-a1c2-63cfa25f0275">349.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7aa0c503f5488795d936ac19312dad_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTEtMS0xLTM2MDk4_8914f46f-8c87-4a39-b7a9-a1b5ebde893e">3,046.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa35aec973a9495d8cfb4d1860d7f186_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTMtMS0xLTM2MDk4_a7ce1bde-e5eb-4d6f-9252-5aa16b6f30e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5278164416d440878ce7f8241506dad2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTUtMS0xLTM2MDk4_472659eb-949f-4a10-8f38-e8e7c39e9def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30503f9548ef49748f6c47f41c46b9fa_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTctMS0xLTM2MDk4_13045646-4f72-4674-ad73-72ab88c65e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692d2c7285d94749b0594132364bf602_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTktMS0xLTM2MDk4_3508d68a-a226-46c7-8b24-8108c4eb8f67">3,046.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e6e217adbf4a0bb420bbb79525b195_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTEtMS0xLTM2MDk4_d332e9e9-a9a9-45b0-af32-9fafc44f1b15">3,816.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230a704d2f5740a0b69a5d2fe32aea0c_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTMtMS0xLTM2MDk4_7e3df6d4-ca6a-487b-a487-de55a1fc05f9">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd8a47a67cb40659b5f2400ba2e2a97_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTUtMS0xLTM2MDk4_33289543-181d-4536-a75a-b3fa31db7925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4af7abd8884c829ce2cf89b4eeb4a6_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTctMS0xLTM2MDk4_ec06ccb8-7955-4a8e-9ccc-d620b25f7560">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0db00ed934147a0b1454ebbfb9605e9_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTktMS0xLTM2MDk4_e773a813-e634-4338-91d8-6213e5ded493">3,808.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91ba6b55fdf460aa45150043f7993d0_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTEtMS0xLTM2MDk4_2f757f12-f15a-4abe-9cc2-df91a4eac479">630.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9090de42c1e1431d880e89e365433af9_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTMtMS0xLTM2MDk4_7a6ea320-04d4-4971-b6e0-3db042a46a1a">363.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9162ecb9fcdc4a8a88c76c029e0ec77f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTUtMS0xLTM2MDk4_749bb863-fb32-4e93-8b46-1c6252eb9e37">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b11998c76c4e07837a915345cd5625_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTctMS0xLTM2MDk4_0b3e5dde-cd33-43b7-84da-ff6baf71f91e">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f60d47dcdc4aea9e98cfeaa8959089_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTktMS0xLTM2MDk4_ef021e79-b320-4030-a1ad-d63f827f75b8">248.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4fe3ccc0a24e18ae11dc80ffeca0f0_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTEtMS0xLTM2MDk4_b85619b8-236f-4328-a217-6098ea7f29d2">1,143.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4e6aa2e94d4863a9d4c4d40db622ff_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTMtMS0xLTM2MDk4_f7619631-2dfa-47ca-8180-75adc1de115d">103.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ada8f6f4d09490b91888fc53f19799a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTUtMS0xLTM2MDk4_bae2649e-88c8-4c12-9015-9f7ce86e2fd3">263.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8ba6c16b8a4854afcda9d5176c4082_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTctMS0xLTM2MDk4_069a766f-2874-4a6c-bd34-5469e479cd10">2.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fef9519e5cf4d83bb440f5dd2dff978_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTktMS0xLTM2MDk4_1a50fba7-45e7-40d9-9dbe-f436acf68f4e">779.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTEtMS0xLTM2MDk4_6e9a5ba5-e6d5-476c-817c-667fd6a61715">16,416.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e10b3bce8240ed99c41e92c2c7c166_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTMtMS0xLTM2MDk4_fd693b1a-89ec-4ec5-8499-0a9308edb57f">1,728.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39b60c7852e34d32bfb74a52b2d6c8ae_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTUtMS0xLTM2MDk4_74fdd925-5684-4aed-8615-7f166403dd0d">2,501.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626717f8b3604479aa9d86b960ead4df_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTctMS0xLTM2MDk4_870f3049-dee9-45d7-9508-7384eaf03f75">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e68a551ac24824aab0b50cf96ac505_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTktMS0xLTM2MDk4_d92b2a75-6021-43bb-8eba-8c43548a9b35">12,170.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd41dfa5131b4ed8a3c4edff4cccd882_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTEtMS0xLTM2MDk4_4784c72f-6922-46a8-a631-f80cf4cefb7e">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dfb78e31d4e43a48f83b015b72c519d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTMtMS0xLTM2MDk4_2ede7485-f12b-48eb-b5d9-179bbafdaa11">40.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d870bd1a8c432ebcf9c58cce764986_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTUtMS0xLTM2MDk4_f66598ac-32e6-4ec6-81e6-cdbdd6340a2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866e79b40fc84b748948629cdaf16e9a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTctMS0xLTM2MDk4_3c855af6-ab22-45c5-98eb-7a81135ce8d5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a07c54e28594ef985fae75cee518345_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTktMS0xLTM2MDk4_f5724da6-8dac-4158-b124-08b43021ed9b">83.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f183c3cbbd4fda982cfd4dd42bb6ee_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTEtMS0xLTM2MDk4_c4d4cfbf-2786-4512-9f4b-93da136ea694">180.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e533a36459c459998922edcc7dc2e06_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTMtMS0xLTM2MDk4_91c8e5cd-c30b-420a-8343-f54ea1288607">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3685410209c4742a6877711165cde44_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTUtMS0xLTM2MDk4_7f37bd70-11c8-4072-9689-9f825f1469d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244b201723df412384c2a82e49dddb47_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTctMS0xLTM2MDk4_675cba5f-23f8-481b-ae48-6af40b34b671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie223fdbc588545c7aa7794612858f25e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTktMS0xLTM2MDk4_bcac8216-917e-45a8-bc0a-499d02ec0a47">132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44600c684d24718a1f3801f118c80eb_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTEtMS0xLTM2MDk4_07db63c8-db96-4792-9f5b-f793715c417f">102.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5f9dbd52e49c9964b39f2bb6a3117_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTMtMS0xLTM2MDk4_74f78cc9-885d-4ab4-a553-356bb24aaa51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1acd17d36146009b635e6ac8876b00_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTUtMS0xLTM2MDk4_99e5e095-c248-40ce-8042-1f7cd927b650">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia121cc72798a41b99b32667d68124755_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTctMS0xLTM2MDk4_2dea557f-e8b0-466a-9976-4871e6443585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddd772d1a82411e9d52cfd46b93391b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTktMS0xLTM2MDk4_b58b6ff1-00b5-4562-9ddf-d0589c820889">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf0bc4572794f0bbc6996cb82ce99da_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTEtMS0xLTM2MDk4_8c1fb847-5b14-4222-b382-6c2c2e4838e7">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec4a130b58aa4fc787b2559b8e658309_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTMtMS0xLTM2MDk4_d63d7d61-2c86-40d8-805b-919f0ed5e100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c2688876344ae09d2527a2174d8cfd_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTUtMS0xLTM2MDk4_3b32ad05-8914-4ff7-aaae-2bf53f0f1e70">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d399445e4a24b55856d4967cfbb5abd_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTctMS0xLTM2MDk4_8cb8bc8e-b7f4-4e26-a0e6-cf7440ead918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ff171bf7ca484fb1a1179c3b99e72a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTktMS0xLTM2MDk4_d3ff9fa9-2cd0-44a1-a7a8-4f4940299a5d">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38811147de6a4ae49619b0c6fb50b5fb_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTEtMS0xLTM2MDk4_ed4a6418-9a56-4c52-b856-38cd0d68e2f4">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49b9ae457524259bb341c9357a21cb2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTMtMS0xLTM2MDk4_8cf7c041-e3b1-4bb6-bf1c-84721173ad7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109ad29c5c0843d19c3fb35636897f6a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTUtMS0xLTM2MDk4_e02f249f-e11f-4d71-bfeb-854c0a471bbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c48fc80fbd4c02894b634f68421b19_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTctMS0xLTM2MDk4_d41cad4a-8fd2-4c40-9730-948a376c2a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923f6a0606ca4c659014e936327d763e_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTktMS0xLTM2MDk4_bd20761c-b210-4287-9cb6-8c94cac26b0c">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ebd34478dc44aa94bd2cd5d0ae09b7_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTEtMS0xLTM2MDk4_863906c6-024a-4392-b93b-6b44cee0ccd7">317.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4dbe652b11144049f9f252b2a082929_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTMtMS0xLTM2MDk4_b7c4e73d-942b-4e47-aa94-12d0ced2d67b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126ac11b05304e3480af55e56aab89f9_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTUtMS0xLTM2MDk4_0a3ddc41-fac6-414c-a88a-e2abc7cc70cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1c1e97cbfa4338851f65cd304431ae_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTctMS0xLTM2MDk4_a74f0209-ddaa-4ecb-9b4f-774fd50d6a05">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15d1d4659da48ea849e744343f5a3d4_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTktMS0xLTM2MDk4_dd19f7e4-29a5-4ea1-aef2-2ea6971632bc">317.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab573539a9a94f85bad389b1d078779b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTEtMS0xLTM2MDk4_f8e5db5b-7460-45b9-bbd5-f0e6b545122d">2,166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f296c7bb394430981a1fb8d6838282a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTMtMS0xLTM2MDk4_7147ab39-c97e-418c-a112-3738a2fdac6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002c38a65f454861808977f397fda65d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTUtMS0xLTM2MDk4_ac1b79f7-05bd-411e-ad7c-bedcc28c259b">2,166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd94f2c6bb2e4e2fa5ffb39664bdf21d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTctMS0xLTM2MDk4_7e598e92-cf58-4ec0-ae45-03ea5de93c0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dad2404b29349fb8450d5b39364906f_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTktMS0xLTM2MDk4_5ed11ca1-b72a-4066-9775-c7f834ad0dd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27235dedb8194dfe8ed6a11ba255ac26_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTEtMS0xLTM2MDk4_1e2d9dc9-50d6-4d82-98af-4da8b377a6e4">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b97858557449bcbd42057fb05bf2b2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTMtMS0xLTM2MDk4_8d7af191-a68d-4cfb-8fed-92bdaa9921fc">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4dad88d4f64153b1ec36fb80920aa3_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTUtMS0xLTM2MDk4_b07ed90e-0063-4f8e-abbd-5936d1f18f7b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16f68bc36bd4ad9878079914f8e282b_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTctMS0xLTM2MDk4_ee8c4be8-ae82-4ade-82fb-57ff89441230">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b81a674c8349d5805272c34a30b9fa_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTktMS0xLTM2MDk4_e0f4dca3-b0f8-42e6-a66a-9f1283064701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2f3b2cbe4349ca9de603412aa190c2_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTEtMS0xLTM2MDk4_bebf0c97-5f32-4785-a61f-5c9d1a33253b">106.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe2b2b2f8174da2975d92a5e46521b9_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTMtMS0xLTM2MDk4_9d64964e-81ce-4500-b957-cf37cddf3946">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4caf2d660c4b4484538e8cbb90b925_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTUtMS0xLTM2MDk4_60953584-795b-48d0-8583-f2f38592aa8c">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i492309902f57471882356fb89a26bd66_I20211231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTctMS0xLTM2MDk4_a10227ec-8e9e-4130-9514-d48a6623e2e0">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00e44884e4324921fffe1db888357_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTktMS0xLTM2MDk4_234bf805-61da-40e2-a420-64d5d839f15f">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTEtMS0xLTM2MDk4_d1b06ccf-7428-43c6-9d92-d38b8c031873">3,361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7920ff7437c4431394c58ae1b77ea77d_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTMtMS0xLTM2MDk4_2fc81c50-4d9e-4ea9-817a-8f776827544e">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a76d7e24404d87b2fb139a19273f9a_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTUtMS0xLTM2MDk4_7d5c6fb3-e021-453b-a095-603b825988bd">2,290.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920509e109ff475b8bc9e2c46f33d0be_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTctMS0xLTM2MDk4_2d3402b2-8445-4fce-a16f-5a0dd25093cb">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5f50dc04544153acdb845c6d785a71_I20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTktMS0xLTM2MDk4_a0cca9e0-492d-424e-811e-2f8818d3c7dc">922.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2021. The activity in the Level 3 investments during the year ended December&#160;31, 2021 was not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6fdff5f4077240c49158886891572e55"><ix:continuation id="i22511b80675642058d35c7e0ce00a180"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd270e9d09cb49339a3220d22dd73473_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtMS0xLTEtMzYwOTg_49dac839-df03-4977-a048-f69c07e4c03e">737.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90078976fc1443fe9588fd6b5904ab69_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtMy0xLTEtMzYwOTg_c03a71ad-990b-4f92-a852-ee5111f7c5f3">476.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5677ed160204f11beec751a2ccee116_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtNS0xLTEtMzYwOTg_ce5b92da-7175-4920-b88f-bc697bf979ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b36d1b515614e75986f6da15379aabd_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtNy0xLTEtMzYwOTg_1a2acb0d-0526-4d03-8403-86447e8bc95c">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9670f5b2d1b401bae5142ec826f2a84_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtOS0xLTEtMzYwOTg_3160d232-69f2-4b99-9bb2-9c6b6572b416">260.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedb4afcb9df4c4e8e4622bdceece6d0_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtMS0xLTEtMzYwOTg_4cd95530-b6a9-4a28-ba01-b0f39660ba56">2,635.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1fedf4fa6a74d72b7aff18d5cad5971_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtMy0xLTEtMzYwOTg_1862f0ae-5da2-4f5c-8fea-be715d0e8613">1,102.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3027fdae9ac423dad98aa4717b2d250_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtNS0xLTEtMzYwOTg_5cc4f1d4-0a14-4924-bc86-4510b9ecd15a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904066c648bf4a7891d0c09bd32f935a_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtNy0xLTEtMzYwOTg_bf32afc4-2081-4b18-9406-d7aa44c0d2a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37beb85aa5242baa69698b7f1ac5a62_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtOS0xLTEtMzYwOTg_f109faaf-7b2c-4c14-a0b6-ff7ca72a275a">1,533.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dab754da4cd430a946579d76e7a4235_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctMS0xLTEtMzYwOTg_f7a44a66-6dce-429e-a05e-d292b84a99a2">4,301.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c886b62fb994e6b8d799a1e75d54ba5_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctMy0xLTEtMzYwOTg_3eaa351a-6a88-40aa-8e3e-89ce5a083d77">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c687db083a348319e2e8ddb46c0e62c_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctNS0xLTEtMzYwOTg_d813377a-a1bd-4621-b226-658c891cc853">3,179.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c04b7697ad04751a168650303409b1b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctNy0xLTEtMzYwOTg_ee011254-5ec9-4507-91c9-73be78f44e0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4204c5315adc45d48e818bbe9a8ba906_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctOS0xLTEtMzYwOTg_d24678e8-9eaf-41b9-b101-1bcf673fab02">1,119.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4986843a114a4fa8abd7bb677f0a6e09_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtMS0xLTEtMzYwOTg_889aa151-7d0c-4585-9c16-c466aed0b116">1,670.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1852094aef8a41098d0642f072f681a3_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtMy0xLTEtMzYwOTg_b2761ae0-3a99-4bec-b49f-3599c1718829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id971a9a8b7eb4b6c844ae83861fff3d9_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtNS0xLTEtMzYwOTg_8ffcd650-f394-4cae-85e8-b99fe530f146">1,670.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05c9d92ee39418698a8b85febf6ef92_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtNy0xLTEtMzYwOTg_37a02cee-882d-444a-9aca-4fbd417171dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a265af7c90b4248bcc3b03e1b75d45e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtOS0xLTEtMzYwOTg_73e88b92-642c-4028-9ec0-7573285eefbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376b64ff0bcc4868b48f64179cccef38_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktMS0xLTEtMzYwOTg_48fa2d11-7725-4d90-ba71-2ba99dea3b19">631.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a3ca1d4022458f96a8a99957fa07fa_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktMy0xLTEtMzYwOTg_e62bd41c-c49c-4c66-bf8d-7aa117dd8ee8">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d1d1c1c3ed4109a81ec41ff3971fe1_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktNS0xLTEtMzYwOTg_79484a97-4419-4c3e-ae5a-b7d3e198bfaf">262.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22e780cae244f9ab866e47a503bb04e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktNy0xLTEtMzYwOTg_823773bb-ad06-4f7c-a550-764c114cb7c8">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1c7cdebbee4183a6490b6aa660776c_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktOS0xLTEtMzYwOTg_d78294ed-a347-412e-b0b8-32d491c6dc2c">354.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098c8e062f114cf895dfab6de7e2a153_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTEtMS0xLTM2MDk4_1f017763-5957-4a35-9005-e70ed59c197c">2,661.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05001400e56b4185b37c3c340b3cb549_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTMtMS0xLTM2MDk4_31c415b1-9fc3-459d-9b40-af7cbcf3e7b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f54761004c14a0fbeed714f829c9a9b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTUtMS0xLTM2MDk4_30b841f9-da7f-401c-abc2-60a6d9903969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab1592b5b5a4ea5803c843fa59ea969_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTctMS0xLTM2MDk4_375aa041-da9f-465d-b79e-086a8820b587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief12a02bce14452ab3abe51ad1dbdb96_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTktMS0xLTM2MDk4_2f980ddc-1bd6-4ae7-9b15-933ab7229a9f">2,661.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8303f3b61154040a4ed58939d6a8db7_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTEtMS0xLTM2MDk4_a9efebe3-6c20-4976-895a-35b9ea918ad6">2,844.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dbef9e3cee42a6aba4ec399d8d2392_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTMtMS0xLTM2MDk4_916512cc-1cb5-4325-86b0-fef6bf805ef2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b9c108036e4a95a83b7d094eaefd7b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTUtMS0xLTM2MDk4_3e37d701-dfcf-4def-97bf-e2afed815d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a011bb0a6704772865e32f9508fda79_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTctMS0xLTM2MDk4_2398ac4a-7fbe-43b6-b452-7a5edde50a86">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90317e246984c68baa7aec717e1b700_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTktMS0xLTM2MDk4_a1e060b3-f230-41c7-9dc2-a1c5a5410289">2,827.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a9ee8915a1448aa53821d3de24626e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTEtMS0xLTM2MDk4_3bf8ffad-f978-410e-b3c0-420481856dad">558.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77dcf7055a13436793411bbc50581e33_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTMtMS0xLTM2MDk4_b9de88f0-654f-43a7-8913-cc4dd53f0af2">259.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54aba7ea557147118c52c20b184223c6_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTUtMS0xLTM2MDk4_3c61b4eb-7603-4e6c-afd3-c0a1b9af7dd9">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4bfc6afcf347469c09d2fffbd3b3ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTctMS0xLTM2MDk4_0b3956f7-d660-4294-aa80-bd96b35b695c">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d6e9fb0a8e41d7a79bcebc0f396ca9_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTktMS0xLTM2MDk4_70c76a07-264c-4467-892b-a213aed53451">286.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286bdb1bdb4a4e99b3a1228c6f203ff6_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTEtMS0xLTM2MDk4_74162ac8-c041-4229-acfa-f272631bd896">1,879.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85922b83894b11b8b77f4c73af1fcd_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTMtMS0xLTM2MDk4_73924e66-684a-484e-92fb-7055f0b2452e">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2ff10cc6de4d44b3171363fb8d3314_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTUtMS0xLTM2MDk4_70efceea-1b05-4f2b-8a5d-2d7ea3d24f83">301.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443731e8b90e4ff1b5ede21f5cedfd96_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTctMS0xLTM2MDk4_94df3ebc-a640-4aa8-94fe-d860ffe89115">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45319fdcff414b46b8cee3c8ecc98372_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTktMS0xLTM2MDk4_580ba749-3ae4-45aa-85ce-b5e8bdaaa8e8">1,499.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTEtMS0xLTM2MDk4_4650aa9c-2ca4-43cc-a834-1cbcc6a49cd5">14,579.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2d59c1620642d784d6b10e9f31a7a2_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTMtMS0xLTM2MDk4_f7471421-9de9-4252-a8e5-a06aec2b576d">1,915.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50063c31ba9749efa23653ec53ec7046_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTUtMS0xLTM2MDk4_31c2b880-5cb6-4039-b35a-c356993b91f1">2,079.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id966a267adc34a0ba8ffaf9925c61ef2_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTctMS0xLTM2MDk4_82aefbc8-d56b-42cb-b0f0-1cf229f9114b">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8eaf7e5d4c4ea48272ed7d73c53069_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTktMS0xLTM2MDk4_fbcf6465-c792-4830-8182-fa8366679dc9">10,542.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id872ed9c15ae4df9bd2ff63acfe92e0a_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTEtMS0xLTM2MDk4_ca55aa23-b1dd-4e03-97f2-c57b4fc655ba">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7e2a5a735740298384d7b6e050d5aa_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTMtMS0xLTM2MDk4_7ee26bb0-9f3f-4c24-bb8e-9fa31b5612e6">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c132cf90104d488c23e6ca6eb8098f_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTUtMS0xLTM2MDk4_97eb3a1f-0180-43e2-bf1c-24b0e5918685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4113c6d6bab42948b9ff02ab6f74741_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTctMS0xLTM2MDk4_2e6d35ef-d2d7-4b5c-8ac1-ae55d95f739c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e88ac2258ee4936ad5dc86525cd9442_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTktMS0xLTM2MDk4_7014f352-56a2-4af5-9bd6-dd511d986fec">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670f1a97ccbf41da8154342d4d6523b4_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTEtMS0xLTM2MDk4_9fde4cab-0edb-42db-b610-c30d29a931c9">162.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3ae3cf49674f30ade8c18fa107c77b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTMtMS0xLTM2MDk4_5bebb6c5-ee5c-4245-8fc2-68844bb5f8af">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e5842c7554e4caa669c0ffca933f3_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTUtMS0xLTM2MDk4_adf4e356-1ada-4ee1-9304-c3a818677f40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cfd8a609414a0db58349eb5ea9a5fe_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTctMS0xLTM2MDk4_233b7203-e9ac-4dcd-8880-d97157f6a6e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0f0411d0c340e5a80b9de1a90ac71a_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTktMS0xLTM2MDk4_7f02397f-5b81-41bd-906f-ca554c080284">104.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fcea8bc696240ccb6279f2fa8f961ff_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTEtMS0xLTM2MDk4_03df58fc-46b5-4104-a427-4686760cc61f">101.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717d2780362b4ed5a803d5d092fc68de_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTMtMS0xLTM2MDk4_55b4909e-f92d-4f13-a75d-c56c472b0e7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89af2a8588fb43c7a9f34777a2e4a820_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTUtMS0xLTM2MDk4_b6d279a6-599f-415a-a0aa-759b5a4aab23">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a8292117714ce7b0efadd7981b2635_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTctMS0xLTM2MDk4_1c58cfa1-5428-4d79-aa0f-e092d70adb71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie331a6b7526d4646ba4c0c78741cf4a3_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTktMS0xLTM2MDk4_2ecf5cfa-28d6-494e-a44f-6d012788308d">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica375fb13ab44116bd7cec8010c65295_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTEtMS0xLTM2MDk4_ee7cfe2f-ba7a-410d-a3f0-57021a14ad8f">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc92d20b166347aba8996743e2f94f5f_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTMtMS0xLTM2MDk4_70efd799-17f1-4ccc-9e73-f75c55fb0f96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i154ab60f7f874167b0110415b0bb6bcf_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTUtMS0xLTM2MDk4_674e1769-bd5d-4d56-909d-b72cd9a0a750">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82568bb9dcf84a24a49d7b60fa84c30e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTctMS0xLTM2MDk4_dc8153bb-0a2b-4178-b851-6cff004d657b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9537a27ef3aa4c4c9ab9cf72607bf998_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTktMS0xLTM2MDk4_b0dd55ed-e68b-4147-aead-cb58de14829c">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1425cdedc7949b0b143bc6ff55254ef_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTEtMS0xLTM2MDk4_3a3be37a-1222-4c42-8fa6-8aedfcde15d2">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80391b34e15c469b9897032dcc29bcae_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTMtMS0xLTM2MDk4_bafc524f-dab6-4450-a1c7-db463fd4f826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie906d9e82b62417aae23edf6f663034e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTUtMS0xLTM2MDk4_078aae54-21e8-49b0-a03d-41efd5dd1697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0008b840b33b4978b52d9f21ad80d88b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTctMS0xLTM2MDk4_f61fdbd9-fcab-45b5-8e21-8e30bae56700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062da986ad0544f289a0f7f67fb3d529_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTktMS0xLTM2MDk4_a5e98d10-477f-4444-8d8e-aa67f2fe6f69">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c8c08e195b457581bae02f1a1a1ed6_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTEtMS0xLTM2MDk4_382495f4-cb24-4937-a561-857dd3257a73">223.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic671a63b2541465ebb7421a6e68854b1_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTMtMS0xLTM2MDk4_d4cda179-bd78-4505-b2fa-b5a693425edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9a8b2e771d41f990fd1f9ea5be38a5_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTUtMS0xLTM2MDk4_228a8dd5-0ebf-4256-93fc-3da4d3b76092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ee2af27ade4a0d8bc08bef2fff9cfc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTctMS0xLTM2MDk4_88ea89f4-ee7c-4244-8bbe-52a3445d7a96">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75775f4e3d5407da9f8fd41bc619cc2_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTktMS0xLTM2MDk4_69c65b8f-8647-4347-9603-71b89d56bf68">221.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4d0bb3ce4b4cd7a9e3ffbc447cb4a9_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTEtMS0xLTM2MDk4_c4525b35-197a-409c-a83b-de251c06d2ba">2,204.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3fdb269b554706bad0f7c0db4c4650_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTMtMS0xLTM2MDk4_3acba794-afa7-4369-b346-cf2d02427617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8f217fe0234a80a11ef720e8b0c5be_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTUtMS0xLTM2MDk4_2399dfb4-d7b6-446d-91c5-d218d462ae23">2,204.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf725fef3924b1ca90629c2fbfd82be_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTctMS0xLTM2MDk4_bcc28976-814d-4bac-9e33-f45a935d5206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e73d975a09b4b51b349b6589f7f2026_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTktMS0xLTM2MDk4_95f9ee05-33cd-462f-8db6-225396f3c7ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2345619fcf84c878d4d255125aff795_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTEtMS0xLTM2MDk4_e16f7412-9c66-41a3-9236-5349b18f2e5d">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f2b6878a0d4219bec7cca02fca3f31_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTMtMS0xLTM2MDk4_77fe6201-c168-4610-9830-e2bbd1467834">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id081a7188b3f482cadd9f20bf9235396_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTUtMS0xLTM2MDk4_784c53da-21ac-4be2-a155-235541e4a07c">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a933ecf8154d50959fd7b679fa2059_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTctMS0xLTM2MDk4_04521daf-0f9b-4f47-9876-b9e0a8d4285c">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c80776c9e5d478fb71a447f058f5795_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTktMS0xLTM2MDk4_7c2fb9e1-ccee-448b-99e6-834b5ddbbea8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9330f1044b4da28b7e3b56aee502c9_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTEtMS0xLTM2MDk4_b3a0b6f7-7bfc-4469-bdfe-8a1db4ca4ed1">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2fa9acd89db451e96eec95ad09cf9c8_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTMtMS0xLTM2MDk4_72113c86-2b02-42df-8c6d-68bf15707d10">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd7cd72ddc74159a112e5175ba27aab_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTUtMS0xLTM2MDk4_1b03895c-e7a4-4e79-9cd3-d694c1f7aaa9">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1884086160c4545b61f9deb3369c36a_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTctMS0xLTM2MDk4_78c733f8-7b0d-4787-8be3-9d700a0dbe15">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3c2d07882344e098b3ebd363334c5e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTktMS0xLTM2MDk4_db3db9b5-f08f-44c1-9805-510cf05022c8">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTEtMS0xLTM2MDk4_622779f1-c563-4140-87f7-d5d4d5958fad">3,227.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e1bafb60044816a73bd73702d87ead_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTMtMS0xLTM2MDk4_95552dfd-b1f2-421c-b652-e26b01b0af93">141.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6128315f59094f028caf8bb50fc29382_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTUtMS0xLTM2MDk4_543056f0-3283-4818-9486-c0cc17319ecb">2,331.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1472d9c0614d2792d02449a8430661_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTctMS0xLTM2MDk4_288a8a9c-ed1c-4938-ae66-188a9398a47e">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f512b891abe4e69bc22f07f86783f45_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTktMS0xLTM2MDk4_0cc06ab9-e68e-4bb5-a367-14fe494740d5">749.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2020. The activity in the Level 3 investments during the year ended December 31, 2020 was not material.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we expect to contribute approximately $<ix:nonFraction unitRef="usd" contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMTIw_9bcbccb5-6838-4040-b692-d0abd2b83dd1">40</ix:nonFraction> million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">100</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3MDI4_2e01fd55-7bc2-4de8-8eb7-d5dd171c1cf9" continuedAt="i9aa22200b91e42af9f948340ab2b6548" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i9aa22200b91e42af9f948340ab2b6548" continuedAt="ia9cdacdb4a8e4c1c84c8c4b8217637e9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkxNzIxMDU_533ffbf3-602c-41d5-85d0-35b55c42f432" continuedAt="i1fe2465f69ed4f30bb3cd0c8ae0a82cf" escape="true">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1fe2465f69ed4f30bb3cd0c8ae0a82cf">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) was protected by a vitamin regimen patent until November 2021, and since then has been protected by pediatric exclusivity through May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chusetts seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="i5a8f4700075e46e181eeffde2392ca23_I20180930" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2ODU2Nzc_8786f57b-7f3c-47b4-936c-654348e1e357">nine</ix:nonFraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is currently scheduled to begin in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that <ix:nonFraction unitRef="patent" contextRef="idaebf92d82564ada897eaa69c56f337c_I20210630" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2ODYwMDc_00737ee0-11b4-43eb-b02f-dde144cd3abe">two</ix:nonFraction> of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ia9cdacdb4a8e4c1c84c8c4b8217637e9" continuedAt="i884e1057210e466a8aeec8593abda50e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021 and November 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Swiss Federal Patent Court, respectively, in preliminary injunction (PI) and main infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis' PI action. Novartis appealed the ruling and in October 2021, the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing. Hearings on the Italian and Swiss PI requests are scheduled for May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Novartis petitioned the Commercial Court of Vienna in PI proceedings and in November 2021, the Austrian court denied Novartis' request. Novartis did not appeal the ruling, and this matter is now closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing occurred February 2022. We await a decision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i2467803c679342dea9a3819f8bbf7baf_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTAyNDE_7c850557-1bd5-452c-b440-0be43500046d">four</ix:nonFraction> purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including <ix:nonFraction unitRef="lawsuit" contextRef="ib12387763bcb4249a0acbacdd6def054_I20111231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTAzODM_e2ea53c7-4c0f-4f42-87c0-0899539375a8">one</ix:nonFraction> in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="if4b71fdf7d6d451ea94e93caa29ecafe_I20120731" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTA0OTA_3b91f566-b560-4da7-a06f-415766e12d7d">one</ix:nonFraction> in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="i5f4e6781ac7b44e984cc9a7e9559b57d_I20171130" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTA1NTY_4849e926-8109-41de-8592-6001c75369cb">one</ix:nonFraction> in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and <ix:nonFraction unitRef="lawsuit" contextRef="ia0462964f7244546aefa834caa5190c4_I20130131" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTA2Mzk_97ec9473-3d93-4b90-80a3-74dda921fc5b">one</ix:nonFraction> in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021. The relevant courts approved the settlement and the deadline for class members to seek settlement funds has now expired. The lawsuits have been dismissed or discontinued. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i884e1057210e466a8aeec8593abda50e" continuedAt="i25fe0a68fab147ac9c5b0bdd6003f349"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="iac210e833f7b4de39ab853cd87ad843d_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEwNjY_f76797a6-0b40-4c4c-ac8e-e5f2da24875d">570</ix:nonFraction> Byetta product liability lawsuits in the U.S. which were first initiated in March 2009 and involve approximately <ix:nonFraction unitRef="plaintiff" contextRef="ibf373b574e5c43eeb34e1e1ca9dc68c7_D20090301-20211231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTExNzc_4a5314b9-36a1-4b3c-b95b-969d40afd8af">805</ix:nonFraction> plaintiffs. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i58d4f95ec17a42b1a27bfd827f5f8a06_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEyMDc_0a607e64-3fe0-4fb4-a23c-ffeec88dea57">55</ix:nonFraction> of these lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i329ac6196728431792b5fc0adace7b76_D20090301-20211231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEyNDU_4426b4d5-750f-487f-aa5f-343863814733">285</ix:nonFraction> plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="ie857e2c012a4416d91e56a0f10db62fa_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEzNjA_d944c190-6334-4bdf-853f-79ef285eb040">515</ix:nonFraction> of the lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i95acadd05dab463fa98262e3b7d9a30c_D20090301-20211231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEzOTY_1a55c37d-ec8c-4b30-9887-fc80035cd98a">515</ix:nonFraction> plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. <ix:nonFraction unitRef="lawsuit" contextRef="i17f2181a9b6d4e6ab309b180381eac2c_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE1ODM_4e2545b6-a42e-4690-aa96-ff93a10ec563">Two</ix:nonFraction> lawsuits, representing approximately <ix:nonFraction unitRef="plaintiff" contextRef="i0d637cc5246347c6a23d9f91a36fba87_D20090301-20211231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE2MjQ_da21c8a3-e5d1-4655-b67f-28d5a5749f6b">two</ix:nonFraction> plaintiffs, have also been filed in various state courts. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i5f1eda23144b47d083c10338438ad3c5_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE3MDA_392887e7-0db4-43db-bf95-360232e78f3f">565</ix:nonFraction> of the lawsuits, involving approximately <ix:nonFraction unitRef="plaintiff" contextRef="i2521580e2ede416981af3b0b347ee8f3_D20090301-20211231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE3NDU_dad75603-2317-4eb7-b7f3-b9330e24cf2d">800</ix:nonFraction> plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while <ix:nonFraction unitRef="plaintiff" contextRef="i1e4899ed067c4d2c9996df4ef5abba7e_D20090301-20211231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE4OTY_05074537-e5ed-4d40-8ded-5eb160812c1a">six</ix:nonFraction> plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, <ix:nonFraction unitRef="plaintiff" contextRef="id09447c7b9f54599a8f05f81d771fab0_D20090301-20211231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE5Nzc_ff662206-89e8-472a-9c34-8fcb98632fd6">one</ix:nonFraction> case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="ic78be52744324235b791e091239d55c9_D20220131-20220131" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzM0MDg0ODYwNTY2MjIx_fb5e4486-7570-4c49-9584-09098ec8b627">311</ix:nonFraction> of the MDL lawsuits have been dismissed as of February 2022. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i506357620067488b978ab8ff85c80057_D20220131-20220131" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1NTg_aa14f161-e59b-45ff-898a-c38f4154a116">17</ix:nonFraction> of the state court lawsuits have been dismissed as of February 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately <ix:nonFraction unitRef="claimant" contextRef="iac210e833f7b4de39ab853cd87ad843d_I20211231" decimals="0" name="lly:LossContingencyNumberOfClaimants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTM0Nzc_d9c2d57b-8bda-4614-8c75-35abe2de30e4">20</ix:nonFraction> additional potential claimants who have not yet filed suit. These additional possible claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i0fe8d453b4a64bcd91db0e517126df58_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTM2ODE_8b9023d1-72f9-4e70-b32d-a02e674cd902">350</ix:nonFraction> Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal MDL in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The parties have reached agreement to resolve the majority of claims pending in the appeal and expect those claims to soon be dismissed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="ie428c3da402741de9dc989224e4a1931_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMTIyOTQ_be26d1ce-ec6d-428a-8266-4c37b8cbb3f2">5</ix:nonFraction> currently pending product liability lawsuits in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs' Fournier's gangrene. Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations and dismissals. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonFraction unitRef="site" contextRef="i3ce97af02d724dd5a6b2d83575df05d1_I20211231" decimals="0" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTU4MjY_876dbac7-8089-4ae1-907f-698d7332b88f">10</ix:nonFraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i25fe0a68fab147ac9c5b0bdd6003f349" continuedAt="i599c07047e1c4e3bb3c4dd41b3461297"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. We have filed a notice of appeal. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i599c07047e1c4e3bb3c4dd41b3461297" continuedAt="ie34ce93578c54df19c014f3b756937a3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several actions, including some with unspecified financial impact, consisting primarily of paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility for more than six months during the affected years and their children who were born during and after this period. We appealed this decision. In July 2018, the appeals court (TRT) generally affirmed the Labor Court's ruling, which included a liquidated award of&#160;<ix:nonFraction unitRef="brl" contextRef="i9f0a8d43e1354331a472dc5baeceebd0_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDAyNjc_a01c6e09-8ee5-47cc-8e05-c7d547a37993">300</ix:nonFraction>&#160;million&#160;Brazilian real. This <ix:nonFraction unitRef="brl" contextRef="i9f0a8d43e1354331a472dc5baeceebd0_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkxNzIxMTE_19fca540-d2b3-4a5a-8e39-82b8494e4497">300</ix:nonFraction>&#160;million Brazilian real liquidated award, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately <ix:nonFraction unitRef="brl" contextRef="iea9d1b8804f84d8d9335353484110e31_D20210930-20210930" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDA1MTY_6303eb99-a818-48d8-a952-b52784594d96">950</ix:nonFraction>&#160;million Brazilian real (approximately $<ix:nonFraction unitRef="usd" contextRef="iea9d1b8804f84d8d9335353484110e31_D20210930-20210930" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzM0MDg0ODYwNTY2MjI2_73cf9a6a-d156-4ff0-9b99-db8cdc591643">170</ix:nonFraction>&#160;million as of December 31, 2021). The TRT also restricted the broad health coverage awarded by the Labor Court to health problems that claimants could prove in a separate evidentiary proceeding arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Public Attorney (LPA) filed an application in the Labor Court for enforcement of the healthcare coverage granted by the TRT in its July 2018 ruling, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action for the LPA to identify and contact those individuals. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of <ix:nonFraction unitRef="brl" contextRef="i3712c098015042f9b63839407eed2efb_D20190701-20190731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1NjI_aefdf649-09d5-4454-9d6e-0f8e0143d9cf">500</ix:nonFraction>&#160;million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling. In June 2021, the court reduced the security deposit or lien to <ix:nonFraction unitRef="brl" contextRef="i4ec2ece19688425e9036c61b5348541e_D20210601-20210630" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1NzU_e8147d9a-5f95-4cfd-ba8b-8c3b25feccd5">100</ix:nonFraction>&#160;million Brazilian real and limited the scope of the initial order. ABL and LPA appealed to the TST, which appeal is currently still under review. In addition, in September 2020, the LPA initiated a second preliminary enforcement of the portion of the July 2018 TRT decision in the Labor Court that prohibits the exposure of workers to the contaminated areas. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s compliance with such portion of the July 2018 TRT decision. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in approximately <ix:nonFraction unitRef="lawsuit" contextRef="id79706b98b434731856afd46cac0b247_I20211231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1ODg_5aa0dd41-1627-458d-b8cf-91e1b11da8e6">25</ix:nonFraction> pending&#160;lawsuits filed in the Labor Court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in more than half of the lawsuits by the trial courts, of which, approximately half of those judgements are on appeal in the labor courts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We cooperated with this investigation. In July 2021 Lilly divested Cialis in China. We consider this matter closed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ie34ce93578c54df19c014f3b756937a3" continuedAt="i4115414e7c2d49c599369d49bd9d70e4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Municipality filed a motion to execute a purported judgment, and the CFI scheduled a hearing in March 2022 to consider the Municipality's motion. We have opposed the Municipality's motion. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. In October 2021 the parties filed cross motions for summary judgment. Trial is scheduled for April 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice's motion to dismiss the relator's second amended complaint. In January 2020, the relator appealed the District Court's dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit, and the relator did not petition the U.S. Supreme Court for certiorari.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="ie0eaa187336948399c69ed01819ea277_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDQ3OTI_3683b517-e837-4853-8658-7960b8e3ba44">two</ix:nonFraction> similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator appealed the state court's decision to the Appellate Division of the New Jersey Superior Court. In January 2022, the relator filed its appellate brief.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court has allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al., </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the U.S. District Court for the District of New Jersey dismissed the <ix:nonFraction unitRef="claim" contextRef="ieeabe64521a64f398e690da708946fca_D20210701-20210731" decimals="INF" name="lly:LitigationClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDc0ODg_3f6245ed-55ba-4b95-b11e-8520e4a9c026">three</ix:nonFraction> antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i4115414e7c2d49c599369d49bd9d70e4" continuedAt="i40c1e0889d0e40399e5907e2814240f0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. After removing the case to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In January 2022, the court granted the motion in part but has allowed the antitrust and conspiracy claims to proceed against us, Sanofi and Novo Nordisk. We, along with Sanofi and Novo Nordisk, have moved the court to reconsider its denial of our motion to dismiss the antitrust and conspiracy claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Mississippi Attorney General's Office (Mississippi AG) initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In response, the Mississippi AG filed a motion to amend its complaint, which the court granted. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received subpoenas from the New York and Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. In January 2022, the Michigan Attorney General filed against us in state court a petition seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the MCPA applies to the conduct it seeks to investigate and allows it to conduct the investigation. The state court granted the State's petition to investigate, authorizing the State to issue civil investigative subpoenas. The State's complaint for declaratory judgment remains pending.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a&#8239;request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members.&#8239;Those requests sought pricing and other commercial information regarding Lilly's insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i40c1e0889d0e40399e5907e2814240f0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. Both parties moved for summary judgment and hearing on the motions took place in August 2021. In October 2021, the Court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which are underway. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. A trial date has not been set.</span></div></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_160"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzE4OTk_da804a80-5dcd-46bc-94ef-137dda10c541" continuedAt="ida0c1cb3062a4e8b9b819452b8256093" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="ida0c1cb3062a4e8b9b819452b8256093" continuedAt="icaeff13f93bb4be5a3a2b7c471e782ed"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzE4ODI_c05aa02d-e779-4a4e-b556-6dbf0b1e24ca" continuedAt="i7ea3359c9d904b2a8db77791c2c02905" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:27.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c8b2889ec6e4963b72ebda5ec3e0226_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItMS0xLTEtMzYwOTg_89d5ea4b-a670-4c45-b4ce-9822278399b0">1,569.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70389d1a8dce4373ba9770278325d644_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItMy0xLTEtMzYwOTg_3d861009-6510-4702-a856-752a31b25db6">22.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7efe1f182bf74c749bcde3ee035a8288_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItNS0xLTEtMzYwOTg_7bd20753-53e7-4598-b724-cac03624d693">3,852.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21f70fcf53724eacba2dff838d3080f3_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItNy0xLTEtMzYwOTg_aaf7f33e-8c2b-45f7-9fd0-066d3b18827c">238.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51cd7b473ca14dc78773ea45b5740f8b_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItOS0xLTEtMzYwOTg_d7e69ecb-6f52-4126-9644-26eaaa62d71e">56.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0475e54cb8944cbbf6fd301a3970da7_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItMTEtMS0xLTM2MDk4_0fe1246c-435e-43d1-ad57-ed2eff44189d">5,740.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf8db92bbdad41589e45f909109c9432_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtMS0xLTEtMzYwOTg_4335e2b6-e4e6-4cd9-87f5-060144373f6a">46.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtMy0xLTEtMzYwOTg_7a349e99-4574-4cc7-9ca0-6ac490bea600">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc77c9789cc449891871245cbbdd250_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtNS0xLTEtMzYwOTg_c09651ac-85b9-4fc1-ac69-a8857c1697b2">967.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtNy0xLTEtMzYwOTg_f33e2495-5d57-498b-af84-eb15950908a0">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtOS0xLTEtMzYwOTg_56270258-521f-41e7-848d-7257b082e3e9">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtMTEtMS0xLTM2MDk4_7ed5675a-a286-467d-9889-f2b8b8ddf20d">997.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf8db92bbdad41589e45f909109c9432_D20190101-20191231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtMS0xLTEtMzYwOTg_8e114a35-de98-40f5-a61d-0510621c9cd1">62.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtMy0xLTEtMzYwOTg_0028dddd-c012-4d8a-b146-c37a8550469b">1.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc77c9789cc449891871245cbbdd250_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtNS0xLTEtMzYwOTg_88fad91a-9d14-46a6-a0a2-16d9e864d47b">181.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtNy0xLTEtMzYwOTg_dd32057a-57c9-42db-803b-ef4a1276a342">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtOS0xLTEtMzYwOTg_dd61bd78-0807-4533-8738-b4b43f6de7c4">84.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtMTEtMS0xLTM2MDk4_73788585-33bf-46fa-899f-5ced652c2dbe">214.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf8db92bbdad41589e45f909109c9432_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtMS0xLTEtMzYwOTg_3f5503fe-68f6-4576-a3b3-2943e903765d">108.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtMy0xLTEtMzYwOTg_b0ee3ece-d5b9-4797-b50d-72e10047c67c">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc77c9789cc449891871245cbbdd250_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtNS0xLTEtMzYwOTg_6884f5a6-cf28-465e-8321-8a18268b978e">785.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtNy0xLTEtMzYwOTg_3016ca42-222b-42b8-8933-70a99d50b861">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtOS0xLTEtMzYwOTg_9519c08c-5e1e-4361-a4e7-0f8f8e03de76">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtMTEtMS0xLTM2MDk4_3958cb9e-779c-46c4-9860-3ee78295edc0">783.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibda565e24c4e4030b83ae8ca958f008f_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTEtMS0xLTM2MDk4_cde4991d-c404-47b0-972d-ba4eac8cf854">1,678.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d1710cee29438bb4194f2e32033a79_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTMtMS0xLTM2MDk4_95d8d82b-63ea-48a0-8348-75726446be22">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7432a131a0fb49ff89baca4d230f866c_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTUtMS0xLTM2MDk4_30a61116-cce5-4b5a-bce7-f77bba39e332">4,638.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i900912a3de074ff99d6a423f98a6bd4c_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTctMS0xLTM2MDk4_163186da-cfb4-4cf7-87e7-f6d4e92d383d">211.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14978ed722694c18a3fc2706b4ca82f1_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTktMS0xLTM2MDk4_ef23ea69-ed40-4f23-bc65-b155c6e7c1b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i164180694aa747c791f72edab93ae1a7_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTExLTEtMS0zNjA5OA_13b66692-1f6d-4d08-9c47-d6bad2367ed3">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTEtMS0xLTM2MDk4_4bf29dd9-92b7-4eb3-aeeb-2f5e1e5e1947">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTMtMS0xLTM2MDk4_dd511929-19a3-4db1-9172-59f85dd68a57">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTUtMS0xLTM2MDk4_ccebb47c-2a90-4e0c-a02c-bf64ca29f865">379.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa4777312b864b708203b734b774366c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTctMS0xLTM2MDk4_33565d1d-0727-40d7-ba0a-3c6c92e7ab1d">133.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTktMS0xLTM2MDk4_cdd8aac7-0ea6-4875-81f5-5fa3de358294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTExLTEtMS0zNjA5OA_b98a3ed8-c4e5-4284-95b6-197dff102fc5">256.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTEtMS0xLTM2MDk4_810eb938-e3b7-4e72-b477-bf65edbf482c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTMtMS0xLTM2MDk4_3005d710-5d01-4ce6-a911-14d1ce2a22c1">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTUtMS0xLTM2MDk4_6b2f0391-ce3c-4530-a2c3-031d9d21659d">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4777312b864b708203b734b774366c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTctMS0xLTM2MDk4_63a745b7-1d37-4a71-82fe-7daa069f5148">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTktMS0xLTM2MDk4_6464e6ba-672e-469d-a9c9-b086931f7298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTExLTEtMS0zNjA5OA_5a00e84a-bd35-4c40-867b-fb8cc59d9ae0">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTEtMS0xLTM2MDk4_bd791633-e3c4-42ab-bff7-15608f9e19ca">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTMtMS0xLTM2MDk4_a1077a7c-59b0-485a-9a2f-a2d991610d28">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTUtMS0xLTM2MDk4_0a73f77e-6f83-48c8-8dd0-a269e0b8a61a">112.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa4777312b864b708203b734b774366c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTctMS0xLTM2MDk4_585634e9-767f-4954-b004-4b61ceecf41c">120.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTktMS0xLTM2MDk4_d7b6f328-5149-4e69-83cf-ab1c3edcfed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTExLTEtMS0zNjA5OA_750256c2-910e-44d7-aa6a-4908478382ab">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37c0f201926f4948bca2dbe17676cc5e_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTEtMS0xLTM2MDk4_a1b5b356-c366-40fc-9dc8-2684773d3aa1">1,427.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c0eb69cf624cc4b293df7b97c976e7_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTMtMS0xLTM2MDk4_7013e4f1-e63a-4e40-9e96-8bcd3cee6a48">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f6183f5a5c9455dbf2c516793377cd0_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTUtMS0xLTM2MDk4_237b13f9-c9ad-48fd-b75e-8ee36c701d90">4,751.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01c9273e754e42ff817a718c1ba70d7d_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTctMS0xLTM2MDk4_a859c593-7aa8-4cd9-9f61-0ddd7921f9fa">332.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic435e2ecf0a9408aaba2f2109d4c1db2_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTktMS0xLTM2MDk4_67b3f177-5d9f-498c-b539-f4e72fdd70ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf58fefc745a46b9862d5a41ca2b485c_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTExLTEtMS0zNjA5OA_2360e988-8524-4279-884f-23a853537c9f">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTEtMS0xLTM2MDk4_db0e7d93-d122-4bcc-ac19-bc964883dbf6">122.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554c64bad97a42be803841abd88811cc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTMtMS0xLTM2MDk4_dfec490c-e468-4348-93b8-6688041fae7b">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTUtMS0xLTM2MDk4_a8e26748-5537-4a90-ae72-f6e47d1d3dfe">1,823.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTctMS0xLTM2MDk4_3eb75af2-9a7d-4f05-9a28-f29fb93091db">106.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie990d35793244c81978b349a80a82099_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTktMS0xLTM2MDk4_3a7866d3-21c5-4e16-9209-a35e56d7353a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTExLTEtMS0zNjA5OA_69baf817-8bf4-4de0-8bef-967801528b19">1,795.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTEtMS0xLTM2MDk4_e02e43b7-3b8e-4d41-8fd7-62ef8d898a70">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554c64bad97a42be803841abd88811cc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTMtMS0xLTM2MDk4_bc408ba5-3833-46cf-bc7b-97d300c95a2f">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTUtMS0xLTM2MDk4_2e09da88-5b13-4a2f-be97-af46dab6214c">344.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTctMS0xLTM2MDk4_cecdc01e-459b-40b6-bf4a-744014ef0cac">13.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie990d35793244c81978b349a80a82099_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTktMS0xLTM2MDk4_b05fcc83-9c69-43fe-b441-61943e01998d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTExLTEtMS0zNjA5OA_f51f6160-1285-4512-bef6-3675f20f344e">357.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTEtMS0xLTM2MDk4_8919e73a-2ecd-4070-bd2e-32547309d280">122.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554c64bad97a42be803841abd88811cc_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTMtMS0xLTM2MDk4_1401922a-d1ff-4f4b-8d0e-7c9ba472a2bf">11.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTUtMS0xLTM2MDk4_9d3d34f8-1bdb-4de5-960c-4d52961f7259">2,167.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTctMS0xLTM2MDk4_7f35b6dd-c7b4-4fbd-9b07-d9ae6007e344">119.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie990d35793244c81978b349a80a82099_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTktMS0xLTM2MDk4_778a06fe-da07-4ad5-8531-633439de2da1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTExLTEtMS0zNjA5OA_434a59c8-bcb8-43cd-a7b2-b3295678216a">2,153.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2021</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9bf6f4a94b544a686ef51fbf1c8c304_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTEtMS0xLTM2MDk4_de655eba-3ff8-4dc7-971d-d05e853a3271">1,550.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2772b8591a3a435d806d664e42747e10_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTMtMS0xLTM2MDk4_843741ba-a24f-4890-911f-7fa46c074f16">3.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18d0b0c520347f3b7f49fd16cebe265_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTUtMS0xLTM2MDk4_d0ae0deb-58e5-4bee-90b1-190759f8de98">2,583.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d26295f837471e92a911cbfa5f09ef_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTctMS0xLTM2MDk4_8efb05e2-25fb-4155-a5a8-cd235b7feb2b">213.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7a7a2ccbdd490e9438393be18ea12f_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTktMS0xLTM2MDk4_136e8e8e-45c7-4408-8577-26de3fe8fea5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if33da3a3872a4c1a8a126e0502034dad_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTExLTEtMS0zNjA5OA_13db9d2c-1bd2-4220-b7bb-f504982f9f5e">4,343.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of January 1, 2019 consists of $<ix:nonFraction unitRef="usd" contextRef="i1f786d93b75241c98d9db2267b3c5983_I20181231" decimals="-7" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzExNTQ0ODcyMDk1MzI2_37a700a6-07e8-45f7-8b82-657ad48dc874">5.73</ix:nonFraction> billion of accumulated other comprehensive loss attributable to controlling interest and $<ix:nonFraction unitRef="usd" contextRef="ibebbd5414c314196b2e7f72291cfad2b_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzExNTQ0ODcyMDk1NDEx_1ce5aff9-fdcd-4909-bab7-330c24ffc0fc">11.0</ix:nonFraction> million of accumulated other comprehensive loss attributable to noncontrolling interest.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="icaeff13f93bb4be5a3a2b7c471e782ed"><ix:continuation id="i7ea3359c9d904b2a8db77791c2c02905"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i456c6ad8d4564976aef8554ffb59ccb7_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzEtMS0xLTEtMzYwOTg_be5b08db-bbdb-459a-ae9f-e04fdb6adb14">136.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4452a2c88c941349af1c9b68847bcb5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzEtMy0xLTEtMzYwOTg_334d0eaa-5a46-41cd-8474-44192a0b9006">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36b8a5e3c0f84e68afcd481209c5d2e3_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzEtNS0xLTEtMzYwOTg_ddbb755e-14f9-40c3-8026-a611e67e5283">18.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65892dc9a2954d38b4ead8cdfcd6ba81_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzItMS0xLTEtMzYwOTg_89d4ecac-8495-4665-a282-5859a4d9a4fc">4.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8d96de74d5a4264aaa3443af2d2593f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzItMy0xLTEtMzYwOTg_9c4082a0-c0ed-4337-9d25-a2a725840ba1">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dd3bf1571cf4ded9e6e79654afd40d3_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzItNS0xLTEtMzYwOTg_8f05a48f-81e0-4bac-b139-549275cd32fa">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6958d74700da422a8372afeee6138499_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzMtMS0xLTEtMzYwOTg_2b514b6c-b9e1-49b9-8fc7-64c17041d1ad">532.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb264b12ab0a49edae53a6a459216f4d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzMtMy0xLTEtMzYwOTg_754c4f85-c151-486f-8085-fcc5acb426de">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabad7b42145343838527d4f8737a08dc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzMtNS0xLTEtMzYwOTg_3cbc818e-d88b-4f0d-94ad-5a02e3c44cf2">184.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie225690e6f6c43e7bf1510e4c46c7696_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzQtMS0xLTEtMzYwOTg_dbd0cfce-dcca-4354-b877-939858f76495">31.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8379681ef59448d18a9ce97f8241d61a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzQtMy0xLTEtMzYwOTg_f2242124-bd8a-4048-9801-b0aab0bafd1f">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4cdbdd02bc04cdf82cfd0ecb1e7506a_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzQtNS0xLTEtMzYwOTg_08d1effe-bed9-425f-ba9b-8ac9e806354c">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzUtMS0xLTEtMzYwOTg_d621cf52-12d5-46ba-a384-46c72f373721">695.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzUtMy0xLTEtMzYwOTg_4450cddf-1ea0-44d9-847c-0b20bab64f0e">200.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzUtNS0xLTEtMzYwOTg_58c9a1e4-d96d-45a8-9715-36bec05fa402">151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzE4NzY_04601b34-7e7f-40f6-83d8-931f05cd8a15" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.230%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc4e3d75ed7a447f964c2076c2654b6d_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzMtMS0xLTEtMzYwOTg_0473b02c-cb02-4658-9b0b-86d7d3a70fa1">55.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bd38897fbf84ba6886a357f48aa2eaf_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzMtMy0xLTEtMzYwOTg_bd79a613-80c7-481c-be69-70ff5445461d">55.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08bfe6219e8843de84f18681cf0d0cbf_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzMtNS0xLTEtMzYwOTg_029a001d-c561-4d3f-b1f6-1608c3c55af3">56.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080cb1f6c4c54fada36e6a66c670db4b_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzQtMS0xLTEtMzYwOTg_b2307f63-a385-40c9-bab0-844995f00857">490.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf4d129e0b547c78a08a57ac046797d_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzQtMy0xLTEtMzYwOTg_592636ed-5767-4a06-95c3-d5f3103e9890">393.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa4547d667b4859a0ef3510f8201e3d_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzQtNS0xLTEtMzYwOTg_7e3646c7-65c2-459e-abe0-3d11c308453d">286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzUtMS0xLTEtMzYwOTg_5f88a3d9-7a4b-44b0-a1a7-e1f41d24df65">435.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzUtMy0xLTEtMzYwOTg_231225d0-9bc0-461c-9b99-fdbd15d5e442">338.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzUtNS0xLTEtMzYwOTg_69be177b-ec26-4932-9771-47dfa6670621">230.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzYtMS0xLTEtMzYwOTg_2cc14482-bbc9-4f08-8c31-8a3d29255b5f">91.5</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzYtMy0xLTEtMzYwOTg_fffe095b-b0cf-4f15-83a8-b79cfb97f5de">71.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzYtNS0xLTEtMzYwOTg_48dff71c-4dc0-4a11-9eba-9acb3317e296">48.3</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzctMS0xLTEtMzYwOTg_60b3c03a-35ea-4a37-abda-03333176c2f3">344.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzctMy0xLTEtMzYwOTg_bade88b4-54c2-4ab5-9c35-a7ec6d37c3d6">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzctNS0xLTEtMzYwOTg_e8a77cea-eb1e-49ee-93cc-28d4791b69c2">181.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16a788a1f3b4a209b13227afbf2188f_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzktMS0xLTEtMzYwOTg_259952c5-1ad1-4ca2-889e-d083dc03f8dd">13.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4726fae6a954ef28f20a75d12754243_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzktMy0xLTEtMzYwOTg_72450186-991c-41f8-912d-851deb73d9e2">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00e2a870edf2467790f0a84a2d627f6c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzktNS0xLTEtMzYwOTg_11bdb294-9f73-4f43-ac77-6c8b0ce98282">51.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from continuing operations (net of tax)</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEwLTEtMS0xLTM2MDk4_a800cc02-b75b-4739-ab79-bd84d694196d">357.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc78576f75247428a588a52665c4852_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEwLTMtMS0xLTM2MDk4_c9696a0f-16d2-4220-8091-499ebbfae193">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEwLTUtMS0xLTM2MDk4_84fb4ffa-584e-4276-8a63-704661430a56">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from discontinued operations (net of tax)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzExLTEtMS0xLTM2MDk4_50009ac5-743f-4c06-9835-97c699342c39">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc78576f75247428a588a52665c4852_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzExLTMtMS0xLTM2MDk4_4d5fefb3-fc82-4367-b4ee-ad18a765d2ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzExLTUtMS0xLTM2MDk4_6861822b-57fb-4982-beff-06e54c4958d6">84.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEyLTEtMS0xLTM2MDk4_aa1f82fd-b7aa-43d8-b14b-d90f17300824">357.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc78576f75247428a588a52665c4852_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEyLTMtMS0xLTM2MDk4_9751806f-c1d8-4f98-8a90-b89dcc48a8e6">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEyLTUtMS0xLTM2MDk4_d5ba3917-13bf-4ece-9b27-2281e314b631">214.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">109</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90ZXh0cmVnaW9uOmI0NGRkMWQwNmU3MTRlNTdiOTQ4MWJjMWViZjBkYjQxXzIxOQ_ea8f1ef5-23f8-4892-9020-b4f152a89ab2" continuedAt="i466d769cc3c848c8b477c658ace760db" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="i466d769cc3c848c8b477c658ace760db"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90ZXh0cmVnaW9uOmI0NGRkMWQwNmU3MTRlNTdiOTQ4MWJjMWViZjBkYjQxXzIwNw_f6f4a18e-4c5e-4faa-b833-cc5470847d22" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzEtMS0xLTEtMzYwOTg_37eecc54-193c-421b-98ad-22cb6d977e47">339.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzEtMy0xLTEtMzYwOTg_8679b273-6596-4d85-beaa-1bbe7e4ad101">359.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzEtNS0xLTEtMzYwOTg_ca5826d4-beb9-468f-9425-e75db2ae4de6">400.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzItMS0xLTEtMzYwOTg_b0b95ec6-0bc9-4751-be0f-0d7e2ab00e7e">25.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzItMy0xLTEtMzYwOTg_6d875a20-5785-4e7c-8fdf-3b78349422e3">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzItNS0xLTEtMzYwOTg_2335815c-1b93-4bc0-85a4-fd8b85b773f6">80.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities (Note 7)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMS0xLTEtNzU3MDc_ba7e0edb-2560-408f-9b7f-ca79e4f4f96e">176.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMy0xLTEtNzU3MTU_e6017fda-589b-419a-80f1-e6c0738698fb">1,442.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtNS0xLTEtNzU3MzA_13c385b4-bf14-48d3-b4c6-3df52c56af0e">401.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMS0xLTEtMzYwOTg_620c4674-8b28-4863-a457-bafe552d4a96">405.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMy0xLTEtMzYwOTg_a765142e-7e87-425d-98ff-0c344acc0557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtNS0xLTEtMzYwOTg_6b9a9526-1075-4d24-a1d3-8964182f2452">252.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzQtMS0xLTEtMzYwOTg_7e09c815-e03a-4ca6-a38a-390a2c972b74">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzQtMy0xLTEtMzYwOTg_c216a0c4-495e-4562-8b5c-7c6f5fe940c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzQtNS0xLTEtMzYwOTg_e9dacabc-f982-41c2-9c35-562bae272c1c">309.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzUtMS0xLTEtMzYwOTg_8243d020-4979-425e-8877-6d22abdf6240">289.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzUtMy0xLTEtMzYwOTg_4565bce9-88f2-4157-993f-fea6921051ee">251.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzUtNS0xLTEtMzYwOTg_b779bc59-9e3f-431f-8b81-e080c8ca2f90">209.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzYtMS0xLTEtMzYwOTg_1308f31b-af45-4828-ba64-4eb6c395ca1d">51.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzYtMy0xLTEtMzYwOTg_ccadd16a-1579-4f8f-b080-cad33280a9ac">195.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzYtNS0xLTEtMzYwOTg_9d44c76f-e2a9-420f-a91c-44acc3bc3355">56.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzctMS0xLTEtMzYwOTg_447f60e9-b220-43c6-9a03-389f0840e31f">201.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzctMy0xLTEtMzYwOTg_c5239c9b-1417-487b-8f34-6b2798b76963">1,171.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzctNS0xLTEtMzYwOTg_581e0f83-ab21-47f3-a6bf-3baf6144a41b">291.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1a85401413cf428bb86d28ee6b337a59_166"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19:&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzI3MjE_24766237-c122-43c7-a092-3023195d622f" continuedAt="i41d1f72840a148e08719203df16dd1d6" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="i41d1f72840a148e08719203df16dd1d6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining <ix:nonFraction unitRef="number" contextRef="ie9ba1030bd04458783b9caf2f17c3b41_I20190311" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzEwNjA_1691d321-fc2e-4a17-a8a7-fd4a80887a23">80.2</ix:nonFraction> percent ownership of Elanco common stock through a tax-free exchange offer. The earnings attributable to the divested, noncontrolling interest for the period from the initial public offering until disposition were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the disposition, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $<ix:nonFraction unitRef="usd" contextRef="iccb9aa249e034756b9c8db5d7fecdf51_D20190101-20190331" decimals="-8" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzE0NDQ_0d7d9a69-73aa-4bc4-bb77-3afc72a0de52">3.7</ix:nonFraction> billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated financial statements for all periods presented. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and net income from discontinued operations in 2019 was $<ix:nonFraction unitRef="usd" contextRef="iecabf182d17143a49900323bf9cdddde_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzM0MDg0ODYwNDY3MzYx_4d29cd5d-455b-43d5-9bfb-00f9f9c52b44">580.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iecabf182d17143a49900323bf9cdddde_D20190101-20191231" decimals="-7" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzcxNDY4MjU1ODY5MjA_8f2606fd-a660-463a-a40a-3bf9416c727b">3.68</ix:nonFraction>&#160;billion, respectively. There were no discontinued operations in 2020 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain related to the disposition of Elanco in the consolidated statement of cash flows includes the operating results of Elanco through the disposition date, which were not material. Net cash flows of our discontinued operations for operating and investing activities were not material for the year ended December 31, 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a transitional services agreement (TSA) with Elanco to facilitate the orderly transfer of various services to Elanco. The TSA related primarily to administrative services, which were generally provided over <ix:nonNumeric contextRef="i5c2697f3892040f38f4824aa3f7f6f6a_D20190311-20190311" name="lly:DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzI1MjM_1e26420d-94fd-45a0-89bc-6e531baa8065">24</ix:nonNumeric> months from the date of disposition, and is now complete. This agreement was not material and did not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">110</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Management's Reports</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report for Financial Statements&#8212;Eli Lilly and Company and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Eli Lilly and Company and subsidiaries is responsible for the accuracy, integrity, and fair presentation of the financial statements. The statements have been prepared in accordance with generally accepted accounting principles in the United States and include amounts based on judgments and estimates by management. In management's opinion, the consolidated financial statements present fairly our financial position, results of operations, and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the system of internal accounting controls, we maintain a code of conduct (known as "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that applies to all employees worldwide, requiring proper overall business conduct, avoidance of conflicts of interest, compliance with laws, and confidentiality of proprietary information. All employees must take training annually on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are required to report suspected violations. A hotline number is available on our lilly.com website and on the internal LillyNow website to enable reporting of suspected violations anonymously. Employees who report suspected violations are protected from discrimination or retaliation by the company. In addition to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the chief executive officer and all financial management must sign a financial code of ethics, which further reinforces their ethical and fiduciary responsibilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm (PCAOB ID: <ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNzIvZnJhZzozYmUyNmQyYTZhZjI0OTM4OTk2YTI4ZmU4YTMyM2E0YS90ZXh0cmVnaW9uOjNiZTI2ZDJhNmFmMjQ5Mzg5OTZhMjhmZThhMzIzYTRhXzcxNDY4MjU1ODY1OTU_4bbf845c-fd05-4278-ae30-6dbc19b91f1e">42</ix:nonNumeric>). Their responsibility is to examine our consolidated financial statements in accordance with generally accepted auditing standards of the Public Company Accounting Oversight Board (United&#160;States). Ernst&#160;&amp; Young's opinion with respect to the fairness of the presentation of the statements is included in Item&#160;8 of our Annual Report on Form 10-K. Ernst&#160;&amp; Young reports directly to the audit committee of the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee includes six nonemployee members of the board of directors, all of whom are independent from our company. The committee charter, which is available on our website, outlines the members' roles and responsibilities. It is the audit committee's responsibility to appoint an independent registered public accounting firm subject to shareholder ratification, pre-approve both audit and non-audit services performed by the independent registered public accounting firm, and review the reports submitted by the firm. The audit committee meets several times during the year with management, the internal auditors, and the independent public accounting firm to discuss audit activities, internal controls, and financial reporting matters, including reviews of our externally published financial results. The internal auditors and the independent registered public accounting firm have full and free access to the committee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established. We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate. Our culture demands integrity and an unyielding commitment to strong internal practices and policies. Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities, operate under a code of conduct and are subject to the highest level of ethical standards.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting&#8212;Eli Lilly and Company and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Eli Lilly and Company and subsidiaries is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. We have global financial policies that govern critical areas, including internal controls, financial accounting and reporting, fiduciary accountability, and safeguarding of corporate assets. Our internal accounting control systems are designed to provide reasonable assurance that assets are safeguarded, that transactions are executed in accordance with management's authorization and are properly recorded, and that accounting records are adequate for preparation of financial statements and other financial information. A staff of internal auditors regularly monitors, on a worldwide basis, the adequacy and effectiveness of internal accounting controls. The general auditor reports directly to the audit committee of the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in "Internal Control&#8212;Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our evaluation under this framework, we concluded that our internal control over financial reporting was effective as of December&#160;31, 2021. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of internal control over financial reporting as of December&#160;31, 2021 has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report, which appears herein. Their responsibility is to evaluate whether internal control over financial reporting was designed and operating effectively.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.919%"><tr><td style="width:1.0%"></td><td style="width:48.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President&#160;and Chief Financial Officer</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">112</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:0.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Eli Lilly and Company</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Eli Lilly and Company and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 23, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Medicaid, Managed Care, and Medicare sales rebate accruals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As described in Note 2 to the consolidated financial statements under the caption "Net Product Revenue," the Company establishes provisions for sales rebate and discounts in the same period as the related sales occur. At December 31, 2021 the Company had $6,845.8 million in sales rebate and discount accruals. A large portion of these accruals are rebates associated with sales in the United States for which payment for purchase of the product is covered by Medicaid, Managed Care, and Medicare. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the Medicaid, Managed Care, and Medicare sales rebate and discount liabilities is challenging because of the subjectivity of certain assumptions required to estimate the rebate liabilities. In calculating the appropriate accrual amount, the Company considers historical Medicaid, Managed Care, and Medicare rebate payments by product as a percentage of their historical sales as well as any significant changes in sales trends, the lag in payment timing, an evaluation of the current Medicaid and Medicare laws and interpretations, the percentage of products that are sold via Medicaid, Managed Care, and Medicare, and product pricing. For Medicaid, there is significant complexity associated with calculating the legislated Medicaid rebates. Management utilizes employees with legislative experience and knowledge in developing assumptions used to calculate Medicaid rebates. Similarly, for Managed Care and Medicare, given variability in prescription drug costs, continued historical year over year increases in enrollees and variability in prescription data, historical rebate information may not be predictive for management to estimate the rebate accrual and thus, management supplements its historical data analysis with qualitative adjustments based upon current utilization.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We tested the Company's controls addressing the identified risks of material misstatement related to the valuation of the sales rebate and discount liabilities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This included testing controls over management's review of the significant assumptions used to calculate the Medicaid, Managed Care, and Medicare rebate liabilities, including the significant assumptions discussed above.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This testing also included management's control to compare actual activity to forecasted activity and controls to ensure the data used to evaluate the significant assumptions was complete and accurate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures included, among others, evaluating for reasonableness the significant assumptions in light of economic trends, product profiles, and other regulatory factors. Our testing involved assessing the historical accuracy of management's estimates by comparing actual activity to previous estimates and performing analytical procedures, based on internal and external data sources, to evaluate the completeness of the reserves. Additionally, our procedures included reviewing a sample of contracts, testing a sample of rebate payments and testing the underlying data used in management's evaluation. For Medicaid, we involved our professionals with an understanding of the statutory reimbursement requirements to assess the consistency of the Company's calculation methodologies with the applicable government regulations and policy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Medicare we evaluated the reasonableness of assumptions made by management in estimating the Medicare coverage gap liability.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Retirement Benefits - Valuation of Alternative Investments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As described in Note 15 to the consolidated financial statements under the caption "Benefit Plan Investments," the Company's benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. At December 31, 2021 the Company had $19,777.4 million in plan assets related to the defined benefit pension plans and retiree health benefit plans. Approximately 38 percent of the total pension and retiree health assets are in hedge funds and private equity-like investment funds ("alternative investments"). These alternative investments are valued using significant unobservable inputs or are valued at net asset value (NAV) reported by the counterparty, adjusted as necessary.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the fair value of these alternative investments is challenging because of the higher estimation uncertainty of the inputs to the fair value calculations, including the underlying net asset values ("NAVs"), discounted cash flow valuations, comparable market valuations, and adjustments for currency, credit, liquidity and other risks. Additionally, certain information regarding the fair value of these alternative investments is based on unaudited information available to management at the time of valuation. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We tested the Company's controls addressing the risks of material misstatement relating to valuation of alternative investments. This included testing management's review controls over alternative investment valuation, which included a comparison of returns to benchmarks and in-person or telephonic meetings with investment firms to discuss valuation policies and procedures, as well as portfolio performance. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures included, among others, comparing fund returns to selected relevant benchmarks and understanding variations, obtaining the latest audited financial statements and comparing to the Company's estimated fair values and reconciling any differences. We also inquired of management about changes to the investment portfolio and/or related investment strategies and considerations. We assessed the historical accuracy of management's estimates by comparing actual activity to previous estimates. We evaluated for contrary evidence by confirming the fair value of the investments and ownership interest directly with the trustees and a sample of managers at year end. </span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNzUvZnJhZzplN2FlZmM4ZjNlYzg0OWYzYmVkODQ2NjhjY2U3ODI3Zi90ZXh0cmVnaW9uOmU3YWVmYzhmM2VjODQ5ZjNiZWQ4NDY2OGNjZTc4MjdmXzI3NDg3NzkwNzMyNzY_5e14dc20-90b0-4e64-954b-d1011961c4e1">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 1940. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNzUvZnJhZzplN2FlZmM4ZjNlYzg0OWYzYmVkODQ2NjhjY2U3ODI3Zi90ZXh0cmVnaW9uOmU3YWVmYzhmM2VjODQ5ZjNiZWQ4NDY2OGNjZTc4MjdmXzI3NDg3NzkwNzMxMjM_4833119c-2c6f-4285-9ff5-675c20a4e0b2">Indianapolis, Indiana</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">115</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_178"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Eli Lilly and Company</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited Eli Lilly and Company and subsidiaries' internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Eli Lilly and Company and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 23, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.549%"><tr><td style="width:1.0%"></td><td style="width:75.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ernst &amp; Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">117</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_184"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's "disclosure controls and procedures," which are defined generally as controls and other procedures designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form&#160;10-K) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December&#160;31, 2021, and concluded that they were effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Ricks and Ms.&#160;Ashkenazi provided a report on behalf of management on our internal control over financial reporting, in which management concluded that the company's internal control over financial reporting is effective at December&#160;31, 2021 based on the framework in "Internal Control&#8212;Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. Due to the inherent limitations, no evaluation over internal control can provide absolute assurance that no material misstatements or fraud exist. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Ernst&#160;&amp; Young LLP, the company's independent registered public accounting firm, issued an attestation report on the company's internal control over financial reporting as of December&#160;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can find the full text of management's report and Ernst&#160;&amp; Young's attestation report in Item&#160;8.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_187"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_1934"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">118</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_190"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part&#160;III</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_193"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors and Executive Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our board of directors is found in our Definitive Proxy Statement, to be dated on or about March&#160;18, 2022 (Proxy Statement), under "Governance - Board Operations and Governance" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our executive officers is found at Item 1, "Business - Executive Officers of the Company" and is incorporated by reference herein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our code of ethics is found in our Proxy Statement under "Governance - Board Oversight of Strategy, Compliance, and Risk Management - Code of Ethics" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the procedures by which shareholders can recommend nominees to our board of directors is found in our Proxy Statement under "Shareholder Engagement on Governance Issues - Shareholder Recommendations and Nominations for Director Candidates" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has appointed an audit committee consisting entirely of independent directors in accordance with applicable Securities and Exchange Commission and New York Stock Exchange requirements for audit committees. Information about our audit committee is found in our Proxy Statement under "Governance - Membership and Meetings of the Board and Its Committees - Audit Committee" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_196"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Executive Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on director compensation, executive compensation, and compensation committee matters can be found in the Proxy Statement under "Governance - Director Compensation," "- Membership and Meetings of the Board and Its Committees - Compensation Committee," "Compensation - Compensation Discussion and Analysis," and "- Executive Compensation." Such information is incorporated in this Annual Report on Form 10-K by reference. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">119</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_199"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to ownership of the company's common stock by management and by persons known by the company to be the beneficial owners of more than five percent of the outstanding shares of common stock is found in the Proxy Statement under "Ownership of Company Stock" and incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information as of December&#160;31, 2021 regarding the company's compensation plans under which shares of the company's common stock have been authorized for issuance.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a) Number of securities to be issued upon exercise of outstanding options, warrants, and rights </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b) Weighted-average exercise price of outstanding options, warrants, and rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 19pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,646,706&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plan not approved by security holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,646,706&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 5,605,694 shares are underlying outstanding equity awards other than options.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_205"></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Person Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the policies and procedures for approval of related person transactions by our board of directors can be found in the Proxy Statement under "Governance - Highlights of the Company's Corporate Governance - Conflicts of Interest and Transactions with Related Persons." Such information is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to director independence can be found in the Proxy Statement under "Governance - Director Independence" and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_208"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Principal Accountant Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the fees and services of our principal independent accountants, Ernst &amp; Young LLP, can be found in the Proxy Statement under "Audit Matters - Item 3. Ratification of the Appointment of the Independent Auditor - Audit Committee Report - Services Performed by the Independent Auditor" and "- Independent Auditor Fees." Such information is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">120</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_211"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Exhibits and Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statements of the company and its subsidiaries are found at Item&#160;8:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Operations&#8212;Years Ended December&#160;31, 2021, 2020, and 2019 </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Comprehensive Income (Loss)&#8212;Years Ended December&#160;31, 2021, 2020, and 2019</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Balance Sheets&#8212;December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Shareholders' Equity&#8212;Years Ended December&#160;31, 2021, 2020, and 2019</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Cash Flows&#8212;Years Ended December&#160;31, 2021, 2020, and 2019</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Notes to Consolidated Financial Statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statement schedules of the company and its subsidiaries have been omitted because they are not required, are inapplicable, or are adequately explained in the financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements of interests of 50&#160;percent or less, which are accounted for by the equity method, have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a significant subsidiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)3.&#160;&#160;&#160;&#160;Exhibits</span></div><div id="i1a85401413cf428bb86d28ee6b337a59_217"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Location</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Amended Articles of Incorporation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013 </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521359144/d246572dex31.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521359144/d246572dex31.htm">Bylaws, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521359144/d246572dex31.htm">Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 16, 2021 </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor trustee to Citibank, N.A., as Trustee</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">Incorporated by reference to Exhibit 4.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">s Registration Statement on Form S-3, Registration No. 333-186979</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed in Exhibit 4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">Incorporated by reference to Exhibit 4.2 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">s Annual Report on Form 10-K for the year ended December 31, 2008</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">Description of the Company's Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">Incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">Description of the Company's 1.000% Notes due 2022, 1.625% Notes due 2026, and 2.125% Notes due 2030</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">Incorporated by reference to Exhibit 4.4 to the  Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">Description of the Company's 6.77% Notes due 2036</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">Incorporated by reference to Exhibit 4.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">Description of the Company's 7 1/8% Notes due 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">Incorporated by reference to Exhibit 4.6 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">Description of the Company's 0.625% Notes due 2031 and 1.700% Notes due 2049</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">Incorporated by reference to Exhibit 4.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit48.htm">4.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit48.htm">Description of the Company's 0.500% Notes due 2033, 1.125% Notes due 2051, and 1.375% Notes due 2061</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit48.htm">Attached </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit49.htm">4.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit49.htm">Description of the Company's 1.625% Notes due 2043</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit49.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">Amended and Restated 2002 Lilly Stock Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">Incorporated by reference to Exhibit 10.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit102.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit102.htm">Form of Performance Award under the 2002 Lilly Stock Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit102.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit103.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit103.htm">Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit103.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit104.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit104.htm">Form of Performance Award under the 2002 Lilly Stock Plan (non-executive officer)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit104.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit105.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit105.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit105.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit106.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit106.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit106.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit107.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit107.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (non-executive officer)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit107.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit108.htm">10.8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit108.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit108.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit109.htm">10.9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit109.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit109.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1010.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lly-20211231x10kexhibit1010.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan (non-executive)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:112%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1010.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1011.htm">10.11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="lly-20211231x10kexhibit1011.htm">Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:112%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1011.htm">Attached </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit101.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit101.htm">Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan (with non-compete)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:112%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit101.htm">Incorporated by reference to Exhibit 10.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit101.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit101.htm">s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit102.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit102.htm">Release Agreement, effective as of February 9, 2021, by and between Eli Lilly and Company and Joshua L. Smiley</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:115%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit102.htm">Incorporated by reference to Exhibit 10.2 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit102.htm">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000122/lly-3312021x10qxexhibit102.htm">s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">The Lilly Deferred Compensation Plan, as amended</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">Incorporated by reference to Exhibit 10.5 to the Company's annual report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">The Lilly Directors' Deferral Plan, as amended</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">Incorporated by reference to Exhibit 10 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1014.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1014.htm">The Eli Lilly and Company Bonus Plan, as amended</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1014.htm">Incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1017.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1017.htm">The Loxo Oncology, Inc. Bonus Plan</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1017.htm">(1)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit1017.htm">Attached </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1015.htm">10.18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1015.htm">2007 Change in Control Severance Pay Plan for Select Employees, as amended</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231x10kexhibit1015.htm">Incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit21.htm">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit21.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit21.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit23.htm">23</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit23.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit23.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit311.htm">Rule 13a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit311.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit312.htm">Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit312.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit32.htm">32</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit32.htm">Section 1350 Certification</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20211231x10kexhibit32.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attached</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attached</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i1a85401413cf428bb86d28ee6b337a59_214"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 16.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Form 10-K Summary</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">123</span></div></div></div><div id="i1a85401413cf428bb86d28ee6b337a59_220"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.185%"><tr><td style="width:1.0%"></td><td style="width:5.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;David A. Ricks</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">David A. Ricks</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President,&#160;and&#160;Chief&#160;Executive&#160;Officer</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2022 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February&#160;23, 2022 by the following persons on behalf of the Registrant and in the capacities indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:50.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;David A. Ricks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer (principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DAVID A. RICKS</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Anat Ashkenazi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (principal financial officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANAT ASHKENAZI</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Donald A. Zakrowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer (principal accounting officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DONALD A. ZAKROWSKI</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ralph Alvarez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RALPH ALVAREZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Katherine Baicker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHERINE BAICKER, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael L. Eskew</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MICHAEL L. ESKEW</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. Erik Fyrwald</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. ERIK FYRWALD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jamere Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAMERE JACKSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Kimberly H. Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIMBERLY H. JOHNSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;William G. Kaelin, Jr., M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WILLIAM G. KAELIN, JR., M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Juan R. Luciano</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUAN R. LUCIANO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Marschall S. Runge, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARSCHALL S. RUNGE, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; Gabrielle Sulzberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GABRIELLE SULZBERGER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jackson P. Tai</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JACKSON P. TAI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Karen Walker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAREN WALKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks Used In This Report</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this report, appear with an initial capital and are followed by the symbol </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actos</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Takeda Pharmaceutical Company Limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Byetta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Amylin Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of Boehringer Ingelheim International GmbH.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Innovent Biologics (Suzhou) Co., Ltd. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viagra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of G.D. Searle LLC, a Viatris Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">126</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>lly-20211231x10kexhibit48.htm
<DESCRIPTION>EX-4.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if9bdaec5ee0240f189c4c5902ed172a5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.8 Description of the Company&#8217;s 0.500% notes due 2033, 1.125% notes due 2051 and 1.375% notes due 2061</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following summary of Eli Lilly and Company&#8217;s above referenced debt securities is based on and qualified by the indenture, dated as of February 1, 1991, between us and Deutsche Bank Trust Company Americas (as successor to Citibank, N.A.), as trustee, and the forms of 0.500% notes due September 2033 (the &#8220;0.500% notes&#8221;), the 1.125% notes due September 2051 (the &#8220;1.125% notes&#8221;) and the 1.375% notes due September 2061 (the &#8220;1.375% notes,&#8221; and collectively with the 0.500% notes and the 1.125% notes, the &#8220;notes&#8221;). For a complete description of the terms and provisions of the notes, refer to the indenture, the form of officers&#8217; certificate setting forth the terms and forms of the notes, all of which are filed as exhibits to the Form 8-A filed with the Securities and Exchange Commission on September 14, 2021. Throughout this exhibit, references to &#8220;we,&#8221; &#8220;the Company,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to Eli Lilly and Company and not to any of its subsidiaries, unless otherwise indicated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The 0.500% notes&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued in an aggregate initial principal amount of &#8364;600,000,000, which remained outstanding as of December 31, 2021, and permit us to issue additional 0.500% notes that may be of the same series as the 0.500% notes as described under &#8220;Further Issues&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">mature on September 14, 2033&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">bear interest at a rate of 0.500% per annum&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are unsecured&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">rank equally with all of our other unsecured and unsubordinated indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued as a separate series under the indenture, in registered, book-entry form only&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are repayable at par at maturity&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are redeemable by us at any time prior to maturity as described below under &#8220;-Optional Redemption&#8221; and in connection with certain developments involving United States taxation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are subject to defeasance and covenant defeasance&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not subject to any sinking fund.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The 1.125% notes&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued in an aggregate initial principal amount of &#8364;500,000,000, which remained outstanding as of December 31, 2021 and permit us to issue additional 1.125% notes that may be of the same series as the 1.125% notes as described under &#8220;Further Issues&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">mature on September 14, 2051&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">bear interest at a rate of 1.125% per annum&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are unsecured&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">rank equally with all of our other unsecured and unsubordinated indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued as a separate series under the indenture, in registered, book-entry form only&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are repayable at par at maturity&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are redeemable by us at any time prior to maturity as described below under &#8220;-Optional Redemption&#8221; and in connection with certain developments involving United States taxation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are subject to defeasance and covenant defeasance&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not subject to any sinking fund.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The 1.375% notes&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued in an aggregate initial principal amount of &#8364;700,000,000, which remained outstanding as of December 31, 2021 and permit us to issue additional 1.375% notes that may be of the same series as the 1.375% notes as described under &#8220;Further Issues&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">mature on September 14, 2061&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">bear interest at a rate of 1.375% per annum&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are unsecured&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">rank equally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with all of our other unsecured and unsubordinated indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued as a separate series under the indenture, in registered, book-entry form only&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are repayable at par at maturity&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are redeemable by us at any time prior to maturity as described below under &#8220;-Optional Redemption&#8221; and in connection with certain developments involving United States taxation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are subject to defeasance and covenant defeasance&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not subject to any sinking fund.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture and the notes do not limit the amount of indebtedness that we may incur or the amount of securities that may be issued by us or our subsidiaries, and contain no financial covenants or similar restrictions on us or our subsidiaries, except as described under the captions &#8220;Limitation on Liens&#8221; and &#8220;Limitation on Sale and Leaseback Transactions.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will pay interest on the notes annually on September 14 of each year, commencing on September 14, 2022, to the persons in whose names such notes are registered at the close of business on August 31 (whether or not a business day), immediately preceding such interest payment date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on the notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes (or from September 14, 2021, if no interest has been paid on the notes), to but excluding the next scheduled interest payment date. This payment convention, which is set forth in the rulebook of the International Capital Market Association, is referred to as ACTUAL&#47;ACTUAL (ICMA).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If any interest payment date falls on a day that is not a business day, we will make the required interest payment </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(together with any additional amounts, if applicable) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">on the next business day, and no interest on such payment will accrue for the period from and after such interest payment date. Similarly, if the stated maturity date or the date of earlier redemption, as the case may be, of the notes falls on a day that is not a business day, we will make the required payment of principal, premium, if any, and interest, if any</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(in each case, together with any additional amounts, if applicable)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, on the next succeeding business day, and no interest on such payment will accrue for the period from and after the maturity date or redemption date, as the case may be.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Business day&#8221; means any day, other than a Saturday or Sunday, (i) that is neither a legal holiday nor a day on which banking institutions are authorized or required by law or regulation to close in the City of New York or London, and (ii) on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, operates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance in Euro</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial holders will be required to pay for the notes in euro, and all payments of interest and principal, including payments made upon any redemption of the notes, will be payable in euro. If, on or after the date of the issuance of the notes, the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then-member states of the European Economic and Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in dollars until the euro is again available to us or so used. The amount payable on any date in euro will be converted into dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second business day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent euro&#47;dollar exchange rate available on or prior to the second business day prior to the relevant payment date, as reported by Bloomberg. Any payment in respect of the notes so made in dollars will not constitute an event of default under the notes or the indenture.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At our option, we may redeem the notes, in whole or in part, at any time or from time to time as described below.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we redeem all or any part of the 0.500% notes, the 1.125% notes or the 1.375% notes prior to the applicable Par Call Date (as defined below), we will pay a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">100% of the principal amount of the notes being redeemed on the redemption date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">as calculated by the Quotation Agent (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest on the applicable series of notes being redeemed that would be due if such series of notes matured on the applicable Par Call Date (in each case, not including the amount, if any, of unpaid interest accrued to, but excluding, the redemption date) discounted to the redemption date, on an annual basis (ACTUAL&#47;ACTUAL (ICMA)) using a discount rate equal to the sum of the Reference Dealer Rate (as defined below), plus 0.150% (or 15 basis points) with respect to the 0.500% notes, 0.200% (or 20 basis points) with respect to the 1.125% notes, or 0.200% (or 20 basis points) with respect to the 1.375% notes&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in each case, accrued and unpaid interest on such notes to, but excluding, the redemption date. If we redeem all or any part of the 0.500% notes, the 1.125% notes or the 1.375% notes on or after the applicable Par Call Date, we will pay a redemption price equal to 100% of the principal amount of such series of notes being redeemed plus accrued and unpaid interest thereon.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, installments of interest on notes that are due and payable on an interest payment date falling on or prior to a redemption date will be payable on such interest payment date to the registered holders as of the close of business on the relevant record date. We will mail notice of any redemption at least 10 days but not more than 60 days before the redemption date to each registered holder of the notes to be redeemed. Subject to any delay in the redemption date or rescission of the notice of redemption described below, once notice of redemption is mailed, the notes called for redemption will become due and payable on the redemption date. Any redemption notice may, at our discretion, be subject to one or more conditions precedent, including completion of a corporate transaction. In such event, the related notice of redemption will describe each such condition and, if applicable, will state that, at our discretion, the date of redemption may be delayed until such time (including more than 60 days after the notice of redemption was given) as any or all such conditions are satisfied or waived, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions have not been satisfied (or waived by us in our sole discretion) by the date of redemption, or by the date of redemption as so delayed. In the case of such delay or rescission, we will provide written notice to the trustee prior to the close of business two business days before the date of redemption and, upon receipt, the trustee will provide such notice to each holder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Par Call Date&#8221; means June 14, 2033 for the 0.500% notes, March 14, 2051 for the 1.125% notes and March 14, 2061 for the 1.375% notes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Quotation Agent&#8221; means the Reference Dealer selected by us.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Reference Dealer&#8221; means any Euro security dealer(s) selected by us.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Reference Dealer Rate&#8221; means, with respect to each Reference Dealer and any redemption date prior to the applicable Par Call Date for the 0.500% notes, the 1.125% notes and the 1.375% notes, the arithmetic average of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">quotations quoted in writing to us by each Reference Dealer of the average midmarket annual yield to maturity of the 0.000% German government bond due August 15, 2031 with respect to the 0.500% notes, the 0.000% German government bond due August 15, 2050 with respect to the 1.125% notes and the 0.000% German government bond due August 15, 2050 with respect to the 1.375% notes, or, if the applicable reference security is no longer outstanding, a similar security in the reasonable judgment of such Reference Dealer at 11&#58;00 a.m. (London time) on the third business day preceding such redemption date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On and after the redemption date, interest will cease to accrue on the notes or any portion of the notes called for redemption (unless we default in the payment of the redemption price). Before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of the notes of the particular series to be redeemed on that date. If fewer than all of the notes of such series are to be redeemed, the notes to be redeemed will be selected pro rata or by the trustee by a method the trustee deems to be fair and appropriate (which may include by lot) or, in case the notes are represented by one or more global notes, beneficial interests therein will be selected for redemption by Clearstream and Euroclear in accordance with their respective applicable procedures therefor. In addition, we may at any time purchase the notes by tender, in the open market or by private agreement, subject to applicable laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes will not be entitled to the benefit of any mandatory redemption or sinking fund provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment of Additional Amounts</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will, subject to the exceptions and limitations set forth below, pay as additional interest on the notes such additional amounts as are necessary so that the net payment by us or a paying agent of the principal of and interest on the notes to a person that is a non-U.S. holder, after deduction for any present or future tax, assessment or governmental charge of the United States or a political subdivision or taxing authority thereof or therein, imposed by withholding with respect to the payment, will not be less than the amount that would have been payable in respect of the notes had no withholding or deduction been required.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our obligation to pay additional amounts shall not apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed or withheld solely because the beneficial owner, or a fiduciary, settlor, beneficiary or member of the beneficial owner if the beneficial owner is an estate, trust or partnership, or a person holding a power over an estate or trust administered by a fiduciary holder&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;is or was present or engaged in a trade or business in the United States or has or had a permanent establishment in the United States&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;is or was a citizen or resident or is or was treated as a resident of the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;is or was a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation for the United States federal income tax purposes, is or was a corporation that has accumulated earnings to avoid United States federal income tax or is or was a private foundation or other tax-exempt organization&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;is or was an actual or constructive &#8220;10-percent shareholder&#8221; of ours, as defined in Section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;is or was a bank receiving interest described in Section 881(c)(3)(A) of the Code&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;to any holder that is not the sole beneficial owner of notes, or that is a fiduciary or partnership, but only to the extent that the beneficial owner, a beneficiary or settlor with respect to the fiduciary, or a member of the partnership would not have been entitled to the payment of an additional amount had such beneficial owner, beneficiary, settlor or member received directly its beneficial or distributive share of the payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed or withheld solely because the beneficial owner or any other person failed to comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of notes, if compliance is required by statute, by regulation of the United States Treasury Department or by an applicable income tax </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed other than by deduction or withholding by us or a paying agent from the payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed or withheld solely because of a change in law, regulation, or administrative or judicial interpretation that becomes effective after the day on which the payment becomes due or is duly provided for, whichever occurs later&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or any similar tax, assessment or governmental charge&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;to any tax, assessment or other governmental charge any paying agent (which term may include us) must withhold from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that would not have been so imposed or withheld but for the presentation by the holder of a note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;to any withholding or deduction pursuant to an agreement described in Section 1471(b) of the Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code (or any regulations or agreements thereunder or official interpretations thereof) or any intergovernmental agreement between the United States and another jurisdiction for cooperation to facilitate the implementation thereof (or any law implementing such an intergovernmental agreement)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x) &#160;&#160;&#160;&#160;in the case of any combination of the above items.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes are subject in all cases to any applicable tax, fiscal or other law or regulation or administrative or judicial interpretation. Except as specifically provided under this heading &#8220;-Payment of Additional Amounts&#8221; and under the heading &#8220;-Redemption Upon a Tax Event,&#8221; we do not have to make any payment with respect to any tax, assessment or governmental charge imposed by any government or a political subdivision or taxing authority.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In particular, we will not pay additional amounts on any note presented for payment by or on behalf of a beneficial owner who would have been able to avoid the withholding or deduction by presenting the relevant note to another paying agent in a member state of the European Union or the United Kingdom.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Upon a Tax Event</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If (i) we become or will become obligated to pay additional amounts as described under the heading &#8220;-Payment of Additional Amounts&#8221; as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated thereunder) of the United States (or any political subdivision or taxing authority thereof or therein), or any change in, or amendment to, any official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after the date of the issuance of the notes, or (ii) a taxing authority of the United States takes an action on or after the date of the issuance of the notes, whether or not with respect to us or any of our affiliates, that results in a substantial probability that we will or may be required to pay such additional amounts, in either case, with respect to the notes for reasons outside our control and after taking reasonable measures available to us to avoid such obligation, then we may, at our option, redeem, as a whole, but not in part, each series of the notes at any time prior to maturity on not less than 30 nor more than 60 calendar days&#8217; prior notice to the holders, at a redemption price equal to 100% of their principal amount, together with unpaid interest accrued thereon to the date fixed for redemption. No redemption pursuant to (ii) above may be made unless we shall have received an opinion of independent counsel to the effect that an act taken by a taxing authority of the United States results in a substantial probability that we will or may be required to pay the additional amounts described under the heading &#8220;-Payment of Additional Amounts&#8221; and we shall have delivered to the trustee a certificate, signed by duly authorized officers, stating that based on such opinion, we are entitled to redeem the notes pursuant to their terms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Further Issues</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may, without the consent of the holders of the notes, issue additional debt securities having the same ranking, interest rate, maturity, redemption provisions and other terms as the notes of a particular series. Any additional debt securities having such similar terms, together with the notes of such series, will constitute a single series of debt securities under the indenture.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitation on Liens</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, and will not permit any of our subsidiaries to, create, assume or suffer to exist any lien on restricted property to secure any of our debt, any debt of any of our subsidiaries or any debt of any other person unless we also secure the debt securities of any series having the benefit of this covenant by a lien equally and ratably with such other debt for so long as such other debt shall be so secured. The indenture contains the following exceptions to the foregoing prohibition&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;liens existing on property owned or leased by a corporation existing when such corporation becomes a subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;liens existing on the date of issuance of the first debt security of the particular series&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;liens existing on property when the property was acquired by us or any of our subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;liens to secure debt incurred prior to, at the time of or within 12 months after the acquisition of restricted property or the completion of the construction, alteration, repair or improvement of restricted property, as the case may be, for the purpose of financing all or a part of the purchase price or cost thereof and liens to the extent they secure debt in excess of such purchase price or cost and for the payment of which recourse may be had only against such restricted property&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;certain liens in favor of governmental entities that are required by the provisions of any contract or statute, or any liens securing industrial development, pollution control or similar revenue bonds&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;any lien securing debt of a subsidiary owing to us or to another subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;any extension, renewal or replacement (or successive extensions, renewals or replacements) in whole or in part of any lien referred to in clauses (i) through (vi) above, inclusive, so long as (1) the principal amount of the debt secured thereby does not exceed the principal amount of debt so secured at the time of the extension, renewal or replacement (except that, where an additional principal amount of debt is incurred to provide funds for the completion of a specific project, the additional principal amount, and any related financing costs, may be secured by the lien as well) and (2) the lien is limited to the same property subject to the lien so extended, renewed or replaced (and improvements on the property)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;any lien that would not otherwise be permitted by clauses (i) through (vii) above, inclusive, securing debt which, together with&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">the aggregate outstanding principal amount of all other debt of ours and our subsidiaries owning restricted property which would otherwise be subject to the foregoing restrictions, and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">the aggregate value of existing sale and leaseback transactions which would be subject to the foregoing restrictions absent this clause (viii), does not exceed 15% of our consolidated net tangible assets.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitation on Sale and Leaseback Transactions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, and will not permit any of our subsidiaries owning restricted property to, enter into any sale and leaseback transaction unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;our company or such subsidiary could incur debt, in a principal amount at least equal to the value of such sale and leaseback transaction, secured by a lien on the property to be leased (without equally and ratably securing the outstanding debt securities) because such lien would be of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">character that no violation of the covenant described under &#8220; Limitations on Liens&#8221; above would result&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;we apply, during the six months following the effective date of the sale and leaseback transaction, an amount equal to the value of the sale and leaseback transaction to the voluntary retirement of funded debt (whether by redemption, defeasance, repurchase, or otherwise) or to the acquisition of restricted property.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions of Certain Terms</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following are the meanings of terms that are important in understanding the covenants previously described&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;consolidated net tangible assets&#8221; means the total assets (less applicable reserves and other properly deductible items) less current liabilities (excluding the amount of those which are by their terms extendable or renewable at the option of the obligor to a date more than 12 months after the date as of which the amount is being determined) and all goodwill, tradenames, trademarks, patents, unamortized debt discount and expense and other like intangible assets, all as set forth on our most recent consolidated balance sheet determined in accordance with generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;funded debt&#8221; means our indebtedness or the indebtedness of a subsidiary owning restricted property maturing by its terms more than one year after its creation and indebtedness classified as long-term debt under generally accepted accounting principles and in each case ranking at least pari passu with the debt securities.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;original issue discount security&#8221; means any debt security which provides for an amount less than the principal amount thereof to be due and payable upon a declaration of acceleration of maturity thereof pursuant to the indenture.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;restricted property&#8221; means</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">any manufacturing facility (or portion thereof) owned or leased by us or any of our subsidiaries and located within the continental United States which, in the opinion of our board of directors (or a committee thereof), is of material importance to our business and the business of our subsidiaries taken as a whole, but no such manufacturing facility (or portion thereof) shall be deemed of material importance if its gross book value, before deducting accumulated depreciation, is less than 2% of our consolidated net tangible assets&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">any shares of capital stock or indebtedness of any subsidiary owning any such manufacturing facility.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;sale and leaseback transaction&#8221; means any arrangement with any person providing for the leasing by us or any subsidiary of any restricted property which has been or is to be sold or transferred by us or such subsidiary to such person, excluding (1) temporary leases for a term, including renewals at the option of the lessee, of not more than three years, (2) leases between us and a subsidiary or between subsidiaries, (3) leases of a restricted property executed by the time of, or within 12 months after the latest of, the acquisition, the completion of construction or improvement, or the commencement of commercial operation of the restricted property, and (4) arrangements pursuant to any provision of law with an effect similar to the former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;subsidiary&#8221; means any corporation more than 50% of the voting stock of which shall at the time be owned by us or by one or more subsidiaries or by us and one or more subsidiaries, but shall not include any corporation of which we and&#47;or one or more subsidiaries owns directly or indirectly, less than 50% of the outstanding stock of all classes having ordinary voting power for the election of directors but more than 50% of the outstanding shares of stock of a class having by its terms ordinary voting power as a class to elect a majority of the board of directors of such corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;value&#8221; means, with respect to a sale and leaseback transaction, an amount equal to the net present value of the lease payments with respect to the term of the lease remaining on the date as of which the amount is being determined, without regard to any renewal or extension options contained in the lease, discounted at the weighted average interest rate on the debt securities of all series (including the yield to maturity on any original issue discount securities) which are outstanding on the effective date of such sale and leaseback transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Because the covenants described above cover only manufacturing facilities in the continental United States, our manufacturing facilities in Puerto Rico and elsewhere in the world are excluded from the operation of the covenants described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as described in &#8220;Merger or Consolidation&#8221; below, there are no other restrictive covenants contained in the indenture. The indenture does not contain any provision which restricts us from incurring, assuming or becoming liable with respect to any indebtedness or other obligations, whether secured or unsecured, or from paying dividends or making other distributions on our capital stock or purchasing or redeeming our capital stock. The indenture does not contain any financial ratios, or specified levels of net worth or liquidity to which we must adhere. In addition, the indenture does not contain any provision which would require that we repurchase or redeem or otherwise modify the terms of any of our debt securities upon a change in control or other events involving us which may adversely affect the creditworthiness of the debt securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Events of Default</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that, with respect to any series of debt securities, an event of default consists of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to pay interest when due on any debt securities of such series that continues for 30 days&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to pay principal or premium, if any, when due (whether at maturity, upon redemption, by declaration or otherwise) on any debt securities of such series&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to observe or perform the covenant in the indenture described below under &#8220;Merger or Consolidation&#8221; after written notice from the trustee or holders of 25% or more in aggregate principal amount of debt securities of such series outstanding thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to observe or perform any of our covenants in the indenture or the debt securities of such series (other than a covenant included in the indenture or the debt securities solely for the benefit of a series of debt securities other than such series), continued for 60 days (except in the case of a violation of the covenant described below under &#8220;Merger or Consolidation&#8221;) after written notice from the trustee or the holders of 25% or more in aggregate principal amount, of debt securities of such series outstanding thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">certain events of our bankruptcy, insolvency or reorganization&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">any other event of default as may be specified for such series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that if an event of default with respect to any series of debt securities at the time outstanding occurs and is continuing, either the trustee or the holders of 25% or more in aggregate principal amount (or, if the debt securities of that series are original issue discount securities, such portion of the principal amount as may be specified in the terms of that series) of debt securities of such series outstanding may declare the principal amount of all debt securities of such series to be due and payable immediately. At any time after a declaration of acceleration with respect to the debt securities of any series has been made and before there has been a sale of property under a judgment or decree for the payment of moneys due, the holders of a majority in aggregate principal amount of the debt securities of such series outstanding may waive the default and rescind the declaration and its consequences if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;we have paid or deposited with the trustee a sum sufficient to pay&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;all matured installments of interest upon all the debt securities of such series&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the principal of and premium, if any, on any and all debt securities of such series which have become due other than by declaration&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;interest on overdue installments of interest, to the extent legally enforceable under applicable law, and on such principal of and premium, if any, on each debt security of such series at the rate borne by such debt security to the date of such payment or deposit or yield to maturity (in the case of an original issue discount security)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the expenses of the trustee, and reasonable compensation to the trustee, agents, attorneys and counsel&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;any and all defaults under the indenture, other than the nonpayment of principal on the debt securities of such series which may have become due by declaration, have been remedied.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that the holders of a majority in aggregate principal amount of the debt securities of any series outstanding under the indenture may, subject to certain exceptions, direct the trustee as to the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any power or trust conferred upon the trustee. The holders of a majority in aggregate principal amount of the debt securities of any series outstanding may on behalf of all holders of debt securities of such series waive any past default and its consequences with respect to debt securities of such series, except a default in the payment of the principal of, premium, if any, or interest, if any, on any of the debt securities of such series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of any debt securities of any series may not institute any proceeding to enforce the indenture or any remedy thereunder unless the trustee shall have failed to act for 60 days after a request and offer of reasonable indemnity by the holders of 25% or more in aggregate principal amount of the debt securities of such series outstanding. However, the right of any holder of any security of any series to enforce payment of the principal of or premium, if any, or interest, if any, on its debt securities when due shall not be impaired without the consent of such holder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The trustee is required to give the holders of any debt security of any series notice of default with respect to such series known to it within 90 days after the happening of the default, unless cured before the giving of such notice. However, except for defaults in payments of the principal of or premium, if any, or interest, if any, on the debt securities of such series, the trustee may withhold notice if and so long as it determines in good faith that the withholding of such notice is in the interests of the holders of the debt securities of such series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are required to deliver to the trustee each year an officers&#8217; certificate stating whether such officers have obtained knowledge of any default by our company in the performance of all covenants and, if so, specifying the nature of such default.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger or Consolidation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that without the consent of the holders of any of the outstanding debt securities under the indenture, we may consolidate with or merge into, or transfer or lease substantially all of our assets to, any domestic corporation, association, company or business trust (as used in this subsection, a &#8220;corporation&#8221;), provided&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">the successor corporation assumes all of our payment obligations under the debt securities and the performance of all of our other covenants under the indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">certain other conditions described in the indenture are met.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Although there is a limited body of case law interpreting the phrase &#8220;substantially all,&#8221; there is no precise established definition of the phrase under applicable law. As a result of this uncertainty&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;there could be a disagreement between us and the holders of debt securities over whether, as a condition to a transfer or lease of our assets, the successor entity is required to assume our obligations under the indenture and, consequently, whether a failure to assume such obligations would result in an event of default under the indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;in the event that the holders of debt securities attempt to declare an event of default and exercise their acceleration rights under the indenture in such circumstances and we contest such action, there can be no assurance as to how a court interpreting applicable law would interpret the phrase &#8220;substantially all&#8221;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;it may be difficult for holders to debt securities to declare an event of default and exercise their acceleration rights.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discharge, Legal Defeasance and Covenant Defeasance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may discharge certain obligations to holders of any series of debt securities that have not already been delivered to the trustee for cancellation and that either have become due and payable or will become due and payable within one year (or are to be called for redemption within one year under arrangements satisfactory to the trustee for the giving of notice) by irrevocably depositing with the trustee, in trust, funds in the currency or currencies in which those debt securities are payable in an amount sufficient to pay the entire indebtedness on those debt securities in respect of principal, premium, if any, and interest, if any, to the date of that deposit (if those debt securities have become due and payable) or to the maturity date, as the case may be.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At our option, we may be discharged, subject to certain terms and conditions, from any and all obligations in respect of the debt securities of any series (except for certain obligations to register the transfer and exchange of debt securities, replace, stolen, lost or mutilated debt securities and coupons, maintain paying agencies and hold moneys for payment in trust) or need not comply with certain restrictive covenants of the indenture if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) &#160;&#160;&#160;&#160;we have deposited with the trustee, in trust, money, and in the case of debt securities and coupons denominated in U.S. dollars, U.S. government obligations or, in the case of debt securities and coupons denominated in a foreign currency, foreign currency government securities, which through the payment of interest thereon and principal thereof in accordance with their terms will provide money or a combination of money, and either U.S. government securities or foreign currency government securities, as the case may be, in an amount sufficient to pay in the currency in which the debt securities are payable all the principal of and premium, if any, and interest, if any, on the debt securities on the date such payments are due in accordance with the debt securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) &#160;&#160;&#160;&#160;(i) no event of default or event which with notice or lapse of time would become an event of default shall have occurred and be continuing on the date of such deposit, (ii) no event of default relating to our bankruptcy, insolvency or reorganization, or event which with notice or lapse of time or both would become such an event of default, shall have occurred within 90 days after the date of such deposit, and (iii) such deposit and discharge will not result in any default or event of default under any material indenture, agreement or other instrument binding upon us or any of our properties&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) &#160;&#160;&#160;&#160;we have delivered to the trustee an opinion of counsel to the effect that such deposit and discharge will not cause the holders of the debt securities of such series to recognize income, gain or loss for federal income tax purposes and that such holders will be subject to federal income tax in the same amounts, manner and time had such deposit and discharge not occurred&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) &#160;&#160;&#160;&#160;we have delivered to the trustee an officers&#8217; certificate and an opinion from our counsel stating that we have complied with all conditions precedent set forth in the indenture or the applicable supplemental indenture relating to the satisfaction and discharge of the indebtedness of the series of debt securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Modification and Waiver</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture contains provisions permitting us and the trustee, with the consent of the holders of not less than a majority of the aggregate principal amount of the notes at the time outstanding, evidenced as provided in the indenture, to execute supplemental indentures for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the indenture or of any supplemental indenture with respect to the notes or of modifying in any manner the rights of the holders of the notes&#59;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no such supplemental indenture shall (i)&#160;extend the fixed maturity, or the earlier optional date of maturity, if any, of any note, or reduce the principal amount thereof or the premium thereon, if any, or reduce the rate or extend the time of payment of interest, if any, thereon or make the principal thereof or premium, if any, or interest, if any, thereon payable in any currency other than as provided pursuant to the indenture or in the notes, without the consent of the Holders of each note so affected&#59; or (ii)&#160;reduce the aforesaid percentage of the notes, the holders of which are required to consent to any such supplemental indenture, without the consent of the holders of all notes then outstanding.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture also contains provisions permitting us and the trustee, without the consent of the holders of the notes, to establish, among other things, the form and terms of any series of debt securities issuable under the indenture by one or more supplemental indentures, to add covenants and to provide for security for the notes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Concerning the Trustee</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deutsche Bank Trust Company Americas is the current trustee under the indenture. The trustee may acquire and hold debt securities and, subject to certain conditions, otherwise deal with us as if it were not trustee under the indenture. The trustee and its affiliates have in the past provided, and may from time to time in the future provide, trustee, commercial banking, investment banking and other services to us in the ordinary course of their respective businesses for which they have received, and will receive, customary compensation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 11</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>3
<FILENAME>lly-20211231x10kexhibit49.htm
<DESCRIPTION>EX-4.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1bbdc914a14c4fe6b57b2d0c8ff75565_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.9 Description of the Company&#8217;s 1.625% notes due 2043</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following summary of Eli Lilly and Company&#8217;s above referenced debt securities is based on and qualified by the indenture, dated as of February 1, 1991, between us and Deutsche Bank Trust Company Americas (as successor to Citibank, N.A.), as trustee, and the forms of 1.625% notes due September 2043 (the &#8220;notes&#8221;). For a complete description of the terms and provisions of the notes, refer to the indenture, the form of officers&#8217; certificate setting forth the terms and form of the notes, all of which are filed as exhibits to the Form 8-A filed with the Securities and Exchange Commission on September 14, 2021. Throughout this exhibit, references to &#8220;we,&#8221; &#8220;the Company,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to Eli Lilly and Company and not to any of its subsidiaries, unless otherwise indicated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued in an aggregate initial principal amount of &#163;250,000,000, which remained outstanding as of December 31, 2021, and permit us to issue additional notes that may be of the same series as the notes as described under &#8220;Further Issues&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">mature on September 14, 2043&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">bear interest at a rate of 1.625% per annum&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are unsecured&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">rank equally with all of our other unsecured and unsubordinated indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">were issued as a separate series under the indenture, in registered, book-entry form only&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are repayable at par at maturity&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are redeemable by us at any time prior to maturity as described below under &#8220;-Optional Redemption&#8221; and in connection with certain developments involving United States taxation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are subject to defeasance and covenant defeasance&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not subject to any sinking fund.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture and the notes do not limit the amount of indebtedness that we may incur or the amount of securities that may be issued by us or our subsidiaries, and contain no financial covenants or similar restrictions on us or our subsidiaries, except as described under the captions &#8220;Limitation on Liens&#8221; and &#8220;Limitation on Sale and Leaseback Transactions.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will pay interest on the notes annually on September 14 of each year, commencing on September 14, 2022, to the persons in whose names such notes are registered at the close of business on August 31 (whether or not a business day), immediately preceding such interest payment date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on the notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes (or from September 14, 2021, if no interest has been paid on the notes), to but excluding the next scheduled interest payment date. This payment convention, which is set forth in the rulebook of the International Capital Market Association, is referred to as ACTUAL&#47;ACTUAL (ICMA).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If any interest payment date falls on a day that is not a business day, we will make the required interest payment </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(together with any additional amounts, if applicable) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">on the next business day, and no interest on such payment will accrue for the period from and after such interest payment date. Similarly, if the stated maturity date or the date of earlier redemption, as the case may be, of the notes falls on a day that is not a business day, we will make the required payment of principal, premium, if any, and interest, if any </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in each case, together with any additional amounts, if applicable)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, on the next succeeding business day, and no interest on such payment will accrue for the period from and after the maturity date or redemption date, as the case may be.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Business day&#8221; means any day, other than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions are authorized or required by law or regulation to close in the City of New York or London.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance in Pounds Sterling (&#8220;GBP&#8221;)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial holders will be required to pay for the notes in GBP, and all payments of interest and principal, including payments made upon any redemption of the notes, will be payable in GBP. If, on or after the date of the issuance of the notes, GBP is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if GBP is no longer being used for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in dollars until GBP is again available to us or so used. The amount payable on any date in GBP will be converted into dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second business day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent GBP&#47;dollar exchange rate available on or prior to the second business day prior to the relevant payment date, as reported by Bloomberg. Any payment in respect of the notes so made in dollars will not constitute an event of default under the notes or the indenture.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At our option, we may redeem the notes, in whole or in part, at any time or from time to time as described below.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we redeem all or any part of the notes prior to the Par Call Date (as defined below), we will pay a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">100% of the principal amount of the notes being redeemed on the redemption date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">as calculated by the Quotation Agent (as defined below), the sum of the present values of the remaining scheduled payments of principal of and interest on the notes being redeemed that would be due if such notes matured on the applicable Par Call Date (in each case, not including the amount, if any, of unpaid interest accrued to, but excluding, the redemption date) discounted to the redemption date, on an annual basis (ACTUAL&#47;ACTUAL (ICMA)) using a discount rate equal to the sum of the Reference Dealer Rate (as defined below), plus 0.100% (or 10 basis points)&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in each case, accrued and unpaid interest on such notes to, but excluding, the redemption date. If we redeem all or any part of the notes on or after the Par Call Date, we will pay a redemption price equal to 100% of the principal amount of such notes being redeemed plus accrued and unpaid interest thereon.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, installments of interest on notes that are due and payable on an interest payment date falling on or prior to a redemption date will be payable on such interest payment date to the registered holders as of the close of business on the relevant record date. We will mail notice of any redemption at least 10 days but not more than 60 days before the redemption date to each registered holder of the notes to be redeemed. Subject to any delay in the redemption date or rescission of the notice of redemption described below, once notice of redemption is mailed, the notes called for redemption will become due and payable on the redemption date. Any redemption notice may, at our discretion, be subject to one or more conditions precedent, including completion of a corporate transaction. In such event, the related notice of redemption will describe each such condition and, if applicable, will state that, at our discretion, the date of redemption may be delayed until such time (including more than 60 days after the notice of redemption was given) as any or all such conditions are satisfied or waived, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions have not been satisfied (or waived by us in our sole discretion) by the date of redemption, or by the date of redemption as so delayed. In the case of such delay or rescission, we will provide written notice to the trustee prior to the close of business two business days before the date of redemption and, upon receipt, the trustee will provide such notice to each holder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Par Call Date&#8221; means March 14, 2043.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Quotation Agent&#8221; means the Reference Dealer selected by us.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Reference Dealer&#8221; means any GBP security dealer(s) selected by us.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Reference Dealer Rate&#8221; means, with respect to each Reference Dealer and any redemption date prior to the Par Call Date for the notes, the arithmetic average of the quotations quoted in writing to us by each Reference Dealer of the average midmarket annual yield to maturity of the 4.500% United Kingdom government bond due December 7, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042 or, if the reference security is no longer outstanding, a similar security in the reasonable judgment of such Reference Dealer at 11&#58;00 a.m. (London time) on the third business day preceding such redemption date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On and after the redemption date, interest will cease to accrue on the notes or any portion of the notes called for redemption (unless we default in the payment of the redemption price). Before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of the notes to be redeemed on that date. If fewer than all of the notes are to be redeemed, the notes to be redeemed will be selected pro rata or by the trustee by a method the trustee deems to be fair and appropriate (which may include by lot) or, in case the notes are represented by one or more global notes, beneficial interests therein will be selected for redemption by Clearstream and Euroclear in accordance with their respective applicable procedures therefor. In addition, we may at any time purchase the notes by tender, in the open market or by private agreement, subject to applicable laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes will not be entitled to the benefit of any mandatory redemption or sinking fund provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment of Additional Amounts</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will, subject to the exceptions and limitations set forth below, pay as additional interest on the notes such additional amounts as are necessary so that the net payment by us or a paying agent of the principal of and interest on the notes to a person that is a non-U.S. holder, after deduction for any present or future tax, assessment or governmental charge of the United States or a political subdivision or taxing authority thereof or therein, imposed by withholding with respect to the payment, will not be less than the amount that would have been payable in respect of the notes had no withholding or deduction been required.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our obligation to pay additional amounts shall not apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed or withheld solely because the beneficial owner, or a fiduciary, settlor, beneficiary or member of the beneficial owner if the beneficial owner is an estate, trust or partnership, or a person holding a power over an estate or trust administered by a fiduciary holder&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;is or was present or engaged in a trade or business in the United States or has or had a permanent establishment in the United States&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;is or was a citizen or resident or is or was treated as a resident of the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;is or was a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation for the United States federal income tax purposes, is or was a corporation that has accumulated earnings to avoid United States federal income tax or is or was a private foundation or other tax-exempt organization&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;is or was an actual or constructive &#8220;10-percent shareholder&#8221; of ours, as defined in Section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;is or was a bank receiving interest described in Section 881(c)(3)(A) of the Code&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;to any holder that is not the sole beneficial owner of notes, or that is a fiduciary or partnership, but only to the extent that the beneficial owner, a beneficiary or settlor with respect to the fiduciary, or a member of the partnership would not have been entitled to the payment of an additional amount had such beneficial owner, beneficiary, settlor or member received directly its beneficial or distributive share of the payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed or withheld solely because the beneficial owner or any other person failed to comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of notes, if compliance is required by statute, by regulation of the United States Treasury Department or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed other than by deduction or withholding by us or a paying agent from the payment&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that is imposed or withheld solely because of a change in law, regulation, or administrative or judicial interpretation that becomes effective after the day on which the payment becomes due or is duly provided for, whichever occurs later&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or any similar tax, assessment or governmental charge&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;to any tax, assessment or other governmental charge any paying agent (which term may include us) must withhold from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;to any tax, assessment or governmental charge that would not have been so imposed or withheld but for the presentation by the holder of a note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;to any withholding or deduction pursuant to an agreement described in Section 1471(b) of the Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code (or any regulations or agreements thereunder or official interpretations thereof) or any intergovernmental agreement between the United States and another jurisdiction for cooperation to facilitate the implementation thereof (or any law implementing such an intergovernmental agreement)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x) &#160;&#160;&#160;&#160;in the case of any combination of the above items.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The notes are subject in all cases to any applicable tax, fiscal or other law or regulation or administrative or judicial interpretation. Except as specifically provided under this heading &#8220;-Payment of Additional Amounts&#8221; and under the heading &#8220;-Redemption Upon a Tax Event,&#8221; we do not have to make any payment with respect to any tax, assessment or governmental charge imposed by any government or a political subdivision or taxing authority.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In particular, we will not pay additional amounts on any note presented for payment by or on behalf of a beneficial owner who would have been able to avoid the withholding or deduction by presenting the relevant note to another paying agent in a member state of the European Union or the United Kingdom.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Upon a Tax Event</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If (i) we become or will become obligated to pay additional amounts as described under the heading &#8220;-Payment of Additional Amounts&#8221; as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated thereunder) of the United States (or any political subdivision or taxing authority thereof or therein), or any change in, or amendment to, any official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after the date of the issuance of the notes, or (ii) a taxing authority of the United States takes an action on or after the date of the issuance of the notes, whether or not with respect to us or any of our affiliates, that results in a substantial probability that we will or may be required to pay such additional amounts, in either case, with respect to the notes for reasons outside our control and after taking reasonable measures available to us to avoid such obligation, then we may, at our option, redeem, as a whole, but not in part, the notes at any time prior to maturity on not less than 30 nor more than 60 calendar days&#8217; prior notice to the holders, at a redemption price equal to 100% of their principal amount, together with unpaid interest accrued thereon to the date fixed for redemption. No redemption pursuant to (ii) above may be made unless we shall have received an opinion of independent counsel to the effect that an act taken by a taxing authority of the United States results in a substantial probability that we will or may be required to pay the additional amounts described under the heading &#8220;-Payment of Additional Amounts&#8221; and we shall have delivered to the trustee a certificate, signed by duly authorized officers, stating that based on such opinion, we are entitled to redeem the notes pursuant to their terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Further Issues</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may, without the consent of the holders of the notes, issue additional debt securities having the same ranking, interest rate, maturity, redemption provisions and other terms as the notes. Any additional debt securities having such similar terms, together with the notes, will constitute a single series of debt securities under the indenture.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitation on Liens</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, and will not permit any of our subsidiaries to, create, assume or suffer to exist any lien on restricted property to secure any of our debt, any debt of any of our subsidiaries or any debt of any other person unless we also secure the debt securities of any series having the benefit of this covenant by a lien equally and ratably with such other debt for so long as such other debt shall be so secured. The indenture contains the following exceptions to the foregoing prohibition&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;liens existing on property owned or leased by a corporation existing when such corporation becomes a subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;liens existing on the date of issuance of the first debt security of the particular series&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;liens existing on property when the property was acquired by us or any of our subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;liens to secure debt incurred prior to, at the time of or within 12 months after the acquisition of restricted property or the completion of the construction, alteration, repair or improvement of restricted property, as the case may be, for the purpose of financing all or a part of the purchase price or cost thereof and liens to the extent they secure debt in excess of such purchase price or cost and for the payment of which recourse may be had only against such restricted property&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;certain liens in favor of governmental entities that are required by the provisions of any contract or statute, or any liens securing industrial development, pollution control or similar revenue bonds&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;any lien securing debt of a subsidiary owing to us or to another subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;any extension, renewal or replacement (or successive extensions, renewals or replacements) in whole or in part of any lien referred to in clauses (i) through (vi) above, inclusive, so long as (1) the principal amount of the debt secured thereby does not exceed the principal amount of debt so secured at the time of the extension, renewal or replacement (except that, where an additional principal amount of debt is incurred to provide funds for the completion of a specific project, the additional principal amount, and any related financing costs, may be secured by the lien as well) and (2) the lien is limited to the same property subject to the lien so extended, renewed or replaced (and improvements on the property)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;any lien that would not otherwise be permitted by clauses (i) through (vii) above, inclusive, securing debt which, together with&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">the aggregate outstanding principal amount of all other debt of ours and our subsidiaries owning restricted property which would otherwise be subject to the foregoing restrictions, and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">the aggregate value of existing sale and leaseback transactions which would be subject to the foregoing restrictions absent this clause (viii), does not exceed 15% of our consolidated net tangible assets.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitation on Sale and Leaseback Transactions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not, and will not permit any of our subsidiaries owning restricted property to, enter into any sale and leaseback transaction unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;our company or such subsidiary could incur debt, in a principal amount at least equal to the value of such sale and leaseback transaction, secured by a lien on the property to be leased (without equally and ratably securing the outstanding debt securities) because such lien would be of a character that no violation of the covenant described under &#8220; Limitations on Liens&#8221; above would result&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;we apply, during the six months following the effective date of the sale and leaseback transaction, an amount equal to the value of the sale and leaseback transaction to the voluntary retirement of funded debt (whether by redemption, defeasance, repurchase, or otherwise) or to the acquisition of restricted property.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions of Certain Terms</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following are the meanings of terms that are important in understanding the covenants previously described&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;consolidated net tangible assets&#8221; means the total assets (less applicable reserves and other properly deductible items) less current liabilities (excluding the amount of those which are by their terms extendable or renewable at the option of the obligor to a date more than 12 months after the date as of which the amount is being determined) and all goodwill, tradenames, trademarks, patents, unamortized debt discount and expense and other like intangible assets, all as set forth on our most recent consolidated balance sheet determined in accordance with generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;funded debt&#8221; means our indebtedness or the indebtedness of a subsidiary owning restricted property maturing by its terms more than one year after its creation and indebtedness classified as long-term debt under generally accepted accounting principles and in each case ranking at least pari passu with the debt securities.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;original issue discount security&#8221; means any debt security which provides for an amount less than the principal amount thereof to be due and payable upon a declaration of acceleration of maturity thereof pursuant to the indenture.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;restricted property&#8221; means</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">any manufacturing facility (or portion thereof) owned or leased by us or any of our subsidiaries and located within the continental United States which, in the opinion of our board of directors (or a committee thereof), is of material importance to our business and the business of our subsidiaries taken as a whole, but no such manufacturing facility (or portion thereof) shall be deemed of material importance if its gross book value, before deducting accumulated depreciation, is less than 2% of our consolidated net tangible assets&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">any shares of capital stock or indebtedness of any subsidiary owning any such manufacturing facility.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;sale and leaseback transaction&#8221; means any arrangement with any person providing for the leasing by us or any subsidiary of any restricted property which has been or is to be sold or transferred by us or such subsidiary to such person, excluding (1) temporary leases for a term, including renewals at the option of the lessee, of not more than three years, (2) leases between us and a subsidiary or between subsidiaries, (3) leases of a restricted property executed by the time of, or within 12 months after the latest of, the acquisition, the completion of construction or improvement, or the commencement of commercial operation of the restricted property, and (4) arrangements pursuant to any provision of law with an effect similar to the former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;subsidiary&#8221; means any corporation more than 50% of the voting stock of which shall at the time be owned by us or by one or more subsidiaries or by us and one or more subsidiaries, but shall not include any corporation of which we and&#47;or one or more subsidiaries owns directly or indirectly, less than 50% of the outstanding stock of all classes having ordinary voting power for the election of directors but more than 50% of the outstanding shares of stock of a class having by its terms ordinary voting power as a class to elect a majority of the board of directors of such corporation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">&#8220;value&#8221; means, with respect to a sale and leaseback transaction, an amount equal to the net present value of the lease payments with respect to the term of the lease remaining on the date as of which the amount is being determined, without regard to any renewal or extension options contained in the lease, discounted at the weighted average interest rate on the debt securities of all series (including the yield to maturity on any original issue discount securities) which are outstanding on the effective date of such sale and leaseback transaction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Because the covenants described above cover only manufacturing facilities in the continental United States, our manufacturing facilities in Puerto Rico and elsewhere in the world are excluded from the operation of the covenants described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as described in &#8220;Merger or Consolidation&#8221; below, there are no other restrictive covenants contained in the indenture. The indenture does not contain any provision which restricts us from incurring, assuming or becoming liable with respect to any indebtedness or other obligations, whether secured or unsecured, or from paying dividends or making other distributions on our capital stock or purchasing or redeeming our capital stock. The indenture does not contain any financial ratios, or specified levels of net worth or liquidity to which we must adhere. In addition, the indenture does not contain any provision which would require that we repurchase or redeem or otherwise modify the terms of any of our debt securities upon a change in control or other events involving us which may adversely affect the creditworthiness of the debt securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Events of Default</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that, with respect to any series of debt securities, an event of default consists of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to pay interest when due on any debt securities of such series that continues for 30 days&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to pay principal or premium, if any, when due (whether at maturity, upon redemption, by declaration or otherwise) on any debt securities of such series&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to observe or perform the covenant in the indenture described below under &#8220;Merger or Consolidation&#8221; after written notice from the trustee or holders of 25% or more in aggregate principal amount of debt securities of such series outstanding thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">failure to observe or perform any of our covenants in the indenture or the debt securities of such series (other than a covenant included in the indenture or the debt securities solely for the benefit of a series of debt securities other than such series), continued for 60 days (except in the case of a violation of the covenant described below under &#8220;Merger or Consolidation&#8221;) after written notice from the trustee or the holders of 25% or more in aggregate principal amount, of debt securities of such series outstanding thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">certain events of our bankruptcy, insolvency or reorganization&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">any other event of default as may be specified for such series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that if an event of default with respect to any series of debt securities at the time outstanding occurs and is continuing, either the trustee or the holders of 25% or more in aggregate principal amount (or, if the debt securities of that series are original issue discount securities, such portion of the principal amount as may be specified in the terms of that series) of debt securities of such series outstanding may declare the principal amount of all debt securities of such series to be due and payable immediately. At any time after a declaration of acceleration with respect to the debt securities of any series has been made and before there has been a sale of property under a judgment or decree for the payment of moneys due, the holders of a majority in aggregate principal amount of the debt securities of such series outstanding may waive the default and rescind the declaration and its consequences if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1)&#160;&#160;&#160;&#160;we have paid or deposited with the trustee a sum sufficient to pay&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;all matured installments of interest upon all the debt securities of such series&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the principal of and premium, if any, on any and all debt securities of such series which have become due other than by declaration&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;interest on overdue installments of interest, to the extent legally enforceable under applicable law, and on such principal of and premium, if any, on each debt security of such series at the rate borne by such debt security to the date of such payment or deposit or yield to maturity (in the case of an original issue discount security)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;the expenses of the trustee, and reasonable compensation to the trustee, agents, attorneys and counsel&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2)&#160;&#160;&#160;&#160;any and all defaults under the indenture, other than the nonpayment of principal on the debt securities of such series which may have become due by declaration, have been remedied.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that the holders of a majority in aggregate principal amount of the debt securities of any series outstanding under the indenture may, subject to certain exceptions, direct the trustee as to the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any power or trust conferred upon the trustee. The holders of a majority in aggregate principal amount of the debt securities of any series outstanding may on behalf of all holders of debt securities of such series waive any past default and its consequences with respect to debt securities of such series, except a default in the payment of the principal of, premium, if any, or interest, if any, on any of the debt securities of such series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of any debt securities of any series may not institute any proceeding to enforce the indenture or any remedy thereunder unless the trustee shall have failed to act for 60 days after a request and offer of reasonable indemnity by the holders of 25% or more in aggregate principal amount of the debt securities of such series outstanding. However, the right of any holder of any security of any series to enforce payment of the principal of or premium, if any, or interest, if any, on its debt securities when due shall not be impaired without the consent of such holder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The trustee is required to give the holders of any debt security of any series notice of default with respect to such series known to it within 90 days after the happening of the default, unless cured before the giving of such notice. However, except for defaults in payments of the principal of or premium, if any, or interest, if any, on the debt securities of such series, the trustee may withhold notice if and so long as it determines in good faith that the withholding of such notice is in the interests of the holders of the debt securities of such series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are required to deliver to the trustee each year an officers&#8217; certificate stating whether such officers have obtained knowledge of any default by our company in the performance of all covenants and, if so, specifying the nature of such default.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger or Consolidation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture provides that without the consent of the holders of any of the outstanding debt securities under the indenture, we may consolidate with or merge into, or transfer or lease substantially all of our assets to, any domestic corporation, association, company or business trust (as used in this subsection, a &#8220;corporation&#8221;), provided&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">the successor corporation assumes all of our payment obligations under the debt securities and the performance of all of our other covenants under the indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">certain other conditions described in the indenture are met.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Although there is a limited body of case law interpreting the phrase &#8220;substantially all,&#8221; there is no precise established definition of the phrase under applicable law. As a result of this uncertainty&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;there could be a disagreement between us and the holders of debt securities over whether, as a condition to a transfer or lease of our assets, the successor entity is required to assume our obligations under the indenture and, consequently, whether a failure to assume such obligations would result in an event of default under the indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;in the event that the holders of debt securities attempt to declare an event of default and exercise their acceleration rights under the indenture in such circumstances and we contest such action, there can be no assurance as to how a court interpreting applicable law would interpret the phrase &#8220;substantially all&#8221;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;it may be difficult for holders to debt securities to declare an event of default and exercise their acceleration rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discharge, Legal Defeasance and Covenant Defeasance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may discharge certain obligations to holders of any series of debt securities that have not already been delivered to the trustee for cancellation and that either have become due and payable or will become due and payable within one year (or are to be called for redemption within one year under arrangements satisfactory to the trustee for the giving of notice) by irrevocably depositing with the trustee, in trust, funds in the currency or currencies in which those debt securities are payable in an amount sufficient to pay the entire indebtedness on those debt securities in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">respect of principal, premium, if any, and interest, if any, to the date of that deposit (if those debt securities have become due and payable) or to the maturity date, as the case may be.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At our option, we may be discharged, subject to certain terms and conditions, from any and all obligations in respect of the debt securities of any series (except for certain obligations to register the transfer and exchange of debt securities, replace, stolen, lost or mutilated debt securities and coupons, maintain paying agencies and hold moneys for payment in trust) or need not comply with certain restrictive covenants of the indenture if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) &#160;&#160;&#160;&#160;we have deposited with the trustee, in trust, money, and in the case of debt securities and coupons denominated in U.S. dollars, U.S. government obligations or, in the case of debt securities and coupons denominated in a foreign currency, foreign currency government securities, which through the payment of interest thereon and principal thereof in accordance with their terms will provide money or a combination of money, and either U.S. government securities or foreign currency government securities, as the case may be, in an amount sufficient to pay in the currency in which the debt securities are payable all the principal of and premium, if any, and interest, if any, on the debt securities on the date such payments are due in accordance with the debt securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) &#160;&#160;&#160;&#160;(i) no event of default or event which with notice or lapse of time would become an event of default shall have occurred and be continuing on the date of such deposit, (ii) no event of default relating to our bankruptcy, insolvency or reorganization, or event which with notice or lapse of time or both would become such an event of default, shall have occurred within 90 days after the date of such deposit, and (iii) such deposit and discharge will not result in any default or event of default under any material indenture, agreement or other instrument binding upon us or any of our properties&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3) &#160;&#160;&#160;&#160;we have delivered to the trustee an opinion of counsel to the effect that such deposit and discharge will not cause the holders of the debt securities of such series to recognize income, gain or loss for federal income tax purposes and that such holders will be subject to federal income tax in the same amounts, manner and time had such deposit and discharge not occurred&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4) &#160;&#160;&#160;&#160;we have delivered to the trustee an officers&#8217; certificate and an opinion from our counsel stating that we have complied with all conditions precedent set forth in the indenture or the applicable supplemental indenture relating to the satisfaction and discharge of the indebtedness of the series of debt securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Modification and Waiver</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture contains provisions permitting us and the trustee, with the consent of the holders of not less than a majority of the aggregate principal amount of the notes at the time outstanding, evidenced as provided in the indenture, to execute supplemental indentures for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the indenture or of any supplemental indenture with respect to the notes or of modifying in any manner the rights of the holders of the notes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no such supplemental indenture shall (i) extend the fixed maturity, or the earlier optional date of maturity, if any, of any note, or reduce the principal amount thereof or the premium thereon, if any, or reduce the rate or extend the time of payment of interest, if any, thereon or make the principal thereof or premium, if any, or interest, if any, thereon payable in any currency other than as provided pursuant to the indenture or the notes, without the consent of the Holders of each note so affected&#59; or (ii) reduce the aforesaid percentage of the notes, the holders of which are required to consent to any such supplemental indenture, without the consent of the holders of all notes then outstanding.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The indenture also contains provisions permitting us and the trustee, without the consent of the holders of the notes, to establish, among other things, the form and terms of any series of debt securities issuable under the indenture by one or more supplemental indentures, to add covenants and to provide for security for the notes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Concerning the Trustee</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deutsche Bank Trust Company Americas is the current trustee under the indenture. The trustee may acquire and hold debt securities and, subject to certain conditions, otherwise deal with us as if it were not trustee under the indenture. The trustee and its affiliates have in the past provided, and may from time to time in the future provide, trustee, commercial banking, investment banking and other services to us in the ordinary course of their respective businesses for which they have received, and will receive, customary compensation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>lly-20211231x10kexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i78fbfdac4e7441f3860e8f406758ad19_53"></div><div style="min-height:64.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.2 Form of Performance Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Performance Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="text-indent:13.5pt"><img alt="a102performancelevelimagev2.jpg" src="a102performancelevelimagev2.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:655px"></div><div style="text-indent:13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">January 1, 2022 &#8211; December 31, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Service Vesting Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">February 1, 2025</font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-64.5pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).   </font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of units eligible to vest (&#8220;Performance Units&#8221;) based on the actual cumulative Earnings Per Share (&#34;EPS&#34;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#34;US GAAP&#34;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.01pt">To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">The number of Performance Units under this Performance Award will be the number resulting from the calculation described in subsection (b) above. </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event the Grantee&#8217;s Service is terminated prior to the Service Vesting Date for any reason or in any circumstance other than as described in Section 3 below, the Award, including any accrued Dividend Equivalent Rights, shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the Performance Units shall vest, provided that if the Qualifying Termination occurs prior to the last day of the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">the Grantee&#8217;s Service is terminated due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Post-Performance Period Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding Section 3(c)(i), in the event the Grantee's Service is terminated due to retirement as a &#8220;retiree&#8221; (as defined in Section 3(c)(i)) subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Performance Units, if any, shall continue to accrue Dividend Equivalent Rights and the Performance Units and Dividend Equivalent Rights shall vest on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, cancel this Performance Award or reduce the number of Performance Units, prorated according to time or other measure as determined appropriate by the Company, if during any period prior to the Service Vesting Date the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Final Written Warning</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee is placed on final written warning (or its equivalent as determined by the Committee) at any time subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Grantee shall forfeit the Performance Units and Dividend Equivalent Rights scheduled to vest on the Service Vesting Date to the extent the Award is the next subsequent Award (when compared to other Awards held by the Grantee) that is scheduled to vest following the date that the Grantee is placed on final written warning (it being understood that all other Awards, if any, that are scheduled to vest on the Service Vesting Date shall also be forfeited).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment (or equivalent as determined by the Committee), and (5) the Grantee&#8217;s Service has been terminated by reason of retirement as a &#8220;retiree&#8221; (as defined in Section (3)(c)(i)) shall be final and binding on the Grantee.  </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Performance Units, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.51pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.85pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">The following shall apply in the event of a Transaction that occurs subsequent to the last day of the Performance Period but prior to the Service Vesting Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Performance Units are not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Performance Units shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">In the event that the Performance Units are converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination prior to the Service Vesting Date, then immediately as of the date of the Covered Termination, the Performance Units shall vest automatically in full.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, a vested Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the Service Vesting Date, including if the Award vests pursuant to Sections 3(b) or 3(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 3(b) subsequent to the last day of the Performance Period, the Award shall be paid to the Grantee no later than sixty (60) days following the date of the Grantee&#8217;s termination of Service under Section 3(b), provided that if the Award is considered an item of nonqualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;), the Award shall be paid within sixty (60) days following the date the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (i) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (ii) the date of the Grantee&#8217;s death, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(i) or Section 4(c)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered NQ Deferred Compensation and the Transaction does not constitute a &#8220;change in control event&#8221; under Section 409A of the Code (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(ii) or Section 4(c)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5, Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(f) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">At any time prior to the Service Vesting Date or until the Performance Units are paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Performance Units in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Restriction Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(d).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Dividend Equivalent Rights, if any, that accrue hereunder shall be settled in cash.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On each date that the Company pays a cash dividend to holders of Shares during the period commencing on the date the number of Performance Units are determined continuing through the date the Performance Units are settled, the Grantee shall be credited with Dividend Equivalent Rights in an amount equal to the total number of Performance Units, multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date.  Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The Dividend Equivalent Rights shall be subject to the same vesting conditions and restrictions as the Performance Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Performance Units with respect to which such Dividend Equivalent Rights were credited are forfeited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the accrual and payment of Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award and any Dividend Equivalent Rights after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any shares of Lilly Stock that may be issued pursuant to this Award.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Performance Units subject to the Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i)&#160;&#160;&#160;&#160;the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>lly-20211231x10kexhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idbc4bc80e1f04f7fa7f78636103a619a_97"></div><div style="min-height:64.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.3 Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Performance Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="text-indent:13.5pt"><img alt="a103performancelevelsimage.jpg" src="a103performancelevelsimage.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:655px"></div><div style="text-indent:13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">January 1, 2022 &#8211; December 31, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Service Vesting Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">February 1, 2025</font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-64.5pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).   </font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of units eligible to vest (&#8220;Performance Units&#8221;) based on the actual cumulative Earnings Per Share (&#34;EPS&#34;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#34;US GAAP&#34;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.01pt">To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">The number of Performance Units under this Performance Award will be the number resulting from the calculation described in subsection (b) above. </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event the Grantee&#8217;s Service is terminated prior to the Service Vesting Date for any reason or in any circumstance other than as described in Section 3 below, the Award, including any accrued Dividend Equivalent Rights, shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date due to the Grantee&#8217;s Retirement, (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the Performance Units shall vest, provided that if the Qualifying Termination occurs prior to the last day of the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Post-Performance Period Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding Section 3(b), in the event the Grantee's Service is terminated due to Retirement subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Performance Units, if any, shall continue to accrue Dividend Equivalent Rights and the Performance Units and Dividend Equivalent Rights shall vest on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to Retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, cancel this Performance Award or reduce the number of Performance Units, prorated according to time or other measure as determined appropriate by the Company, if during any period prior to the Service Vesting Date the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Final Written Warning</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee is placed on final written warning (or its equivalent as determined by the Committee) at any time subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Grantee shall forfeit the Performance Units and Dividend Equivalent Rights scheduled to vest on the Service Vesting Date to the extent the Award is the next subsequent Award (when compared to other Awards held by the Grantee) that is scheduled to vest following the date that the Grantee is placed on final written warning (it being understood that all other Awards, if any, that are scheduled to vest on the Service Vesting Date shall also be forfeited).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Performance Units, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.35pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">The following shall apply in the event of a Transaction that occurs subsequent to the last day of the Performance Period but prior to the Service Vesting Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Performance Units are not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Performance Units shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.35pt">In the event that the Performance Units are converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination prior to the Service Vesting Date, then immediately as of the date of the Covered Termination, the Performance Units shall vest automatically in full.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, a vested Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the Service Vesting Date, including if the Award vests pursuant to Sections 3(b) or 3(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 3(b)(ii) or (iii) subsequent to the last day of the Performance Period, the Award shall be paid to the Grantee no later than sixty (60) days following the date of the Grantee&#8217;s termination of Service under Section 3(b)(ii) or (iii), provided that if the Award is considered an item of nonqualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;), the Award shall be paid within sixty (60) days following the date the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (i) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (ii) the date of the Grantee&#8217;s death, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(i) or Section 4(c)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered NQ Deferred Compensation and the Transaction does not constitute a &#8220;change in control event&#8221; under Section 409A of the Code (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(ii) or Section 4(c)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5, Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(f) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">At any time prior to the Service Vesting Date or until the Performance Units are paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Performance Units in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Restriction Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(d).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Dividend Equivalent Rights, if any, that accrue hereunder shall be settled in cash.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On each date that the Company pays a cash dividend to holders of Shares during the period commencing on the date the number of Performance Units are determined continuing through the date the Performance Units are settled, the Grantee shall be credited with Dividend Equivalent Rights in an amount equal to the total number of Performance Units, multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date.  Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The Dividend Equivalent Rights shall be subject to the same vesting conditions and restrictions as the Performance Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Performance Units with respect to which such Dividend Equivalent Rights were credited are forfeited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the accrual and payment of Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award and any Dividend Equivalent Rights after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any shares of Lilly Stock that may be issued pursuant to this Award.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (A)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B)&#160;any officer, director, executive or senior management capacity or function&#59; (C)&#160;any research and development capacity or function&#59; (D)&#160;any sales management or business development management capacity or function&#59; (E)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font><font style="color:#c00000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Performance Units subject to the Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i)&#160;&#160;&#160;&#160;the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eli Lilly and Company Performance Award Agreement (Executive Officer)</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>lly-20211231x10kexhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibed6bb94eeb64d41884ce72c5573552b_110"></div><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.4 Form of Performance Award under the 2002 Lilly Stock Plan (non-executive officer)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Performance Award Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><img alt="a104performancelevelimagea.jpg" src="a104performancelevelimagea.jpg" style="height:186px;margin-bottom:5pt;vertical-align:text-bottom;width:609px"></div><div style="padding-right:-6.75pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">January 1, 2022 &#8211; December 31, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibed6bb94eeb64d41884ce72c5573552b_113"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.277%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s Acknowledgement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:-2.7pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 2</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;Target Number of Shares&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Vesting</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares eligible to vest based on the actual cumulative Earnings Per Share (&#8220;EPS&#8221;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#8220;US GAAP&#8221;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-top:6pt;padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.04pt">To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-top:6pt;padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.36pt">To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 3</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">The number of Shares eligible to vest under this Performance Award will be the number of Shares resulting from the calculation described in subsection (b) above. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such adjustments are not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below, in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date due to the Grantee&#8217;s Retirement, (ii) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements&#59; or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following July 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 4</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee&#8217;s Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Performance Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee and&#47;or the Company&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee&#8217;s Service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Change in Control</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 5</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Settlement  </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the last day of the Performance Period.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i)&#160;the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s 409A Separation (the &#8220;409A Delayed Payment Date&#8221;), (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 6</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation and&#160;(ii) if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the 409A Delayed Payment Date and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Prohibition Against Transfer</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Grantee&#8217;s Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 7</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A)&#160;withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B)&#160;arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.04pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 8</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Section 409A Compliance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Grantee&#8217;s Acknowledgement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 9</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 10</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on applicable law and that, depending on where the Grantee is based and subject to the conditions set out in such applicable law, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 11</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Performance Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Governing Law and Choice of Venue</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 12</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 13</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Performance Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-22.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 14</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>lly-20211231x10kexhibit105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idbd6ad9d9cfd4b40acdec7e165c25b8b_140"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.5 &#8212; Form of Shareholder Value Award under the 2002 Lilly Stock Plan</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.379%"><tr><td style="width:1.0%"></td><td style="width:14.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Payout</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 6</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Final Lilly Stock Price</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60; $246.99</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$246.99 &#8211;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.85</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.86</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.71</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.72</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.59</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.45</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.46</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$416.32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#62;$416.32</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.264%"><tr><td style="width:1.0%"></td><td style="width:93.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="idbd6ad9d9cfd4b40acdec7e165c25b8b_143"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer) </font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Percent of Target</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the percentage set forth in the Lilly Stock Price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Lilly Stock Price measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">the Grantee&#8217;s Service is terminated due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment, and (5) the Grantee&#8217;s Service has been terminated by reason of retirement as a &#8220;retiree&#8221; (as defined in Section 3(c)(i)) shall be final and binding on the Grantee.  </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death, and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:9.8pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any Shares subject to, or issued pursuant to the Award.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:2.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>8
<FILENAME>lly-20211231x10kexhibit106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i168b725971e04f4f93140a8cb7413357_127"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.6 Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.379%"><tr><td style="width:1.0%"></td><td style="width:14.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Payout</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 6</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Final Lilly Stock Price</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60; $246.99</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$246.99 &#8211;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.85</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.86</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.71</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.72</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.59</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.45</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.46</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$416.32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#62;$416.32</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="i168b725971e04f4f93140a8cb7413357_130"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer) </font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Percent of Target</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the percentage set forth in the Lilly Stock Price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Lilly Stock Price measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date due to the Grantee&#8217;s Retirement, (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:9.8pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any Shares subject to, or issued pursuant to the Award.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:2.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (A)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B)&#160;any officer, director, executive or senior management capacity or function&#59; (C)&#160;any research and development capacity or function&#59; (D)&#160;any sales management or business development management capacity or function&#59; (E)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity. </font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement (Executive Officer)</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>lly-20211231x10kexhibit107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2ba8c34121904dfc821400c4df754aba_86"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.7 &#8212; Form of Shareholder Value Award under the 2002 Lilly Stock Plan (non-executive officer)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Payout</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 5</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.95pt;padding-right:2.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 6</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:-2.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Final Lilly </font></div><div style="padding-left:2.75pt;padding-right:-2.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Price</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60; $130.29</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$130.29</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.85</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$280.86</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:0.05pt;padding-right:0.05pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.71</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$314.72</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$348.59</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.45</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$382.46</font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$416.32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#62;$416.32</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58;&#160;&#160;&#160;&#160;January 1, 2022 &#8211; December 31, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.277%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;Target Number of Shares&#8221;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58; </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">&#8220;Percent of Target&#8221; shall mean the percentage set forth in the Lilly Stock price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Stock Price measured against the performance goal attainment levels set forth in the table, and</font></div><div style="padding-left:58.5pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">&#8220;Final Lilly Stock Price&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below, in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date due to the Grantee&#8217;s Retirement, (ii) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements&#59; or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59;</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following July 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee&#8217;s Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="padding-left:58.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company. </font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee and&#47;or the Company&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee&#8217;s Service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:94.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.51pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="padding-left:94.5pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:94.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.85pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Settlement  </font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s 409A Separation (the &#8220;409A Delayed Payment Date&#8221;), (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation and (ii) if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the 409A Delayed Payment Date and (2) the date of the Grantee&#8217;s death.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="padding-left:58.5pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c).</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Rights of the Grantee</font></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.5pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.5pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Responsibility for Taxes</font></div><div style="padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.5pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.5pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A)&#160;withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B)&#160;arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee. </font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above. </font></div><div><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:32.24pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:108pt;text-indent:-90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.68pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Data Privacy</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:11.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on applicable law and that, depending on where the Grantee is based and subject to the conditions set out in such applicable law, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Shareholder Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.  </font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:25.02pt">Miscellaneous Provisions</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Shareholder Value Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:20.52pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page 14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>10
<FILENAME>lly-20211231x10kexhibit108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1da100f2fa67421da30bc865b7ca77f9_88"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.8 Form of Relative Value Award under the 2002 Lilly Stock Plan</font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Relative Total Shareholder Return Performance Levels&#58;</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:17.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Absolute Percentage Point (pp) Difference from Peer Median TSR</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> -30pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.35pt;padding-right:1.35pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-24.0 pp</font></div><div style="padding-right:-0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-18.0 pp</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-12.0 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-6.0 pp</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-0.01 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-5.9 pp</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peer Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+5.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+6.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+12.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+18.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+24.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> +30 pp</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payout Multiple</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.0</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.25</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.40</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.55</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.70</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.85</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.00</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.30</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.60</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75</font></td></tr></table></div><div style="padding-left:13.5pt;padding-right:18pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="i1da100f2fa67421da30bc865b7ca77f9_91"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The stock prices and cash dividend payments reflected in the calculation of TSR shall be adjusted to reflect stock splits during the Performance Period and dividends shall be assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of TSR.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the comparison between Lilly&#8217;s TSR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group.   </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">the Grantee&#8217;s Service is terminated due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability, (3) the Grantee&#8217;s Service has been terminated as a result a direct result of either a plant closing or a reduction in force, (4) the Grantee&#8217;s Service has been terminated of as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment, and (5) the Grantee&#8217;s Service has been terminated by reason of retirement as a &#8220;retiree&#8221; (as defined in Section 3(c)(i)) shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.89pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>11
<FILENAME>lly-20211231x10kexhibit109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6dfbde3f4b724616af8f3a49cbaced4d_83"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.9 &#8212; Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt;padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Relative Total Shareholder Return Performance Levels&#58;</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:17.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Absolute Percentage Point (pp) Difference from Peer Median TSR</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> -30pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.35pt;padding-right:1.35pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-24.0 pp</font></div><div style="padding-right:-0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-18.0 pp</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-12.0 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-6.0 pp</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-0.01 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-5.9 pp</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peer Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+5.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+6.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+12.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+18.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+24.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> +30 pp</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payout Multiple</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.0</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.25</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.40</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.55</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.70</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.85</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.00</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.30</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.60</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75</font></td></tr></table></div><div style="padding-left:13.5pt;padding-right:18pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:39.6pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="i6dfbde3f4b724616af8f3a49cbaced4d_86"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The stock prices and cash dividend payments reflected in the calculation of TSR shall be adjusted to reflect stock splits during the Performance Period and dividends shall be assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of TSR.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the comparison between Lilly&#8217;s TSR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group.   </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date due to the Grantee&#8217;s Retirement, (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a result a direct result of either a plant closing or a reduction in force and (4) the Grantee&#8217;s Service has been terminated of as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.89pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Competively-Sensitive Capacity&#8221; means&#58; (A)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (B)&#160;any officer, director, executive or senior management capacity or function&#59; (C)&#160;any research and development capacity or function&#59; (D)&#160;any sales management or business development management capacity or function&#59; (E)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (F)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition, the Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>12
<FILENAME>lly-20211231x10kexhibit1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i69297085c0cb4597aa565e82ec42701c_108"></div><div style="min-height:77.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.10 Form of Relative Value Award under the 2002 Lilly Stock Plan (non-executive officer)</font></div><div style="padding-right:39.6pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">(for Executives)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Lilly Relative Total Shareholder Return Performance Levels&#58;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:17.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Absolute Percentage Point (pp) Difference from Peer Median TSR</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> -30pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:1.35pt;padding-right:1.35pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-24.0 pp</font></div><div style="padding-right:-0.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.55pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-18.0 pp</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.65pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-12.0 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-6.0 pp</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-0.01 pp</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="padding-right:-0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-5.9 pp</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peer Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+5.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+6.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+11.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+12.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+17.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+18.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+23.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+24.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+29.9 pp</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> +30 pp</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payout Multiple</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.0</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.25</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.40</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.55</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.70</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.85</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.00</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.30</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.60</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75</font></td></tr></table></div><div style="padding-left:13.5pt"><font><br></font></div><div style="padding-left:13.5pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2022 &#8211; December 31, 2024</font></div><div style="padding-left:126pt;padding-right:126pt;text-align:center;text-indent:-198pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div style="padding-right:31.5pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 2</font></div></div></div><div id="i69297085c0cb4597aa565e82ec42701c_111"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The stock prices and cash dividend payments reflected in the calculation of TSR shall be adjusted to reflect stock splits during the Performance Period and dividends shall be assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of TSR.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the comparison between Lilly&#8217;s TSR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent.   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group.   </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided below, in the event the Grantee&#8217;s Service is terminated (i) on or following the Retirement Vesting Date due to the Grantee&#8217;s Retirement, (ii) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following July 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s and&#47;or the Compamy&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a result a direct result of either a plant closing or a reduction in force and (4) the Grantee&#8217;s Service has been terminated of as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.89pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.01pt">If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.35pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.69pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:14.24pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.67pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.17pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Relative Value Award Agreement</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:100%;padding-left:7.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page 14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>13
<FILENAME>lly-20211231x10kexhibit1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2f6c4b37ecc348498b5e74433ec00fbf_123"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11 &#8212; Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:100%">Restricted Stock Unit Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:400;line-height:100%">(for Executive Officer)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Restricted Stock Unit Award has been granted on &#91;INSERT DATE&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:180pt;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">Vesting Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">100% on &#91;INSERT DATE&#93;</font></div><div style="padding-left:180pt;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(except as otherwise provided in this </font></div><div style="padding-left:180pt;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Restricted Stock Unit Award Agreement)</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:-2.7pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:125%">Table of Contents</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant of Restricted Stock Units</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s Acknowledgement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:-2.7pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Grant of Restricted Stock Units</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the &#8220;Grantee&#8221;) an award of restricted stock units (the &#8220;Restricted Stock Units&#8221; or the &#8220;Award&#8221;) with respect to the number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Restricted Stock Unit Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 11 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Vesting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:15pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">For purposes of the vesting provisions set forth in Section 2 of this Award Agreement, the following definitions will apply&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">&#8220;Disability&#8221; means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as may be determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="padding-left:99pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="padding-left:99pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.67pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.67pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:99pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The Award shall vest at the close of business in Indianapolis, Indiana, U.S.A. on the earliest of the following dates (each, a &#8220;Vesting Date&#8221;)&#58;</font></div><div style="margin-top:12pt;padding-left:99pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.36pt">&#91;INSERT DATE&#93; with respect to 100% of the Award, provided the Grantee is still in active Service on the Vesting Date, </font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to any alternative date(s) set forth in any appendix attached hereto (the &#8220;Appendix&#8221;), or </font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">the date the Grantee&#8217;s Service is terminated (A) due to the Grantee&#8217;s death or (B) by reason of the Grantee&#8217;s Disability, with respect to 100% of the Award, or</font></div><div style="padding-left:99pt"><font><br></font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.04pt">the date the Grantee is subject to a Qualifying Termination, in which case the number of Restricted Stock Units that shall vest shall be reduced proportionally for the portion of the total days between the Grant Date and the Vesting Date specified in 2(b)(i) that the Grantee was not in active Service. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee&#8217;s determination as to whether (A) the Grantee&#8217;s Service has been terminated by reason of Disability, (B) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in workforce, (C) the Grantee&#8217;s Service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment, and (D) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service shall be final and binding on the Grantee.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">In the event the Grantee's Service with the Company or an Affiliate is terminated prior to a Vesting Date for any reason or in any circumstance other than those specified in Sections 2(b)(ii) or 2(b)(iii), any unvested portion of the Award will be forfeited.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The Committee may, at its discretion, cancel the Award or reduce the number of Restricted Stock Units and any accrued Dividend Equivalent Rights, prorated according to time or other measure as deemed appropriate by the Committee, if at any time prior to the Vesting Date, the Grantee has been (i) subject to disciplinary action by the Company, or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">The only Change in Control event that shall result in a benefit under this Section 3 shall be the consummation of a merger, share exchange, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event that the Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Award shall vest automatically in full.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">In the event that the Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to any applicable Vesting Date, the Award shall vest automatically in full. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this provision, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 2(b)(ii) and 2(b)(iii), Grantee&#8217;s termination without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 3, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.&#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Settlement  </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable and generally within sixty (60) days following the applicable Vesting Date, or, if earlier, a vesting event contemplated under the Section 3 above.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">At such time,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 4(c) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">At any time prior to the applicable Vesting Date or until the Award is paid in accordance with this Section 4, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares. The amount of cash shall be calculated based on the Fair Market Value of the Shares on the applicable Vesting Date. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:23.3pt">Rights of the Grantee </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Restricted Stock Units do not entitle the Grantee to any rights of a shareholder of Lilly until such time as the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restricted Stock Units vest and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As long as the Grantee holds Restricted Stock Units granted pursuant to this Award, the Company shall accrue for the Grantee, on each date that the Company pays a cash dividend to holders of Company Shares, Dividend Equivalent Rights equal to the total number of Restricted Stock Units credited to the Grantee under this Award multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date. Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  A report showing the accrued Dividend Equivalent Rights shall be sent to the Grantee periodically, as determined by the Company.  The accrued Dividend Equivalent Rights shall be subject to the same vesting conditions as the Restricted Stock Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Restricted Stock Units with respect to which such Dividend Equivalent Rights were credited are forfeited. Following the applicable Vesting Date, Lilly shall pay to the Grantee in cash all accrued Dividend Equivalent Rights in accordance with Section 4 above.</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Responsibility for Taxes</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Regardless of any action Lilly and&#47;or the Grantee&#8217;s Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Restricted Stock Units, the accrual of Dividend Equivalent Rights, the vesting of the Restricted Stock Units and the lapse of restrictions, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award and&#47;or Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.36pt">In the case of Dividend Equivalent Rights paid to the Grantee and if the Restricted Stock Units are paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt">If the Restricted Stock Units are paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award  (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale,  (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.04pt">If the Restricted Stock Units are paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 7(b)(ii)(A) and (B) above.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee, in which case the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">Lilly may require the Grantee to pay Lilly and&#47;or the Employer any amount of Tax Related Items that Lilly and&#47;or the Employer may be required to withhold or account for as a result of any aspect of this Award that cannot be satisfied by the means previously described.  Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 7. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Section 409A Compliance</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:27.8pt">Grantee&#8217;s Acknowledgement</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future awards of Restricted Stock Units and&#47;or Dividend Equivalent Rights, or benefits in lieu thereof, even if Restricted Stock Units and&#47;or Dividend Equivalent Rights have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">all decisions with respect to future awards of Restricted Stock Units, Dividend Equivalent Rights or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.34pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee's employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee's employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.68pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:20.02pt">Data Privacy</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Share Units or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent. Where required under applicable law, Data may also be disclosed to certain securities or other regulatory authorities where the Company's securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the applicable laws.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner. The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company's legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:29.34pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on applicable law and that, depending on where the Grantee is based and subject to the conditions set out in such applicable law, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not offer an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:20.02pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Insider Trading&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell,&#160; or otherwise dispose of Shares or rights to acquire Shares (e.g., Restricted Stock Units) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing. Without limitation to the foregoing, the Grantee agrees that the Restricted Stock Unit Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:20.02pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana. For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:20.02pt">Miscellaneous Provisions</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.67pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:20.02pt">Compensation Recovery</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time during the three years following the date on which the number of shares of Lilly Stock subject to this Award was determined, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any&#160;shares&#160;of Lilly Stock subject to or issued (or cash paid) pursuant to this Award if&#58;</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a. (i)&#160;&#160;&#160;&#160;the number of&#160;shares of Lilly Stock subject to the Award was calculated based, directly or indirectly, upon the achievement of&#160;financial results (e.g., earnings per share) that were subsequently the subject of restatement of all or a portion of the Company&#8217;s financial statements&#59;</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the number of&#160;shares of Lilly Stock that would have been subject to the Award had the financial results been properly reported would have been lower than the number of&#160;shares&#160;of Lilly Stock actually&#160;subject to the Award.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the company.</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event the number of shares of Lilly Stock subject to the Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will&#58;</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">seek restitution of the shares of Lilly Stock subject to or issued (or cash paid) pursuant to this Award to the extent that the number of shares of Lilly Stock subject to the Award exceeded the number of shares of Lilly Stock that would have been subject to the Award had the inaccuracy or error not occurred, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26pt">issue additional shares of Lilly Stock or make additional cash payment to the extent that the number of shares of Lilly Stock subject to the Award was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Section 14 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:100%;padding-left:20.02pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;INSERT DATE&#93;, through the website of Merrill, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;INSERT DATE&#93;, the Award will be cancelled, subject to the Committee's discretion for unforeseen circumstances. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; _________________________</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Page 14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>14
<FILENAME>lly-20211231x10kexhibit1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4d2853518a504f62a72dacaee3838906_46"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.17 &#8212; The Loxo Oncology, Inc. Bonus Plan</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">The Loxo Oncology, Inc. Bonus Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">(effective January 1, 2021)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4d2853518a504f62a72dacaee3838906_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.  PURPOSE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.  DEFINITIONS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.  ADMINISTRATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.  PARTICIPATION IN THE PLAN</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.  DEFINITION AND COMPUTATION OF COMPANY BONUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.  TIME OF PAYMENT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.  ADMINISTRATIVE GUIDELINES</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.  MISCELLANEOUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.  AMENDMENT, SUSPENSION, OR TERMINATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- i -</font></div></div></div><div id="i4d2853518a504f62a72dacaee3838906_52"></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Loxo Oncology, Inc. Bonus Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(effective January 1, 2021)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 1.  PURPOSE</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The purpose of The Loxo Oncology, Inc. Bonus Plan is to encourage and promote eligible employees to create and deliver innovative pharmaceutical-based health care solutions that enable people to live longer, healthier and more active lives, to outgrow our competitors through a constant stream of pharmaceutical innovation, and to materially increase shareholder value.  The Plan is designed to accomplish the following key objectives&#58;</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:42.68pt">motivate superior employee performance through the implementation of a Company performance-based bonus system for all eligible management employees, United States employees and other employees as may be designated from time to time&#59; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:87pt;text-indent:-51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:42pt">create a direct relationship between key company measurements and individual bonus payouts&#59; and </font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:42.68pt">enable the Company to attract and retain employees that will be instrumental in driving sustained growth and performance of the Company by providing a competitive bonus program that rewards outstanding performance consistent with the Company&#8217;s mission, values and increased shareholder value of Lilly. </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 2.  DEFINITIONS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following words and phrases as used in this Plan will have the following meanings unless a different meaning is clearly required by the context.  Masculine pronouns will refer both to males and to females&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Additional Cash Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means an additional incentive opportunity for Eligible Employees as described in subsection 5.4 below.  The Additional Cash Award is available to Eligible Employees beginning with the 2020 Applicable Year and thereafter. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Applicable Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the calendar year immediately preceding the year in which payment of the Company Bonus (and, for 2020 and thereafter, Additional Cash Award) is payable pursuant to Section 6.  For example, the Applicable Year for 2022 payout is January 1, 2021 through December 31, 2021.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Bonus Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the percentage of Participant Earnings for each Participant as described in Section 5.3(a) below.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (i) with respect to members of the Committee, the Lilly Review Committee&#59; and (ii) with respect to all other Eligible Employees, the Loxo Oncology Steering Committee or its designee.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means Loxo Oncology, Inc.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Company Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the amount of bonus compensation payable to a Participant as described in Section 5 below.  Notwithstanding the foregoing, however, the Committee </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may determine, in its sole discretion, to reduce the amount of a Participant&#8217;s Company Bonus if such Participant becomes eligible to participate in such other bonus program of the Company as may be specifically designated by the Committee.  Such reduction may be by a stated percentage up to and including 100% of the Company Bonus.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Company Performance Bonus Multiple</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the phrase as defined by the terms of The Lilly Bonus Plan and calculated consistent with the terms of such plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Disabled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means a Participant employed by the Company who has become eligible for a payment under The TriNet IV Long-Term Disability Plan, assuming eligibility to participate in that plan&#59; or a Participant employed by Lilly who has become eligible for a payment under The Eli Lilly and Company Long Term Disability Plan, assuming eligibility to participate in that plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means January 1, 2020, as amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">a person who is (1) employed as an employee by the Company on a scheduled basis of twenty (20) or more hours per week and is scheduled to work at least five (5) months per year&#59; and (2) receiving compensation, including short-term disability under The TriNet IV Short-Term Disability Program or similar short-term disability program from the Company for services rendered as an employee&#59; and</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">a person who is (1) employed as an employee by Lilly or a wholly-owned subsidiary of Lilly on a scheduled basis of twenty (20) or more hours per week and is scheduled to work at least five (5) months per year&#59; and (2) receiving compensation, including short-term disability under Lilly&#8217;s Short-Term Disability Illness Pay Program for services rendered as an employee&#59; and (3) designated by the Committee (either on an individual, group, or combined basis) as a member of &#8220;Loxo Oncology at Lilly&#8221; for purposes of eligibility to participate in this Plan.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">Notwithstanding anything herein to the contrary, the term &#8220;Eligible Employee&#8221; will not include&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a person who is Disabled&#59;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a person who is a &#8220;leased employee&#8221; within the meaning of Section 414(n) of the Internal Revenue Code of 1986, as amended, or whose basic compensation for services on behalf of the Company is not paid directly by the Company&#59; </font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a person who is classified as a special status employee because his employment status is temporary, seasonal, or otherwise inconsistent with regular employment status&#59; </font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a person who is eligible to participate in a separate bonus or incentive plan for eligible employees of Loxo Oncology, Inc. as may be specifically designated by the Committee or its designee&#59;  </font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a person who submits to the Committee in writing a request that he not be considered eligible for participation in the Plan&#59; or</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any other category of employees designated by the Committee in its discretion with respect to any Applicable Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Notwithstanding anything herein to the contrary, the term Eligible Employee will not include any person who is not so recorded on the payroll records of the Company, including any such person who is subsequently reclassified by a court of law or regulatory body as a common law employee of the Company.  Consistent with the foregoing, and for purposes of clarification only, the term employee or Eligible Employee does not include any individual who performs services for the Company as an independent contractor or under any other non-employee classification.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means Eli Lilly and Company.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means an Eligible Employee who is participating in the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Participant Earnings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (A) those amounts described below that are paid during the portion of the Applicable Year during which the employee is a Participant in the Plan&#58;</font></div><div><font><br></font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">regular compensation, overtime, shift premiums and other forms of additional compensation determined by and paid currently pursuant to an established formula or procedure&#59; </font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">salary reduction contributions to The Loxo Oncology, Inc. 401(k) Plan or The Lilly Employee 401(k) Plan or elective contributions under any similar tax-qualified plan that is intended to meet the requirements of Section 401(k) of the Internal Revenue Code or similar Company savings program&#59;</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">elective contributions to any cafeteria plan that is intended to meet the requirements of Section 125 of the Internal Revenue Code or other pre-tax contributions to a similar Company benefit plan&#59; </font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">payments made under the terms of The TriNet IV Short-Term Disability Program or other similar Company program during an Applicable Year to a Participant who is on approved leave of absence and is receiving one hundred percent (100%) of his base pay&#59; and</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">other legally-mandated or otherwise required pre-tax deductions from a Participant&#8217;s base salary. </font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the term &#34;Participant Earnings&#34; does not include&#58;</font></div><div><font><br></font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">       compensation paid in lieu of earned vacation&#59; </font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">amounts contributed to a qualified plan (as described in ERISA), except as provided in clause (A)(ii), above&#59;</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">payments made under the terms of The TriNet IV Short-Term Disability Program or other similar Company leave program during an Applicable Year to a Participant who is on approved leave of absence and is receiving less than the full amount of his base pay&#59;</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">amounts paid under this Plan or other bonus or incentive program of the Company&#59;</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">payments made under any severance-type benefit (whether company-sponsored or mandated by law) arising out of or relating to a Participant&#8217;s termination of employment&#59; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">payments based upon the discretion of the Company&#59;</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">amounts paid as commissions, sales bonuses, or any premium payments paid to those deemed by the Company as essential onsite personnel in conjunction with COVID-19 efforts&#59; or</font></div><div style="padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">earnings with respect to the exercise, vesting, or payment of any equity-based awards, including but not limited to stock options, restricted stock units, restricted stock, and performance share units.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means The Loxo Oncology, Inc. Bonus Plan as set forth herein and as hereafter modified or amended from time to time.  The Plan is an incentive compensation program and is not subject to the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), pursuant to Department of Labor Regulation Section 2510.3.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Plant Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the closing of a plant site or other Company location that directly results in termination of employment.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Reduction in Workforce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of employment.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 3.  ADMINISTRATION</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan will be administered by the Committee or, if the name of the Committee is changed, the Plan will be administered by such successor committee.  For all Eligible Employees other than members of the Committee, the Committee may delegate all or a portion of its responsibilities within its sole discretion by resolution.  Any reference in this Plan to the Committee or its authority will be deemed to include such designees (other than with respect to decisions relating to members of the Committee or for purposes of Section 9).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Powers of the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee will have the full power and authority in its discretion to</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">interpret the terms and provisions of the Plan and to determine any and all questions arising under the Plan, including, without limitation, the right to remedy possible ambiguities, inconsistencies, or omissions by a general rule or particular decision&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">adopt, amend and rescind rules consistent with the Plan&#59;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">make exceptions in particular cases to the rules of eligibility for participation in the Plan (except with respect to Eligible Employees who are members of the Committee)&#59; </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">determine whether, to what extent, and under what circumstances payments made or to be made should be recovered or forfeited under Lilly&#8217;s Executive Compensation Recovery Policy as in effect from time to time&#59; and </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">delegate authority for administration of the Plan with respect to any Eligible Employee except for members of the Committee.  The Committee will take all necessary action to approve the timing of payments, as necessary.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Certification of Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Before any amount is paid under the Plan, the Committee will confirm the certification of the Company Performance Bonus Multiple for the Applicable Year from Lilly in writing and the satisfaction of all other material terms of the calculation of the Company Bonus as well as any Additional Cash Award.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Finality of Committee Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any determination by the Committee of the Company Performance Bonus Multiple or any other performance measure, and the level and entitlement to Company Bonus, Additional Cash Award, and any interpretation, rule, or decision adopted by the Committee under the Plan or in carrying out or administering the Plan, will be final and binding for all purposes and upon all interested persons, their heirs, and personal representatives.  The Committee may rely conclusively on determinations made by Lilly and its auditors to determine the Company Performance Bonus Multiple, Additional Cash Award, and related information for administration of the Plan, whether such information is determined by the Company, Lilly, auditors or a third-party vendor engaged specifically to provide such information to the Company.  This subsection is not intended to limit the Committee&#8217;s power, to the extent it deems proper in its discretion, to take any action permitted under the Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 4.  PARTICIPATION IN THE PLAN</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Only Eligible Employees may participate in and receive payments under the Plan.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Commencement of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An Eligible Employee will become a Participant in the Plan on the date on which the individual completes at least one hour of employment as an Eligible Employee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Termination of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An Eligible Employee will cease to be a Participant upon termination of employment with the Company for any reason, or at the time he otherwise ceases to be an Eligible Employee under the Plan&#59; provided, however, a terminated Participant shall be eligible for a Company Bonus and Additional Cash Award to the extent provided in Section 5.6.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 5.  DEFINITION AND COMPUTATION OF COMPANY BONUS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AND ADDITIONAL CASH AWARD</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Computation of Company Bonus for Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Company Bonus amounts will depend significantly on Lilly company performance.  As more specifically described below, a Participant&#8217;s Company Bonus is calculated by multiplying the Participant&#8217;s Bonus Target by his Participant Earnings and the Company Performance Bonus Multiple.  For certain eligible employees, whether an individual met their job expectations may also impact the Company Bonus calculation, as described in Section 5.3(c) below.  Company Bonuses are paid out to eligible Participants in the manner provided below.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Company Performance Bonus Multiple Threshold and Ceiling&#59; Committee&#8217;s Downward Discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company Performance Bonus Multiple will not be less than 0.25 or greater than 2.0 in an Applicable Year.  Notwithstanding the foregoing, at any time prior to certification as described in Section 3.3, the Committee in its discretion may reduce </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company Performance Bonus Multiple (including but not limited to a reduction below 0.25) for some or all Eligible Employees.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Participant Company Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Bonus Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Not later than 90 days after the beginning of the Applicable Year, the Bonus Target for each Participant, whether such Participant is designated on an individual basis or by specified job categories, classifications, levels, or other appropriate classification, will be determined by the Committee on a basis that takes into consideration a Participant's pay grade level and job responsibilities.  The Bonus Target for each Participant for the Applicable Year will be expressed as a percentage of Participant Earnings as of December 31 of the Applicable Year.  No later than early in the Applicable Year, each Participant will receive information regarding the Participant&#8217;s Bonus Target.  In the event that a Participant&#8217;s pay grade level changes during the Applicable Year (e.g., because of promotion, demotion or otherwise), the Participant&#8217;s Bonus Target will be prorated based on the Bonus Target applicable to each pay grade level (with related job responsibilities) and the percentage of time that the Participant is employed at each pay grade level during the Applicable Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Company Bonus Calculation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as described in Section 5.3(c) below, a Participant&#8217;s Company Bonus will equal the product of the Company Performance Bonus Multiple and the Participant&#8217;s Bonus Target and the Participant&#8217;s Earnings.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Adjustment for Individual Performance Multiplier, if Applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything herein to the contrary, all Participants may be subject to individual performance multipliers.  For any such Participants subject to an individual performance multiplier, the amount calculated in Section 5.3(b) above will be adjusted based on whether the Participant met job expectations as determined by the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company at the end of the Applicable Year.  If a Participant does not meet such job expectations, the Participant will receive an individual performance multiplier equal to either 0.0 or 0.5, as determined by the Company.  In that event, the individual performance multiplier will be multiplied by the amount described in Section 5.3(b) above to calculate the Participant&#8217;s Company Bonus.  If a Participant meets job expectations, the Participant&#8217;s Company Bonus will equal the amount calculated in Section 5.3(b) above.  In addition, if a Participant meets job expectations, the Company may increase the Participant&#8217;s Company Bonus by an additional amount based on its determination of the Participant&#8217;s individual performance and related factors.  Not later than 90 days after the beginning of the Applicable Year, the Committee will determine applicable multipliers for meeting job expectations or ranges for the applicable rating system in effect for the Participant.  For each such Participant, such rating will be determined by the Participant&#8217;s supervision.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that a Participant does not receive a year-end performance rating, but is otherwise eligible for a Company Bonus, the amount calculated in Section 5.3(b) will be multiplied by 1.0 so that the Participant&#8217;s actual Company Bonus will be the amount calculated in Section 5.3(b) above.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Computation of Additional Cash Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to Company Bonus amounts described above, Eligible Employees may be eligible for an Additional Cash Award beginning with the 2020 Applicable Year and thereafter.  The Additional Cash Award amounts will depend significantly on Loxo company performance.  In general, a Participant&#8217;s Additional Cash Award will equal the product of the Additional Cash Award Multiple and the Participant&#8217;s Bonus Target and the Participant&#8217;s Earnings.  The Additional Cash Award Multiple may range from 0 to 2.0 and will be calculated as described below.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specifically, the Company will adopt a combination of business objectives that will be assessed at the end of each Applicable Year (beginning with the 2020 Applicable Year) by Lilly for determining whether Loxo will provide an Additional Cash Award to Eligible Employees.  Beginning with the 2021 Applicable Year, such metrics may include, but are not limited to, milestones established by the Company relating to preclinical, clinical, external innovation and&#47;or scientific disclosure objectives.  The achievement of each business objective will result in a point being awarded toward the overall evaluation of Company achievement with critical development milestones carrying more weight than other achievements as defined by the Committee.  Company achievements will result in an Additional Cash Award Multiple between 0 to 2.0 as assessed by Lilly.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Conditions on Company Bonus and Additional Cash Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Payment of any Company Bonus and&#47;or Additional Cash Award is neither guaranteed nor automatic.  A Participant&#8217;s Company Bonus and Additional Cash Award are not considered to be any form of compensation, wages, or benefits, unless and until paid. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Required Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as provided below in this Section 5.6, required by applicable law or as otherwise designated by the Committee, if a Participant is not employed by the Company on the last day of the Applicable Year, or is otherwise not an Eligible Employee on that date, the Participant is not entitled to any Company Bonus payment or Additional Cash Award under this Plan for that Applicable Year.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant who, on the last day of the Applicable Year, is on approved leave of absence under the Family and Medical Leave Act of 1993, military leave under the Uniformed Services Employment and Reemployment </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rights Act, or such other approved leave of absence will be considered to be an Eligible Employee on that date for purposes of this Plan.  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An employee who is a Participant in this Plan for a portion of the Applicable Year and then transfers to a position within the Company in which he is ineligible to participate in this Plan, but who remains employed by the Company on the last day of the Applicable Year, will be treated as satisfying the last-day-of-Applicable Year requirement for purposes of this Plan.  In that event, his Company Bonus and Additional Cash Award will be based on his Participant Earnings for the portion of the Applicable Year in which the employee was a Participant in the Plan.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as described below, a Participant who was an Eligible Employee for some portion of the Applicable Year and then becomes and remains Disabled through the end of the Applicable Year, or dies during the Applicable Year will be considered to satisfy the last-day-of-Applicable-Year requirement described in this Section 5.6 for purposes of this Plan.  </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Plant Closing or Reduction in Workforce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Participant who was an Eligible Employee for some portion of the Applicable Year and whose employment is terminated as a result of his failure to locate a position following a Plant Closing or Reduction in Workforce will be considered to satisfy the last-day-of-Applicable Year requirement described in this Section 5.6 for purposes of this Plan.  The Committee or its designee&#8217;s determination regarding whether a Participant&#8217;s termination is a direct result of either a Plant Closing or a Reduction in Workforce will be final and binding.   </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Notice of Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition, a Participant who submits a notice of resignation from employment with the Company prior to the end of the Applicable Year and whose effective date of resignation is two (2) weeks or less from the date of notice of resignation (or as otherwise required by law) will be considered employed by the Company for purposes of this Plan until the end of his specified notice period.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">New Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If an Eligible Employee began participation in the Plan during an Applicable Year and is eligible for a Company Bonus, his Company Bonus will be based on Participant Earnings paid after the employee became a Participant.  If an Eligible Employee began participation in the Plan during the 2020 Applicable Year before May 1, 2020, remains an Eligible Employee throughout the Applicable Year, and is eligible for an Additional Cash Award, his Additional Cash Award will be based on Participant Earnings for the entire 2020 Applicable Year.  If, however, an Eligible Employee began participation in the Plan during the 2020 Applicable Year on or after May 1, 2020, remains an Eligible Employee throughout the remainder of the Applicable Year, and is eligible for an Additional Cash Award, his Additional Cash Award will be based on Participant Earnings prorated for the period of time between May 1, 2020 and December 31, 2020 that the individual participated in the Plan.  Similarly, any Additional Cash Award for an Eligible Employee who begins participation in the Plan during the 2021 Applicable Year or after (and is otherwise eligible for an Additional Cash Award) will be based on Participant Earnings paid during the Applicable Year. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Minimum Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan, the minimum total amount of Company Bonus and&#47;or Additional Cash Award payable to Participants in the aggregate as a group or applicable subgroup (the &#8220;Minimum Amount&#8221;) may be fixed through a resolution of the Board of Directors of Lilly or the Committee, made before the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">end of the Applicable Year.  The Minimum Amount shall not be reduced or eliminated by the Company, including by either the Board of Directors of the Company or the Committee, following the end of the Applicable Year, but shall be payable to Participants as determined by the Company and consistent with the terms of the Plan.  In addition, the Minimum Amount shall not be reduced by any discretionary action to reduce a particular Participant&#8217;s Company Bonus or Additional Cash Award and shall be payable to persons, as determined by the Company, who are Participants in the Plan during the Applicable Year and eligible to receive a Company Bonus.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 6.  TIME OF PAYMENT</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Payment under the Plan will be made in the year following the Applicable Year on or prior to March 15 of such year.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Terminated Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as provided in Section 5.6 above, in the event an Eligible Employee&#8217;s employment with the Company ends for any reason prior to the last day of the Applicable Year, he will not receive any Company Bonus or Additional Cash Award for the Applicable Year.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Deceased Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event an Eligible Employee dies before payment under the Plan is made, the Committee may, in its sole discretion, authorize the Company to pay to his personal representative or beneficiary an amount not to exceed the amount established by the Committee to reflect the payment accrued at the date of death.  Any such payment would be paid consistent with the timing requirements described in subsection 6.1 above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 7.  ADMINISTRATIVE GUIDELINES</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Establishment and Amendment by the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee may establish objective and nondiscriminatory written guidelines for administering those provisions of the Plan that expressly provide for the determination of eligibility, Company Bonus, Additional Cash Award or benefits on the basis of rules established by the Committee.  The Committee may, from time to time, amend or supplement the administrative guidelines established in accordance with this subsection 7.1.  The administrative guidelines established or amended in accordance with this subsection 7.1 will not be effective to the extent that they materially increase the Plan's liability, or to the extent that they are inconsistent with, or purport to amend, any provision of the Plan set forth in a document other than such administrative guidelines.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment by Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any administrative guidelines established by the Committee pursuant to subsection 7.1 may be amended or revoked by the Board of Directors, either prospectively or retroactively, in accordance with the general amendment procedures set forth in section 9 below.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 8.  MISCELLANEOUS</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Vested Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No employee, participant, beneficiary, or other individual will have a vested right to a Company Bonus or Additional Cash Award or any part thereof until payment is made to him under Section 6.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of the Plan or any action taken by the Company, the Board of Directors of the Company, or the Committee will give any person any right to be retained in the employ of the Company.  The right and power of the Company to dismiss or discharge any Participant for any reason or no reason, with or without notice, is specifically reserved.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After the certification of the calculation of EPS, EPS Change, Revenue, Revenue Change, Pipeline Metrics and any other material terms of the calculation of the Company Performance Bonus Multiple, Company Bonus and Additional Cash Award for the Applicable Year as described in Section 3.3 above, no adjustments will be made to reflect any subsequent change in accounting, the effect of federal, state, or municipal taxes later assessed or determined, or otherwise.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Executive Compensation Recovery Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan, including Section 8.3, all payments made or to be made pursuant to the Plan are subject to Lilly&#8217;s Executive Compensation Recovery Policy, as in effect from time to time.  In addition, nothing herein shall limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its recurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner that it deems appropriate.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Other Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing contained in this Plan, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind, or a fiduciary relationship between the Company and any employee, participant, beneficiary, legal representative, or any other person.  Although Participants generally have no right to any payment from this Plan, to the extent that any Participant acquires a right to receive payments from the Company under the Plan, such right will be no greater than the right of an unsecured general creditor of the Company.  All payments to be made hereunder will be paid from the general funds of the Company and no special or separate fund will be established, and no segregation of assets will be made, to assure payment of such amount.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will make such provisions and take such steps as it may deem necessary or appropriate for the withholding of all federal, state, local, and other taxes required by law to be withheld with respect to Company Bonus and Additional Cash Award payments under the Plan, including, but not limited to, deducting the amount required to be withheld from the amount of cash otherwise payable under the Plan, or from salary or any other amount then or thereafter payable to an employee, Participant, beneficiary, or legal representative.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company Bonus and Additional Cash Award will be based on the currency in which the highest portion of base pay is regularly paid.  The Committee will determine the appropriate foreign exchange conversion methodology in its discretion.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Effect of Plan on other Company plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing contained in this Plan is intended to amend, modify, terminate, or rescind other benefit or compensation plans established or maintained by the Company.  Whether and to what extent a Participant&#8217;s Company </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bonus and Additional Cash Award is taken into account under any other plan will be determined solely in accordance with the terms of such plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Plan and all the rights thereunder will be governed by, and construed in accordance with, the laws of the state of Indiana, without reference to the principles of conflicts of law thereof.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given to the Company or Committee pursuant to the provisions of the Plan will be in writing and directed to Secretary, Loxo Oncology, Inc., Lilly Corporate Center, Indianapolis, IN 46285.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 9.  AMENDMENT, SUSPENSION, OR TERMINATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Board of Directors of the Company will have the right to amend, modify, suspend, revoke, or terminate the Plan, in whole or in part, at any time and without notice, by written resolution of the Board of Directors.  The Committee also will have the right to amend the Plan, except that the Committee may not amend this Section 9.  </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 12 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>15
<FILENAME>lly-20211231x10kexhibit21.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i009b1b7586b947e0b4ee3ce9217753c7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21 &#8212; List of Subsidiaries&#160;&#38; Affiliates</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following are subsidiaries and affiliated corporations of the company at December&#160;31, 2021.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain subsidiaries have been omitted as they are not significant in the aggregate.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1096401 B.C. Unlimited Liability Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acanthas Pharma, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnara Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andean Technical Operations Center</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARMO Biosciences, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AurKa Pharma, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avid Radiopharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CoLucid Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compania Farmaceutica Eli Lilly de Centro America S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermira, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermira Canada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista Ilac Ticaret Ltd. Sti.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista-Produtos Quimicos &#38; Farmaceuticos, LDA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elanco Animal Health Ireland Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elanco Switzerland Holding Sarl</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Dominicana SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO for Trade and Marketing, S.A.E.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Insurance Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Management, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELGO Insurance Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Malaysia) Sdn. Bhd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Philippines), Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (S.A.) (Proprietary) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Singapore) Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Suisse) S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (India) Pvt. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Ireland) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (N.Z.) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Taiwan), Inc.  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Asia Pacific SSC Sdn Bhd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Asia, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Australia Pty. Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Benelux S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly B-H d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Bienes y Servicios S de RL de CV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Cork Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly CR s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Danmark A&#47;S</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly do Brasil Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Egypt, for Trading</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly European Clinical Trial Services SA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Export S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly farmacevtska druzba, d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Finance, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Ges.m.b.H.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Group Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Holdings Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Hrvatska d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Interamerica Inc., y Compania Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Interamerica, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly International Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Ireland Holdings Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Israel Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Italia S.p.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Japan K.K.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Kinsale Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Nederland B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Nigeria Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Norge A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Pakistan (Pvt.) Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Polska Sp.z.o.o. (Ltd.)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Regional Operations GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Romania SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Saudi Arabia Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Services India Private Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Slovakia s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Vostok S.A., Geneva</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly y Compania de Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly y Compania de Venezuela, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glycostasis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greenfield-Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICOS Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone Systems Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone Systems LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irisfarma S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDH I Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly (Shanghai) Management Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asia Ventures Fund I, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asia Ventures Fund II, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asian Ventures Fund III, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Cayman Holdings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Centre for Clinical Pharmacology PTE. LTD.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly China Research and Development Co., Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly del Caribe, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Deutschland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly France S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Global Nederland Holdings B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Global Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Holding GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Holdings B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Hungaria KFT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly ila&#231; ticaret limited &#351;irketi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Japan Financing G.K.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Korea Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Finance B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Finance B.V. - GCC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Holding B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Pharma Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Portugal - Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Suzhou Pharmaceutical Co. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Trading Co. LTD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly USA, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Ventures Fund I LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loxo Oncology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OY Eli Lilly Finland AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaserve-Lilly S.A.C.I.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT. Eli Lilly Indonesia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGX Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spaly Bioquimica, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB Eli Lilly Lietuva</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valquifarma S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Pharma Productos Farmaceuticos</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>16
<FILENAME>lly-20211231x10kexhibit23.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i094609c67d4447a89903c39de8b33acb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 23</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-104057, 333-172422, 333-258801, and 333-258803) of Eli Lilly and Company and in the related Prospectus of our reports dated February&#160;23, 2022, with respect to the consolidated financial statements of Eli Lilly and Company and subsidiaries, and the effectiveness of internal control over financial reporting of Eli Lilly and Company and subsidiaries, included in this Annual Report (10-K) for the year ended December&#160;31, 2021.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Indianapolis, Indiana</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">February&#160;23, 2022 </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>17
<FILENAME>lly-20211231x10kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6806a479c3d94fff8e4145200c2baade_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Ricks, Chair, President, and Chief Executive Officer, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-K of Eli Lilly and Company&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.777%"><tr><td style="width:1.0%"></td><td style="width:6.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief&#160;Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>18
<FILENAME>lly-20211231x10kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib3a47ccf4c6849689f750a4ebbe42ff5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Senior Vice President and Chief Financial Officer, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-K of Eli Lilly and Company&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:13.5pt"><font><br></font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;23, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>19
<FILENAME>lly-20211231x10kexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibd54b3d686bc4a23a41ace32af52e5b9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32 Section&#160;1350 Certification </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#8220;Company&#8221;), does hereby certify that, to the best of their knowledge&#58; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair, President, and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and<br>Chief Financial Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>lly-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9fcc0128-8cb1-4f14-a312-a98ab5e27206,g:b055a216-cbe3-42fc-b7bd-1f3a75142c02-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.lilly.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1001003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1002004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1004006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityStatement" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement">
        <link:definition>1005007 - Statement - Consolidated Statements of Shareholders' Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>1008010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>2104102 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>2305301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>2406402 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.lilly.com/role/RevenueNarrativeDetails">
        <link:definition>2407403 - Disclosure - Revenue (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>2408404 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>2409405 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>2410406 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestiture" roleURI="http://www.lilly.com/role/AcquisitionsandDivestiture">
        <link:definition>2111103 - Disclosure - Acquisitions and Divestiture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitureTables" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureTables">
        <link:definition>2312302 - Disclosure - Acquisitions and Divestiture (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitureNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails">
        <link:definition>2413407 - Disclosure - Acquisitions and Divestiture (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestiturePurchasePriceAllocationDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails">
        <link:definition>2414408 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestiturePurchasePriceAllocationDetails_1" roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1">
        <link:definition>2414408 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitureAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails">
        <link:definition>2415409 - Disclosure - Acquisitions and Divestiture (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>2116104 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>2317303 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
        <link:definition>2418410 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNetProductRevenueDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails">
        <link:definition>2419411 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNarrativeDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails">
        <link:definition>2420412 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialCharges" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges">
        <link:definition>2121105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesTables" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables">
        <link:definition>2322304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails">
        <link:definition>2423413 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails">
        <link:definition>2424414 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.lilly.com/role/Inventories">
        <link:definition>2125106 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.lilly.com/role/InventoriesTables">
        <link:definition>2326305 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.lilly.com/role/InventoriesDetails">
        <link:definition>2427415 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>2128107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>2329306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2430416 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofEffectofRiskManagementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
        <link:definition>2431417 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofFairValueMeasurementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails">
        <link:definition>2432418 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
        <link:definition>2433419 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
        <link:definition>2434420 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails">
        <link:definition>2435421 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails">
        <link:definition>2436422 - Disclosure - Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails">
        <link:definition>2437423 - Disclosure - Financial Instruments (Schedule of Investment Portfolio Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles">
        <link:definition>2138108 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>2339307 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>2440424 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails">
        <link:definition>2441425 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails">
        <link:definition>2442426 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails">
        <link:definition>2443427 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.lilly.com/role/PropertyandEquipment">
        <link:definition>2144109 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.lilly.com/role/PropertyandEquipmentTables">
        <link:definition>2345308 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2446428 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2447429 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofDepreciationExpenseDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails">
        <link:definition>2448430 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofGeographicInformationDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails">
        <link:definition>2449431 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.lilly.com/role/Leases">
        <link:definition>2150110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.lilly.com/role/LeasesTables">
        <link:definition>2351309 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.lilly.com/role/LeasesNarrativeDetails">
        <link:definition>2452432 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails">
        <link:definition>2453433 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2454434 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2454434 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.lilly.com/role/Borrowings">
        <link:definition>2155111 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.lilly.com/role/BorrowingsTables">
        <link:definition>2356310 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails">
        <link:definition>2457435 - Disclosure - Borrowings (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtDetails_1" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1">
        <link:definition>2457435 - Disclosure - Borrowings (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofLongtermNotesDetails" roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails">
        <link:definition>2458436 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails">
        <link:definition>2459437 - Disclosure - Borrowings (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtMaturitiesDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails">
        <link:definition>2460438 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails">
        <link:definition>2461439 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.lilly.com/role/StockBasedCompensation">
        <link:definition>2162112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.lilly.com/role/StockBasedCompensationTables">
        <link:definition>2363311 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2464440 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2465441 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails">
        <link:definition>2466442 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.lilly.com/role/ShareholdersEquity">
        <link:definition>2167113 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.lilly.com/role/ShareholdersEquityDetails">
        <link:definition>2468443 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>2169114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lilly.com/role/IncomeTaxesTables">
        <link:definition>2370312 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2471444 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails">
        <link:definition>2472445 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails">
        <link:definition>2473446 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails">
        <link:definition>2474447 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails">
        <link:definition>2475448 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails">
        <link:definition>2476449 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2477450 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails">
        <link:definition>2478451 - Disclosure - Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>2179115 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>2380313 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails">
        <link:definition>2481452 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails">
        <link:definition>2482453 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNarrativeDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails">
        <link:definition>2483454 - Disclosure - Retirement Benefits (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>2484455 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails">
        <link:definition>2485456 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofFairValueDisclosuresDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails">
        <link:definition>2486457 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>2187116 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>2488458 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>2189117 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>2390314 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails">
        <link:definition>2491459 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails">
        <link:definition>2492460 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2493461 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>2194118 - Disclosure - Other-Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>2395315 - Disclosure - Other - Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>2496462 - Disclosure - Other - Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.lilly.com/role/DiscontinuedOperations">
        <link:definition>2197119 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsDetails" roleURI="http://www.lilly.com/role/DiscontinuedOperationsDetails">
        <link:definition>2498463 - Disclosure - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A395NotesDue2049Member" abstract="true" name="A395NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AdvertisingExpensePercentageOfRevenue" abstract="false" name="AdvertisingExpensePercentageOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2125EuroDenominatedNotesDue2030Member" abstract="true" name="A2125EuroDenominatedNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_November2019EuroDenominatedNotesMember" abstract="true" name="November2019EuroDenominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_LosAngelesMember" abstract="true" name="LosAngelesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MiNATherapeuticsLimitedMember" abstract="true" name="MiNATherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FixedIncomeFundsRepurchasedAgreementsMember" abstract="true" name="FixedIncomeFundsRepurchasedAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" abstract="false" name="LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_TYVYTMember" abstract="true" name="TYVYTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A7125NotesDue2025Member" abstract="true" name="A7125NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" abstract="false" name="BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MaturityDate2019Member" abstract="true" name="MaturityDate2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ImmuNextInc.Member" abstract="true" name="ImmuNextInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A3875NotesDue2039Member" abstract="true" name="A3875NotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_WhyteEtAlVEliLillyEtAlMember" abstract="true" name="WhyteEtAlVEliLillyEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ACImmuneSAMember" abstract="true" name="ACImmuneSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SouthernDistrictOfCaliforniaMember" abstract="true" name="SouthernDistrictOfCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A56YenDenominatedNotesDue2034Member" abstract="true" name="A56YenDenominatedNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" abstract="false" name="RevenuePerformanceObligationSalesReturnsProductExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_AlimtaPatentLitigationMember" abstract="true" name="AlimtaPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuefromContractPaymentTermMinimum" abstract="false" name="RevenuefromContractPaymentTermMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PancreatitisMember" abstract="true" name="PancreatitisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LoxoOncologyInc.Member" abstract="true" name="LoxoOncologyInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsAxis" abstract="true" name="PlaintiffAllegationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_EppVTakedaCanadaIncEtAlMember" abstract="true" name="EppVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AbCelleraBiologicsInc.Member" abstract="true" name="AbCelleraBiologicsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ZyprexaMember" abstract="true" name="ZyprexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A225NotesDue2050Member" abstract="true" name="A225NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FochonPharmaceuticalsLtdMember" abstract="true" name="FochonPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AddDeductAbstract" abstract="true" name="AddDeductAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_QILURegorTherapeuticsIncMember" abstract="true" name="QILURegorTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUSdollarSellJapaneseYenMember" abstract="true" name="BuyUSdollarSellJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CarryforwardMember" abstract="true" name="CarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_A015SwissFrancDenominatedNotesDue2024Member" abstract="true" name="A015SwissFrancDenominatedNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_PrevailTherapeuticsIncMember" abstract="true" name="PrevailTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" abstract="true" name="AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A465NotesDue2044Member" abstract="true" name="A465NotesDue2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ExpirationIn12To18YearsMember" abstract="true" name="ExpirationIn12To18YearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" abstract="false" name="SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_LyciaTherapeuticsIncMember" abstract="true" name="LyciaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ByettaMember" abstract="true" name="ByettaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NumberOfMedicinesRightsToSold" abstract="false" name="NumberOfMedicinesRightsToSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A415NotesDue2059Member" abstract="true" name="A415NotesDue2059Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DisarmTherapeuticsIncMember" abstract="true" name="DisarmTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A37NotesDue2045Member" abstract="true" name="A37NotesDue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" abstract="false" name="RevenuePerformanceObligationSalesRebatePaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_ElancoAnimalHealthIncorporatedMember" abstract="true" name="ElancoAnimalHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfClaimants" abstract="false" name="LossContingencyNumberOfClaimants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_CentrexionTherapeuticsCorporationMember" abstract="true" name="CentrexionTherapeuticsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CymbaltaMember" abstract="true" name="CymbaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_StockAcquiredDuringPeriodValueExchangeOffer" abstract="false" name="StockAcquiredDuringPeriodValueExchangeOffer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_WeilerVTakedaCanadaIncEtAlMember" abstract="true" name="WeilerVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" abstract="false" name="AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lly_PrecisionBiosciencesIncMember" abstract="true" name="PrecisionBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A555NotesDue2037Member" abstract="true" name="A555NotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmployeeLitigationMember" abstract="true" name="EmployeeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A17EuroDeonominatedNotesDue2049Member" abstract="true" name="A17EuroDeonominatedNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A10EuroDenominatedNotesDue2022Member" abstract="true" name="A10EuroDenominatedNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyGBPSellUSDMember" abstract="true" name="BuyGBPSellUSDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DescriptionOfDerivativeActivityVolumePercent" abstract="false" name="DescriptionOfDerivativeActivityVolumePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_ShareholderValueAwardsMember" abstract="true" name="ShareholderValueAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_A31NotesDue2027Member" abstract="true" name="A31NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AmpullaryCancerMember" abstract="true" name="AmpullaryCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SeniorNotesDueMay2050AndSeptember2060Member" abstract="true" name="SeniorNotesDueMay2050AndSeptember2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PurchasedInProcessResearchAndDevelopment" abstract="false" name="PurchasedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_SitryxTherapeuticsLimitedMember" abstract="true" name="SitryxTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LitigationClaimsDismissedNumber" abstract="false" name="LitigationClaimsDismissedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_MaturityDate2023Member" abstract="true" name="MaturityDate2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DefineBenefitPlanOtherMember" abstract="true" name="DefineBenefitPlanOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_COVID19AntibodiesMember" abstract="true" name="COVID19AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A3375NotesDue2029Member" abstract="true" name="A3375NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.000NotesDueJune22022Member" abstract="true" name="A1.000NotesDueJune22022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_UNITEDSTATESAndPUERTORICOMember" abstract="true" name="UNITEDSTATESAndPUERTORICOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A395NotesDue2047Member" abstract="true" name="A395NotesDue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" abstract="false" name="LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EntosPharmaceuticalsIncMember" abstract="true" name="EntosPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A42YenDenominatedNotesDue2029Member" abstract="true" name="A42YenDenominatedNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FixedIncomeFundsEmergingMarketsMember" abstract="true" name="FixedIncomeFundsEmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" abstract="true" name="MilestonePaymentsCapitalizedAsIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EquityMethodAndOtherInvestmentsMember" abstract="true" name="EquityMethodAndOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" abstract="false" name="CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A625EuroDeonominatedNotesDue2031Member" abstract="true" name="A625EuroDeonominatedNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" abstract="false" name="DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" abstract="false" name="RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_A1625EuroDenominatedNotesDue2026Member" abstract="true" name="A1625EuroDenominatedNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" abstract="true" name="MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaid" abstract="false" name="TaxCutAndJobsActTollTaxToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PetraPharmaCorporationMember" abstract="true" name="PetraPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A25NotesDue2060Member" abstract="true" name="A25NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuefromContractPaymentTermMaximum" abstract="false" name="RevenuefromContractPaymentTermMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DesignatedUnusableMember" abstract="true" name="DesignatedUnusableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A55NotesDue2027Member" abstract="true" name="A55NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A275NotesDue2025Member" abstract="true" name="A275NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_A235NotesDue2022Member" abstract="true" name="A235NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LongTermDebtFairValueAdjustment" abstract="false" name="LongTermDebtFairValueAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InsulinMember" abstract="true" name="InsulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsDomain" abstract="true" name="PlaintiffAllegationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AsahiKaseiPharmaCorporationMember" abstract="true" name="AsahiKaseiPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ActosMember" abstract="true" name="ActosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_Expirationwithin5yearsMember" abstract="true" name="Expirationwithin5yearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" abstract="true" name="CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" abstract="true" name="TaxCutAndJobsActTollTaxPaymentDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_Expirationin6YearsMember" abstract="true" name="Expirationin6YearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AvidityBiosciencesInc.Member" abstract="true" name="AvidityBiosciencesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_RigelPharmaceuticalsIncMember" abstract="true" name="RigelPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DomicileOfLitigationDomain" abstract="true" name="DomicileOfLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A5000NotesDue2033Member" abstract="true" name="A5000NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_VariousStateDomicilesMember" abstract="true" name="VariousStateDomicilesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" abstract="false" name="RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" abstract="false" name="RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_DermiraInc.Member" abstract="true" name="DermiraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_EvoxTherapeuticsMember" abstract="true" name="EvoxTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUsdSellEuroMember" abstract="true" name="BuyUsdSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" abstract="false" name="ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_KumquatBiosciencesIncMember" abstract="true" name="KumquatBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RelativeValueAwardsMember" abstract="true" name="RelativeValueAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EddingpharmMember" abstract="true" name="EddingpharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" abstract="true" name="MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrulicityMemberMember" abstract="true" name="TrulicityMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_DeferredTaxAssetsCorrectiveTaxAdjustments" abstract="false" name="DeferredTaxAssetsCorrectiveTaxAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NonCHINAMember" abstract="true" name="NonCHINAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A595NotesDue2037Member" abstract="true" name="A595NotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_JunshiBiosciencesMember" abstract="true" name="JunshiBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProQRTherapeuticsNVMember" abstract="true" name="ProQRTherapeuticsNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A677NotesDue2036Member" abstract="true" name="A677NotesDue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DomicileOfLitigationAxis" abstract="true" name="DomicileOfLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_A045SwissFrancDenominatedNotesDue2028Member" abstract="true" name="A045SwissFrancDenominatedNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" abstract="false" name="AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ThreeLargestWholesalesMember" abstract="true" name="ThreeLargestWholesalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" abstract="false" name="DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_LesseeLeaseRemainingLeaseTerm" abstract="false" name="LesseeLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" abstract="false" name="BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_Expiration5to20YearsMember" abstract="true" name="Expiration5to20YearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsSalesRebatesAndDiscounts" abstract="false" name="DeferredTaxAssetsSalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_TaxYears2013To2015Member" abstract="true" name="TaxYears2013To2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lly_DeferredTaxAssetsForeignTaxRedeterminations" abstract="false" name="DeferredTaxAssetsForeignTaxRedeterminations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A97YenDeonominatedNotesDue2049Member" abstract="true" name="A97YenDeonominatedNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PaymentsForIncomeTaxSettlements" abstract="false" name="PaymentsForIncomeTaxSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_StockAcquiredDuringPeriodSharesExchangeOffer" abstract="false" name="StockAcquiredDuringPeriodSharesExchangeOffer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lly_FoghornTherapeuticsIncMember" abstract="true" name="FoghornTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MerusNVMember" abstract="true" name="MerusNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" abstract="true" name="LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SelpercatinibLOXO292Member" abstract="true" name="SelpercatinibLOXO292Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" abstract="false" name="DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PancreaticCancerOrThyroidCancerMember" abstract="true" name="PancreaticCancerOrThyroidCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A30NotesDue2022Member" abstract="true" name="A30NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProtomerTechnologiesIncMember" abstract="true" name="ProtomerTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_November2019YenDenominatedNotesMember" abstract="true" name="November2019YenDenominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>lly-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9fcc0128-8cb1-4f14-a312-a98ab5e27206,g:b055a216-cbe3-42fc-b7bd-1f3a75142c02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_67ae438c-614c-4392-ab18-52826edacdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_812c466c-f453-4e47-90b8-a954c41b04cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_67ae438c-614c-4392-ab18-52826edacdc6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_812c466c-f453-4e47-90b8-a954c41b04cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_120f5f94-895e-4f9b-a630-bdab6bb5b9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_67ae438c-614c-4392-ab18-52826edacdc6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_120f5f94-895e-4f9b-a630-bdab6bb5b9e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_802b255c-7535-4b17-9e2c-6f08e13a2a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f0ba53b1-64c6-48e9-877a-514eecb8e712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_802b255c-7535-4b17-9e2c-6f08e13a2a17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f0ba53b1-64c6-48e9-877a-514eecb8e712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b7bb8b8e-0d12-4421-ad0a-38911b98a7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_802b255c-7535-4b17-9e2c-6f08e13a2a17" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b7bb8b8e-0d12-4421-ad0a-38911b98a7f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7cbb2785-b8dc-4488-981f-99ffbd067471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b6253835-5847-4836-845b-9e9107174ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7cbb2785-b8dc-4488-981f-99ffbd067471" xlink:to="loc_us-gaap_Revenues_b6253835-5847-4836-845b-9e9107174ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a5d21392-4c4a-4fee-b80e-5ca782ceb14c" xlink:href="lly-20211231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7cbb2785-b8dc-4488-981f-99ffbd067471" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a5d21392-4c4a-4fee-b80e-5ca782ceb14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3f017886-663b-4c5b-95c9-07e7ff348daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c76be473-f5f3-48e6-b0fc-aae7e3f4950d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3f017886-663b-4c5b-95c9-07e7ff348daf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c76be473-f5f3-48e6-b0fc-aae7e3f4950d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87adc60a-de38-48e9-967e-4e82a323bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3f017886-663b-4c5b-95c9-07e7ff348daf" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87adc60a-de38-48e9-967e-4e82a323bf43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3312cac2-d8b4-4246-843b-cb21777e58cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c33af308-8b43-4115-85df-0a52b6217635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3312cac2-d8b4-4246-843b-cb21777e58cb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c33af308-8b43-4115-85df-0a52b6217635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a2fe23b1-be95-4d1b-931c-aa47f549954a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3312cac2-d8b4-4246-843b-cb21777e58cb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a2fe23b1-be95-4d1b-931c-aa47f549954a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:href="lly-20211231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8e9051e9-5321-4d4f-adbc-78a6b56b8e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8e9051e9-5321-4d4f-adbc-78a6b56b8e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_030d76f4-e233-4faf-8205-5cf8a4513c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_030d76f4-e233-4faf-8205-5cf8a4513c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_020358f0-4a07-4517-a843-4fcb33c80d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_020358f0-4a07-4517-a843-4fcb33c80d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_d19ef603-a6c2-43e6-b287-4ad64ec9d3d1" xlink:href="lly-20211231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_d19ef603-a6c2-43e6-b287-4ad64ec9d3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_cb8fbe32-abb6-4d72-aa3e-2a307f2f485e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_cb8fbe32-abb6-4d72-aa3e-2a307f2f485e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d8156dfa-979f-4f1e-bcd4-4923fd7022a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_d33670cc-249d-4859-9b7e-8d87bde8d4bb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d8156dfa-979f-4f1e-bcd4-4923fd7022a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_7d6c9d43-d971-4422-a2a7-fb1a06fa0898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_1f599a3d-17f5-4a0d-a031-6a7b7a1b816b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_7d6c9d43-d971-4422-a2a7-fb1a06fa0898" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_1f599a3d-17f5-4a0d-a031-6a7b7a1b816b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_9324d0d1-5a4b-4aaa-a53c-2d6c6a00d94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_7d6c9d43-d971-4422-a2a7-fb1a06fa0898" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_9324d0d1-5a4b-4aaa-a53c-2d6c6a00d94b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_4739c4bd-f955-4da7-af70-3f33202ad16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_7d6c9d43-d971-4422-a2a7-fb1a06fa0898" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_4739c4bd-f955-4da7-af70-3f33202ad16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_c61dd421-7271-43fb-8e9b-719f20252f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_7d6c9d43-d971-4422-a2a7-fb1a06fa0898" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_c61dd421-7271-43fb-8e9b-719f20252f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_490eadd5-6842-4506-88a8-e357e2eb93c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_10a00ad1-38dd-49b4-8baa-53b24a301674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_490eadd5-6842-4506-88a8-e357e2eb93c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_10a00ad1-38dd-49b4-8baa-53b24a301674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1c6e9102-2bd8-4521-8ef7-64423a6f1b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_490eadd5-6842-4506-88a8-e357e2eb93c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_1c6e9102-2bd8-4521-8ef7-64423a6f1b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7ffe62f1-e6ed-4cbf-9206-b79c300c0625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5125e167-b0be-49e0-917a-01efa80b9f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7ffe62f1-e6ed-4cbf-9206-b79c300c0625" xlink:to="loc_us-gaap_NetIncomeLoss_5125e167-b0be-49e0-917a-01efa80b9f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7be11e3c-5052-4a95-b48c-e13a9083689f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7ffe62f1-e6ed-4cbf-9206-b79c300c0625" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7be11e3c-5052-4a95-b48c-e13a9083689f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a3048863-d16c-4c7e-b7aa-3e03863681fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:to="loc_us-gaap_ShortTermInvestments_a3048863-d16c-4c7e-b7aa-3e03863681fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6676b9fd-d611-43ed-b05e-34b6989c3bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6676b9fd-d611-43ed-b05e-34b6989c3bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0a11e98a-721f-4cff-83e7-c3b0c503aac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:to="loc_us-gaap_InventoryNet_0a11e98a-721f-4cff-83e7-c3b0c503aac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_34f8400d-bbfa-4328-b74b-38d24299309b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_34f8400d-bbfa-4328-b74b-38d24299309b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_10a47668-3bfc-4d62-9b22-a024c4afbb58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:to="loc_us-gaap_OtherReceivables_10a47668-3bfc-4d62-9b22-a024c4afbb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d298efc9-794f-456f-86e2-e81dcf334179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b08453e2-4ad1-4b05-8d64-7b533689d448" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d298efc9-794f-456f-86e2-e81dcf334179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3474aa2a-69cf-4884-a824-c9f096289530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_CommonStockValue_3474aa2a-69cf-4884-a824-c9f096289530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b717c1cb-9319-4796-ace4-b442e0775965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b717c1cb-9319-4796-ace4-b442e0775965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd0f5919-683e-48da-a8ef-cb34c80a0005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd0f5919-683e-48da-a8ef-cb34c80a0005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_3315c051-7ec9-4840-b7c6-7a56ac645642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_3315c051-7ec9-4840-b7c6-7a56ac645642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11a3dc28-9b00-475e-bf9b-1e5e64db9df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11a3dc28-9b00-475e-bf9b-1e5e64db9df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6aca89f2-a011-42a5-8898-b468d73ae453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_TreasuryStockValue_6aca89f2-a011-42a5-8898-b468d73ae453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_84ae0ea8-35bf-4ca2-8238-c67f75b258a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_958dee48-1295-4bbd-965f-7d0a2519a18a" xlink:to="loc_us-gaap_MinorityInterest_84ae0ea8-35bf-4ca2-8238-c67f75b258a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_14a1b67c-285f-459e-95ba-41d0eaf40df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20a89132-50fd-4b1b-a426-91b0fbcb3d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14a1b67c-285f-459e-95ba-41d0eaf40df3" xlink:to="loc_us-gaap_LiabilitiesCurrent_20a89132-50fd-4b1b-a426-91b0fbcb3d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c9765fba-6bf4-4baa-813f-53b9d3b25b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14a1b67c-285f-459e-95ba-41d0eaf40df3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c9765fba-6bf4-4baa-813f-53b9d3b25b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c93d51b-59f5-4bed-9e48-4a61688e24ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14a1b67c-285f-459e-95ba-41d0eaf40df3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c93d51b-59f5-4bed-9e48-4a61688e24ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_befc7933-e141-4d65-be48-1aa6a2c4512c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_14a1b67c-285f-459e-95ba-41d0eaf40df3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_befc7933-e141-4d65-be48-1aa6a2c4512c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2856900c-0071-458e-b806-dc5014be889d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_AssetsCurrent_2856900c-0071-458e-b806-dc5014be889d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_67bb0c36-a4ff-4db6-996b-7cdf14402cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_LongTermInvestments_67bb0c36-a4ff-4db6-996b-7cdf14402cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_89ba133c-40d6-4439-a6fd-e8b7396a875c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_Goodwill_89ba133c-40d6-4439-a6fd-e8b7396a875c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f190410a-f618-44db-a68b-eeb6e5c0b06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f190410a-f618-44db-a68b-eeb6e5c0b06d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_305a9637-585f-4d69-acbb-5fe49e9805b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_305a9637-585f-4d69-acbb-5fe49e9805b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_edddee2c-29e0-45e5-9d96-f1508df317c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_edddee2c-29e0-45e5-9d96-f1508df317c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_4a3b1e91-c728-4425-b91a-596bacb802d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_366ee5bc-ebdf-40ce-8c3e-94a5d3df47c5" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_4a3b1e91-c728-4425-b91a-596bacb802d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_6e4d11ff-2683-42a3-81b9-080cc53b0f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_us-gaap_DebtCurrent_6e4d11ff-2683-42a3-81b9-080cc53b0f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_998c604a-b2fb-4913-8689-9b8a0895ed61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_us-gaap_AccountsPayableCurrent_998c604a-b2fb-4913-8689-9b8a0895ed61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fc5a67f1-1710-4d33-b330-25883175e19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fc5a67f1-1710-4d33-b330-25883175e19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_aa898132-57ff-4e16-b424-8cd745fb4242" xlink:href="lly-20211231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_lly_SalesRebatesAndDiscounts_aa898132-57ff-4e16-b424-8cd745fb4242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_ed570e7d-5ad0-4616-8bfa-fafe437c8c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_us-gaap_DividendsPayableCurrent_ed570e7d-5ad0-4616-8bfa-fafe437c8c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_eda3b911-8521-4af4-b55b-9888e2fe2ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_us-gaap_TaxesPayableCurrent_eda3b911-8521-4af4-b55b-9888e2fe2ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e6970501-f249-40c7-97b3-7133c1a3fafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6110f4c6-8c48-4715-8b7e-a79914aa3570" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e6970501-f249-40c7-97b3-7133c1a3fafa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_f039f174-6f47-4564-9d28-44f6df754662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4f86e375-79f3-43a8-944c-838e541ba986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_f039f174-6f47-4564-9d28-44f6df754662" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4f86e375-79f3-43a8-944c-838e541ba986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0e54f393-5417-4a35-b091-3a13ad272f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_f039f174-6f47-4564-9d28-44f6df754662" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0e54f393-5417-4a35-b091-3a13ad272f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7cf14925-4a29-4c11-953c-7dc8855172b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_f039f174-6f47-4564-9d28-44f6df754662" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7cf14925-4a29-4c11-953c-7dc8855172b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cf5a40f7-4a9c-4dd1-9d79-e4a78e6cfa32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_f039f174-6f47-4564-9d28-44f6df754662" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cf5a40f7-4a9c-4dd1-9d79-e4a78e6cfa32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_76b7dccf-d3f2-42a6-b8be-381d4efa0fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_f039f174-6f47-4564-9d28-44f6df754662" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_76b7dccf-d3f2-42a6-b8be-381d4efa0fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ac3a732c-b36e-46a2-8c02-5346dd3a5f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:to="loc_us-gaap_CommonStockValue_ac3a732c-b36e-46a2-8c02-5346dd3a5f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b3065f26-dd04-490d-a91a-b36ffb893574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b3065f26-dd04-490d-a91a-b36ffb893574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_530a6c1c-82d5-4de0-825a-64d3ad1d9960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_530a6c1c-82d5-4de0-825a-64d3ad1d9960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_f31a419e-0ff6-447b-b35d-1852177dee90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_f31a419e-0ff6-447b-b35d-1852177dee90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c6ebe45-5f64-4cef-8e6c-b487f6c5e6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c6ebe45-5f64-4cef-8e6c-b487f6c5e6ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f4e88886-45ce-4366-af96-184e4313b379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_67dd7685-e483-4e9c-ad5c-99f8691339e6" xlink:to="loc_us-gaap_TreasuryStockValue_f4e88886-45ce-4366-af96-184e4313b379" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5b274f0-4348-4450-9abf-1977e7a6d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a1f005d-39ff-407a-bb53-b3106b10781e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5b274f0-4348-4450-9abf-1977e7a6d5a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a1f005d-39ff-407a-bb53-b3106b10781e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb5ec110-8e4c-4f03-936c-8e4c7eceb419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5b274f0-4348-4450-9abf-1977e7a6d5a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb5ec110-8e4c-4f03-936c-8e4c7eceb419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a3d305d-74f2-4748-8ed1-7ffb4246b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5b274f0-4348-4450-9abf-1977e7a6d5a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a3d305d-74f2-4748-8ed1-7ffb4246b2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af694045-b7ea-4ea8-93b7-449dc4a8ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5b274f0-4348-4450-9abf-1977e7a6d5a2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af694045-b7ea-4ea8-93b7-449dc4a8ca7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c43a2e21-ef18-4025-a7a9-bc26c9cf0b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:to="loc_us-gaap_PaymentsOfDividends_c43a2e21-ef18-4025-a7a9-bc26c9cf0b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_4d6a29f9-0771-4fe6-a36e-93969075fa68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_4d6a29f9-0771-4fe6-a36e-93969075fa68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_24fff5d3-051b-4a0e-b54c-1119da84c4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_24fff5d3-051b-4a0e-b54c-1119da84c4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b55c25ef-13d2-4493-a0fc-82336f792806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b55c25ef-13d2-4493-a0fc-82336f792806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c0444e54-206d-4c35-a67f-365b367f851b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c0444e54-206d-4c35-a67f-365b367f851b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6f12e559-6cca-404f-85bd-bb84cb733726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54414ee5-4430-4244-a0e4-94aaba4a0c4d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6f12e559-6cca-404f-85bd-bb84cb733726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_15e2262c-a934-4105-8f7e-a0ba2effc934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_15e2262c-a934-4105-8f7e-a0ba2effc934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_60dc479f-a908-44eb-9df7-e5f747d39ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_60dc479f-a908-44eb-9df7-e5f747d39ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_15ffa574-f1af-4f4e-854c-88fbd21bcfea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_15ffa574-f1af-4f4e-854c-88fbd21bcfea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_623c57c0-e3e2-4dd8-bba5-7feffdbdfddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_623c57c0-e3e2-4dd8-bba5-7feffdbdfddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_7f9d1698-948e-410b-aa88-62a18b7050e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_7f9d1698-948e-410b-aa88-62a18b7050e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_292044cb-da78-4cc4-9c74-2dbb59a1b600" xlink:href="lly-20211231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_292044cb-da78-4cc4-9c74-2dbb59a1b600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6be06b3b-8b6b-4a29-a8c9-a707873dad4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6be06b3b-8b6b-4a29-a8c9-a707873dad4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_cc21b6b3-806b-421c-a85e-fafd64a55d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_cc21b6b3-806b-421c-a85e-fafd64a55d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_32e5fcfa-ccb6-4880-8bcf-58308c92afec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_32e5fcfa-ccb6-4880-8bcf-58308c92afec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_238c4092-8858-456f-82db-6af970997923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_812f0c3b-3a22-476c-a0c4-21c5887f31ca" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_238c4092-8858-456f-82db-6af970997923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e5e3eb50-483a-49db-a2cc-71bb564bf160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e5e3eb50-483a-49db-a2cc-71bb564bf160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6cd22af2-8827-49fc-9f27-4136576b2202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6cd22af2-8827-49fc-9f27-4136576b2202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_874cc2a4-0fef-4b9a-8357-1d85772f76ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_874cc2a4-0fef-4b9a-8357-1d85772f76ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e876c680-d941-4314-9e33-4d88d358e78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_ShareBasedCompensation_e876c680-d941-4314-9e33-4d88d358e78b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_6bc10d82-bab2-47f0-a163-f64859d497ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_6bc10d82-bab2-47f0-a163-f64859d497ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1089069e-085d-4fc5-9c92-e6d9f7aecdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1089069e-085d-4fc5-9c92-e6d9f7aecdc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2d6c7586-745e-41c0-ab01-13e8b14d4339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2d6c7586-745e-41c0-ab01-13e8b14d4339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_cf8c6bbf-03e4-4cb4-affa-f43643afb960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_cf8c6bbf-03e4-4cb4-affa-f43643afb960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_deb2ed75-0e8b-4736-977a-abab39af672b" xlink:href="lly-20211231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_deb2ed75-0e8b-4736-977a-abab39af672b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d0551b3f-e23f-49fa-9432-9ce1df2e2b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d0551b3f-e23f-49fa-9432-9ce1df2e2b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21b0fff2-70b4-48be-be76-62d484db9896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_NetIncomeLoss_21b0fff2-70b4-48be-be76-62d484db9896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_05f063b1-9138-47c3-820c-30ed7b8ba04a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_05f063b1-9138-47c3-820c-30ed7b8ba04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b93188d0-e1e5-420d-837c-75b47116814f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_GainLossOnInvestments_b93188d0-e1e5-420d-837c-75b47116814f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_a5692106-c06d-4752-a200-fb4219bce167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_a5692106-c06d-4752-a200-fb4219bce167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_27fc419e-0ac8-4bff-a425-b12a0f7c8cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48f59d52-bdda-4df6-a71a-beb5c8b43911" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_27fc419e-0ac8-4bff-a425-b12a0f7c8cb4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_677ea79f-1ff7-487c-9113-5da210745a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_4b3e9de0-6ed5-42d2-b8b9-4552eddd5a6e" xlink:href="lly-20211231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_677ea79f-1ff7-487c-9113-5da210745a5b" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_4b3e9de0-6ed5-42d2-b8b9-4552eddd5a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_98743139-8361-4aa1-b733-2ed5881382cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_677ea79f-1ff7-487c-9113-5da210745a5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_98743139-8361-4aa1-b733-2ed5881382cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_de1df74e-c689-428c-a569-d5f92214283b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_677ea79f-1ff7-487c-9113-5da210745a5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_de1df74e-c689-428c-a569-d5f92214283b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_23a4dbf3-8367-4964-a866-b1a9877eddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_677ea79f-1ff7-487c-9113-5da210745a5b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_23a4dbf3-8367-4964-a866-b1a9877eddc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c11f9882-019a-4b4c-8940-c1fa951692b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_677ea79f-1ff7-487c-9113-5da210745a5b" xlink:to="loc_us-gaap_Goodwill_c11f9882-019a-4b4c-8940-c1fa951692b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_11054c68-c3c1-4fa1-9d9a-faaf324a9cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_155c35c2-241b-44a1-8c61-c3f7049b7ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_11054c68-c3c1-4fa1-9d9a-faaf324a9cde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_155c35c2-241b-44a1-8c61-c3f7049b7ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3953624b-e4a7-4fe9-b751-a3ab90ffadc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_11054c68-c3c1-4fa1-9d9a-faaf324a9cde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3953624b-e4a7-4fe9-b751-a3ab90ffadc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b3aa9bd-20bf-4efe-bc8f-ec291b029c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_11054c68-c3c1-4fa1-9d9a-faaf324a9cde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b3aa9bd-20bf-4efe-bc8f-ec291b029c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_887667a7-4f96-452f-accf-b1109773fbcc" xlink:href="lly-20211231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_11054c68-c3c1-4fa1-9d9a-faaf324a9cde" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_887667a7-4f96-452f-accf-b1109773fbcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ad6ffb5-8c62-4050-9d4a-a189575a3efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a3a68a6b-9c95-4a9e-85b7-b4ffbc66df6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ad6ffb5-8c62-4050-9d4a-a189575a3efa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a3a68a6b-9c95-4a9e-85b7-b4ffbc66df6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e26da34d-7fd8-4567-a1f3-d6b2584dc6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ad6ffb5-8c62-4050-9d4a-a189575a3efa" xlink:to="loc_us-gaap_Goodwill_e26da34d-7fd8-4567-a1f3-d6b2584dc6c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ec5ca0e0-e444-4866-9f50-78796e6816a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f0bc9ec0-4bd6-4782-a1ab-a3d510e3f6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ec5ca0e0-e444-4866-9f50-78796e6816a7" xlink:to="loc_us-gaap_SeveranceCosts1_f0bc9ec0-4bd6-4782-a1ab-a3d510e3f6fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_5d643855-441f-4e03-9afe-442b1bcbc6e8" xlink:href="lly-20211231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ec5ca0e0-e444-4866-9f50-78796e6816a7" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_5d643855-441f-4e03-9afe-442b1bcbc6e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0d2f7fe8-9fcb-40c3-92bb-a35b7e782578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d5533eed-f5f0-4269-8dbb-9d01ae1a7855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0d2f7fe8-9fcb-40c3-92bb-a35b7e782578" xlink:to="loc_us-gaap_InventoryGross_d5533eed-f5f0-4269-8dbb-9d01ae1a7855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_597c99c7-1422-46e5-b5ad-2039c9b2fc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0d2f7fe8-9fcb-40c3-92bb-a35b7e782578" xlink:to="loc_us-gaap_InventoryLIFOReserve_597c99c7-1422-46e5-b5ad-2039c9b2fc8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_88a87f1f-ecdc-4924-bcc1-02972705da36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ced347b0-7c3d-4e05-bb09-9ca94c6a0788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_88a87f1f-ecdc-4924-bcc1-02972705da36" xlink:to="loc_us-gaap_InventoryFinishedGoods_ced347b0-7c3d-4e05-bb09-9ca94c6a0788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_459c2cad-981f-4e24-8a0e-67aeee0d6288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_88a87f1f-ecdc-4924-bcc1-02972705da36" xlink:to="loc_us-gaap_InventoryWorkInProcess_459c2cad-981f-4e24-8a0e-67aeee0d6288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_b2ea1314-2ce6-4704-9fb1-ac74c3347874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_88a87f1f-ecdc-4924-bcc1-02972705da36" xlink:to="loc_us-gaap_InventoryRawMaterials_b2ea1314-2ce6-4704-9fb1-ac74c3347874" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_135f6c93-2308-4db7-9895-ca1b8f2a4f31" xlink:href="lly-20211231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b9d1b438-21fe-4544-96f6-c6e86debf240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_135f6c93-2308-4db7-9895-ca1b8f2a4f31" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b9d1b438-21fe-4544-96f6-c6e86debf240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cb3b7615-aec2-4546-a5f5-feedbef20086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_135f6c93-2308-4db7-9895-ca1b8f2a4f31" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cb3b7615-aec2-4546-a5f5-feedbef20086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ee4de88e-2850-4bb0-a772-6c12cab233d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_135f6c93-2308-4db7-9895-ca1b8f2a4f31" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ee4de88e-2850-4bb0-a772-6c12cab233d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0b6aa6fb-4fc6-4d2d-9b49-d3bc86f13d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_135f6c93-2308-4db7-9895-ca1b8f2a4f31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0b6aa6fb-4fc6-4d2d-9b49-d3bc86f13d76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_676a2f6a-37c7-458b-abb5-359fcbfbf4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_c64ebcc2-1fcf-4963-8f99-18b404f4a8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_676a2f6a-37c7-458b-abb5-359fcbfbf4f5" xlink:to="loc_us-gaap_OtherLongTermInvestments_c64ebcc2-1fcf-4963-8f99-18b404f4a8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c929ca7d-c2e9-4641-b6c2-cb45840b8cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_676a2f6a-37c7-458b-abb5-359fcbfbf4f5" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c929ca7d-c2e9-4641-b6c2-cb45840b8cb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_84d4ca75-17a1-4521-b43d-c2f91c0248fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_676a2f6a-37c7-458b-abb5-359fcbfbf4f5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_84d4ca75-17a1-4521-b43d-c2f91c0248fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_71985a6b-538c-43c0-919e-c88fce8447da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_676a2f6a-37c7-458b-abb5-359fcbfbf4f5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_71985a6b-538c-43c0-919e-c88fce8447da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bcf0725-4a5b-4c7c-a208-76d6e5f24d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5c675428-1784-4031-9b29-80b4edfc2498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bcf0725-4a5b-4c7c-a208-76d6e5f24d4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5c675428-1784-4031-9b29-80b4edfc2498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_332d08ca-4e7d-44f6-8a39-14ca5661d578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bcf0725-4a5b-4c7c-a208-76d6e5f24d4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_332d08ca-4e7d-44f6-8a39-14ca5661d578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f245aaa3-03f1-463f-b566-0e07467d1eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bcf0725-4a5b-4c7c-a208-76d6e5f24d4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f245aaa3-03f1-463f-b566-0e07467d1eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ddde2796-ce86-4a46-bd35-c2b9bab00eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bcf0725-4a5b-4c7c-a208-76d6e5f24d4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_ddde2796-ce86-4a46-bd35-c2b9bab00eca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ade1a9ab-be94-4630-8f55-092e22c4a56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d5924326-e35e-4360-9792-86d496153c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ade1a9ab-be94-4630-8f55-092e22c4a56d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d5924326-e35e-4360-9792-86d496153c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3af1e439-be72-4eca-83ad-9687531b0bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ade1a9ab-be94-4630-8f55-092e22c4a56d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3af1e439-be72-4eca-83ad-9687531b0bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_95e586e2-b76d-47a2-bd7e-21a4ce375b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_972e7c53-6af5-483f-95b5-35cdb1971f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_95e586e2-b76d-47a2-bd7e-21a4ce375b01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_972e7c53-6af5-483f-95b5-35cdb1971f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5b25e875-6eb5-4563-ac7d-a41dddf4cda0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_95e586e2-b76d-47a2-bd7e-21a4ce375b01" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5b25e875-6eb5-4563-ac7d-a41dddf4cda0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d96ba30e-089d-46ef-9dda-e54e9d49e1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_411d29e0-96fe-4312-b4c9-22bb336e08a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d96ba30e-089d-46ef-9dda-e54e9d49e1a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_411d29e0-96fe-4312-b4c9-22bb336e08a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fa354d07-1160-426f-b4c2-aa1b335b6e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d96ba30e-089d-46ef-9dda-e54e9d49e1a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fa354d07-1160-426f-b4c2-aa1b335b6e42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c5167be0-ad7c-4eb3-b76c-55216f450cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_f00b1cce-6020-4c47-b976-6dd32a07757c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c5167be0-ad7c-4eb3-b76c-55216f450cfb" xlink:to="loc_us-gaap_Land_f00b1cce-6020-4c47-b976-6dd32a07757c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_e440127b-9c12-4437-9b4c-155f629071e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c5167be0-ad7c-4eb3-b76c-55216f450cfb" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_e440127b-9c12-4437-9b4c-155f629071e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_0fcdb76b-5ea4-4f9a-a24f-7fdeb2298e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c5167be0-ad7c-4eb3-b76c-55216f450cfb" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_0fcdb76b-5ea4-4f9a-a24f-7fdeb2298e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9090f32a-c20e-4e2a-ab27-93192e67fae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_c5167be0-ad7c-4eb3-b76c-55216f450cfb" xlink:to="loc_us-gaap_ConstructionInProgressGross_9090f32a-c20e-4e2a-ab27-93192e67fae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_73f41f22-274d-479c-83db-359e43a88c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1d9446a7-ecd3-48c5-b24b-de9b7cb06999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_73f41f22-274d-479c-83db-359e43a88c0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1d9446a7-ecd3-48c5-b24b-de9b7cb06999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4f88b34-3b82-4d4a-9715-a608a2a5302e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_73f41f22-274d-479c-83db-359e43a88c0d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4f88b34-3b82-4d4a-9715-a608a2a5302e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f278ccc-07e4-4a8b-aab0-f4e65e806e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d4260ec8-0360-4c45-8be5-eb64f3e72e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f278ccc-07e4-4a8b-aab0-f4e65e806e9a" xlink:to="loc_us-gaap_OperatingLeaseLiability_d4260ec8-0360-4c45-8be5-eb64f3e72e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b947cf6f-b9a7-4c8b-8245-7820b455439f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f278ccc-07e4-4a8b-aab0-f4e65e806e9a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b947cf6f-b9a7-4c8b-8245-7820b455439f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4ac53234-79b6-4bb1-abb6-8af4aa5cd5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4ac53234-79b6-4bb1-abb6-8af4aa5cd5c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_18bde6ed-1659-4f1f-8886-13a63f6860f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_18bde6ed-1659-4f1f-8886-13a63f6860f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_08d6e5fd-591a-4a62-8bb5-b3c63ec18ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_08d6e5fd-591a-4a62-8bb5-b3c63ec18ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cedde097-feb9-425c-838c-17241c1c0a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cedde097-feb9-425c-838c-17241c1c0a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d7785c9c-e557-4bb1-abb4-3ae035fca8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d7785c9c-e557-4bb1-abb4-3ae035fca8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a05b8056-f393-4c19-b93a-2b2457983fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650e7fce-ea2d-48a1-90c7-4f0ce73e3826" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a05b8056-f393-4c19-b93a-2b2457983fdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_16d1231f-45cd-40a8-a69a-d6c04ded6464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_ef569802-c141-44a5-9bc6-1444a5348ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_16d1231f-45cd-40a8-a69a-d6c04ded6464" xlink:to="loc_us-gaap_DebtCurrent_ef569802-c141-44a5-9bc6-1444a5348ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fe0bb0d4-07e9-4698-9d12-ac4edb1af89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_16d1231f-45cd-40a8-a69a-d6c04ded6464" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fe0bb0d4-07e9-4698-9d12-ac4edb1af89c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsScheduleofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_a5d390b3-67ff-49fe-97e4-2ebad786c90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_19c0bf98-0b63-4dc1-bbe5-b0752b1520f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_a5d390b3-67ff-49fe-97e4-2ebad786c90f" xlink:to="loc_us-gaap_NotesPayable_19c0bf98-0b63-4dc1-bbe5-b0752b1520f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable_37df7298-6f55-4fec-8cf0-b7612d97818f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_a5d390b3-67ff-49fe-97e4-2ebad786c90f" xlink:to="loc_us-gaap_OtherNotesPayable_37df7298-6f55-4fec-8cf0-b7612d97818f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_b6f189c0-1264-476a-80be-70e4cf530796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_a5d390b3-67ff-49fe-97e4-2ebad786c90f" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_b6f189c0-1264-476a-80be-70e4cf530796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment_04056bea-6d7e-495d-b229-d6071cb2355e" xlink:href="lly-20211231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_a5d390b3-67ff-49fe-97e4-2ebad786c90f" xlink:to="loc_lly_LongTermDebtFairValueAdjustment_04056bea-6d7e-495d-b229-d6071cb2355e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2874b059-1a6d-42bd-b49f-6b8ded8be7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7ecb5282-d781-4638-b258-a8db87043edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2874b059-1a6d-42bd-b49f-6b8ded8be7c4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7ecb5282-d781-4638-b258-a8db87043edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_b00d8f2b-0dd5-4728-ad4d-18be104532c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2874b059-1a6d-42bd-b49f-6b8ded8be7c4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_b00d8f2b-0dd5-4728-ad4d-18be104532c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53886934-f14a-43f3-b757-501ef33fb9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3261f8e6-15be-4cee-ad35-3d0e59478ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53886934-f14a-43f3-b757-501ef33fb9c8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3261f8e6-15be-4cee-ad35-3d0e59478ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a2cf86d8-6509-4d25-b618-af5cd818dbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53886934-f14a-43f3-b757-501ef33fb9c8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a2cf86d8-6509-4d25-b618-af5cd818dbff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5ce9949a-a9f7-4a6e-bff3-69acd82af128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a376d00c-8643-486f-aad7-b6d1c0eca68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5ce9949a-a9f7-4a6e-bff3-69acd82af128" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a376d00c-8643-486f-aad7-b6d1c0eca68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3ad624c7-749b-4f6b-aa63-c2e3ac907bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5ce9949a-a9f7-4a6e-bff3-69acd82af128" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3ad624c7-749b-4f6b-aa63-c2e3ac907bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4acc1093-8b00-4620-adb4-8a276ab58103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5ce9949a-a9f7-4a6e-bff3-69acd82af128" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4acc1093-8b00-4620-adb4-8a276ab58103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_519b1975-0699-461c-82c6-d920427a7fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e6ffb24a-0f0e-4c75-924e-f0d82b557ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_519b1975-0699-461c-82c6-d920427a7fd8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e6ffb24a-0f0e-4c75-924e-f0d82b557ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_363accb8-c07a-4f2f-a235-515a8fa21466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_519b1975-0699-461c-82c6-d920427a7fd8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_363accb8-c07a-4f2f-a235-515a8fa21466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_776c1877-5612-4264-b194-d224ffabf857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_519b1975-0699-461c-82c6-d920427a7fd8" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_776c1877-5612-4264-b194-d224ffabf857" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e74bf7c9-d50c-4b63-960d-a1f53bc378d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e74bf7c9-d50c-4b63-960d-a1f53bc378d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10422059-bc42-4e58-a30f-7e9cabe1cacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10422059-bc42-4e58-a30f-7e9cabe1cacc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_f66f9d67-c5cb-41ea-a33b-9ebb12a3b9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_f66f9d67-c5cb-41ea-a33b-9ebb12a3b9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_9102e40c-18e1-4614-9702-c4fc8b915e0e" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_9102e40c-18e1-4614-9702-c4fc8b915e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b07f19cd-4543-450a-9d78-cd9b4ac65c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b07f19cd-4543-450a-9d78-cd9b4ac65c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_dc10eed5-dac7-48b1-a166-1834a736d14d" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_dc10eed5-dac7-48b1-a166-1834a736d14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_07ad0f84-947a-4ca2-ad19-a69fc82c92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_07ad0f84-947a-4ca2-ad19-a69fc82c92ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_28c99626-741a-45eb-b8d5-75048a87bf95" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_28c99626-741a-45eb-b8d5-75048a87bf95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_dd59fc83-d60c-4066-ad64-df2d294104df" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_dd59fc83-d60c-4066-ad64-df2d294104df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_70366691-113b-45bd-aa85-ad752929ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_90e4aebb-c15a-4708-b161-e5566ece2566" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_70366691-113b-45bd-aa85-ad752929ff2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e006f771-eca9-4957-b886-72274fdc0106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6cacc810-b18f-443c-979e-87b0dce5ae29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e006f771-eca9-4957-b886-72274fdc0106" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_6cacc810-b18f-443c-979e-87b0dce5ae29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a6a25474-4ad1-4e7c-b002-c7d046fd14b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e006f771-eca9-4957-b886-72274fdc0106" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a6a25474-4ad1-4e7c-b002-c7d046fd14b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_96a803d7-cfc7-4410-8f22-affabef4f4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c1b12ea1-20d2-41c7-8f45-b3797fd46cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_96a803d7-cfc7-4410-8f22-affabef4f4a8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c1b12ea1-20d2-41c7-8f45-b3797fd46cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0adc83d2-985f-4c2b-9db7-fdf19c160e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_96a803d7-cfc7-4410-8f22-affabef4f4a8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0adc83d2-985f-4c2b-9db7-fdf19c160e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_69d949fe-6456-4ddc-b46e-4fb4a0378b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_69d949fe-6456-4ddc-b46e-4fb4a0378b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ae605bce-3a55-4d3c-92dc-0ac4402c46ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ae605bce-3a55-4d3c-92dc-0ac4402c46ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_0777297d-7c69-4087-8136-1b1231b220f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_0777297d-7c69-4087-8136-1b1231b220f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5721ee89-792e-4710-9e3a-c4855d7a30cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5721ee89-792e-4710-9e3a-c4855d7a30cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_d1b69be6-4f6a-48cb-ac2f-478d27a97cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_d1b69be6-4f6a-48cb-ac2f-478d27a97cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c1f1bc1d-37b3-457d-99b4-9a895107e9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c1f1bc1d-37b3-457d-99b4-9a895107e9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2fa8cc9a-9255-4a7a-a260-876282fed6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_738c03df-93ad-4531-97d9-263d4cc30541" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2fa8cc9a-9255-4a7a-a260-876282fed6f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid_1fd9d0f0-eac2-4aa9-a101-64afe55639ba" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_70f85748-8f3a-463f-9208-522abea2ccd0" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_1fd9d0f0-eac2-4aa9-a101-64afe55639ba" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_70f85748-8f3a-463f-9208-522abea2ccd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_91896163-2eab-42c8-ac40-0557691b21bb" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_1fd9d0f0-eac2-4aa9-a101-64afe55639ba" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_91896163-2eab-42c8-ac40-0557691b21bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_5383aa3d-ad64-4adb-821b-0555a7d6060a" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_1fd9d0f0-eac2-4aa9-a101-64afe55639ba" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_5383aa3d-ad64-4adb-821b-0555a7d6060a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e367f0dc-243a-4a7c-92b6-5519a260029b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f6508808-4362-4db6-b2df-41f2b4270077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e367f0dc-243a-4a7c-92b6-5519a260029b" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f6508808-4362-4db6-b2df-41f2b4270077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_29d0c393-926e-4428-b5f6-43f38a128483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e367f0dc-243a-4a7c-92b6-5519a260029b" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_29d0c393-926e-4428-b5f6-43f38a128483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_647cde20-43cf-4593-81d2-9c19afc8418d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e367f0dc-243a-4a7c-92b6-5519a260029b" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_647cde20-43cf-4593-81d2-9c19afc8418d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_28830a21-7e48-4116-8b9a-09c7b1dd0ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e367f0dc-243a-4a7c-92b6-5519a260029b" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_28830a21-7e48-4116-8b9a-09c7b1dd0ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_10b8394b-5391-4d7a-9cd3-96504679e3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e367f0dc-243a-4a7c-92b6-5519a260029b" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_10b8394b-5391-4d7a-9cd3-96504679e3fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_b6025abc-945a-4a70-8218-8282cc6e2ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_d8b5f824-7552-42ae-a7af-4e5e0577b691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_b6025abc-945a-4a70-8218-8282cc6e2ee3" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_d8b5f824-7552-42ae-a7af-4e5e0577b691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_84e1d26f-92c2-48e3-902a-9a5e2a43e032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_b6025abc-945a-4a70-8218-8282cc6e2ee3" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_84e1d26f-92c2-48e3-902a-9a5e2a43e032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_20f16070-c034-43c4-895a-40c18ab0bab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_b6025abc-945a-4a70-8218-8282cc6e2ee3" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_20f16070-c034-43c4-895a-40c18ab0bab5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e967cea2-84eb-440c-b7d6-fe82f8d0d505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_f44afb14-150e-48de-9169-7cb52c411da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e967cea2-84eb-440c-b7d6-fe82f8d0d505" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_f44afb14-150e-48de-9169-7cb52c411da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_eb0b5254-8a67-4310-b31b-fb23aab0d601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e967cea2-84eb-440c-b7d6-fe82f8d0d505" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_eb0b5254-8a67-4310-b31b-fb23aab0d601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5dbbd923-1bff-4dc2-a0bb-c12e8d668533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e967cea2-84eb-440c-b7d6-fe82f8d0d505" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5dbbd923-1bff-4dc2-a0bb-c12e8d668533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_650a1642-3c50-4dad-a8a5-184a7c6e5386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_e967cea2-84eb-440c-b7d6-fe82f8d0d505" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_650a1642-3c50-4dad-a8a5-184a7c6e5386" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_34e098bb-474c-4927-b7b0-3255c31e61b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_34e098bb-474c-4927-b7b0-3255c31e61b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_d6643e06-415a-4ebf-8259-e8a8031e6e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_d6643e06-415a-4ebf-8259-e8a8031e6e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7fa4f5e7-ab40-434c-be0c-711280af1ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7fa4f5e7-ab40-434c-be0c-711280af1ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_24142565-34a8-4c2e-9b6a-346ee18ffb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_24142565-34a8-4c2e-9b6a-346ee18ffb35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6f793f99-a33d-422a-bf31-6a951aa0efcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6f793f99-a33d-422a-bf31-6a951aa0efcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_1dc9f8c9-c9d0-487e-8824-48efdbefcb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cc51733c-b623-4fb8-b25c-4f52503ecc91" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_1dc9f8c9-c9d0-487e-8824-48efdbefcb88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c8f3101b-c669-44ae-bee9-e8ff20fa4170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c8f3101b-c669-44ae-bee9-e8ff20fa4170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_67ef7673-6b53-479a-be4d-dbcd615f84ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_67ef7673-6b53-479a-be4d-dbcd615f84ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_406e5edb-9249-462b-ac70-9686140409c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_406e5edb-9249-462b-ac70-9686140409c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8fc9cfab-6dea-44a0-9502-818227633a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8fc9cfab-6dea-44a0-9502-818227633a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3692cabc-75ab-4489-a84b-37a4edc7801e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_3692cabc-75ab-4489-a84b-37a4edc7801e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_16f907dc-099e-43f2-818b-95bf224aab68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_ea2a0ad6-27a7-4ade-a6e6-23b0cf57289d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_16f907dc-099e-43f2-818b-95bf224aab68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d3f14a9-d9ec-4d88-b5cb-c7d7ffcd4583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_15a2f291-5e7c-45b0-95db-958e05c855da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d3f14a9-d9ec-4d88-b5cb-c7d7ffcd4583" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_15a2f291-5e7c-45b0-95db-958e05c855da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9b48603f-e519-486f-a8ad-277c411bf5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5d3f14a9-d9ec-4d88-b5cb-c7d7ffcd4583" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9b48603f-e519-486f-a8ad-277c411bf5fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9627d7f7-d30f-4ce9-bc80-0023d9a107cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_InterestExpense_9627d7f7-d30f-4ce9-bc80-0023d9a107cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f174d09a-3362-4ad7-832c-5263cd85c82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f174d09a-3362-4ad7-832c-5263cd85c82d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ba04dba8-27d6-4b1c-90fc-b777f2f13d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ba04dba8-27d6-4b1c-90fc-b777f2f13d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d73f9260-1e9f-4f0c-9647-08956facdc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d73f9260-1e9f-4f0c-9647-08956facdc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_1dc06fa9-6580-4bcc-9b65-e760712c6cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_1dc06fa9-6580-4bcc-9b65-e760712c6cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_870ce48a-439a-42c4-81a2-28f4c2129bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_870ce48a-439a-42c4-81a2-28f4c2129bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3a86f09f-ddae-427e-9885-ca457cdca6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f4c8d19-6ec5-40c7-8fde-3fbab5158235" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3a86f09f-ddae-427e-9885-ca457cdca6a6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>lly-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9fcc0128-8cb1-4f14-a312-a98ab5e27206,g:b055a216-cbe3-42fc-b7bd-1f3a75142c02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20211231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i8147ccc8a8974f2796bb845534567b5c_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4dc65892-7ee8-4b22-ae1c-d7dee785c3b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentType_4dc65892-7ee8-4b22-ae1c-d7dee785c3b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_bb7208c2-b3cd-42c5-9bff-8d56fd671d04" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentAnnualReport_bb7208c2-b3cd-42c5-9bff-8d56fd671d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_88f89ae3-9444-48d9-8719-ee012170c37f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentPeriodEndDate_88f89ae3-9444-48d9-8719-ee012170c37f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_81f1760a-391a-4b7e-919d-a53fc9c6bd1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_CurrentFiscalYearEndDate_81f1760a-391a-4b7e-919d-a53fc9c6bd1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_86462e07-51df-4e3f-95c4-bf52c0c16487" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityFileNumber_86462e07-51df-4e3f-95c4-bf52c0c16487" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_185babb6-d57b-45bc-b58b-4e075dec24af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityRegistrantName_185babb6-d57b-45bc-b58b-4e075dec24af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_76bf135d-da49-40b3-baf2-68b1d46bf4dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityIncorporationStateCountryCode_76bf135d-da49-40b3-baf2-68b1d46bf4dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e6d3bfd2-f285-4800-9eed-15b7bd51e4f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityTaxIdentificationNumber_e6d3bfd2-f285-4800-9eed-15b7bd51e4f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5244b926-89cc-45d9-972b-48ff7f4fda82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressAddressLine1_5244b926-89cc-45d9-972b-48ff7f4fda82" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4cba1deb-1b56-49e9-9d41-4b9a860e37e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressCityOrTown_4cba1deb-1b56-49e9-9d41-4b9a860e37e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_405f4f41-d991-46a6-bf0c-a8d407a6fdd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressStateOrProvince_405f4f41-d991-46a6-bf0c-a8d407a6fdd5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_706fa7ab-1d8c-4f23-851f-5f8dfc01c2e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressPostalZipCode_706fa7ab-1d8c-4f23-851f-5f8dfc01c2e1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_03c1a350-a33c-4e3b-9197-c79cd4406b78" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_CityAreaCode_03c1a350-a33c-4e3b-9197-c79cd4406b78" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d7de617-b810-4de9-8a1b-b42842781aeb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_LocalPhoneNumber_3d7de617-b810-4de9-8a1b-b42842781aeb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_162cc142-7fb9-4362-8136-9813d2715e80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_Security12bTitle_162cc142-7fb9-4362-8136-9813d2715e80" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_27f80017-4ba0-413d-9124-0af091ff84b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_TradingSymbol_27f80017-4ba0-413d-9124-0af091ff84b4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_518dcf5c-5740-4338-b462-eb945ae0bea0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_SecurityExchangeName_518dcf5c-5740-4338-b462-eb945ae0bea0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_70238a30-28b4-4b3e-be44-c8ad4abcf674" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_70238a30-28b4-4b3e-be44-c8ad4abcf674" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9e8d2732-6d98-48cb-80e9-cafa8efe482b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityVoluntaryFilers_9e8d2732-6d98-48cb-80e9-cafa8efe482b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ecb81d56-56c3-4f2e-96eb-3cec0588e72f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityCurrentReportingStatus_ecb81d56-56c3-4f2e-96eb-3cec0588e72f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f4cf0bde-21de-40be-be1d-a77f61af3827" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityInteractiveDataCurrent_f4cf0bde-21de-40be-be1d-a77f61af3827" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b52cb742-f43d-4787-b96d-0e24cbe4630c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityFilerCategory_b52cb742-f43d-4787-b96d-0e24cbe4630c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c4782d79-33df-4f2e-a789-1859b21fe076" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntitySmallBusiness_c4782d79-33df-4f2e-a789-1859b21fe076" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c6a7eaf0-c2f8-4b96-b69b-a7bbb4a95f71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityEmergingGrowthCompany_c6a7eaf0-c2f8-4b96-b69b-a7bbb4a95f71" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1774dc78-a6c7-40e2-9cca-f187bb4c8b83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1774dc78-a6c7-40e2-9cca-f187bb4c8b83" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3b8f12e9-6d13-4d61-8fbf-758d1ae33170" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityShellCompany_3b8f12e9-6d13-4d61-8fbf-758d1ae33170" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1d4db431-ece1-4012-8f18-95a433166ab9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityPublicFloat_1d4db431-ece1-4012-8f18-95a433166ab9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d2ac33b6-e9b5-4a38-b443-22888fdf8647" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d2ac33b6-e9b5-4a38-b443-22888fdf8647" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0d4e142e-8b8e-4161-ad51-fa2ffefc52a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentTransitionReport_0d4e142e-8b8e-4161-ad51-fa2ffefc52a2" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e469902e-adab-487e-a8c4-e5c419d1c3fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_AmendmentFlag_e469902e-adab-487e-a8c4-e5c419d1c3fe" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7f7eeecc-dad2-42a4-937e-3e9ee7ec9977" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentFiscalYearFocus_7f7eeecc-dad2-42a4-937e-3e9ee7ec9977" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_05446fab-165e-48e8-84c6-eff3d0cab015" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentFiscalPeriodFocus_05446fab-165e-48e8-84c6-eff3d0cab015" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_65623a65-84ba-4e9f-96e7-9ad4427e9e53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityCentralIndexKey_65623a65-84ba-4e9f-96e7-9ad4427e9e53" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f5076cda-0a35-4c4d-9d2a-c7fc1b1625a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f5076cda-0a35-4c4d-9d2a-c7fc1b1625a8" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_235b7fc0-6fdb-4309-a058-faf032ec3dc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:to="loc_us-gaap_ClassOfStockDomain_235b7fc0-6fdb-4309-a058-faf032ec3dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:to="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bee9a8de-6ae3-41cc-bc93-88b32b3cbff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_us-gaap_CommonClassAMember_bee9a8de-6ae3-41cc-bc93-88b32b3cbff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_a1ba0528-d23f-4ebe-8d27-c90039443c0d" xlink:href="lly-20211231.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1.000NotesDueJune22022Member_a1ba0528-d23f-4ebe-8d27-c90039443c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_b02e315b-5adf-4b6b-a67f-23bc092d020e" xlink:href="lly-20211231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A718NotesDueJune12025Member_b02e315b-5adf-4b6b-a67f-23bc092d020e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_def84ada-7c82-45e4-b1e9-356232abb9d3" xlink:href="lly-20211231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1.625NotesDueJune22026Member_def84ada-7c82-45e4-b1e9-356232abb9d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_6055fdd6-68a8-492a-80a3-52f2abcf8484" xlink:href="lly-20211231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A2.125NotesDueJune32030Member_6055fdd6-68a8-492a-80a3-52f2abcf8484" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_c3073670-8cf6-4c50-b82e-d0a497046242" xlink:href="lly-20211231.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A625Notesdue2031Member_c3073670-8cf6-4c50-b82e-d0a497046242" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_d734f5cd-fb8d-482e-9dd6-4b20cad76471" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A5000NotesDue2033Member_d734f5cd-fb8d-482e-9dd6-4b20cad76471" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_a65f1cff-8481-4a5d-b965-8113f7df4324" xlink:href="lly-20211231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_a65f1cff-8481-4a5d-b965-8113f7df4324" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_e0cc88ff-73eb-442c-b8c7-43abda37f5de" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1625NotesDue2043Member_e0cc88ff-73eb-442c-b8c7-43abda37f5de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_17533293-6077-4e7d-9cf3-86462c78dffe" xlink:href="lly-20211231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1.700Notesdue2049Member_17533293-6077-4e7d-9cf3-86462c78dffe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_1d546684-fcb6-4df8-bb5d-ea1842e595eb" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1125NotesDue2051Member_1d546684-fcb6-4df8-bb5d-ea1842e595eb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_4b5ac5ba-2be9-473f-a54b-5e2a58f4f218" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1375NotesDue2061Member_4b5ac5ba-2be9-473f-a54b-5e2a58f4f218" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="ie15776390f534ae99f048ee27252057c_ConsolidatedStatementsofComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_091a90da-ac56-43ae-9282-7a285b3296ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_NetIncomeLoss_091a90da-ac56-43ae-9282-7a285b3296ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5cb71d96-9a22-4cd5-bdf0-5127cf17e2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5cb71d96-9a22-4cd5-bdf0-5127cf17e2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_3c07b7f9-ad44-4d7b-98b2-5562b67f4110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_3c07b7f9-ad44-4d7b-98b2-5562b67f4110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_71358efe-34a4-484a-aa44-b61f1be490f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_71358efe-34a4-484a-aa44-b61f1be490f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b67e8848-aee6-426a-8475-f3ba6ec91abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b67e8848-aee6-426a-8475-f3ba6ec91abd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c04976ed-9f9d-4b02-92b9-cb7bada5c2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c04976ed-9f9d-4b02-92b9-cb7bada5c2ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_f67017b5-6ab7-4f11-acd5-a5f190d66f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_f67017b5-6ab7-4f11-acd5-a5f190d66f1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e29a21a-ae1d-44da-929e-631f7c015b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e29a21a-ae1d-44da-929e-631f7c015b3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c91b6266-3e6c-41e1-a91c-94ebfd815a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c91b6266-3e6c-41e1-a91c-94ebfd815a4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_7b692000-73ad-43b2-a874-09e743c2fe51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_7b692000-73ad-43b2-a874-09e743c2fe51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_5b556471-f2ce-4af2-a9ca-c4f83c432eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_5b556471-f2ce-4af2-a9ca-c4f83c432eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_b43c5d04-1772-4fa5-adcf-b8be0e06a72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_b43c5d04-1772-4fa5-adcf-b8be0e06a72e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofShareholdersEquityStatement"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="extended" id="ie0283f3eb4cd44bbb10b442e7a721a59_ConsolidatedStatementsofShareholdersEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f4adb641-054f-4351-b655-a07e897704cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f4adb641-054f-4351-b655-a07e897704cc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1ed70e28-d9af-4e9c-8412-29977f3b36ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_SharesIssued_1ed70e28-d9af-4e9c-8412-29977f3b36ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3458ec7d-0615-4200-8272-962b65b87c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3458ec7d-0615-4200-8272-962b65b87c64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2df9b6f3-7da9-4869-a1e1-681d52b74539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_ProfitLoss_2df9b6f3-7da9-4869-a1e1-681d52b74539" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_243d038c-1d19-4c70-80b0-a0ddd6456b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_243d038c-1d19-4c70-80b0-a0ddd6456b63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_94dc902e-88da-4459-a1d4-4d2d18a49d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_Dividends_94dc902e-88da-4459-a1d4-4d2d18a49d2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_c3e01fcd-f196-4294-bc24-5a47832b8143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_c3e01fcd-f196-4294-bc24-5a47832b8143" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4683a802-7f02-487d-889f-8de1a788a413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4683a802-7f02-487d-889f-8de1a788a413" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_897035af-b45e-4e99-aa88-4c68e348709f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_897035af-b45e-4e99-aa88-4c68e348709f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b5cca4bd-4589-45d7-b5f2-775c5172b186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b5cca4bd-4589-45d7-b5f2-775c5172b186" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_fd596618-a394-484d-abb9-134f4b86268d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_fd596618-a394-484d-abb9-134f4b86268d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_18f89650-482c-43c1-bb52-ec275acf2100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_18f89650-482c-43c1-bb52-ec275acf2100" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e4de6aa7-7359-4262-85d1-bdb845f0641e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e4de6aa7-7359-4262-85d1-bdb845f0641e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_440cded4-d873-4d7d-b811-667287d79622" xlink:href="lly-20211231.xsd#lly_StockAcquiredDuringPeriodSharesExchangeOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_440cded4-d873-4d7d-b811-667287d79622" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_68f3ab27-d139-4469-89fb-d325af2eb3a4" xlink:href="lly-20211231.xsd#lly_StockAcquiredDuringPeriodValueExchangeOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_68f3ab27-d139-4469-89fb-d325af2eb3a4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_809681d7-c23b-4468-9500-f4b35c9f1a65" xlink:href="lly-20211231.xsd#lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_809681d7-c23b-4468-9500-f4b35c9f1a65" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_18c16c8e-e813-4d13-ae0d-b6514cd0e490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockholdersEquityOther_18c16c8e-e813-4d13-ae0d-b6514cd0e490" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a7666653-19b3-4323-b224-b5206c52d012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a6fe631-64f0-45b6-88af-b4b06da6d337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f4adb641-054f-4351-b655-a07e897704cc" xlink:to="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:to="loc_us-gaap_EquityComponentDomain_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:to="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0513cb2-7e0f-4963-83fa-4158fe82f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_CommonStockMember_c0513cb2-7e0f-4963-83fa-4158fe82f6ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_050a8ee7-afd6-4717-9527-6d8a96278e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_050a8ee7-afd6-4717-9527-6d8a96278e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ebf603cd-2d26-43cf-8b5d-e035ad69b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_RetainedEarningsMember_ebf603cd-2d26-43cf-8b5d-e035ad69b6cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_4a91b8da-e122-4c00-b48e-20f7c835fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_4a91b8da-e122-4c00-b48e-20f7c835fbf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c6e2091-f253-4159-b5b2-a9366c97ec52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c6e2091-f253-4159-b5b2-a9366c97ec52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2ad6cbbb-36c2-48d2-bc49-6d727eddfd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_TreasuryStockMember_2ad6cbbb-36c2-48d2-bc49-6d727eddfd00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0072d018-4850-4a55-bf25-42494fe07e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0072d018-4850-4a55-bf25-42494fe07e65" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails" xlink:type="extended" id="i472b6f5be3f6487db549a03553adb7b3_SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_77c5cca6-5c73-4cc7-b3e4-8c6c55a3b631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_77c5cca6-5c73-4cc7-b3e4-8c6c55a3b631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_e941d108-be0a-4304-9fb7-3e0b4b533dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_us-gaap_AdvertisingExpense_e941d108-be0a-4304-9fb7-3e0b4b533dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue_9c239ee7-a19c-4b8b-a333-7987911c6964" xlink:href="lly-20211231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_lly_AdvertisingExpensePercentageOfRevenue_9c239ee7-a19c-4b8b-a333-7987911c6964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b482da51-0fa8-4210-b6f4-357d4a8dc015_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b482da51-0fa8-4210-b6f4-357d4a8dc015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_aebd81ee-43b8-4b9c-ae8d-aa7a04b12e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_aebd81ee-43b8-4b9c-ae8d-aa7a04b12e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1423496b-026b-472a-b53b-314e9b7cf777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_aebd81ee-43b8-4b9c-ae8d-aa7a04b12e76" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1423496b-026b-472a-b53b-314e9b7cf777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f14ae74-d73d-4701-95eb-5fd8e58c1f09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9f14ae74-d73d-4701-95eb-5fd8e58c1f09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_808c96d4-fa5e-4fd2-bb15-0ff5da0ddeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_808c96d4-fa5e-4fd2-bb15-0ff5da0ddeaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_0646d20d-6b8b-4bfd-98b7-26025f387917" xlink:href="lly-20211231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_808c96d4-fa5e-4fd2-bb15-0ff5da0ddeaa" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_0646d20d-6b8b-4bfd-98b7-26025f387917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fe060c97-834a-408d-a694-b1f3ccd58501_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:to="loc_srt_OwnershipDomain_fe060c97-834a-408d-a694-b1f3ccd58501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8af7ce1b-607c-4ad5-86ca-6221ec1800f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:to="loc_srt_OwnershipDomain_8af7ce1b-607c-4ad5-86ca-6221ec1800f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_1eaa59cd-a0d1-4b2c-8107-0524fec873f7" xlink:href="lly-20211231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_8af7ce1b-607c-4ad5-86ca-6221ec1800f9" xlink:to="loc_lly_EliLillyAndCompanyMember_1eaa59cd-a0d1-4b2c-8107-0524fec873f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="i297421b68f2149939834d138ba0d2ecc_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_69a1d549-d6f4-452e-93e5-90ff2bfef176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_943f0a41-6427-485f-9ee4-53fc1fae50c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69a1d549-d6f4-452e-93e5-90ff2bfef176" xlink:to="loc_us-gaap_Revenues_943f0a41-6427-485f-9ee4-53fc1fae50c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69a1d549-d6f4-452e-93e5-90ff2bfef176" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:to="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:to="loc_srt_ProductsAndServicesDomain_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:to="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9634ba5c-45da-4584-956f-2e32814a31b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:to="loc_us-gaap_ProductMember_9634ba5c-45da-4584-956f-2e32814a31b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_77b29f87-3365-4542-82c1-6e6548a7531e" xlink:href="lly-20211231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:to="loc_lly_CollaborationandOtherRevenueMember_77b29f87-3365-4542-82c1-6e6548a7531e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_acfb3cb0-0a4f-4e46-af4c-68ef8bbc5887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:to="loc_us-gaap_RoyaltyMember_acfb3cb0-0a4f-4e46-af4c-68ef8bbc5887" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended" id="id9f3beead5f04e988bbd348d086ae829_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum_0f2234d6-b6d3-424b-8cf4-73da41c6a901" xlink:href="lly-20211231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuefromContractPaymentTermMinimum_0f2234d6-b6d3-424b-8cf4-73da41c6a901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum_ced693de-57a0-436b-b57c-85cd78efa515" xlink:href="lly-20211231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuefromContractPaymentTermMaximum_ced693de-57a0-436b-b57c-85cd78efa515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_f4b4cdaa-da39-4496-8129-871cecb1729c" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_f4b4cdaa-da39-4496-8129-871cecb1729c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_713c6918-07d1-4c2b-8e63-765784268557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_713c6918-07d1-4c2b-8e63-765784268557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_3717ed40-2bca-42c3-8333-784849f2350f" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_3717ed40-2bca-42c3-8333-784849f2350f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_a71a74c9-4f0e-4c1d-84f4-128830795022" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_a71a74c9-4f0e-4c1d-84f4-128830795022" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_5bd974ed-9d21-429c-80b8-97ffe60080aa" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_5bd974ed-9d21-429c-80b8-97ffe60080aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_3595cbe4-1604-44f1-b076-79ca3c7f6816" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_3595cbe4-1604-44f1-b076-79ca3c7f6816" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_b0496552-4568-48ee-9bb3-43f03255ece5" xlink:href="lly-20211231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_b0496552-4568-48ee-9bb3-43f03255ece5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b911051d-99d3-432c-a8ac-e6a5265a0588_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:to="loc_srt_NameOfMajorCustomerDomain_b911051d-99d3-432c-a8ac-e6a5265a0588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_011e77fa-0640-4f30-8d06-b4042c720b01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:to="loc_srt_NameOfMajorCustomerDomain_011e77fa-0640-4f30-8d06-b4042c720b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember_0bc498ec-0ac3-45ad-9f3e-27c15c4da16c" xlink:href="lly-20211231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_011e77fa-0640-4f30-8d06-b4042c720b01" xlink:to="loc_lly_ThreeLargestWholesalesMember_0bc498ec-0ac3-45ad-9f3e-27c15c4da16c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_270f6867-3577-4dc6-a99e-aa5c6ae6b28a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_270f6867-3577-4dc6-a99e-aa5c6ae6b28a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_36f22aa3-9b33-404b-96ca-0f9cde44e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:to="loc_us-gaap_SalesRevenueNetMember_36f22aa3-9b33-404b-96ca-0f9cde44e93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8ff81d9f-610a-4309-89aa-f66fafa6f041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:to="loc_us-gaap_AccountsReceivableMember_8ff81d9f-610a-4309-89aa-f66fafa6f041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0942e4bd-262c-43bb-bacf-db06e860fefb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:to="loc_srt_RangeMember_0942e4bd-262c-43bb-bacf-db06e860fefb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:to="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48f3816e-274c-4517-b4a4-919ff8b3e4cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:to="loc_srt_MinimumMember_48f3816e-274c-4517-b4a4-919ff8b3e4cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_417cbcc7-eee6-4b3a-8c73-5b89250d4d59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:to="loc_srt_MaximumMember_417cbcc7-eee6-4b3a-8c73-5b89250d4d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9fdd109a-e699-4308-95ca-bd8361edd2a0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:to="loc_srt_SegmentGeographicalDomain_9fdd109a-e699-4308-95ca-bd8361edd2a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a27ce4f-d31b-40cb-ae0c-9b6bd2fc867e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:to="loc_srt_SegmentGeographicalDomain_6a27ce4f-d31b-40cb-ae0c-9b6bd2fc867e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f73655bd-dd1c-48e8-876b-5eb21008eed1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6a27ce4f-d31b-40cb-ae0c-9b6bd2fc867e" xlink:to="loc_country_US_f73655bd-dd1c-48e8-876b-5eb21008eed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_aa362411-3937-4c6c-83a6-54df8653e28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_aa362411-3937-4c6c-83a6-54df8653e28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_afb12dbd-54d1-49cb-abb7-a96cd83d5516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_aa362411-3937-4c6c-83a6-54df8653e28f" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_afb12dbd-54d1-49cb-abb7-a96cd83d5516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c51386e2-3007-485b-a393-7345296ec62b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c51386e2-3007-485b-a393-7345296ec62b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4aced886-644a-4d53-a873-496b80992fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4aced886-644a-4d53-a873-496b80992fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_85c0d919-a3e9-47ae-ac66-e905f37ac2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4aced886-644a-4d53-a873-496b80992fba" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_85c0d919-a3e9-47ae-ac66-e905f37ac2fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="i7053d142ba0b46d48faea28168fe4608_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_970bd7b3-88c3-4ad3-8d65-5918bc406545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1abc4e88-61a2-410a-bd65-2da65ca61fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_970bd7b3-88c3-4ad3-8d65-5918bc406545" xlink:to="loc_us-gaap_Revenues_1abc4e88-61a2-410a-bd65-2da65ca61fbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_970bd7b3-88c3-4ad3-8d65-5918bc406545" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:to="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7e4d4a2-efbd-4292-b82c-0917af65429b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:to="loc_srt_ProductsAndServicesDomain_d7e4d4a2-efbd-4292-b82c-0917af65429b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:to="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:href="lly-20211231.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_1bab6bfe-c080-4ddf-ab15-cb1fdfb7975a" xlink:href="lly-20211231.xsd#lly_TrulicityMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_TrulicityMemberMember_1bab6bfe-c080-4ddf-ab15-cb1fdfb7975a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_20846cbd-e40a-401c-b5c5-07574d8f6c8f" xlink:href="lly-20211231.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_HumalogMember_20846cbd-e40a-401c-b5c5-07574d8f6c8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_e56fab26-81ca-4640-aa77-5cafabb7548c" xlink:href="lly-20211231.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_HumulinMember_e56fab26-81ca-4640-aa77-5cafabb7548c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_ed17992c-511f-4281-aa84-899ab0b0c7bc" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_JardianceMember_ed17992c-511f-4281-aa84-899ab0b0c7bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_e757c541-9867-4266-a652-5d2594546955" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_BasaglarMember_e757c541-9867-4266-a652-5d2594546955" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_65d9a006-aeb0-4faf-ae76-a3daad8640c8" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_TrajentaBIMember_65d9a006-aeb0-4faf-ae76-a3daad8640c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_773b5c2b-ce75-4266-b0d7-26c44e8d37e3" xlink:href="lly-20211231.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_OtherDiabetesMember_773b5c2b-ce75-4266-b0d7-26c44e8d37e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:href="lly-20211231.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_96b5294b-78a6-4dc5-84eb-9a51e3795fdb" xlink:href="lly-20211231.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_AlimtaMember_96b5294b-78a6-4dc5-84eb-9a51e3795fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_970a22a1-4434-41b4-85fa-20616fd243ad" xlink:href="lly-20211231.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_VerzenioMember_970a22a1-4434-41b4-85fa-20616fd243ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_edad9b15-03ab-4671-a7b7-01b651ac6b18" xlink:href="lly-20211231.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_CyramzaMember_edad9b15-03ab-4671-a7b7-01b651ac6b18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_76bc48b3-8a8d-4559-8cb6-e49e35a42e4e" xlink:href="lly-20211231.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_ErbituxMember_76bc48b3-8a8d-4559-8cb6-e49e35a42e4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_1d05d28e-87f3-43cf-9955-ecaad8f482c7" xlink:href="lly-20211231.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_TYVYTMember_1d05d28e-87f3-43cf-9955-ecaad8f482c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_c5828b11-ccf0-44c4-b0c2-01363c1c5cad" xlink:href="lly-20211231.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_OtherOncologyMember_c5828b11-ccf0-44c4-b0c2-01363c1c5cad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:href="lly-20211231.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_06101de3-fe9c-483f-867f-dd5ea43c002e" xlink:href="lly-20211231.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:to="loc_lly_TaltzMember_06101de3-fe9c-483f-867f-dd5ea43c002e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_cc6f37fa-fbcf-4138-b5d7-3e9e44fc9b00" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:to="loc_lly_OlumiantMember_cc6f37fa-fbcf-4138-b5d7-3e9e44fc9b00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_efd24441-781c-4b11-9e69-e4d201a94a8a" xlink:href="lly-20211231.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:to="loc_lly_OtherImmunologyMember_efd24441-781c-4b11-9e69-e4d201a94a8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:href="lly-20211231.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_1536579d-1860-42b9-959d-05df323b6822" xlink:href="lly-20211231.xsd#lly_CymbaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_CymbaltaMember_1536579d-1860-42b9-959d-05df323b6822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_1aebc8fb-f8b1-4a1a-b00e-08a1cbc42d8b" xlink:href="lly-20211231.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_EmgalityMember_1aebc8fb-f8b1-4a1a-b00e-08a1cbc42d8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_00c979e5-fc0b-4f58-b286-e5eafd62a8f8" xlink:href="lly-20211231.xsd#lly_ZyprexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_ZyprexaMember_00c979e5-fc0b-4f58-b286-e5eafd62a8f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_b647c749-6aa9-4450-8302-605369ddfc92" xlink:href="lly-20211231.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_OtherNeuroscienceMember_b647c749-6aa9-4450-8302-605369ddfc92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:href="lly-20211231.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_f86449f4-1816-4561-9005-e42c86f8ccd4" xlink:href="lly-20211231.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_COVID19AntibodiesMember_f86449f4-1816-4561-9005-e42c86f8ccd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_3dc7b2b2-daa1-488f-a70d-efadbf88dc90" xlink:href="lly-20211231.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_ForteoMember_3dc7b2b2-daa1-488f-a70d-efadbf88dc90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_49176729-ad9b-4f40-8cea-8ea18321afe9" xlink:href="lly-20211231.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_CialisMember_49176729-ad9b-4f40-8cea-8ea18321afe9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_4728658f-5be3-4934-9e4c-586a2a5400df" xlink:href="lly-20211231.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_OtherProductMember_4728658f-5be3-4934-9e4c-586a2a5400df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:to="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b7a33ad-a3d1-456c-9776-de3606314cea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:to="loc_srt_SegmentGeographicalDomain_5b7a33ad-a3d1-456c-9776-de3606314cea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:to="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_14bd346f-ef0f-433d-871f-5497c8c761c9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:to="loc_country_US_14bd346f-ef0f-433d-871f-5497c8c761c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_cfdff890-9c5f-4c0b-b18b-2276f6bc2991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:to="loc_us-gaap_NonUsMember_cfdff890-9c5f-4c0b-b18b-2276f6bc2991" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="i5fa5c857bc7a4b939b126968ba40aa30_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c76e606a-270f-4532-8f20-6471e78e7a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_196ba4fd-9987-43d5-aa58-9e7f670beb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c76e606a-270f-4532-8f20-6471e78e7a2c" xlink:to="loc_us-gaap_Revenues_196ba4fd-9987-43d5-aa58-9e7f670beb2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c76e606a-270f-4532-8f20-6471e78e7a2c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:to="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3cf9fbe2-fd92-4b6a-a37a-bab39369270e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:to="loc_srt_SegmentGeographicalDomain_3cf9fbe2-fd92-4b6a-a37a-bab39369270e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:to="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f3a5c969-c7c5-44f0-9155-4c6e9225696e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_country_US_f3a5c969-c7c5-44f0-9155-4c6e9225696e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b4fa7909-22fc-4a17-b494-0257f345a425" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_srt_EuropeMember_b4fa7909-22fc-4a17-b494-0257f345a425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c319220d-aa64-4b67-bea6-6ed8e64c7597" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_country_JP_c319220d-aa64-4b67-bea6-6ed8e64c7597" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_07903c19-cfa1-4b9c-a204-c03d7fa978e4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_country_CN_07903c19-cfa1-4b9c-a204-c03d7fa978e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_a7cf65e8-d04b-4456-a3fb-a4cf6ca1fad0" xlink:href="lly-20211231.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_lly_OtherForeignCountriesMember_a7cf65e8-d04b-4456-a3fb-a4cf6ca1fad0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestitureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="extended" id="i47f6633390a947b5bc96fe703353becb_AcquisitionsandDivestitureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7c0f77dc-c97f-41fa-94f2-499d47931078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7c0f77dc-c97f-41fa-94f2-499d47931078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_a5f1cd27-bdae-461f-aa41-c3b34b2ab541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_a5f1cd27-bdae-461f-aa41-c3b34b2ab541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1b838746-93c8-4abc-92f9-d5b668349d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1b838746-93c8-4abc-92f9-d5b668349d20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_6e21f186-5cec-419e-b108-eec9afe1b3ce" xlink:href="lly-20211231.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_6e21f186-5cec-419e-b108-eec9afe1b3ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_aeeb82ab-1263-4c6d-9271-733130aff1d3" xlink:href="lly-20211231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_aeeb82ab-1263-4c6d-9271-733130aff1d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5f1dc859-0381-4a59-bba0-15bded393d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5f1dc859-0381-4a59-bba0-15bded393d57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_92a5d954-6425-43df-a856-f44768879307" xlink:href="lly-20211231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_92a5d954-6425-43df-a856-f44768879307" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73ed1023-5628-4ca1-900a-781622c9e19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73ed1023-5628-4ca1-900a-781622c9e19e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_98f150de-861f-4f80-8837-9e97bc83affc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_Goodwill_98f150de-861f-4f80-8837-9e97bc83affc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_33785bae-ec4b-4e7b-a844-9eef321200c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_33785bae-ec4b-4e7b-a844-9eef321200c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c5420935-7b76-416c-a5a6-33c938bd9e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c5420935-7b76-416c-a5a6-33c938bd9e69" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_d6101c34-1703-4f2a-b6ee-41cfd562aabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_d6101c34-1703-4f2a-b6ee-41cfd562aabe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6b955e6c-0020-44d7-ab00-a03eff6e1047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6b955e6c-0020-44d7-ab00-a03eff6e1047" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NumberOfMedicinesRightsToSold_9e7a7053-b182-4a30-93b3-453135d1f290" xlink:href="lly-20211231.xsd#lly_NumberOfMedicinesRightsToSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_NumberOfMedicinesRightsToSold_9e7a7053-b182-4a30-93b3-453135d1f290" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_48048615-7a80-45fd-975e-8f8e67cee8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_48048615-7a80-45fd-975e-8f8e67cee8c4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_04cb6d64-59aa-456b-9836-b0bba7da3968" xlink:href="lly-20211231.xsd#lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_04cb6d64-59aa-456b-9836-b0bba7da3968" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_83ef9988-9c3d-469d-8e32-0afb0343156e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_83ef9988-9c3d-469d-8e32-0afb0343156e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d550cc21-f1c1-4d0a-bff1-d5df62c92456_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d550cc21-f1c1-4d0a-bff1-d5df62c92456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_26389e89-d0b9-433c-874b-1a51afa74cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_26389e89-d0b9-433c-874b-1a51afa74cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_024c5ad5-1297-4d8d-b3d7-9a9e5b4c28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_26389e89-d0b9-433c-874b-1a51afa74cbf" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_024c5ad5-1297-4d8d-b3d7-9a9e5b4c28c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52bd524d-b00b-4612-96ef-371e607c2cc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52bd524d-b00b-4612-96ef-371e607c2cc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cad6c6bf-0bcc-4dea-b61e-c1b52f6e97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cad6c6bf-0bcc-4dea-b61e-c1b52f6e97d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b1470d5b-cf47-45e8-addc-c9e90c192861" xlink:href="lly-20211231.xsd#lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cad6c6bf-0bcc-4dea-b61e-c1b52f6e97d5" xlink:to="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b1470d5b-cf47-45e8-addc-c9e90c192861" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_e78d912b-6e66-4502-a876-467c53bde902" xlink:href="lly-20211231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:to="loc_lly_PrevailTherapeuticsIncMember_e78d912b-6e66-4502-a876-467c53bde902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_9b454772-b060-4ada-8fc8-b2b72b4b7417" xlink:href="lly-20211231.xsd#lly_DermiraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:to="loc_lly_DermiraInc.Member_9b454772-b060-4ada-8fc8-b2b72b4b7417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_10f1d636-e9ce-402f-be0e-96a2c5d7e917" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:to="loc_lly_LoxoOncologyInc.Member_10f1d636-e9ce-402f-be0e-96a2c5d7e917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:to="loc_srt_ProductsAndServicesDomain_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48aa7e65-645a-452d-bb30-c052bb715cfb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:to="loc_srt_ProductsAndServicesDomain_48aa7e65-645a-452d-bb30-c052bb715cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_bba1cc08-04a0-49c8-bcfb-3d880c35c102" xlink:href="lly-20211231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_48aa7e65-645a-452d-bb30-c052bb715cfb" xlink:to="loc_lly_SelpercatinibLOXO292Member_bba1cc08-04a0-49c8-bcfb-3d880c35c102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_075df805-4f64-4ce0-b1e3-df3156026548_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_075df805-4f64-4ce0-b1e3-df3156026548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baf7d619-53bf-491a-bbb2-f6b6abb9579e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baf7d619-53bf-491a-bbb2-f6b6abb9579e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EddingpharmMember_090bbd1a-d708-4552-9300-16810ddf284b" xlink:href="lly-20211231.xsd#lly_EddingpharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baf7d619-53bf-491a-bbb2-f6b6abb9579e" xlink:to="loc_lly_EddingpharmMember_090bbd1a-d708-4552-9300-16810ddf284b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="extended" id="i6e7c1973afbe4864a72e34d63d5a8f71_AcquisitionsandDivestiturePurchasePriceAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d56191a3-8884-4655-b1d3-d8ceac4e70b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d56191a3-8884-4655-b1d3-d8ceac4e70b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d5c5cb7c-4abe-46bc-883d-799c9d16dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d5c5cb7c-4abe-46bc-883d-799c9d16dabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3bcaa287-4e19-4dd5-8422-15143849fbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3bcaa287-4e19-4dd5-8422-15143849fbbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6170230-1495-45b8-8d09-5c54f5b0c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_Goodwill_f6170230-1495-45b8-8d09-5c54f5b0c36c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0991f7ce-a914-464f-acc6-05adc09c3992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0991f7ce-a914-464f-acc6-05adc09c3992" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_7c374d86-ae0a-40c5-8623-e7ef135609e2" xlink:href="lly-20211231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_7c374d86-ae0a-40c5-8623-e7ef135609e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ebbfaeb-e3dc-4a3b-812b-d9d5a471fbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ebbfaeb-e3dc-4a3b-812b-d9d5a471fbd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0a03297-43dd-4ee0-b430-e6dd5d4f666b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0a03297-43dd-4ee0-b430-e6dd5d4f666b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_5e5e1ef4-e901-4466-b7a8-0961d4842617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_5e5e1ef4-e901-4466-b7a8-0961d4842617" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_344069f0-84e6-4df8-b923-0e8737ceefe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_344069f0-84e6-4df8-b923-0e8737ceefe9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_df4cb252-5d62-42cf-982b-929fb1e317ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_df4cb252-5d62-42cf-982b-929fb1e317ee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5fa30fd7-23d1-4bd7-afd7-cd509f146df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5fa30fd7-23d1-4bd7-afd7-cd509f146df2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d79aac61-ce64-4253-abb3-89135b7620ca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:to="loc_srt_ProductsAndServicesDomain_d79aac61-ce64-4253-abb3-89135b7620ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_312ec2bc-4f0f-47cc-b154-47b6cdd77052" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:to="loc_srt_ProductsAndServicesDomain_312ec2bc-4f0f-47cc-b154-47b6cdd77052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_64000cb4-32b6-46f6-a9fd-a6e456ef6028" xlink:href="lly-20211231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_312ec2bc-4f0f-47cc-b154-47b6cdd77052" xlink:to="loc_lly_SelpercatinibLOXO292Member_64000cb4-32b6-46f6-a9fd-a6e456ef6028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d4d502f-1d41-49f0-9f59-1cb344ad5007_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d4d502f-1d41-49f0-9f59-1cb344ad5007_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ffb00fbe-867b-4f50-ba92-e73557fff295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ffb00fbe-867b-4f50-ba92-e73557fff295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_2dfcc6fe-4785-48f8-956e-9ae411269f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ffb00fbe-867b-4f50-ba92-e73557fff295" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_2dfcc6fe-4785-48f8-956e-9ae411269f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48c70368-8d46-4d3f-be0f-3f2259c24f1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48c70368-8d46-4d3f-be0f-3f2259c24f1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_733a4e2b-ba7b-4ea0-9d57-9076057609b9" xlink:href="lly-20211231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:to="loc_lly_PrevailTherapeuticsIncMember_733a4e2b-ba7b-4ea0-9d57-9076057609b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_8ef07fce-ac63-4df1-a410-a641f6f10c5b" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:to="loc_lly_LoxoOncologyInc.Member_8ef07fce-ac63-4df1-a410-a641f6f10c5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestitureAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="extended" id="ib2b1127ac06443dd8eb42b50b9bd461a_AcquisitionsandDivestitureAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_338c3c25-58ee-4a99-9675-3cad15eb837e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b58898e7-077b-4817-b73c-e6df24fa6da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_338c3c25-58ee-4a99-9675-3cad15eb837e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b58898e7-077b-4817-b73c-e6df24fa6da6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_338c3c25-58ee-4a99-9675-3cad15eb837e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:to="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_22c32905-c690-473f-b13f-4f53fcf9c57b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:to="loc_us-gaap_AssetAcquisitionDomain_22c32905-c690-473f-b13f-4f53fcf9c57b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_701e4256-6c52-4ad7-b0cb-64ce43830f78" xlink:href="lly-20211231.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_PrecisionBiosciencesIncMember_701e4256-6c52-4ad7-b0cb-64ce43830f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_e7af7fe5-ff7e-402e-b52a-d8536e8b06b6" xlink:href="lly-20211231.xsd#lly_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_MerusNVMember_e7af7fe5-ff7e-402e-b52a-d8536e8b06b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_6b5fa0a0-87f3-4078-b092-62b7c9769264" xlink:href="lly-20211231.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_6b5fa0a0-87f3-4078-b092-62b7c9769264" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_a9832e27-3b1d-4598-bd2d-f81a44b42a83" xlink:href="lly-20211231.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_a9832e27-3b1d-4598-bd2d-f81a44b42a83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MiNATherapeuticsLimitedMember_1c1cf833-dd89-4358-bfbd-a84385abfb46" xlink:href="lly-20211231.xsd#lly_MiNATherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_MiNATherapeuticsLimitedMember_1c1cf833-dd89-4358-bfbd-a84385abfb46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProtomerTechnologiesIncMember_1ddd02fa-27ce-4b96-ab7f-fd07de8460f5" xlink:href="lly-20211231.xsd#lly_ProtomerTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ProtomerTechnologiesIncMember_1ddd02fa-27ce-4b96-ab7f-fd07de8460f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_KumquatBiosciencesIncMember_53fade52-70dc-4135-b160-605af30f4f01" xlink:href="lly-20211231.xsd#lly_KumquatBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_KumquatBiosciencesIncMember_53fade52-70dc-4135-b160-605af30f4f01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LyciaTherapeuticsIncMember_9569c032-d5c7-406c-ba14-946517681db0" xlink:href="lly-20211231.xsd#lly_LyciaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_LyciaTherapeuticsIncMember_9569c032-d5c7-406c-ba14-946517681db0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProQRTherapeuticsNVMember_cba39862-2523-4716-b39c-0c0e980d9733" xlink:href="lly-20211231.xsd#lly_ProQRTherapeuticsNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ProQRTherapeuticsNVMember_cba39862-2523-4716-b39c-0c0e980d9733" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_QILURegorTherapeuticsIncMember_226bade4-e558-41ac-8b07-cc0ef8f96c06" xlink:href="lly-20211231.xsd#lly_QILURegorTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_QILURegorTherapeuticsIncMember_226bade4-e558-41ac-8b07-cc0ef8f96c06" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FoghornTherapeuticsIncMember_c141f05a-58d3-4e5d-bc1a-a9cf8a1cf775" xlink:href="lly-20211231.xsd#lly_FoghornTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_FoghornTherapeuticsIncMember_c141f05a-58d3-4e5d-bc1a-a9cf8a1cf775" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EntosPharmaceuticalsIncMember_9f32f134-5bfb-46fb-8b98-d5dc962d3397" xlink:href="lly-20211231.xsd#lly_EntosPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_EntosPharmaceuticalsIncMember_9f32f134-5bfb-46fb-8b98-d5dc962d3397" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_6d765664-ae1c-45dc-b949-317bfd726397" xlink:href="lly-20211231.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_6d765664-ae1c-45dc-b949-317bfd726397" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_ba73b873-7e62-4abf-a052-e80f5d6dccbd" xlink:href="lly-20211231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_ba73b873-7e62-4abf-a052-e80f5d6dccbd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_1e284c27-274b-41e5-8821-b16f65d6df62" xlink:href="lly-20211231.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_JunshiBiosciencesMember_1e284c27-274b-41e5-8821-b16f65d6df62" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_aa96c8f5-414a-4ed6-b9e2-f1a50362f532" xlink:href="lly-20211231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_PetraPharmaCorporationMember_aa96c8f5-414a-4ed6-b9e2-f1a50362f532" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember_c73582e2-4551-453d-86b1-806f7e28c571" xlink:href="lly-20211231.xsd#lly_EvoxTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_EvoxTherapeuticsMember_c73582e2-4551-453d-86b1-806f7e28c571" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_95bccc5a-d7b3-42bb-9eea-89fcfe8a006e" xlink:href="lly-20211231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_InnoventBiologicsIncMember_95bccc5a-d7b3-42bb-9eea-89fcfe8a006e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember_f0427782-4a1e-4eb7-8a87-579c18c297b6" xlink:href="lly-20211231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_DisarmTherapeuticsIncMember_f0427782-4a1e-4eb7-8a87-579c18c297b6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FochonPharmaceuticalsLtdMember_b81bae99-1b79-4ec7-98fc-42b87980dbb1" xlink:href="lly-20211231.xsd#lly_FochonPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_FochonPharmaceuticalsLtdMember_b81bae99-1b79-4ec7-98fc-42b87980dbb1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ACImmuneSAMember_4a3bf724-9e55-4dfb-acac-ad2dcc667c5f" xlink:href="lly-20211231.xsd#lly_ACImmuneSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ACImmuneSAMember_4a3bf724-9e55-4dfb-acac-ad2dcc667c5f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmuNextInc.Member_66671838-4fb0-4759-ba8e-d4977def9e96" xlink:href="lly-20211231.xsd#lly_ImmuNextInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ImmuNextInc.Member_66671838-4fb0-4759-ba8e-d4977def9e96" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvidityBiosciencesInc.Member_bbb8ea7e-2c3e-4d69-8df9-49659316a35a" xlink:href="lly-20211231.xsd#lly_AvidityBiosciencesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_AvidityBiosciencesInc.Member_bbb8ea7e-2c3e-4d69-8df9-49659316a35a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CentrexionTherapeuticsCorporationMember_1025ac9e-9e36-4bc8-8733-3b30791f0813" xlink:href="lly-20211231.xsd#lly_CentrexionTherapeuticsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_CentrexionTherapeuticsCorporationMember_1025ac9e-9e36-4bc8-8733-3b30791f0813" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended" id="ie55520458f75474ba518736f7d794324_CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286c4e0e-888f-433c-be30-13d15e19c389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_42c3fc2e-667a-4b86-900a-3cc1549fa4a2" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286c4e0e-888f-433c-be30-13d15e19c389" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_42c3fc2e-667a-4b86-900a-3cc1549fa4a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286c4e0e-888f-433c-be30-13d15e19c389" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99fe8f90-838e-4569-9743-688212d3d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99fe8f90-838e-4569-9743-688212d3d42d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_0f58f725-19ea-4969-aaf8-87f7fd987323" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99fe8f90-838e-4569-9743-688212d3d42d" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_0f58f725-19ea-4969-aaf8-87f7fd987323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:to="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_95e3e9f1-b960-4d83-8d1b-04713f2d162f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:to="loc_srt_ProductsAndServicesDomain_95e3e9f1-b960-4d83-8d1b-04713f2d162f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:to="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_b7174e2a-0b01-4015-ae45-0eaee04a25aa" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:to="loc_lly_JardianceMember_b7174e2a-0b01-4015-ae45-0eaee04a25aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_98f6a89e-cf3b-4d97-a160-ce0dfa66bfe1" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:to="loc_lly_TrajentaBIMember_98f6a89e-cf3b-4d97-a160-ce0dfa66bfe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_9684ff02-a902-49c6-815d-a1374a6f1f60" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:to="loc_lly_BasaglarMember_9684ff02-a902-49c6-815d-a1374a6f1f60" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended" id="i64ae45598ffa4bc5949dde9cd807a3d8_CollaborationsandOtherArrangementsNetProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83634b51-ee28-4175-989a-a3e110fb1768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1ce25655-1994-4000-9241-b3c7defe7757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83634b51-ee28-4175-989a-a3e110fb1768" xlink:to="loc_us-gaap_Revenues_1ce25655-1994-4000-9241-b3c7defe7757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83634b51-ee28-4175-989a-a3e110fb1768" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:to="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_94c559d3-75fa-46ff-8a72-1fe1dec28856_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:to="loc_srt_ProductsAndServicesDomain_94c559d3-75fa-46ff-8a72-1fe1dec28856_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:to="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_d890d015-3c35-445f-ac38-07085711c4bf" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_JardianceMember_d890d015-3c35-445f-ac38-07085711c4bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_23045a03-3585-4c8e-9b0a-4da3f1d76c85" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_BasaglarMember_23045a03-3585-4c8e-9b0a-4da3f1d76c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_e8ff409c-c8e4-43e1-864a-70ed1c3699b0" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_TrajentaBIMember_e8ff409c-c8e4-43e1-864a-70ed1c3699b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_54fb1047-5ba5-47ab-8fe7-0c10f13ee6af" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_OlumiantMember_54fb1047-5ba5-47ab-8fe7-0c10f13ee6af" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended" id="i501b733cf6264e8cb7a46f77234b9402_CollaborationsandOtherArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d629697b-6dec-4ee5-8520-eb6e978904b0" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d629697b-6dec-4ee5-8520-eb6e978904b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_aced7681-f495-402d-891f-e9ba468c9c35" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_aced7681-f495-402d-891f-e9ba468c9c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a988035a-72be-4127-b1ae-42408ee86c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a988035a-72be-4127-b1ae-42408ee86c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f338e91b-d241-4c8c-a71c-186768ef748f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f338e91b-d241-4c8c-a71c-186768ef748f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e14bfd09-1a50-4569-9d8d-968155f9f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_Revenues_e14bfd09-1a50-4569-9d8d-968155f9f9f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80da10e8-33fa-4ea4-a4eb-63f44ef7daea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:to="loc_srt_ProductsAndServicesDomain_80da10e8-33fa-4ea4-a4eb-63f44ef7daea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:to="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_54949e1e-4a61-4baa-84f7-02fd1aa05c4a" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_OlumiantMember_54949e1e-4a61-4baa-84f7-02fd1aa05c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_7b9159ff-24fb-4d3e-9e2d-41e747532551" xlink:href="lly-20211231.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_COVID19AntibodiesMember_7b9159ff-24fb-4d3e-9e2d-41e747532551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_70954302-dd61-440c-ac09-80a828922ffc" xlink:href="lly-20211231.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_TYVYTMember_70954302-dd61-440c-ac09-80a828922ffc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_ed9a1edf-cc47-4902-9853-eeeba13bfeae" xlink:href="lly-20211231.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_LebrikizumabMember_ed9a1edf-cc47-4902-9853-eeeba13bfeae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c862f20a-8a67-415d-8b53-7f04d703aabe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c862f20a-8a67-415d-8b53-7f04d703aabe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_8cfc1602-4ee5-4a82-bb9e-654fd541d6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_8cfc1602-4ee5-4a82-bb9e-654fd541d6ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_cf432996-c6df-4303-bbdf-1cab90556ed5" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_cf432996-c6df-4303-bbdf-1cab90556ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_6fab23f4-8bfa-4cb9-a14b-41021a913295" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_6fab23f4-8bfa-4cb9-a14b-41021a913295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_aabab6a9-b77c-4294-9a6a-d635fde79421" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_aabab6a9-b77c-4294-9a6a-d635fde79421" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_9c745624-08a7-47dd-a94a-9478b450134e" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_9c745624-08a7-47dd-a94a-9478b450134e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_1566d9f1-f463-42da-abcb-1651e65d617d" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_9c745624-08a7-47dd-a94a-9478b450134e" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_1566d9f1-f463-42da-abcb-1651e65d617d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_3fb9b908-9e85-4871-a40a-ff83155f0b58" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_3fb9b908-9e85-4871-a40a-ff83155f0b58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_6c9026e5-b2a0-42e5-9d7c-282fe22a13be" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_6c9026e5-b2a0-42e5-9d7c-282fe22a13be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b9c1287-52e9-4dd8-a97f-edaaac0195d4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:to="loc_srt_SegmentGeographicalDomain_5b9c1287-52e9-4dd8-a97f-edaaac0195d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:to="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_615fce62-2e06-43d3-b47f-10f624b0c532" xlink:href="lly-20211231.xsd#lly_NonCHINAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:to="loc_lly_NonCHINAMember_615fce62-2e06-43d3-b47f-10f624b0c532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_668e77df-af17-4b01-9b99-085e650fa0a0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:to="loc_country_CN_668e77df-af17-4b01-9b99-085e650fa0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f50a2cd6-a750-4368-adb5-46077e4b7411_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:to="loc_dei_EntityDomain_f50a2cd6-a750-4368-adb5-46077e4b7411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:to="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_63b0019a-56a3-4ad6-b289-ca693d7aa0a2" xlink:href="lly-20211231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:to="loc_lly_InnoventBiologicsIncMember_63b0019a-56a3-4ad6-b289-ca693d7aa0a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_c771336d-180b-45e7-bb40-905be0f0faa9" xlink:href="lly-20211231.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:to="loc_lly_RocheMember_c771336d-180b-45e7-bb40-905be0f0faa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5e89c918-b980-4e98-93d0-782c081da4a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5e89c918-b980-4e98-93d0-782c081da4a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_c6fe9bdb-b64e-43e2-911c-7bf96f1ef18d" xlink:href="lly-20211231.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:to="loc_lly_JunshiBiosciencesMember_c6fe9bdb-b64e-43e2-911c-7bf96f1ef18d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_0694a2df-9910-418f-bc26-4d1ef2fe1e6c" xlink:href="lly-20211231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:to="loc_lly_PetraPharmaCorporationMember_0694a2df-9910-418f-bc26-4d1ef2fe1e6c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="extended" id="ie76b60af995140e38d479d13a37fdf05_AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_23594d1e-58b9-4ffd-8f57-92f7624081d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_23594d1e-58b9-4ffd-8f57-92f7624081d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96690629-9f7e-44a3-9019-339c04ec2ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96690629-9f7e-44a3-9019-339c04ec2ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a8f33b40-6eeb-4207-93dc-6078179ab3d7" xlink:href="lly-20211231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a8f33b40-6eeb-4207-93dc-6078179ab3d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fdc4c2f-06c4-4842-9396-cb6174d90074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fdc4c2f-06c4-4842-9396-cb6174d90074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78501b63-3e1e-4ab3-838f-e2ae793e6149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78501b63-3e1e-4ab3-838f-e2ae793e6149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_4cf43b7c-bf41-4f7a-b47b-196b504f2dc1" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78501b63-3e1e-4ab3-838f-e2ae793e6149" xlink:to="loc_lly_LoxoOncologyInc.Member_4cf43b7c-bf41-4f7a-b47b-196b504f2dc1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i415bef46b47d4dfab7d6724529998c4f_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_2ae47f6c-87a4-4b0e-8d06-f7336e870ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_2ae47f6c-87a4-4b0e-8d06-f7336e870ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_b1e871ec-914f-4aed-bd94-ec739aaab445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_b1e871ec-914f-4aed-bd94-ec739aaab445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_10dac25c-9f7a-4670-9748-e6bf91abbac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_10dac25c-9f7a-4670-9748-e6bf91abbac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4c7f5b4d-5be1-42d0-a31d-ca95bfa9edb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4c7f5b4d-5be1-42d0-a31d-ca95bfa9edb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_63429e1d-5781-43a2-86a7-400c8bcbb584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_LongTermDebt_63429e1d-5781-43a2-86a7-400c8bcbb584" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_ca1158f1-a7ae-470d-aa82-217c21787a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_ca1158f1-a7ae-470d-aa82-217c21787a5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_94655f6c-450e-49ae-a543-70e77ebc3cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_94655f6c-450e-49ae-a543-70e77ebc3cf3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_cef4a234-998a-4000-b704-625fb88b2d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_cef4a234-998a-4000-b704-625fb88b2d03" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_7afb99a7-d700-4987-a60c-6b9c6ccd9a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_7afb99a7-d700-4987-a60c-6b9c6ccd9a19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_b3c130ca-1ec4-4c46-bd58-ef7b15cf6209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_b3c130ca-1ec4-4c46-bd58-ef7b15cf6209" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_5ad72ee7-6845-4b1d-9dd1-7cafc4025d41" xlink:href="lly-20211231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_5ad72ee7-6845-4b1d-9dd1-7cafc4025d41" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c4861eea-215f-45dc-b482-af4fe3bfdbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c4861eea-215f-45dc-b482-af4fe3bfdbbe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_c9e675d2-308b-4407-8a68-ad92c3c9b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_c9e675d2-308b-4407-8a68-ad92c3c9b5d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d503e83d-7ea4-4201-aa1f-103b5a1ab035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d503e83d-7ea4-4201-aa1f-103b5a1ab035" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d9d2e057-40bf-4e63-946d-50a3f6975bdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d9d2e057-40bf-4e63-946d-50a3f6975bdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7f2107fb-826e-4e8b-a817-a12a6d1f148d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7f2107fb-826e-4e8b-a817-a12a6d1f148d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_3485b193-1dd2-4752-bf7a-93860355d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7f2107fb-826e-4e8b-a817-a12a6d1f148d" xlink:to="loc_us-gaap_CashFlowHedgingMember_3485b193-1dd2-4752-bf7a-93860355d77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:to="loc_us-gaap_HedgingDesignationDomain_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3498e1d0-4af1-4f9e-b900-0584b82ac2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:to="loc_us-gaap_HedgingDesignationDomain_3498e1d0-4af1-4f9e-b900-0584b82ac2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db73355a-63b4-440a-bd25-b4923f9f10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3498e1d0-4af1-4f9e-b900-0584b82ac2e7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db73355a-63b4-440a-bd25-b4923f9f10ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df8d03fd-ba1a-442d-9f9d-db1174d1f519_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df8d03fd-ba1a-442d-9f9d-db1174d1f519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_218ef912-cf16-4019-bdb5-642baaee2ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_218ef912-cf16-4019-bdb5-642baaee2ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_abcd5638-ef35-4cd2-b1bd-3a8dc62cf9be" xlink:href="lly-20211231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_218ef912-cf16-4019-bdb5-642baaee2ad7" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_abcd5638-ef35-4cd2-b1bd-3a8dc62cf9be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_1efbb777-7027-4e38-af1a-39cf4fb01675" xlink:href="lly-20211231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyUsdSellEuroMember_1efbb777-7027-4e38-af1a-39cf4fb01675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_02f06930-cd0e-4eac-a6d4-fa7830178619" xlink:href="lly-20211231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyEuroSellUsDollarMember_02f06930-cd0e-4eac-a6d4-fa7830178619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_9996e2c1-548a-4fe5-8678-7a01c9b27b7e" xlink:href="lly-20211231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_9996e2c1-548a-4fe5-8678-7a01c9b27b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_2cb65403-f636-4460-8db8-24f942f4dc21" xlink:href="lly-20211231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyGBPSellUSDMember_2cb65403-f636-4460-8db8-24f942f4dc21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_e3f29edf-299d-4e0f-ba50-4d2d221fa5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_us-gaap_CurrencySwapMember_e3f29edf-299d-4e0f-ba50-4d2d221fa5e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_4eeb9665-fb11-4c97-bf85-043a8f1bece2" xlink:href="lly-20211231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_4eeb9665-fb11-4c97-bf85-043a8f1bece2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a0907958-62c7-40a0-b372-3c047f73ba42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_us-gaap_InterestRateSwapMember_a0907958-62c7-40a0-b372-3c047f73ba42" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended" id="i61511320c13f4b3a924d92a33e775068_FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:href="lly-20211231.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8d353e16-3394-4044-af93-8c557168dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8d353e16-3394-4044-af93-8c557168dfda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_691ac533-3594-411e-b546-0a1e1576d5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_691ac533-3594-411e-b546-0a1e1576d5c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_f54dd077-74f8-4379-be78-7ef572b2bcc1" xlink:href="lly-20211231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_lly_CashFlowHedgeAbstract_f54dd077-74f8-4379-be78-7ef572b2bcc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_62f1c6b2-2b39-4eb3-a7e9-c7dfafb2448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_f54dd077-74f8-4379-be78-7ef572b2bcc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_62f1c6b2-2b39-4eb3-a7e9-c7dfafb2448f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ee1d35e8-4c7f-475e-9e47-6bf4a3d6c31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ee1d35e8-4c7f-475e-9e47-6bf4a3d6c31c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_838b2066-860c-4146-bc24-4d07a955ab36" xlink:href="lly-20211231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_838b2066-860c-4146-bc24-4d07a955ab36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b66534d1-de85-4c9c-9e31-59b05f289219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b66534d1-de85-4c9c-9e31-59b05f289219" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_15575e32-e612-474d-844c-71b53837f208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_15575e32-e612-474d-844c-71b53837f208" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:to="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_43cfb54d-0b19-4867-b8a7-6ea8756d80c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:to="loc_us-gaap_HedgingDesignationDomain_43cfb54d-0b19-4867-b8a7-6ea8756d80c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:to="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d8c88009-d597-4fa2-9227-cc32f034b007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d8c88009-d597-4fa2-9227-cc32f034b007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8f1455fb-40e2-4caa-a3f9-2f4404a1c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:to="loc_us-gaap_NondesignatedMember_8f1455fb-40e2-4caa-a3f9-2f4404a1c88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e96887ad-4ea3-489a-a1aa-36a6fff987ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e96887ad-4ea3-489a-a1aa-36a6fff987ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_2fa7bfef-2b37-40ad-92f1-ef25487c6a54" xlink:href="lly-20211231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_lly_HedgedFixedRateDebtMember_2fa7bfef-2b37-40ad-92f1-ef25487c6a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_86383ec9-756e-4946-bd05-135cf23fd261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_InterestRateContractMember_86383ec9-756e-4946-bd05-135cf23fd261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b1637dd7-879c-47a0-9af7-18940d96857a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b1637dd7-879c-47a0-9af7-18940d96857a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_4ec9c892-ba96-4da8-b2c1-ff865d855a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_InterestRateSwapMember_4ec9c892-ba96-4da8-b2c1-ff865d855a8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b13a3bcf-7b33-42a1-960f-1c48e38758aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b13a3bcf-7b33-42a1-960f-1c48e38758aa" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended" id="i8b5c57ae982e420193ad2ce6343c50ef_FinancialInstrumentsScheduleofFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f0320495-6fa9-4e60-8799-4a8faa60586a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f0320495-6fa9-4e60-8799-4a8faa60586a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12fe6607-629c-43da-bb81-fac236da2653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12fe6607-629c-43da-bb81-fac236da2653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_dd7a4f7d-d780-4093-880d-14f35cd0b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_dd7a4f7d-d780-4093-880d-14f35cd0b61a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_07e84884-5a5b-4038-9a8a-55e2081e98dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_07e84884-5a5b-4038-9a8a-55e2081e98dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1da426ec-0391-4782-98cf-2c984456683f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1da426ec-0391-4782-98cf-2c984456683f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_79aecbc8-9c6c-4233-b06c-4704adcf1679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_OtherLongTermInvestments_79aecbc8-9c6c-4233-b06c-4704adcf1679" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a9236224-f003-44e0-8ed3-d732d454c78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_LongTermInvestments_a9236224-f003-44e0-8ed3-d732d454c78b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_615a29bd-2070-40f0-84da-928beb6f7900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_615a29bd-2070-40f0-84da-928beb6f7900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67370b5f-3228-49c0-b9e4-c7089231f4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67370b5f-3228-49c0-b9e4-c7089231f4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_33662806-35cc-4ae6-a9b0-84967043a5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_33662806-35cc-4ae6-a9b0-84967043a5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_3a882480-df34-4945-ab39-5ca2da2efa66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_3a882480-df34-4945-ab39-5ca2da2efa66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3ede6904-7570-4593-a74c-7efd4031b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3ede6904-7570-4593-a74c-7efd4031b38a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_2353ca79-0e6d-4177-bd4d-4d22dd604131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_2353ca79-0e6d-4177-bd4d-4d22dd604131" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_252c43b9-2ffe-4ddc-8af0-f4b20ab40bca" xlink:href="lly-20211231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_lly_OtherEquitySecuritiesMember_252c43b9-2ffe-4ddc-8af0-f4b20ab40bca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_ee7812f3-3ca5-45db-9163-881ae7baa756" xlink:href="lly-20211231.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_lly_MarketableSecuritiesMember_ee7812f3-3ca5-45db-9163-881ae7baa756" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_99a99a3e-733c-497c-a34f-cfddffa84e45" xlink:href="lly-20211231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_99a99a3e-733c-497c-a34f-cfddffa84e45" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f2f79c2-074c-468c-899e-9df57ab5c4c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f2f79c2-074c-468c-899e-9df57ab5c4c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_816c80a6-e10e-4c82-9208-f23f2d153e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_816c80a6-e10e-4c82-9208-f23f2d153e98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5d86d568-63d6-4025-91c3-f5660450ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5d86d568-63d6-4025-91c3-f5660450ce29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_cd316ff3-0647-4baf-ac1e-b60ee9d0322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_cd316ff3-0647-4baf-ac1e-b60ee9d0322e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_64039239-c032-44ea-b534-1886ab026ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_64039239-c032-44ea-b534-1886ab026ca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e35e8e7-64b9-4357-9cd7-67ff169308e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e35e8e7-64b9-4357-9cd7-67ff169308e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_233641e0-693b-4f54-8b9f-caa1787131b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_233641e0-693b-4f54-8b9f-caa1787131b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2da77795-1ab6-4855-bba1-79646e7ad039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2da77795-1ab6-4855-bba1-79646e7ad039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_38813cb1-6aa0-4e40-aaee-87a3bee61631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_38813cb1-6aa0-4e40-aaee-87a3bee61631" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended" id="i6c7e287954694523baa39a8fca94b014_FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ee58d620-2622-4fab-a95c-e675c66d5fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_afaefd22-5135-43d7-a6ea-a507797fcc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ee58d620-2622-4fab-a95c-e675c66d5fe6" xlink:to="loc_us-gaap_LongTermDebt_afaefd22-5135-43d7-a6ea-a507797fcc23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ee58d620-2622-4fab-a95c-e675c66d5fe6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_abc9aeab-d23f-4f4f-a23e-76f4cb33aec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_abc9aeab-d23f-4f4f-a23e-76f4cb33aec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_751afda7-0346-4887-9f9e-f926279bf472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_751afda7-0346-4887-9f9e-f926279bf472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3fc96ec7-cc27-42b0-94d0-8a793c2ae58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3fc96ec7-cc27-42b0-94d0-8a793c2ae58b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3ca59707-f72a-4005-8dff-8ad898c16ed1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3ca59707-f72a-4005-8dff-8ad898c16ed1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_872eec01-8554-46bf-a1d1-cf57ab6db3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_872eec01-8554-46bf-a1d1-cf57ab6db3eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b190b5da-edac-4ef8-84a1-d3637fb8dc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b190b5da-edac-4ef8-84a1-d3637fb8dc71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_632403f0-cbae-407c-8237-0042bc64a6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_632403f0-cbae-407c-8237-0042bc64a6f6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended" id="i57fd175910f34844ae92ff75fb867e73_FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_5916944b-ce17-4667-a40c-3e0d5a674370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_5916944b-ce17-4667-a40c-3e0d5a674370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_e2bbe186-abd5-4435-9d4d-5018c2052bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_e2bbe186-abd5-4435-9d4d-5018c2052bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_26461682-b4f6-43c9-b778-fa762ee778d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_26461682-b4f6-43c9-b778-fa762ee778d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5b243f9a-3aa6-4347-b2d7-fffcf40e2ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5b243f9a-3aa6-4347-b2d7-fffcf40e2ccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d4a0b60-b95c-46be-9e9b-b586fb7653b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d4a0b60-b95c-46be-9e9b-b586fb7653b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b69c338b-22fc-4458-9ac3-56098c8ccba0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b69c338b-22fc-4458-9ac3-56098c8ccba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b20134f6-c6e3-4be2-a256-eb2c9efb890b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:to="loc_us-gaap_FairValueHedgingMember_b20134f6-c6e3-4be2-a256-eb2c9efb890b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_07078349-02f2-4723-9108-3af8d1ff486e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:to="loc_us-gaap_CashFlowHedgingMember_07078349-02f2-4723-9108-3af8d1ff486e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_be43d431-9548-46c3-963a-b4244bdb5235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_be43d431-9548-46c3-963a-b4244bdb5235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b61f803b-50d0-4062-80f7-979a8cc4ed32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b61f803b-50d0-4062-80f7-979a8cc4ed32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f84e529-1d58-42fc-a086-e36e8d02ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f84e529-1d58-42fc-a086-e36e8d02ce9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_87997c98-bd5e-4eac-a2bf-bf6ec649dbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_87997c98-bd5e-4eac-a2bf-bf6ec649dbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c875b732-fbee-45ba-b4d2-34328b22922d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c875b732-fbee-45ba-b4d2-34328b22922d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f4af8aa2-6689-425f-8f67-4140985592ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:to="loc_us-gaap_HedgingDesignationDomain_f4af8aa2-6689-425f-8f67-4140985592ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:to="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6a9c6fe4-86a6-4c82-b208-43c7da46f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6a9c6fe4-86a6-4c82-b208-43c7da46f4d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0490c321-60c6-4bf6-a2ad-2a9150131e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:to="loc_us-gaap_NondesignatedMember_0490c321-60c6-4bf6-a2ad-2a9150131e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_586cd1e4-ab30-4faf-b729-a1f67ff99b52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_586cd1e4-ab30-4faf-b729-a1f67ff99b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_890b3aad-e815-49ca-949d-a55e25ca2819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:to="loc_us-gaap_InterestRateContractMember_890b3aad-e815-49ca-949d-a55e25ca2819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_f9ea66b5-8082-4a89-a62c-fefca2c55e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_f9ea66b5-8082-4a89-a62c-fefca2c55e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e8713205-b13a-4039-93d1-c2abeb769957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e8713205-b13a-4039-93d1-c2abeb769957" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_695782a1-411e-43f1-9116-1aaf73e832b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_695782a1-411e-43f1-9116-1aaf73e832b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ca493d8e-22b8-4357-a2ac-a748efa54052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ca493d8e-22b8-4357-a2ac-a748efa54052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2f3da9f4-c6e7-4dc3-a85e-949d68737c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2f3da9f4-c6e7-4dc3-a85e-949d68737c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_91397bac-2597-427e-a858-a3e3243f0a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_91397bac-2597-427e-a858-a3e3243f0a39" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="id453c2ed2481444ea58e8f3e9a83b0d1_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cf2e0eb2-a8d2-4973-81c2-288523b823ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cf2e0eb2-a8d2-4973-81c2-288523b823ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_afec335e-9def-42e9-9ba2-68ac2bb00391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_afec335e-9def-42e9-9ba2-68ac2bb00391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_408a9230-7612-4306-bd66-56fe26088d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_408a9230-7612-4306-bd66-56fe26088d8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:to="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ecc2389-7caa-436c-b053-d6ac40319e65_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:to="loc_srt_RangeMember_7ecc2389-7caa-436c-b053-d6ac40319e65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:to="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_865e9345-c508-4234-9f6f-4abec8159fe5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:to="loc_srt_MinimumMember_865e9345-c508-4234-9f6f-4abec8159fe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7705d53-a7ec-473b-8a5b-b81a63b00bb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:to="loc_srt_MaximumMember_a7705d53-a7ec-473b-8a5b-b81a63b00bb3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended" id="i6e9c11f5ee9047e59d926c189f753e5f_GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_999223fa-8a24-44eb-8095-a51c4f1aa97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_999223fa-8a24-44eb-8095-a51c4f1aa97f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_586c6294-0e2c-46ea-9085-a0a46b443c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_586c6294-0e2c-46ea-9085-a0a46b443c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5bee27d-3c22-4919-815b-f7e8b18a2507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5bee27d-3c22-4919-815b-f7e8b18a2507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf6765b-7aaa-4df4-891a-64f149a2a181_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5cf6765b-7aaa-4df4-891a-64f149a2a181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_db14c9c3-c17d-4263-959b-b5f76c36ed7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_db14c9c3-c17d-4263-959b-b5f76c36ed7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_83488c5e-65dd-47bd-b4bc-1dc6d56c488d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_83488c5e-65dd-47bd-b4bc-1dc6d56c488d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0963d9da-1115-4a1f-98f4-69694ddca726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f8c9452-275c-41ba-96d0-725bfaf9c4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0963d9da-1115-4a1f-98f4-69694ddca726" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f8c9452-275c-41ba-96d0-725bfaf9c4bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0963d9da-1115-4a1f-98f4-69694ddca726" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4a05b877-ff87-4195-bb5d-6d19d0797d5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4a05b877-ff87-4195-bb5d-6d19d0797d5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_459b19fb-e31b-4eb4-bf3a-4bafe85fec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_459b19fb-e31b-4eb4-bf3a-4bafe85fec3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c2b710f3-0853-47f6-af7e-8e5ea17121a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_459b19fb-e31b-4eb4-bf3a-4bafe85fec3f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c2b710f3-0853-47f6-af7e-8e5ea17121a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="ie1f6120d51ec4f7e98529848595a9ff4_PropertyandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2282b5d-ce09-49d5-b5f9-b1afe87d8915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85707968-5314-4ab9-aeb8-b5ba8381a321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2282b5d-ce09-49d5-b5f9-b1afe87d8915" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85707968-5314-4ab9-aeb8-b5ba8381a321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2282b5d-ce09-49d5-b5f9-b1afe87d8915" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e99fd94e-9c40-4d00-ac28-c0265524c9cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e99fd94e-9c40-4d00-ac28-c0265524c9cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f7c36c47-2edf-480e-ab43-2cdc7a83cbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:to="loc_us-gaap_BuildingMember_f7c36c47-2edf-480e-ab43-2cdc7a83cbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1c7ede28-e8af-4fb3-af45-6c3125302684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:to="loc_us-gaap_EquipmentMember_1c7ede28-e8af-4fb3-af45-6c3125302684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:to="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53d02843-8d73-49f2-9d81-b280ec82edef_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:to="loc_srt_RangeMember_53d02843-8d73-49f2-9d81-b280ec82edef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:to="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_475abc2a-71c6-4663-ab3e-f04e61b8c20e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:to="loc_srt_MinimumMember_475abc2a-71c6-4663-ab3e-f04e61b8c20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c0d26ef-24cf-4cbb-afaa-ddb1bcea827f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:to="loc_srt_MaximumMember_6c0d26ef-24cf-4cbb-afaa-ddb1bcea827f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended" id="ie7b922a6d3a843e7afd6cb365741f3ae_PropertyandEquipmentScheduleofGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7526f8c4-a020-44b9-b7ef-059393e41338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_535f2084-bbd6-46ec-bb4c-6d7eba925fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7526f8c4-a020-44b9-b7ef-059393e41338" xlink:to="loc_us-gaap_NoncurrentAssets_535f2084-bbd6-46ec-bb4c-6d7eba925fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7526f8c4-a020-44b9-b7ef-059393e41338" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:to="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_756b5cf7-03c2-4d44-a5b5-36bcdee1f598_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:to="loc_srt_SegmentGeographicalDomain_756b5cf7-03c2-4d44-a5b5-36bcdee1f598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:to="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember_cb99b0f8-be2d-491d-886f-f6e6dc012b6b" xlink:href="lly-20211231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:to="loc_lly_UNITEDSTATESAndPUERTORICOMember_cb99b0f8-be2d-491d-886f-f6e6dc012b6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_509524bf-829e-4f8b-a234-e38687ab17ec" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:to="loc_country_IE_509524bf-829e-4f8b-a234-e38687ab17ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_2fbd7797-50a1-4ebf-9b1d-112e7aa7087d" xlink:href="lly-20211231.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:to="loc_lly_OtherForeignCountriesMember_2fbd7797-50a1-4ebf-9b1d-112e7aa7087d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended" id="i5857f951c635449188e23b242e47dd93_BorrowingsSummaryofLongtermNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_51564477-c007-4e0f-ada9-315561fa9725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_51564477-c007-4e0f-ada9-315561fa9725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3e7ae009-6a03-4aa6-9619-130182564e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3e7ae009-6a03-4aa6-9619-130182564e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eda84410-d3f2-43b1-bc59-9179047b311b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eda84410-d3f2-43b1-bc59-9179047b311b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c253b123-bcd1-4305-afc6-632b216054f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_LongTermDebt_c253b123-bcd1-4305-afc6-632b216054f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2e710738-c2fc-4252-9449-6eef6e85ccc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2e710738-c2fc-4252-9449-6eef6e85ccc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f2ca2d6-7321-41d7-b5ed-0f22a59d6a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f2ca2d6-7321-41d7-b5ed-0f22a59d6a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_634a9e78-797e-4ce2-a3d1-ebfa60ce4e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7f2ca2d6-7321-41d7-b5ed-0f22a59d6a71" xlink:to="loc_us-gaap_SeniorNotesMember_634a9e78-797e-4ce2-a3d1-ebfa60ce4e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:to="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_abc92dc2-be1f-4939-af8d-ee5cfd8efabf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_abc92dc2-be1f-4939-af8d-ee5cfd8efabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member_79b26ba0-d96c-4be8-9c53-68bd556ade2f" xlink:href="lly-20211231.xsd#lly_A235NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A235NotesDue2022Member_79b26ba0-d96c-4be8-9c53-68bd556ade2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member_8371dd1d-05cb-4cd7-ae97-8eeab1caf83e" xlink:href="lly-20211231.xsd#lly_A30NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A30NotesDue2022Member_8371dd1d-05cb-4cd7-ae97-8eeab1caf83e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member_a4f50e90-b59f-468f-84ab-951070fea2bf" xlink:href="lly-20211231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A10EuroDenominatedNotesDue2022Member_a4f50e90-b59f-468f-84ab-951070fea2bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_79606947-fde8-4707-95ce-bff2d5851d16" xlink:href="lly-20211231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_79606947-fde8-4707-95ce-bff2d5851d16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member_2c643b81-35f5-4f82-974d-2450df5be277" xlink:href="lly-20211231.xsd#lly_A7125NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A7125NotesDue2025Member_2c643b81-35f5-4f82-974d-2450df5be277" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member_85f59bfa-abf3-4669-9407-8cda66275978" xlink:href="lly-20211231.xsd#lly_A275NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A275NotesDue2025Member_85f59bfa-abf3-4669-9407-8cda66275978" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member_14c69d33-48e7-4d6e-b0b4-c3278d1e3ecb" xlink:href="lly-20211231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1625EuroDenominatedNotesDue2026Member_14c69d33-48e7-4d6e-b0b4-c3278d1e3ecb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member_985eccd1-2a08-4194-a581-edcd33be0d31" xlink:href="lly-20211231.xsd#lly_A55NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A55NotesDue2027Member_985eccd1-2a08-4194-a581-edcd33be0d31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member_14fbd0e8-f331-40d6-9d62-e5d510fbf1cc" xlink:href="lly-20211231.xsd#lly_A31NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A31NotesDue2027Member_14fbd0e8-f331-40d6-9d62-e5d510fbf1cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_139c4a63-a534-4843-b873-e20874c635c3" xlink:href="lly-20211231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_139c4a63-a534-4843-b873-e20874c635c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_436377e3-7a98-4808-8f33-be34348959f7" xlink:href="lly-20211231.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A3375NotesDue2029Member_436377e3-7a98-4808-8f33-be34348959f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_0daba310-135e-464c-979b-dede50f2bc82" xlink:href="lly-20211231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_0daba310-135e-464c-979b-dede50f2bc82" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member_40888975-395d-45fc-9506-f98a249b8469" xlink:href="lly-20211231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A2125EuroDenominatedNotesDue2030Member_40888975-395d-45fc-9506-f98a249b8469" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_96d9162e-9b5e-43fe-870b-4a3667fbc6d6" xlink:href="lly-20211231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_96d9162e-9b5e-43fe-870b-4a3667fbc6d6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_caa3533c-4b85-49e2-9a8c-005f867b0086" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A5000NotesDue2033Member_caa3533c-4b85-49e2-9a8c-005f867b0086" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_5d6b7738-4912-4f64-97b7-109c29203d8d" xlink:href="lly-20211231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_5d6b7738-4912-4f64-97b7-109c29203d8d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member_d3bc58e7-2e2e-486a-857e-6dd218247a4d" xlink:href="lly-20211231.xsd#lly_A677NotesDue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A677NotesDue2036Member_d3bc58e7-2e2e-486a-857e-6dd218247a4d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member_11bde8f4-11f2-4783-ade5-f98759f5df06" xlink:href="lly-20211231.xsd#lly_A555NotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A555NotesDue2037Member_11bde8f4-11f2-4783-ade5-f98759f5df06" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member_1f0e64fe-57d4-40bc-b6f9-c7135ee76ac3" xlink:href="lly-20211231.xsd#lly_A595NotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A595NotesDue2037Member_1f0e64fe-57d4-40bc-b6f9-c7135ee76ac3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_5c25c4de-00b6-463b-b2b9-45b9449231fc" xlink:href="lly-20211231.xsd#lly_A3875NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A3875NotesDue2039Member_5c25c4de-00b6-463b-b2b9-45b9449231fc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_c86fbaa5-bd26-4aaa-9869-a4104558ef07" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1625NotesDue2043Member_c86fbaa5-bd26-4aaa-9869-a4104558ef07" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member_3b812a35-1b13-40eb-addd-018107d87f90" xlink:href="lly-20211231.xsd#lly_A465NotesDue2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A465NotesDue2044Member_3b812a35-1b13-40eb-addd-018107d87f90" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member_793e215d-2956-4804-9148-fd0d68cc485e" xlink:href="lly-20211231.xsd#lly_A37NotesDue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A37NotesDue2045Member_793e215d-2956-4804-9148-fd0d68cc485e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member_b15bad8d-92f1-48d8-9d2a-557fa30eec95" xlink:href="lly-20211231.xsd#lly_A395NotesDue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A395NotesDue2047Member_b15bad8d-92f1-48d8-9d2a-557fa30eec95" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_50a3b489-9315-4ec4-9fa5-f0d706472752" xlink:href="lly-20211231.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A395NotesDue2049Member_50a3b489-9315-4ec4-9fa5-f0d706472752" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_74053666-62fb-4195-99f7-6dd883a24af9" xlink:href="lly-20211231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_74053666-62fb-4195-99f7-6dd883a24af9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_eaca6583-a39f-4673-85be-e93dd038a7a1" xlink:href="lly-20211231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_eaca6583-a39f-4673-85be-e93dd038a7a1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_41b025e0-54b2-4d09-b606-075ff5bf0635" xlink:href="lly-20211231.xsd#lly_A225NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A225NotesDue2050Member_41b025e0-54b2-4d09-b606-075ff5bf0635" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_506c64a1-4202-4041-a237-04360125ae2a" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1125NotesDue2051Member_506c64a1-4202-4041-a237-04360125ae2a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_4d4a2fbc-6a81-4511-87cb-aa776cd4fff2" xlink:href="lly-20211231.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A415NotesDue2059Member_4d4a2fbc-6a81-4511-87cb-aa776cd4fff2" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_e9464651-9e54-4693-bd49-c152e5114914" xlink:href="lly-20211231.xsd#lly_A25NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A25NotesDue2060Member_e9464651-9e54-4693-bd49-c152e5114914" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_8c2b952c-f0d6-471a-a313-bd3dcddfbf9a" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1375NotesDue2061Member_8c2b952c-f0d6-471a-a313-bd3dcddfbf9a" xlink:type="arc" order="31"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i62ec9b001aac4fdd8e480a285d9404bf_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cfd74b05-96a8-4f60-91cf-7bc47bf18307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cfd74b05-96a8-4f60-91cf-7bc47bf18307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b8a622ed-811d-45f6-8d16-efc6f7d95d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b8a622ed-811d-45f6-8d16-efc6f7d95d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_f324e437-3fd5-43a1-a59b-27f8be7a4030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentTerm_f324e437-3fd5-43a1-a59b-27f8be7a4030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2b3e0bb7-7cca-4c55-8f9b-9c827018f8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2b3e0bb7-7cca-4c55-8f9b-9c827018f8b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5952f66-19a2-42c5-89f5-a1322d42d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5952f66-19a2-42c5-89f5-a1322d42d1ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_d64466f8-dc5a-4d33-93dd-34ef9c255f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_d64466f8-dc5a-4d33-93dd-34ef9c255f9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_43ef27ff-4c71-4991-b5a2-8f030773467b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_43ef27ff-4c71-4991-b5a2-8f030773467b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6cf32aec-ad3f-42cc-b674-3f3f6333e67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6cf32aec-ad3f-42cc-b674-3f3f6333e67e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_0d225878-04fa-4b21-9e65-97b9b19be8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_0d225878-04fa-4b21-9e65-97b9b19be8f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_f3a83e3b-7b63-425d-8e78-e23fa597dd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_f3a83e3b-7b63-425d-8e78-e23fa597dd88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_60b78a39-8cc4-44b8-8939-72523ec2e440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_60b78a39-8cc4-44b8-8939-72523ec2e440" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7b8d3ecf-ed8a-4825-a9f1-36bb1716521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7b8d3ecf-ed8a-4825-a9f1-36bb1716521b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2291db4e-851b-4ebb-8092-58a18bd7827a" xlink:href="lly-20211231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2291db4e-851b-4ebb-8092-58a18bd7827a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_648cfb5d-7e11-420f-98b2-99b96d21f4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_648cfb5d-7e11-420f-98b2-99b96d21f4d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe576207-bb20-4eaf-93b3-f37502bec6e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe576207-bb20-4eaf-93b3-f37502bec6e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_32fc27b6-c66e-4e4b-aff9-d9a42172bae7" xlink:href="lly-20211231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_32fc27b6-c66e-4e4b-aff9-d9a42172bae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_860db7ec-a5f9-4f3e-b48d-d78ea0eb5616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:to="loc_us-gaap_SeniorNotesMember_860db7ec-a5f9-4f3e-b48d-d78ea0eb5616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2c25fcac-5d7e-43b8-90e0-663c91f7258d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2c25fcac-5d7e-43b8-90e0-663c91f7258d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_e1f88ae3-d7de-4620-b33b-722ac19ed394" xlink:href="lly-20211231.xsd#lly_MaturityDate2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:to="loc_lly_MaturityDate2023Member_e1f88ae3-d7de-4620-b33b-722ac19ed394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2019Member_b0947080-aabf-4d1c-979e-65a6f0acc7ee" xlink:href="lly-20211231.xsd#lly_MaturityDate2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:to="loc_lly_MaturityDate2019Member_b0947080-aabf-4d1c-979e-65a6f0acc7ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9fb60d87-9418-4668-a9a6-66ed28ab7477_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9fb60d87-9418-4668-a9a6-66ed28ab7477_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_186716c0-f92a-4353-a413-81b77661aadc" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A5000NotesDue2033Member_186716c0-f92a-4353-a413-81b77661aadc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_71923be8-ac4e-40e7-8d32-672291ba21ff" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A1125NotesDue2051Member_71923be8-ac4e-40e7-8d32-672291ba21ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_d03e93d8-686d-4bed-8b56-c23086f22439" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A1375NotesDue2061Member_d03e93d8-686d-4bed-8b56-c23086f22439" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_d9a96b85-02e6-4051-8cff-067250ea509e" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A1625NotesDue2043Member_d9a96b85-02e6-4051-8cff-067250ea509e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_951503a8-f5d0-4c5e-a3f2-97f32a0c703a" xlink:href="lly-20211231.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A395NotesDue2049Member_951503a8-f5d0-4c5e-a3f2-97f32a0c703a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_afc45504-7fc9-4457-b50b-936b20476e9a" xlink:href="lly-20211231.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A415NotesDue2059Member_afc45504-7fc9-4457-b50b-936b20476e9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_e684a814-22a9-4f00-ba4a-f18226bab38f" xlink:href="lly-20211231.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A3375NotesDue2029Member_e684a814-22a9-4f00-ba4a-f18226bab38f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:href="lly-20211231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_84eb20ec-8293-4d3a-91d3-f767c7a55552" xlink:href="lly-20211231.xsd#lly_A225NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:to="loc_lly_A225NotesDue2050Member_84eb20ec-8293-4d3a-91d3-f767c7a55552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_3ce9d95d-208c-4733-8912-d96b450fe87f" xlink:href="lly-20211231.xsd#lly_A25NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:to="loc_lly_A25NotesDue2060Member_3ce9d95d-208c-4733-8912-d96b450fe87f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_fd2d4cb3-13b7-49fe-b2b1-fea74092ba68" xlink:href="lly-20211231.xsd#lly_A3875NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A3875NotesDue2039Member_fd2d4cb3-13b7-49fe-b2b1-fea74092ba68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:href="lly-20211231.xsd#lly_November2019EuroDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_3c6a8e9a-9d23-4cf9-a3f8-4bd9c2092d5d" xlink:href="lly-20211231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_3c6a8e9a-9d23-4cf9-a3f8-4bd9c2092d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_5ac768e0-8d6b-4107-8209-7d1717a58331" xlink:href="lly-20211231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_5ac768e0-8d6b-4107-8209-7d1717a58331" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:href="lly-20211231.xsd#lly_November2019YenDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_8f3f90ad-b019-4d35-8a73-6d995a7eb836" xlink:href="lly-20211231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_8f3f90ad-b019-4d35-8a73-6d995a7eb836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_3d3e9f84-2feb-4580-8a17-e50454249024" xlink:href="lly-20211231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_3d3e9f84-2feb-4580-8a17-e50454249024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_adc1c47b-f596-4191-8de0-1a2debc24b4a" xlink:href="lly-20211231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_adc1c47b-f596-4191-8de0-1a2debc24b4a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="icb71bb59af604155ae9ecc37e6dbe4be_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff72d117-c47d-40b7-9b50-9757218351f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff72d117-c47d-40b7-9b50-9757218351f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f9bc487-98e8-458d-a618-2fb760c1eba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f9bc487-98e8-458d-a618-2fb760c1eba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ec01b6a-b299-4432-9665-90bd29ca798d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ec01b6a-b299-4432-9665-90bd29ca798d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ed14896a-5466-4409-9e64-cdd26a4dab6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ed14896a-5466-4409-9e64-cdd26a4dab6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_2dac4022-c460-405a-8515-c7338535aa0b" xlink:href="lly-20211231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_2dac4022-c460-405a-8515-c7338535aa0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66cb4569-5b71-425d-8bb9-5a6c98640570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66cb4569-5b71-425d-8bb9-5a6c98640570" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d0aaaeae-41f9-4ba4-87e2-68dc9d2af67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d0aaaeae-41f9-4ba4-87e2-68dc9d2af67c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dfca2183-3fff-4e55-90e8-3d2cb8c8df3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dfca2183-3fff-4e55-90e8-3d2cb8c8df3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:to="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b44fc330-4642-410f-aa6d-309c33a083e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b44fc330-4642-410f-aa6d-309c33a083e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ba33fe57-00b0-48ef-bd08-ec6642521161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_us-gaap_PerformanceSharesMember_ba33fe57-00b0-48ef-bd08-ec6642521161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_12de0782-9055-4ae9-89e7-0e727b5591ec" xlink:href="lly-20211231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_lly_ShareholderValueAwardsMember_12de0782-9055-4ae9-89e7-0e727b5591ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_0cd6f23d-4375-4849-a63c-f22fcc3a6c1b" xlink:href="lly-20211231.xsd#lly_RelativeValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_lly_RelativeValueAwardsMember_0cd6f23d-4375-4849-a63c-f22fcc3a6c1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_896c0866-4883-4655-9d8b-4489bb843022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_896c0866-4883-4655-9d8b-4489bb843022" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended" id="i79ff1a2953a4464ab3405ab46764edc0_StockBasedCompensationScheduleofAssumptionsUsedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d28ed17d-ae8a-4f1b-ac6e-b9f42d2f4731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d28ed17d-ae8a-4f1b-ac6e-b9f42d2f4731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dbbb5a59-53c5-4446-8516-21c4d163bd68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dbbb5a59-53c5-4446-8516-21c4d163bd68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2638c76a-d18c-4256-bb93-7dadcd81a471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2638c76a-d18c-4256-bb93-7dadcd81a471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:to="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_609cf013-cca1-430f-a56b-e1727609d905_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_609cf013-cca1-430f-a56b-e1727609d905_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_6f7832bf-5526-470d-9e63-5fb19b0d20e2" xlink:href="lly-20211231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:to="loc_lly_ShareholderValueAwardsMember_6f7832bf-5526-470d-9e63-5fb19b0d20e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_8b484c7b-7a0e-41fa-b679-7c6acdf1b426" xlink:href="lly-20211231.xsd#lly_RelativeValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:to="loc_lly_RelativeValueAwardsMember_8b484c7b-7a0e-41fa-b679-7c6acdf1b426" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i1d769d3d49254dba845f508c91e1e4e0_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_cc17c758-50d1-4bca-bd66-4ae2fe2f92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_cc17c758-50d1-4bca-bd66-4ae2fe2f92b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_55e33870-1242-4d75-97c0-ecccfb4dc12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_OperatingLossCarryforwards_55e33870-1242-4d75-97c0-ecccfb4dc12d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f26b1d15-2893-4aed-bf88-718abb77a351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f26b1d15-2893-4aed-bf88-718abb77a351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_72dc76b0-4731-4396-9017-a5b98e8322dd" xlink:href="lly-20211231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_72dc76b0-4731-4396-9017-a5b98e8322dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_400656b5-cf5b-4346-8d99-428c54cde1c0" xlink:href="lly-20211231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_400656b5-cf5b-4346-8d99-428c54cde1c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ad57af44-1031-4088-b4a4-f0bb8fcf0674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ad57af44-1031-4088-b4a4-f0bb8fcf0674" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_306dfc9c-1f65-4312-b440-10a360610d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_306dfc9c-1f65-4312-b440-10a360610d14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForIncomeTaxSettlements_264d96b4-b44d-4ff9-95c6-c300f3d4de2a" xlink:href="lly-20211231.xsd#lly_PaymentsForIncomeTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_lly_PaymentsForIncomeTaxSettlements_264d96b4-b44d-4ff9-95c6-c300f3d4de2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_fe67d11a-9044-4c89-9331-b5adca028faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_fe67d11a-9044-4c89-9331-b5adca028faf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_0687b6cc-0344-47ee-878f-baefe115551a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:to="loc_us-gaap_TaxPeriodDomain_0687b6cc-0344-47ee-878f-baefe115551a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_9e1dff8a-098c-42ad-95f2-4e3819af8909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:to="loc_us-gaap_TaxPeriodDomain_9e1dff8a-098c-42ad-95f2-4e3819af8909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxYears2013To2015Member_b8c4664d-e054-4029-8c31-67323ac11cc9" xlink:href="lly-20211231.xsd#lly_TaxYears2013To2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_9e1dff8a-098c-42ad-95f2-4e3819af8909" xlink:to="loc_lly_TaxYears2013To2015Member_b8c4664d-e054-4029-8c31-67323ac11cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_29044724-538e-4f63-84f3-230d43a2b020_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_29044724-538e-4f63-84f3-230d43a2b020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember_65f247d8-33a1-424a-bfc0-93eab36d3422" xlink:href="lly-20211231.xsd#lly_CarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_CarryforwardMember_65f247d8-33a1-424a-bfc0-93eab36d3422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationin6YearsMember_a0d774f3-0178-4933-92f3-bfdc938ee31d" xlink:href="lly-20211231.xsd#lly_Expirationin6YearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_Expirationin6YearsMember_a0d774f3-0178-4933-92f3-bfdc938ee31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationIn12To18YearsMember_a7c6adba-fe90-46d4-9faf-0cdc61b9bd06" xlink:href="lly-20211231.xsd#lly_ExpirationIn12To18YearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_ExpirationIn12To18YearsMember_a7c6adba-fe90-46d4-9faf-0cdc61b9bd06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember_7724d6a4-8769-435b-ad12-849de1345e12" xlink:href="lly-20211231.xsd#lly_DesignatedUnusableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_DesignatedUnusableMember_7724d6a4-8769-435b-ad12-849de1345e12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationwithin5yearsMember_797d5954-09f0-48c5-a70d-78e03551e194" xlink:href="lly-20211231.xsd#lly_Expirationwithin5yearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_Expirationwithin5yearsMember_797d5954-09f0-48c5-a70d-78e03551e194" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expiration5to20YearsMember_f3009965-ac7e-474f-a8a1-e52ed055fa9e" xlink:href="lly-20211231.xsd#lly_Expiration5to20YearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_Expiration5to20YearsMember_f3009965-ac7e-474f-a8a1-e52ed055fa9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember_6376ceef-728f-4c9b-87f7-dd5495bef93f" xlink:href="lly-20211231.xsd#lly_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_NoExpirationMember_6376ceef-728f-4c9b-87f7-dd5495bef93f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d6ff1804-d101-4095-808b-86416ef8b480_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d6ff1804-d101-4095-808b-86416ef8b480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_aaffc9d2-38da-4e9c-9558-44ad1529d45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_aaffc9d2-38da-4e9c-9558-44ad1529d45e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_257b9871-eb16-487a-ad8d-c37198920f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:to="loc_us-gaap_ForeignCountryMember_257b9871-eb16-487a-ad8d-c37198920f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_82653410-a7ab-4460-98b9-3a50c0468e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_82653410-a7ab-4460-98b9-3a50c0468e92" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended" id="i9f206544d52848f0a7346867bff94a1d_RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3a3614f1-69e0-4aa2-98c1-14f7d1b4c998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3a3614f1-69e0-4aa2-98c1-14f7d1b4c998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fde236f2-87a8-49f2-8473-1ffe39b280ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fde236f2-87a8-49f2-8473-1ffe39b280ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a67c9cd0-7a20-4a84-98ee-cbd8d17fb123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a67c9cd0-7a20-4a84-98ee-cbd8d17fb123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_428f7a00-9a51-4e83-b583-68e6d107c3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_428f7a00-9a51-4e83-b583-68e6d107c3f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2235e235-600c-4d72-a9cb-e7aee977d381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2235e235-600c-4d72-a9cb-e7aee977d381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_287813ca-f7cc-4cbe-bc05-54de2feacae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_287813ca-f7cc-4cbe-bc05-54de2feacae5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_f76abeaa-14a3-4aec-82f6-3d20f94b3dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_f76abeaa-14a3-4aec-82f6-3d20f94b3dde" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_294393ce-be1f-41e3-9b99-80a0bce35537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_715fdfd0-1b87-4672-8713-579f8385af0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_715fdfd0-1b87-4672-8713-579f8385af0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_3bc1c24f-52ff-4b1c-904d-efc2fe983065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_3bc1c24f-52ff-4b1c-904d-efc2fe983065" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_a647ec38-2cde-4b48-b9ca-700a6f8aa834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_a647ec38-2cde-4b48-b9ca-700a6f8aa834" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e2b31b2b-5fea-4c6d-9be5-f73bbd49aae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e2b31b2b-5fea-4c6d-9be5-f73bbd49aae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a2b94a3b-f405-42bd-97b2-3af294aa5a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a2b94a3b-f405-42bd-97b2-3af294aa5a03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5436a511-fee7-4fab-b617-01bfe4cd9d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_845a5d95-7ec2-4961-9ea8-8e088c61af90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_845a5d95-7ec2-4961-9ea8-8e088c61af90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_6398bcb6-9493-4c46-b599-0f46790c9884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_6398bcb6-9493-4c46-b599-0f46790c9884" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4d447772-ccb9-4c1d-ba1c-516898cb1fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4d447772-ccb9-4c1d-ba1c-516898cb1fa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9631faea-209a-4d07-9a40-bd8734ff0819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9631faea-209a-4d07-9a40-bd8734ff0819" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5d29c24f-68a4-4375-bf7c-caeec1447002_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5d29c24f-68a4-4375-bf7c-caeec1447002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_96c2f224-d7f0-42e8-8f04-22638c599858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_96c2f224-d7f0-42e8-8f04-22638c599858" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_db9cc6e9-9d6a-4878-96c2-977b80a650d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_db9cc6e9-9d6a-4878-96c2-977b80a650d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="ic9435e1eb8ad40648f3084f2e41314e5_RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_86af5dc3-1c95-4bac-915b-a26562cf2239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_86af5dc3-1c95-4bac-915b-a26562cf2239" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_ee775dd2-e9ea-44fd-91ea-070994f4e23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_ee775dd2-e9ea-44fd-91ea-070994f4e23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_c8b8bd1f-1e72-4e52-bb40-9ef804eaca46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_c8b8bd1f-1e72-4e52-bb40-9ef804eaca46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8b0e6e7f-2946-4901-9233-9d6861b618f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8b0e6e7f-2946-4901-9233-9d6861b618f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5e32854b-a069-411c-a45f-c759cb6af2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5e32854b-a069-411c-a45f-c759cb6af2d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f8ade252-834c-4823-8778-95be054ae004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f8ade252-834c-4823-8778-95be054ae004" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_86af5dc3-1c95-4bac-915b-a26562cf2239" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a8651a1b-24c5-44b2-b54a-25324111a81e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a8651a1b-24c5-44b2-b54a-25324111a81e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_330b0973-11ef-403e-b2a3-f93e789b93a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_330b0973-11ef-403e-b2a3-f93e789b93a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6fde567d-123e-4bb8-9303-86cf75151b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6fde567d-123e-4bb8-9303-86cf75151b33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended" id="i8e7bbca3989b4d168c299b192adec67b_RetirementBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_af3ef4fc-82f5-40cf-aa61-3f8caf7d29d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_af3ef4fc-82f5-40cf-aa61-3f8caf7d29d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6e1ba1c7-0b69-4b48-8d02-52accd5f7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6e1ba1c7-0b69-4b48-8d02-52accd5f7c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7aa7aed0-aea5-446f-820b-5235360154bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7aa7aed0-aea5-446f-820b-5235360154bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_881d770f-f8c6-418e-99b5-30b91fdc933c" xlink:href="lly-20211231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_881d770f-f8c6-418e-99b5-30b91fdc933c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_353a270b-6166-4c0c-b950-594635e376f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_353a270b-6166-4c0c-b950-594635e376f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_3c4c33b3-4120-4c7b-a246-afddd9e36fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_3c4c33b3-4120-4c7b-a246-afddd9e36fb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a91533ab-e6e2-41b7-bc13-679acd86f41a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a91533ab-e6e2-41b7-bc13-679acd86f41a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_423b8c17-c176-49f3-8b53-b489ab32c19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_423b8c17-c176-49f3-8b53-b489ab32c19b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_d16d1f6e-e768-44d7-ba11-f68168b56c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:to="loc_us-gaap_FixedIncomeFundsMember_d16d1f6e-e768-44d7-ba11-f68168b56c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c3c6d925-e63b-4d94-b579-4f2a3ca66b50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c3c6d925-e63b-4d94-b579-4f2a3ca66b50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_992fa32a-b692-4f28-9690-16ffed422685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_992fa32a-b692-4f28-9690-16ffed422685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_643b131a-5e2d-47ff-b841-155fbd6cd001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_992fa32a-b692-4f28-9690-16ffed422685" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_643b131a-5e2d-47ff-b841-155fbd6cd001" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended" id="idd53dedc8d56484db761cdc9f51ef869_RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ffe10390-3020-49fd-8569-226e711692e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ffe10390-3020-49fd-8569-226e711692e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_81325336-6b7e-46c3-969e-3e4ed1e3dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_81325336-6b7e-46c3-969e-3e4ed1e3dc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_d308b2e6-fc61-4fe1-a07e-cdb18a93e516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_d308b2e6-fc61-4fe1-a07e-cdb18a93e516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9634ec17-2915-4cbb-be5e-5fca97ad7b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9634ec17-2915-4cbb-be5e-5fca97ad7b77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3ef11b6c-664f-48e7-b9a3-edcb1d02f794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3ef11b6c-664f-48e7-b9a3-edcb1d02f794" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ca5e1523-7086-47c7-96c6-c984293fea89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ca5e1523-7086-47c7-96c6-c984293fea89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_08024783-994b-4f0b-82a9-6deb40c5e055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_08024783-994b-4f0b-82a9-6deb40c5e055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_83e9105e-c40c-4135-9532-997f9c1911c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_83e9105e-c40c-4135-9532-997f9c1911c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended" id="icd242872c83f4da9aebbf0226c7cb9a0_RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_5eadc055-dbbd-4964-93d5-8bf1cbc50efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_5eadc055-dbbd-4964-93d5-8bf1cbc50efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_738c694c-a9af-416e-a6dd-82eb5431f80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_738c694c-a9af-416e-a6dd-82eb5431f80b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5f5e50df-8307-45d3-836f-7c1989a2a384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5f5e50df-8307-45d3-836f-7c1989a2a384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_b0acbbc3-d053-493d-91aa-fd6114a72be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_b0acbbc3-d053-493d-91aa-fd6114a72be8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c13f9e1d-7510-46d5-8abc-04426ac2d788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c13f9e1d-7510-46d5-8abc-04426ac2d788" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e2755cee-9192-4d57-ba49-780613fe4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e2755cee-9192-4d57-ba49-780613fe4a35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_44ec980c-512f-42d3-92f2-608a3b1d9478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_44ec980c-512f-42d3-92f2-608a3b1d9478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_8b3c62c7-5d85-4f7a-bdba-bca63d20451d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_8b3c62c7-5d85-4f7a-bdba-bca63d20451d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_75a1a199-79c7-4988-ae95-55e411b1cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_75a1a199-79c7-4988-ae95-55e411b1cf84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_5da9a186-000e-4573-92cf-a9241c3baf45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5df4ed3a-af3e-4052-8b23-88078b5c9467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5df4ed3a-af3e-4052-8b23-88078b5c9467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_61c349d8-3aca-4758-9157-a8f340866bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_61c349d8-3aca-4758-9157-a8f340866bb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_34701369-de84-440c-bfff-5be9277d66ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_34701369-de84-440c-bfff-5be9277d66ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_549e2297-393c-4fbb-9ce0-0c06632a5fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_549e2297-393c-4fbb-9ce0-0c06632a5fd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_32973042-9d8f-4c24-b813-a6580968138d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_32973042-9d8f-4c24-b813-a6580968138d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_6092614d-b0a3-41cb-9aec-91d7be7f9916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_6092614d-b0a3-41cb-9aec-91d7be7f9916" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4fb12493-e71a-4404-9635-659aec7567c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4fb12493-e71a-4404-9635-659aec7567c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_d882c702-b77a-4209-a666-9ef4d9b08c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_d882c702-b77a-4209-a666-9ef4d9b08c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_77c323f0-de78-4b48-b914-e6da9a33502c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_77c323f0-de78-4b48-b914-e6da9a33502c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_d5c343fb-a301-4303-b9d8-aeb7f5ef8e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_d5c343fb-a301-4303-b9d8-aeb7f5ef8e84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c1b01334-653f-48c5-ac75-2af356dbf1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c1b01334-653f-48c5-ac75-2af356dbf1de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_f373b158-08c9-4e10-a6c4-2f4d0417afbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_f373b158-08c9-4e10-a6c4-2f4d0417afbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_227753dc-49cb-417b-9f7c-26c27d121b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_227753dc-49cb-417b-9f7c-26c27d121b12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0b0afc54-2ea1-4c03-b072-cb7e7154321e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0b0afc54-2ea1-4c03-b072-cb7e7154321e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cc6cf119-dc1b-4627-95ac-51473a2d3edc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cc6cf119-dc1b-4627-95ac-51473a2d3edc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_756c1a0a-5243-4169-b4cd-b9e5bc86743a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_756c1a0a-5243-4169-b4cd-b9e5bc86743a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_8bf00a0f-d536-4ee6-9049-f977114cdc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_8bf00a0f-d536-4ee6-9049-f977114cdc9a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended" id="i51a3ffdf092647f8ac2e9238c0a10742_RetirementBenefitsScheduleofFairValueDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2b3214ec-f552-4e81-a92f-224f9d0f1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d815ee0b-1b25-4990-8a84-ab2b6713770f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2b3214ec-f552-4e81-a92f-224f9d0f1f2d" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d815ee0b-1b25-4990-8a84-ab2b6713770f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2b3214ec-f552-4e81-a92f-224f9d0f1f2d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6163c59d-2491-492a-b9cb-9ec45a1e6703_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6163c59d-2491-492a-b9cb-9ec45a1e6703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7c3e07c4-94c2-4685-a118-cc16c431dbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7c3e07c4-94c2-4685-a118-cc16c431dbe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9ad22c93-c5fd-4b74-bb80-a6f6a879bd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9ad22c93-c5fd-4b74-bb80-a6f6a879bd96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_217ddfb8-012f-4649-ae94-b91feb5bb76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_217ddfb8-012f-4649-ae94-b91feb5bb76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_b1ab9252-42ba-4674-bfd1-b26cc2e98375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_b1ab9252-42ba-4674-bfd1-b26cc2e98375" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_1b05089e-e33e-4590-8925-a4fafefa4e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_1b05089e-e33e-4590-8925-a4fafefa4e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_7c4a3dd5-ade7-4aeb-90a4-b771d06291f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_7c4a3dd5-ade7-4aeb-90a4-b771d06291f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_42d44d71-be06-4f81-b135-9ed5bdc46295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_FixedIncomeFundsMember_42d44d71-be06-4f81-b135-9ed5bdc46295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_cf12dbe5-b648-4878-9c61-26bf6bd7d980" xlink:href="lly-20211231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_cf12dbe5-b648-4878-9c61-26bf6bd7d980" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember_4df1fb05-3b00-4139-878f-5b84017124b9" xlink:href="lly-20211231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_lly_FixedIncomeFundsEmergingMarketsMember_4df1fb05-3b00-4139-878f-5b84017124b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_393e5afb-773b-42c6-b4e5-57d328212fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_HedgeFundsMember_393e5afb-773b-42c6-b4e5-57d328212fd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_b237618a-584f-4321-b33b-0aa38909ae7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_EquityFundsMember_b237618a-584f-4321-b33b-0aa38909ae7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_b4887f74-eb5e-4ccd-9042-c4755664831f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_OtherContractMember_b4887f74-eb5e-4ccd-9042-c4755664831f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_4e08bb1b-c2c1-4dad-a16d-71bf8964ef0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_4e08bb1b-c2c1-4dad-a16d-71bf8964ef0b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember_4f4ffab1-7246-4d09-a751-7cea421794dc" xlink:href="lly-20211231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_lly_DefineBenefitPlanOtherMember_4f4ffab1-7246-4d09-a751-7cea421794dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_343dba13-8bd9-4331-ae6a-fad8649e1235_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_343dba13-8bd9-4331-ae6a-fad8649e1235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_df5e5b35-0480-4f62-be72-56486c325e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_df5e5b35-0480-4f62-be72-56486c325e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_0b0c9891-c695-48fe-bbec-28351f212e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_0b0c9891-c695-48fe-bbec-28351f212e5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="ifb0e3ce57a1948d78fbb5dae089b6277_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_fc59eb09-c4fd-453d-8caa-05f0c48476ad" xlink:href="lly-20211231.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_fc59eb09-c4fd-453d-8caa-05f0c48476ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_a1fd268b-3ec5-404b-b190-5a9607114ca1" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyNumberOfPatents_a1fd268b-3ec5-404b-b190-5a9607114ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9348bc9e-2f5e-4542-853b-a641482ee859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9348bc9e-2f5e-4542-853b-a641482ee859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_384cffa9-8649-4a8c-800b-2f01e51892c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_384cffa9-8649-4a8c-800b-2f01e51892c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_30fb32e1-1224-43ec-9f8f-755e8fc7f243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_30fb32e1-1224-43ec-9f8f-755e8fc7f243" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_0941c147-b015-4855-a6e0-110d883d7bdb" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyNumberOfClaimants_0941c147-b015-4855-a6e0-110d883d7bdb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_152a49e8-172d-4743-8be2-9bb5c38474e7" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_152a49e8-172d-4743-8be2-9bb5c38474e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_2aeb2dd1-036b-498a-9cf9-ef506a54c76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_2aeb2dd1-036b-498a-9cf9-ef506a54c76c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber_479ca712-150c-4dc3-98e9-8161e3124a89" xlink:href="lly-20211231.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LitigationClaimsDismissedNumber_479ca712-150c-4dc3-98e9-8161e3124a89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0f29dddb-9f32-4c66-b5f3-c0f3d0746305_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:to="loc_srt_SegmentGeographicalDomain_0f29dddb-9f32-4c66-b5f3-c0f3d0746305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c773d0b6-ec8d-4a17-9565-3172606fc472" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:to="loc_srt_SegmentGeographicalDomain_c773d0b6-ec8d-4a17-9565-3172606fc472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_e6e879e1-dd55-42f2-8314-c61814abeb1e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c773d0b6-ec8d-4a17-9565-3172606fc472" xlink:to="loc_country_BR_e6e879e1-dd55-42f2-8314-c61814abeb1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:to="loc_srt_LitigationCaseTypeDomain_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:to="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaPatentLitigationMember_505a7ee1-e95e-4b3f-a689-d8fce13eb872" xlink:href="lly-20211231.xsd#lly_AlimtaPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_AlimtaPatentLitigationMember_505a7ee1-e95e-4b3f-a689-d8fce13eb872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_6c23e5e5-4d5a-4d80-8071-f391c9d8a844" xlink:href="lly-20211231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_EmgalityPatentLitigationMember_6c23e5e5-4d5a-4d80-8071-f391c9d8a844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_3ded628f-0910-45fc-9c58-08b6159c06b7" xlink:href="lly-20211231.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_3ded628f-0910-45fc-9c58-08b6159c06b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_f0a742d0-b999-4a21-9212-a8806a9a4d4d" xlink:href="lly-20211231.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_f0a742d0-b999-4a21-9212-a8806a9a4d4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_cf239d9b-b023-4deb-80f9-293d4fdbdbf2" xlink:href="lly-20211231.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_cf239d9b-b023-4deb-80f9-293d4fdbdbf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_6fedcd75-f7e3-4850-8285-7682152e2020" xlink:href="lly-20211231.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_6fedcd75-f7e3-4850-8285-7682152e2020" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_2f576bd1-20b9-4f37-a255-d44a5b2de5fd" xlink:href="lly-20211231.xsd#lly_EmployeeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_EmployeeLitigationMember_2f576bd1-20b9-4f37-a255-d44a5b2de5fd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f7a7500d-5808-4c6b-9ac6-af5e05972ee6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:to="loc_srt_ProductsAndServicesDomain_f7a7500d-5808-4c6b-9ac6-af5e05972ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:to="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_3f6a7a0d-aa63-4662-99d8-734b7009d455" xlink:href="lly-20211231.xsd#lly_ActosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_ActosMember_3f6a7a0d-aa63-4662-99d8-734b7009d455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_f7d9cbf7-f0b5-45fd-9971-3e0eb7c80448" xlink:href="lly-20211231.xsd#lly_ByettaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_ByettaMember_f7d9cbf7-f0b5-45fd-9971-3e0eb7c80448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_954760e5-803b-45d8-8f4d-1890f0d783d8" xlink:href="lly-20211231.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_CialisMember_954760e5-803b-45d8-8f4d-1890f0d783d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_5462d790-f1b5-42af-a224-6c62c04b6755" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_JardianceMember_5462d790-f1b5-42af-a224-6c62c04b6755" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_8d14d189-52b5-47b2-b674-c499bcd287c8" xlink:href="lly-20211231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_HumalogHumulinAndForteoMember_8d14d189-52b5-47b2-b674-c499bcd287c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember_ec6f9ab9-48fc-4dc3-9801-ea224a50268c" xlink:href="lly-20211231.xsd#lly_InsulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_InsulinMember_ec6f9ab9-48fc-4dc3-9801-ea224a50268c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a_default" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:to="loc_lly_DomicileOfLitigationDomain_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:to="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_8f329ff2-5968-43a9-9b8b-5fd03365d0a8" xlink:href="lly-20211231.xsd#lly_LosAngelesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:to="loc_lly_LosAngelesMember_8f329ff2-5968-43a9-9b8b-5fd03365d0a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_54a8ca7c-a7e2-4fa5-97bf-267f2f7ff27d" xlink:href="lly-20211231.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_54a8ca7c-a7e2-4fa5-97bf-267f2f7ff27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_8dd1376a-28ad-4025-81a9-b6f686a221aa" xlink:href="lly-20211231.xsd#lly_VariousStateDomicilesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:to="loc_lly_VariousStateDomicilesMember_8dd1376a-28ad-4025-81a9-b6f686a221aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_90d6be5e-613c-4fbd-a147-cc8fe4338c17_default" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:to="loc_lly_PlaintiffAllegationsDomain_90d6be5e-613c-4fbd-a147-cc8fe4338c17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:to="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_11f4e879-e979-4a76-86ca-d3343f0094c9" xlink:href="lly-20211231.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_11f4e879-e979-4a76-86ca-d3343f0094c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_70493349-dc43-4a62-9c7e-4a621db1a0c1" xlink:href="lly-20211231.xsd#lly_PancreatitisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:to="loc_lly_PancreatitisMember_70493349-dc43-4a62-9c7e-4a621db1a0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_23e7743c-6e9a-4769-9382-564637b391d4" xlink:href="lly-20211231.xsd#lly_AmpullaryCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:to="loc_lly_AmpullaryCancerMember_23e7743c-6e9a-4769-9382-564637b391d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4a121496-88f3-4294-a2fd-7deecad18a8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4a121496-88f3-4294-a2fd-7deecad18a8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_54002961-68f7-419b-a103-d6dcf4ad5d52" xlink:href="lly-20211231.xsd#lly_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:to="loc_lly_ProductLiabilityMember_54002961-68f7-419b-a103-d6dcf4ad5d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_2c50113a-265e-40aa-bc4c-148d6d1c33de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_2c50113a-265e-40aa-bc4c-148d6d1c33de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d890abda-4074-4211-babb-18ddbfa56b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d890abda-4074-4211-babb-18ddbfa56b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e55b525-edcd-4302-9051-3b676e24a535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d890abda-4074-4211-babb-18ddbfa56b53" xlink:to="loc_us-gaap_SubsequentEventMember_0e55b525-edcd-4302-9051-3b676e24a535" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i4a9232ed59a9409f80d3763b3b861c85_OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7ec775f-91c9-458a-9a63-97537f5675a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7ec775f-91c9-458a-9a63-97537f5675a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_13bc5cfd-a45b-49e1-a082-16c7781a6b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_13bc5cfd-a45b-49e1-a082-16c7781a6b8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1b84c214-9527-4a96-ab4b-f396faa9934a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1b84c214-9527-4a96-ab4b-f396faa9934a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7981cf76-4bd9-4aba-9e30-716a5c0c5554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7981cf76-4bd9-4aba-9e30-716a5c0c5554" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51f313ec-503d-46b8-b745-ae81fa10fde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e2052257-b1a0-4818-9200-d9b846a21f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e2052257-b1a0-4818-9200-d9b846a21f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_69015b4f-1688-4b21-82e2-8469e5804910_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_69015b4f-1688-4b21-82e2-8469e5804910_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_bde7a0e9-f0a5-4a06-a41c-e6625459d0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_bde7a0e9-f0a5-4a06-a41c-e6625459d0b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_d9f54ee4-3b1f-4594-b1e2-2e974cc5958d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_d9f54ee4-3b1f-4594-b1e2-2e974cc5958d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b741939-fffa-41d2-993f-2ecd2081a0f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:to="loc_us-gaap_EquityComponentDomain_3b741939-fffa-41d2-993f-2ecd2081a0f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:to="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ee5cf32c-3bcc-4068-8ada-4d2f19527e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ee5cf32c-3bcc-4068-8ada-4d2f19527e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_0641aeef-272e-45c7-add4-a0b2bba50924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_0641aeef-272e-45c7-add4-a0b2bba50924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_eef3ba8f-8993-415b-87e2-ee88de847bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_eef3ba8f-8993-415b-87e2-ee88de847bce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_3a10015f-fba9-44d9-b2de-6c33b416ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_3a10015f-fba9-44d9-b2de-6c33b416ab47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c33274b8-3aa7-4009-91ca-eb33a7d49e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c33274b8-3aa7-4009-91ca-eb33a7d49e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_631f5789-5aac-4d51-9f86-3157c395b2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_631f5789-5aac-4d51-9f86-3157c395b2ae" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended" id="ic230cc8015e44739ade2831aab6c8c99_OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5297365a-2563-4e66-84f5-8284b0477669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_583aebea-cdf7-4cf1-8418-9f69d53700b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5297365a-2563-4e66-84f5-8284b0477669" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_583aebea-cdf7-4cf1-8418-9f69d53700b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5297365a-2563-4e66-84f5-8284b0477669" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_471748ea-bd33-466a-83ee-6ecd127a6622_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:to="loc_us-gaap_EquityComponentDomain_471748ea-bd33-466a-83ee-6ecd127a6622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:to="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f66ee27c-56de-4744-87f0-0ba8f0ca98e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f66ee27c-56de-4744-87f0-0ba8f0ca98e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8ab98f40-68b9-4892-906b-376ef051336d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8ab98f40-68b9-4892-906b-376ef051336d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cbde88e0-b1b0-4fb6-be8c-7f4fca9aed64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cbde88e0-b1b0-4fb6-be8c-7f4fca9aed64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c19ff853-bdb4-460a-96d4-b4ceb0497543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c19ff853-bdb4-460a-96d4-b4ceb0497543" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="ie30fb9d5559c4b7f862d95b2b045baae_OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fb918c56-10b5-4a7e-8d0b-0e4ab9893c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fb918c56-10b5-4a7e-8d0b-0e4ab9893c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_209d9da8-7322-4047-8fa2-32723f8f5e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_209d9da8-7322-4047-8fa2-32723f8f5e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b04915a1-a076-4084-9f54-aa58a958ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b04915a1-a076-4084-9f54-aa58a958ebf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_447b4fb3-33b0-45fc-b74f-57e95385007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_447b4fb3-33b0-45fc-b74f-57e95385007d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a53d298c-3989-4449-af6d-17daa2b5735c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a53d298c-3989-4449-af6d-17daa2b5735c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3c9029ec-69c5-4e3e-b925-b42e76ee311c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_ProfitLoss_3c9029ec-69c5-4e3e-b925-b42e76ee311c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f201150-6f26-42e0-9e76-040c0c50cf27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:to="loc_us-gaap_EquityComponentDomain_5f201150-6f26-42e0-9e76-040c0c50cf27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:to="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_0872b94b-6186-41b2-ba94-8bb8b9a1c9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_0872b94b-6186-41b2-ba94-8bb8b9a1c9e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8cd07e1b-d789-40a8-bc0d-92fd97804023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8cd07e1b-d789-40a8-bc0d-92fd97804023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_a968f1f6-a338-4762-a64a-54b702b6b9a0" xlink:href="lly-20211231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:to="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_a968f1f6-a338-4762-a64a-54b702b6b9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_46324906-a976-419d-9aa5-287ded36a472_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_46324906-a976-419d-9aa5-287ded36a472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3ce594d9-2c28-4d34-b6e4-02ceae883443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3ce594d9-2c28-4d34-b6e4-02ceae883443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5f45198c-6f9f-4faa-8981-90046ad0ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3ce594d9-2c28-4d34-b6e4-02ceae883443" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5f45198c-6f9f-4faa-8981-90046ad0ece2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#DiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsDetails" xlink:type="extended" id="i528ef02a6cfd4c7a9bc9d3090a4143f2_DiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_609ab484-8941-47f3-9cf4-71b58a3c7168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_609ab484-8941-47f3-9cf4-71b58a3c7168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_8b3438cf-a630-4bff-8696-5442c1987da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_8b3438cf-a630-4bff-8696-5442c1987da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a37c7b7a-581f-40c0-acab-ac40acdb7885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_Revenues_a37c7b7a-581f-40c0-acab-ac40acdb7885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d668f5b0-5df2-42d6-b5e2-4d64de378529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d668f5b0-5df2-42d6-b5e2-4d64de378529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_cd21083c-be18-429d-8559-9b3410ac351d" xlink:href="lly-20211231.xsd#lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_cd21083c-be18-429d-8559-9b3410ac351d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_16824eef-df40-4280-b1e9-da86b8881260_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:to="loc_srt_OwnershipDomain_16824eef-df40-4280-b1e9-da86b8881260_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ab2fa661-a6bd-421c-98e3-533131b69906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:to="loc_srt_OwnershipDomain_ab2fa661-a6bd-421c-98e3-533131b69906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_3c1878f5-55cf-4c10-99b7-fa65a03a7d8b" xlink:href="lly-20211231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ab2fa661-a6bd-421c-98e3-533131b69906" xlink:to="loc_lly_EliLillyAndCompanyMember_3c1878f5-55cf-4c10-99b7-fa65a03a7d8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6da4fde6-6d2e-43d2-a901-78dea6bd5a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6da4fde6-6d2e-43d2-a901-78dea6bd5a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_839f6964-379a-46fe-926f-baf357362961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6da4fde6-6d2e-43d2-a901-78dea6bd5a9b" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_839f6964-379a-46fe-926f-baf357362961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_89f307a2-66e8-44db-83a0-bf8a16e7b1f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_89f307a2-66e8-44db-83a0-bf8a16e7b1f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c81af8-1ae9-4825-951f-17bcba8b510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c81af8-1ae9-4825-951f-17bcba8b510c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_07f1f813-ffcb-41fb-ab7f-44beab35d157" xlink:href="lly-20211231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c81af8-1ae9-4825-951f-17bcba8b510c" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_07f1f813-ffcb-41fb-ab7f-44beab35d157" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>lly-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9fcc0128-8cb1-4f14-a312-a98ab5e27206,g:b055a216-cbe3-42fc-b7bd-1f3a75142c02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lly_AmpullaryCancerMember_6b8ef37f-730f-4adf-a520-781b2d3b4436_terseLabel_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_label_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer [Member]</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_documentation_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember" xlink:href="lly-20211231.xsd#lly_AmpullaryCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AmpullaryCancerMember" xlink:to="lab_lly_AmpullaryCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_83040912-ccdf-41fc-9970-72b080a432f6_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_48a6cc22-22e7-40b1-a673-0948e0923d1a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_64e37bb0-c1c4-43bb-a57d-ef7123bfd97c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9651803f-7b41-4cf6-8d9c-5c4333f2ac85_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_628bc19b-bfa3-449a-a83c-5485175ca557_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20211231.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9d14341b-afdb-4a5d-a9b2-4b4b51ce9a0e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_5bbebad9-e7fd-41dc-8cc8-5d9cebb5045d_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20211231.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A7125NotesDue2025Member_d8b0e98a-e2e5-45a7-bc85-8d2128eeac65_terseLabel_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% notes due 2025</link:label>
    <link:label id="lab_lly_A7125NotesDue2025Member_label_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_lly_A7125NotesDue2025Member_documentation_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member" xlink:href="lly-20211231.xsd#lly_A7125NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A7125NotesDue2025Member" xlink:to="lab_lly_A7125NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SelpercatinibLOXO292Member_6c58c452-d8f6-4338-a1c1-0d712a6b1df7_terseLabel_en-US" xlink:label="lab_lly_SelpercatinibLOXO292Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selpercatinib (LOXO-292)</link:label>
    <link:label id="lab_lly_SelpercatinibLOXO292Member_label_en-US" xlink:label="lab_lly_SelpercatinibLOXO292Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selpercatinib (LOXO-292) [Member]</link:label>
    <link:label id="lab_lly_SelpercatinibLOXO292Member_documentation_en-US" xlink:label="lab_lly_SelpercatinibLOXO292Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selpercatinib (LOXO-292) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member" xlink:href="lly-20211231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SelpercatinibLOXO292Member" xlink:to="lab_lly_SelpercatinibLOXO292Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_4e496ee9-7667-4c13-a8bf-a39ac2f83580_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LyciaTherapeuticsIncMember_100b708e-bf31-4f80-ad7b-3f527437aafb_terseLabel_en-US" xlink:label="lab_lly_LyciaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lycia Therapeutics, Inc.</link:label>
    <link:label id="lab_lly_LyciaTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_LyciaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lycia Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lly_LyciaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_LyciaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lycia Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LyciaTherapeuticsIncMember" xlink:href="lly-20211231.xsd#lly_LyciaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LyciaTherapeuticsIncMember" xlink:to="lab_lly_LyciaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_254d98f1-5301-450c-8da7-41f45be3c2ac_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20211231.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DermiraInc.Member_a41dd9f7-caa8-44e2-88ec-3041396da22b_terseLabel_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira</link:label>
    <link:label id="lab_lly_DermiraInc.Member_label_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:label id="lab_lly_DermiraInc.Member_documentation_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member" xlink:href="lly-20211231.xsd#lly_DermiraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DermiraInc.Member" xlink:to="lab_lly_DermiraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7739029a-b1c3-4f1e-ba89-553b61fa9270_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0e563b3d-dd41-4f5a-ae88-a6d4bf3aaa93_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_cfeea9af-ce8d-4e1a-b560-f9a79baecc9a_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20211231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_031f9f6d-ac65-4d2a-9faf-d0528bf490d1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recorded for Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_ec3df0e2-549e-42f3-95fa-8aeee01e53f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_bcdd5285-b42d-41a6-8e69-c71445b924ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c4d849b9-4e62-4713-a1c2-eb67eaf5bc0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_de2fcf22-2f39-4cea-af29-b653d7765e2a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_fafe3558-f7b6-4614-b7b3-66544848f044_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LoxoOncologyInc.Member_fd27cbee-4ffc-41bf-b7e2-722a90c6f599_terseLabel_en-US" xlink:label="lab_lly_LoxoOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loxo Oncology, Inc.</link:label>
    <link:label id="lab_lly_LoxoOncologyInc.Member_label_en-US" xlink:label="lab_lly_LoxoOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loxo Oncology, Inc. [Member]</link:label>
    <link:label id="lab_lly_LoxoOncologyInc.Member_documentation_en-US" xlink:label="lab_lly_LoxoOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loxo Oncology, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LoxoOncologyInc.Member" xlink:to="lab_lly_LoxoOncologyInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_3f1f7361-52cc-4520-b09f-b386316505a2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic (benefit) cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75a5cbcd-d234-4896-8d2d-b0e1eef4282d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_0f68a926-4020-4374-9039-4ce4ed17f582_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0199fff3-7ace-4d5c-acc0-b7066391d911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_abe92ec7-a367-40b4-aa42-412294745b40_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4542f106-dadd-4032-a062-57df73992a96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_597551ba-4b7c-44d2-b732-51bc00929b0d_terseLabel_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember" xlink:href="lly-20211231.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RigelPharmaceuticalsIncMember" xlink:to="lab_lly_RigelPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c7242389-bd5a-4bfd-b815-5699023e4fb5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_707a1b49-8d63-4d56-98ab-1b284124a5b7_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20211231.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f69e5973-58ea-460f-9575-a49f1646ab65_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable&#8212;increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_dec0a791-4d4a-48ca-b38a-608ccbefacd3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_48e4c3d8-64e0-4159-bc44-f8f4dd3b0579_terseLabel_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited initial market entry, supply term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_label_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_documentation_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:href="lly-20211231.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:to="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_7911866e-4811-4c29-ad70-05719b1bbc6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_762ef708-f614-4ae2-955a-785005d016b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a2d3047a-c693-46d7-8617-dbfdbffd4995_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_faaf0e12-0150-401d-8c54-7e4ba0c5f4eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_138c5db4-d559-4d6d-b3f9-b8ef70e67259_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0ffc3fb9-6a00-4455-a389-d530f5bbdb56_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6626594d-14db-4d0a-bebf-807aff444e72_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94dc8d6f-34a5-44bf-82ec-6789e4afce91_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_68a9b069-1d5d-4b31-a8d6-d5693804b29f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c2c0cbde-7eaf-4494-92cb-b8d934201991_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_ac7bb320-f7a4-4b58-a0c8-50f17a6d0042_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b3e71a64-e7cb-4bec-8cad-eae494d365b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_33ea862e-f9a7-4721-8476-683cbc338720_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_65a64e44-2369-45e9-892d-2e0753d08f69_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b176b392-f5fc-44ec-b334-51e13adf8a0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_b85d4d8a-9101-487d-8760-c878f3a11698_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_61c52192-5eee-4761-ac6a-9c3e6585a1a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a25d8086-0e4e-4e7c-b876-c87374fb6fa9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_1e0fba0c-dc1a-434f-8da0-f2f06068c1bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-lived Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d931740a-739c-40df-bf99-4fdf3b09d075_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7b07f918-25ec-49d9-ae85-4ad84ce93b4f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3dea1b22-3243-4d45-9293-cac80e9bacea_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f23bfb02-fd24-407d-97b0-dc07e260ad0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_68536b84-8d72-47d5-8068-430fc81b70c5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_268ec1e1-16ea-4b41-95e2-195d13428fbe_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_7bba5880-5701-42b7-9cab-37131e4ea53b_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes, designated as hedge</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DesignatedUnusableMember_436038c7-7fdb-445f-b396-988b20b86851_terseLabel_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated Unusable</link:label>
    <link:label id="lab_lly_DesignatedUnusableMember_label_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated Unusable [Member]</link:label>
    <link:label id="lab_lly_DesignatedUnusableMember_documentation_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember" xlink:href="lly-20211231.xsd#lly_DesignatedUnusableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DesignatedUnusableMember" xlink:to="lab_lly_DesignatedUnusableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JunshiBiosciencesMember_1895cd1a-ae75-41ab-b4f2-7552080dc1e8_terseLabel_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_label_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences [Member]</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_documentation_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember" xlink:href="lly-20211231.xsd#lly_JunshiBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JunshiBiosciencesMember" xlink:to="lab_lly_JunshiBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_78073b3c-0461-4c28-928a-051a2a227808_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2b3c66e2-9607-42af-b234-01f5f501a616_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_5caa0280-536d-4d4b-883c-e89e7d407326_terseLabel_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment on hedged long-term notes</link:label>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_label_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value Adjustment</link:label>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_documentation_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment to carrying value of long term debt to arrive at total fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment" xlink:href="lly-20211231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LongTermDebtFairValueAdjustment" xlink:to="lab_lly_LongTermDebtFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EvoxTherapeuticsMember_e1829127-d696-426b-ba4c-c8fa1f4c414d_terseLabel_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics Limited</link:label>
    <link:label id="lab_lly_EvoxTherapeuticsMember_label_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics [Member]</link:label>
    <link:label id="lab_lly_EvoxTherapeuticsMember_documentation_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember" xlink:href="lly-20211231.xsd#lly_EvoxTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EvoxTherapeuticsMember" xlink:to="lab_lly_EvoxTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationMember_8c639ef6-5070-4966-b27c-80b9ac633a68_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember" xlink:href="lly-20211231.xsd#lly_EmployeeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationMember" xlink:to="lab_lly_EmployeeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_0c5c2f44-1de2-4d5f-8ded-364a2b5d557c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_69136c67-eb3f-4c9a-b80b-5acbb783a3b7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_193de695-67ee-4a02-a7c5-8d024af2c1c9_terseLabel_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_label_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LIFOInventoryAmount" xlink:to="lab_us-gaap_LIFOInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_42bb6dfe-5812-42bc-b234-b8cad05e8da3_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_48582a91-f2c4-4a9c-a78c-c30643d4008b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_99f72a33-414e-410e-9f45-94d28e0aa00e_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds, anticipated payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20211231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_6b8bd7f9-934c-41ea-8e0d-9a66ac7f5135_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposition of ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2d842454-144c-4444-a83a-441cb35e1709_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InnoventBiologicsIncMember_1cb83207-f26d-45af-9f6b-9217af24b7b1_terseLabel_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. (Innovent)</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. [Member]</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember" xlink:href="lly-20211231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InnoventBiologicsIncMember" xlink:to="lab_lly_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_af596d61-0b04-4438-b349-8ce0a46f9e39_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, percentage of net revenue (less than)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NoExpirationMember_54096fdb-8530-45ee-b399-f5be6932df5b_terseLabel_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:label id="lab_lly_NoExpirationMember_label_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration [Member]</link:label>
    <link:label id="lab_lly_NoExpirationMember_documentation_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember" xlink:href="lly-20211231.xsd#lly_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NoExpirationMember" xlink:to="lab_lly_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_484fddec-bda9-4e0c-9c79-7a36bb7744cc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_9fa566b1-30f3-4e7a-8446-231cddd7e6d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_67f711c3-3d9d-4da0-84bf-f63c76c1d981_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dbb3411f-4343-4a7e-90a5-1d216b4ea1e1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_f1ac0dea-0dd1-42bb-8d41-4838e1c00ffa_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b84787-3e15-4ea0-b28b-547b9ea79ac1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_4c9946f0-dccb-4899-9bec-adc6bc3d4d9e_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7f32493d-3d52-4889-ae96-97c06dc5470f_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ByettaMember_c8129658-c166-4e09-a9ae-1e393679d68f_terseLabel_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:label id="lab_lly_ByettaMember_label_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta [Member]</link:label>
    <link:label id="lab_lly_ByettaMember_documentation_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember" xlink:href="lly-20211231.xsd#lly_ByettaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ByettaMember" xlink:to="lab_lly_ByettaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_ab233968-6f6f-4bc5-bc23-bb01950a2807_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_8ed0993c-2322-4892-a754-d13a54e3b7c9_verboseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20211231.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9ed40ea5-d98d-4fd0-a5ca-161cb4c13190_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_38013928-d59c-46b1-a70b-e53580241479_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_9f99054d-fb13-4903-8a38-8d6cbae85149_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones payments</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_6e21c18e-e1a8-4f16-aabd-ee689fc9bfc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7c806d0b-7ce8-494a-af43-cea66a343266_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ACImmuneSAMember_4369d468-90dd-48a8-b5e5-473ce99f980d_terseLabel_en-US" xlink:label="lab_lly_ACImmuneSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AC Immune SA</link:label>
    <link:label id="lab_lly_ACImmuneSAMember_label_en-US" xlink:label="lab_lly_ACImmuneSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AC Immune SA [Member]</link:label>
    <link:label id="lab_lly_ACImmuneSAMember_documentation_en-US" xlink:label="lab_lly_ACImmuneSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AC Immune SA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ACImmuneSAMember" xlink:href="lly-20211231.xsd#lly_ACImmuneSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ACImmuneSAMember" xlink:to="lab_lly_ACImmuneSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_bc2cbc16-9b61-49ac-8923-f0f292f6daaa_verboseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_4e119105-bfa5-4519-8803-f9702345be08_negatedLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_fe294e67-37d9-494c-bc90-92ecfd264ed5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_KumquatBiosciencesIncMember_559d7d22-97f5-44e9-8b1c-94bb9f779236_terseLabel_en-US" xlink:label="lab_lly_KumquatBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kumquat Biosciences Inc.</link:label>
    <link:label id="lab_lly_KumquatBiosciencesIncMember_label_en-US" xlink:label="lab_lly_KumquatBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kumquat Biosciences Inc. [Member]</link:label>
    <link:label id="lab_lly_KumquatBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_KumquatBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kumquat Biosciences Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_KumquatBiosciencesIncMember" xlink:href="lly-20211231.xsd#lly_KumquatBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_KumquatBiosciencesIncMember" xlink:to="lab_lly_KumquatBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_22d65db8-c53c-4837-99d5-5e5c7a149ae4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_09d62b2a-3358-4c73-8182-aa7bb1314fb6_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, monthly reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:href="lly-20211231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_92004e58-8c0c-48f9-a523-127c51be48cc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_0731f009-b323-4efc-b731-d63e0fe47400_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d1842004-723b-4d65-96ae-1a5ab0373d1f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_66ef862d-0e8b-4230-8695-ccf4c7907761_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_81b75598-136c-471a-851d-693daae1f75a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2eca8033-cb9b-448e-8a5b-f9fade117cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges Included in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_75dc150f-bcdb-4e79-b030-1b24efa88c2b_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_ee4a53b9-9171-45d1-9487-b40a01a20980_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_a8c4a9cd-6f9b-4204-b613-2be3a8c5bd36_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_6f7be6ee-ffd0-405a-84b1-5cf7cafb6226_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets</link:label>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeFundsMember" xlink:to="lab_us-gaap_FixedIncomeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9156c54f-bdfc-4432-b272-e3a0a108d3ea_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_9413c7d6-23d7-4e7b-8f62-0a553c81af10_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_40b2108d-5f25-4f64-ae90-224e86ebbc39_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ec7a17d9-e5a6-4e82-88ec-fbd1cca09b9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49578460-b723-443b-8965-af426b4a249f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7a87c8af-fc4d-480d-83b6-91b8f36a5916_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_02eaac48-1da0-444e-a18a-49bb330243a9_terseLabel_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_label_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember" xlink:href="lly-20211231.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrecisionBiosciencesIncMember" xlink:to="lab_lly_PrecisionBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e8ef2304-5dbc-411d-aba6-15df4c5f4292_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_eeb14891-6431-4c66-b9c5-3f20e06d72a4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3e4a4ba3-92c2-4e8a-863a-2fdde3aef822_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff00fe31-c7d3-4d9e-b930-bef1acea3613_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_9372b814-0a99-4e87-8734-1103397ec179_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:to="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_c77d6852-a995-4755-9dc8-05061d1f7228_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_373c5d28-275f-4274-8b91-7a6f91e3f07b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of nonperforming assets</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_566b4bbb-23fd-49cc-a834-6e6f490c328a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_f0a65b57-6d35-4143-86ec-6a87f83606e5_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20211231.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4a951cc4-c1be-4649-8971-04b2f33fd735_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c40b8392-e1c5-4e6d-80ff-f352aedef9e6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_6bd9f9b5-4521-4a06-bba5-20e1423f8da4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A30NotesDue2022Member_e434e2c1-1059-460d-a087-3c206d2c3079_terseLabel_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2022</link:label>
    <link:label id="lab_lly_A30NotesDue2022Member_label_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.0% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A30NotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.0% Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member" xlink:href="lly-20211231.xsd#lly_A30NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A30NotesDue2022Member" xlink:to="lab_lly_A30NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_8e74eeca-6df7-4abe-8f3e-6bc4a78e112f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_5c47dbc3-1694-466e-a4ae-8d91d0825496_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2049Member_7058a4ae-3252-4543-937a-8ab5bff1bfcc_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% notes due 2049</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_label_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member" xlink:href="lly-20211231.xsd#lly_A395NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2049Member" xlink:to="lab_lly_A395NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_c3e81f3d-d2ad-4213-b99f-60b0a492fc3b_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20211231.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_8924fb42-e598-40a4-ae48-46cfd88d364f_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A415NotesDue2059Member_736cdb05-f94c-427f-847a-47dc508add0a_terseLabel_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% notes due 2059</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_label_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_documentation_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member" xlink:href="lly-20211231.xsd#lly_A415NotesDue2059Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A415NotesDue2059Member" xlink:to="lab_lly_A415NotesDue2059Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_a133e50f-4686-488b-89d3-3f7233c785f5_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_91e7a95b-a688-4bb1-9ba9-a5b02cfeeab1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_74c56d00-177a-4f3b-9ba9-703ebba160ce_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b115e90f-48b5-4f95-9bd5-cf940ea2433a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_61433cd0-ac5d-4173-9272-e15a7f50d59f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b3cd6044-4b5d-43b8-8aa3-f35bd7d28fb1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_57346251-d32b-4988-94f7-329af58189f4_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_67e5a78d-43ce-410a-9838-8d8cc893f9f4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_572d8234-9def-4618-8f1d-f62f45a35dc8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2aa63b88-5e52-4571-b3a5-ac5c6b60f66b_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6d216ff4-0618-41aa-978c-5817e8f9ac6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A595NotesDue2037Member_da8f325b-8965-4318-9e31-23500be0bc27_terseLabel_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% notes due 2037</link:label>
    <link:label id="lab_lly_A595NotesDue2037Member_label_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes Due 2037 [Member]</link:label>
    <link:label id="lab_lly_A595NotesDue2037Member_documentation_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes Due 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member" xlink:href="lly-20211231.xsd#lly_A595NotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A595NotesDue2037Member" xlink:to="lab_lly_A595NotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_6be8eb20-7326-4768-98bd-0fe89f15a36d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_cf2a279d-08e7-47f9-bdb2-0357bdac728f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_9966e6e0-69ff-4592-a958-b55626880874_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6445f690-3eab-466b-a497-cbc90240640e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35afe8ab-5ac3-41e6-b21b-b38b5215ff22_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreatitisMember_d31c8df8-e532-448a-843d-5ac5acbe245d_terseLabel_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:label id="lab_lly_PancreatitisMember_label_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis [Member]</link:label>
    <link:label id="lab_lly_PancreatitisMember_documentation_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember" xlink:href="lly-20211231.xsd#lly_PancreatitisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreatitisMember" xlink:to="lab_lly_PancreatitisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_2584c6f9-8fae-44b9-b623-2225ab2a651b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a7a619bd-73bb-409f-8946-b623c1ed4811_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_f71b598a-e304-4ae6-8fb8-a744f1945407_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmuNextInc.Member_617e3bad-6925-4afd-a762-55781632dee6_terseLabel_en-US" xlink:label="lab_lly_ImmuNextInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext, Inc.</link:label>
    <link:label id="lab_lly_ImmuNextInc.Member_label_en-US" xlink:label="lab_lly_ImmuNextInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext, Inc. [Member]</link:label>
    <link:label id="lab_lly_ImmuNextInc.Member_documentation_en-US" xlink:label="lab_lly_ImmuNextInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmuNextInc.Member" xlink:href="lly-20211231.xsd#lly_ImmuNextInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmuNextInc.Member" xlink:to="lab_lly_ImmuNextInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_79c68976-db6d-4d77-88bc-295f28e98adf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets (Note 14)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5cfce657-87eb-428f-bca1-2f81dabdd8a9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_77e03117-7278-4c1d-8550-ff6e191ad792_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20211231.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625EuroDeonominatedNotesDue2031Member_9e22296f-3fe4-485e-9122-2a72c148eafc_terseLabel_en-US" xlink:label="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% euro denominated notes due 2031</link:label>
    <link:label id="lab_lly_A625EuroDeonominatedNotesDue2031Member_label_en-US" xlink:label="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Euro-deonominated Notes Due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625EuroDeonominatedNotesDue2031Member_documentation_en-US" xlink:label="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Euro-deonominated Notes Due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member" xlink:href="lly-20211231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625EuroDeonominatedNotesDue2031Member" xlink:to="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_57bfae01-500c-4e17-b38d-d2753a9b3499_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_f7af7e11-f36d-4d84-9930-044545b1b2fc_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b4a33734-af6c-4aca-ae00-5bf8751651c3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals for the payment of interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_395ff574-38dc-408c-9710-5b2e2ff0cab8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_26a5f50a-478c-459f-b9f1-9ed17e2e784e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_52144b3c-3905-4734-8972-420857361af0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_b594fbdd-d113-48df-b116-04dc1bd19b77_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20211231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CarryforwardMember_6f02a9e1-4669-4929-a3b7-659c0846741e_terseLabel_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carryforward</link:label>
    <link:label id="lab_lly_CarryforwardMember_label_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carryforward [Member]</link:label>
    <link:label id="lab_lly_CarryforwardMember_documentation_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember" xlink:href="lly-20211231.xsd#lly_CarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CarryforwardMember" xlink:to="lab_lly_CarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_09556330-8351-4199-b474-1a3e04a5aa1b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d2200fec-c0a1-48ec-8829-478b93f16de7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0e301cb2-1141-4c05-be8f-e46093bc370e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_c6508aa3-b1fe-4024-b400-00d6337dc88e_terseLabel_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_label_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:href="lly-20211231.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:to="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e3f6dedd-ed4f-4fcc-b635-547a1d1b75cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value&#8232; Authorized shares: 3,200,000&#8232; Issued shares: 954,116 (2021)&#160;and 957,077 (2020)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_073d1a99-410a-4def-b9e8-cd2507fe148f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of the compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_9568ba7d-19dc-4cab-ade3-02478026d878_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_a1a60b16-f50f-4ec0-8c8f-ebc7cf00aca4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-like funds</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_0ebfdeb2-ebea-41fa-aeae-f68ecfc7c7af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FoghornTherapeuticsIncMember_b60eb534-ea24-4eed-9272-b5e070190989_terseLabel_en-US" xlink:label="lab_lly_FoghornTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foghorn Therapeutics Inc.</link:label>
    <link:label id="lab_lly_FoghornTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_FoghornTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foghorn Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_FoghornTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_FoghornTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foghorn Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FoghornTherapeuticsIncMember" xlink:href="lly-20211231.xsd#lly_FoghornTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FoghornTherapeuticsIncMember" xlink:to="lab_lly_FoghornTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_bd069992-69ed-4587-8c2d-0ed8aa0f0b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of businesses, net of cash divested</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_7913ce93-3561-492f-abec-f40934e2b0a4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_410e2b17-c6f9-46b5-9660-7b8b50fbad39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_f3dcbeac-6e43-4184-963b-9ffb2fac75e8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_56e62381-a5de-419c-84ae-22492638033e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestiture</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62623ee5-ab38-4045-8af7-867ca07c94ed_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxYears2013To2015Member_7365eb81-c90b-4d14-812b-35c5041bf6cf_terseLabel_en-US" xlink:label="lab_lly_TaxYears2013To2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2013 to 2015</link:label>
    <link:label id="lab_lly_TaxYears2013To2015Member_label_en-US" xlink:label="lab_lly_TaxYears2013To2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2013 To 2015 [Member]</link:label>
    <link:label id="lab_lly_TaxYears2013To2015Member_documentation_en-US" xlink:label="lab_lly_TaxYears2013To2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2013 To 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxYears2013To2015Member" xlink:href="lly-20211231.xsd#lly_TaxYears2013To2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxYears2013To2015Member" xlink:to="lab_lly_TaxYears2013To2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a0bb38c0-151e-4e1f-a0ce-d55b4e62c4cb_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_423a5c1e-d3a3-4aab-b33d-d5317dccf717_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20211231.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_f8c08795-4e66-403d-91d0-4e6e23b8af84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_73dcbdf2-2ffa-47e0-8a49-e553e1217155_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ca42d97e-9d7b-4f7c-8996-868a419369df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a24762b0-607a-487d-8f3e-08379b22ce6a_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0a2a522f-a310-49e8-ad73-665465e2187e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_dc69bd30-e195-4aa9-883e-517f13e183be_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20211231.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_2cbeaa1f-7645-4a2d-b3b4-768b5110d9de_terseLabel_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4f156aa2-b4a2-4b64-bfce-229b791e521e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_ac665321-dc7c-4940-971b-61d8ebf0402d_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_11aafa9c-7691-44c6-a386-55314a8813b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_4e4fcedd-1cef-46f6-ba0c-5130289aecae_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3-5 Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_5d2e35cc-bea6-48f8-b634-1aeb0d51bd54_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_ccbf976f-4b5e-4c65-9da7-c4597b9a37eb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea42fcde-0b50-49d5-b173-c6fe74aae562_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_e44f5ae8-0e08-499d-a472-64b76a9d4f5f_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_November2019EuroDenominatedNotesMember_92474310-c4bc-47ac-9aff-0b1a72a3f500_terseLabel_en-US" xlink:label="lab_lly_November2019EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Euro-denominated Notes</link:label>
    <link:label id="lab_lly_November2019EuroDenominatedNotesMember_label_en-US" xlink:label="lab_lly_November2019EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Euro-denominated Notes [Member]</link:label>
    <link:label id="lab_lly_November2019EuroDenominatedNotesMember_documentation_en-US" xlink:label="lab_lly_November2019EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Euro-denominated Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019EuroDenominatedNotesMember" xlink:href="lly-20211231.xsd#lly_November2019EuroDenominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_November2019EuroDenominatedNotesMember" xlink:to="lab_lly_November2019EuroDenominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_328b0662-337a-41fa-a680-3618c8668979_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20211231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MiNATherapeuticsLimitedMember_3eea7d20-5992-42e2-b7ef-00bf3e8b0e7a_terseLabel_en-US" xlink:label="lab_lly_MiNATherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiNA Therapeutics Limited</link:label>
    <link:label id="lab_lly_MiNATherapeuticsLimitedMember_label_en-US" xlink:label="lab_lly_MiNATherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiNA Therapeutics Limited [Member]</link:label>
    <link:label id="lab_lly_MiNATherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_lly_MiNATherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiNA Therapeutics Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MiNATherapeuticsLimitedMember" xlink:href="lly-20211231.xsd#lly_MiNATherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MiNATherapeuticsLimitedMember" xlink:to="lab_lly_MiNATherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_cbbd311f-c897-4ef4-8bc7-512dc52c115e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_88079472-981c-47c2-a8d2-d9fd9719fef2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_Expiration5to20YearsMember_aa750451-5869-4b0f-8638-fe710fcdff09_terseLabel_en-US" xlink:label="lab_lly_Expiration5to20YearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration 5 to 20 Years</link:label>
    <link:label id="lab_lly_Expiration5to20YearsMember_label_en-US" xlink:label="lab_lly_Expiration5to20YearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration 5 to 20 Years [Member]</link:label>
    <link:label id="lab_lly_Expiration5to20YearsMember_documentation_en-US" xlink:label="lab_lly_Expiration5to20YearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration 5 to 20 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expiration5to20YearsMember" xlink:href="lly-20211231.xsd#lly_Expiration5to20YearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_Expiration5to20YearsMember" xlink:to="lab_lly_Expiration5to20YearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProQRTherapeuticsNVMember_17d341d6-7d08-489d-97a0-7ff8189b1938_terseLabel_en-US" xlink:label="lab_lly_ProQRTherapeuticsNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQR Therapeutics N.V.</link:label>
    <link:label id="lab_lly_ProQRTherapeuticsNVMember_label_en-US" xlink:label="lab_lly_ProQRTherapeuticsNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQR Therapeutics N.V. [Member]</link:label>
    <link:label id="lab_lly_ProQRTherapeuticsNVMember_documentation_en-US" xlink:label="lab_lly_ProQRTherapeuticsNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQR Therapeutics N.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProQRTherapeuticsNVMember" xlink:href="lly-20211231.xsd#lly_ProQRTherapeuticsNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProQRTherapeuticsNVMember" xlink:to="lab_lly_ProQRTherapeuticsNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ca8610d5-460f-4532-ae74-f176fca04b0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_9bfcca56-8683-4537-b68a-5f979deb5747_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e2c23782-8fc9-4505-97de-0499890946b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_3afce8fb-7843-435f-8a98-f2a81aaef095_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:href="lly-20211231.xsd#lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_316ab5aa-de8f-467f-8041-d007d59d33a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5728a00b-25b6-4e12-955a-67f5f233b549_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_4b8fbfda-b13e-4d63-b2f4-cd4a37bfab8b_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20211231.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_17880968-d54d-4fff-94fa-ba4599da8173_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_22a81429-f22b-4791-aac8-c7f63a2e6ec0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7fae7a72-e9d0-46f4-9561-11474b8626d2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_7f586695-97a1-4c8c-8f90-d2747497b6f2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProductLiabilityMember_6de25191-a9ed-41b3-a2f0-d2479a2e6f8c_terseLabel_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_label_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_documentation_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember" xlink:href="lly-20211231.xsd#lly_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProductLiabilityMember" xlink:to="lab_lly_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e16293a8-4abf-47b8-ba13-2e6aa044778f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_bdb18365-02b2-4684-8de0-c59f021dc699_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6e46b3c7-cc82-442f-8bc0-15898bc8d4c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_b847b48e-73a6-4b7d-8e80-d2138fc42388_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Initiation Of Phase I Trial</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Initiation Of Phase I Trial [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Initiation Of Phase I Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:to="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_fe2d9487-ca07-4f67-beff-6feae8075da4_terseLabel_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% euro denominated notes due 2026</link:label>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_label_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro-denominated Notes Due 2026 [Member]</link:label>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_documentation_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro-denominated Notes Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member" xlink:href="lly-20211231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625EuroDenominatedNotesDue2026Member" xlink:to="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2b7631ad-fa5a-4708-8cdd-bbb67b5f6879_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9d7f34b5-4e05-4d92-a053-8783a05cdd73_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3015d0c3-aff2-4410-86f2-10dfc898c6b0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2cbf2903-d8e8-4d4d-87e0-e2fbf49268c1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0dc7ed0c-adf0-4a02-a57e-da8d7b9b878c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ccd1aa7d-9a3f-4081-bc73-c4b437a7dd08_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cb80ad5-4484-49fa-83c9-eb0837e7d0f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_97d550ef-28c1-4080-b9f0-2314bfcb83cb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_ef18ed3f-8232-49db-a76f-a63511e5770c_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20211231.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_25ad734c-6e4a-41af-b11f-689728627a11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3a3be4c0-8680-4a81-96fc-220cf9b1061d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_884e9ef4-deec-4c42-b7b2-1c8a8bb67564_terseLabel_en-US" xlink:label="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, not discontinued operation, payment to be received</link:label>
    <link:label id="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_label_en-US" xlink:label="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Payment To Be Received</link:label>
    <link:label id="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_documentation_en-US" xlink:label="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Payment To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:href="lly-20211231.xsd#lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:to="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_b45e8e14-e293-4fd0-9172-a5dd522ee1b6_terseLabel_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss franc denominated notes due 2024</link:label>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_label_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc-denominated Notes Due 2024 [Member]</link:label>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_documentation_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc-denominated Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:href="lly-20211231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:to="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_05dee628-5b59-4d09-ace8-2441dd017630_verboseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b6cc04f7-28d3-4ac2-8588-a48feca03468_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd68b964-2a5f-45d5-bbf2-acb28440bb24_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5398bbd5-470c-4a52-99ae-17f3ac452a37_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b2e19ec6-c69b-4168-9bbb-a9e9bfd5835c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_aada0c9f-80da-426c-a586-9fb2fd5bb01e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ce754692-a321-4093-a816-98c586a361a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities&#8212;increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_e191af2c-cdb7-42d0-8741-5a9aa1c17a56_terseLabel_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% euro denominated notes due 2030</link:label>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_label_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro-denominated Notes Due 2030 [Member]</link:label>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_documentation_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro-denominated Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member" xlink:href="lly-20211231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2125EuroDenominatedNotesDue2030Member" xlink:to="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_06bdc438-b75a-47d4-892f-c18f0da014d6_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8bb43f80-e6ae-44ae-9174-0403c81fcec7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_87082e04-c632-4b7a-83a5-ac8de4e2d989_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A235NotesDue2022Member_851eb34e-8157-4612-8722-c144dbb1433e_terseLabel_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_lly_A235NotesDue2022Member_label_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A235NotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member" xlink:href="lly-20211231.xsd#lly_A235NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A235NotesDue2022Member" xlink:to="lab_lly_A235NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_02bf4842-4959-4ac2-a62b-39c0c23b11db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_1aa2753f-ae11-4339-8e5a-25142255af83_terseLabel_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_label_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:href="lly-20211231.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:to="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_84f170ab-1517-4f2d-8663-a09801a94758_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1acb6d7f-2f40-4e6e-9b4f-ea3f56bf7c47_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_8eb629f8-fb5e-4270-98e9-004216632235_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_88d83230-7638-4216-8251-012c8fd86872_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_541e42f5-779e-445f-97d4-d151acd06478_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of antibiotic business in China (Note 3)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_c10c055f-6da7-4342-a1fa-7847a4d8a8a7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to disposition</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_dc18a8d9-544f-461c-9605-9f524eebc20d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of antibiotic business in China</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_2ccca0c9-ecd2-4397-9741-1c2362661445_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20211231.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9656efb8-6b77-4fe2-b484-dad0149cb721_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_89205665-1a98-407a-b4c7-78d76f1eced6_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_e2a75e96-cc8e-413a-a9a0-e41853fa1328_terseLabel_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.42% Japanese yen denominated notes due 2029</link:label>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_label_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.42% Yen-denominated Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.42% Yen-denominated Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member" xlink:href="lly-20211231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A42YenDenominatedNotesDue2029Member" xlink:to="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_4426497d-28ff-4615-9a49-b63830368091_terseLabel_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:href="lly-20211231.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_2da062b5-6ae0-4bdd-92e0-afc92d9625f6_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations percent (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_c9e45c0b-402c-497f-a6bf-77a391a30163_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_8d618cac-06f3-4601-b6cf-c9363e7bcc82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_2ffbfc5f-391a-44db-901e-426588c92cfd_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-3 Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d52e55de-345e-4bab-9e7a-92dfba074f26_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMemberMember_e0ae95e6-8886-4018-b958-68827dfc83ce_terseLabel_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_label_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_documentation_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember" xlink:href="lly-20211231.xsd#lly_TrulicityMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMemberMember" xlink:to="lab_lly_TrulicityMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c453fe4b-b175-46f2-ad95-833b4a4f5251_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_19dfd97a-2c41-4189-9138-98e0e076eee1_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:href="lly-20211231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_db73d805-72b4-4f35-bb92-ac0b04f06bef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3d1b6096-ddbc-4cf5-8b39-97c26c7a898b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_3334bacd-17c1-413f-a406-2c18df00a5e3_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20211231.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dfeb701e-606a-44f1-ac61-4805854c4633_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_f449c065-f693-4487-945a-282fbd02b352_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_9e91fd88-0b9c-4c61-9886-09a90df66089_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_840654f8-0117-4ba9-bf47-4dbf33ac32da_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1b7c4d37-8ed5-465f-a5a9-442b07eb285e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_6c017ec7-7c87-4193-92fa-6a664b0aa3b6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b0138b41-3b7c-4cd7-bff8-0a402ca2646e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VariousStateDomicilesMember_1a5c9a06-5144-42d8-9411-b0a19a9a6e70_terseLabel_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_label_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles [Member]</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_documentation_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember" xlink:href="lly-20211231.xsd#lly_VariousStateDomicilesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VariousStateDomicilesMember" xlink:to="lab_lly_VariousStateDomicilesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_47cb8e83-d987-4f66-afbe-c20be9f3d3b8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_766a9f42-8550-4486-b52e-d4c7592bd7e8_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_c6c19f01-042d-41a1-af8a-8c2dcab62049_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20211231.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvidityBiosciencesInc.Member_636f34e1-498e-419a-9084-e161ca5abdba_terseLabel_en-US" xlink:label="lab_lly_AvidityBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avidity Biosciences, Inc.</link:label>
    <link:label id="lab_lly_AvidityBiosciencesInc.Member_label_en-US" xlink:label="lab_lly_AvidityBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avidity Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_AvidityBiosciencesInc.Member_documentation_en-US" xlink:label="lab_lly_AvidityBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avidity Biosciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvidityBiosciencesInc.Member" xlink:href="lly-20211231.xsd#lly_AvidityBiosciencesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvidityBiosciencesInc.Member" xlink:to="lab_lly_AvidityBiosciencesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProtomerTechnologiesIncMember_f44579bf-0e85-48a8-b6b8-4f18371ebcc5_terseLabel_en-US" xlink:label="lab_lly_ProtomerTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protomer Technologies Inc.</link:label>
    <link:label id="lab_lly_ProtomerTechnologiesIncMember_label_en-US" xlink:label="lab_lly_ProtomerTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protomer Technologies Inc. [Member]</link:label>
    <link:label id="lab_lly_ProtomerTechnologiesIncMember_documentation_en-US" xlink:label="lab_lly_ProtomerTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protomer Technologies Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProtomerTechnologiesIncMember" xlink:href="lly-20211231.xsd#lly_ProtomerTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProtomerTechnologiesIncMember" xlink:to="lab_lly_ProtomerTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_6219e57d-5018-4675-8091-845f64fa554b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f4d673c4-4f86-44d7-8af5-3b12005afeda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 14)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e3ccba55-d8cb-488d-a902-dae050f37188_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2569c704-8145-413e-8afa-286a951bbd1a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e5b185d0-2867-40d8-802e-502aec3f373e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d96e8ef8-c7b9-428c-be94-24ce7801df83_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $22.5 (2021)&#160;and $25.9 (2020)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_ed5ab471-12ef-440a-a124-24038b9919cd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases denied</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e5379213-3bbb-410a-809b-385b19b46dff_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_496ef5f5-0e59-4853-a1fb-c77124a40062_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgeFundsMember_8a423ab1-2e5b-499b-81d8-aa6a16574cb5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge funds</link:label>
    <link:label id="lab_us-gaap_HedgeFundsMember_label_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgeFundsMember" xlink:to="lab_us-gaap_HedgeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fb0bfef4-9ce6-47ff-ac90-37799d9f4ec3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_5557f5ce-ca18-4d30-b5a9-9a5fb0ef2fa0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) from continuing operations:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0f088df3-34f6-4b4d-b5f3-c4264128ba6d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3cc4ceeb-e1d7-4280-b656-d5d3faf749cf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EliLillyAndCompanyMember_94ef8c75-5b86-4cd0-a570-5da605863154_terseLabel_en-US" xlink:label="lab_lly_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_lly_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_lly_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_lly_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_lly_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember" xlink:href="lly-20211231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EliLillyAndCompanyMember" xlink:to="lab_lly_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e9aaad35-5f37-4a7e-a079-44a3e4d00362_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_930341bc-cd53-44bd-a2a8-d0fcd4913c20_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_db2d6992-b548-4a93-b609-c99fd1bc65a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_1e4aa903-f7f7-4a8f-ad9e-8abed9848a4f_terseLabel_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:href="lly-20211231.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_ab42e821-a9a3-4c2a-9dd2-3eece472992c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestiture</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_78aae741-4ebb-4a7b-8a5b-4e6df5f37d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_caa786fd-10a4-4b4d-9147-2b4d6215a765_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_db109c7b-3cb8-48da-8272-ac0980628378_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_2a92b7d0-8ff7-4dd0-a4e6-75cca42b0d9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_4cd04c77-671a-4925-8d6f-51debbf9d5ea_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_aacde9c2-20fe-422d-8bab-d549b1b04312_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_b525bb40-63c0-400f-9dc6-79e2907a712a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_a09e1b16-775d-42ad-9dc6-441315f5663d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid employee benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_7a7cd298-6cf7-4d55-a539-c89f423873dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4293969d-6751-4f1e-bf23-6ccb069ef2d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_bf9b3f0d-c4f5-4672-b002-9be334aad303_terseLabel_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, days from date of shipment, maximum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_label_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Maximum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_documentation_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum" xlink:href="lly-20211231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuefromContractPaymentTermMaximum" xlink:to="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6502e035-d83e-48ec-bda8-8f007530e470_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54567cc6-9dca-4937-b2e8-666d3d2777ba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3875NotesDue2039Member_a46c0927-3406-4e99-bcf3-c75a71f79c60_terseLabel_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2039</link:label>
    <link:label id="lab_lly_A3875NotesDue2039Member_label_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2039 [Member]</link:label>
    <link:label id="lab_lly_A3875NotesDue2039Member_documentation_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member" xlink:href="lly-20211231.xsd#lly_A3875NotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3875NotesDue2039Member" xlink:to="lab_lly_A3875NotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_6a5e4d34-6629-43fa-b127-e2e45f3bcfd6_terseLabel_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Puerto Rican companies contribution</link:label>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_label_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Puerto Rican Contribution to Income before Income Taxes</link:label>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_documentation_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:href="lly-20211231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:to="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_72171451-3a64-47da-b396-911ab8b56b1f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c44fe99e-c3a3-4baf-84a0-c7567cdcc88e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, finite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eba3e5cd-cb18-46e9-8c2b-7c78da7d89d5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_736cd294-557b-4942-b8f9-6519c7d3a00f_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20211231.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_21a36506-0ef8-4511-8b61-46ed6df1fc1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_5fbab353-d67c-436a-a6dc-b12767981504_terseLabel_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, days from date of shipment, minimum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_label_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Minimum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_documentation_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum" xlink:href="lly-20211231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuefromContractPaymentTermMinimum" xlink:to="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6b937049-dc54-409d-9f49-b9d34ac9ba77_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_d00a6fe3-3f44-437d-88db-20dce084aabc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e2f30235-dfd6-4839-9d4f-e6e00fbba34c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ce0420a-48bb-4dba-8366-2a26b24c25e3_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd7d5f91-e330-4bcc-9dd4-78e4a059856a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86864816-88cf-44f1-8695-8a7d16565e29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6eec0531-8f01-440c-b21c-2bb40bd632d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4e843547-c440-4883-b66a-b44368f96781_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e463ccb9-b300-478d-962d-55d62f59d03f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7161e8d5-6236-4850-b3eb-cc5a5fc5ed89_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_09da3b30-163e-41a0-b850-9ece7b0bea5e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_54eca072-4e11-4485-8ade-ea2655afdd88_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, product expiration date</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Product Expiration Date</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Product Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_09a4532a-a693-4cc6-b1d0-435bcb8f4890_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_e9c7e52a-f6d8-439a-aa8a-847f79d1b343_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment, restructuring, and other special charges (Note 5)</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_230e95d4-fa28-4afb-9486-0919ed2131c0_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_58ef02d3-b702-4f8c-8323-80738bca89df_terseLabel_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_label_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember" xlink:href="lly-20211231.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SitryxTherapeuticsLimitedMember" xlink:to="lab_lly_SitryxTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_343b8dc3-133f-4379-bc21-bfb6a44e00bf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e8ec1ea-b1e5-4e02-bced-c08815b2590c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_7897fa89-29b1-4cb0-b3f7-7bad09f9a237_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cddd7451-8220-4096-be55-b26e5c301d50_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e89785d4-55af-4fd2-8a88-204b7bb90078_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f6fef067-3847-4b66-8b78-e93009548da2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of retirement benefit items</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2023Member_b5b256b6-f99e-46df-89cd-cd17f1ce38bd_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_label_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member" xlink:href="lly-20211231.xsd#lly_MaturityDate2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2023Member" xlink:to="lab_lly_MaturityDate2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NonCHINAMember_7bea2b6e-b968-42ca-be6f-7f8fed9bebc5_terseLabel_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of China</link:label>
    <link:label id="lab_lly_NonCHINAMember_label_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA [Member]</link:label>
    <link:label id="lab_lly_NonCHINAMember_documentation_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember" xlink:href="lly-20211231.xsd#lly_NonCHINAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NonCHINAMember" xlink:to="lab_lly_NonCHINAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0038b92c-6725-42ae-ba32-bdaf34ce2559_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_377e1dc6-d97f-40fb-b257-a3ccc56a261a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0152526d-8f29-4856-9eca-0b0aca1ada0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6b8960b-5bac-44ab-86b4-06661bdde4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_90110f27-d254-4982-931c-980aeeae696a_terseLabel_en-US" xlink:label="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China</link:label>
    <link:label id="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_label_en-US" xlink:label="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]</link:label>
    <link:label id="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_documentation_en-US" xlink:label="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:href="lly-20211231.xsd#lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:to="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_90a84e70-e08b-49d1-ad87-13e78cbd6c4c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_4c52ab03-d512-4291-bb60-efd8ebfe7df0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes related to the impact of foreign currency translation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_9323f802-2e8b-425e-8421-3af940907ee6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer_8d712912-ee06-44a2-a5ee-5f1f5141966a_negatedTerseLabel_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of common stock in exchange offer</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer_label_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Value, Exchange Offer</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer_documentation_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Value, Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:href="lly-20211231.xsd#lly_StockAcquiredDuringPeriodValueExchangeOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:to="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_65371429-4e29-47a5-8f9c-688ccd82c4d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_6ed9a376-ba51-4ef4-8922-f4572fb584b8_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A37NotesDue2045Member_60955d67-1773-4b1b-ac4e-ea152f25f56b_terseLabel_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% notes due 2045</link:label>
    <link:label id="lab_lly_A37NotesDue2045Member_label_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% Notes Due 2045 [Member]</link:label>
    <link:label id="lab_lly_A37NotesDue2045Member_documentation_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% Notes Due 2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member" xlink:href="lly-20211231.xsd#lly_A37NotesDue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A37NotesDue2045Member" xlink:to="lab_lly_A37NotesDue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b0eb2b20-773e-4fe5-abed-8e74cdd01807_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impact of Leases to Consolidated Condensed Financial Statements</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_3196bdbf-4937-4df0-aae2-2292404a693f_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_759d6f70-bc7f-4686-a41b-1fc283e70bc8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A97YenDeonominatedNotesDue2049Member_2e4ac2c8-7e85-49fe-9baf-a925936d9719_terseLabel_en-US" xlink:label="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.97% Japanese yen denominated notes due 2049</link:label>
    <link:label id="lab_lly_A97YenDeonominatedNotesDue2049Member_label_en-US" xlink:label="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.97% Yen-deonominated Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A97YenDeonominatedNotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.97% Yen-deonominated Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member" xlink:href="lly-20211231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A97YenDeonominatedNotesDue2049Member" xlink:to="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ElancoAnimalHealthIncorporatedMember_3064a34a-d2b1-4133-86ec-69aa2f5a7b23_verboseLabel_en-US" xlink:label="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:label id="lab_lly_ElancoAnimalHealthIncorporatedMember_label_en-US" xlink:label="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco Animal Health Incorporated [Member]</link:label>
    <link:label id="lab_lly_ElancoAnimalHealthIncorporatedMember_documentation_en-US" xlink:label="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco Animal Health Incorporated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember" xlink:href="lly-20211231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ElancoAnimalHealthIncorporatedMember" xlink:to="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_9bd32381-f9ac-45b0-9a3c-3be93126a40d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_ae5b476d-960b-4844-aad0-c7865446eb88_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_b3f59785-fd14-4e50-b771-e89ffbb093e3_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7224a796-e3ea-4e57-b978-1c6b574cdbcc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_COVID19AntibodiesMember_2ec0a9b3-6c08-4d56-bdd8-2a6e418e0b79_terseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_label_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies [Member]</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_documentation_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember" xlink:href="lly-20211231.xsd#lly_COVID19AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_COVID19AntibodiesMember" xlink:to="lab_lly_COVID19AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_97ef57bf-81c3-44d5-95c8-9ab597f4d1bb_totalLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_bac521be-c30d-46b0-9f8d-2df53f5a2e11_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20211231.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_0e694061-58cd-4165-8142-f1eb4f7a18e7_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:href="lly-20211231.xsd#lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4bbc6e5e-38a2-46a1-8b6c-d3344cc2fbf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyGBPSellUSDMember_6f6bf7a1-e3f4-4ca7-9d57-a10f59b37aa2_terseLabel_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_label_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD [Member]</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_documentation_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember" xlink:href="lly-20211231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyGBPSellUSDMember" xlink:to="lab_lly_BuyGBPSellUSDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_a7f34c57-39b1-4c21-be21-17c220daf3ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (benefit) cost included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AuditInformationAbstract_label_en-US" xlink:label="lab_lly_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_lly_AuditInformationAbstract_documentation_en-US" xlink:label="lab_lly_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AuditInformationAbstract" xlink:href="lly-20211231.xsd#lly_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AuditInformationAbstract" xlink:to="lab_lly_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_Expirationwithin5yearsMember_44f66995-c685-45ae-b020-c37d3ec0b730_terseLabel_en-US" xlink:label="lab_lly_Expirationwithin5yearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration within 5 years</link:label>
    <link:label id="lab_lly_Expirationwithin5yearsMember_label_en-US" xlink:label="lab_lly_Expirationwithin5yearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration within 5 years [Member]</link:label>
    <link:label id="lab_lly_Expirationwithin5yearsMember_documentation_en-US" xlink:label="lab_lly_Expirationwithin5yearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration within 5 years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationwithin5yearsMember" xlink:href="lly-20211231.xsd#lly_Expirationwithin5yearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_Expirationwithin5yearsMember" xlink:to="lab_lly_Expirationwithin5yearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_222e5f02-254f-4667-9ecb-acaab5384966_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac6e9a24-6f65-4977-b4e9-c3cdf9fb12f4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_83d698a7-1123-48c2-8686-8d742ad55ee5_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a33745a4-caf7-43f0-8d3c-aec69d863229_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_07fbb652-c2f0-4a0e-8f1f-2320fafe0549_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_0807c06c-1c47-4173-a7b2-4a3e4a15c22d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A5000NotesDue2033Member_4445f7db-bb41-4b6e-a300-8008f2751f7a_terseLabel_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_671d905b-ad33-4726-98ec-ab0d8c0d0016_verboseLabel_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro denominated notes due 2033</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_label_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.5000% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.5000% Notes Due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A5000NotesDue2033Member" xlink:to="lab_lly_A5000NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a165eafc-530e-4068-a3e6-2313f115a9e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_112af69d-0d2c-4018-8c00-81f3b4d086d6_verboseLabel_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_label_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES And PUERTO RICO [Member]</link:label>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_documentation_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES And PUERTO RICO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember" xlink:href="lly-20211231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_UNITEDSTATESAndPUERTORICOMember" xlink:to="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_961a1053-0ff5-4e68-8da5-23b6781b7e02_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c89e718e-1e6d-4594-aa72-f7327599c115_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_068c45fb-24c1-45bd-bf42-50864f0b2303_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20211231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_5e1c1538-2003-41ac-b44a-ce352936d13c_terseLabel_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_98eb5be9-db92-48e6-955a-d14c2b04eed9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_017f1e72-f6b0-4450-8b31-c2242d66309b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_56a1e4e4-3a93-4f36-af38-b0bebdf4b1ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_5e6a17de-5778-4cbc-afda-05f1edb25de4_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_43f5c397-7984-4bd5-9393-51c4e795d688_verboseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% euro denominated notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_ab876b30-5b6f-467f-a3c2-1a7faa754f39_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20211231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_c9163b22-f0a9-4292-98b1-6d4d147aa2b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_7405db45-23e9-405a-b9ea-8464563bc16c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_4e2b6de7-69ea-4195-9abd-e1743f460077_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8de788b4-65a0-4f4a-a063-a149668b49eb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ActosMember_13abd7e0-76e8-4de1-9e0d-58d0bc00d044_terseLabel_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:label id="lab_lly_ActosMember_label_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos [Member]</link:label>
    <link:label id="lab_lly_ActosMember_documentation_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember" xlink:href="lly-20211231.xsd#lly_ActosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ActosMember" xlink:to="lab_lly_ActosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_cea2218c-00e2-4e80-9d0f-5a0d07064ea5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D charges</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_f88c1d5b-7d3d-4d01-9aae-0504095f6a79_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationDomain_a689086d-430f-4c7d-b7f4-53ec26bd69ef_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_label_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationDomain" xlink:to="lab_lly_DomicileOfLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_fd75a55d-f3e3-4fd7-838a-a323ae6a8414_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9bff6e32-b7e5-4d46-afed-b0e801fb0d77_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_85f31b32-5d23-4b01-84be-3a427fb88658_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_70e1e5e6-76be-4c7b-a6a4-0516985fcd6e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_ae2b88a9-7ad0-4176-9774-7d88c513644e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_62877bb0-1c76-4dd3-bbe3-da30e25a602b_terseLabel_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transitional services agreement, term</link:label>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_label_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term</link:label>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_documentation_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:href="lly-20211231.xsd#lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:to="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2f35248b-900a-4404-8ec2-3e238c655482_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net (Note 9)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_86be120f-8ccf-47dc-9252-0dc2faa6a7e0_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_bb12820c-694e-4f33-8836-27a50789b05d_terseLabel_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% euro denominated notes due 2022</link:label>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_label_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.0% Euro-denominated Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.0% Euro-denominated Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member" xlink:href="lly-20211231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A10EuroDenominatedNotesDue2022Member" xlink:to="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_add29d18-69f8-4ceb-ab11-024d02dac8f9_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1b59073b-7eea-414f-abf0-1dbb0f433833_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_2cec7e38-9243-4f4e-bf9c-b54bcccba435_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_476e63f2-002a-462e-8b33-40adcca7f33f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_bc08112d-cfd7-4dde-915f-ec4e12a54fcd_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites jointly and severally liable for cleanup (fewer than)</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:to="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_40a79065-04cb-491e-ac9f-202b1359e8b1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_7d42c356-e744-486b-b957-ed24d1867640_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, average inventory level (or less)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Average Inventory Level</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Average Inventory Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e0730f60-e823-4ae2-ae98-64a70c8e2f72_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_5546309a-bc10-4e7b-a40c-0696860fe25c_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20211231.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_414c54f2-5f5b-4236-9bf9-6a298c45f692_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e320adb5-65fa-44e9-b988-38e3eafcdbc2_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Note 2)</link:label>
    <link:label id="lab_us-gaap_Revenues_69b46c51-1751-4baf-b688-c866b630b37e_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d8d5d33d-1f14-41a5-9023-674cb9b6687d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_01aa2877-8121-436d-8780-7a715cd3e671_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20211231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_b864c8da-f7ab-460c-9661-f314000220e4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_80972bd0-98b4-4b9d-960a-2338145dc2b2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3a52f14a-ef8a-4d2f-89fa-f6acaae13835_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from discontinued operations - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_14884089-a695-414d-9edf-7da3dd4bb664_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20211231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_fff8ca4d-5d3b-4f18-9cdc-59c74cf9664f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CentrexionTherapeuticsCorporationMember_bb06b18b-0efb-4ee0-a27f-218d7259c82e_terseLabel_en-US" xlink:label="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centrexion Therapeutics Corporation</link:label>
    <link:label id="lab_lly_CentrexionTherapeuticsCorporationMember_label_en-US" xlink:label="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centrexion Therapeutics Corporation [Member]</link:label>
    <link:label id="lab_lly_CentrexionTherapeuticsCorporationMember_documentation_en-US" xlink:label="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centrexion Therapeutics Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CentrexionTherapeuticsCorporationMember" xlink:href="lly-20211231.xsd#lly_CentrexionTherapeuticsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CentrexionTherapeuticsCorporationMember" xlink:to="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_7eaf819a-fa9b-4175-a383-165aad845bde_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_ec3c396f-ac30-4b43-80e6-95877ad5c694_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20211231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_c680757e-27d8-4cee-a8f4-51e100dd2309_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0bf9bd8c-52cb-4c21-b5e0-aec9df85e5dd_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_a172b409-4d39-49e6-ae68-5533a946f85d_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20211231.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8bb32832-5fbd-4764-90d6-353534b70e49_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_091c6f83-128d-4fbd-aad1-8ccbf621d1df_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e80f6d71-0109-4cd4-8644-820c6c16c214_netLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_89b93083-f774-48b0-a917-241006765852_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20211231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_60f9b0c9-10c0-4e1f-99ae-71bbac816d6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_c6e27f4e-01b4-4917-a400-4dfe65e12c5f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future employer contributions, next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_746ca983-7696-408b-912e-e7d9b12dac4f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt (Note 11)</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_f405eff7-2933-46a2-b8ff-266eb101bdf1_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_de509cdd-4588-4658-9a47-19de36e258fa_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_b4468c45-bc76-4ad7-8e52-690f1dc2a50f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_1a6514bd-8f19-4de7-aee0-98dc80598757_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_379e4470-6f53-4d33-bb5a-8bff687b0ce4_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_776ab9b5-de14-4942-ae8b-2d8527bd7ad2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e7892fef-1dc7-4760-8e0d-3c867300ed1a_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_d29ee8ce-b821-421a-9d2c-a7170020dc36_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable (Note 14)</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_03fcff13-141b-4c78-8fa2-9f300d107ca1_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_90c8c25b-5c23-44f4-9793-0e375550f14a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_5c9057ba-e8a3-4e69-8c1e-acf39748d7f5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7defdf58-1c89-40b7-a54a-453c5307af4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_37901c71-9370-4e08-b370-82c6ba937ddd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8e687ec9-4f81-4109-a5d0-6e8042f258e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acd1d504-6fe8-446c-8830-ef6b5a51c5bc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_979475ec-fccb-4bb7-b866-abd776d3ad26_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_a5d1186a-22e3-400f-af94-9afdfdb4a195_verboseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro denominated notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7a41b9d4-dbba-438b-9a87-4b9850d63aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c4a26c2d-5617-43c0-834b-16db4f96ac24_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_4ac4b276-75a2-41ad-a978-21bcd403a64a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3375NotesDue2029Member_9f60c792-3b16-4565-bbf7-9e19329dcbda_terseLabel_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% notes due 2029</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_label_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member" xlink:href="lly-20211231.xsd#lly_A3375NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3375NotesDue2029Member" xlink:to="lab_lly_A3375NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_f1464913-8824-49e6-9735-511161493c49_terseLabel_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense, percentage of revenue</link:label>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_label_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense, Percentage Of Revenue</link:label>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_documentation_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense, Percentage Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue" xlink:href="lly-20211231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AdvertisingExpensePercentageOfRevenue" xlink:to="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c88e9a47-aa22-4601-8134-521cda111f41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_246e3679-5744-4439-896d-ffc375637f3d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_321b28a1-c0e8-4ae6-badc-045f99ae759d_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a512e609-adaa-489e-ab55-b2086738a8a0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4fe08f2b-a413-4d8e-8578-776d03be4662_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1afd476-9f2a-4c21-aa5b-27e8c8c4214e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_892cc358-9b88-4b6b-b833-634801082012_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_556a40e2-3b99-43d2-8688-89c2b2cb4793_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bed8b7c1-43df-4398-ba76-ab67b516f781_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2653e2a5-16f9-4ac1-9bc9-117a33c28a8f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f6f716f8-9048-4afc-aabb-c445cdf469f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_2839fcc2-d26f-459a-81f8-f878b3182bde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_e9d31bc6-e728-4e87-bc90-adcc634dcdf6_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20211231.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d7071bf6-8330-4a40-9860-a05ae7ed38cb_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_c321ecbe-f9fc-4bf5-b2e3-dc341102d64b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_db51f492-ed72-4f74-a875-79bc3001a5ac_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_af206d9a-12f5-442b-bc50-f68375b60f2b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_23cfdef2-0317-410e-90d9-822fe8630412_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20211231.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_7569f1a1-2e13-41cf-9bf9-b898efa267a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e384ec0d-014f-4bda-96dd-05a9d9d4dbbd_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_68cbe4bb-75fa-48ec-996f-66537b181a08_terseLabel_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares expected to be issued (in shares)</link:label>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_label_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued</link:label>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_documentation_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares expected to be issued in the next twelve months under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:href="lly-20211231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:to="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_baaf15c8-663e-4e05-b08d-611b226d26ab_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell USD</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20211231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_407bd28d-7a2f-49f9-b77a-872447d38456_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_960744aa-dbdc-48d8-92ff-1d8a863dc660_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_07b38051-d531-4d9c-9d26-feed00945c4b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e4b2ef9f-030b-4231-a52d-69e96882bca1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of New Financial Accounting Standard</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_9c4329e7-44f7-4039-9a74-67a49c3fe365_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c815820b-fbbc-4eff-8cd8-056e9f5a049e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e01b2cf3-e826-4930-a475-1de63fbd046a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_10d06731-4be4-4e19-9839-2897ef2e9d7c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_04fa36f2-20b8-4016-8a62-29b24f2fa3f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a2210f18-c6e0-4daa-ade1-088c37cd1ca0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3f91561c-b06a-4b09-80ae-124931336f76_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer_a094fb40-15a1-4270-a584-14f7300039f3_terseLabel_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of common stock in exchange offer (in shares)</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer_label_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Shares, Exchange Offer</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer_documentation_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Shares, Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:href="lly-20211231.xsd#lly_StockAcquiredDuringPeriodSharesExchangeOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:to="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5e7f1c25-4eff-45ee-bfed-4a6c52d4b372_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_68b88cc6-c9b8-41b6-81a5-c857cf93754f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 8)</link:label>
    <link:label id="lab_us-gaap_Goodwill_cd2c797c-39d3-49ae-94cd-9686b4e1bae8_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_aa23857a-8fe7-4b9b-b4dd-98554007a998_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_194fbff8-233f-4dff-8fe4-83fc03c2542e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_09b9cce6-a49a-45cd-b313-984f58d544c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Valued at Net Asset Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_a0e390bb-1c00-4ce1-8d97-1cfd2fd65416_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:to="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_39788ec6-76ef-49bc-bacb-4be4204497f6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_44b71adf-aa5d-4ca5-a02c-8c57a913aed9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_468fc570-9cb0-4e7c-8eb9-7817f9f0339a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2df7b01b-dbea-480f-aa01-3b8ad19e6e8a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_151415a5-fa82-4da4-a1f6-c66e00c5d27a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_188bee45-8a20-4c26-91d6-8f5ed9888d10_terseLabel_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of derivative activity volume percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_label_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_documentation_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:href="lly-20211231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:to="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_05f58ccb-5fdc-45d0-abd0-495836065922_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_3853299d-c584-4aec-a19d-3f634e111ab8_terseLabel_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc.</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_label_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_documentation_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member" xlink:href="lly-20211231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AbCelleraBiologicsInc.Member" xlink:to="lab_lly_AbCelleraBiologicsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ZyprexaMember_10ad0440-6cbc-41b5-862c-199b26ceb818_terseLabel_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa&#174;</link:label>
    <link:label id="lab_lly_ZyprexaMember_label_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:label id="lab_lly_ZyprexaMember_documentation_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember" xlink:href="lly-20211231.xsd#lly_ZyprexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ZyprexaMember" xlink:to="lab_lly_ZyprexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_64a1c219-110a-4ccb-a5a4-a5bae7cd6702_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab451ec4-ebe3-4de1-b978-d9ba6e48bd40_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f0aec355-8e8e-41c8-9e46-a0f7f67f0cb3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_bae6e706-9928-4b58-b65f-372f65da4904_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_fc7ca21c-785f-4278-9112-31fd39f86489_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_02919d24-6364-4427-b705-a1ba57766577_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4246fe4a-2697-41b9-b06c-88bc30564ff0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share (EPS)</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ffd89df-574f-4eb7-8032-e659c9233bf5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_68b67331-1f81-40af-a7cd-2f1601db1fd5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d91d4659-ab30-4ae8-8dd0-d5bf8790bbcb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_fac890ee-5461-45b1-8c4d-fbb18d870767_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_0b81614a-aceb-4a39-bad7-8544c3b6e3d8_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member" xlink:href="lly-20211231.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member" xlink:to="lab_lly_A1.000NotesDueJune22022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6ad65b07-7814-45ea-a46e-c1b35ac792a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss and other tax carryforwards and carrybacks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_678b2aab-bd4c-47f2-bf92-e5186730cbb8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_50916123-be28-441f-a8ea-5e4f00c9296d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_95e3cfc3-b0ca-49f9-a5c9-b5e94a0a6d13_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2cd8d032-2687-4ddb-8615-2e55119e1b3b_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_71e2bfd6-0682-4a1e-837e-b05ee3ea0a4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e2c77990-39e0-4c4c-82d7-5af98dddb815_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_78a8e90f-150c-47a4-9d07-d9c97abfdccc_terseLabel_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss franc denominated notes due 2028</link:label>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_label_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc Denominated Notes Due 2028 [Member]</link:label>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_documentation_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc Denominated Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:href="lly-20211231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:to="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9ea6096c-00e2-4497-a83c-1e9dce14fc87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_d81de70e-0a68-4203-a6b2-67488a942edd_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_da784634-df25-4c45-9ab7-809f1826247c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held in employee trust (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9540a2d8-f729-4458-9690-ddebd8cd96cf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_c3480284-3cfb-4963-b33d-57138e7e9802_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash distributed to Elanco upon disposition</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_fe0971de-c709-4a13-964a-8aa4a5a610e2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b6036df4-1dac-4c8b-a18c-f0ca0b6c91dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A555NotesDue2037Member_570cda18-f6bc-437d-acaf-c8b295e21d01_terseLabel_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% notes due 2037</link:label>
    <link:label id="lab_lly_A555NotesDue2037Member_label_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% Notes Due 2037 [Member]</link:label>
    <link:label id="lab_lly_A555NotesDue2037Member_documentation_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% Notes Due 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member" xlink:href="lly-20211231.xsd#lly_A555NotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A555NotesDue2037Member" xlink:to="lab_lly_A555NotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_d6969b51-4a34-4691-bf1b-bd31d1ea0255_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_19ab2663-ff53-4aeb-8282-1c16aea534a7_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fc762db6-ef33-4255-a0d6-c0cac03d6c98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_679d004b-7f17-4e72-b457-d8e7014fe459_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_cd0c3730-545f-48bd-afa6-bec5459c4ce6_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5f8ef2a7-3b43-4ce2-aa70-778d75356b83_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_c8d53a02-21d3-403d-acb3-766028926e8a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Health Coverage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:to="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_00b81f48-0ed9-46aa-9eb4-da308ec1bf55_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20211231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_eef9019f-839e-406f-ac41-1e358719a4e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_707f3a05-cbd3-4679-82ab-c985ad943beb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fb01e7b7-40fc-40e7-9895-74e9fae46082_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7a794ea2-e53f-43a5-ab16-31936f2334f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_eb1ac405-b112-4302-b3e9-65c26926b7a9_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payments Received</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d095b5-74d6-4216-a34f-7e8395d0d7d1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_c972064b-de69-4ce5-92f7-c30e33ee7eda_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_173f60d4-da3b-43a3-b3b9-9114b0a1828f_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A677NotesDue2036Member_e49252c9-9174-4fd1-a87d-4e3e6d323b5d_terseLabel_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% notes due 2036</link:label>
    <link:label id="lab_lly_A677NotesDue2036Member_label_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes Due 2036 [Member]</link:label>
    <link:label id="lab_lly_A677NotesDue2036Member_documentation_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes Due 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member" xlink:href="lly-20211231.xsd#lly_A677NotesDue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A677NotesDue2036Member" xlink:to="lab_lly_A677NotesDue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81893058-8f8d-4c03-8130-8002825a93a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_4a417a17-39ab-4ee9-96d7-47210dccb04a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6d604ca6-0a5b-42cd-bc9f-41600eeef40e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_e1a9dd23-2f7c-418a-9577-7afe60df9059_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 15)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_d48d30eb-7ee8-4333-ad1d-bd0134cc3e08_negatedNetLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_616dc03b-402e-46da-a377-18b9cd359d48_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsdSellEuroMember_89125114-96d7-493b-bc04-297669ee70ea_terseLabel_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember" xlink:href="lly-20211231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsdSellEuroMember" xlink:to="lab_lly_BuyUsdSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MerusNVMember_ddc56eee-c812-467c-8401-5fc27831c779_terseLabel_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:label id="lab_lly_MerusNVMember_label_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V. [Member]</link:label>
    <link:label id="lab_lly_MerusNVMember_documentation_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember" xlink:href="lly-20211231.xsd#lly_MerusNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MerusNVMember" xlink:to="lab_lly_MerusNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_facc7755-18b0-4b7e-a1a6-02c25949e0d6_terseLabel_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment (gain) and other special charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_label_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_documentation_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:href="lly-20211231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:to="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_936a1c0a-b2ec-4af4-9faf-137984eb48e4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_cf10a9cb-70fc-4955-ae19-96102d2c0614_terseLabel_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of California</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_label_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California [Member]</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_documentation_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:href="lly-20211231.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:to="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_efbf95d9-13ce-42aa-9c28-9dda1d30c595_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4eae962e-fec0-42fe-81db-aa1e6f858823_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e7f8ed5b-bb4b-4a26-a29a-07345a3db1dd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fdecc3af-76f7-437d-a0e0-92897397e59b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6c35ed8b-4348-4d23-8696-a41557ecef30_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_020396cc-07fc-4e48-abcb-ac87d3d24593_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Sales Rebates And Discounts</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Sales Rebates And Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:to="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1ca23686-c932-47a2-bbc5-3372a44f38c5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_938ac127-647c-4e03-af66-b9fc1ca01915_terseLabel_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, lease, remaining lease term (up to)</link:label>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Remaining Lease Term</link:label>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LesseeLeaseRemainingLeaseTerm" xlink:href="lly-20211231.xsd#lly_LesseeLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LesseeLeaseRemainingLeaseTerm" xlink:to="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_33594fef-3f6b-4375-9e1e-cf5cdd857d15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_be15d4e2-cbd6-4801-a462-1c390d0b3929_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_b76cf80e-97d8-459f-aae4-ac1f5d7f66a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b05cb77f-dd80-4b64-9b09-2ff82e7b4eea_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2019Member_2c2172da-fa32-4ae9-8c1b-191d2e4cf67f_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019</link:label>
    <link:label id="lab_lly_MaturityDate2019Member_label_en-US" xlink:label="lab_lly_MaturityDate2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2019Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2019Member" xlink:href="lly-20211231.xsd#lly_MaturityDate2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2019Member" xlink:to="lab_lly_MaturityDate2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_86564221-d961-4313-8ef6-80e381f5e7ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e17693f3-12f2-4750-afce-109cc93557b7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_b9264a43-95e7-4208-9c1c-504174574170_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsAxis" xlink:to="lab_lly_PlaintiffAllegationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A31NotesDue2027Member_7b85f472-1a1a-40b3-b21e-6cc362a49ace_terseLabel_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% notes due 2027</link:label>
    <link:label id="lab_lly_A31NotesDue2027Member_label_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_lly_A31NotesDue2027Member_documentation_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member" xlink:href="lly-20211231.xsd#lly_A31NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A31NotesDue2027Member" xlink:to="lab_lly_A31NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f2e4aae6-fe01-455d-9d92-6504bb6eb3f0_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b8ff2a3c-97bd-4991-917f-1642c7e036ec_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_1a735d41-2513-452e-9817-acf415c1b948_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20211231.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b8f2bc7-794a-4b8a-a247-f1a617cbb8f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_529518ec-50c8-4a08-a418-be924f3db459_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1f59b7ed-7635-4d97-8408-b1e6e2e7e9ef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets, target allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_82404151-76d9-4631-9e23-62aac22a1b47_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_44d0bcb4-c637-4140-b663-bd079d35c97a_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfClaimants" xlink:to="lab_lly_LossContingencyNumberOfClaimants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_9ac1bdd2-1e37-48d3-a530-7195b5a35837_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses expected to be reclassified in the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_e96b25ea-1e51-4837-b9f4-5653bc38c630_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_22e51f36-25aa-46fc-9c5b-497ffea01e04_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_e2b704a2-8273-4a4a-875a-3448124665c2_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to disposition of Elanco (Note 19)</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_76a71434-a871-496f-88a5-00ac44e46e63_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to disposition</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_96c6c83a-d86d-4607-b267-88b995e47b80_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a1b4a0d5-b20d-441c-9445-d74160cb2d8c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FochonPharmaceuticalsLtdMember_56ea8321-ede3-40aa-bd83-f3206a97162b_terseLabel_en-US" xlink:label="lab_lly_FochonPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fochon Pharmaceuticals, Ltd.</link:label>
    <link:label id="lab_lly_FochonPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_lly_FochonPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fochon Pharmaceuticals, Ltd. [Member]</link:label>
    <link:label id="lab_lly_FochonPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_lly_FochonPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fochon Pharmaceuticals, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FochonPharmaceuticalsLtdMember" xlink:href="lly-20211231.xsd#lly_FochonPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FochonPharmaceuticalsLtdMember" xlink:to="lab_lly_FochonPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_20cbe3be-7db3-447d-b3c9-e8e2226806eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A25NotesDue2060Member_ff3f189f-57d8-4006-8a5a-63251912ffa6_terseLabel_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% notes due 2060</link:label>
    <link:label id="lab_lly_A25NotesDue2060Member_label_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Notes Due 2060 [Member]</link:label>
    <link:label id="lab_lly_A25NotesDue2060Member_documentation_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Notes Due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member" xlink:href="lly-20211231.xsd#lly_A25NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A25NotesDue2060Member" xlink:to="lab_lly_A25NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_20cd83d9-a49a-45b6-8e75-6a03d2e69748_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales rebate payment period (up to)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Rebate Payment Period</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Rebate Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:to="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7eba9057-86f4-4f3d-a380-47f435a79e7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d1129b8d-6484-4822-9f99-fbf9a71fcf31_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_06990245-8a46-4e88-8361-205cfc62adc3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a6a1dbf4-8c6b-4551-883a-edab453ffed2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6a5e492f-7333-449e-ad33-5cd7688602ee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_2211c559-8cab-4d2d-ad42-f48e81cb09bf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense under the plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_314bc8f8-4458-4ec9-85ba-e30b62d7b7f2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_95d43572-393a-4904-a431-99043c1c1b46_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f5436cac-4962-4896-b5f2-c427f55e047d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards and carrybacks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_4ce5d2a4-7bcc-4e68-87b7-a690255e5fae_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:href="lly-20211231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ec120d28-fa5e-4711-9d0f-ef3c5478de9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_365aa6e8-8b27-449d-b472-99c65dafa517_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_f5b61190-8db8-4f6b-ac54-c933945e82d3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_962c3406-0741-4794-bd9a-e8a8a761cbad_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_57e0999f-d4d0-47b6-8da2-d5a1215663e3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_973f8cc3-fa28-45a0-b28e-ec462dae11c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term notes, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_7c277a6f-9e0b-4f48-8973-9d2b1f6f52e2_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5a5c01ae-b49b-4826-b214-67c80c8a2475_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from continuing operations - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00ee40e3-a932-4dce-9033-7f3eeae0acfe_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_cc525286-0672-4447-ad57-405b4732b59c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c3959abb-b37d-4cfe-a0c2-14bd9634b755_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_b72230a2-d9b0-4b78-b4cc-dbc70268808d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from discontinued operations - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_de6d64d0-0171-4aef-92db-dc212e9a8fd1_terseLabel_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used</link:label>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</link:label>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_documentation_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:href="lly-20211231.xsd#lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:to="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a33e9379-c1af-4ee3-96e1-c2502ac3db1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_b7d0f463-5ed1-49f9-b96c-62a4ffb4310c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains (losses) on securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EddingpharmMember_8245efc0-ac87-4d80-8f45-297e6575a40b_terseLabel_en-US" xlink:label="lab_lly_EddingpharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eddingpharm</link:label>
    <link:label id="lab_lly_EddingpharmMember_label_en-US" xlink:label="lab_lly_EddingpharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eddingpharm [Member]</link:label>
    <link:label id="lab_lly_EddingpharmMember_documentation_en-US" xlink:label="lab_lly_EddingpharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eddingpharm [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EddingpharmMember" xlink:href="lly-20211231.xsd#lly_EddingpharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EddingpharmMember" xlink:to="lab_lly_EddingpharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_ca7cb731-4996-4391-b9b4-efc1b0666c86_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_baf3d61d-0845-4672-8e6a-8ddd1ea65825_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_6105f726-0673-43ca-badb-9310a52c65ce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_8d2cd540-470a-44d7-98db-80e39574586e_terseLabel_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales</link:label>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_label_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales [Member]</link:label>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_documentation_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember" xlink:href="lly-20211231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ThreeLargestWholesalesMember" xlink:to="lab_lly_ThreeLargestWholesalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8262235d-2754-40e8-9a9c-59710e0e0c16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a5b69c4b-c012-4b9a-a2e2-f4c21f53cc7b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_17c8a82c-9c5f-47b7-8f88-457e77f4df9c_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_a0cd1f1e-8e36-44c3-9f67-b845c4ad8dfc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_780f13d5-6c10-4380-96eb-1df7b27cbd44_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_91d4b985-2a01-4ca7-8b8e-ce9877f5cdd5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1fa6360-dc81-4204-a31f-6afac3fec9d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c5c101e0-6099-4d42-9994-7ba4fca303ac_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e16588cd-b33e-4cca-8bfd-4d5950f214a9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_23c1d051-c0a3-4ae5-b756-6cae27d607c3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_774ffdac-c2a8-4750-883f-29086b0b11bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_45ac3a32-20ff-4bb4-9338-a624c66f5a91_terseLabel_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_label_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Investments [Member]</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_documentation_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:href="lly-20211231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:to="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_5c5b9c40-ad0c-4694-911e-41a1d0d134a7_terseLabel_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_label_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al. [Member]</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_documentation_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:href="lly-20211231.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:to="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_fa4bfdde-d558-45c2-a1f8-34f01b269543_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8d9e0f1d-f4e4-44fd-b896-fd190bdc5923_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_05befdbe-ff46-465f-bbbc-dfee700d2bd3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f9b841ce-69f0-438b-8d2f-f65886c9fab8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired (Note 3)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5c3d80bc-583e-4b7b-920d-e47b2f39be9e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_51a1037d-bf97-4792-9477-e54574739c60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_18797bfd-47a5-4aae-b836-5b37abc72275_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in the consolidated balance sheet consisted&#160;of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_64c346e0-b610-47fe-afa1-d1f069385aea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3d401005-7034-49e3-a57f-0aa9145e837d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2b60b50f-fe8b-4f4c-9cc1-b8f6479b0465_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_f8d905d5-df3f-4b21-8490-eca65b31ac98_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_cd6780fa-a3e6-42c1-a989-2ffc03ff6d00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ee97d5aa-6ea5-493e-b2fe-3763e67e372b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_deda5f5c-46c2-44e8-b4c7-0a87c4a204a8_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8212;net, (income) expense (Note 18)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9b804691-8ae9-4a3d-98e6-5cfe3a5927e3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_d14c0ca9-7175-4103-a9ae-bd656caa4616_verboseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20211231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6f29d906-5f49-434f-9971-82201f2731c8_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d1c9bece-4a4c-4086-b421-c9dc209ad6ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_689fec61-2436-4357-9b37-0491fc56f78f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities on long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b057006-1eac-4dfb-b1f1-359b7de8f58d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 17)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8e3a6daa-6fdd-44a4-9a6f-1e4aaf051a50_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a94e261d-175f-4dcb-9028-0e5d64f02f6e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_311b295b-0f18-4bd3-838d-102b14a7b554_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_49b09eaf-ce66-44ac-92ba-97841aa5c2e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_ebd67f9f-1928-416e-9886-285b48894ae9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable (Note 14)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_bf759f85-24f9-4017-804e-926a9c591061_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_d9445d57-55ca-4a71-a03e-96a7a28a46a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_325e60b4-2b60-4ae0-995d-f309a7d0d1dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_da45730d-b511-4af3-bf98-e7b71ffccc08_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_041be320-12ac-45bb-a30f-527be6cc0614_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_1fad181e-9d03-40db-a269-1dc381eded69_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Income Tax Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Income Tax Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:href="lly-20211231.xsd#lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A275NotesDue2025Member_11bba33c-5756-48cf-827d-ede33c1d39b5_terseLabel_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2025</link:label>
    <link:label id="lab_lly_A275NotesDue2025Member_label_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_lly_A275NotesDue2025Member_documentation_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member" xlink:href="lly-20211231.xsd#lly_A275NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A275NotesDue2025Member" xlink:to="lab_lly_A275NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_4d2c6203-2328-4371-88dd-0d65f605fcab_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_65e9bc73-0989-4686-a86f-daf87eb224f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_95e025ff-742a-43a6-ae2c-696e86ea56d3_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_47c1e519-ccf4-4372-9649-99f76a146c69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AddDeductAbstract_33096c7f-c5a6-442f-8c28-c60ff80bb415_terseLabel_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (deduct):</link:label>
    <link:label id="lab_lly_AddDeductAbstract_label_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (Deduct) [Abstract]</link:label>
    <link:label id="lab_lly_AddDeductAbstract_documentation_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (Deduct) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AddDeductAbstract" xlink:href="lly-20211231.xsd#lly_AddDeductAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AddDeductAbstract" xlink:to="lab_lly_AddDeductAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_510bab0b-cfb6-485c-9310-257708bb5621_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase for benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_November2019YenDenominatedNotesMember_f3f070e0-06c4-4876-a07f-391380b01c29_terseLabel_en-US" xlink:label="lab_lly_November2019YenDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Yen-denominated Notes</link:label>
    <link:label id="lab_lly_November2019YenDenominatedNotesMember_label_en-US" xlink:label="lab_lly_November2019YenDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Yen-denominated Notes [Member]</link:label>
    <link:label id="lab_lly_November2019YenDenominatedNotesMember_documentation_en-US" xlink:label="lab_lly_November2019YenDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Yen-denominated Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019YenDenominatedNotesMember" xlink:href="lly-20211231.xsd#lly_November2019YenDenominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_November2019YenDenominatedNotesMember" xlink:to="lab_lly_November2019YenDenominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_9ce6c3e6-da32-48b1-9fb8-446ade8b93f0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_ab68e32d-129c-48dd-9a79-817d345a750b_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to USD</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20211231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_83942a98-85b3-4ece-9ead-ccadb5176be4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_f9edab0b-c918-4b2e-bf91-aafab713e6c6_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20211231.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_97ba4590-56db-402f-92ca-38a1fa256697_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_44e7a938-c84d-4c13-b14c-f05739ded2db_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e61b6b13-90be-4cb3-9220-5ea0b206decb_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6d324645-f82b-4863-b94e-8383e1e85896_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_91fab40f-7a11-4aa9-8a93-6573c92cb259_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_Expirationin6YearsMember_1cc2cea2-bd3f-4cf3-9c9d-94a8e0476446_terseLabel_en-US" xlink:label="lab_lly_Expirationin6YearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 6 Years</link:label>
    <link:label id="lab_lly_Expirationin6YearsMember_label_en-US" xlink:label="lab_lly_Expirationin6YearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 6 Years [Member]</link:label>
    <link:label id="lab_lly_Expirationin6YearsMember_documentation_en-US" xlink:label="lab_lly_Expirationin6YearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 6 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationin6YearsMember" xlink:href="lly-20211231.xsd#lly_Expirationin6YearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_Expirationin6YearsMember" xlink:to="lab_lly_Expirationin6YearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_4c0ebf7e-4ba9-4c29-9b4e-4e4259de4fdd_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20211231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1f7d1a12-46cb-470e-b802-b60ced96d872_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b527e462-93c4-43f6-88e9-8dc67ef3e89d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2bc8a112-6eda-4fa4-a497-36173ed4d2a5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_33e619fe-866d-48e2-8594-56f2ec284656_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_1f521ff5-da5e-4080-8631-d3048d1755bd_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_36388a0b-8510-4756-9cc7-f9eecc74057a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e5f5b285-d78a-47c3-aea4-6b58d5c0c957_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 7)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0986954f-d655-4cc2-937c-cf82dd640171_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationAxis_6862d087-3ded-4897-9971-902b6cdaf5eb_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_label_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationAxis" xlink:to="lab_lly_DomicileOfLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_16e8e0c7-9074-467d-8d0e-a17d5853539e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_e01518f9-12c0-45ca-ac93-8d41b41192c3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_c03ccae9-27bc-481f-aff4-9a5a2f5839f0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29e492f6-48fa-4551-9a36-e974b96bd8b0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_786d80fe-38f5-429b-82e3-54f261adc5d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_bac8bb5a-49e3-4d28-9a68-ac0ef471f7c6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_QILURegorTherapeuticsIncMember_e0fcbff7-df67-485b-bd19-10b8cf78822c_terseLabel_en-US" xlink:label="lab_lly_QILURegorTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QILU Regor Therapeutics Inc.</link:label>
    <link:label id="lab_lly_QILURegorTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_QILURegorTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QILU Regor Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_QILURegorTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_QILURegorTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QILU Regor Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_QILURegorTherapeuticsIncMember" xlink:href="lly-20211231.xsd#lly_QILURegorTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_QILURegorTherapeuticsIncMember" xlink:to="lab_lly_QILURegorTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_b7c2193a-8edc-48b5-b217-9d2b98ded979_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_743c9292-173b-43b1-8efb-4e804be32ff7_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_ef1fd5a6-88ca-441b-b459-92a99a41f335_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0fbb94d4-cbd8-435f-b306-7da0dc2fb09a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_698b0336-4a24-47e1-bd12-51d6c20c9b34_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated benefit obligation for our defined benefit pension plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_09c283e8-ff14-4c24-bcec-d98fa3ca6e3f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_40b2df5a-aaa7-4f81-b15d-9a199eae9cb5_terseLabel_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_label_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Claims Dismissed, Number</link:label>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_documentation_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber" xlink:href="lly-20211231.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LitigationClaimsDismissedNumber" xlink:to="lab_lly_LitigationClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_44e63cfe-68c9-4188-91b4-212c448375a3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_2a58c765-cc30-46fd-9048-abf106009812_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b59b3ba2-6044-4801-bd45-b76df325d6cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1fd52e39-6022-4e16-bb3a-c7f6f3224ca2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e612f922-93cd-425c-bd0c-13f8fda8e6a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_aceeaab2-00de-4773-bbad-7e8bf4b149da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6204f661-d8d0-4838-bca7-52504f68cdf1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_d279d7d7-c62b-47c1-a965-90231de3f8b6_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20211231.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a38b581c-3c8a-4aaf-bcf3-6b70be0d75cf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (income) loss before income taxes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A465NotesDue2044Member_500ac219-0bfc-42aa-9283-604f15db3327_terseLabel_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% notes due 2044</link:label>
    <link:label id="lab_lly_A465NotesDue2044Member_label_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% Notes Due 2044 [Member]</link:label>
    <link:label id="lab_lly_A465NotesDue2044Member_documentation_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% Notes Due 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member" xlink:href="lly-20211231.xsd#lly_A465NotesDue2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A465NotesDue2044Member" xlink:to="lab_lly_A465NotesDue2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_626df29b-5348-4a90-a50a-eb5d1cf07a94_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in defined benefit pension and retiree health benefit plans (Note 15)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_117018e0-5389-4cda-82de-b2f5f541723d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss) during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_146a92bb-dd5c-4b17-8dda-144b2a59d43c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d252a712-d6cc-4623-9eca-ad0daf47c5e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_918ad8f6-c700-4c14-87ae-62d55b667e59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss (Note 11)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_638a4dcd-7364-4bc0-97fc-e94d55c0b565_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A225NotesDue2050Member_262ede1b-00bb-43cd-9e71-45f85385e73b_terseLabel_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2050</link:label>
    <link:label id="lab_lly_A225NotesDue2050Member_label_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes Due 2050 [Member]</link:label>
    <link:label id="lab_lly_A225NotesDue2050Member_documentation_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member" xlink:href="lly-20211231.xsd#lly_A225NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A225NotesDue2050Member" xlink:to="lab_lly_A225NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_4449610a-5436-48c5-8910-af9c655ec9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d02727cf-25b2-4394-af2f-74e0f9e65edb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_38462887-eff1-4271-b621-1e6ab8e75e0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_3d820e94-6a73-418c-9b82-8e6257c7a8f8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_cc38ba3c-cfe9-4cfa-bdd1-76a4ebb04774_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_81bd0484-fc9b-4047-b3b6-d1710162b055_terseLabel_en-US" xlink:label="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Elanco</link:label>
    <link:label id="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_label_en-US" xlink:label="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on Equity of Sale of Noncontrolling Interest in Subsidiary</link:label>
    <link:label id="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_documentation_en-US" xlink:label="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on Equity of Sale of Noncontrolling Interest in Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:href="lly-20211231.xsd#lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:to="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_24555e08-70a3-4cb0-b52a-bd89a779140b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_fd7c0245-c98c-4b6b-8bb3-7567464a8b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_b3d4de54-3885-439e-890c-e38c5ae95b2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_45f9fa73-a844-4882-a434-296a21c06d72_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d86aa69b-cd0b-4e7e-99c7-7275ae0fb28e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable_a6e15e06-57c9-4e12-84c7-041679963eb5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase and redemption of notes payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6a36487f-2dc5-4e0b-87d2-f41f676bd35a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9993dd39-e32f-41eb-8d1b-70bb95b0d370_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8e860847-3d7b-49a8-a9c4-d2a94aeb057a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_81913696-6466-4e98-b638-1fff95a2ebfe_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition date fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_7c51d288-a034-4a0f-9822-6e03f28f1f8a_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20211231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_b729a46a-538c-43c7-87d5-efde1dbde3e9_terseLabel_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of global investments in plan assets</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_label_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage of Global Investments in Plan Assets</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_documentation_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:href="lly-20211231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:to="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_7e1de8a0-95b1-4bcd-b5f1-a220506ec13b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_877a672d-11a1-410c-9d80-9641ceee3060_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_be936198-b633-4335-aa35-9f255c93f52a_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20211231.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_923767ef-97e6-4ab5-ab53-35fbe14d438d_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20211231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_aafe9686-96b2-4eba-a050-248b146703a4_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_5472f01c-ef8a-4b0a-8291-16a104697d90_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8eaab1d1-80e5-460c-bd69-3464472a7258_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c2ab1ec9-4d57-4cd0-ba66-202de7d9624c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0ad4f268-2d43-4a9f-ad12-164e8976c988_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A17EuroDeonominatedNotesDue2049Member_e749b881-c862-4ce3-b48f-ed741ba30c02_terseLabel_en-US" xlink:label="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% euro denominated notes due 2049</link:label>
    <link:label id="lab_lly_A17EuroDeonominatedNotesDue2049Member_label_en-US" xlink:label="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro-deonominated Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A17EuroDeonominatedNotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro-deonominated Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member" xlink:href="lly-20211231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A17EuroDeonominatedNotesDue2049Member" xlink:to="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_ac523f04-0e4e-43aa-981a-b40b61317712_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_5c523ed2-3412-48c6-bb35-c632a4d78574_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b2ab0e79-d00c-4ab7-9fa8-263c670adc2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_e0ee9ec0-52d8-471a-af33-900960979d23_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial (gain) loss included in net income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_817ac627-1660-49fd-94aa-6b9349c1c80b_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_dd2c1e29-1f87-4d25-bc51-c312b19785a6_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20211231.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_aa1fb2a7-d6da-4a68-b333-89d80ca149a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_80774fbb-513e-421f-8e84-22080be2b0a1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_8957c056-2e80-4c92-aa57-d0ecc1abbe5b_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNotesPayable_a66ce60b-fb73-4118-93dd-13d5f98d5559_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherNotesPayable_label_en-US" xlink:label="lab_us-gaap_OtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNotesPayable" xlink:to="lab_us-gaap_OtherNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c68108e7-3174-41d7-86c7-f3b6e32ccf0c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_348649a4-2292-442d-93de-0e79cf147515_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 7)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_34da60aa-07d9-4adf-86a3-7c5931895291_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bf96ddb7-9575-49e5-a89f-b2d6425e2dd7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4793d86a-85ce-4eb4-bcd4-ce0b25b27dda_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_640fba2b-4968-4ab1-9839-cfa3b6e4892d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PetraPharmaCorporationMember_007fb0f6-b323-479f-8281-2eaf7687535a_terseLabel_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation (Petra)</link:label>
    <link:label id="lab_lly_PetraPharmaCorporationMember_label_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_PetraPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember" xlink:href="lly-20211231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PetraPharmaCorporationMember" xlink:to="lab_lly_PetraPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d881070a-c68c-46ec-b0dc-73e8efc4cf90_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b28c3f2f-2d46-4416-87dd-b04b07ca4995_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3e1d7e7f-d902-402a-a421-d140e54f313b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d4fafb0c-6e0f-4c4a-81d2-301a54a13d42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_9eede272-daf9-458a-b6cf-bc52c2417ee8_terseLabel_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable, estimated timing of future cash outflows not possible</link:label>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_label_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</link:label>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_documentation_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:href="lly-20211231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:to="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5eab9c28-4539-4aad-a59a-52b6362cda28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_afe9be9b-989f-44a0-a546-e617cc61632b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_57414882-ba4d-487d-9ac3-40f77f188c1c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PaymentsForIncomeTaxSettlements_a0f27fe4-4344-4e47-b7d6-6ef8b557ed83_terseLabel_en-US" xlink:label="lab_lly_PaymentsForIncomeTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for income tax settlements</link:label>
    <link:label id="lab_lly_PaymentsForIncomeTaxSettlements_label_en-US" xlink:label="lab_lly_PaymentsForIncomeTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Income Tax Settlements</link:label>
    <link:label id="lab_lly_PaymentsForIncomeTaxSettlements_documentation_en-US" xlink:label="lab_lly_PaymentsForIncomeTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Income Tax Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForIncomeTaxSettlements" xlink:href="lly-20211231.xsd#lly_PaymentsForIncomeTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PaymentsForIncomeTaxSettlements" xlink:to="lab_lly_PaymentsForIncomeTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_cd2a36bf-d68c-4f71-ad48-6b6875a17d58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 6)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_e47c0cc7-080b-4205-ae44-7ae6b6bde031_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_762af202-f58f-4495-8562-a989087dadf6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7164b598-51f5-4619-a6d6-8cdf7fe4cb61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f8bb5fef-cace-4f93-a022-e5434d9f689e_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20211231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_659e4de8-2f74-4190-9f85-17abf8d50287_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2047Member_67663841-24fc-4425-8f20-af9566e11aa7_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% notes due 2047</link:label>
    <link:label id="lab_lly_A395NotesDue2047Member_label_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2047 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2047Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2047</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member" xlink:href="lly-20211231.xsd#lly_A395NotesDue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2047Member" xlink:to="lab_lly_A395NotesDue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_cce624e8-65d3-4806-b802-12cc630d99df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7ef2bfb8-cbe8-4d4e-9ae0-789bba29078e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_10923336-f708-4514-b771-10fe3755ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9c039be6-1bdd-4a1b-a0ea-e8e2eea79f9c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_11ad066d-64e7-4a31-a0f3-f1aefe304efe_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_c0c72ddd-e113-4382-be54-0255d36efc2c_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_54fa5db0-412c-443d-9fb7-aaa4d1b41a4c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-based intangibles</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f6d1ae01-a2bc-4b47-9734-25e954836c22_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_b24e1e1e-45a5-4e41-9c2f-f80752bf42fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_9cab6a60-36d0-454a-9504-39c9621b70c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CymbaltaMember_4d0c4c57-9180-4b6e-a1b5-2d3acaf2fa97_terseLabel_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta&#174;</link:label>
    <link:label id="lab_lly_CymbaltaMember_label_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:label id="lab_lly_CymbaltaMember_documentation_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember" xlink:href="lly-20211231.xsd#lly_CymbaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CymbaltaMember" xlink:to="lab_lly_CymbaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_9230d6e9-87c3-427e-abdb-2d72d7b335e7_terseLabel_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets</link:label>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_label_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds Emerging Markets [Member]</link:label>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_documentation_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember" xlink:href="lly-20211231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FixedIncomeFundsEmergingMarketsMember" xlink:to="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_21b0b521-147d-4da3-adec-6f7f927f19e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1df4ec6f-8692-4920-91bd-a52d58dc38df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_25bdf821-f450-4583-bae5-23ddbfb7890e_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:to="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EntosPharmaceuticalsIncMember_42624cac-d257-4df2-87a1-4fd934ddd88f_terseLabel_en-US" xlink:label="lab_lly_EntosPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entos Pharmaceuticals Inc.</link:label>
    <link:label id="lab_lly_EntosPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lly_EntosPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entos Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_lly_EntosPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lly_EntosPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entos Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EntosPharmaceuticalsIncMember" xlink:href="lly-20211231.xsd#lly_EntosPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EntosPharmaceuticalsIncMember" xlink:to="lab_lly_EntosPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_92107b93-8236-4122-a4f1-44368c92394c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cdb7a11a-f484-46fd-a8f7-c65789d7deab_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_146fa37a-afea-44fb-864c-cbf036a4fc4c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_035c4bef-d3ba-41b4-b91f-ebf3465265b3_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_bda82c3b-04a9-4571-bb71-cfd9f2bc1b3e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5bfa57a5-5548-4949-9e5c-f5ea3f713f7f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_8ab2bd29-9589-4227-8082-fb5ba4ba7424_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_43ca738c-bbd7-4da5-a94d-fc8e249af954_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1cae2c23-b1cd-404a-983c-ff8a7c65fe1c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2fd3e413-da25-4ec8-a209-2b2b54e9a788_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_215f4abb-df5f-4ce9-b6c3-7fccb290da4b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_edc31cca-64e9-4051-b0b9-ea71a7ec4ab2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_90e19fa1-3ae6-45b1-b0ab-30d067672560_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations, including Puerto Rico</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ac6615d9-1425-449c-9f86-b5126e1c09aa_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ExpirationIn12To18YearsMember_8edac44f-a618-4b1c-964c-432e9ff4aa75_terseLabel_en-US" xlink:label="lab_lly_ExpirationIn12To18YearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 12 to 18 Years</link:label>
    <link:label id="lab_lly_ExpirationIn12To18YearsMember_label_en-US" xlink:label="lab_lly_ExpirationIn12To18YearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration In 12 To 18 Years [Member]</link:label>
    <link:label id="lab_lly_ExpirationIn12To18YearsMember_documentation_en-US" xlink:label="lab_lly_ExpirationIn12To18YearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration In 12 To 18 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationIn12To18YearsMember" xlink:href="lly-20211231.xsd#lly_ExpirationIn12To18YearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ExpirationIn12To18YearsMember" xlink:to="lab_lly_ExpirationIn12To18YearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c323267-8b05-4cec-ab60-51a9028dcd41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6be80629-403b-4248-933e-55f634352a41_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_5f72ea57-e7e9-4fd4-8232-03031e19304b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Net Gains (Losses) on&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_8bccfb34-67e1-457b-8c0b-f3eaf60341e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_85393eb1-8fd2-4d34-a790-f250c2ae37de_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f7e8d5fb-6186-4c99-8842-b2219007c5d1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_4a9972b5-300e-4664-9ed2-080fc1e41f20_negatedNetLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_992378ce-56f1-4c97-9c9f-c0f02b1c0c72_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_196e06cd-fef4-48d0-a475-e4bcb23fec04_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_4cda9c94-db1d-4ba3-bfac-03dc15691753_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_04d87920-7b74-4a4a-92b7-9cae02fa1a33_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for interest on borrowings</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0920df3d-7cad-49b3-be5d-0981da6fdbab_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_acd4689a-f65f-4b14-a485-e2924a6b6637_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d150eb35-f525-4db3-afe5-b3270fc23774_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_a6458629-45b6-4649-aaf9-7963def5a55a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_03bed4e6-d8cf-4cd0-a42a-6c49ec1644a6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_5d308e60-a32a-4d7d-a446-d12bc607e565_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_598aff4c-1ac8-4236-8b46-8db9be3f8b3d_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20211231.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_c558a4c2-01fc-4ef6-8a1f-3eb429f3e8c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f00f3533-f4b2-4bcb-ba41-d258c940cad3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_668d3ff3-2869-4aa0-b49e-c646294b7d35_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_78e29292-5cb2-4034-8025-28765293ba3a_terseLabel_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 and September 2060</link:label>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_label_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 And September 2060 [Member]</link:label>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_documentation_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 And September 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:href="lly-20211231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:to="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1e19854e-248a-41b9-9623-5a9afc249922_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fb96460b-5ee6-4826-92af-f1deb9550140_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3f670dba-ac89-4076-819d-c4a88989caa8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_7a238fbc-7704-434b-be2e-06dea0fc8d3c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2d369147-1aa8-48de-87ef-ed8ab569a13d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3b596c95-275c-4cf8-b198-070457b1da50_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LosAngelesMember_797f20d1-95f7-4f55-92f5-e1e9667243a3_terseLabel_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:label id="lab_lly_LosAngelesMember_label_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:label id="lab_lly_LosAngelesMember_documentation_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember" xlink:href="lly-20211231.xsd#lly_LosAngelesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LosAngelesMember" xlink:to="lab_lly_LosAngelesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_e5dfe2fe-5954-4d27-a12f-ab9f94f47425_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_07e3eb27-6985-421c-a524-68729a8e2364_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_4e1d67cf-03e7-459d-bfff-222153d35854_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaPatentLitigationMember_71d70108-b909-47f4-b97f-9a54962d668d_terseLabel_en-US" xlink:label="lab_lly_AlimtaPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta Patent Litigation</link:label>
    <link:label id="lab_lly_AlimtaPatentLitigationMember_label_en-US" xlink:label="lab_lly_AlimtaPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_AlimtaPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_AlimtaPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaPatentLitigationMember" xlink:href="lly-20211231.xsd#lly_AlimtaPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaPatentLitigationMember" xlink:to="lab_lly_AlimtaPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_e011c3f1-7bf6-4267-93f8-ce65ed884058_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A55NotesDue2027Member_7aa9164f-1c34-4134-96ca-6e88768ae1d8_terseLabel_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% notes due 2027</link:label>
    <link:label id="lab_lly_A55NotesDue2027Member_label_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_lly_A55NotesDue2027Member_documentation_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member" xlink:href="lly-20211231.xsd#lly_A55NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A55NotesDue2027Member" xlink:to="lab_lly_A55NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_7be700fe-6bb2-4541-863c-1a7c6f05ddc0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9037f354-7552-4cd5-82e0-40ead759a94b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_51210e44-5d72-4950-bb2f-93121e1c69b8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net (Note 8)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cea54cce-91e6-4379-8de8-59a219d0e28e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1e41d771-ea1d-4305-a255-b7fe1b0997f7_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_d314f2c1-89d2-4d31-92be-63711b6a0787_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_ce2beb19-6ec0-4891-80b3-3957099ef1b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_98c60489-fa2c-4103-b6b3-1a989b79ff22_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities (Note 14)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_91f3597b-e23e-4597-905a-64ee9b899d2a_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_c235fa80-79bc-4aff-a161-eb8b370c317d_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20211231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b5eb8c1d-ac7b-41e2-9d34-416fea1bfde0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_1845005e-3cb4-460d-ba00-0aec3a8e5a6b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term notes</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_db97b8f2-70f0-434b-afa9-2e4148593754_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from continuing operations - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3308cc35-9183-4289-8d1e-3976071162ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations (Note 19)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7014696e-e5c9-4959-ab27-3c3860ccfa39_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications from discontinued operations (net of tax)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0790b98c-59f7-46f3-80d7-0babe9f92e00_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_74d9ae5d-c055-43aa-badd-8f732de3865d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_30eccedf-3fa0-4c6d-9b42-0c231a3db548_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5cf70972-281f-4272-b096-989a15f76602_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3626d0d8-b810-45eb-8d45-0a52fee14b78_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ce751ef3-8d5c-4dcf-a3b4-f0cfea782143_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_bb155eea-374f-435a-8e0e-00ad4887a8f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_324220f9-9df3-48b4-8c80-7b4092e50c7c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2cb09e6f-d8d9-4d9d-bb38-b0dc775c5450_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_65944ce6-6339-4793-b11a-a5734327fbb3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Controlling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_99555f21-7588-48ee-bdb6-e5e9297c30de_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d890da34-2730-49b2-ba56-91b129ecfb83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_0c8f62ba-7af5-4e55-aafa-f3f6cf16f5b2_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes related to the impact of foreign currency translation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_cadf0b57-3dcc-4680-a537-080237c9a197_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_ca50b13b-ab10-416f-b9c1-75d47419b4fc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 7)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_11ad3482-86df-4c1e-bcc2-8149a7d8b057_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fa620f77-b3c3-42bc-95de-63d0c57309ff_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d85c1447-238e-428b-b708-f16b40495e10_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_5a0f9f5e-a973-4d44-bbad-de948363a5ad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5ad8d92a-bbef-4c2d-8fc7-640a130ca7b7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InsulinMember_2c53aeb7-2599-4fe8-abd2-0f5270474cdd_terseLabel_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin</link:label>
    <link:label id="lab_lly_InsulinMember_label_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin [Member]</link:label>
    <link:label id="lab_lly_InsulinMember_documentation_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember" xlink:href="lly-20211231.xsd#lly_InsulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InsulinMember" xlink:to="lab_lly_InsulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_30faffe7-ff14-46d3-9449-b50f08338735_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax redeterminations</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Redeterminations</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Redeterminations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:to="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_d4ca1576-78ee-4085-a491-112477bf21a3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_8f3691ee-cf85-41ef-923c-e150064053a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for sale of antibiotic business in China</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f83616d0-b664-49b4-b9a7-e74bc3a9f607_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f044ab0a-eb94-4fdb-ab21-adacf8d5c096_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4418db04-3eac-4e97-b7ce-691ae41c32a5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7dd90eb3-182a-4cf1-89bb-6b6d5affdd7a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_588af444-8e56-456c-ad51-5ac0c0015ad9_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TYVYTMember_257bf50c-34eb-45b9-9735-e39fe4506b02_terseLabel_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyvyt&#174;</link:label>
    <link:label id="lab_lly_TYVYTMember_label_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT [Member]</link:label>
    <link:label id="lab_lly_TYVYTMember_documentation_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember" xlink:href="lly-20211231.xsd#lly_TYVYTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TYVYTMember" xlink:to="lab_lly_TYVYTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_97657f5b-1b9d-4a22-89c3-0a67244e54e3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NumberOfMedicinesRightsToSold_187251b2-4a0f-4db2-93df-3ab6f84a7091_terseLabel_en-US" xlink:label="lab_lly_NumberOfMedicinesRightsToSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of legacy antibiotic medicines rights sold</link:label>
    <link:label id="lab_lly_NumberOfMedicinesRightsToSold_label_en-US" xlink:label="lab_lly_NumberOfMedicinesRightsToSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medicines, Rights To, Sold</link:label>
    <link:label id="lab_lly_NumberOfMedicinesRightsToSold_documentation_en-US" xlink:label="lab_lly_NumberOfMedicinesRightsToSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medicines, Rights To, Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NumberOfMedicinesRightsToSold" xlink:href="lly-20211231.xsd#lly_NumberOfMedicinesRightsToSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NumberOfMedicinesRightsToSold" xlink:to="lab_lly_NumberOfMedicinesRightsToSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b4053a63-dd67-4746-94ec-8bf7eefcd469_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_c2ef6c3d-23e3-4ce8-ba66-65e3a966f5f5_terseLabel_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal tax expense, utilization of net operating loss carryforward</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_label_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_documentation_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:href="lly-20211231.xsd#lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:to="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_db6a9e4b-48e1-443f-9df0-925e1b558af9_terseLabel_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer or Thyroid Cancer</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_label_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer [Member]</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_documentation_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:href="lly-20211231.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:to="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_ebc52db6-7615-46c4-86af-b840e0b5ce08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_51f5f587-ed10-414f-8ce7-3dfa31f76926_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_11c1c44d-4f8b-4a04-9f47-e4be3599cbe1_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correlative tax adjustments</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Corrective Tax Adjustments</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Corrective Tax Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:to="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_11b6bf25-6de6-4b38-a3f2-f79cf142bcdb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_9550a8be-5fdd-4847-a96e-8ab73e9c6086_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_ce767168-c9f6-4d36-9bef-2568636f3976_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_378da2bf-cab1-4a12-9f79-695bea0ec469_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long-term Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c5bf6ac2-9f33-484d-b351-febd12d24fcd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e3633981-bf28-4371-8f69-25f32e080909_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d217261f-5e5f-4ed9-8028-518e354c7703_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8e989941-0b0f-4277-92b3-ae32f399d8cc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_a510a89c-0fec-434a-8c5b-c544f4019144_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20211231.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_08e92ccc-917b-4679-9bf4-ea0f1bcd9209_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates replacement cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_0444b0f7-d023-4437-ae8a-c17fed1263db_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3047ebcb-bb99-485d-b75c-bd804482f2a9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_7f21c884-e113-462e-a06d-9fc4b6e5446a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Portion of Cash&#160;Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ShareholderValueAwardsMember_002aba1b-d813-49d4-a071-aacc5e7dfe6b_terseLabel_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards</link:label>
    <link:label id="lab_lly_ShareholderValueAwardsMember_label_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards [Member]</link:label>
    <link:label id="lab_lly_ShareholderValueAwardsMember_documentation_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember" xlink:href="lly-20211231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ShareholderValueAwardsMember" xlink:to="lab_lly_ShareholderValueAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_96cb3a82-4d4e-4e2f-92d8-2ccb892aa8be_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_a1d31ab0-8547-4e38-aa2d-ca52c75dba39_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_5dca37d7-24ae-4dc6-88ff-e50ede8f102a_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Tax Act Toll Tax</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxPaymentDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:to="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_0bbed922-5467-4ee3-a238-9d09a2b46642_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_618c55d5-5062-439d-8084-3accc54c3a6a_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20211231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9565c72c-f570-4fe5-b83d-9569fbebd90d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 11)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5825669d-47bd-4a4c-b555-ad2555c3bcf4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c39e666-ada5-4c48-adcc-69aef71dbbe7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_5d59e5a3-1946-46fd-980f-a9f8b68e6623_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_bf93dec6-868c-4fe1-a881-10b9db39c105_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d85902de-68db-4f97-8320-638d2e6f3db4_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8a83e59e-8904-4852-ba3b-2e3fe34bcdd5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications for the period, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_edc1e35c-678f-48c2-b433-a5ffbf70300f_terseLabel_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:href="lly-20211231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_17f20f2b-af21-4c5c-8563-91827142f6d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_dca60259-686d-4123-ab86-e0d88bb3d288_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RelativeValueAwardsMember_f20b0c24-5c3b-48e7-8d01-084f54fdf52f_terseLabel_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards</link:label>
    <link:label id="lab_lly_RelativeValueAwardsMember_label_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards [Member]</link:label>
    <link:label id="lab_lly_RelativeValueAwardsMember_documentation_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember" xlink:href="lly-20211231.xsd#lly_RelativeValueAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RelativeValueAwardsMember" xlink:to="lab_lly_RelativeValueAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_613a9444-0801-456b-8acd-097b57e4af41_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b5d87a44-3c83-4786-a4b3-5beb2baf5a3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_ab736614-eee9-4f38-97f1-45a71ff34856_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20211231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ace0ecb0-528f-4177-9e98-816de1052710_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_dc3df72a-b372-4c7e-8270-fff2bc16379c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3e4aa112-304e-42b0-aadd-01d8e8263547_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-lived Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_350bbb78-cf71-428e-9b35-32cf39266079_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10a0a577-11bc-4e6d-af8b-3c83d6563a2c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_7396e13d-d05e-4a68-9fb8-2a27bcabf8b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_18239637-5c34-4b25-a621-d30ba4f84d7f_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c5c1d7d3-7b44-41de-a2be-f29b7cdfd295_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_e7261699-9199-4195-bb6a-d73a947e9f33_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent value rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_label_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_documentation_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:href="lly-20211231.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:to="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_414adb7a-6f2a-4fd3-a933-298cc335ba41_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_acfab37f-1c36-4772-a0e7-f08626f5dcb1_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapses of statutes of limitation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_31e4e1da-61e6-4e2e-9ae2-74242caafc6e_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 Year</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_0d488104-2b22-4747-86d0-4e508b92893a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_52714ea6-e277-4a11-859d-6725ab02cf36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_a7c97008-39d3-4871-9a12-94f29bc2b4b8_terseLabel_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember" xlink:href="lly-20211231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrevailTherapeuticsIncMember" xlink:to="lab_lly_PrevailTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_0d932990-22d4-455e-9478-8e4607795856_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20211231.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c7d9d5c1-173d-4ba9-aa7f-3a6a7799f91d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_501e3a65-a2c6-47d5-b99a-359aca3a482c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_aab8e498-4138-4a64-8679-e351c1aaf7f6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_0de36d3b-d563-45dc-9baf-eb5e873c64ca_verboseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance&#174;</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_2e28d8c2-b28c-4e99-983c-f43a777f18a5_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20211231.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_32a640d6-a853-4248-9783-dc1832c8d8ae_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsDomain" xlink:to="lab_lly_PlaintiffAllegationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_1bb7c7fe-6a5b-4d44-9605-0296ce9facf3_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_68f17794-13ec-4933-a643-16568d265126_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_8df1191c-da97-46ec-abfe-01b1b316174a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_44c6ea2e-293b-4d87-b54d-fdc8510e2cce_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e09a762-c821-46ef-ab36-7b59b42c7332_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_3db6a87b-3913-4e0f-be36-656bf76bcffa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_0b75eab6-2ddb-41a8-a28b-aaaaeaa5cea0_terseLabel_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc.</link:label>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember" xlink:href="lly-20211231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisarmTherapeuticsIncMember" xlink:to="lab_lly_DisarmTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherContractMember_19f74a73-8b59-4334-8aef-787e87ce8ced_terseLabel_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash value of trust owned insurance contract</link:label>
    <link:label id="lab_us-gaap_OtherContractMember_label_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherContractMember" xlink:to="lab_us-gaap_OtherContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_72bd0b0b-bef9-469e-8fac-eae70aeec9e0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_353085a8-2e19-4145-8604-8c121e6914d4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_06b2d45a-2a3b-45b8-979c-e7e2174cca19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_467ad3d4-9d34-445e-ad7e-98b90ff6d017_verboseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta&#174;</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b75ed9ec-0a24-46c5-b219-76dd29da4986_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_595d0dc5-2594-4e0c-a6cf-70c80850790c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_f251a5c3-794e-4067-94ad-46bf2eacb562_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_02fc3050-39f8-4d16-a8a3-8c5011f3a883_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_32d13c23-a46d-4f34-8bfb-e17c52154fe7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_34e04815-cabe-4c71-add0-3fb29c5e58d6_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_542d9227-aaf2-4c53-b56e-b13aa40b61ac_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_b36858bd-b9c3-4a94-ab69-0e1c7ac09a3a_terseLabel_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Japanese Yen</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_label_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_documentation_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:href="lly-20211231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:to="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_5c0b5145-45f4-4874-8bf9-83029c39509d_terseLabel_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_label_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Define Benefit Plan, Other [Member]</link:label>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_documentation_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Define Benefit Plan, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember" xlink:href="lly-20211231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefineBenefitPlanOtherMember" xlink:to="lab_lly_DefineBenefitPlanOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_b0dec01d-8009-421b-8c48-edea51752be2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_48c6d57e-2b4d-414e-8105-7f1f2f0c8e9e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_73363f81-cc0a-43b7-8cc6-d4433d1942fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_68fd189e-3813-42f6-b857-fd51d4d8222f_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount recognized</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_d17055c0-48af-4e10-9b35-4c04d9447050_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax at the U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_e812b9e0-3f44-40fb-9278-a3c1de1a551e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment, Restructuring, And Other Special Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1398d20d-59e3-4048-8c99-251320f1cca9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year (2019 includes $677.5 of discontinued operations)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4a940fa7-88f5-47b4-9041-16906c8c2eb0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at End of Year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_ac65cae4-2e0b-4a59-b92c-b1ac77ec7b27_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_0b979bdf-79fd-4b66-88fa-a1a4a54b32d0_terseLabel_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets - repurchase agreements</link:label>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_label_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds - Repurchased Agreements [Member]</link:label>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_documentation_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds - Repurchased Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:href="lly-20211231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:to="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_d0ee0e5d-89e6-476e-88f8-e99ef2b07aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_630339de-606c-4f36-af3f-91f93a190fc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_fb7ca22b-5a90-49ed-b60d-f9da08c1553b_terseLabel_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.56% Japanese yen denominated notes due 2034</link:label>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_label_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.56% Yen-denominated Notes Due 2034 [Member]</link:label>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_documentation_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.56% Yen-denominated Notes Due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member" xlink:href="lly-20211231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A56YenDenominatedNotesDue2034Member" xlink:to="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_bc0bae93-1792-4921-8a71-41d839af1bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e7ed7c26-51ff-438f-b348-ce9f0e6e4436_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_85bfe729-3ad6-4876-8184-21cd9ac8d836_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications from continuing operations (net of tax)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_94a6bf0e-f532-476d-9c24-e882b34f1de8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_c7ef05bc-ce09-486e-ac2b-2c0d0f7c346f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_dfa37195-20e2-4a7d-a94e-da40a33410a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets related to state net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_f27a5b76-a9d3-4680-ae88-f5a55759a06d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_0f3655f0-64b1-4bfc-a443-45fe74ea5d8a_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_620240a6-8981-4830-9639-ec93eff9ef69_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d8239471-216d-4792-86f4-1933cccb4d74_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_ba684826-3107-4814-a70b-1e2690f1d0a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Postemployment Benefit Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_34ae3532-abed-4661-b742-0cd02c77b110_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized note discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_00537702-54ee-4347-b154-a96237a4f0f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>lly-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9fcc0128-8cb1-4f14-a312-a98ab5e27206,g:b055a216-cbe3-42fc-b7bd-1f3a75142c02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5a457337-8e11-4615-a20e-b1182bc4c8dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a457337-8e11-4615-a20e-b1182bc4c8dd" xlink:to="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_235b7fc0-6fdb-4309-a058-faf032ec3dc5" xlink:to="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bee9a8de-6ae3-41cc-bc93-88b32b3cbff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_us-gaap_CommonClassAMember_bee9a8de-6ae3-41cc-bc93-88b32b3cbff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_a1ba0528-d23f-4ebe-8d27-c90039443c0d" xlink:href="lly-20211231.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1.000NotesDueJune22022Member_a1ba0528-d23f-4ebe-8d27-c90039443c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_b02e315b-5adf-4b6b-a67f-23bc092d020e" xlink:href="lly-20211231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A718NotesDueJune12025Member_b02e315b-5adf-4b6b-a67f-23bc092d020e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_def84ada-7c82-45e4-b1e9-356232abb9d3" xlink:href="lly-20211231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1.625NotesDueJune22026Member_def84ada-7c82-45e4-b1e9-356232abb9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_6055fdd6-68a8-492a-80a3-52f2abcf8484" xlink:href="lly-20211231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A2.125NotesDueJune32030Member_6055fdd6-68a8-492a-80a3-52f2abcf8484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_c3073670-8cf6-4c50-b82e-d0a497046242" xlink:href="lly-20211231.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A625Notesdue2031Member_c3073670-8cf6-4c50-b82e-d0a497046242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_d734f5cd-fb8d-482e-9dd6-4b20cad76471" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A5000NotesDue2033Member_d734f5cd-fb8d-482e-9dd6-4b20cad76471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_a65f1cff-8481-4a5d-b965-8113f7df4324" xlink:href="lly-20211231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_a65f1cff-8481-4a5d-b965-8113f7df4324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_e0cc88ff-73eb-442c-b8c7-43abda37f5de" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1625NotesDue2043Member_e0cc88ff-73eb-442c-b8c7-43abda37f5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_17533293-6077-4e7d-9cf3-86462c78dffe" xlink:href="lly-20211231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1.700Notesdue2049Member_17533293-6077-4e7d-9cf3-86462c78dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_1d546684-fcb6-4df8-bb5d-ea1842e595eb" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1125NotesDue2051Member_1d546684-fcb6-4df8-bb5d-ea1842e595eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_4b5ac5ba-2be9-473f-a54b-5e2a58f4f218" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64c2992f-f12a-4104-9e46-e9e0d6c6a8c4" xlink:to="loc_lly_A1375NotesDue2061Member_4b5ac5ba-2be9-473f-a54b-5e2a58f4f218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_d37ef1ee-8bc0-4f7d-afb4-ac7c03c45c29" xlink:to="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4dc65892-7ee8-4b22-ae1c-d7dee785c3b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentType_4dc65892-7ee8-4b22-ae1c-d7dee785c3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_bb7208c2-b3cd-42c5-9bff-8d56fd671d04" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentAnnualReport_bb7208c2-b3cd-42c5-9bff-8d56fd671d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_88f89ae3-9444-48d9-8719-ee012170c37f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentPeriodEndDate_88f89ae3-9444-48d9-8719-ee012170c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_81f1760a-391a-4b7e-919d-a53fc9c6bd1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_CurrentFiscalYearEndDate_81f1760a-391a-4b7e-919d-a53fc9c6bd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_86462e07-51df-4e3f-95c4-bf52c0c16487" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityFileNumber_86462e07-51df-4e3f-95c4-bf52c0c16487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_185babb6-d57b-45bc-b58b-4e075dec24af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityRegistrantName_185babb6-d57b-45bc-b58b-4e075dec24af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_76bf135d-da49-40b3-baf2-68b1d46bf4dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityIncorporationStateCountryCode_76bf135d-da49-40b3-baf2-68b1d46bf4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e6d3bfd2-f285-4800-9eed-15b7bd51e4f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityTaxIdentificationNumber_e6d3bfd2-f285-4800-9eed-15b7bd51e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5244b926-89cc-45d9-972b-48ff7f4fda82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressAddressLine1_5244b926-89cc-45d9-972b-48ff7f4fda82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4cba1deb-1b56-49e9-9d41-4b9a860e37e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressCityOrTown_4cba1deb-1b56-49e9-9d41-4b9a860e37e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_405f4f41-d991-46a6-bf0c-a8d407a6fdd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressStateOrProvince_405f4f41-d991-46a6-bf0c-a8d407a6fdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_706fa7ab-1d8c-4f23-851f-5f8dfc01c2e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityAddressPostalZipCode_706fa7ab-1d8c-4f23-851f-5f8dfc01c2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_03c1a350-a33c-4e3b-9197-c79cd4406b78" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_CityAreaCode_03c1a350-a33c-4e3b-9197-c79cd4406b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d7de617-b810-4de9-8a1b-b42842781aeb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_LocalPhoneNumber_3d7de617-b810-4de9-8a1b-b42842781aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_162cc142-7fb9-4362-8136-9813d2715e80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_Security12bTitle_162cc142-7fb9-4362-8136-9813d2715e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_27f80017-4ba0-413d-9124-0af091ff84b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_TradingSymbol_27f80017-4ba0-413d-9124-0af091ff84b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_518dcf5c-5740-4338-b462-eb945ae0bea0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_SecurityExchangeName_518dcf5c-5740-4338-b462-eb945ae0bea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_70238a30-28b4-4b3e-be44-c8ad4abcf674" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_70238a30-28b4-4b3e-be44-c8ad4abcf674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9e8d2732-6d98-48cb-80e9-cafa8efe482b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityVoluntaryFilers_9e8d2732-6d98-48cb-80e9-cafa8efe482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ecb81d56-56c3-4f2e-96eb-3cec0588e72f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityCurrentReportingStatus_ecb81d56-56c3-4f2e-96eb-3cec0588e72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f4cf0bde-21de-40be-be1d-a77f61af3827" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityInteractiveDataCurrent_f4cf0bde-21de-40be-be1d-a77f61af3827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b52cb742-f43d-4787-b96d-0e24cbe4630c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityFilerCategory_b52cb742-f43d-4787-b96d-0e24cbe4630c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c4782d79-33df-4f2e-a789-1859b21fe076" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntitySmallBusiness_c4782d79-33df-4f2e-a789-1859b21fe076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c6a7eaf0-c2f8-4b96-b69b-a7bbb4a95f71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityEmergingGrowthCompany_c6a7eaf0-c2f8-4b96-b69b-a7bbb4a95f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1774dc78-a6c7-40e2-9cca-f187bb4c8b83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1774dc78-a6c7-40e2-9cca-f187bb4c8b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3b8f12e9-6d13-4d61-8fbf-758d1ae33170" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityShellCompany_3b8f12e9-6d13-4d61-8fbf-758d1ae33170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_1d4db431-ece1-4012-8f18-95a433166ab9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityPublicFloat_1d4db431-ece1-4012-8f18-95a433166ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d2ac33b6-e9b5-4a38-b443-22888fdf8647" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d2ac33b6-e9b5-4a38-b443-22888fdf8647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0d4e142e-8b8e-4161-ad51-fa2ffefc52a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentTransitionReport_0d4e142e-8b8e-4161-ad51-fa2ffefc52a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e469902e-adab-487e-a8c4-e5c419d1c3fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_AmendmentFlag_e469902e-adab-487e-a8c4-e5c419d1c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7f7eeecc-dad2-42a4-937e-3e9ee7ec9977" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentFiscalYearFocus_7f7eeecc-dad2-42a4-937e-3e9ee7ec9977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_05446fab-165e-48e8-84c6-eff3d0cab015" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentFiscalPeriodFocus_05446fab-165e-48e8-84c6-eff3d0cab015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_65623a65-84ba-4e9f-96e7-9ad4427e9e53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_EntityCentralIndexKey_65623a65-84ba-4e9f-96e7-9ad4427e9e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f5076cda-0a35-4c4d-9d2a-c7fc1b1625a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_12565b71-c2bb-4ab7-90c1-24eafc366b04" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f5076cda-0a35-4c4d-9d2a-c7fc1b1625a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AuditInformation" xlink:type="simple" xlink:href="lly-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_AuditInformationAbstract_89dd3c2f-2197-4b3d-8696-5cb81f2a5c92" xlink:href="lly-20211231.xsd#lly_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_bfece0fe-5fc5-4202-976c-5f334ae6a1b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AuditInformationAbstract_89dd3c2f-2197-4b3d-8696-5cb81f2a5c92" xlink:to="loc_dei_AuditorName_bfece0fe-5fc5-4202-976c-5f334ae6a1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_52e2108b-3eef-4693-9c00-70a144e2d77f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AuditInformationAbstract_89dd3c2f-2197-4b3d-8696-5cb81f2a5c92" xlink:to="loc_dei_AuditorFirmId_52e2108b-3eef-4693-9c00-70a144e2d77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_655f015b-3081-49e0-a561-f61b0a07f585" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AuditInformationAbstract_89dd3c2f-2197-4b3d-8696-5cb81f2a5c92" xlink:to="loc_dei_AuditorLocation_655f015b-3081-49e0-a561-f61b0a07f585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dbbd66a4-1ccb-4496-be74-4da0cf39bda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_Revenues_dbbd66a4-1ccb-4496-be74-4da0cf39bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d219eb30-1b7d-47b6-af90-969390edb4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d219eb30-1b7d-47b6-af90-969390edb4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f371721c-88a3-47c3-b71d-e2292a31a723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f371721c-88a3-47c3-b71d-e2292a31a723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d05b2ff4-8821-46d7-b120-73419584d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d05b2ff4-8821-46d7-b120-73419584d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_efeac487-b24a-4563-ac95-3a8b32b62954" xlink:href="lly-20211231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_efeac487-b24a-4563-ac95-3a8b32b62954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_fcaf39fd-8c50-459d-9713-c162740122d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_fcaf39fd-8c50-459d-9713-c162740122d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9040b451-1211-4b89-be54-6bce9d9ea906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9040b451-1211-4b89-be54-6bce9d9ea906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_dc2e206d-ffa8-4204-bbaa-3f61403692c0" xlink:href="lly-20211231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a34dca7b-51fd-4957-986a-5fed2e9c33bd" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_dc2e206d-ffa8-4204-bbaa-3f61403692c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef724683-c3c1-4e37-b925-8f489263ce96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef724683-c3c1-4e37-b925-8f489263ce96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68081774-bb25-4fe4-88f8-8435aeb32dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68081774-bb25-4fe4-88f8-8435aeb32dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b97b6569-7eff-4d24-9d5b-0ee82083e129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b97b6569-7eff-4d24-9d5b-0ee82083e129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5cd7415a-acb1-41b2-9bd2-52e05d4e0fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5cd7415a-acb1-41b2-9bd2-52e05d4e0fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b13c9ac7-0772-4b1a-8538-4b1852a9c944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_NetIncomeLoss_b13c9ac7-0772-4b1a-8538-4b1852a9c944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_034148a7-08b5-46b2-a322-16bb88eeb02d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_034148a7-08b5-46b2-a322-16bb88eeb02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_5e3f56a2-8774-4edf-9d74-f0bf75a77aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_5e3f56a2-8774-4edf-9d74-f0bf75a77aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_af223c9e-dcd0-41eb-8449-3932d3201ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:to="loc_us-gaap_EarningsPerShareBasic_af223c9e-dcd0-41eb-8449-3932d3201ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d2899c6e-61b5-464f-a606-f5e6ffc12c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d2899c6e-61b5-464f-a606-f5e6ffc12c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_891e6751-2bf4-4e55-b377-62d3238c3203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_891e6751-2bf4-4e55-b377-62d3238c3203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_21f384a4-5847-413e-a835-abd8c13eb8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b239dd1c-cee5-4341-82c7-acb3714d89eb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_21f384a4-5847-413e-a835-abd8c13eb8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_71049bf2-7035-4059-9c59-4505872dea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c9f9b6dd-8798-410b-a9e1-04e23853caac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_71049bf2-7035-4059-9c59-4505872dea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_167f2e40-c19a-493e-a49a-ed85866f95b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_71049bf2-7035-4059-9c59-4505872dea01" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_167f2e40-c19a-493e-a49a-ed85866f95b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_381fa4a1-bd52-4f56-b0ee-bc0f21921c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_71049bf2-7035-4059-9c59-4505872dea01" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_381fa4a1-bd52-4f56-b0ee-bc0f21921c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c354ddd7-1dad-43ad-b5d7-694f09cab8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c354ddd7-1dad-43ad-b5d7-694f09cab8f1" xlink:to="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_7b692000-73ad-43b2-a874-09e743c2fe51" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_5b556471-f2ce-4af2-a9ca-c4f83c432eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_5b556471-f2ce-4af2-a9ca-c4f83c432eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_b43c5d04-1772-4fa5-adcf-b8be0e06a72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bb220fe9-dd30-4e1e-92ae-b99f6f4bbcf2" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_b43c5d04-1772-4fa5-adcf-b8be0e06a72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_671b521a-e902-4b20-9542-6a061b83d27c" xlink:to="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_091a90da-ac56-43ae-9282-7a285b3296ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_NetIncomeLoss_091a90da-ac56-43ae-9282-7a285b3296ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5cb71d96-9a22-4cd5-bdf0-5127cf17e2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5cb71d96-9a22-4cd5-bdf0-5127cf17e2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_3c07b7f9-ad44-4d7b-98b2-5562b67f4110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_3c07b7f9-ad44-4d7b-98b2-5562b67f4110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_71358efe-34a4-484a-aa44-b61f1be490f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_71358efe-34a4-484a-aa44-b61f1be490f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b67e8848-aee6-426a-8475-f3ba6ec91abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b67e8848-aee6-426a-8475-f3ba6ec91abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c04976ed-9f9d-4b02-92b9-cb7bada5c2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_0f54a7b3-8254-42eb-b021-eecc8d6fc44f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c04976ed-9f9d-4b02-92b9-cb7bada5c2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_f67017b5-6ab7-4f11-acd5-a5f190d66f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_f67017b5-6ab7-4f11-acd5-a5f190d66f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e29a21a-ae1d-44da-929e-631f7c015b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e29a21a-ae1d-44da-929e-631f7c015b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c91b6266-3e6c-41e1-a91c-94ebfd815a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbf49e68-dc53-46b6-8472-c40984366f5b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c91b6266-3e6c-41e1-a91c-94ebfd815a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1a681ade-0aaa-4461-8a35-7e51fc54ad40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a681ade-0aaa-4461-8a35-7e51fc54ad40" xlink:to="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4381f852-3e36-4e58-84c5-b09e8453c48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4381f852-3e36-4e58-84c5-b09e8453c48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_537ce57e-ad24-4211-b895-8b1730b668ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_ShortTermInvestments_537ce57e-ad24-4211-b895-8b1730b668ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1d454f78-df57-459c-b84d-773c60e80fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1d454f78-df57-459c-b84d-773c60e80fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_177edeac-70d7-4fb6-bbed-b3760b28d1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_OtherReceivables_177edeac-70d7-4fb6-bbed-b3760b28d1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5171bcd8-5a9b-4862-8aea-b864dcdd5f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_InventoryNet_5171bcd8-5a9b-4862-8aea-b864dcdd5f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_f775eae1-e1f4-4703-befc-5a25fe219464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_f775eae1-e1f4-4703-befc-5a25fe219464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0a5933a7-a703-4bbc-937a-c934f18d94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93651ca5-4d4b-42fa-a376-1e91c8964ddb" xlink:to="loc_us-gaap_AssetsCurrent_0a5933a7-a703-4bbc-937a-c934f18d94c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_ed477f9d-cdae-4c94-9054-5e4af90fc940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_LongTermInvestments_ed477f9d-cdae-4c94-9054-5e4af90fc940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f0525ba4-c706-41b1-a1ff-e0a27aa02b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_Goodwill_f0525ba4-c706-41b1-a1ff-e0a27aa02b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e51cc5e0-e1fa-47bf-a088-309059df9a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e51cc5e0-e1fa-47bf-a088-309059df9a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_10a92dd2-98ed-4352-ba2e-85feb2fb34a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_10a92dd2-98ed-4352-ba2e-85feb2fb34a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_307f6a23-15ad-43c9-855b-f7461a2378ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_307f6a23-15ad-43c9-855b-f7461a2378ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_42a70f50-a993-440c-98fb-4436e118c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_42a70f50-a993-440c-98fb-4436e118c32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e09bac54-3785-4ce3-831b-bde58111c551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c43c74a0-9c10-4917-b46f-d179d19d2b93" xlink:to="loc_us-gaap_Assets_e09bac54-3785-4ce3-831b-bde58111c551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a681ade-0aaa-4461-8a35-7e51fc54ad40" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c786c843-8b2d-4227-91e2-090ca8ed7a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_DebtCurrent_c786c843-8b2d-4227-91e2-090ca8ed7a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2e0a5424-3879-49b6-995d-a54f885ffcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_AccountsPayableCurrent_2e0a5424-3879-49b6-995d-a54f885ffcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2c7bf016-fee9-40f6-8347-fa4170f90bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2c7bf016-fee9-40f6-8347-fa4170f90bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_c3697f20-7962-4f6a-91ac-22be9b27333b" xlink:href="lly-20211231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_lly_SalesRebatesAndDiscounts_c3697f20-7962-4f6a-91ac-22be9b27333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_4b37d41a-f6d7-45c9-9ecd-9f9cc749dd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_DividendsPayableCurrent_4b37d41a-f6d7-45c9-9ecd-9f9cc749dd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_657278ee-8b99-4558-a0f2-f439ca2b82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_TaxesPayableCurrent_657278ee-8b99-4558-a0f2-f439ca2b82f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_bb540e3c-e573-4e3d-804d-4cfd1a326b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_bb540e3c-e573-4e3d-804d-4cfd1a326b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_11e6fe21-18f7-4243-ba8a-0c73ee19bd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37fb95bb-2275-49a3-9cf4-330ea1eb1772" xlink:to="loc_us-gaap_LiabilitiesCurrent_11e6fe21-18f7-4243-ba8a-0c73ee19bd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ea0d0370-2acb-41a2-82f1-921a19adf865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ea0d0370-2acb-41a2-82f1-921a19adf865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_94087219-e2dd-43a7-94a7-c7f8b02d427b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_94087219-e2dd-43a7-94a7-c7f8b02d427b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_52ca8235-97d6-4460-84a4-12a85878ddbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_52ca8235-97d6-4460-84a4-12a85878ddbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_753d376e-6f38-4781-a3b3-31b0a6c55f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_753d376e-6f38-4781-a3b3-31b0a6c55f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e3274b3f-168b-4f1c-8e09-e3d57169d152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e3274b3f-168b-4f1c-8e09-e3d57169d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_5a269d61-1393-4fe7-b209-65d41f6c1e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2bf5e72e-becd-4a69-830a-7c628e947681" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_5a269d61-1393-4fe7-b209-65d41f6c1e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2e07bb6c-eaea-4849-928a-37d36b38eac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2e07bb6c-eaea-4849-928a-37d36b38eac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ed0014d3-cc91-45db-bcc1-37525e7462d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_CommonStockValue_ed0014d3-cc91-45db-bcc1-37525e7462d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0c91e4d9-660b-4471-aa42-68b9617838ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0c91e4d9-660b-4471-aa42-68b9617838ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab88a593-3dc8-48c2-aa64-d1cd93b23173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab88a593-3dc8-48c2-aa64-d1cd93b23173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_ce1ca942-f184-4527-9abe-0c97bc9589c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_ce1ca942-f184-4527-9abe-0c97bc9589c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2416f9d-731c-4c28-9c74-a8d9411a7c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d2416f9d-731c-4c28-9c74-a8d9411a7c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c40b48e7-1324-44a5-967b-7dcee2552af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_TreasuryStockValue_c40b48e7-1324-44a5-967b-7dcee2552af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_96000752-489d-425e-af7e-08232aa43a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_StockholdersEquity_96000752-489d-425e-af7e-08232aa43a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1f87d67b-8a23-4b62-a793-5147923e42fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_MinorityInterest_1f87d67b-8a23-4b62-a793-5147923e42fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5918c785-4cfe-4a59-bd34-466ab592f7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_21dbc405-5354-4778-bb84-b35f2cc09d2a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5918c785-4cfe-4a59-bd34-466ab592f7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f86fc9d0-e328-4ba7-a882-433b11e79d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b0822a5-62e0-43ca-a6ee-577922244d45" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f86fc9d0-e328-4ba7-a882-433b11e79d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d317be78-8e1a-4157-96d1-1d1f9dbeb997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_df888db7-9d9e-4c5b-8382-c1ee2d6ed2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d317be78-8e1a-4157-96d1-1d1f9dbeb997" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_df888db7-9d9e-4c5b-8382-c1ee2d6ed2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_03989667-fb7d-45bb-ac61-4921c6969017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d317be78-8e1a-4157-96d1-1d1f9dbeb997" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_03989667-fb7d-45bb-ac61-4921c6969017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_161180dd-a261-42ed-bbad-b385335b6fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d317be78-8e1a-4157-96d1-1d1f9dbeb997" xlink:to="loc_us-gaap_CommonStockSharesIssued_161180dd-a261-42ed-bbad-b385335b6fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofShareholdersEquityStatement"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_55bf7ac1-7f13-44db-b57c-333de60014fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_55bf7ac1-7f13-44db-b57c-333de60014fa" xlink:to="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_406e78e8-ff2a-4d8b-a0d4-ccfab429e8e2" xlink:to="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0513cb2-7e0f-4963-83fa-4158fe82f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_CommonStockMember_c0513cb2-7e0f-4963-83fa-4158fe82f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_050a8ee7-afd6-4717-9527-6d8a96278e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_050a8ee7-afd6-4717-9527-6d8a96278e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ebf603cd-2d26-43cf-8b5d-e035ad69b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_RetainedEarningsMember_ebf603cd-2d26-43cf-8b5d-e035ad69b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_4a91b8da-e122-4c00-b48e-20f7c835fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_4a91b8da-e122-4c00-b48e-20f7c835fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c6e2091-f253-4159-b5b2-a9366c97ec52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c6e2091-f253-4159-b5b2-a9366c97ec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2ad6cbbb-36c2-48d2-bc49-6d727eddfd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_TreasuryStockMember_2ad6cbbb-36c2-48d2-bc49-6d727eddfd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0072d018-4850-4a55-bf25-42494fe07e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7da470cb-808c-41dc-9965-eee484251d43" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0072d018-4850-4a55-bf25-42494fe07e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f4adb641-054f-4351-b655-a07e897704cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7c2707e6-df94-4f21-b005-ee646a540ae0" xlink:to="loc_us-gaap_StatementLineItems_f4adb641-054f-4351-b655-a07e897704cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f4adb641-054f-4351-b655-a07e897704cc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1ed70e28-d9af-4e9c-8412-29977f3b36ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_SharesIssued_1ed70e28-d9af-4e9c-8412-29977f3b36ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3458ec7d-0615-4200-8272-962b65b87c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3458ec7d-0615-4200-8272-962b65b87c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2df9b6f3-7da9-4869-a1e1-681d52b74539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_ProfitLoss_2df9b6f3-7da9-4869-a1e1-681d52b74539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_243d038c-1d19-4c70-80b0-a0ddd6456b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_243d038c-1d19-4c70-80b0-a0ddd6456b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_94dc902e-88da-4459-a1d4-4d2d18a49d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_Dividends_94dc902e-88da-4459-a1d4-4d2d18a49d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_c3e01fcd-f196-4294-bc24-5a47832b8143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_c3e01fcd-f196-4294-bc24-5a47832b8143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4683a802-7f02-487d-889f-8de1a788a413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_4683a802-7f02-487d-889f-8de1a788a413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_897035af-b45e-4e99-aa88-4c68e348709f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_897035af-b45e-4e99-aa88-4c68e348709f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b5cca4bd-4589-45d7-b5f2-775c5172b186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b5cca4bd-4589-45d7-b5f2-775c5172b186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_fd596618-a394-484d-abb9-134f4b86268d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_fd596618-a394-484d-abb9-134f4b86268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_18f89650-482c-43c1-bb52-ec275acf2100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_18f89650-482c-43c1-bb52-ec275acf2100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e4de6aa7-7359-4262-85d1-bdb845f0641e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e4de6aa7-7359-4262-85d1-bdb845f0641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_440cded4-d873-4d7d-b811-667287d79622" xlink:href="lly-20211231.xsd#lly_StockAcquiredDuringPeriodSharesExchangeOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_440cded4-d873-4d7d-b811-667287d79622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_68f3ab27-d139-4469-89fb-d325af2eb3a4" xlink:href="lly-20211231.xsd#lly_StockAcquiredDuringPeriodValueExchangeOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_68f3ab27-d139-4469-89fb-d325af2eb3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_809681d7-c23b-4468-9500-f4b35c9f1a65" xlink:href="lly-20211231.xsd#lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_809681d7-c23b-4468-9500-f4b35c9f1a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_18c16c8e-e813-4d13-ae0d-b6514cd0e490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockholdersEquityOther_18c16c8e-e813-4d13-ae0d-b6514cd0e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a7666653-19b3-4323-b224-b5206c52d012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_SharesIssued_a7666653-19b3-4323-b224-b5206c52d012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a6fe631-64f0-45b6-88af-b4b06da6d337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d098d79-a9bb-4673-9dee-39d4438a9fe2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a6fe631-64f0-45b6-88af-b4b06da6d337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c72a1166-eaf5-40d4-9c87-5588e610f472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_77277f28-4d15-4a69-9317-fe93e4c87eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c72a1166-eaf5-40d4-9c87-5588e610f472" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_77277f28-4d15-4a69-9317-fe93e4c87eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e2c28a4b-fdd8-45db-bb34-c663af34a011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2c28a4b-fdd8-45db-bb34-c663af34a011" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_898cc3ad-eac7-45ba-8f1f-bbd0e68a4de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_898cc3ad-eac7-45ba-8f1f-bbd0e68a4de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36095838-7541-4b55-b490-b188cae83f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_898cc3ad-eac7-45ba-8f1f-bbd0e68a4de0" xlink:to="loc_us-gaap_NetIncomeLoss_36095838-7541-4b55-b490-b188cae83f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_898cc3ad-eac7-45ba-8f1f-bbd0e68a4de0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_5e22c79c-b4c9-4eb5-bc71-4a9914dd312d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_5e22c79c-b4c9-4eb5-bc71-4a9914dd312d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d102ba5f-8d7f-4bca-a864-fc4d3c82d8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d102ba5f-8d7f-4bca-a864-fc4d3c82d8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_54a46b9b-7f35-40f1-81d8-64dd504c187f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_54a46b9b-7f35-40f1-81d8-64dd504c187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d4e8412a-026f-43b0-adcc-dc73f382f487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d4e8412a-026f-43b0-adcc-dc73f382f487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2d597726-66f5-4749-bf1e-a76c60a67482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2d597726-66f5-4749-bf1e-a76c60a67482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8bab096e-12e7-4bbf-bb22-97db4d14171c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_ShareBasedCompensation_8bab096e-12e7-4bbf-bb22-97db4d14171c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_2a3d704c-82a1-494c-9174-e3ce5dd1c218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_GainLossOnInvestments_2a3d704c-82a1-494c-9174-e3ce5dd1c218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_98ee3965-597b-4de8-9e46-014d7d523fde" xlink:href="lly-20211231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_98ee3965-597b-4de8-9e46-014d7d523fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_dc758475-d1f1-4670-84c6-ed7ef21625b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_dc758475-d1f1-4670-84c6-ed7ef21625b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ff6334a-6f7b-4dac-ae5a-3c39199be876" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_a24365f8-2a8a-4823-9a23-74cd450af37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_a24365f8-2a8a-4823-9a23-74cd450af37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4b751354-682f-4892-8646-3b240e13d760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4b751354-682f-4892-8646-3b240e13d760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f2b3f169-69ff-4b4a-bb0a-de65dc96db12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f2b3f169-69ff-4b4a-bb0a-de65dc96db12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_622140a3-e98d-496d-b9d2-d1048ff14fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_622140a3-e98d-496d-b9d2-d1048ff14fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cdc264d7-63d5-425f-a38f-61f60b8efdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_119bbcd4-3a0d-4cf1-813e-ee977fc3d1e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cdc264d7-63d5-425f-a38f-61f60b8efdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86d75074-4384-460a-a40b-4acc4a66f557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_898cc3ad-eac7-45ba-8f1f-bbd0e68a4de0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86d75074-4384-460a-a40b-4acc4a66f557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_7e72f306-db5b-43b1-9b02-38d869e9375e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_7e72f306-db5b-43b1-9b02-38d869e9375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_afc1fa7a-0500-421b-a9c4-dc0b50c5db75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_afc1fa7a-0500-421b-a9c4-dc0b50c5db75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b50bf4df-75eb-4aef-ba95-8251dd6d7f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b50bf4df-75eb-4aef-ba95-8251dd6d7f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1364e7eb-a6aa-40db-969c-19edb8579b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1364e7eb-a6aa-40db-969c-19edb8579b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_0422f398-9dbe-4611-914c-2d969b5b9faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_0422f398-9dbe-4611-914c-2d969b5b9faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_b05973fe-cc41-452a-b614-a4621e5d0c24" xlink:href="lly-20211231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_b05973fe-cc41-452a-b614-a4621e5d0c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2fc93c07-19f3-49c8-92b8-33ada09e9b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2fc93c07-19f3-49c8-92b8-33ada09e9b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_867233fd-4a01-4585-9e11-f9bd83ec531b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_867233fd-4a01-4585-9e11-f9bd83ec531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_d1c062ec-b11d-4049-b0cf-32bf1419e7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_d1c062ec-b11d-4049-b0cf-32bf1419e7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5464f987-78df-4ee8-b9c9-da96c8dd98d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5464f987-78df-4ee8-b9c9-da96c8dd98d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b71c55e-3e7b-4224-836b-bbf8c823f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49e4ba86-73ee-466b-b2c2-272be8c71d69" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0b71c55e-3e7b-4224-836b-bbf8c823f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_94832417-4d5a-4489-bd05-d6798196b960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_PaymentsOfDividends_94832417-4d5a-4489-bd05-d6798196b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_7f6ec664-08e2-448f-a9c3-08c0e08e9539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_7f6ec664-08e2-448f-a9c3-08c0e08e9539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e795b451-8c54-4c04-bb68-116e52e13b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e795b451-8c54-4c04-bb68-116e52e13b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_535a24d8-8aff-47e4-92de-c214fdfd8a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_535a24d8-8aff-47e4-92de-c214fdfd8a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f400c132-89b1-4fc1-a846-c1285a91e7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f400c132-89b1-4fc1-a846-c1285a91e7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_43469f31-c5d1-4fa0-9550-f56a7cf29ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_43469f31-c5d1-4fa0-9550-f56a7cf29ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c9dd3cf-8c4f-4e3a-86ef-b717de2d0aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_00e640af-5371-43a4-a37a-840d5e378747" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c9dd3cf-8c4f-4e3a-86ef-b717de2d0aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6419068-dee0-4987-9d83-20f3742f3794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6419068-dee0-4987-9d83-20f3742f3794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10b77ef9-56c6-4e92-a1ab-1ee809bfdda0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10b77ef9-56c6-4e92-a1ab-1ee809bfdda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_35e5dc73-dadc-4e05-9e39-b1eff388cdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_35e5dc73-dadc-4e05-9e39-b1eff388cdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b2a3d26a-5500-4f45-b165-a02d765cf530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_f86d2032-bfc1-43cb-a581-a40c0484a43d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b2a3d26a-5500-4f45-b165-a02d765cf530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="lly-20211231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_41cc790f-6334-4484-a439-46e995e929ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_cd4d0e9e-53e9-4b06-a781-0dbc04d56566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_41cc790f-6334-4484-a439-46e995e929ea" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_cd4d0e9e-53e9-4b06-a781-0dbc04d56566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard" xlink:type="simple" xlink:href="lly-20211231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_279c6d23-53fb-4d3f-ad56-3a4f74c68cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8fce3b63-7444-4e5e-be65-3b2d9efdbb06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_279c6d23-53fb-4d3f-ad56-3a4f74c68cd5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8fce3b63-7444-4e5e-be65-3b2d9efdbb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies" xlink:type="simple" xlink:href="lly-20211231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e21212db-7423-485a-b5d3-631e0c84be1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e21212db-7423-485a-b5d3-631e0c84be1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_be0e4dad-5b89-4d09-82c7-ed847ffc9b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_be0e4dad-5b89-4d09-82c7-ed847ffc9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4fdc2b35-cc73-4b7c-9657-f6724351e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4fdc2b35-cc73-4b7c-9657-f6724351e44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_9daf8069-51bb-4527-85b5-21780540b5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_9daf8069-51bb-4527-85b5-21780540b5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e471f9ac-e104-4b1c-ae8c-a3d0bb8d81dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e471f9ac-e104-4b1c-ae8c-a3d0bb8d81dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_ef51efc3-0f6e-40ba-b1a7-8a34146cdf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_ef51efc3-0f6e-40ba-b1a7-8a34146cdf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_b33ce21e-0e65-4c87-88e3-05586d29aec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_b33ce21e-0e65-4c87-88e3-05586d29aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7353ab13-3293-495f-aba0-828f33ed0e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7353ab13-3293-495f-aba0-828f33ed0e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_33151280-cc1f-4580-894d-29a0c3b24067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_33151280-cc1f-4580-894d-29a0c3b24067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5988b1f2-e559-4eff-b779-abc6be0368c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5988b1f2-e559-4eff-b779-abc6be0368c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5583559e-f2b0-4d0e-bcb6-4d95b399c372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5583559e-f2b0-4d0e-bcb6-4d95b399c372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4b0c9677-3630-46d4-afbd-1bb50ac27e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4b0c9677-3630-46d4-afbd-1bb50ac27e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_430236f8-1a0c-42d6-a5ea-e9c834cc519b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_430236f8-1a0c-42d6-a5ea-e9c834cc519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a5e4cc66-7342-4920-b8a8-733aef175bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a5e4cc66-7342-4920-b8a8-733aef175bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_733662bd-7801-4899-b183-9ec242ce48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ae0f2a7-60be-42b7-8cd0-9461784f5e8a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_733662bd-7801-4899-b183-9ec242ce48e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1b0722b4-a412-44ef-95ea-4f25c97c5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1b0722b4-a412-44ef-95ea-4f25c97c5bd4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_aebd81ee-43b8-4b9c-ae8d-aa7a04b12e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b482da51-0fa8-4210-b6f4-357d4a8dc015" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_aebd81ee-43b8-4b9c-ae8d-aa7a04b12e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1423496b-026b-472a-b53b-314e9b7cf777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_aebd81ee-43b8-4b9c-ae8d-aa7a04b12e76" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1423496b-026b-472a-b53b-314e9b7cf777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_808c96d4-fa5e-4fd2-bb15-0ff5da0ddeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9f14ae74-d73d-4701-95eb-5fd8e58c1f09" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_808c96d4-fa5e-4fd2-bb15-0ff5da0ddeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_0646d20d-6b8b-4bfd-98b7-26025f387917" xlink:href="lly-20211231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_808c96d4-fa5e-4fd2-bb15-0ff5da0ddeaa" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_0646d20d-6b8b-4bfd-98b7-26025f387917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8af7ce1b-607c-4ad5-86ca-6221ec1800f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_fe060c97-834a-408d-a694-b1f3ccd58501" xlink:to="loc_srt_OwnershipDomain_8af7ce1b-607c-4ad5-86ca-6221ec1800f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_1eaa59cd-a0d1-4b2c-8107-0524fec873f7" xlink:href="lly-20211231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_8af7ce1b-607c-4ad5-86ca-6221ec1800f9" xlink:to="loc_lly_EliLillyAndCompanyMember_1eaa59cd-a0d1-4b2c-8107-0524fec873f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a5ff4bb1-c934-4da2-bd5f-64fa84c058d6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_77c5cca6-5c73-4cc7-b3e4-8c6c55a3b631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_77c5cca6-5c73-4cc7-b3e4-8c6c55a3b631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_e941d108-be0a-4304-9fb7-3e0b4b533dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_us-gaap_AdvertisingExpense_e941d108-be0a-4304-9fb7-3e0b4b533dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue_9c239ee7-a19c-4b8b-a333-7987911c6964" xlink:href="lly-20211231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c5e127a-dba9-4e2d-8937-70ba7c743909" xlink:to="loc_lly_AdvertisingExpensePercentageOfRevenue_9c239ee7-a19c-4b8b-a333-7987911c6964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20211231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30eb8014-9f97-4b9a-9cb8-9deeb91e86c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7ead5853-70ad-4ff5-8ced-5f6dd2b51f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30eb8014-9f97-4b9a-9cb8-9deeb91e86c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7ead5853-70ad-4ff5-8ced-5f6dd2b51f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e826710f-630f-4991-854b-65a32b8699eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f4df1fcc-ddc0-449a-a2eb-0af0afc2cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e826710f-630f-4991-854b-65a32b8699eb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f4df1fcc-ddc0-449a-a2eb-0af0afc2cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f97c9d47-21ee-4f36-86b5-817b937c296d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e826710f-630f-4991-854b-65a32b8699eb" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f97c9d47-21ee-4f36-86b5-817b937c296d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93936f17-1fb0-4d99-80e6-6a95833e58b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93936f17-1fb0-4d99-80e6-6a95833e58b3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:to="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f66e2814-3cac-4d88-a6d9-67b2acc5e6f4" xlink:to="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9634ba5c-45da-4584-956f-2e32814a31b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:to="loc_us-gaap_ProductMember_9634ba5c-45da-4584-956f-2e32814a31b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_77b29f87-3365-4542-82c1-6e6548a7531e" xlink:href="lly-20211231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:to="loc_lly_CollaborationandOtherRevenueMember_77b29f87-3365-4542-82c1-6e6548a7531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_acfb3cb0-0a4f-4e46-af4c-68ef8bbc5887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c00ab30c-719d-4f6d-b3af-fd0b05f70a5b" xlink:to="loc_us-gaap_RoyaltyMember_acfb3cb0-0a4f-4e46-af4c-68ef8bbc5887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_69a1d549-d6f4-452e-93e5-90ff2bfef176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_10e4f4cf-5b04-41cb-a560-84546a713902" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_69a1d549-d6f4-452e-93e5-90ff2bfef176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_943f0a41-6427-485f-9ee4-53fc1fae50c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_69a1d549-d6f4-452e-93e5-90ff2bfef176" xlink:to="loc_us-gaap_Revenues_943f0a41-6427-485f-9ee4-53fc1fae50c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d1dc0d74-d4be-4e03-b1f3-0f1830330b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d1dc0d74-d4be-4e03-b1f3-0f1830330b17" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_011e77fa-0640-4f30-8d06-b4042c720b01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b911051d-99d3-432c-a8ac-e6a5265a0588" xlink:to="loc_srt_NameOfMajorCustomerDomain_011e77fa-0640-4f30-8d06-b4042c720b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember_0bc498ec-0ac3-45ad-9f3e-27c15c4da16c" xlink:href="lly-20211231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_011e77fa-0640-4f30-8d06-b4042c720b01" xlink:to="loc_lly_ThreeLargestWholesalesMember_0bc498ec-0ac3-45ad-9f3e-27c15c4da16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_270f6867-3577-4dc6-a99e-aa5c6ae6b28a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_36f22aa3-9b33-404b-96ca-0f9cde44e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:to="loc_us-gaap_SalesRevenueNetMember_36f22aa3-9b33-404b-96ca-0f9cde44e93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8ff81d9f-610a-4309-89aa-f66fafa6f041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3b3f68d-cc2c-44cf-ac87-460d77cb66ec" xlink:to="loc_us-gaap_AccountsReceivableMember_8ff81d9f-610a-4309-89aa-f66fafa6f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0942e4bd-262c-43bb-bacf-db06e860fefb" xlink:to="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48f3816e-274c-4517-b4a4-919ff8b3e4cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:to="loc_srt_MinimumMember_48f3816e-274c-4517-b4a4-919ff8b3e4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_417cbcc7-eee6-4b3a-8c73-5b89250d4d59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2ddb361-cd37-4b7f-b6da-a75a51133087" xlink:to="loc_srt_MaximumMember_417cbcc7-eee6-4b3a-8c73-5b89250d4d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a27ce4f-d31b-40cb-ae0c-9b6bd2fc867e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9fdd109a-e699-4308-95ca-bd8361edd2a0" xlink:to="loc_srt_SegmentGeographicalDomain_6a27ce4f-d31b-40cb-ae0c-9b6bd2fc867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f73655bd-dd1c-48e8-876b-5eb21008eed1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6a27ce4f-d31b-40cb-ae0c-9b6bd2fc867e" xlink:to="loc_country_US_f73655bd-dd1c-48e8-876b-5eb21008eed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_aa362411-3937-4c6c-83a6-54df8653e28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_94f1c0a4-1b2a-4eb5-a33a-c96b8d037d35" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_aa362411-3937-4c6c-83a6-54df8653e28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_afb12dbd-54d1-49cb-abb7-a96cd83d5516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_aa362411-3937-4c6c-83a6-54df8653e28f" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_afb12dbd-54d1-49cb-abb7-a96cd83d5516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4aced886-644a-4d53-a873-496b80992fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c51386e2-3007-485b-a393-7345296ec62b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4aced886-644a-4d53-a873-496b80992fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_85c0d919-a3e9-47ae-ac66-e905f37ac2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4aced886-644a-4d53-a873-496b80992fba" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_85c0d919-a3e9-47ae-ac66-e905f37ac2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_5dd69587-a85f-404b-82a3-d7cc1c41a6e9" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum_0f2234d6-b6d3-424b-8cf4-73da41c6a901" xlink:href="lly-20211231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuefromContractPaymentTermMinimum_0f2234d6-b6d3-424b-8cf4-73da41c6a901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum_ced693de-57a0-436b-b57c-85cd78efa515" xlink:href="lly-20211231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuefromContractPaymentTermMaximum_ced693de-57a0-436b-b57c-85cd78efa515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_f4b4cdaa-da39-4496-8129-871cecb1729c" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_f4b4cdaa-da39-4496-8129-871cecb1729c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_713c6918-07d1-4c2b-8e63-765784268557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_713c6918-07d1-4c2b-8e63-765784268557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_3717ed40-2bca-42c3-8333-784849f2350f" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_3717ed40-2bca-42c3-8333-784849f2350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_a71a74c9-4f0e-4c1d-84f4-128830795022" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_a71a74c9-4f0e-4c1d-84f4-128830795022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_5bd974ed-9d21-429c-80b8-97ffe60080aa" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_5bd974ed-9d21-429c-80b8-97ffe60080aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_3595cbe4-1604-44f1-b076-79ca3c7f6816" xlink:href="lly-20211231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_3595cbe4-1604-44f1-b076-79ca3c7f6816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_b0496552-4568-48ee-9bb3-43f03255ece5" xlink:href="lly-20211231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_43b94881-62c2-4af5-af09-3cd993436b5e" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_b0496552-4568-48ee-9bb3-43f03255ece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7421b761-4058-433d-954d-ea887cb8db9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_829de6cc-ad4b-421b-ba50-74206f9a9536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7421b761-4058-433d-954d-ea887cb8db9a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_829de6cc-ad4b-421b-ba50-74206f9a9536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f169097a-1410-4a38-9ee3-889c6c0a243b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f169097a-1410-4a38-9ee3-889c6c0a243b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:to="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7e4d4a2-efbd-4292-b82c-0917af65429b" xlink:to="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:href="lly-20211231.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_1bab6bfe-c080-4ddf-ab15-cb1fdfb7975a" xlink:href="lly-20211231.xsd#lly_TrulicityMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_TrulicityMemberMember_1bab6bfe-c080-4ddf-ab15-cb1fdfb7975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_20846cbd-e40a-401c-b5c5-07574d8f6c8f" xlink:href="lly-20211231.xsd#lly_HumalogMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_HumalogMember_20846cbd-e40a-401c-b5c5-07574d8f6c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_e56fab26-81ca-4640-aa77-5cafabb7548c" xlink:href="lly-20211231.xsd#lly_HumulinMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_HumulinMember_e56fab26-81ca-4640-aa77-5cafabb7548c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_ed17992c-511f-4281-aa84-899ab0b0c7bc" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_JardianceMember_ed17992c-511f-4281-aa84-899ab0b0c7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_e757c541-9867-4266-a652-5d2594546955" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_BasaglarMember_e757c541-9867-4266-a652-5d2594546955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_65d9a006-aeb0-4faf-ae76-a3daad8640c8" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_TrajentaBIMember_65d9a006-aeb0-4faf-ae76-a3daad8640c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_773b5c2b-ce75-4266-b0d7-26c44e8d37e3" xlink:href="lly-20211231.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_d46da9d6-c70d-4dbf-b1d4-1f0d9352f03c" xlink:to="loc_lly_OtherDiabetesMember_773b5c2b-ce75-4266-b0d7-26c44e8d37e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:href="lly-20211231.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_96b5294b-78a6-4dc5-84eb-9a51e3795fdb" xlink:href="lly-20211231.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_AlimtaMember_96b5294b-78a6-4dc5-84eb-9a51e3795fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_970a22a1-4434-41b4-85fa-20616fd243ad" xlink:href="lly-20211231.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_VerzenioMember_970a22a1-4434-41b4-85fa-20616fd243ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_edad9b15-03ab-4671-a7b7-01b651ac6b18" xlink:href="lly-20211231.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_CyramzaMember_edad9b15-03ab-4671-a7b7-01b651ac6b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_76bc48b3-8a8d-4559-8cb6-e49e35a42e4e" xlink:href="lly-20211231.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_ErbituxMember_76bc48b3-8a8d-4559-8cb6-e49e35a42e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_1d05d28e-87f3-43cf-9955-ecaad8f482c7" xlink:href="lly-20211231.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_TYVYTMember_1d05d28e-87f3-43cf-9955-ecaad8f482c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_c5828b11-ccf0-44c4-b0c2-01363c1c5cad" xlink:href="lly-20211231.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_d64fa51e-6f2a-41c6-9cbc-3ca9d31a088e" xlink:to="loc_lly_OtherOncologyMember_c5828b11-ccf0-44c4-b0c2-01363c1c5cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:href="lly-20211231.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_06101de3-fe9c-483f-867f-dd5ea43c002e" xlink:href="lly-20211231.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:to="loc_lly_TaltzMember_06101de3-fe9c-483f-867f-dd5ea43c002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_cc6f37fa-fbcf-4138-b5d7-3e9e44fc9b00" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:to="loc_lly_OlumiantMember_cc6f37fa-fbcf-4138-b5d7-3e9e44fc9b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_efd24441-781c-4b11-9e69-e4d201a94a8a" xlink:href="lly-20211231.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_ba31f596-18a1-42d4-81ca-1a51efb04218" xlink:to="loc_lly_OtherImmunologyMember_efd24441-781c-4b11-9e69-e4d201a94a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:href="lly-20211231.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_1536579d-1860-42b9-959d-05df323b6822" xlink:href="lly-20211231.xsd#lly_CymbaltaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_CymbaltaMember_1536579d-1860-42b9-959d-05df323b6822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_1aebc8fb-f8b1-4a1a-b00e-08a1cbc42d8b" xlink:href="lly-20211231.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_EmgalityMember_1aebc8fb-f8b1-4a1a-b00e-08a1cbc42d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_00c979e5-fc0b-4f58-b286-e5eafd62a8f8" xlink:href="lly-20211231.xsd#lly_ZyprexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_ZyprexaMember_00c979e5-fc0b-4f58-b286-e5eafd62a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_b647c749-6aa9-4450-8302-605369ddfc92" xlink:href="lly-20211231.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_d338f070-41f2-4e0b-aa77-f33b81784a32" xlink:to="loc_lly_OtherNeuroscienceMember_b647c749-6aa9-4450-8302-605369ddfc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:href="lly-20211231.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0f66214e-4194-49d6-b339-7aa5f9c91036" xlink:to="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_f86449f4-1816-4561-9005-e42c86f8ccd4" xlink:href="lly-20211231.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_COVID19AntibodiesMember_f86449f4-1816-4561-9005-e42c86f8ccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_3dc7b2b2-daa1-488f-a70d-efadbf88dc90" xlink:href="lly-20211231.xsd#lly_ForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_ForteoMember_3dc7b2b2-daa1-488f-a70d-efadbf88dc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_49176729-ad9b-4f40-8cea-8ea18321afe9" xlink:href="lly-20211231.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_CialisMember_49176729-ad9b-4f40-8cea-8ea18321afe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_4728658f-5be3-4934-9e4c-586a2a5400df" xlink:href="lly-20211231.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_cd596365-a7b7-4a68-b56b-37c38891c02e" xlink:to="loc_lly_OtherProductMember_4728658f-5be3-4934-9e4c-586a2a5400df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:to="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5b7a33ad-a3d1-456c-9776-de3606314cea" xlink:to="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_14bd346f-ef0f-433d-871f-5497c8c761c9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:to="loc_country_US_14bd346f-ef0f-433d-871f-5497c8c761c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_cfdff890-9c5f-4c0b-b18b-2276f6bc2991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc43fb20-a172-4f7f-b0cb-58ff02c4863f" xlink:to="loc_us-gaap_NonUsMember_cfdff890-9c5f-4c0b-b18b-2276f6bc2991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_970bd7b3-88c3-4ad3-8d65-5918bc406545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_48dac734-660c-447b-82e5-c629cd251049" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_970bd7b3-88c3-4ad3-8d65-5918bc406545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1abc4e88-61a2-410a-bd65-2da65ca61fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_970bd7b3-88c3-4ad3-8d65-5918bc406545" xlink:to="loc_us-gaap_Revenues_1abc4e88-61a2-410a-bd65-2da65ca61fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7d230809-652c-4a4e-ab5b-99adeb2c89a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7d230809-652c-4a4e-ab5b-99adeb2c89a2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:to="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3cf9fbe2-fd92-4b6a-a37a-bab39369270e" xlink:to="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f3a5c969-c7c5-44f0-9155-4c6e9225696e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_country_US_f3a5c969-c7c5-44f0-9155-4c6e9225696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b4fa7909-22fc-4a17-b494-0257f345a425" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_srt_EuropeMember_b4fa7909-22fc-4a17-b494-0257f345a425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c319220d-aa64-4b67-bea6-6ed8e64c7597" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_country_JP_c319220d-aa64-4b67-bea6-6ed8e64c7597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_07903c19-cfa1-4b9c-a204-c03d7fa978e4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_country_CN_07903c19-cfa1-4b9c-a204-c03d7fa978e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_a7cf65e8-d04b-4456-a3fb-a4cf6ca1fad0" xlink:href="lly-20211231.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce3440a7-aba8-43bb-80d5-17986432ab3f" xlink:to="loc_lly_OtherForeignCountriesMember_a7cf65e8-d04b-4456-a3fb-a4cf6ca1fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c76e606a-270f-4532-8f20-6471e78e7a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6b2362a1-7e31-46e8-987b-bd80a8b469a0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c76e606a-270f-4532-8f20-6471e78e7a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_196ba4fd-9987-43d5-aa58-9e7f670beb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c76e606a-270f-4532-8f20-6471e78e7a2c" xlink:to="loc_us-gaap_Revenues_196ba4fd-9987-43d5-aa58-9e7f670beb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestiture"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_40062eab-d827-4216-8e53-7d3f71e2b857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_bc465c9b-7f65-41b0-953d-b8d3b64dc0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_40062eab-d827-4216-8e53-7d3f71e2b857" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_bc465c9b-7f65-41b0-953d-b8d3b64dc0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a1450a62-e7f2-4f68-a17d-e9cd7e436f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_40062eab-d827-4216-8e53-7d3f71e2b857" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a1450a62-e7f2-4f68-a17d-e9cd7e436f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestitureTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5e73e6c1-35ac-44b0-8e9c-6aa9f18408f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_160350de-4fab-4e4d-88f0-6b019b2d161e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5e73e6c1-35ac-44b0-8e9c-6aa9f18408f9" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_160350de-4fab-4e4d-88f0-6b019b2d161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_3335cab3-902b-4d64-83cd-a685571cec7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5e73e6c1-35ac-44b0-8e9c-6aa9f18408f9" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_3335cab3-902b-4d64-83cd-a685571cec7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestitureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_eed1b781-709b-43a9-98b0-e92fa30bd9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_eed1b781-709b-43a9-98b0-e92fa30bd9c5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_26389e89-d0b9-433c-874b-1a51afa74cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d550cc21-f1c1-4d0a-bff1-d5df62c92456" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_26389e89-d0b9-433c-874b-1a51afa74cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_024c5ad5-1297-4d8d-b3d7-9a9e5b4c28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_26389e89-d0b9-433c-874b-1a51afa74cbf" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_024c5ad5-1297-4d8d-b3d7-9a9e5b4c28c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cad6c6bf-0bcc-4dea-b61e-c1b52f6e97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_52bd524d-b00b-4612-96ef-371e607c2cc8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cad6c6bf-0bcc-4dea-b61e-c1b52f6e97d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b1470d5b-cf47-45e8-addc-c9e90c192861" xlink:href="lly-20211231.xsd#lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cad6c6bf-0bcc-4dea-b61e-c1b52f6e97d5" xlink:to="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b1470d5b-cf47-45e8-addc-c9e90c192861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b7c7cbb-9fe9-4b72-bf7c-165aa9361b42" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_e78d912b-6e66-4502-a876-467c53bde902" xlink:href="lly-20211231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:to="loc_lly_PrevailTherapeuticsIncMember_e78d912b-6e66-4502-a876-467c53bde902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_9b454772-b060-4ada-8fc8-b2b72b4b7417" xlink:href="lly-20211231.xsd#lly_DermiraInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:to="loc_lly_DermiraInc.Member_9b454772-b060-4ada-8fc8-b2b72b4b7417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_10f1d636-e9ce-402f-be0e-96a2c5d7e917" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f896ebeb-a8ab-416f-a07a-f48cac3f01d9" xlink:to="loc_lly_LoxoOncologyInc.Member_10f1d636-e9ce-402f-be0e-96a2c5d7e917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48aa7e65-645a-452d-bb30-c052bb715cfb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_104a2eea-3e9d-43e8-ac7b-0d8e22fa28ec" xlink:to="loc_srt_ProductsAndServicesDomain_48aa7e65-645a-452d-bb30-c052bb715cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_bba1cc08-04a0-49c8-bcfb-3d880c35c102" xlink:href="lly-20211231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_48aa7e65-645a-452d-bb30-c052bb715cfb" xlink:to="loc_lly_SelpercatinibLOXO292Member_bba1cc08-04a0-49c8-bcfb-3d880c35c102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baf7d619-53bf-491a-bbb2-f6b6abb9579e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_075df805-4f64-4ce0-b1e3-df3156026548" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baf7d619-53bf-491a-bbb2-f6b6abb9579e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EddingpharmMember_090bbd1a-d708-4552-9300-16810ddf284b" xlink:href="lly-20211231.xsd#lly_EddingpharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_baf7d619-53bf-491a-bbb2-f6b6abb9579e" xlink:to="loc_lly_EddingpharmMember_090bbd1a-d708-4552-9300-16810ddf284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c9dfb42-335c-4694-881e-573a7a301d11" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7c0f77dc-c97f-41fa-94f2-499d47931078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7c0f77dc-c97f-41fa-94f2-499d47931078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_a5f1cd27-bdae-461f-aa41-c3b34b2ab541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_a5f1cd27-bdae-461f-aa41-c3b34b2ab541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1b838746-93c8-4abc-92f9-d5b668349d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1b838746-93c8-4abc-92f9-d5b668349d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_6e21f186-5cec-419e-b108-eec9afe1b3ce" xlink:href="lly-20211231.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_6e21f186-5cec-419e-b108-eec9afe1b3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_aeeb82ab-1263-4c6d-9271-733130aff1d3" xlink:href="lly-20211231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_aeeb82ab-1263-4c6d-9271-733130aff1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5f1dc859-0381-4a59-bba0-15bded393d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5f1dc859-0381-4a59-bba0-15bded393d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_92a5d954-6425-43df-a856-f44768879307" xlink:href="lly-20211231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_92a5d954-6425-43df-a856-f44768879307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73ed1023-5628-4ca1-900a-781622c9e19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73ed1023-5628-4ca1-900a-781622c9e19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_98f150de-861f-4f80-8837-9e97bc83affc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_Goodwill_98f150de-861f-4f80-8837-9e97bc83affc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_33785bae-ec4b-4e7b-a844-9eef321200c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_33785bae-ec4b-4e7b-a844-9eef321200c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c5420935-7b76-416c-a5a6-33c938bd9e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c5420935-7b76-416c-a5a6-33c938bd9e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_d6101c34-1703-4f2a-b6ee-41cfd562aabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_d6101c34-1703-4f2a-b6ee-41cfd562aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6b955e6c-0020-44d7-ab00-a03eff6e1047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6b955e6c-0020-44d7-ab00-a03eff6e1047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NumberOfMedicinesRightsToSold_9e7a7053-b182-4a30-93b3-453135d1f290" xlink:href="lly-20211231.xsd#lly_NumberOfMedicinesRightsToSold"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_NumberOfMedicinesRightsToSold_9e7a7053-b182-4a30-93b3-453135d1f290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_48048615-7a80-45fd-975e-8f8e67cee8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_48048615-7a80-45fd-975e-8f8e67cee8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_04cb6d64-59aa-456b-9836-b0bba7da3968" xlink:href="lly-20211231.xsd#lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_04cb6d64-59aa-456b-9836-b0bba7da3968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_83ef9988-9c3d-469d-8e32-0afb0343156e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3555dfeb-9923-4c4c-82b8-b771264312d7" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_83ef9988-9c3d-469d-8e32-0afb0343156e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_46b7f3d1-beee-477a-a07b-549f12808599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_46b7f3d1-beee-477a-a07b-549f12808599" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_312ec2bc-4f0f-47cc-b154-47b6cdd77052" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d79aac61-ce64-4253-abb3-89135b7620ca" xlink:to="loc_srt_ProductsAndServicesDomain_312ec2bc-4f0f-47cc-b154-47b6cdd77052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_64000cb4-32b6-46f6-a9fd-a6e456ef6028" xlink:href="lly-20211231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_312ec2bc-4f0f-47cc-b154-47b6cdd77052" xlink:to="loc_lly_SelpercatinibLOXO292Member_64000cb4-32b6-46f6-a9fd-a6e456ef6028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ffb00fbe-867b-4f50-ba92-e73557fff295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d4d502f-1d41-49f0-9f59-1cb344ad5007" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ffb00fbe-867b-4f50-ba92-e73557fff295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_2dfcc6fe-4785-48f8-956e-9ae411269f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ffb00fbe-867b-4f50-ba92-e73557fff295" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_2dfcc6fe-4785-48f8-956e-9ae411269f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_48c70368-8d46-4d3f-be0f-3f2259c24f1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_733a4e2b-ba7b-4ea0-9d57-9076057609b9" xlink:href="lly-20211231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:to="loc_lly_PrevailTherapeuticsIncMember_733a4e2b-ba7b-4ea0-9d57-9076057609b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_8ef07fce-ac63-4df1-a410-a641f6f10c5b" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa008c5b-cde5-4489-94a7-7402a7992f22" xlink:to="loc_lly_LoxoOncologyInc.Member_8ef07fce-ac63-4df1-a410-a641f6f10c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1eff74b3-cff2-4188-966c-c4ed43e69ba8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d56191a3-8884-4655-b1d3-d8ceac4e70b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d56191a3-8884-4655-b1d3-d8ceac4e70b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d5c5cb7c-4abe-46bc-883d-799c9d16dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d5c5cb7c-4abe-46bc-883d-799c9d16dabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3bcaa287-4e19-4dd5-8422-15143849fbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3bcaa287-4e19-4dd5-8422-15143849fbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6170230-1495-45b8-8d09-5c54f5b0c36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_Goodwill_f6170230-1495-45b8-8d09-5c54f5b0c36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0991f7ce-a914-464f-acc6-05adc09c3992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0991f7ce-a914-464f-acc6-05adc09c3992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_7c374d86-ae0a-40c5-8623-e7ef135609e2" xlink:href="lly-20211231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_7c374d86-ae0a-40c5-8623-e7ef135609e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ebbfaeb-e3dc-4a3b-812b-d9d5a471fbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5ebbfaeb-e3dc-4a3b-812b-d9d5a471fbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0a03297-43dd-4ee0-b430-e6dd5d4f666b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0a03297-43dd-4ee0-b430-e6dd5d4f666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_5e5e1ef4-e901-4466-b7a8-0961d4842617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_5e5e1ef4-e901-4466-b7a8-0961d4842617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_344069f0-84e6-4df8-b923-0e8737ceefe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_344069f0-84e6-4df8-b923-0e8737ceefe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_df4cb252-5d62-42cf-982b-929fb1e317ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_df4cb252-5d62-42cf-982b-929fb1e317ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5fa30fd7-23d1-4bd7-afd7-cd509f146df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00365559-d26e-465a-93cf-23d9b88df819" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5fa30fd7-23d1-4bd7-afd7-cd509f146df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AcquisitionsandDivestitureAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b11ed7d3-9f3a-45ed-b10f-6b76010d0c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b11ed7d3-9f3a-45ed-b10f-6b76010d0c1b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:to="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_22c32905-c690-473f-b13f-4f53fcf9c57b" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_701e4256-6c52-4ad7-b0cb-64ce43830f78" xlink:href="lly-20211231.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_PrecisionBiosciencesIncMember_701e4256-6c52-4ad7-b0cb-64ce43830f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_e7af7fe5-ff7e-402e-b52a-d8536e8b06b6" xlink:href="lly-20211231.xsd#lly_MerusNVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_MerusNVMember_e7af7fe5-ff7e-402e-b52a-d8536e8b06b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_6b5fa0a0-87f3-4078-b092-62b7c9769264" xlink:href="lly-20211231.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_6b5fa0a0-87f3-4078-b092-62b7c9769264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_a9832e27-3b1d-4598-bd2d-f81a44b42a83" xlink:href="lly-20211231.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_a9832e27-3b1d-4598-bd2d-f81a44b42a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MiNATherapeuticsLimitedMember_1c1cf833-dd89-4358-bfbd-a84385abfb46" xlink:href="lly-20211231.xsd#lly_MiNATherapeuticsLimitedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_MiNATherapeuticsLimitedMember_1c1cf833-dd89-4358-bfbd-a84385abfb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProtomerTechnologiesIncMember_1ddd02fa-27ce-4b96-ab7f-fd07de8460f5" xlink:href="lly-20211231.xsd#lly_ProtomerTechnologiesIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ProtomerTechnologiesIncMember_1ddd02fa-27ce-4b96-ab7f-fd07de8460f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_KumquatBiosciencesIncMember_53fade52-70dc-4135-b160-605af30f4f01" xlink:href="lly-20211231.xsd#lly_KumquatBiosciencesIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_KumquatBiosciencesIncMember_53fade52-70dc-4135-b160-605af30f4f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LyciaTherapeuticsIncMember_9569c032-d5c7-406c-ba14-946517681db0" xlink:href="lly-20211231.xsd#lly_LyciaTherapeuticsIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_LyciaTherapeuticsIncMember_9569c032-d5c7-406c-ba14-946517681db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProQRTherapeuticsNVMember_cba39862-2523-4716-b39c-0c0e980d9733" xlink:href="lly-20211231.xsd#lly_ProQRTherapeuticsNVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ProQRTherapeuticsNVMember_cba39862-2523-4716-b39c-0c0e980d9733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_QILURegorTherapeuticsIncMember_226bade4-e558-41ac-8b07-cc0ef8f96c06" xlink:href="lly-20211231.xsd#lly_QILURegorTherapeuticsIncMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_QILURegorTherapeuticsIncMember_226bade4-e558-41ac-8b07-cc0ef8f96c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FoghornTherapeuticsIncMember_c141f05a-58d3-4e5d-bc1a-a9cf8a1cf775" xlink:href="lly-20211231.xsd#lly_FoghornTherapeuticsIncMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_FoghornTherapeuticsIncMember_c141f05a-58d3-4e5d-bc1a-a9cf8a1cf775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EntosPharmaceuticalsIncMember_9f32f134-5bfb-46fb-8b98-d5dc962d3397" xlink:href="lly-20211231.xsd#lly_EntosPharmaceuticalsIncMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_EntosPharmaceuticalsIncMember_9f32f134-5bfb-46fb-8b98-d5dc962d3397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_6d765664-ae1c-45dc-b949-317bfd726397" xlink:href="lly-20211231.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_6d765664-ae1c-45dc-b949-317bfd726397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_ba73b873-7e62-4abf-a052-e80f5d6dccbd" xlink:href="lly-20211231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_ba73b873-7e62-4abf-a052-e80f5d6dccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_1e284c27-274b-41e5-8821-b16f65d6df62" xlink:href="lly-20211231.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_JunshiBiosciencesMember_1e284c27-274b-41e5-8821-b16f65d6df62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_aa96c8f5-414a-4ed6-b9e2-f1a50362f532" xlink:href="lly-20211231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_PetraPharmaCorporationMember_aa96c8f5-414a-4ed6-b9e2-f1a50362f532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember_c73582e2-4551-453d-86b1-806f7e28c571" xlink:href="lly-20211231.xsd#lly_EvoxTherapeuticsMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_EvoxTherapeuticsMember_c73582e2-4551-453d-86b1-806f7e28c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_95bccc5a-d7b3-42bb-9eea-89fcfe8a006e" xlink:href="lly-20211231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_InnoventBiologicsIncMember_95bccc5a-d7b3-42bb-9eea-89fcfe8a006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember_f0427782-4a1e-4eb7-8a87-579c18c297b6" xlink:href="lly-20211231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_DisarmTherapeuticsIncMember_f0427782-4a1e-4eb7-8a87-579c18c297b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FochonPharmaceuticalsLtdMember_b81bae99-1b79-4ec7-98fc-42b87980dbb1" xlink:href="lly-20211231.xsd#lly_FochonPharmaceuticalsLtdMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_FochonPharmaceuticalsLtdMember_b81bae99-1b79-4ec7-98fc-42b87980dbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ACImmuneSAMember_4a3bf724-9e55-4dfb-acac-ad2dcc667c5f" xlink:href="lly-20211231.xsd#lly_ACImmuneSAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ACImmuneSAMember_4a3bf724-9e55-4dfb-acac-ad2dcc667c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmuNextInc.Member_66671838-4fb0-4759-ba8e-d4977def9e96" xlink:href="lly-20211231.xsd#lly_ImmuNextInc.Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_ImmuNextInc.Member_66671838-4fb0-4759-ba8e-d4977def9e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvidityBiosciencesInc.Member_bbb8ea7e-2c3e-4d69-8df9-49659316a35a" xlink:href="lly-20211231.xsd#lly_AvidityBiosciencesInc.Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_AvidityBiosciencesInc.Member_bbb8ea7e-2c3e-4d69-8df9-49659316a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CentrexionTherapeuticsCorporationMember_1025ac9e-9e36-4bc8-8733-3b30791f0813" xlink:href="lly-20211231.xsd#lly_CentrexionTherapeuticsCorporationMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4be6a0bd-fdef-4180-bd9b-182a038bb8f0" xlink:to="loc_lly_CentrexionTherapeuticsCorporationMember_1025ac9e-9e36-4bc8-8733-3b30791f0813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_338c3c25-58ee-4a99-9675-3cad15eb837e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5891d356-84a0-4ed1-b3fa-7db6308b95d1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_338c3c25-58ee-4a99-9675-3cad15eb837e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b58898e7-077b-4817-b73c-e6df24fa6da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_338c3c25-58ee-4a99-9675-3cad15eb837e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b58898e7-077b-4817-b73c-e6df24fa6da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c00e5dc1-08c1-451d-98af-71dbdc7f4a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_253e8b36-bb42-464e-b5d6-6ace66d017b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c00e5dc1-08c1-451d-98af-71dbdc7f4a06" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_253e8b36-bb42-464e-b5d6-6ace66d017b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c41e494f-f76b-4a69-97ca-be5f646c5126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0886dafc-4ef3-4556-8779-efdeb9537d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c41e494f-f76b-4a69-97ca-be5f646c5126" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0886dafc-4ef3-4556-8779-efdeb9537d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3737b8a3-ab89-4dab-a46d-0a2fd2e33f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3737b8a3-ab89-4dab-a46d-0a2fd2e33f15" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99fe8f90-838e-4569-9743-688212d3d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5f867c0c-5f8c-4b82-b460-f9e3c9cd076d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99fe8f90-838e-4569-9743-688212d3d42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_0f58f725-19ea-4969-aaf8-87f7fd987323" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99fe8f90-838e-4569-9743-688212d3d42d" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_0f58f725-19ea-4969-aaf8-87f7fd987323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:to="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_95e3e9f1-b960-4d83-8d1b-04713f2d162f" xlink:to="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_b7174e2a-0b01-4015-ae45-0eaee04a25aa" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:to="loc_lly_JardianceMember_b7174e2a-0b01-4015-ae45-0eaee04a25aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_98f6a89e-cf3b-4d97-a160-ce0dfa66bfe1" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:to="loc_lly_TrajentaBIMember_98f6a89e-cf3b-4d97-a160-ce0dfa66bfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_9684ff02-a902-49c6-815d-a1374a6f1f60" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5bd1cac9-da16-4fcd-81c7-03d8c31f86a3" xlink:to="loc_lly_BasaglarMember_9684ff02-a902-49c6-815d-a1374a6f1f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286c4e0e-888f-433c-be30-13d15e19c389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ce26b50c-8689-457f-bcae-ac3ae46367db" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286c4e0e-888f-433c-be30-13d15e19c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_42c3fc2e-667a-4b86-900a-3cc1549fa4a2" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_286c4e0e-888f-433c-be30-13d15e19c389" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_42c3fc2e-667a-4b86-900a-3cc1549fa4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01e825db-8a45-44c4-a350-741476e0e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01e825db-8a45-44c4-a350-741476e0e2d7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:to="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_94c559d3-75fa-46ff-8a72-1fe1dec28856" xlink:to="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_d890d015-3c35-445f-ac38-07085711c4bf" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_JardianceMember_d890d015-3c35-445f-ac38-07085711c4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_23045a03-3585-4c8e-9b0a-4da3f1d76c85" xlink:href="lly-20211231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_BasaglarMember_23045a03-3585-4c8e-9b0a-4da3f1d76c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_e8ff409c-c8e4-43e1-864a-70ed1c3699b0" xlink:href="lly-20211231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_TrajentaBIMember_e8ff409c-c8e4-43e1-864a-70ed1c3699b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_54fb1047-5ba5-47ab-8fe7-0c10f13ee6af" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9eab4a9a-6fe9-4c12-a1bd-b3bba02317ab" xlink:to="loc_lly_OlumiantMember_54fb1047-5ba5-47ab-8fe7-0c10f13ee6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83634b51-ee28-4175-989a-a3e110fb1768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60cacd9f-7b91-476f-8df3-25b6eac4068b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83634b51-ee28-4175-989a-a3e110fb1768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1ce25655-1994-4000-9241-b3c7defe7757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83634b51-ee28-4175-989a-a3e110fb1768" xlink:to="loc_us-gaap_Revenues_1ce25655-1994-4000-9241-b3c7defe7757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da1a0b91-cc31-4380-aea8-399d26b30fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_da1a0b91-cc31-4380-aea8-399d26b30fbf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_80da10e8-33fa-4ea4-a4eb-63f44ef7daea" xlink:to="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_54949e1e-4a61-4baa-84f7-02fd1aa05c4a" xlink:href="lly-20211231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_OlumiantMember_54949e1e-4a61-4baa-84f7-02fd1aa05c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_7b9159ff-24fb-4d3e-9e2d-41e747532551" xlink:href="lly-20211231.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_COVID19AntibodiesMember_7b9159ff-24fb-4d3e-9e2d-41e747532551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_70954302-dd61-440c-ac09-80a828922ffc" xlink:href="lly-20211231.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_TYVYTMember_70954302-dd61-440c-ac09-80a828922ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_ed9a1edf-cc47-4902-9853-eeeba13bfeae" xlink:href="lly-20211231.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cd550fd7-3673-467e-9f3e-98888ee93809" xlink:to="loc_lly_LebrikizumabMember_ed9a1edf-cc47-4902-9853-eeeba13bfeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c862f20a-8a67-415d-8b53-7f04d703aabe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_8cfc1602-4ee5-4a82-bb9e-654fd541d6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_8cfc1602-4ee5-4a82-bb9e-654fd541d6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_cf432996-c6df-4303-bbdf-1cab90556ed5" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_cf432996-c6df-4303-bbdf-1cab90556ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_6fab23f4-8bfa-4cb9-a14b-41021a913295" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_6fab23f4-8bfa-4cb9-a14b-41021a913295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_aabab6a9-b77c-4294-9a6a-d635fde79421" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_aabab6a9-b77c-4294-9a6a-d635fde79421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_9c745624-08a7-47dd-a94a-9478b450134e" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_9c745624-08a7-47dd-a94a-9478b450134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_1566d9f1-f463-42da-abcb-1651e65d617d" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_9c745624-08a7-47dd-a94a-9478b450134e" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_1566d9f1-f463-42da-abcb-1651e65d617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_3fb9b908-9e85-4871-a40a-ff83155f0b58" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_3fb9b908-9e85-4871-a40a-ff83155f0b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_6c9026e5-b2a0-42e5-9d7c-282fe22a13be" xlink:href="lly-20211231.xsd#lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71b43133-f9fd-4aa3-9519-d965a5aeee06" xlink:to="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_6c9026e5-b2a0-42e5-9d7c-282fe22a13be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5b9c1287-52e9-4dd8-a97f-edaaac0195d4" xlink:to="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_615fce62-2e06-43d3-b47f-10f624b0c532" xlink:href="lly-20211231.xsd#lly_NonCHINAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:to="loc_lly_NonCHINAMember_615fce62-2e06-43d3-b47f-10f624b0c532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_668e77df-af17-4b01-9b99-085e650fa0a0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b1aab564-752f-43c9-8a02-accbea53ecdd" xlink:to="loc_country_CN_668e77df-af17-4b01-9b99-085e650fa0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f50a2cd6-a750-4368-adb5-46077e4b7411" xlink:to="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_63b0019a-56a3-4ad6-b289-ca693d7aa0a2" xlink:href="lly-20211231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:to="loc_lly_InnoventBiologicsIncMember_63b0019a-56a3-4ad6-b289-ca693d7aa0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_c771336d-180b-45e7-bb40-905be0f0faa9" xlink:href="lly-20211231.xsd#lly_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0fcda956-273f-42cf-b847-2298c304f57f" xlink:to="loc_lly_RocheMember_c771336d-180b-45e7-bb40-905be0f0faa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5e89c918-b980-4e98-93d0-782c081da4a6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_c6fe9bdb-b64e-43e2-911c-7bf96f1ef18d" xlink:href="lly-20211231.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:to="loc_lly_JunshiBiosciencesMember_c6fe9bdb-b64e-43e2-911c-7bf96f1ef18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_0694a2df-9910-418f-bc26-4d1ef2fe1e6c" xlink:href="lly-20211231.xsd#lly_PetraPharmaCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9e34f765-da49-4f9c-92b8-16ddeb9afebd" xlink:to="loc_lly_PetraPharmaCorporationMember_0694a2df-9910-418f-bc26-4d1ef2fe1e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02601ace-0da2-4f64-9c4d-2b4b83417b2e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d629697b-6dec-4ee5-8520-eb6e978904b0" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_d629697b-6dec-4ee5-8520-eb6e978904b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_aced7681-f495-402d-891f-e9ba468c9c35" xlink:href="lly-20211231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_aced7681-f495-402d-891f-e9ba468c9c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a988035a-72be-4127-b1ae-42408ee86c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a988035a-72be-4127-b1ae-42408ee86c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f338e91b-d241-4c8c-a71c-186768ef748f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f338e91b-d241-4c8c-a71c-186768ef748f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e14bfd09-1a50-4569-9d8d-968155f9f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e70f741-bf55-4c0a-a3da-63053d84be5c" xlink:to="loc_us-gaap_Revenues_e14bfd09-1a50-4569-9d8d-968155f9f9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20211231.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cf497876-7864-4768-abaf-13d982c560a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_93a543ba-3419-4139-abd9-8f02fecf51a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cf497876-7864-4768-abaf-13d982c560a3" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_93a543ba-3419-4139-abd9-8f02fecf51a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20211231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_10bbc819-23b0-48df-8da0-6a4dd23ae1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e4e5a3ed-8194-41ed-ac84-caaae0b348dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_10bbc819-23b0-48df-8da0-6a4dd23ae1d5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e4e5a3ed-8194-41ed-ac84-caaae0b348dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7d3b474f-d94b-4073-98b6-dca829edacb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_aa60e0a6-6839-43b7-bfbe-8ff247cc0468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7d3b474f-d94b-4073-98b6-dca829edacb2" xlink:to="loc_us-gaap_SeveranceCosts1_aa60e0a6-6839-43b7-bfbe-8ff247cc0468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_08dbf872-ee5b-41c6-a55d-aeeafda8b782" xlink:href="lly-20211231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7d3b474f-d94b-4073-98b6-dca829edacb2" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_08dbf872-ee5b-41c6-a55d-aeeafda8b782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_4ab9135f-ce0c-4f39-9bf3-d43492820424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7d3b474f-d94b-4073-98b6-dca829edacb2" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_4ab9135f-ce0c-4f39-9bf3-d43492820424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dec70d8c-ebea-4088-b42e-a143b3b90a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dec70d8c-ebea-4088-b42e-a143b3b90a9e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78501b63-3e1e-4ab3-838f-e2ae793e6149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7fdc4c2f-06c4-4842-9396-cb6174d90074" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78501b63-3e1e-4ab3-838f-e2ae793e6149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_4cf43b7c-bf41-4f7a-b47b-196b504f2dc1" xlink:href="lly-20211231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78501b63-3e1e-4ab3-838f-e2ae793e6149" xlink:to="loc_lly_LoxoOncologyInc.Member_4cf43b7c-bf41-4f7a-b47b-196b504f2dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1f0615a1-c440-4a0c-b167-b2e36ced2e3f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_23594d1e-58b9-4ffd-8f57-92f7624081d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_23594d1e-58b9-4ffd-8f57-92f7624081d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96690629-9f7e-44a3-9019-339c04ec2ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96690629-9f7e-44a3-9019-339c04ec2ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a8f33b40-6eeb-4207-93dc-6078179ab3d7" xlink:href="lly-20211231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_32b1cb45-b4a8-427a-94b0-6a92f17fa222" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a8f33b40-6eeb-4207-93dc-6078179ab3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Inventories" xlink:type="simple" xlink:href="lly-20211231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_89201859-c219-4f80-98ee-97c07e0e0aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_30740999-90d4-4df4-914a-5866b3e889e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_89201859-c219-4f80-98ee-97c07e0e0aa9" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_30740999-90d4-4df4-914a-5866b3e889e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesTables" xlink:type="simple" xlink:href="lly-20211231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d89cf4af-02ac-4901-82b9-8af8058b384e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ad2f4e18-6520-4362-80e8-f3666f167bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d89cf4af-02ac-4901-82b9-8af8058b384e" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ad2f4e18-6520-4362-80e8-f3666f167bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8f0863be-c514-488c-a19f-e480e8be8eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryFinishedGoods_8f0863be-c514-488c-a19f-e480e8be8eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_73d59328-454c-4085-8e56-a86f53d34bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryWorkInProcess_73d59328-454c-4085-8e56-a86f53d34bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_80ef124f-9247-4610-be48-ace31e90e2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryRawMaterials_80ef124f-9247-4610-be48-ace31e90e2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5f9fe862-aa7b-4062-85db-f942cb0ae5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryGross_5f9fe862-aa7b-4062-85db-f942cb0ae5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_3dc37034-6c44-41bd-916a-d6674662901d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryLIFOReserve_3dc37034-6c44-41bd-916a-d6674662901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d55ac9c6-5aeb-4de0-a40b-483ef6b104c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryNet_d55ac9c6-5aeb-4de0-a40b-483ef6b104c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_ef79a6f0-d34e-4dd2-8890-2921de7bcd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_LIFOInventoryAmount_ef79a6f0-d34e-4dd2-8890-2921de7bcd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_1b033bcc-a611-4149-ac53-c0c28db06f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a2f0151-7033-43b0-b6e4-4be3b21c5140" xlink:to="loc_us-gaap_InventoryWriteDown_1b033bcc-a611-4149-ac53-c0c28db06f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9188e23c-7e68-4529-b841-9058788bafec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_10505689-9180-4352-82d3-f3c62940cc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9188e23c-7e68-4529-b841-9058788bafec" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_10505689-9180-4352-82d3-f3c62940cc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_576ec1e2-2111-4abb-88ec-f34d4851688f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_576ec1e2-2111-4abb-88ec-f34d4851688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_26e01be5-5a22-4042-b7af-6db82c71bd08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_26e01be5-5a22-4042-b7af-6db82c71bd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f4ac4de2-735b-49d8-812d-a3d003e0721c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f4ac4de2-735b-49d8-812d-a3d003e0721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d56c15a4-d647-41cd-9ede-0388dda0e0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d56c15a4-d647-41cd-9ede-0388dda0e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_43e3bdcb-7262-4235-8081-b159ad07d79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_43e3bdcb-7262-4235-8081-b159ad07d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_3b7029f8-bc8e-4c06-a1b8-30bf4b12d5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_3b7029f8-bc8e-4c06-a1b8-30bf4b12d5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_31a32fe6-cfc7-44c6-8ed4-ad81beb3e82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_31a32fe6-cfc7-44c6-8ed4-ad81beb3e82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b901f5d3-635b-4ebf-b417-f556a589ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b901f5d3-635b-4ebf-b417-f556a589ef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_d41c47da-bb73-4c27-98bd-40b6a76279ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c2840097-ab4d-4a8d-99fe-fdcc52acbc47" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_d41c47da-bb73-4c27-98bd-40b6a76279ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46f64d0d-f140-43d6-a639-632800099e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46f64d0d-f140-43d6-a639-632800099e5e" xlink:to="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7f2107fb-826e-4e8b-a817-a12a6d1f148d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d9d2e057-40bf-4e63-946d-50a3f6975bdf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7f2107fb-826e-4e8b-a817-a12a6d1f148d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_3485b193-1dd2-4752-bf7a-93860355d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7f2107fb-826e-4e8b-a817-a12a6d1f148d" xlink:to="loc_us-gaap_CashFlowHedgingMember_3485b193-1dd2-4752-bf7a-93860355d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3498e1d0-4af1-4f9e-b900-0584b82ac2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_adb7e94f-2e2f-45a3-b9e8-4f32f159afd1" xlink:to="loc_us-gaap_HedgingDesignationDomain_3498e1d0-4af1-4f9e-b900-0584b82ac2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db73355a-63b4-440a-bd25-b4923f9f10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3498e1d0-4af1-4f9e-b900-0584b82ac2e7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_db73355a-63b4-440a-bd25-b4923f9f10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_218ef912-cf16-4019-bdb5-642baaee2ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df8d03fd-ba1a-442d-9f9d-db1174d1f519" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_218ef912-cf16-4019-bdb5-642baaee2ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_abcd5638-ef35-4cd2-b1bd-3a8dc62cf9be" xlink:href="lly-20211231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_218ef912-cf16-4019-bdb5-642baaee2ad7" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_abcd5638-ef35-4cd2-b1bd-3a8dc62cf9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_43238c9b-2fe7-45dc-8ab7-23d49ce4ec90" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_1efbb777-7027-4e38-af1a-39cf4fb01675" xlink:href="lly-20211231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyUsdSellEuroMember_1efbb777-7027-4e38-af1a-39cf4fb01675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_02f06930-cd0e-4eac-a6d4-fa7830178619" xlink:href="lly-20211231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyEuroSellUsDollarMember_02f06930-cd0e-4eac-a6d4-fa7830178619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_9996e2c1-548a-4fe5-8678-7a01c9b27b7e" xlink:href="lly-20211231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_9996e2c1-548a-4fe5-8678-7a01c9b27b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_2cb65403-f636-4460-8db8-24f942f4dc21" xlink:href="lly-20211231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_BuyGBPSellUSDMember_2cb65403-f636-4460-8db8-24f942f4dc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_e3f29edf-299d-4e0f-ba50-4d2d221fa5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_us-gaap_CurrencySwapMember_e3f29edf-299d-4e0f-ba50-4d2d221fa5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_4eeb9665-fb11-4c97-bf85-043a8f1bece2" xlink:href="lly-20211231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_4eeb9665-fb11-4c97-bf85-043a8f1bece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a0907958-62c7-40a0-b372-3c047f73ba42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_585b843a-bbe2-4189-b392-9b54bc9a3d5d" xlink:to="loc_us-gaap_InterestRateSwapMember_a0907958-62c7-40a0-b372-3c047f73ba42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_46d6338e-485e-4ef2-848f-271026ba44e3" xlink:to="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_2ae47f6c-87a4-4b0e-8d06-f7336e870ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_2ae47f6c-87a4-4b0e-8d06-f7336e870ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_b1e871ec-914f-4aed-bd94-ec739aaab445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_b1e871ec-914f-4aed-bd94-ec739aaab445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_10dac25c-9f7a-4670-9748-e6bf91abbac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_10dac25c-9f7a-4670-9748-e6bf91abbac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4c7f5b4d-5be1-42d0-a31d-ca95bfa9edb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4c7f5b4d-5be1-42d0-a31d-ca95bfa9edb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_63429e1d-5781-43a2-86a7-400c8bcbb584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_LongTermDebt_63429e1d-5781-43a2-86a7-400c8bcbb584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_ca1158f1-a7ae-470d-aa82-217c21787a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_ca1158f1-a7ae-470d-aa82-217c21787a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_94655f6c-450e-49ae-a543-70e77ebc3cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_94655f6c-450e-49ae-a543-70e77ebc3cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_cef4a234-998a-4000-b704-625fb88b2d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_cef4a234-998a-4000-b704-625fb88b2d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_7afb99a7-d700-4987-a60c-6b9c6ccd9a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_7afb99a7-d700-4987-a60c-6b9c6ccd9a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_b3c130ca-1ec4-4c46-bd58-ef7b15cf6209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_b3c130ca-1ec4-4c46-bd58-ef7b15cf6209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_5ad72ee7-6845-4b1d-9dd1-7cafc4025d41" xlink:href="lly-20211231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_5ad72ee7-6845-4b1d-9dd1-7cafc4025d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c4861eea-215f-45dc-b482-af4fe3bfdbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c4861eea-215f-45dc-b482-af4fe3bfdbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_c9e675d2-308b-4407-8a68-ad92c3c9b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_c9e675d2-308b-4407-8a68-ad92c3c9b5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d503e83d-7ea4-4201-aa1f-103b5a1ab035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_650023f0-3322-4df8-88ff-9fcd2bc24ddf" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d503e83d-7ea4-4201-aa1f-103b5a1ab035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c5ba9e4-51ee-4d59-bba2-87e19b5fdbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c5ba9e4-51ee-4d59-bba2-87e19b5fdbf9" xlink:to="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:to="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_43cfb54d-0b19-4867-b8a7-6ea8756d80c4" xlink:to="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d8c88009-d597-4fa2-9227-cc32f034b007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d8c88009-d597-4fa2-9227-cc32f034b007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8f1455fb-40e2-4caa-a3f9-2f4404a1c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3302ad57-0b62-41e0-9d4f-83c150639b33" xlink:to="loc_us-gaap_NondesignatedMember_8f1455fb-40e2-4caa-a3f9-2f4404a1c88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e96887ad-4ea3-489a-a1aa-36a6fff987ed" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_2fa7bfef-2b37-40ad-92f1-ef25487c6a54" xlink:href="lly-20211231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_lly_HedgedFixedRateDebtMember_2fa7bfef-2b37-40ad-92f1-ef25487c6a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_86383ec9-756e-4946-bd05-135cf23fd261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_InterestRateContractMember_86383ec9-756e-4946-bd05-135cf23fd261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b1637dd7-879c-47a0-9af7-18940d96857a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b1637dd7-879c-47a0-9af7-18940d96857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_4ec9c892-ba96-4da8-b2c1-ff865d855a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_InterestRateSwapMember_4ec9c892-ba96-4da8-b2c1-ff865d855a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b13a3bcf-7b33-42a1-960f-1c48e38758aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_817fb91e-5ccd-49be-997f-9f5f2c1e2c9c" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b13a3bcf-7b33-42a1-960f-1c48e38758aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e017456f-a030-43dc-81d5-91a220cc4874" xlink:to="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:href="lly-20211231.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8d353e16-3394-4044-af93-8c557168dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_8d353e16-3394-4044-af93-8c557168dfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_691ac533-3594-411e-b546-0a1e1576d5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_77e5ee77-18f2-44e7-831a-821b11e1ae5d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_691ac533-3594-411e-b546-0a1e1576d5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_f54dd077-74f8-4379-be78-7ef572b2bcc1" xlink:href="lly-20211231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_lly_CashFlowHedgeAbstract_f54dd077-74f8-4379-be78-7ef572b2bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_62f1c6b2-2b39-4eb3-a7e9-c7dfafb2448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_f54dd077-74f8-4379-be78-7ef572b2bcc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_62f1c6b2-2b39-4eb3-a7e9-c7dfafb2448f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ee1d35e8-4c7f-475e-9e47-6bf4a3d6c31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ee1d35e8-4c7f-475e-9e47-6bf4a3d6c31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_838b2066-860c-4146-bc24-4d07a955ab36" xlink:href="lly-20211231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_838b2066-860c-4146-bc24-4d07a955ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b66534d1-de85-4c9c-9e31-59b05f289219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b66534d1-de85-4c9c-9e31-59b05f289219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_15575e32-e612-474d-844c-71b53837f208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_68568a49-7d7a-4a05-87e7-2948c11d890a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_15575e32-e612-474d-844c-71b53837f208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fef660e2-b9ad-4bde-af98-f0688de0aad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fef660e2-b9ad-4bde-af98-f0688de0aad5" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_615a29bd-2070-40f0-84da-928beb6f7900" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67370b5f-3228-49c0-b9e4-c7089231f4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_67370b5f-3228-49c0-b9e4-c7089231f4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_33662806-35cc-4ae6-a9b0-84967043a5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_33662806-35cc-4ae6-a9b0-84967043a5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_3a882480-df34-4945-ab39-5ca2da2efa66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_3a882480-df34-4945-ab39-5ca2da2efa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3ede6904-7570-4593-a74c-7efd4031b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3ede6904-7570-4593-a74c-7efd4031b38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_2353ca79-0e6d-4177-bd4d-4d22dd604131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_2353ca79-0e6d-4177-bd4d-4d22dd604131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_252c43b9-2ffe-4ddc-8af0-f4b20ab40bca" xlink:href="lly-20211231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_lly_OtherEquitySecuritiesMember_252c43b9-2ffe-4ddc-8af0-f4b20ab40bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_ee7812f3-3ca5-45db-9163-881ae7baa756" xlink:href="lly-20211231.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_lly_MarketableSecuritiesMember_ee7812f3-3ca5-45db-9163-881ae7baa756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_99a99a3e-733c-497c-a34f-cfddffa84e45" xlink:href="lly-20211231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce081ad2-ae2f-498f-a45f-50ca6996e825" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_99a99a3e-733c-497c-a34f-cfddffa84e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2f2f79c2-074c-468c-899e-9df57ab5c4c0" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_816c80a6-e10e-4c82-9208-f23f2d153e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_816c80a6-e10e-4c82-9208-f23f2d153e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5d86d568-63d6-4025-91c3-f5660450ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5d86d568-63d6-4025-91c3-f5660450ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_cd316ff3-0647-4baf-ac1e-b60ee9d0322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_cd316ff3-0647-4baf-ac1e-b60ee9d0322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_64039239-c032-44ea-b534-1886ab026ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6f2a61f9-dc10-4886-9961-2b00c6cbc227" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_64039239-c032-44ea-b534-1886ab026ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e35e8e7-64b9-4357-9cd7-67ff169308e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_233641e0-693b-4f54-8b9f-caa1787131b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_233641e0-693b-4f54-8b9f-caa1787131b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2da77795-1ab6-4855-bba1-79646e7ad039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2da77795-1ab6-4855-bba1-79646e7ad039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_38813cb1-6aa0-4e40-aaee-87a3bee61631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6403b643-5b47-40d1-b337-431cbb42be96" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_38813cb1-6aa0-4e40-aaee-87a3bee61631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a82e14cc-0a13-4a78-8b86-db9300303bf4" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f0320495-6fa9-4e60-8799-4a8faa60586a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f0320495-6fa9-4e60-8799-4a8faa60586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12fe6607-629c-43da-bb81-fac236da2653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12fe6607-629c-43da-bb81-fac236da2653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_dd7a4f7d-d780-4093-880d-14f35cd0b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_dd7a4f7d-d780-4093-880d-14f35cd0b61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_07e84884-5a5b-4038-9a8a-55e2081e98dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_07e84884-5a5b-4038-9a8a-55e2081e98dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1da426ec-0391-4782-98cf-2c984456683f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_1da426ec-0391-4782-98cf-2c984456683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_79aecbc8-9c6c-4233-b06c-4704adcf1679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_OtherLongTermInvestments_79aecbc8-9c6c-4233-b06c-4704adcf1679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a9236224-f003-44e0-8ed3-d732d454c78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cb5751cf-6f29-4998-ba90-1056da396ff9" xlink:to="loc_us-gaap_LongTermInvestments_a9236224-f003-44e0-8ed3-d732d454c78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28cb3242-2f81-4929-af62-ab70eae27633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28cb3242-2f81-4929-af62-ab70eae27633" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_82c4ea0e-b319-47c6-bbc9-7b021c5c3f57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_abc9aeab-d23f-4f4f-a23e-76f4cb33aec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_abc9aeab-d23f-4f4f-a23e-76f4cb33aec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_751afda7-0346-4887-9f9e-f926279bf472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_751afda7-0346-4887-9f9e-f926279bf472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3fc96ec7-cc27-42b0-94d0-8a793c2ae58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85f7be16-52c8-4b16-9006-67fddcb678b3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3fc96ec7-cc27-42b0-94d0-8a793c2ae58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3ca59707-f72a-4005-8dff-8ad898c16ed1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_872eec01-8554-46bf-a1d1-cf57ab6db3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_872eec01-8554-46bf-a1d1-cf57ab6db3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b190b5da-edac-4ef8-84a1-d3637fb8dc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b190b5da-edac-4ef8-84a1-d3637fb8dc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_632403f0-cbae-407c-8237-0042bc64a6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_28440d23-11a7-4aed-8b96-22c2db81c47b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_632403f0-cbae-407c-8237-0042bc64a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ee58d620-2622-4fab-a95c-e675c66d5fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1117dea2-d396-4a1f-b3ac-fbcfe26e804b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ee58d620-2622-4fab-a95c-e675c66d5fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_afaefd22-5135-43d7-a6ea-a507797fcc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ee58d620-2622-4fab-a95c-e675c66d5fe6" xlink:to="loc_us-gaap_LongTermDebt_afaefd22-5135-43d7-a6ea-a507797fcc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_82b72422-d758-4e0c-b340-108194964495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_82b72422-d758-4e0c-b340-108194964495" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b69c338b-22fc-4458-9ac3-56098c8ccba0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b20134f6-c6e3-4be2-a256-eb2c9efb890b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:to="loc_us-gaap_FairValueHedgingMember_b20134f6-c6e3-4be2-a256-eb2c9efb890b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_07078349-02f2-4723-9108-3af8d1ff486e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:to="loc_us-gaap_CashFlowHedgingMember_07078349-02f2-4723-9108-3af8d1ff486e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_be43d431-9548-46c3-963a-b4244bdb5235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e0d42cf8-fc33-4b39-b739-4080e5db6703" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_be43d431-9548-46c3-963a-b4244bdb5235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_b61f803b-50d0-4062-80f7-979a8cc4ed32" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f84e529-1d58-42fc-a086-e36e8d02ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f84e529-1d58-42fc-a086-e36e8d02ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_87997c98-bd5e-4eac-a2bf-bf6ec649dbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_87997c98-bd5e-4eac-a2bf-bf6ec649dbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c875b732-fbee-45ba-b4d2-34328b22922d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3e95bf74-0ae9-4c94-9714-4eff63b6663d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c875b732-fbee-45ba-b4d2-34328b22922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f4af8aa2-6689-425f-8f67-4140985592ff" xlink:to="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6a9c6fe4-86a6-4c82-b208-43c7da46f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6a9c6fe4-86a6-4c82-b208-43c7da46f4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0490c321-60c6-4bf6-a2ad-2a9150131e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1223a6f6-947f-4474-a050-2f4dc39c08b6" xlink:to="loc_us-gaap_NondesignatedMember_0490c321-60c6-4bf6-a2ad-2a9150131e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_586cd1e4-ab30-4faf-b729-a1f67ff99b52" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_890b3aad-e815-49ca-949d-a55e25ca2819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:to="loc_us-gaap_InterestRateContractMember_890b3aad-e815-49ca-949d-a55e25ca2819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_f9ea66b5-8082-4a89-a62c-fefca2c55e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_f9ea66b5-8082-4a89-a62c-fefca2c55e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e8713205-b13a-4039-93d1-c2abeb769957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa3059be-6c36-46df-b9b3-37d8b2e0a1b2" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e8713205-b13a-4039-93d1-c2abeb769957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_695782a1-411e-43f1-9116-1aaf73e832b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ca493d8e-22b8-4357-a2ac-a748efa54052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ca493d8e-22b8-4357-a2ac-a748efa54052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2f3da9f4-c6e7-4dc3-a85e-949d68737c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2f3da9f4-c6e7-4dc3-a85e-949d68737c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_91397bac-2597-427e-a858-a3e3243f0a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2330ecab-da31-4189-8e84-005c6e22ad7b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_91397bac-2597-427e-a858-a3e3243f0a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c23ff92c-fec3-43d2-ae56-e00d8e8e8ac5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_5916944b-ce17-4667-a40c-3e0d5a674370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_5916944b-ce17-4667-a40c-3e0d5a674370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_e2bbe186-abd5-4435-9d4d-5018c2052bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_e2bbe186-abd5-4435-9d4d-5018c2052bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_26461682-b4f6-43c9-b778-fa762ee778d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_26461682-b4f6-43c9-b778-fa762ee778d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5b243f9a-3aa6-4347-b2d7-fffcf40e2ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5b243f9a-3aa6-4347-b2d7-fffcf40e2ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d4a0b60-b95c-46be-9e9b-b586fb7653b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d245810-013d-4825-9931-98281255d553" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d4a0b60-b95c-46be-9e9b-b586fb7653b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35a59be7-9831-412f-8cb9-e1355c86f1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0d4dd9-9b94-4a5c-8e0c-77907ffe2756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35a59be7-9831-412f-8cb9-e1355c86f1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0d4dd9-9b94-4a5c-8e0c-77907ffe2756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_22c835d4-cf32-43d9-92a4-edd969d648e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35a59be7-9831-412f-8cb9-e1355c86f1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_22c835d4-cf32-43d9-92a4-edd969d648e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2201c3ca-543b-46a3-a300-718587ee0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35a59be7-9831-412f-8cb9-e1355c86f1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2201c3ca-543b-46a3-a300-718587ee0d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_bad2471f-d808-442a-9e9d-f27c24947607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35a59be7-9831-412f-8cb9-e1355c86f1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_bad2471f-d808-442a-9e9d-f27c24947607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_fd1ef87c-7c03-42f3-8033-d4ff63ca13f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35a59be7-9831-412f-8cb9-e1355c86f1d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_fd1ef87c-7c03-42f3-8033-d4ff63ca13f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c440980-dce0-41b1-ab2c-12552836b9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2498aafe-2091-4298-9c82-db2d42aef0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c440980-dce0-41b1-ab2c-12552836b9b1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2498aafe-2091-4298-9c82-db2d42aef0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a25216ad-44f4-44c4-bcef-186cd2020fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c440980-dce0-41b1-ab2c-12552836b9b1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a25216ad-44f4-44c4-bcef-186cd2020fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_fedca3b9-2f08-4df0-9065-642558208ee3" xlink:href="lly-20211231.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c440980-dce0-41b1-ab2c-12552836b9b1" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_fedca3b9-2f08-4df0-9065-642558208ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e413aa9d-dcda-44ef-9bc5-62f9c746d2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c440980-dce0-41b1-ab2c-12552836b9b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e413aa9d-dcda-44ef-9bc5-62f9c746d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9126a8d1-d900-4cff-b59d-8b484e1a2b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_82e4d943-fb2b-4eb9-9a9c-f74bff47dda7" xlink:href="lly-20211231.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9126a8d1-d900-4cff-b59d-8b484e1a2b99" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_82e4d943-fb2b-4eb9-9a9c-f74bff47dda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_d7ea8312-e87d-499d-96aa-3492a1dab9f0" xlink:href="lly-20211231.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9126a8d1-d900-4cff-b59d-8b484e1a2b99" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_d7ea8312-e87d-499d-96aa-3492a1dab9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_838a1769-7f72-4a8c-9f17-3d52e6babc34" xlink:href="lly-20211231.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9126a8d1-d900-4cff-b59d-8b484e1a2b99" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_838a1769-7f72-4a8c-9f17-3d52e6babc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b0719b00-eb63-4489-aeb3-59065fdf2107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_33be6f2f-35b1-4f52-a0d5-f2f7889396ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b0719b00-eb63-4489-aeb3-59065fdf2107" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_33be6f2f-35b1-4f52-a0d5-f2f7889396ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f4005f5-77e3-43c9-915c-f50888af0c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ea05ef31-cd7c-4195-9f85-846f5824e24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f4005f5-77e3-43c9-915c-f50888af0c37" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ea05ef31-cd7c-4195-9f85-846f5824e24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_62b15390-7e00-45e4-8695-74e61bcc9741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f4005f5-77e3-43c9-915c-f50888af0c37" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_62b15390-7e00-45e4-8695-74e61bcc9741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_66652788-5825-442d-a2dc-d32632107dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f4005f5-77e3-43c9-915c-f50888af0c37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_66652788-5825-442d-a2dc-d32632107dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6a375033-b32d-4cb6-9d18-31943d93bd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f4005f5-77e3-43c9-915c-f50888af0c37" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6a375033-b32d-4cb6-9d18-31943d93bd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e44d6f78-4c2e-45bc-b0ab-ad572de37b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e44d6f78-4c2e-45bc-b0ab-ad572de37b35" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:to="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7ecc2389-7caa-436c-b053-d6ac40319e65" xlink:to="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_865e9345-c508-4234-9f6f-4abec8159fe5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:to="loc_srt_MinimumMember_865e9345-c508-4234-9f6f-4abec8159fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a7705d53-a7ec-473b-8a5b-b81a63b00bb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0f61f357-762c-4c35-bbac-52366400b95c" xlink:to="loc_srt_MaximumMember_a7705d53-a7ec-473b-8a5b-b81a63b00bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_af546cb4-4bd2-4933-8813-ebc0a27001c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cf2e0eb2-a8d2-4973-81c2-288523b823ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cf2e0eb2-a8d2-4973-81c2-288523b823ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_afec335e-9def-42e9-9ba2-68ac2bb00391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_afec335e-9def-42e9-9ba2-68ac2bb00391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_408a9230-7612-4306-bd66-56fe26088d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_412030ea-54ad-44ba-862f-5b1f5c81aada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_408a9230-7612-4306-bd66-56fe26088d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d31baac-a4ca-47f5-877a-b89412634025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d31baac-a4ca-47f5-877a-b89412634025" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5cf6765b-7aaa-4df4-891a-64f149a2a181" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_db14c9c3-c17d-4263-959b-b5f76c36ed7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_db14c9c3-c17d-4263-959b-b5f76c36ed7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_83488c5e-65dd-47bd-b4bc-1dc6d56c488d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6d6c2553-c1f9-4f7c-8802-3fc882f37683" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_83488c5e-65dd-47bd-b4bc-1dc6d56c488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d3de3432-0e5b-4df9-8281-6b6ad30beab8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_999223fa-8a24-44eb-8095-a51c4f1aa97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_999223fa-8a24-44eb-8095-a51c4f1aa97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_586c6294-0e2c-46ea-9085-a0a46b443c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_586c6294-0e2c-46ea-9085-a0a46b443c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5bee27d-3c22-4919-815b-f7e8b18a2507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_47059684-1fd6-4826-994c-f861ab1f5643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5bee27d-3c22-4919-815b-f7e8b18a2507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d31baac-a4ca-47f5-877a-b89412634025" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_459b19fb-e31b-4eb4-bf3a-4bafe85fec3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a05b877-ff87-4195-bb5d-6d19d0797d5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_459b19fb-e31b-4eb4-bf3a-4bafe85fec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c2b710f3-0853-47f6-af7e-8e5ea17121a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_459b19fb-e31b-4eb4-bf3a-4bafe85fec3f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c2b710f3-0853-47f6-af7e-8e5ea17121a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0963d9da-1115-4a1f-98f4-69694ddca726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_10e46239-26ce-452c-b198-13a116db675b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0963d9da-1115-4a1f-98f4-69694ddca726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f8c9452-275c-41ba-96d0-725bfaf9c4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0963d9da-1115-4a1f-98f4-69694ddca726" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f8c9452-275c-41ba-96d0-725bfaf9c4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8f45b8d7-bfb3-49a9-ab98-a22fd437b5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d31baac-a4ca-47f5-877a-b89412634025" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8f45b8d7-bfb3-49a9-ab98-a22fd437b5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6ed3900c-a760-4048-9404-05dee220dc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8f45b8d7-bfb3-49a9-ab98-a22fd437b5db" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6ed3900c-a760-4048-9404-05dee220dc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_89eaa58d-f82b-4277-90d0-e24c8b420acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8f45b8d7-bfb3-49a9-ab98-a22fd437b5db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_89eaa58d-f82b-4277-90d0-e24c8b420acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e565f2ab-2992-485f-9d69-af8092dd7799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8f45b8d7-bfb3-49a9-ab98-a22fd437b5db" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e565f2ab-2992-485f-9d69-af8092dd7799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d8177f4f-e333-4651-94e2-0db47c681c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_09988a0c-f1b8-4ec1-a8cb-c7f8ae2b4d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d8177f4f-e333-4651-94e2-0db47c681c2a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_09988a0c-f1b8-4ec1-a8cb-c7f8ae2b4d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d02f425b-6f9d-4a3e-a263-461c3fc6b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d02f425b-6f9d-4a3e-a263-461c3fc6b79e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a77151b0-6db9-45c0-891d-45971c14fb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a77151b0-6db9-45c0-891d-45971c14fb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_21f6a8f6-1960-4a46-95a8-2c4dbbed000f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_21f6a8f6-1960-4a46-95a8-2c4dbbed000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_03a429b8-55a2-48aa-8898-75f328199c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_03a429b8-55a2-48aa-8898-75f328199c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9c96d5ca-bc9f-4609-aa4e-ca4206122dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9c96d5ca-bc9f-4609-aa4e-ca4206122dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c0e1cfca-658b-4afe-a218-06b46b6096e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1e6c40f-cdfd-4081-99b8-2c86c1a31ff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c0e1cfca-658b-4afe-a218-06b46b6096e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bc26818b-121c-4d20-bcc2-36a2fb6a246c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6e4fe1b5-9d69-4d2a-8ba0-3e515392c10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bc26818b-121c-4d20-bcc2-36a2fb6a246c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6e4fe1b5-9d69-4d2a-8ba0-3e515392c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e9b5d1fc-84ab-4799-8001-43a14c038cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fd4a993c-32ac-49c4-b07f-a85ed7a28747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e9b5d1fc-84ab-4799-8001-43a14c038cf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fd4a993c-32ac-49c4-b07f-a85ed7a28747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_fdfe79cd-b89a-430f-bc95-4c0b6626a609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e9b5d1fc-84ab-4799-8001-43a14c038cf1" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_fdfe79cd-b89a-430f-bc95-4c0b6626a609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_39967a00-3ee6-43c0-b8af-01115e30ccf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_39967a00-3ee6-43c0-b8af-01115e30ccf7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e99fd94e-9c40-4d00-ac28-c0265524c9cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f7c36c47-2edf-480e-ab43-2cdc7a83cbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:to="loc_us-gaap_BuildingMember_f7c36c47-2edf-480e-ab43-2cdc7a83cbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_1c7ede28-e8af-4fb3-af45-6c3125302684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daac3e17-ef30-471b-8d72-9311a3f88b14" xlink:to="loc_us-gaap_EquipmentMember_1c7ede28-e8af-4fb3-af45-6c3125302684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:to="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_53d02843-8d73-49f2-9d81-b280ec82edef" xlink:to="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_475abc2a-71c6-4663-ab3e-f04e61b8c20e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:to="loc_srt_MinimumMember_475abc2a-71c6-4663-ab3e-f04e61b8c20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c0d26ef-24cf-4cbb-afaa-ddb1bcea827f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a9dc725b-6239-4ae1-a331-e8ac7c1771f1" xlink:to="loc_srt_MaximumMember_6c0d26ef-24cf-4cbb-afaa-ddb1bcea827f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2282b5d-ce09-49d5-b5f9-b1afe87d8915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_39cd7162-b934-4301-a369-459c74751ccb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2282b5d-ce09-49d5-b5f9-b1afe87d8915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85707968-5314-4ab9-aeb8-b5ba8381a321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2282b5d-ce09-49d5-b5f9-b1afe87d8915" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85707968-5314-4ab9-aeb8-b5ba8381a321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_27f7516b-0104-4a95-bec9-8dca2075e0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_Land_27f7516b-0104-4a95-bec9-8dca2075e0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_051119a2-d9e8-4f5a-8826-59243f38db37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_051119a2-d9e8-4f5a-8826-59243f38db37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_ad523443-d2f1-4356-a75d-e8e5ca161f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_ad523443-d2f1-4356-a75d-e8e5ca161f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_4c7b11e6-ee07-4747-babb-5d4d8d22d004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_ConstructionInProgressGross_4c7b11e6-ee07-4747-babb-5d4d8d22d004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c6ff3e14-e4b3-4909-9954-770e97f884b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c6ff3e14-e4b3-4909-9954-770e97f884b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_06a82395-0674-4048-8b49-0f91068c6e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_06a82395-0674-4048-8b49-0f91068c6e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d6a3926e-109b-4304-846e-1574e180ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf409dc3-8653-4741-9e84-61f9105bacea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d6a3926e-109b-4304-846e-1574e180ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentScheduleofDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c879ea7b-a3da-48d8-8a80-95667ea61bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_66cd78ab-c7d2-47a1-98f1-b0e346575a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c879ea7b-a3da-48d8-8a80-95667ea61bfa" xlink:to="loc_us-gaap_Depreciation_66cd78ab-c7d2-47a1-98f1-b0e346575a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23017d1e-e581-486c-bf34-1202268f8551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23017d1e-e581-486c-bf34-1202268f8551" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:to="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_756b5cf7-03c2-4d44-a5b5-36bcdee1f598" xlink:to="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember_cb99b0f8-be2d-491d-886f-f6e6dc012b6b" xlink:href="lly-20211231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:to="loc_lly_UNITEDSTATESAndPUERTORICOMember_cb99b0f8-be2d-491d-886f-f6e6dc012b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_509524bf-829e-4f8b-a234-e38687ab17ec" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:to="loc_country_IE_509524bf-829e-4f8b-a234-e38687ab17ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_2fbd7797-50a1-4ebf-9b1d-112e7aa7087d" xlink:href="lly-20211231.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_60696974-04bb-424c-8a05-a5c6d3e2190e" xlink:to="loc_lly_OtherForeignCountriesMember_2fbd7797-50a1-4ebf-9b1d-112e7aa7087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7526f8c4-a020-44b9-b7ef-059393e41338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c213fb8f-f0d7-4f10-9d86-db61fcec428e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7526f8c4-a020-44b9-b7ef-059393e41338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_535f2084-bbd6-46ec-bb4c-6d7eba925fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7526f8c4-a020-44b9-b7ef-059393e41338" xlink:to="loc_us-gaap_NoncurrentAssets_535f2084-bbd6-46ec-bb4c-6d7eba925fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Leases" xlink:type="simple" xlink:href="lly-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4ba5b2e3-54cf-4eee-9582-98010f647998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_33e5be81-8f58-4798-8699-75e4d9763c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ba5b2e3-54cf-4eee-9582-98010f647998" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_33e5be81-8f58-4798-8699-75e4d9763c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_ff618a92-6c4a-466c-a7e0-4951534a8d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ba5b2e3-54cf-4eee-9582-98010f647998" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_ff618a92-6c4a-466c-a7e0-4951534a8d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesTables" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b68c0352-05bd-4326-8fcb-a56b5e699620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4f1f7da8-9580-4fb2-98f1-36ba1a42ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b68c0352-05bd-4326-8fcb-a56b5e699620" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4f1f7da8-9580-4fb2-98f1-36ba1a42ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c9537e56-95b4-4285-ab97-22a6a5158e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b68c0352-05bd-4326-8fcb-a56b5e699620" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c9537e56-95b4-4285-ab97-22a6a5158e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_98fda448-b247-4b8f-a8aa-15ee93e028a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LesseeLeaseRemainingLeaseTerm_c877559e-9e36-4377-94bd-ab152e5232db" xlink:href="lly-20211231.xsd#lly_LesseeLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_98fda448-b247-4b8f-a8aa-15ee93e028a4" xlink:to="loc_lly_LesseeLeaseRemainingLeaseTerm_c877559e-9e36-4377-94bd-ab152e5232db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2b06e7ce-c573-46f3-943f-ddfb666cb43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_98fda448-b247-4b8f-a8aa-15ee93e028a4" xlink:to="loc_us-gaap_OperatingLeaseCost_2b06e7ce-c573-46f3-943f-ddfb666cb43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_58243982-11fe-440a-b4c3-06c94d35d4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5252ed29-7166-41dc-8cc0-441a1f350353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58243982-11fe-440a-b4c3-06c94d35d4e2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5252ed29-7166-41dc-8cc0-441a1f350353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_df419d7f-516b-4542-82bf-cbb9f9b51d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58243982-11fe-440a-b4c3-06c94d35d4e2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_df419d7f-516b-4542-82bf-cbb9f9b51d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8fb4cafc-c20e-41c0-9ee8-8c1e4e944b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58243982-11fe-440a-b4c3-06c94d35d4e2" xlink:to="loc_us-gaap_OperatingLeasePayments_8fb4cafc-c20e-41c0-9ee8-8c1e4e944b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d44302be-d80c-48e4-9d8d-00c2e2db398e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58243982-11fe-440a-b4c3-06c94d35d4e2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d44302be-d80c-48e4-9d8d-00c2e2db398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e5f7854-db3f-4043-97fc-6ba7e030ffeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e5f7854-db3f-4043-97fc-6ba7e030ffeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_67c1d5fb-0f24-435f-a087-3e216412844b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_67c1d5fb-0f24-435f-a087-3e216412844b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f04a048-5f61-4a6c-af52-ba3bc4ee0e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f04a048-5f61-4a6c-af52-ba3bc4ee0e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3cbcb53e-30ae-43dc-9c5c-6ed548b6ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3cbcb53e-30ae-43dc-9c5c-6ed548b6ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8f842040-c96f-4f69-a95c-aa778e38b07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8f842040-c96f-4f69-a95c-aa778e38b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_490253f9-2d3d-435c-98da-1b7500352685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_490253f9-2d3d-435c-98da-1b7500352685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9778c0c4-a12c-4f4d-9790-dbcefe4eaf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9778c0c4-a12c-4f4d-9790-dbcefe4eaf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0c26eb41-807f-43c0-bcdf-c371ead89a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0c26eb41-807f-43c0-bcdf-c371ead89a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2b48a16-974f-49e9-a36a-84ad7083b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2b48a16-974f-49e9-a36a-84ad7083b3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_4cfac83a-6576-4bef-a577-5380bba676d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61a0252e-25c3-404e-97db-7e78cd4a9fd0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_4cfac83a-6576-4bef-a577-5380bba676d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lly-20211231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Borrowings" xlink:type="simple" xlink:href="lly-20211231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_88b6ab9a-5672-421d-8e4c-433ddcbe2961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_726dea98-6214-448f-8974-dbaa57cfa1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_88b6ab9a-5672-421d-8e4c-433ddcbe2961" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_726dea98-6214-448f-8974-dbaa57cfa1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsTables" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_96d389b0-b9f0-4981-b9ff-becc24a5b43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_a0e12dfe-6c7e-4b0d-af80-c1071ebc66e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_96d389b0-b9f0-4981-b9ff-becc24a5b43b" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_a0e12dfe-6c7e-4b0d-af80-c1071ebc66e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3b5e84c2-4cf7-4c58-adef-895c6ecca596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_96d389b0-b9f0-4981-b9ff-becc24a5b43b" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3b5e84c2-4cf7-4c58-adef-895c6ecca596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_43dc83c7-16d4-4418-9b16-8b42dc1174e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_96d389b0-b9f0-4981-b9ff-becc24a5b43b" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_43dc83c7-16d4-4418-9b16-8b42dc1174e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_d0d9d036-8fae-4c6f-a4d3-1b6ac895b8c2" xlink:href="lly-20211231.xsd#lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_96d389b0-b9f0-4981-b9ff-becc24a5b43b" xlink:to="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_d0d9d036-8fae-4c6f-a4d3-1b6ac895b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_95f9d87a-1203-4d23-820d-d19769768874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_us-gaap_NotesPayable_95f9d87a-1203-4d23-820d-d19769768874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable_0c03a595-8ba0-4d22-8502-97777d7820e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_us-gaap_OtherNotesPayable_0c03a595-8ba0-4d22-8502-97777d7820e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_458b4db1-10ac-4350-b3d5-6fa0b82e9368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_458b4db1-10ac-4350-b3d5-6fa0b82e9368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment_66071b1a-c05d-4164-b05a-e48febb2ead7" xlink:href="lly-20211231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_lly_LongTermDebtFairValueAdjustment_66071b1a-c05d-4164-b05a-e48febb2ead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_4f20fb30-af58-44df-aeb7-34c5c8d0f701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_4f20fb30-af58-44df-aeb7-34c5c8d0f701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_cab50b8b-86f0-47ff-9a4b-f9d917a21bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_us-gaap_DebtCurrent_cab50b8b-86f0-47ff-9a4b-f9d917a21bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0a333fe3-b67e-476d-bc6b-aff325b3ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f69a092-efe6-4fff-a83d-87eef06e8ea0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0a333fe3-b67e-476d-bc6b-aff325b3ad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsScheduleofDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3987ccda-dc56-4f06-b369-bf0e53eda6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3987ccda-dc56-4f06-b369-bf0e53eda6b4" xlink:to="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f2ca2d6-7321-41d7-b5ed-0f22a59d6a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2e710738-c2fc-4252-9449-6eef6e85ccc6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f2ca2d6-7321-41d7-b5ed-0f22a59d6a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_634a9e78-797e-4ce2-a3d1-ebfa60ce4e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7f2ca2d6-7321-41d7-b5ed-0f22a59d6a71" xlink:to="loc_us-gaap_SeniorNotesMember_634a9e78-797e-4ce2-a3d1-ebfa60ce4e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:to="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_abc92dc2-be1f-4939-af8d-ee5cfd8efabf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member_79b26ba0-d96c-4be8-9c53-68bd556ade2f" xlink:href="lly-20211231.xsd#lly_A235NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A235NotesDue2022Member_79b26ba0-d96c-4be8-9c53-68bd556ade2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member_8371dd1d-05cb-4cd7-ae97-8eeab1caf83e" xlink:href="lly-20211231.xsd#lly_A30NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A30NotesDue2022Member_8371dd1d-05cb-4cd7-ae97-8eeab1caf83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member_a4f50e90-b59f-468f-84ab-951070fea2bf" xlink:href="lly-20211231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A10EuroDenominatedNotesDue2022Member_a4f50e90-b59f-468f-84ab-951070fea2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_79606947-fde8-4707-95ce-bff2d5851d16" xlink:href="lly-20211231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_79606947-fde8-4707-95ce-bff2d5851d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member_2c643b81-35f5-4f82-974d-2450df5be277" xlink:href="lly-20211231.xsd#lly_A7125NotesDue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A7125NotesDue2025Member_2c643b81-35f5-4f82-974d-2450df5be277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member_85f59bfa-abf3-4669-9407-8cda66275978" xlink:href="lly-20211231.xsd#lly_A275NotesDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A275NotesDue2025Member_85f59bfa-abf3-4669-9407-8cda66275978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member_14c69d33-48e7-4d6e-b0b4-c3278d1e3ecb" xlink:href="lly-20211231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1625EuroDenominatedNotesDue2026Member_14c69d33-48e7-4d6e-b0b4-c3278d1e3ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member_985eccd1-2a08-4194-a581-edcd33be0d31" xlink:href="lly-20211231.xsd#lly_A55NotesDue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A55NotesDue2027Member_985eccd1-2a08-4194-a581-edcd33be0d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member_14fbd0e8-f331-40d6-9d62-e5d510fbf1cc" xlink:href="lly-20211231.xsd#lly_A31NotesDue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A31NotesDue2027Member_14fbd0e8-f331-40d6-9d62-e5d510fbf1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_139c4a63-a534-4843-b873-e20874c635c3" xlink:href="lly-20211231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_139c4a63-a534-4843-b873-e20874c635c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_436377e3-7a98-4808-8f33-be34348959f7" xlink:href="lly-20211231.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A3375NotesDue2029Member_436377e3-7a98-4808-8f33-be34348959f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_0daba310-135e-464c-979b-dede50f2bc82" xlink:href="lly-20211231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_0daba310-135e-464c-979b-dede50f2bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member_40888975-395d-45fc-9506-f98a249b8469" xlink:href="lly-20211231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A2125EuroDenominatedNotesDue2030Member_40888975-395d-45fc-9506-f98a249b8469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_96d9162e-9b5e-43fe-870b-4a3667fbc6d6" xlink:href="lly-20211231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_96d9162e-9b5e-43fe-870b-4a3667fbc6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_caa3533c-4b85-49e2-9a8c-005f867b0086" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A5000NotesDue2033Member_caa3533c-4b85-49e2-9a8c-005f867b0086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_5d6b7738-4912-4f64-97b7-109c29203d8d" xlink:href="lly-20211231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_5d6b7738-4912-4f64-97b7-109c29203d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member_d3bc58e7-2e2e-486a-857e-6dd218247a4d" xlink:href="lly-20211231.xsd#lly_A677NotesDue2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A677NotesDue2036Member_d3bc58e7-2e2e-486a-857e-6dd218247a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member_11bde8f4-11f2-4783-ade5-f98759f5df06" xlink:href="lly-20211231.xsd#lly_A555NotesDue2037Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A555NotesDue2037Member_11bde8f4-11f2-4783-ade5-f98759f5df06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member_1f0e64fe-57d4-40bc-b6f9-c7135ee76ac3" xlink:href="lly-20211231.xsd#lly_A595NotesDue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A595NotesDue2037Member_1f0e64fe-57d4-40bc-b6f9-c7135ee76ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_5c25c4de-00b6-463b-b2b9-45b9449231fc" xlink:href="lly-20211231.xsd#lly_A3875NotesDue2039Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A3875NotesDue2039Member_5c25c4de-00b6-463b-b2b9-45b9449231fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_c86fbaa5-bd26-4aaa-9869-a4104558ef07" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1625NotesDue2043Member_c86fbaa5-bd26-4aaa-9869-a4104558ef07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member_3b812a35-1b13-40eb-addd-018107d87f90" xlink:href="lly-20211231.xsd#lly_A465NotesDue2044Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A465NotesDue2044Member_3b812a35-1b13-40eb-addd-018107d87f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member_793e215d-2956-4804-9148-fd0d68cc485e" xlink:href="lly-20211231.xsd#lly_A37NotesDue2045Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A37NotesDue2045Member_793e215d-2956-4804-9148-fd0d68cc485e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member_b15bad8d-92f1-48d8-9d2a-557fa30eec95" xlink:href="lly-20211231.xsd#lly_A395NotesDue2047Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A395NotesDue2047Member_b15bad8d-92f1-48d8-9d2a-557fa30eec95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_50a3b489-9315-4ec4-9fa5-f0d706472752" xlink:href="lly-20211231.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A395NotesDue2049Member_50a3b489-9315-4ec4-9fa5-f0d706472752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_74053666-62fb-4195-99f7-6dd883a24af9" xlink:href="lly-20211231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_74053666-62fb-4195-99f7-6dd883a24af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_eaca6583-a39f-4673-85be-e93dd038a7a1" xlink:href="lly-20211231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_eaca6583-a39f-4673-85be-e93dd038a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_41b025e0-54b2-4d09-b606-075ff5bf0635" xlink:href="lly-20211231.xsd#lly_A225NotesDue2050Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A225NotesDue2050Member_41b025e0-54b2-4d09-b606-075ff5bf0635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_506c64a1-4202-4041-a237-04360125ae2a" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1125NotesDue2051Member_506c64a1-4202-4041-a237-04360125ae2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_4d4a2fbc-6a81-4511-87cb-aa776cd4fff2" xlink:href="lly-20211231.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A415NotesDue2059Member_4d4a2fbc-6a81-4511-87cb-aa776cd4fff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_e9464651-9e54-4693-bd49-c152e5114914" xlink:href="lly-20211231.xsd#lly_A25NotesDue2060Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A25NotesDue2060Member_e9464651-9e54-4693-bd49-c152e5114914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_8c2b952c-f0d6-471a-a313-bd3dcddfbf9a" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a8f17e-9732-4a61-b2e9-67e8d712cb27" xlink:to="loc_lly_A1375NotesDue2061Member_8c2b952c-f0d6-471a-a313-bd3dcddfbf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e6a0daa-4bb4-409f-b5ec-dda3b6b69e9c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_51564477-c007-4e0f-ada9-315561fa9725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_51564477-c007-4e0f-ada9-315561fa9725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3e7ae009-6a03-4aa6-9619-130182564e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3e7ae009-6a03-4aa6-9619-130182564e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eda84410-d3f2-43b1-bc59-9179047b311b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eda84410-d3f2-43b1-bc59-9179047b311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c253b123-bcd1-4305-afc6-632b216054f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_71dec9fd-cfe7-4102-acbc-9e850cb9fa2a" xlink:to="loc_us-gaap_LongTermDebt_c253b123-bcd1-4305-afc6-632b216054f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2895eef9-7a42-4b77-b5a6-3b8776cedb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2895eef9-7a42-4b77-b5a6-3b8776cedb89" xlink:to="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe576207-bb20-4eaf-93b3-f37502bec6e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_32fc27b6-c66e-4e4b-aff9-d9a42172bae7" xlink:href="lly-20211231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_32fc27b6-c66e-4e4b-aff9-d9a42172bae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_860db7ec-a5f9-4f3e-b48d-d78ea0eb5616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8f038c2-9455-4b53-968f-4280ab2780c5" xlink:to="loc_us-gaap_SeniorNotesMember_860db7ec-a5f9-4f3e-b48d-d78ea0eb5616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2c25fcac-5d7e-43b8-90e0-663c91f7258d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_e1f88ae3-d7de-4620-b33b-722ac19ed394" xlink:href="lly-20211231.xsd#lly_MaturityDate2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:to="loc_lly_MaturityDate2023Member_e1f88ae3-d7de-4620-b33b-722ac19ed394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2019Member_b0947080-aabf-4d1c-979e-65a6f0acc7ee" xlink:href="lly-20211231.xsd#lly_MaturityDate2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_40121edf-8f34-49c9-aba2-aa76522b5953" xlink:to="loc_lly_MaturityDate2019Member_b0947080-aabf-4d1c-979e-65a6f0acc7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fb60d87-9418-4668-a9a6-66ed28ab7477" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_186716c0-f92a-4353-a413-81b77661aadc" xlink:href="lly-20211231.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A5000NotesDue2033Member_186716c0-f92a-4353-a413-81b77661aadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_71923be8-ac4e-40e7-8d32-672291ba21ff" xlink:href="lly-20211231.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A1125NotesDue2051Member_71923be8-ac4e-40e7-8d32-672291ba21ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_d03e93d8-686d-4bed-8b56-c23086f22439" xlink:href="lly-20211231.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A1375NotesDue2061Member_d03e93d8-686d-4bed-8b56-c23086f22439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_d9a96b85-02e6-4051-8cff-067250ea509e" xlink:href="lly-20211231.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A1625NotesDue2043Member_d9a96b85-02e6-4051-8cff-067250ea509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_951503a8-f5d0-4c5e-a3f2-97f32a0c703a" xlink:href="lly-20211231.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A395NotesDue2049Member_951503a8-f5d0-4c5e-a3f2-97f32a0c703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_afc45504-7fc9-4457-b50b-936b20476e9a" xlink:href="lly-20211231.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A415NotesDue2059Member_afc45504-7fc9-4457-b50b-936b20476e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_e684a814-22a9-4f00-ba4a-f18226bab38f" xlink:href="lly-20211231.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A3375NotesDue2029Member_e684a814-22a9-4f00-ba4a-f18226bab38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:href="lly-20211231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_84eb20ec-8293-4d3a-91d3-f767c7a55552" xlink:href="lly-20211231.xsd#lly_A225NotesDue2050Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:to="loc_lly_A225NotesDue2050Member_84eb20ec-8293-4d3a-91d3-f767c7a55552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_3ce9d95d-208c-4733-8912-d96b450fe87f" xlink:href="lly-20211231.xsd#lly_A25NotesDue2060Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_fb6681e0-1f88-4c7b-8712-ab795dfa9a12" xlink:to="loc_lly_A25NotesDue2060Member_3ce9d95d-208c-4733-8912-d96b450fe87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_fd2d4cb3-13b7-49fe-b2b1-fea74092ba68" xlink:href="lly-20211231.xsd#lly_A3875NotesDue2039Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_A3875NotesDue2039Member_fd2d4cb3-13b7-49fe-b2b1-fea74092ba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:href="lly-20211231.xsd#lly_November2019EuroDenominatedNotesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_3c6a8e9a-9d23-4cf9-a3f8-4bd9c2092d5d" xlink:href="lly-20211231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_3c6a8e9a-9d23-4cf9-a3f8-4bd9c2092d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_5ac768e0-8d6b-4107-8209-7d1717a58331" xlink:href="lly-20211231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_8b533d17-b9c7-4eed-8589-f93fc97e966f" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_5ac768e0-8d6b-4107-8209-7d1717a58331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:href="lly-20211231.xsd#lly_November2019YenDenominatedNotesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f0b3f3cf-0836-46d8-8e47-0016a9170464" xlink:to="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_8f3f90ad-b019-4d35-8a73-6d995a7eb836" xlink:href="lly-20211231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_8f3f90ad-b019-4d35-8a73-6d995a7eb836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_3d3e9f84-2feb-4580-8a17-e50454249024" xlink:href="lly-20211231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_3d3e9f84-2feb-4580-8a17-e50454249024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_adc1c47b-f596-4191-8de0-1a2debc24b4a" xlink:href="lly-20211231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019YenDenominatedNotesMember_d2f4e498-d679-4430-80e6-f5a0edea5702" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_adc1c47b-f596-4191-8de0-1a2debc24b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_14070d47-3eae-4269-ab37-9947b826eb78" xlink:to="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cfd74b05-96a8-4f60-91cf-7bc47bf18307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cfd74b05-96a8-4f60-91cf-7bc47bf18307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b8a622ed-811d-45f6-8d16-efc6f7d95d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b8a622ed-811d-45f6-8d16-efc6f7d95d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_f324e437-3fd5-43a1-a59b-27f8be7a4030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentTerm_f324e437-3fd5-43a1-a59b-27f8be7a4030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2b3e0bb7-7cca-4c55-8f9b-9c827018f8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2b3e0bb7-7cca-4c55-8f9b-9c827018f8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5952f66-19a2-42c5-89f5-a1322d42d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5952f66-19a2-42c5-89f5-a1322d42d1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_d64466f8-dc5a-4d33-93dd-34ef9c255f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_d64466f8-dc5a-4d33-93dd-34ef9c255f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_43ef27ff-4c71-4991-b5a2-8f030773467b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_43ef27ff-4c71-4991-b5a2-8f030773467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6cf32aec-ad3f-42cc-b674-3f3f6333e67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6cf32aec-ad3f-42cc-b674-3f3f6333e67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_0d225878-04fa-4b21-9e65-97b9b19be8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_0d225878-04fa-4b21-9e65-97b9b19be8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_f3a83e3b-7b63-425d-8e78-e23fa597dd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_f3a83e3b-7b63-425d-8e78-e23fa597dd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_60b78a39-8cc4-44b8-8939-72523ec2e440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_60b78a39-8cc4-44b8-8939-72523ec2e440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7b8d3ecf-ed8a-4825-a9f1-36bb1716521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7b8d3ecf-ed8a-4825-a9f1-36bb1716521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2291db4e-851b-4ebb-8092-58a18bd7827a" xlink:href="lly-20211231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_2291db4e-851b-4ebb-8092-58a18bd7827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_648cfb5d-7e11-420f-98b2-99b96d21f4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_da47038e-33ea-4ce0-9f8f-ce5a0726b6cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_648cfb5d-7e11-420f-98b2-99b96d21f4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsScheduleofDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_24a67538-6821-45ce-a0f6-795436bbe963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_24a67538-6821-45ce-a0f6-795436bbe963" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_169efae2-bfd2-4f8a-a392-ad26dc4d2d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_169efae2-bfd2-4f8a-a392-ad26dc4d2d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_95c00aa4-bd7d-474b-88c0-be12b526b8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_95c00aa4-bd7d-474b-88c0-be12b526b8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ad5c207b-451e-4578-a57e-ab0fe9308bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ad5c207b-451e-4578-a57e-ab0fe9308bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_53654f64-c38a-4e8d-9791-8084e064ccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_53654f64-c38a-4e8d-9791-8084e064ccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c19630bb-90c2-4bca-863e-1cd434539205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_ff7d1c3d-50e7-4415-84cd-2ad08b1d0794" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_c19630bb-90c2-4bca-863e-1cd434539205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_740fe198-4051-42e1-b963-218dfadb852e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cada5e7f-95fb-449a-b62e-b9794bbfd745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_740fe198-4051-42e1-b963-218dfadb852e" xlink:to="loc_us-gaap_InterestPaidNet_cada5e7f-95fb-449a-b62e-b9794bbfd745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb106463-7df8-469c-9809-cf3bf0a088d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b76eff25-1876-4b36-a094-fe8fdf98564e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb106463-7df8-469c-9809-cf3bf0a088d6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b76eff25-1876-4b36-a094-fe8fdf98564e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d46a58d7-4a5b-4ec2-baff-5a9d2981a790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_363ea473-fb87-47b1-b8a1-bcee3a557d09" xlink:href="lly-20211231.xsd#lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d46a58d7-4a5b-4ec2-baff-5a9d2981a790" xlink:to="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_363ea473-fb87-47b1-b8a1-bcee3a557d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_48fb7d18-29d7-413f-9a2e-7e9b0357b44d" xlink:href="lly-20211231.xsd#lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d46a58d7-4a5b-4ec2-baff-5a9d2981a790" xlink:to="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_48fb7d18-29d7-413f-9a2e-7e9b0357b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95aedde1-e738-40d8-8fea-f54946221bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6300cc64-a6c3-4c81-ba9f-8e8a6edf77b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95aedde1-e738-40d8-8fea-f54946221bf2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6300cc64-a6c3-4c81-ba9f-8e8a6edf77b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6918f210-354f-4b25-87cd-6fef9de9ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95aedde1-e738-40d8-8fea-f54946221bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6918f210-354f-4b25-87cd-6fef9de9ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65ce4c3e-29de-47eb-aaab-16f3f033f4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65ce4c3e-29de-47eb-aaab-16f3f033f4c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:to="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b44fc330-4642-410f-aa6d-309c33a083e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ba33fe57-00b0-48ef-bd08-ec6642521161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_us-gaap_PerformanceSharesMember_ba33fe57-00b0-48ef-bd08-ec6642521161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_12de0782-9055-4ae9-89e7-0e727b5591ec" xlink:href="lly-20211231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_lly_ShareholderValueAwardsMember_12de0782-9055-4ae9-89e7-0e727b5591ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_0cd6f23d-4375-4849-a63c-f22fcc3a6c1b" xlink:href="lly-20211231.xsd#lly_RelativeValueAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_lly_RelativeValueAwardsMember_0cd6f23d-4375-4849-a63c-f22fcc3a6c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_896c0866-4883-4655-9d8b-4489bb843022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adad09e6-a963-48ce-9a66-d220d57a9abc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_896c0866-4883-4655-9d8b-4489bb843022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0699bf8-710d-4ffd-801d-59747f0cfba4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff72d117-c47d-40b7-9b50-9757218351f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff72d117-c47d-40b7-9b50-9757218351f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f9bc487-98e8-458d-a618-2fb760c1eba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7f9bc487-98e8-458d-a618-2fb760c1eba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ec01b6a-b299-4432-9665-90bd29ca798d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ec01b6a-b299-4432-9665-90bd29ca798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ed14896a-5466-4409-9e64-cdd26a4dab6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ed14896a-5466-4409-9e64-cdd26a4dab6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_2dac4022-c460-405a-8515-c7338535aa0b" xlink:href="lly-20211231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_2dac4022-c460-405a-8515-c7338535aa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66cb4569-5b71-425d-8bb9-5a6c98640570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66cb4569-5b71-425d-8bb9-5a6c98640570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d0aaaeae-41f9-4ba4-87e2-68dc9d2af67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d0aaaeae-41f9-4ba4-87e2-68dc9d2af67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dfca2183-3fff-4e55-90e8-3d2cb8c8df3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2eea74e2-ddb1-4d30-bef3-6b844fda1694" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dfca2183-3fff-4e55-90e8-3d2cb8c8df3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd11f7a6-daed-4af9-8fa4-740d450e81c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd11f7a6-daed-4af9-8fa4-740d450e81c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:to="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_609cf013-cca1-430f-a56b-e1727609d905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_6f7832bf-5526-470d-9e63-5fb19b0d20e2" xlink:href="lly-20211231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:to="loc_lly_ShareholderValueAwardsMember_6f7832bf-5526-470d-9e63-5fb19b0d20e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_8b484c7b-7a0e-41fa-b679-7c6acdf1b426" xlink:href="lly-20211231.xsd#lly_RelativeValueAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f824a5c-82eb-4b9e-9174-30bdc2c7f52c" xlink:to="loc_lly_RelativeValueAwardsMember_8b484c7b-7a0e-41fa-b679-7c6acdf1b426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ce96c597-f3ab-4364-bb55-14998b3bf749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d28ed17d-ae8a-4f1b-ac6e-b9f42d2f4731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d28ed17d-ae8a-4f1b-ac6e-b9f42d2f4731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dbbb5a59-53c5-4446-8516-21c4d163bd68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dbbb5a59-53c5-4446-8516-21c4d163bd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2638c76a-d18c-4256-bb93-7dadcd81a471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57525e4a-795e-4e86-b5f8-0cb7b4c4dd4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2638c76a-d18c-4256-bb93-7dadcd81a471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="lly-20211231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_91568c5b-e98f-47a6-b94b-f200f3afdfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_36ea6507-2321-43fc-a9c6-946a7a203cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_91568c5b-e98f-47a6-b94b-f200f3afdfe0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_36ea6507-2321-43fc-a9c6-946a7a203cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a32e4bf7-c5f7-493b-8f86-6b65c7a0223a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a32e4bf7-c5f7-493b-8f86-6b65c7a0223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_afded606-8467-4c7b-a101-0f9d24573cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_afded606-8467-4c7b-a101-0f9d24573cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_22dd4af6-3390-4365-a547-4bfd0256a1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_22dd4af6-3390-4365-a547-4bfd0256a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f1eee17a-2c70-49e1-8474-e52b4f7311c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f1eee17a-2c70-49e1-8474-e52b4f7311c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bd64791d-d498-480f-a6a1-7d75fbe12890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bd64791d-d498-480f-a6a1-7d75fbe12890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_1fa446d7-82a3-4bf3-9c0f-159bcfaf00e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_1fa446d7-82a3-4bf3-9c0f-159bcfaf00e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_55dfcded-a0c0-415e-93a2-d44db444379e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b7c9f176-1c3e-423d-bb64-2c414630cbec" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_55dfcded-a0c0-415e-93a2-d44db444379e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9bbe6f56-a484-4ec8-9559-e190a7b50bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_235b551e-7a75-4639-959a-25805eee300b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9bbe6f56-a484-4ec8-9559-e190a7b50bc6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_235b551e-7a75-4639-959a-25805eee300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ac930417-db97-445b-bac8-92696a4da6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f59e774a-36e4-4f6e-8026-108d0911384f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac930417-db97-445b-bac8-92696a4da6c3" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f59e774a-36e4-4f6e-8026-108d0911384f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e8f7bcbe-7fdd-47d0-b12d-d840381d316b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac930417-db97-445b-bac8-92696a4da6c3" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e8f7bcbe-7fdd-47d0-b12d-d840381d316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_90a16dc5-d5aa-44f4-9aa4-45bcd896f2c9" xlink:href="lly-20211231.xsd#lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac930417-db97-445b-bac8-92696a4da6c3" xlink:to="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_90a16dc5-d5aa-44f4-9aa4-45bcd896f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3ffc795c-45ef-4a26-9e00-5c43b2f64d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac930417-db97-445b-bac8-92696a4da6c3" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3ffc795c-45ef-4a26-9e00-5c43b2f64d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_8cfaf3fb-0b84-4464-8a21-a66467c37272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac930417-db97-445b-bac8-92696a4da6c3" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_8cfaf3fb-0b84-4464-8a21-a66467c37272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06edd7a2-eceb-4b51-89a1-88d15b01a452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06edd7a2-eceb-4b51-89a1-88d15b01a452" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_9e1dff8a-098c-42ad-95f2-4e3819af8909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_0687b6cc-0344-47ee-878f-baefe115551a" xlink:to="loc_us-gaap_TaxPeriodDomain_9e1dff8a-098c-42ad-95f2-4e3819af8909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxYears2013To2015Member_b8c4664d-e054-4029-8c31-67323ac11cc9" xlink:href="lly-20211231.xsd#lly_TaxYears2013To2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_9e1dff8a-098c-42ad-95f2-4e3819af8909" xlink:to="loc_lly_TaxYears2013To2015Member_b8c4664d-e054-4029-8c31-67323ac11cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_29044724-538e-4f63-84f3-230d43a2b020" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember_65f247d8-33a1-424a-bfc0-93eab36d3422" xlink:href="lly-20211231.xsd#lly_CarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_CarryforwardMember_65f247d8-33a1-424a-bfc0-93eab36d3422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationin6YearsMember_a0d774f3-0178-4933-92f3-bfdc938ee31d" xlink:href="lly-20211231.xsd#lly_Expirationin6YearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_Expirationin6YearsMember_a0d774f3-0178-4933-92f3-bfdc938ee31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationIn12To18YearsMember_a7c6adba-fe90-46d4-9faf-0cdc61b9bd06" xlink:href="lly-20211231.xsd#lly_ExpirationIn12To18YearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_ExpirationIn12To18YearsMember_a7c6adba-fe90-46d4-9faf-0cdc61b9bd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember_7724d6a4-8769-435b-ad12-849de1345e12" xlink:href="lly-20211231.xsd#lly_DesignatedUnusableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_DesignatedUnusableMember_7724d6a4-8769-435b-ad12-849de1345e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationwithin5yearsMember_797d5954-09f0-48c5-a70d-78e03551e194" xlink:href="lly-20211231.xsd#lly_Expirationwithin5yearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_Expirationwithin5yearsMember_797d5954-09f0-48c5-a70d-78e03551e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expiration5to20YearsMember_f3009965-ac7e-474f-a8a1-e52ed055fa9e" xlink:href="lly-20211231.xsd#lly_Expiration5to20YearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_Expiration5to20YearsMember_f3009965-ac7e-474f-a8a1-e52ed055fa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember_6376ceef-728f-4c9b-87f7-dd5495bef93f" xlink:href="lly-20211231.xsd#lly_NoExpirationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3896132f-9b60-41f5-8d3a-2ddc22d164ed" xlink:to="loc_lly_NoExpirationMember_6376ceef-728f-4c9b-87f7-dd5495bef93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d6ff1804-d101-4095-808b-86416ef8b480" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_aaffc9d2-38da-4e9c-9558-44ad1529d45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_aaffc9d2-38da-4e9c-9558-44ad1529d45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_257b9871-eb16-487a-ad8d-c37198920f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:to="loc_us-gaap_ForeignCountryMember_257b9871-eb16-487a-ad8d-c37198920f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_82653410-a7ab-4460-98b9-3a50c0468e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5d6fbb05-4593-402c-b415-9214234376c2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_82653410-a7ab-4460-98b9-3a50c0468e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c5f24c86-5a10-4053-bae5-fb970054a111" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_cc17c758-50d1-4bca-bd66-4ae2fe2f92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_cc17c758-50d1-4bca-bd66-4ae2fe2f92b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_55e33870-1242-4d75-97c0-ecccfb4dc12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_OperatingLossCarryforwards_55e33870-1242-4d75-97c0-ecccfb4dc12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f26b1d15-2893-4aed-bf88-718abb77a351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f26b1d15-2893-4aed-bf88-718abb77a351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_72dc76b0-4731-4396-9017-a5b98e8322dd" xlink:href="lly-20211231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_72dc76b0-4731-4396-9017-a5b98e8322dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_400656b5-cf5b-4346-8d99-428c54cde1c0" xlink:href="lly-20211231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_400656b5-cf5b-4346-8d99-428c54cde1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ad57af44-1031-4088-b4a4-f0bb8fcf0674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ad57af44-1031-4088-b4a4-f0bb8fcf0674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_306dfc9c-1f65-4312-b440-10a360610d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_306dfc9c-1f65-4312-b440-10a360610d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForIncomeTaxSettlements_264d96b4-b44d-4ff9-95c6-c300f3d4de2a" xlink:href="lly-20211231.xsd#lly_PaymentsForIncomeTaxSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_lly_PaymentsForIncomeTaxSettlements_264d96b4-b44d-4ff9-95c6-c300f3d4de2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_fe67d11a-9044-4c89-9331-b5adca028faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_45cc0f0e-90c3-4990-ad5e-0bdda49be362" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_fe67d11a-9044-4c89-9331-b5adca028faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_714db46c-a847-43e3-9749-dd4b2f59a52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5fa0b34e-9433-4b52-aa1b-0da816b8c9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_714db46c-a847-43e3-9749-dd4b2f59a52f" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5fa0b34e-9433-4b52-aa1b-0da816b8c9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_487acac5-e014-4f34-97de-253460d2a342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5fa0b34e-9433-4b52-aa1b-0da816b8c9e3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_487acac5-e014-4f34-97de-253460d2a342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ae51ffd0-724c-452d-9d41-dd5005eddd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5fa0b34e-9433-4b52-aa1b-0da816b8c9e3" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ae51ffd0-724c-452d-9d41-dd5005eddd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_60c5640f-e884-4355-a62c-b5df696b8017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5fa0b34e-9433-4b52-aa1b-0da816b8c9e3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_60c5640f-e884-4355-a62c-b5df696b8017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a6a1f1f8-13ba-43e1-9d83-b7a7020416ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5fa0b34e-9433-4b52-aa1b-0da816b8c9e3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a6a1f1f8-13ba-43e1-9d83-b7a7020416ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_06b9805e-27d2-4d13-bd9a-18fef433b3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_714db46c-a847-43e3-9749-dd4b2f59a52f" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_06b9805e-27d2-4d13-bd9a-18fef433b3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d5326c0d-db7a-4809-9d31-fe34c2fd2285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_06b9805e-27d2-4d13-bd9a-18fef433b3e3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d5326c0d-db7a-4809-9d31-fe34c2fd2285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e8957889-9d42-4c16-93eb-c7c588b8f57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_06b9805e-27d2-4d13-bd9a-18fef433b3e3" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e8957889-9d42-4c16-93eb-c7c588b8f57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1206efc0-d66f-4413-af4e-e171445f747a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_06b9805e-27d2-4d13-bd9a-18fef433b3e3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1206efc0-d66f-4413-af4e-e171445f747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c76f58f7-b679-4782-a486-07ea0ea36005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_06b9805e-27d2-4d13-bd9a-18fef433b3e3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c76f58f7-b679-4782-a486-07ea0ea36005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92e4fa71-4cbf-41f4-9d9c-f91a624f3cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_714db46c-a847-43e3-9749-dd4b2f59a52f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92e4fa71-4cbf-41f4-9d9c-f91a624f3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_fee0e906-a32b-4e6c-9b6f-e5341fb6d8c5" xlink:href="lly-20211231.xsd#lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_714db46c-a847-43e3-9749-dd4b2f59a52f" xlink:to="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_fee0e906-a32b-4e6c-9b6f-e5341fb6d8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5d73a385-e6e9-4e71-8f7d-cd18dd4188fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d73a385-e6e9-4e71-8f7d-cd18dd4188fb" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_12ce8979-7614-4ec5-814e-fc27ff0f1c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_12ce8979-7614-4ec5-814e-fc27ff0f1c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_78bbcc65-d47f-4d4e-81ab-8133d3370ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_78bbcc65-d47f-4d4e-81ab-8133d3370ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d4050e19-aab7-45a7-8265-8a94df837e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d4050e19-aab7-45a7-8265-8a94df837e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a7f65f61-55f3-4c0e-9087-ad16513245b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a7f65f61-55f3-4c0e-9087-ad16513245b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_c3175d5a-b07e-46b2-b1d1-c38495d0d205" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_c3175d5a-b07e-46b2-b1d1-c38495d0d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_691c2d5d-9b4b-413a-bc18-e0adc2639a50" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_691c2d5d-9b4b-413a-bc18-e0adc2639a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_3443b830-23d5-4eff-a80c-3edba536964e" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_3443b830-23d5-4eff-a80c-3edba536964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_b56e4bc5-fbfa-46e2-ad62-77fe1d0b2f51" xlink:href="lly-20211231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_b56e4bc5-fbfa-46e2-ad62-77fe1d0b2f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_226cff49-ff70-4710-95ad-7b7d8f0c5703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_226cff49-ff70-4710-95ad-7b7d8f0c5703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e2dd62b0-a681-4973-8e42-4eac88756ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e2dd62b0-a681-4973-8e42-4eac88756ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f23d18d0-afd5-4352-aa5c-2f0576eb5b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f23d18d0-afd5-4352-aa5c-2f0576eb5b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6374e085-8dfa-43ff-8151-960f3998ab66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6374e085-8dfa-43ff-8151-960f3998ab66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a4287f54-85e8-42b2-baa2-050c4ecab7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0a743cd0-05f9-401e-ba73-8b453d4fa1db" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a4287f54-85e8-42b2-baa2-050c4ecab7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d73a385-e6e9-4e71-8f7d-cd18dd4188fb" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_90b60204-2851-4674-8492-3271ab89fc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_90b60204-2851-4674-8492-3271ab89fc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_bd891adb-b347-475c-af5b-d0726c5bcda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_bd891adb-b347-475c-af5b-d0726c5bcda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_ef4bc3c4-1c2c-4700-8db7-0e39de456143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_ef4bc3c4-1c2c-4700-8db7-0e39de456143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d586880a-04dc-437a-8367-454bce2ccbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d586880a-04dc-437a-8367-454bce2ccbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0d7d3b1e-8154-4742-9191-07e799866d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0d7d3b1e-8154-4742-9191-07e799866d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_181dcc9e-817f-4334-8490-15449cb607ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_181dcc9e-817f-4334-8490-15449cb607ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f58eb353-4b01-4cc8-a414-2a9323e5191e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f58eb353-4b01-4cc8-a414-2a9323e5191e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_35c93845-dd24-4d85-8099-cdfea627c034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ebb57655-492f-4ad9-b9e7-97093042c32f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_35c93845-dd24-4d85-8099-cdfea627c034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_874b7361-3797-4eba-9b3e-3e02de52b6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d73a385-e6e9-4e71-8f7d-cd18dd4188fb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_874b7361-3797-4eba-9b3e-3e02de52b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_229d2774-a100-4769-846d-0dc42d504eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_cdfd7a05-c55b-47d6-b7d7-296b2d57f451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_229d2774-a100-4769-846d-0dc42d504eaf" xlink:to="loc_us-gaap_IncomeTaxesPaid_cdfd7a05-c55b-47d6-b7d7-296b2d57f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_86ba1d85-7f02-4c18-a29f-2036f851f616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_384a75b7-f758-4da1-ba9a-18c7127fd6b0" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxPaymentDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_86ba1d85-7f02-4c18-a29f-2036f851f616" xlink:to="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_384a75b7-f758-4da1-ba9a-18c7127fd6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid_9191a308-c09d-4080-a1c0-e39384ba80f9" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_384a75b7-f758-4da1-ba9a-18c7127fd6b0" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaid_9191a308-c09d-4080-a1c0-e39384ba80f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_3e388ffb-a206-4849-aadd-4bd2b521eff8" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_384a75b7-f758-4da1-ba9a-18c7127fd6b0" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_3e388ffb-a206-4849-aadd-4bd2b521eff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_aeac012c-ee20-42b4-8e29-e16a63f8eedf" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_384a75b7-f758-4da1-ba9a-18c7127fd6b0" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_aeac012c-ee20-42b4-8e29-e16a63f8eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_b7c231ac-9e44-4696-ac75-3b564bb1e78c" xlink:href="lly-20211231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_384a75b7-f758-4da1-ba9a-18c7127fd6b0" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_b7c231ac-9e44-4696-ac75-3b564bb1e78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_47490e8d-5ce9-4c28-a776-740eb22ce552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4ec86ac6-c81b-44e8-a3ae-0d800cc61878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47490e8d-5ce9-4c28-a776-740eb22ce552" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4ec86ac6-c81b-44e8-a3ae-0d800cc61878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AddDeductAbstract_42cbc991-85bb-4d69-9598-c0d96557be2c" xlink:href="lly-20211231.xsd#lly_AddDeductAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47490e8d-5ce9-4c28-a776-740eb22ce552" xlink:to="loc_lly_AddDeductAbstract_42cbc991-85bb-4d69-9598-c0d96557be2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_2a32d081-8e93-4546-a4d9-33909dfe090d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_42cbc991-85bb-4d69-9598-c0d96557be2c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_2a32d081-8e93-4546-a4d9-33909dfe090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_0bc37f3b-61ee-4c71-b91f-219dacb9ac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_42cbc991-85bb-4d69-9598-c0d96557be2c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_0bc37f3b-61ee-4c71-b91f-219dacb9ac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1dc6dafd-507c-44f9-b7ed-354dae179cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_42cbc991-85bb-4d69-9598-c0d96557be2c" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1dc6dafd-507c-44f9-b7ed-354dae179cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0011c243-9c80-4743-b059-5d74e490cbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_42cbc991-85bb-4d69-9598-c0d96557be2c" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0011c243-9c80-4743-b059-5d74e490cbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_026e0c28-1e8d-4350-ac01-eb96de9a3afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47490e8d-5ce9-4c28-a776-740eb22ce552" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_026e0c28-1e8d-4350-ac01-eb96de9a3afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ab3d3df-3f7e-41f6-b5d6-7fbe686bfcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ab3d3df-3f7e-41f6-b5d6-7fbe686bfcb2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ac6a1325-cf93-4963-8ea4-41f962500416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ac6a1325-cf93-4963-8ea4-41f962500416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_134036fe-0136-45a1-9370-0debf5c7b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_134036fe-0136-45a1-9370-0debf5c7b0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_39677a23-0f9a-4d66-b9db-e91dcf53bab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_39677a23-0f9a-4d66-b9db-e91dcf53bab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b7668834-392b-4a04-a4b1-855a5bfa97e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b7668834-392b-4a04-a4b1-855a5bfa97e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_7bc48816-066b-4722-bcf8-c47cc4ca947d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_7bc48816-066b-4722-bcf8-c47cc4ca947d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3e808d0e-8f51-4a73-8857-8ea69f8a0e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3e808d0e-8f51-4a73-8857-8ea69f8a0e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_16b74e4c-5722-4528-a166-90f777dd930d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_16b74e4c-5722-4528-a166-90f777dd930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_64d4440a-965b-4c20-8842-8237c0489b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_64d4440a-965b-4c20-8842-8237c0489b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e4c214fe-695e-4509-a177-2daac1f04a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c012b7f0-ca4c-4df8-8c8f-190a7f5deca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e4c214fe-695e-4509-a177-2daac1f04a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ed3db00-feb7-4537-a1ac-b92e2294ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3be0e97f-d19d-4e81-98dd-e1dec29fbbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ed3db00-feb7-4537-a1ac-b92e2294ce1e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3be0e97f-d19d-4e81-98dd-e1dec29fbbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2dd1822e-b7a2-47fe-b4e8-97924b4b5b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_24b0728b-80ae-40c1-920c-2ff5d3ce5d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2dd1822e-b7a2-47fe-b4e8-97924b4b5b97" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_24b0728b-80ae-40c1-920c-2ff5d3ce5d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_828ed66a-7959-4cf0-baf0-42cbfa85e858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_828ed66a-7959-4cf0-baf0-42cbfa85e858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_3c8171d7-ee0a-4e0d-a5dd-79323f21e202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_3c8171d7-ee0a-4e0d-a5dd-79323f21e202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_bdc09dde-cd25-42c4-bb79-b41d3cb0f48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_bdc09dde-cd25-42c4-bb79-b41d3cb0f48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_916639b8-2100-47bb-8ed9-1bd0e8752521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_916639b8-2100-47bb-8ed9-1bd0e8752521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_47c2344d-b397-47b6-9dae-7cc7569c5934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_47c2344d-b397-47b6-9dae-7cc7569c5934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_c1602c66-51e0-41b6-938b-6f05853f8b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_c1602c66-51e0-41b6-938b-6f05853f8b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_dc0ab2db-cd9b-41c3-a421-547988f75629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_dc0ab2db-cd9b-41c3-a421-547988f75629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_5d4c0ae1-6d50-4db6-b6f9-b6d309c5152f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_5d4c0ae1-6d50-4db6-b6f9-b6d309c5152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_cb76ef97-25e5-4b99-a631-b2832712abee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_cb76ef97-25e5-4b99-a631-b2832712abee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_28096cd9-5f38-4ca3-b554-2473825d68f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_28096cd9-5f38-4ca3-b554-2473825d68f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_28088563-be7c-402f-af26-83b12390a5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a0af1592-e307-4336-b9bb-1664e86b85d2" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_28088563-be7c-402f-af26-83b12390a5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_33db1a4b-5342-4e56-81af-5ed2818f1bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_33db1a4b-5342-4e56-81af-5ed2818f1bc6" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5d29c24f-68a4-4375-bf7c-caeec1447002" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_96c2f224-d7f0-42e8-8f04-22638c599858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_96c2f224-d7f0-42e8-8f04-22638c599858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_db9cc6e9-9d6a-4878-96c2-977b80a650d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_15123b99-828e-419d-a697-4bcbf4075aea" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_db9cc6e9-9d6a-4878-96c2-977b80a650d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_40a9aa3d-e7f1-4dcc-aa31-5baafafeb821" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3a3614f1-69e0-4aa2-98c1-14f7d1b4c998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_3a3614f1-69e0-4aa2-98c1-14f7d1b4c998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fde236f2-87a8-49f2-8473-1ffe39b280ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fde236f2-87a8-49f2-8473-1ffe39b280ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a67c9cd0-7a20-4a84-98ee-cbd8d17fb123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a67c9cd0-7a20-4a84-98ee-cbd8d17fb123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_428f7a00-9a51-4e83-b583-68e6d107c3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_428f7a00-9a51-4e83-b583-68e6d107c3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2235e235-600c-4d72-a9cb-e7aee977d381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2235e235-600c-4d72-a9cb-e7aee977d381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_287813ca-f7cc-4cbe-bc05-54de2feacae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_287813ca-f7cc-4cbe-bc05-54de2feacae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_f76abeaa-14a3-4aec-82f6-3d20f94b3dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_f76abeaa-14a3-4aec-82f6-3d20f94b3dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_294393ce-be1f-41e3-9b99-80a0bce35537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1d13850d-7015-44fa-aec8-772026ce939e" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_294393ce-be1f-41e3-9b99-80a0bce35537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_715fdfd0-1b87-4672-8713-579f8385af0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_715fdfd0-1b87-4672-8713-579f8385af0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_3bc1c24f-52ff-4b1c-904d-efc2fe983065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_3bc1c24f-52ff-4b1c-904d-efc2fe983065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_a647ec38-2cde-4b48-b9ca-700a6f8aa834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_a647ec38-2cde-4b48-b9ca-700a6f8aa834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e2b31b2b-5fea-4c6d-9be5-f73bbd49aae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e2b31b2b-5fea-4c6d-9be5-f73bbd49aae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a2b94a3b-f405-42bd-97b2-3af294aa5a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_a2b94a3b-f405-42bd-97b2-3af294aa5a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5436a511-fee7-4fab-b617-01bfe4cd9d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f5430d22-e564-41fe-a431-1eaf727a0eb2" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5436a511-fee7-4fab-b617-01bfe4cd9d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_845a5d95-7ec2-4961-9ea8-8e088c61af90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_845a5d95-7ec2-4961-9ea8-8e088c61af90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_6398bcb6-9493-4c46-b599-0f46790c9884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_6398bcb6-9493-4c46-b599-0f46790c9884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4d447772-ccb9-4c1d-ba1c-516898cb1fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4d447772-ccb9-4c1d-ba1c-516898cb1fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9631faea-209a-4d07-9a40-bd8734ff0819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_65feff96-b1da-41c5-a240-741cb03c1395" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9631faea-209a-4d07-9a40-bd8734ff0819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c024af75-1ba8-4eeb-ae87-136f549b9bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c024af75-1ba8-4eeb-ae87-136f549b9bbb" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a8651a1b-24c5-44b2-b54a-25324111a81e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_330b0973-11ef-403e-b2a3-f93e789b93a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_330b0973-11ef-403e-b2a3-f93e789b93a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6fde567d-123e-4bb8-9303-86cf75151b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fbc884c-2a12-4954-8df5-242f69d59255" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6fde567d-123e-4bb8-9303-86cf75151b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_86af5dc3-1c95-4bac-915b-a26562cf2239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ee678590-6c1e-4172-b8f6-2d2e37bdca5d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_86af5dc3-1c95-4bac-915b-a26562cf2239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_86af5dc3-1c95-4bac-915b-a26562cf2239" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_ee775dd2-e9ea-44fd-91ea-070994f4e23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_ee775dd2-e9ea-44fd-91ea-070994f4e23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_c8b8bd1f-1e72-4e52-bb40-9ef804eaca46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_c8b8bd1f-1e72-4e52-bb40-9ef804eaca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8b0e6e7f-2946-4901-9233-9d6861b618f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8b0e6e7f-2946-4901-9233-9d6861b618f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5e32854b-a069-411c-a45f-c759cb6af2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_5e32854b-a069-411c-a45f-c759cb6af2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f8ade252-834c-4823-8778-95be054ae004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b74d1008-fea9-4384-ab56-c4fdbb4d4ccf" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f8ade252-834c-4823-8778-95be054ae004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b40393a6-04f7-474c-9822-0fbf6791f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b40393a6-04f7-474c-9822-0fbf6791f60b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a91533ab-e6e2-41b7-bc13-679acd86f41a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_423b8c17-c176-49f3-8b53-b489ab32c19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_423b8c17-c176-49f3-8b53-b489ab32c19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_d16d1f6e-e768-44d7-ba11-f68168b56c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a4a1582a-4b18-4169-99d2-56a403132769" xlink:to="loc_us-gaap_FixedIncomeFundsMember_d16d1f6e-e768-44d7-ba11-f68168b56c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_992fa32a-b692-4f28-9690-16ffed422685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c3c6d925-e63b-4d94-b579-4f2a3ca66b50" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_992fa32a-b692-4f28-9690-16ffed422685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_643b131a-5e2d-47ff-b841-155fbd6cd001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_992fa32a-b692-4f28-9690-16ffed422685" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_643b131a-5e2d-47ff-b841-155fbd6cd001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5b8003df-9d09-4670-8094-df4ea8697560" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_af3ef4fc-82f5-40cf-aa61-3f8caf7d29d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_af3ef4fc-82f5-40cf-aa61-3f8caf7d29d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6e1ba1c7-0b69-4b48-8d02-52accd5f7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6e1ba1c7-0b69-4b48-8d02-52accd5f7c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7aa7aed0-aea5-446f-820b-5235360154bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7aa7aed0-aea5-446f-820b-5235360154bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_881d770f-f8c6-418e-99b5-30b91fdc933c" xlink:href="lly-20211231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_881d770f-f8c6-418e-99b5-30b91fdc933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_353a270b-6166-4c0c-b950-594635e376f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_353a270b-6166-4c0c-b950-594635e376f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_3c4c33b3-4120-4c7b-a246-afddd9e36fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_48eb13e9-3bb3-4bd6-979a-718b68ba0c97" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_3c4c33b3-4120-4c7b-a246-afddd9e36fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b150ab86-0098-4e31-824d-4f769f471bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b150ab86-0098-4e31-824d-4f769f471bd1" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ca5e1523-7086-47c7-96c6-c984293fea89" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_08024783-994b-4f0b-82a9-6deb40c5e055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_08024783-994b-4f0b-82a9-6deb40c5e055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_83e9105e-c40c-4135-9532-997f9c1911c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4458b54a-4489-43dd-9c62-f40bde19e06c" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_83e9105e-c40c-4135-9532-997f9c1911c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c6786aa-3648-47ad-b30d-d553493f85e0" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ffe10390-3020-49fd-8569-226e711692e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ffe10390-3020-49fd-8569-226e711692e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_81325336-6b7e-46c3-969e-3e4ed1e3dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_81325336-6b7e-46c3-969e-3e4ed1e3dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_d308b2e6-fc61-4fe1-a07e-cdb18a93e516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_d308b2e6-fc61-4fe1-a07e-cdb18a93e516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9634ec17-2915-4cbb-be5e-5fca97ad7b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9634ec17-2915-4cbb-be5e-5fca97ad7b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3ef11b6c-664f-48e7-b9a3-edcb1d02f794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e0bc2274-d427-4efc-b031-751f935f8e93" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3ef11b6c-664f-48e7-b9a3-edcb1d02f794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3bb37e5c-b48b-40df-a646-b95ee905e124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3bb37e5c-b48b-40df-a646-b95ee905e124" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cc6cf119-dc1b-4627-95ac-51473a2d3edc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_756c1a0a-5243-4169-b4cd-b9e5bc86743a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_756c1a0a-5243-4169-b4cd-b9e5bc86743a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_8bf00a0f-d536-4ee6-9049-f977114cdc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_cf653484-9c7c-4279-938f-c0f04ef677bc" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_8bf00a0f-d536-4ee6-9049-f977114cdc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4a26f74-f75a-4866-a914-32cc1d930b12" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_5eadc055-dbbd-4964-93d5-8bf1cbc50efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_5eadc055-dbbd-4964-93d5-8bf1cbc50efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_738c694c-a9af-416e-a6dd-82eb5431f80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_738c694c-a9af-416e-a6dd-82eb5431f80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5f5e50df-8307-45d3-836f-7c1989a2a384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5f5e50df-8307-45d3-836f-7c1989a2a384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_b0acbbc3-d053-493d-91aa-fd6114a72be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_b0acbbc3-d053-493d-91aa-fd6114a72be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c13f9e1d-7510-46d5-8abc-04426ac2d788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c13f9e1d-7510-46d5-8abc-04426ac2d788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e2755cee-9192-4d57-ba49-780613fe4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_fa826b7d-acbe-42d7-b0c7-fa605ab77554" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e2755cee-9192-4d57-ba49-780613fe4a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_44ec980c-512f-42d3-92f2-608a3b1d9478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_44ec980c-512f-42d3-92f2-608a3b1d9478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_8b3c62c7-5d85-4f7a-bdba-bca63d20451d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_d9ab2d85-cec4-40bb-aede-dd758d427995" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_8b3c62c7-5d85-4f7a-bdba-bca63d20451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_75a1a199-79c7-4988-ae95-55e411b1cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_75a1a199-79c7-4988-ae95-55e411b1cf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_5da9a186-000e-4573-92cf-a9241c3baf45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_aedd0baf-aca0-4029-9a55-1734621f969d" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_5da9a186-000e-4573-92cf-a9241c3baf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5df4ed3a-af3e-4052-8b23-88078b5c9467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5df4ed3a-af3e-4052-8b23-88078b5c9467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_61c349d8-3aca-4758-9157-a8f340866bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_61c349d8-3aca-4758-9157-a8f340866bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_34701369-de84-440c-bfff-5be9277d66ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_34701369-de84-440c-bfff-5be9277d66ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_549e2297-393c-4fbb-9ce0-0c06632a5fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_549e2297-393c-4fbb-9ce0-0c06632a5fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_32973042-9d8f-4c24-b813-a6580968138d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_32973042-9d8f-4c24-b813-a6580968138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_6092614d-b0a3-41cb-9aec-91d7be7f9916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_6092614d-b0a3-41cb-9aec-91d7be7f9916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4fb12493-e71a-4404-9635-659aec7567c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_773d4b0a-1b19-44e2-be8f-117903661909" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4fb12493-e71a-4404-9635-659aec7567c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_6997589b-738e-4071-8849-61e12a1485f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_d882c702-b77a-4209-a666-9ef4d9b08c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_d882c702-b77a-4209-a666-9ef4d9b08c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_77c323f0-de78-4b48-b914-e6da9a33502c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_77c323f0-de78-4b48-b914-e6da9a33502c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_d5c343fb-a301-4303-b9d8-aeb7f5ef8e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_d5c343fb-a301-4303-b9d8-aeb7f5ef8e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c1b01334-653f-48c5-ac75-2af356dbf1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c1b01334-653f-48c5-ac75-2af356dbf1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_f373b158-08c9-4e10-a6c4-2f4d0417afbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_f373b158-08c9-4e10-a6c4-2f4d0417afbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_227753dc-49cb-417b-9f7c-26c27d121b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_227753dc-49cb-417b-9f7c-26c27d121b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0b0afc54-2ea1-4c03-b072-cb7e7154321e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_728e772c-2155-4422-b4aa-d2479a8ea60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0b0afc54-2ea1-4c03-b072-cb7e7154321e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_af417bfb-1b18-434e-a4e4-6fc3b4057dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_af417bfb-1b18-434e-a4e4-6fc3b4057dad" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6163c59d-2491-492a-b9cb-9ec45a1e6703" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7c3e07c4-94c2-4685-a118-cc16c431dbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7c3e07c4-94c2-4685-a118-cc16c431dbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9ad22c93-c5fd-4b74-bb80-a6f6a879bd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9ad22c93-c5fd-4b74-bb80-a6f6a879bd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_217ddfb8-012f-4649-ae94-b91feb5bb76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_217ddfb8-012f-4649-ae94-b91feb5bb76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_b1ab9252-42ba-4674-bfd1-b26cc2e98375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc4af06b-548d-43d0-8c30-f79ddc5abd9f" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_b1ab9252-42ba-4674-bfd1-b26cc2e98375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_7ebd50e6-2ec1-4d13-ba0a-b072ee4f8847" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_1b05089e-e33e-4590-8925-a4fafefa4e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_1b05089e-e33e-4590-8925-a4fafefa4e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_7c4a3dd5-ade7-4aeb-90a4-b771d06291f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_7c4a3dd5-ade7-4aeb-90a4-b771d06291f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_42d44d71-be06-4f81-b135-9ed5bdc46295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_FixedIncomeFundsMember_42d44d71-be06-4f81-b135-9ed5bdc46295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_cf12dbe5-b648-4878-9c61-26bf6bd7d980" xlink:href="lly-20211231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_cf12dbe5-b648-4878-9c61-26bf6bd7d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember_4df1fb05-3b00-4139-878f-5b84017124b9" xlink:href="lly-20211231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_lly_FixedIncomeFundsEmergingMarketsMember_4df1fb05-3b00-4139-878f-5b84017124b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_393e5afb-773b-42c6-b4e5-57d328212fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_HedgeFundsMember_393e5afb-773b-42c6-b4e5-57d328212fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_b237618a-584f-4321-b33b-0aa38909ae7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_EquityFundsMember_b237618a-584f-4321-b33b-0aa38909ae7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_b4887f74-eb5e-4ccd-9042-c4755664831f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_OtherContractMember_b4887f74-eb5e-4ccd-9042-c4755664831f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_4e08bb1b-c2c1-4dad-a16d-71bf8964ef0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_4e08bb1b-c2c1-4dad-a16d-71bf8964ef0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember_4f4ffab1-7246-4d09-a751-7cea421794dc" xlink:href="lly-20211231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a71ab12f-d293-4496-8991-ea6ac5875c5a" xlink:to="loc_lly_DefineBenefitPlanOtherMember_4f4ffab1-7246-4d09-a751-7cea421794dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_343dba13-8bd9-4331-ae6a-fad8649e1235" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_df5e5b35-0480-4f62-be72-56486c325e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_df5e5b35-0480-4f62-be72-56486c325e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_0b0c9891-c695-48fe-bbec-28351f212e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_27630b6a-5c79-48db-b6b4-fe43de76f052" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_0b0c9891-c695-48fe-bbec-28351f212e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2b3214ec-f552-4e81-a92f-224f9d0f1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_098c4dcb-1b8d-4231-8228-515f36fa5986" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2b3214ec-f552-4e81-a92f-224f9d0f1f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d815ee0b-1b25-4990-8a84-ab2b6713770f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2b3214ec-f552-4e81-a92f-224f9d0f1f2d" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d815ee0b-1b25-4990-8a84-ab2b6713770f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20211231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_896cf1fa-1007-4fb1-b3c4-b08466045bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97839494-1558-49ec-8017-991ffd22cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_896cf1fa-1007-4fb1-b3c4-b08466045bc9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_97839494-1558-49ec-8017-991ffd22cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b04c34-3fdb-4c1a-b521-1f1af2df17d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b04c34-3fdb-4c1a-b521-1f1af2df17d8" xlink:to="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c773d0b6-ec8d-4a17-9565-3172606fc472" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0f29dddb-9f32-4c66-b5f3-c0f3d0746305" xlink:to="loc_srt_SegmentGeographicalDomain_c773d0b6-ec8d-4a17-9565-3172606fc472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_e6e879e1-dd55-42f2-8314-c61814abeb1e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c773d0b6-ec8d-4a17-9565-3172606fc472" xlink:to="loc_country_BR_e6e879e1-dd55-42f2-8314-c61814abeb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a8cf687c-e9c6-4561-94ab-4e1a9c9d41d6" xlink:to="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaPatentLitigationMember_505a7ee1-e95e-4b3f-a689-d8fce13eb872" xlink:href="lly-20211231.xsd#lly_AlimtaPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_AlimtaPatentLitigationMember_505a7ee1-e95e-4b3f-a689-d8fce13eb872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_6c23e5e5-4d5a-4d80-8071-f391c9d8a844" xlink:href="lly-20211231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_EmgalityPatentLitigationMember_6c23e5e5-4d5a-4d80-8071-f391c9d8a844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_3ded628f-0910-45fc-9c58-08b6159c06b7" xlink:href="lly-20211231.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_3ded628f-0910-45fc-9c58-08b6159c06b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_f0a742d0-b999-4a21-9212-a8806a9a4d4d" xlink:href="lly-20211231.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_f0a742d0-b999-4a21-9212-a8806a9a4d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_cf239d9b-b023-4deb-80f9-293d4fdbdbf2" xlink:href="lly-20211231.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_cf239d9b-b023-4deb-80f9-293d4fdbdbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_6fedcd75-f7e3-4850-8285-7682152e2020" xlink:href="lly-20211231.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_6fedcd75-f7e3-4850-8285-7682152e2020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_2f576bd1-20b9-4f37-a255-d44a5b2de5fd" xlink:href="lly-20211231.xsd#lly_EmployeeLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f4c84614-6821-43bd-996f-20d5400af039" xlink:to="loc_lly_EmployeeLitigationMember_2f576bd1-20b9-4f37-a255-d44a5b2de5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f7a7500d-5808-4c6b-9ac6-af5e05972ee6" xlink:to="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_3f6a7a0d-aa63-4662-99d8-734b7009d455" xlink:href="lly-20211231.xsd#lly_ActosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_ActosMember_3f6a7a0d-aa63-4662-99d8-734b7009d455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_f7d9cbf7-f0b5-45fd-9971-3e0eb7c80448" xlink:href="lly-20211231.xsd#lly_ByettaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_ByettaMember_f7d9cbf7-f0b5-45fd-9971-3e0eb7c80448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_954760e5-803b-45d8-8f4d-1890f0d783d8" xlink:href="lly-20211231.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_CialisMember_954760e5-803b-45d8-8f4d-1890f0d783d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_5462d790-f1b5-42af-a224-6c62c04b6755" xlink:href="lly-20211231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_JardianceMember_5462d790-f1b5-42af-a224-6c62c04b6755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_8d14d189-52b5-47b2-b674-c499bcd287c8" xlink:href="lly-20211231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_HumalogHumulinAndForteoMember_8d14d189-52b5-47b2-b674-c499bcd287c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember_ec6f9ab9-48fc-4dc3-9801-ea224a50268c" xlink:href="lly-20211231.xsd#lly_InsulinMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d241bf87-8157-42ac-93aa-5f9b57a4ac76" xlink:to="loc_lly_InsulinMember_ec6f9ab9-48fc-4dc3-9801-ea224a50268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:href="lly-20211231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationAxis_7e3faf34-dccc-44fd-bbea-4dccf7e2f31a" xlink:to="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_8f329ff2-5968-43a9-9b8b-5fd03365d0a8" xlink:href="lly-20211231.xsd#lly_LosAngelesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:to="loc_lly_LosAngelesMember_8f329ff2-5968-43a9-9b8b-5fd03365d0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_54a8ca7c-a7e2-4fa5-97bf-267f2f7ff27d" xlink:href="lly-20211231.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_54a8ca7c-a7e2-4fa5-97bf-267f2f7ff27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_8dd1376a-28ad-4025-81a9-b6f686a221aa" xlink:href="lly-20211231.xsd#lly_VariousStateDomicilesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_a1042f34-2ec5-48ab-aebe-f651a42c430a" xlink:to="loc_lly_VariousStateDomicilesMember_8dd1376a-28ad-4025-81a9-b6f686a221aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:href="lly-20211231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsAxis_90d6be5e-613c-4fbd-a147-cc8fe4338c17" xlink:to="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_11f4e879-e979-4a76-86ca-d3343f0094c9" xlink:href="lly-20211231.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_11f4e879-e979-4a76-86ca-d3343f0094c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_70493349-dc43-4a62-9c7e-4a621db1a0c1" xlink:href="lly-20211231.xsd#lly_PancreatitisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:to="loc_lly_PancreatitisMember_70493349-dc43-4a62-9c7e-4a621db1a0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_23e7743c-6e9a-4769-9382-564637b391d4" xlink:href="lly-20211231.xsd#lly_AmpullaryCancerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_f1b53167-dda7-4e5c-bcd9-8c4db9810092" xlink:to="loc_lly_AmpullaryCancerMember_23e7743c-6e9a-4769-9382-564637b391d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a121496-88f3-4294-a2fd-7deecad18a8f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_54002961-68f7-419b-a103-d6dcf4ad5d52" xlink:href="lly-20211231.xsd#lly_ProductLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:to="loc_lly_ProductLiabilityMember_54002961-68f7-419b-a103-d6dcf4ad5d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_2c50113a-265e-40aa-bc4c-148d6d1c33de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_182030f9-12a3-4187-89ac-e35e28210555" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_2c50113a-265e-40aa-bc4c-148d6d1c33de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d890abda-4074-4211-babb-18ddbfa56b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf1c92bd-b7be-4d13-aed5-3d88aeeb987e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d890abda-4074-4211-babb-18ddbfa56b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e55b525-edcd-4302-9051-3b676e24a535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d890abda-4074-4211-babb-18ddbfa56b53" xlink:to="loc_us-gaap_SubsequentEventMember_0e55b525-edcd-4302-9051-3b676e24a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_27449f93-acfc-47ed-bac2-5f4672289f46" xlink:to="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_fc59eb09-c4fd-453d-8caa-05f0c48476ad" xlink:href="lly-20211231.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_fc59eb09-c4fd-453d-8caa-05f0c48476ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_a1fd268b-3ec5-404b-b190-5a9607114ca1" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyNumberOfPatents_a1fd268b-3ec5-404b-b190-5a9607114ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9348bc9e-2f5e-4542-853b-a641482ee859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9348bc9e-2f5e-4542-853b-a641482ee859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_384cffa9-8649-4a8c-800b-2f01e51892c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_384cffa9-8649-4a8c-800b-2f01e51892c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_30fb32e1-1224-43ec-9f8f-755e8fc7f243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_30fb32e1-1224-43ec-9f8f-755e8fc7f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_0941c147-b015-4855-a6e0-110d883d7bdb" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyNumberOfClaimants_0941c147-b015-4855-a6e0-110d883d7bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_152a49e8-172d-4743-8be2-9bb5c38474e7" xlink:href="lly-20211231.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_152a49e8-172d-4743-8be2-9bb5c38474e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_2aeb2dd1-036b-498a-9cf9-ef506a54c76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_2aeb2dd1-036b-498a-9cf9-ef506a54c76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber_479ca712-150c-4dc3-98e9-8161e3124a89" xlink:href="lly-20211231.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26286a22-caa8-4335-b357-44d71ee7cabc" xlink:to="loc_lly_LitigationClaimsDismissedNumber_479ca712-150c-4dc3-98e9-8161e3124a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6b01266c-1203-48cc-828e-3c425c72b1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_015a0b87-fdfb-42d6-946d-a037bd00aedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6b01266c-1203-48cc-828e-3c425c72b1bd" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_015a0b87-fdfb-42d6-946d-a037bd00aedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_98b58ab4-256b-4526-8200-28597d9cf0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_20d5161c-88fb-48a3-9f7d-4944e5a7d43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_98b58ab4-256b-4526-8200-28597d9cf0cd" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_20d5161c-88fb-48a3-9f7d-4944e5a7d43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f9d6d56d-f02f-4cd1-ad8d-8a514a5f16bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_98b58ab4-256b-4526-8200-28597d9cf0cd" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_f9d6d56d-f02f-4cd1-ad8d-8a514a5f16bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_964b27ad-348e-401c-9dbe-8b15919f1745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_964b27ad-348e-401c-9dbe-8b15919f1745" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_69015b4f-1688-4b21-82e2-8469e5804910" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_bde7a0e9-f0a5-4a06-a41c-e6625459d0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_bde7a0e9-f0a5-4a06-a41c-e6625459d0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_d9f54ee4-3b1f-4594-b1e2-2e974cc5958d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_52ecd2b3-e9b8-44f7-b71f-fd1094f9248b" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_d9f54ee4-3b1f-4594-b1e2-2e974cc5958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b741939-fffa-41d2-993f-2ecd2081a0f8" xlink:to="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ee5cf32c-3bcc-4068-8ada-4d2f19527e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ee5cf32c-3bcc-4068-8ada-4d2f19527e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_0641aeef-272e-45c7-add4-a0b2bba50924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_0641aeef-272e-45c7-add4-a0b2bba50924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_eef3ba8f-8993-415b-87e2-ee88de847bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_eef3ba8f-8993-415b-87e2-ee88de847bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_3a10015f-fba9-44d9-b2de-6c33b416ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d3ab7db0-fe21-49e8-97c3-1851d8006ef2" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_3a10015f-fba9-44d9-b2de-6c33b416ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c33274b8-3aa7-4009-91ca-eb33a7d49e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c33274b8-3aa7-4009-91ca-eb33a7d49e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_631f5789-5aac-4d51-9f86-3157c395b2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_416fd987-4bf2-4247-a486-e88ac3328924" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_631f5789-5aac-4d51-9f86-3157c395b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c7163a1e-7688-4403-924c-28545f29b106" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7ec775f-91c9-458a-9a63-97537f5675a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7ec775f-91c9-458a-9a63-97537f5675a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_13bc5cfd-a45b-49e1-a082-16c7781a6b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_13bc5cfd-a45b-49e1-a082-16c7781a6b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1b84c214-9527-4a96-ab4b-f396faa9934a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1b84c214-9527-4a96-ab4b-f396faa9934a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7981cf76-4bd9-4aba-9e30-716a5c0c5554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7981cf76-4bd9-4aba-9e30-716a5c0c5554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51f313ec-503d-46b8-b745-ae81fa10fde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_f7367ffa-0155-46cc-adb2-6c473b004d8f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51f313ec-503d-46b8-b745-ae81fa10fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e2052257-b1a0-4818-9200-d9b846a21f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d9eec9a1-02aa-46c7-8e62-996f92eb8f58" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e2052257-b1a0-4818-9200-d9b846a21f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5ae51124-1fc1-479e-87c1-470297bca31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5ae51124-1fc1-479e-87c1-470297bca31d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_471748ea-bd33-466a-83ee-6ecd127a6622" xlink:to="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f66ee27c-56de-4744-87f0-0ba8f0ca98e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f66ee27c-56de-4744-87f0-0ba8f0ca98e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8ab98f40-68b9-4892-906b-376ef051336d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8ab98f40-68b9-4892-906b-376ef051336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cbde88e0-b1b0-4fb6-be8c-7f4fca9aed64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_cbde88e0-b1b0-4fb6-be8c-7f4fca9aed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c19ff853-bdb4-460a-96d4-b4ceb0497543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8955e10a-ae7e-4fe1-b2ac-ee9a9663ebdb" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c19ff853-bdb4-460a-96d4-b4ceb0497543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5297365a-2563-4e66-84f5-8284b0477669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_52b91e20-24a6-4cac-bf47-a7abc055025f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5297365a-2563-4e66-84f5-8284b0477669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_583aebea-cdf7-4cf1-8418-9f69d53700b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5297365a-2563-4e66-84f5-8284b0477669" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_583aebea-cdf7-4cf1-8418-9f69d53700b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_493e0566-87b9-4bba-b1b7-bb29703d4061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_493e0566-87b9-4bba-b1b7-bb29703d4061" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f201150-6f26-42e0-9e76-040c0c50cf27" xlink:to="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_0872b94b-6186-41b2-ba94-8bb8b9a1c9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_0872b94b-6186-41b2-ba94-8bb8b9a1c9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8cd07e1b-d789-40a8-bc0d-92fd97804023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ef0a988b-fe4f-4cc1-b10b-a944cf904fc1" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8cd07e1b-d789-40a8-bc0d-92fd97804023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_a968f1f6-a338-4762-a64a-54b702b6b9a0" xlink:href="lly-20211231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7de0c4d7-390e-4340-8e21-40ae1bb9be23" xlink:to="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_a968f1f6-a338-4762-a64a-54b702b6b9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3ce594d9-2c28-4d34-b6e4-02ceae883443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_46324906-a976-419d-9aa5-287ded36a472" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3ce594d9-2c28-4d34-b6e4-02ceae883443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5f45198c-6f9f-4faa-8981-90046ad0ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_3ce594d9-2c28-4d34-b6e4-02ceae883443" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5f45198c-6f9f-4faa-8981-90046ad0ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_40ca60a9-eb6b-4bdb-9bb9-c20c740f3b83" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fb918c56-10b5-4a7e-8d0b-0e4ab9893c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fb918c56-10b5-4a7e-8d0b-0e4ab9893c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_209d9da8-7322-4047-8fa2-32723f8f5e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_209d9da8-7322-4047-8fa2-32723f8f5e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b04915a1-a076-4084-9f54-aa58a958ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b04915a1-a076-4084-9f54-aa58a958ebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_447b4fb3-33b0-45fc-b74f-57e95385007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_447b4fb3-33b0-45fc-b74f-57e95385007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a53d298c-3989-4449-af6d-17daa2b5735c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a53d298c-3989-4449-af6d-17daa2b5735c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3c9029ec-69c5-4e3e-b925-b42e76ee311c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_605e7db7-952e-4b24-871c-9f6288201fdc" xlink:to="loc_us-gaap_ProfitLoss_3c9029ec-69c5-4e3e-b925-b42e76ee311c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_35086949-ac4e-46b1-a16e-db8c8c4c43d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2abc1b05-3d33-4434-84cd-8ddbee40b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_35086949-ac4e-46b1-a16e-db8c8c4c43d8" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2abc1b05-3d33-4434-84cd-8ddbee40b11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a7a4e531-59cf-4644-be01-9afed449820c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_645c5ba9-060c-47b8-b839-11f95db5171c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a7a4e531-59cf-4644-be01-9afed449820c" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_645c5ba9-060c-47b8-b839-11f95db5171c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_657f28d1-7c71-4e76-869a-e2780dfa048a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_InterestExpense_657f28d1-7c71-4e76-869a-e2780dfa048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_17614f40-bff2-4d77-8861-82cff6ee1a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_InvestmentIncomeInterest_17614f40-bff2-4d77-8861-82cff6ee1a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0e480e23-f9d6-4897-81ba-aff23109663f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_0e480e23-f9d6-4897-81ba-aff23109663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43cd3421-4407-4baa-800d-8861790363fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43cd3421-4407-4baa-800d-8861790363fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_87a863f4-7da0-4b82-95e5-dcf5eb026853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_87a863f4-7da0-4b82-95e5-dcf5eb026853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_c02c8036-0d4a-46af-8262-2e37ae20df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_c02c8036-0d4a-46af-8262-2e37ae20df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7b05dd47-de18-4b08-ad4a-61e6c2370cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7b05dd47-de18-4b08-ad4a-61e6c2370cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7344e86c-b382-4a28-a682-1172645cdc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2bf8a7fa-36ca-450f-acfa-109d6a603468" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7344e86c-b382-4a28-a682-1172645cdc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="lly-20211231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2b615268-5d9b-4fa5-a544-3342838ad609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_265b9c42-0c79-4371-9ff3-c94395b48eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2b615268-5d9b-4fa5-a544-3342838ad609" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_265b9c42-0c79-4371-9ff3-c94395b48eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lly-20211231.xsd#DiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d47394c7-14fe-4b24-9f7a-e1da36f5cb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d47394c7-14fe-4b24-9f7a-e1da36f5cb3d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ab2fa661-a6bd-421c-98e3-533131b69906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_16824eef-df40-4280-b1e9-da86b8881260" xlink:to="loc_srt_OwnershipDomain_ab2fa661-a6bd-421c-98e3-533131b69906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_3c1878f5-55cf-4c10-99b7-fa65a03a7d8b" xlink:href="lly-20211231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ab2fa661-a6bd-421c-98e3-533131b69906" xlink:to="loc_lly_EliLillyAndCompanyMember_3c1878f5-55cf-4c10-99b7-fa65a03a7d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6da4fde6-6d2e-43d2-a901-78dea6bd5a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6cdbc5ac-d2e8-442b-99d1-1de7ae89d65a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6da4fde6-6d2e-43d2-a901-78dea6bd5a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_839f6964-379a-46fe-926f-baf357362961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6da4fde6-6d2e-43d2-a901-78dea6bd5a9b" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_839f6964-379a-46fe-926f-baf357362961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c81af8-1ae9-4825-951f-17bcba8b510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89f307a2-66e8-44db-83a0-bf8a16e7b1f4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c81af8-1ae9-4825-951f-17bcba8b510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_07f1f813-ffcb-41fb-ab7f-44beab35d157" xlink:href="lly-20211231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f7c81af8-1ae9-4825-951f-17bcba8b510c" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_07f1f813-ffcb-41fb-ab7f-44beab35d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d12d65cd-9a2f-4be8-894e-8057a27917b8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_609ab484-8941-47f3-9cf4-71b58a3c7168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_609ab484-8941-47f3-9cf4-71b58a3c7168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_8b3438cf-a630-4bff-8696-5442c1987da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_8b3438cf-a630-4bff-8696-5442c1987da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a37c7b7a-581f-40c0-acab-ac40acdb7885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_Revenues_a37c7b7a-581f-40c0-acab-ac40acdb7885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d668f5b0-5df2-42d6-b5e2-4d64de378529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d668f5b0-5df2-42d6-b5e2-4d64de378529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_cd21083c-be18-429d-8559-9b3410ac351d" xlink:href="lly-20211231.xsd#lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_893b1ba1-7a47-4e73-8515-d93c79684573" xlink:to="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_cd21083c-be18-429d-8559-9b3410ac351d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>a102performancelevelimagev2.jpg
<TEXT>
begin 644 a102performancelevelimagev2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #) H\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-
M5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK1
M0!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5
M_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,
MG?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#
M_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?
MP_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\
M_"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-
M5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK1
M0!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5
M_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,
MG?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#
M_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?
MP_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\
M_"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
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MTGX#_:M_:,MO&?CSQG':^-I4N]'\!?#ZWL+MH]'CD1@]Q+<^3Y3W,B*?FW8
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M,1,XMF@65MH5CC;VZXYKZR^"<GBB;X*^"I/&P=?%[Z):MJPE14<71A7S=RJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW5[J_P!ZO;L_-"UM*ZUU:7>S3M]WXJVZ9]Q6-Y+>+.9;*>Q,<SQ*)VC)E4'
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M[1.  T;$HV!D'%=9H>B:?X:T:QTG2K.'3M+L8$MK6SMD"10Q(H5$51P%
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M1=)^%\%[IEYKUOXVU2]MO#GAR/2?$NI:7$;V[E"+))':7$:R^6N^3YP>(R.
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MLQVZ"]O8OAEX@ACFFQ\[(@L?E7.<#D@8R2<DZO\ PTMX1_Z!'Q _\-QXA_\
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M1,SLA/T_X9\+:7X/TV:PTBU^R6DU[=Z@\?F.^9[FXDN9WRQ)^:::1L=!NP
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MPM\,?%#_ (1S_A)],_M/_A'=:MO$.E_Z1+%]GO[?=Y,W[MEW;=[?*V5.>0:
M/(-6_:LTJ'XT>%=,@M/'">'KGP_J]S>6;?#W6Q-+=1W.FK;R*AL?-942:Z#,
M@V R('Y:+)I/[5FE3?&CQ5ID]IXX?P];>'](N;.S7X>ZV9HKJ2YU);B1D%CY
MJJZ0VH5G&PF-PG*RX]TN?"VEWGBK3O$DMKOUK3[*YT^VN?,<>7!<2023)M!V
MG<UK <D$C9P0"V2V\+:79^*M1\216NS6M0LK;3[FY\QSYD%O)/)"FTG:-K74
MYR "=_)("X /"_A#^U9I6M>%+^XUZT\<7]\GB#7+:.6V^'NMR*MK%JMU%:QD
MPV)4,D"1(RGYU96$F) XKB?^&PI?^&+_ /A)]WC#_A87_"O_ .TO[8_X0+5/
ML?\ :?\ 9WF?:/.^Q?9/*\[Y]^?)V\YV5]5>&?"VE^#]-FL-(M?LEI->W>H/
M'YCOF>YN)+F=\L2?FFFD;'0;L    97_  JWPQ_PJO\ X5Q_9G_%&?V-_P (
M]_9GVB7_ (\/(\CR?-W>9_JOEW;MW?.>: /(/'W[5FE:;XK^&MOI=IXXM;&_
M\036VJQ3?#W6T:YM1I6H2K'&)+'<[">*W?;%E]L;$_NUD-&K?M6:5#\:/"NF
M06GCA/#USX?U>YO+-OA[K8FENH[G35MY%0V/FLJ)-=!F0; 9$#\M%GW36?"V
ME^(-2T*_O[7[1=Z'>MJ&GR>8Z^1.UO-;%\ @-^YN9EPV1\^<9 (+GPMI=YXJ
MT[Q)+:[]:T^RN=/MKGS''EP7$D$DR;0=IW-:P')!(V<$ MD \+TG]JS2IOC1
MXJTR>T\</X>MO#^D7-G9K\/=;,T5U)<ZDMQ(R"Q\U5=(;4*SC83&X3E9<6OA
MI^UQHOBCP[>7FKZ+XP2[BUK5K%!IGP_U^:+R+?4;BW@+,MHX$IABC,BY!63>
MI5""B^U6WA;2[/Q5J/B2*UV:UJ%E;:?<W/F.?,@MY)Y(4VD[1M:ZG.0 3OY)
M 7!X9\+:7X/TV:PTBU^R6DU[=Z@\?F.^9[FXDN9WRQ)^:::1L=!NP     ?*
MO_#84O\ PQ?_ ,)/N\8?\+"_X5__ &E_;'_"!:I]C_M/^SO,^T>=]B^R>5YW
MS[\^3MYSLK _;$^+VA>/M5_9WT_3+#Q1:W$?Q@\.SL^M^$]5TJ$J&G4@2W=M
M$C-EA\@8L0"0,*2/K3_A5OAC_A5?_"N/[,_XHS^QO^$>_LS[1+_QX>1Y'D^;
MN\S_ %7R[MV[OG/->?\ [3GP5USXT?\ "I_[$NM/M?\ A$_B!I/BN^_M"21/
M,M;7S?,2+8C9E/F#:&VJ<'+"@#VNBBB@ KRKQ'_R=-\//^Q,\3?^EV@UZK7E
M7B/_ ).F^'G_ &)GB;_TNT&@#U6BBB@ HHHH \J_9I_Y)UJ__8Y^+/\ U(=1
MKU6O*OV:?^2=:O\ ]CGXL_\ 4AU&O5: "BBB@ KYS^,?[1C^$?C.? \7Q'^'
MWPW@M=#AU6>]\<V_G&ZDFGEC2* ?;[7[JPLS'YOOITS7T97AD/AGXK^$_BQX
M_P#$>C>&?!?B"P\0368M+C4/$]WI]S#;06ZHL3QIILZ_ZQIWR'Q^\Z=:G[2^
M?Y6_6_R*^R_E^=_R5OF4=%\;?%/QIXP'A_PYXS\ W=E9Z#::S=>)H_#%U<VE
MZUW-<"W6WC35 %410;BWFR;MRD8!P,.X_:2\31>"O#\UWJ?A+07OM?O]#G\=
M:A:S-H'^C.RQRI#]H5@9V4H@>X"AD?YV.U6[2S_9M\,^-/%GB?Q3\3O!/A#Q
M5K.J7-N;-;[3X=3%A:QVL*>0DL\"MCSA._ &=X/!.!N>-] \<Z;>VL/@S3/"
MFN>$FT[^S[CPIKT[Z;!$5)VR1316UQE2AV&%H]N%4@CD&MK7Z_\ #ZM=?LZ*
MVNM[7$O>=U_6EGH_/WM7?2RWL;GPQU3Q?J&DW\/C2RT^+4[.\:"'4=(RMGJE
MN41TN8HF=WB!WE#&SL0T;$,RD&NQKSOX$_#&?X3^!7T:<V,+3W]UJ"Z=I$;1
MV&G+-(7%K;*<8B3.!PH)+-M3.T>B4WT]%]]M?+?MIVT)ZOU?YZ?T]>^H5XW^
MT)\4O%7PNN/"UQH;:!+::CJ$&G#2[Z&>?4=5N99HU6WM51T6+;%Y\K3/Y@41
M\QXRP]DK@_'/P/\ "'Q&\7>'O%&MVNHG7_#ZR)IM]I^M7M@\"R%?,7%O-&&#
M;5#!@00,'CBE]J-]KZ^G]?T]FW\+2WM_7]?=;=>+:+^TIXT\06/B.Y%QX0\/
MV*V$VMV6J:S;W*PZ5I\&HS6D[72B4&XD$</F*%, R^PD;=S;O@K]H+QMXA\2
M?!6QU+PI:Z5IWC33;J[O[V<M'(98[9IHU@@+EH@0%=A+D@2*HW$,PZWQ!^RE
M\+O%&E^(-.U'PY--9:[<1W-]%'JM[%ETG:X41%)@8$\YFE,<6Q"[%B"3FNPM
M?ACX>MKKPO=-!>7EYX969=+N]0U*YNYXO-0QR%Y)9&:8E3C,I8CMBI@FH6EO
M_P /^5TO.UW>]E,DW*ZV_P"&_.S]+V5K7?SS^TI^V/KGP"^(/BW2)-%L&\.V
M7A%=2L-<N5<QPZQ(+QK>VN0)%S%,+1U4KM.\!<DR+CI]-_;4T!M L+O5/!OB
MW2M2U"#2[G3],N+6U$VI07UPEM#/!BY9%3S9$#+*Z2*&4E.:].\>? OP+\3K
M?Q);^*/#\.L0^(K&VTW4XYII0)X+>222!1M8;&1YI&#IM;)'/ Q@>'OV4?A=
MX7M8[>Q\.3-'%+8R0->:M>W3VXLYA/:Q1/+,S10QR@,(4(CSU4BM*=E93VNO
M6UVW\]4ETLK;ZFE2SNX;VT];17W73?J[^1J_#OX^>$OB$MG;"]3P]XBN;N^L
M5\,ZU=6T>I>=:2M%<JL<<KK*$9"2T3.N,'->C5B>%/!>C>![6_MM$L_L4-]?
MW.J7"^:\F^YN)#+,^78XW.Q.!@#.  .*VZ71=[:^O6WEV)ZNVU]/3I?SMN%%
M%%( HHKY4\*ZQ\2;']OZZT/Q7XNCO_#EYX,OM2TS0-,22&SM(EU**.%I%+'S
MKCR_O2$#!9E7Y>I'WIJ'>_X)O]!O2#GVM^+2_4^JZ*^5_P!L;0WUGQ/\/?"_
MAS7_ !5H/C;QQJZ:<E]HOBG4[)+#3[=#/>726L-PL#2+& @+1GF52<X KR?P
MO\2O'4VN>#_%6G^*-:.I^*/'^O\ @LZ9J%[-/8PVD,5REF?LS,45XGM4=I%4
M.^Z3>6J%)N]EKK\]8I6]7)+[^P27+9_TM)/\HO\ #N?H!17P;\-_B7XJ^"^I
M:'HOQG\5:SH%EI=X=:O3>:C+JEU)OL4AAMI7@:9FADN(M4O"K-MCC@C+"-04
M7[OAF2XA26-@\;J&5E.00>016SC973NO+^M[W7X]2+ZV:M_7_#/YCZ***@H*
M*** "BBO+OVBO^$9T_X>S:_XS\::YX+\*Z%)_:%_-H>J/ISW:JI5;=YHL389
MF&$A='9MHR<X,RDHJ[*C'F=D>HT5\\_LAZMXM^*G[*^G7WB74]<TN[UP7K:7
MJ-Q)&VJ0:=)+(+*5I'1E>40E")'5MWRL=V>?G_Q=\0/%WP=_X6]X&M?%WB:!
MSJWAG3]&A\0:G+J&JV]E=SI:W6I)=LSX2=@^Q%?,39^2$D*-'%J?L^KM:_=M
M*S[-7UWM9]F0I+D=3HKW]%U7=/IM?U:3_0:BO@'Q)!\9/$7_  LCP-\/_$&O
MWMKX(\6RPVUY/KKQWD4-QI2S6IFNYIE>>"WN9-SH[R,R%05D VU[W^S=\<M%
M^(7B+Q%:77B6>[\3ZQ<2:O::+*D_DV>F*D*6XB9E$09X6@N9$1BP-VI8 %:4
M?>2:ZI/Y-)_DWY:/4'[N_=K[FU^?YK0^@Z***0PHHHH ***^=?VPO'VM^&3\
M+_#ND)KCP>*O$ZZ?J$/AN86]_<VZ6\TQMH9S)'Y+2-&@\P21[5#'>HR:3>J7
M=I?>[#Z-]DW]RN?15%>._ ;4-,^(?P%2VT#Q3XP>)OMNF-J?B":)]=TZ=)9(
MY(I)"C(TL+@J';S,[%)9^I^6_%WQ \7?!W_A;W@:U\7>)H'.K>&=/T:'Q!J<
MNH:K;V5W.EK=:DEVS/A)V#[$5\Q-GY(20HIKW^2.[M;SNTEW[WTOI=JZ5Q:*
M#F^E[^5OZ\NV[2?Z#45\ ^)(/C)XB_X61X&^'_B#7[VU\$>+98;:\GUUX[R*
M&XTI9K4S7<TRO/!;W,FYT=Y&9"H*R ;:][_9N^.6B_$+Q%XBM+KQ+/=^)]8N
M)-7M-%E2?R;/3%2%+<1,RB(,\+07,B(Q8&[4L "M$?>2:ZI/Y-)_DWY:/43]
MW?NU]S:_/\UH?0=%%%(84444 %%9GB9=8?PWJJ^'WLX]>-K*-/?459K9;C8?
M*,H3YBF[;NV\XSBO@K1?BE\2O#/P'^,MOK7C?4==\4K\58?"@UZ(-#]DMYY;
M&*3[-'N/V= LDFQ5/RE\@[N:4;RDX+>RMYWE&/YR5_U'+W8<[V_R3E^29^A%
M%> ?LQ:]J@\5?&7P+=ZIJFK:=X1\2):Z5>ZK=27=REM/9PSB%IY2SR^6\CX:
M0LV"H).!7S3\?/%_C']G3XG7?@_3_'OC%+'Q1I^G6%I>>)-4>^N=1NI]6A2Z
MO;-E^2T\FWG,)1!#R498\+YA:]Z4(Q^VE;YJZO\ KO\ -7:6T9R?V+W^3L_Z
M[>>C_16BO@'Q)!\9/$7_  LCP-\/_$&OWMKX(\6RPVUY/KKQWD4-QI2S6IFN
MYIE>>"WN9-SH[R,R%05D VU[W^S=\<M%^(7B+Q%:77B6>[\3ZQ<2:O::+*D_
MDV>F*D*6XB9E$09X6@N9$1BP-VI8 %:<?>2:ZI/Y-)_DWY:/43]W?NU]S:_/
M\UH?0=%%%(84444 %%9GB9=8?PWJJ^'WLX]>-K*-/?459K9;C8?*,H3YBF[;
MNV\XSBOD3X!_&;Q3\./AA\=-4\=^([OQ_P")M%\>W6B::A4QB]NWBM8[:SMH
M=Q$*/-( $4X7<S'^(TD[N2[*_KJE9>=VBN71/N[>FC=WY:'V=17R_P#\$_=<
M\::]\)?&,?CWQ!=:_P")['QGJVGW-Y-</,L;1L@*0[R=L2L6VH/E Z"O"OCY
MXO\ &/[.GQ.N_!^G^/?&*6/BC3].L+2\\2:H]]<ZC=3ZM"EU>V;+\EIY-O.8
M2B"'DHRQX7S#5GSP@MYI6[7:NO\ A_G:U[1=<DYO:#=_1.S_ ,[?KO\ HK17
MP#XD@^,GB+_A9'@;X?\ B#7[VU\$>+98;:\GUUX[R*&XTI9K4S7<TRO/!;W,
MFYT=Y&9"H*R ;:][_9N^.6B_$+Q%XBM+KQ+/=^)]8N)-7M-%E2?R;/3%2%+<
M1,RB(,\+07,B(Q8&[4L "M$?>2:ZI/Y-)_DWY:/4'[N_=K[FU^?YK0^@Z***
M0PHHI&SM..O;-)Z*X"T5^<'C3X@_%[PG=?M'Z;XH^)DDOB.S3PI'91Z&LUM;
MPF[ED\VRTY 6:*65#Y:S<,6VLQ0#*_2/[&NL:[J&G_$W2]:U36!_9/BJXM++
M0_$5^VH:KHEN88I$AN+EFD$Q;>9$(DF4*ZCS&((6H^]>W17_ /2?_DE_PUFW
M4_=RY?-+[TVG^']:I?1U%?!WQ.\9>*_V7_&GQ+MK/QCXJO[>/X=7NK:5_P )
M=J)U*35]4BE+O>6P&8K=($E1'A"PAL*1$57>89E^)QU_Q1\-?"/B'Q3XCB;0
M/#/BF9)==E&HLLLTD=_#;7LTZ-"91$KA?-15PZH5!Q4*5TFM;V_.:^Y*$G]V
ME[I$ERNS_K2'XOG2^_7:_P![T5\I?LU?&EI_&%KX?\?>,9;GQE-IMGH%GIRM
M-+;75Q:12"^NRZIY(EENH[Q%+,&=+(E1@-767'[8V@V_[0-O\,_^$8\4M')I
M$FH-JO\ PC>J[Q,MRL'EBV^Q[FA.[=]J#>4, 9Y!K5Q]]0B[WO:W6UW^7XZ;
MDWT<FK6M?RO_ ,'_ #V/H&O*O$?_ "=-\//^Q,\3?^EV@UZK7E7B/_DZ;X>?
M]B9XF_\ 2[0:@9ZK1110 4444 >5?LT_\DZU?_L<_%G_ *D.HUZK7E7[-/\
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M:+8Q1?#*6Q\1W^K/I<$&J7.H:99,HLIKKSTFO--BF8#R61@+8@,1@L*9\/\
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M+XGE^)EQX;\ ZQHMVUHEK-XB22WOR;2*Z3R)IXH"[%9@I3R\AE/4$$\SX/\
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MN]_Z_KL?#_P?N[[4/B=\$[K4Y(9-1N/#GAV:Y:WMH[:+S&TC6RP2*-51%!)
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M_%7GZ=JFO6MM<0[M?OW7?&\@9<JRL,CD,#T->@?\-8_!#_HLGP__ /"HL?\
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MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^
M&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU
M6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^
M&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU
M6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>a103performancelevelsimage.jpg
<TEXT>
begin 644 a103performancelevelsimage.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #) H\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-
M5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK1
M0!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5
M_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,
MG?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#
M_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?
MP_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\
M_"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-
M5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK1
M0!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5
M_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,
MG?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#
M_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?
MP_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\
M_"7L?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L
M?_C5'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5
M'_#)WP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)
MWP0_Z(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_
MZ(W\/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\
M/_\ PE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\
MPE['_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5'_#)WP0_Z(W\/_\ PE['
M_P"-5ZK10!Y5_P ,G?!#_HC?P_\ _"7L?_C5<II/PG\$?"_]J;P5_P (;X-\
M/^$OMW@SQ%]K_L+2X++[1LOM#V>9Y2+NV[WQG.-S8ZFOH"O*O$?_ "=-\//^
MQ,\3?^EV@T >JT444 %%%% 'E7[-/_).M7_['/Q9_P"I#J->JUY5^S3_ ,DZ
MU?\ ['/Q9_ZD.HUZK0!Y/^TE\?K;]G?P+9:U_8%]XJUC5=2@T;2-$T]UCDO+
MV;(BC+MD(I*G+8.,C@YKRGP_^WQ8:;X1^*EU\3/!%_\ #OQ;\.8X)M5\-_;X
MM0,R7 'V;R+A J.9&*KV W+R1G':?MG_ +5&G_LE?!V;Q3+9KJFMWDPL-'T]
MV*I+<LK-ND(Y$:*I9L<G 48W9'PNNG^%_CQ^Q_\ &]O!GC:;XM_&_6#8>(_%
MES9Z7=VN4AG1DM+9)84W11)'(%51EB.@&U1G%W<[O1=>WP[+K9<TFWI:RWU-
MN57A?2[^_??UT2MK?75:'V%\,?VV)]8O_%ND?$WX<ZA\+_$.@^'#XN33CJ,6
MI_;=* .94>-4 D##;Y1&<D<YR!E_!_\ ;LU/QY\0O ^A>+OA1J?P_P!$^(%M
M/=>#]<N=5AO!J:1J)/WL**&MRT95@"6SN'4'=7EG@3X^>$_BG^U-K/Q[T2?4
M)/AIX#^&;6.K:JUG+"GVTSF=K51(J[Y%0G@<9"\X(-<Y^RS^T[X!_:?_ &GM
M+\>>/_&,4'C0/<Z7X$^'=OI]V\6DQ,I\RXFN?)\I[B1%/.[: ?7:L?3%7JQB
MUT=UY<TTK=W*T;6TW=K-6Y6W[)R]/OY8MKR46W>^NRNF>Q_$'_@H;=>#?$7B
M^]L/A+K&N?"[P9K*:#XB\;)J<,)M;DNJ/Y5H5+S*I=/F#+]X9QD9^I_%'CC2
MO"7@/5/%]Y*\FBZ=ITFJ2R6Z;G>%(S(=B\9)4<#N2*_-_P#:(_;-^&OQV^/%
M[\-O'7C9?!7P6\(Z@K:K#'875U<^*[R"7_49@B<16J.G.2"V 1R08_L/Q-\0
M_B;\/_$6K^-=5G\ P_L]:7I;ZEYEO'?#Q!Y*VN]0$.(,F3@+Q\I ZUS1=\-S
MWMN^;RMN_5W<5O;>^YO)6K\MOE\]EUT5N9[7VMJCAOA%^W?J/CCQ]X)T7QC\
M*=2^'FA>/K6>[\(:]=:M#=KJ4<2>9^]B10;<M&58!BV=P['=4'@W_@H,GBKQ
MSX?\WX;ZEIWPK\3:_)X9T'Q\^I0R+>WRL44-9A?,CC=T<*Y8]!Q]X+X3^S9^
MTGX#_:M_:,MO&?CSQG':^-I4N]'\!?#ZWL+MH]'CD1@]Q+<^3Y3W,B*?FW8
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M,1,XMF@65MH5CC;VZXYKZR^"<GBB;X*^"I/&P=?%[Z):MJPE14<71A7S=RJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW5[J_P!ZO;L_-"UM*ZUU:7>S3M]WXJVZ9]Q6-Y+>+.9;*>Q,<SQ*)VC)E4'
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M[1.  T;$HV!D'%=9H>B:?X:T:QTG2K.'3M+L8$MK6SMD"10Q(H5$51P%
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M1=)^%\%[IEYKUOXVU2]MO#GAR/2?$NI:7$;V[E"+))':7$:R^6N^3YP>(R.
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MLQVZ"]O8OAEX@ACFFQ\[(@L?E7.<#D@8R2<DZO\ PTMX1_Z!'Q _\-QXA_\
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M1,SLA/T_X9\+:7X/TV:PTBU^R6DU[=Z@\?F.^9[FXDN9WRQ)^:::1L=!NP
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MPM\,?%#_ (1S_A)],_M/_A'=:MO$.E_Z1+%]GO[?=Y,W[MEW;=[?*V5.>0:
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M]B9XF_\ 2[0:@9ZK1110 4444 >5?LT_\DZU?_L<_%G_ *D.HUZK7E7[-/\
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M:+8Q1?#*6Q\1W^K/I<$&J7.H:99,HLIKKSTFO--BF8#R61@+8@,1@L*9\/\
M]JC4-6T?P]J>H>&B/"DWV73;O79M522_6^?34OF)MH[:.-XL,$,BLC%R<0A.
M:]0\,_ ;P3X32U^PZ;=RS6]XU^EWJ.JWE]<F8VS6N7GGE>1P(79%5F*J#\H!
M -0Z#^SSX \,:Y8:MINA/!<6,4<5O U_<R6J-';BV28VS2&%IQ !%YY0R[/E
MWXXH>\K=;6_7[_SUZ6:5[*_G_P #]/QTUNN5^$?Q4\:^//BE/#K^C0>'= N_
M"UGK.FZ?!?)>$^=/* \KB)&278$#1@O&I'RN^2:Y?QE^U?J'PX\+Z5JLOATZ
MCI]UJ>K6MSJ^MZBUG9VOV?4&MHH6NHK)H(GDZ1_:F@CPH#SELL?7/A[\#/!G
MPMU:ZU+PWIMU:7EQ:QV):YU2[NTAM8V9H[>%)I76&%"[;8XPJ+N(  JGKW[.
M_@/Q'9PVUSIE];)&UV2^F:S>V,LJW4S37$4LD$R-+$\C%C$Y9,GA11LHJ/2]
M_3F;W]&ETVVMH/K)OK;_ -)2?XZ_K?4D^(?CJZT'7OAR]C>!=*U;4KA;WRU2
M03VZZ;=3J V#CYXD;*D9QC."<^4>'_VPM>\2>"]<\0VGPIUYX8(+2\TO_0-7
M$5S;SRA-TK-I@</&C+(XM4NUVY*NP&:^@;SP7HE])H33:=%C0Y#+IT<9*1VY
M,#P8"*0I'E2.NT@@9Z9 (XBP_9C^'&EZ;J%C:Z)=107GDA6_M>],EDL,C20I
M92&;?9)&[,42V,:KG@"E*]W;;I_7W"6T;[]?Z_K\-?*M$_;@35]2\%!O#^C0
M:)XADAMSKG_"1.;%YWGEC,5I<FT%O+(J1B4P7$UM<8;:(3(-E>J?&7QIXK\*
M^*/AQ9>'(;&2SU?5KBVU-KNY,3^2EC<3 (/)DR08]_5,F-5R%=BM>S_94^&=
MC<)/#HNH+*TR7-V6U[4&&J2K)YB/?@SXOF5NAN?-( "CY0!7=^+/ NC>-I-'
MDU>WGEDTB]&H6<EO>36S1S"-X\DQ.I92DCJR-E&#$$&BHN:#4='K_7R^_P Q
MQNF[[6_S_P" >!>"/VH?$]C\*HM0\6>'+%]?3P[HNJV3IJ_&JF]9H5\Q4MLQ
M2^9&3Y%NEPS>8JQ+(YV4^W_:]US5O!-GK6D> +>XO8]/UO4M4L;_ %>XL?LL
M>EW2P3I%YMD)7D?<&1)8H<<A]AKUC4/@'X&U+18=*DTFXAM8+"QTV![/4[NV
MG@@LY#+:B.:.59$:-R2)%8.<X+$<5'HO[/7@'P_I,^F66B2)9SVNH6<JRZA=
M3,\5](LMX"[R%B9'4,6SD'.",G.DI)SE*W>WXV_2]OEV&K*R]+_K^.WXF;\6
MO'WB?0]>^&4?A>*QET[7=3FBU!KRX,3^0MA<3+L'DR9(,>_JF3&JY"NQ7S/P
MG^U=XCT/X4VNH^,/"HN]?;0M#O[#^S;J6[;57U!V@1IHK>T+P,)4W,D$<^%<
M; Y&ROH#Q%\/-!\51:%'J-K.PT.Z6\L&M[R>W:*18WBY:-U+J4D=61B58,0P
M-8MY\"/ U]H?]D3:'NL1IEIHZ*MW.KQ6UJY>V$<@?>DD;L6652) P!W9 (G9
MRMLVON5[_-Z?U:TKX5?>WXW_ "M^FVI2\#^-]?\ BW\)[S48[&Z^'7B&7[1:
MK)J6G7#+:NI*BXCBNX;:21",,IEBCR>JD#GRO3/%7CC7/[)T'2?B+JMUH'B'
MQ$UII/CNXT[3_M\]I%I\MQ*8%6V%L\;3P[8YC!\\?F%=P\N4^S-\%?"#_#34
MO +Z=<R>&-329+Z%]2NFN+KSF+2M+=&7SW9R3N=I"Q!P3CBLV3]G?P9<>&WT
M.Z_X2._L_M27L4U]XLU:XN[6959 UO=27)F@^1W4B)U#*[ Y#$%2MK;LO^#_
M %UV>@U>ROOK^6G]=-UJ>7V_C?QWXD\,_#O7[/QY+%XHUNUL?LO@[3=+M?LN
MH%)%^WW5R\B23);[&W;XY(A'F-?WDDB(WI?@_P 3>*[KX\^.= UN[L3H=IHV
MF7^EV-E"<P"6XOXW:65OFD=Q;QL0 JIPH#$-(XW[-?@./7[76;*UUK1;RVL[
M33HTT3Q+J>G6_P!FMMWV>$P6]PD3(FY\*RD'>V<[CGN[?PQIEKXGO?$,5MMU
MB]M(+">Y\QCOAA>5XDVYVC:T\IR!D[N2<#%W6OJ_QV]/3IT#3E:7:/X--_A=
M=WU/G3Q/\;?&/AOQA\0=/N-3C73O^$FTS3/#\PM8P;?_ )!QN[5B5PYDCNI)
M$)!8!9N1M7&[J7[4VHZ/9ZWJUWX+C_L".SUJZT:XAU<-<WS:;+Y<R3PF$+;^
M80QC*R2Y4?.$)"UZAKWP<\'>)H+V'5-$CO([S6+;7YM\T@/V^W$0AG4ALJ5$
M$0PN%(4@@[FSE_\ #._@!KO7[AM#DD.N0W5O=PR:A=/ D=RV^Y%O$9=EMYS@
M-(8%0NP#-DC-1'X8I]%9_P#@*5_OO^#=VVBM+W\[_+73\OT:2UYM/VFM(\):
M+XGE^)EQX;\ ZQHMVUHEK-XB22WOR;2*Z3R)IXH"[%9@I3R\AE/4$$\SX/\
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MN]_Z_KL?#_P?N[[4/B=\$[K4Y(9-1N/#GAV:Y:WMH[:+S&TC6RP2*-51%!)
M55     KT[XS?%;Q!X9^,"Z19>+SH=Q#%I#Z+X66TMY/^$F:>\DCO5_>1M,_
MDQ*I_P!'=/*W>9)N0@5])45M.2E4YTK*]_Z_X*?H0HVC9OHE]W]>7J?*<GQI
M\0PZEXVN+/X@?VCX[T]-<6+X6#2(KDVT=MYOV.?9"BW<8=(X9/,FD:*;[0%C
M"F2+#M'^/FG>&;KP[>#XXVWCSP;+KBVNJ>(+VUL8[>SWZ==.MK)>VT4=MDS1
MP$1@+*A=5=F$J"OJJBL_LV\DOZ_J_=O8TE9M_/\ %:?=_5GJ?,_P*^)WB3QW
MJFAZSXE\;SZ9HT7A?0[^33I;:RMXKV]OI+N'$SM%O4ET@"1Q,GS@#G<5/TQ1
M152:;T0NMPHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O*O$?_)TWP\_[$SQ-_Z7:#7JM>5>(_\ DZ;X
M>?\ 8F>)O_2[0: /5:*** "BBB@#YJ^"7[0GPL\#^%_$.B>)/B7X/\/ZU:^,
M_%7GZ=JFO6MM<0[M?OW7?&\@9<JRL,CD,#T->@?\-8_!#_HLGP__ /"HL?\
MX[7I6FZ38Z+;O;Z?96]A;O--<M%;1+&K2RR-++(0H +/([NS=69F)R235N@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^
M&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU
M6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^
M&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=KU6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU
M6B@#RK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#
MRK_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(
M?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__
M (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%
MC_\ ':/^&L?@A_T63X?_ /A46/\ \=KU6B@#RK_AK'X(?]%D^'__ (5%C_\
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>a104performancelevelimagea.jpg
<TEXT>
begin 644 a104performancelevelimagea.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #+ I8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\
MC5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>J
MT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >
M5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\
M#)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP
M0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(
MW\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_
M /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE
M['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_X
MU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_P
MR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$
M/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-
M_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__
M ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>
MQ_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\
MC5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>J
MT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >
M5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\
M#)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP
M0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(
MW\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_
M /PE['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE
M['_XU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_X
MU1_PR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_P
MR=\$/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$
M/^B-_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-
M_#__ ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__
M ,)>Q_\ C5>JT4 >5?\ #)WP0_Z(W\/_ /PE['_XU1_PR=\$/^B-_#__ ,)>
MQ_\ C5>JT4 >*?LY>$]#\#^*/C9HGAO1M/\ #^BVOC.'R-.TNU2VMX=V@:.[
M;(T 5<LS,<#DL3U->UUY5\&_^2B_';_L<[;_ -1[1J]5H **** "BBB@#RK]
MFG_DG6K_ /8Y^+/_ %(=1KU6O*OV:?\ DG6K_P#8Y^+/_4AU&O5: ///CI\=
MO"W[//@5O%/BN2\:U>YCLK2RTZW-Q=7MU)GRX(8QC<[;6QD@<')%<U\%?VL?
M!GQJTWQ9-#::WX-U+PGAM=T3Q?8_8+_3XRA=998]S (55CG/0<@9&6?M;?&#
MX?\ P(^%7_":>/\ 1K/Q FFWD4NBZ=<6T<TLNI#+0>27!$;C:S>8.4"L1DX!
M^7OAUX9'Q+^ G[1OCB7QEX7\8_&?Q_X>FEO]%\'ZG;WZ:/;):NEI9 1R-EP,
MJ6)Y8  MMW-BYN,*LM^5/[[)I>;W;[*W6U]E!2E3B].9I>NMGZ):6[RTVO;Z
M%^"W[<G@#XX>.+;PQIFE>*= N=2MI;W0[WQ'I)L[37;>(D22V4A8^8H W?,%
M..V00,;PW_P42^%_BCX@:;X>M=/\50Z-JFJ'1--\:76CF+0;Z^' @BN2^XL6
MX&4 XR<#FOFWX6>./#?Q2\??L.Z5X0UJPU34/"_AN_D\00V<B2MIT:Z?#"Z7
M(4DQ[G5UP^,[@>]:%C\5OAC^U)\;?#?A/2]?\$_#OX&_#SQ E]8Z6][::=>>
M)]8#L8S;6NY2EN))&.X+F0N>K,?+[>1*K&&ZNUZI2MS?=HEUEY'+S-TG/K9/
MT;3]W[TGKM%_,^A/''_!0[X8^ _'VK>';O3?%E]IFB:A'I6M^+=/T8RZ)I-T
MS;?*N+C<"K!N#M1N3QGG'TW',DT2RHZO&RAE=3D$'D$'TK\Y_P!H3XM?#CXU
M?$_7O@#H>O>"_AE\/(-534?B'XDU"\M-,DU6Y256:TM59E,LQ:)1).0<%.3A
M0)/KO2O'WCY?BM'X5A^$L,?PHCM@+?QXOB:U>-XA;AEQ9;?-V[OW>=W3YNE<
M]/WJ*EU?7HU9:^2O?EZM:]F]:GNU&NBZ=5KIZNWQ::?>EY_X;_X*)?"_Q1\0
M--\/6NG^*H=&U35#HFF^-+K1S%H-]?#@017)?<6+<#* <9.!S6AXS_;V^&W@
M?XH7G@Z^L?$UQ::;?PZ5JWBRSTHRZ'I5Y+]R"YN=PV/DJ#A2 3R>&Q\VV/Q6
M^&/[4GQM\-^$]+U_P3\._@;\//$"7UCI;WMIIUYXGU@.QC-M:[E*6XDD8[@N
M9"YZLQ\OR[XA>)=(\._LZ_M5_"_5=0M8?B3K/Q.:73=!D9%OKU)[NT>"2*'.
MYU*JQRH( (_O4Z?O<EU>^OG)<T(_)OFD[=N6_4N45SN-[*Z5_P"72;?K;E5^
MFZ]/N;XU?MV> O@EXVU'PM=Z)XN\5ZCH]HE_KDOA;1_MD&BV[@,LMW(74(I5
M@V1NP.O) ,_Q6_;C^'_PQM_##6>F>)_']QXATDZ_9VG@S2C?2KIP )NY S($
MCYYR<C!R!7@?[5?QL\.6?BBZ^ WA?5?!W@WQQXJTJ"V\>^/]>DMK&*SL1"%*
M-(Y0W-RT<C!$).U9.,9+)VWQ*^(GP4\.?#'1/V?9?'VK^ ?#%_X12YT7QYIN
MHP065U:P%5\N*]WD2R2;3NC5<.K,H(+J#G-N-)RB[M/3SLI-_)65NKM+RM,/
M>G'F5DUJNU^6WS=WIT]V_G]4?#?XAZ%\6/ NB>+_  S>?;]"UBW6ZM9RA0E3
MP0RGD,"""#T(-?.>L_\ !13PSI_BKQAHFF?"?XL>*QX4U*XTO5-3\.^'(KRR
MBFA8AR9%N/E&!N^8*<8) KI/^">OB*_\4?L@_#V]O])L]'9;>:W@AL+3[+#+
M#'/(D<PC[&15#D_Q%BW>OF3]GGX4?%;XC?%+]I)_ ?QKD^&&D+\0]2@O;"'P
MS:ZD]RY8YD6:5U:([2%&WIC/6MJT7"O*G#HFU\G%*_7KKU(IO]PISWNE^$KV
MZ=-.EC[W^$?Q8\-_'#X=Z-XU\)7IOM"U2,R0NZ%)$96*O&ZG[K*RLI'J."1@
MUV%?EA^V!\%7^!NA_ /X)Z-K.CV_PXG;4YM2O?'^IW5CH^IZA\LH^W36C(Z8
M+,R#<%!*Y)P37'S>'=4UC]DWP/X8OO&ND^(_#K?&BPTS2;SPE/J)M]-@:.17
MM[6XO(TD>.-F;RY$:0<\2,1PURU9/V?=)?.2CKVU=UW5KV;L%N1+GWLW]T7+
MTV5GKH^]C])?V@_VE/#_ .SI8^'I-7T3Q'XFU+Q!>FPTS1O"VGB]O;F0+N;;
M&74' [9R<\ \UZ=H^HG6-'L;\VES8&Z@CG^RWB!)X=RAMDB@G:XS@C)P0:_/
MG]JS]D'X2Z'\1OV8O!]IX4\OP]=:[=:--:_VA=$O:,'N3&7\W=GS9';?G=SC
M=CBO)O&%C\+?%,G[2.O_ !F\87.C?&#PCJ]_:^#;2YUV>SN=-M(8@VG?8+<.
M@E#MCH&R,,<%R[8*:49MZ\K?W)0V75OG3Z=5TUTE%\T4NMOO;EOV7NO\.^GZ
MUT5^8^A?"]OVFOVG/@UIOQEM+V[N[CX.6^HZO8&XEM6NYUO'V>?Y95LY99&0
M\;U&1QBL3XT?!GPU\2/CA^VCJ.MI?._A7P[I^I:5;VM]+;P172:>6BF9(V D
M9/+PH?( =N.>-:B]E?FZ<[^4)<OWNST]->R@O:?#_<^^:BU]W-K^1^J=%?E[
M\)]%3X5_'O\ 92\:0ZKK=YKOC[P9J-_XLOKO4I[R74PFGK<1H5D8@!"5VHH
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MI,$L(@MKQI5^RRB223S)(]BYE4H'WG]VN.2/O-Q73_)O\HR?R]+C]V/,]O\
M@I?FTOGZGT517QI=?MO:AHMK\5==U+4M$%EX;?6$T/PT?#U_;7.J+93BW$JZ
ME)-]GF E/[Q(8V9%922IR*]M^ OQ4U_QMK'CSPQXJ_LN?Q!X1U&WLYK[1K:6
MVMKJ.>UBN$=89))6C(\QD(\QL[-W&[:"/OI-=4I?)Z?\/_P&$O<=GW:^:W/7
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/QEX0
ML?'&BOIFHW&J6UL763S-'U:[TR?*]/WUK+')CU7=@]P:W*0C((J9+FBT-.Q\
M>?LU>*A\-_V2?^%M:QJ>O^*==\N\CN3XD\9W+6T@74)(8\F^N3;P8"H"ZKO(
M! #LVUII/^"@(L_A_P#%;6;GP.LNN^ )-*\_3;/4YQ;7T5_(BQ/%/<6<,@QN
M8_- %.T%6*L&KU>7]E/PC+\ X?A+_:&MIH5O<_;;;4H[J-+^WN!=F[25'$>S
M<DIR,H1@ $&N=U+]B+PKKVF_$2VUKQ?XPUJZ\>_V<VMZA=W5H)G>RE$D+QJE
MLL<9P%0A4V[5&%!R3HM9/F>FGRU7Z<WX=]%HG==_U_RV_P" KP>+OVIO%?A?
M7-9T&+X=Z=JFO>&_#$OBOQ#!;^)&6"UM]\@MX()6M 9IY%B9F5EB1,<._?D/
M$'_!0[2-+L_#"PZ/H-KJNI>$+3QA>VOB/Q;!I,<45PFY+2UEDB/VFY.&PI6-
M<;267.!:_:F^#WBSQ+X\U34O!_@[Q'>2ZUX-N/#MSK'AOQ#IUHERS.QAMKZW
MNU5UB4NS^?;2^: 63:0175^$_P!D*WTGPKX)9/%_B#PCXRTGPA9^$]4U;PG/
M!&-0MX8P-C">"4+M<N4D0)(-W## Q$;N+;[_ /RS\/X?GO:_6G[K2>NG_P A
M?Y_';Y;6=LKX7_M.>)/BY^TEI&C:!8:8WPTU+P+:^*8I;FX>+4$\^4J&9!$R
MLZLOEF(.J@%GWL<)7T_7F5C\ ](TGXI:+X\T_6]>M=6T_0T\.SPR74=U'J5F
MCET%S)/'),SAVW>8LBLQ'S%AD'TVM)<MDH^?_I3:_"QFKW;?E_Z2D_QN%%%%
M04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Y5\&_\ DHOQV_['.V_]1[1J]5KRKX-_\E%^.W_8YVW_
M *CVC5ZK0 4444 %%%% 'E7[-/\ R3K5_P#L<_%G_J0ZC7JM>5?LT_\ ).M7
M_P"QS\6?^I#J->JT %<YJ'Q"\/Z7XYTGP==:AY7B/5;6:\L[+R9#YL4142-O
M"[%(W# 9@3@X!VG'1U\D?&3Q)<:'\='\<VMJFI7'AO4[/PW9V9.UIKJ;2K^5
M(5.#@RRWMFGY'M2O9K^GV5OFU^6['9M.W37RTU?X7^=CZ8T/QYH7B7Q%XAT+
M3+\7>J:!)##J4*Q.%@>5/,1=Y4*QV\D*3MR,X)KG_%2>'[7XE:'J&N^([N*>
MSTZ\O[#19MBV,0A"I<7S,(MV]([E8_GDV!9#M3=EJ^>O">M/\,= T:;6_%*:
M?;:M\0VLM4U^XN39P,UI!*;E2^[ %Q?V\X$9(#>>4P?NGC/&WBA/B'X-^,7B
MC4]7U&VTF73VTJRNKBZFL_L%OJ.J&U#;BRF&-(K*WF=#A<2/O&&;)KI;M\K\
MJ:^]NUMU9^3#2_*^KM;K;F:?W6U[W/N/0O$EAXD@\_3VFEMVBBF29[:6*.1)
M$#HR,Z@.-K#.TG!X.#Q1#XFTVX\37?A^.YW:Q:VD-]/;!&^2&5Y$C<MC;\S0
MRC&<_(>*^.[/QAX8\/MX3T3Q)\1=<\+^!;B[\07T%TWB:ZC%Q9VTB6%C;&^\
MWS LBB2>-5D#N\>5Y)!XJQ\;^.8/AU%X@O=5FT&'4M?M/#FJZMXJUF;19HM*
MMK.:YMTNM12&5[661[E(WE**^_*[D=\BKIZPVT^5W;7T;L[7OK8B-]I;Z_AK
MIWO%-K9:IWL?H;17DG[,,FMW'PR-UJ^HQ:E9W-_/+I$D>JW>J[+$D"-#>7<$
M,UP-PD*RLAW(4(=QACZW3DN73^O3U74(RYE=!1114E!17$?%3XH0_#/3=+\K
M2+[Q)KNLWHT[2=#TTQK/>7!1Y"-TC*B(D<<CN[$!50]3@'B_^%N?%K_H@NH?
M^%3IO_Q= 'M=%>*?\+<^+7_1!=0_\*G3?_BZ/^%N?%K_ *(+J'_A4Z;_ /%T
M >RWEI#J%I-:W$:S6\R-')&XR'4C!!]B#7BGA']DGP[X(T^YM]*\4^+K>X>'
M3K&VOX]1CCN;+3[*<S6]A$Z1+^XRSHV\/(Z.59SQB;_A;GQ:_P"B"ZA_X5.F
M_P#Q='_"W/BU_P!$%O\ \?%.F_\ Q="T=U_5OZ?WM=6/=<KV_K_@?<GT1D2_
MLU> OB5K_BB/6_%GB+QS!8_VAHS:-JVIK/%H;WT44LZ1.(Q-N,4L13S9)/+5
MP$VCBO1_A3\(=-^$]MK)MM4U37]5UJ[6\U+6-:DB>ZNI%B2&/=Y4<<8"QQ(H
M"H,XR<L23XK\/?!_QB^"GB#Q1XF?PS:^/IO'=U_;.J:1I^KQ6IT6]!:-8HWG
M"K-%]F6UC+<-O@8X(<;>Z_X6Y\6O^B"ZA_X5.F__ !=$?=5EVM\KW_,3][?O
M?YGM=%>*?\+<^+7_ $074/\ PJ=-_P#BZ/\ A;GQ:_Z(+J'_ (5.F_\ Q= '
MSC^V%(OB'XD?&Z74S_I'@?X:VFM>&)3( ^GWS7,[F[@/6.4M#$FY<$J-N<-B
MO=OV@/A'XM_:0^#/@31+&YT/3FEU/2]7UZ'Q!:O=6\L$*^<\!@3;YV91'E"\
M8*AAN%<S\0M%\0_%35[+4_%'[--_J5Y:QB ,OC.T@2>$2"40W"1SJMQ$)%#^
M7*'3(SC-)'X2\'^//BQY7Q)^#^K^!?%_BQX;C3]=C\0%_M-S80R;$AN+.X#V
MDZ023,-@3S$67+-M(J(QY8*+Z._W2<K_ #NK_P"%?)O6;FNUOOC&/X6;7J>%
M>'=<T7XU>(_ O@+7/"'AWP_X6TC3O&45YH6AVJ6NDS:G931P"[AM_P#EF0'>
M5,Y9&<D,2-Q^OOV/?$FL>,/V7/A?K&O2S7&KW>@VKSSW#%I)B$ $C$\DLH#$
MGUK1U;]F?X;:SX/T?PO-X;\C1](\[[$EC?7-K-&)@PN 9XI%E<2[F\P,Y$FX
M[]U>BZ3I-EH.EV>F:;:PV.GV<*6]O:VZ!(XHT4*J*HX    'M6D7RQ:>K=M>
M[7-=^5^9*W1)>2,VKS4EHM?E?ELO/9N_=OU+=%%%(L**** "BBB@#Y]_;HUJ
M\TGX!R06TSVUOJFNZ/I5]+')L(M)[^&.9<^C(Q0^SGM6?^RGI]OI'B_X\^![
M*QA@\%:)XJ6#2]-15^RVT<]C!+/;QQXVI&'=CL VCS",5[UXP\'Z/X^\-7_A
M_P 06$>IZ/?1^7<6LI(##(((((*L" 0P(((!!!%<7!^S?\.[?P]INBC0'EL=
M/UV/Q-$UQJ%U+</J<;;DNIIWE,L[YQ_K68$  @@ 4J:Y7+FVEI\FX?DHMKNY
M6TU83][EMT_12_.ZOV2Z['S;\'_@WH_C'XB?M ^,OAOX:\,^#[O3(;KX?^$_
M[/T^/3[6.XCA!NKF801_.6N65=^UB$BP.ISTW[''AB/X$_$#6O@O?>'?"$6N
MZ/X7TK4Y/%'A;2/L$NI1L9(62[+,[S2K)&["7(#!R=B'BOH+1?@MX*\/^#M?
M\*6F@0'P[KUS>7>IZ?<R27$=U)=,6N"WF,QPY8_*, 9X H^&_P &?"/PE%\W
MAG39[>XOEACN;R^U"YO[F6.)2L,9FN)))/+0$A4W;5R< 9-53O&W^%)^;2=_
M3WI.7GM9()^\G;^9M>2NK>KY8I?CJSMJ***0!1110 4444 9GB;3[_5_#>JV
M.EZHVB:G=6LL-KJ:0K,UI*R$),(V^5RK$-M/!Q@U\S_L"Z'/X9M_CCI-SJ^H
M:_/9_$?4('U35I1+=7)6VM1OD8  L?8 #H !7U77FVH_LY_#S5O"?C3PS=^'
MO-T3QEJ+ZKKMK]MN!]LNG,9:3<)-T>?*C^6,JOR].3DA[LY2[QM_Y-%_DG^'
MRIVE&,7TE?Y6:?YH^)_#/B#4-/\ $W@WXD6,0E\?ZQ\3?$^BZG.LB^;<6$4-
MV$M9&_BBA%O R*?E4KD8W5T7[($S:3\0?@/J>F_/?>// &I:IXKN$<;K^ZCN
M('CNI\??E#S21AVRP5MN<#%?7VD_ /P'H?CY_&EEH(B\0L\TRS&[G>"*6552
M::.W9S#'+(J@/(B!V PQ-/\  ?P'\"_#+Q!>ZWX;T(:?J-U$UN9&NIYU@A:0
MRM#;I([+;Q&1BYCB"*6Y(S2HKV?*GT27I:#C9>3;YGY]'N95$ZCD]KN__D_-
M?U2]WT[;'?4444RPHHHH **** $;)4X.#ZU\A_LG^$]5\$_M7?M!:7K?BO4O
M&FJ)8^'9;C5]4"*\KO#<L0D: +'&"2%1>%'<G)/U[7%3?!OP?<:UXTU:31]V
MH>,K*+3]=F^TS?Z9!%&\4:8WXCPDCC,84G.220#2NXMM=OZ]/,K1Q<'UM^#3
M_*Y\G?M,1^%=1_:<\'>"?AMH;7OQOU;6]/UW7/$T4TSS:#I-N5,FZ9F/DQRQ
M+L^SIM1@^67<Z;K5EX#U;X _M,Z;XM\::)X'\5W'Q,\=W=KI^I0Z4SZUHL;6
MA%ILO9"/D$5N4>)8UP78B1\XKVKPC^Q3\)/ &N/K'AG1]<\/:C)%;02S:7XM
MU>W\Z*W14ACD5+H"1$5%4*P(P.G)KJ] _9W^'OA?QLWBS3?#_P!GUG[3<7L6
M;VX>UM[B<8GG@M6D,$,L@)#R1HK-N;).3FJ=J?+;I>_HW'1=E:*5]T[OKI%2
M]12]$EZI2U?SEMU5ETU]'HHHI#"BBB@ HHHH *^5/"NL?$FQ_;^NM#\5^+H[
M_P .7G@R^U+3- TQ)(;.TB74HHX6D4L?.N/+^](0,%F5?EZ_5=<--\(='N/C
M3;?$YKF^&OV^@R>'EMQ(GV4V[SK.7*[-WF;D SNQC/&>:(^[4C+HN;\8M+\;
M#>M.4>KM^$D_RN?/W[7$GC[0/B$WC>72M8O_ (.>$_"TUYJD&C>-KOP_/<73
M7"F1T6T</.\,$>520QH?,8!\\'SWQE\:O$5]X@\;_$31_$.O06GA3QIX:T/2
M='2\F6TN-.NH[7[0LUMNV2O+]K+"1U+J53:PKZ$U3]D?3M<\.G0=4^)7Q&U;
M1KJVELM5LM1UU;E-6MY)WF,4WF1,8\;S'O@,3F,*A8@"M#5OV3?!.J>.D\1)
M)J.GV;7MCJ=WX=LGACTV]N[)-EI/*GE&3=& F%214;RTW*V**7N2CS;)_P#M
M_,[][QO%>MGIJ36]Y24=VFO_ "6RMVUM)^B:UT/:****!A1110 4444 (V=I
MQU[9KY5_9;UCXD']I+XX:#\1?%R>)+W3K/09X;73T>#3; S17#O';0LQP.%!
M<_,^T%NP'U77G$'P+T>S\:_$;Q5::MK-EK'CFPM;"^FMKE(S:+;Q21126I";
MHY )2VYBWS!2 ,8*NXMM*^G]?\.5HX.+ZV_-?I<\>_;&T-]9\3_#WPOX<U_Q
M5H/C;QQJZ:<E]HOBG4[)+#3[=#/>726L-PL#2+& @+1GF52<X KF?"-_XS^&
M'[0\5W\4=.U_^RO&'C"ZTCPC<Q>.;V:&TACM<6J3Z6C_ &9DE2&63S&9W#O\
MR*<-7T!8_ '1[;Q?\._$UWK>O:QK'@C2+C2+*YU.[2=[M9HXTDGN6,>YYB(@
M=ZE<EFR#GBG;_LX:.WQ T_Q1JOB7Q/XDCTK49]7TG1-;OTNK+3;N5&1I8B8_
M..U7<(DDKI'N.Q5P,5!*G)6?5W]+K;SLKI]')IZ$3;G%Z:V5O6S_  NTFNT;
MK70]:HHHI#/*O@W_ ,E%^.W_ &.=M_ZCVC5ZK7E7P;_Y*+\=O^QSMO\ U'M&
MKU6@ HHHH **** /*OV:?^2=:O\ ]CGXL_\ 4AU&O5:\J_9I_P"2=:O_ -CG
MXL_]2'4:]5H **** "BBB@#!@\'V<'CF\\5>;</J%SIT&F>4S+Y4<4<LLF5&
MW(9C-\V21A$P!@YWJ**.EOZ[AN[_ -;6_)!1110 4444 ?%7Q$\7>#/ W_!3
M[2=9\:^(M'\+V=K\*0UI?:W?PV<)N&U2=/+5Y2 6,;RG .<*W;-?0'_#6/P0
M_P"BR?#_ /\ "HL?_CM<I_PJWQ/_ ,-]?\+'_LS_ (HS_A6?_"/?VG]HB_X_
M_P"U?/\ )\K=YG^J^;=MV]LYXKZ H \J_P"&L?@A_P!%D^'_ /X5%C_\=H_X
M:Q^"'_19/A__ .%18_\ QVO5:* /*O\ AK'X(?\ 19/A_P#^%18__':Y;X@_
MMH_"G1--L8/#WQ1\ ZEK6I7D=E;M)XBM'M;4'+27%PRRC;&D:.<$KO?9&""X
M->_5YSXN^">F^.-5UJ\U74;R9=6BMK&: ;0BZ=&XDELEXXCN'W><?O.I"YPB
MX .'^'_[:/PI\4Z=J&IZK\4? .CVDU]*NEVEQXBM(KK[(F$62=&ERKR,LD@7
M"E4>,, X:NI_X:Q^"'_19/A__P"%18__ !VO5%4(H50%4#  Z"EH \J_X:Q^
M"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':]5HH \J_X:Q^"'_1
M9/A__P"%18__ !VO!/VU_P!K3X=Z-\$SXM\!_$?P+XF\;^$]7L=8T?28-:M[
MUKF7S1;R*8H9A(R^3<3$["#@'G&:^T*\_P#CU\%=#_:)^$^N_#WQ)=:A9:+K
M'D>?/I<B1W"^5/'.NQG1U&6B4'*G@GH>0 >/^'_V]/ATWP2\">*-6\<>!YO%
MFKPZ$NK:';>(;:!K&6\FMHKMS&TCNBVPGEE97Y"PL&9>6'0:E^VA\++?XJ>'
MM$M_BE\/Y?#=YHVIWM[J/_"0VI\BZAGL$MHO,$VQ?,2XNVVL-S>3E2 C9] M
M?@KH=G\)_"/P]2ZU Z+X8_L7['.TB?:)/[,GMI[?S&V;3N:UC#X5<@MMVD@C
MH+WP38WWC[1O%TDMP-2TK3+[2H(E9?):*[EM)9&8;<E@UE%M(( #/D'(( /'
M]-_;0^%EQ\5/$.B7'Q2^'\7ANST;3+VRU'_A(;4>?=33WZ7,7F&;8WEI;VC;
M5&Y?.RQ(=<'@W]M#X6:QXB\=VFK?%+X?V-AI.M1V6D3_ /"0VL?VRU.G64[2
M[FF(DQ<3W,>Y,+^ZVXW*Q/L%EX)L;'Q]K/BZ.6X.I:KIECI4\3,ODK%:2W<L
M;*-N0Q:]EW$D@A4P!@DGAGP38^%=:\6:G:2W$EQXEU--5O%F92L<JV5M9A8P
M%!"^7:1G!).YF.<$  'S_P"(/V]/ATOP2\=^*-)\<>!X?%FD0ZZNDZ'<^(;:
M=KZ6SFN8K1Q&LB.ZW(@BE54Y*S*%9N&/0?$O]M#X6>&_#MG=^'OBE\/]5OY-
M:TFRE@_X2&UFVVL^HV\%W+M28$>7;R32;C\J^7N8%5(KT"Z^"NAWGPG\7?#U
M[K4!HOB?^VOMDZR)]HC_ +3GN9[CRVV;1M:ZD"95L +NW$$GH/''@FQ\?Z+;
M:9J$MQ#;P:GIVJJULRJQEL[V&\B4EE(VF2W0,,9*E@"#@@ \?\9?MH?"S1_$
M7@2TTGXI?#^^L-6UJ2RU>?\ X2&UD^QVHTZ]G67<LP$>;B"VCW/E?WNW&YE(
MMWO[:GP>M?'VC:!'\2O \^FWVF7U]/K2^*+/R;66"6T2.W;Y\;I5N977+ XM
MGP&Y*^J^)O!-CXJUKPGJ=W+<1W'AK4WU6S6%E"R2M97-F5D!4DKY=W(< @[E
M4YP""7O@FQOO'VC>+I);@:EI6F7VE01*R^2T5W+:2R,PVY+!K*+:00 &?(.0
M0 >/^#?VT/A9K'B+QW::M\4OA_8V&DZU'9:1/_PD-K']LM3IUE.TNYIB),7$
M]S'N3"_NMN-RL3RM]^WAX(A^!/C[Q-#\0?A_)XSTC_A(_P"Q]'_MJ _;?LEU
M=QZ?^Y$_F2>?%#;O\A'F>;E,!EQ]%>&?!-CX5UKQ9J=I+<27'B74TU6\69E*
MQRK96UF%C 4$+Y=I&<$D[F8YP0!S]U\%=#O/A/XN^'KW6H#1?$_]M?;)UD3[
M1'_:<]S/<>6VS:-K74@3*M@!=VX@D@'SK\'O^"B?A77OV2Q\1O&GB?P/;?$6
M#3-3OI?!MIK45E-/+;RW M[=(999)4:5(HL9#$F0$ @@5Z5XR_;0^%FC^(O
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M#:Q_;+4Z=93M+N:8B3%Q/<Q[DPO[K;C<K$\K_P -X>"/^&6?^$V_X6#\/_\
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M8V/C[6?%T<MP=2U73+'2IXF9?)6*TENY8V4;<ABU[+N))!"I@#!)/ _@FQ\
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M(]-\/6FMVMBDMSJ,VHZNNFVUG;1Q-(SM)Y<CLS%51$2,Y9QDH.:]$KS;XX_
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M#H>DP:TWB"VTO3H%AF_T)#<W@NXKL>:=TT-I9>=N7RQFYA!0 AF4/?2:Z_\
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M:5;06]CXJ:UA76K<P$&&1+M4#JZ%01CY>,$%208?X:7]/M)>OX$J]O.S^_\
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M-RL,_*17:? #XEWWQ.\-:Q=WFJ:'XCBT_5)+"U\1>&HGBT[58ECC?SH%:6;
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M]HU>JT %%%% !1110!Y5^S3_ ,DZU?\ ['/Q9_ZD.HUZK7E7[-/_ "3K5_\
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M?\,T^$?^@O\ $#_PX_B'_P"3J/\ AFGPC_T%_B!_X<?Q#_\ )U 'JM%>5?\
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M/_#C^(?_ ).H_P"&:?"/_07^('_AQ_$/_P G4 >JT5Y5_P ,T^$?^@O\0/\
MPX_B'_Y.H_X9I\(_]!?X@?\ AQ_$/_R=0!ZK17E7_#-/A'_H+_$#_P ./XA_
M^3J/^&:?"/\ T%_B!_X<?Q#_ /)U 'JM%>5?\,T^$?\ H+_$#_PX_B'_ .3J
M/^&:?"/_ $%_B!_X<?Q#_P#)U 'JM%>5?\,T^$?^@O\ $#_PX_B'_P"3J/\
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M_)U 'JM%>5?\,T^$?^@O\0/_  X_B'_Y.H_X9I\(_P#07^('_AQ_$/\ \G4
M>JT5Y5_PS3X1_P"@O\0/_#C^(?\ Y.H_X9I\(_\ 07^('_AQ_$/_ ,G4 >JT
M5Y5_PS3X1_Z"_P 0/_#C^(?_ ).H_P"&:?"/_07^('_AQ_$/_P G4 >JT5Y5
M_P ,T^$?^@O\0/\ PX_B'_Y.H_X9I\(_]!?X@?\ AQ_$/_R=0!ZK17E7_#-/
MA'_H+_$#_P ./XA_^3J/^&:?"/\ T%_B!_X<?Q#_ /)U 'JM%>5?\,T^$?\
MH+_$#_PX_B'_ .3J/^&:?"/_ $%_B!_X<?Q#_P#)U 'JM%>5?\,T^$?^@O\
M$#_PX_B'_P"3J/\ AFGPC_T%_B!_X<?Q#_\ )U !\&_^2B_';_L<[;_U'M&K
MU6N4^'OPQT#X7V>J6^@QZA_Q-+W^T+VXU35KO4KBXG\F* .\UU+)(<101(!N
MP @P!75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>lly-20211231_g1.jpg
<TEXT>
begin 644 lly-20211231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5_PM'_@JI_T:S\,O_"XE_P#B: /IBBOF?_A:/_!53_HUGX9?^%Q+_P#$T?\
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M+X3? B6/18M TZ=1);+=7)#27$K1LK,D@9TR 9,Y1.Y_9<TK_@JE_P $_/\
M@H#X4_9&^-GQ5\9?M(_ /XD:+?S:'\3]6\-,^K>!=0M4#^3JEW"&5X9=R1K)
M,V7>0%-@BD5OK7PO\0M>_:&_84T_XE_L6^,- LM5\6_#6*\^&^LZK$9].M+J
M:R#6C3H@),<;E0Z %AL9<9&*_/'XC?M1_P#!=K]AW]L_]FKX3_MA_M%_!7Q9
MX4^-?Q3@\-WEKX'\'S17$4 D@\XF2>--A*S *5R00: /N_X^_P#!4W_@GK^R
MYK/BKPY\?_VKO"WAC4O!-YIEKXGTR^GD:YLI]0@:XLX_*C1GD:6%'E 0-A$9
MC@ FM'XQ_P#!27]A#]G[X&^'/VDOC+^U+X2T#P7XPL8[SPEK-YJ&?[:@DC61
M7M(4!EN!L=6/EHQ4,"<9KX(_9U_99^ _[0/_  <Z_MA^,?C=\+="\6GPGX#\
M&)HMAXDTJ*]MK>6[T6P62<13*R>:$A*!\9"RR $;C6I^S#\(?A?\</\ @Y*_
M:"M?BSX$T>[L_P!GOX5^$-$^"GABZT^,V6@6-U86\\L]G;[?+B*2.Z*R*-BS
ME1CC !]Y?LE?M]?L:?MV:#?>(_V1_P!HKPWXY@TMU75(-)NR+JRW9V&:VE"S
M1*V&VLZ -M."<&NH^$G[2'P,^/&O^+_"WP?^)FF^(-0\ ^(I=!\8VE@[%])U
M*/.^VER!AQ@Y STK\\/^"@W@3P9^R_\ \%\?V+OCA^S[H-GH'BCXNS^*/"_Q
M+M=&@6!?$&E0VML\<MU'& )&B:=G\Q@6)@AR<0J!T7_!!IA_PU3^WVF>1^UG
MK!(]BTF* /N7PQ^U+^SWXT^(?CWX3^%OBOI5]XC^%T5K)\0-(@D8S:&EQ"\\
M!G&,#?%&[C!/"FO#O&__  7._P""1_PZL_#M_P"+OV\? UO%XJLQ=Z(8+F:X
M,MN9&C$LBPQL;="Z. TH0':2,CFOE[]B>>&Y_P""L?\ P5'DMY5=1I'@U25.
M1N70-04CZ@@C\*W_ /@V'_9*_9NTC_@BSX+\1K\,_#^L7GQ6AU:X^(-WJ.FQ
M7/\ ;&W4KJT6UGWJ=\,4,"1B(Y0$.V,NV0#]'O!/C?P;\2O".F^/_AYXKTW7
M="UBSCN])UG2+U+FUO8'&Y)8I8R5D1@<AE)!K4K\U_\ @VMFF\&_"W]I3]F7
MPQ>3W/@+X2_M5>+/#GPYDEF:1+;2TE1UMHV).55F,OUN6/.:_2B@ HHHH **
M*\0_;>\=_M\^!/"NAW?[ _P&\#^/-7GU"1-?M/''BF32XK6V"91XG13O8OP1
MV'- 'M]%? /_  T/_P '''_2.K]G_P#\.[<?_&Z/^&A_^#CC_I'5^S__ .'=
MN/\ XW0!]_45\ _\-#_\'''_ $CJ_9__ /#NW'_QNO%_V_?^"L/_  7"_P""
M?O[,NM?M$_M"?L5_ 3PWH]O)'I]C?6WQ)N;ZX:^N"4@6*V" SL#F0ID#9$Y)
M !- 'SO_ ,%D/^#AKQ)^S5_P6\^&G@?X2^([BZ^'/P*U!K'XH:=82DIK=S?J
ML>I1%0<2-:6Y18@?N7*2YZ5^[WA/Q7X;\=^%=,\<>#M:M]2TC6=/AOM*U&TD
M#Q75M,@DBE1A]Y61E8'N"*_@C\6>*_$GCOQ5J?CCQCK5QJ6KZSJ$U]JNHW<A
M>6ZN9G,DLKL?O,SLS$]R37[K?\&[_P#P5J_X*K_%?]G&/]AK]E;X%?"OXB77
MPDTM6MI_'?C:XTO41I$L[B%%4*RS10,1#N&-B- A'W20#^A:BO@'_AH?_@XX
M_P"D=7[/_P#X=VX_^-T?\-#_ /!QQ_TCJ_9__P##NW'_ ,;H ^_J*^ ?^&A_
M^#CC_I'5^S__ .'=N/\ XW7M_P"Q#\3/^"G_ ([\5:Y:?M\?LQ_#?P'I$&GQ
MOH%WX'\:2ZI+=7)?#I*CJ-BA.01U/% 'T;+((HVE*L0JDD*N2?H.]?CQ^P%X
M+_;?_P""]'PR\0?MS_$/_@JE\3_@_P"&KSQIJ6E^#OA3\$=0ATL^'[2V<*B7
M]P 9)[AE8.5D&<%7#!75$_7/Q]XY\,?#'P+K7Q*\;:@]IHOA[2;G4]7NX[62
M=H;6")I97$<2M)(0B,=J*S-C !) K\R]/_X(T?L$?M]V2?\ !2G_ ()5?MC?
M%+X&WOQ)>?4%\2_";6;C3]-U2=;B6.:2?3I1%*C><D@:)7A3.[*98F@#U3_@
MGI9_\%1/V5?VW_%7[#?[6GCCQ)\;/A#+X-C\0_#?X[:MH AN;*X\X1R:-J$\
M>5EFQYK@LS/B-&X68)'YU_P4T^-WQF^+?_!7_P"%'_!,G7?VQO&?[/OPK\3_
M  ONO$J>+?A]J<6EZMXJUQ+F>-=,BU&6-UMA'%")-@'SEBK!C)"5B_8W_:._
MX*4_L)_\%0O!W_!*K_@H!\?](^.7AOXJ>$=2U?X8?$V#14T_5K22PAFGEM[V
M).&4QV\O+-*VYXB)C\Z+X%\0OV6/B_\ \'3&O?&GQWXW^-%MX ^&?P2\<ZUX
M*^!?AG3M&@DN;C7H(8C+J>JW#HTP@E5[?,$1 PP PT!:8 ^L_P#@W_\ VEOC
M]\;/#/QV^%'Q,^.NH?%_P7\*/B]=>&OAE\8]5"/<>)=/0$LDEP@VW;0_NCYX
MSO%P,,5"X\?_ &S;7]M/]K7_ (+\WO[!OP<_X*'?$;X,>$;']GNV\6B/P;(L
MB27B7XMV!B=E +K,"6SG]V!BN5_X)5?\%;_VA/!_QA^"/_!$X_L,:1X6^)/@
M>_U;0_C=!;V(T_3M*TJP@BF@UJS%N/*9KI7D9LKLDE='1MMPF(?VN_AU^V1\
M3O\ @Y\U+P[^P[^T7H?PP\8I^RQ;3W7B+Q!X4CUB"2P&J*)+<02<!F=H6#]0
M(R/XJ -S]NW]G[_@K;_P2*_9JUC]OOX2_P#!7_Q?\6K3X?W5G=^*?AY\4_#-
MM+9:QITEU%!(B2B1GB8&12=FQBN[;(K !OU0_9_^+FF?'_X#^"?CQHNF2V5G
MXV\(Z;K]I9SMEX(KRUCN%C8X&2HD )QU%?GC\6/^",?_  4^_;KL;/X0_P#!
M2C_@KA#XE^$BZE;7GB#P%\._AC::+)KWDRB189KI&#(FY5;D2*&56"!E5Q^E
MWA?PSH'@KPUIW@WPII,-AI>DV,-EIMC;+MCMK>) D<:CLJJH 'H* /SV_P""
MP?Q:_:Y\>_MV_LT?\$\?V-OVL-3^#U]\0;/Q3KWCOQCI>D07S6.F6%G');L\
M4Q4,K2).GWD^8J<G&*[W]B']@[]O7X2?&W1_C/\ %[_@M9XC^-W@RTANX[SP
M9<_#^PL[34'>!XXV-S!=2%3%(RR8 .2@!QFLC]L7_@E9_P $\?\ @HM_P4ET
MWQ]^TA\?)?$GBKP?\+TTW4/@1IGC2&T\S2S>/,E]>6]JZ7OD-+=*#EEBD*P
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M_P""._\ RCD^'7_<7_\ 3O>T?\.=_P#@G)_T;K_Y=VK_ /R77N?P=^#OPX^
M/PXT[X2?"3P[_9/A[2?._L_3_MDT_E>;,\TG[R9W=LR2.W+'&<#    .FHHH
MH **** /F+_@D5_P3B_X=6_L::?^R/\ \+D_X3O[#KU_J7_"0?\ "/?V7O\
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M[_@J7_PN3?\ ;/@Z/ G_  @O_"/8V8O([G[;]M^T<_ZO;Y7D#KG?QBOIVB@
MHHHH ^-_VZ_^"57BSX^_M.^&/V^/V//VH[[X*?''PQH3Z%-XEB\.PZOIOB#2
M&<O]BO[*5T64!F.V0-E>"58QQ&.C^RG_ ,$H_BEX=_:YM/V__P#@H/\ M>7'
MQP^*N@:--I/@%;7PK#HFB>$;:962=K2SB=]]Q(C,K3L0=LC AB%9?M:B@#X=
M_:&_X)3?M Z=^U_XF_;C_P"";?[:W_"E?%_Q#TZUM/BAH&K^"H=>T3Q&]LGE
MV][Y$DD?V>Z1.-ZYW9;[N^7S/1O^";G_  3:T[]@[3_'/CWQ]\:-5^*?Q:^*
MVNIJ_P 3_B;K=A':2ZM-&K)!!#;1LRVUK"KN(X@S;=[ $*$1/IRB@#\X[7_@
MB_\ MH_LVW_C/X;_ /!-/_@J!<_"#X1^.]:NM3E\":I\-[;6IO"L]T?])_LB
M[>>-H$;)V)@>60&#%\O7US^P5^Q%\'_^">/[+_AW]EGX*?;)]+T199KW5]4D
M#WFK7TSF2XO;AP &DD=B>.%4*@PJ@5['10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 52\2^(M&\(>'-0\6>(KY;;3]+LI;N_N7!(BAC
M0N[G'. JD_A5VJ?B#0=(\5:#?>%_$-BEU8:E9RVM];29VS0R(4=#CL5)'XT
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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MBBB@ HHHH **** "BBB@#P7]KG_DN'P,_P"Q[E_]$5[U7@O[7/\ R7#X&?\
M8]R_^B*]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8
M_P#(L7O_ %P-:59OC'_D6+W_ *X&@"YIW_(/@_ZXK_(5-4.G?\@^#_KBO\A4
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^!_P#D
M$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A4 ;%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/X'_Y!$O_ %^S?^A5
ML5C^!_\ D$2_]?LW_H5;% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!X+^US_R7#X&?]CW+_P"B*]ZKP7]KG_DN'P,_['N7_P!$
M5[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S0!L4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?^18O
M?^N!K2K-\8_\BQ>_]<#0!<T[_D'P?]<5_D*FJ'3O^0?!_P!<5_D*FH ****
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MM@\=001SP3\/5ZO^Q=K%YIOQWL;"V<B/4+*Y@N .A41F49_X%&M 'V;1110
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M'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M7L%DS>$4CN_[0#M=W""6/<;?,49:5N-JG!Q[Q_P4?_X)0S^,_P!D7X8^$_\
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M9?\ ([WO_7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'
MP?\ 7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5CV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?^18O?\
MK@:TJS?&/_(L7O\ UP- %S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'
M\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0
MJV*Q_ __ "")?^OV;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5CV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?^18O?\
MK@:TJS?&/_(L7O\ UP- %S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'
M\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0
MJV*Q_ __ "")?^OV;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %9OC'_ )%B]_ZX&M*LWQC_ ,BQ>_\
M7 T 7-._Y!\'_7%?Y"IJAT[_ )!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@
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M6=G$$C7NQZEF/=B<DGN30!HPPPV\*6]O$L<:*%1$7 4#@  =!3J** "BBB@
MHHHH **** ,?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*MB@ HHHH ***
M* "BBB@ HHHH *1F55+,0 !DD]J6L?XA^$5\?^ -=\"/J<UD-;T>ZL#>6_\
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MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
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M TB4 ?\ +Y+_ .A5LUC^!_\ D$2_]?LW_H5;% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L?P/_R")?\ K]F_]"K8K'\#_P#((E_Z_9O_ $*@#8HHHH **** "BBB@ HH
MHH **** "BBN6^+7Q,L_AEX;%\EH;W5+V46VBZ7'R]W<-PJ@#G:"02>P]R 0
M#&^,?CW7CJ%M\(?AI*#XDUF,F2Y'*Z7:='N'QT/4*/7WP#T_P\\!:#\-?"EM
MX2\/1$0P+F69_OSRG[TCGNQ/Y< < 5C?!SX9WG@FPNO$7BV[%[XGUN03ZW?=
M<-_#"GI&@X '7'I@#M* "BBB@ HHHH **** "BBB@ HHHH **** ,?P/_P @
MB7_K]F_]"K8K'\#_ /((E_Z_9O\ T*MB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \%_:Y_P"2X? S_L>Y?_1%>]5X+^US_P E
MP^!G_8]R_P#HBO>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO_7E%_,UL5CV7_([WO\ UY1?S- &Q1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]_ZX&M*LWQC_P BQ>_]
M<#0!<T[_ )!\'_7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O\ R%]'_P"OT_\
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M !UZT ;&A:'I/AK1[;0-"L4MK.TA$5O!&.$4=/K]>I/-6Z** "BBB@ HHHH
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M /7Z?_036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A4 ;%%%
M% !1110 4444 %<]\3OB-H_PP\*3>)-51II"PBL;*+F2[G;A(D'4DG\@">U;
M&LZSI?A[2;C7-:O4MK2TA:6XGD.%1 ,DUYK\-M&U/XP^+X_CEXSL9(=.MMR>
M#=)G'^JB/6[=?[[_ ,/H,'G"F@#7^#7PYUC16N_B-\076?Q5KH#WK#E;*'JE
MK'Z*HQG'4CJ< GO*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0JV* "BBB@ HHHH **** "
MBBB@ K"^*/C6;X:_#/Q%\1;?POJ&N2:!H5YJ2:+I**UUJ!@A>46\(8@&63;L
M4$@;F&2*W:* /R#^,9_X)N?\%T=;_8Y_:(\0_ 'P]=:-\4?&OB[1_',5SY4&
MM6RV/A769EL;R]M"DZ&&:V@N$4N !Y;C*L":_P#P2&_;^3]A?_@E_P#M'?%?
MQY>>._BU\%?@!\=M7\.?"S6M&\F_U*^\,I<6T,#1//+$DMM%YZ2EPV$CDD"C
M;&$7W#]JG_@VR_X)^?M"?M-^%/CAX=^$UOX7TFZ\2:CJ'Q>T#0/$>I:=#XEB
MGTVZAC$,-M,L=M)]JFB>1HA%OB\U3DN<_;?PO_9E_9]^"_P(M/V8?AA\'M T
MCX?6>E2Z;%X0ATY'L7M90PFCEC<,)A)O<R&3<9"[%RQ8D@'Q]_P5#_9]_P""
M5G[5_P#P3J\??MX_$KP+X!+:E\,G\0>&/C19Z?;6^MPSI9[M,>#48P)VD$H@
MC2WWD.V(BASMKXE\>?$SXWV_[%G_  2S_P""C7[8VK7S?\(;\3H;+QYXGUIF
M+P:9JC^39:G=R-SM:SLX97F;[QD!)+.,_>6B?\&X_P#P1^T+QQ;^,8/V6)+F
MSL]3.HV7A'4?&.JW.@P71)8R#3I;EK<@DM^[96CP2-F.*^M?B_\  ?X-_'WX
M1:K\!/C+\-M(\1>#=:L!9:EX<U&T5K66 8**%&-A0JK(RX9&164@J" #X*_X
M.B_&VF>(O^"73_LN>$[^WO\ QE\<?'OAOPWX"T2WF#SZG<?VI:W9:)%R60"!
M07 *@RQ@G+KG#U33]'_9#_X.:OA]K'CG4X[+0OC!^R@_@GPGJE\PBBN]9T_4
MX9WM%9N/,,%M"0N<LUPBC)8 _1/[*_\ P0Z_X)H_L<?%^P^/'P7^ 4Y\4Z+;
MM;^&M2\2^*M1UC^PH6!!2R2]GE2W^5BH=1O ) 8!CGUO]L;]AC]E7]OOX8Q?
M"/\ :P^$5EXKTBUO!>:8TEQ-;76G70&!/;7-NZ30/@X)1QN'# CB@#XJ_P""
ML5]IWQY_X+'?L*_LL^ [V*_\0>$_&FK_ !!\66ELX9M(TNS@A>":<#_5K,\,
MR(3C+*!U89_2^OGO]BC_ ():_L0_\$^]5UOQ5^S-\'VT_P 1>)8EBU[Q7K>M
M7>JZK>Q*05A:ZO)9)$B!5#Y:%5)1202H-?0E !7E_P 5OV2OAK\8O%S^-/%&
MO^*+>[>!(3'I/B.:VAVH, [$.,^I[UZA10!\>_&3]EWX>_!_X[?!R;PQK?B2
MX.I>-#%.-5U^:Y"A(]PV;S\ISU(ZCBOJK_A!](_Y^;W_ ,"VKQW]KG_DN'P,
M_P"Q[E_]$5[U0!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^
MD?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>
M_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S
M>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%
MM6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_
M^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%
M% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'
M_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_
M /"#Z1_S\WO_ (%M69:^%=.D\4W5@T]SLCMHV4BX;=DD]375UCV7_([WO_7E
M%_,T '_"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_
M  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8_
M_"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I
M'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"
M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M$'TC_GYO?_ MJV*\T^+?BS7/&7B)/@1\.;TQ7UW$)/$6JQ\C3+,]1G_GJX.
M.N#GC.0 <]+X=L_C_P"/)= TJZNCX*T&XVZG<_:68:M=KR(4/0QIP2>_;JI'
MJ4?@318HUBBFNU50 JK=,  .PJSX2\*:'X'\.6GA7PW9"WL[*()#&.I]6)[L
M3DD]R36C0!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
M@6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q1
M0!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_^!;4
M?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &-
MX%4+HTBCM>2CG_>K9K'\#_\ ((E_Z_9O_0JV* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#P7]KG_DN'P,_['N7_P!$5[U7@O[7
M/_)</@9_V/<O_HBO>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F:
M-BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'[?&+PMX*N/&&N^$=3T#35\(-);VK7=QI?V+R1Y:!4>$3<<C?L3.%T?VV_\
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M44 %%%% !1110 4444 %%%% !1110 4444 %8]E_R.][_P!>47\S6Q6/9?\
M([WO_7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'P?\
M7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_
M^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
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MZMY0)(Y48=59&5@>X(KJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#P7]KG_DN'P,_['N7_P!$5[U7@O[7/_)</@9_V/<O_HBO
M>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F: -BBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_R+%[_
M -<#6E6;XQ_Y%B]_ZX&@"YIW_(/@_P"N*_R%35#IW_(/@_ZXK_(5-0 4444
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M\ =?>K= &1X.\!>#?A_IHTGP;X<M=/AP-X@C^:3'=V/S.?=B36O110 4444
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MN'P,_P"Q[E_]$5[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWY?8^HY%6-)_9VTW5;^/Q#\8O$]YXNU%#N2*]_=V4!_Z9VZ_+[<Y!]!7I
MP!@#H** ([6TM;&V2SLK:.&&-0L<42!50#L . *DHHH **** "BBB@ HHHH
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M\>Z]:*EM""(XHX+6^BAB498X1%RSLQRS,3Y?_P 0N/\ P0H_Z,9_\R;XG_\
MEG0!_(%7]/W_  :$?\%(O^&D_P!C;4/V(?B-KWG>+O@UM_L'[1+F2\\-SN?(
MQGEOLTI: ]EC>V7O7MOA7_@V!_X(9ZEITD][^P_O=;F1 ?\ A9?B8<!L <:E
M7L7[(?\ P0__ ."8/[!GQE@_: _9,_9MN/"'BV#3Y[%=4A\>Z]=J]M, )(I(
M+J^EAE4X4X=&PR*PPRJ0 ?5]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '@O[7/\ R7#X&?\ 8]R_^B*]ZKP7]KG_ )+A\#/^Q[E_
M]$5[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5CV7_ ".][_UY1?S-;%8]E_R.][_UY1?S- &Q1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;XQ_P"1
M8O?^N!K2K-\8_P#(L7O_ %P- %S3O^0?!_UQ7^0J:H=._P"0?!_UQ7^0J:@
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MPIX.\/6.DZ780B&QTW3+1(+>VC'1(XT 5%'H !5ZBB@ HHHH **** ,?P/\
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M^B*]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 5C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A4 ;%%%% !1110
M4444 %%%% !117(?&W]H'X&?LU^!Y_B7^T'\7_#?@K0+?(DU?Q/K,-E 6QG8
MK2L-[GLBY8G@ F@#KZ*_/35?^"Z'B?\ :<U*X\%?\$@OV&O'GQ]N5F:!OB)J
MMLWAKP7:.#M9CJ%ZJO<%""3$B(7 ^1CFH/\ AUW_ ,%(_P!N/_B9_P#!5#_@
MHQ?Z+X:NOFG^"O[-Z2:'I)0\F"ZU.4&\O8R,!HV& 1E7YS0![-^UU_P6G_X)
MY_L;^(_^%:^,_C3_ ,);X_EF,%E\,_AI9-KVOW-Q_P \/LUKD02''"SO%GUK
MQG_A>7_!>/\ ;\_<?L]_L^>&/V1_ 5W]SQI\7%76_%\L)Z2V^CQ_N+209YBN
M^>,AZ^K/V1?^">7[%'[!_AS_ (1O]DS]F[PQX-#PB*ZU.QLO-U&\4=I[V8O<
M3\C.))& [8KV:@#X6^#W_! /]D6S\;VWQN_;<\9^,?VG/B+#\P\1_&G6&O[&
MU8G+):Z6#]EAAR 1$ZRA<<$5]O:'H6A^&-'MO#OAK1K33M/LH5AL[&QMUAA@
MC485$1 %50.   !5NB@ HHHH **** "BBB@ HHHH **** ,?P/\ \@B7_K]F
M_P#0JV*Q_ __ "")?^OV;_T*MB@ HHHH **** "BBB@ HHHH *I^(-!TCQ5H
M-]X7\0V*75AJ5G+:WUM)G;-#(A1T..Q4D?C5RL+XH^!H?BA\,_$7PTN-=U#2
MX_$6A7>F/J>DW+0W5F+B%XC-#(I!CE3?N5@00P!'2@#\4_B-^QC_ ,%0_P#@
MD'^T%^SA\(/V4/$'A'X_?#CP]\2/%=_\#OA[XDG.D:]9R3^'=7FO=.FO#BW>
M(6LUY)'*6RTX7Y$5ME?I%^P7^V=^SY_P6-_9-U?6O''P BM'TKQ'<>&OB=\*
M/B#I<-__ &/K-FT;R6L\<T>R=58QNCM&IR.51T95_-B'Q'_P6'_X)_\ Q1_9
M;_96^,O[%LWQMUWX7_$3Q:/A/X\T3XBVD*_$"WN/#>LQI!<F[8R64UO%</,[
MS8S%;E0&8"23Z ^%7[$W_!5?]B+_ ();_&_Q3\"/".D^)_VM/VAOB3J'B_7;
M+0-<LK6R\+7&IS+YQMYKV:*&1[:'S74[R!-,H7S4CRX!VW_!6[]OCQ#\0Y-4
M_P""./\ P3?\/V_C7XZ_$/09M&\2O8$?V5\.="N(_)N;[49D!6"002%8XA\Z
MET8C<88IO&/VT?V5?#G[&?QD_P""5_[$^C:O+J?AWP5\3KB*XO[B/8+[4[6"
MSE2Z*9(0O<23R*N3MWX!.,US?_!.3PQ_P6M_X)J_!/\ X5C\)/\ @W^T75?$
M&KS?;O'GQ UG]I+P_)JWBK4F):2[NI6F9B-S.4BW%8PQZLSNWU-^WA^R5^VS
M_P %#?V(/A)\>++X5:)\*_VG?A%XZL_'OACP5J7B.'4K"*_M)Y%;2Y;VW)C>
M.XA$3[@=N]41F5=[  RO^#JFQTZX_P""(?Q4U&ZP+G3]6\-W&FR9PT<_]NV,
M>Y3V/ER2<CL37(?!J_U7QI_P=#'4_'P9[S3/V%;*;2Q..8Y9-;M3*RYZ'=<7
M ./5JSOVD_AY_P %1_\ @M&/ ?[(W[2'_!/S_AGWX1:9XOT_7OC-KVN?$+3]
M8GUZ.R?S%TG3HK,DE))!DS.-HPC9&S9+Z]_P4C_9+_:Y\$?MQ?#'_@K#^P)\
M,M-\?^,/!?A6[\&_$/X87VMQ:9+XG\.32M.@M;J;$4<\$TDD@#_>/EX#;"C@
M'$_\%N"^F?\ !1S_ ()Y>)-(^758_CO?644B??\ L=Q%9I=+_NE N?:OTJK\
MX?A/\ _V[O\ @HO_ ,%)?AK^W-^VW^RZGP1^''P#TO4V^&WP_P!3\4VNK:MK
MFN:A$L,U_<M:$QPPQ(B%$;#AX4(W*[$?H]0 5Y?\5O"G[6>K^+GO/@_\5_"^
MD:*8$"66K:$]Q,) /G8N".">@KU"B@#X]^,GAG]I_2/CM\'#\7_B=X;U=)/&
MA&FC2M%:W,+B/+E\D[@5X [&OJK[%XW_ .@W9?\ @,?\:\=_:Y_Y+A\#/^Q[
ME_\ 1%>]4 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!
MNR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO
M_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!
MNR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO
M_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!
MNR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO
M_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!
MNR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO
M_ 8_XUL44 8_V+QO_P!!NR_\!C_C69:VOBD^*;J./5+87 MHS)(8#M*Y. !7
M5UCV7_([WO\ UY1?S- !]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44
M 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-4?$MIXM30;I[[5K5XA$?,1+<@D>QKIJS?&/_(L7O\ UP- %2RL
M_&ALXC%K-F%\I=H-L<@8^M2_8O&__0;LO_ 8_P"-:6G?\@^#_KBO\A4U &/]
MB\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT
M?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^
M-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR
M_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;
MLO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+
MQO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]
MB\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XU
ML44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_
M ,!C_C7BGQK_ &N-7^'VM3^$/"-W9:G?VS%+NY,!\F!^Z#!R[#OT /')R!ZQ
M\<?&%WX"^$NN^*M/D*7-M9%;:0?P2R,(T;\&<'\*^!W=Y',DC%F8Y9B<DF@#
MTFZ_:V^.EYJ$-_<>*8&^SR;XH?[-@"*?P3)_.O5_@I^UQJ_Q!UJ#PAXNN[+3
M+^Y8):7(@/DSOV0Y.48]NH)XX. ?EZE1WC<21L593E6!P0: /O3Q?XNG\ Z:
M=6\8^/=)T^#G:;B(AG([*H^9S[ $UQUA\2_CK\2G\OX6>&X[73G^[XBU^T,$
M3#^]%%R[CT.,>H%._9T^&W@;Q1X*TKXN>(;.?6M=OX2TVH:W<&Y:-T=D(C#?
M*@#*<<9'K7KU 'D]C^S=J&HZLGB7XE^+AXIU%#F,ZK$3;0GN$@!V >Q!'M7>
MP:7XPM84MK;5;"..-0J1QVF%4#H !T%;=% &/]B\;_\ 0;LO_ 8_XT?8O&__
M $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\
M;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__
M $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\
M;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__
M $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\
M;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__
M $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XUF>%;7Q3)ITC6&J6T:?:9 5D@).
M[=R:ZNL?P/\ \@B7_K]F_P#0J #[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
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M;-&[H2I!*NRG@D5=HHH **** "BBB@ HHHH **** /!?VN?^2X? S_L>Y?\
MT17O5>"_M<_\EP^!G_8]R_\ HBO>J "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMBL>R_Y'>]
M_P"O*+^9H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *S?&/_(L7O_7 UI5F^,?^18O?^N!H N:=_P @^#_KBO\
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MQ\RC]*^0G1XW,<BE64X92,$&OTCKP[X\_L=Z?\0-5G\8> +^#3=3N&+W=I<
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M#INFV<5O;V\2QP6\$81(T48554<*    .!4M% !1110 4444 %%%% !1110
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MY%C0CW#$56_X:+_X**_%+Y/A!^Q%I/A"UD_U.L_$_P 6*/\ ONSM!YR8^IH
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M6_BW\&/[6\0ZMY/]H:A_PD>I0>;Y4*0Q_NX;A$7$<:+PHSC)R22>9_X<[_\
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M 4444 %%%% !1110 5CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S0!L4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45%>7MGIUJ][J%W%!
M#&N9)II JJ/4D\"N UC]I7P-]N?0_ -CJ'BS45X^S:!:F6-3V+RGY O^T":
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M  D']N?\)%]H/VK^TO/^T?:M_7S?._>;O[W-?T.?!S_@\,\0>.OAAH?]E_\
M!-;Q9XP\3QZ9!#XAOM%\3K:Z:U^L:B8K(]FPB5GRZH2Q56 ).,D _<"BOS4^
M#O[8O_!?K_@H'\.=.^*W[-'[+GP ^"/@_7/.%GJWQ+\9WWB+4@D4TD#M%%I\
M44>\21N )5 ./<5TW_#IO_@H_P#'8>;^VC_P7&^*DEK./WWA_P"!?ARP\&10
MKWB6[B$LTJ]?F=0Q!P: /N+XE_&'X2?!?03XI^,7Q2\.>$],7.[4?$VMV]A
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M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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MKP)X7OAH]S#-=Z@6VIIVFLMQ.6_N[4S@^QQ69>_$/]HSQLFSP7\,5\-6C_\
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MQ_LSZ*1G.9+JZ<_FTI-:$'_!-G]A&V?S(_V7O"I.,8DLV<?DS$4 =!<?M=_
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^
M^EK8HH QO I+:-(Q7&;R7@]OFK9K'\#_ /((E_Z_9O\ T*MB@ HHHH ****
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M (1/_A$_[0_YE[[?]J^U?9O^GB'9M^S_ .UG?VQS],T4 ?F;_P 0ZG_5X?\
MYC[_ .^%4]#_ .#>O^V;1KK_ (:[\O;,\>W_ (0#.=IQG_C_ !7Z?5C^!_\
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M>./B[^R;\!-$8_\ 'Q8V6J:]J=OQ_&UVRVC'TP1T->:>,/V:/%^NPM-^VO\
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M,B] P<-@A5S@]/7VJ_/_ ,%]_B]91EK[_@A1^VL"!T@^$4DHS]5?I[U^C5%
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M/A+J&G6VF_$C]HOXP^*K>WC"+8:IXW*VBK_=2*.-?+7_ &0U=1X5_P""4O[
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M_GQA_P"_0H _**?_ (-G?@9\5KD3_MF?\%+?CG\859@;A/$OBZX_>'V\R:8
M>@P<5ZO\)O\ @W/_ ."+WPFDCEB^"":\\>-LGB#4VD?_ +[B6-OR-?H-_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H4 >!_#_]@C_@G+\,84MO"/[-W@=8XQB--1TT
M7P7Z"Y\S'UKU;PEI/P5\ PFW\">'?#^BQD8*:3ID5L"/3$:BNF_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5
M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M.=*^SBYWH/\ 3;GS5D:X# ?)M*M][?\ +]RT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5CV7_([WO_ %Y1?S-;%8]E
M_P CO>_]>47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5F^,?^18O?\ K@:TJS?&/_(L7O\ UP- %S3O^0?!
M_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z
M_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*@#8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\ 0JV* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P7]KG_DN'P,_['N7_ -$5
M[U7@O[7/_)</@9_V/<O_ *(KWJ@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1WO?\
MKRB_F: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "LWQC_R+%[_UP-:59OC'_D6+W_K@: +FG?\ (/@_ZXK_ "%3
M5#IW_(/@_P"N*_R%34 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?
MI_\ 036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5C^!_^01+_ -?LW_H5;%8_@?\ Y!$O_7[-_P"A4 ;%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &/X'_P"01+_U^S?^A5L5C^!_^01+_P!?LW_H5;% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X+^US_ ,EP^!G_ &/<O_HB
MO>J\%_:Y_P"2X? S_L>Y?_1%>]4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8]E_P CO>_]>47\S6Q6/9?\CO>_
M]>47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5F^,?\ D6+W_K@:TJS?&/\ R+%[_P!<#0!<T[_D'P?]<5_D
M*FJ'3O\ D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT
M_P#H)K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0J -BBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#'\#_ /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"K8H **** "BBB@ HHHH
M **** "BBB@ HHHH **KKJVE-JK:$NIVYODMUG>S$R^:L3,5$A3.0I96 ;&"
M5([58H **** "BBB@ HHHH \%_:Y_P"2X? S_L>Y?_1%>]5X+^US_P EP^!G
M_8]R_P#HBO>J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\
M8_\ (L7O_7 UI5F^,?\ D6+W_K@: +FG?\@^#_KBO\A4U0Z=_P @^#_KBO\
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MS5_X+9(VO_\ !27_ ()Y>"-&^?5I/CEJ&J)#'R_V.SALY+E\?W0A!/TK]*J
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M5\]'_#NKX'_]#=X[_P#"OGH ]ZHKP7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\
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MUSXM^%%UXJ\7C2]*\*V%[:LGB:83&65V#;GZLO' [4 ?9M%>"_\ #NKX'_\
M0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C
M_AW5\#_^AN\=_P#A7ST >]45X+_P[J^!_P#T-WCO_P *^>C_ (=U? __ *&[
MQW_X5\] 'O5%>"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7ST >]45X+
M_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/0![U17@O\ P[J^!_\
MT-WCO_PKYZ/^'=7P/_Z&[QW_ .%?/0![U17@O_#NKX'_ /0W>.__  KYZ/\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ />J*\%_X=U? __H;O'?\
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M*\%_X=U? _\ Z&[QW_X5\]'_  [J^!__ $-WCO\ \*^>@#WJBO!?^'=7P/\
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M8R7>6=XKA RL-RM]I?M2?\$8/V:OC[^Q5\._V/?ASK^L_#B3X-7-A?\ P?\
M&_AYQ)J7AO4;1<1W66*^>7;YY064R/APRNJL/L&B@#\[M4_X(X?MC?M9>+?"
M.G?\%5?^"D:_%_X;^"=:@U>U^&WACX:6OAVT\0WT'^JFU22*5S/&.\"J%.XX
M*Y.?9O\ @HG_ ,$SKO\ ;&\:_#_]I#X#_M :E\(/C;\*;BX;P/\ $33-(BU"
M/[-<+MN+"]M)&5;JVD&1M+#;O?A@[JWU769XQ\:^#?AWX;N?&7Q \6Z9H6D6
M04WFJZQ?QVMM &<(N^61E5<LRJ,D9+ =30!\??LE?\$L?C)X5_:_B_X* ?\
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M=B<T ;]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R'Q$_:"^
MOP@U*#1OBS\;O"'A>\NH/.MK3Q%XEM;*6:+<5WJLTBEER",@8R"*;X!_:'^
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M/&7QN^"_PYU^R\*?$+XN^%]!U34@/[.TW6=?MK6XNLMM'EQRNK/EN/E!YXH
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M.K?8].C,MQ''+=7$FY6:.")GF,:,'?R]J_,PK\R/^"0/P=_:9^"7_!?WX_\
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M ;_B8>8Q8.M '[34444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y
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M'OC_ *3XH^(FM7&A)?'PE_:5Q?W-M>W-E-^[E^RI<QH\$ORM*?+;&_%?4O\
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M'QE^RW^P%^P=X[_:'U_X:7(M/B/K&@:U8Z/HVB7G.;$7MXVV>Z4JX:)0,%&
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MU3X=_$7PII^NZ#K5C)9:OHVK6B7%M>V\BE7BEC<%71@2"",&OC3PG_P;E_\
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M%T32;58;>S@085$1> .Y/4DDG))-;U%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\!W/_!KS_P $+KNXDN[C]AS=)*Y=V_X69XG&23DGC4J^_**
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565265464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,347,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant's Proxy Statement for the 2022 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228571197672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Indianapolis, Indiana<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565048696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue (Note 2)</a></td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">7,312.8<span></span>
</td>
<td class="nump">5,483.3<span></span>
</td>
<td class="nump">4,721.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,025.9<span></span>
</td>
<td class="nump">6,085.7<span></span>
</td>
<td class="nump">5,595.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">6,431.6<span></span>
</td>
<td class="nump">6,121.2<span></span>
</td>
<td class="nump">6,213.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">874.9<span></span>
</td>
<td class="nump">660.4<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Asset impairment, restructuring, and other special charges (Note 5)</a></td>
<td class="nump">316.1<span></span>
</td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">575.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8212;net, (income) expense (Note 18)</a></td>
<td class="nump">201.6<span></span>
</td>
<td class="num">(1,171.9)<span></span>
</td>
<td class="num">(291.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">22,162.9<span></span>
</td>
<td class="nump">17,309.9<span></span>
</td>
<td class="nump">17,053.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">6,155.5<span></span>
</td>
<td class="nump">7,229.9<span></span>
</td>
<td class="nump">5,265.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 14)</a></td>
<td class="nump">573.8<span></span>
</td>
<td class="nump">1,036.2<span></span>
</td>
<td class="nump">628.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">5,581.7<span></span>
</td>
<td class="nump">6,193.7<span></span>
</td>
<td class="nump">4,637.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations (Note 19)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3,680.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,581.7<span></span>
</td>
<td class="nump">$ 6,193.7<span></span>
</td>
<td class="nump">$ 8,318.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings from continuing operations - basic (in usd per share)</a></td>
<td class="nump">$ 6.15<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 4.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings from discontinued operations - basic (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3.95<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic (in usd per share)</a></td>
<td class="nump">6.15<span></span>
</td>
<td class="nump">6.82<span></span>
</td>
<td class="nump">8.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings from continuing operations - diluted (in usd per share)</a></td>
<td class="nump">6.12<span></span>
</td>
<td class="nump">6.79<span></span>
</td>
<td class="nump">4.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings from discontinued operations - diluted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3.93<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted (in usd per share)</a></td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 6.79<span></span>
</td>
<td class="nump">$ 8.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">906,963<span></span>
</td>
<td class="nump">907,634<span></span>
</td>
<td class="nump">931,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">911,681<span></span>
</td>
<td class="nump">912,505<span></span>
</td>
<td class="nump">935,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of sales, operating expenses, and other-net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228571049672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,581.7<span></span>
</td>
<td class="nump">$ 6,193.7<span></span>
</td>
<td class="nump">$ 8,318.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss) from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Change in foreign currency translation gains (losses)</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
<td class="num">(89.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Change in net unrealized gains (losses) on securities</a></td>
<td class="num">(15.9)<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Change in defined benefit pension and retiree health benefit plans (Note 15)</a></td>
<td class="nump">2,699.4<span></span>
</td>
<td class="num">(157.1)<span></span>
</td>
<td class="num">(970.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Change in effective portion of cash flow hedges</a></td>
<td class="nump">151.6<span></span>
</td>
<td class="num">(152.9)<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss) from continuing operations before income taxes</a></td>
<td class="nump">2,848.6<span></span>
</td>
<td class="num">(173.7)<span></span>
</td>
<td class="num">(991.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations</a></td>
<td class="num">(695.3)<span></span>
</td>
<td class="nump">200.9<span></span>
</td>
<td class="nump">151.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">2,153.3<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(783.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">7,735.0<span></span>
</td>
<td class="nump">6,220.9<span></span>
</td>
<td class="nump">7,535.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss) from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">2,153.3<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(840.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss) from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 56.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564126616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 7)</a></td>
<td class="nump">$ 3,818.5<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 7)</a></td>
<td class="nump">90.1<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $22.5 (2021)&#160;and $25.9 (2020)</a></td>
<td class="nump">6,672.8<span></span>
</td>
<td class="nump">5,875.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,454.4<span></span>
</td>
<td class="nump">1,053.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 6)</a></td>
<td class="nump">3,886.0<span></span>
</td>
<td class="nump">3,980.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,530.6<span></span>
</td>
<td class="nump">2,871.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,452.4<span></span>
</td>
<td class="nump">17,462.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 7)</a></td>
<td class="nump">3,212.6<span></span>
</td>
<td class="nump">2,966.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 8)</a></td>
<td class="nump">3,892.0<span></span>
</td>
<td class="nump">3,766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net (Note 8)</a></td>
<td class="nump">7,691.9<span></span>
</td>
<td class="nump">7,450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets (Note 14)</a></td>
<td class="nump">2,489.3<span></span>
</td>
<td class="nump">2,830.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 9)</a></td>
<td class="nump">8,985.1<span></span>
</td>
<td class="nump">8,681.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,082.7<span></span>
</td>
<td class="nump">3,475.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">48,806.0<span></span>
</td>
<td class="nump">46,633.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt (Note 11)</a></td>
<td class="nump">1,538.3<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,670.6<span></span>
</td>
<td class="nump">1,606.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">958.1<span></span>
</td>
<td class="nump">997.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">6,845.8<span></span>
</td>
<td class="nump">5,853.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">885.5<span></span>
</td>
<td class="nump">770.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable (Note 14)</a></td>
<td class="nump">126.9<span></span>
</td>
<td class="nump">495.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,027.5<span></span>
</td>
<td class="nump">2,750.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,052.7<span></span>
</td>
<td class="nump">12,481.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 11)</a></td>
<td class="nump">15,346.4<span></span>
</td>
<td class="nump">16,586.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 15)</a></td>
<td class="nump">1,954.1<span></span>
</td>
<td class="nump">4,094.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable (Note 14)</a></td>
<td class="nump">3,920.0<span></span>
</td>
<td class="nump">3,837.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities (Note 14)</a></td>
<td class="nump">1,733.7<span></span>
</td>
<td class="nump">2,099.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,644.3<span></span>
</td>
<td class="nump">1,707.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">24,598.5<span></span>
</td>
<td class="nump">28,326.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value&#8232; Authorized shares: 3,200,000&#8232; Issued shares: 954,116 (2021)&#160;and 957,077 (2020)</a></td>
<td class="nump">596.3<span></span>
</td>
<td class="nump">598.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,833.4<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">8,958.5<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 17)</a></td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(52.7)<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders' equity</a></td>
<td class="nump">8,979.2<span></span>
</td>
<td class="nump">5,641.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">175.6<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">9,154.8<span></span>
</td>
<td class="nump">5,825.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 48,806.0<span></span>
</td>
<td class="nump">$ 46,633.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales rebates and discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568303560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued (in shares)</a></td>
<td class="nump">954,116<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228560177704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity Statement - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 661.0<span></span>
</td>
<td class="nump">$ 6,583.6<span></span>
</td>
<td class="nump">$ 11,395.9<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (5,729.2)<span></span>
</td>
<td class="num">$ (69.4)<span></span>
</td>
<td class="nump">$ 1,080.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,318.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(794.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,430.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,363.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,427.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">$ (4,400.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,400.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="num">(210.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_StockAcquiredDuringPeriodSharesExchangeOffer', window );">Acquisition of common stock in exchange offer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_StockAcquiredDuringPeriodValueExchangeOffer', window );">Acquisition of common stock in exchange offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,027.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary', window );">Deconsolidation of Elanco</a></td>
<td class="num">(1,028.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.8<span></span>
</td>
<td class="nump">6,685.3<span></span>
</td>
<td class="nump">4,920.4<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">$ (60.8)<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,193.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,786.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="num">(212.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">5,825.2<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,581.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,153.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,201.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,246.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="num">(287.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 9,154.8<span></span>
</td>
<td class="nump">$ 596.3<span></span>
</td>
<td class="nump">$ 6,833.4<span></span>
</td>
<td class="nump">$ 8,958.5<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (4,343.1)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="nump">$ 175.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact on Equity of Sale of Noncontrolling Interest in Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_StockAcquiredDuringPeriodSharesExchangeOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Acquired During Period, Shares, Exchange Offer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_StockAcquiredDuringPeriodSharesExchangeOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_StockAcquiredDuringPeriodValueExchangeOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Acquired During Period, Value, Exchange Offer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_StockAcquiredDuringPeriodValueExchangeOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568283736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared per share (in usd per share)</a></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228566279000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,581.7<span></span>
</td>
<td class="nump">$ 6,193.7<span></span>
</td>
<td class="nump">$ 8,318.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain related to disposition of Elanco (Note 19)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3,680.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of antibiotic business in China (Note 3)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(309.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,547.6<span></span>
</td>
<td class="nump">1,323.9<span></span>
</td>
<td class="nump">1,232.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 11)</a></td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">252.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(802.3)<span></span>
</td>
<td class="num">(134.5)<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">342.8<span></span>
</td>
<td class="nump">308.1<span></span>
</td>
<td class="nump">312.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment gains</a></td>
<td class="num">(178.0)<span></span>
</td>
<td class="num">(1,438.5)<span></span>
</td>
<td class="num">(403.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">874.9<span></span>
</td>
<td class="nump">660.4<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash operating activities, net</a></td>
<td class="nump">511.4<span></span>
</td>
<td class="nump">333.9<span></span>
</td>
<td class="nump">499.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Other changes in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Receivables&#8212;(increase) decrease</a></td>
<td class="num">(1,278.3)<span></span>
</td>
<td class="num">(1,350.2)<span></span>
</td>
<td class="num">(127.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories&#8212;(increase) decrease</a></td>
<td class="num">(235.9)<span></span>
</td>
<td class="num">(533.4)<span></span>
</td>
<td class="num">(258.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets&#8212;(increase) decrease</a></td>
<td class="nump">1,515.4<span></span>
</td>
<td class="num">(457.1)<span></span>
</td>
<td class="num">(602.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable&#8212;increase (decrease)</a></td>
<td class="num">(359.7)<span></span>
</td>
<td class="nump">322.0<span></span>
</td>
<td class="num">(221.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities&#8212;increase (decrease)</a></td>
<td class="num">(664.1)<span></span>
</td>
<td class="nump">1,271.3<span></span>
</td>
<td class="num">(477.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">7,260.7<span></span>
</td>
<td class="nump">6,499.6<span></span>
</td>
<td class="nump">4,836.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,309.8)<span></span>
</td>
<td class="num">(1,387.9)<span></span>
</td>
<td class="num">(1,033.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">129.7<span></span>
</td>
<td class="nump">136.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(83.5)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
<td class="num">(42.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of noncurrent investments</a></td>
<td class="nump">800.0<span></span>
</td>
<td class="nump">757.1<span></span>
</td>
<td class="nump">609.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="num">(929.9)<span></span>
</td>
<td class="num">(358.7)<span></span>
</td>
<td class="num">(247.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PurchasedInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="num">(563.4)<span></span>
</td>
<td class="num">(641.2)<span></span>
</td>
<td class="num">(319.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired (Note 3)</a></td>
<td class="num">(747.4)<span></span>
</td>
<td class="num">(849.3)<span></span>
</td>
<td class="num">(6,917.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Cash distributed to Elanco upon disposition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(374.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash received for sale of antibiotic business in China</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">354.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">102.8<span></span>
</td>
<td class="num">(248.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used for Investing Activities</a></td>
<td class="num">(2,762.3)<span></span>
</td>
<td class="num">(2,258.9)<span></span>
</td>
<td class="num">(8,082.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(3,086.8)<span></span>
</td>
<td class="num">(2,687.1)<span></span>
</td>
<td class="num">(2,409.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(1,494.2)<span></span>
</td>
<td class="nump">995.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">2,410.8<span></span>
</td>
<td class="nump">2,062.3<span></span>
</td>
<td class="nump">6,556.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(1,905.4)<span></span>
</td>
<td class="num">(276.5)<span></span>
</td>
<td class="num">(2,866.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(1,250.0)<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
<td class="num">(4,400.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(295.9)<span></span>
</td>
<td class="num">(241.6)<span></span>
</td>
<td class="num">(200.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used for Financing Activities</a></td>
<td class="num">(4,131.3)<span></span>
</td>
<td class="num">(3,137.1)<span></span>
</td>
<td class="num">(2,324.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(205.7)<span></span>
</td>
<td class="nump">216.0<span></span>
</td>
<td class="num">(89.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">161.4<span></span>
</td>
<td class="nump">1,319.6<span></span>
</td>
<td class="num">(5,660.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year (2019 includes $677.5 of discontinued operations)</a></td>
<td class="nump">3,657.1<span></span>
</td>
<td class="nump">2,337.5<span></span>
</td>
<td class="nump">7,998.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Year</a></td>
<td class="nump">$ 3,818.5<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
<td class="nump">$ 2,337.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228569276424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Discontinued operations cash</a></td>
<td class="nump">$ 677.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565166536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard</a></td>
<td class="text">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco Animal Health Incorporated (Elanco) common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development costs, which are expensed as incurred.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense includes the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share (EPS)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and Internet advertising, totaled approximately $1.2 billion, $1.1 billion, and $1.1 billion in 2021, 2020, and 2019, respectively, which was less than 5 percent of revenue each year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standard</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform, </span>provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard can be adopted immediately and is applicable to contracts entered into before January 1, 2023. We do not expect the transition from the use of LIBOR to an alternative reference rate to have a material impact to our consolidated statements of operations or balance sheets at the initial transition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570923224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,957.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,694.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,377.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,845.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $175.0 million, $135.6 million, and $301.5 million during the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December&#160;31, 2021, 2020, and 2019, our three largest wholesalers each accounted for between 15 percent and 20 percent of consolidated revenue. Further, they each accounted for between 18 percent and 28 percent of accounts receivable as of December&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. The following describe the most significant of these judgments:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Returns - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual U.S. product returns have been less than 2 percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record adjustments to revenue as a result of changes in estimates, for the judgments described above, for our most significant U.S. sales returns, rebates and discounts liability balances. Such adjustments for products shipped in previous periods resulted in approximately 2 percent or less increase to U.S revenue during each of the years ended December 31, 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Other Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">262.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.8&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities balances disclosed above as of December&#160;31, 2021 and 2020 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,914.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,557.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,320.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,132.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">807.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">683.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">832.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">389.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">588.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,719.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,909.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,529.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,468.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">827.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">834.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">515.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">481.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">210.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,028.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,712.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,542.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">670.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">791.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,881.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,479.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">542.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">614.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,283.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,978.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">441.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">707.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">233.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,566.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,563.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,811.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,507.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:38.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,811.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,776.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,187.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,367.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,661.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,702.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568565080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions and Divestiture</a></td>
<td class="text">Acquisitions and Divestiture<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December&#160;31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the year ended December 31, 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Loxo Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.018%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$4.60 billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately 12 years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QILU Regor Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for metabolic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entos Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $96.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $30.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture</span></div>In October 2019, we completed a transaction in which we sold the rights in China for two legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $354.8 million and $40.3 million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recognized a gain of $309.8 million in other&#8212;net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Divestiture</a></td>
<td class="text">Acquisitions and Divestiture<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December&#160;31, 2021, 2020, and 2019, we recorded acquired IPR&amp;D charges of $874.9 million, $660.4 million, and $239.6&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the year ended December 31, 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Loxo Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.018%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$4.60 billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately 12 years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QILU Regor Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for metabolic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entos Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $96.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $30.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture</span></div>In October 2019, we completed a transaction in which we sold the rights in China for two legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $354.8 million and $40.3 million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recognized a gain of $309.8 million in other&#8212;net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568131720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto, as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta and Basaglar in the U.S, Europe and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. These milestones are being amortized through their respective term under the collaboration which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) any supplementary protection certificates or extensions thereto. The table below summarizes the net milestones capitalized (deferred) at December 31 for the compounds included in this collaboration: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.216%"><tr><td style="width:1.0%"/><td style="width:59.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(149.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2019, in the most significant markets, we and Boehringer Ingelheim shared equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We recorded our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We recorded our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we recorded our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company was entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments may have resulted in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may have been reduced by any performance payments we made related to these products. Similarly, performance payments we may have received related to Basaglar effectively reduced Boehringer Ingelheim's share of the gross margin, which reduced our cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, we and Boehringer Ingelheim modernized the alliance. For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,490.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">892.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $260.0 million and $210.0 million were capitalized as intangible assets as of December 31, 2021 and 2020, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $100.0&#160;million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to an EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,115.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also had the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of sales-based milestones in 2021, milestone payments of $195.0&#160;million were capitalized as intangible assets and are being amortized to cost of sales over the estimated useful life of etesevimab. During the year ended December 31, 2020, we recognized $50.0&#160;million of research and development expenses related to development milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized $2.24 billion and $871.2&#160;million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we plan to pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a regulatory approval for Tyvyt in China in 2021, we capitalized a milestone payment of $40.0&#160;million as an intangible asset which is being amortized to cost of sales through the term of the collaboration. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $195.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt: </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones, and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. As of December&#160;31, 2021 and 2020, contract liabilities were not material. During the twelve months ended December&#160;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Petra</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. Our more significant, near term milestones include a development milestone of approximately $205&#160;million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $164&#160;million in 2023 contingent upon achieving clinical proof of concept.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228571020728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Asset Impairment, Restructuring, And Other Special Charges</a></td>
<td class="text">Asset Impairment, Restructuring, and Other Special Charges<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">303.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance costs recognized during the years ended December 31, 2020 and 2019 were incurred as a result of actions taken worldwide to reduce our cost structure. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div>Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $400.7 million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570924664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,372.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">717.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,851.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,886.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised $1.36 billion and $1.21 billion of total inventories at December&#160;31, 2021 and 2020, respectively.</span></div>We recognized a net inventory impairment charge related to our COVID-19 antibodies of $339.7&#160;million during the year ended December 31, 2021 in cost of sales in our consolidated statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570850776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December&#160;31, 2021, we had outstanding foreign currency forward commitments to purchase 4.43 billion U.S. dollars and sell 3.92 billion euro; commitments to purchase 3.84&#160;billion euro and sell 4.37&#160;billion U.S. dollars; commitments to purchase 159.2&#160;million U.S. dollars and sell 18.26 billion Japanese yen, and commitments to purchase 223.0 million British pounds and sell 296.0 million U.S. dollars, which all have settlement dates within 180 days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $7.90 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.02&#160;billion as of December&#160;31, 2021 and 2020, respectively, of which $5.79 billion and $4.50&#160;billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December&#160;31, 2021 and 2020, respectively. At December&#160;31, 2021, we had outstanding cross currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December&#160;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December&#160;31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75&#160;billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12 months, we expect to reclassify $16.5 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the years ended December&#160;31, 2021, 2020, and 2019, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,379.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,379.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,379.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">232.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,279.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">487.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,279.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,279.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">548.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">771.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,966.8&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,884.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,595.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of December 31, 2021, we had approximately $828&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be invested over a period of up to 10 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:42.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5      Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10    Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated statements of operations for equity securities were $176.9&#160;million, $1.44 billion, and $401.2&#160;million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. The net gains/losses recognized for the years ended December 31, 2021, 2020, and 2019 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2021, 2020, and 2019 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 97 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $550.5 million and $754.9 million&#160;of accounts receivable as of December&#160;31, 2021 and 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2021, 2020, and 2019 were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568010856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The changes in goodwill during 2021 and 2020 were primarily related to our acquisitions of Prevail and Dermira, respectively. See Note 3 for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2021, 2020, and 2019.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,987.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,229.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,758.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,984.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,056.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,289.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,766.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,076.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,727.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,349.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,925.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,925.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,981.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,289.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,691.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,727.8)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of the fair values of acquired IPR&amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;D projects that had no alternative future use. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in marketed products in 2021 primarily related to the sale of rights to Qbrexza in 2021 as well as the impairment of a Phase I molecule related to a contract-based intangible. See Note 5 for additional information. These decreases were more than offset by the recognition of several milestones related to the COVID-19 therapies that occurred in 2021. The increase in the acquired IPR&amp;D in 2021 is due to the acquisition of Prevail. See Note 3 for additional information regarding intangible assets acquired in a recent business combination and Note 4 for additional information regarding capitalized milestone payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDA_50a976ec-2fe9-4481-a965-701914495450">one</span> to 20 years. As of December&#160;31, 2021, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 14 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2021 is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570710552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25">three</span> to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,588.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,326.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,937.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,961.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,252.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,976.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,570.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,985.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,681.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:69.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">787.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest costs were not material for the years ended December&#160;31, 2021, 2020, and 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:38.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,620.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,113.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,702.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,691.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,013.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,648.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564955064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $159.4 million, $154.6 million, and $172.8 million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2021, 2020, and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2021, 2020, and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.906%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $159.4 million, $154.6 million, and $172.8 million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2021, 2020, and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2021, 2020, and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.906%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570760952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,741.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,348.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,884.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,595.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,538.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,346.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,586.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.35% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.00% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">99.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00% euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">678.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">737.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.15% Swiss franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">654.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">679.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.125% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">229.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">847.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">922.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">364.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">377.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">401.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.45% Swiss franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">436.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,150.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.42% Japanese yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">199.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">222.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.125% euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">847.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">922.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.625% euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">678.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">737.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.50% euro denominated notes due 2033</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">678.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.56% Japanese yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">80.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.77% notes due 2036</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">158.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">444.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">476.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.95% notes due 2037</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">266.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">284.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">240.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% British pound denominated notes due 2043</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">337.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.65% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">38.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">386.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">412.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">347.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">436.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">958.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.70% euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,130.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,229.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.97% Japanese yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">66.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.25% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,250.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.125% euro denominated notes due 2051</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">565.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.15% notes due 2059</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">591.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,000.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.50% notes due 2060</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.375% euro denominated notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">791.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(105.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(76.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16,741.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,348.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had a total of $5.26 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2026 and a $2.00&#160;billion 364-day facility that expires in November 2022, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $2.00 billion facilities as of December&#160;31, 2021. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2021 and 2020 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#8364;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $1.00&#160;billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $1.15&#160;billion of 3.375 percent fixed-rate notes due in March 2029, $850.0&#160;million of 3.875 percent fixed-rate notes due in March 2039, $1.50&#160;billion of 3.95 percent fixed-rate notes due in March 2049, and $1.00&#160;billion of 4.15 percent fixed-rate notes due in March 2059, with interest to be paid semi-annually. We used the net cash proceeds of $4.45&#160;billion from the offering to repay commercial paper that was issued in connection with the acquisition of Loxo and for general corporate purposes.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued euro-denominated notes consisting of &#8364;600.0 million of 0.625 percent fixed-notes due November 2031 and &#8364;1.00 billion of 1.70 percent fixed-rate notes due in November 2049 with interest to be paid annually. We paid $2.27 billion, comprised of $1.75 billion of net cash proceeds from the offering and proceeds from commercial paper, to purchase and redeem certain higher interest rate U.S. dollar denominated notes with an aggregate principal amount of $2.00 billion and a net carrying value of $2.01&#160;billion, resulting in a debt extinguishment loss of $252.5 million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued Japanese Yen-denominated notes consisting of &#165;22.92&#160;billion of 0.42 percent fixed-rate notes due in November 2029, &#165;9.28&#160;billion of 0.56 percent fixed-rate notes due in November 2034, and &#165;7.64&#160;billion of 0.97 percent fixed-rate notes due in November 2049, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $356.6&#160;million for general corporate purposes, including the repayment of outstanding commercial paper.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2021 and 2020, including the effects of interest rate swaps for hedged debt obligations, were 2.27 percent and 2.61 percent, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570919544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 50.6 million additional shares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2021, 2020, and 2019 were $198.57, $137.33, and $112.09, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 0.7 million shares, 1.1 million shares, and 1.2&#160;million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately 0.7 million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested PAs was $66.1 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2021, 2020, and 2019 were $230.19, $139.14, and $95.01, respectively, determined using the following assumptions:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.90&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, approximately 1.0 million shares, 0.8 million shares, and 1.0 million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately 0.5&#160;million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested SVAs was $47.0 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relative Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we granted RVAs to officers and management that are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2021 and 2020 were $286.71 and $179.90, respectively, determined using the following assumptions:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.048%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.95</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.89&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested RVAs was $18.6 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December&#160;31, 2021, 2020, and 2019 were $196.30, $135.42, and $108.43, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 0.7 million, 1.1 million, and 1.5 million shares were granted and approximately 0.6 million, 0.6 million, and 0.8 million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately 0.9 million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested RSUs was $161.4 million, which will be amortized over the weighted-average remaining requisite service period of 25 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570707544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020, and 2019, we repurchased $1.25 billion, $500.0 million, and $4.40 billion, respectively, of shares associated with our share repurchase programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we repurchased $1.00 billion of shares, which completed our $8.00 billion share repurchase program authorized in June 2018. Additionally, our board authorized a $5.00 billion share repurchase program in May 2021. In 2021, we repurchased $250.0 million of shares under the $5.00 billion share repurchase program. As of December 31, 2021, we had $4.75 billion remaining under the $5.00 billion share repurchase program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 5.0 million authorized shares of preferred stock. As of December&#160;31, 2021 and 2020, no preferred stock was issued.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee benefit trust that held 50.0 million shares of our common stock at both December&#160;31, 2021 and 2020, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01&#160;billion at both December&#160;31, 2021 and 2020, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2021, 2020, and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567945880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">938.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">466.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,376.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(977.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(802.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2021, 2020, and 2019 current tax expense includes $64.7 million, $144.4 million, and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,347.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">634.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">463.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and other tax carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">832.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">560.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">274.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">275.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">477.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,662.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(875.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,786.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,801.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,583.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,516.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,465.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(596.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(560.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(338.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(303.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(132.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,030.7)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,071.2)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">755.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, based on filed tax returns we have tax credit carryforwards and carrybacks of $859.9&#160;million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $21.5&#160;million, if unused, will expire between 2030 and 2040. The remaining portion of the tax credit carryforwards is related to federal tax credits of $76.2 million, international tax credits of $115.3&#160;million, and state tax credits of $498.1 million, all of which are fully reserved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $2.21 billion: $832.6 million will expire by 2026; $818.2&#160;million will expire between 2027 and 2041; and $561.5 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $230.0&#160;million are fully reserved as of December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and Puerto Rican companies contributed approximately 28 percent, 39 percent, and 44 percent for the years ended December&#160;31, 2021, 2020, and 2019, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2021 and December 31, 2020, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,598.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2021 are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years </span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additional noncurrent income tax payables of $2.02&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,292.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(458.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(100.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,551.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">310.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,798.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.70&#160;billion and $1.67 billion at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months. For tax years 2013-2015, all matters were effectively settled in 2019. As a result, our gross uncertain tax positions were reduced by approximately $200&#160;million, we made a cash payment of approximately $125 million, and our consolidated results were benefited by an immaterial reduction in tax expense. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, our accruals for the payment of interest and penalties totaled $220.1&#160;million and $196.7&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570838216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,225.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,251.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,753.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">369.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(564.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(630.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(173.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,565.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,225.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,663.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,579.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,227.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,458.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(630.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,416.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,361.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,149.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,646.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,697.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,908.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(497.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(117.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,082.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">668.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,910.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,749.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,878.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(204.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,919.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,530.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(614.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,082.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $750.4&#160;million decrease in benefit obligation in 2021 was driven primarily by an increase in the discount rate. The $2.13&#160;billion increase in the benefit obligation in 2020 was driven by a decrease in the discount rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,360.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,770.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,542.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,824.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,532.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,682.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">973.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,824.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total accumulated benefit obligation for our defined benefit pension plans was $16.44 billion and $17.03&#160;billion at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">369.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(949.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(146.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(120.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, and 2019:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial (gain) loss included in net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335.9)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,158.7)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $167.3 million, $164.3 million, and $145.2 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2021, 2020, and 2019 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit Plan Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 75 percent growth investments and 25 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,816.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,416.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2021. The activity in the Level 3 investments during the year ended December&#160;31, 2021 was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2020. The activity in the Level 3 investments during the year ended December 31, 2020 was not material.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we expect to contribute approximately $40 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570710552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) was protected by a vitamin regimen patent until November 2021, and since then has been protected by pediatric exclusivity through May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chusetts seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is currently scheduled to begin in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021 and November 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Swiss Federal Patent Court, respectively, in preliminary injunction (PI) and main infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis' PI action. Novartis appealed the ruling and in October 2021, the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing. Hearings on the Italian and Swiss PI requests are scheduled for May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Novartis petitioned the Commercial Court of Vienna in PI proceedings and in November 2021, the Austrian court denied Novartis' request. Novartis did not appeal the ruling, and this matter is now closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing occurred February 2022. We await a decision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and one in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021. The relevant courts approved the settlement and the deadline for class members to seek settlement funds has now expired. The lawsuits have been dismissed or discontinued. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. which were first initiated in March 2009 and involve approximately 805 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Two lawsuits, representing approximately two plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately 311 of the MDL lawsuits have been dismissed as of February 2022. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment. Approximately 17 of the state court lawsuits have been dismissed as of February 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately 20 additional potential claimants who have not yet filed suit. These additional possible claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal MDL in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The parties have reached agreement to resolve the majority of claims pending in the appeal and expect those claims to soon be dismissed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in 5 currently pending product liability lawsuits in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs' Fournier's gangrene. Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations and dismissals. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. We have filed a notice of appeal. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several actions, including some with unspecified financial impact, consisting primarily of paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility for more than six months during the affected years and their children who were born during and after this period. We appealed this decision. In July 2018, the appeals court (TRT) generally affirmed the Labor Court's ruling, which included a liquidated award of&#160;300&#160;million&#160;Brazilian real. This 300&#160;million Brazilian real liquidated award, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately 950&#160;million Brazilian real (approximately $170&#160;million as of December 31, 2021). The TRT also restricted the broad health coverage awarded by the Labor Court to health problems that claimants could prove in a separate evidentiary proceeding arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Public Attorney (LPA) filed an application in the Labor Court for enforcement of the healthcare coverage granted by the TRT in its July 2018 ruling, requested restrictions on Lilly Brasil&#8217;s assets in Brazil, and required Lilly Brasil and Antibi&#243;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action for the LPA to identify and contact those individuals. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of 500&#160;million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling. In June 2021, the court reduced the security deposit or lien to 100&#160;million Brazilian real and limited the scope of the initial order. ABL and LPA appealed to the TST, which appeal is currently still under review. In addition, in September 2020, the LPA initiated a second preliminary enforcement of the portion of the July 2018 TRT decision in the Labor Court that prohibits the exposure of workers to the contaminated areas. The Labor Court is currently assessing the status of Lilly Brasil&#8217;s compliance with such portion of the July 2018 TRT decision. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in approximately 25 pending&#160;lawsuits filed in the Labor Court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in more than half of the lawsuits by the trial courts, of which, approximately half of those judgements are on appeal in the labor courts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We cooperated with this investigation. In July 2021 Lilly divested Cialis in China. We consider this matter closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Municipality filed a motion to execute a purported judgment, and the CFI scheduled a hearing in March 2022 to consider the Municipality's motion. We have opposed the Municipality's motion. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. In October 2021 the parties filed cross motions for summary judgment. Trial is scheduled for April 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice's motion to dismiss the relator's second amended complaint. In January 2020, the relator appealed the District Court's dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit, and the relator did not petition the U.S. Supreme Court for certiorari.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator appealed the state court's decision to the Appellate Division of the New Jersey Superior Court. In January 2022, the relator filed its appellate brief.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court has allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al., </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. After removing the case to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In January 2022, the court granted the motion in part but has allowed the antitrust and conspiracy claims to proceed against us, Sanofi and Novo Nordisk. We, along with Sanofi and Novo Nordisk, have moved the court to reconsider its denial of our motion to dismiss the antitrust and conspiracy claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Mississippi Attorney General's Office (Mississippi AG) initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In response, the Mississippi AG filed a motion to amend its complaint, which the court granted. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received subpoenas from the New York and Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. In January 2022, the Michigan Attorney General filed against us in state court a petition seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the MCPA applies to the conduct it seeks to investigate and allows it to conduct the investigation. The state court granted the State's petition to investigate, authorizing the State to issue civil investigative subpoenas. The State's complaint for declaratory judgment remains pending.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a&#8239;request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members.&#8239;Those requests sought pricing and other commercial information regarding Lilly's insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. Both parties moved for summary judgment and hearing on the motions took place in August 2021. In October 2021, the Court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which are underway. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. A trial date has not been set.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570816120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:27.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,569.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,740.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(967.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,427.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,751.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,496.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,823.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,795.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,167.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,153.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2021</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,550.2)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,583.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(213.0)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,343.1)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of January 1, 2019 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(532.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(695.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.230%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">490.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(91.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from continuing operations (net of tax)</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from discontinued operations (net of tax)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570756296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other-Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other-Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities (Note 7)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(176.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,442.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(289.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(51.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">201.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,171.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228569275304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. The earnings attributable to the divested, noncontrolling interest for the period from the initial public offering until disposition were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the disposition, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $3.7 billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated financial statements for all periods presented. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and net income from discontinued operations in 2019 was $580.0&#160;million and $3.68&#160;billion, respectively. There were no discontinued operations in 2020 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain related to the disposition of Elanco in the consolidated statement of cash flows includes the operating results of Elanco through the disposition date, which were not material. Net cash flows of our discontinued operations for operating and investing activities were not material for the year ended December 31, 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a transitional services agreement (TSA) with Elanco to facilitate the orderly transfer of various services to Elanco. The TSA related primarily to administrative services, which were generally provided over 24 months from the date of disposition, and is now complete. This agreement was not material and did not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564937848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development costs, which are expensed as incurred.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense includes the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share (EPS)</a></td>
<td class="text">Earnings Per Share (EPS)We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text">Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Implementation of New Financial Accounting Standard</a></td>
<td class="text">Implementation of New Financial Accounting Standard<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform, </span>provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard can be adopted immediately and is applicable to contracts entered into before January 1, 2023. We do not expect the transition from the use of LIBOR to an alternative reference rate to have a material impact to our consolidated statements of operations or balance sheets at the initial transition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25">three</span> to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans</a></td>
<td class="text">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228569276424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,957.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,694.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,377.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,845.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $175.0 million, $135.6 million, and $301.5 million during the years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"><tr><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,914.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,557.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,320.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,132.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">807.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">683.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">832.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">389.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">588.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,719.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,909.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,529.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,468.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">827.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">834.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">515.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">481.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">210.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,028.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,712.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,542.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">670.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">324.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">791.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,881.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,479.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">542.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">614.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,283.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,978.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">441.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">707.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">233.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,566.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,563.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,811.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,507.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:38.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,811.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,776.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,187.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,367.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,661.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,702.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,318.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,539.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Amounts Recorded for Contract Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">262.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.8&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228571005640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 7 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.018%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$4.60 billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately 12 years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of Research and Development Assets Acquired Other than Through Business Combination</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V. </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QILU Regor Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for metabolic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new oncology medicines</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entos Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $96.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $30.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570816120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements</a></td>
<td class="text">The table below summarizes the net milestones capitalized (deferred) at December 31 for the compounds included in this collaboration: <div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.216%"><tr><td style="width:1.0%"/><td style="width:59.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(149.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,490.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">892.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,115.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table summarizes our revenue recognized in China with respect to Tyvyt: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.7&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570722792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Other Operating Cost and Expense, by Component</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">303.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">316.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567938328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,372.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">717.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,851.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,886.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563968344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Net Investment Hedges Included in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,379.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,379.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,361.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,379.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">232.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">235.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,279.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">487.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,279.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,279.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">548.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">771.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.9&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,966.8&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,884.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,157.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,595.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:42.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5      Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10    Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (Loss) on Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567039880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-lived Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,987.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,229.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,758.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,984.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,056.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,289.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,766.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,076.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,727.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,349.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,925.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,925.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,981.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,289.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,691.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,727.8)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-lived Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,987.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,229.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,758.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,984.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,056.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,289.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,766.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,076.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,727.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,349.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,925.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,925.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,981.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,289.7)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,691.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.8&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,727.8)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,450.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">628.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2021 is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563908520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,588.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,326.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,937.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,961.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,252.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,976.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,570.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,985.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,681.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:69.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">787.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-lived Assets by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:38.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,620.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,113.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,702.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,691.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,013.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,648.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567094200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Impact of Leases to Consolidated Condensed Financial Statements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.906%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30">Total</span></span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563926728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,741.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,348.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,884.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,595.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,538.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,346.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,586.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.35% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.00% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">99.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00% euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">678.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">737.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.15% Swiss franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">654.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">679.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.125% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">229.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">847.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">922.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">364.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">377.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">401.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.45% Swiss franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">436.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,150.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.42% Japanese yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">199.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">222.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.125% euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">847.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">922.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.625% euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">678.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">737.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.50% euro denominated notes due 2033</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">678.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.56% Japanese yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">80.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.77% notes due 2036</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">158.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">444.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">476.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.95% notes due 2037</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">266.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">284.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">240.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% British pound denominated notes due 2043</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">337.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.65% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">38.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">386.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">412.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">347.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">436.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">958.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.70% euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,130.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,229.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.97% Japanese yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">66.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.25% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,250.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.125% euro denominated notes due 2051</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">565.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.15% notes due 2059</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">591.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,000.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.50% notes due 2060</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.375% euro denominated notes due 2061</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">791.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(105.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(76.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16,741.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,348.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock', window );">Schedule of Additional Borrowings Disclosures</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Borrowings Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563871400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock', window );">Schedule of Additional Stock-Based Compensation Disclosures</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">342.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock', window );">Share-based Compensation Awards, Fair Value Assumptions Used</a></td>
<td class="text">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2021, 2020, and 2019 were $230.19, $139.14, and $95.01, respectively, determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.90&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2021 and 2020 were $286.71 and $179.90, respectively, determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.048%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.95</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.89&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568100280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">938.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">466.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,376.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(977.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(802.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) The 2021, 2020, and 2019 current tax expense includes $64.7 million, $144.4 million, and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,347.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">634.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">463.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and other tax carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">832.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">560.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.2&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">274.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">275.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">477.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,662.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(875.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,786.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,801.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,583.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,516.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,465.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(596.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(560.6)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(338.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(303.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(132.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,030.7)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,071.2)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">755.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock', window );">Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,598.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2021 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years </span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,292.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(458.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(100.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">573.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,551.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">310.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(38.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,798.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Income Tax Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228560040984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock', window );">Schedule of Changes in Accumulated Postemployment Benefit Obligations</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,225.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,251.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,753.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">369.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(564.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(630.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(173.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,565.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,225.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,663.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Changes in Fair Value of Plan Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,579.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,227.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,458.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(630.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,416.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,361.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,149.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,646.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,697.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,908.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(497.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(117.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,082.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Recognized in Balance Sheet</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">668.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,910.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,749.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,878.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(204.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,919.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,530.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(614.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,770.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,082.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027-2031</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,360.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,770.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,542.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,824.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,532.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,682.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">973.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,824.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">369.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">337.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(949.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(146.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(120.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, and 2019:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,072.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial (gain) loss included in net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335.9)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,158.7)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,816.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,416.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570856616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:27.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,569.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,740.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(967.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,427.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,751.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,496.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,823.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,795.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(122.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,167.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,153.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2021</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,550.2)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,583.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(213.0)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,343.1)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of January 1, 2019 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136.2)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(532.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(695.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.230%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">490.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">435.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(91.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">344.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from continuing operations (net of tax)</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from discontinued operations (net of tax)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.4&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570850184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other - Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities (Note 7)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(176.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,442.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(289.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(51.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">201.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,171.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563999624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Narrative) (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AdvertisingExpensePercentageOfRevenue', window );">Advertising expense, percentage of revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Elanco | Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Disposition of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AdvertisingExpensePercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advertising Expense, Percentage Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AdvertisingExpensePercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lly_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lly_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559867784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">25,957.9<span></span>
</td>
<td class="nump">22,694.8<span></span>
</td>
<td class="nump">20,377.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,360.5<span></span>
</td>
<td class="nump">1,845.0<span></span>
</td>
<td class="nump">1,942.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="nump">$ 135.6<span></span>
</td>
<td class="nump">$ 301.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228571129512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuefromContractPaymentTermMinimum', window );">Revenue, performance obligation, payment terms, days from date of shipment, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuefromContractPaymentTermMaximum', window );">Revenue, performance obligation, payment terms, days from date of shipment, maximum</a></td>
<td class="text">70 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt', window );">Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod', window );">Revenue, performance obligation, sales rebate payment period (up to)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate', window );">Revenue, performance obligation, sales returns, product expiration date</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel', window );">Revenue, performance obligation, sales returns, average inventory level (or less)</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue', window );">Revenue, performance obligation, sales returns, percentage of net revenue (less than)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Revenue Benchmark | Minimum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Revenue Benchmark | Maximum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Accounts Receivable | Minimum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Accounts Receivable | Maximum | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Rebate Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesRebatePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Average Inventory Level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Product Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuefromContractPaymentTermMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract, Payment Term, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuefromContractPaymentTermMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuefromContractPaymentTermMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuefromContractPaymentTermMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570923224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 262.6<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228557223496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">16,811.0<span></span>
</td>
<td class="nump">14,229.3<span></span>
</td>
<td class="nump">12,722.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">11,507.4<span></span>
</td>
<td class="nump">10,310.5<span></span>
</td>
<td class="nump">9,596.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">8,719.3<span></span>
</td>
<td class="nump">7,909.1<span></span>
</td>
<td class="nump">7,529.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,468.8<span></span>
</td>
<td class="nump">3,925.3<span></span>
</td>
<td class="nump">3,602.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,914.4<span></span>
</td>
<td class="nump">3,835.9<span></span>
</td>
<td class="nump">3,155.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,557.6<span></span>
</td>
<td class="nump">1,232.2<span></span>
</td>
<td class="nump">972.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,320.7<span></span>
</td>
<td class="nump">1,485.6<span></span>
</td>
<td class="nump">1,669.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,132.3<span></span>
</td>
<td class="nump">1,140.3<span></span>
</td>
<td class="nump">1,151.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">832.9<span></span>
</td>
<td class="nump">866.4<span></span>
</td>
<td class="nump">879.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">389.6<span></span>
</td>
<td class="nump">393.2<span></span>
</td>
<td class="nump">410.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,490.8<span></span>
</td>
<td class="nump">1,153.8<span></span>
</td>
<td class="nump">944.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">807.3<span></span>
</td>
<td class="nump">620.8<span></span>
</td>
<td class="nump">565.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">683.5<span></span>
</td>
<td class="nump">533.0<span></span>
</td>
<td class="nump">378.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">892.5<span></span>
</td>
<td class="nump">1,124.4<span></span>
</td>
<td class="nump">1,112.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">588.3<span></span>
</td>
<td class="nump">842.3<span></span>
</td>
<td class="nump">876.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">304.2<span></span>
</td>
<td class="nump">282.1<span></span>
</td>
<td class="nump">236.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">372.5<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
<td class="nump">590.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">82.1<span></span>
</td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">224.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">290.4<span></span>
</td>
<td class="nump">263.0<span></span>
</td>
<td class="nump">365.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">173.6<span></span>
</td>
<td class="nump">162.5<span></span>
</td>
<td class="nump">158.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">111.2<span></span>
</td>
<td class="nump">81.5<span></span>
</td>
<td class="nump">88.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,028.8<span></span>
</td>
<td class="nump">2,792.1<span></span>
</td>
<td class="nump">2,608.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,712.5<span></span>
</td>
<td class="nump">2,527.2<span></span>
</td>
<td class="nump">2,005.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,233.9<span></span>
</td>
<td class="nump">1,265.3<span></span>
</td>
<td class="nump">1,219.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">827.5<span></span>
</td>
<td class="nump">1,064.7<span></span>
</td>
<td class="nump">896.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">834.9<span></span>
</td>
<td class="nump">618.2<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">515.0<span></span>
</td>
<td class="nump">294.4<span></span>
</td>
<td class="nump">124.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">358.1<span></span>
</td>
<td class="nump">381.9<span></span>
</td>
<td class="nump">335.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">674.8<span></span>
</td>
<td class="nump">650.8<span></span>
</td>
<td class="nump">589.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">481.8<span></span>
</td>
<td class="nump">480.1<span></span>
</td>
<td class="nump">487.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">66.4<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">55.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">418.1<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">418.1<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">120.1<span></span>
</td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">210.7<span></span>
</td>
<td class="nump">152.3<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,881.8<span></span>
</td>
<td class="nump">1,372.3<span></span>
</td>
<td class="nump">1,059.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,479.0<span></span>
</td>
<td class="nump">1,089.6<span></span>
</td>
<td class="nump">734.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,288.5<span></span>
</td>
<td class="nump">1,016.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">670.4<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="nump">349.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,115.1<span></span>
</td>
<td class="nump">638.9<span></span>
</td>
<td class="nump">426.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">324.1<span></span>
</td>
<td class="nump">63.8<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">791.0<span></span>
</td>
<td class="nump">575.0<span></span>
</td>
<td class="nump">384.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">614.8<span></span>
</td>
<td class="nump">487.3<span></span>
</td>
<td class="nump">356.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,283.7<span></span>
</td>
<td class="nump">1,344.0<span></span>
</td>
<td class="nump">1,366.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">42.1<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">542.8<span></span>
</td>
<td class="nump">725.6<span></span>
</td>
<td class="nump">675.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">434.5<span></span>
</td>
<td class="nump">325.9<span></span>
</td>
<td class="nump">154.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">142.7<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">390.7<span></span>
</td>
<td class="nump">360.5<span></span>
</td>
<td class="nump">377.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">102.0<span></span>
</td>
<td class="nump">73.2<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">207.5<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
<td class="nump">305.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,566.4<span></span>
</td>
<td class="nump">1,668.4<span></span>
</td>
<td class="nump">1,169.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,563.5<span></span>
</td>
<td class="nump">1,424.4<span></span>
</td>
<td class="nump">1,887.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,978.0<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">261.4<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">441.6<span></span>
</td>
<td class="nump">510.3<span></span>
</td>
<td class="nump">645.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">360.3<span></span>
</td>
<td class="nump">536.0<span></span>
</td>
<td class="nump">759.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">61.8<span></span>
</td>
<td class="nump">231.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">707.9<span></span>
</td>
<td class="nump">545.4<span></span>
</td>
<td class="nump">658.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">136.1<span></span>
</td>
<td class="nump">246.4<span></span>
</td>
<td class="nump">291.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 233.9<span></span>
</td>
<td class="nump">$ 321.8<span></span>
</td>
<td class="nump">$ 469.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CymbaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CymbaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ZyprexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ZyprexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565127656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">16,811.0<span></span>
</td>
<td class="nump">14,229.3<span></span>
</td>
<td class="nump">12,722.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,776.8<span></span>
</td>
<td class="nump">4,187.7<span></span>
</td>
<td class="nump">3,765.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,367.0<span></span>
</td>
<td class="nump">2,583.1<span></span>
</td>
<td class="nump">2,547.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,661.4<span></span>
</td>
<td class="nump">1,116.9<span></span>
</td>
<td class="nump">939.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,702.2<span></span>
</td>
<td class="nump">$ 2,422.7<span></span>
</td>
<td class="nump">$ 2,344.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559839704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>medicine</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874.9<span></span>
</td>
<td class="nump">$ 660.4<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747.4<span></span>
</td>
<td class="nump">849.3<span></span>
</td>
<td class="nump">6,917.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,892.0<span></span>
</td>
<td class="nump">3,766.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,905.4<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td class="nump">2,866.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 309.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction', window );">Contingent value right, monthly reduction | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities assumed</a></td>
<td class="nump">$ 106.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member', window );">Dermira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,326.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,670.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc. | Selpercatinib (LOXO-292)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600.0<span></span>
</td>
<td class="nump">$ 4,600.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China | Eddingpharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_NumberOfMedicinesRightsToSold', window );">Number of legacy antibiotic medicines rights sold | medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from divestiture of businesses, net of cash divested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived', window );">Disposal group, not discontinued operation, payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Number Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Payment To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_NumberOfMedicinesRightsToSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Medicines, Rights To, Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_NumberOfMedicinesRightsToSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lly_EddingpharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lly_EddingpharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564582696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Purchase Price Allocation) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>Feb. 15, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,892.0<span></span>
</td>
<td class="nump">$ 3,766.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="nump">$ 6,917.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 90.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="num">(106.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(31.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="nump">903.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(90.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="num">(65.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,670.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,326.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,032.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,917.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contract-based intangibles | Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member', window );">Selpercatinib (LOXO-292) | Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228555352056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Asset Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="17">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874.9<span></span>
</td>
<td class="nump">$ 660.4<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember', window );">Precision Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_MerusNVMember', window );">Merus N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember', window );">Asahi Kasei Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember', window );">Rigel Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember', window );">MiNA Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember', window );">Protomer Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember', window );">Kumquat Biosciences Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember', window );">Lycia Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember', window );">ProQR Therapeutics N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_QILURegorTherapeuticsIncMember', window );">QILU Regor Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember', window );">Foghorn Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">316.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_EntosPharmaceuticalsIncMember', window );">Entos Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember', window );">Sitryx Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member', window );">AbCellera Biologics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember', window );">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember', window );">Petra Pharma Corporation (Petra)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember', window );">Evox Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember', window );">Disarm Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember', window );">Fochon Pharmaceuticals, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_ACImmuneSAMember', window );">AC Immune SA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="nump">$ 127.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_ImmuNextInc.Member', window );">ImmuNext, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_AvidityBiosciencesInc.Member', window );">Avidity Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember', window );">Centrexion Therapeutics Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_QILURegorTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_QILURegorTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_EntosPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_EntosPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_ACImmuneSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_ACImmuneSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_ImmuNextInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_ImmuNextInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_AvidityBiosciencesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_AvidityBiosciencesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563997448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details) - Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="nump">$ 136.1<span></span>
</td>
<td class="nump">$ 156.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="nump">88.5<span></span>
</td>
<td class="nump">114.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="num">$ (149.3)<span></span>
</td>
<td class="num">$ (168.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564082040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Net Product Revenue) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,318.4<span></span>
</td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,490.8<span></span>
</td>
<td class="nump">1,153.8<span></span>
</td>
<td class="nump">944.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">892.5<span></span>
</td>
<td class="nump">1,124.4<span></span>
</td>
<td class="nump">1,112.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">372.5<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
<td class="nump">590.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,115.1<span></span>
</td>
<td class="nump">$ 638.9<span></span>
</td>
<td class="nump">$ 426.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565796600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874.9<span></span>
</td>
<td class="nump">$ 660.4<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,318.4<span></span>
</td>
<td class="nump">24,539.8<span></span>
</td>
<td class="nump">22,319.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember', window );">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember', window );">Petra Pharma Corporation (Petra)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 174.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,661.4<span></span>
</td>
<td class="nump">1,116.9<span></span>
</td>
<td class="nump">939.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized As Intangible Assets | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember', window );">Milestone Payments, Success-based Regulatory And Sales-based | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember', window );">Milestone Payments, Contingent Upon Initiation Of Phase I Trial | Petra Pharma Corporation (Petra)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember', window );">Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept | Petra Pharma Corporation (Petra)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115.1<span></span>
</td>
<td class="nump">638.9<span></span>
</td>
<td class="nump">426.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Royalty Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations percent (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260.0<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Sales-based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240.0<span></span>
</td>
<td class="nump">871.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418.1<span></span>
</td>
<td class="nump">$ 308.7<span></span>
</td>
<td class="nump">$ 134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Milestone Payments, Capitalized As Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Milestone Payments, Success-based Regulatory And Sales-based | Outside of China | Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Milestone Payments, Success-based Regulatory And Sales-based | China | Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Development and Regulatory | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Sales-based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Sales-based | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_NonCHINAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_NonCHINAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567616952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 77.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="nump">303.1<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
<td class="nump">497.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total asset impairment, restructuring, and other special charges</a></td>
<td class="nump">$ 316.1<span></span>
</td>
<td class="nump">$ 131.2<span></span>
</td>
<td class="nump">$ 575.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567781800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">$ 128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets, indefinite-lived</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="nump">$ 303.1<span></span>
</td>
<td class="num">$ (20.0)<span></span>
</td>
<td class="nump">$ 497.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567611480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 761.9<span></span>
</td>
<td class="nump">$ 758.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,372.7<span></span>
</td>
<td class="nump">2,535.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials and supplies</a></td>
<td class="nump">717.2<span></span>
</td>
<td class="nump">651.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates replacement cost)</a></td>
<td class="nump">3,851.8<span></span>
</td>
<td class="nump">3,945.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Increase to LIFO cost</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">34.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,886.0<span></span>
</td>
<td class="nump">3,980.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LIFOInventoryAmount', window );">LIFO Inventory Amount</a></td>
<td class="nump">1,360.0<span></span>
</td>
<td class="nump">$ 1,210.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 339.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LIFOInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LIFOInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564446632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#8364; in Millions, &#165; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1', window );">Average remaining maturity of foreign currency derivatives</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">$ 16,741.2<span></span>
</td>
<td class="nump">$ 16,348.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Foreign currency-denominated notes, designated as hedge</a></td>
<td class="nump">$ 5,790.0<span></span>
</td>
<td class="nump">4,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Losses expected to be reclassified in the next 12 months</a></td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded commitments to invest in venture capital funds</a></td>
<td class="nump">$ 828.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Unfunded commitments to invest in venture capital funds, anticipated payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment gains on equity securities</a></td>
<td class="nump">$ 176.9<span></span>
</td>
<td class="nump">1,442.2<span></span>
</td>
<td class="nump">$ 401.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Percentage of nonperforming assets</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Accounts receivable derecognized</a></td>
<td class="nump">$ 550.5<span></span>
</td>
<td class="nump">754.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember', window );">Buy USD Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">4,430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euro Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">4,370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember', window );">Buy USD Sell Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">159.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 18,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember', window );">Buy GBP Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 223.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">296.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">1,020.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">7,900.0<span></span>
</td>
<td class="nump">$ 6,020.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Designated as Hedging Instrument | Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564565768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Effect of Risk Management) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="nump">$ 263.0<span></span>
</td>
<td class="num">$ (209.7)<span></span>
</td>
<td class="nump">$ 60.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="num">(404.0)<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="num">(110.9)<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">213.7<span></span>
</td>
<td class="num">(207.9)<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">42.3<span></span>
</td>
<td class="num">(53.7)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="num">(78.5)<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">112.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="nump">78.5<span></span>
</td>
<td class="num">(86.9)<span></span>
</td>
<td class="num">(112.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="num">(102.4)<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="nump">$ 204.6<span></span>
</td>
<td class="num">$ (123.7)<span></span>
</td>
<td class="nump">$ 61.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228556576520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Fair Value Measurement) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 3,212.6<span></span>
</td>
<td class="nump">$ 2,966.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,379.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">90.1<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">548.1<span></span>
</td>
<td class="nump">373.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">3,212.6<span></span>
</td>
<td class="nump">2,966.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,379.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,379.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,361.0<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">136.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">232.7<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">109.8<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">109.8<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">109.8<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">22.2<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,279.7<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">487.0<span></span>
</td>
<td class="nump">311.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,279.7<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,279.7<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember', window );">Equity method investments | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 771.5<span></span>
</td>
<td class="nump">$ 471.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564147960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">$ (16,741.2)<span></span>
</td>
<td class="num">$ (16,348.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(16,884.7)<span></span>
</td>
<td class="num">(16,595.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(18,157.7)<span></span>
</td>
<td class="num">(19,038.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(18,157.7)<span></span>
</td>
<td class="num">(19,038.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228556854968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Not Designated as Hedging Instrument | Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(70.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign Exchange Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(70.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign Exchange Contract | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign Exchange Contract | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign Exchange Contract | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(70.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Carrying Amount | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Carrying Amount | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Carrying Amount | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">33.2<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">33.2<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">33.2<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Carrying Amount | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228566246728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 581.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less Than 1 Year</a></td>
<td class="nump">75.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">216.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">126.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More Than 10 Years</a></td>
<td class="nump">$ 162.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559892920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">250.7<span></span>
</td>
<td class="nump">348.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 290.2<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559911400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Investment Portfolio Activity) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 174.7<span></span>
</td>
<td class="nump">$ 264.8<span></span>
</td>
<td class="nump">$ 431.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564565000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564852696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">$ 8,056.6<span></span>
</td>
<td class="nump">$ 8,076.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,289.7)<span></span>
</td>
<td class="num">(1,727.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">5,766.9<span></span>
</td>
<td class="nump">6,349.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Carrying Amount, Gross</a></td>
<td class="nump">9,981.6<span></span>
</td>
<td class="nump">9,177.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,289.7)<span></span>
</td>
<td class="num">(1,727.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Carrying Amount, Net</a></td>
<td class="nump">7,691.9<span></span>
</td>
<td class="nump">7,450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,925.0<span></span>
</td>
<td class="nump">1,101.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">7,987.2<span></span>
</td>
<td class="nump">7,984.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,229.2)<span></span>
</td>
<td class="num">(1,659.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">5,758.0<span></span>
</td>
<td class="nump">6,324.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,229.2)<span></span>
</td>
<td class="num">(1,659.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">69.4<span></span>
</td>
<td class="nump">92.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(60.5)<span></span>
</td>
<td class="num">(68.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (60.5)<span></span>
</td>
<td class="num">$ (68.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565164440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 628.8<span></span>
</td>
<td class="nump">$ 428.2<span></span>
</td>
<td class="nump">$ 225.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228568298072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 570.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">483.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">433.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">417.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">$ 408.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559922936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567600104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 258.7<span></span>
</td>
<td class="nump">$ 226.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">7,588.1<span></span>
</td>
<td class="nump">7,326.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">8,937.2<span></span>
</td>
<td class="nump">8,560.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,177.8<span></span>
</td>
<td class="nump">2,138.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,961.8<span></span>
</td>
<td class="nump">18,252.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(9,976.7)<span></span>
</td>
<td class="num">(9,570.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 8,985.1<span></span>
</td>
<td class="nump">$ 8,681.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567880152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Depreciation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 787.0<span></span>
</td>
<td class="nump">$ 765.2<span></span>
</td>
<td class="nump">$ 814.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559900120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Geographic Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 10,013.3<span></span>
</td>
<td class="nump">$ 9,648.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">6,620.0<span></span>
</td>
<td class="nump">6,113.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,702.3<span></span>
</td>
<td class="nump">1,786.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,691.0<span></span>
</td>
<td class="nump">$ 1,747.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567589368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LesseeLeaseRemainingLeaseTerm', window );">Lessee, lease, remaining lease term (up to)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease expense</a></td>
<td class="nump">$ 159.4<span></span>
</td>
<td class="nump">$ 154.6<span></span>
</td>
<td class="nump">$ 172.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LesseeLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LesseeLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564123304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 156.7<span></span>
</td>
<td class="nump">$ 160.9<span></span>
</td>
<td class="nump">$ 153.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 163.5<span></span>
</td>
<td class="nump">$ 136.7<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564430808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Maturities of Operating Lease Liabilities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 148.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">117.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">95.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">79.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">64.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2026</a></td>
<td class="nump">270.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">775.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">90.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 685.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other noncurrent liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228555322536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Schedule of Debt) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Long-term notes</a></td>
<td class="nump">$ 16,741.2<span></span>
</td>
<td class="nump">$ 16,348.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other long-term debt</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(84.2)<span></span>
</td>
<td class="num">(89.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LongTermDebtFairValueAdjustment', window );">Fair value adjustment on hedged long-term notes</a></td>
<td class="nump">216.9<span></span>
</td>
<td class="nump">320.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="nump">16,884.7<span></span>
</td>
<td class="nump">16,595.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less current portion</a></td>
<td class="num">(1,538.3)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 15,346.4<span></span>
</td>
<td class="nump">$ 16,586.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LongTermDebtFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment to carrying value of long term debt to arrive at total fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LongTermDebtFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559051144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Summary of Long-term Notes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized note discounts</a></td>
<td class="num">$ (105.2)<span></span>
</td>
<td class="num">$ (76.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">$ 16,741.2<span></span>
</td>
<td class="nump">16,348.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.35% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.00% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 99.2<span></span>
</td>
<td class="nump">99.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.00% euro denominated notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 678.2<span></span>
</td>
<td class="nump">737.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% Swiss franc denominated notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 654.7<span></span>
</td>
<td class="nump">679.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.125% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">7.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="nump">229.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 560.6<span></span>
</td>
<td class="nump">560.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% euro denominated notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 847.7<span></span>
</td>
<td class="nump">922.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.5% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 364.3<span></span>
</td>
<td class="nump">377.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.1% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 401.5<span></span>
</td>
<td class="nump">401.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.45% Swiss franc denominated notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 436.4<span></span>
</td>
<td class="nump">453.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 930.6<span></span>
</td>
<td class="nump">1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.42% Japanese yen denominated notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 199.0<span></span>
</td>
<td class="nump">222.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.125% euro denominated notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 847.7<span></span>
</td>
<td class="nump">922.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.625% euro denominated notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 678.2<span></span>
</td>
<td class="nump">737.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.50% euro denominated notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 678.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.56% Japanese yen denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 80.5<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.77% notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 158.6<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.55% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 444.7<span></span>
</td>
<td class="nump">476.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.95% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 266.8<span></span>
</td>
<td class="nump">284.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 240.3<span></span>
</td>
<td class="nump">360.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 337.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.65% notes due 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 38.3<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.7% notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 386.8<span></span>
</td>
<td class="nump">412.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 347.0<span></span>
</td>
<td class="nump">436.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 958.2<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.70% euro denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,130.3<span></span>
</td>
<td class="nump">1,229.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.97% Japanese yen denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 66.3<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.25% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.125% euro denominated notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 565.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 591.3<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.375% euro denominated notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 791.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A235NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A235NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A30NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A30NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A10EuroDenominatedNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A10EuroDenominatedNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A015SwissFrancDenominatedNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A015SwissFrancDenominatedNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A7125NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A7125NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A275NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A275NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625EuroDenominatedNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625EuroDenominatedNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A55NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A55NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A31NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A31NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A045SwissFrancDenominatedNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A045SwissFrancDenominatedNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A2125EuroDenominatedNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A2125EuroDenominatedNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A677NotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A677NotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A555NotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A555NotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A595NotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A595NotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A465NotesDue2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A465NotesDue2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A37NotesDue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A37NotesDue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228553773784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 252,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,346,400,000<span></span>
</td>
<td class="nump">$ 16,586,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DescriptionOfDerivativeActivityVolumePercent', window );">Description of derivative activity volume percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member', window );">Maturity Date, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member', window );">Maturity Date, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for debt extinguishment</a></td>
<td class="nump">$ 1,910,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">405,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">541,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">408,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">$ 219,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Payments for repurchase and redemption of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,270,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchase aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due May 2050 and September 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.25% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 988,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | November 2019 Euro-denominated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.625% euro denominated notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.70% euro denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | November 2019 Yen-denominated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.42% Japanese yen denominated notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 22,920,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.56% Japanese yen denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 9,280,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.97% Japanese yen denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 7,640,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DescriptionOfDerivativeActivityVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Derivative Activity Volume Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DescriptionOfDerivativeActivityVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_SeniorNotesDueMay2050AndSeptember2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_SeniorNotesDueMay2050AndSeptember2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_November2019EuroDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_November2019EuroDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_November2019YenDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_November2019YenDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565272584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Schedule of Debt Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Maturities on long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,531.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">657.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">778.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">$ 847.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567587992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash payments for interest on borrowings</a></td>
<td class="nump">$ 338.0<span></span>
</td>
<td class="nump">$ 345.8<span></span>
</td>
<td class="nump">$ 305.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564955064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 342.8<span></span>
</td>
<td class="nump">$ 308.1<span></span>
</td>
<td class="nump">$ 306.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="nump">$ 72.0<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228553707256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 198.57<span></span>
</td>
<td class="nump">$ 137.33<span></span>
</td>
<td class="nump">$ 112.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember', window );">Shareholder Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 230.19<span></span>
</td>
<td class="nump">$ 139.14<span></span>
</td>
<td class="nump">$ 95.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember', window );">Relative Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 286.71<span></span>
</td>
<td class="nump">$ 179.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 18.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 196.30<span></span>
</td>
<td class="nump">$ 135.42<span></span>
</td>
<td class="nump">$ 108.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 161.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares expected to be issued in the next twelve months under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559844584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Assumptions Used) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember', window );">Shareholder Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
<td class="nump">2.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">31.42%<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember', window );">Relative Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">30.95%<span></span>
</td>
<td class="nump">19.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228555343320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase for treasury</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 4,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,750.0<span></span>
</td>
<td class="nump">$ 4,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrustShares', window );">Shares held in employee trust (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrustShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16701-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrustShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228560099640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes', window );">Domestic and Puerto Rican companies contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible', window );">Long-term income taxes payable, estimated timing of future cash outflows not possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,020.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="nump">$ 1,670.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accruals for the payment of interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.1<span></span>
</td>
<td class="nump">$ 196.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember', window );">Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin6YearsMember', window );">Expiration in 6 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationIn12To18YearsMember', window );">Expiration in 12 to 18 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets related to state net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember', window );">Expiration within 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember', window );">Expiration 5 to 20 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember', window );">No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=lly_TaxYears2013To2015Member', window );">Tax Years 2013 to 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PaymentsForIncomeTaxSettlements', window );">Payments for income tax settlements</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForIncomeTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Income Tax Settlements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForIncomeTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin6YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin6YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationIn12To18YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationIn12To18YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=lly_TaxYears2013To2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=lly_TaxYears2013To2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228556579752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Composition of Income Tax Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 938.5<span></span>
</td>
<td class="nump">$ 567.6<span></span>
</td>
<td class="nump">$ 280.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">466.0<span></span>
</td>
<td class="nump">650.4<span></span>
</td>
<td class="nump">299.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(28.4)<span></span>
</td>
<td class="num">(47.3)<span></span>
</td>
<td class="num">(14.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,376.1<span></span>
</td>
<td class="nump">1,170.7<span></span>
</td>
<td class="nump">565.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(977.5)<span></span>
</td>
<td class="num">(97.4)<span></span>
</td>
<td class="nump">141.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">174.6<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(24.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax (benefit) expense</a></td>
<td class="num">(802.3)<span></span>
</td>
<td class="num">(134.5)<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">573.8<span></span>
</td>
<td class="nump">1,036.2<span></span>
</td>
<td class="nump">628.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward', window );">Current federal tax expense, utilization of net operating loss carryforward</a></td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="nump">$ 144.4<span></span>
</td>
<td class="nump">$ 153.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567335512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="nump">$ 2,347.4<span></span>
</td>
<td class="nump">$ 2,560.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Compensation and benefits</a></td>
<td class="nump">634.7<span></span>
</td>
<td class="nump">1,045.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards and carrybacks</a></td>
<td class="nump">463.7<span></span>
</td>
<td class="nump">523.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss and other tax carryforwards and carrybacks</a></td>
<td class="nump">645.4<span></span>
</td>
<td class="nump">488.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsSalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">832.3<span></span>
</td>
<td class="nump">461.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsCorrectiveTaxAdjustments', window );">Correlative tax adjustments</a></td>
<td class="nump">560.8<span></span>
</td>
<td class="nump">404.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsForeignTaxRedeterminations', window );">Foreign tax redeterminations</a></td>
<td class="nump">274.9<span></span>
</td>
<td class="nump">242.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="nump">150.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">275.1<span></span>
</td>
<td class="nump">135.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">477.9<span></span>
</td>
<td class="nump">605.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">6,662.2<span></span>
</td>
<td class="nump">6,618.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="num">(875.6)<span></span>
</td>
<td class="num">(816.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,786.6<span></span>
</td>
<td class="nump">5,801.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Earnings of foreign subsidiaries</a></td>
<td class="num">(1,583.3)<span></span>
</td>
<td class="num">(1,905.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(1,516.1)<span></span>
</td>
<td class="num">(1,465.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventories</a></td>
<td class="num">(596.4)<span></span>
</td>
<td class="num">(623.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid employee benefits</a></td>
<td class="num">(560.6)<span></span>
</td>
<td class="num">(410.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(338.7)<span></span>
</td>
<td class="num">(315.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Financial instruments</a></td>
<td class="num">(303.0)<span></span>
</td>
<td class="num">(216.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease assets</a></td>
<td class="num">(132.6)<span></span>
</td>
<td class="num">(134.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(5,030.7)<span></span>
</td>
<td class="num">(5,071.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 755.9<span></span>
</td>
<td class="nump">$ 730.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsCorrectiveTaxAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Corrective Tax Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsCorrectiveTaxAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsForeignTaxRedeterminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Foreign Tax Redeterminations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsForeignTaxRedeterminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsSalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Sales Rebates And Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsSalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570954088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Cash Payments of Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash payments of income taxes</a></td>
<td class="nump">$ 1,598.8<span></span>
</td>
<td class="nump">$ 954.6<span></span>
</td>
<td class="nump">$ 1,180.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228569347464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract', window );"><strong>2017 Tax Act Toll Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaid', window );">Total</a></td>
<td class="nump">$ 2,149.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear', window );">Less than 1 Year</a></td>
<td class="nump">253.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears', window );">1-3 Years</a></td>
<td class="nump">1,109.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears', window );">3-5 Years</a></td>
<td class="nump">$ 785.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, Payment, Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228555343224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at the U.S. federal statutory tax rate</a></td>
<td class="nump">$ 1,292.6<span></span>
</td>
<td class="nump">$ 1,518.3<span></span>
</td>
<td class="nump">$ 1,105.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AddDeductAbstract', window );"><strong>Add (deduct):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">International operations, including Puerto Rico</a></td>
<td class="num">(458.2)<span></span>
</td>
<td class="num">(297.2)<span></span>
</td>
<td class="num">(242.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(100.5)<span></span>
</td>
<td class="num">(97.9)<span></span>
</td>
<td class="num">(108.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign-derived intangible income deduction</a></td>
<td class="num">(86.7)<span></span>
</td>
<td class="num">(71.5)<span></span>
</td>
<td class="num">(15.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(73.4)<span></span>
</td>
<td class="num">(15.5)<span></span>
</td>
<td class="num">(111.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">$ 573.8<span></span>
</td>
<td class="nump">$ 1,036.2<span></span>
</td>
<td class="nump">$ 628.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AddDeductAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Add (Deduct) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AddDeductAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564504808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,551.9<span></span>
</td>
<td class="nump">$ 2,108.6<span></span>
</td>
<td class="nump">$ 2,034.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">310.3<span></span>
</td>
<td class="nump">225.6<span></span>
</td>
<td class="nump">187.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">310.8<span></span>
</td>
<td class="nump">425.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(52.4)<span></span>
</td>
<td class="num">(100.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(38.5)<span></span>
</td>
<td class="num">(72.0)<span></span>
</td>
<td class="num">(260.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses of statutes of limitation</a></td>
<td class="num">(49.7)<span></span>
</td>
<td class="num">(41.7)<span></span>
</td>
<td class="num">(161.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation', window );">Changes related to the impact of foreign currency translation</a></td>
<td class="num">(66.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation', window );">Changes related to the impact of foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,798.3<span></span>
</td>
<td class="nump">$ 2,551.9<span></span>
</td>
<td class="nump">$ 2,108.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228570193240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="num">$ (26.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559771160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">$ 18,225.5<span></span>
</td>
<td class="nump">$ 16,251.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">369.2<span></span>
</td>
<td class="nump">325.5<span></span>
</td>
<td class="nump">$ 250.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">337.8<span></span>
</td>
<td class="nump">425.8<span></span>
</td>
<td class="nump">486.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="num">(564.3)<span></span>
</td>
<td class="nump">1,563.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(630.1)<span></span>
</td>
<td class="num">(587.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailment loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="num">(173.1)<span></span>
</td>
<td class="nump">245.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">17,565.0<span></span>
</td>
<td class="nump">18,225.5<span></span>
</td>
<td class="nump">16,251.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">14,579.0<span></span>
</td>
<td class="nump">12,858.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">2,458.1<span></span>
</td>
<td class="nump">1,802.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">318.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(630.1)<span></span>
</td>
<td class="num">(587.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="num">(122.2)<span></span>
</td>
<td class="nump">187.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">16,416.0<span></span>
</td>
<td class="nump">14,579.0<span></span>
</td>
<td class="nump">12,858.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="num">(1,149.0)<span></span>
</td>
<td class="num">(3,646.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net actuarial (gain) loss</a></td>
<td class="nump">3,908.2<span></span>
</td>
<td class="nump">6,515.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service (benefit) cost</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">2,770.4<span></span>
</td>
<td class="nump">2,884.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">1,753.7<span></span>
</td>
<td class="nump">1,601.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) loss</a></td>
<td class="num">(86.1)<span></span>
</td>
<td class="nump">142.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(79.3)<span></span>
</td>
<td class="num">(75.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailment loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">1,663.8<span></span>
</td>
<td class="nump">1,753.7<span></span>
</td>
<td class="nump">1,601.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">3,227.0<span></span>
</td>
<td class="nump">2,768.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">202.6<span></span>
</td>
<td class="nump">539.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(79.3)<span></span>
</td>
<td class="num">(75.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">3,361.4<span></span>
</td>
<td class="nump">3,227.0<span></span>
</td>
<td class="nump">$ 2,768.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="nump">1,697.6<span></span>
</td>
<td class="nump">1,473.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net actuarial (gain) loss</a></td>
<td class="num">(497.2)<span></span>
</td>
<td class="num">(349.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service (benefit) cost</a></td>
<td class="num">(117.6)<span></span>
</td>
<td class="num">(177.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">$ 1,082.8<span></span>
</td>
<td class="nump">$ 946.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564092952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">$ (1,954.1)<span></span>
</td>
<td class="num">$ (4,094.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">668.5<span></span>
</td>
<td class="nump">299.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(68.3)<span></span>
</td>
<td class="num">(67.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">(1,749.3)<span></span>
</td>
<td class="num">(3,878.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive (income) loss before income taxes</a></td>
<td class="nump">3,919.5<span></span>
</td>
<td class="nump">6,530.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">2,770.4<span></span>
</td>
<td class="nump">2,884.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,910.2<span></span>
</td>
<td class="nump">1,697.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">(204.8)<span></span>
</td>
<td class="num">(216.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive (income) loss before income taxes</a></td>
<td class="num">(614.7)<span></span>
</td>
<td class="num">(526.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">$ 1,082.8<span></span>
</td>
<td class="nump">$ 946.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567334440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease', window );">Defined benefit obligation, period increase (decrease)</a></td>
<td class="num">$ (750.4)<span></span>
</td>
<td class="nump">$ 2,130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense under the plans</a></td>
<td class="nump">$ 167.3<span></span>
</td>
<td class="nump">164.3<span></span>
</td>
<td class="nump">$ 145.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets', window );">Percentage of global investments in plan assets</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Total accumulated benefit obligation for our defined benefit pension plans</a></td>
<td class="nump">$ 16,440.0<span></span>
</td>
<td class="nump">$ 17,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected future employer contributions, next fiscal year</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Plan assets, target allocation</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Plan assets, target allocation</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228560140344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate for benefit obligation</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate for net benefit costs</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase for benefit obligation</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase for net benefit costs</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets for net benefit costs</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate for benefit obligation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate for net benefit costs</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets for net benefit costs</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228556522408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 3,360.3<span></span>
</td>
<td class="nump">$ 15,770.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,542.8<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,542.8<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="nump">2,699.4<span></span>
</td>
<td class="num">(157.1)<span></span>
</td>
<td class="num">$ (970.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">631.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">641.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">669.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">686.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">707.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">3,919.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">973.4<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">2,532.0<span></span>
</td>
<td class="nump">14,682.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">973.4<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">369.2<span></span>
</td>
<td class="nump">325.5<span></span>
</td>
<td class="nump">250.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">337.8<span></span>
</td>
<td class="nump">425.8<span></span>
</td>
<td class="nump">486.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(949.3)<span></span>
</td>
<td class="num">(901.5)<span></span>
</td>
<td class="num">(839.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service (benefit) cost</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gain) loss</a></td>
<td class="nump">487.7<span></span>
</td>
<td class="nump">396.3<span></span>
</td>
<td class="nump">284.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">249.6<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
<td class="nump">190.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial gain (loss) arising during period</a></td>
<td class="nump">2,072.4<span></span>
</td>
<td class="num">(663.0)<span></span>
</td>
<td class="num">(1,461.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Plan amendments during period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax', window );">Curtailment gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (benefit) cost included in net income</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Amortization of net actuarial (gain) loss included in net income</a></td>
<td class="nump">487.7<span></span>
</td>
<td class="nump">396.3<span></span>
</td>
<td class="nump">284.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency exchange rate changes and other</a></td>
<td class="nump">47.2<span></span>
</td>
<td class="num">(71.5)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="nump">2,611.5<span></span>
</td>
<td class="num">(335.9)<span></span>
</td>
<td class="num">(1,158.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">89.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">89.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">93.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">93.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">94.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">477.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">223.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(146.2)<span></span>
</td>
<td class="num">(158.1)<span></span>
</td>
<td class="num">(144.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service (benefit) cost</a></td>
<td class="num">(59.6)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(62.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gain) loss</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(120.9)<span></span>
</td>
<td class="num">(136.1)<span></span>
</td>
<td class="num">(111.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial gain (loss) arising during period</a></td>
<td class="nump">142.5<span></span>
</td>
<td class="nump">238.8<span></span>
</td>
<td class="nump">246.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Plan amendments during period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax', window );">Curtailment gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (benefit) cost included in net income</a></td>
<td class="num">(59.6)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(62.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Amortization of net actuarial (gain) loss included in net income</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency exchange rate changes and other</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="nump">$ 88.0<span></span>
</td>
<td class="nump">$ 178.7<span></span>
</td>
<td class="nump">$ 188.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228554435624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Fair Value Disclosures) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 16,416.0<span></span>
</td>
<td class="nump">$ 14,579.0<span></span>
</td>
<td class="nump">$ 12,858.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,361.4<span></span>
</td>
<td class="nump">3,227.0<span></span>
</td>
<td class="nump">$ 2,768.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember', window );">U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,325.4<span></span>
</td>
<td class="nump">737.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember', window );">U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">124.7<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember', window );">International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,722.7<span></span>
</td>
<td class="nump">2,635.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember', window );">International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">180.6<span></span>
</td>
<td class="nump">162.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,496.0<span></span>
</td>
<td class="nump">4,301.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">102.2<span></span>
</td>
<td class="nump">101.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember', window );">Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(1,376.2)<span></span>
</td>
<td class="num">(1,670.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember', window );">Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">611.0<span></span>
</td>
<td class="nump">631.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember', window );">Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,046.8<span></span>
</td>
<td class="nump">2,661.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">275.4<span></span>
</td>
<td class="nump">229.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember', window );">Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,816.4<span></span>
</td>
<td class="nump">2,844.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember', window );">Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">317.8<span></span>
</td>
<td class="nump">223.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,166.8<span></span>
</td>
<td class="nump">2,204.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">630.3<span></span>
</td>
<td class="nump">558.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">36.2<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember', window );">Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,143.6<span></span>
</td>
<td class="nump">1,879.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember', window );">Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">106.1<span></span>
</td>
<td class="nump">157.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,728.4<span></span>
</td>
<td class="nump">1,915.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">147.5<span></span>
</td>
<td class="nump">141.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">430.4<span></span>
</td>
<td class="nump">476.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">40.9<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">815.0<span></span>
</td>
<td class="nump">1,102.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">47.7<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">363.8<span></span>
</td>
<td class="nump">259.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">103.2<span></span>
</td>
<td class="nump">60.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,501.7<span></span>
</td>
<td class="nump">2,079.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,290.0<span></span>
</td>
<td class="nump">2,331.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,356.6<span></span>
</td>
<td class="nump">3,179.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">80.5<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(1,376.2)<span></span>
</td>
<td class="num">(1,670.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">250.5<span></span>
</td>
<td class="nump">262.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,166.8<span></span>
</td>
<td class="nump">2,204.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">263.2<span></span>
</td>
<td class="nump">301.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12,170.5<span></span>
</td>
<td class="nump">10,542.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">922.4<span></span>
</td>
<td class="nump">749.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">893.7<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">83.7<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,907.7<span></span>
</td>
<td class="nump">1,533.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">132.9<span></span>
</td>
<td class="nump">104.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,136.8<span></span>
</td>
<td class="nump">1,119.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">349.1<span></span>
</td>
<td class="nump">354.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,046.8<span></span>
</td>
<td class="nump">2,661.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">275.4<span></span>
</td>
<td class="nump">229.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,808.8<span></span>
</td>
<td class="nump">2,827.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">317.3<span></span>
</td>
<td class="nump">221.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">248.3<span></span>
</td>
<td class="nump">286.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">779.3<span></span>
</td>
<td class="nump">1,499.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 63.5<span></span>
</td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559592904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">154 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>BRL (R$) </div>
<div>patent</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>site </div>
<div>plaintiff </div>
<div>lawsuit </div>
<div>claimant</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>patent</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jul. 31, 2012 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup', window );">Number of sites jointly and severally liable for cleanup (fewer than) | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ActosMember', window );">Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfClaimants', window );">Number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases denied</a></td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatic Cancer or Thyroid Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatitis | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Ampullary Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Los Angeles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Southern District of California | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Various State Domiciles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Various State Domiciles | Product Liability | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases denied</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_InsulinMember', window );">Insulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LitigationClaimsDismissedNumber', window );">Number of claims dismissed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_AlimtaPatentLitigationMember', window );">Alimta Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm', window );">Limited initial market entry, supply term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember', window );">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember', window );">Epp v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil | Employee Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 950<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LitigationClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation, Claims Dismissed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LitigationClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfClaimants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Claimants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfClaimants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ActosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ActosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ByettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ByettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreatitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreatitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_LosAngelesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_LosAngelesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_InsulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_InsulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_AlimtaPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_AlimtaPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228565706280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 5,825.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">1,795.4<span></span>
</td>
<td class="num">$ (256.2)<span></span>
</td>
<td class="num">$ (997.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">357.9<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">214.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">2,153.3<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(783.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">9,154.8<span></span>
</td>
<td class="nump">5,825.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">(5,740.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">(5,729.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,343.1)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember', window );">AOCI Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">2,153.3<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(840.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,427.5)<span></span>
</td>
<td class="num">(1,678.0)<span></span>
</td>
<td class="num">(1,569.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(122.7)<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
<td class="num">(46.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(62.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(122.7)<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
<td class="num">(108.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,550.2)<span></span>
</td>
<td class="num">(1,427.5)<span></span>
</td>
<td class="num">(1,678.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(22.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(11.9)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,751.0)<span></span>
</td>
<td class="num">(4,638.6)<span></span>
</td>
<td class="num">(3,852.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">1,823.4<span></span>
</td>
<td class="num">(379.7)<span></span>
</td>
<td class="num">(967.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">2,167.4<span></span>
</td>
<td class="num">(112.4)<span></span>
</td>
<td class="num">(785.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,583.6)<span></span>
</td>
<td class="num">(4,751.0)<span></span>
</td>
<td class="num">(4,638.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(332.7)<span></span>
</td>
<td class="num">(211.9)<span></span>
</td>
<td class="num">(238.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">106.6<span></span>
</td>
<td class="num">(133.8)<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">119.7<span></span>
</td>
<td class="num">(120.8)<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(213.0)<span></span>
</td>
<td class="num">(332.7)<span></span>
</td>
<td class="num">(211.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations | Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">84.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228564421384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (695.3)<span></span>
</td>
<td class="nump">$ 200.9<span></span>
</td>
<td class="nump">$ 151.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(136.2)<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
<td class="num">(18.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(532.0)<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">184.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (31.8)<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="num">$ (7.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228563889240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">$ 51.4<span></span>
</td>
<td class="num">$ (195.5)<span></span>
</td>
<td class="num">$ (56.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">6,155.5<span></span>
</td>
<td class="nump">7,229.9<span></span>
</td>
<td class="nump">5,265.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="num">(573.8)<span></span>
</td>
<td class="num">(1,036.2)<span></span>
</td>
<td class="num">(628.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Reclassifications from continuing operations (net of tax)</a></td>
<td class="nump">5,581.7<span></span>
</td>
<td class="nump">6,193.7<span></span>
</td>
<td class="nump">4,637.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Reclassifications from discontinued operations (net of tax)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3,680.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Reclassifications from continuing operations (net of tax)</a></td>
<td class="nump">357.9<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">130.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Reclassifications from discontinued operations (net of tax)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">84.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications for the period, net of tax</a></td>
<td class="nump">357.9<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">214.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Amortization of retirement benefit items | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">435.5<span></span>
</td>
<td class="nump">338.3<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="num">(91.5)<span></span>
</td>
<td class="num">(71.0)<span></span>
</td>
<td class="num">(48.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications for the period, net of tax</a></td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="num">(55.4)<span></span>
</td>
<td class="num">(55.0)<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">490.9<span></span>
</td>
<td class="nump">393.3<span></span>
</td>
<td class="nump">286.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="num">$ (51.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228567115688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other - Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 339.8<span></span>
</td>
<td class="nump">$ 359.6<span></span>
</td>
<td class="nump">$ 400.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(25.4)<span></span>
</td>
<td class="num">(33.0)<span></span>
</td>
<td class="num">(80.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment gains on equity securities</a></td>
<td class="num">(176.9)<span></span>
</td>
<td class="num">(1,442.2)<span></span>
</td>
<td class="num">(401.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">252.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of antibiotic business in China</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(309.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(289.7)<span></span>
</td>
<td class="num">(251.8)<span></span>
</td>
<td class="num">(209.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(51.4)<span></span>
</td>
<td class="nump">195.5<span></span>
</td>
<td class="nump">56.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 201.6<span></span>
</td>
<td class="num">$ (1,171.9)<span></span>
</td>
<td class="num">$ (291.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140228559623176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3,680.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,318.4<span></span>
</td>
<td class="nump">24,539.8<span></span>
</td>
<td class="nump">22,319.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">3,680.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,680.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm', window );">Transitional services agreement, term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=lly_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Discontinued Operations, Disposed of by Sale | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Disposition of ownership interest</a></td>
<td class="nump">80.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lly_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lly_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>lly-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20211231.xsd" xlink:type="simple"/>
    <context id="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib999762467224e169f22d930370a98cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id219efe1b1d547adb5713a0601859853_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5badd592a21c4a338eed272300758c16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i822be716a0774b71a20856f8866c402a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i333cc430d5f24f45a3a99e2e1060db9c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id1a06f9ea4dd4dcabf049aeb8fab3e59_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5593b99da6745cb9b411b2031bc3e15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i350adfc8d85547d9a3c4e39ba5c1a2fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id11a42da50f242f2a8b81a0a0173884f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6ef7ac05a14478b89f3032c4251b7ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4663754a3a444cb9830c13af3caf35bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18a38bac34cb4ca8800ba1a18314f494_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica0f6e15b180491b9202fefd783ba908_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib49b2b7f42884738a47622d8db6c8d71_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i71f2ebcb04234bb78d53e95c789a7b18_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i386013c272b445c8b61ea4782a574cd9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6da9dd99174a476bbcf317f5a6d40e2f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1f786d93b75241c98d9db2267b3c5983_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5d195254fb024cf89d97aaed06aee2a4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iafb85a614be34013a6354f3d76b46357_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia85d124a50b14e73af531af45079e36c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id73859b7dcd34e62805fa367251b795b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i27c5a45e3bbf4d98a9b6fa76889230d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib74aad145fd948ae9241828f24c78548_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e3201d8c6744198aed86ef435de4ee7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i442a597afbe14853a841ac8d37aa9e20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ad901c3559244039c17a109cdaa8bf4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b908b0dc9bf437c83b6a218c5c17f88_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40e50a9ab65b4a50b58927a520657bd2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ed8c31b73e04315b4155a37149b9553_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24f4e379653645eb9685399ff3793535_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76aeae647cb549b29344d42e8dcaf22e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i844c6baec2a24ddfb0175699e7c9dc89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62a1f40609cb46c88a55f8a58cc0d213_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98a5b8a498064844963780b1fa864865_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee2e8d9c52ce423296c40435172ba45f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic59cb920c729498ca310e03243606c6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1cc336a64ff4c18b6d2f64e83fb7ca5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6461da26ed149deab96c87d5cfef978_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6224d7ff3d6b43fb824c0b8619fad9b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15da3dd702544a0897dc45c712757909_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i075446bdf9684175b09f4719c83305db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5960a9f72a304f2d91d83b22d8017bcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39610d1c5d9d46bc880d62462c72fd8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8449ae740dff423f9a21a63ae89c9c0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a0bae0b2bc940ec8f928a12995eb037_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25abdb96f76b4a36b8f4b2e517289462_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a0ee22589c346b4ba844a54471306b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaa5fbd37ece44598769646bdacd67e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2161fbcc13a94af3a14765cc6ce775d6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie9ba1030bd04458783b9caf2f17c3b41_I20190311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lly:EliLillyAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-11</instant>
        </period>
    </context>
    <context id="i99ba0120ed084c1da3c0cb9a06a3535c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i595bde8d325b4f8cbe525ae5a8cc043a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bbc4ab2a1ab4437a863acf75b60865b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02e084561da84353a68fc13b0b1f1065_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id78db9bb959f4a65b59c065a865101de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i768c5436d8e0411f87860a079a65368a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if66a9d0bc8c447a7854e1d121fdd3fd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i447315375734437a83fd432f1d82adc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b153236a1d746dc8a5d74cfd7f107eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d45ee2631a0458287be066c530c6943_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4cb03da6839043d3aa73f8b83497cb73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2dc431125a344f3a63a4412d26d8a50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52a79ebd44a14e7d82fceef0898c5849_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b94e10336ae4cbb8c40c7c7092d7840_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie2cff9b89ea946558f2bb3511379631b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8113e64d76f847a682da0b64b7063dbe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ed77f1070fa4a9ea80eb29d531c5ba2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7cd4eb0f13b417caac242fba3efbbb7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd89b253c657495cbf93efa71c826c3c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29dffcb1c75e447186d0449682c8fa4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba3938017a09480e9b6c89ec4a92190a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id826775b3fff46ea93386f9abf618ef5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i894124740513476f9e7e298369f85ae6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i61882a82645e44f0a5cd7626f0f4dfad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f18bbf764ba4e309b4033e323311922_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d1ace1a30ff430eaa6398df95d6adaa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46ba46a0dc564f5784eafb2834664c13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib713ca7d34c54a46bedf84120eebdddb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bbd7358f9a44cc88fca6a40a7f752fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9cd2cb43377431bbd784ed4ddbb902d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id79b2564a4684bfa9b4e8e9903612823_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6229ebed99384ddbb1c1e41cca2e59c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a64281a74ce486b8871c0204881291e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4531e2c9cdf04fb883d1a76bcdaa75e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ba5f87a65a34af5bfab01d9bc64e2a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f8386db744f4affa13508c19b5df3ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcb37f86b5bf4fc1b82f022c4ace7930_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i18d1e272d16d4280b14162a8a5ae7248_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49f67b8b79d7454aa2e6e8e2b5d56679_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a59b1db34b94c5b98790e3b0b011098_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i90bb2847aa5f47228628aa3e17c89913_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b7e8500d4804c3c92d4e3b21e6f0979_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cde1cb13d724c348cf0aa37a2ee59fb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab22f8425aa742719232da9a982b98dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6aa9d24bc7c349259210cb5ddc15b20d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib40488cc77fe48a9983b2d76229a1dcd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf934f62efbd4bdc9ad148a1e8d39475_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if84b38b1fbdf4b4baafbe6846c60b875_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e50f47eeaad4777a025c7b8314d19ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c03a2130e8e4b15b3e45e071937aca3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i51b3bf965c6b4aedbc71cd1b54cc2247_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23b8fc33095f47ce91f0fb991ada922c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab862c66ad8f40b58f51d2e670bc2d65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefe81546f9364a4d9ebf816f2afe77ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c49328469d94560909e62a300fb15cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5845ce666250472aacd23b84c3e4c403_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4abe14ed7d746c2a4d0112b075ac9cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4df3bf3464b489caa60ad6df0783bbe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5174aeaa35294f1097a209bd1b7845b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icceb1eff5cdd4984b54eff367696ca4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64371009fdca47a9bea3857741540621_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bc100215d1f4fa9816b460de125dfa8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i243440aa810243239953f41351bdcf24_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a3a7bc030e446fb82edf9a7f6f92844_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia101d6eca8f243bb98e9561330ac20b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i122fb9e7cbb34242a643302cb8dac50c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec68387645db4b4f92d21db543507a42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idaa12801a6f24c04b0786f055da95eda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d7b63b2d4824ebd8b98d1a3e0bec191_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49adc5d81365456dacca8f1348186c71_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4404efba44734e41af51f0f6e510b480_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba7197e9a2124fe299c14e4eaaecce76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87c95be326e745df83b5161e9b90eb8b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i54524c6278e14aeba0959cc606b06515_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib118e8524e0a4034a5733e9334f28db0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19e0f9785fd343efa0193891217b008a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if79c5294ee4f4ef681fd908091186ae4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ef513531c7049ef9396372c3a862b18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i279a034c277f4a1ab4e300b899b21d54_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2570b2af4dc0432b9372301788fad363_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3338ad8173349e988242ec0e6f04e1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ffe64f002d641c6a9b980be3ed01dcc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie17e3c0297594484b5fc11d78d43ee29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03d777c538b14159ac60b1362f07fb22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if890ac36822f469d8ddea5dfd470c95c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id361aece11434b678eaf1e55548add4a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifabd8a9ea7f3489f96d642962db788ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2245dfc68e249d0a3b540ce6711b4d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7abf976b41e94d6abcc6e5fdc45e8040_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i098a3086a33e473685588ae2026e5f1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1126ae549787451f9bb5e56ec4579eac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia458924680af4b66841795f4b0921155_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee79c787a98549fbb814a8a2d8423bbf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c16c6e39bc54a20a076eddb68a38dc3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1df57ca285b34436ad72599838d20b63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cd23ae2c169427ea701232617ba23e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72c6dd0e87a04241b80ae67b85eaac34_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia145809c4057498dbea07cefe5b3af5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89a4f3931810408b8426d88ab25f2543_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7563fab9a921489c8c33ab7ddf46db30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59d2921396f2408f81b37c768c975994_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29c6d36f572740b5958ea1e5a869f0e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b26b6ce6fb747bbb9e0775792261b89_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1aeb1d3ab83b4f499609731a48e300dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i786023411d90417782c4325faf5d0199_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaeb4acbcaa7a4e1d9a4bf8429bc4c60f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieea541b5215c48e7be8cfa4c03730bb4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76285bcbd8264a4d88f79ec61700d427_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i690e96d0ed8f4be1b474dfd0143fec7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic78854061d9a4a8094725b7186b33c24_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i566b619706fc4300afef9a4b18065698_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf9c8432ad704f298370bae297a97816_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i948ab3ff4ae849d798539c9be859e02d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9ad9e5e91ec46c58d5c3d879543ad79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ddfd937e21f452faab9486fd44a1792_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id12a0757fc294a8a9f3e7f4e96ad2b79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32a6e3cb90de4b7fbc1a26ec8413acad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8356524214f4293839013dae33b408e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82c4fc8c4be9466483d1f9c47e96410f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a7951f7fd96467c823ac40837825eac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa237d56f2a04c60baf2abac03b59800_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81e4b2fc062e409eb90fc22b3ecac117_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85af31eff3fd4bcfbe2f8093e081a909_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ec77e9a200a45bcb3e18647fab83ba0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i047fada9bd1a4eed91bd54b125f10f2b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i905d5bb1f6a644aa9480da295c712847_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41e35fbd704c46248a24dedd85300ea9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icaa7c39af28c4bc5993971a70aa09d60_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50f4f924f3ad4797bf23e88d55c7d012_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e9109389a244076841dca316010ff8c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ca2f0cae6db46e1969f249939f14190_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d55d846ec5c43f0859bff0869b8d85d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib62fbafb830b45f18b06599b0a020555_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2370ca55475d4c2392256a9363409c09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia73989eaa96b4c098c63cf6dfabe07da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ba680c3a60c4c94b757bfbbdffadfcd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib446da6700c5431bb4dfa20d113e3796_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1c8904967084c20a526f2bea52ae9d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i476342288dcd4c35aab4ebcef726722f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9c18e45789f14afab755bf84d42ee66f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f55af49432141a9a5b2a16fc58b0038_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e993b0bc60d4c04b3d713bcaf91ff26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id444acee0b204bdc95711361bd992be1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2cf1f9d51d284edaa1b7ef76c6479ef9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i070feb5d9c28438b8531680d930b657a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff9628b9ed2749ddae9bef49cb39bb99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i702fa5c2e0c34c519b69e8801bee2eea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc40e99c9fe5483eb7a04d9734858a85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7c20349b02348d9bb87dc176d930352_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia55d7bb83bed4b79933fb93ad8dc8ce2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia61dcb4e367e49e69e147967d3466245_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i10c3070f248e45bfb4c8b53127810450_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i027e829cf3a94fdb838086c03633207d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i926e2ce8db484a19b6686864f7dce2d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16730972cec04bc9b31ee8293f90b16f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ad2157f26744eac8a277f68ec6e9f75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93492794bd9d4ade882f1194e9f5d0c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i86210214b8d04600afad8c88d79dd48b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i657903dac3a84f118dfd3c2d2d0b4f45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i925c14ebf59d401e90944a793809c61c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6718cacc2a5a484ea0fe4ebcd8d0f0a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e3108d4822f4200ba775774e2c6d17b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81bc73f6221746d8bf84498f9556f8ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc2d4950c43e4823b068eca9c847caf9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c2d91be0889414c97992735d48a782e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07e5b3258a5645c4b9f053f742b53b7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3650248e7a546aba24f1190e20ee44c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib423ef1778dc4914ac8a36e61d82d79e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec20cacccc854ae999285ef6ae4bf265_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9166c1982686472cb2be38f81d2bdc5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i099a16e9db4d42d3ad065da66bb72352_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee0929e27d1f44afae4a0ec0efbc7d3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a0bf62c9bad4a789c15447bb315106d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b796c46dd2848e0bcfe542ee2f9ea37_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6126155439840c494a0d59a4c901ef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15079d32a6af431cbe2362c300da4d30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8495e35a20ac4d5fa299dbb1a540308e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2101347099ea4c55aa493f4b7e3e75f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f9fdd9cfde64d12a304f9907a75d463_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8243736e267647a7a63b74278bfe227c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69102089b51742579ff9ad41273b6e5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea3630db9f3642a0bf1262ba09e339ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88e4d52b72a54afba956fc68e8d09cb9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i034bec2524a34f378ecb3ac05b076873_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i364bef469c6b409eb2e05dec7fa48bec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00a1ac288cb249769f4020a76446066e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bc25daef9774ec8ba96201a6d17c48f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id884085efd444ed5a42695f06ab42933_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic25b2eb90e2f49aaa97ed46e09ddedc5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4fec7ee5a58242fcbbf477d186e1a542_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81ed3edf12174b94967056072504bcad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07c8ab2aa0454112b333a7f6f112c62e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82e0bdec56134029ae9680e3db1ec79b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie1e356ee1b9d440e875c1efc62a80b33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52fa75e3f5284c179ee6b4ab5243be53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibad81ef38f2d4e57bd00e5dd2c0a168f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab8591d057cc4eec92033c36fb05fd49_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic0df35c8a12146d0bcdb02fe162f2cb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74307f9a9f5f43698c550cd45a1c8b8c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib51a0dd6c879443684c594e3c15c31cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if65921f0a4824d3b8e3297260e7cb19d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3c951e01e904d87b87e2c491d7f9dcd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04193007085b41a38db99637f0c0d6af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d224ea9b86e4818acc1bd5468570078_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i164330216f6841af817f8d04691a5b0b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if13e5ce657124ce698dc637219f87ea0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e7e25f558c047e4ac74c9e031a5a865_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i028aeea4c2e64264850f271d8ffb0481_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd215bb90d2941cb94a58ff2fd939bbe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cf899c4538e4ec6b299cfa3908d15fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98f3427b27d748f5ba11f0d766ffe5d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bb2e32e1ad2454892693138d44916ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id558c6364b764995aa2b6842b75cf8db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96cf3dcfa7cc4f1396ca4bc3f3f3bf8d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i636eda8cc422414eae95184d5ae5708b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i4d886a39796d42f5809576721f051d0f_I20210122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="ie98abec6e97245e78d9fc27b845e6067_D20210122-20210122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="ia99148e294d448a3b8022b7ab548973c_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="iaef95a45c6244b97901afb132b2e8ede_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i0e8e1b30058b460e98b4ea10699f32c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i800aa827b6e345e58b4aa9e11e49e882_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="id65135fb98c54b32b997c038034eab2f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:SelpercatinibLOXO292Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id02a7381a3be4e38890430d12e20673b_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i600f4904f99849f2ad5f229699acc149_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:SelpercatinibLOXO292Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="id7d716a1f4534165962c18f76f7af45c_D20190215-20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="i9950f4e9a0354b2fa627384fb3ed7958_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i2670d0faa7f348ceb8cb0477e2bbd7ec_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="id7d1e0d5a52d4681bade2958b5aa1a4c_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i6feddb3904ec46578edf8428b7b289a5_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20656f42f67e4b3ca3072208a9060499_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MiNATherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="iec4ebbe67054429582ac383c3ca59a99_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProtomerTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i1f63838d417e4d52a843ed3cdc791134_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:KumquatBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i9fe5e5a2099d4c20964ac1055881f0e0_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:LyciaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i625c2c9631a44ce4add09fd63dbb08e4_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProQRTherapeuticsNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bb6a0e595d94643bec576021c87b042_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:QILURegorTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia358c590fff34220b7173f72a36ae251_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:FoghornTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44a67f18c7ea48ea95d82f120474b9f0_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:EntosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2bb6fc6a416848fea9d309fc8093b580_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i00fc657efa784f17b8ef30a51ea8a755_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie824a9d4024d4da5b3b95622f0f82015_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i6d8c7a108f87404bad726fa03ba1f4b3_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ifba7dfdc0b6a4b679a897b2cc2ae3a36_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:EvoxTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib187355b4ba34c879321b64031638699_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i01c3dbabca1c4ca8b1462ca74374ab69_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:DisarmTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i14514c12fe4a4a7eac789632d8162634_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:FochonPharmaceuticalsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="idc045dfe17704aa1bf6a4e76fc728f04_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65311cc8393345fda909ba57dd56598f_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ImmuNextInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id64076c56e50481bbcc81b0f17931613_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AvidityBiosciencesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i8d547a0ec4c74b6b9cc9b20749c49656_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:CentrexionTherapeuticsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i86ed8956b9f74476a74b29069c13a878_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i15ffbfb3b6be4f91b268691cc52236e2_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="ie1f10220b2a3487cad57915da408086c_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if9afc4eaa56b444c8eefdac063ce4a28_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i8a5d6173c0cd4f7ab337f6b352f5a84c_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ia3f8e0aa5a644441a2554b382567027e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8fafa3bd40547eda95f4f50a6dbab51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77ebe26c48d94c40a9b534da5ed3e8d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i853d77493c24496b99d5233e605a2605_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9c6112bfb3344d99c577b0fc24fd405_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa9ef0f44c884bf695c4900d1d6d8b9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied98305e265a49d9bdc89506cb9d5cd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i136e92857ae343079e9fdebb19210eb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i399d8f462fc045509a0e309187f2f20c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9c6636c6e8b4149a436c5c7f6ae3d8f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i486722122165416c854ef981a6e4ff97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb15db3b22d7456aa9d475cfe3645e22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d89303e28444753a87b86f2491e9dfd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8434b474adc4712945fa8b15221a062_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34c1f715e391472e9c4295cbc73dfcc5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4fc1b15a414543789a445369b1f1c319_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie508b8edff5e4d49ac5daeb3e44ee7d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fa8514e03e541bab9bb427c8c8e408d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05b90b30620c4805b8c68b6df7e498b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id33d1a73df7248168e83573873688d81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60f74e83d5644e2c8fbb2e5c78bfd650_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ffacbc5450e4178843413354209aaed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bb740f8f8fb49248e01e2ab80d6ae9d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i249d33d5a06a4082a59829e958e69da7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48acf53cf4c149ba854e91d6ea82b05a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1a83cd101f14432a8f149d6a0e602f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9a3812ca43742f1ae973a2b31a04adc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief25801843e9467799271bdda2e99bd9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e413d56e5d84f349849637c0f978d4b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4e4260516b4243cab0755138b1cb1e20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96a4b9d553f8498a8d8c5c1b0148aee5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89ae01d552e14307ade61a2e8ce4818f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8ec11f13ec44ec886a4d089e6954497_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfd825e2456741c6b9498e5c19f301ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42cba64a30364790b8eb1eb2ae66c5e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45283f4c7fdc40bf9a23a33c5df93208_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaf2be9f580f44fd8e954526bb36e7f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e72a7d25b8a40b99e28b009e54e5649_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7bd696f56304ea8940548378684aacd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponInitiationOfPhaseITrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7efe9a1356e9485983eeb603c301d153_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76e71ae8b5064232b5cf8e0340ad9913_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04f34fc75a9044519a55f0a841ded99b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic28ad2006eb14d37878a695f14e7352c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20261b7a34e44eef9f687c2383ca625d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fe06c36179f415f8d86b66fba575560_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia33be6c87c2c473f9a400403f197ba1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf59c02dd99c40c1952252de92c7253e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62bec06499364dfeacd40d1298f61c82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6cb727e20f143faa3e3a38b9dfff0c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacadc29206d84c3fa7fd83b205a66414_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13cf07612b294643a8bc48b8588f1f8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7edcbbba5dfc46c38e6a76c687dd5837_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6411281e97d94731863b39b1923f21a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bc442230d5c4382b155b07c92135617_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3963f62afd047ba88fb5cbe40c1d155_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8de4d107e8a743a9aaf08d126d7c581c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd8aad08f18b4154898d2ecd801df8d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e0f3057dc4a4dd1ab06ea189bd4a2fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c3cc7a81d924d63acfe2aeb96bbdd40_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1125c3d05584e4488d02c8aa1c758e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i172c281918af4f27986511aa04ee513f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d4ac65858f54342b86be7fc605a4ffe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b70f245d0994606a77553c858e70e2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bf867828fd8402cab098ff96e91c5b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i231f5158b0a54e01b77ad8a5c7af7e1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idea923d9282a47d6b6affe9918bcfb47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iccdf591423b44978b57ec5e6980efa0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87e3b85955b94cd59588c3c75b0d84c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2733925e7174df2a7294f9cc18f29d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48d907c6902548ad9042a61cf12bc57c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1034a9c1ab4a439abf5f9b58a0013acc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3c7e5f9100c44eb48c6a8b02af879981_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i242bd07c45d542379d0e0d769eb01235_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f207cd4c10c40c58e5e98e94e0977fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic01d3d2786ef48c7b3a9a7abc2347162_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ca22a25490746b2a01afb869b9c9451_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cacf599a2654a73aeb964f7e22ed6fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd392ae258dd4c8682df0b88169ff443_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a9309322cbf4299ba4880f01282b66d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6c1fe3ce37c429a96afdfe79afa5af8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id782339ced69430ea75a51f82b17fa9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5366462e14a747678162a92e578671fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i873a6f3b952448949d4f521a40683c05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5af1d3d2625a408dbe57ea38651c828d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic77f19b3dbbc4c1d80c04d076b72b774_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2626088ca7db42dd977c6aebdf6b049b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5386daa8d43b4f8fbff09fb65341a6f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87d69d72b4fd4b7b89d28f60a414253c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1ffc73d6c5b44b9afdbee59fdd53fd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i167566322d3e4bad868eb0f8ff25fb59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0a69147b72c429dbae1a73cd1a2182c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57f41fed5a2748dd899cdc2d6df25422_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac07bef7ae3f4c03ab806ac0355474b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdffc1192c114929a5c33da248552b55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bc6a1a7f28f40fb9514b1428d9518a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a4d104ab06043e094df62100f0da340_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66fc52f2565b4f23a7e7a380898faab8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i908a1e69c3d14ca19b78ad94abf18315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if243f863e61d40228ccaf6b6475f9534_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d669a981bf145e98752c8ae97287ef1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i814218cfc2834473ba1512b07052cb1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id88d4e701c504e9b93b9007e768400d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a0e6c24bfd5491e8a07010acbd5b7a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icde117f5d3be4373957394d16191ee0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3f07bbac3664847aaeae5a2475a657f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e1eb7cb09f94a6c988ce5500bf74a37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfc632f8e72b402d89710b5655c6a876_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i306e14d7ddca4e21b4794cb488fce5b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9895d0dae6d7445ea42921b93f0a9c68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10c09ae807e54da4a01d2cfc00bd5e06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e05a36b4b8c46ab99d9337d3cd3d4f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3af9bc2dbbf14e6d8e3d8e05279f0cbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic30bf5e4d039481f8d19ae86d4a50d87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f8cf31dd8d64f55aa42897b097ff8bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88230f75c60c479dbd0b6cf91c9e74fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia445641f8593463bbe60fb23e89ff376_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5fca9cdf5874c528fd7153bb23cf79e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i031c8be8676a417ca167ea02c5249ecb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bf98252eb304398b10e2fa6fa205edb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fe70f0bb1ff48bbb5988ae3b9d281fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief06bdf136c6446e86155ffb29485c04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3ac021a9eb94f3c991cd84f64525cc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibaa29f9114014c86920bd9c97e83e197_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i316934550e024acbbd6325dc2c36d8a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94ee87f534b7486eb812b3019d90f10e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie004b16f34fb49528fc900ea4eb9ab5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdd5c0e714b6457c9291715287cdcb10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i887f5d8d558444408da6b729be6176e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i167ec5deb3594dfea6abdbaeb717e48e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1675ab4c41749a9a192e7bb01d5570c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e36489b4fd04ec19524988a99361ff3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95497ef3752c49bea81162355fe898f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id804f4973bed4a98bead10d90e4a5ec4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4f48f77a9304c3d928d59f5cda4e8cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i574e8be0dcbe46febe19bb311f0b3e9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia594156723e841d78c3dd942261e75ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfcfab070c414ee789784a20354c6b69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8628ddde09c14992bc17930fcf88de35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a22aba314ec4e5b8758419c0aced782_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia193b0c52b7842c9af258c8e25683106_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4f335ad729d456583d5537025bce75c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadf7334b5c1440cd914d71e8eb5158ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie64ce11134d3479a80fbee093c8eeb0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia33787997401459d96a225f2f2ddfdaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55d528edb81f432ea8b0d77df211e863_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic46f810428ec41a0854465f3dd3eeb28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if288edb5c28645d78092d94621a6e314_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie426e3b515ca4c32966ac2238ae9f29d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb03dc979e1948809868f9121af92653_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b512c10faf4454e92e2820bdebb03cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb330dcd0a3d42cc853a2009b99f4554_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i344dc72ffe804d559e7ecfd187252c52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6319d8f9aaa3462cbc841393e3484980_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdc78c865a114757a146a87ed649467d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11a588f349f449d29c4cd500d935548a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd9df1bc022c4981908c34ce7da7d7c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2efecde667454dafa903f13553e58c5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bf529e3651a448988c0e69800bad62e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f60e90823904e52907d87d841e42ffc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69d818676d44496c9f05bbd23d02b4e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i827063ec6d8b47cc8ef73cadbb5e308c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie26af35be2884e2e8476d92958017ea6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cd801c4ac2b4ba5929965024c9495c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08b14338524644f794041da64329d7ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d6f2f073c974e75b0df61d368ef3198_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a8dbbb22358480a9d1227dd77b3d9c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i591b41c97ee542518e6b5bf5504d3133_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice0f72bd70654124b4ddbe68456882ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82a1d18f3f5f4e94a780c2d35119942e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfd739cb8ecf4fce97d2650748700a73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45e3a34c12fe45458f64b1588317741a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2ba73fdaaa94d918532bf88e602aea4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e862569cb8e4d77b08bc51be4980e34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ee4fbb4cad946a0b316ae9a0d5c2f7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03be72af30a547c281fc637c8b272953_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6de4ea09bc4b4318aa35ba040cbaddd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i734334d67c56497ea2fe5de69c592773_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8795f816d3e4ca2aaba6e653e468c06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf0573899a39469e83be2b20e0eb8b87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibda2686ddc2d4cd0b6656354b98930b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2859719f266a46efb30de54c44c9888d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17438a4e988240c58930bd2fca58fe5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bc3c2c66d9e4d0da075849aa425fa7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2746f9d419c14a098e97957fdfe7641a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4b77e24600d447186fdb36b48034cda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i103492ff7b1c4667ac257e9154cd5beb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30df961528f4463793f7905786bea152_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i643183966d6848f3b666d367edf73743_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70569b8f4108449c84afeaf1c43a3dbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a291d5a17ef4657b4a29f981d818719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id14bc637594d43eba77368fce832327f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60e070cb04b247668d999c7e61d52938_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d6d03e2ed8d4d58992474db5137bc29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b03d00bc65a4499823bf2ae6673dc24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1690d7f6c7cf4875b045a1c058aacdff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4526f1f10b794ec991819ce33cc96cab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i237291a28a7343ae877503eaf0fa41a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92d5a9e0154c43b2b5d3386c1d0b0538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe2d1bbead584d8e8b7d3a56191796b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2f78d8a998c493b824d37739f09cee9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b6f347e0f6d4d7688e6ede323ba93ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec315121c623474c92f184ce17dafae2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70f76462cfe94c048d2e8e07abc8ac06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87ba7848623e4295a4d08297c9dcfc05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93c838ae6a6741a289a916ea6b2a18f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11fb983303214a0fab76fb48ca842390_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4ebf2c8591c4a65a69ef2a0f9a1c023_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f2e86153cfd4c15b9467efd88051085_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62613c2b0b0949e8a36439ddee87c7d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida9a7f6d784f4d7b8b53c4631c9e75eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93d10b06674c46a98dd32098076c5e36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffde3a7d917c478db3902cc934826508_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3392ad7d22c4bf7b9a4a1c59ed94a0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2c20187921d4be8beea2d674ea20464_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia914bdc1f6a941bea69658cc92f5058b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3a2be087dc94b038c7c193e1cce0685_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf95a7cf14e94274ab9c3f3de25a81aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic901be7c5ce4440f886d70a9f0528564_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e8afdee24674791bca30cb8d138a90d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic10a9d80e8d1486caea9af7c720bf668_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ba53f9f1da64ce78f2027435c7eeb45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45fa035c9b02420dafaa115085c6e8f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9383a6db72eb499a9b97a5c2952db425_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie531ec456aac40d486f50a514ec2ebe5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9815b1af955c480e81629936863a716d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92a9323f52794ceeaceff691b1800d6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3a57eb5302145278ada333579227b74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i757bec4b105a4991afb95cd0de81960c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i828c4fd6a50342c5a0296de836f61ccf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1549f6338d244929cd807e3277907a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3c486aeafe64057905b3c05060eedc7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba4a476458934d3d96c4cac37450ee31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86faebb6ff9045eba6433aa67924475e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib85d997efea3485690a6a131ac2e8edb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if46d6fa65cff4aa58bb12b8d03b24b7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6e4a32babb7454bbabcc34a329041d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33be57ca2aa9408c95b321d324369f80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifafdd7dbd10c49a3ae14d232fa79500b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9497e574157241008a6608086202bffd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaca73150a1e34797a7531629fc846e9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3edfd436e4164d2f80725061a45ac456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabf0dcd71d534c529a1afa8977dd40ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c09aa7a84a1474780ee33c2cf2dc8e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14e573d0614c4b0dafebc560bf1e985c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2550d98cc4814022b18b1a19bba41105_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i726ef58174614df18141c66c144a35ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfdc5e7be96a48c89529e9addbc8ad7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92e2941af15b4d969e19eddd03468386_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6e0725e0711473c9cc3cffd0a7eedf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if26698e02933442c83d95b1cd9eee56d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i154de6e52643472eac6dcdf2abeed4ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07da3333727b4428aad7bfefccb6d377_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67dfd1e097624c6488862d5324309a2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93730e7e82dc4832803e374edfe8ead2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75deddf561c0493e8e46b607e2749a0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48bd23b8192c4011a4b88d56642b3f8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if60345d16c5f4360a5db3ba0799c8e53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5686e91f0d54967a085ff54595dcd73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3de88e24648844a59b518e653fed8863_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeef731d794a4687b24f3700ad5eb752_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ef2c7899afb4acea061037c69340c76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9eaacf39e2ea44ed8c2e4582391bdcb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21429821125945baa4970226531ad503_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie460a9111eb84d4a80874905c816ec62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80b1d20b9535421399292eaeb2e1404d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eb82f7d9a12471bb259d4ecd5857cf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ddfc74445594fbfaaea12c6240ebc86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2102d6980fea4c88a7c3bd4a75c97991_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4b59c5814594a1298d4215076efeee8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4662c8bc38545fb8b2d9cb09707ea95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69e119752ce84afebbd0e53e707424ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffa8f1a49264490990fa783782542124_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d037b9981404553a0d4424d89b04955_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f18ee96f0b945dea57a5126d8ac86e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ad3157951114b79b6573431cb911415_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia474b21ab0f644219eba3b34a8113881_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa96c35099cd409caaa67bff540585fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c29dcff71ec45a593556dfe25bd76e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a94c884519b4702b3f5dc1c813be663_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69442670727945548dd575b353aadf52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c0e225dc9f24b699d469b030eab3e0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9a35afa117740c1980f3bb027fc8dd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6648301f7e343c8b1397283a5da0166_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a776f2958104fed92c610952957426f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i231000e09f2d43bb84cd04cf8c324914_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68a00f397c444157b4b4d73e2eea183b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06f29fc3788e4afabc141f44cf4cd192_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f2fca1966da41f8adc01f317059c621_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18bfe7750c7f43cfbb99996103ae776d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72baca3e465440cdae1136e4d7206b9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8af2d2c452d42a8b7cd8f16e4ebd74b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36aea259f0b34f19ba983964d19353fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4361ba8f6e1e4492a8664a509357866c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i935c853cb5344480a0fde97d3a5bbf26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd87a02ecce94de892c2873f98f3488e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c6d753d735746cd823811c9493f0574_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i849ed38906ec4ff5b38dd57dffe8ecf1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1eff0e4f1e846f2890a8d5f2938a568_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13a5deea4c6d48b7a2eafbede3b86af1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51b466072109461f818c9dc82d5550bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77673fc123d84b82ac7de1c624dc395f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id057083c27874cbd98e27c582abf0489_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if03f60cda085426697bf93f5635d81c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f2170ade6674e849351094a6814a792_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea2f9c7572f84dd09b8fc2143f1c7713_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87692d02cc64457990db62efd471306d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d63bfbf5dc1474eb7e49de284e9b9bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib618046f71cd4612a921448bdebdc46a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaec709b7886f4f2cb0cfba7f68baeac3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i89f7f06fe81f4197af8d197ea94e6fad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i07ecd2cf284544f3a2b8a03785d285bc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i841cd3e00f484488bd7b6b817257e859_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf79b1977acf44dfb438b2b46b217354_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i551b1c26feb64783b8cdff78bf43afdc_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a28246e7f384385969289659ed183cd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2874fde88d0443708940891c7b27e2c3_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4501b277cafa4a86baa5a206571b8208_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d3a4dd737f64e34a0e898318bacdb1f_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i89a543f8c48547aa9e78a63f01f33c83_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i9c2ba1b9c9854a9488d1f797845e5637_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic1dff00d32cb4ba2b10f010cbd418d9e_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i88fafea838de4336a9206daa5e470df6_D20200801-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDueMay2050AndSeptember2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a25b1bbb8494f0cbd38976a0a587f00_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="id3b13e3f15a94aa09c71215b3ab2d172_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i5ae5dc6dd3d94739aca17ae8276b5801_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="if2a86269df3d466591806fc6e81d3051_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i21e3b9057af3454595d19c23e9d0f7bd_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i80ade2425c63414ea6978d8687390db3_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i709f676fc9614b42b1b0311c076d8dc4_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ie11cc64930a449558e5ae1a4c19b6806_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i982bcc21bc3a40c48ddab9f94be23c67_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019EuroDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i8a2998c6421144a5959f9da4218d7f13_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i7f0d0d5ad7314fd8aba39a1931772306_D20191101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f666283299a422782250b8f89a2f761_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="id13727de8f3441d299f77635f64f9362_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i41718151ae0142b0a3f6ffa452de44fb_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="id60cdef46f66424db1dd39767e60ddd8_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019YenDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id842f1546f35423585d05e7ce66b80c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4b33128ceba4b25a2ac485bd4f78d97_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica452a7bd83c44088dffeaca9fe9e6e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5abc04db6b73450ab221929c47623631_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd1522d5872545dc9d89fb44d73b59ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i294da3bef2c24972816679da2293ee28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5bfe01bbc4845fa8a1d24e9e0d98eb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i51954a83d3fc4e158da2a14d11be3b67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b72858f1e1a4cbea5c56de4e31319a8_D20210101-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie76506d8813f4a7fa6b07b99e9f4ddbb_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i368ce9c4630f4059918b97512f0fc80f_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i4b37dec9dc524596b81869a5a184313c_D20210501-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc1c1179afa04c4888ffdac81ad4e1bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:CarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibefae15cacca4b6fb80885f8b7f6034d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationin6YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ca9c900f5ba4830a421d9f973e97825_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationIn12To18YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a7ea2349e0e4231b618eb04ea877890_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64908cb8d2bc48e58b3df38be9554dc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3fcde25a10741c89da748954342eb63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27a0a2d94ade4455b3533cea592bf9d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationwithin5yearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7929b7916024d43ad8c5746cb69f8db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expiration5to20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7227f8a46eda4c649d9047310a103ffd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f0a88d32df74c0cb0fcdd7915d26f3a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iff79519d513f4f68bf15f66911ffa849_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icddb724942ed473c88a3646e8ec26fcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f87d43e733a4aae95d03ad94fe423bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0f092b15cc046d898a11dda527a6927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fd80bbb97874a039463577583da19c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3801f5e548df453081ee2e595cad72da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99352080eaa64b8aa55bab4783a9052b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4622c6482f3d45069c12df64c7dd78b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i968dbf693bb54261a0cad1975a0f50cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41cc8775b020470392c03bca0264fe6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i673f610f07dd4af7a79e6fae5b2a77f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i764e26f54c2b4e88b9f325ce95d6d91a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if78fcffa5fcb4363b925527a37fdd04d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7cb49a7d1f0485eb5048fc42c817807_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51c7d73826fb4c3ea998d99f0cab890a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1338ebe78ec64e74910cb8e168f15f3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12cb2759a4414f6a87de7960536796f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a59bd989ed047e89cfeadb49552c829_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b4ea41679f04d40a1f04042e79615f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i913594ad00c9409d8b93872f5b5fbb98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bdaefce21c9475cb128cd1bec0b2b54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95b14f14bed9450fbcce11d6df4b26a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i603f1e71c9ed4e7b8d938450da375dbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d5edaf21db341aaa94c8e50e73bb216_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a706cd4ae4a48b185995bdd2f78fd3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78fc7d44d8cd48aea3c78cadc0049519_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b8bd8f7cd5b4670a3e7ff6635118b75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f83daf4fca54e40bbaab49dd09cc5a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31478b67a9a7415d8e22de1ce680a740_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5636680a6e4e4350b3fad57180768fbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e43baf9dd8e4024aaad2773c4f843c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d32acfe18e3466fa5910b344222cd82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iede2b770f3c64ba68bc39044be90f109_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96f7db50ad1c415288b9ea85aa6709fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a91711f8ddc4cb89e215732b94181ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d7aa0c503f5488795d936ac19312dad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa35aec973a9495d8cfb4d1860d7f186_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5278164416d440878ce7f8241506dad2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30503f9548ef49748f6c47f41c46b9fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i692d2c7285d94749b0594132364bf602_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21e6e217adbf4a0bb420bbb79525b195_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i230a704d2f5740a0b69a5d2fe32aea0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dd8a47a67cb40659b5f2400ba2e2a97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a4af7abd8884c829ce2cf89b4eeb4a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0db00ed934147a0b1454ebbfb9605e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib91ba6b55fdf460aa45150043f7993d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9090de42c1e1431d880e89e365433af9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9162ecb9fcdc4a8a88c76c029e0ec77f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4b11998c76c4e07837a915345cd5625_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74f60d47dcdc4aea9e98cfeaa8959089_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae4fe3ccc0a24e18ae11dc80ffeca0f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e4e6aa2e94d4863a9d4c4d40db622ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ada8f6f4d09490b91888fc53f19799a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae8ba6c16b8a4854afcda9d5176c4082_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fef9519e5cf4d83bb440f5dd2dff978_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20e10b3bce8240ed99c41e92c2c7c166_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39b60c7852e34d32bfb74a52b2d6c8ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i626717f8b3604479aa9d86b960ead4df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93e68a551ac24824aab0b50cf96ac505_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd41dfa5131b4ed8a3c4edff4cccd882_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6dfb78e31d4e43a48f83b015b72c519d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96d870bd1a8c432ebcf9c58cce764986_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i866e79b40fc84b748948629cdaf16e9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a07c54e28594ef985fae75cee518345_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87f183c3cbbd4fda982cfd4dd42bb6ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e533a36459c459998922edcc7dc2e06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3685410209c4742a6877711165cde44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i244b201723df412384c2a82e49dddb47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie223fdbc588545c7aa7794612858f25e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib44600c684d24718a1f3801f118c80eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64a5f9dbd52e49c9964b39f2bb6a3117_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a1acd17d36146009b635e6ac8876b00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia121cc72798a41b99b32667d68124755_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ddd772d1a82411e9d52cfd46b93391b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bf0bc4572794f0bbc6996cb82ce99da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec4a130b58aa4fc787b2559b8e658309_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6c2688876344ae09d2527a2174d8cfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d399445e4a24b55856d4967cfbb5abd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35ff171bf7ca484fb1a1179c3b99e72a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38811147de6a4ae49619b0c6fb50b5fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if49b9ae457524259bb341c9357a21cb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i109ad29c5c0843d19c3fb35636897f6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48c48fc80fbd4c02894b634f68421b19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i923f6a0606ca4c659014e936327d763e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9ebd34478dc44aa94bd2cd5d0ae09b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4dbe652b11144049f9f252b2a082929_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i126ac11b05304e3480af55e56aab89f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c1c1e97cbfa4338851f65cd304431ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie15d1d4659da48ea849e744343f5a3d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab573539a9a94f85bad389b1d078779b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f296c7bb394430981a1fb8d6838282a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i002c38a65f454861808977f397fda65d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd94f2c6bb2e4e2fa5ffb39664bdf21d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dad2404b29349fb8450d5b39364906f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27235dedb8194dfe8ed6a11ba255ac26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41b97858557449bcbd42057fb05bf2b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica4dad88d4f64153b1ec36fb80920aa3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia16f68bc36bd4ad9878079914f8e282b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3b81a674c8349d5805272c34a30b9fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff2f3b2cbe4349ca9de603412aa190c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebe2b2b2f8174da2975d92a5e46521b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa4caf2d660c4b4484538e8cbb90b925_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i492309902f57471882356fb89a26bd66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2db00e44884e4324921fffe1db888357_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7920ff7437c4431394c58ae1b77ea77d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87a76d7e24404d87b2fb139a19273f9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i920509e109ff475b8bc9e2c46f33d0be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab5f50dc04544153acdb845c6d785a71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd270e9d09cb49339a3220d22dd73473_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90078976fc1443fe9588fd6b5904ab69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5677ed160204f11beec751a2ccee116_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b36d1b515614e75986f6da15379aabd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9670f5b2d1b401bae5142ec826f2a84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibedb4afcb9df4c4e8e4622bdceece6d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1fedf4fa6a74d72b7aff18d5cad5971_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3027fdae9ac423dad98aa4717b2d250_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i904066c648bf4a7891d0c09bd32f935a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if37beb85aa5242baa69698b7f1ac5a62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dab754da4cd430a946579d76e7a4235_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c886b62fb994e6b8d799a1e75d54ba5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c687db083a348319e2e8ddb46c0e62c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c04b7697ad04751a168650303409b1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4204c5315adc45d48e818bbe9a8ba906_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4986843a114a4fa8abd7bb677f0a6e09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1852094aef8a41098d0642f072f681a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id971a9a8b7eb4b6c844ae83861fff3d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia05c9d92ee39418698a8b85febf6ef92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a265af7c90b4248bcc3b03e1b75d45e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i376b64ff0bcc4868b48f64179cccef38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28a3ca1d4022458f96a8a99957fa07fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0d1d1c1c3ed4109a81ec41ff3971fe1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia22e780cae244f9ab866e47a503bb04e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb1c7cdebbee4183a6490b6aa660776c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i098c8e062f114cf895dfab6de7e2a153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05001400e56b4185b37c3c340b3cb549_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f54761004c14a0fbeed714f829c9a9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ab1592b5b5a4ea5803c843fa59ea969_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief12a02bce14452ab3abe51ad1dbdb96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8303f3b61154040a4ed58939d6a8db7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9dbef9e3cee42a6aba4ec399d8d2392_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2b9c108036e4a95a83b7d094eaefd7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a011bb0a6704772865e32f9508fda79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia90317e246984c68baa7aec717e1b700_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85a9ee8915a1448aa53821d3de24626e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77dcf7055a13436793411bbc50581e33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54aba7ea557147118c52c20b184223c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c4bfc6afcf347469c09d2fffbd3b3ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56d6e9fb0a8e41d7a79bcebc0f396ca9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i286bdb1bdb4a4e99b3a1228c6f203ff6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e85922b83894b11b8b77f4c73af1fcd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa2ff10cc6de4d44b3171363fb8d3314_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i443731e8b90e4ff1b5ede21f5cedfd96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45319fdcff414b46b8cee3c8ecc98372_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd2d59c1620642d784d6b10e9f31a7a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50063c31ba9749efa23653ec53ec7046_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id966a267adc34a0ba8ffaf9925c61ef2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f8eaf7e5d4c4ea48272ed7d73c53069_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id872ed9c15ae4df9bd2ff63acfe92e0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd7e2a5a735740298384d7b6e050d5aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76c132cf90104d488c23e6ca6eb8098f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4113c6d6bab42948b9ff02ab6f74741_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e88ac2258ee4936ad5dc86525cd9442_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i670f1a97ccbf41da8154342d4d6523b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide3ae3cf49674f30ade8c18fa107c77b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i257e5842c7554e4caa669c0ffca933f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54cfd8a609414a0db58349eb5ea9a5fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad0f0411d0c340e5a80b9de1a90ac71a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fcea8bc696240ccb6279f2fa8f961ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i717d2780362b4ed5a803d5d092fc68de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89af2a8588fb43c7a9f34777a2e4a820_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41a8292117714ce7b0efadd7981b2635_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie331a6b7526d4646ba4c0c78741cf4a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica375fb13ab44116bd7cec8010c65295_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc92d20b166347aba8996743e2f94f5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i154ab60f7f874167b0110415b0bb6bcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82568bb9dcf84a24a49d7b60fa84c30e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9537a27ef3aa4c4c9ab9cf72607bf998_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1425cdedc7949b0b143bc6ff55254ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80391b34e15c469b9897032dcc29bcae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie906d9e82b62417aae23edf6f663034e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0008b840b33b4978b52d9f21ad80d88b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i062da986ad0544f289a0f7f67fb3d529_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5c8c08e195b457581bae02f1a1a1ed6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic671a63b2541465ebb7421a6e68854b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d9a8b2e771d41f990fd1f9ea5be38a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2ee2af27ade4a0d8bc08bef2fff9cfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id75775f4e3d5407da9f8fd41bc619cc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f4d0bb3ce4b4cd7a9e3ffbc447cb4a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c3fdb269b554706bad0f7c0db4c4650_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c8f217fe0234a80a11ef720e8b0c5be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdf725fef3924b1ca90629c2fbfd82be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e73d975a09b4b51b349b6589f7f2026_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2345619fcf84c878d4d255125aff795_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8f2b6878a0d4219bec7cca02fca3f31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id081a7188b3f482cadd9f20bf9235396_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9a933ecf8154d50959fd7b679fa2059_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c80776c9e5d478fb71a447f058f5795_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf9330f1044b4da28b7e3b56aee502c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2fa9acd89db451e96eec95ad09cf9c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffd7cd72ddc74159a112e5175ba27aab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1884086160c4545b61f9deb3369c36a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f3c2d07882344e098b3ebd363334c5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06e1bafb60044816a73bd73702d87ead_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6128315f59094f028caf8bb50fc29382_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea1472d9c0614d2792d02449a8430661_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f512b891abe4e69bc22f07f86783f45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a8f4700075e46e181eeffde2392ca23_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="idaebf92d82564ada897eaa69c56f337c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2467803c679342dea9a3819f8bbf7baf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib12387763bcb4249a0acbacdd6def054_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="if4b71fdf7d6d451ea94e93caa29ecafe_I20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-31</instant>
        </period>
    </context>
    <context id="i5f4e6781ac7b44e984cc9a7e9559b57d_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="ia0462964f7244546aefa834caa5190c4_I20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="iac210e833f7b4de39ab853cd87ad843d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf373b574e5c43eeb34e1e1ca9dc68c7_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58d4f95ec17a42b1a27bfd827f5f8a06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i329ac6196728431792b5fc0adace7b76_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie857e2c012a4416d91e56a0f10db62fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95acadd05dab463fa98262e3b7d9a30c_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17f2181a9b6d4e6ab309b180381eac2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d637cc5246347c6a23d9f91a36fba87_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f1eda23144b47d083c10338438ad3c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2521580e2ede416981af3b0b347ee8f3_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e4899ed067c4d2c9996df4ef5abba7e_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id09447c7b9f54599a8f05f81d771fab0_D20090301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic78be52744324235b791e091239d55c9_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i506357620067488b978ab8ff85c80057_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i0fe8d453b4a64bcd91db0e517126df58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie428c3da402741de9dc989224e4a1931_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ce97af02d724dd5a6b2d83575df05d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f0a8d43e1354331a472dc5baeceebd0_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="iea9d1b8804f84d8d9335353484110e31_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3712c098015042f9b63839407eed2efb_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i4ec2ece19688425e9036c61b5348541e_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id79706b98b434731856afd46cac0b247_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0eaa187336948399c69ed01819ea277_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeabe64521a64f398e690da708946fca_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i49de5751f19b463f82f0525d37e01c83_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:AlimtaPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c8b2889ec6e4963b72ebda5ec3e0226_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i70389d1a8dce4373ba9770278325d644_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7efe1f182bf74c749bcde3ee035a8288_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i21f70fcf53724eacba2dff838d3080f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51cd7b473ca14dc78773ea45b5740f8b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id0475e54cb8944cbbf6fd301a3970da7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icf8db92bbdad41589e45f909109c9432_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iecc77c9789cc449891871245cbbdd250_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibda565e24c4e4030b83ae8ca958f008f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98d1710cee29438bb4194f2e32033a79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7432a131a0fb49ff89baca4d230f866c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i900912a3de074ff99d6a423f98a6bd4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14978ed722694c18a3fc2706b4ca82f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i164180694aa747c791f72edab93ae1a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa4777312b864b708203b734b774366c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37c0f201926f4948bca2dbe17676cc5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8c0eb69cf624cc4b293df7b97c976e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f6183f5a5c9455dbf2c516793377cd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01c9273e754e42ff817a718c1ba70d7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic435e2ecf0a9408aaba2f2109d4c1db2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf58fefc745a46b9862d5a41ca2b485c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i554c64bad97a42be803841abd88811cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie990d35793244c81978b349a80a82099_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9bf6f4a94b544a686ef51fbf1c8c304_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2772b8591a3a435d806d664e42747e10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib18d0b0c520347f3b7f49fd16cebe265_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34d26295f837471e92a911cbfa5f09ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a7a7a2ccbdd490e9438393be18ea12f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if33da3a3872a4c1a8a126e0502034dad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibebbd5414c314196b2e7f72291cfad2b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i456c6ad8d4564976aef8554ffb59ccb7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4452a2c88c941349af1c9b68847bcb5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36b8a5e3c0f84e68afcd481209c5d2e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65892dc9a2954d38b4ead8cdfcd6ba81_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8d96de74d5a4264aaa3443af2d2593f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7dd3bf1571cf4ded9e6e79654afd40d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6958d74700da422a8372afeee6138499_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb264b12ab0a49edae53a6a459216f4d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iabad7b42145343838527d4f8737a08dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie225690e6f6c43e7bf1510e4c46c7696_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8379681ef59448d18a9ce97f8241d61a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4cdbdd02bc04cdf82cfd0ecb1e7506a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc4e3d75ed7a447f964c2076c2654b6d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2bd38897fbf84ba6886a357f48aa2eaf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08bfe6219e8843de84f18681cf0d0cbf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i080cb1f6c4c54fada36e6a66c670db4b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idbf4d129e0b547c78a08a57ac046797d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfa4547d667b4859a0ef3510f8201e3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie16a788a1f3b4a209b13227afbf2188f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4726fae6a954ef28f20a75d12754243_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00e2a870edf2467790f0a84a2d627f6c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2bc78576f75247428a588a52665c4852_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iccb9aa249e034756b9c8db5d7fecdf51_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iecabf182d17143a49900323bf9cdddde_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c2697f3892040f38f4824aa3f7f6f6a_D20190311-20190311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-11</startDate>
            <endDate>2019-03-11</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lly:right</measure>
    </unit>
    <unit id="medicine">
        <measure>lly:medicine</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>lly:plaintiff</measure>
    </unit>
    <unit id="claimant">
        <measure>lly:claimant</measure>
    </unit>
    <unit id="site">
        <measure>lly:site</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="claim">
        <measure>lly:claim</measure>
    </unit>
    <dei:DocumentAnnualReport
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF8yLTEtMS0xLTM2MDk4_e316f2b2-4063-42b9-977a-a851e954c00f">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF8zLTEtMS0xLTM2MDk4_f0d53db8-6f49-449f-8044-90b55f399e34">false</dei:DocumentTransitionReport>
    <dei:AmendmentFlag
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF80LTEtMS0xLTM2MDk4_fbaf8e9b-103a-4f75-817a-ce9aeb7bdc01">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF81LTEtMS0xLTM2MDk4_65ed4c20-dad1-4ea9-8b76-c3f9fe69887d">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF82LTEtMS0xLTM2MDk4_99f5a310-af60-4598-b549-914fd96f9847">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV83L2ZyYWc6NDQyZDk5ZjVkNjYwNDYxYjkwMjRiNTJkNmZiNzFhMzIvdGFibGU6MDBjZjhhZmVkMWJmNGFjYWIyNTU1OWVjZjk2MGI2OTgvdGFibGVyYW5nZTowMGNmOGFmZWQxYmY0YWNhYjI1NTU5ZWNmOTYwYjY5OF83LTEtMS0xLTM2MDk4_9461a90a-b15d-4718-a9c9-2f59a3bfd30e">0000059478</dei:EntityCentralIndexKey>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i828c4fd6a50342c5a0296de836f61ccf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDA_50a976ec-2fe9-4481-a965-701914495450">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i86faebb6ff9045eba6433aa67924475e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm
      contextRef="i49de5751f19b463f82f0525d37e01c83_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTcvZnJhZzpkMzQxYTIxYzA4MzQ0MDQ4YWRmMmUwZTBiOTRkZThlMS90ZXh0cmVnaW9uOmQzNDFhMjFjMDgzNDQwNDhhZGYyZTBlMGI5NGRlOGUxXzI1OQ_d3bff026-8cb3-4cdd-9cc7-13ef9a84de20">P21D</lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm>
    <dei:DocumentType
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgw_4428cc0f-cd87-499a-81d9-12718e1b7218">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yMDE_8561bf7d-b968-402f-9ee3-11848d290ab5">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yMDE_d522a18a-e62a-4eeb-9299-6afffda02ce9">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg0_3c99796a-cd14-4415-b34b-2d2519bded77">001-06351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yMzc_d46d5a0d-91cb-4b55-8cb3-0150bf2b4c2d">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6NDU2MDNjZjA5MzJlNGI3MGI4NmMyZmE2M2M2MWQ3Y2IvdGFibGVyYW5nZTo0NTYwM2NmMDkzMmU0YjcwYjg2YzJmYTYzYzYxZDdjYl8wLTItMS0xLTM2MDk4_bb38eb09-5993-4faf-9726-b90c3d327a7c">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6NDU2MDNjZjA5MzJlNGI3MGI4NmMyZmE2M2M2MWQ3Y2IvdGFibGVyYW5nZTo0NTYwM2NmMDkzMmU0YjcwYjg2YzJmYTYzYzYxZDdjYl8wLTUtMS0xLTM2MDk4_3de46c3e-2c6c-4c46-8997-f00564290242">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgx_e3455463-56a4-4c71-9392-9f63005f4a4b">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgy_c6b70c08-2fb9-43ec-bb68-2bb66f8b3de1">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg3_acb105da-94e0-43bd-936a-623faf7440db">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg5_1c79ac83-c8fb-44ff-b925-8bab2f5f1681">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF80NTY_a9aa84b0-b3b5-4ba0-8ee5-0f977321013e">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg4_4bd20f5b-ce2c-482b-b937-dd40303f0497">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib999762467224e169f22d930370a98cc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xLTAtMS0xLTM2MDk4_e3699240-2a25-46b3-90c1-c6afa0910b4b">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib999762467224e169f22d930370a98cc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xLTEtMS0xLTM2MDk4_9e4434fb-c8fe-45de-b2fd-2b4b7f215e85">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib999762467224e169f22d930370a98cc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xLTItMS0xLTM2MDk4_5551320f-c62c-4706-b002-bcb69fb548ae">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8yLTAtMS0xLTM2MDk4_d76822a4-b490-47f7-8192-6fb32f8ed3bd">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8yLTEtMS0xLTM2MDk4_13b5b791-4032-453a-8ccf-851060b70327">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8a1a1acbd5334f5689b71e30a6037d46_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8yLTItMS0xLTM2MDk4_6544ffb3-371b-4062-9058-86c89321004f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8zLTAtMS0xLTM2MDk4_ff2cb2d5-30fd-43b6-b2dc-47a7428d1c3f">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8zLTEtMS0xLTM2MDk4_56ebe9da-cdee-49bb-8044-063c173d5955">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i841b5c62cc854ade9d0e045504acebf3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8zLTItMS0xLTM2MDk4_2caa25cd-9c4e-4ab4-a4f4-5ae8ed60534e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF80LTAtMS0xLTM2MDk4_be2ee041-46e6-4d0e-99a1-5b9a1df1c874">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF80LTEtMS0xLTM2MDk4_5c54ad91-915c-4349-91ce-2e7313d6966a">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i31a6479d8aa44f0e93e4fa10d4d45c42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF80LTItMS0xLTM2MDk4_66662b98-303d-4003-8b77-f4d6c1afd8e2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id219efe1b1d547adb5713a0601859853_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF81LTAtMS0xLTM2MDk4_aaa8bf20-21ab-4044-aaba-7be01059ac6e">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id219efe1b1d547adb5713a0601859853_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF81LTEtMS0xLTM2MDk4_c579c998-db0d-4ff1-a232-d6e8db9fbac7">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id219efe1b1d547adb5713a0601859853_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF81LTItMS0xLTM2MDk4_7e0b46cf-0277-4b7d-9c42-e5c490d33bce">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i5badd592a21c4a338eed272300758c16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF82LTAtMS0xLTM2MDk4_23b179dc-6307-4a86-a320-372577f00ddf">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5badd592a21c4a338eed272300758c16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF82LTEtMS0xLTM2MDk4_0b1c5e21-715e-4446-93e3-85c2b2ad7e9f">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5badd592a21c4a338eed272300758c16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF82LTItMS0xLTM2MDk4_259e5e68-97a9-409d-ab95-3d4d42d303bd">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTAtMS0xLTg1MTY2_07b5846c-98da-4401-b40c-7a7eef4215d3">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTEtMS0xLTg1MTY2_9c44e37a-253e-4051-97ee-a1355bf262fe">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id2d6b30c3fd44fe895612e6eab98a464_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTItMS0xLTg1MTY2_502051c6-6176-47a5-97c3-a894c9ec011a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTAtMS0xLTM2MDk4_0c1ead68-ffb8-4b14-b04a-bfc4d379cb1a">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTEtMS0xLTM2MDk4_3202eff6-b042-4530-9578-125d95f1123c">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4c1867f7417743d3b0e1c2fc348036b4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF83LTItMS0xLTM2MDk4_4dec5099-3ad9-4471-aa75-4678524035e0">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF85LTAtMS0xLTg1MTY5_fa98c14f-079c-496b-85fa-241b1cda4426">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF85LTEtMS0xLTg1MTY5_7ad06af4-902c-4b9a-b862-a17cd4c3f49e">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9a84c74aad91404eabc1df4eb35729d1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF85LTItMS0xLTg1MTY5_469a6ad1-8332-41c7-bfa7-2953c124be78">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i822be716a0774b71a20856f8866c402a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF84LTAtMS0xLTM2MDk4_8fe9b277-1ad7-418b-8a1c-d8fc4fce2aa3">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i822be716a0774b71a20856f8866c402a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF84LTEtMS0xLTM2MDk4_ac96a1ea-d3a8-4e20-8e42-d27da5e5828d">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i822be716a0774b71a20856f8866c402a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF84LTItMS0xLTM2MDk4_65d27e48-2b9a-4188-8c1a-7993bd3745d8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMS0wLTEtMS04NTE3Mw_0de78b51-3140-4cd9-a8d2-8c9df12b3cd0">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMS0xLTEtMS04NTE3Mw_2420096a-af3d-45b5-befb-12cb604f2d33">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4c8315c954044b369a1f45a72eee1ac8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMS0yLTEtMS04NTE3Mw_ad587919-2f0f-4536-8f8f-33d7e27ec9ea">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMi0wLTEtMS04NTE3Mw_55c0da52-d45c-4676-8068-9065222c6dbf">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMi0xLTEtMS04NTE3Mw_db8f21e1-a1c7-4509-89ea-e4a177fdeac4">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9b302b5f9de4472f96d46ef86e04a74b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MWQwOWE3ODg4OWEyNDBkOTk5Njk3OWU4ZGZiN2E4NTgvdGFibGVyYW5nZToxZDA5YTc4ODg5YTI0MGQ5OTk2OTc5ZThkZmI3YTg1OF8xMi0yLTEtMS04NTE3Mw_dbda52a1-0ba5-47f8-b421-c5edf609e8f1">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDkw_c0a93b3d-24c1-4b3d-8679-138d7b9d8b81">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDgz_b9fd407a-5398-4a61-8072-116e18f1a864">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDkx_122ce800-9ef3-4d06-a1c9-8e8da1308bb5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDky_8e6fbf07-0150-4eca-9e65-e5670d5fefe3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MDZhMTYxOWUxNzA3NDU2Zjk0MmFjM2U4ODhkZmE5YTQvdGFibGVyYW5nZTowNmExNjE5ZTE3MDc0NTZmOTQyYWMzZTg4OGRmYTlhNF8wLTAtMS0xLTM2MDk4_cd3e54cb-93ae-40fb-a0dd-e6d0bef91c48">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MDZhMTYxOWUxNzA3NDU2Zjk0MmFjM2U4ODhkZmE5YTQvdGFibGVyYW5nZTowNmExNjE5ZTE3MDc0NTZmOTQyYWMzZTg4OGRmYTlhNF8xLTctMS0xLTM2MDk4_945ed3b0-d9b7-4fe4-9126-5a107e8f5ef0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGFibGU6MDZhMTYxOWUxNzA3NDU2Zjk0MmFjM2U4ODhkZmE5YTQvdGFibGVyYW5nZTowNmExNjE5ZTE3MDc0NTZmOTQyYWMzZTg4OGRmYTlhNF8yLTctMS0xLTM2MDk4_1dd57e93-633e-4595-b84d-e35924715e7a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg1_645f973d-6134-4e21-a15a-bfb998a5486c">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDg2_7d43fda4-9d57-4ac3-9f5c-c06dd8d4a2ea">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i333cc430d5f24f45a3a99e2e1060db9c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yODYz_235bf960-80b1-4713-93e7-6cdeaa8c052e"
      unitRef="usd">193649000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id1a06f9ea4dd4dcabf049aeb8fab3e59_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8yOTIy_57f6881d-1404-4a2d-973d-56c4969c904f"
      unitRef="shares">952347126</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV80L2ZyYWc6ZDQzNzcwMGZiMGJmNGY3MDkwMzBiMDI3NzFkYzYyNmQvdGV4dHJlZ2lvbjpkNDM3NzAwZmIwYmY0ZjcwOTAzMGIwMjc3MWRjNjI2ZF8zMDkz_a5812c85-3d39-4f80-b208-a9d2f1a0e236">Portions of the Registrant's Proxy Statement for the 2022 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMS00LTEtMS0zNjA5OA_2f6b4858-3c12-4b09-b54e-ff8f1aab6e96"
      unitRef="usd">28318400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMS02LTEtMS0zNjA5OA_d0159511-328d-4c54-8062-b6f7e55124cc"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMS04LTEtMS0zNjA5OA_189b6c5a-946f-46ce-a1a9-3754e7ed26ab"
      unitRef="usd">22319500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMy00LTEtMS0zNjA5OA_93f03b0c-8624-4d3c-a4c6-ce060a990d60"
      unitRef="usd">7312800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMy02LTEtMS0zNjA5OA_72f1356c-16f3-46f8-ade3-12f569dc74a4"
      unitRef="usd">5483300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMy04LTEtMS0zNjA5OA_3452ec99-c1f2-4a15-9046-3c696338e3b2"
      unitRef="usd">4721200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNC00LTEtMS0zNjA5OA_dffe095b-189e-4847-a474-b61d8d4ff3ae"
      unitRef="usd">7025900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNC02LTEtMS0zNjA5OA_87e81b3c-958f-40cf-8212-93ad3061216d"
      unitRef="usd">6085700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNC04LTEtMS0zNjA5OA_08b5dce8-cdcd-429e-a5f1-93e2791dd7a9"
      unitRef="usd">5595000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNS00LTEtMS0zNjA5OA_b1abd1be-3b54-40bd-8140-8204debb5885"
      unitRef="usd">6431600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNS02LTEtMS0zNjA5OA_92e16706-ec7c-413b-8f0f-cf095b45b3f0"
      unitRef="usd">6121200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNS04LTEtMS0zNjA5OA_75bf68f7-1f4c-4b54-8001-2659de60f573"
      unitRef="usd">6213800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNi00LTEtMS0zNjA5OA_600f65c8-df53-4de2-9768-87bd5a501e49"
      unitRef="usd">874900000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNi02LTEtMS0zNjA5OA_3b1fb55f-4b90-4539-9972-fccaa9afbb37"
      unitRef="usd">660400000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNi04LTEtMS0zNjA5OA_719233dd-4803-476a-8e4c-95e1850e4e8e"
      unitRef="usd">239600000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNy00LTEtMS0zNjA5OA_dfce4b27-d82e-46f5-bb9e-608325fe306b"
      unitRef="usd">316100000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNy02LTEtMS0zNjA5OA_01132e42-10c9-424e-be35-fa3b546879be"
      unitRef="usd">131200000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfNy04LTEtMS0zNjA5OA_93fcca7a-078d-49a2-bf98-37d107a4031c"
      unitRef="usd">575600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOC00LTEtMS0zNjA5OA_4a103795-4690-45c8-b7e6-6cfccefe011e"
      unitRef="usd">-201600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOC02LTEtMS0zNjA5OA_b7c7a090-809f-49dd-afc9-18f9ab61da68"
      unitRef="usd">1171900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOC04LTEtMS0zNjA5OA_4beb65c6-e454-4f1f-b169-b0302f5631d4"
      unitRef="usd">291600000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOS00LTEtMS0zNjA5OA_175e8b71-b258-46b3-bb0a-44013038c642"
      unitRef="usd">22162900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOS02LTEtMS0zNjA5OA_78cd0b03-1715-4bad-b029-e8ed09618ff9"
      unitRef="usd">17309900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfOS04LTEtMS0zNjA5OA_2dd90eb3-2df5-43cb-981a-2727ae09312d"
      unitRef="usd">17053600000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTAtNC0xLTEtMzYwOTg_a00ba516-f26f-4da5-8f68-b98da62829e5"
      unitRef="usd">6155500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTAtNi0xLTEtMzYwOTg_8845dad0-3969-4a1b-b57d-7eaa2880e066"
      unitRef="usd">7229900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTAtOC0xLTEtMzYwOTg_dd6aae4c-5f74-49b1-9ea3-a3280a46fddc"
      unitRef="usd">5265900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTEtNC0xLTEtMzYwOTg_c2d480b9-4326-4ba6-ade4-8f6e3da5b8d7"
      unitRef="usd">573800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTEtNi0xLTEtMzYwOTg_2199eab7-98ad-47b6-8da3-2d081b145112"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTEtOC0xLTEtMzYwOTg_03336bcf-c3ac-4449-b39b-54aea2eccd86"
      unitRef="usd">628000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTItNC0xLTEtMzYwOTg_a971d431-d92d-4d16-84c3-48e7a115e5f4"
      unitRef="usd">5581700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTItNi0xLTEtMzYwOTg_f7de0f60-63db-4a38-8e3c-cd1ebdf4c278"
      unitRef="usd">6193700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTItOC0xLTEtMzYwOTg_0ac679ce-5b40-4d26-95eb-3639e6faebaa"
      unitRef="usd">4637900000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTMtNC0xLTEtMzYwOTg_0219fb5f-a7c1-4515-8e2e-34c5cfbff98f"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTMtNi0xLTEtMzYwOTg_2b8c7a5d-caa7-440d-86e3-d0fe13d8cdb6"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTMtOC0xLTEtMzYwOTg_0efe270a-a610-4729-adda-d22ba6718e44"
      unitRef="usd">3680500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTQtNC0xLTEtMzYwOTg_9ca74bff-4f12-4430-966b-fc2e088715cb"
      unitRef="usd">5581700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTQtNi0xLTEtMzYwOTg_89c3c5e8-67eb-4fa6-abbe-91965cf69cc5"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTQtOC0xLTEtMzYwOTg_28294dc5-36f0-45a0-8974-70bdff925ff8"
      unitRef="usd">8318400000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTctNC0xLTEtMzYwOTg_18349996-b3c7-4664-9a0b-5367bc75c52a"
      unitRef="usdPerShare">6.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTctNi0xLTEtMzYwOTg_dca4dafe-1655-4d25-a80e-4290ab3b9eac"
      unitRef="usdPerShare">6.82</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTctOC0xLTEtMzYwOTg_62a3be15-bc89-453b-b820-1dbd057d5a41"
      unitRef="usdPerShare">4.98</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTgtNC0xLTEtMzYwOTg_8ae66d9f-41e1-42c7-8c61-5bfcff445d8c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTgtNi0xLTEtMzYwOTg_c2b85f1a-9a93-4b90-9543-964559daedd8"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTgtOC0xLTEtMzYwOTg_317e000e-97a6-4ddc-b5e1-454c1fe6ca52"
      unitRef="usdPerShare">3.95</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTktNC0xLTEtMzYwOTg_21fb8791-cf7a-4c3d-9c0c-f4bbd1802f56"
      unitRef="usdPerShare">6.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTktNi0xLTEtMzYwOTg_3ce68b7b-c473-4c2d-94bc-508080a9b229"
      unitRef="usdPerShare">6.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMTktOC0xLTEtMzYwOTg_0591d6b7-8fa8-40e8-8651-c2e309a7eafc"
      unitRef="usdPerShare">8.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjEtNC0xLTEtMzYwOTg_88cf8192-7751-4c5d-8268-a4c00f3fffcc"
      unitRef="usdPerShare">6.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjEtNi0xLTEtMzYwOTg_63eef34e-c0f1-46bf-af3c-af5e9bc7740b"
      unitRef="usdPerShare">6.79</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjEtOC0xLTEtMzYwOTg_90854680-30b6-4302-9ea4-c43c839b14d8"
      unitRef="usdPerShare">4.96</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjItNC0xLTEtMzYwOTg_fea9606c-3a09-4bdb-81a3-961f5c4fc01f"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjItNi0xLTEtMzYwOTg_1405120f-7c3e-40b8-a1c9-aade2b650bda"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjItOC0xLTEtMzYwOTg_2dffaaa0-6c15-4f7f-a029-182460cf6be6"
      unitRef="usdPerShare">3.93</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjMtNC0xLTEtMzYwOTg_65b0ab03-fa00-4fec-9a54-6a3d2dea0332"
      unitRef="usdPerShare">6.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjMtNi0xLTEtMzYwOTg_87c970ea-cc2b-4714-a194-c269a90a62db"
      unitRef="usdPerShare">6.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjMtOC0xLTEtMzYwOTg_aef53688-f717-43c4-9745-8941b0a64dc2"
      unitRef="usdPerShare">8.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjYtNC0xLTEtMzYwOTg_9416ddba-f508-44e4-9cfc-c36b3123e39b"
      unitRef="shares">906963000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjYtNi0xLTEtMzYwOTg_0f10c486-617d-47d7-87fe-30e187a65d5e"
      unitRef="shares">907634000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjYtOC0xLTEtMzYwOTg_836676b6-d346-4866-aaa5-bf621107e5c7"
      unitRef="shares">931059000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjctNC0xLTEtMzYwOTg_61d6b9cf-8038-417a-a636-02ca26893a59"
      unitRef="shares">911681000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjctNi0xLTEtMzYwOTg_e0c1ba4d-4a0a-42b5-8ee2-c9451cd3ca32"
      unitRef="shares">912505000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84NS9mcmFnOjI0OGZlYmQ5ZjdhYzRlMmE5NjkxOTU0YWM0ZWE5YzQ3L3RhYmxlOjg5NGYzMGQ5MDA2YTRlYTJiYTkxYjYwYWRjMDA4N2U3L3RhYmxlcmFuZ2U6ODk0ZjMwZDkwMDZhNGVhMmJhOTFiNjBhZGMwMDg3ZTdfMjctOC0xLTEtMzYwOTg_fc95c3bc-14b3-4af3-886a-bb0677ab69c4"
      unitRef="shares">935684000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMS00LTEtMS0zNjA5OA_a064a5ef-5803-4249-a3b0-439b556ce7bb"
      unitRef="usd">5581700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMS02LTEtMS0zNjA5OA_5c796367-3c44-48d4-998f-71298d479ccb"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMS04LTEtMS0zNjA5OA_f315e93e-2d6a-41bd-8617-ad8cb4058643"
      unitRef="usd">8318400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMy00LTEtMS0zNjA5OA_35b90ba7-cb94-4605-b873-5d26b0e6fcec"
      unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMy02LTEtMS0zNjA5OA_c8f316b0-e268-47bf-96a2-ca602f442915"
      unitRef="usd">122100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMy04LTEtMS0zNjA5OA_762c4cfb-715c-4202-8524-72e1b97f7926"
      unitRef="usd">-89900000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNC00LTEtMS0zNjA5OA_2ba8863f-a51f-418c-b521-2f47578fac2f"
      unitRef="usd">-15900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNC02LTEtMS0zNjA5OA_d245ede0-eaea-405f-865f-ffc91ee2053b"
      unitRef="usd">14200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNC04LTEtMS0zNjA5OA_dd94bb48-7511-4f27-9cd9-473439f36ebe"
      unitRef="usd">34400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNS00LTEtMS0zNjA5OA_c09dddf7-4b8f-4272-bbf0-ac0717b3091f"
      unitRef="usd">-2699400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNS02LTEtMS0zNjA5OA_f93df287-c1ff-4851-9d24-04272978b6f1"
      unitRef="usd">157100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNS04LTEtMS0zNjA5OA_7df109e5-12b7-4af1-a734-8156a3751f31"
      unitRef="usd">970000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNi00LTEtMS0zNjA5OA_967ee535-7784-4323-8fa3-48ff9b23c295"
      unitRef="usd">151600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNi02LTEtMS0zNjA5OA_236585e5-69a7-4e2c-a81d-f279d8e4b3a8"
      unitRef="usd">-152900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNi04LTEtMS0zNjA5OA_05aa4bbd-a229-4d8f-b3ac-c96ecb257333"
      unitRef="usd">34300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNy00LTEtMS0zNjA5OA_c78821a5-834c-49e5-8ac0-8d657fe31a17"
      unitRef="usd">2848600000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNy02LTEtMS0zNjA5OA_69c23f9e-43c9-4a48-9fa5-42910df3aa19"
      unitRef="usd">-173700000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfNy04LTEtMS0zNjA5OA_11ce8d91-85b3-4956-999b-278f6b605ebb"
      unitRef="usd">-991200000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOC00LTEtMS0zNjA5OA_0a189ccf-bb59-4a80-93d0-2f73ade6ae52"
      unitRef="usd">695300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOC02LTEtMS0zNjA5OA_c3a44ebe-1e6f-48d8-8430-f0b3c14371f2"
      unitRef="usd">-200900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOC04LTEtMS0zNjA5OA_a05efdff-feb8-42f6-8e8b-3a6afb1cd31a"
      unitRef="usd">-151000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5593b99da6745cb9b411b2031bc3e15_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOS00LTEtMS0zNjA5OA_18333278-bf08-4121-9a8e-1505778fa824"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i350adfc8d85547d9a3c4e39ba5c1a2fc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOS02LTEtMS0zNjA5OA_d0b31f91-5eb4-4942-8868-6284be918f30"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id11a42da50f242f2a8b81a0a0173884f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfOS04LTEtMS0zNjA5OA_669807bf-7214-43e7-944e-33589288cb11"
      unitRef="usd">-840200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib6ef7ac05a14478b89f3032c4251b7ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTAtNC0xLTEtMzYwOTg_08ae4b7f-50c3-4892-9dc1-60907bdcf12d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4663754a3a444cb9830c13af3caf35bb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTAtNi0xLTEtMzYwOTg_86e681aa-c209-4584-9879-e9a9c83c64fc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i18a38bac34cb4ca8800ba1a18314f494_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTAtOC0xLTEtMzYwOTg_77c33c72-a32b-473f-b349-aa9f92c8074d"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTEtNC0xLTEtMzYwOTg_2a3176f5-e0ef-4be9-b5ea-fd0f65d17277"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTEtNi0xLTEtMzYwOTg_f3f5bd09-3b6b-4399-be58-89f657c35488"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTEtOC0xLTEtMzYwOTg_3bea0885-1677-4c82-b139-fc5b8f468a4f"
      unitRef="usd">-783400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTItNC0xLTEtMzYwOTg_6621bb25-93e8-4ea1-8a55-ef0ece292b00"
      unitRef="usd">7735000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTItNi0xLTEtMzYwOTg_4ccaee39-9aaf-4fab-9741-68e7aa30f163"
      unitRef="usd">6220900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV84OC9mcmFnOmIzZjBkMTlkODIzZDQ3NmZiNWM4MTE3NTNjOWMxZWM3L3RhYmxlOmI4OTY1MmZjNmRmODQxOGM4YjBlNDVjM2M5ZTczMDlhL3RhYmxlcmFuZ2U6Yjg5NjUyZmM2ZGY4NDE4YzhiMGU0NWMzYzllNzMwOWFfMTItOC0xLTEtMzYwOTg_f27439a4-0883-48f1-ac8c-3c6ea3cb5c06"
      unitRef="usd">7535000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMy00LTEtMS0zNjA5OA_c785657a-a445-4f72-b935-1ebfb96748f6"
      unitRef="usd">3818500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMy02LTEtMS0zNjA5OA_d386f271-59f3-4ee6-99c5-ed60611a8aff"
      unitRef="usd">3657100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNC00LTEtMS0zNjA5OA_92c52679-a223-47d7-b007-d697c5b4f8b6"
      unitRef="usd">90100000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNC02LTEtMS0zNjA5OA_8d55acaa-3bbe-4ffe-b1f4-f0e68cde007c"
      unitRef="usd">24200000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS0wLTEtMS0zNjA5OC90ZXh0cmVnaW9uOjAyZGUyZjQ3ZThjYTQ1OTc4YzJiN2IzZjcyYWI4N2ZhXzQ3_08404094-9094-4d60-a9e3-ae7fe8f5df36"
      unitRef="usd">22500000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS0wLTEtMS0zNjA5OC90ZXh0cmVnaW9uOjAyZGUyZjQ3ZThjYTQ1OTc4YzJiN2IzZjcyYWI4N2ZhXzYx_0732bea4-2e7e-4495-bd28-1b574165753a"
      unitRef="usd">25900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS00LTEtMS0zNjA5OA_a0b1db77-5825-4744-a9c7-e0b6a8366b6d"
      unitRef="usd">6672800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNS02LTEtMS0zNjA5OA_3aebca66-b8e4-4350-a8a8-495a6f33012b"
      unitRef="usd">5875300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivables
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNi00LTEtMS0zNjA5OA_1afb888e-7d0c-47be-a768-89f61dfefd49"
      unitRef="usd">1454400000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNi02LTEtMS0zNjA5OA_2c1eff7c-8d2a-4125-9d72-44c67129ba02"
      unitRef="usd">1053700000</us-gaap:OtherReceivables>
    <us-gaap:InventoryNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNy00LTEtMS0zNjA5OA_b5f45dca-8555-490c-8f49-2d93ef08e9a1"
      unitRef="usd">3886000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNy02LTEtMS0zNjA5OA_0268bf3f-3ba5-411a-ab55-76983b023115"
      unitRef="usd">3980300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfOC00LTEtMS0zNjA5OA_5f4a25ca-47ec-4b8e-908f-2da7123ffa02"
      unitRef="usd">2530600000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfOC02LTEtMS0zNjA5OA_a59c3d6c-8bff-4db8-91c5-20ee8319ce7b"
      unitRef="usd">2871500000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTAtNC0xLTEtMzYwOTg_2547a693-13b0-4a4a-8ca2-1e593e2318fa"
      unitRef="usd">18452400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTAtNi0xLTEtMzYwOTg_104dcd2b-4149-4860-a16a-dfb71573b686"
      unitRef="usd">17462100000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTEtNC0xLTEtMzYwOTg_9a1ec573-4a16-459e-8835-3ebe9d4461ed"
      unitRef="usd">3212600000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTEtNi0xLTEtMzYwOTg_1b570f9f-77c5-4b0b-957f-8bfd865735f3"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTItNC0xLTEtMzYwOTg_a6b6708a-bce3-455c-b533-c2c05f78f5d9"
      unitRef="usd">3892000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTItNi0xLTEtMzYwOTg_68a20bb9-c2e9-491f-948e-0733867945c6"
      unitRef="usd">3766500000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTMtNC0xLTEtMzYwOTg_43f5aa3a-7bd2-4243-8424-d5f7f7b10336"
      unitRef="usd">7691900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTMtNi0xLTEtMzYwOTg_c0fcb7b4-93b4-4369-aa62-693af26d73b6"
      unitRef="usd">7450000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTQtNC0xLTEtMzYwOTg_2f9d75bf-cf11-4f88-9501-e69ccf30d286"
      unitRef="usd">2489300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTQtNi0xLTEtMzYwOTg_d21b2730-137d-4386-a06b-976e1a32a8e3"
      unitRef="usd">2830400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTUtNC0xLTEtMzYwOTg_f1890466-5f82-4999-9856-c7f219ebcba1"
      unitRef="usd">8985100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTUtNi0xLTEtMzYwOTg_dced8d05-9e93-4223-a892-15c4d41ba0c3"
      unitRef="usd">8681900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTctNC0xLTEtMzYwOTg_006527f0-d7f8-41c1-975d-e9b2c062886b"
      unitRef="usd">4082700000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTctNi0xLTEtMzYwOTg_470a358b-9121-47c8-804e-e0937a462291"
      unitRef="usd">3475400000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:Assets
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTktNC0xLTEtMzYwOTg_f51f2a02-68ae-48ff-b3d8-743c86eab273"
      unitRef="usd">48806000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMTktNi0xLTEtMzYwOTg_855d5cf1-7871-4478-944a-42ea9c1dc354"
      unitRef="usd">46633100000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjItNC0xLTEtMzYwOTg_ad120af0-0b38-4502-b784-01351238b665"
      unitRef="usd">1538300000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjItNi0xLTEtMzYwOTg_086d427d-33fc-436b-be55-e8f8f34a2734"
      unitRef="usd">8700000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjMtNC0xLTEtMzYwOTg_e76b145d-e5d2-4818-be08-eacbd0147df7"
      unitRef="usd">1670600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjMtNi0xLTEtMzYwOTg_da5e14e4-5988-4beb-8579-8b054a54eb1d"
      unitRef="usd">1606700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjQtNC0xLTEtMzYwOTg_be1b2f15-3693-4ede-bb7a-dc89a05b4784"
      unitRef="usd">958100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjQtNi0xLTEtMzYwOTg_136728b3-373e-48e8-b22a-15aa7b54ce2e"
      unitRef="usd">997200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjUtNC0xLTEtMzYwOTg_fe980c7a-9d64-4a29-9ae9-e49347f50ef4"
      unitRef="usd">6845800000</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjUtNi0xLTEtMzYwOTg_4261cc29-3d64-41ce-bc2c-ebd5b4e31b9d"
      unitRef="usd">5853000000</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjYtNC0xLTEtMzYwOTg_b4a422a9-d914-4fbf-9116-04e814e12ebc"
      unitRef="usd">885500000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjYtNi0xLTEtMzYwOTg_95076fe3-2aba-4e67-a54b-52ceb710f885"
      unitRef="usd">770600000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjctNC0xLTEtMzYwOTg_5ce7aec6-e0bb-4ce1-8c5d-92ce03730dea"
      unitRef="usd">126900000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjctNi0xLTEtMzYwOTg_e184e9d1-2c3f-480c-bcbb-0f8cdcdb902e"
      unitRef="usd">495100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjgtNC0xLTEtMzYwOTg_61eee2dc-1815-4270-832d-6265a633a3c1"
      unitRef="usd">3027500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMjgtNi0xLTEtMzYwOTg_553d314b-51ca-4f35-9142-5552877cdf3a"
      unitRef="usd">2750300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzAtNC0xLTEtMzYwOTg_e1584477-5834-4241-a456-22a814d7ce01"
      unitRef="usd">15052700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzAtNi0xLTEtMzYwOTg_9358681f-b795-4418-be4a-f6bfac90c8e4"
      unitRef="usd">12481600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzItNC0xLTEtMzYwOTg_f5282aef-f0f8-451c-9c81-d50a0e03f9de"
      unitRef="usd">15346400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzItNi0xLTEtMzYwOTg_a2ba9ba2-9c07-403f-bb02-c0abb7299e0e"
      unitRef="usd">16586600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzMtNC0xLTEtMzYwOTg_34904b7f-3573-420c-9158-17694473ba21"
      unitRef="usd">1954100000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzMtNi0xLTEtMzYwOTg_4e1f5830-436b-4eb2-aaad-633c035934ae"
      unitRef="usd">4094500000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzQtNC0xLTEtMzYwOTg_be7ddb0b-91a5-4b06-8227-48b552333786"
      unitRef="usd">3920000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzQtNi0xLTEtMzYwOTg_d4c35dd4-fd42-4794-8b27-0d6c7fce32e3"
      unitRef="usd">3837800000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNC0xLTEtNjExMTQ_4b596070-ee1e-4841-8fa4-11101c56b004"
      unitRef="usd">1733700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNi0xLTEtNjExMTc_f99c5e51-1a4b-48b4-84ef-84a24a1745cf"
      unitRef="usd">2099900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNC0xLTEtMzYwOTg_fae6028c-8b07-4cc6-88bc-d9a719623bcb"
      unitRef="usd">1644300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzUtNi0xLTEtMzYwOTg_72a70790-2d31-4568-a8b7-95539b2274a0"
      unitRef="usd">1707500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzgtNC0xLTEtMzYwOTg_408cc0aa-40cc-49bf-be68-4d088b83b8e7"
      unitRef="usd">24598500000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzgtNi0xLTEtMzYwOTg_0235ebef-7f8a-4aa1-b0b1-22fd87d2158e"
      unitRef="usd">28326300000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzktNC0xLTEtMzYwOTg_8b8d8bb6-7c4d-48ad-b117-2851032cfa1b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfMzktNi0xLTEtMzYwOTg_c3964bbd-4164-4fff-99b3-9dfc92e87f2f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV81Mg_d01b82ae-b11c-47fd-bc67-259206d53fc4"
      unitRef="shares">3200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV81Mg_f67e200c-98c7-4349-a7ae-2a9b8549e93b"
      unitRef="shares">3200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV83Mw_d8de427f-f303-49ac-b584-fa6b4cb375f5"
      unitRef="shares">954116</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo5ZWFiY2M5NDY4Yjc0OTI1OWI2YjU4Y2JiZmNmY2I3ZV84Nw_0c258676-1fe5-417e-964b-f1bba2882773"
      unitRef="shares">957077</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtNC0xLTEtMzYwOTg_8ef85419-be93-4fd2-8332-61f251b46111"
      unitRef="usd">596300000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDEtNi0xLTEtMzYwOTg_aeaf363a-46fd-4d6b-bf13-6008b720e05d"
      unitRef="usd">598200000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDItNC0xLTEtMzYwOTg_9e86f992-4423-4542-bde0-b83041476aef"
      unitRef="usd">6833400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDItNi0xLTEtMzYwOTg_f280791f-53e7-4e80-a2ed-d8098c3652da"
      unitRef="usd">6778500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDMtNC0xLTEtMzYwOTg_b280cc66-9eaf-495a-b93e-c09235f28dee"
      unitRef="usd">8958500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDMtNi0xLTEtMzYwOTg_9be5adbb-fa77-467a-9a86-c692a70b590f"
      unitRef="usd">7830200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDQtNC0xLTEtMzYwOTg_5ca2b732-7bb7-4cce-96a1-1e137a5d7f2d"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDQtNi0xLTEtMzYwOTg_5ebf123a-96f9-4875-9262-c18ee98ef9a2"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDUtNC0xLTEtMzYwOTg_4f55fdcd-fe4a-47da-9152-ad964cf49e6c"
      unitRef="usd">-4343100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDUtNi0xLTEtMzYwOTg_683ffd55-6190-428e-87e3-14daa8e511c4"
      unitRef="usd">-6496400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDYtNC0xLTEtMzYwOTg_5746a773-4d11-405c-884c-4144774884aa"
      unitRef="usd">52700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDYtNi0xLTEtMzYwOTg_0cd6c885-c77b-459d-9f73-12661c9afdd7"
      unitRef="usd">55700000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDctNC0xLTEtMzYwOTg_94fc7d9a-a48d-4c7e-8d65-0e70b0a527b9"
      unitRef="usd">8979200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDctNi0xLTEtMzYwOTg_feb7074e-b156-4770-a3f4-821e4077b3ed"
      unitRef="usd">5641600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDgtNC0xLTEtMzYwOTg_5288005d-1081-4547-9cb2-8a066f0813c6"
      unitRef="usd">175600000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDgtNi0xLTEtMzYwOTg_5dbc7113-e6a6-4c78-a942-6e1f1c2dc42d"
      unitRef="usd">183600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDktNC0xLTEtMzYwOTg_8f1534b6-7965-4835-92be-0c85612062ff"
      unitRef="usd">9154800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNDktNi0xLTEtMzYwOTg_f863b454-4677-432d-b375-df16322f849c"
      unitRef="usd">5825200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNTAtNC0xLTEtMzYwOTg_7de9d405-81fe-4b64-9a26-7c8fa964a5ae"
      unitRef="usd">48806000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85MS9mcmFnOjQwMjQ0Nzg5MGZkMDRlNWE4MzdmMzU1NjBiZjUxNzM2L3RhYmxlOjBmZjJmYzAzMzQ0NzQyM2M4MzA1N2QwMjc2YzM4ZTk2L3RhYmxlcmFuZ2U6MGZmMmZjMDMzNDQ3NDIzYzgzMDU3ZDAyNzZjMzhlOTZfNTAtNi0xLTEtMzYwOTg_107f93a4-c923-4986-a891-4cef46424fb6"
      unitRef="usd">46633100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ib49b2b7f42884738a47622d8db6c8d71_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xLTEtMS0zNjA5OA_91e0e90b-b2ce-428b-b015-561d4fc58bb5"
      unitRef="shares">1057639000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib49b2b7f42884738a47622d8db6c8d71_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0zLTEtMS0zNjA5OA_e5f8944b-1ec3-42d5-9f2a-daae951a92d6"
      unitRef="usd">661000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71f2ebcb04234bb78d53e95c789a7b18_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy01LTEtMS0zNjA5OA_045fe533-fa8a-44c4-b4f7-1fb2c07c5290"
      unitRef="usd">6583600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i386013c272b445c8b61ea4782a574cd9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy03LTEtMS0zNjA5OA_c5a6c4cb-0b36-458d-806a-12c9371d8695"
      unitRef="usd">11395900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6da9dd99174a476bbcf317f5a6d40e2f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy05LTEtMS0zNjA5OA_f4e01c52-fb69-4936-b12d-49caf1224323"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f786d93b75241c98d9db2267b3c5983_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xMS0xLTEtMzYwOTg_40f9ced5-4211-4c2c-a92d-d7cbe5011079"
      unitRef="usd">-5729200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5d195254fb024cf89d97aaed06aee2a4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xMy0xLTEtMzYwOTg_b6995842-bfbd-4860-a9d8-e8974e5ffc20"
      unitRef="shares">604000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d195254fb024cf89d97aaed06aee2a4_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xNS0xLTEtMzYwOTg_7dcbe2f1-a003-486b-a686-92c2bd2d7c17"
      unitRef="usd">-69400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafb85a614be34013a6354f3d76b46357_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMy0xNy0xLTEtMzYwOTg_6613c979-2738-4279-b74b-0d6fb3499db4"
      unitRef="usd">1080400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNC03LTEtMS0zNjA5OA_fba86ce4-7b7f-44c7-94a3-8a31f95cff58"
      unitRef="usd">8318400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNC0xNy0xLTEtMzYwOTg_116f7ff3-76b8-4d47-b4e1-c72c31f7e7f3"
      unitRef="usd">37700000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia85d124a50b14e73af531af45079e36c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNS0xMS0xLTEtMzYwOTg_5dd094d0-f908-4dd6-9d22-db127bc5c6b5"
      unitRef="usd">-794400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNS0xNy0xLTEtMzYwOTg_fd6c9342-361a-4c9b-9cd6-fd18108f118e"
      unitRef="usd">11000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNi0wLTEtMS0zNjA5OC90ZXh0cmVnaW9uOjc3NjkzYTRmODllYTRjM2ViZWIzN2NiMWUxMjIyYzhlXzc2OTY1ODEzOTQ0ODE_c02fe7d4-b4a3-4cf7-bdf3-dfdad726b43a"
      unitRef="usdPerShare">2.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNi03LTEtMS0zNjA5OA_dc4bc245-4925-44b6-9817-750750186611"
      unitRef="usd">2430500000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0xLTEtMS0zNjA5OA_fd13a471-1e90-4a18-a0ba-373e158aab55"
      unitRef="shares">102640000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0zLTEtMS0zNjA5OA_674ed41c-0c32-4a9b-8ebd-783f42790bdf"
      unitRef="usd">64100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ifb0ebf4846f8469aa4175b5fcd9f0f30_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy03LTEtMS0zNjA5OA_44a89f35-900a-4b47-abb7-aad97926fb39"
      unitRef="usd">12363400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0xMy0xLTEtMzYwOTg_8ec82693-b4ff-420d-8330-cc84a66f256d"
      unitRef="shares">102640000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfNy0xNS0xLTEtMzYwOTg_e0ef78b3-6ad6-48d7-b12f-4e96a9824276"
      unitRef="usd">-12427500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOC0xMy0xLTEtMzYwOTg_a9043e24-1123-4487-bf83-0faf1cf33452"
      unitRef="shares">37639000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOC0xNS0xLTEtMzYwOTg_4184d0bd-b129-4313-a39b-3e9b98acbf24"
      unitRef="usd">4400000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0xLTEtMS0zNjA5OA_06872b50-3707-4cce-bb8c-f63a477a60e0"
      unitRef="shares">3057000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic00d8cb70ee742c1880aa19135ee1930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0zLTEtMS0zNjA5OA_5cf2a3a0-c58e-41b4-b239-8c0df97f521f"
      unitRef="usd">1900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id73859b7dcd34e62805fa367251b795b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS01LTEtMS0zNjA5OA_aff8a076-1793-44ac-9dc9-315c470924f1"
      unitRef="usd">-210700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0xMy0xLTEtMzYwOTg_194afbf7-94a4-4163-bd75-ad33c1a9fd95"
      unitRef="shares">74000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfOS0xNS0xLTEtMzYwOTg_456da579-79a7-46ee-b64c-3d77cfe839c5"
      unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id73859b7dcd34e62805fa367251b795b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTAtNS0xLTEtMzYwOTg_361866e8-0661-469b-9e59-c357bb294b29"
      unitRef="usd">312400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <lly:StockAcquiredDuringPeriodSharesExchangeOffer
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTEtMTMtMS0xLTQxODIw_0d5f0629-6398-429d-9a34-efd230987d0f"
      unitRef="shares">65001000</lly:StockAcquiredDuringPeriodSharesExchangeOffer>
    <lly:StockAcquiredDuringPeriodValueExchangeOffer
      contextRef="iee53cda08ced49258f6fa1c9aebeb341_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTEtMTUtMS0xLTQxODMz_e00b6ea1-66dc-4fdb-b932-75c1e4e69e34"
      unitRef="usd">8027500000</lly:StockAcquiredDuringPeriodValueExchangeOffer>
    <lly:ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTItMTctMS0xLTM2MDk4_2d729844-fb78-471c-a03b-4839486eb6ab"
      unitRef="usd">-1028900000</lly:ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary>
    <us-gaap:StockholdersEquityOther
      contextRef="ic65882f2e6334160a0cfce12f6c66b5f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTMtMTctMS0xLTM2MDk4_fbee7ecd-ec6b-45cd-8ea9-d8d6420ec567"
      unitRef="usd">8000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i27c5a45e3bbf4d98a9b6fa76889230d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMS0xLTEtMzYwOTg_94d261f3-3595-4a42-be0d-655733046d80"
      unitRef="shares">958056000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27c5a45e3bbf4d98a9b6fa76889230d0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMy0xLTEtMzYwOTg_4c60e665-1c84-4c3a-92e8-7b93db446000"
      unitRef="usd">598800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib74aad145fd948ae9241828f24c78548_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtNS0xLTEtMzYwOTg_7b38dd60-7e01-4a4e-9365-f589dd3b4c11"
      unitRef="usd">6685300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e3201d8c6744198aed86ef435de4ee7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtNy0xLTEtMzYwOTg_f9c07f01-ffaa-4534-9840-a74f0d8b1d22"
      unitRef="usd">4920400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i442a597afbe14853a841ac8d37aa9e20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtOS0xLTEtMzYwOTg_af48d418-08b1-4555-8078-81fc10a0df5f"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ad901c3559244039c17a109cdaa8bf4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTEtMS0xLTM2MDk4_07867320-aabb-430e-a561-d4cb873f1772"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i4b908b0dc9bf437c83b6a218c5c17f88_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTMtMS0xLTM2MDk4_22e33b6e-d0b8-4719-9c5d-f8760a0c65c5"
      unitRef="shares">530000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b908b0dc9bf437c83b6a218c5c17f88_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTUtMS0xLTM2MDk4_1ec65a62-780a-4a51-bff8-5245213d8683"
      unitRef="usd">-60800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40e50a9ab65b4a50b58927a520657bd2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTQtMTctMS0xLTM2MDk4_1c042bb9-a1da-4dfe-8bd9-bb2da5a1682c"
      unitRef="usd">92200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTUtNy0xLTEtMzYwOTg_c6dca2ba-b2a1-4443-88e0-ebdefe39ce1b"
      unitRef="usd">6193700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTUtMTctMS0xLTM2MDk4_72ec3a2f-ff66-45ab-bc75-5dd7a14900ba"
      unitRef="usd">126600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8ed8c31b73e04315b4155a37149b9553_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTYtMTEtMS0xLTM2MDk4_4dface74-8064-40cb-adc5-c234d9e8f3cc"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTYtMTctMS0xLTM2MDk4_28f4a1c9-7012-4e37-9123-468e49a30869"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTctMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjpiNzk0OTYzN2I5MjU0NmNmODVhOWE2ZGRhYjA1NDNkNF83Njk2NTgxMzk0NDgx_cfa34860-5131-4841-921e-af1e6eff1f39"
      unitRef="usdPerShare">3.07</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTctNy0xLTEtMzYwOTg_2447f6f7-f198-4e94-9d1e-4e1b6f20c168"
      unitRef="usd">2786200000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMS0xLTEtMzYwOTg_13b6d76e-69f1-4355-8d04-8eb1ed318bbc"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMy0xLTEtMzYwOTg_511231d4-19c1-454f-bc46-5b112a15d7ed"
      unitRef="usd">2300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i1816dd16cb2e46b79e3be25583cad02b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtNy0xLTEtMzYwOTg_8f5d440e-1713-45f8-a509-56121e693516"
      unitRef="usd">497700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMTMtMS0xLTM2MDk4_fb8dd9a4-e5d6-43b7-af9a-df1017c80d8d"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTgtMTUtMS0xLTM2MDk4_6b15b8b0-e37f-430c-a6f7-07c31d9ccd4d"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTktMTMtMS0xLTM2MDk4_04952cff-b9c4-4b3f-9c6d-d1de8c1d954d"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMTktMTUtMS0xLTM2MDk4_a5dba540-9a28-45c0-9ab7-e491646a6fdc"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMS0xLTEtMzYwOTg_725ad3cf-e810-4678-ac41-442878f95361"
      unitRef="shares">2648000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i74d6d4eb8a654a9c9a4e23209152b8c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMy0xLTEtMzYwOTg_feba0acc-77bb-4937-a07d-63676590722d"
      unitRef="usd">1700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtNS0xLTEtMzYwOTg_d9cd7336-72b4-441a-8507-2856494e6c40"
      unitRef="usd">-212700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMTMtMS0xLTM2MDk4_d5913793-8b65-4dc8-b53b-bf8bb82b3c3e"
      unitRef="shares">43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i24f4e379653645eb9685399ff3793535_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjAtMTUtMS0xLTM2MDk4_1a930324-3ff1-42fb-90e4-71f433fb379a"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjEtNS0xLTEtMzYwOTg_7d51dacd-957c-4ba6-ac6d-1314cefb52a2"
      unitRef="usd">308100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i953428edeaff4b748abe9a1237ab9ca3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjQtNS0xLTEtMzYwOTg_1a2f0234-733b-4433-ae4f-73f985df134d"
      unitRef="usd">2200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i87f9a44f4b5c4f5492f2aafd639603de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjQtMTctMS0xLTM2MDk4_dfccd75d-66cf-4511-8906-5dd752d5040c"
      unitRef="usd">35200000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i76aeae647cb549b29344d42e8dcaf22e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMS0xLTEtMzYwOTg_b4b3b9f5-e111-4aae-937f-b15265976a1c"
      unitRef="shares">957077000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76aeae647cb549b29344d42e8dcaf22e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMy0xLTEtMzYwOTg_9b08bdf5-d64b-41fe-9e2c-aeff0c09d033"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i844c6baec2a24ddfb0175699e7c9dc89_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtNS0xLTEtMzYwOTg_e8d7512f-6319-4980-b3b9-6def6e34311d"
      unitRef="usd">6778500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62a1f40609cb46c88a55f8a58cc0d213_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtNy0xLTEtMzYwOTg_f74456f1-cb89-4235-bd10-3626ce84dd53"
      unitRef="usd">7830200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98a5b8a498064844963780b1fa864865_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtOS0xLTEtMzYwOTg_2ef36c87-edb1-46f0-9e5e-1ad0cc8d4892"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee2e8d9c52ce423296c40435172ba45f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTEtMS0xLTM2MDk4_6224992b-b504-48f7-baf3-e8941d151ae1"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ic59cb920c729498ca310e03243606c6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTMtMS0xLTM2MDk4_9f938671-d361-4cf6-96ff-647f5c84f12f"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic59cb920c729498ca310e03243606c6a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTUtMS0xLTM2MDk4_c8a25912-6103-4eac-9419-04e13e7ffe76"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1cc336a64ff4c18b6d2f64e83fb7ca5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjUtMTctMS0xLTM2MDk4_33ee561c-f545-4f10-972e-39a97be7e6fe"
      unitRef="usd">183600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjYtNy0xLTEtMzYwOTg_ac50741f-313a-4b47-94c8-01241316a5b7"
      unitRef="usd">5581700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjYtMTctMS0xLTM2MDk4_89e74151-67da-4c53-85d5-2238050c91ab"
      unitRef="usd">3400000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6224d7ff3d6b43fb824c0b8619fad9b4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjctMTEtMS0xLTM2MDk4_59a11ce3-f87e-4594-b00a-a0d7ed777d77"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjctMTctMS0xLTM2MDk4_c920f750-0eec-4cb3-b25b-dd23741f2be8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjgtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjozNDIwN2Q5NzhhZDk0MGQ5OWI5YzgyNDJkNjZiOWJlNV83Njk2NTgxMzk0NDgx_f6f31a67-7220-41b8-90e4-008cdbc69007"
      unitRef="usdPerShare">3.53</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjgtNy0xLTEtMzYwOTg_f80ca892-12b8-4588-a345-85a866344322"
      unitRef="usd">3201700000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMS0xLTEtMzYwOTg_16ddc55c-86e8-49d6-b113-ac76fa6a1a64"
      unitRef="shares">5412000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMy0xLTEtMzYwOTg_764c1346-1564-485d-8cc3-47288f2384f8"
      unitRef="usd">3400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktNy0xLTEtMzYwOTg_b2504977-40f9-49b3-968a-0abf0a1f0b43"
      unitRef="usd">1246600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMTMtMS0xLTM2MDk4_17411d1e-22d3-470b-a4e5-5f202b9141b5"
      unitRef="shares">5412000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMjktMTUtMS0xLTM2MDk4_3067fdb0-d169-4508-811e-575c6803469e"
      unitRef="usd">-1250000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzAtMTMtMS0xLTM2MDk4_c47070e9-6834-40f7-ac02-b4a3af3aa409"
      unitRef="shares">5412000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzAtMTUtMS0xLTM2MDk4_65e160ce-6c5d-4ca9-ac3c-9ebf54c3a2ad"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMS0xLTEtMzYwOTg_e633ce28-2879-4652-92d7-a7c01702aa50"
      unitRef="shares">2451000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i439b778727d34b8dac6f83af917c3d18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMy0xLTEtMzYwOTg_7e0f02f3-2db3-47b7-a2ab-d23cc1a8eb9e"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i15da3dd702544a0897dc45c712757909_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtNS0xLTEtMzYwOTg_80a2d499-638e-43d7-96f0-c870571ea3fa"
      unitRef="usd">-287900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMTMtMS0xLTM2MDk4_eb0d4a55-1149-4170-ab2a-d4a0ab0bcac6"
      unitRef="shares">24000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ief1877a0643040e3aaa70848d1e05f6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzEtMTUtMS0xLTM2MDk4_0b1b162d-776b-4322-b736-5e8dadb836fc"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i15da3dd702544a0897dc45c712757909_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzItNS0xLTEtMzYwOTg_4ac2f3dc-c507-4819-a3b5-5d80975c834a"
      unitRef="usd">342800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="if6461da26ed149deab96c87d5cfef978_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzUtNy0xLTEtNDE5ODU_698b43c7-3d02-4cf1-9b52-3613e960871d"
      unitRef="usd">5100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia10e158f9e5f4539ac32095d0aa8debf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzUtMTctMS0xLTM2MDk4_a726d25b-7356-4902-808e-d802a776fa7f"
      unitRef="usd">11400000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i075446bdf9684175b09f4719c83305db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMS0xLTEtMzYwOTg_826b5864-de8d-49f4-94d1-93c65d7f5941"
      unitRef="shares">954116000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i075446bdf9684175b09f4719c83305db_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMy0xLTEtMzYwOTg_aae769fa-65ea-4d3e-9200-e42575c18885"
      unitRef="usd">596300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5960a9f72a304f2d91d83b22d8017bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtNS0xLTEtMzYwOTg_ec28db14-6117-4e5d-b394-d97474e35387"
      unitRef="usd">6833400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39610d1c5d9d46bc880d62462c72fd8e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtNy0xLTEtMzYwOTg_30ba8e18-ee84-452f-9adc-53bd36689993"
      unitRef="usd">8958500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8449ae740dff423f9a21a63ae89c9c0f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtOS0xLTEtMzYwOTg_b1c7c383-1158-417f-8204-77981de5c71f"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a0bae0b2bc940ec8f928a12995eb037_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTEtMS0xLTM2MDk4_9ad8ccf3-f969-448e-a503-01d01fd3f15f"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i25abdb96f76b4a36b8f4b2e517289462_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTMtMS0xLTM2MDk4_57abdb11-11de-4669-839b-1ba954821138"
      unitRef="shares">463000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25abdb96f76b4a36b8f4b2e517289462_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTUtMS0xLTM2MDk4_57e71cf9-8a6f-4c93-a6ef-644cadba52b6"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a0ee22589c346b4ba844a54471306b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85NC9mcmFnOjk1Mjk3Njk2ZGMwMDQ4NWZhMDgyMTEzZDc4YzY5Y2IxL3RhYmxlOjJiZjI1NmE5NWJmZjRkMTE4NmM2ZDQzNzkwMDZhNTc5L3RhYmxlcmFuZ2U6MmJmMjU2YTk1YmZmNGQxMTg2YzZkNDM3OTAwNmE1NzlfMzYtMTctMS0xLTM2MDk4_a92cf04a-0a5f-4344-bd54-d2c9dea6e130"
      unitRef="usd">175600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMi00LTEtMS0zNjA5OA_a064a5ef-5803-4249-a3b0-439b556ce7bb"
      unitRef="usd">5581700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMi02LTEtMS0zNjA5OA_5c796367-3c44-48d4-998f-71298d479ccb"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMi04LTEtMS0zNjA5OA_f315e93e-2d6a-41bd-8617-ad8cb4058643"
      unitRef="usd">8318400000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNC00LTEtMS0zNjA5OA_3a748cda-d867-463f-a369-eccb4c99e9c0"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNC02LTEtMS0zNjA5OA_4f51ed51-f01a-46d4-8774-4fc2371e8889"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNC04LTEtMS0zNjA5OA_711e3155-d49f-4a76-be0a-d3c01f9fa8fb"
      unitRef="usd">3680500000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNS00LTEtMS0zNjA5OA_e3db80da-9aaf-425d-a05a-c67c7c77bcfe"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNS02LTEtMS0zNjA5OA_97e1817f-a543-4b54-b22c-5d2497bb89f7"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNS04LTEtMS0zNjA5OA_68bc8df3-53be-4e59-8ac8-d40f63b5a676"
      unitRef="usd">309800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNi00LTEtMS0zNjA5OA_ac714d32-8b97-4281-ba13-d4e06ad175a2"
      unitRef="usd">1547600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNi02LTEtMS0zNjA5OA_489ae14e-9aab-4321-abd0-b7137a84cde3"
      unitRef="usd">1323900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNi04LTEtMS0zNjA5OA_e18d4b61-fba6-4c2a-805c-661d10146141"
      unitRef="usd">1232600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy00LTEtMS04NTI3Mg_94677957-c376-4223-85ac-1429c4377a64"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy02LTEtMS04NTI3Mg_da86af03-f415-478d-9bc0-fdd6f1d0e0c6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy04LTEtMS04NTI3Mg_447cd1bd-18dd-4336-9abf-cda17cd11171"
      unitRef="usd">-252500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy00LTEtMS0zNjA5OA_5adc4333-5361-4f73-86df-daea4b8af846"
      unitRef="usd">802300000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy02LTEtMS0zNjA5OA_691d0bde-3912-48a2-b34a-5c1c495b3bee"
      unitRef="usd">134500000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNy04LTEtMS0zNjA5OA_a6419dfe-6dcf-4fde-aeac-be8cd0cc53ce"
      unitRef="usd">-62400000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOC00LTEtMS0zNjA5OA_6867446c-14a2-4795-a787-fbb5f3d2463d"
      unitRef="usd">342800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOC02LTEtMS0zNjA5OA_07e6bbe3-fa31-449a-8882-d7b28841751c"
      unitRef="usd">308100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOC04LTEtMS0zNjA5OA_576d5fa9-d71d-4189-be5a-4e21661bcc12"
      unitRef="usd">312400000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOS00LTEtMS0zNjA5OA_518f95b6-afdf-4190-9808-a0af16ad5454"
      unitRef="usd">178000000.0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOS02LTEtMS0zNjA5OA_4ffc864f-2e5a-4bb3-b258-6cbe8fb8a51d"
      unitRef="usd">1438500000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfOS04LTEtMS0zNjA5OA_8d746745-e3ea-4bae-8a19-1422ed578207"
      unitRef="usd">403100000</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTAtNC0xLTEtMzYwOTg_76fc6429-fb84-407e-a6c6-e70476bafbce"
      unitRef="usd">874900000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTAtNi0xLTEtMzYwOTg_dde86e1f-1dfe-4eb1-9fb2-4de15ebe8fbb"
      unitRef="usd">660400000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTAtOC0xLTEtMzYwOTg_5a42b9fa-3d35-4ebd-90a3-bb4bde515150"
      unitRef="usd">239600000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTEtNC0xLTEtMzYwOTg_aef20b70-ea86-44fc-a12d-9862a5a4440e"
      unitRef="usd">511400000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTEtNi0xLTEtMzYwOTg_2a9a6b21-efa7-45e4-a7e9-c78c6f88a2c7"
      unitRef="usd">333900000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTEtOC0xLTEtMzYwOTg_af18db97-853e-43e4-9407-4ba3f1d118d1"
      unitRef="usd">499300000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTMtNC0xLTEtMzYwOTg_aa932607-f0ae-4e33-89cf-ac7c9fa79126"
      unitRef="usd">1278300000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTMtNi0xLTEtMzYwOTg_7e23d35b-a00a-44e8-b4ef-19c19fe8f9c7"
      unitRef="usd">1350200000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTMtOC0xLTEtMzYwOTg_e7cd689e-fb29-4b14-9b85-9f42aa334589"
      unitRef="usd">127200000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTQtNC0xLTEtMzYwOTg_bff79d63-43aa-4c99-84c1-4b3e0c8fb4b6"
      unitRef="usd">235900000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTQtNi0xLTEtMzYwOTg_7d84b8f9-a21f-400e-9d1b-59b3826648c9"
      unitRef="usd">533400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTQtOC0xLTEtMzYwOTg_7e03d37b-073e-4785-92cc-f8455386bac9"
      unitRef="usd">258700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTUtNC0xLTEtMzYwOTg_e4a58bc6-70dd-4ebf-8beb-f272462726d1"
      unitRef="usd">-1515400000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTUtNi0xLTEtMzYwOTg_d0525a6d-7db0-4d92-8e80-e3ac94e2a496"
      unitRef="usd">457100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTUtOC0xLTEtMzYwOTg_062a1343-5f85-4324-a8c7-bd212be809bc"
      unitRef="usd">602300000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTYtNC0xLTEtMzYwOTg_8ad5308d-0c11-4276-abce-0add61cd7768"
      unitRef="usd">-359700000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTYtNi0xLTEtMzYwOTg_f997917f-45e2-4b11-a9d1-a88f235c4547"
      unitRef="usd">322000000.0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTYtOC0xLTEtMzYwOTg_b3f4bf1a-0cf9-4796-94bc-520a11c72fe2"
      unitRef="usd">-221300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTctNC0xLTEtMzYwOTg_3e81056a-ae9b-416f-bb91-61082b708583"
      unitRef="usd">-664100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTctNi0xLTEtMzYwOTg_55e8e1cc-d110-4de4-b4f9-c4c27c373d46"
      unitRef="usd">1271300000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTctOC0xLTEtMzYwOTg_0108a826-d5b2-4e92-85ab-c1ea3df761ac"
      unitRef="usd">-477700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTgtNC0xLTEtMzYwOTg_fabcab39-6af9-4306-8df1-cc67b538a150"
      unitRef="usd">7260700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTgtNi0xLTEtMzYwOTg_b4fa0558-8411-4d18-9965-14d10ff5beb9"
      unitRef="usd">6499600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMTgtOC0xLTEtMzYwOTg_792f9c45-ed0e-45e6-b1b0-120c28079d00"
      unitRef="usd">4836600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjAtNC0xLTEtMzYwOTg_83cd7b1d-2d1c-4140-9d9e-7920a70b2f99"
      unitRef="usd">1309800000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjAtNi0xLTEtMzYwOTg_9d1304a8-5281-4484-8cca-512485d7ddbe"
      unitRef="usd">1387900000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjAtOC0xLTEtMzYwOTg_6775a46c-603e-488a-a90a-ef2bc9cedf3d"
      unitRef="usd">1033900000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjEtNC0xLTEtMzYwOTg_86731175-fa3d-42e0-a9f4-0594816acfe7"
      unitRef="usd">47400000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjEtNi0xLTEtMzYwOTg_ad9ace9f-ab77-44de-a3ae-9df839c946a9"
      unitRef="usd">129700000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjEtOC0xLTEtMzYwOTg_e42fef64-767a-45ea-a12b-c3e4d87933b2"
      unitRef="usd">136600000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjItNC0xLTEtMzYwOTg_18c24744-c0c6-4dc8-871b-6fdc7560f978"
      unitRef="usd">83500000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjItNi0xLTEtMzYwOTg_8444794e-d707-421a-bd5e-7b9fb46b990f"
      unitRef="usd">11400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjItOC0xLTEtMzYwOTg_f1f2bb5f-6357-42e1-8336-26d13bfc3ecb"
      unitRef="usd">42700000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjMtNC0xLTEtMzYwOTg_6fd44347-79c8-449c-bbd4-2b3dabd7ba5d"
      unitRef="usd">800000000.0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjMtNi0xLTEtMzYwOTg_4fae9ec8-7551-4ae1-bdee-b91891ebea36"
      unitRef="usd">757100000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjMtOC0xLTEtMzYwOTg_c7d8f9fc-cf4d-4f1d-aa47-e00b0b644516"
      unitRef="usd">609800000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjQtNC0xLTEtMzYwOTg_53dbf9ac-7bd4-4543-8dab-c62077d9656f"
      unitRef="usd">929900000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjQtNi0xLTEtMzYwOTg_7e572a74-9eae-43ac-91cd-fb4ce9876693"
      unitRef="usd">358700000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjQtOC0xLTEtMzYwOTg_32dfcc7c-80f2-4517-bbf2-2b96b42c74d3"
      unitRef="usd">247500000</us-gaap:PaymentsToAcquireOtherInvestments>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjUtNC0xLTEtMzYwOTg_0bc32afe-7edf-4214-bf6b-7206b4fea643"
      unitRef="usd">563400000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjUtNi0xLTEtMzYwOTg_52364d58-e614-4275-815b-002e149f79d2"
      unitRef="usd">641200000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjUtOC0xLTEtMzYwOTg_ea165013-f8eb-4549-9110-78ebd96ee35d"
      unitRef="usd">319600000</lly:PurchasedInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjYtNC0xLTEtMzYwOTg_2f11ef27-3c5d-4bc2-a3e5-a0f70401170c"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjYtNi0xLTEtMzYwOTg_7b12a14c-ff64-4ca9-852a-6b7a7ade8a04"
      unitRef="usd">849300000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjYtOC0xLTEtMzYwOTg_60b73a0e-ac75-47bb-9af4-fc2953b7c886"
      unitRef="usd">6917700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjctNC0xLTEtMzYwOTg_6b74535b-8d66-4e84-a487-c1de1eb373a3"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjctNi0xLTEtMzYwOTg_17f84ffe-59ce-4751-a455-d65926430632"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjctOC0xLTEtMzYwOTg_271b1dc9-0bcb-42cd-9764-5162bcccf8dc"
      unitRef="usd">374000000.0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjgtNC0xLTEtMzYwOTg_20a8a578-73a6-4a6e-bcf1-fc453dd15625"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjgtNi0xLTEtMzYwOTg_e6eb8142-c84d-4bf1-8b66-649155bd84e5"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjgtOC0xLTEtMzYwOTg_5149e949-cd78-4535-b6df-e452f3865920"
      unitRef="usd">354800000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjktNC0xLTEtMzYwOTg_eb63e2e2-74ef-4a30-af01-9b0100aed8de"
      unitRef="usd">-24300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjktNi0xLTEtMzYwOTg_e1317e79-274b-46e1-b31c-e8013b46472c"
      unitRef="usd">-102800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMjktOC0xLTEtMzYwOTg_4079d1b7-6936-4b6d-b6ca-8f6cb1b46862"
      unitRef="usd">248700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzAtNC0xLTEtMzYwOTg_f26191db-6857-43c3-967a-57267a3b19f1"
      unitRef="usd">-2762300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzAtNi0xLTEtMzYwOTg_99954367-d476-4afd-83c9-d3762ec03e19"
      unitRef="usd">-2258900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzAtOC0xLTEtMzYwOTg_87763083-a45e-4cb9-9261-6cc36d438dd2"
      unitRef="usd">-8082900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzItNC0xLTEtMzYwOTg_5e23a1f1-3091-42ee-850b-a6000ffb517f"
      unitRef="usd">3086800000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzItNi0xLTEtMzYwOTg_01cddf44-f0ef-4682-af42-b31475f9a7f3"
      unitRef="usd">2687100000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzItOC0xLTEtMzYwOTg_05903be1-c2ba-4aa5-9848-83616d0c0560"
      unitRef="usd">2409800000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzMtNC0xLTEtMzYwOTg_7d2009d6-d3c4-4fec-9e9a-ba3e23f6537f"
      unitRef="usd">-4000000.0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzMtNi0xLTEtMzYwOTg_c4c9ccd9-9e85-4e54-8d88-af99def796be"
      unitRef="usd">-1494200000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzMtOC0xLTEtMzYwOTg_5bc5ac25-c95d-4353-95c6-13eb3b09ea79"
      unitRef="usd">995400000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzQtNC0xLTEtMzYwOTg_e61411fe-19fe-4917-9da5-4900bb7462b4"
      unitRef="usd">2410800000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzQtNi0xLTEtMzYwOTg_27c7069a-c829-466b-854e-b190d9d6f7ae"
      unitRef="usd">2062300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzQtOC0xLTEtMzYwOTg_8a6becad-62fb-4d9a-a8a1-2e10c11bbb52"
      unitRef="usd">6556400000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzUtNC0xLTEtMzYwOTg_4d3cb1ce-20c2-4260-b351-51bc2a884397"
      unitRef="usd">1905400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzUtNi0xLTEtMzYwOTg_b759faf4-16b1-43ac-a387-83898c4cbdd6"
      unitRef="usd">276500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzUtOC0xLTEtMzYwOTg_a60347e8-566c-4cee-bf1c-91d385665ea4"
      unitRef="usd">2866400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzYtNC0xLTEtMzYwOTg_22b1a60b-ebbf-46d5-a610-3cc40f74ddfe"
      unitRef="usd">1250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzYtNi0xLTEtMzYwOTg_b459d312-69da-4516-8705-a2d80da2edc9"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzYtOC0xLTEtMzYwOTg_c0cc33a3-c798-499d-8c4b-3fe9b0bc698a"
      unitRef="usd">4400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzgtNC0xLTEtMzYwOTg_0eed52de-3fc7-4e95-8360-8e5acd33b9c6"
      unitRef="usd">-295900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzgtNi0xLTEtMzYwOTg_954b283e-6025-428c-8920-74c3cdd090c8"
      unitRef="usd">-241600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzgtOC0xLTEtMzYwOTg_c0ca0bb0-e694-4f42-87a3-9b5179e6ffb9"
      unitRef="usd">-200100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzktNC0xLTEtMzYwOTg_96ffdccf-6001-4286-86df-af2955d35d17"
      unitRef="usd">-4131300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzktNi0xLTEtMzYwOTg_0e52510d-9a53-446e-a1a5-d5961223fed9"
      unitRef="usd">-3137100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfMzktOC0xLTEtMzYwOTg_4ecbf66a-8499-4565-b1a9-3e70548c9503"
      unitRef="usd">-2324500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDAtNC0xLTEtMzYwOTg_fbc98cf7-314c-445e-81a3-f95135cbdc01"
      unitRef="usd">-205700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDAtNi0xLTEtMzYwOTg_7173bfe6-8404-4ff9-8c70-bbc3afbdbe69"
      unitRef="usd">216000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDAtOC0xLTEtMzYwOTg_aa7c7261-81b7-4650-a647-bee2b4230351"
      unitRef="usd">-89900000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDEtNC0xLTEtMzYwOTg_0a000cc3-6e75-45a1-8add-ae9eeda1ac71"
      unitRef="usd">161400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDEtNi0xLTEtMzYwOTg_81efa0a8-32b9-41db-bd93-63aa532fa01e"
      unitRef="usd">1319600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDEtOC0xLTEtMzYwOTg_b8eaf80d-8b0b-4a3f-b62e-96ebda03b51d"
      unitRef="usd">-5660700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjowYWNhNjExNTUxNWM0MTk1YmI0MDIzMjE2ZjFiZmJlOV82MQ_e47da504-bc19-4b11-8115-d3091448dfed"
      unitRef="usd">677500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItNC0xLTEtMzYwOTg_f95e5502-051a-415b-8321-c939ecb67542"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItNi0xLTEtMzYwOTg_d44ab462-da34-483a-b1ce-71daa3108942"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2161fbcc13a94af3a14765cc6ce775d6_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDItOC0xLTEtMzYwOTg_cadaf098-6c97-43e0-b8e3-c15dba05b590"
      unitRef="usd">7998200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDMtNC0xLTEtMzYwOTg_16e3bced-850d-4b00-ab7c-ecb8ffb64672"
      unitRef="usd">3818500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDMtNi0xLTEtMzYwOTg_ca7578f0-624a-4738-ae79-d93b91fae959"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV85Ny9mcmFnOjc2Zjk0NTQ2YTUzZjRlMTc5NWE0NjNkZWE3ZmQ4NjVlL3RhYmxlOjllNmU1YmU1ZjkwMDQyMTliODYzZGQ1Nzc5MTcwZWYzL3RhYmxlcmFuZ2U6OWU2ZTViZTVmOTAwNDIxOWI4NjNkZDU3NzkxNzBlZjNfNDMtOC0xLTEtMzYwOTg_74121cdd-5315-4baf-a1cd-58d0814b85b9"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MDg_88ee945e-a959-4f43-84e4-1dc852a4149e">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco Animal Health Incorporated (Elanco) common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Research and development costs, which are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D expense includes the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings Per Share (EPS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and Internet advertising, totaled approximately $1.2 billion, $1.1 billion, and $1.1 billion in 2021, 2020, and 2019, respectively, which was less than 5 percent of revenue each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform, &lt;/span&gt;provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard can be adopted immediately and is applicable to contracts entered into before January 1, 2023. We do not expect the transition from the use of LIBOR to an alternative reference rate to have a material impact to our consolidated statements of operations or balance sheets at the initial transition.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie9ba1030bd04458783b9caf2f17c3b41_I20190311"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzE2NzQ_be812c18-fdba-48bf-a6b6-23564bb8c024"
      unitRef="number">0.802</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MDA_e4139798-d2a7-4612-9b46-3a6bda094379">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Research and development costs, which are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D expense includes the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MTU_84c901fd-6fed-44c0-8a1f-c5017b2cee36">Earnings Per Share (EPS)We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg3OTc_356d792c-bbab-4c52-a10c-5071185b1fe4">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MTk_19e64d0f-03d9-4291-9ddc-285ee4f2deb9">Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2MDQ_fce93b7d-82ab-4319-89f8-5d9171f24cfa"
      unitRef="usd">1200000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2MDg_13854916-29a0-473d-99e3-0cb61172be07"
      unitRef="usd">1100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2MTY_01c6ed46-2e49-4f14-b178-4c4d0977e0b5"
      unitRef="usd">1100000000</us-gaap:AdvertisingExpense>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2Nzg_39ec4ce5-c3ee-4f68-a3b8-7a726f2980f5"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2Nzg_cde85914-f1eb-427f-a61f-39bbc65acc33"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0XzQ2Nzg_da07c667-0f60-4b53-814e-7c31171c9ddb"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDMvZnJhZzplOTEzMDY2MjQzOTc0NDMyOWM1NDFlMGE2NjhmMWU3NC90ZXh0cmVnaW9uOmU5MTMwNjYyNDM5NzQ0MzI5YzU0MWUwYTY2OGYxZTc0Xzg4MTM_3b9e9419-c589-45ab-974d-007f36081e22">Implementation of New Financial Accounting Standard&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Update 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform, &lt;/span&gt;provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard can be adopted immediately and is applicable to contracts entered into before January 1, 2023. We do not expect the transition from the use of LIBOR to an alternative reference rate to have a material impact to our consolidated statements of operations or balance sheets at the initial transition.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODM5_c994e3c6-c96d-4ea5-9af6-bd33b4d7046e">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,957.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,694.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,377.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,360.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,845.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,318.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $175.0 million, $135.6 million, and $301.5 million during the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December&#160;31, 2021, 2020, and 2019, our three largest wholesalers each accounted for between 15 percent and 20 percent of consolidated revenue. Further, they each accounted for between 18 percent and 28 percent of accounts receivable as of December&#160;31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. The following describe the most significant of these judgments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sales Rebates and Discounts - Background and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sales Returns - Background and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Actual U.S. product returns have been less than 2 percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record adjustments to revenue as a result of changes in estimates, for the judgments described above, for our most significant U.S. sales returns, rebates and discounts liability balances. Such adjustments for products shipped in previous periods resulted in approximately 2 percent or less increase to U.S revenue during each of the years ended December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration and Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;262.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract liabilities balances disclosed above as of December&#160;31, 2021 and 2020 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,914.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,155.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,557.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,320.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,132.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;807.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;683.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;832.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;389.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;588.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;173.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,719.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,909.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,468.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,602.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,233.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;827.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;834.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;515.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;358.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;674.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;481.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;210.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,028.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,712.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,542.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;670.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;324.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;791.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,881.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,479.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;542.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;434.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;390.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;614.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,283.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,978.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;441.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;360.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;707.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;233.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,566.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,563.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,811.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,507.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,310.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,596.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trajenta revenue includes Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,811.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,776.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,367.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,661.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,702.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,318.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODI5_1dc34034-7357-42dd-941d-1c946ae6d9bc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,957.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,694.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,377.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,360.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,845.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,318.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $175.0 million, $135.6 million, and $301.5 million during the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.537%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,914.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,155.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,557.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,320.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,132.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;807.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;683.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;832.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;389.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;588.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;173.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;111.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,719.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,909.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,468.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,602.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,233.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;827.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;834.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;515.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;358.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;674.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;481.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;210.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,028.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,792.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,712.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,542.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;670.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;324.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;791.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,881.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,479.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;542.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;434.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;390.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;614.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,283.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,978.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;441.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;360.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;707.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;233.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,566.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,563.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,811.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,507.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,310.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,596.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trajenta revenue includes Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,811.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,776.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,367.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,661.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,702.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,318.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,539.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i99ba0120ed084c1da3c0cb9a06a3535c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzEtMS0xLTEtMzYwOTg_ee4358e8-ddde-4680-b764-691e43edcb75"
      unitRef="usd">25957900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i595bde8d325b4f8cbe525ae5a8cc043a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzEtMy0xLTEtMzYwOTg_cfeb36cd-84f6-4ace-ad12-14bdc7615aec"
      unitRef="usd">22694800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9bbc4ab2a1ab4437a863acf75b60865b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzEtNS0xLTEtMzYwOTg_3ce40e11-c6b1-44c4-8e53-62e8eb827f8d"
      unitRef="usd">20377300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02e084561da84353a68fc13b0b1f1065_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzItMS0xLTEtMzYwOTg_db5ddf1e-6388-45e9-a7a5-a7138099119e"
      unitRef="usd">2360500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id78db9bb959f4a65b59c065a865101de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzItMy0xLTEtMzYwOTg_658295a9-3072-43b8-b251-43a9f2e5acb8"
      unitRef="usd">1845000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i768c5436d8e0411f87860a079a65368a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzItNS0xLTEtMzYwOTg_2fda8d72-2615-4628-a566-85d122bb601f"
      unitRef="usd">1942200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzMtMS0xLTEtMzYwOTg_abb2093f-aea0-4653-ba77-190bbd28232b"
      unitRef="usd">28318400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzMtMy0xLTEtMzYwOTg_0d43956e-3026-428f-a68f-39efb012af5d"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo2ZTE5MTlkOTQ5YjY0NTZjYmQ1MmEzOTQ5YThjNzdjZS90YWJsZXJhbmdlOjZlMTkxOWQ5NDliNjQ1NmNiZDUyYTM5NDlhOGM3N2NlXzMtNS0xLTEtMzYwOTg_d03f1c18-fa87-4492-b726-2fa236768e3a"
      unitRef="usd">22319500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if66a9d0bc8c447a7854e1d121fdd3fd9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzIyOA_77826cbf-8212-4103-9a51-09a9f056b55b"
      unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i447315375734437a83fd432f1d82adc3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzIzMg_37aa5559-5304-4eaf-8939-13a9f864eab9"
      unitRef="usd">135600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b153236a1d746dc8a5d74cfd7f107eb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI0MA_cb50aaca-5d81-48dc-a82e-ef247bd7f5da"
      unitRef="usd">301500000</us-gaap:Revenues>
    <lly:RevenuefromContractPaymentTermMinimum
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzE0ODI_c55a6d0b-c54e-4bbc-b96f-b06bf45ac3a6">P30D</lly:RevenuefromContractPaymentTermMinimum>
    <lly:RevenuefromContractPaymentTermMaximum
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODE2_b3c24c49-52d5-45f5-ad82-ad7094f63f95">P70D</lly:RevenuefromContractPaymentTermMaximum>
    <lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzE3NDk_44b74601-350e-478e-86f8-03ad7380e976">P1Y</lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d45ee2631a0458287be066c530c6943_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI2OTk_1c58574e-7591-4a51-b582-8743fff89b68"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4cb03da6839043d3aa73f8b83497cb73_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI2OTk_239760d1-e16f-4bd7-903d-6438c145df62"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie2dc431125a344f3a63a4412d26d8a50_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI2OTk_ff5b45ca-5ffc-40ae-b226-415bfd6d4f58"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i52a79ebd44a14e7d82fceef0898c5849_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3MDY_4113e22e-2955-400b-9507-7a5d844c9dfd"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4b94e10336ae4cbb8c40c7c7092d7840_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3MDY_4549500d-0971-4028-9f93-3151bf55dd84"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie2cff9b89ea946558f2bb3511379631b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3MDY_f1e97063-9678-4c3f-9b48-c08009b295a9"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8113e64d76f847a682da0b64b7063dbe_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3NzU_4aa02ed8-8972-4ab5-af41-1ac80f391c5f"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9ed77f1070fa4a9ea80eb29d531c5ba2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3NzU_aa08497d-5f02-48a8-b50a-dd1fdc51aa75"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if7cd4eb0f13b417caac242fba3efbbb7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3ODI_5473a5d5-ffc6-4cbf-b54f-e877b9825f6c"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd89b253c657495cbf93efa71c826c3c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzI3ODI_ec7ed4da-9b90-4999-a5ff-1b513e7cff02"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <lly:RevenuePerformanceObligationSalesRebatePaymentPeriod
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzQ4MTI_c44ce60e-caad-4b0f-a71d-de4f49b71ceb">P6M</lly:RevenuePerformanceObligationSalesRebatePaymentPeriod>
    <lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzU3NjA_d175cb35-c3aa-46a9-8970-18221ed89903">P24M</lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate>
    <lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzc4MTE_387e27d9-3877-4ded-b779-4cf70ca35402">P1M</lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzg0OTA_1edf31d0-18fe-46f3-8012-b02eb0352b45"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzg0OTA_dd66df47-d8e6-444c-8d95-b743e5270414"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzg0OTA_e3581415-e89c-4ca6-8cb2-e5adbbe287ef"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i29dffcb1c75e447186d0449682c8fa4f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzkwMzQ_70f00547-7f69-4928-82cd-e03d3e2dc4e0"
      unitRef="number">2</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="iba3938017a09480e9b6c89ec4a92190a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzkwMzQ_71b6d9c7-7ecc-4690-9b18-e56b6d1158cf"
      unitRef="number">2</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="id826775b3fff46ea93386f9abf618ef5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzkwMzQ_e26ce411-6321-42db-918e-d261fc7627fc"
      unitRef="number">2</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90ZXh0cmVnaW9uOjViZjU4NWZkNzQ5ZDQ5ZGJiNTFjMDY0ZWM3ZmUwYTIxXzEzODE3_bf71109c-0673-4fb4-8f02-ec91d4c7ec20">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;262.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTpjNDY2ZDM0ODMxYWE0OTYyOTA5MWJiNWZhMjFmNGQ4Yy90YWJsZXJhbmdlOmM0NjZkMzQ4MzFhYTQ5NjI5MDkxYmI1ZmEyMWY0ZDhjXzEtMS0xLTEtMzYwOTg_7eb71144-7e72-49e2-b8ab-e966ffb5d66c"
      unitRef="usd">262600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTpjNDY2ZDM0ODMxYWE0OTYyOTA5MWJiNWZhMjFmNGQ4Yy90YWJsZXJhbmdlOmM0NjZkMzQ4MzFhYTQ5NjI5MDkxYmI1ZmEyMWY0ZDhjXzEtMy0xLTEtMzYwOTg_e639413e-86c6-4422-ac36-35ee0d1f4d82"
      unitRef="usd">276800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i894124740513476f9e7e298369f85ae6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtMy0xLTEtMzYwOTg_6d13b9c5-1a53-4fe7-84e1-d50f9686554e"
      unitRef="usd">4914400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61882a82645e44f0a5cd7626f0f4dfad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtNS0xLTEtMzYwOTg_56769034-85e4-4032-b52c-c128fcd9f9f0"
      unitRef="usd">3835900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f18bbf764ba4e309b4033e323311922_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtNy0xLTEtMzYwOTg_0ed1bf03-acb7-4547-9bd9-95ebef810a03"
      unitRef="usd">3155200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d1ace1a30ff430eaa6398df95d6adaa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtOS0xLTEtMzYwOTg_e2c6c01c-ef23-43e6-a167-50310363f263"
      unitRef="usd">1557600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46ba46a0dc564f5784eafb2834664c13_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtMTEtMS0xLTM2MDk4_4959504d-baa1-445d-bb2c-74f768bb77e2"
      unitRef="usd">1232200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib713ca7d34c54a46bedf84120eebdddb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzYtMTMtMS0xLTM2MDk4_f2abb794-ff99-4536-8ac1-53a56e6335a0"
      unitRef="usd">972700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bbd7358f9a44cc88fca6a40a7f752fb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctMy0xLTEtMzYwOTg_7c1adf9b-66cf-4e2c-939e-7fc1d67c4e13"
      unitRef="usd">1320700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9cd2cb43377431bbd784ed4ddbb902d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctNS0xLTEtMzYwOTg_5f2e7063-7072-4b6a-92f0-e73227eb3755"
      unitRef="usd">1485600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id79b2564a4684bfa9b4e8e9903612823_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctNy0xLTEtMzYwOTg_ea0c11cb-8a57-41a9-a968-da825467b01b"
      unitRef="usd">1669700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6229ebed99384ddbb1c1e41cca2e59c8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctOS0xLTEtMzYwOTg_ceb737bf-7284-4e33-b3d8-1501ee9fb807"
      unitRef="usd">1132300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a64281a74ce486b8871c0204881291e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctMTEtMS0xLTM2MDk4_3cff7c48-d451-4967-b993-f50880b928f4"
      unitRef="usd">1140300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4531e2c9cdf04fb883d1a76bcdaa75e7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzctMTMtMS0xLTM2MDk4_0d995b08-2120-4231-9d93-96fb48968ed3"
      unitRef="usd">1151000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ba5f87a65a34af5bfab01d9bc64e2a9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMy0xLTEtNzEzMzg_909ddc7c-ae69-4fc0-9c86-4691eb94668b"
      unitRef="usd">807300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f8386db744f4affa13508c19b5df3ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNS0xLTEtNzEzMzg_1d143bcd-5e1f-4c1d-8f9f-2c2812609a02"
      unitRef="usd">620800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcb37f86b5bf4fc1b82f022c4ace7930_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNy0xLTEtNzEzMzg_47d14b51-2eb6-4846-9125-05948f0cfd9a"
      unitRef="usd">565900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18d1e272d16d4280b14162a8a5ae7248_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtOS0xLTEtNzEzMzg_2b1597e0-4b9a-4514-a01e-b45cefd19429"
      unitRef="usd">683500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49f67b8b79d7454aa2e6e8e2b5d56679_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTEtMS0xLTcxMzM4_8369b738-db9c-4b0d-95f4-240da5b011b6"
      unitRef="usd">533000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a59b1db34b94c5b98790e3b0b011098_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTMtMS0xLTcxMzM4_4eb2d630-8b38-4d2e-85aa-e38a2352685d"
      unitRef="usd">378300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90bb2847aa5f47228628aa3e17c89913_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMy0xLTEtMzYwOTg_f38368f4-e03d-4961-a849-9828edb4e05e"
      unitRef="usd">832900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b7e8500d4804c3c92d4e3b21e6f0979_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNS0xLTEtMzYwOTg_29ec8ea9-3638-4856-bcf7-c3ab470f1dd6"
      unitRef="usd">866400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cde1cb13d724c348cf0aa37a2ee59fb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtNy0xLTEtMzYwOTg_02ddc49d-bacf-4c08-8d2b-2ab6b3e11e69"
      unitRef="usd">879700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab22f8425aa742719232da9a982b98dc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtOS0xLTEtMzYwOTg_9deb2d73-d749-43d7-bb20-d1b140abd288"
      unitRef="usd">389600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6aa9d24bc7c349259210cb5ddc15b20d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTEtMS0xLTM2MDk4_78b3ff1b-aae7-40e4-9cab-ece49feb5a5e"
      unitRef="usd">393200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib40488cc77fe48a9983b2d76229a1dcd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzgtMTMtMS0xLTM2MDk4_e1cf2bed-4f95-4b48-b77f-5dfe49097a8f"
      unitRef="usd">410400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf934f62efbd4bdc9ad148a1e8d39475_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTMtMS0xLTM2MDk4_acd5068c-70fc-4d6e-bfd1-509a27c0eca6"
      unitRef="usd">588300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if84b38b1fbdf4b4baafbe6846c60b875_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTUtMS0xLTM2MDk4_aea461b4-86d1-4b0f-b6bb-11f183ecdec3"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e50f47eeaad4777a025c7b8314d19ca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTctMS0xLTM2MDk4_53fefc21-a297-4702-b24a-fd79e2996c7c"
      unitRef="usd">876200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c03a2130e8e4b15b3e45e071937aca3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTktMS0xLTM2MDk4_27361b82-581d-485c-a384-43da21ac0968"
      unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51b3bf965c6b4aedbc71cd1b54cc2247_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTExLTEtMS0zNjA5OA_568f2877-93fd-4d9d-ba20-72b20bf26432"
      unitRef="usd">282100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23b8fc33095f47ce91f0fb991ada922c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEwLTEzLTEtMS0zNjA5OA_85050470-4bb8-4031-9fe3-39510b904ba0"
      unitRef="usd">236300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab862c66ad8f40b58f51d2e670bc2d65_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTMtMS0xLTM2MDk4_b8ec0c71-ff7f-456d-9291-afec88b5ea90"
      unitRef="usd">82100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefe81546f9364a4d9ebf816f2afe77ba_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTUtMS0xLTM2MDk4_1d95701f-94a1-4d29-bff6-30322e5e90b9"
      unitRef="usd">95600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c49328469d94560909e62a300fb15cc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTctMS0xLTM2MDk4_c4e0b93c-14fc-43f2-9f55-d3732b13710f"
      unitRef="usd">224800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5845ce666250472aacd23b84c3e4c403_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTktMS0xLTM2MDk4_01f36de5-9c6a-4509-8adf-9d71e3d82317"
      unitRef="usd">290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4abe14ed7d746c2a4d0112b075ac9cc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTExLTEtMS0zNjA5OA_a619640c-d9dc-4a41-b3c8-92b2f04f0cf1"
      unitRef="usd">263000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4df3bf3464b489caa60ad6df0783bbe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzExLTEzLTEtMS0zNjA5OA_0c857383-5b00-49b1-8b9a-22969e199acc"
      unitRef="usd">365800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5174aeaa35294f1097a209bd1b7845b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTMtMS0xLTM2MDk4_d9bb9d95-9daa-4718-a9bd-901bd371a396"
      unitRef="usd">173600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icceb1eff5cdd4984b54eff367696ca4e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTUtMS0xLTM2MDk4_c3601b21-1bf7-45b5-8f46-a0975d9612e1"
      unitRef="usd">162500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64371009fdca47a9bea3857741540621_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTctMS0xLTM2MDk4_de32145a-9bf0-4b8f-a183-d585dd865427"
      unitRef="usd">158000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bc100215d1f4fa9816b460de125dfa8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTktMS0xLTM2MDk4_cd2acbfa-d114-4085-895a-3682b2070da7"
      unitRef="usd">111200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i243440aa810243239953f41351bdcf24_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTExLTEtMS0zNjA5OA_07adc992-6ad4-4b00-8fff-3825766e346e"
      unitRef="usd">81500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a3a7bc030e446fb82edf9a7f6f92844_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEyLTEzLTEtMS0zNjA5OA_3e4b9f17-6348-46b2-a250-460d0318cc19"
      unitRef="usd">88100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia101d6eca8f243bb98e9561330ac20b5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTMtMS0xLTM2MDk4_18832992-5c0c-4559-b802-69a77b3b5801"
      unitRef="usd">8719300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i122fb9e7cbb34242a643302cb8dac50c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTUtMS0xLTM2MDk4_fe8aa2d1-de6f-47bc-b4a7-29a13602e988"
      unitRef="usd">7909100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec68387645db4b4f92d21db543507a42_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTctMS0xLTM2MDk4_3741b091-85da-4a7e-97d2-c1b3f1826cc4"
      unitRef="usd">7529500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idaa12801a6f24c04b0786f055da95eda_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTktMS0xLTM2MDk4_998e7454-9b8e-4be3-b251-d19669df3cda"
      unitRef="usd">4468800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d7b63b2d4824ebd8b98d1a3e0bec191_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTExLTEtMS0zNjA5OA_1c1fc7cc-6e48-483a-98f7-a8bc3fb34295"
      unitRef="usd">3925300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49adc5d81365456dacca8f1348186c71_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzEzLTEzLTEtMS0zNjA5OA_7166d717-895a-4b77-9305-ed20b3ba7dc4"
      unitRef="usd">3602600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4404efba44734e41af51f0f6e510b480_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTMtMS0xLTM2MDk4_2a822dbf-c235-4942-8662-b01eb134784a"
      unitRef="usd">1233900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba7197e9a2124fe299c14e4eaaecce76_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTUtMS0xLTM2MDk4_11eea74e-080a-49b9-b1df-59afc94b045f"
      unitRef="usd">1265300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87c95be326e745df83b5161e9b90eb8b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTctMS0xLTM2MDk4_56026ff2-b759-42fa-a70f-c67ec0288c46"
      unitRef="usd">1219500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54524c6278e14aeba0959cc606b06515_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTktMS0xLTM2MDk4_ae62af01-ecd5-48cd-98d3-1c96fa2fc833"
      unitRef="usd">827500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib118e8524e0a4034a5733e9334f28db0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTExLTEtMS0zNjA5OA_67544414-edee-45ee-a068-e3bb01a86c0e"
      unitRef="usd">1064700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19e0f9785fd343efa0193891217b008a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE2LTEzLTEtMS0zNjA5OA_4f04fb94-bebb-4ea5-b026-9ca30ce8aaec"
      unitRef="usd">896400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if79c5294ee4f4ef681fd908091186ae4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTMtMS0xLTcxMzQ3_40dd202a-f445-4bcc-abd9-a61900c3e8cc"
      unitRef="usd">834900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ef513531c7049ef9396372c3a862b18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTUtMS0xLTcxMzQ3_79077636-18ee-4a6c-a98e-50a9492fac12"
      unitRef="usd">618200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i279a034c277f4a1ab4e300b899b21d54_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTctMS0xLTcxMzQ3_5e97201b-7f0b-49ba-912b-6528398554b3"
      unitRef="usd">454800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2570b2af4dc0432b9372301788fad363_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTktMS0xLTcxMzQ3_45c73b5a-53c9-42d9-9499-1f61b0fe1c86"
      unitRef="usd">515000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3338ad8173349e988242ec0e6f04e1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTExLTEtMS03MTM0Nw_edd63a71-70b7-4ba2-8488-bfb933aff083"
      unitRef="usd">294400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ffe64f002d641c6a9b980be3ed01dcc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTEzLTEtMS03MTM0Nw_8b9fd1c2-b6a9-47cb-8002-1b267ae5dabe"
      unitRef="usd">124900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie17e3c0297594484b5fc11d78d43ee29_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTMtMS0xLTM2MDk4_5ad2df00-99e1-4196-a792-819def96c95a"
      unitRef="usd">358100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03d777c538b14159ac60b1362f07fb22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTUtMS0xLTM2MDk4_615cc2b6-5d2c-4b69-ab37-c72cca349043"
      unitRef="usd">381900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if890ac36822f469d8ddea5dfd470c95c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTctMS0xLTM2MDk4_fad52308-c5d2-435e-bac8-9acce15f36d7"
      unitRef="usd">335300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id361aece11434b678eaf1e55548add4a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTktMS0xLTM2MDk4_fd53bc7b-5ec7-4e89-9679-371cc9cf8171"
      unitRef="usd">674800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifabd8a9ea7f3489f96d642962db788ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTExLTEtMS0zNjA5OA_d41ffb2b-658b-4c74-abf4-fe6e18bc164f"
      unitRef="usd">650800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2245dfc68e249d0a3b540ce6711b4d8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE3LTEzLTEtMS0zNjA5OA_e8e07755-76c2-448d-a8dc-e57d5988ce0a"
      unitRef="usd">589900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7abf976b41e94d6abcc6e5fdc45e8040_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTMtMS0xLTM2MDk4_14967e64-bfe3-4b56-bbe3-8150d0b34118"
      unitRef="usd">481800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i098a3086a33e473685588ae2026e5f1c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTUtMS0xLTM2MDk4_a3220491-1d6a-466b-9e9e-4cbfd498a2aa"
      unitRef="usd">480100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1126ae549787451f9bb5e56ec4579eac_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTctMS0xLTM2MDk4_db4bd14b-8066-466a-b65e-95cc922d592d"
      unitRef="usd">487900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia458924680af4b66841795f4b0921155_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTktMS0xLTM2MDk4_e9fe1013-c402-413c-acce-deb4f4dcf74f"
      unitRef="usd">66400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee79c787a98549fbb814a8a2d8423bbf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTExLTEtMS0zNjA5OA_af3408a4-63c9-46b4-852c-14d0857beb5b"
      unitRef="usd">56300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c16c6e39bc54a20a076eddb68a38dc3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzE5LTEzLTEtMS0zNjA5OA_c90d51ee-23db-4f3b-b569-a941a7825f07"
      unitRef="usd">55400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1df57ca285b34436ad72599838d20b63_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTMtMS0xLTY0Mzc0_e6775145-90f6-40ec-bffd-93d035badf76"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cd23ae2c169427ea701232617ba23e9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTUtMS0xLTY1NTQ3_a3581052-584c-4e6e-951c-8bcca73cb708"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72c6dd0e87a04241b80ae67b85eaac34_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTctMS0xLTY1NTUz_238a462d-a91c-4487-9c64-b2200e314f04"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia145809c4057498dbea07cefe5b3af5a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTktMS0xLTY0Mzgw_aea058d5-5256-46b3-909d-622018e992ad"
      unitRef="usd">418100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89a4f3931810408b8426d88ab25f2543_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTExLTEtMS02NTU1OQ_b5f828a1-e668-4f19-9931-2afba9db5e82"
      unitRef="usd">308700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7563fab9a921489c8c33ab7ddf46db30_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTEzLTEtMS02NTU2Ng_46a341ad-31d6-4e34-808e-32a2dd24131a"
      unitRef="usd">134000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59d2921396f2408f81b37c768c975994_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTMtMS0xLTM2MDk4_40c86c15-af42-48ce-8611-ef44a4600eba"
      unitRef="usd">120100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29c6d36f572740b5958ea1e5a869f0e2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTUtMS0xLTM2MDk4_820bf29a-c332-4039-b4c0-d0a3644ca809"
      unitRef="usd">46600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b26b6ce6fb747bbb9e0775792261b89_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTctMS0xLTM2MDk4_7cfc17e9-eab9-4880-8ceb-47f0a786ea47"
      unitRef="usd">111000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1aeb1d3ab83b4f499609731a48e300dd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTktMS0xLTM2MDk4_f36347da-f3b6-474c-a2e0-bb199a2f202b"
      unitRef="usd">210700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i786023411d90417782c4325faf5d0199_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTExLTEtMS0zNjA5OA_65bb3023-14c5-48ad-8a94-95231c614f59"
      unitRef="usd">152300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaeb4acbcaa7a4e1d9a4bf8429bc4c60f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIwLTEzLTEtMS0zNjA5OA_aaa6141d-a2d3-40bc-b7aa-3a279922b485"
      unitRef="usd">205300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieea541b5215c48e7be8cfa4c03730bb4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTMtMS0xLTM2MDk4_8e1bebc4-dbba-4bb3-a48b-043c87ddd5d9"
      unitRef="usd">3028800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76285bcbd8264a4d88f79ec61700d427_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTUtMS0xLTM2MDk4_1e61ee6e-34d0-483f-bf09-8ffae3f6bb02"
      unitRef="usd">2792100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i690e96d0ed8f4be1b474dfd0143fec7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTctMS0xLTM2MDk4_0383cc45-0707-4ea0-b921-953f9495b769"
      unitRef="usd">2608500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic78854061d9a4a8094725b7186b33c24_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTktMS0xLTM2MDk4_77519c0a-3271-4792-9a8c-463c130c1499"
      unitRef="usd">2712500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i566b619706fc4300afef9a4b18065698_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTExLTEtMS0zNjA5OA_2f2193c3-c4e0-4193-a4d8-84bf6122bee4"
      unitRef="usd">2527200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf9c8432ad704f298370bae297a97816_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzIxLTEzLTEtMS0zNjA5OA_c30d314f-603b-44a7-b0f5-486f991167c7"
      unitRef="usd">2005900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i948ab3ff4ae849d798539c9be859e02d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTMtMS0xLTM2MDk4_d7db212c-8e20-40d3-a269-cfa994c82ff0"
      unitRef="usd">1542400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9ad9e5e91ec46c58d5c3d879543ad79_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTUtMS0xLTM2MDk4_900f5ba1-7c07-479c-b6e2-84d6c13bbb13"
      unitRef="usd">1288500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ddfd937e21f452faab9486fd44a1792_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTctMS0xLTM2MDk4_952fec7c-5a85-40ca-84a4-995db6cf12e9"
      unitRef="usd">1016800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id12a0757fc294a8a9f3e7f4e96ad2b79_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTktMS0xLTM2MDk4_c0545e27-ec9c-4284-97e7-8f3b3d74deae"
      unitRef="usd">670400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32a6e3cb90de4b7fbc1a26ec8413acad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTExLTEtMS0zNjA5OA_53a99f17-8811-40e2-a740-70ba9e3b6084"
      unitRef="usd">500000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8356524214f4293839013dae33b408e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI0LTEzLTEtMS0zNjA5OA_7c53c87f-7938-4dda-8cd2-a1745654c48b"
      unitRef="usd">349600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82c4fc8c4be9466483d1f9c47e96410f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTMtMS0xLTM2MDk4_f8dc86dc-9ab0-4757-bf0a-0d19f432b9d1"
      unitRef="usd">324100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a7951f7fd96467c823ac40837825eac_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTUtMS0xLTM2MDk4_16df1184-163d-4dc3-8d29-a64b573d5639"
      unitRef="usd">63800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa237d56f2a04c60baf2abac03b59800_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTctMS0xLTM2MDk4_fc325547-382b-446f-959d-94540f03d0b5"
      unitRef="usd">42200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81e4b2fc062e409eb90fc22b3ecac117_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTktMS0xLTM2MDk4_afea76d6-7c79-456a-a4d7-872ab5e879f4"
      unitRef="usd">791000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85af31eff3fd4bcfbe2f8093e081a909_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTExLTEtMS0zNjA5OA_9c2aa6b5-7acb-445f-bd65-002b5a7983d0"
      unitRef="usd">575000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ec77e9a200a45bcb3e18647fab83ba0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI1LTEzLTEtMS0zNjA5OA_3a2b6e06-240a-4c20-967b-25b32417cc16"
      unitRef="usd">384700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i047fada9bd1a4eed91bd54b125f10f2b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTMtMS0xLTM2MDk4_5ee35e83-aa1d-4d21-b7b7-4cd9abb3cfa6"
      unitRef="usd">15300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i905d5bb1f6a644aa9480da295c712847_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTUtMS0xLTM2MDk4_903c0926-1fcb-4fa3-baa2-8ae2bdc33d52"
      unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41e35fbd704c46248a24dedd85300ea9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTctMS0xLTM2MDk4_63502cee-0d8f-4880-8e15-76baca3dbb72"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icaa7c39af28c4bc5993971a70aa09d60_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTktMS0xLTM2MDk4_83d817a3-43d1-4532-9f25-5f3d6fa88523"
      unitRef="usd">17600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50f4f924f3ad4797bf23e88d55c7d012_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTExLTEtMS0zNjA5OA_5886a249-2e8f-4064-b491-3f200cf8fa83"
      unitRef="usd">14600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e9109389a244076841dca316010ff8c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI2LTEzLTEtMS0zNjA5OA_86ebcce0-59e2-4ab2-a7de-db840ea1f604"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ca2f0cae6db46e1969f249939f14190_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTMtMS0xLTM2MDk4_b017e9d9-5924-4695-b6c8-ec8c34247107"
      unitRef="usd">1881800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d55d846ec5c43f0859bff0869b8d85d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTUtMS0xLTM2MDk4_8f6bec3e-953e-4525-847a-3d6abae3c941"
      unitRef="usd">1372300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib62fbafb830b45f18b06599b0a020555_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTctMS0xLTM2MDk4_86ccb4ba-7eb2-4956-8813-cba33d4565d9"
      unitRef="usd">1059000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2370ca55475d4c2392256a9363409c09_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTktMS0xLTM2MDk4_f3e992b7-57bd-4126-a9af-6738f243ea97"
      unitRef="usd">1479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia73989eaa96b4c098c63cf6dfabe07da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTExLTEtMS0zNjA5OA_ec861698-1139-4fe6-8e2d-200df6119f91"
      unitRef="usd">1089600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ba680c3a60c4c94b757bfbbdffadfcd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzI3LTEzLTEtMS0zNjA5OA_3e258393-5343-490f-8798-cabd09f1bd59"
      unitRef="usd">734300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib446da6700c5431bb4dfa20d113e3796_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTMtMS0xLTM2MDk4_e79dcfec-2478-4607-922a-4a72bcd5a164"
      unitRef="usd">38700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1c8904967084c20a526f2bea52ae9d1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTUtMS0xLTM2MDk4_f11689d6-7e25-4115-8955-6fbe2f07ee53"
      unitRef="usd">42100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i476342288dcd4c35aab4ebcef726722f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTctMS0xLTM2MDk4_11f58634-43fd-444c-b872-b525ac0b0d54"
      unitRef="usd">49600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c18e45789f14afab755bf84d42ee66f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTktMS0xLTM2MDk4_c9025687-5570-4afd-a0fc-4d460f9d83ff"
      unitRef="usd">542800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f55af49432141a9a5b2a16fc58b0038_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTExLTEtMS0zNjA5OA_9c2db3fc-ec79-47f6-ac92-10282703a26c"
      unitRef="usd">725600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e993b0bc60d4c04b3d713bcaf91ff26_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMwLTEzLTEtMS0zNjA5OA_c359fd6e-d2df-417c-a9db-acca3c465cfb"
      unitRef="usd">675800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id444acee0b204bdc95711361bd992be1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTMtMS0xLTcxMzYy_01105ca5-80e2-47e2-a051-f58621aed59a"
      unitRef="usd">434500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cf1f9d51d284edaa1b7ef76c6479ef9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTUtMS0xLTcxMzYy_3d5b25b2-85cb-4c3a-83d0-26ff7f029af0"
      unitRef="usd">325900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i070feb5d9c28438b8531680d930b657a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTctMS0xLTcxMzYy_d4a95a68-d320-4304-89aa-d658861473be"
      unitRef="usd">154900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff9628b9ed2749ddae9bef49cb39bb99_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTktMS0xLTcxMzYy_fc6c8d1f-21ca-4e2b-a0c4-6b680e4cc02b"
      unitRef="usd">142700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i702fa5c2e0c34c519b69e8801bee2eea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTExLTEtMS03MTM2Mg_49cc2290-38ea-4f4f-b360-170107f54507"
      unitRef="usd">37000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc40e99c9fe5483eb7a04d9734858a85_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMyLTEzLTEtMS03MTM2Mg_253403dd-59dd-4057-88dc-e4438fe8d832"
      unitRef="usd">7700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7c20349b02348d9bb87dc176d930352_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTMtMS0xLTM2MDk4_4d4c2131-74df-492d-b66f-a197a9e07e4c"
      unitRef="usd">39600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia55d7bb83bed4b79933fb93ad8dc8ce2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTUtMS0xLTM2MDk4_8319a61b-4fd4-4a97-bc1e-4b4eb125f65d"
      unitRef="usd">46100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia61dcb4e367e49e69e147967d3466245_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTctMS0xLTM2MDk4_ba17e7e5-d507-461e-b234-3740e4cfbe47"
      unitRef="usd">41000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i10c3070f248e45bfb4c8b53127810450_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTktMS0xLTM2MDk4_495031cd-96f7-4742-b6cc-85d5d1131b24"
      unitRef="usd">390700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i027e829cf3a94fdb838086c03633207d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTExLTEtMS0zNjA5OA_10fc477d-8174-404b-b189-aaf658e7e283"
      unitRef="usd">360500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i926e2ce8db484a19b6686864f7dce2d8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzMxLTEzLTEtMS0zNjA5OA_ce5ee6b5-561a-4988-a079-4ab0b7551126"
      unitRef="usd">377600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16730972cec04bc9b31ee8293f90b16f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTMtMS0xLTM2MDk4_5fc78b4b-f09d-4db5-b23e-6ad27e55f0ca"
      unitRef="usd">102000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ad2157f26744eac8a277f68ec6e9f75_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTUtMS0xLTM2MDk4_09763793-66f8-404c-997d-8ac3236698b1"
      unitRef="usd">73200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93492794bd9d4ade882f1194e9f5d0c6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTctMS0xLTM2MDk4_4a713193-9781-48de-86db-25c1762134be"
      unitRef="usd">111000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86210214b8d04600afad8c88d79dd48b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTktMS0xLTM2MDk4_86cb4e78-65b7-4ba2-99bc-c4d008524a3f"
      unitRef="usd">207500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i657903dac3a84f118dfd3c2d2d0b4f45_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTExLTEtMS0zNjA5OA_0b27f454-3a7e-4c58-9f85-4082f0a1ed23"
      unitRef="usd">220900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i925c14ebf59d401e90944a793809c61c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM0LTEzLTEtMS0zNjA5OA_aca4dfc4-c6a2-468f-9e3e-3f31f5d6b53b"
      unitRef="usd">305300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6718cacc2a5a484ea0fe4ebcd8d0f0a1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTMtMS0xLTM2MDk4_57efc918-3fce-4bb5-a6eb-0a0dd35b7547"
      unitRef="usd">614800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e3108d4822f4200ba775774e2c6d17b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTUtMS0xLTM2MDk4_5946707c-be97-4cca-8d2c-15079a6edf89"
      unitRef="usd">487300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81bc73f6221746d8bf84498f9556f8ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTctMS0xLTM2MDk4_0a310384-a864-4c75-8a92-a319632bca98"
      unitRef="usd">356500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc2d4950c43e4823b068eca9c847caf9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTktMS0xLTM2MDk4_8d2adf4f-f970-473d-87e0-6177e5a1cd2b"
      unitRef="usd">1283700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c2d91be0889414c97992735d48a782e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTExLTEtMS0zNjA5OA_ec1442fe-de65-49ac-bf18-b96251075e6a"
      unitRef="usd">1344000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07e5b3258a5645c4b9f053f742b53b7e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM1LTEzLTEtMS0zNjA5OA_c54fe1b0-b000-48da-ab0f-5fe09662ffb9"
      unitRef="usd">1366400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3650248e7a546aba24f1190e20ee44c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTMtMS0xLTcxMzc0_0fe95bc6-1ca6-4013-8a39-589d076d27fa"
      unitRef="usd">1978000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib423ef1778dc4914ac8a36e61d82d79e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTUtMS0xLTcxMzc0_c8227bf4-ed3d-4951-835f-0c5ccdde3668"
      unitRef="usd">850000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec20cacccc854ae999285ef6ae4bf265_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTctMS0xLTcxMzc0_df4a03cd-360d-4edd-ba0d-da20c269ce7d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9166c1982686472cb2be38f81d2bdc5e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTktMS0xLTcxMzc0_9f5d8287-03b1-4817-ae89-cc7152404d4b"
      unitRef="usd">261400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i099a16e9db4d42d3ad065da66bb72352_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTExLTEtMS03MTM3NA_05875ec8-150e-417b-baa8-59a7350ee17c"
      unitRef="usd">21200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee0929e27d1f44afae4a0ec0efbc7d3f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM5LTEzLTEtMS03MTM3NA_306756ce-ca65-45c6-adc0-ce71604ec6ac"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a0bf62c9bad4a789c15447bb315106d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTMtMS0xLTM2MDk4_e46a1cc5-027a-4aaf-978d-8c29e8786e6e"
      unitRef="usd">441600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b796c46dd2848e0bcfe542ee2f9ea37_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTUtMS0xLTM2MDk4_4d952ddd-5ef2-4f08-847e-676f7a154483"
      unitRef="usd">510300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6126155439840c494a0d59a4c901ef6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTctMS0xLTM2MDk4_1711a164-7e7f-48a2-893f-d65777499c48"
      unitRef="usd">645500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15079d32a6af431cbe2362c300da4d30_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTktMS0xLTM2MDk4_00dfb368-9bfc-4746-8fbe-95cde257e065"
      unitRef="usd">360300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8495e35a20ac4d5fa299dbb1a540308e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTExLTEtMS0zNjA5OA_ec7049ef-2e4a-47aa-93f6-8046ca49b0fd"
      unitRef="usd">536000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2101347099ea4c55aa493f4b7e3e75f2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzM4LTEzLTEtMS0zNjA5OA_90d25f94-f3f6-48a2-b676-66e94659745d"
      unitRef="usd">759100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f9fdd9cfde64d12a304f9907a75d463_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTMtMS0xLTM2MDk4_98aa355d-acfc-4935-846c-7a0c487ba480"
      unitRef="usd">10600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8243736e267647a7a63b74278bfe227c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTUtMS0xLTM2MDk4_b6cb7b88-2579-4c63-b720-55c32ee2f254"
      unitRef="usd">61800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69102089b51742579ff9ad41273b6e5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTctMS0xLTM2MDk4_0ad84edf-0da3-4c4b-826e-7c6b73511da9"
      unitRef="usd">231700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea3630db9f3642a0bf1262ba09e339ee_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTktMS0xLTM2MDk4_ac845cde-cad2-4eab-b9e1-747bc7511c26"
      unitRef="usd">707900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88e4d52b72a54afba956fc68e8d09cb9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTExLTEtMS0zNjA5OA_7bd69e0f-2113-47e2-8227-6365f3f6151f"
      unitRef="usd">545400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i034bec2524a34f378ecb3ac05b076873_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQwLTEzLTEtMS0zNjA5OA_0107e6af-d325-4af8-97e3-908645f17d48"
      unitRef="usd">658800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i364bef469c6b409eb2e05dec7fa48bec_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTMtMS0xLTM2MDk4_18e8b23b-8d2d-41ee-83ab-af895578e58c"
      unitRef="usd">136100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00a1ac288cb249769f4020a76446066e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTUtMS0xLTM2MDk4_273bd448-40ed-476b-b952-8ac829c5f834"
      unitRef="usd">246400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9bc25daef9774ec8ba96201a6d17c48f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTctMS0xLTM2MDk4_9a2721b9-4461-4c17-9bc0-9ab772781d6d"
      unitRef="usd">291900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id884085efd444ed5a42695f06ab42933_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTktMS0xLTM2MDk4_85d66b0b-c600-4c28-868d-1f12b627f833"
      unitRef="usd">233900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic25b2eb90e2f49aaa97ed46e09ddedc5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTExLTEtMS0zNjA5OA_d089c401-d19f-4257-ab26-3f9a1b6302df"
      unitRef="usd">321800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fec7ee5a58242fcbbf477d186e1a542_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQxLTEzLTEtMS0zNjA5OA_ab8afc95-1aef-4c99-b38d-59c3963cd364"
      unitRef="usd">469700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81ed3edf12174b94967056072504bcad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTMtMS0xLTM2MDk4_801d85f4-3d6f-413e-a214-1b040e182056"
      unitRef="usd">2566400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07c8ab2aa0454112b333a7f6f112c62e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTUtMS0xLTM2MDk4_dd896edb-7db7-4b87-b6d3-fdbdd1a2568e"
      unitRef="usd">1668400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82e0bdec56134029ae9680e3db1ec79b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTctMS0xLTM2MDk4_4e3245ec-a71b-4644-99fc-9968cab4672f"
      unitRef="usd">1169100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1e356ee1b9d440e875c1efc62a80b33_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTktMS0xLTM2MDk4_6a9c9d6c-2814-4cd1-99c3-2d5c47fb723b"
      unitRef="usd">1563500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52fa75e3f5284c179ee6b4ab5243be53_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTExLTEtMS0zNjA5OA_71ccdeac-c44c-4f5e-9e65-f0ea1386706f"
      unitRef="usd">1424400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibad81ef38f2d4e57bd00e5dd2c0a168f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQyLTEzLTEtMS0zNjA5OA_022a8b26-c4eb-49a7-8ab9-3a7e0d27ee57"
      unitRef="usd">1887700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab8591d057cc4eec92033c36fb05fd49_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTMtMS0xLTM2MDk4_a8496c01-0866-4d07-918a-2355617a4403"
      unitRef="usd">16811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0df35c8a12146d0bcdb02fe162f2cb8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTUtMS0xLTM2MDk4_e1db797f-7690-4e3c-a56a-3d1205e39442"
      unitRef="usd">14229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74307f9a9f5f43698c550cd45a1c8b8c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTctMS0xLTM2MDk4_cb52dbb8-c7e3-4aaa-b0e8-7c7aa33ca9e8"
      unitRef="usd">12722600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib51a0dd6c879443684c594e3c15c31cd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTktMS0xLTM2MDk4_2c1a2c95-1de7-4ec2-9ee6-ea77c072df44"
      unitRef="usd">11507400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if65921f0a4824d3b8e3297260e7cb19d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTExLTEtMS0zNjA5OA_db8085a1-fd48-4f77-9a34-bad34693be3d"
      unitRef="usd">10310500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3c951e01e904d87b87e2c491d7f9dcd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTo1YzQxZGIxNzNmYzE0NmMwOTk3MTM5MDAxNmVjYjBlNC90YWJsZXJhbmdlOjVjNDFkYjE3M2ZjMTQ2YzA5OTcxMzkwMDE2ZWNiMGU0XzQ0LTEzLTEtMS0zNjA5OA_c92b658b-0b7b-4ec9-8de8-c9c8c5f986c7"
      unitRef="usd">9596800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab8591d057cc4eec92033c36fb05fd49_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzMtNC0xLTEtMzYwOTg_c79439d1-938c-4607-9390-82bd231c7541"
      unitRef="usd">16811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0df35c8a12146d0bcdb02fe162f2cb8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzMtNi0xLTEtMzYwOTg_89771b13-d713-4fcc-86fd-a3a7fa5f6380"
      unitRef="usd">14229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74307f9a9f5f43698c550cd45a1c8b8c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzMtOC0xLTEtMzYwOTg_407a17bb-8915-446d-9a94-65eefd98c86c"
      unitRef="usd">12722600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04193007085b41a38db99637f0c0d6af_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzQtNC0xLTEtMzYwOTg_23b9688a-da4e-42e7-93ce-b358362d1764"
      unitRef="usd">4776800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d224ea9b86e4818acc1bd5468570078_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzQtNi0xLTEtMzYwOTg_29cccf9b-045a-487b-855e-c86c4b931dd5"
      unitRef="usd">4187700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i164330216f6841af817f8d04691a5b0b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzQtOC0xLTEtMzYwOTg_53d8a64f-355b-47d7-b54c-fd076aabb029"
      unitRef="usd">3765000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if13e5ce657124ce698dc637219f87ea0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzUtNC0xLTEtMzYwOTg_b5f07b89-732f-49f5-bfe2-b83c6d3e85e4"
      unitRef="usd">2367000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e7e25f558c047e4ac74c9e031a5a865_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzUtNi0xLTEtMzYwOTg_fcecd08d-e97d-46f2-8ec3-e1484da30563"
      unitRef="usd">2583100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i028aeea4c2e64264850f271d8ffb0481_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzUtOC0xLTEtMzYwOTg_4ae4f967-3df8-4dc1-af0a-f452c5b26218"
      unitRef="usd">2547600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd215bb90d2941cb94a58ff2fd939bbe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzYtNC0xLTEtMzYwOTg_10f96403-36b0-4421-891d-4bf7b1e697fc"
      unitRef="usd">1661400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cf899c4538e4ec6b299cfa3908d15fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzYtNi0xLTEtMzYwOTg_c632f525-68d3-4aec-a167-1bfb892200b1"
      unitRef="usd">1116900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98f3427b27d748f5ba11f0d766ffe5d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzYtOC0xLTEtMzYwOTg_a8f9c32e-a786-4998-9ef4-066227449207"
      unitRef="usd">939400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bb2e32e1ad2454892693138d44916ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzctNC0xLTEtMzYwOTg_e85f119a-4f59-47d7-8dfe-3d37e0021052"
      unitRef="usd">2702200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id558c6364b764995aa2b6842b75cf8db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzctNi0xLTEtMzYwOTg_e3969f8d-b184-4627-b7e4-b4751b1acaa9"
      unitRef="usd">2422700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96cf3dcfa7cc4f1396ca4bc3f3f3bf8d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzctOC0xLTEtMzYwOTg_091162a6-5ffd-4511-99c9-c654aef2b696"
      unitRef="usd">2344900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzgtNC0xLTEtMzYwOTg_86f6abcc-ef7e-4d33-8729-6c4d9d86ed1e"
      unitRef="usd">28318400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzgtNi0xLTEtMzYwOTg_b7ba1b3c-db99-4b0f-928f-a73d4fdc21ba"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMDkvZnJhZzo1YmY1ODVmZDc0OWQ0OWRiYjUxYzA2NGVjN2ZlMGEyMS90YWJsZTozNjUzNTA1MGM0ZDU0MGQyOWU5ZmJlMWRiYzgzYzUzMS90YWJsZXJhbmdlOjM2NTM1MDUwYzRkNTQwZDI5ZTlmYmUxZGJjODNjNTMxXzgtOC0xLTEtMzYwOTg_7ac73087-1559-49eb-814c-2716e3828ff8"
      unitRef="usd">22319500000</us-gaap:Revenues>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwMDEw_82280466-9b5f-49fd-967e-6f42e8859ec5">Acquisitions and Divestiture&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December&#160;31, 2021, 2020, and 2019, we recorded acquired IPR&amp;amp;D charges of $874.9 million, $660.4 million, and $239.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are unable to provide the results of operations for the year ended December 31, 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Loxo Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at February 15, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred - net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$4.60 billion of the acquired IPR&amp;amp;D relates to selpercatinib (LOXO-292).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately 12 years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MiNA Therapeutics Limited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protomer Technologies Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Glucose-sensing insulin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kumquat Biosciences Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical small molecules that stimulate tumor-specific immune responses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lycia Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Several potential modalities across a spectrum of therapeutic areas and diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ProQR Therapeutics N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;QILU Regor Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for metabolic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foghorn Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new oncology medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;316.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Entos Pharmaceuticals Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets for the potential treatment of neurological disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fochon Pharmaceuticals, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical molecule targeting  hematological malignancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AC Immune SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2019 &amp;amp; September 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ImmuNext, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novel immunometabolism target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avidity Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential new medicines in immunology and other select indications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centrexion Therapeutics Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expenses of $96.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in January 2019 upon entering into a license agreement and $30.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in September 2019 upon entering into an amendment to the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestiture&lt;/span&gt;&lt;/div&gt;In October 2019, we completed a transaction in which we sold the rights in China for two legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $354.8 million and $40.3 million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recognized a gain of $309.8 million in other&#x2014;net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwMDEw_e7b6866f-2683-49c4-88a5-cd0721208e08">Acquisitions and Divestiture&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, February 2020 and 2019, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail), Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development in 2021, 2020, and 2019, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December&#160;31, 2021, 2020, and 2019, we recorded acquired IPR&amp;amp;D charges of $874.9 million, $660.4 million, and $239.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are unable to provide the results of operations for the year ended December 31, 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the year ended December 31, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2&#160;million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included because this acquisition did not have a material impact on our consolidated statements of operations for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Loxo Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at February 15, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred - net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$4.60 billion of the acquired IPR&amp;amp;D relates to selpercatinib (LOXO-292).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately 12 years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MiNA Therapeutics Limited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protomer Technologies Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Glucose-sensing insulin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kumquat Biosciences Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical small molecules that stimulate tumor-specific immune responses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lycia Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Several potential modalities across a spectrum of therapeutic areas and diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ProQR Therapeutics N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;QILU Regor Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for metabolic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foghorn Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new oncology medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;316.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Entos Pharmaceuticals Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets for the potential treatment of neurological disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fochon Pharmaceuticals, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical molecule targeting  hematological malignancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AC Immune SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2019 &amp;amp; September 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ImmuNext, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novel immunometabolism target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avidity Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential new medicines in immunology and other select indications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centrexion Therapeutics Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expenses of $96.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in January 2019 upon entering into a license agreement and $30.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in September 2019 upon entering into an amendment to the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestiture&lt;/span&gt;&lt;/div&gt;In October 2019, we completed a transaction in which we sold the rights in China for two legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $354.8 million and $40.3 million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recognized a gain of $309.8 million in other&#x2014;net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzk5OTY_6f945ef9-d0e4-4c20-a012-bf171d5b55b7">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed because the compound acquired had no alternative future use.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEyNTQ_1ca061c8-a1b8-413c-a5be-46fa588f3edc"
      unitRef="usd">874900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEyNTg_cdde136a-75df-422f-8c6f-2dafd0f3bd0f"
      unitRef="usd">660400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEyNjY_8098eae9-0875-4c12-81ea-b576cb585e1c"
      unitRef="usd">239600000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDAyNTI_68e203bc-2564-4a39-97c1-5fd26ecee3d5"
      unitRef="usdPerShare">22.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i636eda8cc422414eae95184d5ae5708b_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDAyOTQ_6f8872fc-2237-4708-b09b-8f86e6eed957"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="i636eda8cc422414eae95184d5ae5708b_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDAzMzQ_566bfdbb-3ab5-41ce-b259-b46e5f5da745"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDA0NDk_b0f86ca8-c9d0-4a80-8f94-865c4c831843"
      unitRef="usdPerShare">4.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDA1MDU_cc6d0cc3-eaaa-4de8-b33d-150b723b5a5c"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
      contextRef="i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzEwOTk1MTE2NDA5MjM_95a6eb31-fcb0-4f33-a508-4bb63bbf1815"
      unitRef="usdPerShare">0.083</lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzI3NDg3NzkwOTQyMTc_f462eefb-14fb-4662-9673-0bc79bdf8e3a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Prevail as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 7 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at February 15, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred - net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$4.60 billion of the acquired IPR&amp;amp;D relates to selpercatinib (LOXO-292).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contract-based intangibles for Vitrakvi and a Phase I molecule which were amortized to cost of sales on a straight-line basis over their estimated useful lives and were expected to have a weighted average useful life of approximately 12 years from the acquisition date. In the fourth quarter of 2021 we impaired the intangible for the Phase I molecule. See Note 5 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzEtMS0xLTEtNDI0ODM_7ef41d79-d977-4bc5-b037-eee8bd438b82"
      unitRef="usd">90500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzItMS0xLTEtNDI0ODM_2edca7b0-0a2a-47d0-ac98-63fa53bfd951"
      unitRef="usd">824000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzMtMS0xLTEtNDI0ODM_2b3edf95-0324-48a2-87ff-057d580e861f"
      unitRef="usd">126800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzQtMS0xLTEtNDI0ODM_c049a6c2-243f-49ca-be68-8cd06954e8af"
      unitRef="usd">106000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzUtMS0xLTEtNDI0ODM_4ca8bb4c-1676-4e9f-a62d-a2afb77ecd99"
      unitRef="usd">-31500000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzYtMS0xLTEtNDI0ODM_12ae728d-6120-4c90-9ae8-0135e0887689"
      unitRef="usd">903800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ie98abec6e97245e78d9fc27b845e6067_D20210122-20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzgtMS0xLTEtNDI0ODM_44d308a4-8ce2-49d1-a6b4-2ce246f78e0d"
      unitRef="usd">90500000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i4d886a39796d42f5809576721f051d0f_I20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzktMS0xLTEtNDI0ODM_c29be1b2-0886-4ea3-9a6a-071410a5c223"
      unitRef="usd">65900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie98abec6e97245e78d9fc27b845e6067_D20210122-20210122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpkNWY3ZTNiNjIyZTI0NjRiYjQxZDNjMGY1YjA4MzlkNi90YWJsZXJhbmdlOmQ1ZjdlM2I2MjJlMjQ2NGJiNDFkM2MwZjViMDgzOWQ2XzEwLTEtMS0xLTg1MzYx_4841a279-3700-4a13-ada0-2956cbd6fe6b"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia99148e294d448a3b8022b7ab548973c_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzE0NDU_a8bac373-e4a7-46b5-aca1-1444e8964aac"
      unitRef="usd">849300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill
      contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIxMDE_75d001c1-0f33-4d01-b195-62ed5dae6282"
      unitRef="usd">86800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIxMjY_c88498b2-f3fb-49dd-8588-468c8f2f15e3"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIxOTk_a0253aa5-056d-4900-ac06-d5510906977a"
      unitRef="usd">49500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="iaef95a45c6244b97901afb132b2e8ede_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIyMjU_fe6a3c12-a3e5-472f-a015-373ca6c44aaa"
      unitRef="usd">375500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0e8e1b30058b460e98b4ea10699f32c6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzIyNjI_a3a39e94-c420-4215-9d40-7f5a034dbeb0"
      unitRef="usd">276200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i800aa827b6e345e58b4aa9e11e49e882_D20190201-20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzI5OTA_cd1f4bf7-4bc5-4e98-85bf-1bef549ab472"
      unitRef="usd">6920000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id65135fb98c54b32b997c038034eab2f_I20190630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzM2OTc_56c2ba59-7ef8-4751-aa11-16478564f58f"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzEtMS0xLTEtMzYwOTg_555c677b-bc6e-421c-a302-cfafbc4a625a"
      unitRef="usd">4670000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzItMS0xLTEtMzYwOTg_5ad8673c-c06a-44f5-a757-0a71d69efc01"
      unitRef="usd">980000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzMtMS0xLTEtMzYwOTg_d1cfb97c-5a99-4754-a929-4d1850853955"
      unitRef="usd">1032800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzQtMS0xLTEtMzYwOTg_4018705c-bd36-4d53-ba38-f7edd361f946"
      unitRef="usd">-26400000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzUtMS0xLTEtMzYwOTg_5e2b57f9-9c9a-4f15-90d7-f66a6be0c214"
      unitRef="usd">4590800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzYtMS0xLTEtMzYwOTg_a8ade55a-91c7-4aac-b1b0-7ee457897c7d"
      unitRef="usd">2326900000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="id02a7381a3be4e38890430d12e20673b_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpmZjhjMDRhMDE4ZmY0MWYyYmYwZDY1OWY5MzhiNWFhOC90YWJsZXJhbmdlOmZmOGMwNGEwMThmZjQxZjJiZjBkNjU5ZjkzOGI1YWE4XzctMS0xLTEtMzYwOTg_a8b4d8a4-7fdb-4dcd-8465-84a575d4e213"
      unitRef="usd">6917700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i600f4904f99849f2ad5f229699acc149_I20190215"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzQwODU_8733a7bd-5fc2-42ae-bd67-f8f9ab79a819"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id7d716a1f4534165962c18f76f7af45c_D20190215-20190215"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzQzODM_b7d883e0-4a10-448e-b644-3eee75b60e60">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzk5OTA_9246e1dc-9b4a-4d15-8efe-d95e7e6d5513">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table and narrative summarize our asset acquisitions during 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MiNA Therapeutics Limited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protomer Technologies Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Glucose-sensing insulin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kumquat Biosciences Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical small molecules that stimulate tumor-specific immune responses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lycia Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Several potential modalities across a spectrum of therapeutic areas and diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ProQR Therapeutics N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;QILU Regor Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for metabolic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foghorn Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new oncology medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;316.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Entos Pharmaceuticals Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new nucleic acid-based therapies targeting the central and peripheral nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets for the potential treatment of neurological disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fochon Pharmaceuticals, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical molecule targeting  hematological malignancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AC Immune SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2019 &amp;amp; September 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ImmuNext, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novel immunometabolism target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avidity Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential new medicines in immunology and other select indications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centrexion Therapeutics Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expenses of $96.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in January 2019 upon entering into a license agreement and $30.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in September 2019 upon entering into an amendment to the license agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9950f4e9a0354b2fa627384fb3ed7958_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEtNi0xLTEtMzYwOTg_9477d216-c63a-4c2b-8fd0-e1392b17784b"
      unitRef="usd">107800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i2670d0faa7f348ceb8cb0477e2bbd7ec_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzItNi0xLTEtMzYwOTg_64e966c3-1c96-4b04-93f1-00473adf6c55"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id7d1e0d5a52d4681bade2958b5aa1a4c_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzMtNi0xLTEtMzYwOTg_8f4e13fe-9aea-419a-b6e9-fa7ebbb49e32"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6feddb3904ec46578edf8428b7b289a5_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzQtNi0xLTEtMzYwOTg_3403e4f1-924b-4d7c-b8b2-c641ada34001"
      unitRef="usd">125000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i20656f42f67e4b3ca3072208a9060499_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzUtNi0xLTEtMzYwOTg_d7e0dcd5-8b3c-43e7-a200-5c4fde05c71b"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iec4ebbe67054429582ac383c3ca59a99_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzYtNi0xLTEtMzYwOTg_605791ee-c59f-44d9-ab2e-a813c4fc5cdc"
      unitRef="usd">57300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1f63838d417e4d52a843ed3cdc791134_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzctNi0xLTEtMzYwOTg_06df1840-7bd0-4848-b5a0-6117956bb191"
      unitRef="usd">55000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9fe5e5a2099d4c20964ac1055881f0e0_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzgtNi0xLTEtNDI2NDk_17eca403-b02b-4d2d-8d5d-94973c49af5d"
      unitRef="usd">35000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i625c2c9631a44ce4add09fd63dbb08e4_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzgtNi0xLTEtMzYwOTg_ecb35293-2f0a-412a-97aa-faf6bf9939ff"
      unitRef="usd">26700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8bb6a0e595d94643bec576021c87b042_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEwLTYtMS0xLTg1Mzg5_e61b46b9-6748-436a-ab69-53bc1841129a"
      unitRef="usd">30000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia358c590fff34220b7173f72a36ae251_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzExLTYtMS0xLTg1Mzg5_05b7703a-4943-4e6e-ad80-64640aa679b2"
      unitRef="usd">316600000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i44a67f18c7ea48ea95d82f120474b9f0_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzExLTYtMS0xLTY4Mjgx_06fb0400-2523-4cf3-bd11-1d8fd05fca6a"
      unitRef="usd">30000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i2bb6fc6a416848fea9d309fc8093b580_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEwLTYtMS0xLTM2MDk4_ec398e5f-363a-43a2-9d8b-1810c4a94541"
      unitRef="usd">52300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i00fc657efa784f17b8ef30a51ea8a755_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzExLTYtMS0xLTM2MDk4_a2ba33a2-3adb-4852-8f00-7af38fa9effd"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie824a9d4024d4da5b3b95622f0f82015_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEyLTYtMS0xLTM2MDk4_2d0598ed-752b-4a4f-b64d-a7271490a5c0"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6d8c7a108f87404bad726fa03ba1f4b3_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEzLTYtMS0xLTQyNTU0_dee1725b-d51f-40b1-818f-a3aa9a419b73"
      unitRef="usd">174800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ifba7dfdc0b6a4b679a897b2cc2ae3a36_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE0LTYtMS0xLTQyNTU3_e8c65637-b84c-4040-9993-5cf06b2df27d"
      unitRef="usd">22000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib187355b4ba34c879321b64031638699_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE1LTYtMS0xLTQyNTYw_f7d7df8a-c2fe-4224-8eb6-9565e5030874"
      unitRef="usd">200000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i01c3dbabca1c4ca8b1462ca74374ab69_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE2LTYtMS0xLTQyNTYz_38a1df59-1cac-4082-87b1-d950bd079c46"
      unitRef="usd">126300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i14514c12fe4a4a7eac789632d8162634_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzEzLTYtMS0xLTM2MDk4_341d996b-484f-47c9-a7b6-00e57b7cd376"
      unitRef="usd">40000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="idc045dfe17704aa1bf6a4e76fc728f04_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE1LTYtMS0xLTM2MDk4_b60e1419-eea4-411b-af2f-632258f56bfa"
      unitRef="usd">127100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i65311cc8393345fda909ba57dd56598f_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE2LTYtMS0xLTM2MDk4_79f792a3-4112-419b-8174-f2270ba98b4f"
      unitRef="usd">40000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id64076c56e50481bbcc81b0f17931613_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE3LTYtMS0xLTM2MDk4_528dbe65-5cc1-4a6e-890f-50962382d635"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8d547a0ec4c74b6b9cc9b20749c49656_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90YWJsZTpiNWNhY2EyMTZlNzI0Zjk3YjY5YTkxOWE2NWZiOGQ4OS90YWJsZXJhbmdlOmI1Y2FjYTIxNmU3MjRmOTdiNjlhOTE5YTY1ZmI4ZDg5XzE4LTYtMS0xLTM2MDk4_1daab156-df47-4323-8130-dff028fb2d8b"
      unitRef="usd">47500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i86ed8956b9f74476a74b29069c13a878_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzU1Mzk_43347cdd-fa77-4b53-a4c5-02c28f4a5210"
      unitRef="usd">25000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i15ffbfb3b6be4f91b268691cc52236e2_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzU2MzM_56e67f2f-be4a-481d-9e6f-db213765985f"
      unitRef="usd">96900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie1f10220b2a3487cad57915da408086c_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzU2OTU_d8078b12-485b-4315-a91c-5dc379e423d4"
      unitRef="usd">30200000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <lly:NumberOfMedicinesRightsToSold
      contextRef="if9afc4eaa56b444c8eefdac063ce4a28_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzYyNDI_3b9a6bdc-95bb-433e-a63e-62a1ca28d2a9"
      unitRef="medicine">2</lly:NumberOfMedicinesRightsToSold>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="if9afc4eaa56b444c8eefdac063ce4a28_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzY0NTM_cbf25c02-198f-4974-8df5-da6f86f7e7d0"
      unitRef="usd">354800000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <lly:DisposalGroupNotDiscontinuedOperationPaymentToBeReceived
      contextRef="i8a5d6173c0cd4f7ab337f6b352f5a84c_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzY0NjA_cb0babab-22f8-49f4-8242-c23fc6d0afd1"
      unitRef="usd">40300000</lly:DisposalGroupNotDiscontinuedOperationPaymentToBeReceived>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ia3f8e0aa5a644441a2554b382567027e_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTIvZnJhZzoyZmUyNmJiMzc5NTA0ZDRhOTY4Njc3MzdkZjQzOWU2ZC90ZXh0cmVnaW9uOjJmZTI2YmIzNzk1MDRkNGE5Njg2NzczN2RmNDM5ZTZkXzY1OTQ_895eec64-e283-4ba6-a4b3-2f635b6a1458"
      unitRef="usd">309800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEzMzM1_9a05e989-3f6e-4a03-bc7e-3531b195a716">Collaborations and Other Arrangements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto, as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Jardiance, Trajenta and Basaglar in the U.S, Europe and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. These milestones are being amortized through their respective term under the collaboration which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) any supplementary protection certificates or extensions thereto. The table below summarizes the net milestones capitalized (deferred) at December 31 for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.216%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2019, in the most significant markets, we and Boehringer Ingelheim shared equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We recorded our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We recorded our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we recorded our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company was entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments may have resulted in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may have been reduced by any performance payments we made related to these products. Similarly, performance payments we may have received related to Basaglar effectively reduced Boehringer Ingelheim's share of the gross margin, which reduced our cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, we and Boehringer Ingelheim modernized the alliance. For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,490.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;892.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $260.0 million and $210.0 million were capitalized as intangible assets as of December 31, 2021 and 2020, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $100.0&#160;million of potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant, including sales of baricitinib that were made pursuant to an EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,115.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also had the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of sales-based milestones in 2021, milestone payments of $195.0&#160;million were capitalized as intangible assets and are being amortized to cost of sales over the estimated useful life of etesevimab. During the year ended December 31, 2020, we recognized $50.0&#160;million of research and development expenses related to development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to EUAs or similar regulatory authorizations, we recognized $2.24 billion and $871.2&#160;million of net product revenue associated with our sales of our COVID-19 antibodies during the years ended December&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sintilimab Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we plan to pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a regulatory approval for Tyvyt in China in 2021, we capitalized a milestone payment of $40.0&#160;million as an intangible asset which is being amortized to cost of sales through the term of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $195.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones, and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. As of December&#160;31, 2021 and 2020, contract liabilities were not material. During the twelve months ended December&#160;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Petra&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; inhibitor. Our more significant, near term milestones include a development milestone of approximately $205&#160;million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $164&#160;million in 2023 contingent upon achieving clinical proof of concept.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEzMzU4_1fb60269-1767-4213-b6e8-2bafe93e423a">The table below summarizes the net milestones capitalized (deferred) at December 31 for the compounds included in this collaboration: &lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.216%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,490.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;892.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,115.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table summarizes our revenue recognized in China with respect to Tyvyt: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ic8fafa3bd40547eda95f4f50a6dbab51_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzItMS0xLTEtNjg1Njc_0faa60d4-c503-4988-a546-32c031646cba"
      unitRef="usd">136100000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i77ebe26c48d94c40a9b534da5ed3e8d8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzItMi0xLTEtMzYwOTg_349200b6-2d4a-4687-abad-cc7b6b3f4680"
      unitRef="usd">156200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i853d77493c24496b99d5233e605a2605_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzMtMS0xLTEtNjg1NTQ_918edf71-eb6a-4338-9511-6e39afc81a52"
      unitRef="usd">88500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ib9c6112bfb3344d99c577b0fc24fd405_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzMtMi0xLTEtNDI3NDQ_1e812965-bc67-4d4c-8ebe-29fc4ab86d60"
      unitRef="usd">114600000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="iaa9ef0f44c884bf695c4900d1d6d8b9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzQtMS0xLTEtNjg1NzU_93f71402-6ca7-4ab2-a0ec-4bcdb27a6efa"
      unitRef="usd">-149300000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ied98305e265a49d9bdc89506cb9d5cd6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTpjYjAzZWNhOWY4OGE0OTYxODIyNWY4MjBlOWRiMjUyZS90YWJsZXJhbmdlOmNiMDNlY2E5Zjg4YTQ5NjE4MjI1ZjgyMGU5ZGIyNTJlXzMtMi0xLTEtMzYwOTg_022a465b-9362-4e03-a763-ad84686df7b7"
      unitRef="usd">-168000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i136e92857ae343079e9fdebb19210eb1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzItMS0xLTEtMzYwOTg_01017acd-ea80-4e59-b8d8-0f8cea9d0fe8"
      unitRef="usd">1490800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i399d8f462fc045509a0e309187f2f20c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzItMy0xLTEtMzYwOTg_a843246e-9f20-4ea3-9678-a3ab90f782a7"
      unitRef="usd">1153800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9c6636c6e8b4149a436c5c7f6ae3d8f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzItNS0xLTEtMzYwOTg_3d50f42d-cf4f-42ee-ba04-623069760d89"
      unitRef="usd">944200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i486722122165416c854ef981a6e4ff97_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMS0xLTEtNDI3ODE_e541f512-34a8-453e-9b47-7200e24cfc39"
      unitRef="usd">892500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb15db3b22d7456aa9d475cfe3645e22_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMy0xLTEtNDI3Nzg_50df9222-893d-42fb-9000-9935891cec95"
      unitRef="usd">1124400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d89303e28444753a87b86f2491e9dfd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtNS0xLTEtNDI3ODQ_6b86da31-bb06-4f56-879c-b67e59bb2268"
      unitRef="usd">1112600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8434b474adc4712945fa8b15221a062_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMS0xLTEtMzYwOTg_fb2dd6eb-e5c5-43dc-be86-ab79615c196f"
      unitRef="usd">372500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34c1f715e391472e9c4295cbc73dfcc5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtMy0xLTEtMzYwOTg_6b77112a-2813-4d3c-8161-49daadcdd914"
      unitRef="usd">358500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fc1b15a414543789a445369b1f1c319_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplMjJmNjMwOTJmMGI0ZDRlODU2YjI1YzlhYzAyZTkxYy90YWJsZXJhbmdlOmUyMmY2MzA5MmYwYjRkNGU4NTZiMjVjOWFjMDJlOTFjXzMtNS0xLTEtMzYwOTg_c1f03e0c-54d2-4582-8b2d-4565d049f91c"
      unitRef="usd">590600000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="ie508b8edff5e4d49ac5daeb3e44ee7d3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzYxNzA_d35b5d68-7048-43c7-841a-00f7aa3d1842"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i8fa8514e03e541bab9bb427c8c8e408d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzQzOTgwNDY1MzkxMjc_221e32ef-e417-4f0f-b0d2-9f8cf25a7fdf"
      unitRef="usd">260000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i05b90b30620c4805b8c68b6df7e498b5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzY3Mjg_54c24bd9-abed-4ab5-a091-6033b93cb4ce"
      unitRef="usd">210000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="id33d1a73df7248168e83573873688d81_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzcwODg_203f0d80-fe3d-42fa-beb3-a8fea7108cf5"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i60f74e83d5644e2c8fbb2e5c78bfd650_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzcyMjQ_dae2e2f1-a57f-4988-a912-984ad490e5eb"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i7ffacbc5450e4178843413354209aaed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplNDFhOWVhNjhhNTQ0MmYyOWUyOTllZGQ2OWY0Njc1Ni90YWJsZXJhbmdlOmU0MWE5ZWE2OGE1NDQyZjI5ZTI5OWVkZDY5ZjQ2NzU2XzEtMS0xLTEtMzYwOTg_2d00d0fa-6bd9-4f28-bbcc-1c3c9180a219"
      unitRef="usd">1115100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bb740f8f8fb49248e01e2ab80d6ae9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplNDFhOWVhNjhhNTQ0MmYyOWUyOTllZGQ2OWY0Njc1Ni90YWJsZXJhbmdlOmU0MWE5ZWE2OGE1NDQyZjI5ZTI5OWVkZDY5ZjQ2NzU2XzEtMy0xLTEtMzYwOTg_a4917510-53e0-404e-828c-3abee49f1097"
      unitRef="usd">638900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i249d33d5a06a4082a59829e958e69da7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTplNDFhOWVhNjhhNTQ0MmYyOWUyOTllZGQ2OWY0Njc1Ni90YWJsZXJhbmdlOmU0MWE5ZWE2OGE1NDQyZjI5ZTI5OWVkZDY5ZjQ2NzU2XzEtNS0xLTEtMzYwOTg_7772597b-7e2e-4c0d-b395-e93a239a8b22"
      unitRef="usd">426900000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i48acf53cf4c149ba854e91d6ea82b05a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzI3NDg3NzkxMDc5MjY_0b3dde24-7132-4cd7-8b0d-485093c232a3"
      unitRef="usd">195000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if1a83cd101f14432a8f149d6a0e602f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzI3NDg3NzkxMDc5NDI_3a4f85fc-bed3-4119-9594-4f90926ddaff"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9a3812ca43742f1ae973a2b31a04adc_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzE2NDkyNjc0NjM0OTM_0d3cafe4-aeed-4bb9-a2b8-84da9a00e3cb"
      unitRef="usd">2240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief25801843e9467799271bdda2e99bd9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzE2NDkyNjc0NjM2NDY_2d838093-8b3f-4ad1-b283-bf8a0dd49cb1"
      unitRef="usd">871200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i5e413d56e5d84f349849637c0f978d4b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzcxNDY4MjU2MTkwNjE_7fd3c807-8f94-479d-b088-9c2385135542"
      unitRef="usd">40000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i4e4260516b4243cab0755138b1cb1e20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwMzE1_118da4d7-3608-46a7-8f72-28663eada047"
      unitRef="usd">825000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i96a4b9d553f8498a8d8c5c1b0148aee5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwMzYx_32b251c2-4580-4833-bc96-5d9ec22efcfc"
      unitRef="usd">195000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i89ae01d552e14307ade61a2e8ce4818f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTo0MGRhYmM1Mzc4OTk0ZDFhYjZiNmMyMDgyODAxODM0OS90YWJsZXJhbmdlOjQwZGFiYzUzNzg5OTRkMWFiNmI2YzIwODI4MDE4MzQ5XzItNS0xLTEtNDMwODE_cac46780-05ab-4386-a7de-a74de795693f"
      unitRef="usd">418100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8ec11f13ec44ec886a4d089e6954497_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTo0MGRhYmM1Mzc4OTk0ZDFhYjZiNmMyMDgyODAxODM0OS90YWJsZXJhbmdlOjQwZGFiYzUzNzg5OTRkMWFiNmI2YzIwODI4MDE4MzQ5XzItNy0xLTEtNDMwODE_ec111761-e28c-4928-85fe-52851a728a20"
      unitRef="usd">308700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfd825e2456741c6b9498e5c19f301ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90YWJsZTo0MGRhYmM1Mzc4OTk0ZDFhYjZiNmMyMDgyODAxODM0OS90YWJsZXJhbmdlOjQwZGFiYzUzNzg5OTRkMWFiNmI2YzIwODI4MDE4MzQ5XzEtMy0xLTEtNjg3OTQ_5425c907-f0e2-4231-b632-5014576a13f2"
      unitRef="usd">134000000.0</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i42cba64a30364790b8eb1eb2ae66c5e1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyMDUw_7063d8a7-963d-4c58-91ee-4e4e028e275e"
      unitRef="usd">180000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i45283f4c7fdc40bf9a23a33c5df93208_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyMTU1_aa2c871e-aa1f-43ed-836d-85c52cf5c6f1"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="icaf2be9f580f44fd8e954526bb36e7f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyODEx_aad61345-3d0e-4f9c-b3d9-92a9dcfda7dd"
      unitRef="usd">85000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i2e72a7d25b8a40b99e28b009e54e5649_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEyOTA5_f166a5b6-0bbf-4270-8e0f-97d6deb83d3e"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ie7bd696f56304ea8940548378684aacd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwOTk1MTE2NTU0MzA_dbcc66b0-9597-4f41-aaeb-e8753733c2ee"
      unitRef="usd">205000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7efe9a1356e9485983eeb603c301d153_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTUvZnJhZzo2YTNlZDE0NGM0ZDQ0MmI5OTQzNWE0ZjAwNWM5MzgyMy90ZXh0cmVnaW9uOjZhM2VkMTQ0YzRkNDQyYjk5NDM1YTRmMDA1YzkzODIzXzEwOTk1MTE2NTU1NDM_2a01489e-f87d-430c-8119-f8043639ded3"
      unitRef="usd">164000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzEwNzA_f0c591a7-3a0a-49b6-9348-358e1ed987df">Asset Impairment, Restructuring, and Other Special Charges&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (gain) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;303.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;316.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance costs recognized during the years ended December 31, 2020 and 2019 were incurred as a result of actions taken worldwide to reduce our cost structure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. &lt;/span&gt;&lt;/div&gt;Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $400.7 million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards.</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzEwNjQ_3b4e5122-14a7-4a5c-a3f3-43d760d6caaf">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (gain) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;303.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;316.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzEtMS0xLTEtMzYwOTg_8eea55fe-b56b-41a9-9ea0-2d20e0079ded"
      unitRef="usd">13000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzEtMy0xLTEtMzYwOTg_a6dbbdbe-1945-4400-9c77-35e7226251d6"
      unitRef="usd">151200000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzEtNS0xLTEtMzYwOTg_f30a6708-15ac-4d5d-beab-d8942d913008"
      unitRef="usd">77800000</us-gaap:SeveranceCosts1>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzMtMS0xLTEtMzYwOTg_653db8dc-f09e-4530-bc64-c905c0cc4f94"
      unitRef="usd">303100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzMtMy0xLTEtMzYwOTg_b86f2b53-b9be-4ae3-96df-0fa681be8833"
      unitRef="usd">-20000000.0</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzMtNS0xLTEtMzYwOTg_bd071071-c544-4e3e-b943-7ba701a2190f"
      unitRef="usd">497800000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzQtMS0xLTEtMzYwOTg_92c62eda-0587-4a49-9eac-ff439bbfc426"
      unitRef="usd">316100000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzQtMy0xLTEtMzYwOTg_fd3f5846-fd89-430b-8b87-ffbb39d60790"
      unitRef="usd">131200000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90YWJsZTo4NWRhMDViNjJjMzk0YTgxYWMzY2RlOTlkNzQ2NGIwZC90YWJsZXJhbmdlOjg1ZGEwNWI2MmMzOTRhODFhYzNjZGU5OWQ3NDY0YjBkXzQtNS0xLTEtMzYwOTg_29d04535-3fb1-473c-8b1a-c01f6c2ada73"
      unitRef="usd">575600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzExNTQ0ODcyMDk1NDY2_7049f8c1-a112-4280-95a1-eb19c2d61db1"
      unitRef="usd">128000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzExNTQ0ODcyMDk1NDQ1_4b0edd23-e2b6-446a-8256-8dc83005fedf"
      unitRef="usd">108100000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i76e71ae8b5064232b5cf8e0340ad9913_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMTgvZnJhZzpiYjEwMTY2NWRhOWU0NmQ4OGJhNDUwNWZjNzEyMDEyYS90ZXh0cmVnaW9uOmJiMTAxNjY1ZGE5ZTQ2ZDg4YmE0NTA1ZmM3MTIwMTJhXzYzMw_a6695e17-dfb3-4578-a6c1-5e1d4113b938"
      unitRef="usd">400700000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzYwMQ_65a0a216-4742-47cd-b6bd-43330f17a754">Inventories&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;761.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,372.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;717.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates replacement cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,851.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,886.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,980.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories valued under the LIFO method comprised $1.36 billion and $1.21 billion of total inventories at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;We recognized a net inventory impairment charge related to our COVID-19 antibodies of $339.7&#160;million during the year ended December 31, 2021 in cost of sales in our consolidated statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic evolved during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzYwOA_f4f863e5-6dca-46df-aa1f-5cb550926013">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzYxNw_49a06a33-6952-4a48-bc20-a8020794b03a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;761.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,372.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;717.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates replacement cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,851.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,886.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,980.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzEtMS0xLTEtMzYwOTg_aa760040-7970-48a0-a980-4501c4211976"
      unitRef="usd">761900000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzEtMy0xLTEtMzYwOTg_9d86b5f9-9980-4553-8acd-a6c508cc98c8"
      unitRef="usd">758900000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzItMS0xLTEtMzYwOTg_235d3f17-ef76-4e06-973b-1dca018a27ef"
      unitRef="usd">2372700000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzItMy0xLTEtMzYwOTg_93ed2781-102b-44b1-aab6-b4ee377764dc"
      unitRef="usd">2535400000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzMtMS0xLTEtMzYwOTg_1f5af9e9-eb15-4e84-bb74-d91e329ae6c8"
      unitRef="usd">717200000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzMtMy0xLTEtMzYwOTg_d8002b63-7b2a-4160-92fa-6c400816880c"
      unitRef="usd">651200000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzQtMS0xLTEtMzYwOTg_30469f51-5d52-4b5b-baeb-4604aaab36db"
      unitRef="usd">3851800000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzQtMy0xLTEtMzYwOTg_2a3f94b7-f0c6-4446-ae82-f56a5cd59f1d"
      unitRef="usd">3945500000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzUtMS0xLTEtMzYwOTg_a99a687a-925d-41a0-b9fe-e269d8ba8b50"
      unitRef="usd">-34200000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzUtMy0xLTEtMzYwOTg_7eec3a12-037e-4ee1-a8b0-f43cc8cc90f8"
      unitRef="usd">-34800000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzYtMS0xLTEtMzYwOTg_7b181697-c13d-4fef-abce-8bed77341b9d"
      unitRef="usd">3886000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90YWJsZTpkYjMxMGI4Yjc5OTU0NGQyOTkxMTk1MWIzZGZkMzUxNy90YWJsZXJhbmdlOmRiMzEwYjhiNzk5NTQ0ZDI5OTExOTUxYjNkZmQzNTE3XzYtMy0xLTEtMzYwOTg_ad470dc3-7ac8-46e1-a494-84447062ce7d"
      unitRef="usd">3980300000</us-gaap:InventoryNet>
    <us-gaap:LIFOInventoryAmount
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzUzOA_ea15a25a-11f2-4b00-a61c-f5e896fedd0d"
      unitRef="usd">1360000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:LIFOInventoryAmount
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzU0NQ_1b79d523-8c6f-4db0-8cee-98e8c21bd202"
      unitRef="usd">1210000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:InventoryWriteDown
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjEvZnJhZzpjZDA5ZTliZDFkMzU0YTQwOWU4OGI3MmY3MWE5YmU0ZC90ZXh0cmVnaW9uOmNkMDllOWJkMWQzNTRhNDA5ZTg4YjcyZjcxYTliZTRkXzExNTQ0ODcyMDkzMTA0_3cf167cd-de01-4a93-a969-ee1e4ac9ef62"
      unitRef="usd">339700000</us-gaap:InventoryWriteDown>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTYz_2d499527-a87d-44db-92cd-47982ec19f6d">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December&#160;31, 2021, we had outstanding foreign currency forward commitments to purchase 4.43 billion U.S. dollars and sell 3.92 billion euro; commitments to purchase 3.84&#160;billion euro and sell 4.37&#160;billion U.S. dollars; commitments to purchase 159.2&#160;million U.S. dollars and sell 18.26 billion Japanese yen, and commitments to purchase 223.0 million British pounds and sell 296.0 million U.S. dollars, which all have settlement dates within 180 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $7.90 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.02&#160;billion as of December&#160;31, 2021 and 2020, respectively, of which $5.79 billion and $4.50&#160;billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of December&#160;31, 2021 and 2020, respectively. At December&#160;31, 2021, we had outstanding cross currency swaps with notional amounts of $1.02 billion swapping U.S. dollars to euro and $1.00&#160;billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December&#160;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December&#160;31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75&#160;billion, which have settlement dates ranging between 2023 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Effect of Risk Management Instruments on the Consolidated Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(78.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;204.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;213.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12 months, we expect to reclassify $16.5 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#x2013;net, (income) expense. During the years ended December&#160;31, 2021, 2020, and 2019, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,379.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,379.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,361.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,379.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;90.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;136.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;232.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,279.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;487.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,279.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,279.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;548.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;771.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,212.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,884.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of December 31, 2021, we had approximately $828&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be invested over a period of up to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5      Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10    Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More Than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gains recognized in our consolidated statements of operations for equity securities were $176.9&#160;million, $1.44 billion, and $401.2&#160;million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. The net gains/losses recognized for the years ended December 31, 2021, 2020, and 2019 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2021, 2020, and 2019 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 97 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable Factoring Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $550.5 million and $754.9 million&#160;of accounts receivable as of December&#160;31, 2021 and 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2021, 2020, and 2019 were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTMw_7ddbd1c9-d737-4a0e-b5a6-96ca549ab1d5">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTM3_4649f05e-a483-4f3c-9242-cbf3db1757f9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTA4_e01fb2e6-a2c8-4dc5-80b3-b8c0bb35c972">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss) and, upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQyMjQ_ab33b0ca-3e18-48c0-bdf7-507dd0caac64">P12M</us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i04f34fc75a9044519a55f0a841ded99b_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzMTA_9a4b7226-4129-443a-b9f5-2ef3782e4891"
      unitRef="usd">4430000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i04f34fc75a9044519a55f0a841ded99b_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzMzU_f2a4883e-d6aa-4e40-b67c-23857c7cc562"
      unitRef="eur">3920000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic28ad2006eb14d37878a695f14e7352c_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzNjg_80746a0a-afd9-4111-ba12-58e79b60b11d"
      unitRef="eur">3840000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ic28ad2006eb14d37878a695f14e7352c_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQzODU_68aba537-6868-4706-8c09-d23817fccefd"
      unitRef="usd">4370000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i20261b7a34e44eef9f687c2383ca625d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ0MjY_06550ac8-3531-492a-b3af-9756e337492a"
      unitRef="usd">159200000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i20261b7a34e44eef9f687c2383ca625d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ0NTE_758b89d1-27ef-4930-80c7-aae67e351ad8"
      unitRef="jpy">18260000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i6fe06c36179f415f8d86b66fba575560_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ0OTY_82570ed0-960b-4005-8077-383be247c691"
      unitRef="gbp">223000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i6fe06c36179f415f8d86b66fba575560_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ1MjM_45659656-9bab-4ba4-bd15-ae88ed9985fd"
      unitRef="usd">296000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ1NjQ_72bba9bf-ea28-47af-91dd-4dcfd1f8ff84">P180D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:LongTermDebt
      contextRef="ia33be6c87c2c473f9a400403f197ba1f_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ3NTk_597c1ef7-fedd-48ae-86f4-23dd04dbf157"
      unitRef="usd">7900000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibf59c02dd99c40c1952252de92c7253e_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ3NjY_ec6b6ffe-7018-4b52-b25e-b9b486a900d4"
      unitRef="usd">6020000000.00</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ4MTA_99bf1e2b-5688-49da-8a62-0182fc47bf1d"
      unitRef="usd">5790000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzQ4MTc_3eb38886-84e2-4578-b097-8ef6a01caa3f"
      unitRef="usd">4500000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i62bec06499364dfeacd40d1298f61c82_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzUwNTk_4ebc9d3d-7d4c-479e-bcbb-29979c0e57ba"
      unitRef="usd">1020000000.00</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ic6cb727e20f143faa3e3a38b9dfff0c3_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzUwOTY_2836ebc7-c6fa-4e41-9f3b-30a5d949af6b"
      unitRef="usd">1000000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzY4Njk_5b223b63-4676-41a4-a223-0dee630a0eb6"
      unitRef="number">0.13</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iacadc29206d84c3fa7fd83b205a66414_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzc1Nzg_f48d6b2c-5487-4be0-99d5-8b7107e56af5"
      unitRef="usd">1750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTc0_0a9bddce-8207-41fc-a86b-e6129c1d92f9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(78.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;204.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i13cf07612b294643a8bc48b8588f1f8d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzItMS0xLTEtMzYwOTg_e399b6d3-9e6f-490a-b3e2-2ce83a60e741"
      unitRef="usd">78500000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i7edcbbba5dfc46c38e6a76c687dd5837_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzItMy0xLTEtMzYwOTg_9a218302-ee52-43d3-b0e4-e88ce3381dcd"
      unitRef="usd">-86900000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i6411281e97d94731863b39b1923f21a0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzItNS0xLTEtMzYwOTg_f9a34b4c-6a30-4e94-aa4c-cb4027c296da"
      unitRef="usd">-112100000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i7bc442230d5c4382b155b07c92135617_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzMtMS0xLTEtMzYwOTg_0fdb75e1-43a6-4595-99ff-d9bcc772392c"
      unitRef="usd">-78500000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="if3963f62afd047ba88fb5cbe40c1d155_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzMtMy0xLTEtMzYwOTg_eb671c6e-f1de-4568-93cc-97fa00e6a75a"
      unitRef="usd">86900000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i8de4d107e8a743a9aaf08d126d7c581c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzMtNS0xLTEtMzYwOTg_48a193d0-b4d6-45ec-888e-14cff5ae0e1a"
      unitRef="usd">112100000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7bc442230d5c4382b155b07c92135617_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzUtMS0xLTEtMzYwOTg_f5e70f54-9e68-474f-ac9f-e8712a1ff24d"
      unitRef="usd">16600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="if3963f62afd047ba88fb5cbe40c1d155_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzUtMy0xLTEtMzYwOTg_cdb249e7-ff13-4fcc-b873-8106c6176be1"
      unitRef="usd">16400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8de4d107e8a743a9aaf08d126d7c581c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzUtNS0xLTEtMzYwOTg_843d5ec9-c13f-4203-834f-12c8dfba3a36"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ibd8aad08f18b4154898d2ecd801df8d1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzYtMS0xLTEtMzYwOTg_00871951-7262-44df-a4d4-61dbb6ebf7ac"
      unitRef="usd">41800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i1e0f3057dc4a4dd1ab06ea189bd4a2fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzYtMy0xLTEtMzYwOTg_c940b9c3-e434-40a8-8728-8f3eee69de84"
      unitRef="usd">-102400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2c3cc7a81d924d63acfe2aeb96bbdd40_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzYtNS0xLTEtMzYwOTg_e7f22fe6-ca56-4149-89cd-2986caab2e9f"
      unitRef="usd">-17100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ib1125c3d05584e4488d02c8aa1c758e9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzctMS0xLTEtMzYwOTg_404907b5-5ef2-4081-a9f9-259a3c400661"
      unitRef="usd">-204600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i172c281918af4f27986511aa04ee513f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzctMy0xLTEtMzYwOTg_bae4ad90-d94e-43e4-8dbc-ec8b9861e17d"
      unitRef="usd">123700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i9d4ac65858f54342b86be7fc605a4ffe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzctNS0xLTEtMzYwOTg_32c59a1d-792c-4a14-acc0-30f58a67c82f"
      unitRef="usd">-61900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzgtMS0xLTEtMzYwOTg_8532b679-3e4c-4db7-af32-a39d96de985e"
      unitRef="usd">-263000000.0</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzgtMy0xLTEtMzYwOTg_8283cd0d-87ba-4524-a270-b6c25e8a3933"
      unitRef="usd">209700000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphYTVkMjMwYzI1MDQ0N2ExYmUzOTBiNDI5OTZhYmY3OS90YWJsZXJhbmdlOmFhNWQyMzBjMjUwNDQ3YTFiZTM5MGI0Mjk5NmFiZjc5XzgtNS0xLTEtMzYwOTg_26c65b78-b8c0-4582-ac3b-427a39d7e2c3"
      unitRef="usd">-60700000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDk5_45054e8b-a499-4c17-add6-2b4dabfb44d6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;213.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDk5_c91c5558-01af-41f4-8ee7-b8de5eeeeba9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;213.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8b70f245d0994606a77553c858e70e2d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzItMS0xLTEtMzYwOTg_cba464a9-ce82-45e6-b82b-eea21ab916c7"
      unitRef="usd">435000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0bf867828fd8402cab098ff96e91c5b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzItMy0xLTEtMzYwOTg_b4492c3e-1865-4b58-a928-c72b5dedf420"
      unitRef="usd">-404000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i231f5158b0a54e01b77ad8a5c7af7e1a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzItNS0xLTEtMzYwOTg_65615bf8-f007-4955-9731-097ca7d70288"
      unitRef="usd">40100000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="idea923d9282a47d6b6affe9918bcfb47_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzMtMS0xLTEtMzYwOTg_bcf43e7c-26aa-43d6-b521-a5582ff50758"
      unitRef="usd">213700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iccdf591423b44978b57ec5e6980efa0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzMtMy0xLTEtMzYwOTg_7a3a9c10-b4d9-4b3f-bc46-ab9990fb6a08"
      unitRef="usd">-207900000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i87e3b85955b94cd59588c3c75b0d84c6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzMtNS0xLTEtMzYwOTg_96ea8a73-cdd0-44d0-83c4-5d95fdbb568e"
      unitRef="usd">47400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="if2733925e7174df2a7294f9cc18f29d0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzYtMS0xLTEtMzYwOTg_7e3b6915-3481-47b3-ad86-42f669bdb07d"
      unitRef="usd">97600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i48d907c6902548ad9042a61cf12bc57c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzYtMy0xLTEtMzYwOTg_9a6fd370-f024-4b19-831b-c5ae7aab4264"
      unitRef="usd">-110900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i1034a9c1ab4a439abf5f9b58a0013acc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzYtNS0xLTEtMzYwOTg_629f7d56-f9a9-4868-a186-d0ab635f5b02"
      unitRef="usd">31600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="idea923d9282a47d6b6affe9918bcfb47_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzctMS0xLTEtMzYwOTg_6025ea90-678f-4490-91b5-2f06bde82858"
      unitRef="usd">42300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="iccdf591423b44978b57ec5e6980efa0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzctMy0xLTEtMzYwOTg_89dac576-e423-4412-85de-9ecad7f1f6e3"
      unitRef="usd">-53700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i87e3b85955b94cd59588c3c75b0d84c6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpiNjZmZmNmNjFkMTY0ZDViOGViOGViNTc5YjQxNTgxNS90YWJsZXJhbmdlOmI2NmZmY2Y2MWQxNjRkNWI4ZWI4ZWI1NzliNDE1ODE1XzctNS0xLTEtMzYwOTg_4d084783-4855-42bf-81fe-ac73ca0cc299"
      unitRef="usd">-8300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzgzMjc_bfc7e511-135c-4067-b571-887cd70cef5c"
      unitRef="usd">-16500000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTEz_e1798ecb-ca58-42d3-be8d-c36c21739907">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,379.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,379.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,361.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,379.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;90.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;136.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;232.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;235.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,279.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;487.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,279.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,279.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;548.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;771.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,212.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtMS0xLTEtMzYwOTg_8b71d884-37d6-47a0-930b-bbd82cef9e8b"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i242bd07c45d542379d0e0d769eb01235_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtMy0xLTEtMzYwOTg_3dfff4e9-c191-481d-b259-97ae22596086"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5f207cd4c10c40c58e5e98e94e0977fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtNS0xLTEtMzYwOTg_ff466a6c-3e25-4438-9b9a-48c51842fc14"
      unitRef="usd">2361000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic01d3d2786ef48c7b3a9a7abc2347162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtNy0xLTEtMzYwOTg_dbc65f0a-01ad-4ad1-8061-1f8ffb45722a"
      unitRef="usd">18500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7ca22a25490746b2a01afb869b9c9451_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtOS0xLTEtMzYwOTg_eedc1a2d-249d-415a-989c-ee10316e8a7a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0cacf599a2654a73aeb964f7e22ed6fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMtMTEtMS0xLTM2MDk4_006cf3fc-7859-4eb5-8fcc-4fd6c00f6918"
      unitRef="usd">2379500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibd392ae258dd4c8682df0b88169ff443_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtMS0xLTEtMzYwOTg_68f7c03b-ea8e-4cd6-94b7-62bca4dc8ae3"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6a9309322cbf4299ba4880f01282b66d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtMy0xLTEtMzYwOTg_017eea14-bba7-404c-9ddb-8e1a85bccc98"
      unitRef="usd">25600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie6c1fe3ce37c429a96afdfe79afa5af8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtNS0xLTEtMzYwOTg_7463ea52-1bf0-45b3-a520-5ea9dbca4be8"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id782339ced69430ea75a51f82b17fa9e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtNy0xLTEtMzYwOTg_5309397e-04e5-42c8-89dc-9b0c8c85aff1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5366462e14a747678162a92e578671fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtOS0xLTEtMzYwOTg_f6bb7e54-1b02-4bf5-85de-78d410f7d419"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i873a6f3b952448949d4f521a40683c05_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzUtMTEtMS0xLTM2MDk4_1de66f0b-77d5-4d15-8019-6b7e46c8d6ef"
      unitRef="usd">25700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5af1d3d2625a408dbe57ea38651c828d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtMS0xLTEtMzYwOTg_2b85cb3a-d514-4e49-84df-4aa99211874b"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic77f19b3dbbc4c1d80c04d076b72b774_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtMy0xLTEtMzYwOTg_857b9c52-a00a-49eb-b041-b6d38f79c786"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2626088ca7db42dd977c6aebdf6b049b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtNS0xLTEtMzYwOTg_972794d3-f64f-49c6-977c-40eaffe40399"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5386daa8d43b4f8fbff09fb65341a6f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtNy0xLTEtMzYwOTg_b645c99f-3d1b-4364-beb2-92576a6e1e3f"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i87d69d72b4fd4b7b89d28f60a414253c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtOS0xLTEtMzYwOTg_af53201b-6da6-4981-8eaf-2f27bec44e8e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie1ffc73d6c5b44b9afdbee59fdd53fd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzYtMTEtMS0xLTM2MDk4_33e03330-064c-4e8f-94ab-6c828b7f4a18"
      unitRef="usd">43700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i167566322d3e4bad868eb0f8ff25fb59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMS0xLTEtODQ5MzM_d7355d5c-ec45-4b72-8e58-860725be4a91"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie0a69147b72c429dbae1a73cd1a2182c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMy0xLTEtODQ5NDE_1d72a628-35db-42bd-a3a1-39bb154bcb1c"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i57f41fed5a2748dd899cdc2d6df25422_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNS0xLTEtODQ5NDk_d9551cea-81f6-48a8-811b-54366b36bcbc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iac07bef7ae3f4c03ab806ac0355474b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNy0xLTEtODQ5NTc_726c1983-8647-434b-ae6d-291ac555dd51"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icdffc1192c114929a5c33da248552b55_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctOS0xLTEtODQ5Nzk_8adc6b3d-1f4c-493e-ace7-382e4b78c724"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4bc6a1a7f28f40fb9514b1428d9518a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMTEtMS0xLTg0OTg3_b7d607ad-208a-4a20-924d-4eee604dc6b7"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1a4d104ab06043e094df62100f0da340_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMS0xLTEtMzYwOTg_10a9444e-e835-4821-a310-a3c849e8f9ac"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i66fc52f2565b4f23a7e7a380898faab8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMy0xLTEtMzYwOTg_409db513-34d7-4d3f-a6b2-5eaf46cb2431"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i908a1e69c3d14ca19b78ad94abf18315_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNS0xLTEtMzYwOTg_524288e9-8650-4e33-a017-ae10d544e928"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if243f863e61d40228ccaf6b6475f9534_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctNy0xLTEtMzYwOTg_fd025085-68a9-43e9-901f-98b127b85dd2"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4d669a981bf145e98752c8ae97287ef1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctOS0xLTEtMzYwOTg_42247870-f5b2-4dae-931a-83753a3415c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i814218cfc2834473ba1512b07052cb1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzctMTEtMS0xLTM2MDk4_96b682d2-3482-48bd-bde0-d301d3863298"
      unitRef="usd">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id88d4e701c504e9b93b9007e768400d8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtMS0xLTEtMzYwOTg_de031d33-5e83-45f6-9f78-36c2f850ea3d"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5a0e6c24bfd5491e8a07010acbd5b7a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtMy0xLTEtMzYwOTg_2c6a9ed2-6e4e-4725-9cfd-8178d6738370"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icde117f5d3be4373957394d16191ee0b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtNS0xLTEtMzYwOTg_4b1d465f-5092-4bdd-9cf9-ce98636d09c7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib3f07bbac3664847aaeae5a2475a657f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtNy0xLTEtMzYwOTg_d66ccbec-2faf-4022-9962-da7abf75ea1c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9e1eb7cb09f94a6c988ce5500bf74a37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtOS0xLTEtMzYwOTg_c2a3636f-fae8-497d-9c0c-e04f09ba40e8"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icfc632f8e72b402d89710b5655c6a876_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzgtMTEtMS0xLTM2MDk4_3131c728-939e-4247-ab77-43517d734bb1"
      unitRef="usd">14300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEwLTEtMS0xLTM2MDk4_7eeac32a-83a5-46ab-9cfd-80705bcc98f6"
      unitRef="usd">90100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibd392ae258dd4c8682df0b88169ff443_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTEtMS0xLTM2MDk4_365ff496-ec2e-47c5-a477-d06ec8e089db"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6a9309322cbf4299ba4880f01282b66d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTMtMS0xLTM2MDk4_5ba33991-634a-4d41-b14b-05b154b3c576"
      unitRef="usd">136800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie6c1fe3ce37c429a96afdfe79afa5af8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTUtMS0xLTM2MDk4_f1079e69-8d30-4135-838f-139f6c0402b4"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id782339ced69430ea75a51f82b17fa9e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTctMS0xLTM2MDk4_99c048e3-64d0-42d8-aaf8-b56d3fd92d3d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5366462e14a747678162a92e578671fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTktMS0xLTM2MDk4_e428de92-6b2f-47a9-9647-60da79fd43df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i873a6f3b952448949d4f521a40683c05_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEyLTExLTEtMS0zNjA5OA_c42f6c5e-648c-4ff2-bfd3-23fbfa43c5f2"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5af1d3d2625a408dbe57ea38651c828d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTEtMS0xLTM2MDk4_f756eb66-3641-48ba-9fbb-f9f1e6fcdc60"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic77f19b3dbbc4c1d80c04d076b72b774_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTMtMS0xLTM2MDk4_d0e7bfd6-ee28-42e0-ba38-0ad58dcf22da"
      unitRef="usd">232700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2626088ca7db42dd977c6aebdf6b049b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTUtMS0xLTM2MDk4_96836dc1-adf0-4a3f-821e-052774fdafba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5386daa8d43b4f8fbff09fb65341a6f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTctMS0xLTM2MDk4_b8de8a18-0ae6-46cd-a7c5-2c4b8d85e043"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i87d69d72b4fd4b7b89d28f60a414253c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTktMS0xLTM2MDk4_59928fbb-73a6-4a9c-a780-49c5e7c8f6e1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie1ffc73d6c5b44b9afdbee59fdd53fd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzEzLTExLTEtMS0zNjA5OA_4e0341ac-8a9a-4372-986c-c1ed67e6c3e2"
      unitRef="usd">235300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i167566322d3e4bad868eb0f8ff25fb59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTEtMS0xLTM2MDk4_37bb24d2-5734-419b-bd48-4fcd4fc7b134"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie0a69147b72c429dbae1a73cd1a2182c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTMtMS0xLTM2MDk4_a35ddc92-b181-4cf1-8121-473a4344be48"
      unitRef="usd">108100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i57f41fed5a2748dd899cdc2d6df25422_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTUtMS0xLTM2MDk4_51f221c7-c037-499a-9d64-bee309aeb819"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iac07bef7ae3f4c03ab806ac0355474b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTctMS0xLTM2MDk4_d0a1269a-8a43-489b-a25d-6d95e5b42780"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icdffc1192c114929a5c33da248552b55_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTktMS0xLTM2MDk4_ff9f9691-23cd-4f6d-86d9-2a0bd5893a10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4bc6a1a7f28f40fb9514b1428d9518a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE0LTExLTEtMS0zNjA5OA_6a18ba7f-949a-4c3f-9432-ac612dda9422"
      unitRef="usd">109800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1a4d104ab06043e094df62100f0da340_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTEtMS0xLTM2MDk4_4077d677-db76-4877-9aad-c0bc7c1de4ff"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i66fc52f2565b4f23a7e7a380898faab8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTMtMS0xLTM2MDk4_2d638a02-8a7d-421d-889d-ec6e8ab00586"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i908a1e69c3d14ca19b78ad94abf18315_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTUtMS0xLTM2MDk4_838a51b7-46cf-45a7-839b-5fa83408e8ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if243f863e61d40228ccaf6b6475f9534_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTctMS0xLTM2MDk4_8509cbc5-16cf-4fb2-98ee-e48ce6831685"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4d669a981bf145e98752c8ae97287ef1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTktMS0xLTM2MDk4_4cf94ad7-12f6-4064-be63-4e357d32f526"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i814218cfc2834473ba1512b07052cb1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE1LTExLTEtMS0zNjA5OA_0a531ed4-8132-4f3a-b4ff-76dbd61e015d"
      unitRef="usd">23100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i306e14d7ddca4e21b4794cb488fce5b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTEtMS0xLTM2MDk4_98d7f38e-6e78-4e44-81ac-560b1da82d35"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9895d0dae6d7445ea42921b93f0a9c68_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTMtMS0xLTM2MDk4_82d7cf74-e690-4c8f-91b5-5e096e22b771"
      unitRef="usd">22200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i10c09ae807e54da4a01d2cfc00bd5e06_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTUtMS0xLTM2MDk4_10ef9dbb-2a36-4820-a6e9-ce55e92df7b4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9e05a36b4b8c46ab99d9337d3cd3d4f8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTctMS0xLTM2MDk4_7fd2fea8-b823-4a69-af5d-438565f6208f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3af9bc2dbbf14e6d8e3d8e05279f0cbd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTktMS0xLTM2MDk4_7dfc1a3e-6aff-4be9-8fba-b9deac59c73e"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic30bf5e4d039481f8d19ae86d4a50d87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE2LTExLTEtMS0zNjA5OA_a842f636-4d75-4446-a748-295d236fa116"
      unitRef="usd">108100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0f8cf31dd8d64f55aa42897b097ff8bc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTEtMS0xLTM2MDk4_220b3780-58e8-49b6-99f5-25d9114af229"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i88230f75c60c479dbd0b6cf91c9e74fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTMtMS0xLTM2MDk4_eeb5f66c-0e2d-479a-9228-d223df7b3721"
      unitRef="usd">487000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia445641f8593463bbe60fb23e89ff376_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTUtMS0xLTM2MDk4_06edfd45-b06d-4889-85b6-c8ea21f99c13"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if5fca9cdf5874c528fd7153bb23cf79e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTctMS0xLTM2MDk4_fed2e29b-f221-4158-8786-8ace44a7ef23"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i031c8be8676a417ca167ea02c5249ecb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTktMS0xLTM2MDk4_04774fe0-caf0-4eb4-a98f-71717097c6b2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3bf98252eb304398b10e2fa6fa205edb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE3LTExLTEtMS0zNjA5OA_5a62eeca-ca3f-42af-bab6-7ec89b98cd6d"
      unitRef="usd">1279700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE4LTEtMS0xLTM2MDk4_67361666-c93c-40fe-884b-3001cde32ce4"
      unitRef="usd">548100000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i4fe70f0bb1ff48bbb5988ae3b9d281fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzE5LTEtMS0xLTM2MDk4_64991fff-1422-439b-be97-b8a02e9a27c3"
      unitRef="usd">771500000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIwLTEtMS0xLTM2MDk4_ee63fa4c-6672-4cdc-833a-549c38da38f2"
      unitRef="usd">3212600000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTEtMS0xLTM2MDk4_e7b72bfc-7f01-4219-81f2-d81159bf361a"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3ac021a9eb94f3c991cd84f64525cc3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTMtMS0xLTM2MDk4_e385376a-c370-4c35-a585-ba3ec07024ac"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibaa29f9114014c86920bd9c97e83e197_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTUtMS0xLTM2MDk4_b02f3d13-7fdf-4852-a1a7-4871e3f22e46"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i316934550e024acbbd6325dc2c36d8a5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTctMS0xLTM2MDk4_398d1fa1-a9f2-4d96-8078-5e02f9d19a5a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i94ee87f534b7486eb812b3019d90f10e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTktMS0xLTM2MDk4_ab1756e4-b7f0-4d98-a0f2-cb8cbd207d2b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie004b16f34fb49528fc900ea4eb9ab5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzIzLTExLTEtMS0zNjA5OA_b046a52f-bbba-4a8c-bea4-cb5ead1b795a"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibdd5c0e714b6457c9291715287cdcb10_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTEtMS0xLTM2MDk4_9ae33e3c-86f7-42cc-9d01-fffedd72ca0e"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i887f5d8d558444408da6b729be6176e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTMtMS0xLTM2MDk4_d75f2296-4fd4-4759-b843-cdba1a4d348b"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i167ec5deb3594dfea6abdbaeb717e48e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTUtMS0xLTM2MDk4_ffd1ba18-3924-4d6a-b990-04728aadf810"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if1675ab4c41749a9a192e7bb01d5570c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTctMS0xLTM2MDk4_35a8f16a-ae53-4817-8020-5d44636d14b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5e36489b4fd04ec19524988a99361ff3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTktMS0xLTM2MDk4_563cee55-1744-4df9-ad2b-3687852f27a4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i95497ef3752c49bea81162355fe898f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI1LTExLTEtMS0zNjA5OA_e7b1e3b7-5e51-4cb4-b003-71e428720642"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id804f4973bed4a98bead10d90e4a5ec4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTEtMS0xLTM2MDk4_5becd78e-80b2-4115-82bc-11155f40188e"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic4f48f77a9304c3d928d59f5cda4e8cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTMtMS0xLTM2MDk4_f4af5b2b-bb79-4be4-bc01-4535f732e2e7"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i574e8be0dcbe46febe19bb311f0b3e9d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTUtMS0xLTM2MDk4_eee3f72c-73e0-40a2-81f8-655f66da4e4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia594156723e841d78c3dd942261e75ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTctMS0xLTM2MDk4_a8a35128-dc46-411c-b485-4061c75a7c3e"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibfcfab070c414ee789784a20354c6b69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTktMS0xLTM2MDk4_5d9017ef-532b-401b-a3a2-88ebd95bc5e6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8628ddde09c14992bc17930fcf88de35_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI2LTExLTEtMS0zNjA5OA_ac3019a5-6453-4a4c-bb0a-218a57ae49f4"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3a22aba314ec4e5b8758419c0aced782_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTEtMS0xLTM2MDk4_6ca18702-c92a-41bc-8ec4-0a6767317991"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia193b0c52b7842c9af258c8e25683106_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTMtMS0xLTM2MDk4_877a7b39-912e-4b66-9355-9a6bf2db2ad2"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic4f335ad729d456583d5537025bce75c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTUtMS0xLTM2MDk4_fb114b36-43b6-42aa-ba2a-4f16ac717d51"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iadf7334b5c1440cd914d71e8eb5158ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTctMS0xLTM2MDk4_921c63cf-2e32-4f6f-8bc4-9204b735b9e7"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie64ce11134d3479a80fbee093c8eeb0b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTktMS0xLTM2MDk4_d0c63f55-c39b-4052-8f68-b6664e397cde"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia33787997401459d96a225f2f2ddfdaf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI3LTExLTEtMS0zNjA5OA_bde6be94-63f2-4c85-adf6-305de8dc6740"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i55d528edb81f432ea8b0d77df211e863_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTEtMS0xLTM2MDk4_a77e459c-0260-44bd-9b2c-4ca2de055637"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic46f810428ec41a0854465f3dd3eeb28_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTMtMS0xLTM2MDk4_a02a3831-120c-4882-b2aa-ff862f7ea925"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if288edb5c28645d78092d94621a6e314_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTUtMS0xLTM2MDk4_b1865c92-c078-44ca-8d6f-6c3537091a9a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie426e3b515ca4c32966ac2238ae9f29d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTctMS0xLTM2MDk4_e29bda9b-1a67-4d70-80df-5b3cf3fcdc51"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifb03dc979e1948809868f9121af92653_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTktMS0xLTM2MDk4_16868774-b3e1-4e6f-b71b-9a64cf507379"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6b512c10faf4454e92e2820bdebb03cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzI4LTExLTEtMS0zNjA5OA_3f706d0d-74fb-4e70-a876-15f347845f93"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMwLTEtMS0xLTM2MDk4_74250a44-3832-4bdc-ab34-16e0d87ab04a"
      unitRef="usd">24200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibdd5c0e714b6457c9291715287cdcb10_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTEtMS0xLTM2MDk4_96e1a36b-4190-4b45-ac8a-f3627da255db"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i887f5d8d558444408da6b729be6176e3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTMtMS0xLTM2MDk4_d0251b15-b450-4970-92ad-7e6880554ea7"
      unitRef="usd">74300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i167ec5deb3594dfea6abdbaeb717e48e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTUtMS0xLTM2MDk4_c7d84ada-3270-4bad-986f-762fb8d650a0"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if1675ab4c41749a9a192e7bb01d5570c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTctMS0xLTM2MDk4_a46eee0f-24ad-4831-b8f2-2aebb3710659"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5e36489b4fd04ec19524988a99361ff3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTktMS0xLTM2MDk4_c7d40c97-a578-4842-9dee-84d7e19cd9b4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i95497ef3752c49bea81162355fe898f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMyLTExLTEtMS0zNjA5OA_108eddcc-345c-4e16-9e9d-ec7f2ff453eb"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id804f4973bed4a98bead10d90e4a5ec4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTEtMS0xLTM2MDk4_17195649-c38a-4c55-b582-8b0dd3c8e414"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic4f48f77a9304c3d928d59f5cda4e8cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTMtMS0xLTM2MDk4_b55969f6-dcfc-4a08-b83f-1527dc44748e"
      unitRef="usd">126800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i574e8be0dcbe46febe19bb311f0b3e9d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTUtMS0xLTM2MDk4_e144b948-5033-42ee-af48-baadd1152641"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia594156723e841d78c3dd942261e75ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTctMS0xLTM2MDk4_f18cbf10-b220-4d7d-a871-6776ddb77f88"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibfcfab070c414ee789784a20354c6b69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTktMS0xLTM2MDk4_a845ae94-dcfd-442b-a4a8-493fa6f11c58"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8628ddde09c14992bc17930fcf88de35_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzMzLTExLTEtMS0zNjA5OA_e5d906f9-cf22-4b2c-83ba-abdd6294003f"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibb330dcd0a3d42cc853a2009b99f4554_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTEtMS0xLTM2MDk4_4f91b7af-b2ad-4294-900d-78a7e5afc87e"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i344dc72ffe804d559e7ecfd187252c52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTMtMS0xLTM2MDk4_4f186e3d-a24d-4c6a-b9a0-afd53d90ba9c"
      unitRef="usd">101400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6319d8f9aaa3462cbc841393e3484980_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTUtMS0xLTM2MDk4_6d1e7852-be4c-4ac0-a76b-c0bb03511869"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifdc78c865a114757a146a87ed649467d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTctMS0xLTM2MDk4_d4908944-ba34-478f-88ed-a6fbe2b4a151"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i11a588f349f449d29c4cd500d935548a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTktMS0xLTM2MDk4_ef51e7bc-4e9e-4e4d-b79a-4da8f8662d70"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="icd9df1bc022c4981908c34ce7da7d7c9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM0LTExLTEtMS0zNjA5OA_fe15b3d8-f54a-4e64-a580-27cb7f56fb52"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3a22aba314ec4e5b8758419c0aced782_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTEtMS0xLTM2MDk4_dd6e4635-13bb-4fb6-9d01-854690972ac2"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia193b0c52b7842c9af258c8e25683106_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTMtMS0xLTM2MDk4_51822ed2-6f94-4dfa-ac0c-4c1c0208150c"
      unitRef="usd">23700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic4f335ad729d456583d5537025bce75c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTUtMS0xLTM2MDk4_4db6b501-b04a-4313-85e4-e7e675e7159a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iadf7334b5c1440cd914d71e8eb5158ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTctMS0xLTM2MDk4_0e11d854-5dff-4e7d-af2c-3904eef447a7"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie64ce11134d3479a80fbee093c8eeb0b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTktMS0xLTM2MDk4_6b5b545f-2c2f-4962-8656-07552e0c8692"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia33787997401459d96a225f2f2ddfdaf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM1LTExLTEtMS0zNjA5OA_f895f2f3-be3d-4d13-a0ed-a8ae18fb08fb"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2efecde667454dafa903f13553e58c5a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTEtMS0xLTM2MDk4_0390390b-cd43-477d-8101-4ef9d02c2608"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3bf529e3651a448988c0e69800bad62e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTMtMS0xLTM2MDk4_842e6e5f-2dbc-4e72-bf3a-54c97c912c44"
      unitRef="usd">31800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4f60e90823904e52907d87d841e42ffc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTUtMS0xLTM2MDk4_971e8fe7-9c40-4650-aebf-dc0789b52db0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i69d818676d44496c9f05bbd23d02b4e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTctMS0xLTM2MDk4_bde72a9e-38e7-49e9-9e35-65ec01a1cd62"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i827063ec6d8b47cc8ef73cadbb5e308c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTktMS0xLTM2MDk4_69c0b8a8-509f-43c7-b5d0-7b7bec484803"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie26af35be2884e2e8476d92958017ea6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM2LTExLTEtMS0zNjA5OA_7815a318-5fab-4c58-90cf-5dc2ae8fa968"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9cd801c4ac2b4ba5929965024c9495c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTEtMS0xLTM2MDk4_5a167203-29ad-4936-bdc1-78f54aa42b9c"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i08b14338524644f794041da64329d7ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTMtMS0xLTM2MDk4_65ad7c38-8e5d-4921-aae7-ed27bd55d2fc"
      unitRef="usd">311600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1d6f2f073c974e75b0df61d368ef3198_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTUtMS0xLTM2MDk4_db76dc64-0783-44ce-9444-4506a0739ebc"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1a8dbbb22358480a9d1227dd77b3d9c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTctMS0xLTM2MDk4_19d47b8c-3edc-4089-bb20-0d5635eea68e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i591b41c97ee542518e6b5bf5504d3133_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTktMS0xLTM2MDk4_f6e28b48-c790-453b-ab8e-2d38df431bad"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ice0f72bd70654124b4ddbe68456882ba_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM3LTExLTEtMS0zNjA5OA_350fda93-d06e-4773-bfde-e6fa2a4340aa"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM4LTEtMS0xLTM2MDk4_c6306c73-5f23-495f-b2fb-668ca4b5742b"
      unitRef="usd">373900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i82a1d18f3f5f4e94a780c2d35119942e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzM5LTEtMS0xLTM2MDk4_a2f4dd1e-c66e-4fab-8173-15aaa930da36"
      unitRef="usd">471800000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTpmZDdjODkyM2FlZjc0NGMzODYwNDI3YjdiZDUyMDFlNy90YWJsZXJhbmdlOmZkN2M4OTIzYWVmNzQ0YzM4NjA0MjdiN2JkNTIwMWU3XzQwLTEtMS0xLTM2MDk4_d4d23521-6db7-4237-b34f-c1ab414a717a"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDcw_11d6de28-70f2-4e2b-a89c-e37f0579465c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,884.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,157.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i3c7e5f9100c44eb48c6a8b02af879981_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctMS0xLTEtMzYwOTg_dbd23875-9615-4ec4-ab84-3557ce00579f"
      unitRef="usd">16884700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5f207cd4c10c40c58e5e98e94e0977fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctMy0xLTEtMzYwOTg_19bd90b7-f6aa-48b8-9203-779043001c1a"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic01d3d2786ef48c7b3a9a7abc2347162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctNS0xLTEtMzYwOTg_ce8e28a8-98df-463d-9baa-ad3167800fab"
      unitRef="usd">18157700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7ca22a25490746b2a01afb869b9c9451_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctNy0xLTEtMzYwOTg_732994ec-bdf8-4a6a-b4b5-556a125e0de9"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0cacf599a2654a73aeb964f7e22ed6fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzctOS0xLTEtMzYwOTg_ef07fbce-7cee-403c-846f-852b17f3d55b"
      unitRef="usd">18157700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ief06bdf136c6446e86155ffb29485c04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtMS0xLTEtMzYwOTg_464c4952-327d-4746-8750-de8d51dbfb35"
      unitRef="usd">16595300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibaa29f9114014c86920bd9c97e83e197_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtMy0xLTEtMzYwOTg_a6851bac-d590-4da7-b6f9-5a74e4c27520"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i316934550e024acbbd6325dc2c36d8a5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtNS0xLTEtMzYwOTg_ecd7c1ef-d301-4197-9e79-7af1b823108b"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i94ee87f534b7486eb812b3019d90f10e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtNy0xLTEtMzYwOTg_798e4cb0-2cee-4861-b351-5749d006c80c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie004b16f34fb49528fc900ea4eb9ab5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowNTRiMzdiYWEyYmE0ODMwOTNmMzQ3MzdmZTNiZGExNi90YWJsZXJhbmdlOjA1NGIzN2JhYTJiYTQ4MzA5M2YzNDczN2ZlM2JkYTE2XzgtOS0xLTEtMzYwOTg_df090aed-58d5-4e55-a191-375ac5c5998b"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTY5_6ec892b7-9ccb-4d15-a2e7-f48be31e8fa0">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ibfd739cb8ecf4fce97d2650748700a73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtMS0xLTEtMzYwOTg_1b1351c8-9b0c-4aa5-adc6-62ecd60c353d"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtMy0xLTEtMzYwOTg_a57b543b-5917-4af2-9c67-1683cd68f8e3"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i45e3a34c12fe45458f64b1588317741a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtNS0xLTEtMzYwOTg_1387e175-cbc0-49ea-a2d5-aa4dca5fd3e4"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia2ba73fdaaa94d918532bf88e602aea4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtNy0xLTEtMzYwOTg_2c4a0ab3-68d2-4b41-9842-0bafb965abf6"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzUtOS0xLTEtMzYwOTg_e4cde581-49b6-43d3-89fc-471860a40cc5"
      unitRef="usd">4800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibfd739cb8ecf4fce97d2650748700a73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtMS0xLTEtMzYwOTg_ef16d031-ecae-430c-adcd-b28742077522"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtMy0xLTEtMzYwOTg_2736ba66-d8b1-46b7-a5da-77dbae6d76c7"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i45e3a34c12fe45458f64b1588317741a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtNS0xLTEtMzYwOTg_29280e45-57c0-465b-8d2f-eaa74048c7c4"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia2ba73fdaaa94d918532bf88e602aea4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtNy0xLTEtMzYwOTg_b5449374-08d9-4640-a5a4-eefd36e9108c"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzYtOS0xLTEtMzYwOTg_867b21ae-cc14-4d08-b795-303ad6750d73"
      unitRef="usd">78300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibfd739cb8ecf4fce97d2650748700a73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctMS0xLTEtODUzNTE_a008c051-bd82-45dd-8a47-ac301dc125cd"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i602c5e3d8c8a46199b0d7d2915f7e736_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctMy0xLTEtODUzNjU_c4a84f62-6ee3-4f25-a86e-a1f1d3ac6b19"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i45e3a34c12fe45458f64b1588317741a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctNS0xLTEtODUzNzM_615ca43e-c5c7-4db6-b7f3-9c9dc4cb819c"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia2ba73fdaaa94d918532bf88e602aea4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctNy0xLTEtODUzODM_ce4880e6-6646-4131-aec6-962e4d46cfc6"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7a5814f639d244b6b5dcfe68d7ea50a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzctOS0xLTEtODUzOTM_a53bf99c-e8b0-47c2-badc-48fbc222cb87"
      unitRef="usd">7600000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7e862569cb8e4d77b08bc51be4980e34_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktMS0xLTEtMzYwOTg_d8045674-1897-4c3e-a912-1ea2eabe9797"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2ee4fbb4cad946a0b316ae9a0d5c2f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktMy0xLTEtMzYwOTg_5aec66f0-d471-404d-a48f-762595df46cf"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i03be72af30a547c281fc637c8b272953_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktNS0xLTEtMzYwOTg_acbb793a-8d61-4e67-8be5-ce507f219ace"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i6de4ea09bc4b4318aa35ba040cbaddd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktNy0xLTEtMzYwOTg_b56c651f-1e20-4be3-abdf-5fbe2bb7d401"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i734334d67c56497ea2fe5de69c592773_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzktOS0xLTEtMzYwOTg_c4c10ac4-ebf6-4c8b-a89f-28baf8f209cc"
      unitRef="usd">49200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7e862569cb8e4d77b08bc51be4980e34_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTEtMS0xLTM2MDk4_1c079672-98be-4832-8f0c-25d587702646"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2ee4fbb4cad946a0b316ae9a0d5c2f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTMtMS0xLTM2MDk4_e739018c-ab3a-4910-bad1-e67c7c16f847"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i03be72af30a547c281fc637c8b272953_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTUtMS0xLTM2MDk4_280fe966-0d83-48f7-8f40-2e366e8c3198"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6de4ea09bc4b4318aa35ba040cbaddd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTctMS0xLTM2MDk4_aeacb1a2-f33b-49d8-96cd-decd12583ae5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i734334d67c56497ea2fe5de69c592773_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEwLTktMS0xLTM2MDk4_2e2c4c2a-d61d-4086-98d6-c9bbbc3afbc4"
      unitRef="usd">31700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib8795f816d3e4ca2aaba6e653e468c06_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTEtMS0xLTM2MDk4_3bd517a9-9aa2-4c3d-a304-882ac6888946"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibf0573899a39469e83be2b20e0eb8b87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTMtMS0xLTM2MDk4_553c7f6f-76aa-42b1-b16c-9dae9ce8d1e5"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibda2686ddc2d4cd0b6656354b98930b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTUtMS0xLTM2MDk4_877db820-f23e-447f-bdf5-466f98b21e72"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2859719f266a46efb30de54c44c9888d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTctMS0xLTM2MDk4_9805fb37-0314-4345-8e7e-15a67816ded8"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i17438a4e988240c58930bd2fca58fe5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzEzLTktMS0xLTM2MDk4_865641db-68f8-4ea2-88ad-63ddff3caa2a"
      unitRef="usd">31300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ib8795f816d3e4ca2aaba6e653e468c06_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTEtMS0xLTM2MDk4_711fa734-223d-4134-9c6c-8fd4631b833e"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibf0573899a39469e83be2b20e0eb8b87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTMtMS0xLTM2MDk4_011095e4-685b-42b0-b387-0b0f952e80ed"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibda2686ddc2d4cd0b6656354b98930b5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTUtMS0xLTM2MDk4_ada61cb7-7ad9-4ccd-8a17-d342ef5dea7e"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2859719f266a46efb30de54c44c9888d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTctMS0xLTM2MDk4_c0a65ef0-9857-472c-905a-27933fa9d679"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i17438a4e988240c58930bd2fca58fe5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE0LTktMS0xLTM2MDk4_15e717e9-ba2b-4878-a085-d484c861084a"
      unitRef="usd">1200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i6bc3c2c66d9e4d0da075849aa425fa7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTEtMS0xLTM2MDk4_2ed0faf1-f296-4ad6-b822-cb9283374e7e"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2746f9d419c14a098e97957fdfe7641a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTMtMS0xLTM2MDk4_704c3521-2ff6-49bf-97f7-6f53042dad71"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib4b77e24600d447186fdb36b48034cda_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTUtMS0xLTM2MDk4_8f781826-030c-4979-8149-0e26ee2a52ca"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i103492ff7b1c4667ac257e9154cd5beb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTctMS0xLTM2MDk4_29eadd74-c99a-472c-89e5-e412100f6b38"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i30df961528f4463793f7905786bea152_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE4LTktMS0xLTM2MDk4_d6118eeb-805d-4f70-8569-dd753de51e6f"
      unitRef="usd">33200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6bc3c2c66d9e4d0da075849aa425fa7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTEtMS0xLTM2MDk4_db754db1-89c1-4b01-9234-830e50ce03d9"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2746f9d419c14a098e97957fdfe7641a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTMtMS0xLTM2MDk4_67c775f0-8a37-47cc-bcf9-97560df6edad"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib4b77e24600d447186fdb36b48034cda_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTUtMS0xLTM2MDk4_90d48601-83b4-4f16-9dd2-98e13870d634"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i103492ff7b1c4667ac257e9154cd5beb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTctMS0xLTM2MDk4_c83fd10f-60b8-441e-a300-ac1be3f00e90"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i30df961528f4463793f7905786bea152_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzE5LTktMS0xLTM2MDk4_19bb0186-e4af-4ddd-a076-7114987ba24e"
      unitRef="usd">1300000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i643183966d6848f3b666d367edf73743_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTEtMS0xLTM2MDk4_4bd08447-2d5b-4eeb-8f08-a50a71c7d321"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i70569b8f4108449c84afeaf1c43a3dbb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTMtMS0xLTM2MDk4_14f536ac-e15e-4d69-beea-19bfe835a6e3"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3a291d5a17ef4657b4a29f981d818719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTUtMS0xLTM2MDk4_510fc84d-5db6-4bf2-9bea-fb297d574212"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id14bc637594d43eba77368fce832327f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTctMS0xLTM2MDk4_9c2ff7cd-a4c6-4505-b2b0-f3c9f001331a"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i60e070cb04b247668d999c7e61d52938_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIxLTktMS0xLTM2MDk4_8c8ffd83-4522-42ce-b2e1-464a838ba2ce"
      unitRef="usd">9900000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i643183966d6848f3b666d367edf73743_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTEtMS0xLTM2MDk4_e19a4e88-1447-494d-a5b5-b034fe49d9fd"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i70569b8f4108449c84afeaf1c43a3dbb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTMtMS0xLTM2MDk4_453a7ea3-32dc-44c5-949e-9505cc04380b"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i3a291d5a17ef4657b4a29f981d818719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTUtMS0xLTM2MDk4_58a28299-a9c3-48fe-b3f1-ff05d0a60940"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id14bc637594d43eba77368fce832327f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTctMS0xLTM2MDk4_c1561278-3fdf-435d-990b-0b326e160a8e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i60e070cb04b247668d999c7e61d52938_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzIzLTktMS0xLTM2MDk4_395077e3-f7f8-4b90-95e5-5a1822240934"
      unitRef="usd">35300000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i643183966d6848f3b666d367edf73743_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTEtMS0xLTM2MDk4_3888a5a6-18a1-458c-a735-3f9c4286279f"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i70569b8f4108449c84afeaf1c43a3dbb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTMtMS0xLTM2MDk4_dab4a837-577d-4d61-b013-800167f35e16"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3a291d5a17ef4657b4a29f981d818719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTUtMS0xLTM2MDk4_c9655c01-125e-4c9d-97fd-ca4653277c93"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id14bc637594d43eba77368fce832327f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTctMS0xLTM2MDk4_daf64b0a-2d3a-4653-8fbf-201d20ee9ea5"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60e070cb04b247668d999c7e61d52938_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzI2LTktMS0xLTM2MDk4_104b9516-8d91-4fbf-ab90-177c21f3283f"
      unitRef="usd">70500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1d6d03e2ed8d4d58992474db5137bc29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTEtMS0xLTM2MDk4_efeabb54-e50d-4624-8b28-d0ab9747011e"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9b03d00bc65a4499823bf2ae6673dc24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTMtMS0xLTM2MDk4_696e2cd4-9c86-4eb2-aedc-2a5fcc977f22"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1690d7f6c7cf4875b045a1c058aacdff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTUtMS0xLTM2MDk4_d83446d5-faa6-4ab8-992b-2acc929e8894"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i4526f1f10b794ec991819ce33cc96cab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTctMS0xLTM2MDk4_4cdb06b8-19dc-41c5-9285-6d5fdbbb1b73"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i237291a28a7343ae877503eaf0fa41a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzMyLTktMS0xLTM2MDk4_7c1dba99-d108-4e75-b97f-c30ab5b1e6c2"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i92d5a9e0154c43b2b5d3386c1d0b0538_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTEtMS0xLTM2MDk4_f79e4727-1d34-4a41-b154-c5cf87e43a3a"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibe2d1bbead584d8e8b7d3a56191796b9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTMtMS0xLTM2MDk4_479f2efc-48d2-45f1-af1b-6f18930af640"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib2f78d8a998c493b824d37739f09cee9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTUtMS0xLTM2MDk4_3289047a-94cd-4405-ae1a-9d1dd787069a"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0b6f347e0f6d4d7688e6ede323ba93ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTctMS0xLTM2MDk4_45f08a15-4ba5-4ba3-b71e-6f56092a4e77"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iec315121c623474c92f184ce17dafae2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM2LTktMS0xLTM2MDk4_db997aaf-3ae0-4214-8876-17a0e21bf6e1"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i92d5a9e0154c43b2b5d3386c1d0b0538_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM3LTEtMS0xLTQ0NTI1_210748cd-dc8b-4a23-a225-5d719c861757"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibe2d1bbead584d8e8b7d3a56191796b9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM4LTMtMS0xLTg3Mzcz_3efe218d-7da9-45f0-88b6-3f06bb5d18a5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib2f78d8a998c493b824d37739f09cee9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM3LTUtMS0xLTQ0NTQw_8a7f8c8e-b742-4c40-a97c-a5497a052e3e"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0b6f347e0f6d4d7688e6ede323ba93ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM4LTctMS0xLTg3Mzcz_7655e946-caa7-4a36-94a2-0570b3a822dd"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iec315121c623474c92f184ce17dafae2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM3LTktMS0xLTQ0NTUy_97b3bbc8-1a8c-41bb-a3c6-29500f210689"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i70f76462cfe94c048d2e8e07abc8ac06_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTEtMS0xLTM2MDk4_e5b906bf-b4b0-4ba3-9eb9-48465544ed80"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i87ba7848623e4295a4d08297c9dcfc05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTMtMS0xLTM2MDk4_8132bc47-229f-4e8b-8a10-a6657df0a03c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i93c838ae6a6741a289a916ea6b2a18f9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTUtMS0xLTM2MDk4_041e6136-e6ae-41df-ab8c-d4c3d8e8e7b1"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i11fb983303214a0fab76fb48ca842390_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTctMS0xLTM2MDk4_2f37de92-d1dd-431e-920b-0f55f466b30c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if4ebf2c8591c4a65a69ef2a0f9a1c023_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzM5LTktMS0xLTM2MDk4_88a3058b-b94a-46b1-a9b8-ad7f1fd12f85"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i70f76462cfe94c048d2e8e07abc8ac06_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTEtMS0xLTM2MDk4_80ed8554-e6e2-4be7-a356-1df5f754a616"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i87ba7848623e4295a4d08297c9dcfc05_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTMtMS0xLTM2MDk4_f90669f5-9e52-447d-8861-8615efe85e59"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i93c838ae6a6741a289a916ea6b2a18f9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTUtMS0xLTM2MDk4_77c44b45-7c11-4ac3-a1e5-27e4b8fe55e6"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i11fb983303214a0fab76fb48ca842390_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTctMS0xLTM2MDk4_95e817aa-893e-4dac-9464-95d429f7fba4"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if4ebf2c8591c4a65a69ef2a0f9a1c023_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQwLTktMS0xLTM2MDk4_1eaff941-e74f-4585-a217-cfe46f858f7b"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8f2e86153cfd4c15b9467efd88051085_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTEtMS0xLTM2MDk4_adfb925f-6b89-4fd3-8ee9-3da96744002b"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i62613c2b0b0949e8a36439ddee87c7d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTMtMS0xLTM2MDk4_50078baa-a0b9-4ffc-a40b-27cb76d19374"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ida9a7f6d784f4d7b8b53c4631c9e75eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTUtMS0xLTM2MDk4_062c1ef2-b32e-453d-ad95-0289cb6a643d"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i93d10b06674c46a98dd32098076c5e36_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTctMS0xLTM2MDk4_46f712f2-d54a-429c-b099-33b11ac6b6f5"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iffde3a7d917c478db3902cc934826508_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQzLTktMS0xLTM2MDk4_8a6d80b6-d4d5-4ec4-984d-91202f83c793"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie3392ad7d22c4bf7b9a4a1c59ed94a0d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTEtMS0xLTM2MDk4_0c93445e-66fc-4a64-8219-094d4098e4ab"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia2c20187921d4be8beea2d674ea20464_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTMtMS0xLTM2MDk4_91605c70-2edd-40aa-a403-747a94303ae3"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia914bdc1f6a941bea69658cc92f5058b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTUtMS0xLTM2MDk4_33364078-add1-4e7a-9b1b-1b091ec39ad1"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic3a2be087dc94b038c7c193e1cce0685_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTctMS0xLTM2MDk4_0ae31574-d4ce-40fc-a664-f0e181902ef5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iaf95a7cf14e94274ab9c3f3de25a81aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ0LTktMS0xLTM2MDk4_c4f2ee2d-4d4b-42e4-8ce8-88721f089372"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic901be7c5ce4440f886d70a9f0528564_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTEtMS0xLTM2MDk4_1a9959bc-f247-47d7-a01a-6ba6b8f1a8b0"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0e8afdee24674791bca30cb8d138a90d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTMtMS0xLTM2MDk4_bcda2439-2a51-41cd-8155-780652100695"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic10a9d80e8d1486caea9af7c720bf668_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTUtMS0xLTM2MDk4_9234b341-cdba-42d8-9bdb-37079195ffdb"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i9ba53f9f1da64ce78f2027435c7eeb45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTctMS0xLTM2MDk4_fb15478c-394b-4a4e-b973-dd8ffb98046c"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i45fa035c9b02420dafaa115085c6e8f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ2LTktMS0xLTM2MDk4_5ab417fe-606a-40e8-b374-54bda3ef7cf7"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ic901be7c5ce4440f886d70a9f0528564_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTEtMS0xLTM2MDk4_5e1b5a2d-5833-4fd4-a458-d15cec8d9200"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0e8afdee24674791bca30cb8d138a90d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTMtMS0xLTM2MDk4_836532ee-4a9c-4e83-89b3-b19deaae35f2"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ic10a9d80e8d1486caea9af7c720bf668_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTUtMS0xLTM2MDk4_3bc05510-77da-473c-b4b2-89c817f7bcd1"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i9ba53f9f1da64ce78f2027435c7eeb45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTctMS0xLTM2MDk4_b09b356d-91ed-4eac-ac73-afb41005ce05"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i45fa035c9b02420dafaa115085c6e8f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTo0MjhiOTgzOGQ1Zjg0YzFhODQ2ZmJlMDJkNjFhY2Y2MC90YWJsZXJhbmdlOjQyOGI5ODM4ZDVmODRjMWE4NDZmYmUwMmQ2MWFjZjYwXzQ3LTktMS0xLTM2MDk4_d6abfa41-0f35-4226-8dbc-0b9563ea1299"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwMzI3_4e47c1b9-fc8d-4462-b413-159194d511c2"
      unitRef="usd">828000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNDQ2_e43912db-f05a-4426-bc04-d82514a488cd">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTQ3_f9dd5275-ca5d-4d43-9fc0-2d2fe3514d01">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5      Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10    Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More Than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItMS0xLTEtMzYwOTg_b2dbe182-9763-4179-b53d-c5aab8956560"
      unitRef="usd">581000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItMy0xLTEtMzYwOTg_e9bc9dab-f7ff-49ee-8611-56bba9ae4cea"
      unitRef="usd">75900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItNS0xLTEtMzYwOTg_a5917f3b-8e50-4bd9-9861-b3146eb16e0b"
      unitRef="usd">216500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItNy0xLTEtMzYwOTg_4b0d2f76-fbee-4a01-8bd4-f6ff16eb48cf"
      unitRef="usd">126400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTphOWVmMGJiY2U0Zjc0ZGU4ODA2ZWRjYTU4YjJjNDI5My90YWJsZXJhbmdlOmE5ZWYwYmJjZTRmNzRkZTg4MDZlZGNhNThiMmM0MjkzXzItOS0xLTEtMzYwOTg_6a10028c-8a60-4af1-aafd-9b27329d250d"
      unitRef="usd">162200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNjc0_c4b8f519-16e3-4d7a-9b48-01206f18d4ac"
      unitRef="usd">176900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNjc4_b3bbdf2e-9801-4912-b87e-faad18ae9bb5"
      unitRef="usd">1440000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEwNjg1_6eb89d94-b918-4d2d-a5c7-0b62d3b0550c"
      unitRef="usd">401200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MDg0_3a9e527e-3429-43c5-b35a-5d807b75f48f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzEtMS0xLTEtMzYwOTg_52881071-a397-4d8f-b877-cbefa25d5412"
      unitRef="usd">9700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzEtMy0xLTEtMzYwOTg_290aa402-919c-4b8b-81ae-0eb24ace6d63"
      unitRef="usd">20900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzItMS0xLTEtMzYwOTg_c336c417-a104-4f03-b318-37d77af5f64e"
      unitRef="usd">5200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzItMy0xLTEtMzYwOTg_508c7bd6-9bf9-4836-9b82-507d57318a36"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzMtMS0xLTEtMzYwOTg_bd23c6c0-0ec6-4769-9ff2-99e16ddf85a8"
      unitRef="usd">250700000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzMtMy0xLTEtMzYwOTg_867d21fb-f3eb-4166-9671-631f990d82b9"
      unitRef="usd">348900000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzQtMS0xLTEtMzYwOTg_89b57ccf-57d7-4fe1-baf0-7f85fbc96469"
      unitRef="usd">290200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZToyODNlMGQ2ZmU2YWU0NjVmYjhmNzZlOGMwOGYwY2ViMy90YWJsZXJhbmdlOjI4M2UwZDZmZTZhZTQ2NWZiOGY3NmU4YzA4ZjBjZWIzXzQtMy0xLTEtMzYwOTg_36c964fd-e7bd-4bf3-931f-8a27ede78e2b"
      unitRef="usd">11400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEyNTI1_80105f93-4322-4666-b53d-e78509f61e58"
      unitRef="number">0.97</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzE0MTIx_1cdc0227-84e7-4030-8635-7b18688c8e16">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzEtMS0xLTEtMzYwOTg_f27257de-8ce4-4e1d-87a2-df7afe223ff4"
      unitRef="usd">174700000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzEtMy0xLTEtMzYwOTg_5f6d35b4-e7b2-4fad-837a-1ffe8b7a3402"
      unitRef="usd">264800000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzEtNS0xLTEtMzYwOTg_7126fd98-6c3c-4bf4-a115-c7382daeff0c"
      unitRef="usd">431600000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzItMS0xLTEtMzYwOTg_50a8c3b2-fb1f-4e1f-8283-988079bcc620"
      unitRef="usd">2800000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzItMy0xLTEtMzYwOTg_182a0e36-d218-4f1f-877d-b44f6b1991ba"
      unitRef="usd">4500000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzItNS0xLTEtMzYwOTg_227a77eb-c935-4b79-b695-58d194e161e6"
      unitRef="usd">4900000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzMtMS0xLTEtMzYwOTg_c448744b-60a1-4542-bd62-ff95f86b08f1"
      unitRef="usd">1700000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzMtMy0xLTEtMzYwOTg_c698a662-3125-470d-8d71-6b3b02b0ded3"
      unitRef="usd">8200000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90YWJsZTowN2M3OTU0ZmQxYTc0ZjQxOTdmZDg1MjY2ZTliZTM4ZS90YWJsZXJhbmdlOjA3Yzc5NTRmZDFhNzRmNDE5N2ZkODUyNjZlOWJlMzhlXzMtNS0xLTEtMzYwOTg_4d0bd96e-ada4-4085-ab1d-433b61fe7710"
      unitRef="usd">3000000.0</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEzODE3_69d6e49d-f82d-4d47-b405-1e50dbd35a94"
      unitRef="usd">550500000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjQvZnJhZzphY2M2OGQ3MzE5N2Q0ZWVhODliZTlhYTQxY2ZiOTc0Yy90ZXh0cmVnaW9uOmFjYzY4ZDczMTk3ZDRlZWE4OWJlOWFhNDFjZmI5NzRjXzEzODI0_a85e50f5-58db-4a53-9f37-e7655a7ba5e7"
      unitRef="usd">754900000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1ODI_358b9e90-4c7f-4df2-9479-bdba1d33d643">Goodwill and Other Intangibles&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The changes in goodwill during 2021 and 2020 were primarily related to our acquisitions of Prevail and Dermira, respectively. See Note 3 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,987.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,758.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,984.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,056.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,766.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,076.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,349.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,925.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,925.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,981.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,691.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D consists of the fair values of acquired IPR&amp;amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;amp;D projects that had no alternative future use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in marketed products in 2021 primarily related to the sale of rights to Qbrexza in 2021 as well as the impairment of a Phase I molecule related to a contract-based intangible. See Note 5 for additional information. These decreases were more than offset by the recognition of several milestones related to the COVID-19 therapies that occurred in 2021. The increase in the acquired IPR&amp;amp;D in 2021 is due to the acquisition of Prevail. See Note 3 for additional information regarding intangible assets acquired in a recent business combination and Note 4 for additional information regarding capitalized milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDA_50a976ec-2fe9-4481-a965-701914495450"&gt;one&lt;/span&gt; to 20 years. As of December&#160;31, 2021, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to finite-lived intangible assets was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;628.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1NTQ_fcfebfba-e544-458c-8939-0b0f90f78a68">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&amp;amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;amp;D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the "income method," which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzgzNA_210b56ad-f18a-42ee-8285-b80e647e58e8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzgzNA_3482346c-e862-461d-a0a8-ac91b6613101"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzgzNA_8ac94439-55cb-417f-8898-0a57f0db4fee"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1NTA_03a974f4-14f0-4a69-a3cb-31108618e207">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,987.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,758.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,984.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,056.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,766.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,076.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,349.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,925.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,925.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,981.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,691.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1ODY_9287ada1-29c7-465a-9ea0-3c4a2e6858bf">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,987.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,758.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,984.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,056.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,766.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,076.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,349.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,925.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,925.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,981.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,691.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9383a6db72eb499a9b97a5c2952db425_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtMS0xLTEtMzYwOTg_6d6d549b-3b91-4c79-9880-0988b2540879"
      unitRef="usd">7987200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9383a6db72eb499a9b97a5c2952db425_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtMy0xLTEtMzYwOTg_6859c350-7eb1-40ee-8801-999384c6c6e3"
      unitRef="usd">2229200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9383a6db72eb499a9b97a5c2952db425_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtNS0xLTEtMzYwOTg_677735e9-c9e8-4194-9b94-194e54580ca0"
      unitRef="usd">5758000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie531ec456aac40d486f50a514ec2ebe5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtNy0xLTEtMzYwOTg_5a8318de-732b-48f6-8392-5e35796ab257"
      unitRef="usd">7984000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie531ec456aac40d486f50a514ec2ebe5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtOS0xLTEtMzYwOTg_b022a9c8-dc76-483a-b26b-5e17a20ffcc4"
      unitRef="usd">1659500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie531ec456aac40d486f50a514ec2ebe5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzMtMTEtMS0xLTM2MDk4_02687a10-47b4-48ed-9de3-e6dd80b417d6"
      unitRef="usd">6324500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9815b1af955c480e81629936863a716d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtMS0xLTEtMzYwOTg_5e772b51-0969-4acf-b853-52585baaff59"
      unitRef="usd">69400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9815b1af955c480e81629936863a716d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtMy0xLTEtMzYwOTg_562f2a4f-055d-4f34-bd62-ab23548ff2c7"
      unitRef="usd">60500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9815b1af955c480e81629936863a716d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtNS0xLTEtMzYwOTg_418e41af-a562-4431-8ad3-d3f2933fced1"
      unitRef="usd">8900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i92a9323f52794ceeaceff691b1800d6f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtNy0xLTEtMzYwOTg_0d6aa1f3-2da7-44c5-8437-28aeae878eb6"
      unitRef="usd">92800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i92a9323f52794ceeaceff691b1800d6f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtOS0xLTEtMzYwOTg_1a5784ea-c75b-4a85-bcb6-ee36b4de127f"
      unitRef="usd">68300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i92a9323f52794ceeaceff691b1800d6f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzQtMTEtMS0xLTM2MDk4_e16e8365-2d6b-483b-902c-9caceca97675"
      unitRef="usd">24500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtMS0xLTEtMzYwOTg_04f59002-4737-412c-9999-50049f57e8da"
      unitRef="usd">8056600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtMy0xLTEtMzYwOTg_6fe53300-2683-4625-b0cb-4dbd5d0d0ab6"
      unitRef="usd">2289700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtNS0xLTEtMzYwOTg_da1f935e-1127-4f22-935f-90fc2a171366"
      unitRef="usd">5766900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtNy0xLTEtMzYwOTg_b1810054-3f1e-43d8-a60f-420de5818a93"
      unitRef="usd">8076800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtOS0xLTEtMzYwOTg_18b37e41-67af-4f18-8ced-c8a448c46bc5"
      unitRef="usd">1727800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzUtMTEtMS0xLTM2MDk4_9ab3c556-9eb5-4615-956b-d0b9436e19c2"
      unitRef="usd">6349000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia3a57eb5302145278ada333579227b74_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctMS0xLTEtMzYwOTg_71662aac-b87a-4623-b64a-1bc6c1593e56"
      unitRef="usd">1925000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia3a57eb5302145278ada333579227b74_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctNS0xLTEtMzYwOTg_ed4137a8-5242-420b-96e5-b607b3777aed"
      unitRef="usd">1925000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i757bec4b105a4991afb95cd0de81960c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctNy0xLTEtMzYwOTg_5e7f8fc4-1f11-4286-b489-d4b928ca5f9e"
      unitRef="usd">1101000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i757bec4b105a4991afb95cd0de81960c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzctMTEtMS0xLTM2MDk4_d82f7b1c-b58b-4295-b794-acf153e6afb7"
      unitRef="usd">1101000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtMS0xLTEtMzYwOTg_d271105a-d2c7-40c3-896e-38a50d96fedf"
      unitRef="usd">9981600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtMy0xLTEtMzYwOTg_8619ca75-dd8d-4445-bb5f-7e0d0d043856"
      unitRef="usd">2289700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtNS0xLTEtMzYwOTg_011646ae-615e-4e2d-98ab-809a04b88e7b"
      unitRef="usd">7691900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtNy0xLTEtMzYwOTg_48ddd2e2-eb13-44d7-99c7-da1feccdef13"
      unitRef="usd">9177800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtOS0xLTEtMzYwOTg_b4d6723f-9c14-4ddf-82e6-6c40e20491bf"
      unitRef="usd">1727800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpkOGQ4ZjM3ODQyNjc0NTIxODkyNzdhZDAwZTgzOWUyMi90YWJsZXJhbmdlOmQ4ZDhmMzc4NDI2NzQ1MjE4OTI3N2FkMDBlODM5ZTIyXzgtMTEtMS0xLTM2MDk4_52ac1966-1f9f-42d4-805a-22ccbcea98e2"
      unitRef="usd">7450000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id1549f6338d244929cd807e3277907a7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUwMDY_ccb2a177-9fba-4bd0-b7d5-c3ee9421accb">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzUxMjQ_2febeb18-5909-49f9-9a2a-067f127f1b26">P14Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1ODE_1ac3a383-ec98-40d1-9846-0755bef7ee05">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to finite-lived intangible assets was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;628.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTphMjg5YjQ2ZTRhOGU0Nzk3YThlYTgzMDExMGM3MWVlNC90YWJsZXJhbmdlOmEyODliNDZlNGE4ZTQ3OTdhOGVhODMwMTEwYzcxZWU0XzEtMS0xLTEtMzYwOTg_0b7a2252-71f2-4a46-a123-6e755e6290f8"
      unitRef="usd">628800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTphMjg5YjQ2ZTRhOGU0Nzk3YThlYTgzMDExMGM3MWVlNC90YWJsZXJhbmdlOmEyODliNDZlNGE4ZTQ3OTdhOGVhODMwMTEwYzcxZWU0XzEtMy0xLTEtMzYwOTg_6690ca52-64ad-4c2f-a9b7-c0bdc1d6e296"
      unitRef="usd">428200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTphMjg5YjQ2ZTRhOGU0Nzk3YThlYTgzMDExMGM3MWVlNC90YWJsZXJhbmdlOmEyODliNDZlNGE4ZTQ3OTdhOGVhODMwMTEwYzcxZWU0XzEtNS0xLTEtMzYwOTg_f6f0c6c9-4693-4030-a5f0-a4c735dd279d"
      unitRef="usd">225800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90ZXh0cmVnaW9uOmQyZGZlMGNiZjUwNjRlZDNiMjhhN2E5NjE2Nzc3ZDM0XzU1NDQ_cc0a253b-5b6f-47fe-be65-cb09214bfc3f">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtMS0xLTEtMzYwOTg_2d693b69-d00c-48c1-af66-e85975eb4e0d"
      unitRef="usd">570900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtMy0xLTEtMzYwOTg_cfcdea51-1bf6-41c6-944f-b9b5aaea67f1"
      unitRef="usd">483500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtNS0xLTEtMzYwOTg_c10fa555-86ed-43ea-9337-1719fb04b7b2"
      unitRef="usd">433700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtNy0xLTEtMzYwOTg_4a3744fb-dd6c-49a1-afd9-fb7ab6cbb72f"
      unitRef="usd">417100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMjcvZnJhZzpkMmRmZTBjYmY1MDY0ZWQzYjI4YTdhOTYxNjc3N2QzNC90YWJsZTpmMTJmYmVlYWRkMWU0OGRiYjBiZjdlNjkzNThjZWY0Mi90YWJsZXJhbmdlOmYxMmZiZWVhZGQxZTQ4ZGJiMGJmN2U2OTM1OGNlZjQyXzEtOS0xLTEtMzYwOTg_c4c041b9-979f-432b-984b-00d66959f092"
      unitRef="usd">408800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMDQ_3dda055f-00cb-47f0-8ea0-cbc5cd58e6ee">Property and Equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25"&gt;three&lt;/span&gt; to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,588.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,326.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,937.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,961.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,976.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,570.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,985.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,681.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;787.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized interest costs were not material for the years ended December&#160;31, 2021, 2020, and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,620.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,113.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,702.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,786.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,691.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,013.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,648.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMjg_0a70aeb9-91aa-4b26-be17-5061e7aef55c">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3Mg_c2ca9446-ba42-42df-9645-2b8b4da36e25"&gt;three&lt;/span&gt; to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia3c486aeafe64057905b3c05060eedc7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI0NQ_58c65805-1f47-4e23-944a-62d9bd6080c0">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iba4a476458934d3d96c4cac37450ee31_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI1MQ_c1cc413b-7bb3-46da-8f0f-2ac68e0feb58">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib85d997efea3485690a6a131ac2e8edb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzI3OA_f8c802bb-a195-4d5a-8a0b-c16412938667">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMjk_e5365d6d-e17a-4b6a-aea8-103f26665125">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,588.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,326.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,937.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,961.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,976.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,570.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,985.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,681.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;787.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzEtMS0xLTEtMzYwOTg_b1484a9b-b393-4044-8402-4131649ba0f9"
      unitRef="usd">258700000</us-gaap:Land>
    <us-gaap:Land
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzEtMy0xLTEtMzYwOTg_add6db52-1094-4004-8719-ff6792c708ef"
      unitRef="usd">226800000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzItMS0xLTEtMzYwOTg_e2363015-25ff-44dc-bd7b-d5511a100510"
      unitRef="usd">7588100000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzItMy0xLTEtMzYwOTg_6ffcb065-afd4-4ef4-a6d2-5a715dcb6120"
      unitRef="usd">7326100000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzMtMS0xLTEtMzYwOTg_c28c3e0c-57fd-4406-9992-3502bb4e377f"
      unitRef="usd">8937200000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzMtMy0xLTEtMzYwOTg_0df47a96-d288-4e79-811c-83b64366dd7a"
      unitRef="usd">8560900000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzUtMS0xLTEtMzYwOTg_f4ed9a58-f66e-4ad1-a2eb-d3046b3e822d"
      unitRef="usd">2177800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzUtMy0xLTEtMzYwOTg_7eba83d1-f70c-4626-bafc-3f625a61ca1c"
      unitRef="usd">2138800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzYtMS0xLTEtMzYwOTg_5ef68895-ad00-4c3a-a6ca-2817b51b9f39"
      unitRef="usd">18961800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzYtMy0xLTEtMzYwOTg_4b73c629-ce60-4b79-990a-d150d112a485"
      unitRef="usd">18252600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzctMS0xLTEtMzYwOTg_0c19996d-5b86-40e6-a963-260e829bdd0c"
      unitRef="usd">9976700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzctMy0xLTEtMzYwOTg_d725f3bf-2981-49cd-9f41-1b4933b68e3b"
      unitRef="usd">9570700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzgtMS0xLTEtMzYwOTg_dd0907f3-7972-4cfe-a3cb-8d27e9d313f9"
      unitRef="usd">8985100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZToyMDRkNzFmYTIyMDQ0MzAyYmIwMjdhZjNjNDI5NmI4MC90YWJsZXJhbmdlOjIwNGQ3MWZhMjIwNDQzMDJiYjAyN2FmM2M0Mjk2YjgwXzgtMy0xLTEtMzYwOTg_967ca337-d0d9-4cb1-9a3f-5c5f16fe5fff"
      unitRef="usd">8681900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo4NDlkMmQxOGY4MTY0YjIyODkyYWVlZGVhMDI4MDYyMS90YWJsZXJhbmdlOjg0OWQyZDE4ZjgxNjRiMjI4OTJhZWVkZWEwMjgwNjIxXzEtMS0xLTEtMzYwOTg_d2f7b535-8246-4217-a678-e391a108e995"
      unitRef="usd">787000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo4NDlkMmQxOGY4MTY0YjIyODkyYWVlZGVhMDI4MDYyMS90YWJsZXJhbmdlOjg0OWQyZDE4ZjgxNjRiMjI4OTJhZWVkZWEwMjgwNjIxXzEtMy0xLTEtMzYwOTg_1bb3f6be-76c7-46d7-a818-29eb90facc7a"
      unitRef="usd">765200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo4NDlkMmQxOGY4MTY0YjIyODkyYWVlZGVhMDI4MDYyMS90YWJsZXJhbmdlOjg0OWQyZDE4ZjgxNjRiMjI4OTJhZWVkZWEwMjgwNjIxXzEtNS0xLTEtMzYwOTg_c9b41e08-3169-4d89-b020-8b7b3533efa7"
      unitRef="usd">814700000</us-gaap:Depreciation>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90ZXh0cmVnaW9uOjY3MWIxNWJkNzhjMjQ0YmViYjJlZWQyYjZiNzg0ZWIyXzEyMTU_4ea198a2-c103-44dd-85b7-ebe4dafa9082">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,620.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,113.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,702.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,786.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,691.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,013.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,648.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="if46d6fa65cff4aa58bb12b8d03b24b7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzMtNC0xLTEtMzYwOTg_f0c28297-34bd-4c18-ba7c-93f5855bcf55"
      unitRef="usd">6620000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id6e4a32babb7454bbabcc34a329041d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzMtNi0xLTEtMzYwOTg_7e6886ee-43c9-4098-8619-4728e733e543"
      unitRef="usd">6113600000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i33be57ca2aa9408c95b321d324369f80_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzQtNC0xLTEtMzYwOTg_74b46021-bf8e-4ad3-ab93-6547f2639713"
      unitRef="usd">1702300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ifafdd7dbd10c49a3ae14d232fa79500b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzQtNi0xLTEtMzYwOTg_a7c30fdc-3f8c-4a17-9340-cfe2a029bc45"
      unitRef="usd">1786900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9497e574157241008a6608086202bffd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzUtNC0xLTEtMzYwOTg_45dfdcc7-9d87-4609-bca8-f3f245ac25a4"
      unitRef="usd">1691000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iaca73150a1e34797a7531629fc846e9d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzUtNi0xLTEtMzYwOTg_d5083cdc-b570-433c-b6c5-7b7ef1bb4e76"
      unitRef="usd">1747700000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzYtNC0xLTEtMzYwOTg_a23fae8f-f1f3-48ab-90ed-74521d1a705d"
      unitRef="usd">10013300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzAvZnJhZzo2NzFiMTViZDc4YzI0NGJlYmIyZWVkMmI2Yjc4NGViMi90YWJsZTo0NTg0NzJhYmVjNGE0MjIwOTM4MTIwZGQ5NzZhZGNiMC90YWJsZXJhbmdlOjQ1ODQ3MmFiZWM0YTQyMjA5MzgxMjBkZDk3NmFkY2IwXzYtNi0xLTEtMzYwOTg_a6d95fd2-8b96-4b0c-bf11-fa3b850f4b96"
      unitRef="usd">9648200000</us-gaap:NoncurrentAssets>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MTA_04aa283a-2179-4cd1-ba76-ede3b9b15077">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $159.4 million, $154.6 million, and $172.8 million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2021, 2020, and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;163.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MTE_5801bf07-9530-4e11-b5a3-c459e49cecbf">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. We have leases with terms up to 14 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $159.4 million, $154.6 million, and $172.8 million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2021, 2020, and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;163.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <lly:LesseeLeaseRemainingLeaseTerm
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzEwOQ_eb85f30e-7710-486b-b1dc-e8a0a8a4a4c5">P14Y</lly:LesseeLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzE1Mjg_8847798c-04f7-400b-af8a-cb644a00dc30"
      unitRef="usd">159400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0Xzc2OTY1ODEzOTc3NzE_e7771309-497a-476b-aa20-01a60cf7c917"
      unitRef="usd">154600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0Xzc2OTY1ODEzOTc3MzA_d84ffc8c-9cf1-417c-8c48-7ddd75fd67a5"
      unitRef="usd">172800000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MTI_7c748e60-b868-4208-a168-09594db1c100">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2021, 2020, and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;163.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzEtMi0xLTEtMzYwOTg_3bed232a-5480-4a45-87d5-5ce8dcba1177">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzEtMy0xLTEtMzYwOTg_4da36a51-e5a7-450b-baf8-1eb051a1795e">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzItMi0xLTEtMzYwOTg_627292ab-d734-45f7-ac42-4b4c6e051700"
      unitRef="number">0.030</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0ZThhYWExYzc1M2Q0MzM4YWRlMWE3MzMwZDE1MWJkNC90YWJsZXJhbmdlOjRlOGFhYTFjNzUzZDQzMzhhZGUxYTczMzBkMTUxYmQ0XzItMy0xLTEtMzYwOTg_4139d270-2126-4cf2-acc9-dfafe95cd722"
      unitRef="number">0.033</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzEtMi0xLTEtMzYwOTg_aa50091e-9796-4380-80fe-9b4a98584aff"
      unitRef="usd">156700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzEtMy0xLTEtMzYwOTg_d4276345-f9c2-4967-98d8-5a77cc966b81"
      unitRef="usd">160900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzEtNC0xLTEtNjUwOTg_cfdcd99c-0b2f-4a75-890c-e475fee198c5"
      unitRef="usd">153600000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzItMi0xLTEtMzYwOTg_d5f4c01d-f1dc-4c00-ab67-a4eb6be86425"
      unitRef="usd">163500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzItMy0xLTEtMzYwOTg_5c206754-6136-481e-9c70-51c0cf7b172e"
      unitRef="usd">136700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTo0MjAwODVlYzJmNDU0ZDgwYWRiNGQ1MjI4OWQxMGQ0OS90YWJsZXJhbmdlOjQyMDA4NWVjMmY0NTRkODBhZGI0ZDUyMjg5ZDEwZDQ5XzItNC0xLTEtNjUxMDQ_0f6f73e2-6cbb-49b9-8751-ef1f32fbde5a"
      unitRef="usd">81200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90ZXh0cmVnaW9uOmFhNGVlYzg1N2YzMDQ1ZjNiZGY5NGQ3NmU4MmJmM2Y0XzI3MDk_a1712258-bfcb-4b6d-aefd-526a5a5c6b4b">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMC0xLTEtMzYwOTg_efb93eac-655c-4219-a3fe-02daa7c67c30"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzEtMS0xLTEtMzYwOTg_e98bad78-afc7-41e1-a3cd-f597b235b068"
      unitRef="usd">148400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzItMS0xLTEtMzYwOTg_3f73a8f4-3158-4e88-94dc-adcabe4603f6"
      unitRef="usd">117600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzMtMS0xLTEtMzYwOTg_3bc145e7-bfd1-47db-b3c7-8a5a6a4d9a34"
      unitRef="usd">95400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzQtMS0xLTEtMzYwOTg_864b511a-5954-44fc-bc2a-07ed50c6f4e5"
      unitRef="usd">79700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzUtMS0xLTEtMzYwOTg_2012bbac-9c37-4f02-872b-43dbcb504235"
      unitRef="usd">64500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzYtMS0xLTEtMzYwOTg_1e8d4427-06bc-4679-b252-7718fefbbb15"
      unitRef="usd">270200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzctMS0xLTEtMzYwOTg_eca84d70-3aba-44d2-b008-5b7c1e7e35bf"
      unitRef="usd">775800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzgtMS0xLTEtMzYwOTg_dc7895fa-ce5e-4dad-be40-f44d1e524b56"
      unitRef="usd">90100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzMvZnJhZzphYTRlZWM4NTdmMzA0NWYzYmRmOTRkNzZlODJiZjNmNC90YWJsZTpjOTA0YzRjODIxMWQ0MTZhODhmODllMmQ1ZDM1MTJmMC90YWJsZXJhbmdlOmM5MDRjNGM4MjExZDQxNmE4OGY4OWUyZDVkMzUxMmYwXzktMS0xLTEtMzYwOTg_ed2f2ec6-7308-4b0b-bf7c-11087126a049"
      unitRef="usd">685700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwNzU_130dd784-1d58-4b3d-afab-df3a9d23ed1e">Borrowings&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term notes &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,741.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,348.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(84.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment on hedged long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,884.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,595.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,538.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,346.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term notes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;750.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.00% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;99.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00% euro denominated notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;678.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;737.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.15% Swiss franc denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;654.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;679.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.125% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;217.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% euro denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;847.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;364.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;377.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;401.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.45% Swiss franc denominated notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;436.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.375% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;930.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.42% Japanese yen denominated notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;199.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;222.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.125% euro denominated notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;847.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.625% euro denominated notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;678.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;737.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.50% euro denominated notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;678.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.56% Japanese yen denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;80.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.77% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;158.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;444.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.95% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;266.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;284.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.875% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;240.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;360.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% British pound denominated notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;337.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.65% notes due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;38.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;386.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;347.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;958.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.70% euro denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,130.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,229.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.97% Japanese yen denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;66.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.25% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,250.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.125% euro denominated notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;565.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.15% notes due 2059&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;591.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.50% notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.375% euro denominated notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;791.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(105.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(76.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;16,741.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16,348.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, we had a total of $5.26 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2026 and a $2.00&#160;billion 364-day facility that expires in November 2022, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $2.00 billion facilities as of December&#160;31, 2021. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2021 and 2020 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering have been, and will continue to be, used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#x20ac;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#xa3;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations for the year ended December 31, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we issued $1.00&#160;billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we issued $1.15&#160;billion of 3.375 percent fixed-rate notes due in March 2029, $850.0&#160;million of 3.875 percent fixed-rate notes due in March 2039, $1.50&#160;billion of 3.95 percent fixed-rate notes due in March 2049, and $1.00&#160;billion of 4.15 percent fixed-rate notes due in March 2059, with interest to be paid semi-annually. We used the net cash proceeds of $4.45&#160;billion from the offering to repay commercial paper that was issued in connection with the acquisition of Loxo and for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we issued euro-denominated notes consisting of &#x20ac;600.0 million of 0.625 percent fixed-notes due November 2031 and &#x20ac;1.00 billion of 1.70 percent fixed-rate notes due in November 2049 with interest to be paid annually. We paid $2.27 billion, comprised of $1.75 billion of net cash proceeds from the offering and proceeds from commercial paper, to purchase and redeem certain higher interest rate U.S. dollar denominated notes with an aggregate principal amount of $2.00 billion and a net carrying value of $2.01&#160;billion, resulting in a debt extinguishment loss of $252.5 million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we issued Japanese Yen-denominated notes consisting of &#xa5;22.92&#160;billion of 0.42 percent fixed-rate notes due in November 2029, &#xa5;9.28&#160;billion of 0.56 percent fixed-rate notes due in November 2034, and &#xa5;7.64&#160;billion of 0.97 percent fixed-rate notes due in November 2049, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $356.6&#160;million for general corporate purposes, including the repayment of outstanding commercial paper.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amounts of maturities on long-term debt for the next five years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities on long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2021 and 2020, including the effects of interest rate swaps for hedged debt obligations, were 2.27 percent and 2.61 percent, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments for interest on borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwODE_98f8227c-a331-4c9a-9f46-7a925359e6e2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term notes &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,741.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,348.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(84.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment on hedged long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;216.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,884.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,595.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,538.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,346.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzItMS0xLTEtMzYwOTg_8998e6d1-0581-4b9d-ab17-a395c527f8f2"
      unitRef="usd">16741200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzItMy0xLTEtMzYwOTg_7197e12d-24d1-40d0-97cc-71cf30615b42"
      unitRef="usd">16348700000</us-gaap:NotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzMtMS0xLTEtMzYwOTg_23b6a293-3d86-4d11-9a53-5448e4edfb65"
      unitRef="usd">10800000</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzMtMy0xLTEtMzYwOTg_d6dd63ca-9cac-4085-89ce-774889189290"
      unitRef="usd">14800000</us-gaap:OtherNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzQtMS0xLTEtMzYwOTg_b0539674-59e6-4b00-99dd-b7ce698672a5"
      unitRef="usd">84200000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzQtMy0xLTEtMzYwOTg_e35338fa-a7eb-4e0e-9671-e2d3c701de9d"
      unitRef="usd">89100000</us-gaap:UnamortizedDebtIssuanceExpense>
    <lly:LongTermDebtFairValueAdjustment
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzUtMS0xLTEtMzYwOTg_be0082f6-cba8-47ca-a30f-d01cf456213b"
      unitRef="usd">216900000</lly:LongTermDebtFairValueAdjustment>
    <lly:LongTermDebtFairValueAdjustment
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzUtMy0xLTEtMzYwOTg_4cc25a7e-990d-4fde-85e4-610582bac123"
      unitRef="usd">320900000</lly:LongTermDebtFairValueAdjustment>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzYtMS0xLTEtMzYwOTg_5b311013-638a-439d-a32a-a549fad22daa"
      unitRef="usd">16884700000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzYtMy0xLTEtMzYwOTg_e64d0623-3396-4743-962f-a4f92fe04797"
      unitRef="usd">16595300000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzctMS0xLTEtMzYwOTg_0c187ade-239a-4d44-988f-56482f307641"
      unitRef="usd">1538300000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzctMy0xLTEtMzYwOTg_9909e67d-6a15-4091-8a7f-c1cb9a7ba914"
      unitRef="usd">8700000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzgtMS0xLTEtMzYwOTg_e0e64f10-65f5-4831-9554-36e6b842351a"
      unitRef="usd">15346400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4YzA5NTI3ZDZjNTM0MTM3ODNjOTA3NTg4MjlmNTQ1Ny90YWJsZXJhbmdlOjhjMDk1MjdkNmM1MzQxMzc4M2M5MDc1ODgyOWY1NDU3XzgtMy0xLTEtMzYwOTg_2fa2ad7a-8107-4ae9-bcc4-6034f94cf969"
      unitRef="usd">16586600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwNTY_c5989739-3a7f-41d6-8924-32bb2c4c88bd">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term notes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;750.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.00% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;99.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00% euro denominated notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;678.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;737.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.15% Swiss franc denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;654.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;679.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.125% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;217.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% euro denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;847.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;364.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;377.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;401.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.45% Swiss franc denominated notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;436.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.375% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;930.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.42% Japanese yen denominated notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;199.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;222.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.125% euro denominated notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;847.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.625% euro denominated notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;678.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;737.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.50% euro denominated notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;678.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.56% Japanese yen denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;80.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.77% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;158.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;444.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.95% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;266.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;284.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.875% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;240.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;360.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% British pound denominated notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;337.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.65% notes due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;38.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;386.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;347.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;958.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.70% euro denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,130.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,229.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.97% Japanese yen denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;66.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.25% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,250.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.125% euro denominated notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;565.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.15% notes due 2059&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;591.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.50% notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.375% euro denominated notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;791.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(105.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(76.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;16,741.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16,348.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3edfd436e4164d2f80725061a45ac456_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo4MmQzZjI2ZThhOTA0NGY4OGUwNjc2OTkxYjRlMWM4MF80_20e699b4-f78e-4a00-b774-cf362f636ff0"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3edfd436e4164d2f80725061a45ac456_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEtMS0xLTEtMzYwOTg_371c6a06-302a-4f68-a262-ea08670e25e0"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iabf0dcd71d534c529a1afa8977dd40ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEtMy0xLTEtMzYwOTg_eb372b19-480b-4cb7-a3ed-a4d885595180"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4c09aa7a84a1474780ee33c2cf2dc8e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzItMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjpiOTFkM2Y3ZDA4YTU0OGY2OWFkYzBmOGNkNzU0YzBlMV80_9c04b8a0-9370-4bb3-8eae-fb9b3d5a57ee"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4c09aa7a84a1474780ee33c2cf2dc8e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzItMS0xLTEtMzYwOTg_4d7eaf10-b50b-4859-885a-2760b6591fcd"
      unitRef="usd">99200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i14e573d0614c4b0dafebc560bf1e985c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzItMy0xLTEtMzYwOTg_587bce9d-854e-4034-a52c-433e1e56f0d1"
      unitRef="usd">99200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2550d98cc4814022b18b1a19bba41105_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo1ZWFhNWVmNzU3ZGI0YzAyYjc1ODg0MzViZDEwZGRhZl80_fc701c12-2cc5-44cc-8b7f-4e09faa74118"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2550d98cc4814022b18b1a19bba41105_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMtMS0xLTEtMzYwOTg_3ae3b3b7-7ef2-4a8f-98ec-8049bea555b2"
      unitRef="usd">678200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i726ef58174614df18141c66c144a35ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMtMy0xLTEtMzYwOTg_bd1396cf-81d7-4e5f-842a-e2c201dc367b"
      unitRef="usd">737900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idfdc5e7be96a48c89529e9addbc8ad7e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzQtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjpiZjM1MzY3YmVhZGE0ZWNkODRlYzU0OTY0Mjc4MmE2N180_03a62c9f-954e-4715-b662-c461441e575d"
      unitRef="number">0.0015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idfdc5e7be96a48c89529e9addbc8ad7e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzQtMS0xLTEtMzYwOTg_9859da0f-c56d-447d-b791-6e1bec979a6e"
      unitRef="usd">654700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i92e2941af15b4d969e19eddd03468386_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzQtMy0xLTEtMzYwOTg_3931e9d9-74f9-4c68-a53d-26ca0351cbfd"
      unitRef="usd">679700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia6e0725e0711473c9cc3cffd0a7eedf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzUtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo0NGZkN2YyZjE5YTk0NGZlOTFiMzM1Y2RlMDI1N2ZlYl80_796ef9fa-2d68-4a15-a162-7f260e77de7d"
      unitRef="number">0.07125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia6e0725e0711473c9cc3cffd0a7eedf8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzUtMS0xLTEtMzYwOTg_55ee09f1-7ad9-4e2e-a06e-cf350468cd50"
      unitRef="usd">217500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if26698e02933442c83d95b1cd9eee56d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzUtMy0xLTEtMzYwOTg_abe0e1dc-b135-4f19-ab78-b9b468ff3ea6"
      unitRef="usd">229700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i154de6e52643472eac6dcdf2abeed4ed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzYtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjplOWYzNTI3MTlmMjU0MWJhOGRiNzJhYTc2YzQxYWIxNF80_e1cb5c9d-2567-46a6-b7f7-00401e0575d8"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i154de6e52643472eac6dcdf2abeed4ed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzYtMS0xLTEtMzYwOTg_cd6e75b0-b5ba-4444-bec8-5c53249c7ec3"
      unitRef="usd">560600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07da3333727b4428aad7bfefccb6d377_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzYtMy0xLTEtMzYwOTg_3b11bb16-145e-42d2-b6d1-793ad37ab7a4"
      unitRef="usd">560600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i67dfd1e097624c6488862d5324309a2b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzctMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjplNjgxYWVhZjc3NTM0NTJlODI5NTI1NDU4MzQwZDQ3YV80_f59cd359-9882-4e96-8bb6-dad383fd4274"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i67dfd1e097624c6488862d5324309a2b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzctMS0xLTEtMzYwOTg_79017192-317d-482b-99ca-6bf8674ba023"
      unitRef="usd">847700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93730e7e82dc4832803e374edfe8ead2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzctMy0xLTEtMzYwOTg_edcdc278-ab32-462b-bd2d-0d1d4316e409"
      unitRef="usd">922400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i75deddf561c0493e8e46b607e2749a0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzgtMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjozY2EzZTZiODAyYzA0OWJkOTk3YjFlZTkzYWE3YmVhM180_115ee838-0f8a-4ed0-b0aa-ecda78a9cedf"
      unitRef="number">0.055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i75deddf561c0493e8e46b607e2749a0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzgtMS0xLTEtMzYwOTg_0eff1171-cd1c-4ea5-85b9-697d744802ac"
      unitRef="usd">364300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i48bd23b8192c4011a4b88d56642b3f8a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzgtMy0xLTEtMzYwOTg_f3ece1c6-cc5e-457b-825b-9049ecdab498"
      unitRef="usd">377500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if60345d16c5f4360a5db3ba0799c8e53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzktMC0xLTEtMzYwOTgvdGV4dHJlZ2lvbjo2NGZiZmI3ZDQzY2M0OGRlOWUzYTllOTk0YTM2ZWQ0Zl80_2e030777-0465-488c-8c1d-8522a3374d85"
      unitRef="number">0.031</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if60345d16c5f4360a5db3ba0799c8e53_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzktMS0xLTEtMzYwOTg_d9513f10-7c6a-4e33-86da-feae9a05e4ec"
      unitRef="usd">401500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if5686e91f0d54967a085ff54595dcd73_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzktMy0xLTEtMzYwOTg_7678c829-108c-4371-89b3-94a8a2a8431a"
      unitRef="usd">401500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3de88e24648844a59b518e653fed8863_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEwLTAtMS0xLTM2MDk4L3RleHRyZWdpb246M2ViMTlhNjRjNWI0NDgwNzlhNmIxMzU0Y2IwZjEwNGZfNA_d96d8081-974a-4e12-bf9b-2cebfb05856f"
      unitRef="number">0.0045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3de88e24648844a59b518e653fed8863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEwLTEtMS0xLTM2MDk4_0e6f7328-cc11-4937-8067-ec5e251c99b9"
      unitRef="usd">436400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifeef731d794a4687b24f3700ad5eb752_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEwLTMtMS0xLTM2MDk4_bd8d2073-b974-44ce-856d-829c18c5e09f"
      unitRef="usd">453200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ef2c7899afb4acea061037c69340c76_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzExLTAtMS0xLTM2MDk4L3RleHRyZWdpb246Njc3N2U5MDk3YzU5NGJiNDk2ZjU1MGI1ZWZmN2RiNzVfNA_ecdfe0aa-4611-46db-80a1-d1707e069762"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0ef2c7899afb4acea061037c69340c76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzExLTEtMS0xLTM2MDk4_30dd9faf-1b6a-4bc7-baa4-f667a1fc1897"
      unitRef="usd">930600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9eaacf39e2ea44ed8c2e4582391bdcb8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzExLTMtMS0xLTM2MDk4_0ab46dbc-a091-453a-8761-4fc74381f6a5"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21429821125945baa4970226531ad503_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEyLTAtMS0xLTM2MDk4L3RleHRyZWdpb246OTMyYjc2YjEzZDM0NGE5OWIzYzU2YTIyMmEzMTE0MTBfNA_3edaa05f-f2ad-4f2b-bdda-9252ed84beab"
      unitRef="number">0.0042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i21429821125945baa4970226531ad503_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEyLTEtMS0xLTM2MDk4_d81d7f21-c990-476e-b7bb-11b8a6d76794"
      unitRef="usd">199000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie460a9111eb84d4a80874905c816ec62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEyLTMtMS0xLTM2MDk4_7350481a-1d45-4dc7-91d8-76264e67eb5d"
      unitRef="usd">222400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i80b1d20b9535421399292eaeb2e1404d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEzLTAtMS0xLTM2MDk4L3RleHRyZWdpb246OWQwNGQ4Yjk4ZGQxNGU3Y2FmMzM1MjJjZDExYTljYzBfNA_2e492906-5522-4416-a370-97ddca0cfb38"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i80b1d20b9535421399292eaeb2e1404d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEzLTEtMS0xLTM2MDk4_2df0d7ff-8c36-4102-b2af-504f5bd6fd32"
      unitRef="usd">847700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1eb82f7d9a12471bb259d4ecd5857cf6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzEzLTMtMS0xLTM2MDk4_135e6496-6da4-4639-b7a6-6d6a01aa9d7c"
      unitRef="usd">922400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6ddfc74445594fbfaaea12c6240ebc86_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE0LTAtMS0xLTM2MDk4L3RleHRyZWdpb246OWNmMjJkMjE1M2ZmNDI5OWE5Y2MzNWQwZGQwYTA1ZmNfNA_402486a8-18ad-4a7f-a115-413414fdf8bb"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6ddfc74445594fbfaaea12c6240ebc86_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE0LTEtMS0xLTM2MDk4_5fd2f096-bf21-46c3-ab9d-19b355f5cf1d"
      unitRef="usd">678200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2102d6980fea4c88a7c3bd4a75c97991_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE0LTMtMS0xLTM2MDk4_0b6eb76e-6eb8-44c6-995a-ad82a29d35e2"
      unitRef="usd">737900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4b59c5814594a1298d4215076efeee8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTAtMS0xLTc3MTE0L3RleHRyZWdpb246MTg1ODg5MjVjMzQyNGQ0YzkwYmY3MzdmZWUzYTgxMGVfNzY5NjU4MTM5NDQ3OA_dc3ec8d4-fdd2-4419-b1d9-7da63668499b"
      unitRef="number">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4b59c5814594a1298d4215076efeee8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTEtMS0xLTc3MTI1_38424e56-3c23-4853-87cf-12f0e4e78602"
      unitRef="usd">678200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic4662c8bc38545fb8b2d9cb09707ea95_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTMtMS0xLTc3MTMz_2fe464a1-06fd-465f-85fd-3a8d30f39390"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i69e119752ce84afebbd0e53e707424ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZGY5ZjIwYzc5YzQ2NDM2OWFkZWJlZDk0OGI4YjUyNzJfNA_cddbd0e8-5cfd-4fb2-a99d-5d75070ff089"
      unitRef="number">0.0056</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i69e119752ce84afebbd0e53e707424ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTEtMS0xLTM2MDk4_97982662-8bc4-42b3-b3b4-7dfd8b4edca1"
      unitRef="usd">80500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iffa8f1a49264490990fa783782542124_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE1LTMtMS0xLTM2MDk4_ae818d38-b147-4156-8fc1-663127dcdaed"
      unitRef="usd">90000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d037b9981404553a0d4424d89b04955_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE2LTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZGExYmNlNmI2NGY2NDY2ZDg4YTZkMzY0OTZhYmE2YjNfNA_c0587041-b362-4c2d-bfb2-1a09b56fc4ac"
      unitRef="number">0.0677</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3d037b9981404553a0d4424d89b04955_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE2LTEtMS0xLTM2MDk4_6f6eea18-2c43-4f86-ae69-c2f2f91ef94c"
      unitRef="usd">158600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0f18ee96f0b945dea57a5126d8ac86e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE2LTMtMS0xLTM2MDk4_0edbe95a-a3cd-45e5-b2b9-3088e333ed68"
      unitRef="usd">174400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ad3157951114b79b6573431cb911415_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE3LTAtMS0xLTM2MDk4L3RleHRyZWdpb246MWZhNDFkOWQ0ODJlNDIyMDg5ZTkwODkwN2ViMDg4M2NfNA_c5300cbd-1275-4fbb-9725-078e4939f21f"
      unitRef="number">0.0555</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1ad3157951114b79b6573431cb911415_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE3LTEtMS0xLTM2MDk4_0b2900be-7195-4855-9781-222f1c4556f0"
      unitRef="usd">444700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia474b21ab0f644219eba3b34a8113881_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE3LTMtMS0xLTM2MDk4_3fbe9030-2612-4348-861e-5f8ca1731c20"
      unitRef="usd">476200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa96c35099cd409caaa67bff540585fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE4LTAtMS0xLTM2MDk4L3RleHRyZWdpb246NDE2OTM5Mjg1ODliNGNkOTgwNmJkYzZmODgyM2U2MzBfNA_d000478a-9d6d-4658-8c28-db6930d8a6b4"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa96c35099cd409caaa67bff540585fa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE4LTEtMS0xLTM2MDk4_6e2630b8-c57c-42eb-90ba-26c2f2114e14"
      unitRef="usd">266800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4c29dcff71ec45a593556dfe25bd76e0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE4LTMtMS0xLTM2MDk4_5a83fc51-39ec-4214-86d3-2e5f32985c09"
      unitRef="usd">284100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4a94c884519b4702b3f5dc1c813be663_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE5LTAtMS0xLTM2MDk4L3RleHRyZWdpb246MDRhNTBhY2Q0N2Y2NGJlN2E2NGQwNzI3YTM0ODRlNDNfNA_d6d5e45a-0d05-45c0-880a-a801804b958e"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4a94c884519b4702b3f5dc1c813be663_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE5LTEtMS0xLTM2MDk4_5fdc011b-2d16-4229-be31-c8a87b3572b2"
      unitRef="usd">240300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i69442670727945548dd575b353aadf52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzE5LTMtMS0xLTM2MDk4_5b7cbe6d-c32f-46f5-b75f-2c6324e4f7a2"
      unitRef="usd">360700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9c0e225dc9f24b699d469b030eab3e0f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTAtMS0xLTc3MTUyL3RleHRyZWdpb246YzBmNGM0OWFmNmY1NGYwNGE5ODdlMWU1MTJhNDNjNWNfNzY5NjU4MTM5NDQ4OQ_ce7cb319-44cb-469e-b634-e235232be93a"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9c0e225dc9f24b699d469b030eab3e0f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTEtMS0xLTc3MTUy_058e44d2-dff6-4f1f-aff8-bc134b58189a"
      unitRef="usd">337100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib9a35afa117740c1980f3bb027fc8dd0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTMtMS0xLTc3MTc5_30761cd6-ec22-42ab-aff0-e9cbd32316a3"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie6648301f7e343c8b1397283a5da0166_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIwLTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZjNkZjI1YWQ2NzY3NDQ2NjlmMWM1ZjdlYzE1ODU1MGFfNA_5ef944e0-ae89-4b39-a1c0-86fb19b64119"
      unitRef="number">0.0465</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie6648301f7e343c8b1397283a5da0166_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIwLTEtMS0xLTM2MDk4_96fa8331-9cd9-4e3d-8b04-a5c76b28b000"
      unitRef="usd">38300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2a776f2958104fed92c610952957426f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIwLTMtMS0xLTM2MDk4_0593b177-27ce-4191-a077-17579726f791"
      unitRef="usd">43000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i231000e09f2d43bb84cd04cf8c324914_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTAtMS0xLTM2MDk4L3RleHRyZWdpb246NjQ5OTdjZmMyZmM1NDc2ZWI5MmEwMzlkMmQ0YjkxZWJfNA_da66cd0f-18ee-4b5c-8401-2c173d9e8519"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i231000e09f2d43bb84cd04cf8c324914_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTEtMS0xLTM2MDk4_55bfe914-3d06-48af-9002-75ac375a0a7a"
      unitRef="usd">386800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i68a00f397c444157b4b4d73e2eea183b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIxLTMtMS0xLTM2MDk4_126375de-6089-4b02-8f1e-4dd5182adf0b"
      unitRef="usd">412500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06f29fc3788e4afabc141f44cf4cd192_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIyLTAtMS0xLTM2MDk4L3RleHRyZWdpb246ZDdiMmZiMmExZTM4NGViYjljMmUzNzI2MjM0MTIxMWZfNA_d1f19807-22e9-4f10-ba64-e79056a149d2"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06f29fc3788e4afabc141f44cf4cd192_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIyLTEtMS0xLTM2MDk4_de78d676-73bc-4025-ac82-43d4c1121bb7"
      unitRef="usd">347000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4f2fca1966da41f8adc01f317059c621_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIyLTMtMS0xLTM2MDk4_2e5ad84b-5acd-468b-b387-236eccdfbadd"
      unitRef="usd">436100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i18bfe7750c7f43cfbb99996103ae776d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIzLTAtMS0xLTM2MDk4L3RleHRyZWdpb246MmUxZDYwMTY1ZGI4NGM2MGE2MTlhNDE0N2RmODhlNDBfNA_00b0e87e-2188-40fd-b105-e8ffd644dc84"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i18bfe7750c7f43cfbb99996103ae776d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIzLTEtMS0xLTM2MDk4_7c7c4340-9c5f-4a74-94d6-1b64847dfb13"
      unitRef="usd">958200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i72baca3e465440cdae1136e4d7206b9e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzIzLTMtMS0xLTM2MDk4_4269610b-664f-4bfd-acf2-84813b52a5b8"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib8af2d2c452d42a8b7cd8f16e4ebd74b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI0LTAtMS0xLTM2MDk4L3RleHRyZWdpb246NWM4OGM2ZGJjMmI2NDgyOGJlMzI2ZTE1MjRjYTVkYjZfNzY5NjU4MTM5NDQ3OA_153a1dbe-2294-4a4b-bada-2198d1950cf9"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib8af2d2c452d42a8b7cd8f16e4ebd74b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI0LTEtMS0xLTM2MDk4_7cd2adbc-89c9-404a-88fd-b10b1ada81de"
      unitRef="usd">1130300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i36aea259f0b34f19ba983964d19353fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI0LTMtMS0xLTM2MDk4_10250d68-9aba-4554-b617-4319d319fa92"
      unitRef="usd">1229900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4361ba8f6e1e4492a8664a509357866c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI1LTAtMS0xLTM2MDk4L3RleHRyZWdpb246Yjk1ZGNhN2JhZjY3NDJlNjg4ODFjYzhmZTBhNWMwNGJfNA_bd4cd7b4-41d4-4581-bcab-25f81baa96ef"
      unitRef="number">0.0097</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4361ba8f6e1e4492a8664a509357866c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI1LTEtMS0xLTM2MDk4_dd8ef064-081c-48f4-9c67-2de347c923f9"
      unitRef="usd">66300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i935c853cb5344480a0fde97d3a5bbf26_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI1LTMtMS0xLTM2MDk4_fe25100d-14c0-430a-bada-b9fb530b7534"
      unitRef="usd">74100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd87a02ecce94de892c2873f98f3488e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI2LTAtMS0xLTM2MDk4L3RleHRyZWdpb246YzE1NzAxNDc4NWRiNDBkYjlmYWZhZDQ0YTlkYjg2NDlfNA_982baab6-0d25-4d90-b33f-d3d74083c7b2"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icd87a02ecce94de892c2873f98f3488e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI2LTEtMS0xLTM2MDk4_14baa796-bbfa-4a57-be6a-ddc5deb322c5"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9c6d753d735746cd823811c9493f0574_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI2LTMtMS0xLTM2MDk4_cf9a9960-dbe9-44b9-be45-08a84cbbfc7b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i849ed38906ec4ff5b38dd57dffe8ecf1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTAtMS0xLTc3MTYwL3RleHRyZWdpb246NTcxZGI5YWFkMGZiNDA3MDg4NTI1NDllMGU0MDAwZjFfNzY5NjU4MTM5NDQ4MA_eb58cd5d-b24c-404a-96cf-ba8024538d1b"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i849ed38906ec4ff5b38dd57dffe8ecf1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTEtMS0xLTc3MTYw_048f5bfb-812e-407a-81ea-a41a66feabd7"
      unitRef="usd">565200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib1eff0e4f1e846f2890a8d5f2938a568_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTMtMS0xLTc3MTg4_33f34fd6-8f6d-4bfa-bb4c-dbddd92f28f6"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i13a5deea4c6d48b7a2eafbede3b86af1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI4LTAtMS0xLTM2MDk4L3RleHRyZWdpb246MDNjZGUzZWM1YTU3NDFmYmE0NWFjMzAwZTVjODI2MzJfNA_842b983e-5677-4f54-8e73-ded51a4c32ad"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i13a5deea4c6d48b7a2eafbede3b86af1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI4LTEtMS0xLTM2MDk4_35640c60-400a-4eb8-bed3-a729e9132867"
      unitRef="usd">591300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i51b466072109461f818c9dc82d5550bc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI4LTMtMS0xLTM2MDk4_61a8ea72-71e5-415c-8d06-22cc7f76790a"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i77673fc123d84b82ac7de1c624dc395f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI5LTAtMS0xLTM2MDk4L3RleHRyZWdpb246OGM3NDZmY2MzMWE0NDI2YWE4Y2MyMjg3ZTE1MjllYThfNzY5NjU4MTM5NDQ2MQ_a7b13c06-fb1d-48c5-8300-70dbb25897f6"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i77673fc123d84b82ac7de1c624dc395f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI5LTEtMS0xLTM2MDk4_2964159a-9551-4308-b4d7-9d575f70dfd2"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id057083c27874cbd98e27c582abf0489_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzI5LTMtMS0xLTM2MDk4_ea155a5e-8969-4c07-8439-c881e06cb20e"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if03f60cda085426697bf93f5635d81c0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMzLTAtMS0xLTc3MTY5L3RleHRyZWdpb246ODgwMDg4NzM3MzY5NGQwMmFkM2E4ZWYxNTJkNzg5ZTVfNzY5NjU4MTM5NDQ4MA_67d35128-788e-4d6b-9478-34bc8a33b895"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if03f60cda085426697bf93f5635d81c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMzLTEtMS0xLTc3MTY5_fde6769d-4779-44c4-99fe-d225012d98a6"
      unitRef="usd">791200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9f2170ade6674e849351094a6814a792_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMzLTMtMS0xLTc3MTk2_2d92860d-e267-4707-a006-b0c9cd558a77"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTEtMS0xLTM2MDk4_8414799b-75cd-4ce7-8314-7faf7676c102"
      unitRef="usd">105200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMwLTMtMS0xLTM2MDk4_0331602d-9f29-4028-a032-fc0f7c0b6544"
      unitRef="usd">76700000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMxLTEtMS0xLTM2MDk4_ce523505-df2e-41fb-87fc-b097eab6d1e0"
      unitRef="usd">16741200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZTo4NmVlNTg3NTAxYmY0MTZmYTMwMjNmYzdjN2JlZjQ5Ny90YWJsZXJhbmdlOjg2ZWU1ODc1MDFiZjQxNmZhMzAyM2ZjN2M3YmVmNDk3XzMxLTMtMS0xLTM2MDk4_950e4fac-078b-4840-b09e-ca88fe15d72f"
      unitRef="usd">16348700000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzM4Ng_9f9dd9a9-db47-4df3-9f79-2c3b91d2d2b4"
      unitRef="usd">5260000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iea2f9c7572f84dd09b8fc2143f1c7713_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQ2NA_9884340d-a00f-4f53-8ef6-9c5188197667"
      unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i87692d02cc64457990db62efd471306d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzUxOQ_9d66f86d-3cec-440b-8523-fd6f0f4de450"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i0d63bfbf5dc1474eb7e49de284e9b9bd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzUyMg_a94289a0-8cff-45fc-a203-65e51cb0eee5">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iea2f9c7572f84dd09b8fc2143f1c7713_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzY2OA_9884340d-a00f-4f53-8ef6-9c5188197667"
      unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i87692d02cc64457990db62efd471306d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzY3NQ_9d66f86d-3cec-440b-8523-fd6f0f4de450"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib618046f71cd4612a921448bdebdc46a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzE5OTY_1e7b7d3a-9002-42ba-85e0-cfc611a72636"
      unitRef="eur">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib618046f71cd4612a921448bdebdc46a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIwMDM_9b406ef4-ae3c-4b0d-8bb3-03594e20279d"
      unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaec709b7886f4f2cb0cfba7f68baeac3_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzMzM_68bc4aae-0a8b-46ef-b67a-e6aa8c649ab8"
      unitRef="eur">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaec709b7886f4f2cb0cfba7f68baeac3_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzNDA_03309689-b359-4b6f-adf5-5d210f80b8ac"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i89f7f06fe81f4197af8d197ea94e6fad_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzODc_2b73cc15-c65d-40b6-931c-c8f2489076e3"
      unitRef="eur">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i89f7f06fe81f4197af8d197ea94e6fad_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzIzOTQ_a7c5407e-e958-462c-9976-b788082d1224"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i07ecd2cf284544f3a2b8a03785d285bc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI1MjM_12aeabcb-4957-4795-846a-63b86cf250b3"
      unitRef="gbp">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07ecd2cf284544f3a2b8a03785d285bc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI1MzA_d3729480-0fd8-4578-b9b0-2d8dcc5e4d30"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI2MTc_9207cd74-5e98-4705-863f-4339d56cefe0"
      unitRef="usd">1910000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI3ODQ_db86fc5a-e5f4-4967-9bbe-6ac18ce9a7a5"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI4MzI_32f1967c-d242-4081-bde4-b616b80b9cad"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i2a0e59f25cb94afe98ceaf60da50d844_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzI5OTg_db86fc5a-e5f4-4967-9bbe-6ac18ce9a7a5"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i841cd3e00f484488bd7b6b817257e859_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxMTE_2156c3f5-a68c-4cec-acd9-0346f250d0ae"
      unitRef="usd">541800000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaf79b1977acf44dfb438b2b46b217354_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxMTg_5881843e-bbbc-4190-aaeb-9f23c78c9800"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i551b1c26feb64783b8cdff78bf43afdc_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxMzg_e707ecda-90e7-4f9a-be66-ec0d1e01c213"
      unitRef="usd">408700000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6a28246e7f384385969289659ed183cd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxNDU_173b0059-fa31-4be9-8bad-e02d93ed44ec"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i2874fde88d0443708940891c7b27e2c3_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxNjk_a8fbaa9e-5dbb-4be6-8f77-ce117337514a"
      unitRef="usd">219400000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4501b277cafa4a86baa5a206571b8208_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwOTk1MTE2MzMxNzY_e0d41102-cf4f-480a-b20e-78f5bde1ff93"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8d3a4dd737f64e34a0e898318bacdb1f_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2Xzk5NQ_cfffd20f-a314-4279-af52-4685c8c5bfac"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8d3a4dd737f64e34a0e898318bacdb1f_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEwMDE_dc590781-ec0f-41d7-b294-7ceb270202e2"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i89a543f8c48547aa9e78a63f01f33c83_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzExMjk_c9a2f0cc-4ccd-4bfb-898a-9e6f13df5ab5"
      unitRef="usd">988600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9c2ba1b9c9854a9488d1f797845e5637_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEyNDg_c99b64cb-1e06-4830-bc36-1d8169f77217"
      unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9c2ba1b9c9854a9488d1f797845e5637_I20200831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEyNTQ_f9ee41cf-e945-48a5-b64e-d810c7183248"
      unitRef="number">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic1dff00d32cb4ba2b10f010cbd418d9e_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEzMTQ_7f83e37b-399a-436c-a6f2-f0769c2b016c"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic1dff00d32cb4ba2b10f010cbd418d9e_I20200831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzEzMjQ_8ed9e8b3-99df-4b5d-bc1b-9ebb7245715c"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i88fafea838de4336a9206daa5e470df6_D20200801-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzE0NTI_7c06a4c7-19eb-4da3-810d-ab81514d4a0d"
      unitRef="usd">1070000000.00</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7a25b1bbb8494f0cbd38976a0a587f00_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4MTE_a64f26b7-9abd-42fa-b5b5-47ac872aa5f1"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a25b1bbb8494f0cbd38976a0a587f00_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4MjU_7f02fb58-9cf2-44eb-9ca4-b6487015f7e2"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id3b13e3f15a94aa09c71215b3ab2d172_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4ODA_aed29dc1-4f5e-4434-b3ea-0990d3479c9c"
      unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3b13e3f15a94aa09c71215b3ab2d172_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4OTU_1ec5afe1-26a1-43ef-b904-e722a43e2bab"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5ae5dc6dd3d94739aca17ae8276b5801_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4NjU_d32c9ab2-4681-433d-80af-2c88e543f1fc"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ae5dc6dd3d94739aca17ae8276b5801_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI4NDY_1fd7fc46-59cb-4022-8f26-a221b873f2c4"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if2a86269df3d466591806fc6e81d3051_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5MTU_ecfc6d38-f8ae-4ed6-bc0b-30303ea9882b"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2a86269df3d466591806fc6e81d3051_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5Mjk_09bbcca9-2321-4cd5-a071-0df59a57011b"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i21e3b9057af3454595d19c23e9d0f7bd_D20190201-20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5NDg_0b966bd5-652e-4867-bd1a-8529eea7f7a2"
      unitRef="usd">4450000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i80ade2425c63414ea6978d8687390db3_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwMzk_145926be-57b3-4717-a5fd-4a24a7c5fa8d"
      unitRef="eur">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i80ade2425c63414ea6978d8687390db3_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwNDU_9f035ad3-c7b0-4620-99c0-f3ac7ed84145"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i709f676fc9614b42b1b0311c076d8dc4_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwOTE_dbef1360-6122-4f03-b929-a815cbc8c44c"
      unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i709f676fc9614b42b1b0311c076d8dc4_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIwOTc_a9892c70-8ac4-4500-9383-c342fddde4f9"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="ie11cc64930a449558e5ae1a4c19b6806_D20191101-20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIxODk_17f6bdfc-4057-4411-b08c-7158f36967aa"
      unitRef="usd">-2270000000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i982bcc21bc3a40c48ddab9f94be23c67_D20191101-20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzIyMDY_7f84263d-8e61-4c7a-88c9-72bdbc2ce61e"
      unitRef="usd">1750000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i8a2998c6421144a5959f9da4218d7f13_I20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI0MDQ_3cd39f84-ed6d-4bda-915e-40110703d8d8"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8a2998c6421144a5959f9da4218d7f13_I20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI0MzU_b04f188c-ac1b-4990-8d14-d92b4b06ae13"
      unitRef="usd">2010000000.00</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7f0d0d5ad7314fd8aba39a1931772306_D20191101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI0ODI_bdc299ca-e8c5-4e23-9409-cd89cb2f3439"
      unitRef="usd">-252500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f666283299a422782250b8f89a2f761_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODI5OTQ_721415fd-5a8d-4f2b-9a4e-5bc111faad68"
      unitRef="jpy">22920000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f666283299a422782250b8f89a2f761_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwMDg_16e66480-0241-456e-b71d-431ef1f2b79e"
      unitRef="number">0.0042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id13727de8f3441d299f77635f64f9362_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNDE_7f83c0c5-66d9-4b6d-b54e-c1ef49e098e6"
      unitRef="jpy">9280000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id13727de8f3441d299f77635f64f9362_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNTQ_0dd0e658-cb8b-4739-a8be-ecfde0d92c81"
      unitRef="number">0.0056</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i41718151ae0142b0a3f6ffa452de44fb_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwMjc_9a3ea866-fc46-45cf-b91a-807f7cf29212"
      unitRef="jpy">7640000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41718151ae0142b0a3f6ffa452de44fb_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNzQ_70c5fb82-e62e-4558-a5ea-dc378bf8863c"
      unitRef="number">0.97</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="id60cdef46f66424db1dd39767e60ddd8_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzI3NDg3NzkwODMwNzY_42523ce3-0ef7-41ad-a748-bf9d4dfbce58"
      unitRef="usd">356600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwODI_993f441a-cf6a-4f7c-8cf0-ad097852f129">&lt;div style="margin-bottom:8pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amounts of maturities on long-term debt for the next five years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities on long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtMS0xLTEtMzYwOTg_b53049ce-e42c-40e9-83f6-2be3f22f25a6"
      unitRef="usd">1531500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtMy0xLTEtMzYwOTg_540471b6-f9ec-46a5-a8d9-8b043301e288"
      unitRef="usd">3300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtNS0xLTEtMzYwOTg_dbc29fdf-6c77-4683-a934-5484d6ad11e2"
      unitRef="usd">657100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtNy0xLTEtMzYwOTg_1d28cf0b-443a-4e78-85a1-bca1ec82d6a2"
      unitRef="usd">778900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToyZWVkNTA2NGJmOTY0ZmUwYWZhOWRiZTZkN2JkYWNiNy90YWJsZXJhbmdlOjJlZWQ1MDY0YmY5NjRmZTBhZmE5ZGJlNmQ3YmRhY2I3XzEtOS0xLTEtMzYwOTg_10bc7d4f-36c5-440f-9227-7f1bd2bfbe28"
      unitRef="usd">847900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <lly:DescriptionOfDerivativeActivityVolumePercent
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzMxODQ_92bf97c3-87b1-4611-a450-7a31804ec790"
      unitRef="number">0.13</lly:DescriptionOfDerivativeActivityVolumePercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzM0NzQ_b17d995c-1aec-49c9-8cdc-4c7f54d82ec7"
      unitRef="number">0.0227</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzM0ODE_4e359766-1c5c-4962-a00c-282f18902cd9"
      unitRef="number">0.0261</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90ZXh0cmVnaW9uOjNiZDIyNGE0MDgzZTQ1ODBiNGQ3OGQxNjQ5NzM4NjQ2XzQwODM_cd1ac5b5-fca2-4578-b93e-ae0847d96892">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments for interest on borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToxNDBiZjkzODE1NzA0MWUyYjA0MDAzNjVhNjg3NDEzOS90YWJsZXJhbmdlOjE0MGJmOTM4MTU3MDQxZTJiMDQwMDM2NWE2ODc0MTM5XzEtMS0xLTEtMzYwOTg_b404eb66-fde2-4155-8a5d-f9cc759bf841"
      unitRef="usd">338000000.0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToxNDBiZjkzODE1NzA0MWUyYjA0MDAzNjVhNjg3NDEzOS90YWJsZXJhbmdlOjE0MGJmOTM4MTU3MDQxZTJiMDQwMDM2NWE2ODc0MTM5XzEtMy0xLTEtMzYwOTg_01a9134f-b7cd-4489-bf27-c1084a2afdab"
      unitRef="usd">345800000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xMzkvZnJhZzozYmQyMjRhNDA4M2U0NTgwYjRkNzhkMTY0OTczODY0Ni90YWJsZToxNDBiZjkzODE1NzA0MWUyYjA0MDAzNjVhNjg3NDEzOS90YWJsZXJhbmdlOjE0MGJmOTM4MTU3MDQxZTJiMDQwMDM2NWE2ODc0MTM5XzEtNS0xLTEtMzYwOTg_82bdae4e-98bd-495d-b7a3-cb95890086d3"
      unitRef="usd">305500000</us-gaap:InterestPaidNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MzM_7fd2a0a9-01f3-4972-8d1e-be9d2d637155">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and the related tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 50.6 million additional shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2021, 2020, and 2019 were $198.57, $137.33, and $112.09, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 0.7 million shares, 1.1 million shares, and 1.2&#160;million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately 0.7 million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested PAs was $66.1 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Value Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2021, 2020, and 2019 were $230.19, $139.14, and $95.01, respectively, determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, approximately 1.0 million shares, 0.8 million shares, and 1.0 million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately 0.5&#160;million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested SVAs was $47.0 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Relative Value Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, we granted RVAs to officers and management that are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2021 and 2020 were $286.71 and $179.90, respectively, determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested RVAs was $18.6 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December&#160;31, 2021, 2020, and 2019 were $196.30, $135.42, and $108.43, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 0.7 million, 1.1 million, and 1.5 million shares were granted and approximately 0.6 million, 0.6 million, and 0.8 million shares were issued during the years ended December&#160;31, 2021, 2020, and 2019, respectively. Approximately 0.9 million shares are expected to be issued in 2022. As of December&#160;31, 2021, the total remaining unrecognized compensation cost related to nonvested RSUs was $161.4 million, which will be amortized over the weighted-average remaining requisite service period of 25 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTI_5aaad746-6be5-49f6-91ee-980b63bfda22">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MjY_8041fc35-a222-417f-8cb4-a3c32e117861">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and the related tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;342.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzEtMS0xLTEtMzYwOTg_e7ad8d6a-d10a-4453-a8c6-960b7a23e2eb"
      unitRef="usd">342800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzEtMy0xLTEtMzYwOTg_970d7f5b-0835-4ad5-b6ac-133dc8b506ad"
      unitRef="usd">308100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzEtNS0xLTEtMzYwOTg_4706adb6-5e32-41ee-b204-d3abee487850"
      unitRef="usd">306800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzItMS0xLTEtMzYwOTg_475f0bd0-79e3-4985-bc96-128b4480bbf3"
      unitRef="usd">72000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzItMy0xLTEtMzYwOTg_398272fe-914a-4a73-8610-fc6642fde3d5"
      unitRef="usd">64700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozOTZlMDZiNDA4OWM0ODE4OGRhNDkxZTQ5Zjc5ZTExMi90YWJsZXJhbmdlOjM5NmUwNmI0MDg5YzQ4MTg4ZGE0OTFlNDlmNzllMTEyXzItNS0xLTEtMzYwOTg_7347e02a-3cff-4ec2-a922-40566585ad89"
      unitRef="usd">64400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzY5Ng_16b9ca79-dfdf-4241-adc4-4af56430d855"
      unitRef="shares">50600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTM_592a566a-80f5-4071-9bad-67fe4f60013d">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzEyMTk_77fd34eb-4eca-4663-8e65-7a486f0c9685"
      unitRef="usdPerShare">198.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id842f1546f35423585d05e7ce66b80c2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzEyMjM_cd76cb3b-36fe-4f8e-823d-cb60e9c83caa"
      unitRef="usdPerShare">137.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic4b33128ceba4b25a2ac485bd4f78d97_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzEyMzE_317000ed-7e5c-42f0-8b8a-ed8fc30063bb"
      unitRef="usdPerShare">112.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE0MDk_f6692f70-1e8d-41bc-96c5-894400b0d680"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="id842f1546f35423585d05e7ce66b80c2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE0MjA_64766abc-a9e8-44fa-94ad-8123437f5973"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ic4b33128ceba4b25a2ac485bd4f78d97_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE0MzU_569e96ba-7a92-465f-bc7a-4c51fdf0c31b"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE1MjQ_0a48c408-aaa7-4e99-b318-4f692ab369f4"
      unitRef="shares">700000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ica452a7bd83c44088dffeaca9fe9e6e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE2NTc_57cadc92-893a-40da-878c-9f62a85e0f11"
      unitRef="usd">66100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1604ce8b33a44ee2b3cc159a6999d7ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzE3NDk_d6ad94ff-11c3-4adc-8694-f8a360391652">P12M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1NDM_7517a5ad-2fc1-40fd-9c7c-b74bc07ee541">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTQ_47256d61-98de-42f8-80d6-6288d1ea0314">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2021, 2020, and 2019 were $230.19, $139.14, and $95.01, respectively, determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The weighted-average fair value of the RVA units granted during the years ended December&#160;31, 2021 and 2020 were $286.71 and $179.90, respectively, determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI4MTg_0fc4372f-51c1-4c86-80b4-45eecadd000c"
      unitRef="usdPerShare">230.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI4MjI_ef5205f8-6335-4f22-9afb-8988b146dc5c"
      unitRef="usdPerShare">139.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI4MzA_2ab21b62-ae44-4e5e-8f44-1855c618d3f1"
      unitRef="usdPerShare">95.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzEtMS0xLTEtMzYwOTg_0bbb20a7-c312-4c34-9549-1a6505b8c6e2"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzEtMy0xLTEtMzYwOTg_5a235ac8-29ab-4f2d-962f-fdfcf598ef3d"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzEtNS0xLTEtMzYwOTg_27dd4d3f-fd8e-4921-9a4f-53337c842556"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzItMS0xLTEtMzYwOTg_56364485-b59b-42ca-a660-bffb9876776f"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzItMy0xLTEtMzYwOTg_3a068bde-0506-42d3-9db3-3cb796cbce79"
      unitRef="number">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzItNS0xLTEtMzYwOTg_d484ea6a-e86f-42df-96a9-ad8ab0e38c78"
      unitRef="number">0.0246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzMtMS0xLTEtMzYwOTg_9ea6371a-1814-4a87-96d5-133e8a389051"
      unitRef="number">0.3142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzMtMy0xLTEtMzYwOTg_eab3a753-0cf3-49d9-89f5-6c4dde260b68"
      unitRef="number">0.2090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTozNDIwOGJmYThkOWY0NWYxYWRjOGQ2NjZjNmFiMDYyMS90YWJsZXJhbmdlOjM0MjA4YmZhOGQ5ZjQ1ZjFhZGM4ZDY2NmM2YWIwNjIxXzMtNS0xLTEtMzYwOTg_99e1140b-52de-4ebd-ab20-95b3363827f5"
      unitRef="number">0.2100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI5MzQ_56b85b93-9f9d-4bc7-9c56-a8e60b4adfbd"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i5abc04db6b73450ab221929c47623631_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI5NDU_de0b10ce-708f-4234-bfaf-e8707d62ed10"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ia68f70f2b41548d6aeef30bb4fa52e62_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzI5NjA_bd7352ae-50a0-450b-9368-3902c9538177"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzMwNDk_72ade34c-b03d-4f78-9016-0858b7d42bfb"
      unitRef="shares">500000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="icd1522d5872545dc9d89fb44d73b59ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzMxODM_e5879e74-1a9a-4d15-b1c4-9c266e7e091e"
      unitRef="usd">47000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzMyNzU_e058d1c1-061d-4e2b-8b70-db180d7c21b5">P21M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MzA_f2aaf8ac-e7a3-48d7-a09c-5731e3241044">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQzNTk_7ada5ec9-c18e-4cbf-a27f-7dc2e18fea3a"
      unitRef="usdPerShare">286.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzc2OTY1ODE0MDAwNzc_57104d17-8719-433e-8152-1b4e433ab418"
      unitRef="usdPerShare">179.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzEtMS0xLTEtMzYwOTg_a5c9f3b9-e760-4d8d-96f3-707e8fade5bc"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzEtMi0xLTEtODU1Nzg_40880b98-71a5-4ea3-add4-6274dbc1d928"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzItMS0xLTEtMzYwOTg_6b851133-4913-4042-8701-894408c0b246"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzItMi0xLTEtODU1Nzg_e4591053-e354-43ad-ae8c-9da68d63ecc6"
      unitRef="number">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzMtMS0xLTEtMzYwOTg_2553b8c8-3feb-4d4c-911e-1be6bf853292"
      unitRef="number">0.3095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1440fc25e84b4a3e8825af380e4a9ec0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90YWJsZTpmM2IyMzY5OGJjOGM0Zjg2YWZjZjIyMjU5NTgxNmM3Mi90YWJsZXJhbmdlOmYzYjIzNjk4YmM4YzRmODZhZmNmMjIyNTk1ODE2YzcyXzMtMi0xLTEtODU1Nzg_3aec7bf0-0509-4e12-88e8-ae1f8e49e7a7"
      unitRef="number">0.1989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic5bfe01bbc4845fa8a1d24e9e0d98eb6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ1MDA_6bce32b0-6764-496d-941d-cd725984c96f"
      unitRef="usd">18600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i294da3bef2c24972816679da2293ee28_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ1OTI_03a45eaf-fbe4-41fd-b597-ca18db410c38">P21M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ4Nzg_9679f80d-c5c4-4655-8f82-333e0b1a9719">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ5NjM_5e5a77c3-3f09-457f-81bc-fdbc37889498"
      unitRef="usdPerShare">196.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ5Njc_f50e9e40-59ee-40b5-996b-78ce888ca2f9"
      unitRef="usdPerShare">135.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzQ5NzU_a4782adc-61c0-4162-bdb9-d71a7aeb720e"
      unitRef="usdPerShare">108.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxMzA_156a8315-9f93-4126-a357-9f9a6833f786"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxMzQ_3569264b-c41c-45db-9ff5-173f71a5e01b"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxNDI_25d79252-4b7a-452a-939f-83582f11971e"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxODM_25a9a39d-b7a0-49eb-85ae-4ae8fbab52cb"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i2e70b2599bbf4740934455a660ea26e0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxODc_5edfbd82-46c6-494e-8ae7-99b13df99ab5"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i90742f0e329a419985a3a95a0dd4abc2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUxOTU_6fc62380-493e-4987-9ae9-80da340dce04"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzUyODQ_be7226fc-3062-4fb1-8f76-bf60502ded6f"
      unitRef="shares">900000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i51954a83d3fc4e158da2a14d11be3b67_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU0MTg_acf67640-c7b4-4f47-927c-a944f77c0649"
      unitRef="usd">161400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if3d9af7f082f48fbabe6cfc8cb95e9f3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDIvZnJhZzozY2Q3MGJiZWQwNzY0ZDlkOTY3NTlmMmY5ODg4YjRjZC90ZXh0cmVnaW9uOjNjZDcwYmJlZDA3NjRkOWQ5Njc1OWYyZjk4ODhiNGNkXzU1MTA_7841c9ee-0260-4601-a867-2d0017247b4c">P25M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzk4Nw_7d2e1da6-339f-48b4-9d6c-22dc262171e1">Shareholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, 2020, and 2019, we repurchased $1.25 billion, $500.0 million, and $4.40 billion, respectively, of shares associated with our share repurchase programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we repurchased $1.00 billion of shares, which completed our $8.00 billion share repurchase program authorized in June 2018. Additionally, our board authorized a $5.00 billion share repurchase program in May 2021. In 2021, we repurchased $250.0 million of shares under the $5.00 billion share repurchase program. As of December 31, 2021, we had $4.75 billion remaining under the $5.00 billion share repurchase program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 5.0 million authorized shares of preferred stock. As of December&#160;31, 2021 and 2020, no preferred stock was issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an employee benefit trust that held 50.0 million shares of our common stock at both December&#160;31, 2021 and 2020, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01&#160;billion at both December&#160;31, 2021 and 2020, and is shown as a reduction of shareholders' equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NjI2_e5d4ab04-8a25-483d-94e3-42deed6e195b"
      unitRef="usd">1250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzc3_a2c53ec6-1e32-45ac-a3e1-093575478a75"
      unitRef="usd">500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzg0_b07dd692-de54-4127-93c8-0d07051e4601"
      unitRef="usd">4400000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0b72858f1e1a4cbea5c56de4e31319a8_D20210101-20210430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NjQ4_d4867302-97d7-4ae8-8ffc-3a08d9e3e6e0"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie76506d8813f4a7fa6b07b99e9f4ddbb_I20180630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzg3OTYwOTMwMjQ3NzY_f6da495a-6c3c-470b-ad5b-b5f7a559fb8d"
      unitRef="usd">8000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i368ce9c4630f4059918b97512f0fc80f_I20210531"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0Njkw_3fe0023a-5b89-40be-83e1-d559dcd91bc1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4b37dec9dc524596b81869a5a184313c_D20210501-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NzQx_310e9709-9186-4e6f-a347-cf85434ed67f"
      unitRef="usd">250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i368ce9c4630f4059918b97512f0fc80f_I20210531"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NzEw_3fe0023a-5b89-40be-83e1-d559dcd91bc1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzE3MDQyNDMwMjM0NzY2_c774d88a-5d11-4711-a9f5-fb5c0beff755"
      unitRef="usd">4750000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i368ce9c4630f4059918b97512f0fc80f_I20210531"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzYwNDczMTM5NTcxNTg_3fe0023a-5b89-40be-83e1-d559dcd91bc1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzI3NQ_fb36504c-61ff-4a08-aa17-6ee5066adf42"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzMzMw_8064073e-2adc-4dcc-b7ae-8b46294f7bab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzMzMw_8e1043a4-8214-4f46-a4ab-7b29ef80c666"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesHeldInEmployeeTrustShares
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzQwOA_0e7e2950-302a-4e8e-b295-2ef817c132e9"
      unitRef="shares">50000000</us-gaap:CommonStockSharesHeldInEmployeeTrustShares>
    <us-gaap:CommonStockSharesHeldInEmployeeTrustShares
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzQwOA_1cabc412-7846-4027-9ff3-58af4a91ea14"
      unitRef="shares">50000000</us-gaap:CommonStockSharesHeldInEmployeeTrustShares>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzYxNQ_5e4b3307-19c5-4973-9de4-d67336d7a05c"
      unitRef="usd">3010000000.00</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDUvZnJhZzpjYTU0NWQyNGMwYzE0NjFhOTgwNGRlYmM0MzgyYmRmMi90ZXh0cmVnaW9uOmNhNTQ1ZDI0YzBjMTQ2MWE5ODA0ZGViYzQzODJiZGYyXzYxNQ_ea1457be-58f2-4e35-b3c9-807d93c90cd0"
      unitRef="usd">3010000000.00</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMzE_0413e464-2e95-4eee-8f69-014079fc9add">Income Taxes&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is the composition of income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;938.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;466.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,376.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(977.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(802.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The 2021, 2020, and 2019 current tax expense includes $64.7 million, $144.4 million, and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,347.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;634.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;463.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss and other tax carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;645.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;832.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Correlative tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;560.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax redeterminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;274.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;275.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;477.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,662.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(875.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(816.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,786.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,801.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,583.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,516.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,465.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(596.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(623.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(560.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(338.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(303.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(132.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,030.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,071.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;755.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, based on filed tax returns we have tax credit carryforwards and carrybacks of $859.9&#160;million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $21.5&#160;million, if unused, will expire between 2030 and 2040. The remaining portion of the tax credit carryforwards is related to federal tax credits of $76.2 million, international tax credits of $115.3&#160;million, and state tax credits of $498.1 million, all of which are fully reserved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $2.21 billion: $832.6 million will expire by 2026; $818.2&#160;million will expire between 2027 and 2041; and $561.5 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $230.0&#160;million are fully reserved as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic and Puerto Rican companies contributed approximately 28 percent, 39 percent, and 44 percent for the years ended December&#160;31, 2021, 2020, and 2019, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2021 and December 31, 2020, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,598.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Tax Cuts and Job Act (2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, including a one-time repatriation transition tax (also known as the 'Toll Tax') on unremitted foreign earnings. The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight-year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3-5 Years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act Toll Tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have additional noncurrent income tax payables of $2.02&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,292.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add (deduct):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations, including Puerto Rico&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(458.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(100.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(73.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,551.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;310.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(49.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes related to the impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,798.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.70&#160;billion and $1.67 billion at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. examination of tax years 2016-2018 began in 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months. For tax years 2013-2015, all matters were effectively settled in 2019. As a result, our gross uncertain tax positions were reduced by approximately $200&#160;million, we made a cash payment of approximately $125 million, and our consolidated results were benefited by an immaterial reduction in tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and 2020, our accruals for the payment of interest and penalties totaled $220.1&#160;million and $196.7&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNDU_7ed070e1-df56-4cd0-aaa9-afbccc94c54b">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNjM_c1095f95-80f0-401c-b289-c80c3c499e9e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is the composition of income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;938.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;466.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,376.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(977.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;174.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(802.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) The 2021, 2020, and 2019 current tax expense includes $64.7 million, $144.4 million, and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards.</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzItMS0xLTEtMzYwOTg_96ce5361-735f-47a9-abd4-c1f6ad68e5dc"
      unitRef="usd">938500000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzItMy0xLTEtMzYwOTg_20ca5ce0-b025-4ec1-967f-7e013f5bd043"
      unitRef="usd">567600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzItNS0xLTEtMzYwOTg_2af5b36a-2a5c-4fe3-8680-d6963e2226b9"
      unitRef="usd">280200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzMtMS0xLTEtMzYwOTg_7e88c779-68c2-4101-8575-366cc1a5d317"
      unitRef="usd">466000000.0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzMtMy0xLTEtMzYwOTg_7dd4d43e-f9ab-432a-8e22-1d6b2468c8ad"
      unitRef="usd">650400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzMtNS0xLTEtMzYwOTg_b0badba9-fde1-4b1d-9912-bbd490ea6868"
      unitRef="usd">299800000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzQtMS0xLTEtMzYwOTg_0083da6b-6f80-49d5-8710-90ff608c2261"
      unitRef="usd">-28400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzQtMy0xLTEtMzYwOTg_78db3861-c97e-4948-8a47-d2f45769e5b2"
      unitRef="usd">-47300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzQtNS0xLTEtMzYwOTg_5c6e67bb-c959-4e8d-8773-775e3958a046"
      unitRef="usd">-14400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzUtMS0xLTEtMzYwOTg_3688c54b-4852-4b3f-ac18-5c5131c1ac9d"
      unitRef="usd">1376100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzUtMy0xLTEtMzYwOTg_d4efa742-3d11-43a8-8c85-2d05467d15ec"
      unitRef="usd">1170700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzUtNS0xLTEtMzYwOTg_e14090bf-a635-44fd-9e45-011c8c46cf3a"
      unitRef="usd">565600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzctMS0xLTEtMzYwOTg_c4564095-f926-408c-b18a-7b3191dbbf61"
      unitRef="usd">-977500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzctMy0xLTEtMzYwOTg_4a98cb6e-df6d-4471-b68f-89f80e3f605b"
      unitRef="usd">-97400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzctNS0xLTEtMzYwOTg_b130cf34-834e-485a-ac64-55cac9986bea"
      unitRef="usd">141300000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzgtMS0xLTEtMzYwOTg_f22ebc39-44a7-49f7-a06a-cc742a3f3ef9"
      unitRef="usd">174600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzgtMy0xLTEtMzYwOTg_dea801ed-fd77-4652-9e75-8f9ba3194514"
      unitRef="usd">-16600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzgtNS0xLTEtMzYwOTg_8971291c-4440-4a89-8980-85760f7c2ce7"
      unitRef="usd">-24100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzktMS0xLTEtMzYwOTg_a414ba36-9516-4ca4-86b6-00aa37e2887c"
      unitRef="usd">600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzktMy0xLTEtMzYwOTg_453ddba4-0def-4e2a-921f-08408d38eccc"
      unitRef="usd">-20500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzktNS0xLTEtMzYwOTg_fb48ee9d-0708-4367-b710-a36a0e41e832"
      unitRef="usd">-54800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzEwLTEtMS0xLTM2MDk4_37f33593-4e88-4c1a-98ec-0ea1fff0dd4c"
      unitRef="usd">-802300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzEwLTMtMS0xLTM2MDk4_4e2a47c2-c4f9-41bd-b8a6-e7f319e48196"
      unitRef="usd">-134500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzEwLTUtMS0xLTM2MDk4_80442353-2b7c-4714-952c-9f4a557cee81"
      unitRef="usd">62400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzExLTEtMS0xLTM2MDk4_93c9574b-e4dd-4bb8-8e7a-11b10ad611b6"
      unitRef="usd">573800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzExLTMtMS0xLTM2MDk4_2740af60-4ea5-4366-b030-1bc13b84a53f"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpkYmQ3MzI3ZDZlMjU0NzBlYjA4NWZiOWJkNGY5NjUyMC90YWJsZXJhbmdlOmRiZDczMjdkNmUyNTQ3MGViMDg1ZmI5YmQ0Zjk2NTIwXzExLTUtMS0xLTM2MDk4_68609ea4-1bfd-4773-acbf-e90d70fc3445"
      unitRef="usd">628000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2Xzc2OTY1ODE0MDQwODE_9d70fb73-5e6d-4c23-acc2-3313ffc73e83"
      unitRef="usd">64700000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzE1ODM_414cd480-8b2e-4d89-84d6-8c9e2e453e12"
      unitRef="usd">144400000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzE1OTA_0733ca02-e9a7-4f67-bf89-4ca8d7e7f990"
      unitRef="usd">153100000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNzk_d41aae1d-615f-4abd-bd72-a2644433f0ea">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,347.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;634.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;463.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss and other tax carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;645.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;832.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Correlative tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;560.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax redeterminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;274.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;275.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;477.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,662.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(875.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(816.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,786.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,801.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,583.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,516.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,465.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(596.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(623.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(560.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(338.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(303.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(132.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,030.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,071.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;755.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzItMS0xLTEtMzYwOTg_1b035e80-0830-4129-81df-27fb1e79f9f8"
      unitRef="usd">2347400000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzItMy0xLTEtMzYwOTg_fefed61e-6179-4edd-beda-9a7e95098ee8"
      unitRef="usd">2560600000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzMtMS0xLTEtMzYwOTg_4bd6dedf-be32-4f94-9dc1-10d88c840146"
      unitRef="usd">634700000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzMtMy0xLTEtMzYwOTg_84277d72-0d0d-47c2-ad8d-eb47374e11fd"
      unitRef="usd">1045600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzQtMS0xLTEtMzYwOTg_c17f7755-5ab0-4061-90de-bad80153385a"
      unitRef="usd">463700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzQtMy0xLTEtMzYwOTg_96227f5f-b348-41ec-87c1-8c0de51e92b5"
      unitRef="usd">523500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzUtMS0xLTEtMzYwOTg_da998ebc-d756-4a1e-a897-f179909a2e38"
      unitRef="usd">645400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzUtMy0xLTEtMzYwOTg_c2ed3e01-a841-4036-830a-83284390b5a5"
      unitRef="usd">488300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <lly:DeferredTaxAssetsSalesRebatesAndDiscounts
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzYtMS0xLTEtMzYwOTg_b2b9a1b9-1022-48e0-935a-0cf0ce0bf6fe"
      unitRef="usd">832300000</lly:DeferredTaxAssetsSalesRebatesAndDiscounts>
    <lly:DeferredTaxAssetsSalesRebatesAndDiscounts
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzYtMy0xLTEtMzYwOTg_0e87d798-c1e4-4d62-b733-dad88ed65801"
      unitRef="usd">461300000</lly:DeferredTaxAssetsSalesRebatesAndDiscounts>
    <lly:DeferredTaxAssetsCorrectiveTaxAdjustments
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzctMS0xLTEtMzYwOTg_ece77bbc-7d8d-47b2-becf-5c897ead8a54"
      unitRef="usd">560800000</lly:DeferredTaxAssetsCorrectiveTaxAdjustments>
    <lly:DeferredTaxAssetsCorrectiveTaxAdjustments
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzctMy0xLTEtMzYwOTg_1998fa1f-4426-4e6b-b320-acec634e890b"
      unitRef="usd">404200000</lly:DeferredTaxAssetsCorrectiveTaxAdjustments>
    <lly:DeferredTaxAssetsForeignTaxRedeterminations
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzgtMS0xLTEtMzYwOTg_e346c3cc-8843-45c1-bbfd-ee3727e74c4d"
      unitRef="usd">274900000</lly:DeferredTaxAssetsForeignTaxRedeterminations>
    <lly:DeferredTaxAssetsForeignTaxRedeterminations
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzgtMy0xLTEtMzYwOTg_57a2b640-0a1c-4012-bd00-ac36c6e6b193"
      unitRef="usd">242800000</lly:DeferredTaxAssetsForeignTaxRedeterminations>
    <lly:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzktMS0xLTEtMzYwOTg_73172ddf-1f40-48e8-a588-ac79a2a056f9"
      unitRef="usd">150000000.0</lly:DeferredTaxAssetsOperatingLeaseLiability>
    <lly:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzktMy0xLTEtMzYwOTg_d534bc18-0c32-486b-85dc-c241d03c0032"
      unitRef="usd">150700000</lly:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEwLTEtMS0xLTM2MDk4_5b2c6bf6-a566-4b6c-8f4b-a2dd68a5549c"
      unitRef="usd">275100000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEwLTMtMS0xLTM2MDk4_3e38cd9a-cc66-4711-9378-9a5c92b96514"
      unitRef="usd">135200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzExLTEtMS0xLTM2MDk4_18bff183-7d0c-4a6f-9f56-6d4ec548d829"
      unitRef="usd">477900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzExLTMtMS0xLTM2MDk4_2ddd1ebe-f312-43db-97d5-2d91ab2e9b9d"
      unitRef="usd">605800000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEyLTEtMS0xLTM2MDk4_1ed46cb4-b127-442b-a5d0-2ae977be31db"
      unitRef="usd">6662200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEyLTMtMS0xLTM2MDk4_5b64d06f-6d56-4034-9d99-dbeca8bc2138"
      unitRef="usd">6618000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEzLTEtMS0xLTM2MDk4_044ffa42-85ba-4649-a60d-ee429532c3b4"
      unitRef="usd">875600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzEzLTMtMS0xLTM2MDk4_536681c7-fb02-4e54-8cb9-979b3dea6cfa"
      unitRef="usd">816300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE0LTEtMS0xLTM2MDk4_74cc116c-dab8-48f3-a19d-a14a2066abc0"
      unitRef="usd">5786600000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE0LTMtMS0xLTM2MDk4_fa694401-68c8-4ecb-a2e7-9ba7458a5764"
      unitRef="usd">5801700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE2LTEtMS0xLTM2MDk4_cf874699-5379-4a19-8d2d-535aa4115c7b"
      unitRef="usd">1583300000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE2LTMtMS0xLTM2MDk4_3cbf17cc-9f43-4925-868b-5a211a0dc785"
      unitRef="usd">1905300000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE3LTEtMS0xLTM2MDk4_adbe89af-f60d-4acf-bb31-23d4753f5478"
      unitRef="usd">1516100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE3LTMtMS0xLTM2MDk4_edc36d21-7e73-4896-800e-6db9a6b17cac"
      unitRef="usd">1465700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE4LTEtMS0xLTM2MDk4_c41193c8-2272-4d5d-968a-98260a3022a0"
      unitRef="usd">596400000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE4LTMtMS0xLTM2MDk4_c696fc4d-4e97-4aa4-a3fe-1daab1da9c16"
      unitRef="usd">623700000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE5LTEtMS0xLTM2MDk4_1324bc25-d49a-4fe1-9e83-3208d019763a"
      unitRef="usd">560600000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzE5LTMtMS0xLTM2MDk4_6b855712-2450-487f-8f57-a7c0e4c4b905"
      unitRef="usd">410100000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIwLTEtMS0xLTM2MDk4_04ac0d08-7b18-4b6f-9d29-f2f7f3c62dc0"
      unitRef="usd">338700000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIwLTMtMS0xLTM2MDk4_2bdbf4db-b466-40c1-85c7-8506c42f54d0"
      unitRef="usd">315200000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIxLTEtMS0xLTM2MDk4_443d8eab-6a49-4152-a19c-b6d12f2bb2c0"
      unitRef="usd">303000000.0</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIxLTMtMS0xLTM2MDk4_cf5b8f65-2512-400e-9f00-21509b4ed3ce"
      unitRef="usd">216900000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIyLTEtMS0xLTM2MDk4_07b1bbfd-2ce6-4754-ab6a-02fe7ecd14ff"
      unitRef="usd">132600000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIyLTMtMS0xLTM2MDk4_4b9e28b6-540c-49b0-9226-06811444f240"
      unitRef="usd">134300000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIzLTEtMS0xLTM2MDk4_dd91cb55-303d-4b96-95b1-103f197859b3"
      unitRef="usd">5030700000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzIzLTMtMS0xLTM2MDk4_53f03966-a617-4a75-a094-aecd48e961da"
      unitRef="usd">5071200000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzI0LTEtMS0xLTM2MDk4_4e8d950b-0875-4ab2-88d9-0c13eb69d4e4"
      unitRef="usd">755900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo3YjBmZGQxNWI3ZGM0OWUxYWQyYzM5YzVhM2I0YjJmNC90YWJsZXJhbmdlOjdiMGZkZDE1YjdkYzQ5ZTFhZDJjMzljNWEzYjRiMmY0XzI0LTMtMS0xLTM2MDk4_92786260-b0a3-4954-b17b-7a71bd9de081"
      unitRef="usd">730500000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ifc1c1179afa04c4888ffdac81ad4e1bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzIzMTg_6da9c9bb-fb69-4ad2-80f1-553acb366d5d"
      unitRef="usd">859900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ibefae15cacca4b6fb80885f8b7f6034d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzIzNjI_d128c212-bedd-4884-bb3c-d6bf483cba38"
      unitRef="usd">148800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7ca9c900f5ba4830a421d9f973e97825_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI0MDA_549b169f-1a64-46eb-97ab-1765ce5703e8"
      unitRef="usd">21500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7a7ea2349e0e4231b618eb04ea877890_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI1Mzc_40f8510e-e1fb-46a4-9fa0-9953ebc74fc6"
      unitRef="usd">76200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i64908cb8d2bc48e58b3df38be9554dc3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI1NzA_69fb8f12-a1d6-444b-b4f0-4063a0f1c30b"
      unitRef="usd">115300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id3fcde25a10741c89da748954342eb63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI1OTk_a0104c9d-149e-4406-a7ff-9d3f915f68b1"
      unitRef="usd">498100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ifc1c1179afa04c4888ffdac81ad4e1bb_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI3ODA_085db38d-5be4-4380-843b-5f459caca366"
      unitRef="usd">2210000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i27a0a2d94ade4455b3533cea592bf9d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI3ODQ_522510c6-9f87-4df7-8472-87a7d350c3ca"
      unitRef="usd">832600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic7929b7916024d43ad8c5746cb69f8db_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI4MDY_7a6771fb-7b6a-4fd7-8a61-38d4fa5ebe05"
      unitRef="usd">818200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7227f8a46eda4c649d9047310a103ffd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzI4NDQ_105b7253-b6aa-4b83-9860-87fac700a267"
      unitRef="usd">561500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="id3fcde25a10741c89da748954342eb63_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMwOTY_02b68762-30bb-4791-bc6d-a22208b477ba"
      unitRef="usd">230000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMyMDU_3f878cca-9947-4a91-8c3c-ac29e19c1505"
      unitRef="number">0.28</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMyMDk_92214bf2-0fd1-4b8c-890f-ae98461d42fd"
      unitRef="number">0.39</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzMyMTc_438b83a8-ad11-46b0-9193-66f68a67cc87"
      unitRef="number">0.44</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzNDg_5d818bd4-50a3-4d0c-aa64-461717bdb856">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,598.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2021 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3-5 Years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act Toll Tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo2ZDQ1MzcyMjIyNDE0MWMxOWE3ZmRkYWNkNjZiNzI5Mi90YWJsZXJhbmdlOjZkNDUzNzIyMjI0MTQxYzE5YTdmZGRhY2Q2NmI3MjkyXzEtMS0xLTEtMzYwOTg_2b34423f-6cb8-49e1-85f3-c2f95209bedd"
      unitRef="usd">1598800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo2ZDQ1MzcyMjIyNDE0MWMxOWE3ZmRkYWNkNjZiNzI5Mi90YWJsZXJhbmdlOjZkNDUzNzIyMjI0MTQxYzE5YTdmZGRhY2Q2NmI3MjkyXzEtMy0xLTEtMzYwOTg_c2b33972-3b2e-4a29-a7d9-16ca4cae2124"
      unitRef="usd">954600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo2ZDQ1MzcyMjIyNDE0MWMxOWE3ZmRkYWNkNjZiNzI5Mi90YWJsZXJhbmdlOjZkNDUzNzIyMjI0MTQxYzE5YTdmZGRhY2Q2NmI3MjkyXzEtNS0xLTEtMzYwOTg_7f32ff37-a586-4a99-9d0b-cb8fbb9c73cb"
      unitRef="usd">1180500000</us-gaap:IncomeTaxesPaid>
    <lly:TaxCutAndJobsActTollTaxToBePaid
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtMS0xLTEtMzYwOTg_15da671f-ca0f-4724-8a53-bc7d0de4e5e8"
      unitRef="usd">2149500000</lly:TaxCutAndJobsActTollTaxToBePaid>
    <lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtMi0xLTEtMzYwOTg_e1f5a1b1-df3b-4790-bf79-eda35307c54e"
      unitRef="usd">253700000</lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear>
    <lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtMy0xLTEtMzYwOTg_c44cad36-5aaf-4219-ac68-18c80bbc5f72"
      unitRef="usd">1109900000</lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears>
    <lly:TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNGQ0YWRiMDhmMjU0M2I2YmE3OTY3ZTVlNTcxYTk3Zi90YWJsZXJhbmdlOmM0ZDRhZGIwOGYyNTQzYjZiYTc5NjdlNWU1NzFhOTdmXzEtNC0xLTEtMzYwOTg_952afe54-7c7c-4076-9391-1e296bcfd890"
      unitRef="usd">785900000</lly:TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears>
    <lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzcxNDY4MjU1OTA2OTI_0aab1fc4-4924-4cd8-a7f0-7220811c89b5"
      unitRef="usd">2020000000.00</lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMjk_c45d1953-8ca1-4f2d-9c47-8bcef5091cdf">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,292.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add (deduct):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations, including Puerto Rico&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(458.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(100.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(73.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;573.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Includes the impact of Puerto Rico Excise Tax, GILTI tax, and other U.S. taxation of foreign income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzEtMS0xLTEtMzYwOTg_b3581d4e-11cd-4b30-b392-7d9c7a53528f"
      unitRef="usd">1292600000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzEtMy0xLTEtMzYwOTg_2de0bd11-7cba-49f9-b37c-100db265a79f"
      unitRef="usd">1518300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzEtNS0xLTEtMzYwOTg_b5c618b4-4ef6-496a-80a9-1c55d6dfe9e8"
      unitRef="usd">1105800000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzMtMS0xLTEtMzYwOTg_0b04c0ec-6183-4345-96ce-66815d9f8735"
      unitRef="usd">458200000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzMtMy0xLTEtMzYwOTg_94236f2c-fcf1-4857-8f7f-b13b7b6138cb"
      unitRef="usd">297200000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzMtNS0xLTEtMzYwOTg_3c83ba30-402a-4b25-a9e9-31c2f77ea057"
      unitRef="usd">242000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzQtMS0xLTEtMzYwOTg_89acdbd3-b722-4d29-9d35-c3fbc1213c2c"
      unitRef="usd">100500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzQtMy0xLTEtMzYwOTg_25ff16c5-64dd-4707-a45b-eaf9db85fc71"
      unitRef="usd">97900000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzQtNS0xLTEtMzYwOTg_ef1e33b9-e820-4763-8498-923bda8ccf7e"
      unitRef="usd">108800000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzUtMS0xLTEtMzYwOTg_a4500acb-f7b1-4d9d-8cb8-6391a6f8f525"
      unitRef="usd">-86700000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzUtMy0xLTEtMzYwOTg_024dbf33-355b-4b50-9927-a614812e36d0"
      unitRef="usd">-71500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzUtNS0xLTEtMzYwOTg_5da222e8-828a-41b4-9975-d2d46449697d"
      unitRef="usd">-15500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzctMS0xLTEtMzYwOTg_9aaa1052-98cc-467c-b9cc-520a4bce5116"
      unitRef="usd">-73400000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzctMy0xLTEtMzYwOTg_8fdbd63e-8eec-440b-b648-40ddffdf8b1b"
      unitRef="usd">-15500000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzctNS0xLTEtMzYwOTg_a3485ea8-4693-4f4e-925d-2ec68f8b8308"
      unitRef="usd">-111500000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzgtMS0xLTEtMzYwOTg_b6f294e3-da22-4c55-916c-25d568aec85a"
      unitRef="usd">573800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzgtMy0xLTEtMzYwOTg_553c9817-b0f8-4ed8-9c14-a0d43ec98d1c"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTpjNzk5YWMzZDNkZDU0MGYyODNjNDM2YzE2NmZlZTY0Ny90YWJsZXJhbmdlOmM3OTlhYzNkM2RkNTQwZjI4M2M0MzZjMTY2ZmVlNjQ3XzgtNS0xLTEtMzYwOTg_1f4cd09d-9c7f-44c8-9fb3-4774e3a96067"
      unitRef="usd">628000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMzM_42598c65-788f-4f88-8ac5-b8c91896097f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,551.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;310.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(49.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes related to the impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,798.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzEtMS0xLTEtMzYwOTg_cb93a9d3-5f8a-4679-9877-bd35615ac9d2"
      unitRef="usd">2551900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzEtMy0xLTEtMzYwOTg_cd92a97b-85f6-4592-a932-a044abb781d8"
      unitRef="usd">2108600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2161fbcc13a94af3a14765cc6ce775d6_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzEtNS0xLTEtMzYwOTg_bbeb55f6-c0dd-4b1f-8106-50ac3d04438a"
      unitRef="usd">2034600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzItMS0xLTEtMzYwOTg_816ed780-60b3-4c95-90f1-832b75266c1e"
      unitRef="usd">310300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzItMy0xLTEtMzYwOTg_290c7f2c-26d0-461a-b231-c23ce8eacc8c"
      unitRef="usd">225600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzItNS0xLTEtMzYwOTg_dd1b5a91-3990-4fe0-94a6-97ddf99174c2"
      unitRef="usd">187200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzMtMS0xLTEtMzYwOTg_1dc66e70-428b-4521-80a5-ed2a8136fd91"
      unitRef="usd">98600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzMtMy0xLTEtMzYwOTg_0c20257c-5b6b-4990-9faf-f98168e3ed0c"
      unitRef="usd">310800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzMtNS0xLTEtMzYwOTg_40f73a9d-6418-4788-9233-6a60378e417e"
      unitRef="usd">425300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzQtMS0xLTEtMzYwOTg_161e3f6a-6f9a-46e1-975d-f838140600bb"
      unitRef="usd">8100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzQtMy0xLTEtMzYwOTg_5f952f3f-a3c0-4d8e-802b-de97ba7114e4"
      unitRef="usd">52400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzQtNS0xLTEtMzYwOTg_b85934ef-3b2f-4f3f-9cc0-4e2c793cbfdd"
      unitRef="usd">100300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzUtMS0xLTEtMzYwOTg_c202e473-4f2e-4ea0-abe7-187b2f29464b"
      unitRef="usd">38500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzUtMy0xLTEtMzYwOTg_0ed34c41-c454-41ae-9471-7674ad20a743"
      unitRef="usd">72000000.0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzUtNS0xLTEtMzYwOTg_981df580-a462-4f7b-9bcc-50dd02b2a1d9"
      unitRef="usd">260500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzYtMS0xLTEtMzYwOTg_e765b5cf-b398-482e-b770-c9699e499f77"
      unitRef="usd">49700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzYtMy0xLTEtMzYwOTg_93b41e8d-9d35-4c39-89c5-35a86b098eb4"
      unitRef="usd">41700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzYtNS0xLTEtMzYwOTg_b8fc3540-9080-49a7-88a6-71ca362f4be7"
      unitRef="usd">161500000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzctMS0xLTEtMzYwOTg_5f701e03-11c8-463f-963a-cb17dcb8786d"
      unitRef="usd">66200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzctMy0xLTEtMzYwOTg_d9950b5b-970f-4039-91bc-e0c7c38050cf"
      unitRef="usd">73000000.0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzctNS0xLTEtMzYwOTg_e4a97d47-b19a-47cc-99bf-1fd9b9fb9658"
      unitRef="usd">16200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzgtMS0xLTEtMzYwOTg_7e365d8c-1164-4019-98ed-54671d01a73c"
      unitRef="usd">2798300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzgtMy0xLTEtMzYwOTg_3e8a8e02-5b09-4fa4-a94b-acf15ac5e025"
      unitRef="usd">2551900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icaa5fbd37ece44598769646bdacd67e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTo5Mjk0OGE1OGRmN2U0ZTYyYTRjNTZlZWZhZjYwMzBiNC90YWJsZXJhbmdlOjkyOTQ4YTU4ZGY3ZTRlNjJhNGM1NmVlZmFmNjAzMGI0XzgtNS0xLTEtMzYwOTg_eca49140-feb6-4bb0-9cb8-822f0ac6460a"
      unitRef="usd">2108600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzUyMjg_03988c4a-fd59-4bb1-b493-a350993d9d75"
      unitRef="usd">1700000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzUyMzU_b831902f-38a7-436d-8f4a-4950c763753c"
      unitRef="usd">1670000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i6f0a88d32df74c0cb0fcdd7915d26f3a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzU4ODc_88813c03-6c8b-44d3-b43c-2c4e8045dce1"
      unitRef="usd">200000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <lly:PaymentsForIncomeTaxSettlements
      contextRef="iff79519d513f4f68bf15f66911ffa849_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzU5MzE_38aa9be1-da3a-4b1a-b1ce-002f779b4337"
      unitRef="usd">125000000</lly:PaymentsForIncomeTaxSettlements>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTowY2QwZGM1NDAxZDE0YmZlOWNlMDUzMmI0MzFkZWZiZC90YWJsZXJhbmdlOjBjZDBkYzU0MDFkMTRiZmU5Y2UwNTMyYjQzMWRlZmJkXzEtMS0xLTEtMzYwOTg_0590c5be-11a2-40ef-8293-b5148c04a620"
      unitRef="usd">20500000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTowY2QwZGM1NDAxZDE0YmZlOWNlMDUzMmI0MzFkZWZiZC90YWJsZXJhbmdlOjBjZDBkYzU0MDFkMTRiZmU5Y2UwNTMyYjQzMWRlZmJkXzEtMy0xLTEtMzYwOTg_262fa834-889c-4072-a379-e41ff49be509"
      unitRef="usd">34000000.0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90YWJsZTowY2QwZGM1NDAxZDE0YmZlOWNlMDUzMmI0MzFkZWZiZC90YWJsZXJhbmdlOjBjZDBkYzU0MDFkMTRiZmU5Y2UwNTMyYjQzMWRlZmJkXzEtNS0xLTEtMzYwOTg_b64e5ae1-d520-424e-9ca1-dd79c9af582f"
      unitRef="usd">-26400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMDA_4397d22d-65ac-444d-b914-9a6906d80301"
      unitRef="usd">220100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNDgvZnJhZzo3YTM4MDdiMTQzZDM0MmE5YTliM2IzYmM1NDA0OWRiNi90ZXh0cmVnaW9uOjdhMzgwN2IxNDNkMzQyYTlhOWIzYjNiYzU0MDQ5ZGI2XzYzMDc_5f27965f-9e64-4c66-8712-c270f7c797cd"
      unitRef="usd">196700000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzgx_29615f1e-7a51-4e9d-a680-af6ce51062bf">Retirement Benefits&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,225.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,251.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,753.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;369.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(564.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(173.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,565.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,663.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,579.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,227.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,458.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;131.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(122.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,416.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,361.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,149.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,646.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,697.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,473.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,908.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(497.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(117.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,770.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,082.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the consolidated balance sheet consisted&#160;of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;668.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,910.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,749.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,878.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(204.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (income) loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,919.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,530.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(614.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,770.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,082.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $750.4&#160;million decrease in benefit obligation in 2021 was driven primarily by an increase in the discount rate. The $2.13&#160;billion increase in the benefit obligation in 2020 was driven by a decrease in the discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our weighted-average assumptions as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retiree health benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,360.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,770.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,542.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,824.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health &lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,532.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,682.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;212.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;973.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,824.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total accumulated benefit obligation for our defined benefit pension plans was $16.44 billion and $17.03&#160;billion at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit expense included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;369.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(949.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(146.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;249.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(120.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020, and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined&#160;Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree&#160;Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss) arising during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,072.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial (gain) loss included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss) during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,611.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,158.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $167.3 million, $164.3 million, and $145.2 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2021, 2020, and 2019 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Benefit Plan Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 75 percent growth investments and 25 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets include cash and cash equivalents and mark-to-market value of derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,816.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,416.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2021. The activity in the Level 3 investments during the year ended December&#160;31, 2021 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2020. The activity in the Level 3 investments during the year ended December 31, 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we expect to contribute approximately $40 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzQ4_92b762ff-4f69-4c43-b695-67eec539dc94">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,225.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,251.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,753.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;369.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(564.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(173.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,565.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,663.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtMS0xLTEtMzYwOTg_820a6f65-41c3-40b4-b836-e109866a9863"
      unitRef="usd">18225500000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtMy0xLTEtMzYwOTg_08a14d38-aae2-4784-9b00-6ea8584833f2"
      unitRef="usd">16251000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtNS0xLTEtMzYwOTg_ab816b50-8c28-44c7-a63a-94bc89297ac3"
      unitRef="usd">1753700000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i9fd80bbb97874a039463577583da19c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzMtNy0xLTEtMzYwOTg_ab0295dd-6c41-45f1-92d2-92516cdccdc1"
      unitRef="usd">1601400000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtMS0xLTEtMzYwOTg_605845f8-dc33-45dd-8104-e8b697e525ca"
      unitRef="usd">369200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtMy0xLTEtMzYwOTg_60ea9be4-9f7f-4dce-a9d1-d2d0c0e7724d"
      unitRef="usd">325500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtNS0xLTEtMzYwOTg_0429a983-69fc-4fdc-8cf0-ccf3126efb72"
      unitRef="usd">49200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzQtNy0xLTEtMzYwOTg_74fac149-95d7-4ab6-88e0-ef6848630da0"
      unitRef="usd">40800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtMS0xLTEtMzYwOTg_0b76dd0f-3db4-494c-8fb1-aebcf33aeae7"
      unitRef="usd">337800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtMy0xLTEtMzYwOTg_fd084e0e-c1ab-43ac-a3f3-877ebe0073fc"
      unitRef="usd">425800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtNS0xLTEtMzYwOTg_06b301ae-b237-499a-a782-e9c93da6c9b2"
      unitRef="usd">32500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzUtNy0xLTEtMzYwOTg_b06cf40d-7336-416d-90b6-61943a876575"
      unitRef="usd">43700000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtMS0xLTEtMzYwOTg_8b90e59b-713c-446f-b83f-f61153da041a"
      unitRef="usd">564300000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtMy0xLTEtMzYwOTg_db167d20-c2b2-4a3e-a4de-f748cc7f9bbc"
      unitRef="usd">-1563100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtNS0xLTEtMzYwOTg_beceb83a-f4bf-498c-8f43-2ad44e2d800a"
      unitRef="usd">86100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzYtNy0xLTEtMzYwOTg_25c0efc2-e6b2-453f-8052-03a1028d457f"
      unitRef="usd">-142100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctMS0xLTEtMzYwOTg_5eb80016-f533-4f59-8d7a-83861eb271e4"
      unitRef="usd">630100000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctMy0xLTEtMzYwOTg_5027075b-ca65-4bb0-ba35-8f1a07eaba77"
      unitRef="usd">587200000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctNS0xLTEtMzYwOTg_e50d7a6d-6e6f-41df-9a90-e698dab1b967"
      unitRef="usd">79300000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzctNy0xLTEtMzYwOTg_4d6afcbb-6e55-4332-8366-d039d4df046d"
      unitRef="usd">75100000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktMS0xLTEtMzYwOTg_fd26185b-eab0-4cb0-bf6e-9ebef874ce0d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktMy0xLTEtMzYwOTg_d811767f-ff94-4c70-8d67-977623bfa20b"
      unitRef="usd">2200000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktNS0xLTEtMzYwOTg_0c7881e3-6cdb-4c1c-a568-f0c679163bc6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzktNy0xLTEtMzYwOTg_bd188ecf-cf81-4ca6-ab65-7b7c712ea2bc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTEtMS0xLTM2MDk4_f1bce172-4a8c-4d3f-a8ad-44cdb27c64a7"
      unitRef="usd">-173100000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTMtMS0xLTM2MDk4_5ae2cf1f-e5a0-449b-9bd0-80d41db5999b"
      unitRef="usd">245100000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTUtMS0xLTM2MDk4_949d132a-69ff-4ddc-95e1-29c8bbff38ea"
      unitRef="usd">-6200000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzEwLTctMS0xLTM2MDk4_743c6d54-8e38-465e-b9d1-871e0c28f783"
      unitRef="usd">800000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTEtMS0xLTM2MDk4_ae373dcd-f7f5-4c6e-8b19-b0889d29429a"
      unitRef="usd">17565000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTMtMS0xLTM2MDk4_9d83d118-b45b-4286-a8dc-0c02b046335f"
      unitRef="usd">18225500000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTUtMS0xLTM2MDk4_5f0cb63a-c3c2-4641-b694-10310089f8f8"
      unitRef="usd">1663800000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxZmJjZmI2ZDNlM2I0ODI1ODY2Y2M5NDI2MjhkZjI4OC90YWJsZXJhbmdlOjFmYmNmYjZkM2UzYjQ4MjU4NjZjYzk0MjYyOGRmMjg4XzExLTctMS0xLTM2MDk4_b81bfcf3-088d-40c0-95e7-3542242a8644"
      unitRef="usd">1753700000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDI3_8124ec18-4239-465a-ae07-986d983236a3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,579.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,227.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,458.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;131.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(630.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(122.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,416.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,361.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtMS0xLTEtMzYwOTg_1b2f36bd-998e-4e45-a919-87d00e25413a"
      unitRef="usd">14579000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtMy0xLTEtMzYwOTg_63f8bd3b-9cc2-407a-a38f-04354a092a8f"
      unitRef="usd">12858000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtNS0xLTEtMzYwOTg_b068ba71-35bb-4800-91e7-f665fe924b0e"
      unitRef="usd">3227000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9fd80bbb97874a039463577583da19c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzEtNy0xLTEtMzYwOTg_55cd5cb3-b478-4675-b35a-c960a8f7b7a3"
      unitRef="usd">2768200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItMS0xLTEtMzYwOTg_f1a58075-a707-417f-b83a-edb1dd6d0d14"
      unitRef="usd">2458100000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItMy0xLTEtMzYwOTg_78cb17e2-bbb7-420f-ac7a-f60050197cd2"
      unitRef="usd">1802400000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItNS0xLTEtMzYwOTg_e54d5879-4ab8-4190-99d2-25c6f7b2e608"
      unitRef="usd">202600000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzItNy0xLTEtMzYwOTg_78c8a465-25ce-4570-b1ae-c2430498af99"
      unitRef="usd">539000000.0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtMS0xLTEtMzYwOTg_ef8b48aa-0244-4ef1-9926-f57115b4e36f"
      unitRef="usd">131200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtMy0xLTEtMzYwOTg_84b05180-c4a0-4379-a858-7d3626085bd8"
      unitRef="usd">318800000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtNS0xLTEtMzYwOTg_51fb6741-d4e8-4e12-8ce6-988b7903f729"
      unitRef="usd">11100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzMtNy0xLTEtMzYwOTg_fafba15f-747b-4b74-a920-533f80f378b4"
      unitRef="usd">-5100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtMS0xLTEtMzYwOTg_ace3df89-f5c2-40a2-b02e-db2b32edbf49"
      unitRef="usd">630100000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtMy0xLTEtMzYwOTg_e2a2ba40-d5c2-4abe-8cf6-883d05005e03"
      unitRef="usd">587200000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtNS0xLTEtMzYwOTg_7da5cab7-a296-4a43-ac80-84cab0306cef"
      unitRef="usd">79300000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzQtNy0xLTEtMzYwOTg_adb712fb-ff51-452e-86a4-755fa274a978"
      unitRef="usd">75100000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtMS0xLTEtMzYwOTg_db8b0cc8-5fc9-4ddb-9cef-2088b9b1bb62"
      unitRef="usd">-122200000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtMy0xLTEtMzYwOTg_f76d5812-0a0f-469b-928a-ccb7c6f4add6"
      unitRef="usd">187000000.0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtNS0xLTEtMzYwOTg_d8e3b6b0-1f84-444e-90ae-315a55be3f62"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzUtNy0xLTEtMzYwOTg_fefc52f7-d70b-4e1c-8835-81d02b2c70f9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtMS0xLTEtMzYwOTg_9c809b23-a6b6-481a-9e96-416871ece78a"
      unitRef="usd">16416000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtMy0xLTEtMzYwOTg_aa4cfe89-45f1-4acc-b53e-13710dfd1f33"
      unitRef="usd">14579000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtNS0xLTEtMzYwOTg_abca3f1b-3446-4569-937a-8f2edbe62347"
      unitRef="usd">3361400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2NmUyOGNiM2U2MzY0MDczODM5M2E4Njc0N2FlZjRmZC90YWJsZXJhbmdlOjY2ZTI4Y2IzZTYzNjQwNzM4MzkzYTg2NzQ3YWVmNGZkXzYtNy0xLTEtMzYwOTg_6d84e45c-e397-44fc-8754-57f70f92911c"
      unitRef="usd">3227000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDIw_bf74edf5-9f86-43ca-9df5-a24b7f9e71c8">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,149.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,646.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,697.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,473.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,908.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(497.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(117.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,770.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,082.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtMS0xLTEtMzYwOTg_71fbd14d-9075-4b9d-9dff-ad8371077631"
      unitRef="usd">-1149000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtMy0xLTEtMzYwOTg_979de631-36aa-40bd-85c0-5b8bdb2a74ea"
      unitRef="usd">-3646500000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtNS0xLTEtMzYwOTg_34f53465-fbe0-4aca-a1d8-8fa3ff545d34"
      unitRef="usd">1697600000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzAtNy0xLTEtMzYwOTg_3fc99abf-75d9-4d65-afd3-dc63b4edb4e0"
      unitRef="usd">1473300000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtMS0xLTEtMzYwOTg_fc6ea856-d53d-487c-ac34-3f607c10d35d"
      unitRef="usd">-3908200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtMy0xLTEtMzYwOTg_94ec2bf6-cf3d-455b-a4f3-97482a685e28"
      unitRef="usd">-6515500000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtNS0xLTEtMzYwOTg_1dfe51e8-032d-48a1-84de-0ec3bf82af71"
      unitRef="usd">497200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzEtNy0xLTEtMzYwOTg_b26e39a7-308d-451b-9a3d-b0cfc799019a"
      unitRef="usd">349100000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItMS0xLTEtMzYwOTg_a7b12604-74ae-427d-ae5b-0a1669eb9d25"
      unitRef="usd">11200000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItMy0xLTEtMzYwOTg_7726226b-ef34-4fca-bb01-3ab871606d6e"
      unitRef="usd">15400000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItNS0xLTEtMzYwOTg_ae79a697-5e16-4a0e-ba65-1129d188501a"
      unitRef="usd">-117600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzItNy0xLTEtMzYwOTg_46178404-03c4-4d38-974c-13227e86af67"
      unitRef="usd">-177600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtMS0xLTEtMzYwOTg_4a0c870c-edaa-4043-afa3-a803a3b3a722"
      unitRef="usd">2770400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtMy0xLTEtMzYwOTg_bd5ac25c-b15c-4bab-a772-ba9dc143f7b3"
      unitRef="usd">2884400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtNS0xLTEtMzYwOTg_a843aeeb-b276-4efd-b879-eb743eb50b62"
      unitRef="usd">1082800000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphZThkMzkwOTExNmU0ZjgyYTU2M2U3MmFlMDQ4ZDE2NC90YWJsZXJhbmdlOmFlOGQzOTA5MTE2ZTRmODJhNTYzZTcyYWUwNDhkMTY0XzMtNy0xLTEtMzYwOTg_67af63d9-1d77-4fd8-9cf4-29541ae7b52c"
      unitRef="usd">946600000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzEz_03493948-a606-4206-b4bd-7604ea1a427f">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the consolidated balance sheet consisted&#160;of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;668.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,910.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,749.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,878.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(204.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (income) loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,919.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,530.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(614.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(526.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,770.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,082.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtMS0xLTEtMzYwOTg_ae7c6462-41c1-48c1-b4e0-5ca1b9288d36"
      unitRef="usd">668500000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtMy0xLTEtMzYwOTg_0380943a-62b1-4f31-a814-dd0299ff770b"
      unitRef="usd">299600000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtNS0xLTEtMzYwOTg_c48636b7-9ae6-4162-9a96-6bab338e8e9a"
      unitRef="usd">1910200000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzEtNy0xLTEtMzYwOTg_96360a76-ca92-4c57-a265-896c7c463b33"
      unitRef="usd">1697000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItMS0xLTEtMzYwOTg_3b183628-9827-4dca-a38a-822a40562ae1"
      unitRef="usd">68300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItMy0xLTEtMzYwOTg_ec07e48e-8990-4f2d-a321-54cfbdc29d1e"
      unitRef="usd">67900000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItNS0xLTEtMzYwOTg_0f2ed45c-a94c-4256-a0d2-aa669f973bf5"
      unitRef="usd">7900000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzItNy0xLTEtMzYwOTg_c332f283-8034-444c-a54c-48d5fb3312f2"
      unitRef="usd">7400000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtMS0xLTEtMzYwOTg_71611946-0ec1-49b5-bb8c-bbbffab92777"
      unitRef="usd">1749300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtMy0xLTEtMzYwOTg_8333c9b6-cafe-4e47-b0f1-724fc180a7de"
      unitRef="usd">3878200000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtNS0xLTEtMzYwOTg_914b3df1-8e6a-4531-a64a-ed60c88491f2"
      unitRef="usd">204800000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzMtNy0xLTEtMzYwOTg_a403b360-ff98-4dcb-9eb1-409a55e956a2"
      unitRef="usd">216300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtMS0xLTEtMzYwOTg_02820799-952d-4a44-8d30-2a96af82356a"
      unitRef="usd">3919500000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtMy0xLTEtMzYwOTg_3ceeab87-ec78-4f22-8ea8-e84e9f215bc9"
      unitRef="usd">6530900000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtNS0xLTEtMzYwOTg_28a70fb2-dcb7-497d-a1ad-dd686eb6c532"
      unitRef="usd">-614700000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzQtNy0xLTEtMzYwOTg_61b11d24-8eb0-4325-89e3-8b2662c4a334"
      unitRef="usd">-526700000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtMS0xLTEtMzYwOTg_49c94d2f-3bc9-40c7-9ea6-ffb348441cd8"
      unitRef="usd">2770400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtMy0xLTEtMzYwOTg_82d51313-9493-4c41-83ec-74aaedc9ecf9"
      unitRef="usd">2884400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtNS0xLTEtMzYwOTg_d8083ab5-75dd-4ca8-a1e9-08fa4b83b701"
      unitRef="usd">1082800000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTphYTQxM2Q0NzZkZDQ0ZTdlODYyNGYxMmQ2ZDI5ZmNlZi90YWJsZXJhbmdlOmFhNDEzZDQ3NmRkNDRlN2U4NjI0ZjEyZDZkMjlmY2VmXzUtNy0xLTEtMzYwOTg_946a8028-27dd-4987-9d4b-15ed0ad25ec4"
      unitRef="usd">946600000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM0MDg0ODYwNDc2MjU2_0510a535-40fd-47e6-b977-833fb559d880"
      unitRef="usd">-750400000</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzE0ODA_8f2a3252-cbb8-403b-af7d-f9233e80bdc4"
      unitRef="usd">2130000000</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzgz_9e36c983-8f72-436b-9811-87548db5a55f">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our weighted-average assumptions as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItMS0xLTEtMzYwOTg_2102911f-2dda-4fb1-9634-6b4465506d15"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItMy0xLTEtMzYwOTg_6ed22668-7418-4ae7-a313-93c90294ef4e"
      unitRef="number">0.024</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItNS0xLTEtMzYwOTg_207f22dd-cc20-42c1-b9f5-30b9d3d0ea30"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItNy0xLTEtMzYwOTg_c3275a96-0938-4310-a290-7510e2718faa"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItOS0xLTEtMzYwOTg_037093f3-5822-4e25-b175-43e8d1570dfb"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i9fd80bbb97874a039463577583da19c4_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzItMTEtMS0xLTM2MDk4_33ec5cc0-a149-4df9-9fdd-47a80ef6c54c"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtMS0xLTEtMzYwOTg_3f4c0466-177b-4c63-8192-bb48a9976691"
      unitRef="number">0.024</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtMy0xLTEtMzYwOTg_fbbb5fa8-e1cf-4a68-af78-425234003904"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtNS0xLTEtMzYwOTg_c1e39720-bd29-46e6-8fe8-787889d77061"
      unitRef="number">0.040</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtNy0xLTEtMzYwOTg_734e4c97-3015-4cb5-ad80-007154742974"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtOS0xLTEtMzYwOTg_f63d4065-2c9a-4971-9873-235e1524fd5c"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzMtMTEtMS0xLTM2MDk4_ef2a54a9-2319-4489-ac9d-d41739a75588"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzQtMS0xLTEtMzYwOTg_a3cbfb1b-09ba-4db8-814e-7b44abece92f"
      unitRef="number">0.035</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzQtMy0xLTEtMzYwOTg_0d9715e3-d4d3-4590-b175-faad0f369abd"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i4f87d43e733a4aae95d03ad94fe423bc_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzQtNS0xLTEtMzYwOTg_6c2f139c-ddc1-40b8-b2e6-9ad0fdd7fe42"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzUtMS0xLTEtMzYwOTg_8e634ea1-ddb9-4561-85c3-94b351f0ade0"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzUtMy0xLTEtMzYwOTg_c3f64818-f09b-4529-90dd-59e4e2b281a1"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzUtNS0xLTEtMzYwOTg_1ea4d285-6e67-4f97-80f8-c1ccb58b8885"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtMS0xLTEtMzYwOTg_31d4552e-71eb-42e8-8327-d7f1a6c1c105"
      unitRef="number">0.068</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtMy0xLTEtMzYwOTg_2f9c26d3-f170-4c4a-bfac-08e86c8f706d"
      unitRef="number">0.073</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtNS0xLTEtMzYwOTg_c0cbee36-2fab-4276-b2d0-455510ddf07c"
      unitRef="number">0.074</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtNy0xLTEtMzYwOTg_50e4fa13-cad0-4e1d-9e89-9657533927dc"
      unitRef="number">0.050</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtOS0xLTEtMzYwOTg_e27d75bd-b3f9-4201-a30c-03322f1cb6cd"
      unitRef="number">0.060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpjNjk5ODczMjFlYjA0YjdiYTk4YTg5ZWE1MmUxZjFiNy90YWJsZXJhbmdlOmM2OTk4NzMyMWViMDRiN2JhOThhODllYTUyZTFmMWI3XzYtMTEtMS0xLTM2MDk4_af7e4f1b-214f-4e52-a053-9d14ed269d94"
      unitRef="number">0.060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzI0_cbb3ae6e-d514-4b44-bd37-3c4c57cc083e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retiree health benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtMS0xLTEtMzYwOTg_3314aee8-b86c-4655-ba6c-29778243ca69"
      unitRef="usd">631900000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtMy0xLTEtMzYwOTg_dc48915f-22ba-4260-bd92-7837cd75edb7"
      unitRef="usd">641800000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtNS0xLTEtMzYwOTg_aea64740-ac1a-4e72-a6d0-e244586bc92c"
      unitRef="usd">669400000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtNy0xLTEtMzYwOTg_c17aa179-7b7f-405b-9aeb-88172cffff7d"
      unitRef="usd">686600000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtOS0xLTEtMzYwOTg_700d9d47-1630-497a-8775-965301023d75"
      unitRef="usd">707500000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzEtMTEtMS0xLTM2MDk4_b6a30449-0a9e-4e0e-bdf5-f6777b9701ca"
      unitRef="usd">3919700000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItMS0xLTEtMzYwOTg_67ffa697-d3b7-4c36-a8eb-3f81ae01a8ea"
      unitRef="usd">89400000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItMy0xLTEtMzYwOTg_49b8ba53-5e23-49c7-bf2b-0ecd7395ecc4"
      unitRef="usd">89500000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItNS0xLTEtMzYwOTg_9648d4f4-fd2c-4cee-b2da-0bbf37feb8f7"
      unitRef="usd">93100000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItNy0xLTEtMzYwOTg_930cbb4e-7f67-4fde-a3b9-63c3d8b99590"
      unitRef="usd">93900000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItOS0xLTEtMzYwOTg_f7ac388a-5c30-4f14-a7ea-d31e81866ca6"
      unitRef="usd">94500000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo1NDFkNGVkODlhOTY0NGUyOWRhZDhjNTZkNjhlZTY1Zi90YWJsZXJhbmdlOjU0MWQ0ZWQ4OWE5NjQ0ZTI5ZGFkOGM1NmQ2OGVlNjVmXzItMTEtMS0xLTM2MDk4_ba2b3085-03a5-4143-87f7-540a9703fb01"
      unitRef="usd">477700000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDIz_d223db18-a2fc-4f9d-b4e5-3989427757a7">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,360.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,770.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,542.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,824.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzEtMS0xLTEtMzYwOTg_13c63b25-24ba-4daf-ae66-615f7d886f55"
      unitRef="usd">3360300000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzEtMy0xLTEtMzYwOTg_e9fd3051-fa22-4241-9d4c-55b889a05069"
      unitRef="usd">15770700000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ie685003a00ac4b9e88ea5a5aad91acf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzItMS0xLTEtMzYwOTg_398b7853-be87-4172-ad6d-68778fd0e991"
      unitRef="usd">1542800000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ica0f6e15b180491b9202fefd783ba908_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTozODcyMWUyN2RhNGM0OTcyOWQyMDIxM2U2NDc0NDdjYi90YWJsZXJhbmdlOjM4NzIxZTI3ZGE0YzQ5NzI5ZDIwMjEzZTY0NzQ0N2NiXzItMy0xLTEtMzYwOTg_2e91c4fe-1148-4615-92b1-7ba7cb96c7b0"
      unitRef="usd">11824400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzg0_75a78f45-e592-4b6b-a891-d09b2abbb240">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health &lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,532.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,682.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;212.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;973.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,824.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItMS0xLTEtMzYwOTg_8301ca0f-991b-403c-bfa4-a01c739013df"
      unitRef="usd">2532000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItMy0xLTEtMzYwOTg_f367df91-ae62-4e22-ad07-4ac8a9abddd6"
      unitRef="usd">14682300000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItNS0xLTEtMzYwOTg_781c9e09-b584-47b2-93e0-1a1d60f64a21"
      unitRef="usd">212600000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzItNy0xLTEtMzYwOTg_3bbc2ed2-8f3a-4c8b-8800-0db6eaf2ac9d"
      unitRef="usd">223800000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtMS0xLTEtMzYwOTg_d5958d10-b6bc-4077-a433-b8d0d045fe44"
      unitRef="usd">973400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtMy0xLTEtMzYwOTg_dd9ba72d-2fe6-4d93-9d5f-a020e961a5c3"
      unitRef="usd">11824400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtNS0xLTEtMzYwOTg_f795095a-b821-4f62-a60a-4b9585340bf5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTo2N2JkZTRkZTllOTI0OGY3OTNkZWQ5NDJhOGVkNGY3Ni90YWJsZXJhbmdlOjY3YmRlNGRlOWU5MjQ4Zjc5M2RlZDk0MmE4ZWQ0Zjc2XzMtNy0xLTEtMzYwOTg_8abe2f88-9980-465e-924a-df38d9f6da18"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzMyNzA_5b490bf6-2138-4d4e-a107-f20607f149f2"
      unitRef="usd">16440000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzMyNzc_2db87658-0bfe-4301-8a97-9d86273ed47a"
      unitRef="usd">17030000000.00</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzM0_83fb0948-ba87-4b25-a6b9-57533579b285">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit expense included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;369.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;337.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(949.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(146.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;249.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(120.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtMS0xLTEtMzYwOTg_057684dc-14cc-445b-9080-24da7dd8c637"
      unitRef="usd">369200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtMy0xLTEtMzYwOTg_236d3a2d-372f-42bf-899d-53f8ef0bf85b"
      unitRef="usd">325500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtNS0xLTEtMzYwOTg_99e3dc91-0354-4220-9c8d-5d734eb6243b"
      unitRef="usd">250400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtNy0xLTEtMzYwOTg_e1680e48-db14-4b5a-aab8-8d54502a0dd1"
      unitRef="usd">49200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtOS0xLTEtMzYwOTg_6f1ae7e8-d565-4f32-ba0f-b9ee52a3520e"
      unitRef="usd">40800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzMtMTEtMS0xLTM2MDk4_60d4cca5-9f9d-49ae-8cc3-6dc27fd9fb9f"
      unitRef="usd">36300000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtMS0xLTEtMzYwOTg_9f607502-6587-4b52-9dac-d1f609d8b7ad"
      unitRef="usd">337800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtMy0xLTEtMzYwOTg_83f1005c-cfdc-4e98-908f-299a8e2eaebe"
      unitRef="usd">425800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtNS0xLTEtMzYwOTg_1813a6b8-6b93-47db-8336-78a8c2880a69"
      unitRef="usd">486000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtNy0xLTEtMzYwOTg_aa914e73-14de-43aa-88fe-c1dd1e70ae84"
      unitRef="usd">32500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtOS0xLTEtMzYwOTg_2d2cb9cf-9d64-4937-aad9-ac67f15ac88e"
      unitRef="usd">43700000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzQtMTEtMS0xLTM2MDk4_aef6c320-3960-4365-95e5-9ca35065138c"
      unitRef="usd">58000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtMS0xLTEtMzYwOTg_9e367a0b-79eb-4c6f-a969-9319d1bf50ec"
      unitRef="usd">949300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtMy0xLTEtMzYwOTg_387366cc-1cd9-4b93-bc83-be5c1c72ebf2"
      unitRef="usd">901500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtNS0xLTEtMzYwOTg_33706b23-9790-498c-aab6-c972a9181b53"
      unitRef="usd">839600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtNy0xLTEtMzYwOTg_dad9284a-5df1-46c9-8186-42dc5c6714e4"
      unitRef="usd">146200000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtOS0xLTEtMzYwOTg_cd3c7937-87ae-489b-a042-56f5c3f4c6bb"
      unitRef="usd">158100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzUtMTEtMS0xLTM2MDk4_e593f05b-717c-4b4c-ad5e-b60a01be7b87"
      unitRef="usd">144300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtMS0xLTEtMzYwOTg_7dd6c289-1c57-4de3-aee3-052cbfa14f76"
      unitRef="usd">4200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtMy0xLTEtMzYwOTg_9cd2ff18-efbf-43d7-9821-ac5cd1105d0f"
      unitRef="usd">4500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtNS0xLTEtMzYwOTg_371712b8-ca2f-44fc-bc61-c70755bfc72a"
      unitRef="usd">6100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtNy0xLTEtMzYwOTg_bd999046-a7d3-42b0-b06a-cf457346b789"
      unitRef="usd">-59600000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtOS0xLTEtMzYwOTg_579a1630-d022-4a67-8da3-42bceef0f0a4"
      unitRef="usd">-59500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzYtMTEtMS0xLTM2MDk4_48677d20-0d24-4103-827e-e587683d3a01"
      unitRef="usd">-62900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctMS0xLTEtMzYwOTg_13097c8b-19e6-4d4a-8934-58647ee917c9"
      unitRef="usd">-487700000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctMy0xLTEtMzYwOTg_2d127e62-1cf8-4a2a-9243-4545ba570e88"
      unitRef="usd">-396300000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctNS0xLTEtMzYwOTg_c22039c1-591d-4b9b-812a-45d4da1e6ec8"
      unitRef="usd">-284900000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctNy0xLTEtMzYwOTg_60450550-7aad-4770-bfeb-32bccb2bebe1"
      unitRef="usd">-3200000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctOS0xLTEtMzYwOTg_877f5aa0-e87c-4f01-b597-b1bc696648be"
      unitRef="usd">3000000.0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzctMTEtMS0xLTM2MDk4_359a45b0-9155-46c5-9792-5091ab202444"
      unitRef="usd">-1900000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtMS0xLTEtMzYwOTg_ab55a35c-e1ed-40c6-ab95-4b40bb2e6b12"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtMy0xLTEtMzYwOTg_087dd47d-9cea-44b3-a1fb-6ed8910dc455"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtNS0xLTEtMzYwOTg_9c571ef7-5469-4b7c-88ba-716c9a21a087"
      unitRef="usd">-2200000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtNy0xLTEtMzYwOTg_84cadd56-8920-48bd-8117-2b9502714f35"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtOS0xLTEtMzYwOTg_bd201c1f-8a76-4791-9b01-5138285f51d5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzgtMTEtMS0xLTM2MDk4_012b36de-8199-422c-a28c-7a9745260249"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTEtMS0xLTM2MDk4_1eebffb2-5194-4134-8738-1d211d986eec"
      unitRef="usd">249600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTMtMS0xLTM2MDk4_186e5804-1082-430b-a3d6-96efb78d9a0d"
      unitRef="usd">250600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTUtMS0xLTM2MDk4_e102dd37-1222-45a2-bc0d-28e2f43a3e6f"
      unitRef="usd">190000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTctMS0xLTM2MDk4_607588fc-f47c-4fb0-a2c5-0bf74e28c360"
      unitRef="usd">-120900000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTktMS0xLTM2MDk4_e6c6beda-538d-4c65-be79-de479ad38c6c"
      unitRef="usd">-136100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToxMTdlMjFiNjY2NTc0ZThjOTJhNWZkNzQ2ODA5Zjc4YS90YWJsZXJhbmdlOjExN2UyMWI2NjY1NzRlOGM5MmE1ZmQ3NDY4MDlmNzhhXzEwLTExLTEtMS0zNjA5OA_3f30b2f1-0b29-497d-839b-fe4d1f4b80d5"
      unitRef="usd">-111000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMzg4_380d0abb-f53c-4796-a760-9489e01bbc33">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020, and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined&#160;Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree&#160;Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss) arising during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,072.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial (gain) loss included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss) during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,611.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,158.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItMS0xLTEtMzYwOTg_0a110182-07ee-4fc7-9854-9be446bbe05a"
      unitRef="usd">2072400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItMy0xLTEtMzYwOTg_8f13c2f3-5194-4fc7-881b-23c4a935cbe5"
      unitRef="usd">-663000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItNS0xLTEtMzYwOTg_55c073e8-0d13-4be6-90d9-794dfc18ec8f"
      unitRef="usd">-1461000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItNy0xLTEtMzYwOTg_76464467-d753-4c3a-a0e1-df5f46b60cb5"
      unitRef="usd">142500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItOS0xLTEtMzYwOTg_074eba3e-f791-412d-9c75-367eb708a1a2"
      unitRef="usd">238800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzItMTEtMS0xLTM2MDk4_62205767-92a6-48a3-bd93-a6215ab370df"
      unitRef="usd">246100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtMS0xLTEtMzYwOTg_d069a845-b1fe-44d5-8f1f-489686752a76"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtMy0xLTEtMzYwOTg_a20e6859-a09d-4ae0-b3f3-9890afb3acc7"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtNS0xLTEtMzYwOTg_9160f660-1fa8-42f7-a1ce-e6d0374a3f38"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtNy0xLTEtMzYwOTg_254d917a-77b3-4836-acdc-7f1b6bbc4178"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtOS0xLTEtMzYwOTg_b92dce56-bc30-41e3-8333-f3f6904a2f8a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzMtMTEtMS0xLTM2MDk4_7fb9cc0c-2f8e-41d5-ba71-3639c139be9e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtMS0xLTEtMzYwOTg_dfc51e88-6e6f-4f3c-867d-545741c982e7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtMy0xLTEtMzYwOTg_4dee4cba-d3f9-485e-80e4-eb53d5328678"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtNS0xLTEtMzYwOTg_2956b16c-0136-41a3-9f4d-8b1352cd9c66"
      unitRef="usd">19000000.0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtNy0xLTEtMzYwOTg_c4066ded-33d6-4465-aef3-75eba6c45756"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtOS0xLTEtMzYwOTg_eb2bbdf7-2f30-416e-a899-4e11e52eb5b6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzQtMTEtMS0xLTM2MDk4_e544fb3c-c12a-4de1-89b8-2b95e8388420"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtMS0xLTEtMzYwOTg_9ec1e43c-de5f-4948-9b3e-6eb61ce77da7"
      unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtMy0xLTEtMzYwOTg_74d251ca-62ae-4a11-a2ed-19e0ca8eb446"
      unitRef="usd">4500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtNS0xLTEtMzYwOTg_a05d4534-c85c-4637-b817-909b2902d19f"
      unitRef="usd">6100000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtNy0xLTEtMzYwOTg_01d51f35-bdde-4e98-a449-5e930f34f43c"
      unitRef="usd">-59600000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtOS0xLTEtMzYwOTg_851491f7-4460-47a8-9cdf-759b8e25d7bb"
      unitRef="usd">-59500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzUtMTEtMS0xLTM2MDk4_2d5dc73c-8acc-4993-a060-a7dd1d76cfdf"
      unitRef="usd">-62900000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtMS0xLTEtMzYwOTg_3474d115-9d2b-4ea1-991f-62990f283993"
      unitRef="usd">487700000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtMy0xLTEtMzYwOTg_9bfbe002-e2ac-4fff-b0c1-fbd537a5e354"
      unitRef="usd">396300000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtNS0xLTEtMzYwOTg_4e4eef92-1015-464b-8759-914e6835ddf3"
      unitRef="usd">284900000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtNy0xLTEtMzYwOTg_7d20de1f-da62-4631-b9c5-1469dc72b406"
      unitRef="usd">3200000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtOS0xLTEtMzYwOTg_0067174b-960d-4293-bcc9-d628be2aa3c5"
      unitRef="usd">-3000000.0</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzYtMTEtMS0xLTM2MDk4_901c13f9-86fb-45d5-9052-ebf91825602f"
      unitRef="usd">1900000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctMS0xLTEtMzYwOTg_f5a47889-b615-4f66-b067-bf4a8d23fcf9"
      unitRef="usd">47200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctMy0xLTEtMzYwOTg_1482ef1d-73cf-493f-9cb5-7eb91ef858be"
      unitRef="usd">-71500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctNS0xLTEtMzYwOTg_a5e83935-774a-47b0-be07-a3e21d9a73b6"
      unitRef="usd">-7700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctNy0xLTEtMzYwOTg_99746818-0100-4eb3-bc89-adfd5d7f0ecd"
      unitRef="usd">1900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctOS0xLTEtMzYwOTg_29b9fbee-9d8a-43f3-8aa3-a1e54717d2e0"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzctMTEtMS0xLTM2MDk4_2d7750f6-d1fe-4255-9460-640c76b195ac"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtMS0xLTEtMzYwOTg_3d84b571-17bf-4a05-90b5-82918417f0e1"
      unitRef="usd">-2611500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="id369ccb5dbb6413bb99fcbfb67aab216_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtMy0xLTEtMzYwOTg_abdf66f8-720d-46e1-a880-9408fb5b65aa"
      unitRef="usd">335900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i3c9d02813c614efa9bd46b87dedd140c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtNS0xLTEtMzYwOTg_a6decb57-88f4-4410-afd0-ca112b7a72fc"
      unitRef="usd">1158700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i3801f5e548df453081ee2e595cad72da_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtNy0xLTEtMzYwOTg_32fe5a96-831e-4c60-899e-6e0b46a28315"
      unitRef="usd">-88000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i9f1f511dd064405daed63f752fbda15e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtOS0xLTEtMzYwOTg_ac3ef7b0-5169-4a3b-ad25-3c67fae91962"
      unitRef="usd">-178700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="if2cc2aaf246247c4ba74bdc22af26b59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTpmYjVkNTZlNzc3ZTM0ZjYzYWU1ODExZTI4MDVjN2U4Yi90YWJsZXJhbmdlOmZiNWQ1NmU3NzdlMzRmNjNhZTU4MTFlMjgwNWM3ZThiXzgtMTEtMS0xLTM2MDk4_c070d1af-f16c-423a-88fb-9d55d024c0fa"
      unitRef="usd">-188700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM4ODA_75efb26a-650b-4130-9aa9-87944d1a8a0c"
      unitRef="usd">167300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM4ODQ_a56d9aff-33b2-45ba-8402-ecbc0f6002c3"
      unitRef="usd">164300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzM4OTI_95315920-8d53-4d2c-a3db-b09c4bd27558"
      unitRef="usd">145200000</us-gaap:DefinedContributionPlanCostRecognized>
    <lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzQ0MzE_177d5ca4-6812-45e0-a5ac-6e3d959cad4a"
      unitRef="number">0.80</lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i968dbf693bb54261a0cad1975a0f50cb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzYxMjY_c5cb8082-0ab3-45d3-b6f1-6755b27b0adb"
      unitRef="number">0.75</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i41cc8775b020470392c03bca0264fe6d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzYxNTI_121dd39f-04c9-49b0-ab9b-93af1cd825c8"
      unitRef="number">0.25</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyNDA5_c9d754e4-82c8-4de9-b2b0-126c4c795bb2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2021 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,816.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,416.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i673f610f07dd4af7a79e6fae5b2a77f2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtMS0xLTEtMzYwOTg_298f3249-d4e3-4565-994c-adcac701c0c4"
      unitRef="usd">1325400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i764e26f54c2b4e88b9f325ce95d6d91a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtMy0xLTEtMzYwOTg_1c35f83a-d1c9-44bb-9413-4d1db8cf2a05"
      unitRef="usd">430400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if78fcffa5fcb4363b925527a37fdd04d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtNS0xLTEtMzYwOTg_07962594-2a4a-4e25-aa26-abfdf6e9864a"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia7cb49a7d1f0485eb5048fc42c817807_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtNy0xLTEtMzYwOTg_3218bf01-b0e2-4793-a26b-7a7850182ff1"
      unitRef="usd">1200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i51c7d73826fb4c3ea998d99f0cab890a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzQtOS0xLTEtMzYwOTg_b583efcb-6470-4af4-99b5-3a5cb54e5859"
      unitRef="usd">893700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1338ebe78ec64e74910cb8e168f15f3c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtMS0xLTEtMzYwOTg_486a10c0-3a86-45db-a140-aa1a974f9c24"
      unitRef="usd">2722700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12cb2759a4414f6a87de7960536796f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtMy0xLTEtMzYwOTg_30b3f97e-e63d-420e-9b3e-be6b30285b92"
      unitRef="usd">815000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a59bd989ed047e89cfeadb49552c829_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtNS0xLTEtMzYwOTg_1737f01f-9617-4186-9020-b5b33ee19daf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6b4ea41679f04d40a1f04042e79615f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtNy0xLTEtMzYwOTg_dbe96a33-320f-4820-97a5-cbf48b7e8585"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i913594ad00c9409d8b93872f5b5fbb98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzUtOS0xLTEtMzYwOTg_dc3a7064-e860-4b59-9fe8-ad8b9e252e8b"
      unitRef="usd">1907700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2bdaefce21c9475cb128cd1bec0b2b54_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctMS0xLTEtMzYwOTg_19fe0e8f-7ed6-443c-a530-c0e73d7f9548"
      unitRef="usd">4496000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i95b14f14bed9450fbcce11d6df4b26a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctMy0xLTEtMzYwOTg_a1e810aa-8592-4db5-ac81-01cb4b5fb972"
      unitRef="usd">2600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i603f1e71c9ed4e7b8d938450da375dbd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctNS0xLTEtMzYwOTg_961691a9-eb74-4ff5-9727-cf40a05cc135"
      unitRef="usd">3356600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d5edaf21db341aaa94c8e50e73bb216_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctNy0xLTEtMzYwOTg_ac6a3d5f-a8e9-4eff-bad1-3e4b3c16a4c0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1a706cd4ae4a48b185995bdd2f78fd3c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzctOS0xLTEtMzYwOTg_24457064-929c-42f2-8e35-7f9fbbdaa2bd"
      unitRef="usd">1136800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i78fc7d44d8cd48aea3c78cadc0049519_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtMS0xLTEtMzYwOTg_aabbe2df-44fc-48c6-bede-89db1e74f816"
      unitRef="usd">-1376200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b8bd8f7cd5b4670a3e7ff6635118b75_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtMy0xLTEtMzYwOTg_07e26b3c-e460-4f2b-bd33-47f88c3309e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f83daf4fca54e40bbaab49dd09cc5a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtNS0xLTEtMzYwOTg_5f78c8b7-df5c-41ff-a7d8-18db9cf6c330"
      unitRef="usd">-1376200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i31478b67a9a7415d8e22de1ce680a740_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtNy0xLTEtMzYwOTg_baef05eb-fa5e-41bd-91e0-d096dd10c436"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5636680a6e4e4350b3fad57180768fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzgtOS0xLTEtMzYwOTg_90902115-61e2-435e-bcb4-eed6120aa7b2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e43baf9dd8e4024aaad2773c4f843c2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktMS0xLTEtMzYwOTg_c5f91409-41d3-4713-8dde-9b2ba285fef1"
      unitRef="usd">611000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d32acfe18e3466fa5910b344222cd82_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktMy0xLTEtMzYwOTg_dae8bbbf-f63a-4e46-bdfc-e4027a0671fb"
      unitRef="usd">11300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iede2b770f3c64ba68bc39044be90f109_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktNS0xLTEtMzYwOTg_8eedf1e9-6b2f-40fb-9764-3666160d0c7c"
      unitRef="usd">250500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i96f7db50ad1c415288b9ea85aa6709fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktNy0xLTEtMzYwOTg_14a4f55f-6ec5-4aed-ae75-b96530fe1821"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a91711f8ddc4cb89e215732b94181ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzktOS0xLTEtMzYwOTg_f5101df8-5ae9-44d4-a1c2-63cfa25f0275"
      unitRef="usd">349100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d7aa0c503f5488795d936ac19312dad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTEtMS0xLTM2MDk4_8914f46f-8c87-4a39-b7a9-a1b5ebde893e"
      unitRef="usd">3046800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa35aec973a9495d8cfb4d1860d7f186_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTMtMS0xLTM2MDk4_a7ce1bde-e5eb-4d6f-9252-5aa16b6f30e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5278164416d440878ce7f8241506dad2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTUtMS0xLTM2MDk4_472659eb-949f-4a10-8f38-e8e7c39e9def"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i30503f9548ef49748f6c47f41c46b9fa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTctMS0xLTM2MDk4_13045646-4f72-4674-ad73-72ab88c65e29"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i692d2c7285d94749b0594132364bf602_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzExLTktMS0xLTM2MDk4_3508d68a-a226-46c7-8b24-8108c4eb8f67"
      unitRef="usd">3046800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i21e6e217adbf4a0bb420bbb79525b195_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTEtMS0xLTM2MDk4_d332e9e9-a9a9-45b0-af32-9fafc44f1b15"
      unitRef="usd">3816400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i230a704d2f5740a0b69a5d2fe32aea0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTMtMS0xLTM2MDk4_7e3df6d4-ca6a-487b-a487-de55a1fc05f9"
      unitRef="usd">2100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2dd8a47a67cb40659b5f2400ba2e2a97_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTUtMS0xLTM2MDk4_33289543-181d-4536-a75a-b3fa31db7925"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2a4af7abd8884c829ce2cf89b4eeb4a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTctMS0xLTM2MDk4_ec06ccb8-7955-4a8e-9ccc-d620b25f7560"
      unitRef="usd">5500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic0db00ed934147a0b1454ebbfb9605e9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEyLTktMS0xLTM2MDk4_e773a813-e634-4338-91d8-6213e5ded493"
      unitRef="usd">3808800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib91ba6b55fdf460aa45150043f7993d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTEtMS0xLTM2MDk4_2f757f12-f15a-4abe-9cc2-df91a4eac479"
      unitRef="usd">630300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9090de42c1e1431d880e89e365433af9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTMtMS0xLTM2MDk4_7a6ea320-04d4-4971-b6e0-3db042a46a1a"
      unitRef="usd">363800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9162ecb9fcdc4a8a88c76c029e0ec77f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTUtMS0xLTM2MDk4_749bb863-fb32-4e93-8b46-1c6252eb9e37"
      unitRef="usd">7500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib4b11998c76c4e07837a915345cd5625_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTctMS0xLTM2MDk4_0b3e5dde-cd33-43b7-84da-ff6baf71f91e"
      unitRef="usd">10700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74f60d47dcdc4aea9e98cfeaa8959089_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzEzLTktMS0xLTM2MDk4_ef021e79-b320-4030-a1ad-d63f827f75b8"
      unitRef="usd">248300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae4fe3ccc0a24e18ae11dc80ffeca0f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTEtMS0xLTM2MDk4_b85619b8-236f-4328-a217-6098ea7f29d2"
      unitRef="usd">1143600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e4e6aa2e94d4863a9d4c4d40db622ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTMtMS0xLTM2MDk4_f7619631-2dfa-47ca-8180-75adc1de115d"
      unitRef="usd">103200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ada8f6f4d09490b91888fc53f19799a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTUtMS0xLTM2MDk4_bae2649e-88c8-4c12-9015-9f7ce86e2fd3"
      unitRef="usd">263200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae8ba6c16b8a4854afcda9d5176c4082_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTctMS0xLTM2MDk4_069a766f-2874-4a6c-bd34-5469e479cd10"
      unitRef="usd">-2100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2fef9519e5cf4d83bb440f5dd2dff978_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE0LTktMS0xLTM2MDk4_1a50fba7-45e7-40d9-9dbe-f436acf68f4e"
      unitRef="usd">779300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTEtMS0xLTM2MDk4_6e9a5ba5-e6d5-476c-817c-667fd6a61715"
      unitRef="usd">16416000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20e10b3bce8240ed99c41e92c2c7c166_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTMtMS0xLTM2MDk4_fd693b1a-89ec-4ec5-8499-0a9308edb57f"
      unitRef="usd">1728400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i39b60c7852e34d32bfb74a52b2d6c8ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTUtMS0xLTM2MDk4_74fdd925-5684-4aed-8615-7f166403dd0d"
      unitRef="usd">2501700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i626717f8b3604479aa9d86b960ead4df_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTctMS0xLTM2MDk4_870f3049-dee9-45d7-9508-7384eaf03f75"
      unitRef="usd">15400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i93e68a551ac24824aab0b50cf96ac505_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE1LTktMS0xLTM2MDk4_d92b2a75-6021-43bb-8eba-8c43548a9b35"
      unitRef="usd">12170500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd41dfa5131b4ed8a3c4edff4cccd882_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTEtMS0xLTM2MDk4_4784c72f-6922-46a8-a631-f80cf4cefb7e"
      unitRef="usd">124700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6dfb78e31d4e43a48f83b015b72c519d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTMtMS0xLTM2MDk4_2ede7485-f12b-48eb-b5d9-179bbafdaa11"
      unitRef="usd">40900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i96d870bd1a8c432ebcf9c58cce764986_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTUtMS0xLTM2MDk4_f66598ac-32e6-4ec6-81e6-cdbdd6340a2f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i866e79b40fc84b748948629cdaf16e9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTctMS0xLTM2MDk4_3c855af6-ab22-45c5-98eb-7a81135ce8d5"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a07c54e28594ef985fae75cee518345_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzE5LTktMS0xLTM2MDk4_f5724da6-8dac-4158-b124-08b43021ed9b"
      unitRef="usd">83700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87f183c3cbbd4fda982cfd4dd42bb6ee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTEtMS0xLTM2MDk4_c4d4cfbf-2786-4512-9f4b-93da136ea694"
      unitRef="usd">180600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2e533a36459c459998922edcc7dc2e06_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTMtMS0xLTM2MDk4_91c8e5cd-c30b-420a-8343-f54ea1288607"
      unitRef="usd">47700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if3685410209c4742a6877711165cde44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTUtMS0xLTM2MDk4_7f37bd70-11c8-4072-9689-9f825f1469d5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i244b201723df412384c2a82e49dddb47_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTctMS0xLTM2MDk4_675cba5f-23f8-481b-ae48-6af40b34b671"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie223fdbc588545c7aa7794612858f25e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIwLTktMS0xLTM2MDk4_bcac8216-917e-45a8-bc0a-499d02ec0a47"
      unitRef="usd">132900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib44600c684d24718a1f3801f118c80eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTEtMS0xLTM2MDk4_07db63c8-db96-4792-9f5b-f793715c417f"
      unitRef="usd">102200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64a5f9dbd52e49c9964b39f2bb6a3117_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTMtMS0xLTM2MDk4_74f78cc9-885d-4ab4-a553-356bb24aaa51"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2a1acd17d36146009b635e6ac8876b00_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTUtMS0xLTM2MDk4_99e5e095-c248-40ce-8042-1f7cd927b650"
      unitRef="usd">80500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia121cc72798a41b99b32667d68124755_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTctMS0xLTM2MDk4_2dea557f-e8b0-466a-9976-4871e6443585"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5ddd772d1a82411e9d52cfd46b93391b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIyLTktMS0xLTM2MDk4_b58b6ff1-00b5-4562-9ddf-d0589c820889"
      unitRef="usd">21700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7bf0bc4572794f0bbc6996cb82ce99da_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTEtMS0xLTM2MDk4_8c1fb847-5b14-4222-b382-6c2c2e4838e7"
      unitRef="usd">51600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iec4a130b58aa4fc787b2559b8e658309_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTMtMS0xLTM2MDk4_d63d7d61-2c86-40d8-805b-919f0ed5e100"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6c2688876344ae09d2527a2174d8cfd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTUtMS0xLTM2MDk4_3b32ad05-8914-4ff7-aaae-2bf53f0f1e70"
      unitRef="usd">23700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3d399445e4a24b55856d4967cfbb5abd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTctMS0xLTM2MDk4_8cb8bc8e-b7f4-4e26-a0e6-cf7440ead918"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i35ff171bf7ca484fb1a1179c3b99e72a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzIzLTktMS0xLTM2MDk4_d3ff9fa9-2cd0-44a1-a7a8-4f4940299a5d"
      unitRef="usd">27900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38811147de6a4ae49619b0c6fb50b5fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTEtMS0xLTM2MDk4_ed4a6418-9a56-4c52-b856-38cd0d68e2f4"
      unitRef="usd">275400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if49b9ae457524259bb341c9357a21cb2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTMtMS0xLTM2MDk4_8cf7c041-e3b1-4bb6-bf1c-84721173ad7e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i109ad29c5c0843d19c3fb35636897f6a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTUtMS0xLTM2MDk4_e02f249f-e11f-4d71-bfeb-854c0a471bbc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i48c48fc80fbd4c02894b634f68421b19_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTctMS0xLTM2MDk4_d41cad4a-8fd2-4c40-9730-948a376c2a69"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i923f6a0606ca4c659014e936327d763e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI1LTktMS0xLTM2MDk4_bd20761c-b210-4287-9cb6-8c94cac26b0c"
      unitRef="usd">275400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia9ebd34478dc44aa94bd2cd5d0ae09b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTEtMS0xLTM2MDk4_863906c6-024a-4392-b93b-6b44cee0ccd7"
      unitRef="usd">317800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie4dbe652b11144049f9f252b2a082929_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTMtMS0xLTM2MDk4_b7c4e73d-942b-4e47-aa94-12d0ced2d67b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i126ac11b05304e3480af55e56aab89f9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTUtMS0xLTM2MDk4_0a3ddc41-fac6-414c-a88a-e2abc7cc70cf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1c1c1e97cbfa4338851f65cd304431ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTctMS0xLTM2MDk4_a74f0209-ddaa-4ecb-9b4f-774fd50d6a05"
      unitRef="usd">500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie15d1d4659da48ea849e744343f5a3d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI2LTktMS0xLTM2MDk4_dd19f7e4-29a5-4ea1-aef2-2ea6971632bc"
      unitRef="usd">317300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab573539a9a94f85bad389b1d078779b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTEtMS0xLTM2MDk4_f8e5db5b-7460-45b9-bbd5-f0e6b545122d"
      unitRef="usd">2166800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5f296c7bb394430981a1fb8d6838282a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTMtMS0xLTM2MDk4_7147ab39-c97e-418c-a112-3738a2fdac6e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i002c38a65f454861808977f397fda65d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTUtMS0xLTM2MDk4_ac1b79f7-05bd-411e-ad7c-bedcc28c259b"
      unitRef="usd">2166800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd94f2c6bb2e4e2fa5ffb39664bdf21d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTctMS0xLTM2MDk4_7e598e92-cf58-4ec0-ae45-03ea5de93c0c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3dad2404b29349fb8450d5b39364906f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI3LTktMS0xLTM2MDk4_5ed11ca1-b72a-4066-9775-c7f834ad0dd3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27235dedb8194dfe8ed6a11ba255ac26_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTEtMS0xLTM2MDk4_1e2d9dc9-50d6-4d82-98af-4da8b377a6e4"
      unitRef="usd">36200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i41b97858557449bcbd42057fb05bf2b2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTMtMS0xLTM2MDk4_8d7af191-a68d-4cfb-8fed-92bdaa9921fc"
      unitRef="usd">34500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica4dad88d4f64153b1ec36fb80920aa3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTUtMS0xLTM2MDk4_b07ed90e-0063-4f8e-abbd-5936d1f18f7b"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia16f68bc36bd4ad9878079914f8e282b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTctMS0xLTM2MDk4_ee8c4be8-ae82-4ade-82fb-57ff89441230"
      unitRef="usd">1000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if3b81a674c8349d5805272c34a30b9fa_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI4LTktMS0xLTM2MDk4_e0f4dca3-b0f8-42e6-a66a-9f1283064701"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iff2f3b2cbe4349ca9de603412aa190c2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTEtMS0xLTM2MDk4_bebf0c97-5f32-4785-a61f-5c9d1a33253b"
      unitRef="usd">106100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebe2b2b2f8174da2975d92a5e46521b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTMtMS0xLTM2MDk4_9d64964e-81ce-4500-b957-cf37cddf3946"
      unitRef="usd">24400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifa4caf2d660c4b4484538e8cbb90b925_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTUtMS0xLTM2MDk4_60953584-795b-48d0-8583-f2f38592aa8c"
      unitRef="usd">18300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i492309902f57471882356fb89a26bd66_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTctMS0xLTM2MDk4_a10227ec-8e9e-4130-9514-d48a6623e2e0"
      unitRef="usd">-100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2db00e44884e4324921fffe1db888357_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzI5LTktMS0xLTM2MDk4_234bf805-61da-40e2-a420-64d5d839f15f"
      unitRef="usd">63500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4622c6482f3d45069c12df64c7dd78b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTEtMS0xLTM2MDk4_d1b06ccf-7428-43c6-9d92-d38b8c031873"
      unitRef="usd">3361400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7920ff7437c4431394c58ae1b77ea77d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTMtMS0xLTM2MDk4_2fc81c50-4d9e-4ea9-817a-8f776827544e"
      unitRef="usd">147500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87a76d7e24404d87b2fb139a19273f9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTUtMS0xLTM2MDk4_7d5c6fb3-e021-453b-a095-603b825988bd"
      unitRef="usd">2290000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i920509e109ff475b8bc9e2c46f33d0be_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTctMS0xLTM2MDk4_2d3402b2-8445-4fce-a16f-5a0dd25093cb"
      unitRef="usd">1500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab5f50dc04544153acdb845c6d785a71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZToyNGNlOTE1MmI1ODI0ZGE4OTI5MGRkZjQ0ODc4ODU5Zi90YWJsZXJhbmdlOjI0Y2U5MTUyYjU4MjRkYTg5MjkwZGRmNDQ4Nzg4NTlmXzMwLTktMS0xLTM2MDk4_a0cca9e0-492d-424e-811e-2f8818d3c7dc"
      unitRef="usd">922400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd270e9d09cb49339a3220d22dd73473_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtMS0xLTEtMzYwOTg_49dac839-df03-4977-a048-f69c07e4c03e"
      unitRef="usd">737600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i90078976fc1443fe9588fd6b5904ab69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtMy0xLTEtMzYwOTg_c03a71ad-990b-4f92-a852-ee5111f7c5f3"
      unitRef="usd">476100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5677ed160204f11beec751a2ccee116_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtNS0xLTEtMzYwOTg_ce5b92da-7175-4920-b88f-bc697bf979ed"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b36d1b515614e75986f6da15379aabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtNy0xLTEtMzYwOTg_1a2acb0d-0526-4d03-8403-86447e8bc95c"
      unitRef="usd">1000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9670f5b2d1b401bae5142ec826f2a84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzQtOS0xLTEtMzYwOTg_3160d232-69f2-4b99-9bb2-9c6b6572b416"
      unitRef="usd">260500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibedb4afcb9df4c4e8e4622bdceece6d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtMS0xLTEtMzYwOTg_4cd95530-b6a9-4a28-ba01-b0f39660ba56"
      unitRef="usd">2635800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1fedf4fa6a74d72b7aff18d5cad5971_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtMy0xLTEtMzYwOTg_1862f0ae-5da2-4f5c-8fea-be715d0e8613"
      unitRef="usd">1102300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if3027fdae9ac423dad98aa4717b2d250_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtNS0xLTEtMzYwOTg_5cc4f1d4-0a14-4924-bc86-4510b9ecd15a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i904066c648bf4a7891d0c09bd32f935a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtNy0xLTEtMzYwOTg_bf32afc4-2081-4b18-9406-d7aa44c0d2a9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if37beb85aa5242baa69698b7f1ac5a62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzUtOS0xLTEtMzYwOTg_f109faaf-7b2c-4c14-a0b6-ff7ca72a275a"
      unitRef="usd">1533500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6dab754da4cd430a946579d76e7a4235_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctMS0xLTEtMzYwOTg_f7a44a66-6dce-429e-a05e-d292b84a99a2"
      unitRef="usd">4301300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c886b62fb994e6b8d799a1e75d54ba5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctMy0xLTEtMzYwOTg_3eaa351a-6a88-40aa-8e3e-89ce5a083d77"
      unitRef="usd">2900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c687db083a348319e2e8ddb46c0e62c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctNS0xLTEtMzYwOTg_d813377a-a1bd-4621-b226-658c891cc853"
      unitRef="usd">3179200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9c04b7697ad04751a168650303409b1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctNy0xLTEtMzYwOTg_ee011254-5ec9-4507-91c9-73be78f44e0f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4204c5315adc45d48e818bbe9a8ba906_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzctOS0xLTEtMzYwOTg_d24678e8-9eaf-41b9-b101-1bcf673fab02"
      unitRef="usd">1119200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4986843a114a4fa8abd7bb677f0a6e09_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtMS0xLTEtMzYwOTg_889aa151-7d0c-4585-9c16-c466aed0b116"
      unitRef="usd">-1670800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1852094aef8a41098d0642f072f681a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtMy0xLTEtMzYwOTg_b2761ae0-3a99-4bec-b49f-3599c1718829"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id971a9a8b7eb4b6c844ae83861fff3d9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtNS0xLTEtMzYwOTg_8ffcd650-f394-4cae-85e8-b99fe530f146"
      unitRef="usd">-1670800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia05c9d92ee39418698a8b85febf6ef92_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtNy0xLTEtMzYwOTg_37a02cee-882d-444a-9aca-4fbd417171dd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a265af7c90b4248bcc3b03e1b75d45e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzgtOS0xLTEtMzYwOTg_73e88b92-642c-4028-9ec0-7573285eefbf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i376b64ff0bcc4868b48f64179cccef38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktMS0xLTEtMzYwOTg_48fa2d11-7725-4d90-ba71-2ba99dea3b19"
      unitRef="usd">631000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i28a3ca1d4022458f96a8a99957fa07fa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktMy0xLTEtMzYwOTg_e62bd41c-c49c-4c66-bf8d-7aa117dd8ee8"
      unitRef="usd">14200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0d1d1c1c3ed4109a81ec41ff3971fe1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktNS0xLTEtMzYwOTg_79484a97-4419-4c3e-ae5a-b7d3e198bfaf"
      unitRef="usd">262700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia22e780cae244f9ab866e47a503bb04e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktNy0xLTEtMzYwOTg_823773bb-ad06-4f7c-a550-764c114cb7c8"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieb1c7cdebbee4183a6490b6aa660776c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzktOS0xLTEtMzYwOTg_d78294ed-a347-412e-b0b8-32d491c6dc2c"
      unitRef="usd">354000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i098c8e062f114cf895dfab6de7e2a153_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTEtMS0xLTM2MDk4_1f017763-5957-4a35-9005-e70ed59c197c"
      unitRef="usd">2661300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i05001400e56b4185b37c3c340b3cb549_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTMtMS0xLTM2MDk4_31c415b1-9fc3-459d-9b40-af7cbcf3e7b0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f54761004c14a0fbeed714f829c9a9b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTUtMS0xLTM2MDk4_30b841f9-da7f-401c-abc2-60a6d9903969"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ab1592b5b5a4ea5803c843fa59ea969_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTctMS0xLTM2MDk4_375aa041-da9f-465d-b79e-086a8820b587"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ief12a02bce14452ab3abe51ad1dbdb96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzExLTktMS0xLTM2MDk4_2f980ddc-1bd6-4ae7-9b15-933ab7229a9f"
      unitRef="usd">2661300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8303f3b61154040a4ed58939d6a8db7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTEtMS0xLTM2MDk4_a9efebe3-6c20-4976-895a-35b9ea918ad6"
      unitRef="usd">2844700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id9dbef9e3cee42a6aba4ec399d8d2392_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTMtMS0xLTM2MDk4_916512cc-1cb5-4325-86b0-fef6bf805ef2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2b9c108036e4a95a83b7d094eaefd7b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTUtMS0xLTM2MDk4_3e37d701-dfcf-4def-97bf-e2afed815d73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a011bb0a6704772865e32f9508fda79_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTctMS0xLTM2MDk4_2398ac4a-7fbe-43b6-b452-7a5edde50a86"
      unitRef="usd">16900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia90317e246984c68baa7aec717e1b700_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEyLTktMS0xLTM2MDk4_a1e060b3-f230-41c7-9dc2-a1c5a5410289"
      unitRef="usd">2827800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85a9ee8915a1448aa53821d3de24626e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTEtMS0xLTM2MDk4_3bf8ffad-f978-410e-b3c0-420481856dad"
      unitRef="usd">558900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77dcf7055a13436793411bbc50581e33_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTMtMS0xLTM2MDk4_b9de88f0-654f-43a7-8913-cc4dd53f0af2"
      unitRef="usd">259600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54aba7ea557147118c52c20b184223c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTUtMS0xLTM2MDk4_3c61b4eb-7603-4e6c-afd3-c0a1b9af7dd9"
      unitRef="usd">6900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c4bfc6afcf347469c09d2fffbd3b3ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTctMS0xLTM2MDk4_0b3956f7-d660-4294-aa80-bd96b35b695c"
      unitRef="usd">5800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i56d6e9fb0a8e41d7a79bcebc0f396ca9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzEzLTktMS0xLTM2MDk4_70c76a07-264c-4467-892b-a213aed53451"
      unitRef="usd">286600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i286bdb1bdb4a4e99b3a1228c6f203ff6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTEtMS0xLTM2MDk4_74162ac8-c041-4229-acfa-f272631bd896"
      unitRef="usd">1879200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e85922b83894b11b8b77f4c73af1fcd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTMtMS0xLTM2MDk4_73924e66-684a-484e-92fb-7055f0b2452e"
      unitRef="usd">60400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa2ff10cc6de4d44b3171363fb8d3314_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTUtMS0xLTM2MDk4_70efceea-1b05-4f2b-8a5d-2d7ea3d24f83"
      unitRef="usd">301200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i443731e8b90e4ff1b5ede21f5cedfd96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTctMS0xLTM2MDk4_94df3ebc-a640-4aa8-94fe-d860ffe89115"
      unitRef="usd">18000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i45319fdcff414b46b8cee3c8ecc98372_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE0LTktMS0xLTM2MDk4_580ba749-3ae4-45aa-85ce-b5e8bdaaa8e8"
      unitRef="usd">1499600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icddb724942ed473c88a3646e8ec26fcc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTEtMS0xLTM2MDk4_4650aa9c-2ca4-43cc-a834-1cbcc6a49cd5"
      unitRef="usd">14579000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd2d59c1620642d784d6b10e9f31a7a2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTMtMS0xLTM2MDk4_f7471421-9de9-4252-a8e5-a06aec2b576d"
      unitRef="usd">1915500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i50063c31ba9749efa23653ec53ec7046_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTUtMS0xLTM2MDk4_31c2b880-5cb6-4039-b35a-c356993b91f1"
      unitRef="usd">2079200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id966a267adc34a0ba8ffaf9925c61ef2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTctMS0xLTM2MDk4_82aefbc8-d56b-42cb-b0f0-1cf229f9114b"
      unitRef="usd">41800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1f8eaf7e5d4c4ea48272ed7d73c53069_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE1LTktMS0xLTM2MDk4_fbcf6465-c792-4830-8182-fa8366679dc9"
      unitRef="usd">10542500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id872ed9c15ae4df9bd2ff63acfe92e0a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTEtMS0xLTM2MDk4_ca55aa23-b1dd-4e03-97f2-c57b4fc655ba"
      unitRef="usd">68300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd7e2a5a735740298384d7b6e050d5aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTMtMS0xLTM2MDk4_7ee26bb0-9f3f-4c24-bb8e-9fa31b5612e6"
      unitRef="usd">45000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i76c132cf90104d488c23e6ca6eb8098f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTUtMS0xLTM2MDk4_97eb3a1f-0180-43e2-bf1c-24b0e5918685"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if4113c6d6bab42948b9ff02ab6f74741_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTctMS0xLTM2MDk4_2e6d35ef-d2d7-4b5c-8ac1-ae55d95f739c"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e88ac2258ee4936ad5dc86525cd9442_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzE5LTktMS0xLTM2MDk4_7014f352-56a2-4af5-9bd6-dd511d986fec"
      unitRef="usd">23200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i670f1a97ccbf41da8154342d4d6523b4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTEtMS0xLTM2MDk4_9fde4cab-0edb-42db-b610-c30d29a931c9"
      unitRef="usd">162300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ide3ae3cf49674f30ade8c18fa107c77b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTMtMS0xLTM2MDk4_5bebb6c5-ee5c-4245-8fc2-68844bb5f8af"
      unitRef="usd">58100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i257e5842c7554e4caa669c0ffca933f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTUtMS0xLTM2MDk4_adf4e356-1ada-4ee1-9304-c3a818677f40"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54cfd8a609414a0db58349eb5ea9a5fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTctMS0xLTM2MDk4_233b7203-e9ac-4dcd-8880-d97157f6a6e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad0f0411d0c340e5a80b9de1a90ac71a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIwLTktMS0xLTM2MDk4_7f02397f-5b81-41bd-906f-ca554c080284"
      unitRef="usd">104200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2fcea8bc696240ccb6279f2fa8f961ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTEtMS0xLTM2MDk4_03df58fc-46b5-4104-a427-4686760cc61f"
      unitRef="usd">101500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i717d2780362b4ed5a803d5d092fc68de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTMtMS0xLTM2MDk4_55b4909e-f92d-4f13-a75d-c56c472b0e7a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89af2a8588fb43c7a9f34777a2e4a820_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTUtMS0xLTM2MDk4_b6d279a6-599f-415a-a0aa-759b5a4aab23"
      unitRef="usd">80300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i41a8292117714ce7b0efadd7981b2635_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTctMS0xLTM2MDk4_1c58cfa1-5428-4d79-aa0f-e092d70adb71"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie331a6b7526d4646ba4c0c78741cf4a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIyLTktMS0xLTM2MDk4_2ecf5cfa-28d6-494e-a44f-6d012788308d"
      unitRef="usd">21200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica375fb13ab44116bd7cec8010c65295_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTEtMS0xLTM2MDk4_ee7cfe2f-ba7a-410d-a3f0-57021a14ad8f"
      unitRef="usd">53500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idc92d20b166347aba8996743e2f94f5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTMtMS0xLTM2MDk4_70efd799-17f1-4ccc-9e73-f75c55fb0f96"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i154ab60f7f874167b0110415b0bb6bcf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTUtMS0xLTM2MDk4_674e1769-bd5d-4d56-909d-b72cd9a0a750"
      unitRef="usd">24700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82568bb9dcf84a24a49d7b60fa84c30e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTctMS0xLTM2MDk4_dc8153bb-0a2b-4178-b851-6cff004d657b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9537a27ef3aa4c4c9ab9cf72607bf998_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzIzLTktMS0xLTM2MDk4_b0dd55ed-e68b-4147-aead-cb58de14829c"
      unitRef="usd">28800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id1425cdedc7949b0b143bc6ff55254ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTEtMS0xLTM2MDk4_3a3be37a-1222-4c42-8fa6-8aedfcde15d2"
      unitRef="usd">229700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80391b34e15c469b9897032dcc29bcae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTMtMS0xLTM2MDk4_bafc524f-dab6-4450-a1c7-db463fd4f826"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie906d9e82b62417aae23edf6f663034e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTUtMS0xLTM2MDk4_078aae54-21e8-49b0-a03d-41efd5dd1697"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0008b840b33b4978b52d9f21ad80d88b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTctMS0xLTM2MDk4_f61fdbd9-fcab-45b5-8e21-8e30bae56700"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i062da986ad0544f289a0f7f67fb3d529_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI1LTktMS0xLTM2MDk4_a5e98d10-477f-4444-8d8e-aa67f2fe6f69"
      unitRef="usd">229700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id5c8c08e195b457581bae02f1a1a1ed6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTEtMS0xLTM2MDk4_382495f4-cb24-4937-a561-857dd3257a73"
      unitRef="usd">223400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic671a63b2541465ebb7421a6e68854b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTMtMS0xLTM2MDk4_d4cda179-bd78-4505-b2fa-b5a693425edf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d9a8b2e771d41f990fd1f9ea5be38a5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTUtMS0xLTM2MDk4_228a8dd5-0ebf-4256-93fc-3da4d3b76092"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia2ee2af27ade4a0d8bc08bef2fff9cfc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTctMS0xLTM2MDk4_88ea89f4-ee7c-4244-8bbe-52a3445d7a96"
      unitRef="usd">1600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id75775f4e3d5407da9f8fd41bc619cc2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI2LTktMS0xLTM2MDk4_69c65b8f-8647-4347-9603-71b89d56bf68"
      unitRef="usd">221800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f4d0bb3ce4b4cd7a9e3ffbc447cb4a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTEtMS0xLTM2MDk4_c4525b35-197a-409c-a83b-de251c06d2ba"
      unitRef="usd">2204600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7c3fdb269b554706bad0f7c0db4c4650_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTMtMS0xLTM2MDk4_3acba794-afa7-4369-b346-cf2d02427617"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c8f217fe0234a80a11ef720e8b0c5be_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTUtMS0xLTM2MDk4_2399dfb4-d7b6-446d-91c5-d218d462ae23"
      unitRef="usd">2204600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifdf725fef3924b1ca90629c2fbfd82be_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTctMS0xLTM2MDk4_bcc28976-814d-4bac-9e33-f45a935d5206"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0e73d975a09b4b51b349b6589f7f2026_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI3LTktMS0xLTM2MDk4_95f9ee05-33cd-462f-8db6-225396f3c7ab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2345619fcf84c878d4d255125aff795_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTEtMS0xLTM2MDk4_e16f7412-9c66-41a3-9236-5349b18f2e5d"
      unitRef="usd">25800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8f2b6878a0d4219bec7cca02fca3f31_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTMtMS0xLTM2MDk4_77fe6201-c168-4610-9830-e2bbd1467834"
      unitRef="usd">24500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id081a7188b3f482cadd9f20bf9235396_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTUtMS0xLTM2MDk4_784c53da-21ac-4be2-a155-235541e4a07c"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9a933ecf8154d50959fd7b679fa2059_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTctMS0xLTM2MDk4_04521daf-0f9b-4f47-9876-b9e0a8d4285c"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c80776c9e5d478fb71a447f058f5795_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI4LTktMS0xLTM2MDk4_7c2fb9e1-ccee-448b-99e6-834b5ddbbea8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf9330f1044b4da28b7e3b56aee502c9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTEtMS0xLTM2MDk4_b3a0b6f7-7bfc-4469-bdfe-8a1db4ca4ed1"
      unitRef="usd">157900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2fa9acd89db451e96eec95ad09cf9c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTMtMS0xLTM2MDk4_72113c86-2b02-42df-8c6d-68bf15707d10"
      unitRef="usd">14100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iffd7cd72ddc74159a112e5175ba27aab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTUtMS0xLTM2MDk4_1b03895c-e7a4-4e79-9cd3-d694c1f7aaa9"
      unitRef="usd">21100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic1884086160c4545b61f9deb3369c36a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTctMS0xLTM2MDk4_78c733f8-7b0d-4787-8be3-9d700a0dbe15"
      unitRef="usd">1700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8f3c2d07882344e098b3ebd363334c5e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzI5LTktMS0xLTM2MDk4_db3db9b5-f08f-44c1-9805-510cf05022c8"
      unitRef="usd">121000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0f092b15cc046d898a11dda527a6927_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTEtMS0xLTM2MDk4_622779f1-c563-4140-87f7-d5d4d5958fad"
      unitRef="usd">3227000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06e1bafb60044816a73bd73702d87ead_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTMtMS0xLTM2MDk4_95552dfd-b1f2-421c-b652-e26b01b0af93"
      unitRef="usd">141700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6128315f59094f028caf8bb50fc29382_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTUtMS0xLTM2MDk4_543056f0-3283-4818-9486-c0cc17319ecb"
      unitRef="usd">2331400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea1472d9c0614d2792d02449a8430661_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTctMS0xLTM2MDk4_288a8a9c-ed1c-4938-ae66-188a9398a47e"
      unitRef="usd">4000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f512b891abe4e69bc22f07f86783f45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90YWJsZTplYjk2YmY5ZmNjOGE0ZTNlYjkzNzNjZDgxNTI1NWRkMy90YWJsZXJhbmdlOmViOTZiZjlmY2M4YTRlM2ViOTM3M2NkODE1MjU1ZGQzXzMwLTktMS0xLTM2MDk4_0cc06ab9-e68e-4bb5-a367-14fe494740d5"
      unitRef="usd">749900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i99352080eaa64b8aa55bab4783a9052b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTEvZnJhZzoyNDgzZTY1ZjU5YjY0YmEwYTE3OTJkYWEyZWJlNzdmYi90ZXh0cmVnaW9uOjI0ODNlNjVmNTliNjRiYTBhMTc5MmRhYTJlYmU3N2ZiXzEyMTIw_9bcbccb5-6838-4040-b692-d0abd2b83dd1"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3MDI4_2e01fd55-7bc2-4de8-8eb7-d5dd171c1cf9">Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alimta Patent Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alimta (pemetrexed) was protected by a vitamin regimen patent until November 2021, and since then has been protected by pediatric exclusivity through May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Europe, Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, we were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;chusetts seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is currently scheduled to begin in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Taltz Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021 and November 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Swiss Federal Patent Court, respectively, in preliminary injunction (PI) and main infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis' PI action. Novartis appealed the ruling and in October 2021, the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing. Hearings on the Italian and Swiss PI requests are scheduled for May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, Novartis petitioned the Commercial Court of Vienna in PI proceedings and in November 2021, the Austrian court denied Novartis' request. Novartis did not appeal the ruling, and this matter is now closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zyprexa Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing occurred February 2022. We await a decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Actos&#xae; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in Quebec filed July 2012 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Whyte et al. v. Eli Lilly et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Saskatchewan filed November 2017 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Weiler v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and one in Alberta filed January 2013 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Epp v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021. The relevant courts approved the settlement and the deadline for class members to seek settlement funds has now expired. The lawsuits have been dismissed or discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Byetta&#xae; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. which were first initiated in March 2009 and involve approximately 805 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Two lawsuits, representing approximately two plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately 311 of the MDL lawsuits have been dismissed as of February 2022. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment. Approximately 17 of the state court lawsuits have been dismissed as of February 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of approximately 20 additional potential claimants who have not yet filed suit. These additional possible claims allege damages for pancreatic cancer or thyroid cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cialis Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal MDL in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The JPML ordered the transfer of the existing cases to the now-renamed MDL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The parties have reached agreement to resolve the majority of claims pending in the appeal and expect those claims to soon be dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in 5 currently pending product liability lawsuits in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs' Fournier's gangrene. Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations and dismissals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;340B Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. We have filed a notice of appeal. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Branchburg Manufacturing Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Brazil Litigation &#x2013; Cosmopolis Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several actions, including some with unspecified financial impact, consisting primarily of paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility for more than six months during the affected years and their children who were born during and after this period. We appealed this decision. In July 2018, the appeals court (TRT) generally affirmed the Labor Court's ruling, which included a liquidated award of&#160;300&#160;million&#160;Brazilian real. This 300&#160;million Brazilian real liquidated award, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately 950&#160;million Brazilian real (approximately $170&#160;million as of December 31, 2021). The TRT also restricted the broad health coverage awarded by the Labor Court to health problems that claimants could prove in a separate evidentiary proceeding arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Labor Public Attorney (LPA) filed an application in the Labor Court for enforcement of the healthcare coverage granted by the TRT in its July 2018 ruling, requested restrictions on Lilly Brasil&#x2019;s assets in Brazil, and required Lilly Brasil and Antibi&#xf3;ticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action for the LPA to identify and contact those individuals. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit or lien of 500&#160;million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling. In June 2021, the court reduced the security deposit or lien to 100&#160;million Brazilian real and limited the scope of the initial order. ABL and LPA appealed to the TST, which appeal is currently still under review. In addition, in September 2020, the LPA initiated a second preliminary enforcement of the portion of the July 2018 TRT decision in the Labor Court that prohibits the exposure of workers to the contaminated areas. The Labor Court is currently assessing the status of Lilly Brasil&#x2019;s compliance with such portion of the July 2018 TRT decision. These matters are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lilly Brasil is also named in approximately 25 pending&#160;lawsuits filed in the Labor Court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in more than half of the lawsuits by the trial courts, of which, approximately half of those judgements are on appeal in the labor courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;China NDRC Antitrust Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We cooperated with this investigation. In July 2021 Lilly divested Cialis in China. We consider this matter closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Puerto Rico Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Municipality filed a motion to execute a purported judgment, and the CFI scheduled a hearing in March 2022 to consider the Municipality's motion. We have opposed the Municipality's motion. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. In October 2021 the parties filed cross motions for summary judgment. Trial is scheduled for April 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice's motion to dismiss the relator's second amended complaint. In January 2020, the relator appealed the District Court's dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit, and the relator did not petition the U.S. Supreme Court for certiorari.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator appealed the state court's decision to the Appellate Division of the New Jersey Superior Court. In January 2022, the relator filed its appellate brief.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing Litigation, Investigations, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. Insulin Pricing Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re. Insulin Pricing Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; MSP Recovery Claims&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. Insulin Pricing Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court has allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;County of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Harris Texas v. Eli Lilly &amp;amp; Co., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. After removing the case to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In January 2022, the court granted the motion in part but has allowed the antitrust and conspiracy claims to proceed against us, Sanofi and Novo Nordisk. We, along with Sanofi and Novo Nordisk, have moved the court to reconsider its denial of our motion to dismiss the antitrust and conspiracy claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Mississippi Attorney General's Office (Mississippi AG) initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In response, the Mississippi AG filed a motion to amend its complaint, which the court granted. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received subpoenas from the New York and Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. In January 2022, the Michigan Attorney General filed against us in state court a petition seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the MCPA applies to the conduct it seeks to investigate and allows it to conduct the investigation. The state court granted the State's petition to investigate, authorizing the State to issue civil investigative subpoenas. The State's complaint for declaratory judgment remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a&#x202f;request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members.&#x202f;Those requests sought pricing and other commercial information regarding Lilly's insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research Corporation Technologies, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. Both parties moved for summary judgment and hearing on the motions took place in August 2021. In October 2021, the Court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration, which are underway. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. A trial date has not been set.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkxNzIxMDU_533ffbf3-602c-41d5-85d0-35b55c42f432">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="i5a8f4700075e46e181eeffde2392ca23_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2ODU2Nzc_8786f57b-7f3c-47b4-936c-654348e1e357"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="idaebf92d82564ada897eaa69c56f337c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2ODYwMDc_00737ee0-11b4-43eb-b02f-dde144cd3abe"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2467803c679342dea9a3819f8bbf7baf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTAyNDE_7c850557-1bd5-452c-b440-0be43500046d"
      unitRef="lawsuit">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib12387763bcb4249a0acbacdd6def054_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTAzODM_e2ea53c7-4c0f-4f42-87c0-0899539375a8"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if4b71fdf7d6d451ea94e93caa29ecafe_I20120731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTA0OTA_3b91f566-b560-4da7-a06f-415766e12d7d"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5f4e6781ac7b44e984cc9a7e9559b57d_I20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTA1NTY_4849e926-8109-41de-8592-6001c75369cb"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia0462964f7244546aefa834caa5190c4_I20130131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTA2Mzk_97ec9473-3d93-4b90-80a3-74dda921fc5b"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iac210e833f7b4de39ab853cd87ad843d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEwNjY_f76797a6-0b40-4c4c-ac8e-e5f2da24875d"
      unitRef="lawsuit">570</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ibf373b574e5c43eeb34e1e1ca9dc68c7_D20090301-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTExNzc_4a5314b9-36a1-4b3c-b95b-969d40afd8af"
      unitRef="plaintiff">805</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i58d4f95ec17a42b1a27bfd827f5f8a06_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEyMDc_0a607e64-3fe0-4fb4-a23c-ffeec88dea57"
      unitRef="lawsuit">55</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i329ac6196728431792b5fc0adace7b76_D20090301-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEyNDU_4426b4d5-750f-487f-aa5f-343863814733"
      unitRef="plaintiff">285</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie857e2c012a4416d91e56a0f10db62fa_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEzNjA_d944c190-6334-4bdf-853f-79ef285eb040"
      unitRef="lawsuit">515</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i95acadd05dab463fa98262e3b7d9a30c_D20090301-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTEzOTY_1a55c37d-ec8c-4b30-9887-fc80035cd98a"
      unitRef="plaintiff">515</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i17f2181a9b6d4e6ab309b180381eac2c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE1ODM_4e2545b6-a42e-4690-aa96-ff93a10ec563"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i0d637cc5246347c6a23d9f91a36fba87_D20090301-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE2MjQ_da21c8a3-e5d1-4655-b67f-28d5a5749f6b"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5f1eda23144b47d083c10338438ad3c5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE3MDA_392887e7-0db4-43db-bf95-360232e78f3f"
      unitRef="lawsuit">565</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i2521580e2ede416981af3b0b347ee8f3_D20090301-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE3NDU_dad75603-2317-4eb7-b7f3-b9330e24cf2d"
      unitRef="plaintiff">800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i1e4899ed067c4d2c9996df4ef5abba7e_D20090301-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE4OTY_05074537-e5ed-4d40-8ded-5eb160812c1a"
      unitRef="plaintiff">6</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id09447c7b9f54599a8f05f81d771fab0_D20090301-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTE5Nzc_ff662206-89e8-472a-9c34-8fcb98632fd6"
      unitRef="plaintiff">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="ic78be52744324235b791e091239d55c9_D20220131-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzM0MDg0ODYwNTY2MjIx_fb5e4486-7570-4c49-9584-09098ec8b627"
      unitRef="lawsuit">311</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i506357620067488b978ab8ff85c80057_D20220131-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1NTg_aa14f161-e59b-45ff-898a-c38f4154a116"
      unitRef="lawsuit">17</us-gaap:LossContingencyClaimsDismissedNumber>
    <lly:LossContingencyNumberOfClaimants
      contextRef="iac210e833f7b4de39ab853cd87ad843d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTM0Nzc_d9c2d57b-8bda-4614-8c75-35abe2de30e4"
      unitRef="claimant">20</lly:LossContingencyNumberOfClaimants>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0fe8d453b4a64bcd91db0e517126df58_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTM2ODE_8b9023d1-72f9-4e70-b32d-a02e674cd902"
      unitRef="lawsuit">350</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie428c3da402741de9dc989224e4a1931_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMTIyOTQ_be26d1ce-ec6d-428a-8266-4c37b8cbb3f2"
      unitRef="lawsuit">5</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
      contextRef="i3ce97af02d724dd5a6b2d83575df05d1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE2OTU4MjY_876dbac7-8089-4ae1-907f-698d7332b88f"
      unitRef="site">10</lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i9f0a8d43e1354331a472dc5baeceebd0_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDAyNjc_a01c6e09-8ee5-47cc-8e05-c7d547a37993"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i9f0a8d43e1354331a472dc5baeceebd0_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkxNzIxMTE_19fca540-d2b3-4a5a-8e39-82b8494e4497"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="iea9d1b8804f84d8d9335353484110e31_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDA1MTY_6303eb99-a818-48d8-a952-b52784594d96"
      unitRef="brl">950000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="iea9d1b8804f84d8d9335353484110e31_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzM0MDg0ODYwNTY2MjI2_73cf9a6a-d156-4ff0-9b99-db8cdc591643"
      unitRef="usd">170000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i3712c098015042f9b63839407eed2efb_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1NjI_aefdf649-09d5-4454-9d6e-0f8e0143d9cf"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i4ec2ece19688425e9036c61b5348541e_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1NzU_e8147d9a-5f95-4cfd-ba8b-8c3b25feccd5"
      unitRef="brl">100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id79706b98b434731856afd46cac0b247_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzI3NDg3NzkyMDc1ODg_5aa0dd41-1627-458d-b8cf-91e1b11da8e6"
      unitRef="lawsuit">25</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie0eaa187336948399c69ed01819ea277_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDQ3OTI_3683b517-e837-4853-8658-7960b8e3ba44"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LitigationClaimsDismissedNumber
      contextRef="ieeabe64521a64f398e690da708946fca_D20210701-20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNTQvZnJhZzo1NTU3YzBmMTE3NDM0ZTEwYTY0MjA3MzRkYWViMzQyYy90ZXh0cmVnaW9uOjU1NTdjMGYxMTc0MzRlMTBhNjQyMDczNGRhZWIzNDJjXzEwOTk1MTE3MDc0ODg_3f6245ed-55ba-4b95-b11e-8520e4a9c026"
      unitRef="claim">3</lly:LitigationClaimsDismissedNumber>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzE4OTk_da804a80-5dcd-46bc-94ef-137dda10c541">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,569.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,740.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(967.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,823.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;106.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,795.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,167.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,153.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of January 1, 2019 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(136.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(532.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(695.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other &lt;br/&gt;Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;490.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(91.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from continuing operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from discontinued operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzE4ODI_c05aa02d-e779-4a4e-b556-6dbf0b1e24ca">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,569.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,740.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(967.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,823.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;106.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,795.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(122.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,167.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,153.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,550.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,583.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(213.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,343.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of January 1, 2019 consists of $5.73 billion of accumulated other comprehensive loss attributable to controlling interest and $11.0 million of accumulated other comprehensive loss attributable to noncontrolling interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(136.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(532.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(695.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c8b2889ec6e4963b72ebda5ec3e0226_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItMS0xLTEtMzYwOTg_89d5ea4b-a670-4c45-b4ce-9822278399b0"
      unitRef="usd">-1569700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70389d1a8dce4373ba9770278325d644_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItMy0xLTEtMzYwOTg_3d861009-6510-4702-a856-752a31b25db6"
      unitRef="usd">-22100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7efe1f182bf74c749bcde3ee035a8288_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItNS0xLTEtMzYwOTg_7bd20753-53e7-4598-b724-cac03624d693"
      unitRef="usd">-3852700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21f70fcf53724eacba2dff838d3080f3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItNy0xLTEtMzYwOTg_aaf7f33e-8c2b-45f7-9fd0-066d3b18827c"
      unitRef="usd">-238900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51cd7b473ca14dc78773ea45b5740f8b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItOS0xLTEtMzYwOTg_d7e69ecb-6f52-4126-9644-26eaaa62d71e"
      unitRef="usd">-56800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0475e54cb8944cbbf6fd301a3970da7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzItMTEtMS0xLTM2MDk4_0fe1246c-435e-43d1-ad57-ed2eff44189d"
      unitRef="usd">-5740200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icf8db92bbdad41589e45f909109c9432_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtMS0xLTEtMzYwOTg_4335e2b6-e4e6-4cd9-87f5-060144373f6a"
      unitRef="usd">-46200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtMy0xLTEtMzYwOTg_7a349e99-4574-4cc7-9ca0-6ac490bea600"
      unitRef="usd">28900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iecc77c9789cc449891871245cbbdd250_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtNS0xLTEtMzYwOTg_c09651ac-85b9-4fc1-ac69-a8857c1697b2"
      unitRef="usd">-967600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtNy0xLTEtMzYwOTg_f33e2495-5d57-498b-af84-eb15950908a0"
      unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtOS0xLTEtMzYwOTg_56270258-521f-41e7-848d-7257b082e3e9"
      unitRef="usd">-27200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzQtMTEtMS0xLTM2MDk4_7ed5675a-a286-467d-9889-f2b8b8ddf20d"
      unitRef="usd">-997600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icf8db92bbdad41589e45f909109c9432_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtMS0xLTEtMzYwOTg_8e114a35-de98-40f5-a61d-0510621c9cd1"
      unitRef="usd">62100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtMy0xLTEtMzYwOTg_0028dddd-c012-4d8a-b146-c37a8550469b"
      unitRef="usd">1900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iecc77c9789cc449891871245cbbdd250_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtNS0xLTEtMzYwOTg_88fad91a-9d14-46a6-a0a2-16d9e864d47b"
      unitRef="usd">-181700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtNy0xLTEtMzYwOTg_dd32057a-57c9-42db-803b-ef4a1276a342"
      unitRef="usd">-12500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtOS0xLTEtMzYwOTg_dd61bd78-0807-4533-8738-b4b43f6de7c4"
      unitRef="usd">-84000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzUtMTEtMS0xLTM2MDk4_73788585-33bf-46fa-899f-5ced652c2dbe"
      unitRef="usd">-214200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icf8db92bbdad41589e45f909109c9432_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtMS0xLTEtMzYwOTg_3f5503fe-68f6-4576-a3b3-2943e903765d"
      unitRef="usd">-108300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibbb697e65cbd492ea86a4099ea5223f8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtMy0xLTEtMzYwOTg_b0ee3ece-d5b9-4797-b50d-72e10047c67c"
      unitRef="usd">27000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iecc77c9789cc449891871245cbbdd250_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtNS0xLTEtMzYwOTg_6884f5a6-cf28-465e-8321-8a18268b978e"
      unitRef="usd">-785900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia4481aa4e8da49a4b4d4c4bba935ef80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtNy0xLTEtMzYwOTg_3016ca42-222b-42b8-8933-70a99d50b861"
      unitRef="usd">27000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie042dc7ac55b4bca9a34b4d5722f5c44_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtOS0xLTEtMzYwOTg_9519c08c-5e1e-4361-a4e7-0f8f8e03de76"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzYtMTEtMS0xLTM2MDk4_3958cb9e-779c-46c4-9860-3ee78295edc0"
      unitRef="usd">-783400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibda565e24c4e4030b83ae8ca958f008f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTEtMS0xLTM2MDk4_cde4991d-c404-47b0-972d-ba4eac8cf854"
      unitRef="usd">-1678000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98d1710cee29438bb4194f2e32033a79_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTMtMS0xLTM2MDk4_95d8d82b-63ea-48a0-8348-75726446be22"
      unitRef="usd">4900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7432a131a0fb49ff89baca4d230f866c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTUtMS0xLTM2MDk4_30a61116-cce5-4b5a-bce7-f77bba39e332"
      unitRef="usd">-4638600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i900912a3de074ff99d6a423f98a6bd4c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTctMS0xLTM2MDk4_163186da-cfb4-4cf7-87e7-f6d4e92d383d"
      unitRef="usd">-211900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14978ed722694c18a3fc2706b4ca82f1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTktMS0xLTM2MDk4_ef23ea69-ed40-4f23-bc65-b155c6e7c1b0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i164180694aa747c791f72edab93ae1a7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEwLTExLTEtMS0zNjA5OA_13b66692-1f6d-4d08-9c47-d6bad2367ed3"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTEtMS0xLTM2MDk4_4bf29dd9-92b7-4eb3-aeeb-2f5e1e5e1947"
      unitRef="usd">250500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTMtMS0xLTM2MDk4_dd511929-19a3-4db1-9172-59f85dd68a57"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTUtMS0xLTM2MDk4_ccebb47c-2a90-4e0c-a02c-bf64ca29f865"
      unitRef="usd">-379700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iaa4777312b864b708203b734b774366c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTctMS0xLTM2MDk4_33565d1d-0727-40d7-ba0a-3c6c92e7ab1d"
      unitRef="usd">-133800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTktMS0xLTM2MDk4_cdd8aac7-0ea6-4875-81f5-5fa3de358294"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzEzLTExLTEtMS0zNjA5OA_b98a3ed8-c4e5-4284-95b6-197dff102fc5"
      unitRef="usd">-256200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTEtMS0xLTM2MDk4_810eb938-e3b7-4e72-b477-bf65edbf482c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTMtMS0xLTM2MDk4_3005d710-5d01-4ce6-a911-14d1ce2a22c1"
      unitRef="usd">-3100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTUtMS0xLTM2MDk4_6b2f0391-ce3c-4530-a2c3-031d9d21659d"
      unitRef="usd">-267300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iaa4777312b864b708203b734b774366c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTctMS0xLTM2MDk4_63a745b7-1d37-4a71-82fe-7daa069f5148"
      unitRef="usd">-13000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTktMS0xLTM2MDk4_6464e6ba-672e-469d-a9c9-b086931f7298"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE0LTExLTEtMS0zNjA5OA_5a00e84a-bd35-4c40-867b-fb8cc59d9ae0"
      unitRef="usd">-283400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic8cb9cf192624457b0d840232d91d057_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTEtMS0xLTM2MDk4_bd791633-e3c4-42ab-bff7-15608f9e19ca"
      unitRef="usd">250500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6ee92609d5bd4752989241b2ae032b1b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTMtMS0xLTM2MDk4_a1077a7c-59b0-485a-9a2f-a2d991610d28"
      unitRef="usd">9900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib1c399ba696e4e1c913ebb6c7d430e40_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTUtMS0xLTM2MDk4_0a73f77e-6f83-48c8-8dd0-a269e0b8a61a"
      unitRef="usd">-112400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa4777312b864b708203b734b774366c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTctMS0xLTM2MDk4_585634e9-767f-4954-b004-4b61ceecf41c"
      unitRef="usd">-120800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i61ede390a73c4b1fa67ef56777fbc0bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTktMS0xLTM2MDk4_d7b6f328-5149-4e69-83cf-ab1c3edcfed5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE1LTExLTEtMS0zNjA5OA_750256c2-910e-44d7-aa6a-4908478382ab"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37c0f201926f4948bca2dbe17676cc5e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTEtMS0xLTM2MDk4_a1b5b356-c366-40fc-9dc8-2684773d3aa1"
      unitRef="usd">-1427500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8c0eb69cf624cc4b293df7b97c976e7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTMtMS0xLTM2MDk4_7013e4f1-e63a-4e40-9e96-8bcd3cee6a48"
      unitRef="usd">14800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f6183f5a5c9455dbf2c516793377cd0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTUtMS0xLTM2MDk4_237b13f9-c9ad-48fd-b75e-8ee36c701d90"
      unitRef="usd">-4751000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01c9273e754e42ff817a718c1ba70d7d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTctMS0xLTM2MDk4_a859c593-7aa8-4cd9-9f61-0ddd7921f9fa"
      unitRef="usd">-332700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic435e2ecf0a9408aaba2f2109d4c1db2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTktMS0xLTM2MDk4_67b3f177-5d9f-498c-b539-f4e72fdd70ad"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf58fefc745a46b9862d5a41ca2b485c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE3LTExLTEtMS0zNjA5OA_2360e988-8524-4279-884f-23a853537c9f"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTEtMS0xLTM2MDk4_db0e7d93-d122-4bcc-ac19-bc964883dbf6"
      unitRef="usd">-122700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i554c64bad97a42be803841abd88811cc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTMtMS0xLTM2MDk4_dfec490c-e468-4348-93b8-6688041fae7b"
      unitRef="usd">-11900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTUtMS0xLTM2MDk4_a8e26748-5537-4a90-ae72-f6e47d1d3dfe"
      unitRef="usd">1823400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTctMS0xLTM2MDk4_3eb75af2-9a7d-4f05-9a28-f29fb93091db"
      unitRef="usd">106600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie990d35793244c81978b349a80a82099_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTktMS0xLTM2MDk4_3a7866d3-21c5-4e16-9209-a35e56d7353a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzE5LTExLTEtMS0zNjA5OA_69baf817-8bf4-4de0-8bef-967801528b19"
      unitRef="usd">1795400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTEtMS0xLTM2MDk4_e02e43b7-3b8e-4d41-8fd7-62ef8d898a70"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i554c64bad97a42be803841abd88811cc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTMtMS0xLTM2MDk4_bc408ba5-3833-46cf-bc7b-97d300c95a2f"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTUtMS0xLTM2MDk4_2e09da88-5b13-4a2f-be97-af46dab6214c"
      unitRef="usd">-344000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTctMS0xLTM2MDk4_cecdc01e-459b-40b6-bf4a-744014ef0cac"
      unitRef="usd">-13100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie990d35793244c81978b349a80a82099_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTktMS0xLTM2MDk4_b05fcc83-9c69-43fe-b441-61943e01998d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIwLTExLTEtMS0zNjA5OA_f51f6160-1285-4512-bef6-3675f20f344e"
      unitRef="usd">-357900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6ce5e6927b2647efb094b21afb35fe6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTEtMS0xLTM2MDk4_8919e73a-2ecd-4070-bd2e-32547309d280"
      unitRef="usd">-122700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i554c64bad97a42be803841abd88811cc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTMtMS0xLTM2MDk4_1401922a-d1ff-4f4b-8d0e-7c9ba472a2bf"
      unitRef="usd">-11100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3288192071cc415fbb90571c8b3a9e82_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTUtMS0xLTM2MDk4_9d3d34f8-1bdb-4de5-960c-4d52961f7259"
      unitRef="usd">2167400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i379303d0a5f04e849c0a6d0cb2c8dfca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTctMS0xLTM2MDk4_7f35b6dd-c7b4-4fbd-9b07-d9ae6007e344"
      unitRef="usd">119700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie990d35793244c81978b349a80a82099_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTktMS0xLTM2MDk4_778a06fe-da07-4ad5-8531-633439de2da1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIxLTExLTEtMS0zNjA5OA_434a59c8-bcb8-43cd-a7b2-b3295678216a"
      unitRef="usd">2153300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9bf6f4a94b544a686ef51fbf1c8c304_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTEtMS0xLTM2MDk4_de655eba-3ff8-4dc7-971d-d05e853a3271"
      unitRef="usd">-1550200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2772b8591a3a435d806d664e42747e10_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTMtMS0xLTM2MDk4_843741ba-a24f-4890-911f-7fa46c074f16"
      unitRef="usd">3700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib18d0b0c520347f3b7f49fd16cebe265_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTUtMS0xLTM2MDk4_d0ae0deb-58e5-4bee-90b1-190759f8de98"
      unitRef="usd">-2583600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34d26295f837471e92a911cbfa5f09ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTctMS0xLTM2MDk4_8efb05e2-25fb-4155-a5a8-cd235b7feb2b"
      unitRef="usd">-213000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a7a7a2ccbdd490e9438393be18ea12f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTktMS0xLTM2MDk4_136e8e8e-45c7-4408-8577-26de3fe8fea5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if33da3a3872a4c1a8a126e0502034dad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZTo5MzZkZjM2Nzg4NGE0MjQ0OTNjZDc3MWEzZDEzMDQ2MS90YWJsZXJhbmdlOjkzNmRmMzY3ODg0YTQyNDQ5M2NkNzcxYTNkMTMwNDYxXzIzLTExLTEtMS0zNjA5OA_13db9d2c-1bd2-4220-b7bb-f504982f9f5e"
      unitRef="usd">-4343100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f786d93b75241c98d9db2267b3c5983_I20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzExNTQ0ODcyMDk1MzI2_37a700a6-07e8-45f7-8b82-657ad48dc874"
      unitRef="usd">-5730000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibebbd5414c314196b2e7f72291cfad2b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzExNTQ0ODcyMDk1NDEx_1ce5aff9-fdcd-4909-bab7-330c24ffc0fc"
      unitRef="usd">11000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i456c6ad8d4564976aef8554ffb59ccb7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzEtMS0xLTEtMzYwOTg_be5b08db-bbdb-459a-ae9f-e04fdb6adb14"
      unitRef="usd">136200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ib4452a2c88c941349af1c9b68847bcb5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzEtMy0xLTEtMzYwOTg_334d0eaa-5a46-41cd-8474-44192a0b9006"
      unitRef="usd">-128300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i36b8a5e3c0f84e68afcd481209c5d2e3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzEtNS0xLTEtMzYwOTg_ddbb755e-14f9-40c3-8026-a611e67e5283"
      unitRef="usd">18400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i65892dc9a2954d38b4ead8cdfcd6ba81_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzItMS0xLTEtMzYwOTg_89d4ecac-8495-4665-a282-5859a4d9a4fc"
      unitRef="usd">-4700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ia8d96de74d5a4264aaa3443af2d2593f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzItMy0xLTEtMzYwOTg_9c4082a0-c0ed-4337-9d25-a2a725840ba1"
      unitRef="usd">4300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i7dd3bf1571cf4ded9e6e79654afd40d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzItNS0xLTEtMzYwOTg_8f05a48f-81e0-4bac-b139-549275cd32fa"
      unitRef="usd">7400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6958d74700da422a8372afeee6138499_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzMtMS0xLTEtMzYwOTg_2b514b6c-b9e1-49b9-8fc7-64c17041d1ad"
      unitRef="usd">532000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ibb264b12ab0a49edae53a6a459216f4d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzMtMy0xLTEtMzYwOTg_754c4f85-c151-486f-8085-fcc5acb426de"
      unitRef="usd">-44800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="iabad7b42145343838527d4f8737a08dc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzMtNS0xLTEtMzYwOTg_3cbc818e-d88b-4f0d-94ad-5a02e3c44cf2"
      unitRef="usd">-184100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ie225690e6f6c43e7bf1510e4c46c7696_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzQtMS0xLTEtMzYwOTg_dbd0cfce-dcca-4354-b877-939858f76495"
      unitRef="usd">31800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8379681ef59448d18a9ce97f8241d61a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzQtMy0xLTEtMzYwOTg_f2242124-bd8a-4048-9801-b0aab0bafd1f"
      unitRef="usd">-32100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ic4cdbdd02bc04cdf82cfd0ecb1e7506a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzQtNS0xLTEtMzYwOTg_08d1effe-bed9-425f-ba9b-8ac9e806354c"
      unitRef="usd">7300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzUtMS0xLTEtMzYwOTg_d621cf52-12d5-46ba-a384-46c72f373721"
      unitRef="usd">695300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzUtMy0xLTEtMzYwOTg_4450cddf-1ea0-44d9-847c-0b20bab64f0e"
      unitRef="usd">-200900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToxYTU2ZGZiZjMxNzg0NjY1YjljYTY4MzVmNzE3NzE5NC90YWJsZXJhbmdlOjFhNTZkZmJmMzE3ODQ2NjViOWNhNjgzNWY3MTc3MTk0XzUtNS0xLTEtMzYwOTg_58c9a1e4-d96d-45a8-9715-36bec05fa402"
      unitRef="usd">-151000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90ZXh0cmVnaW9uOjliZGFkNmI4ZWEzMjQyYTg5NGVkZDFiNTlmOTQ5ZTlkXzE4NzY_04601b34-7e7f-40f6-83d8-931f05cd8a15">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other &lt;br/&gt;Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;490.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;435.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(91.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;344.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from continuing operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from discontinued operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifc4e3d75ed7a447f964c2076c2654b6d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzMtMS0xLTEtMzYwOTg_0473b02c-cb02-4658-9b0b-86d7d3a70fa1"
      unitRef="usd">-55400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2bd38897fbf84ba6886a357f48aa2eaf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzMtMy0xLTEtMzYwOTg_bd79a613-80c7-481c-be69-70ff5445461d"
      unitRef="usd">-55000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i08bfe6219e8843de84f18681cf0d0cbf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzMtNS0xLTEtMzYwOTg_029a001d-c561-4d3f-b1f6-1608c3c55af3"
      unitRef="usd">-56800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i080cb1f6c4c54fada36e6a66c670db4b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzQtMS0xLTEtMzYwOTg_b2307f63-a385-40c9-bab0-844995f00857"
      unitRef="usd">490900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idbf4d129e0b547c78a08a57ac046797d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzQtMy0xLTEtMzYwOTg_592636ed-5767-4a06-95c3-d5f3103e9890"
      unitRef="usd">393300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icfa4547d667b4859a0ef3510f8201e3d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzQtNS0xLTEtMzYwOTg_7e3646c7-65c2-459e-abe0-3d11c308453d"
      unitRef="usd">286800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzUtMS0xLTEtMzYwOTg_5f88a3d9-7a4b-44b0-a1a7-e1f41d24df65"
      unitRef="usd">435500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzUtMy0xLTEtMzYwOTg_231225d0-9bc0-461c-9b99-fdbd15d5e442"
      unitRef="usd">338300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzUtNS0xLTEtMzYwOTg_69be177b-ec26-4932-9771-47dfa6670621"
      unitRef="usd">230000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzYtMS0xLTEtMzYwOTg_2cc14482-bbc9-4f08-8c31-8a3d29255b5f"
      unitRef="usd">91500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzYtMy0xLTEtMzYwOTg_fffe095b-b0cf-4f15-83a8-b79cfb97f5de"
      unitRef="usd">71000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzYtNS0xLTEtMzYwOTg_48dff71c-4dc0-4a11-9eba-9acb3317e296"
      unitRef="usd">48300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i1e906856b74448c18dd1af48306aa1e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzctMS0xLTEtMzYwOTg_60b3c03a-35ea-4a37-abda-03333176c2f3"
      unitRef="usd">344000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if1c8d9d334ea4a3488001c13c24ae2ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzctMy0xLTEtMzYwOTg_bade88b4-54c2-4ab5-9c35-a7ec6d37c3d6"
      unitRef="usd">267300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3ee0955d33b54a27ac2a18c4b2b47ee5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzctNS0xLTEtMzYwOTg_e8a77cea-eb1e-49ee-93cc-28d4791b69c2"
      unitRef="usd">181700000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie16a788a1f3b4a209b13227afbf2188f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzktMS0xLTEtMzYwOTg_259952c5-1ad1-4ca2-889e-d083dc03f8dd"
      unitRef="usd">13900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib4726fae6a954ef28f20a75d12754243_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzktMy0xLTEtMzYwOTg_72450186-991c-41f8-912d-851deb73d9e2"
      unitRef="usd">16100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i00e2a870edf2467790f0a84a2d627f6c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzktNS0xLTEtMzYwOTg_11bdb294-9f73-4f43-ac77-6c8b0ce98282"
      unitRef="usd">-51500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEwLTEtMS0xLTM2MDk4_a800cc02-b75b-4739-ab79-bd84d694196d"
      unitRef="usd">357900000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bc78576f75247428a588a52665c4852_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEwLTMtMS0xLTM2MDk4_c9696a0f-16d2-4220-8091-499ebbfae193"
      unitRef="usd">283400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEwLTUtMS0xLTM2MDk4_84fb4ffa-584e-4276-8a63-704661430a56"
      unitRef="usd">130200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzExLTEtMS0xLTM2MDk4_50009ac5-743f-4c06-9835-97c699342c39"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2bc78576f75247428a588a52665c4852_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzExLTMtMS0xLTM2MDk4_4d5fefb3-fc82-4367-b4ee-ad18a765d2ac"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzExLTUtMS0xLTM2MDk4_6861822b-57fb-4982-beff-06e54c4958d6"
      unitRef="usd">84000000.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEyLTEtMS0xLTM2MDk4_aa1f82fd-b7aa-43d8-b14b-d90f17300824"
      unitRef="usd">357900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2bc78576f75247428a588a52665c4852_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEyLTMtMS0xLTM2MDk4_9751806f-c1d8-4f98-8a90-b89dcc48a8e6"
      unitRef="usd">283400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1ed69d69097a4b83bd4fa2fa98cbc64f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjAvZnJhZzo5YmRhZDZiOGVhMzI0MmE4OTRlZGQxYjU5Zjk0OWU5ZC90YWJsZToyYzBjOTFjMjAzNmI0NGYwOGNkOTYxMDU3NWFlNGQxMi90YWJsZXJhbmdlOjJjMGM5MWMyMDM2YjQ0ZjA4Y2Q5NjEwNTc1YWU0ZDEyXzEyLTUtMS0xLTM2MDk4_d5ba3917-13bf-4ece-9b27-2281e314b631"
      unitRef="usd">214200000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90ZXh0cmVnaW9uOmI0NGRkMWQwNmU3MTRlNTdiOTQ4MWJjMWViZjBkYjQxXzIxOQ_ea8f1ef5-23f8-4892-9020-b4f152a89ab2">Other&#x2013;Net, (Income) Expense&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;339.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment gains on equity securities (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(176.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,442.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;405.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of antibiotic business in China (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;201.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,171.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90ZXh0cmVnaW9uOmI0NGRkMWQwNmU3MTRlNTdiOTQ4MWJjMWViZjBkYjQxXzIwNw_f6f4a18e-4c5e-4faa-b833-cc5470847d22">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;339.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment gains on equity securities (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(176.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,442.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;405.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of antibiotic business in China (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(289.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(51.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;201.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,171.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzEtMS0xLTEtMzYwOTg_37eecc54-193c-421b-98ad-22cb6d977e47"
      unitRef="usd">339800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzEtMy0xLTEtMzYwOTg_8679b273-6596-4d85-beaa-1bbe7e4ad101"
      unitRef="usd">359600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzEtNS0xLTEtMzYwOTg_ca5826d4-beb9-468f-9425-e75db2ae4de6"
      unitRef="usd">400600000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzItMS0xLTEtMzYwOTg_b0b95ec6-0bc9-4751-be0f-0d7e2ab00e7e"
      unitRef="usd">25400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzItMy0xLTEtMzYwOTg_6d875a20-5785-4e7c-8fdf-3b78349422e3"
      unitRef="usd">33000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzItNS0xLTEtMzYwOTg_2335815c-1b93-4bc0-85a4-fd8b85b773f6"
      unitRef="usd">80400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMS0xLTEtNzU3MDc_ba7e0edb-2560-408f-9b7f-ca79e4f4f96e"
      unitRef="usd">176900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMy0xLTEtNzU3MTU_e6017fda-589b-419a-80f1-e6c0738698fb"
      unitRef="usd">1442200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtNS0xLTEtNzU3MzA_13c385b4-bf14-48d3-b4c6-3df52c56af0e"
      unitRef="usd">401200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMS0xLTEtMzYwOTg_620c4674-8b28-4863-a457-bafe552d4a96"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtMy0xLTEtMzYwOTg_a765142e-7e87-425d-98ff-0c344acc0557"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzMtNS0xLTEtMzYwOTg_6b9a9526-1075-4d24-a1d3-8964182f2452"
      unitRef="usd">-252500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzQtMS0xLTEtMzYwOTg_7e09c815-e03a-4ca6-a38a-390a2c972b74"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzQtMy0xLTEtMzYwOTg_c216a0c4-495e-4562-8b5c-7c6f5fe940c0"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzQtNS0xLTEtMzYwOTg_e9dacabc-f982-41c2-9c35-562bae272c1c"
      unitRef="usd">309800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzUtMS0xLTEtMzYwOTg_8243d020-4979-425e-8877-6d22abdf6240"
      unitRef="usd">-289700000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzUtMy0xLTEtMzYwOTg_4565bce9-88f2-4157-993f-fea6921051ee"
      unitRef="usd">-251800000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzUtNS0xLTEtMzYwOTg_b779bc59-9e3f-431f-8b81-e080c8ca2f90"
      unitRef="usd">-209900000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzYtMS0xLTEtMzYwOTg_1308f31b-af45-4828-ba64-4eb6c395ca1d"
      unitRef="usd">51400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzYtMy0xLTEtMzYwOTg_ccadd16a-1579-4f8f-b080-cad33280a9ac"
      unitRef="usd">-195500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzYtNS0xLTEtMzYwOTg_9d44c76f-e2a9-420f-a91c-44acc3bc3355"
      unitRef="usd">-56600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzctMS0xLTEtMzYwOTg_447f60e9-b220-43c6-9a03-389f0840e31f"
      unitRef="usd">-201600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9c4a15c775054696a3aba6396423ca18_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzctMy0xLTEtMzYwOTg_c5239c9b-1417-487b-8f34-6b2798b76963"
      unitRef="usd">1171900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i14540fa4a0fd4e9f8782af219d54ed88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjMvZnJhZzpiNDRkZDFkMDZlNzE0ZTU3Yjk0ODFiYzFlYmYwZGI0MS90YWJsZTpiY2U3OGRkNDYwNDE0ZTRiYjlkMTI1YzU4Nzk1OGUzMC90YWJsZXJhbmdlOmJjZTc4ZGQ0NjA0MTRlNGJiOWQxMjVjNTg3OTU4ZTMwXzctNS0xLTEtMzYwOTg_581e0f83-ab21-47f3-a6bf-3baf6144a41b"
      unitRef="usd">291600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzI3MjE_24766237-c122-43c7-a092-3023195d622f">Discontinued Operations&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. The earnings attributable to the divested, noncontrolling interest for the period from the initial public offering until disposition were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the disposition, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $3.7 billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated financial statements for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue and net income from discontinued operations in 2019 was $580.0&#160;million and $3.68&#160;billion, respectively. There were no discontinued operations in 2020 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain related to the disposition of Elanco in the consolidated statement of cash flows includes the operating results of Elanco through the disposition date, which were not material. Net cash flows of our discontinued operations for operating and investing activities were not material for the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a transitional services agreement (TSA) with Elanco to facilitate the orderly transfer of various services to Elanco. The TSA related primarily to administrative services, which were generally provided over 24 months from the date of disposition, and is now complete. This agreement was not material and did not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie9ba1030bd04458783b9caf2f17c3b41_I20190311"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzEwNjA_1691d321-fc2e-4a17-a8a7-fd4a80887a23"
      unitRef="number">0.802</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="iccb9aa249e034756b9c8db5d7fecdf51_D20190101-20190331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzE0NDQ_0d7d9a69-73aa-4bc4-bb77-3afc72a0de52"
      unitRef="usd">3700000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:Revenues
      contextRef="iecabf182d17143a49900323bf9cdddde_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzM0MDg0ODYwNDY3MzYx_4d29cd5d-455b-43d5-9bfb-00f9f9c52b44"
      unitRef="usd">580000000</us-gaap:Revenues>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iecabf182d17143a49900323bf9cdddde_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzcxNDY4MjU1ODY5MjA_8f2606fd-a660-463a-a40a-3bf9416c727b"
      unitRef="usd">3680000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <lly:DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm
      contextRef="i5c2697f3892040f38f4824aa3f7f6f6a_D20190311-20190311"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNjYvZnJhZzpjMDc3YzY2MGIzY2Y0MDFiYTUzZTg2ZDg4ZTg4YmM5MC90ZXh0cmVnaW9uOmMwNzdjNjYwYjNjZjQwMWJhNTNlODZkODhlODhiYzkwXzI1MjM_1e26420d-94fd-45a0-89bc-6e531baa8065">P24M</lly:DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm>
    <dei:AuditorFirmId
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNzIvZnJhZzozYmUyNmQyYTZhZjI0OTM4OTk2YTI4ZmU4YTMyM2E0YS90ZXh0cmVnaW9uOjNiZTI2ZDJhNmFmMjQ5Mzg5OTZhMjhmZThhMzIzYTRhXzcxNDY4MjU1ODY1OTU_4bbf845c-fd05-4278-ae30-6dbc19b91f1e">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNzUvZnJhZzplN2FlZmM4ZjNlYzg0OWYzYmVkODQ2NjhjY2U3ODI3Zi90ZXh0cmVnaW9uOmU3YWVmYzhmM2VjODQ5ZjNiZWQ4NDY2OGNjZTc4MjdmXzI3NDg3NzkwNzMyNzY_5e14dc20-90b0-4e64-954b-d1011961c4e1">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFhODU0MDE0MTNjZjQyOGJiODZkMjhlZTZiMzM3YTU5L3NlYzoxYTg1NDAxNDEzY2Y0MjhiYjg2ZDI4ZWU2YjMzN2E1OV8xNzUvZnJhZzplN2FlZmM4ZjNlYzg0OWYzYmVkODQ2NjhjY2U3ODI3Zi90ZXh0cmVnaW9uOmU3YWVmYzhmM2VjODQ5ZjNiZWQ4NDY2OGNjZTc4MjdmXzI3NDg3NzkwNzMxMjM_4833119c-2c6f-4285-9ff5-675c20a4e0b2">Indianapolis, Indiana</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>138
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M8YEP%1_3^C#^"-/K29E#EM9VMV9SZ:_% ^N%3=<+8'!5#T9OZ5@DM09I@<&
M',=8%6P:Y*L8L9O7R2S,8-ZW:W=((W3_.+JAMF&Q(#@TS\USP,$/[%[ =(=%
M):_9@WZOC'QWS--M(R.O'1JP!R2A1NG@2""]'1JY^O33"$#ZT58VMMUIL.Z?
M@!HA70(B"QV:A3XSV\%6V*G-$0<IZ)R.@@Y2T&F,@AJE@R.!_'..Y9]&0"4@
M:04)Z#1%0(V0)@%=)*"K(Z!GN5MA]RAE)*![.@*Z2$"W,0)JE Z.!!+0/9:
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M.@"^GPKHR^4;=8+U UQ7_P=02P,$%     @ #EA75(R+6FH= @  < 4  !@
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6R-E%UOVC 4AO^*E8M=503,Q[8.
M(D%I-20ZH5;;-$V[,,DAL>J/S#Y9VG\_VPD9DR#B)O&QS_OX/4Z.Y[4V+[8
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MA#RJ&2+-QLBMZ\.5--C5;EGBW 5E#?!^+:5YV]C6[B9Y]@]02P,$%     @
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MWQ=%_?RF^=+9X:N8%_\ 4$L#!!0    (  Y85U3%RG#E:@(  .(%   8
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M_HD;8.V\^4?33K\[JM=<&A"X<I3Q8'01@6XG2FM8U80>6RKK.C9L*S>$4?L
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M7/VA4D?SMMA6594ZF,N]C!)9: #\OE-0%S<?] W:-Q1O_P]02P,$%     @
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MAUULV\&=TO%JCDU6L]J+6DD;.NUQ@\V/;8<8_*:$:Z%Q!VEAHQM*[E'ZCG*
MY".4(<D[G\U$HWP!H\8<1^MLI]^0HK!!@C;.((#A+P>U E^IAU S@'S$38I
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MG2#NJ+D*0II%U /P;M-(F<)S) 3&_HQ1AJ"1-93XMXA83T/X<! ;CIWR4(Q
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M2]776]#V)&8%DV*E^+.&NNU;[ET,!=TE-[%+W\]8\.')ISJ<DMP4ZF("!I@
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M.,'!T7!RQM>TW@AIXY\JM&/?(M#YJL*<+53X.,<F>26C995192DU'N2['5N
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M89<MW8#?=TW3N2^T@/\;C>__%U!+ P04    "  .6%=4X-48JE43  "X:
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M<!][O,YK_:#%VQ1&JI?K<@1]B7E&9BO)/AFO/5HBDP+J3C.?_37K"S\3B\*
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M]#MW\,;D*2H$+BMT$?B>+R60<8*,OY1-']DNOT9C%VVK F33+"OX7&@ZA]J
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*56;6_C-@S^*X31#W=
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MN^J* >27E:K@)TJF&L6=T=;BSG0I[ /*"]7!8?*Z](85&VI0?_MH<%I*D?M
M6!JU*:Y&L=GK?TXH$K;3.:V$]B9^6,%9YWPV&]MX*^]Z^ ZZA6FSPY9YTZY:
MB']DG/DT=_E/K9KHS[F;0R#GMC< X\NCG$CA]W]D>8 B.;1QOZ/AOU(+W4I-
M.GGI!)>(P,6I\#IM'J1O#KG9/=[CQ?#9- *B,<IATSSR&(5PGRRF039*+X]1
MH93SVSB;"X83'NQZ;\IA#QXO"FSFI:IB/00)43"J;B>?!21*,OL958J13OR^
MJ6_K<_/38 4S!L.O;'2/VXV#G0<\@U%C-749[3(\ZK(!M3!]4LN"X$\.'0",
MCZIF[%XST).,0N&<*"9-QJ^G#IW]VG;GG@V&,]L=?[INE)U.6M^1\'8SNQOI
M_;+&R(]H?^D/;(SR5N]SX.G>"$W#@TCO]Z/^I:JS^NOHA>\[J3^$!^VP/@6I
ME"LMJ=3QYV-*4?P42D$XZT*(J"5.'(ZII<G3(NCW+7)!%/\1[06UPH=XL%'
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MMVW1'\QVYR0O5/3;L\!P@/.!@TY'@<<O.LVYAD*:FJU2[FM?<78G9S_J."/
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M(>1;L0].G?$N78[B.XI>0YU@P9?X2G/$W;$Z53Y6&:D>JC^8+$5(VYLALX3
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MK&^C)V?\3N4S+PY]+PJB\(GYXF&;L<P7?_XVO?]^LVZ[!FKQ/T\LD P+)+)
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MH")OBC;7L@"M9DU$H=A;FR7/!UQ=-G"7Y6(3:J^LI2$!W7BCP)Y6'!LQQX,
M<[6Y@V :Y!FTF_YPY'HML<041CT+*6[>JR;GY+<3=!&NSG]^Y](H".C"AJF2
M?_ 8)?[@Q3!4^\F(P>,8GX\GJM1@BT9U. -')@Q2&,N15/P/!BA29Z PELN&
MFU>(BF%SG(!_ST_PF!@[-@8!WW\Z(O_2;N1"K+P\P0)<66("^"&/\7YA_H"%
MLZI"Y(42*D8D$D=]4$^O JWY/>AS!H!FUZ."35<T#-(K ZAJEUYLH$Z'K#IY
M6WB5NB&$+3!Q9NR()I25)_AWX:YUZ16]2_VKGAJW?=1A8%.(NOY1;\BLI1V&
M/@.6U'EF;\)ITGC/%);3E\C623BVC_!"_Y9M[@LX,#T%_%-5'Q!IL%.P^)"!
MN+*ML0QG$-;M<;5NBIQ#'?.A5F0-2-5[LZBH14K,]*$%-TJ.$'(F=D<2&X('
M\J_U@(-*\9 P][: DP*<&)"_@/[CL<3RZQ+F_A_B&,0/J):@!ULDD4]G$/IL
M#G+OQ%&[RV]J<=GBNY%IX9Q$@0*[RSMJ$Z<?N3=(Q*L;NUTA HY="^'<)PVT
M9">!7#:A:=26]8E1G;8]1*ML<!$>8NM-#:T!5?C=.+J'E&^M-#ITDR+XH(@?
M,3\$?\[YL>#'\BX*D)!]=\44A%>$%$"D*WXGH03-!?(6AM%%NA"(L0R6 CET
MB%X.3O(2Z[V48U-&\A5S%'RL$(69V !8+1UL5!K[JJ^:JIY0M&VTD\<N3$P>
M"%BU[3EF/4LAST+G:\>+OW]B =EZO C@I( MY@(XED\@9>1G223HWD\C.N8O
MW_1S7LK:X @7_JE\^0V9]ILG:1%X-D>"*VESXB^ S\A-Y!RB8E'$S.XZ2U=+
MQI>!H>=9"^VOJSLZK*?)>*XV89@+UKP$L$V2 <]0("^1(@0CQ'D2A_ET%;1<
MN*_R-!/X^ADAB-9>M0XH[":>A2ZXKNA3ODA&C_'*VV$B<GH"4Z<0]_6TI/'2
M%#5>FK(&)#?7Z#O1IZ7$P;L@WNN5CB1EA!_K'9)W/X,>;E8F"5D%(9/'FQ1)
MMF1LB905;D(FXO);JB0PNJ8K_J'E3G5Z"L@GK,XP^Y!\7,^++RZSB)@F?1AQ
M_>7$(4GIWN(5-QXA#UD!$47(F)CQTKU>K;D\57NQWS]>%Q!%D.A4D**0E' 5
MB)TATP](.X]B*17Q"#DO2+J*HB5X7TQ@+R4D)H6[X8YNQ;HXG@6"EM4"#'QL
M(KXQ$&TJX>IWJO)8*Z,T+"DXTW)GF[[AEV:>>*%@&8G"WK":%&B>^,DBU,<L
MIHE:QZDH<I10)=Z+'D)V&UU#F<YJI70C=95K,K3?KB((Q><WA*L+=1G[_45:
M[::6M'$CK6>5_7R1Z^GRM16>,88O+F E2XY?:L-?LA[ :70BA/Q>7/_S^OE8
M&1:P!HK[)H[GUE1\.I(EC]-4QZMEJHN\*;\!F@4ZVA R*>ZUV3U6:$T<Z?89
MG1]240DZ"F&H *CUE"X,8H</=5-N'I _: QY[)MCW4KTPV9PH.=!WK"#8!O)
MA8 =@(;N,0; 7B-3;'[$JZT"5XON9'?KEG1.9BC/.T0(EI!,#W>1;5@#.P%1
M?^FGU<N6EVCB!J8 1O QV8;.VDYX-L F*"6?5UCT#M2=[V?B\A'ND!)43*'&
MB268L[X3+I@;FD*&S]^)^UN'Y60.[;#%CL]R0N<^Z#Q<0\B6R;FBO5KW!_%T
M>J/3(ME8,!&0I_'ZIFAU\>TTWBAIG%3;!DKM"+%9T1:>M39=@B2)TH/ '+XA
M-M9Y(:-%BEIKIE#Q-S%$0T3F239!F@WN6;SANPIDF9(RM<1=$YID+X)A2.58
M?,PDT^DTG>1UL44PL^GSX&M,\!>,5+0?\?OOO=%? ;0:0V/4OCA:91QEYY8[
M9][/LY]F,M/['D*LO0]%7ANF#!%/9UR?"FX3TDL#N@?:@57575FOF1Z.^W63
MTK*N=G=@T,&K,DGFS"B'#G]BR^([!-65ZE-AM .T';)*ZE78^AHZ,!2P-FK'
M4$C.D!VF)J8+ 4>X:03QH@9);SJY,))Y)YP_:;L3&HCY1:@#^\6A8/M[$-*)
M%W<V^:?Z 4,;7<LH*-1- 8OH)\PP=$OY@V7M5BP)YI^/UE\BQ^],2D("Q#_H
M^@&6YT:P_ZQD0!#E(/^<%>KUKUJXF!M:3R8+*V2:NO3'-7B*HAOR<BEP"%\Y
MY\ NX7=18<@_U'3,P&=6(DV9A;44^*?6\D'S'E?4KFY$S]Y5@RL>N)79.TZL
M$O&I[J;8;E7C\,QXWGOXC;IOS=FS+9-4Q<U5#(PL,;$((K*KNLNT:Z]MU';J
M"ECM443EX"\F=@0!P30,NN89$2RRN,^$@EN24,#W:-*TTN=3)3"J5C>6W<<,
M "+OI;(S<)W$@5O?C7.+.L!U(G(=11GZ5GO.H>A8-V,]&,E1+>*GNDR6Z)'A
MY1X]17?R$0L_B2XS]/L$! ?@9EZHFQ%QF'K;@0\BFNQ8;$JAOV2VK+,P"06,
MX2S9]R6317INX(NR:/>2FS5UOQ.G*P+641MR;_=F>E,:TLPW92]OC4@R )X[
M"( .6: .K.T.,]Q)!5B$!$OJC3ERHD,&1]4?)IQ0A7[$9W?$3>KQY-#) _.P
M>P/76FTHFLF:V*8Y4<6'M%L[U%Q!1L JVKH*JYT;J]ZNZLB4VMITM8JF8QVA
M0TNAU?G QUU8!;F^4ZS0&]PU)%-H:4<4-&JC0YGV+<?L9'Z<A2N[06,'9P[3
MM[#$%AST!*9"-VZ3,W1Z@35[FC25O[&V[!1NAZ!\,429"C&T3]!L(9%^$J:6
M\R%,@64/6,AQW3J(CW>(/=P9*#QQ\8;ET_$NF:J2JF]+"@92"PJTR@SRG!B?
M19\2]F C< 7B.WU:^3U=F+[OKBP^3FCQ#?,PH>(38PV(&34']^&4O458)$/
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MM?ATZ)9C!Y] 9;I\=HL(3*W)/.P5Z5939WS>PY("#:#1S\2D+;08 I'!*N<
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M^MU2T^7M!TO3X*W?$0D#><GA]P9GOI#*2>>RWGELC@@@SF+S@AHFKUP_XDQ
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M ZYO:T ,\X,+#/^WZ9O_!5!+ P04    "  .6%=4IX=. M<H   Z@@  &0
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M8ZW^!GR%)#"VG(<#J$#IY(8#;8]=U"U@LSN'T/0>BMU#IL/D%_11R.V<E);
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MBKODP RKN O']IT$A4W" @FJS XZB>,*FUIT(H[,#6#]>E0W,KCEA$Q2B0H
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M4BC>-9")%+#C_&'15<R-O!A?01'#QC,(W'SWN(F5CV81MJV.Z_/?\'J<//2
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M0FM* ,UJ3!8SG:_QQR7 ![BA>A/E'8*J"-ZY]CV_._;8K?8O9]??_"MB4MZ
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M V'\5RC_X/26O_PLM7.ZYB&J++('+<#[E4:6;A](P/Y3X,7_ 5!+ P04
M"  .6%=4N,<V] 4#  "(!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6RM54N/VS80_BL#)0AL8*,')>W:&]O /I(VAVP7&Z0]%#W0\M@B(I$..8HW
M_[Y#2E9<-+OIH1<-A_SFFQ<Y6AR,_>QJ1(+'MM%N&=5$^\LD<56-K72QV:/F
MDZVQK216[2YQ>XMR$XS:)A%I>IZT4NEHM0A[]W:U,!TU2N.]!=>UK;3?KK$Q
MAV641<>-![6KR6\DJ\5>[O CTJ?]O64M&5DVJD7ME-%@<;N,KK++Z\+C ^!W
MA0=WL@:?R=J8SUYYOUE&J0\(&ZS(,T@67_$&F\83<1A?!LYH=.D-3]=']G<A
M=\YE+1W>F.8/M:%Z&<TBV.!6=@T]F,.O..13>K[*-"Y\X=!C"_98=8Y,.QBS
MWBK=2_DXU.'$8)8^82 & Q'B[AV%*&\ER=7"F@-8CV8VOPBI!FL.3FG?E(]D
M^52Q':U^HQKMZSND,YB\UY5I<0IO'[GE#A<)L0,/2ZJ![+HG$T^090(^&$VU
M@[=Z@YM_$B0<V1B>.(9W+9YEO,4JACP[ Y&*[!F^?$PW#WSY$WQW1O-]MI*4
MWD&?+TR&?*?PY]7:D>6+\M<SKHK151%<%?]/9?\#V:L7,Y%E;WY(":<('1!J
M0." J P_)4>X ;,%1L/6-/PFN1*7H;S^D_(GFW-E""TZ&FU?0I[/XYF7Y3P^
M9UFD*<L1J(9:BC(NIC#)\SAE,4N]Q@'S^5>&\6LFV/&H<, O$K]TBKZ!PZJS
MBA0ZF-P90KA@R^SB/)Y[>584(A:\*M+,RUM<^[!\ SOEZL#8&'>TS;(IAU;&
M D(MQ!L0I8A+^(6=>I].-NCSEYK46AE2%:P[Q]5F!D;<U$K+@2J?CAQ'.<E3
MKL(4'I"4Q>![C1JWBF#?2,YJ(F;SV,<ORLP#)X(-.(_0G7^W9,(H+E V+SG$
M\IP+^O,VOO0M"BW@XF07F:?GM9CSYO1']S8YF0XMVEV8@8ZO0Z>I'Q3C[CAF
MK_KI\AW>S^@/TNY\\QK<LFD:7Y01V'[N]0J9?9@U:T,\N<*RYE\%6@_@\ZWA
MR@Z*=S#^?%9_ U!+ P04    "  .6%=4SA5Y\GH$  "0"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6RE5MMRVS80_94=31[:&5<7RD[<C*P9.T[;
M/*3QV&GST.D#1"Y%C$&  4#)[M?W+$A3DFN[MQ>) +%GSYZ]$(NM\[>A8HYT
M5QL;SD95C,W;R23D%=<JC%W#%F]*YVL5L?3K26@\JR(9U6:23:>O)[72=K1<
MI+TKOURX-AIM^<I3:.M:^?L+-FY[-IJ-'C:N];J*LC%9+AJUYAN.OS17'JO)
M@%+HFFW0SI+G\FQT/GM[<2SGTX%?-6_#WC-))"OG;F7QH3@;3840&\ZC("C\
M;?@=&R- H/&UQQP-+L5P__D!_8<4.V)9J<#OG/FBBUB=C4Y'5'"I6A.OW?8G
M[N,Y$;S<F9!^:=N=/3D94=Z&Z.K>& QJ;;M_==?KL&=P.GW&(.L-LL2[<Y18
M7JJHE@OOMN3E--#D(86:K$%.6TG*3?1XJV$7EY<ZY,Y&;5LNZ%/#7HE883&)
M )<CD[P'NNB LF> 9AE]!% 5Z+TMN#@$F(#50"U[H':1O8AXR?F8YK,CRJ;9
M[ 6\^1#J/.'-_UVHI&Q!>->XH S]Z%W;!/KM?!6B1\G\_H+CX\'Q<7)\_/\U
M_D] ],G21^7SBF9)K=GW1[1EREW=&(XX&BNF(D6H4RNXDESKT5/2M=JNZ70Z
MS@AX.=M(;FO9ATHW<NZ]439W@E7#$.68WP(.(JTK4A35W7>E9R:^RRMEUPR3
MDOV8/L,C*R_@$#A&KU=M5"O#%%U/9\,!W([(.BM!>6>,4-$VLL<KPL!))T%+
MNX)*[^JT!N.HD:FF71F==P[%L(4PYB#,+8  ']$OP(3-F,[!!G$']*Q$]TB8
M(X"GO5)[,/C:*@]#.3B(ZCEW:ZO_@*J*UI /.T8ED=U3.JNF\>Y."P-S3Z_F
MXS>TTHA4G$GA 1+#-$!W0'1B"XO<M(4$)8A_XP4X0=:[RG"[RH"E9!KO@C.Z
M2!"EMG C$H:(#4S8&)+:RIA>[; C-:9KWC!P$UV+SP38N9J[A+S@5R2C+;B]
M.D%Y33&\4M@)!CJ\/MT) 5\-I_%L[E/M(&]]\E[VD$T3G R(KN;^04;ZBNXS
M?:#,H(><RU6HJ,1'*_3YX) L>@Y(3E='80_TH3,>NQ5XE$^ET:-/5.7/4'7/
M7=^>ST4NJ=J1D/BUE69**U$1/L'U+WZ&CKI'9Q++E";,6*Y7J/%Y/SG&] 6=
MFWI0<"$ANMPKVP4B-<-^HW/@JS4:/XGUS>>;\V_QW8K5H(.C4N7::!&T4\T7
M[-$!":OLFFJC4&MMV$'"K /HD@G8(9>-1P]Y+0B@5.!+J&5 2\T,]@<*KQE3
M#!5]#U.WT1*LV\!O=DQU]YT:)HID1_@<-I7H&B#@=ABDPDKO!R[5?:"P&!6Z
M2)O(G<39-LA_VY6.6HDD*01M2].RS?E130%A@C3M>K1!=>:2SUV5A785^&LK
M#)XH<8EF_-17:[)W2ZC9K]-=*( G)F=W81AVA^O6>7?+V!WO[FKXVJPU2M%P
M"=/I^ UN-[Z[_W2+Z)ITYUBYB!M,>JQP960O!_"^="X^+,3!< E=_@E02P,$
M%     @ #EA75'G"<UCV$@  &3L  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S N>&ULW5M;;QLYEOXKA =H)( L7]*=SG0N0*XS!M+3AMV9/"SV@:JB)$ZJ
MBFJ29<?SZ_<[YY"LDBQ5,DEC@=V7Q)**A^?ZG0M9SVZ=_Q36QD3UN6VZ\/QH
M'>/FEY.34*U-J\/<;4R'7Y;.MSKBHU^=A(TWNN9%;7-R?GKZ^*35MCMZ\8R_
MN_0OGKD^-K8SEUZ%OFVUOWME&G?[_.CL*']Q95?K2%^<O'BVT2MS;>*'S:7'
MIY-"I;:MZ8)UG?)F^?SHY=DOK\Z>T )^XI_6W(;1WXI$63CWB3Y<U,^/3HDC
MTY@J$@F-_V[,:],T1 E\_)&('I4]:>'X[TS]'0L/818ZF->N^6CKN'Y^].1(
MU6:I^R9>N=N_FR303T2O<DW@?]5M>O;T2%5]B*Y-B\%!:SOY7W].BOB:!>=I
MP3GS+1LQEV]TU"^>>7>K/#T-:O0'B\JKP9SMR"K7T>-7BW7QQ;580[FENK:K
MSBYMI;NH7E:5Z[MHNY6Z=(VMK E*=[6Z:#>-@5&B9IUBU3^@^'>VTUUE=3->
M=QVQ0/M:/<@4'CX[B6"9-CZI$GNOA+WS ^R=G:M?71?70;WM:E-O$SB!K$7@
M\RSPJ_-)BF],-5>/SF;J_/3\;(+>HZ+ 1TSOT0%Z^S3U7R\7(7HXW']/;/!C
MV>!'WN#' QM<F6"TK]:L_S?F!H&T(0NHMY\1FL'P]R^K/WKK#0S4'5]Z5YD0
MU,&%#RXNKW[0[>;IF[T6^3YVPG?QL_U0/7K(9/*VJYJ^-BJNC5JZ!K "W?^B
M?OC+D_/SQT\/$ZA<B&&F;M>6?O0F4ZR59J*]![_S0N=7VQA$7V?41M\Q ;=H
M[(K]?GA>;;QU7D4'A%KUC8X.L:0W&^]N$ T(#^(2G^J^BN.]=57Y'LMOUZ;C
M9\ HMO"&U$:^5#85$FWAQE78.<Q'&L[*RP)E#05>:3L;*3)9?")G/D?C.]TT
M=UD]6T3 [+^ F-"4SCO4^+>*>-X"114<NPM:,-5A!TB_UO3#H@_P%1BZ<NT"
MB$!/S.C'J&JG.A?56M^0NRK=, N$QVK9QQX*Z8.93P3+3R58?IKTSK?:=U!?
M4)?@ZWI-JG[P]O)ZKY]_&Z6/1E6ZJ<C6AO*!K12^YLQ0*R?&O.5<8.ICR.N1
MVU37MPN0@?:AFQ9/!2((<_0Q$$RRQ9M>+&:62ZB;'H8AO:!MDU<LO6O5QD5\
M25;=:!^!.1O- !0,? /F-O"/+3YKV_3@YW^?4]>C HBN^G0LVX(H^:AD#[C:
MRNLV3!G^<3'\XTES(45#E$Z]IK#LJCOU.[EIPQOM,_ZW4U._;:"J# ,B8;\(
MMK;:VZ0IF_#I X(/4B,51OSRX,/\>OZ0XQ\!Y3P2&E%@(.L[CB@*U+PGQ:H&
M7A3J=PE ;$#D(H)0#H#" H #>C=4 26T,-V-]:YC  '"$-;M$ )L(>U;Q/3*
M="1.PFV&D!HAK,-ZKGY?$Z<!!0XCAQL$1SGX!<DA*DL:D^; *7O$?4DM@SH@
ME-?4@'3M@R(P66WYJ,H^6C1$?#,KC+(&4 P ?QF"B2)-8_7"-AP0N[P,Y&4=
M=$;25X R[, *$?E'3"5_#X)ID!E8RS)ENIEDAVI:"QMB$3RXI:E=%Q <I>#P
M9DTE[PVCN&L!.HT+X>%4B/Q<0N3G2:=^64-_T;+@.5GO"XW_G,IKSBV0V*$(
M).W>VH@\-WKR4+YE,]&/*6>Q-N"9GPPI<P9$:QK^@Y^KX?&6*BO.'+DBF-+-
MDZ*;)Y-2?4-=NT]UDYM0@_5+V.C*/#^"G8/Q-^;H6W;>]UU0'S8UA0.5M<>G
MJ&^OS-)0F!AU1=_C([J8F9I0UE^+LOXZJ:Q7.=&_'A+]7D^:)O,!%3V%+N"L
M-7'MZAD'3PJ<4GW<"^2 #I)\S(R#" &)Q=837FU,):6%QF?483VORN#(A(-E
M;;/&$HA7$ (%?"U05?0?"+O)/@D/,O(6<Z$N Y;RHK)?*N3P7:L[0!8C,1"N
MU9^ !*,^*R\6O&+1-JQ.V0R 1'K.=62/NA9IE- ;9G4W1I!OM.]81MI^0*)9
MR@0H3M&EZ$5C9JC'@EH8TXW4&-3*N?K6-LT4_!=4&RDS2'G'],;1_%6Z33A*
M^B63@/Z(\OS#!JKF%#;Z5KR%REK4DXVKF#9TK'<+8ZEK;PEU6C@.(13R7D&C
MA:DTJL]$K=T@LNJ!R%I#B>X;*M:STZ$#/YW&GHYJ?T>)86^#/+WZ(W/"W#<Z
MQ&,+Q2RMQU](Q^K!^XMWOSU,\5529:O_A>TBEQAD'CMPH+(F4V$"RP%GI+#C
M5/@;IZKQ"H)O]CZN1=@A>?\=3MZ-.)DK^I2,1]W2YQ0%DMJI$=HT ,K2N$UJ
M>C3K.)O4U6L'..RB>+&ZLN'33+V&E6WD#WNU/TUQP&G;(3'UXLQ<'Y0B'<Z&
MY$]-E:*ZV:E*MD3]\(DC RF-0KJC.IZ>INCRNF9T,_:&8E7P 5420A@*7:#%
M)?0G,X28T.GCVN%!W5"Y#U[LHH>!.%8;NS3' 84698/4C1+"<A9AK]!<GR"7
M2%?A?$8W<H][S#P%VPW549X$#ZF&)-:IR\O8QSU(,.83(Q]B=D6A3?[!DN^6
M"YP(JBT+Q;5W_6K-3+ANY4AD4=YQ*G@W-%NH>U\4%'K48I5!&8AP\"CE=F2A
MPI987ILFE<Y+D.& & $3&=/&7I#XA[^</3Y]"EG0#MF8"E_ APN\;V+><.,]
M+)/Y@_2]A#6PON[N!N3<>A8* H@WK"@:Q4HJ&PT<YNJB8X/YFL2336M7L<-Q
M7^4A*.F7='L\RCJ;-)0"_@\2<(YHV?K4Z8D_9I$81(G5SNQ7B7)^M*%%TC*>
MC9VJ/!<$B8NII.2F0I9+_='  [MWKD-BX?DR20:;L%L:S[VM8>7L"C4.-KCY
M'CW?IS&M8+4"M'?I^S4:CA*E7-9/%IEGYP, G7\1ZB5>]V+-].*/1M""JB8$
M&W.)D&LLPJT>0T$JO^'5L<\PCU R;'^:I<)^#=45]Y)NJ3"@IX618*%H!KP/
M%1"C]LB/AWVWH'RH2I T*&) )]YM/R^3,#:59*?<EA&SM5UR!1M3TJ"NE[I3
M>B*-+^+=AOF^1WN8!UZ,]H/K48;7'7>K5#Y)0XW(X-IE7)G9;@G6V2/A8.1=
MFI.A=]R1%"R>$,)DOG)YRW;AMIGG2=S@IRD3F43B ZD/D#7J"X]1Q,W4 ^D'
M'^;"99A4OG-[E7MO\$:'-I:G?JF"!92/:V1!"*,% ^X;5S+Q3%R'8LQ"E=;3
MKS.9"8$1T,4?TD:'5#V2-F0:M*"FA_>5$C8_1Z*B_O3@;C1>#*5@@<\C,U4T
M4H7R;&NI&Q^8RV5OT.V 1R\)!:2=MZ,*5^ID&^[WWU_2,SGQI@=D5(=\.2E/
M>I9*>Y1'W)F,0V&;K5'IGEB"!_[[*YCZ:/+,9P\OH['L889)MQ;15 TU_6!0
MEN"@N>@T+0V\^4S,3L/C<)1R]F@2X=X8#ZBA(GM_)3R]FNQ3%PIRWC?,?F0.
MGJN-E(160$Y#=%C\_RB?CB87J/-JR7ANN42OE2.9GEAIVX4,5[D3&[6S,MG8
M<OJ%H8!9FWI%-=2OP]9B\)#J<L]YE4\V:73%HRG*8:EA=%O:2#;[HT<^Y# 3
MJS%VC'1VKX@E 6M#N,BJHYU  _7D';6*(^]E=H/T9'L)DG_S8*>61IA&/ *(
MHB)N\S,"EC!(_8"</:2)V*#G* UJ[O?OJ7U$*%F@[QAE2,&YW/E>)7"27#;P
M]:R#>P+)N"_!.I9H:32[!%W('GW;2Y&T;Q)(5)@<Y$&/%Y"B&"&@B)(_DD,S
M J:))GT6+]HZL]%IB)F7WI.?=D)1=OSM*J&IPPB=Q[ZQ3)/U,L.-H\EZ"I:2
M"NN>K1TV+J99;X/.I4^ ]2=H=:X&R)'LKJNQB)0[QV(&ED72_Z 1O3.(&H5%
M;@Y8M"S9#LX7&Z*/V1E*4W'.F#N)K\-)\MGTV>W?TFA'CO+1TW<K2^@N(_.]
MD/N5!/.8B--\FEKE8E5L:P\=$1Z:8TG.7UK./Z.)>A[-S%79'=#"!5I+O1YI
ME4HVSJ<$F*DJ&R<W0#12-66YKJ>^=<:E"UP3 B!5)L392H@I55)'3?;F 2X5
M/NA7>,C![ 6N_#@28AH6P:%H#=RXG-G0)$ZF*(**M&]C/]%4BG,VR<(NN*,4
M/,NU%S]D8^ 2@[%,>CDTB4NJX:B)YB/R[Z'/26:;_DPR"*R2A(M4_S(E+JM]
M.G(>D8386XR6C5++)]E@T,QV8[I=9,X)I[8RY5<</Y,Z] 8,-W",T3%Z.E\?
MGT1$<@*]C,D;TYR$AZ1N$34?MNT[Y2?G*D<6\]PAA3+$O#^+S&?L?\H1.[OC
M(".CE$M#NA+A*79LN9 @^T\?R#\5.K<V& ;ON^UCG-$T=:ZNT;#]PP&B'\D\
MZ0N"L]-,SU9!\H8'3+G[:_4=-:5]V.<T>Z?P5 ;M:&*D\X.(Q-5U'RV[#!$_
M2I5'ZN..AG-8K=[3'0J2>M@VM0&ECN:1.^U,\B^D]+M+QYH"^!Q!@I9AF)!1
M23JZP,)-A8/2/0UD[+_3C,SMRB\J),0LI<E6UD;"RX>QR1[LV"@=^WP*7(BQ
M)W/;'XK;E.1;;A)DD L]C>@)=QMS0TUT*O,"%(D644<NH#W<I)+H7-M 0V1J
M[*C#X,Y^61J\/*FD&EDW=R$/>"3_S\J!=27=<MTC)5-!02?8Z?SD"UK1TNEV
M-#'-'7Q2: +X9%)IZ2E2*.K!J]RJD$5<F]"&Y!#,*?[8PC@*"3F_H#@D7GF2
MP7E&.#T0,#GG\>&UR44(K5]20V..&S;F_4BGX\&&8;DQ>6:G%]!8NA;@MI%@
M1O G7@V-F:V#."] OR>-DF^7G%O2.#P?8$GZ0J@N^X;'S[3_K;<1+D#5^XP+
MMD&7<_5ED:3,^G^5T?-QG7C%_[WTGOC?M=6?F_;I,/Q;_8+OUY$ZLZUWQAS$
MDMB=SD_X)%3B<);:";KE(:<'VU7-'OTQZRG/?J.DS$)^./<".V7Q;J <1 [X
M"I7Z^XSVA4C;42+Y =_[ZCW-]F50>#@_'C$P]H&O>BP "Y/-RW"S[VSZ0MZE
MIP/HB,B^;'1"G[<0?7-PG/YU]"2-9$)D.CZ6+B,#GI3(A;@ $V'9C0UE.@D@
M1^5FRVV 16^;FKNY;;)<I,&?^!K><%Z6#DSI3@M5 \?$9#ZMU9)8PM:-/5AQ
M2&H%7VG \^#LG%SMIU-U9^@"%7&WS0V/U:=L,5RV.YN^'\?W(=.5OM>C*WTS
M]=NFC*0N^"B/@(0,MK^]G-[FHQE:Y3U>?/!B(7P^WX4=926Y.4!'DOZ&IIE#
MCRT85ML;6P/HU0KE=S2F7!8>S&4H$4A W>2@2-?./G(RO:'[;YVYI61#<^BZ
MW)],QX_I4B5QGB9_7"S>I:]HV@$9PE+\@FCPJ1B67[Z<J>M_XI\K^H?67EU_
M2.0G(VRX'W8V?;7K0J+X=_WYP/QU>OD;NG!$0!2)0)F*I$%''N6G0@S/E.MT
M9 '3TKP5>LBG/A4YOHFW=)UD.(640UX9 X*"C'_(#"5&3*>Y'J2?&WV;!F=R
MGV^'PWPP":6O&A3FS1@*41\>TV-EOP=_NWC_^X5<WX03N.\4+HWPQ]Y-RQ;P
MM242.Y?G2%P]GO74?/*O@%^YN.2Z5,Y\10DP7C@;%$4)&H7XNN/R&UV%Y4M"
M-$]9T'7%D%K>GB_??-;ESE/"+)#EW-<#K.B44>K8D0R[<RZY&7+H[H_T#H.$
M6^<I6W>6^5P?E4E65>HEJ;]:<8V<VF4@(8*3,$AT8]=.PET&['A4^F46D(ZI
M6I[WF^ :/N:>#*KA8N'9],U"P&-K\QE11W#)%_?DWNO>*)NF]UXN4L@;394G
M/)J-+_SJ9L_Q N.?./N0/<IE";83]=K2'W/<+AMIJ_C88.5I:BF)$'K>NHTG
MU];X6&,8Q7/]O>?J%V*,-^3WE2@$:#R:E@V-E\Q=\BYWJFJT;</H+( VE*DO
M3XSI7LVL'.+F5ROR%>5!X.'.1FZ:/W-'6D8;"P=VI$=O3)JX:Y1_^'B7Z- /
M6]YH.WDUC@URH]&XTB/8H)<0%W:8FQS)!R4LLZA\Y+RTS="1)FYYHM4109EN
M\U%<XG+H>%-:LSZW\!]'O\GA;GFC1N09KH1#DE%CGGBCI[W<(.*;+3KR$:#V
M\DI $JD/>H5F[CU^:.CE.,[!,@XKG;K<+2BR\J%\UZ6W]'A@/CZ'OZ\L'J%7
MXS"Z_TK-UUER_BK=_4LU0*<9ONDB!-)JJRO3QS2<R),( 5SX4> LP=C#/5G?
M\%5"RA3YMA<$E3M(\E*%3 3KVJ;K[_<E$SXE3HM+C!(+,IAT'QKE!]()W3^
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M^V#>T(H?!:);/*X*35BNW&:^F85M(ZC+!^Z!:KX'JD?? R]KXM]!QHUKZ3I
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MT<8(5E.#1H:'M'N#SFN9< E*41:%MDY;Y[K38I<NAEX/W_YE"J[W>,E7U)F
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M3L,QV3S+PQ'<LPV].XN:,T$D9$4Z;EOA&(V3<9C"69[0^*@L$W#,6L)YY2[
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M;(N3:71U^=)7_XS?3RXGJR,N^^,_9T,S)[JL5?>2PCM(\B(LW;N(PY67L[
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M0YUCS3P?'NS!:.3F,;OFJD8$#)36?>!TM]*RD%Q1(!Q_'F>AK?/Y$L[@ZF;
MG/T?YOCF_PC$E-+_WQ"2QIZ/EXGAN@1@P7^W2FRY+)BHMF7S+,0+$AT#56)%
MWR-YMPHSE6J?3:C%/YVT@79"4"X$.:&/6!^Q3\AMG4M$0M9H4IT%A!-ZH>L1
MT<&XY=&K7/>! G<%1B=QV.&0CE'AQ. QSVC'5>J3_@,ERCZR&H/B!Y;&,2"
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MN,OW<;%F4KX<4#TQ$NB(!($5L=@6Y&#\BH9GCN^;+>^<T<B?&^.IL$.SK$
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MWOR4_1!E;]IF:S[^( 5M4YG+C>!@7]J _]=-T^YN2,'P-?#L/U!+ P04
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M$#160KEH'"']Y8+;T*4#IO$5\O1>V3)<SKDA8I 38>&*$N&(,A=%*3MJ1<3
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MYE<IC 5)8]/C>#Z@+01T8'A["O=HT+(CLTA^P6'=RG$(NR\Z'X.><,N><-V
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M;F%(',(Q\1G\=U$:J^G._'\D5#Z%RGVH_(E0]_24ZKY%4!L8"GXT^)^J?3R
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MWUH2DA45*%T41+$XI8+^O8W/7(M\"Z@XZ5GJX&G-%K0Y^]--C1^-A@[UU@]
M0]>AEW:8$M/N-&,OAM'RTWP8T.^XWKKFM;@AUR0Z*P+0P] ;%*MV?M"4RM+8
M\LN&_A.HG0&=;Q15=E1<@.G/L_X!4$L#!!0    (  Y85U2PV"F;3P,  ,()
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;-56VV[;.!#]E8'0!1+
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MT@'KAQNZ9*%V#O1]I93=3]P"[;5M]AU02P,$%     @ #EA75-'Y49(V P
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M;S= YZ2A<_)^=/CS-CIA)\YVTCEMZ)P>E,Y$2)SBZB511:FDYX%8H5(R!KL
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M"AD85O8S;#<*(SN%1/(ZL;Z6@1#E=(5]+-H>F#T9+#B8EV2L8&"JD24J$HW
ML[*?9_^25[?+?'-3'.+1URJ!]F1BM2T# <KI>EMR4MIG9#++X4!+LL3!X+Q2
ML0F4#,PJ^YFU$X(1Q!083R:6WRIPH)HNOQ45RZX1W]WA@8$90>*U8&#:X EO
M^PX"M:I^:J5Q&$E-*G"?2JR^56!!-5U]*RJ1C9/=-8ZK(PP/PUIVQVJF+FD=
MBFW[^M':93^UOLR;IEKEU2 OJ<!U*K'(5H$"U721K:@H=E[0UJ<P $$$X(+%
M051CJ\"MJI];VQ$8IB45&$\EEM@J,*":+K$5E<3:.4I+%.84F=PN.)@UL>%!
M!V+5_<1*PC"2E70@/IU87NM @'JZO-94#LM,=6="5PQ,.$&6 3F8-#%>TH%7
M=3^OOJOR?Q>;.A_D)1VH3B>6U1IMITR7U9K*8&DI+W$P[<@".0/3S>0KPDHZ
M,*ON9]9V^P^SD@Y\IQ.+:1T(4$\7TYJ*Y.;KG7D?7QIGBG@]USU%%DP1T0PN
M+A*>P+>ZGV])>$:RE0E\:!*+;1.(T4P7VX;*8^$SLCQ[A.$YE##=H8.I2S8S
MVD@P3&!;T\^VK^O[HIJ-WT8R@05-8HUM CN:Z1K;4%4,5A*-S<$,8;;%$=9:
M=M*Q( 3*-?V42X(PMD>@S>W$>ML$CC33];;A=#20\9N!.:"Q8% NQH+MFPDL
M; ;VNC<WY:J\>QS1,0+_F<2*VP8BM-,5MZ4:66:";N0Q.&$]G4UQ.).YV*:J
M#11K^RD6Q6!DO["!_FQBM6T#']KI:MM2A2PLT(D5A]/"DJ5 #I=ET040&YC6
M]C/M]ZOE>OS$R@8&M(EUMPU4:*?K;LL(92$E61]G<89N;K.X>,J313E$_23;
MB</8?A%XSR:6WS;0H9TNORTCF)NO.^D6% :94=W=O@57G3>Q%7(7:-;UT^QO
M1?5[L5F68_N%"]SG$NMN%ZC03=?=CBIE)Q7I%@S,@"/LQ,"4C@H+%QC6]3,L
M"</(;N$"_;G$,MP%1G339?BQ:&O5%;J=PE%U+3Q=&V1@NR7$R$CA LVZ?IJ]
M>JSR]>^CAPH7J,\EUN .)3I.U^".JN/=&D<W5Y.#-7/9KM;F8%+'EJ)<(%?7
M3Z[=*(S-W0S4YQ-+;1^XT$^7VI[*8V,5F<MR,$VWCQB8=C[6)WR@6-]/L3]4
MU\OZX?/8/N$#\_G$6ML'"O33M;9G=J";+SN) @?+B*!@838:A<"LOI]9NU$8
MVR<"]?G$8ML',O33Q;:G^GB7PY&AGRY;,46T(;-:#J5CLR@?V-;WL^V[QX^/
M]>":N4=YY<D3RW%F^3FIY50:*Z!C!8>3C8+N3F-/N-8JE(RT/V0HF3SK9U@4
M@1'ILAG**,]2IY1G**<\.R.I/*,;UAD)PR!FT8_I7#I*'\_ZR;4=@+$IY!G*
M(<]2)Y%G*(L\.R.-/&/RR-D^P>2'LWW"?$F?0%GD63_#'M9FQZ\#0H;2R+/4
M>>092B3/SL@DSQ@%+<B0?,7AE"'9LB=8.SLSDIP)V+\S8. AP1C;15J.FL22
M&[#5!J:+[E/9EH(#FL/,X4#3[ .VOBPJ,@#;> 9\/*_6ZX?-V Z"[3206&\#
M]M? =,5]*MMJ8\?,;5G@;H^<1H.*^(:]HXXP1+L#[IU6,$9W$,2(D%B  W;:
MP'0)?BK;:D)EB2L,F)SRC.;9+CB@E2K>01#Y#MAXWN6K^O?1,RODK &16'\#
M\MB F*[ 3V7;+*0$=2-Q0.%H>@@+S,#$%@H!67A@P,/3CL?83H+\-2 2*W)
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MZS A@/4)^NEDE4(_&NMV0$FDY;[=/BO!M/3-G3IL1>5:$+46<;T6U;E+L"@
M3S7OC#]5TS5SOZ=86$IN+;W<WG+F4QH(M.0,2E7CXT"^T]4R4;%YP"V'=<K!
MIVJ^C>HZL?O4P%::;.LUN8[(51F1"01?T P^]A)\0U35X?QES@)..=2G0+B3
MK=U6<]OH:P=MI>6V7LM?]TKIPFYWI5WO@\:-ST#Y)]1KPE<AY%I$EV!GC%Q0
M 5Y^E2PO)$N++T,+)B6+BY]K2J"XY@/@^9(Q^7*1?VRJOPV?_ ]02P,$%
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MR Y+"Y\GA;3>[\C5A Y;@E:$1'9"'DOH"6J@(G1<U,8<5'L7M'/Q9R ]0?L
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M(G( $:<<@%( >@\P*P!&"C": LP48#8%6"G >@\P*@ X!>"F/=@IP&X*&*2
M05/ , 4,FP*@OL^<WAB2);N0[2JFX#[=L'&^X3[AL''&X3[EL''.X3[IL)#U
M2L@^[;!QWN$^\;!QYN$^];"0^ZHM!??)AX7LXZI=N,\^:IQ]M,\^*F2_$I)M
M]B3[_9VL))HT=KAS=A*R%Q#&[46\^" 1M@0OI(@&L08O>"BN4H'C9^?N[RV-
M:*R'$7"")1@+28PXY=N0@*/S*!*W@7R;S^!H3+A#/7'T)_BQ&(.C3Y_!)T #
M<$L]+VYRTN=B8''XOIL.8K0;!*H8! 2W+.#K"%P&2[(LP2_4^&$=_J&F?Z0(
MT!>,9K2B/:TCI(PX)JX&#/@%(!W!D@%=J.$+LA%PO1(^5L//MRME[Y=J^/76
M4\*OU/!;YTV%_EJ'#I6=?ZL9NQ,HX1,U_(X]9\3K)?!K-?R[R[/>R^ W=<0'
MRMZGC8DO0]\V)[X,?M=XR<)A"?Q[XS57"I_5K/A-J.S]OO'<2^'SQHNN%+YH
MOMO+F'_X?UKSHSF\K/?'QO#W<S]03B.[(1E)/*,BWF@;B3-1E+_K@'^FXAR8
M<.)'_RKZ,+,^S*0/4W73"\D23&;S/QQ_\]<8N&LG7)&R>]?#+I:=Q(HMS?/9
MP#8U,=?G/,G%5ACKFGG8ZK'8"AE##6>M#J9C9=.QE-.9A<2EB2D:41:YE 0N
MB;Z 2>!J"K)P%AUWEA [Z\-N+R'?[ *)4+>U03F)@VP( ^40;DFXC<"=]JCB
M;)@%&W;&&=1EZ::WR%H:;)"CS<2:5<X:S-6/4#V(R%E3<"-L, 4ST;OO@ L6
M;ECHQ)-6S1/)+E!W;$K=@4:;;.Z"6?F=K%=P*64)JG5I3E?$2UETR993U_'J
M-S*4.@&M[HB4>@%Q>T1^38/EB82H:E5*/8%J0;FE=^?@84U"9Y/P&($I]2E7
MUO902@4<=,>CU! X;(_'JS38P8*LH!%)A4%JA9F%3%A0$H('XJX#YK$5)5'=
M>D12.Q#LC$<DY0.A]GB\3(/E[RZ6K1D53$IU06IUN=GZO[<.S]^A:WF4NH',
M[GB4ZH'49<8'>;0*Z]&J6H]26I!:6J9O+G4.]G6M.B*I&<CNCD6I'4A=9WR(
MQ7$:+,^B4<6B%!:D%A:QJ^_GA^I84_<84C$,O3,2#2D<1DW1\1$2+])@!U4W
MUNQR&@VI*X9:5^XGTQ]@3E8L/.2R9D$:.2?4G14RI'@8+9JA41KL8$%6U#V&
M5!9#K2Q7;+5F8? Q&J5H&-T9&$.JA]&BA1FEP?+%N %QE1$TI+H8:G6Y##B+
MWE>0M51*Y3"Z\S6FU!"S15\S2H,U69&F%!A3+3 +RL.WUX]6D*;4#K,[2V-*
M 3%;M#2W:;"#R@=553YF[EE+C;[\C-^P"A[CVB>N(.OWMBF5P^S.T9A20<P6
M'<W4+#J:7"6><JUL<SA,*4&F6H(6:R=8K1T*KK=!)$QYOM:\8-H7,.5+#1P5
MKWY6L22UQ^S.%9E2@LP67=$T#88;V'1+ZI-5XXH(%ZNY^+ #'"575&Q:4H&L
M[KR1)77(:M$;3:VB-X*V6?7DS9(Z9:EUZO*9?5AK+2E 5G?NR,H]@VW1'=U8
M17>$4 6-4J8LM4Q-@H ]DX!+H=VY(W"TOZ)<FE)GK.Z,DB7EQ&K1*%U;1:.$
M]*J=+L7&4HO-F$9BDW_,<&*I([@[KX2ED. 6O=(U+GHE*,Q2116 I=!@M=!<
M,7<M9E=XMAG?DE33E!J"NS-+6&H);M$L37#1+)D5:Q)+H<$U0G,!)KZ_%?-:
MG*OFE'N_TYT_PE(T<(O^Z X7W_$8NH8.JZAY2:LAUH9Z[A\\A"Q*(!#9&JS(
MBE0KK%:K."5WY)77RX,4']R=V;*E"-DMFJU[NVBVJE:T+17*KE&H9[JD_.U#
M;R]MJ3QV=U;+EO)CMVBU9G;)VZ.*\M^6VF2KM>E"W.!#\AI/[Z"6:O8ZSI8"
M9'?GN6RI2G:+GNM[&BR_K4V[\'*SG_M.SB<B5NQ,(^"R;<!W7RAD9[/OB\^3
M[^S>G1_!XSDL.?\ CQ]W7P_+\+N/F6_%T&D0 8\\B:YT+>8XW'T?O/O!V2;Y
M2N\GXYSYR>&:.$L2Q@W$]2?&^/Y'W$'VE?;9?U!+ P04    "  .6%=432(Y
M8L<"  "!"   &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6S-5EU/VS 4
M_2M6AB:0(%_]A+65H-4TIJ%5,+:':0^7YK;Q<.+,=EO8K]^U$[*4E<+#'GA)
M?)U[CL^]Q[(S6$MUJU-$P^XRD>NAEQI3G 2!GJ68@?9E@3E]F4N5@:%0+0)=
M*(3$@3(1Q&'8#3+@N3<:N+FI&@WDT@B>XU0QO<PR4/=G*.1ZZ$7>P\0E7Z3&
M3@2C00$+O$)S74P514'-DO ,<\UESA3.A]YI=#*.0@MP&5\YKG5CS&PI-U+>
MVN \&7JA580"9\92 +U6.$8A+!/I^%61>O6:%M@</["_=\53,3>@<2S%-YZ8
M=.CU/9;@');"7,KU!ZP*ZEB^F13:/=FZR@T]-EMJ([,*3 HRGI=ON*L:T0!$
M[2< <06(7PIH58"6*[14YLJ:@('10,DU4S:;V.S ]<:AJ1J>6QNOC**OG'!F
M1.4+N)$*;%,U@SQAGTV*BITJ!?D"R3&CV?X%%TA:<J3Q!.>H%"8'; P%-R#X
M;QO0O $N] $[8G4ZF\*]HSAD$US1IBELY):YQ,52@)'J_K!)U."G^65F<\AH
M(KV^FK#]O0.VQWAN5Q!6\2 PU 5;2S"K*CXK*XZ?J'B",Y^UHD,6AW&T!3Y^
M.3S<A ?4^]J N#8@=GSM)_@^@DHXY#-\^R;JM=_M8&S5C"W'V'K>4NI;PT?7
M]F9<.FU2R-DFZ/LGXF3G!C/]8X>B=JVHO;/&QNXIJOVPS;>2I.=([/&S&D6M
MKD\>K9KV;,GJ=/VXSMI0V*D5=G8J_*+@)\F"9TWHUH3=5V)"KU;4^Q\FE"3]
M1GO[?;_SR(-_DZ*H[7>W>]"O!?9W"CP##0L!ZED/CFO"XU?B013^/6[#_^%"
MQ=+<Y4=1^]AO/3*BRNMLY'7[CXP(&O>#O9PO0"TXG?8"YP0+_1[A57G?E8&1
MA;LR;J2A"\@-4_I'0&43Z/M<2O,0V%NH_NL8_0%02P,$%     @ #EA75+ZJ
M")E3 P  D@P  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULS5==;YLP
M%/TK%INF5MH FX_ ED1JRJ9U6K>JW<?#M <7G,!F[,QVDNW?SS:4T(2F59_Z
MDF!SSN'>>^!R&6^X^"U+0A3X6U,F)TZIU/*UY\F\)#66+E\2IL_,N:BQTDNQ
M\.12$%Q84DT]Y/NQ5^.*.=.QW;L0TS%?*5HQ<B& 7-4U%O]FA/+-Q('.S<9E
MM2B5V?"FXR5>D"NBOBXOA%YYG4I1U83)BC,@R'SBG,#7&8P-P2*^560C>\?
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MF@&X62B^M"/A-5=ZP+2'I?YH(,( ]/DYY^IF82[0?89,_P-02P,$%     @
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M['T%IT+!R12<N@ININ#65<"9 DYCOPU6&NDAD>3J0O!G(!)I92WYD<*5:JL
MLRB964]2J*=,Z<DKA4A )ER0!.<8D&@*'N2""G M!(GF5$TB&8/VGT0D(FMZ
M!MI#*@D+XC/P%GQZ&H+VFS/P!K (W+,@2(Q<=*5R+#'?]3,G;K9.H HG(+CG
MD5S$X#::TFF)_N"(/C(8Z*J(Y&%!+V&Y04:+]V0#;'@.D(6L,G_,VD/J=U[4
M88GZL+YZV=MO:ZO#?HGZG5G]CU6DU*TRYW=":><SS$[MV<=GV)H6IU4ZV8K7
MVXDG%R0"NTI_?U VP4C2,/['X)&3>^2D'CD5'EW[7U=,T"D8C1]_(^'R_1#X
M"R+FM&SJ#K:V>JFMA*?75U[/Z:C KHN('DIA;'6<7:G;0RED]SLXE]H9CIL/
MQS4.YY&N:;0J=WZKZ15?Z-G0VW=L6"+GN,HU;V\ )7+(AOV.6SX$G \!&X?P
MI#"?+P@#:O+%"P9N&(]]1B.?QFHJ=,[!!SGM@/;ATS/#=.CE+^\U9()ZN4?>
MZ2;HS=:66\3$*H>CG[^_;WS_F$I!P%B],B1JI&*9Y0?03I^8@@XMG7BLAH0=
M%I(A/&'@,V/%Y0P5-7CEP8=(>X&,7@P6+"*F\6CJA4WA7JC)%YK9UT17F6J1
M7R#&\("NRN0@Q/NL?%LBUU>LYE0@I!D7FBE7E3I4E68J,&.R24ND<S @2R9)
MP+ZKZ7,=@U$D57#9)%!QCV.JBJA_P4^A.:A)%N*FS ;-O;!7+Y(Q6&:A+)T8
M6RNX"'B_(NE 3;/0S+-E,#ZM?!7P^&VR79F"1SI?!41RL0'7*D9/1"EDCWX6
MG)JD8;\A<")-ZL@Z'8$.,V-%5-V*U(4TAR,SAY>N3;4[8"H:*A:?EBJ/C2(F
MV3:E/<R21!>K*("/@I% X?J*](<TR2/4%/1TND#V*19C9@7O5!P5BQ'IO(#,
M>:$.;M?^@M&UN@,&2IWY"JZQX'R6H*AD?;J4K\1/IP#D-@4_3?#(7$;7Q0\?
MDBFNR(E(,SDR,_E#L H9B>1OOZ@BZ+UI/)J?D=>4&&O61>;:V%2^9*J]W;+$
M[<"]\B63*Y8EV/8.JI<2,0<5BYS=_;@F:=M,TKM(J07SR#<DD)M\X:FTYU,5
M/5,GQ=:$;,.&H&AK]K6/E-@[YHGVX1R(I!>Y[83Q2<#F66=L286?^-A>+8'D
M9V7P'WDGLCJ6]:O)_4)+Q4S4!PB6D>=0S=2 +_-(ZUIFMUAM#^F,"I6TS]3]
M59C(J*"8_-2<;CM-@5X3MUVS=C>39&9E9UN-K;V%G GM9$)84<'8FL9M,XV_
M$EU3E#2;VTUIBM@Z'=@UR_4CR'F'Z<VJ D7SOFWF_5J@%/8'ICZE9FJG*3T2
M1].Y4[.^-J.06:F%@J-YVSG"VP^?1\.WL*]V8Y)-^)3M)^)=NYI0G:8T2IQ"
ME_K_-THRU1WB0<X^/3F'[0^O!SNH @5-H8Z90C]NUIOC=9ZC"<]I2F/"T03H
MF,M98_1[AX49] [*O$RL6 [:EM?I[7\4Z!UD&FA7E...)DO'3)8%C"K(ZEC#
MRA1&39M.4YH4KF95UUS_UF.PN\Q*$1>G@L!<S9ZNF3V/P_(##:B'E8S9E *U
M 4Y[QNK6*(KX.@GG#>,!GS-?61Q%?@>T7YZ8MK^N)F*W*>T+5Y.X>Y+VA7O8
MOO!01?O"U6SMFMGZI,">",W"%\2F-#-<G13<DS0SW))F1E5GV-7L[YK9_P.=
M"/:%?5^%9'+* MS5_.TVI??A:C)WS35P74CZAPNLZ@.Q)FUL)NU7(9+V./R%
M:5.+-87CIO0SL*9C;*Z+:R*36=E9+%Y%3L.:=[&9=VM 4V]CA#7;XJ8T%K F
M47R2Q@(^[!E 5/79 Q=.4)CI\L= J+,@-%GBIO0*L*9/?))> 3X\/ $M>Q^,
M;N%\74C%/#T)&0.?KR*Y/5.6W\U/6UZG9PSW[@_@N]OMF4EM9GN$\YZ(.8MB
M$-"9,FEU>LHEL3T5N;V0?)F>XIMP*7F8_EQ0,J4B$5#/9YS+EXOD!?G9U*O_
M %!+ P04    "  .6%=4R0_/D_@"  #@!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6R-54UOXC 0_2M6U$,K44(2"&T%2'QTM3U4K6"[>UCMP20#
ML>K86=N4]M_OV E9OL4%;.>]F7DS]DQO+=6[S@ ,^<RYT'TO,Z9X\'V=9)!3
MW90%"/RRD"JG!K=JZ>M" 4T=*>=^V&K%?DZ9\ 8]=_:J!CVY,IP)>%5$K_*<
MJJ\1<+GN>X&W.9BR96;L@3_H%70),S!OQ:O"G5];25D.0C,IB()%WQL&#Y/8
MXAW@)X.UWEH3JV0NY;O=/*5]KV4# @Z)L18H_GW &#BWAC",OY5-KW9IB=OK
MC?5O3CMJF5,-8\E_L=1D?>_.(RDLZ(J;J5Q_ATI/Q]I+)-?NEZPK;,LCR4H;
MF5=DC"!GHORGGU4>M@A!?((05H1PG] ^08@J0G0IH5T1VBXSI127APDU=-!3
M<DV41:,UNW#)=&R4SX0M^\PH_,J09P9#K?%N/>4%90JK:1ID"MJH56)6BHEE
M@U"1DA>3@2*S A)&.1EG5"U!DULRPTN8KC@0N:@P+P4H:I!(QE(;1W[\Q"NJ
MH4'F7WB8%U*@&W(] 4,9US=HYFTV(==7-^2*,$&>&>=X(73/-RC/!NDGE911
M*24\(24(R;,4)M/D4:20[AKP,2]U<L)-<D;A68L32)HD"AHD;(7!D8#&E]-;
M1^B3B^G!_1DU45WJR-F+3MC;*:PKS10X-9"2H7U\S# LZN_A'%'X&O^<\=BN
M/;:=Q_8)CS/XP.L@$CA6S)+:<53;G#X&0=3S/[;36T*ZVY!.T QW49-#5+?;
MO*M!.Y%WZL@[9R,OGP6KGP6Y7F(+O7%9D^ZFZ^HU).5K.*:P='&W%5C4BIK!
MGL@2%6^A;NUMV9%X:*E]?U)C7&N,SVK\(0W&3_>4-K"9'S2 BR7'![6(@OA
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MA896:A]7<-LATAC ^X40^F5@ O3WI]E_4$L#!!0    (  Y85U3'4%B.;@8
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MX/>IA!0MO]@'K%_LG?P'4$L#!!0    (  Y85U0;B.,) @4  %\5   9
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MJE*;E&IZ@KPNB>\NQJ_=[%4RTXZ,19RY/3T4"_IBOM,1.O![TO@]&?3[B\Y
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MNP!ZOU3*ODS<J5=?<J,_4$L#!!0    (  Y85U2U4ZVVT (  )@'   9
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;)5576_:,!3]*U=1'UII2\@'@5:
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MS)U<_<!6T-#Q99)I_X15LW:4!I#5VDC>@FT&G(KF39Y;(S8 \6@'(&D!R7O
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ME5M@YY=2FG7'!>@N-]/_4$L#!!0    (  Y85U2%/[E(+P0  ,P1   9
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M!NKYBC'Y>J%?Z*L/.--_ 5!+ P04    "  .6%=451FT=6X"  #E!0  &0
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M/MJV6>J[%(19H.<+SM6I8\YW?SMGOP%02P,$%     @ #EA75*_U-#.# @
MU @  !D   !X;"]W;W)K<VAE971S+W-H965T-S,N>&ULO59=;]HP%/TK5IY:
MJ6KB\-56@%1*IU5:)]1JV\.T!Y/<$*O^2&UG4&D_?K8#ADHC\$#W0OQQS[GG
M'@??#)=2O>@2P* 59T*/HM*8ZB:.=58")_I25B#L3B$5)\9.U2+6E0*2>Q!G
M<9HD_9@3*J+QT*_-U'@H:\.H@)E"NN:<J+<),+D<13C:+#S116G<0CP>5F0!
MSV"^53-E9W%@R2D'H:D42$$QBF[QS01W'<!'?*>PU#MCY$J92_GB)@_Y*$J<
M(F"0&4=![.,WW %CCLGJ>%V31B&G ^Z.-^R??/&VF#G1<"?9#YJ;<A1=12B'
M@M3,/,GE9U@7U'-\F63:_Z)E$]OM12BKM9%\#;8*.!7-DZS61NP <'\/(%T#
M4J^[2>153HDAXZ&22Z1<M&5S U^J1UMQ5+A3>3;*[E*+,^.9L@>LS!LB(D?W
MKS6MK.4&G7TE2A%GV#DZFX(AE.GS86QL1H>+LS7[I&%/][#C%#U*84J-[D4.
M^7N"V$H->M.-WDG:RCB%[!)U\ 5*DQ2W\'5"_1W/U]W#-ZDIRZE8H#_HD0K*
M:]Y"V@VD74_:.6#J!9HQ8MU\[^W/+S8</1C@^E=+LEY(UFNMX%X;:M].R%&M
MH:@98K2 ?QU5.XT]JC<@2K<HZ@=%_:,]):L#G@X"Z>#C/;T*R:Y.XVD[32\Y
MZ.EU4'3=KBB4>LR+BI/MWS_Y>%OQSFV#3V/L 9[.06-QNM64'F_MP?<5;V\6
MW/D/UF[O'-P]D;7M/&EOO[?Q3J/AH!:^G6J4R5J8IN>$U="R;YM&M0UO^OTC
M40LJ-&)06&AR.;#7DVI::#,QLO)M:RZ-;8)^6-K/#E NP.X74IK-Q"4('S+C
MOU!+ P04    "  .6%=4%7?9:.,"  "2"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970W-"YX;6R=EFUOVC 0Q[^*%?5%*[5Y)$\5(+6P:9-6"15U>S'MA4D,
M6'7BU'9*^^UW3D($C6'5>$'BY/YWOSO[[(QW7#S++2$*O16LE!-KJU1UZS@R
MVY("2YM7I(0W:RX*K& H-HZL!,%Y(RJ8X[MNY!28EM9TW#Q;B.F8UXK1DBP$
MDG518/%^3QC?32S/VC]XI)NMT@^<Z;C"&[(DZJE:"!@YO9><%J24E)=(D/7$
MNO-N9ZFV;PQ^4K*3!_=(9[+B_%D/ON<3R]5 A)%,:0\8+J]D1AC3C@#CI?-I
M]2&U\/!^[_UKDSODLL*2S#C[17.UG5B)A7*RQC53CWSWC73YA-I?QIEL_M&N
MLW4ME-52\:(3 T%!R_:*W[HZ' B\T0F!WPG\SPJ"3A TB;9D35ISK/!T+/@.
M"6T-WO1-4YM&#=G04L_B4@EX2T&GI@L!"T*H=X3+''UYJ6D%4Z30Y1*62UXS
M@O@:F6VNT.6<*$R9O$(WZ&DY1Y<75^@"T1(]4,9@CN3848"H SE9AW/?XO@G
M<.8DLU'@72/?]3V#?/9YN7LL=Z P?77\OCI^XR_X1W6NT8)A*,MQD7[?K:02
ML!#_G D5]*&")M3H1*@?X-M4KU85-RK=DJ]3/TSL>.R\'I;%8.5'=M);'2&-
M>J316:3[FK*<EAOC/+;2Y"!B'":)[7T ,Y@%0.:9R<*>+#Q+UL^!B2P<A$S2
M(+9A7]O_/D(:%&'DVJD9,NHAH[.0,^@ )>IVNX*NJ 3?""*-U8P&!+X7QP<3
MV(*:S(+DU#S'/6A\%O2HO\F^M-=H([B9-AY@>$D:>0-<DYT?^G9DYDUZWN1\
MJT 18?_/ZJ)F6)$<MFTXP3**=:5-O,F XR9-X\B.3R\)DR2,7;/D*(NTSR+]
MKZJ7Q+BJTT&')VD2#OK-8!8EWF I.P<GACZM'[#8T%(B1M8@A#2A)41[ K8#
MQ:OF$%EQ!4=2<[N%CP8BM &\7W.N]@-]+O6?(=._4$L#!!0    (  Y85U1=
M--<#9 (  ,\%   9    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;(U4WT_;
M,!#^5TX1#U1BS8^&EJ$T$B5,VP-21<7V,.W!3:Z-A6,'VZ'PW\]VTA!8RWA)
M?/9]W]WG.U^R$_)!E8@:GBO&U=PKM:XO?5_E)59$C46-W)QLA*R(-J;<^JJ6
M2 H'JI@?!<'4KPCE7IJXO:5,$]%H1CDN):BFJHA\62 3N[D7>ON-.[HMM=WP
MTZ0F6URAOJ^7TEA^SU+0"KFB@H/$S=R["B^SV/H[AY\4=VJP!JMD+<2#-7X4
M<R^P"2'#7%L&8GY/>(V,62*3QF/'Z?4A+7"XWK-_<]J-EC51>"W8+UKH<NY=
M>%#@AC1,WXG==^STG%N^7##EOK#K? ,/\D9I475@DT%%>?LGS]T]# #A] @@
MZ@#1>T!\!##I )// N(.X*[:;Z6X>\B()FDBQ0ZD]39L=N$NTZ&-?,IMV5=:
MFE-J<#I=2M-!4K\ X07</#:T-C75<+HR_54T#$%L($/343DEKE WSZ;C%([@
M-$--*%,C^ +WJPQ.3T9P I3#+67,>*K$UR9!&\;/NV06;3+1D63""&X%UZ6"
M&UY@\9; -\IZ>=%>WB+ZD#'#? R3\ RB( H/)'3]>7AP )Y]&AY^_4#-I"_6
MQ/%-_E.L,U@R8JKTMF:_K]9*2_.0_GP0*NY#Q2Y4?#3U0<VQK?FA@K8LYX[%
MCIBG='8Q2_RGX1VW/K.AS_1\'+WURO[UN@CC\2M7*\,?M'J%<NM&AH)<-%RW
M;='O]E/IRCW&=_L+,ZW:X?)*TXZZ6R*WE"M@N#&4P7AFU,EV?+2&%K5[4&NA
MS?-TR]),7)36P9QOA-![PP;H9WCZ%U!+ P04    "  .6%=4V_J3,\\"  #2
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6RU5EU/VS 4_2M6Q -(
MD,1)F[2HK33:?50"K:)B>YCV8!*WL7#B8#L4_OVNG32D4#HD1!\:?]QS[KG'
MCIW11L@[E5&JT6/."S5V,JW+<\]3249SHEQ1T@)F5D+F1$-7KCU52DI2"\JY
M%_A^Y.6$%<YD9,<6<C(2E>:LH N)5)7G1#Y=4"XV8P<[VX%KMLZT&? FHY*L
MZ9+JFW(AH>>U+"G+::&8*)"DJ['S!9]/<6  -N(7HQO5:2-3RJT0=Z8S3\>.
M;Q113A-M* @\'NB4<FZ80,=]0^JT.0VPV]ZR?[/%0S&W1-&IX+]9JK.Q,W!0
M2E>DXOI:;'[0IJ"^X4L$5_8?;9I8WT%)I;3(&S HR%E1/\EC8T0'@'MO ((&
M$+P7$#: T!9:*[-ES8@FDY$4&R1--+"9AO7&HJ$:5IAE7&H)LPQP>K*0L".D
M?D*D2-'7^XJ5L$8:'2]AOZ05ITBLT'<JUI*4&4O0O*AW#JS "3J>44T85R?H
M#-TL9^CXZ 0=(5:@*\8Y1*B1IT&B2>0EC9R+6D[PAIP935P4XE,4^ '> Y^^
M'^[OPCTPIG4G:-T)+%_X'W=.T8(3L&77I#^7$([FFN;J[X%D89LLM,EZ;R2[
M%,7ZC,.F3A%1BNJ]]M44L:4PK^C#!/L^#MUPY#UT?7H=-XQZ Q?>[NT/MX@=
MM;U6;>^@VAMWZ5H_%A4X)- U2\0!$_HM;?_S'8_:9-''':\IHHZ3460VUX[=
M=="@&X1A5:+]'L>MOOB@OKFD8$)ZH-)!RS3X?%N';;+AQVT=OG(,QW[P:A_O
M"QM$[G"_L=A_/O;\@QI_ZHQ*!(<9G/,%2D15:,FH.E ][ARI^//-QL]G% X^
M;G?#T>\:&0WQ"[>;J)WC)>[%;OS";J]SX9C;_HK(-2L4XG0%0-^-(8^L+]"Z
MHT5I[Z!;H>%&L\T,/CJH- $POQ)";SOF6FL_8R;_ %!+ P04    "  .6%=4
MH7=<3&L"   T!@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6R-55UO
MVC 4_2M741] Z@CY@'XH1"K-IDTJ4]6JV\.T!Y-<B%7'SFSST7\_VPD9K8#Q
M0NR;>\X]UQ>?)!LA7U6)J&%;,:XF7JEU?>O[*B^Q(FH@:N3FS4+(BFBSE4M?
MU1))X4 5\\/A<.Q7A'(O35SL4::)6&E&.3Y*4*NJ(O)MBDQL)E[@[0)/=%EJ
M&_#3I"9+?$;]4C]*L_,[EH)6R!45'"0N)MY=<)N-;+Y+^$%QH_;68#N9"_%J
M-]^*B3>T@I!AKBT#,8\UWB-CELC(^--R>EU)"]Q?[]B_N-Y-+W.B\%ZPG[30
MY<2[]J# !5DQ_20V7['MQPG,!5/N%S9-[BCR(%\I+:H6;!14E#=/LFW/80\0
MC(\ PA80?@3$1P!1"XC.!<0M('8GT[3BSB$CFJ2)%!N0-MNPV84[3(<V[5-N
MQ_ZLI7E+#4ZG#V@.34'O.Y&2V!'TH9>A)I2I/GR"E^<,>A=]N #*8489,[-2
MB:]-98OW\[;*M*D2'JD2A# 37)<*/O,"B_<$OI'<Z0YWNJ?A2<8,\P%$P26$
MPS X(.C^?/CP #P[&Q[<G.@FZJ80.;[H]!1^W<V5EN8J_#[!&7><L>.,CW(J
MA7@)S')?FBMJ38#R91, C;*"WJH&+?J'!GJ:/(CA#8E4)W2..IVC_^BT<G!K
MC$SA(24-_,K!K8NMTV!T,X@3?[T_[T-9\6#\/BL[D'45#JZ[K*8#?^\^52B7
MSI<4Y&+%=?,7[:*=]=VY&_\A/C66V#C8/YK&3V=$+BE79A@+0SD<7!EELO&H
M9J-%[6[M7&CC 6Y9&EM':1/,^X40>K>Q!;H/1?H74$L#!!0    (  Y85U1N
M;%.H!P,  (@(   9    >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;)U6;4_;
M,!#^*Z=HDT :>>T+H+82M$-#&AH",3Y,^^ F3F/AV)WMMO#O=W9"UI8T8_O2
M^N6>Q_?<V7<9;:1ZT@6E!IY++O38*XQ9G@>!3@M:$NW+)16XDTM5$H-3M0CT
M4E&2.5#)@S@,!T%)F/ F([=VJR8CN3*<"7JK0*_*DJB72\KE9NQ%WNO"'5L4
MQBX$D]&2+.@]-0_+6X6SH&')6$F%9E* HOG8NXC.9T-K[PR^,[K16V.P2N92
M/MG)=3;V0NL0Y30UEH'@WYI.*>>6"-WX57-ZS9$6N#U^9;]RVE'+G&@ZE?R1
M9:88>Z<>9#0G*V[NY.8+K?7T+5\JN7:_L*EM0P_2E3:RK,'H0<E$]4^>ZSAL
M :+! 4!< ^)]0.\ (*D!R7L!O1K0<Y&II+@XS(@ADY&2&U#6&MGLP 73H5$^
M$S;M]T;A+D.<F7RE&#0-1]?E$E, ,H=ZQ4B82J$E9QDQ-+.3#+.-HRLFB$@9
MX7!O< OO@-''<#2CAC".HQ-XN)_!T8=C^ !,P WC'#.L1X%!?^VI05K[=EGY
M%A_P+8KA1@I3:/B,9V>[! $*;=3&KVHOXT[&&4U]2*)/$(=QU.+0]/WPL 4^
M>S<\.NM0DS2Y2QQ?TIV['Q=S;11F[V<'9Z_A[#G.W@'.1_=0:'9"UE3AN\>G
M;8L'$PO@]C@P5)5MJ>RF'<(+):KM#DS_ [BCK-\HZ_^;LHSI5*Z$ 86WN$U2
M-U_BA^''-D%_@R7[L!TY@T;.H)/GVQ)5&)N7E.@"<JS?&G(E2Y#-CLM8Z\.K
MN(>.VW:&]23J#_SA*%AO*VFQ&H3^V:[5K(TK\0>-U8Z\82-OV"G/]9\3F9^L
M\,X1K:G1(.=88016(*PJ]#DMB, L8N<#@>UE3S5P1N:,,\/: S!LD9;X_;T
MM%@E;\(T>VMU&OGQGOY@JT:75"U<K]/@;F!5P)K5IIU>N"ZRMWZ);;;JBG]H
MJAY]0]2""8T!R)$R](=X$U75]ZJ)D4O7">;28%]QPP(_%:BR!KB?2VE>)_:
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MZB=AYXG<X*P%9Z? J0N<[8'SOI^[67G+RD^Q,A<KWV-EB9^Z647+*HZRKA=
M)#I$+/:(<1[ZL1O9;Y']H\B? C!#S%[5&G_HI G.Z]C?7]H\]0LW/ J_4DAX
M%/] E$*TJAL@<YT1=/A$@3,=A/N'*O3#?O<YX$PGGT6GU\()C_;N:E:DATY6
M])5MHO@H\+]<>=DFRX]+- 4,Q&R'2:KWE&->4KU3$Z&HK4DO=QLP%6[&"+KC
M3665!']U^G_"#5CI8\<%+QLI#9%]Y6Q7 @PZ-</4WT<LEY0K?8H66C_T<YT
MY+:D;3L@:EM&9@)T4;+-E?X,(-),T.,+(>"S8RI3^V$Q^@M02P,$%     @
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M9G'&4[38<*%%%B3T5&H<I4-PD4JQHU:W<2[4B%<]+UI61=K:%4D)3*CB=<?
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ML?W_WXRM<7Z4ZDWO 0QYK[G0,V]O3/,4!'J[AYIJ7S8@<*62JJ8&0[4+=*.
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M6KY",.6^L.]C P^*5FE1]V"304UY]R?/?1U&@/#R!"#J =%[0'("$/> ^+.
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M\\_-[.I&S1M--_B61.XH5\!P:RB#R951)[MATAE:-.YY;80VC]4M*S-_4=H
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MR:=3\ FX0*P(IP)$*;A/(RD^5QINHCA6853;I^KMV)4*=-:UNR@ 7N4 40M
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M5)[+#%/EHX'K!>KYG#&YF^@-*F?>_PU02P,$%     @ #EA75-YP3?J, P
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M:*EY&@IAB_-8O-+]$U2"7.4OH#$O?M&^M'5=#04Y%S2IP))!0M+R'_^H$M$
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M+DG%2=&/[U!23#F6F VP?HEUX=S.C,X,F:.UTM_,DG.+GO),FN/>TMK5Y\'
MI$N>,]-7*R[AS5SIG%FXU8N!66G.9J50G@U(%"6#G G9FQZ5SV[T]$@5-A.2
MWVADBCQG^OF49VI]W,.]EP>W8K&T[L%@>K1B"W['[?WJ1L/=8*-E)G(NC5 2
M:3X_[IW@SQ=QY 3*%;\+OC:-:^1">5#JF[NYG!WW(N<1SWAJG0H&/X_\C&>9
MTP1^_%,K[6UL.L'F]8OVG\O@(9@'9OB9ROX0,[L\[HU[:,;GK,CLK5K_PNN
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MUYRI]^CJCFG*<[B:HA\/=^CJW7OT#O$2?>5Y#KNDEG,-D.:GYFD#]*D&(@-
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M.M0NP9ZOE*+OP,U?_WH67U!+ P04    "  .6%=4]2[TUWL#  !H"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6R-5MMNVS@0_15"Z$,"-+K9LN7
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M"H*J ?A]*Z5YF]0.NN9R]3]02P,$%     @ #EA75 !N^\WJ P  IPP  !D
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MB_HP<5L!F*AM+__QZ:();E9'0(5*VZ@L[M#O\12G4<O5$?U)0W]RD?YO;&?
M;X2QS.YMU1:\Y-8_A'V:)J=,AI,@ZVCJ0]$N:MF#HBD]IXI&;UDWNJCK9LOD
M!DY>#E[NL!!R$O$P8LDBZ[<D?R%6,VG$6='U>D=,TS3H[E(?C*;GW@O:JB+H
M_ZKGIEZO?>:R,U>!QF\LXXLLL;3XEW14.SC*(!D^7]W'N0_7D[>6?;CCQ%5)
M"5L57 EZXRMA0W*7O:N2IQEMJNUK7V-VQA>N"O>5X9N;JH2_91KSL2$"UN@R
M"C),';JJBJN.53M?)SXJBU6G;V[QGP1H!\#YM5+VM>,6:/Z;S/\!4$L#!!0
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M"5BS#3UF\@M__LB:@L(RWXIG1?4_>&YB@PE8'0O)]\U@I6"?YO5/^KV9B,X
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M4)C=R/'!F88LG9"A*SH?$.Y\X) .H)AN84Y#ED[(T'J="@AW*O 7-0"%F1I
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M!"@R8]&( 0$*3A9-! 2<OMWN/NS@2AA<S*3 ) P))H,\=1D3$P*4F;%GQ',
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MQ_7T"@9LH<"0FC@PI) ZQV\5Q.ZAEB9,:B?,\6ZH4=!;1-SIE]D%" 16;]@
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M63+V70_N5E/'UQE!!874+G+U\PQSJ"KM2>7QHW7J=#&U8?_YU?L7 Z]@EKF
M.:O^(2M93IW402M8Y[M*/K+]'] "Q=I?P2IA_J-]HTTB!Q4[(5G=&JL,:D*;
MW_RE78B> 4Y.& 2M03 T.!4A; W"2PVBUB R*].@F'58Y#*?33C;(Z[5RIM^
M,(MIK!4^H7K?GR17;XFRD[._9 D<7:.O(#^BT1TM6 U7Z/.+^JX$H-$"9$XJ
M<:44WYX6:/3A"GU A*)[4E5JV\3$DRH)[<HKVH"W3<#@1$ <H'M&92G09[J"
MU:$#3V7?(02O"+?!68\+*%P4XH\H\ -L26A^N;EO,5]<;(ZS,S1AMR&A\1>>
M\/>5476H>2X)W:!F/]"HW8\K]._-4DBN#LM_9T)%7:C(A(I.A+JC$C@(B:!Q
M;]O,QL/8>- UY'D6AIF;3KSG_@I;5''F)H>JQ;$J\OV>Z@ B[B#BRR"(62L;
M0^,@[<6]#F(W&C TJJ2O"L,!@<53ZKN*XNT/VW&2#B<YBZ/.H2)Y5D"JN$JT
M495;(%4?X<>.R)](0+'C1!*PGKSD.#T\3MQL0&J315'@!@-:BR[R<4]V0#CN
M",=G"?]DHB%ZT9_XCHC2D+*U*M=+:<,:'^41^?$PV_GX:/_\ <^QGR .W-B.
MDW8XZ5F<W]4.:1R15Z A<BK)DC!)"K3<"256M$HQ+PG-;7#I>VG/WU4LTN.-
M"OW^*3T@RSJR["S9(TC"P6S.$BBLB43;*K?7_,QRQ-+,'0]0;+(8#\O)PB93
M/)F=!_MO=YU_EJBY[$:DO>7.E+W6T4$**M%AS;#(<!;W/JF&QR*+DU.%#_>N
M;OP^SJ^_I '&OU%S?U]"AH^JL+JYAK5Z;I%=8SS&PV*RL F##!_1>;T>I0:^
M,;V>0 7;4=G<]=ULUT_>F"YJ,'^K^TS3^[RY:9K4^YQO=+FL8*U<^NY8E6O>
M]'W-0+*MZ8263*J^RCR6JE<&K@7J_9HQ^3K0 ;KN>_8_4$L#!!0    (  Y8
M5U1+!6["@@,  /,,   :    >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6S5
M5]^/VC@0_E>LJ">UTA[Y12!4@-2%I;=2>[=:KM>'J@_>9 "K3IS:!KK2_?$W
M=D+(;9,LJOK2%XB=^6:^\7QC.].CD%_4#D"3;QG/U<S9:5V\=EV5[""C:B *
MR/'-1LB,:AS*K:L*"32UH(R[@>>-W(RRW)E/[=R=G$_%7G.6PYTD:I]E5#Y>
M Q?'F>,[IXE[MMUI,^'.IP7=PAKTA^).XLBMO:0L@UPQD1,)FYGSQG^]\H<&
M8"W^87!4C6=B4GD0XHL9W*8SQS.,@$.BC0N*?P=8 .?&$_+X6CEUZI@&V'P^
M>5_9Y#&9!ZI@(?A'ENK=S(D=DL*&[KF^%\<_H$HH,OX2P97])<?*UG-(LE=:
M9!48&60L+__IMVHA&@!,M!T05(#@4D!8 <)+ <,*,+P4$%6 Z%+ J *,[-J7
MBV57>DDUG4^E.!)IK-&;>;#ELFA<8)8;9:VUQ+<,<7J^9"H1N6;Y'E+R5P&2
MFH(K\G()FC*N7I'?R8?UDKQ\\8J\("PG[QGGQF+J:@QOG+A)%>JZ#!5TA'I/
MY8#X_A4)/'_2 E]<  ^[X<M^^!*2$SSP6^ WE\.]%OCJ8OA3\BY6K"Y;4)<M
ML/["#G^W>2(R(&M--6"?ZRMR33G-$YRR^Q'-4_(F39DI)N7$5)D+M9>@R,.C
M&19"X?Q;*?:%NB+HCN]3EF])EQX^O4,&Y!:CJ<\]_,.:?VCY#SOXO\4]#S<F
MCO13H@5)+2-+MZVTI;/(.C-[Y6&.-3@TJ_>LQ:JT&#<LPE'L#:+:['^)#.M$
MAKV)W,,!<*W:VF%9(N-&Q" ._7@P?,*]Q6X8A9-!_"2#%KL@]"==*41U"E%O
M"G^B7IC54UL2T;-+_ZS%*OJ.>-_2CVK>HU[>'5*]JN2-DV)CU+ZF',B_Y,;T
MA^C1[KB.._XE>R^N^<<_L?<6\7?E#<>>UUZZ24UA\J-=LRJ1HT:\*.X(YWOG
M4\[[<8VO*G#T1* =01M'J]\;]&])<W62@0)Y8 EJ@&XE5+K1(+/6<[3?;S D
M&>IDIWK$X)]/$C_H]7;#&7F'A_JC%>Y"9 7-'[%??G9[^>>SP0]_R0;SSX>"
MWW\J+,\M959)''.0:L<*U"#6')1NK7J_3]PP ^^W-GINX_IG/@?PIK1EF!:'
M#7KR!F,4MBQOV.5 B\+>"!^$QONE?=SA5PE(8X#O-T+HT\!<,NOOG/E_4$L#
M!!0    (  Y85U11R>T(9@,  *46   -    >&PO<W1Y;&5S+GAM;-U8T6[:
M,!3]E2B=IE::&D+60%9 VI J3=JF2NW#WBI#'+#D.)EC.NCC?J7JV[YBG[(O
MF6\<$J"^C/9AA05!['MRSSV^ODX<>H5:<'HUI50Y\Y2+HN].E<K?>5XQGM*4
M%*=93H5&DDRF1.FNG'A%+BF)"W!*N==NM4(O)4RX@YZ8I1>I*IQQ-A.J[W9K
MDV-.'^.^ZX=O7<?0#;.8]MV;X]??9IDZ?^68\]&;HZ/6S<GYIOVX!$Y<STIZ
MM@/I*4Y[BA*'Z\0-T=\<.SLIVB8)I>[N1KV5&R6/[.2_?_Q$)JA!MDY1IV4G
M_O6 \-; =EH?H;W':.\?TWI5Y0YZ22:: @Y<8]!Q24J=6\+[[I!P-I(,O!*2
M,KXPYC88QAG/I*/TRM%"?+ 4=P;V30\65<63,I'),K:)8'Y'U>4;P+(' AGG
MM<"V:PR#7DZ4HE)<Z$YY<6E\!#E5^WJ1:X43219^^\QM',J3#C+*9$QE'<9W
MEZ9!C],$Y$@VF<)99;D'H%)9JALQ(Y-,D%+#TJ-J:-HQY?P*[CA?DS7N>;(R
MHV69B+JI!55-0V,ZP+_*9KA7:<-G\3HYN\W4AYD>CBC[4"GT4M*$S<O^/*D%
M8.P^SD[RG"_><S81*36#WSG@H$>6?LXTD^Q.1X-2&6L#E:YS2Z5BXU7+=TGR
M:SI7RW*:)[CF]@%J_K=YGE!!)>&KHG7M[W.6GZVX>D2_A.;RMK*IV"HRZ.R_
MQFI;LN\BPT,0>0#3'43[K[':/.Z[R$/(9.?%[NQ/$>GOO\C]S*-7[2A7MJUK
MF];:ZL#+0=_] B\AO GJC&:,*R:JWI3%,16/]JZ:7I&1?@=?X]?7QS0A,ZZN
M:[#O-NW/-&:S-*JONH1$5%<U[4\P/+T17KZ9Z%A,Q'1.XV'5E9-1V71T0T>M
M#G#81"[*PXY@/@:S(X!A<3 %F(_QPN+\3^/IHN,Q&*:M:T6ZJ$\7]3%>-F18
M?K X=I]('_:11E$0A"&6T>'0JF"(Y2T,X6MGP[2!!Q8'(CTMU_ALXQ6RO0ZP
M.=U6(=A(\4K$1HKG&A![WL CBNRSC<4!#VP6L-J!^/8X4%-VGR" 6<6T82L8
M1Z((0Z 6[34:ADAV0OC8YP=;)4$0178$,+N"(, 06(TX@BD #1@2!.5S<.-Y
MY"V?4U[SQ_3@#U!+ P04    "  .6%=4EXJ[',     3 @  "P   %]R96QS
M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0
M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S
M##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H
M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  Y85U10>9I.,P<  ,A&   /
M    >&PO=V]R:V)O;VLN>&ULQ9Q=;]LV%(;_BN";)< RR[(^BZ9 /MHM0)H&
M2=?;@9%IFZ@L>A2=-/WUHV0[.5SD=[LY]E5B298?4R2?PX_C]T_:?'_0^GOP
M8U'5S>E@;NWRW7#8E'.Y$,UO>BEK=V:JS4)8]]+,ALW22#%IYE+:136,PC =
M+H2J!Q_>;^]U:X;TA;:RM$K7[F![X)N23\WK^?9E\*@:]: J99]/!]W_E1P$
M"U6KA?HI)Z>#<! T<_WTAS;JIZZMJ.Y+HZOJ=#!:G_@FC57EF\/W+>17\=!T
M1ZQXN!,.Y'20ANZ&4V4:VUW1W5\XQD?I+EZ_6EG]2556FDMAY>]&KY:JGK6W
M<=]B2+Y&5P[;O^M"?&?^3S'JZ525\E*7JX6L[;H<C:Q:P+J9JV4S"&JQD*>#
M"_TH37 K9K+]4NY3KB;K+V@=&2DN\TZY$^9JTC'R\9RM)LH&5_7ZS>XLP8H
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MCGVIK[68;'^(9?LC,A_^ 5!+ P04    "  .6%=4,,:<)@P#  !O/P  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=M+3N- %$;AK: L ->M=[6
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M>]7; _3VJK<'Z.U5;P_0VZO>'J"W5[T]0&^O>GN WE[U]@"]@^H= 'H'U3L
M] ZJ=P#H';J')0"]@^H= 'H'U3L ] ZJ=P#H'53O - [J-X!H'=0O0- [ZAZ
M1X#>4?6. +VCZAT!>D?5.P+TCMW#;H#>4?6. +VCZAT!>D?5.P+TCJIW!.@=
M5>\(T#NIW@F@=U*]$T#OI'HG@-Y)]4X O9/JG0!ZI^YE)4#OI'HG@-Y)]4X
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M2P$"% ,4    "  .6%=4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  Y85U2&"Z@Y[0   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M  Y85U297)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ #EA75"<\X%^O"   S#4  !@
M     ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M  Y85U2,BUIJ'0(  ' %   8              " @?$0  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  .6%=4W83?7/,%  "$&   &
M            @(%$$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ #EA75,53(AMY!   X1   !@              ("!;1D  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (  Y85U0V6L4#_@<  *L@
M   8              " @1P>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  .6%=4H.1S=F4"  #5!0  &               @(%0)@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ #EA75-!'8<=3
M"   EBD  !@              ("!ZR@  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    (  Y85U3%RG#E:@(  .(%   8              "
M@70Q  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  .6%=4
M\-?-)%\)  "M*   &               @($4-   >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ #EA75-!!I4+Z 0  \0,  !D
M     ("!J3T  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Y85U0:?@ YQ0,  .$(   9              "
M@16'  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ #EA7
M5$M:5-IA P  BP<  !D              ("!$8L  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  .6%=4M).E)?(8  "\5@  &0
M        @(&IC@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   (  Y85U0Y),5<J0D  '(;   9              " @=*G  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ #EA75-;OH.D)!   \@@
M !D              ("!LK$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  .6%=4GDL$5G(&   P'0  &0              @('RM0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  Y85U0^*$)B
M-0L  $,C   9              " @9N\  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ #EA75"H5.BT["   11T  !D
M ("!!\@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  .
M6%=4E$!BK/<#  #<"0  &0              @(%YT   >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (  Y85U01E/7$*PX  . D   9
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M970R."YX;6Q02P$"% ,4    "  .6%=4SA5Y\GH$  "0"@  &0
M    @($D, $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M  Y85U1YPG-8]A(  !D[   9              " @=4T 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ #EA75$1*RH:;"   _1(  !D
M             ("! D@! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  .6%=4$\(V:= *  "A'0  &0              @('44 $ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  Y85U0BEJ QL@,
M  $(   9              " @=M; 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ #EA75( A#YC5 @  -P8  !D              ("!
MQ%\! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  .6%=4
MD[[QPZP"  !_!0  &0              @('08@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    (  Y85U0YFZ,X>0H  +@G   9
M      " @;-E 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ #EA75#JJGC\6!   / T  !D              ("!8W ! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  .6%=4^GJ)<*,#   ^"
M&0              @(&P= $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    (  Y85U1NM!T-?@,  #L(   9              " @8IX 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ #EA75))<W0")
M!0  ( \  !D              ("!/WP! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  .6%=4:)49-VL#  #D!P  &0
M@('_@0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  Y8
M5U1X39]3& @  !D4   9              " @:&% 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ #EA75/?+261&#0  G"L  !D
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M=#0W+GAM;%!+ 0(4 Q0    (  Y85U1Q8/.GCP0  /44   9
M  " @;NL 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M#EA75!M^["() @  @00  !D              ("!@;$! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    "  .6%=4>F.::SL.  "C:@  &0
M            @('!LP$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    (  Y85U1-<PL!<P,  "P-   9              " @3/" 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ #EA75)PA;M7X!@
M)QX  !D              ("!W<4! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    "  .6%=460M,'_$$  !R%   &0              @($,
MS0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (  Y85U3H
MQ@&=; <  +$M   9              " @332 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ #EA75$TB.6+' @  @0@  !D
M     ("!U]D! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Y85U2=?9G0+@,  $L)   9              "
M@2GN 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ #EA7
M5,=06(YN!@  Y!L  !D              ("!CO$! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    "  .6%=4&XCC"0(%  !?%0  &0
M        @($S^ $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   (  Y85U2I+6@+IPL  .Q?   9              " @6S] 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ #EA75-W".SV% P  (0X
M !D              ("!2@D" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    "  .6%=4H/D@"7D)   N5P  &0              @($&#0(
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (  Y85U04B-2
M<0(  .T%   9              " @;86 @!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ #EA75.T<)):G @  \ 8  !D
M ("!7AD" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  .
M6%=4M5.MMM "  "8!P  &0              @($\' ( >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (  Y85U00>N+PO (  .@(   9
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M970W,RYX;6Q02P$"% ,4    "  .6%=4%7?9:.,"  "2"   &0
M    @(%V+@( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M  Y85U1=--<#9 (  ,\%   9              " @9 Q @!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ #EA75-OZDS// @  T@@  !D
M             ("!*S0" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    "  .6%=4H7=<3&L"   T!@  &0              @($Q-P( >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    (  Y85U1N;%.H!P,
M (@(   9              " @=,Y @!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ #EA75+%OV6WD @  9 @  !D              ("!
M$3T" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  .6%=4
M?;3!\/("  !U"   &0              @($L0 ( >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    (  Y85U2&LI(["PH  #9+   9
M      " @55# @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ #EA75'$#IKKV"@  L$P  !D              ("!ETT" 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    "  .6%=4GO=&=S("  "#!0
M&0              @('$6 ( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+
M 0(4 Q0    (  Y85U19E5Q:9@(  -T%   9              " @2U; @!X
M;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ #EA75"-OH1F3
M @  M08  !D              ("!RET" 'AL+W=O<FMS:&5E=',O<VAE970X
M-2YX;6Q02P$"% ,4    "  .6%=4:%EU8U0%   .&@  &0
M@(&48 ( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    (  Y8
M5U3*Z?.#&0,  *4+   9              " @1]F @!X;"]W;W)K<VAE971S
M+W-H965T.#<N>&UL4$L! A0#%     @ #EA75-YP3?J, P  U@P  !D
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M=#DR+GAM;%!+ 0(4 Q0    (  Y85U1@TNT[0P(  $D%   9
M  " @0-_ @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @
M#EA75/4N]-=[ P  : H  !D              ("!?8$" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-"YX;6Q02P$"% ,4    "  .6%=4 &[[S>H#  "G#   &0
M            @($OA0( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4
M Q0    (  Y85U3OZOFU=0(  .T%   9              " @5") @!X;"]W
M;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ #EA75#4:8N/)!@
M "$  !D              ("!_(L" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX
M;6Q02P$"% ,4    "  .6%=45RWJ(\X#  "R#0  &0              @('\
MD@( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    (  Y85U3N
M=/%MO0,  $@,   9              " @0&7 @!X;"]W;W)K<VAE971S+W-H
M965T.3DN>&UL4$L! A0#%     @ #EA75&/XYTZ  P  *@\  !H
M     ("!]9H" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%
M  @ #EA75)?IVR,1"0  GC$  !H              ("!K9X" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ #EA75"XZ=T7D$0  FL$
M !H              ("!]J<" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL
M4$L! A0#%     @ #EA75&UKO9"6!P  N2L  !H              ("!$KH"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @ #EA75#HR
M)EHE"   E3   !H              ("!X,$" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#0N>&UL4$L! A0#%     @ #EA75+;#XH'3 P  .0X  !H
M     ("!/<H" 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%
M  @ #EA75-^'L0'R!   7A<  !H              ("!2,X" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%     @ #EA75'O$:-ZL P  B0L
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M;',O+G)E;'-02P$"% ,4    "  .6%=44'F:3C,'  #(1@  #P
M    @ &*WP( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ #EA75##&G"8,
M P  ;S\  !H              ( !ZN8" 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ #EA75"BDL[1T @  $ST  !,
M ( !+NH" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     '0 = #L'P  T^P"
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1011</ContextCount>
  <ElementCount>629</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>249</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Shareholders' Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1008010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Acquisitions and Divestiture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestiture</Role>
      <ShortName>Acquisitions and Divestiture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138108 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144109 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2150110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155111 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2162112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2167113 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2169114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2179115 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2187116 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2189117 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2194118 - Disclosure - Other-Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other-Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2197119 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Acquisitions and Divestiture (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitureTables</Role>
      <ShortName>Acquisitions and Divestiture (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestiture</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Inventories</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2339307 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2351309 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Leases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Borrowings</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2363311 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2370312 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2380313 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2390314 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2395315 - Disclosure - Other - Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other - Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Acquisitions and Divestiture (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestiture (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitureTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions and Divestiture (Purchase Price Allocation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitureTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Acquisitions and Divestiture (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions and Divestiture (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitureTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Net Product Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/InventoriesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Effect of Risk Management) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Fair Value Measurement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails</Role>
      <ShortName>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Schedule of Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Schedule of Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails</Role>
      <ShortName>Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Financial Instruments (Schedule of Investment Portfolio Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails</Role>
      <ShortName>Financial Instruments (Schedule of Investment Portfolio Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2443427 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Schedule of Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2449431 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails</Role>
      <ShortName>Property and Equipment (Schedule of Geographic Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2452432 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2453433 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails</Role>
      <ShortName>Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2454434 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases (Maturities of Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2457435 - Disclosure - Borrowings (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofDebtDetails</Role>
      <ShortName>Borrowings (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails</Role>
      <ShortName>Borrowings (Summary of Long-term Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2459437 - Disclosure - Borrowings (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2460438 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails</Role>
      <ShortName>Borrowings (Schedule of Debt Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails</Role>
      <ShortName>Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2464440 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2465441 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2466442 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Assumptions Used) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2468443 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/ShareholdersEquity</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2471444 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2472445 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2473446 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2474447 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2475448 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails</Role>
      <ShortName>Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2476449 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2477450 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2478451 - Disclosure - Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2481452 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2482453 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2483454 - Disclosure - Retirement Benefits (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsNarrativeDetails</Role>
      <ShortName>Retirement Benefits (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2484455 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2485456 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2486457 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2488458 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2491459 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2492460 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2493461 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2496462 - Disclosure - Other - Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other - Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="lly-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2498463 - Disclosure - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/DiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/DiscontinuedOperations</ParentRole>
      <Position>108</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lly-20211231.htm">lly-20211231.htm</File>
    <File>lly-20211231.xsd</File>
    <File>lly-20211231_cal.xml</File>
    <File>lly-20211231_def.xml</File>
    <File>lly-20211231_lab.xml</File>
    <File>lly-20211231_pre.xml</File>
    <File>lly-20211231x10kexhibit1010.htm</File>
    <File>lly-20211231x10kexhibit1011.htm</File>
    <File>lly-20211231x10kexhibit1017.htm</File>
    <File>lly-20211231x10kexhibit102.htm</File>
    <File>lly-20211231x10kexhibit103.htm</File>
    <File>lly-20211231x10kexhibit104.htm</File>
    <File>lly-20211231x10kexhibit105.htm</File>
    <File>lly-20211231x10kexhibit106.htm</File>
    <File>lly-20211231x10kexhibit107.htm</File>
    <File>lly-20211231x10kexhibit108.htm</File>
    <File>lly-20211231x10kexhibit109.htm</File>
    <File>lly-20211231x10kexhibit21.htm</File>
    <File>lly-20211231x10kexhibit23.htm</File>
    <File>lly-20211231x10kexhibit311.htm</File>
    <File>lly-20211231x10kexhibit312.htm</File>
    <File>lly-20211231x10kexhibit32.htm</File>
    <File>lly-20211231x10kexhibit48.htm</File>
    <File>lly-20211231x10kexhibit49.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lly-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2198">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="70">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>144
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20211231.htm": {
   "axisCustom": 2,
   "axisStandard": 40,
   "contextCount": 1011,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 984,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://www.lilly.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 10
   },
   "keyCustom": 58,
   "keyStandard": 571,
   "memberCustom": 161,
   "memberStandard": 83,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "icaa5fbd37ece44598769646bdacd67e4_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "icaa5fbd37ece44598769646bdacd67e4_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i99352080eaa64b8aa55bab4783a9052b_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484455 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails",
     "shortName": "Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i99352080eaa64b8aa55bab4783a9052b_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485456 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
     "shortName": "Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i99352080eaa64b8aa55bab4783a9052b_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486457 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
     "shortName": "Retirement Benefits (Schedule of Fair Value Disclosures) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i673f610f07dd4af7a79e6fae5b2a77f2_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i3ce97af02d724dd5a6b2d83575df05d1_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
      "reportCount": 1,
      "unique": true,
      "unitRef": "site",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488458 - Disclosure - Contingencies (Details)",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i3ce97af02d724dd5a6b2d83575df05d1_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
      "reportCount": 1,
      "unique": true,
      "unitRef": "site",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ica0f6e15b180491b9202fefd783ba908_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2491459 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2492460 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i456c6ad8d4564976aef8554ffb59ccb7_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2493461 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i4087c38c7e2f4891af8a6f423b425b46_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2496462 - Disclosure - Other - Net, (Income) Expense (Details)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other - Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2498463 - Disclosure - Discontinued Operations (Details)",
     "role": "http://www.lilly.com/role/DiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "iccb9aa249e034756b9c8db5d7fecdf51_D20190101-20190331",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenue",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Acquisitions and Divestiture",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestiture",
     "shortName": "Acquisitions and Divestiture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Inventories",
     "role": "http://www.lilly.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - Financial Instruments",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138108 - Disclosure - Goodwill and Other Intangibles",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144109 - Disclosure - Property and Equipment",
     "role": "http://www.lilly.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.lilly.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150110 - Disclosure - Leases",
     "role": "http://www.lilly.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155111 - Disclosure - Borrowings",
     "role": "http://www.lilly.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.lilly.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167113 - Disclosure - Shareholders' Equity",
     "role": "http://www.lilly.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169114 - Disclosure - Income Taxes",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179115 - Disclosure - Retirement Benefits",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2187116 - Disclosure - Contingencies",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2189117 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2194118 - Disclosure - Other-Net, (Income) Expense",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other-Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2197119 - Disclosure - Discontinued Operations",
     "role": "http://www.lilly.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Statements of Operations",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Policies)",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenue (Tables)",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Acquisitions and Divestiture (Tables)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitureTables",
     "shortName": "Acquisitions and Divestiture (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Inventories (Tables)",
     "role": "http://www.lilly.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339307 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351309 - Disclosure - Leases (Tables)",
     "role": "http://www.lilly.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Borrowings (Tables)",
     "role": "http://www.lilly.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363311 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.lilly.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2370312 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.lilly.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2380313 - Disclosure - Retirement Benefits (Tables)",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2390314 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2395315 - Disclosure - Other - Net, (Income) Expense (Tables)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other - Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Narrative) (Details)",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i99ba0120ed084c1da3c0cb9a06a3535c_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenuefromContractPaymentTermMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenue (Narrative) (Details)",
     "role": "http://www.lilly.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenuefromContractPaymentTermMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Balance Sheets",
     "role": "http://www.lilly.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ib51a0dd6c879443684c594e3c15c31cd_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i04193007085b41a38db99637f0c0d6af_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Acquisitions and Divestiture (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
     "shortName": "Acquisitions and Divestiture (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i71fb9ec508c94ce1bb1b48ca7cfd29ae_I20210131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
     "shortName": "Acquisitions and Divestiture (Purchase Price Allocation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i4d886a39796d42f5809576721f051d0f_I20210122",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Acquisitions and Divestiture (Asset Acquisitions) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
     "shortName": "Acquisitions and Divestiture (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i9950f4e9a0354b2fa627384fb3ed7958_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ic8fafa3bd40547eda95f4f50a6dbab51_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
     "shortName": "Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ic8fafa3bd40547eda95f4f50a6dbab51_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
     "shortName": "Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
     "shortName": "Collaborations and Other Arrangements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i48acf53cf4c149ba854e91d6ea82b05a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges - Schedule of Other Operating Cost and Expense, by Component (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Inventories (Details)",
     "role": "http://www.lilly.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
     "shortName": "Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
     "shortName": "Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i3c7e5f9100c44eb48c6a8b02af879981_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
     "shortName": "Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i3c7e5f9100c44eb48c6a8b02af879981_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie3392ad7d22c4bf7b9a4a1c59ed94a0d_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie3392ad7d22c4bf7b9a4a1c59ed94a0d_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails",
     "shortName": "Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Financial Instruments (Schedule of Investment Portfolio Activity) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails",
     "shortName": "Financial Instruments (Schedule of Investment Portfolio Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ib49b2b7f42884738a47622d8db6c8d71_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Shareholders' Equity Statement",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
     "shortName": "Consolidated Statements of Shareholders' Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ib49b2b7f42884738a47622d8db6c8d71_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443427 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ia3c486aeafe64057905b3c05060eedc7_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Property and Equipment (Narrative) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ia3c486aeafe64057905b3c05060eedc7_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails",
     "shortName": "Property and Equipment (Schedule of Depreciation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449431 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
     "shortName": "Property and Equipment (Schedule of Geographic Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:LesseeLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452432 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.lilly.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:LesseeLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453433 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)",
     "role": "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails",
     "shortName": "Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454434 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)",
     "role": "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases (Maturities of Operating Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457435 - Disclosure - Borrowings (Schedule of Debt) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
     "shortName": "Borrowings (Schedule of Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
     "shortName": "Borrowings (Summary of Long-term Notes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459437 - Disclosure - Borrowings (Narrative) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460438 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails",
     "shortName": "Borrowings (Schedule of Debt Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails",
     "shortName": "Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464440 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)",
     "role": "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465441 - Disclosure - Stock-Based Compensation (Narrative) (Details)",
     "role": "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466442 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)",
     "role": "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails",
     "shortName": "Stock-Based Compensation (Schedule of Assumptions Used) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i37ea27c7722e4caba00019cc039ac2ad_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i0b72858f1e1a4cbea5c56de4e31319a8_D20210101-20210430",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468443 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.lilly.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i0b72858f1e1a4cbea5c56de4e31319a8_D20210101-20210430",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471444 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472445 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes (Schedule of Composition of Income Tax Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473446 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474447 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutAndJobsActTollTaxToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475448 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails",
     "shortName": "Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutAndJobsActTollTaxToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476449 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ica0f6e15b180491b9202fefd783ba908_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477450 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i2161fbcc13a94af3a14765cc6ce775d6_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478451 - Disclosure - Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails",
     "shortName": "Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "icddb724942ed473c88a3646e8ec26fcc_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481452 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
     "shortName": "Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i2c9102d327e04ff088fec4c67db2c025_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "ie685003a00ac4b9e88ea5a5aad91acf6_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482453 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
     "shortName": "Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i99352080eaa64b8aa55bab4783a9052b_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483454 - Disclosure - Retirement Benefits (Narrative) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
     "shortName": "Retirement Benefits (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20211231.htm",
      "contextRef": "i22de8effd1e0473ea9e6b2ebf9fa4dfd_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 249,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "verboseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r879",
      "r880",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A015SwissFrancDenominatedNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% Swiss Franc-denominated Notes Due 2024",
        "label": "0.15% Swiss Franc-denominated Notes Due 2024 [Member]",
        "terseLabel": "0.15% Swiss franc denominated notes due 2024"
       }
      }
     },
     "localname": "A015SwissFrancDenominatedNotesDue2024Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A045SwissFrancDenominatedNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.45% Swiss Franc Denominated Notes Due 2028",
        "label": "0.45% Swiss Franc Denominated Notes Due 2028 [Member]",
        "terseLabel": "0.45% Swiss franc denominated notes due 2028"
       }
      }
     },
     "localname": "A045SwissFrancDenominatedNotesDue2028Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A10EuroDenominatedNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.0% Euro-denominated Notes Due 2022",
        "label": "1.0% Euro-denominated Notes Due 2022 [Member]",
        "terseLabel": "1.00% euro denominated notes due 2022"
       }
      }
     },
     "localname": "A10EuroDenominatedNotesDue2022Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes Due 2051",
        "label": "1.125% Notes Due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051",
        "verboseLabel": "1.125% euro denominated notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes Due 2061",
        "label": "1.375% Notes Due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061",
        "verboseLabel": "1.375% euro denominated notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625EuroDenominatedNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Euro-denominated Notes Due 2026",
        "label": "1.625% Euro-denominated Notes Due 2026 [Member]",
        "terseLabel": "1.625% euro denominated notes due 2026"
       }
      }
     },
     "localname": "A1625EuroDenominatedNotesDue2026Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due 2043",
        "label": "1.625% Notes Due 2043 [Member]",
        "terseLabel": "1.625% Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A17EuroDeonominatedNotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.7% Euro-deonominated Notes Due 2049 [Member]",
        "label": "1.7% Euro-deonominated Notes Due 2049 [Member]",
        "terseLabel": "1.70% euro denominated notes due 2049"
       }
      }
     },
     "localname": "A17EuroDeonominatedNotesDue2049Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2125EuroDenominatedNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Euro-denominated Notes Due 2030",
        "label": "2.125% Euro-denominated Notes Due 2030 [Member]",
        "terseLabel": "2.125% euro denominated notes due 2030"
       }
      }
     },
     "localname": "A2125EuroDenominatedNotesDue2030Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A225NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Notes Due 2050 [Member]",
        "label": "2.25% Notes Due 2050 [Member]",
        "terseLabel": "2.25% notes due 2050"
       }
      }
     },
     "localname": "A225NotesDue2050Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A235NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A235NotesDue2022Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A25NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.5% Notes Due 2060",
        "label": "2.5% Notes Due 2060 [Member]",
        "terseLabel": "2.50% notes due 2060"
       }
      }
     },
     "localname": "A25NotesDue2060Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A275NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% Notes Due 2025",
        "label": "2.75% Notes Due 2025 [Member]",
        "terseLabel": "2.75% notes due 2025"
       }
      }
     },
     "localname": "A275NotesDue2025Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A30NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.0% Notes Due 2022",
        "label": "3.0% Notes Due 2022 [Member]",
        "terseLabel": "3.00% notes due 2022"
       }
      }
     },
     "localname": "A30NotesDue2022Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A31NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.1% Notes Due 2027",
        "label": "3.1% Notes Due 2027 [Member]",
        "terseLabel": "3.1% notes due 2027"
       }
      }
     },
     "localname": "A31NotesDue2027Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3375NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes Due 2029",
        "label": "3.375% Notes Due 2029 [Member]",
        "terseLabel": "3.375% notes due 2029"
       }
      }
     },
     "localname": "A3375NotesDue2029Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A37NotesDue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.7% Notes Due 2045",
        "label": "3.7% Notes Due 2045 [Member]",
        "terseLabel": "3.7% notes due 2045"
       }
      }
     },
     "localname": "A37NotesDue2045Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3875NotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2039 [Member]",
        "label": "3.875% Notes Due 2039 [Member]",
        "terseLabel": "3.875% notes due 2039"
       }
      }
     },
     "localname": "A3875NotesDue2039Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2047",
        "label": "3.95% Notes Due 2047 [Member]",
        "terseLabel": "3.95% notes due 2047"
       }
      }
     },
     "localname": "A395NotesDue2047Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2049 [Member]",
        "label": "3.95% Notes Due 2049 [Member]",
        "terseLabel": "3.95% notes due 2049"
       }
      }
     },
     "localname": "A395NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A415NotesDue2059Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2059 [Member]",
        "label": "4.15% Notes Due 2059 [Member]",
        "terseLabel": "4.15% notes due 2059"
       }
      }
     },
     "localname": "A415NotesDue2059Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A42YenDenominatedNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".42% Yen-denominated Notes Due 2029 [Member]",
        "label": ".42% Yen-denominated Notes Due 2029 [Member]",
        "terseLabel": "0.42% Japanese yen denominated notes due 2029"
       }
      }
     },
     "localname": "A42YenDenominatedNotesDue2029Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A465NotesDue2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.65% Notes Due 2044",
        "label": "4.65% Notes Due 2044 [Member]",
        "terseLabel": "4.65% notes due 2044"
       }
      }
     },
     "localname": "A465NotesDue2044Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A5000NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".5000% Notes Due 2033",
        "label": ".5000% Notes Due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033",
        "verboseLabel": "0.50% euro denominated notes due 2033"
       }
      }
     },
     "localname": "A5000NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A555NotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.55% Notes Due 2037",
        "label": "5.55% Notes Due 2037 [Member]",
        "terseLabel": "5.55% notes due 2037"
       }
      }
     },
     "localname": "A555NotesDue2037Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A55NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.5% Notes Due 2027",
        "label": "5.5% Notes Due 2027 [Member]",
        "terseLabel": "5.5% notes due 2027"
       }
      }
     },
     "localname": "A55NotesDue2027Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A56YenDenominatedNotesDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".56% Yen-denominated Notes Due 2034 [Member]",
        "label": ".56% Yen-denominated Notes Due 2034 [Member]",
        "terseLabel": "0.56% Japanese yen denominated notes due 2034"
       }
      }
     },
     "localname": "A56YenDenominatedNotesDue2034Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A595NotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes Due 2037",
        "label": "5.95% Notes Due 2037 [Member]",
        "terseLabel": "5.95% notes due 2037"
       }
      }
     },
     "localname": "A595NotesDue2037Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625EuroDeonominatedNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Euro-deonominated Notes Due 2031 [Member]",
        "label": ".625% Euro-deonominated Notes Due 2031 [Member]",
        "terseLabel": "0.625% euro denominated notes due 2031"
       }
      }
     },
     "localname": "A625EuroDeonominatedNotesDue2031Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A677NotesDue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77% Notes Due 2036",
        "label": "6.77% Notes Due 2036 [Member]",
        "terseLabel": "6.77% notes due 2036"
       }
      }
     },
     "localname": "A677NotesDue2036Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A7125NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.125% Notes Due 2025",
        "label": "7.125% Notes Due 2025 [Member]",
        "terseLabel": "7.125% notes due 2025"
       }
      }
     },
     "localname": "A7125NotesDue2025Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A97YenDeonominatedNotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".97% Yen-deonominated Notes Due 2049",
        "label": ".97% Yen-deonominated Notes Due 2049 [Member]",
        "terseLabel": "0.97% Japanese yen denominated notes due 2049"
       }
      }
     },
     "localname": "A97YenDeonominatedNotesDue2049Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ACImmuneSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AC Immune SA [Member]",
        "label": "AC Immune SA [Member]",
        "terseLabel": "AC Immune SA"
       }
      }
     },
     "localname": "ACImmuneSAMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AbCelleraBiologicsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbCellera Biologics Inc. [Member]",
        "label": "AbCellera Biologics Inc. [Member]",
        "terseLabel": "AbCellera Biologics Inc."
       }
      }
     },
     "localname": "AbCelleraBiologicsInc.Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible",
        "label": "Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible",
        "terseLabel": "Long-term income taxes payable, estimated timing of future cash outflows not possible"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)",
        "label": "Acquired in-process research and development",
        "verboseLabel": "Acquired in-process research and development (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ActosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actos",
        "label": "Actos [Member]",
        "terseLabel": "Actos"
       }
      }
     },
     "localname": "ActosMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AddDeductAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Add (Deduct) [Abstract]",
        "label": "Add (Deduct) [Abstract]",
        "terseLabel": "Add (deduct):"
       }
      }
     },
     "localname": "AddDeductAbstract",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_AdvertisingExpensePercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advertising Expense, Percentage Of Revenue",
        "label": "Advertising Expense, Percentage Of Revenue",
        "terseLabel": "Advertising expense, percentage of revenue"
       }
      }
     },
     "localname": "AdvertisingExpensePercentageOfRevenue",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AlimtaPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta Patent Litigation",
        "label": "Alimta Patent Litigation [Member]",
        "terseLabel": "Alimta Patent Litigation"
       }
      }
     },
     "localname": "AlimtaPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AmpullaryCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ampullary Cancer",
        "label": "Ampullary Cancer [Member]",
        "terseLabel": "Ampullary Cancer"
       }
      }
     },
     "localname": "AmpullaryCancerMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AsahiKaseiPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asahi Kasei Pharma Corporation",
        "label": "Asahi Kasei Pharma Corporation [Member]",
        "terseLabel": "Asahi Kasei Pharma Corporation"
       }
      }
     },
     "localname": "AsahiKaseiPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "label": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "terseLabel": "Asset impairment (gain) and other special charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.lilly.com/20211231",
     "xbrltype": "stringItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvidityBiosciencesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avidity Biosciences, Inc. [Member]",
        "label": "Avidity Biosciences, Inc. [Member]",
        "terseLabel": "Avidity Biosciences, Inc."
       }
      }
     },
     "localname": "AvidityBiosciencesInc.Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "verboseLabel": "Basaglar\u00ae"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs",
        "label": "Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction",
        "terseLabel": "Contingent value right, monthly reduction"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "label": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "terseLabel": "Number of contingent value rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euro Sell USD"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyGBPSellUSDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy GBP Sell USD",
        "label": "Buy GBP Sell USD [Member]",
        "terseLabel": "Buy GBP Sell USD"
       }
      }
     },
     "localname": "BuyGBPSellUSDMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSdollarSellJapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US dollar Sell Japanese Yen [Member]",
        "label": "Buy US dollar Sell Japanese Yen [Member]",
        "terseLabel": "Buy USD Sell Japanese Yen"
       }
      }
     },
     "localname": "BuyUSdollarSellJapaneseYenMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsdSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy USD Sell Euro [Member]",
        "label": "Buy USD Sell Euro [Member]",
        "terseLabel": "Buy USD Sell Euro"
       }
      }
     },
     "localname": "BuyUsdSellEuroMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ByettaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Byetta",
        "label": "Byetta [Member]",
        "terseLabel": "Byetta"
       }
      }
     },
     "localname": "ByettaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_COVID19AntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Antibodies",
        "label": "COVID-19 Antibodies [Member]",
        "terseLabel": "COVID-19 Antibodies"
       }
      }
     },
     "localname": "COVID19AntibodiesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Carryforward [Member]",
        "label": "Carryforward [Member]",
        "terseLabel": "Carryforward"
       }
      }
     },
     "localname": "CarryforwardMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.",
        "label": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]",
        "terseLabel": "Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al."
       }
      }
     },
     "localname": "CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CentrexionTherapeuticsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centrexion Therapeutics Corporation [Member]",
        "label": "Centrexion Therapeutics Corporation [Member]",
        "terseLabel": "Centrexion Therapeutics Corporation"
       }
      }
     },
     "localname": "CentrexionTherapeuticsCorporationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations percent (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Rights (Obligations)",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Milestones payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales, operating expenses, and other-net",
        "label": "Cost of sales, operating expenses, and other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward",
        "label": "Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward",
        "terseLabel": "Current federal tax expense, utilization of net operating loss carryforward"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CymbaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cymbalta [Member]",
        "label": "Cymbalta [Member]",
        "terseLabel": "Cymbalta\u00ae"
       }
      }
     },
     "localname": "CymbaltaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsCorrectiveTaxAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Corrective Tax Adjustments",
        "label": "Deferred Tax Assets, Corrective Tax Adjustments",
        "terseLabel": "Correlative tax adjustments"
       }
      }
     },
     "localname": "DeferredTaxAssetsCorrectiveTaxAdjustments",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsForeignTaxRedeterminations": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Foreign Tax Redeterminations",
        "label": "Deferred Tax Assets, Foreign Tax Redeterminations",
        "terseLabel": "Foreign tax redeterminations"
       }
      }
     },
     "localname": "DeferredTaxAssetsForeignTaxRedeterminations",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsSalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Sales Rebates And Discounts",
        "label": "Deferred Tax Assets, Sales Rebates And Discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsSalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DefineBenefitPlanOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Define Benefit Plan, Other [Member]",
        "label": "Define Benefit Plan, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefineBenefitPlanOtherMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance",
        "label": "Defined Benefit Plan, Percentage of Global Investments in Plan Assets",
        "terseLabel": "Percentage of global investments in plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DermiraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermira, Inc. [Member]",
        "label": "Dermira, Inc. [Member]",
        "terseLabel": "Dermira"
       }
      }
     },
     "localname": "DermiraInc.Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DescriptionOfDerivativeActivityVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Derivative Activity Volume Percent",
        "label": "Description of Derivative Activity Volume Percent",
        "terseLabel": "Description of derivative activity volume percent"
       }
      }
     },
     "localname": "DescriptionOfDerivativeActivityVolumePercent",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DesignatedUnusableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.",
        "label": "Designated Unusable [Member]",
        "terseLabel": "Designated Unusable"
       }
      }
     },
     "localname": "DesignatedUnusableMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DisarmTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disarm Therapeutics, Inc.",
        "label": "Disarm Therapeutics, Inc. [Member]",
        "terseLabel": "Disarm Therapeutics, Inc."
       }
      }
     },
     "localname": "DisarmTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term",
        "label": "Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term",
        "terseLabel": "Transitional services agreement, term"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Payment To Be Received",
        "label": "Disposal Group, Not Discontinued Operation, Payment To Be Received",
        "terseLabel": "Disposal group, not discontinued operation, payment to be received"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationPaymentToBeReceived",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.",
        "label": "Domestic and Puerto Rican Contribution to Income before Income Taxes",
        "terseLabel": "Domestic and Puerto Rican companies contribution"
       }
      }
     },
     "localname": "DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DomicileOfLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Axis]",
        "terseLabel": "Domicile of Litigation [Axis]"
       }
      }
     },
     "localname": "DomicileOfLitigationAxis",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_DomicileOfLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Domain]",
        "terseLabel": "Domicile of Litigation [Domain]"
       }
      }
     },
     "localname": "DomicileOfLitigationDomain",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EddingpharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eddingpharm [Member]",
        "label": "Eddingpharm [Member]",
        "terseLabel": "Eddingpharm"
       }
      }
     },
     "localname": "EddingpharmMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ElancoAnimalHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elanco Animal Health Incorporated [Member]",
        "label": "Elanco Animal Health Incorporated [Member]",
        "verboseLabel": "Elanco"
       }
      }
     },
     "localname": "ElancoAnimalHealthIncorporatedMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly And Company [Member]",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation [Member]",
        "label": "Employee Litigation [Member]",
        "terseLabel": "Employee Litigation"
       }
      }
     },
     "localname": "EmployeeLitigationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EntosPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entos Pharmaceuticals Inc.",
        "label": "Entos Pharmaceuticals Inc. [Member]",
        "terseLabel": "Entos Pharmaceuticals Inc."
       }
      }
     },
     "localname": "EntosPharmaceuticalsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EppVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epp V. Takeda Canada Inc. Et Al.",
        "label": "Epp V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Epp v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "EppVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EquityMethodAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method and Other Investments [Member]",
        "label": "Equity Method And Other Investments [Member]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodAndOtherInvestmentsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EvoxTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evox Therapeutics",
        "label": "Evox Therapeutics [Member]",
        "terseLabel": "Evox Therapeutics Limited"
       }
      }
     },
     "localname": "EvoxTherapeuticsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_Expiration5to20YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration 5 to 20 Years [Member]",
        "label": "Expiration 5 to 20 Years [Member]",
        "terseLabel": "Expiration 5 to 20 Years"
       }
      }
     },
     "localname": "Expiration5to20YearsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ExpirationIn12To18YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration In 12 To 18 Years [Member]",
        "label": "Expiration In 12 To 18 Years [Member]",
        "terseLabel": "Expiration in 12 to 18 Years"
       }
      }
     },
     "localname": "ExpirationIn12To18YearsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_Expirationin6YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration in 6 Years [Member]",
        "label": "Expiration in 6 Years [Member]",
        "terseLabel": "Expiration in 6 Years"
       }
      }
     },
     "localname": "Expirationin6YearsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_Expirationwithin5yearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration within 5 years [Member]",
        "label": "Expiration within 5 years [Member]",
        "terseLabel": "Expiration within 5 years"
       }
      }
     },
     "localname": "Expirationwithin5yearsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Unfunded commitments to invest in venture capital funds, anticipated payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_FixedIncomeFundsEmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.",
        "label": "Fixed Income Funds Emerging Markets [Member]",
        "terseLabel": "Emerging markets"
       }
      }
     },
     "localname": "FixedIncomeFundsEmergingMarketsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FixedIncomeFundsRepurchasedAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Income Funds - Repurchased Agreements [Member]",
        "label": "Fixed Income Funds - Repurchased Agreements [Member]",
        "terseLabel": "Developed markets - repurchase agreements"
       }
      }
     },
     "localname": "FixedIncomeFundsRepurchasedAgreementsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FochonPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fochon Pharmaceuticals, Ltd.",
        "label": "Fochon Pharmaceuticals, Ltd. [Member]",
        "terseLabel": "Fochon Pharmaceuticals, Ltd."
       }
      }
     },
     "localname": "FochonPharmaceuticalsLtdMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FoghornTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foghorn Therapeutics Inc.",
        "label": "Foghorn Therapeutics Inc. [Member]",
        "terseLabel": "Foghorn Therapeutics Inc."
       }
      }
     },
     "localname": "FoghornTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Hedged Fixed Rate Debt"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmuNextInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImmuNext, Inc. [Member]",
        "label": "ImmuNext, Inc. [Member]",
        "terseLabel": "ImmuNext, Inc."
       }
      }
     },
     "localname": "ImmuNextInc.Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact on Equity of Sale of Noncontrolling Interest in Subsidiary",
        "label": "Impact on Equity of Sale of Noncontrolling Interest in Subsidiary",
        "terseLabel": "Deconsolidation of Elanco"
       }
      }
     },
     "localname": "ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics, Inc.",
        "label": "Innovent Biologics, Inc. [Member]",
        "terseLabel": "Innovent Biologics, Inc. (Innovent)"
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InsulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insulin",
        "label": "Insulin [Member]",
        "terseLabel": "Insulin"
       }
      }
     },
     "localname": "InsulinMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "verboseLabel": "Jardiance\u00ae"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JunshiBiosciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Junshi Biosciences",
        "label": "Junshi Biosciences [Member]",
        "terseLabel": "Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)"
       }
      }
     },
     "localname": "JunshiBiosciencesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_KumquatBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kumquat Biosciences Inc.",
        "label": "Kumquat Biosciences Inc. [Member]",
        "terseLabel": "Kumquat Biosciences Inc."
       }
      }
     },
     "localname": "KumquatBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]",
        "label": "Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]",
        "terseLabel": "Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China"
       }
      }
     },
     "localname": "LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LesseeLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Remaining Lease Term",
        "label": "Lessee, Lease, Remaining Lease Term",
        "terseLabel": "Lessee, lease, remaining lease term (up to)"
       }
      }
     },
     "localname": "LesseeLeaseRemainingLeaseTerm",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LitigationClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation, Claims Dismissed, Number",
        "label": "Litigation, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LitigationClaimsDismissedNumber",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LongTermDebtFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment to carrying value of long term debt to arrive at total fair value.",
        "label": "Long-term Debt, Fair Value Adjustment",
        "terseLabel": "Fair value adjustment on hedged long-term notes"
       }
      }
     },
     "localname": "LongTermDebtFairValueAdjustment",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_LosAngelesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Los Angeles",
        "label": "Los Angeles [Member]",
        "terseLabel": "Los Angeles"
       }
      }
     },
     "localname": "LosAngelesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "label": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "terseLabel": "Limited initial market entry, supply term"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LossContingencyNumberOfClaimants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Claimants",
        "label": "Loss Contingency, Number Of Claimants",
        "terseLabel": "Number of claimants"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimants",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "label": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "terseLabel": "Number of sites jointly and severally liable for cleanup (fewer than)"
       }
      }
     },
     "localname": "LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LoxoOncologyInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loxo Oncology, Inc. [Member]",
        "label": "Loxo Oncology, Inc. [Member]",
        "terseLabel": "Loxo Oncology, Inc."
       }
      }
     },
     "localname": "LoxoOncologyInc.Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LyciaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lycia Therapeutics, Inc.",
        "label": "Lycia Therapeutics, Inc. [Member]",
        "terseLabel": "Lycia Therapeutics, Inc."
       }
      }
     },
     "localname": "LyciaTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date, 2019 [Member]",
        "label": "Maturity Date, 2019 [Member]",
        "terseLabel": "Maturity Date, 2019"
       }
      }
     },
     "localname": "MaturityDate2019Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date, 2023",
        "label": "Maturity Date, 2023 [Member]",
        "terseLabel": "Maturity Date, 2023"
       }
      }
     },
     "localname": "MaturityDate2023Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merus N.V.",
        "label": "Merus N.V. [Member]",
        "terseLabel": "Merus N.V."
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MiNATherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MiNA Therapeutics Limited",
        "label": "MiNA Therapeutics Limited [Member]",
        "terseLabel": "MiNA Therapeutics Limited"
       }
      }
     },
     "localname": "MiNATherapeuticsLimitedMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Capitalized As Intangible Assets",
        "label": "Milestone Payments, Capitalized As Intangible Assets [Member]",
        "terseLabel": "Milestone Payments, Capitalized As Intangible Assets"
       }
      }
     },
     "localname": "MilestonePaymentsCapitalizedAsIntangibleAssetsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept",
        "label": "Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept [Member]",
        "terseLabel": "Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept"
       }
      }
     },
     "localname": "MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Upon Initiation Of Phase I Trial",
        "label": "Milestone Payments, Contingent Upon Initiation Of Phase I Trial [Member]",
        "terseLabel": "Milestone Payments, Contingent Upon Initiation Of Phase I Trial"
       }
      }
     },
     "localname": "MilestonePaymentsContingentUponInitiationOfPhaseITrialMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory And Sales-based",
        "label": "Milestone Payments, Success-based Regulatory And Sales-based [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory And Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.",
        "label": "No Expiration [Member]",
        "terseLabel": "No Expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NonCHINAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-CHINA",
        "label": "Non-CHINA [Member]",
        "terseLabel": "Outside of China"
       }
      }
     },
     "localname": "NonCHINAMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_November2019EuroDenominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Euro-denominated Notes",
        "label": "November 2019 Euro-denominated Notes [Member]",
        "terseLabel": "November 2019 Euro-denominated Notes"
       }
      }
     },
     "localname": "November2019EuroDenominatedNotesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_November2019YenDenominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Yen-denominated Notes",
        "label": "November 2019 Yen-denominated Notes [Member]",
        "terseLabel": "November 2019 Yen-denominated Notes"
       }
      }
     },
     "localname": "November2019YenDenominatedNotesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NumberOfMedicinesRightsToSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Medicines, Rights To, Sold",
        "label": "Number Of Medicines, Rights To, Sold",
        "terseLabel": "Number of legacy antibiotic medicines rights sold"
       }
      }
     },
     "localname": "NumberOfMedicinesRightsToSold",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other Diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries",
        "verboseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other Neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreaticCancerOrThyroidCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatic Cancer Or Thyroid Cancer",
        "label": "Pancreatic Cancer Or Thyroid Cancer [Member]",
        "terseLabel": "Pancreatic Cancer or Thyroid Cancer"
       }
      }
     },
     "localname": "PancreaticCancerOrThyroidCancerMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreatitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatitis",
        "label": "Pancreatitis [Member]",
        "terseLabel": "Pancreatitis"
       }
      }
     },
     "localname": "PancreatitisMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PaymentsForIncomeTaxSettlements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Income Tax Settlements",
        "label": "Payments For Income Tax Settlements",
        "terseLabel": "Payments for income tax settlements"
       }
      }
     },
     "localname": "PaymentsForIncomeTaxSettlements",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_PetraPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Petra Pharma Corporation",
        "label": "Petra Pharma Corporation [Member]",
        "terseLabel": "Petra Pharma Corporation (Petra)"
       }
      }
     },
     "localname": "PetraPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PlaintiffAllegationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Axis]",
        "terseLabel": "Plaintiff Allegations [Axis]"
       }
      }
     },
     "localname": "PlaintiffAllegationsAxis",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_PlaintiffAllegationsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Domain]",
        "terseLabel": "Plaintiff Allegations [Domain]"
       }
      }
     },
     "localname": "PlaintiffAllegationsDomain",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrecisionBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Biosciences, Inc.",
        "label": "Precision Biosciences, Inc. [Member]",
        "terseLabel": "Precision Biosciences, Inc."
       }
      }
     },
     "localname": "PrecisionBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrevailTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevail Therapeutics Inc.",
        "label": "Prevail Therapeutics Inc. [Member]",
        "terseLabel": "Prevail Therapeutics Inc."
       }
      }
     },
     "localname": "PrevailTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProQRTherapeuticsNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics N.V.",
        "label": "ProQR Therapeutics N.V. [Member]",
        "terseLabel": "ProQR Therapeutics N.V."
       }
      }
     },
     "localname": "ProQRTherapeuticsNVMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProtomerTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protomer Technologies Inc.",
        "label": "Protomer Technologies Inc. [Member]",
        "terseLabel": "Protomer Technologies Inc."
       }
      }
     },
     "localname": "ProtomerTechnologiesIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PurchasedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchased in-process research and development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_QILURegorTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "QILU Regor Therapeutics Inc.",
        "label": "QILU Regor Therapeutics Inc. [Member]",
        "terseLabel": "QILU Regor Therapeutics Inc."
       }
      }
     },
     "localname": "QILURegorTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RelativeValueAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative Value Awards",
        "label": "Relative Value Awards [Member]",
        "terseLabel": "Relative Value Awards"
       }
      }
     },
     "localname": "RelativeValueAwardsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less)"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt",
        "label": "Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt",
        "terseLabel": "Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesRebatePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Rebate Payment Period",
        "label": "Revenue, Performance Obligation, Sales Rebate Payment Period",
        "terseLabel": "Revenue, performance obligation, sales rebate payment period (up to)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesRebatePaymentPeriod",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Average Inventory Level",
        "label": "Revenue, Performance Obligation, Sales Returns, Average Inventory Level",
        "terseLabel": "Revenue, performance obligation, sales returns, average inventory level (or less)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsAverageInventoryLevel",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue",
        "label": "Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue",
        "terseLabel": "Revenue, performance obligation, sales returns, percentage of net revenue (less than)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Product Expiration Date",
        "label": "Revenue, Performance Obligation, Sales Returns, Product Expiration Date",
        "terseLabel": "Revenue, performance obligation, sales returns, product expiration date"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsProductExpirationDate",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuefromContractPaymentTermMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract, Payment Term, Maximum",
        "label": "Revenue from Contract, Payment Term, Maximum",
        "terseLabel": "Revenue, performance obligation, payment terms, days from date of shipment, maximum"
       }
      }
     },
     "localname": "RevenuefromContractPaymentTermMaximum",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuefromContractPaymentTermMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract, Payment Term",
        "label": "Revenue from Contract, Payment Term, Minimum",
        "terseLabel": "Revenue, performance obligation, payment terms, days from date of shipment, minimum"
       }
      }
     },
     "localname": "RevenuefromContractPaymentTermMinimum",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RigelPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rigel Pharmaceuticals, Inc.",
        "label": "Rigel Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Rigel Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RigelPharmaceuticalsIncMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales rebates and discounts",
        "label": "Sales rebates and discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Borrowings Disclosures [Table Text Block]",
        "label": "Schedule of Additional Borrowings Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Additional Borrowings Disclosures"
       }
      }
     },
     "localname": "ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Income Tax Disclosures [Table Text Block]",
        "label": "Schedule of Additional Income Tax Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax"
       }
      }
     },
     "localname": "ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]",
        "label": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Additional Stock-Based Compensation Disclosures"
       }
      }
     },
     "localname": "ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_SelpercatinibLOXO292Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selpercatinib (LOXO-292) [Member]",
        "label": "Selpercatinib (LOXO-292) [Member]",
        "terseLabel": "Selpercatinib (LOXO-292)"
       }
      }
     },
     "localname": "SelpercatinibLOXO292Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SeniorNotesDueMay2050AndSeptember2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due May 2050 And September 2060",
        "label": "Senior Notes Due May 2050 And September 2060 [Member]",
        "terseLabel": "Senior Notes Due May 2050 and September 2060"
       }
      }
     },
     "localname": "SeniorNotesDueMay2050AndSeptember2060Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares expected to be issued in the next twelve months under the plan.",
        "label": "Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued",
        "terseLabel": "Shares expected to be issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]",
        "label": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]",
        "terseLabel": "Share-based Compensation Awards, Fair Value Assumptions Used"
       }
      }
     },
     "localname": "SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ShareholderValueAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.",
        "label": "Shareholder Value Awards [Member]",
        "terseLabel": "Shareholder Value Awards"
       }
      }
     },
     "localname": "ShareholderValueAwardsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SitryxTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sitryx Therapeutics Limited [Member]",
        "label": "Sitryx Therapeutics Limited [Member]",
        "terseLabel": "Sitryx Therapeutics Limited"
       }
      }
     },
     "localname": "SitryxTherapeuticsLimitedMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SouthernDistrictOfCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southern District Of California",
        "label": "Southern District Of California [Member]",
        "terseLabel": "Southern District of California"
       }
      }
     },
     "localname": "SouthernDistrictOfCaliforniaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_StockAcquiredDuringPeriodSharesExchangeOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Acquired During Period, Shares, Exchange Offer",
        "label": "Stock Acquired During Period, Shares, Exchange Offer",
        "terseLabel": "Acquisition of common stock in exchange offer (in shares)"
       }
      }
     },
     "localname": "StockAcquiredDuringPeriodSharesExchangeOffer",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "lly_StockAcquiredDuringPeriodValueExchangeOffer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Acquired During Period, Value, Exchange Offer",
        "label": "Stock Acquired During Period, Value, Exchange Offer",
        "negatedTerseLabel": "Acquisition of common stock in exchange offer"
       }
      }
     },
     "localname": "StockAcquiredDuringPeriodValueExchangeOffer",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to USD"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TYVYTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYVYT",
        "label": "TYVYT [Member]",
        "terseLabel": "Tyvyt\u00ae"
       }
      }
     },
     "localname": "TYVYTMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaxCutAndJobsActTollTaxPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, Payment, Due",
        "label": "Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]",
        "terseLabel": "2017 Tax Act Toll Tax"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxPaymentDueAbstract",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaid": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaid",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 3.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years",
        "terseLabel": "1-3 Years"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 2.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years",
        "terseLabel": "3-5 Years"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 1.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year",
        "terseLabel": "Less than 1 Year"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidWithinOneYear",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxYears2013To2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Years 2013 To 2015 [Member]",
        "label": "Tax Years 2013 To 2015 [Member]",
        "terseLabel": "Tax Years 2013 to 2015"
       }
      }
     },
     "localname": "TaxYears2013To2015Member",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ThreeLargestWholesalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Largest Wholesales [Member]",
        "label": "Three Largest Wholesales [Member]",
        "terseLabel": "Three Largest Wholesales"
       }
      }
     },
     "localname": "ThreeLargestWholesalesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "verboseLabel": "Trajenta\u00ae"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member] [Member]",
        "label": "Trulicity [Member] [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMemberMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_UNITEDSTATESAndPUERTORICOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES And PUERTO RICO [Member]",
        "label": "UNITED STATES And PUERTO RICO [Member]",
        "verboseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UNITEDSTATESAndPUERTORICOMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VariousStateDomicilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various State Domiciles",
        "label": "Various State Domiciles [Member]",
        "terseLabel": "Various State Domiciles"
       }
      }
     },
     "localname": "VariousStateDomicilesMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WeilerVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weiler V. Takeda Canada Inc. Et Al.",
        "label": "Weiler V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WeilerVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WhyteEtAlVEliLillyEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Whyte Et Al. V. Eli Lilly Et Al.",
        "label": "Whyte Et Al. V. Eli Lilly Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WhyteEtAlVEliLillyEtAlMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ZyprexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyprexa [Member]",
        "label": "Zyprexa [Member]",
        "terseLabel": "Zyprexa\u00ae"
       }
      }
     },
     "localname": "ZyprexaMember",
     "nsuri": "http://www.lilly.com/20211231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r95",
      "r97",
      "r175",
      "r176",
      "r361",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r235",
      "r432",
      "r437",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r360",
      "r397",
      "r533",
      "r538",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r780",
      "r843",
      "r847",
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r360",
      "r397",
      "r533",
      "r538",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r780",
      "r843",
      "r847",
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r235",
      "r432",
      "r437",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r231",
      "r432",
      "r435",
      "r783",
      "r842",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r231",
      "r432",
      "r435",
      "r783",
      "r842",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r360",
      "r397",
      "r472",
      "r533",
      "r538",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r780",
      "r843",
      "r847",
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r360",
      "r397",
      "r472",
      "r533",
      "r538",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r780",
      "r843",
      "r847",
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r175",
      "r176",
      "r361",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r432",
      "r436",
      "r845",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r432",
      "r436",
      "r845",
      "r856",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r74",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r29",
      "r57",
      "r236",
      "r237"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $22.5 (2021)\u00a0and $25.9 (2020)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r51",
      "r791",
      "r824"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable (Note 14)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r112",
      "r121",
      "r122",
      "r123",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans",
        "verboseLabel": "Amortization of retirement benefit items"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r104",
      "r112",
      "r121",
      "r122",
      "r123",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r107",
      "r112",
      "r121",
      "r122",
      "r123",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72",
      "r312"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r99",
      "r112",
      "r121",
      "r122",
      "r123",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r112",
      "r121",
      "r122",
      "r123",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Effective Portion of Cash\u00a0Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r112",
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Net Gains (Losses) on\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r60",
      "r109",
      "r111",
      "r112",
      "r826",
      "r852",
      "r853"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 17)",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r108",
      "r112",
      "r121",
      "r122",
      "r123",
      "r179",
      "r180",
      "r181",
      "r647",
      "r848",
      "r849",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "AOCI Attributable to Controlling Interest"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r555",
      "r556",
      "r557",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r541",
      "r552",
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r64",
      "r238",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r160",
      "r292",
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r108",
      "r112",
      "r121",
      "r122",
      "r123",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r108",
      "r112",
      "r121",
      "r122",
      "r123",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions and Divestiture"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r252",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r170",
      "r221",
      "r224",
      "r229",
      "r264",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r642",
      "r649",
      "r710",
      "r745",
      "r747",
      "r789",
      "r823"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r31",
      "r33",
      "r93",
      "r170",
      "r264",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r642",
      "r649",
      "r710",
      "r745",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r247",
      "r250",
      "r812"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r247",
      "r249",
      "r811"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r247",
      "r251",
      "r813"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r247",
      "r248",
      "r810"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r240",
      "r244",
      "r272",
      "r798"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r241",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r241",
      "r272"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Percentage of nonperforming assets"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Average Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Average remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "AverageRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r543",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r35",
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r529",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r529",
      "r534",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r626",
      "r627",
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r625",
      "r628",
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedTerseLabel": "Contingent consideration liability, other noncurrent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions and Divestiture"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "negatedTerseLabel": "Fair value of CVR liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes",
        "terseLabel": "Deferred income tax liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Finite-lived intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Long-term debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Acquisition date fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedTerseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r27",
      "r68",
      "r162"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents (Note 7)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r155",
      "r162",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "terseLabel": "Discontinued operations cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r155",
      "r162",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at End of Year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year (2019 includes $677.5 of discontinued operations)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r155",
      "r713"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Cash distributed to Elanco upon disposition"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r187",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r187",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r167",
      "r170",
      "r194",
      "r195",
      "r196",
      "r198",
      "r200",
      "r208",
      "r209",
      "r210",
      "r264",
      "r346",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r395",
      "r396",
      "r400",
      "r404",
      "r710",
      "r883"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r634",
      "r635",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r82",
      "r331",
      "r799",
      "r831"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r340",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r343",
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividend declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedTerseLabel": "Employee benefit trust",
        "terseLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrustShares": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.",
        "label": "Common Stock, Shares Held in Employee Trust, Shares",
        "terseLabel": "Shares held in employee trust (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrustShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r56",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock\u2014no par value\u2028 Authorized shares: 3,200,000\u2028 Issued shares: 954,116 (2021)\u00a0and 957,077 (2020)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r117",
      "r119",
      "r132",
      "r640",
      "r653",
      "r805",
      "r837"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r131",
      "r141",
      "r804",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r235",
      "r708",
      "r709",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r235",
      "r708",
      "r709",
      "r855",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r235",
      "r708",
      "r709",
      "r855",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r211",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk, Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r213",
      "r214",
      "r235",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r235",
      "r708",
      "r709",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Contract-based intangibles"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded for Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r421",
      "r422",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r473",
      "r522",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r134",
      "r783"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r473",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r599",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r599"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r599",
      "r606",
      "r608"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r599",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r212",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "negatedLabel": "Less current portion",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt (Note 11)"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r374",
      "r381",
      "r382",
      "r384",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r169",
      "r178",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r388",
      "r389",
      "r390",
      "r391",
      "r728",
      "r790",
      "r793",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r49",
      "r385",
      "r793",
      "r820"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term notes, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r357",
      "r388",
      "r389",
      "r726",
      "r728",
      "r729"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r79",
      "r387",
      "r726",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r79",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r80",
      "r169",
      "r178",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r388",
      "r389",
      "r390",
      "r391",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchase aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r80",
      "r169",
      "r178",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r412",
      "r413",
      "r414",
      "r415",
      "r725",
      "r726",
      "r728",
      "r729",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r370",
      "r725",
      "r729"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized note discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r255",
      "r274",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r600",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r600",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets (Note 14)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r160",
      "r171",
      "r600",
      "r606",
      "r607",
      "r608"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r52",
      "r53",
      "r589",
      "r792",
      "r819"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities (Note 14)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r600",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax loss and other tax carryforwards and carrybacks"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets related to state net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r595",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards and carrybacks"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.",
        "label": "Deferred Tax Liabilities, Derivatives",
        "negatedLabel": "Financial instruments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid employee benefits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedLabel": "Earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Total accumulated benefit obligation for our defined benefit pension plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r106",
      "r112",
      "r493"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Accumulated other comprehensive (income) loss before income taxes"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r112",
      "r493"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrecognized net actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r112",
      "r493"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Unrecognized prior service (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r462",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r448",
      "r488",
      "r516",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Recognized actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r448",
      "r489",
      "r517",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r446",
      "r470"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Net amount recognized"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts recognized in the consolidated balance sheet consisted\u00a0of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r104",
      "r109",
      "r492"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "terseLabel": "Amortization of net actuarial (gain) loss included in net income"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r45",
      "r446",
      "r447",
      "r470",
      "r522",
      "r788",
      "r822"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate for benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase for benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r497",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected return on plan assets for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation at end of year",
        "periodStartLabel": "Benefit obligation at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r457",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)",
        "verboseLabel": "Defined benefit obligation, period increase (decrease)"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r500",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in benefit obligation:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r464",
      "r473",
      "r475",
      "r520",
      "r522",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCurtailments": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment",
        "terseLabel": "Curtailment loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r473",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r473",
      "r475",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r473",
      "r475",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "verboseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r483",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected future employer contributions, next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r448",
      "r487",
      "r515",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r461",
      "r473",
      "r475",
      "r476",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "netLabel": "Fair value of plan assets",
        "periodEndLabel": "Fair value of plan assets at end of year",
        "periodStartLabel": "Fair value of plan assets at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency exchange rate changes and other adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r446",
      "r470",
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r448",
      "r453",
      "r486",
      "r514",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r484",
      "r512",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Components of net periodic (benefit) cost:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r508",
      "r509",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r508",
      "r509",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r466",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency exchange rate changes and other adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r472",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Plan assets, target allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "auth_ref": [
      "r473",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "DefinedBenefitPlanRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r449",
      "r491",
      "r519"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailment loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r451",
      "r485",
      "r513",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r506",
      "r507",
      "r510",
      "r511",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Postretirement Health Coverage [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "DefinedBenefitPostretirementHealthCoverageMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense under the plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r160",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r160",
      "r219"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r657",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r97",
      "r666",
      "r669",
      "r674",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r664",
      "r666",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r657",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r656",
      "r659",
      "r660",
      "r664",
      "r665",
      "r670",
      "r674",
      "r682",
      "r684",
      "r687",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r656",
      "r659",
      "r664",
      "r665",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Marketed products"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r432",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r309",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r160",
      "r309",
      "r314"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedLabel": "Gain on sale of antibiotic business in China (Note 3)",
        "negatedTerseLabel": "Gain on sale of antibiotic business in China",
        "terseLabel": "Gain related to disposition"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r25",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r529",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r416",
      "r815"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r38",
      "r77"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r133",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r192",
      "r194",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r691",
      "r692",
      "r806",
      "r838"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings per share - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r133",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r194",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r691",
      "r692",
      "r806",
      "r838"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings per share - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share (EPS)"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r713"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of the compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r121",
      "r122",
      "r123",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r207",
      "r265",
      "r411",
      "r416",
      "r555",
      "r556",
      "r557",
      "r602",
      "r603",
      "r690",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721",
      "r848",
      "r849",
      "r850",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFundsMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.",
        "label": "Equity Funds [Member]",
        "terseLabel": "Equity-like funds"
       }
      }
     },
     "localname": "EquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r703"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net investment gains on equity securities",
        "terseLabel": "Net investment gains on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r372",
      "r388",
      "r389",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of debt, amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r694",
      "r695",
      "r696",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r694",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r694",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r372",
      "r388",
      "r389",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r522",
      "r695",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r372",
      "r388",
      "r389",
      "r694",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r372",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r372",
      "r473",
      "r475",
      "r480",
      "r522",
      "r695",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r372",
      "r388",
      "r389",
      "r473",
      "r475",
      "r480",
      "r522",
      "r695",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r372",
      "r388",
      "r389",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r522",
      "r695",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r701"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Unfunded commitments to invest in venture capital funds"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r697",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r475",
      "r693",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Investments Valued at Net Asset Value"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r372",
      "r388",
      "r389",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r522",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r258",
      "r259",
      "r260",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r383",
      "r409",
      "r689",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r293",
      "r297",
      "r301",
      "r305",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r301",
      "r785"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Carrying Amount, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r293",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r301",
      "r784"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Carrying Amount, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FixedIncomeFundsMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments.",
        "label": "Fixed Income Funds [Member]",
        "terseLabel": "Developed markets"
       }
      }
     },
     "localname": "FixedIncomeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r97",
      "r473",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r666",
      "r673"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedTerseLabel": "Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r138",
      "r160",
      "r242"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Net investment gains"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (Loss) on Investments"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r160",
      "r648"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedLabel": "Gain related to disposition of Elanco (Note 19)",
        "terseLabel": "Gain related to disposition"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r160",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Debt extinguishment loss (Note 11)"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r285",
      "r287",
      "r747",
      "r787"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill (Note 8)",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r289",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r160",
      "r286",
      "r288",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgeFundsMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in registered hedge funds.",
        "label": "Hedge Funds [Member]",
        "terseLabel": "Hedge funds"
       }
      }
     },
     "localname": "HedgeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r664",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r160",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets, finite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r160",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, indefinite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r128",
      "r221",
      "r223",
      "r225",
      "r228",
      "r230",
      "r786",
      "r801",
      "r808",
      "r840"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r170",
      "r182",
      "r221",
      "r223",
      "r225",
      "r228",
      "r230",
      "r264",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r640",
      "r692",
      "r710"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Reclassifications from continuing operations (net of tax)",
        "totalLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r125",
      "r133",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r194",
      "r198",
      "r199",
      "r692",
      "r800",
      "r802",
      "r806",
      "r833"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings from continuing operations - basic (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r125",
      "r133",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r194",
      "r198",
      "r199",
      "r200",
      "r692",
      "r806",
      "r833",
      "r836",
      "r838"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings from continuing operations - diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r21",
      "r24",
      "r613",
      "r834"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net income",
        "terseLabel": "Net income from discontinued operations (Note 19)",
        "verboseLabel": "Reclassifications from discontinued operations (net of tax)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r129",
      "r133",
      "r195",
      "r198",
      "r199",
      "r806",
      "r834",
      "r836",
      "r838"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings from discontinued operations - basic (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r195",
      "r198",
      "r199",
      "r654"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings from discontinued operations - diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r529",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r22",
      "r23",
      "r24",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r575",
      "r587",
      "r594",
      "r604",
      "r609",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r173",
      "r190",
      "r191",
      "r220",
      "r573",
      "r605",
      "r611",
      "r841"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income taxes",
        "terseLabel": "Income taxes (Note 14)",
        "totalLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails",
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r569",
      "r570",
      "r587",
      "r588",
      "r593",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Income tax at the U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "General business credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "negatedLabel": "International operations, including Puerto Rico"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r157",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash payments of income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Receivables\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities\u2014increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable\u2014increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r295",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r295",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Carrying Amount, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r291",
      "r299"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net (Note 8)",
        "totalLabel": "Carrying Amount, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r126",
      "r218",
      "r724",
      "r727",
      "r807"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r153",
      "r156",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash payments for interest on borrowings"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r688"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedLabel": "Losses expected to be reclassified in the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r97",
      "r473",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates replacement cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedTerseLabel": "Increase to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r28",
      "r89",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories (Note 6)",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r90",
      "r165",
      "r206",
      "r279",
      "r281",
      "r282",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory Write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r137",
      "r217"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r263",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LIFOInventoryAmount": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.",
        "label": "LIFO Inventory Amount",
        "terseLabel": "LIFO Inventory Amount"
       }
      }
     },
     "localname": "LIFOInventoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r34",
      "r71"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Impact of Leases to Consolidated Condensed Financial Statements"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r63",
      "r170",
      "r264",
      "r710",
      "r747",
      "r795",
      "r829"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r78",
      "r170",
      "r264",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r643",
      "r649",
      "r650",
      "r710",
      "r745",
      "r746",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r49",
      "r50",
      "r170",
      "r264",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r643",
      "r649",
      "r650",
      "r710",
      "r745",
      "r746"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Long-lived Assets by Geographic Areas"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r49",
      "r371",
      "r386",
      "r388",
      "r389",
      "r793",
      "r825"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "negatedLabel": "Long-term debt, including current portion",
        "terseLabel": "Total long-term notes",
        "totalLabel": "Total long-term notes"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities on long-term debt"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r178",
      "r344",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r178",
      "r344",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r178",
      "r344",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r178",
      "r344",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r178",
      "r344",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note 11)",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments (Note 7)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r80",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of cases denied"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r331",
      "r334",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r85",
      "r170",
      "r264",
      "r346",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r710",
      "r794",
      "r828"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "verboseLabel": "Disposition of ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r243",
      "r473",
      "r475",
      "r522",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used for Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used for Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r155",
      "r158",
      "r161"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r115",
      "r118",
      "r123",
      "r130",
      "r161",
      "r170",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r197",
      "r221",
      "r223",
      "r225",
      "r228",
      "r230",
      "r264",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r692",
      "r710",
      "r803",
      "r835"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Implementation of New Financial Accounting Standard"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r416",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2014net, (income) expense (Note 18)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r49",
      "r793",
      "r825"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Long-term notes"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r733",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r730"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r732",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r737",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r736",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r26",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standard"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandard"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r107",
      "r109",
      "r492"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Plan amendments during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r98",
      "r109",
      "r711",
      "r712",
      "r714"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Change in foreign currency translation gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r109",
      "r113",
      "r114",
      "r492"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Amortization of prior service (benefit) cost included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r101",
      "r102",
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "terseLabel": "Change in net unrealized gains (losses) on securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r112",
      "r121",
      "r122",
      "r124",
      "r715",
      "r717",
      "r721"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r121",
      "r122",
      "r131",
      "r262",
      "r715",
      "r720",
      "r721",
      "r804",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss) from continuing operations:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r100",
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "terseLabel": "Change in effective portion of cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r100",
      "r109",
      "r667",
      "r671",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r109",
      "r113",
      "r672"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax": {
     "auth_ref": [
      "r109",
      "r113",
      "r492"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax",
        "terseLabel": "Curtailment gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r98",
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Foreign currency exchange rate changes and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r675"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r116",
      "r119",
      "r121",
      "r122",
      "r124",
      "r131",
      "r411",
      "r715",
      "r720",
      "r721",
      "r804",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Net other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r116",
      "r119",
      "r640",
      "r641",
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]",
        "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r106",
      "r109",
      "r492",
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "negatedLabel": "Change in defined benefit pension and retiree health benefit plans (Note 15)",
        "negatedTotalLabel": "Total other comprehensive income (loss) during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r104",
      "r109",
      "r492"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Actuarial gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r110",
      "r121",
      "r131",
      "r573",
      "r610",
      "r612",
      "r715",
      "r718",
      "r721",
      "r804",
      "r836"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedLabel": "Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items",
        "negatedNetLabel": "Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherContractMember": {
     "auth_ref": [
      "r97",
      "r473",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is classified as other.",
        "label": "Other Contract [Member]",
        "terseLabel": "Cash value of trust owned insurance contract"
       }
      }
     },
     "localname": "OtherContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r254",
      "r273",
      "r473",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r443",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other-Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r37",
      "r77",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r69",
      "r832"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "terseLabel": "Other, net (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r49",
      "r793",
      "r825"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Other Notes Payable",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r143",
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Payment for debt extinguishment"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3)",
        "terseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D charges"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r472",
      "r474",
      "r480",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r522",
      "r524",
      "r525",
      "r527",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r48",
      "r446",
      "r447",
      "r470",
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Other current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51",
      "r446",
      "r447",
      "r470",
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedNetLabel": "Accrued retirement benefits",
        "terseLabel": "Accrued retirement benefits (Note 15)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r444",
      "r446",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r500",
      "r503",
      "r507",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r528",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r500",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r55",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r30",
      "r32",
      "r283",
      "r284"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash received for sale of antibiotic business in China"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from divestiture of businesses, net of cash divested"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r148",
      "r152"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "negatedTerseLabel": "Payments for repurchase and redemption of notes payable"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sales of noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r24",
      "r115",
      "r118",
      "r123",
      "r154",
      "r170",
      "r182",
      "r190",
      "r191",
      "r221",
      "r223",
      "r225",
      "r228",
      "r230",
      "r264",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r640",
      "r644",
      "r645",
      "r652",
      "r653",
      "r692",
      "r710",
      "r808"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "verboseLabel": "Total reclassifications for the period, net of tax"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r317",
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r71",
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r43",
      "r44",
      "r313",
      "r747",
      "r814",
      "r830"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net (Note 9)",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r313",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r43",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r43",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r112",
      "r121",
      "r122",
      "r124",
      "r715",
      "r719",
      "r721"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r565",
      "r782",
      "r874"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Asset Impairment, Restructuring, And Other Special Charges"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)",
        "totalLabel": "Total asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r59",
      "r416",
      "r558",
      "r747",
      "r827",
      "r851",
      "r853"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r265",
      "r555",
      "r556",
      "r557",
      "r602",
      "r603",
      "r690",
      "r848",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r500",
      "r503",
      "r507",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r500",
      "r503",
      "r507",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r215",
      "r216",
      "r222",
      "r226",
      "r227",
      "r231",
      "r232",
      "r235",
      "r431",
      "r432",
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r434",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r127",
      "r170",
      "r215",
      "r216",
      "r222",
      "r226",
      "r227",
      "r231",
      "r232",
      "r235",
      "r264",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r710",
      "r808"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue (Note 2)"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/DiscontinuedOperationsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r735",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Payments Received"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r213",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r508",
      "r509",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r112",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r508",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r187",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.",
        "label": "Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Postemployment Benefit Obligations"
       }
      }
     },
     "localname": "ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r80",
      "r178",
      "r388",
      "r390",
      "r412",
      "r413",
      "r414",
      "r415",
      "r725",
      "r726",
      "r729",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Long-term Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r506",
      "r507",
      "r510",
      "r511",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r293",
      "r300",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r293",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-lived Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-lived Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r39",
      "r65",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "terseLabel": "Schedule of Net Funded Status"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Net Investment Hedges Included in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r72",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Research and Development Assets Acquired Other than Through Business Combination"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Other Operating Cost and Expense, by Component"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r543",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r3",
      "r5",
      "r6",
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesScheduleofOtherOperatingCostandExpensebyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r540",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r543",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation, Option and Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r47",
      "r796",
      "r797",
      "r821"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments (Note 7)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r167",
      "r170",
      "r194",
      "r195",
      "r196",
      "r198",
      "r200",
      "r208",
      "r209",
      "r210",
      "r264",
      "r346",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r395",
      "r396",
      "r400",
      "r404",
      "r411",
      "r710",
      "r883"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r84",
      "r121",
      "r122",
      "r123",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r207",
      "r265",
      "r411",
      "r416",
      "r555",
      "r556",
      "r557",
      "r602",
      "r603",
      "r690",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721",
      "r848",
      "r849",
      "r850",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r207",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r55",
      "r56",
      "r411",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r55",
      "r56",
      "r411",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "netLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r55",
      "r56",
      "r416",
      "r542",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r56",
      "r61",
      "r62",
      "r170",
      "r239",
      "r264",
      "r710",
      "r747"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r122",
      "r170",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r264",
      "r265",
      "r416",
      "r555",
      "r556",
      "r557",
      "r602",
      "r603",
      "r638",
      "r639",
      "r651",
      "r690",
      "r710",
      "r715",
      "r716",
      "r721",
      "r849",
      "r850",
      "r892"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r396",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r416",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r722",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r722",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r722",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r577",
      "r586",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Income Tax Contingencies"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable (Note 14)"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r762"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Accounts receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r258",
      "r259",
      "r260",
      "r383",
      "r409",
      "r689",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r716"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Foreign currency-denominated notes, designated as hedge"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r83",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r56",
      "r411",
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r56",
      "r411",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r56",
      "r411",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r83",
      "r418",
      "r419"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r411",
      "r416",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase for treasury"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r500",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r174",
      "r473",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r568",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation",
        "negatedLabel": "Changes related to the impact of foreign currency translation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accruals for the payment of interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation",
        "terseLabel": "Changes related to the impact of foreign currency translation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapses of statutes of limitation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r193",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r192",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 16
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6283291-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16701-113920"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r875": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r876": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r877": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r878": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r879": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r880": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r881": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r882": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r883": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r884": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r885": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r886": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r887": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r888": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r889": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r890": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r891": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>145
<FILENAME>0000059478-22-000068-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-22-000068-xbrl.zip
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M< ;(3E^B_X VUFICR4X@YI[@RN)"0%^X&C?*ZK^A'8GAR_PP->K-?2"' BT
M]7IM;K4O=3*^RN:A.D1V>B!LU<,OWN;DQ8"W:EQM".R3!<H4SCK];!2V@V>G
MAP$Z08T5)"/' +UW-8,XC?;(!I>5 IL'])5EIX<!M"^)%I\H!A][#VJ*&A 2
MM::O^>##Y@%ZA=GI82"EX,&I119N*K8)D+,0*W*),Q7>P#$Z2'9Z( ,<65@B
MI-)WA<B./$ %)U@+-^?DZJK'QVQWOTA9.P*4F%F*8P>UMFQL"I%(4J%:D#8&
MF@&RTY<(4W2]/8^)ADJ&6! YA*;_AZ68ZJS?&)BN,CM]B?B08J'^)1":"#JF
M*/J$)MO&J,]CV!A\ALE.7R)2(EUWJ 17!#0*H-Z^#'RPR66&T#8&J8&STY<(
M60EJ]<B9DASI""M]IRDQWH&/)I;(&P/9E66G+Q&<9DOQ/G($==R+Q1RK:Q$$
M?<NI\.98OJO/3E\F2A&BK>RB5-OW<]&@2KV(5$-ITBB-LMO?T([$\!T'6.V@
M#=A(0H/@B4O/:H5JF+%*_NCV:>-&=9#L]"#81J?Q6&K-UYA!;2DZ*"9CM-2X
MTCB[(J^APS(\T. IIX3)I>HA8^42&WIN9%/QU6Z@:;ZZ[/0@@$JSF!)K(.@-
M&/',G P"]DVM0HL;:)6O,CL]"*0V5/:U)N," !ND5 N$DJQ+(9&AS8-TF.ST
M(.":I*#&7!M%/%E2:*A!LE30>Q-JOKKN+F.VNU^D[4R@:)A:<JRFM+E*MJ+/
MO>V*L2F7LC'0#)&=OCR8/$5KJBVA4M615!!-[;L1NI)<JR@; ].59J<O#Y^>
MD&9)8&IKX'PC=I:C9T$J5$S;&'P&RDY?(E)L,HO)+A=2W[%H;.^0K2,*DHU/
M&X/4T-GIRX/,!<XU4VR]6P3[F+%!=M(G%)#4!FX,9%>7G;[4\23B7%!#YU69
M(+/:0E9_+UEO^MY2FP+. -GIR^PNR*'EOJ%X$8! F"+%[I)SJ3')%:X8^:P[
M<(G5X\Y&V]2AM9X)N'FVD&(H)19)*=1X=1UH/N\.7%YW%Z',UGB3JU$*8&\L
M2;TZJ/4T6(;3_HIDO%W;D7JJ6F_'ZVV>\JS(DWV1U:U9?>?A][ZITWG?*&!Y
M^UB?',Z7/+V_F!\=+O4KID=5!_#'>ZN^VP3G;O_N^:W9Y("G_RT\7>WWLR\.
MYXNNJ)\8]I_\1<O%ZKM'O\UDL=R?'+Y_TLG#B3[07]/-$,^._^Z)SF_=!W?A
M9-L?Q:*<_.@/S=S'[\OIQ_65=OOX"4^_]*HKX[?L?TCYMYM:S([ZM?S)IBR'
M^O#\"RZ^)8L.(&.=D6H0BJWLBRF9V$3N-;%CV .^\^['Q;P>E=6CQ1-9O)H4
M^1#_LW<W,0T5*.0J6+T+&1J6+$%=2PG<:[S \P@J8-<%OV$JF',NP-FQY0S@
M$Z-&V*6ED*/!.(K^&FN"WS M-(P3-9RAETD@J,7DB$W]L=RK^*R)8]ALY\_Q
MZ_)]1V,#SO-3S>39:=S]6%Z)BNDF&M2:4./RG"E0 ]81&*@HCCHN@X(XBK5[
M:POH0,L(L 3PL:(8L+9OGM;[!2;BOA (>=06=EA AS&Y+4:F:G+! I"XM\,1
M6ZVSK5;?ZABF53\MF8_GQQJ??2I4&J6%5="\#3Z%Y$\]'@4-O(;L%1W742RL
M7!?\AED!G14]YR/;FB#6@AST06DUJ<>39#-<UBO!;Z"N;Q6"B(O>LH& #E,6
M$V,)WI1(X$>"WV.>O3@#K3_=F<PF!T<'EY5;NC.?%;V64U%]/%G^>OOXMLS*
M_@$O?OW=OD8\E>69W.[*IX*<OW,!3X\/?\?2.T?+U?R@SX/][N#+R.7M\,OY
MXOP,[V41G^XO1![RXH4L5[_LS_77]SNPB2,%2C:^:DCGR8"OGCGYAAD]4"HY
MC46I;D;*-1HIP_@$XFH!K[YV8'7J6M\+@0&LJT[C+@YF)#[YS4BY3B-EF(2]
MXT22*P#W[O8:\[0BT@P2EH PENCU]R.%7]^,E)N1<KEY@DP@UO1EHJ*>6,8"
MIJ22#+F:$,:P/<#-2+EF(V6@?1=<:8TRDC!!# &;R]D':WNW*V_'T$7R9J1<
MLY$R4.Y2QX1$J*GO!I8TLG>538Z0DXF^YK',[JU+G'*KE/G1;*6#I<CD%>=/
M%E'=#)81#1:2FDYR^J8QL(H+&LF.:O"VA,QNI*'*S6#9\,$R2+324NG=8DVS
MO>XX%>;BP+7,7EK..8U468;RP6X&RR8K2ZU(V05?8DA H>1&.DPXV8(N%C^6
MJN.;P7+-!LL@RJ(>5VLEVY*"]"5H&/MB%]+8I: Z9FT$RO*6*?M]Q#R8G1%V
M,GMQ=[F:'.B-^1BOSN+PU=%BMNQK8:;3^6]]<<RG4+X0K]ZNN+DO\Q<+/MR?
M%)Z>GO_DVA;'WSU[LEE65WT1\KT' AL"]>4IQX(D17U[9\GP"*SN#9'6P2)5
M5>F40O:M-8C"Y#W&1IQ;M"@MC" S?T.D=4A<(X%UD, $ZR$IA22)(_21&@:6
M. *+]->UV4\71R>?.RLD'#U-!NIJ:!$=J]&![@$UPZ'4%%ULID%M7$?@ 5TS
MF@RSTJ-9S+FE")E!O*$,QGOQSGMKR;D1R-+UHLDPHF.KY2*6O5'OQ1MACIZP
M-@HU<N4QN,'K1)/W>HD\V\CX&Z*:D\BFEA"AA80@W+)##S%"L6.I KZ.?!DF
MS$[6%^Y]>4L 94Z6VA!ZCP7)M=9QKX_9:+X,M(0\YYI\;\C. *4@ML*1P7!J
M*;B61Z]'_WUTP-/YB]&[*P,E6ZA45S)XGQ)XV\FB"E1!+4DFX\8?_&P,/8:9
M2DM])BUVH4'(C37H$10BXZ-UZ,:RFF_SZ3&,N$3G2-0#(?)X8C)LL0*V%'82
MJ(QAGX!UH,?&!SF)(SBTG* (8,R(R1:U4X!H'=FQ%$9>)YX,(C<0O!57U"=I
M!IK2Q%<E3<RE,J<@Z49NUHTG0P4U'!JJ5>D+0KD%]4RRL95RB2".Q[+,[<]Y
M\@,OZJ3/_8W>,1E&<'Q#C['F!-"4((VM#P:+I1QJ\S+NQH4;1I!ATF@E^]34
M%5'; :W8C*X9YPIPD41^+,O_K@-!!IK'Z7MCN>2JC55]5Y,MV.@8.; D!V,)
M;2[)2[@B,HY2:X!:3!ESHIH@ &OL&P7%J=2$&!.-1&NN%U,&$1W'@;*MV??%
MYR5DPD1&>CM78ZTA'(GH7"NF#*,^9')V?0VIQCF0G,/HD-F+306)SF:%UU]]
M_C(0/II.9J-W3@8J6<M),!A3 0T47\A54#OBK,1F:#22<PWH,8C.V%+%EFQ]
M54^U>,#2C%J/I)Z)!&KCKQ'8%'H,(RZ<G6L(+C G<,F2\ZXR,:%3EZ2.97W<
M>K@A%Z/B.%6&F:J#7)+:$'*!E!1%HYI:;,C.C*4VX#KQ9)A<&O2)O%)2:@+(
M1'T_W%Y"[XAM+74D<G.->#*,[M1&'EITTG*%7 MQM<H7VS<84B#'OYO);5[R
MBRF/OW1^H"87"-ECMDJ/!GU?3&Y9(D(LT60\X\?ZZ\UUX,<PZ3,)ID$28:Z0
M4F+C0DD9O85JJ8Q_KY6-X<= 50'%>';6&T&!K#ZJ%PAB-,#1T+?P6))FZ^&'
M7)"+HQ2:8+//C6(H?7MLJ1KAV%)M#E"*<S"6;DK7BBC#*([/V(KWAGH:O@C9
M9EHFLER9G"LC49SK1)2A4FH878F1*S8P.6 +MCJ)R>3BZ@9LU/ATP2_U>_CV
M@]$[)\-HCC1!&R!J#-R74U22W-#&YKA)2GG\%6F;Q)!!Q"86(.\TW*5*$*(A
M0Q(=>Z.28T,9B]A<"X8,HS(!(12),;I@(#GF4KN' D4#G0+F)L#Y(FP<I=ST
M;;_%@M34MU$L3A7'*"&R28$+G1J3$<C--:/*(+K3NQQI..PA0@:DPAP-UUB;
M2>CS:=?Z$>C.]:+*0 )D$[ P^^ (FC64V!G*U>:DTI3'WU'M9'?K;0WG9+4!
M;?<&DIXBV4IKH=0*A) #Z#,?4Z18&,:_V'/#2#),L ,^66.H5:5$8LK"'D-*
MH#&RB<Z.1'2N"TF&6N99E"/.AFH;-":T,4,T5:P+M?%8UN"L!TDVOLF  P]@
MF-$:?>@\4? -K \VU](<W.C.FK)E$ 'R[#GE8KP1@-@R.JF-.+78R"' C0"M
M)UL&FM]1'M0HA5$-B0;%A$(A6N\-%V?R^.=W-L93&49[K',MDZ22LP<'CM6_
M]<:5C)5+,&-)MUT'?@RS@WV)Z#%%"#5#!I68ZFS5R-@'DQC&WSQZ8_@Q4&DT
MLW5H+$?5EV(@FX2QF1 J4Y ZEJ[1ZY&#O2 71RDTJ:8<^_(*0 >2*_856Y:]
MF"Q%#<=(A.9:$6685FK$M82*UL< (:H;TIU7ZP$MQI+&DF"[3D091GH #$C+
M#) \"%ANH5<Y1@G69$ S$NGY<_!N32<'*QZ]8S*,WF1.EI(0.^N@B2,J5EDB
MS%**I#@2O=E\=@RSX7TJ%+)X%R5I:-/0YV"C%<ID)./X&PUL"#L&JA: H,%,
M= G% DMF0X%*B29F$X,=2])L/5R0"S%QG!)C+0HJ5<0P& \<DO="WD-S6+,9
MB<1<(YH,T]2&Q#1*&%KUT/?S5E/E437%IFP,CF7UY_6AR3"BTQ*57ITF DWC
MFHBV53)H2*U,9(&1B,Z?0_>S+-[(;#(?O5,RC-H8T?C6!V]+,D#2R%/TR17/
M&%VV.!*UN0[\&&;)9R)6)Z2XE!JPY=SW^C09B;*S-8R_+F!C^#&,OKB03';<
MH!8#WF52X^&-38B-JX\W:W"^ !='*33%>X]<T6HTHT)#B Z<%--;=(*,9L^;
M:T6484JA6Y,(S1A7(]@2F3*AR>*E&EM'L^[S.A%E&.D1F\07XR@I<- 75K1B
M;4U8-1X6-_Y=;^X<+_C@S?C3K0-%-KZFE$KH+=3 !N+>-LWZZ)I)+9]N4#\"
MP;D&]!AFF2>2X>(C.M=ZCP&L53C45B&90F$L,K/Y]!BH LU'RU+$6O"08T+A
M9B6$ .K$5AA+!=K0]-CX53:-<T4FX=0\(#6*ZK4ZBJYFC8&EW:C,VO%DF)VC
MG>L5 26B.*!JV.< IDA,UF:H8]GKYAKQ9!C=29P;I9C!"D&-G$N)$EHM$ 0-
MC+_\[.XB3U9'KT?OE@P4U!"R-QC9>X&DWFL(B"QZCLX2._Z%-1M#CV&* JR+
M+ $H88)@&^4<)$11ZY'41QE_4+,I]!AHV28$) <1#3<-:B*"3;V5:S:D4A)N
M*M NGXJC5!F11$5-"!.J+6DYHP5&=A7!^9S'$M1<)YX,M+&:C>J>>LHE #O#
M)D6I-4=U4K 6/Q*YN48\&6CSZ-I"*NPP9 _@(]?D0M\7":LS>31% G_1YF[O
MY[VGHW=*!@II>M=6#6'4EA"X))RZH+AH4V;G9?R;=VX(.091F.1*K-6(^B(&
M'-BLKJOT[<6#,!<__O*SS2#'4%UH-)XQ5,"$!(0UBSH@19JHS' +XY^CN0IR
M;/P,#1)#\^0M6@,&L\8PL2)R=J&Y /Y&7]:,)<,(38B^<28F9WO79RS><TZU
M-H@U>W,C-.O%DH&6<%)U2A!/O2^-P88V^U12Q-*+T&C\JVE.NN0]FI7Y=/[B
M>/1NR4"--TE]5A\UY'6I;WY$ 86M!,9(S<CX"\\VC"3#K*O)+N98)+:<(.6<
M24Q*(9'3R#<CC5YO-HLD ^7-6+*MZH>@S]" *!I*WC)@7X15ZXW<K*=S,E O
M-(S&>;"VD@&;$KH"7H,<#86KLG+\B;1-9<L@ J2F!;CDPIP81#G#D)O&QI0+
ME&C:C0"M)UL&6FLC',#FX&PHJCXI"Y;&4(Q/WN2\ 8'/IG@J VE/[)-[)5=T
M)]MY(K9$4J)-ZJ> &\L6TM>!'\,LZB0C%*N1OB%P%ILA06WJEH!O4M(&J,VF
M\&,8?2D)L>]T=.*',!H%S86<+,;L?7$W^K)^CL@P0A-BS-%2,K%I=&,,-VG=
M=;5H8H@T_GXU&TB48>*;1@4U_N6:##1'Z)/)+(X24T(;;Q1G[8@RC/00(&??
M&K @4$V$P5,AC7 "B7'C3[(]Y>GJS>C]DH&:<1)7DB!DI4 L 6LHOF*B %XM
MR_AS:AM"CD$DQE0-8<@G<;9!<(TYJS&)K0*P333^76PV@QP#-1"PCDT*J15'
M??$$-2^I@4;!7%U.8^E.LQZU\1<AXBCU1?W3*+YD,E4@IY:+91=%/5?KN7 =
MB;Y<'Y8,$\N@#S$X<!8:./+H555\9?$^@T$9B=!<&Y8,HSA]OK<5+)"%($9
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M*Q?/"&I4L+;JBZNNFKYY[%@TZ'HR9J P*!0+DEM0,3)6R!  )]*HF4JT8VE
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MZ=,WHW?>[CSZ^<&VI9/U.?,Z^>(H#N+%27,!C>U[7A#$E(A<LKE6=D*4*XW
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M,(^@\.GBIJ:#)/7>Y+74SI4+:/18N3)\75:26G+62*NV AJ$H41.L6C$76M
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MIVCOTS\^QW2I&Y[B+7 H$85[ >O.;8EHSF$N$&1^1^B<5#COS<_ A8E&<=.
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M6(Z8&P\J%4-VOEIW9][W+,2P^6+#0&R%9Y6Q8.$Y2@-CX&'W-)+B/*>\SS*
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MR>"I]C1.:N6787WXB)4\!"TK!$-#$&7KV3W:$*HB6QG6Q?)#LVQ<5LZ%-BP
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MB2XG ''BO?@?WE?".R;@=DZ@X-OJ^HX-=3D!DI4J:D::Z?2.N+$3N&L";CA
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M<RWC6%_M6RMRL];VYP@3MW,*!G,V([5. T8J:7,V+4MN8@AOT%'Y01&X8:;
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M&IV5H?.T1/B08J0N&=O^J=$-_(EWK3UZUK'R"9'"AK75H5VT><5V(? 3$/B
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M-\7A<=K-WM(]'+UE(F&NJ $-7*M[9YP8L[@[7?G\+\OGW^&A3I5TW"B=K[.
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M-/\2_LDFU3-G(46D#PEC[,*P,"%+!:\TBV.N-Q<ISTW*I:7>@>UH2'4"U.D
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M+'RO=587MGM+IR):!S<=.@1"!I5N!#UE< COT,EH7^FTH0V=!=O(VJ0TM:@
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M8(, ?A^\[)+PK9QN2ILH;AVDJ%"F)',;-FOD!O[E,1*^L_!2DT(28_@Q4U&
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M!;$6!O=B@6<7.7KU<,WM\$GR?/:191O%OXZWIK"08#QQ(R+=T*4>HW'L.!Z
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M>;OKN6NE;=JKQ4K%S+0?W>1F/4H1O.GA20YZYU]9S%A$N6-SC_LVY<RQ(Z7
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M@IJ</Z./O/J.&KQTFNE3&ZV/]B?K$3)O^-0B'MGK7#E =:!$)_"^QS>M0LV
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MK=^!?E"3Z[9G;/&$P5*GXS<IE+EDF.*, >EI=J0)UJ1 S_.Y>R<4?NSN>%[
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MS-LC&[1"=V/'Q9^'X,"QG.&#P*;C!G6;,R_+Z='2[F7G<B4%6F_9>\"DR%)
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MDJLDQ6/5<E@;_,K\)@V#+JSBKGDJGN(FT-SA*;]+W\_/5,9UG1^/IA^6YN#
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M!=DM?D32,H6VM3)T#]1Z:E"ZQ./*CD%L;33L@E$B2047"&..[][-_<3X/=<
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MDV4LDF_ES7AR<TM\' I_?5!QN7RRX.?\36X$Z;YQ%(*$G$EN$$*QR0+?>9T
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M%</-9<+O(?"AIE\;S#2!5_R>0G4M47;C"I!V"KQGRJ1]?>MU]W)W$9:])IB
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M%FNHO%M4*,L3:;(M\&HNO ](U6O??FLAG-OE8SU9?"#Z-F$RW2AG__MVD'4
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MN+II^TGZ>]0Q47;RJ?FB+GR1/^-O7%61W-G?&<%R6A'AYK-Z>IC=UE_>88B
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M0MFW&SO,Q&DTTU:Q[87FG'=HYZ56$/#]>+/O_T!F&'M*>T%82T+\/W6L.F.
ML"+$%."_M=]0O1RPB;8.> I^(S<3H\''9%',\M%+%+\%)#PVF;-!"F2$T3.V
M  1M3YXVW3II-R@,!D1',+1.@B?P4[:A.QF-%W+'>P/7]JL(8_">?KLFRB;9
MZSL>J54/C1#PFL;(&B=TU&&_)AM6^X3F@'3M\N8-T('ZJ753(APK5@-!)7Z\
MJZG3G!J3(+[435L .^(T)TKDAJ%H2[A<+B5Q>N21W*Z:0%20/9LMRSJ6BBC.
MJ/P'U_825T@&UC!I'3)O0]:')L-B//Q/*^6W[5N^+?]& =N\Y[Y[E>WCHIL
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ML7_"1URV+O<]H',#(2W2Z7T78.G3S<2U!S[F*Z9O)?I-S+,H^QQFCY(_Q N
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M&N<M4W_9#?69;/VH?=>]R&6A]\\3&P)F*!I6D<@=<VDD=AGZ\:$)=B)<-*T
M6._/.'_RFHJ;&/N3A+ :;LI'O?%#P9_2NR;,5)KSX>#'_VQ1KKI!YMF^85_/
MB_.&_>!!XDEAP_ZV.B_;=>^"['OK&%S>U_YKRA"K/=0N7N[:[\F2$L%%FON*
M]Y>I7E!EC9B"#[,_=KD@\ZNDKC1/2MP(,@H;M?K#;=I31A.OE+VX8MHCU@-D
M343^ 7Y^*-I$U65;^@S+'&.&*Z-\73O"XV5*C!*;)PW51B#LNK2AO6ZP)BC
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M)3TA5A0O&+T9-4WJ7=YT^AW_>)VJL'MUWR>0<JO)KE!-\K$K)N6&FT,K&>4
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M&Q?W"BZN"KZ61-/N_[H6(S3=9*WR>_N-@$8:(J(51B8NS27J".I[II[*.-/
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M%"%6$DI');F\6)N_ -%O!S;Z$3'%,LF\J.S2;X,H;#5;%A?XT&#E4UW5D?T
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M(C'L'R4T*1&14^YN_GD5,%D6P4FN5RE/$:#HF#I\36/QL_KC-3;"].W9SUY
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M$B5O_TQ%G'4:^BWP>+HE',G8./K-O#9?R1'?<.P"8KH RWQT>4Q8TUO<P.K
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M77H01G)$M\1L($8VAP/DSF$]FGJ]\!@^5 VT_9+(&Z2Y+8:,*%[0OHB7J--
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MCL\&RT12@<<I%5DRCFYJ*/]NK&E(:(>1,@%O34E]G9)_4+KW.>T';H;?I:E
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MTSJ4:I+:%KY/ )LGZWHB*XR9?3&$2Z7OPF#B)^DD4]ZH[?,GX]@(P@0;T>*
MEV%:R1%HLH&+UN>31Z]:AAMAWUAL>)K_=A/ZZ83ZX#:H#22U@A61;+_(4Q:&
M]DT840NYO <E1K& ,G#4'35P,G J@IKY0E.MPN$0L\7@;7YX2PUH;1Z9,8VP
M5[)I+):_8$?R(;4_E6..XW0B&]J79P!S4U1LY\JMX(7O9WEH>CMEV5J=W[$
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MH'"C-*\\QW@;I:/8.'-OO#B$2\[#"8%3&)%PX&\1N !:ZMB+]V$B6"0H@\S
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MA3\254B,*CZ>NXRA$N\#Y=L&)73HA[<Q\QZ@X0#.\5WJUC."XX+S9QNTAQO
M\X1XUPBTJQP\N-<SL$'RW/?M9"S?X;>I7FH2^VY /'B@DQNW8>2[H.B!H'B?
M-T $ >6';+ S;-%J\E/TW"34HG%B_P&PYBQG&PW]%&O8I;E F1C$5,&H$FY#
MNO30T,3WAC%Y !LL<9&[*:N-G,;(^,<V)OF&+@DXEM5D%,1@87Y#H9"$1AY.
M I9L3SW7EU83]K/$:^@!V?TDU&6;219D,=DO>5O(6T%"$^0<>B9MK,EGGJ_O
MG6R9$-W78-*JSBC985-RYY.MV@7\$M[B>NCIU&O 'OD4_=*<0;(GK7%$/[YB
M;P VQ@39.XH$FZ$ N[>@.%'[QU;3.L65Q&#U^MC/$XZ^5%TI'4;B#&QD;V2S
M<68KW/("[,Q4Y]%R&$5+(D2MU!NEM4<;])(XLPO!?&5Q7YA0:1RE4YH=&;"M
M^5TI7[!Z($3Q#43J=.K/7C&&TD$L_DQQB6F@UL'OSQY_-@6E6,+P7QEBLB !
M7PWD649#Q5%O942M8Y3T/Z5\$R%I9(0^+<H+)FZ34R+=1+J"G>MGMHL"G11=
M7&P8E*IKE%6,S'@J(DT-RMFQ:5P+87P&HC*L7A8,U9^2>Z(H+V>2,3]83$B+
M!M7.1PIRZ&0JI=,7(^4$$$@ML=9W51$0\%3L:$4:_"2$+]B;P8R7F:OBMY7T
MT'Y)V0V$J2'J("!H?DDGMA^.:L%PCV X\@(@4?2P>C%0RBOFQ5):9)R?V0.0
MZ@>.P6<>PYA/!3I_A&2U1'-V,D:/ S$)]@F"90"KMB/2@ND8D#JCOQP-:W6P
MJ=UO/'_3XCT+>8'8BUW:.IF\RI;/QA%V;(^+#JN" 4F\0#H<R3<_F=I.4O+N
MS(4ET#Y27(??IEL9DIWA\@A<ZCL0H91*L1(C>FV,->&B'IE/^)UB 3L:9A@2
M0P.8GH8&EF*#DLG'8S2KB+>BTSD3K.36!S"(RAYT5(.1[E1??F3BNC+X'@PU
M\;1YZOMPYHD&EY_Q7/X.,:N6FEHO2L4\RI(Y?.:%-*)HX(7J#.LRV\U=5JMH
MGMG:JDJ9^O1LU"'M7!KI&T(B/9]-@(76-LO*-HMJSF4:;\  # (97)MX[C';
MB, .B:0K;G[LAJL$>"A\#(QS6KPS,]Y]EV[I*UMO&UNA T@17YD=B-BU@UEF
MCN*1H_TX:C_H(F?"0"%)B!KZ*7I4R!+)KA-JWQ2U:J!\G;#K/M,W7,R# S5\
MA),5I*4".D>#Z56 =)J)@ GR?.SQ%RD2<N:DC=%8XI DQBKF_<:QR%8:9]8F
MV(J4)TF!=W:-XI;X$60\@GTZ#CPPN=#%JCEDLWVB^N7I,*' ''K5YXT<UGT:
MAG3",@O!*'5D!&)$7*1!I@^;-[ LZ8G.M*V$<BB\6(M(S+*Z#7;53V1J%RU*
M(6P>_O.+9_#(E8>I[RJ##*=*2(T-=09^Q?IF63VEI=.L@XT/Y*)?X5RYL7%&
MK@$\%447D'')RGK#N-*S*YA5G%$4JHJ,]H/BL91C(O. ."N%O$%P!#'HYVH)
M&W-Y4)G%I.0IW>E&R%+T-!3,0@!A'_.A @5T  >WD >5>3(YS"3GVW L3$8>
M!S-CA&ND;]%AP_V',""*71Q \D^$S;QU0M%<3#AB$U FV$PP'04Y!F5%I4'"
M<L 16B L$G^FH*<0_VKD=T2"+&)'\ WP4X1S>SV'-B0M&?2AYGDQ",,LK?4^
M3W\Q*XSE@-SX7*)&SOJD8($%W:"M.[5G:,'K%C3;W)G$R%BI<'4W(:JQ1<02
ML & 6(5"1B@^FA0?S!3BI+11F'@L(K0$G$C"DV@JCC-&+!\_FTL_(G9O&N_9
M,)E0-$^'*\X?"H;V31@1$*?JF.4Y2^%\1I,KM/@]VY$H-_(\Z# J2_HJ$!=A
M=R'[I\&W9L FOUJ,=&?',@KO2&\<X)<4U3/_!V;.B^BO?^FWK)/7L?$I#$+'
M)PO_#([,('1G!J^53J($<&$3#2+G4FDX $LDP/.*,-8SW$@@EOE>T4_*!"</
M"8V(&LYDP!_E[A2=N-30%I5B]H8J'TR>EJ4V+GTH1+X:!#,5"&-3U#8LSTG4
MDD4#%QN#-*3F/B_WY<OUG<X=AEM.YQ3!"%Y&MD7N-I?^(TP3E-_$!LEU3F'&
MI[8[S3<J:5 VE?"&"#[.KLA7 M>G>+1I@4I3N@,7]^LGL!'R6Z'S2//C@O5,
M$7$MZZJ0<)!E02AWM5P!+5"EV7$RA#_/K;W 36-IU.>M+Y;R6RVX5$7I5: #
M@?DPT@&NSJUL4(9Q+5*#%:U[L.F"((F="" 4S%20=4Z)Q*\4Z/0\5HJN8-F3
M8/@K^_!#&+K&IXPGDKI _:!);/P) @"%J8U>/2SO8RU!>57D^J5$( (F+DRS
MT9R44CHR2@/K:)!Q.IEFI%9J G\IY()Z\$+2K4G:2^]FC$* HNB2MGUANYPF
M,2^]D>:4J%(,%#@>4&4L36?O!PK?!C(B&4L$T\&F].H&YYQ$Z3276EE^-+Z3
MUA/F@2J0[)0=W$ "QX2-@1T0?;LBX %R0_4+\J9LP"<FC'(ZI':M%(E:-NQ<
MSB(FW&*(2RC50K]2X36[.@^VD,:OY04QC&G-<':9$68A($J5DA>7HE#Y.J9I
MHB0"'F"9@:;2:FY78))5/*\8%KM(Q,2P&L:+-VK_QRK/-CMNEU+"7E*Z\ID4
M5H]0O5_0WP^+R.7^>"] )<\NZ>I>6:/%_E[Q%!D4W7$Z^$,R4&!U&-]([.^2
M?=S87"?$ZC!_7Q(@HF(.Y6?X SANC'(3R>8UNRLX34S+5P?K?6RX\+(XD8YM
MF1(GD0VO,GS[-C;" D>6[A0B1<'Q'5+-\A/(P6-47?$1$5DYI>*_L1 VIAP9
MZZ21;P^89Z:J(S+/4YE>_6LXB/%D&$?X$]Y%O\,WKW)52@X(M3GC(>8$!SM1
M!@[ZAV3]3JXMV1.T@GYDIL5]^8DR]1W>K?('\QP [IG7,N&$BAM$HS]KY$XP
MOIMES@ 57F2M>4+K#(LO@!Z0];JYZ\F+M=U(GJMO'Q4J5GA9QV-\!<"/YSQ@
MJX?W22/T,E7-13L0W=A$&5-A8Z >C(?S,!A%*M-V/M_!FRC1D@N+PE8H(4%)
M>EX84@88&<R+*%:I'0YX(:=LO+3,;E/5Y"B0SZ5I^%B'N?*C)Z%+B;28NTD1
M1/3K 4$?$TH*!((1S]"MI+#YJK,(+;^)>D[0GDB[)0YD.U*91V( =3=2WE@Z
M?SQ2EMB!XB FD1L;>:Q><+%7D1*R6C!.ZH&OL&I6ZNY@VWE4%XMPE&>U)'=\
MKFZ*D9BI%(K%Q%AYQ<=^D;$IOBB1#.BF];!C'6%RJ\X@XM^=LZ_P%9J?98'[
M,F<N\%R\1FHJ%#'/5!V /4"3@BO?,0&0J9$VP159S(*B7%.?22W5BW(=G1!#
M]TN>S+HDSFW7<I%E]DMA8<NLS$UXEY4+HY%9UUA:%RS8"+#;8V6#*L5[0,9
MZ'CRT;I+X4LTPH1G.TL&?0=K"[&7YGEXG"V'5J--3<Q(+TN9. \G$X_\,7+[
MH,[X*?FS,EGGZ9F .A+Y/??G$4B?.)SUQ7'%R_R^=3F0[J&W=M!#?Q_6GTO]
M/7- SV&2J*K^FU7CQ8GL<L#N*BZZS6HT-!V,0H'8,=-3A:JW.$/=]\2-,C$S
M!@#R100C8 .LZH2W0>Y1_DIZ6%YG&^?EP$J;GA2$CZU!LU'L&$+790]BQ190
MA!P<;XPB6Q9CLD.2>P/H#K-" 34*8_:/@.H*=$WI7,'85J/75<E-V19S)V$5
M$7Y1Z+##B0X$5E0GT;E'F5PD:%!EQN)BS@H%W=JAXFWVK1/:973#-5Z"B@TJ
MX!1+J,<L/%DP'>&]F(,\PJ10+B]_>=(Y,3O&A/7%AA$(2O>AZ]527AE3G_Q,
MF-@&D(ILEYSO[#$<(9)N;) =7#)K')W_?O4J?SV/6(/O,'_(2[ Z5FTF3D+G
MVSCT711Z><9Q;F*_[)C-57>B)2K#L7EI]9IJ5Z]0M\45-W3;4CFPT:^>N6A=
M1<_I-)01;"^*D[(*:GIGMA7EID*?6R"4)9)G*V=R]&>9G2Z3ZG\+*%OZ?^ :
M4-(:Q@=8#:4WO)>NP O@;C,*-%Q/8;DFW.%*)9Q7+E^59987J2AS#_O9Q+1C
M4.BE)G5V]OOI,3=-1@^QUIF#(D"R<P/K+ %F/KA"EM51T(Z?Q\Q#YP=Y531J
MHEQ<&;KLY<0'W]V[H$&<CAUJA9)!Y896>1+DM<'2<FE"V?HF9@4O/AIK \%J
MO .Z*ROF$GE_BXMEH:![5387#5B&GJG?O(MGO,6(463+:H12SH$<H-\Y-=MW
M<X!UJ<Z')7K?O!_IQ!XTD ( T;X2"C+T8OO8O2&+?=DJ]L5H$LA1V!4G0QAY
M$P&,VTJ;%'!P+!-JX71.L<)#D$\N\0"!'[5E@.2(L\XF2UK:9/&H]V_/2#*!
M+1?FN_HGJ%C??V /(C!R<%O<D(;J$?&K?*FX$G0:Z4OF]"*@]N\>)A7-C/$,
M&-O8<R-04V/C* UD42/Z#_*F!BD"WHXF1GPK*+CZ2CJ&I+P S=:5E<'4KP X
MFURG5G?0W823,R\EX"1JV\_X7,F[JW]XK-.[#L_'\'NX_,STS-.L\<EFCHR=
MZS'D@"F<E#Q8K6M@8*L"!:%]&WAXS+#]!UQ[]>XK=HOQ!IADS\K7QR___G+<
M;G:-HZD7)>& +&=O\"J_Z<W7_\EOR@JI8H$R<:[M;K.13?[)VH$4EF(<78E$
MW$S"5TR]5'"$GG=?%F2?*1$:S7GZ\QAD)F71G3HHZ!HDFC&!7T5XI ")G<C+
M@DE9#>X 1 *Z LB6#4":3UB,<^/_2KJJLF/;WO"Q96GJL%:=:^]K N&YC?;*
MV.:MY;8Y[LQS__["L^Q^M].T.E;;&79:_<&@WW-;?2%Z@W;[Q.Z>_F_/>E$]
M@WZKU>998ND5^]4H,Z;UFF8W5[$\_HI3P*O(.;X6; [JC HFSP33FG^(6*\7
MS\WJ >4$X(E;94>6Q4V<^=&%/KKD IC&XF?UQVLU"\4+:*ETT^NBDZBD,H&<
M<?RS).G34[-W:B%5RR$J\L62X$TB>-7HM_!;US)[_=[2GYNFM?2WNQYKM<U3
MZCB\_F/O_JU[TC[PQ7;,;KN_TF/O&<2C^BTW#2;9A4;0IPN7EK1F=JCR;Z%X
MAJAS,T=[OCEC^5B<_V"L[1TV:26^G96.MZW&"IVN[X7%/9<^%M0+/;<7^V,W
M[VZ1714\H%1:O;7XW=L\#' UGX8^*[SI2["$4,<^IXCM.L/#%J<@N'W\9W-M
MY3<)C14[RJ._<YX&'KS?^2TWC2ILO)P.7C[=KE_/1RPKL%VKU^A;(-NW/[+S
MKW^Q>LW73P9M_'5-J*\U&VR=]<QSR#T[2.7XW=N#5+Y=J]-HM4[-]@&3]<9?
M\"SJPJKX[C].1Y"3DJJO"7Q)$TQY,\HT@FRG*XQ%O9=O548D6HUN\\3L5%XD
MEI/0D[*'N5<NY0"[20]+3GJST;::9G=_L/,XOE0=%MS:B)E6?18\[[Q>3ZF0
M3MO6@IC=,35SL_;:!J!21>'5Z@.SZN^ \-HT-K:K&#]NO0^T!_?E(&_67MSY
M@UP.CE:GT6V?FOW#.%:;,"EW0F7I+JHL2X=A5B8F;4><E1X&JM8L&PU::#](
MU4C4T!IS3WENE!=&5 :X6J"Z\PR!:L",V>3\BW4CU3W+[/=:FX^G6F:K\[#@
M[W,]MH[^ED8=C9O8-!;B:75D]JXPTQYN<R4?VOYL]US+?#SX2.KOH9].%FSW
ME3QE&PD'546AM4ZK%QK9WN[_3TT 5@5C8S4!;), >C4!['^\$#LYK2+N=H9L
MCZQ72RAV1VEOU_'1.0A\['[@]*BU#%%/%2W=&6Z^,Z'']Z5]WQ^CR^P,^<J2
MIH?I+#M*R/N*RP>:'C46*[5+ZZ"PN,<F@JRU<!9K+=;4A9XV,EX5NK#6C0)O
M&CH[=&IJ BK-E*L)J":@1^4MU 2TEMQ>):G#VE12QWQ4KCRGXW.*Q<<\, 1[
M( -TU<1'0AV NI*=5?+YX-R%6?57]@+CAF)KLF&R1=VB\H%P-+\HH%Z^:E*)
M[%=%DPR^1JGO.5XRJT<^W@U_[D;TU?:3'S6H[@95)<^/2C[(.CX_\!1E!Z9A
M?($;/!N[894>K=]%]$,$7JA1#K<;S!J84](8-JW';H<TB<L(YY>Y;!TRK\S1
M1T#3=+ IMUKZK/IO%49)&&^Q?^%'+TZR,5_<UW!Q)A+\-,)VE%]G-[.D)OG[
MN / #N=HVL\XFU'=4MV6T.T=; G]_(FGJS5#4HRKF'Z*67>+2:?/T 6ISSF7
MZ^:6MKMF^^0)NB US7[SH<V#[FXL] 2)L#NU6,NTK.4_UXM]W&([6\DP;EF[
ME&)<B093<U+>:G$._[J-@)[:-WVOD7Q'%5NV$ZN[-TFZ=5.LC3;%BL+;91DU
MFSU?+6LWSM>2-EML91U $OPF<_T/X'Q)+P7SWQIV:\'N:PAVZ&8%_J&!I,);
MJ3L3%C$[[[??TZYJ=7M"])LU3JW.SG6SJ$Q9?=V=L#Y''+]O=+LG9J\^1_4Y
MJL_1([;;:W1.+/.T/D?U.=HL?O?V')5OM]MH]OKF _.Y]X*J-_Z"*K<]:CUO
ML]PG&XY4OMM?THGMAZ/M9HXT'YPYHM>W<C[ ?A0E+M.$VZVF>5)Y"5[A]K'[
M10Y6NV6V:W*HR8$$5:/3;>_ -(R:'+:CMS1ZK:ZY;N.B"B-G3SI_'YV\VD@<
M9$<4RI(DZYU1+EN/42ZK6Z"\3)LX/>GO@/C83&'T0TS91XF/72.'5L_:G=A5
M30Q/K5JVVJ<[8&G4Y+ 5K/1/+'/=JNP*HV9/^K-__G0@+3@*Y9Q[8L,M#7UW
M6CL@ABML->X3.?1.FC4QU,20Z616R^S7Y'!HY+"DRTGCI-^O!_U53BMK=9[5
MV[>]C9[YWB2Q]ZR7WS*UK-5N[TXF515MKGTBAW[KQ.S6Q% 3 ZMES=IS>HCD
ML"P*VVZ=KAV%K3!R]L19=F2U'AF&W:V\OE_MR/7L()]N4?G@:_N0,OOZS9,=
M"*]4V%K<)V+H]=L[H$_6Q+ E6[-SVJS=?(='#LO<?%:WO?9D[0HC9U_<?*<'
MXN93_5$/PM'7;W=J-]_AF?+EQ-"UNG5Z9$T,62E6Y[3F#8='#N58.;5:YLG^
MH&9/G'R=0RO=3>';77'P%9N^'X*/K]W: 8%185-QGXBAW3_=@99&-3%L*Y^D
MU:K)X?#(89F/K]4%[K _R-D3'Y\>DCR RETU*&E7%,JCSB&5Z[9;'=.JO,2H
ML(V[3\1P<FK5KLF:&+(0H=6M></AD4,Y5GKM?IU_6#E=\J1[2*[)\UED3W[8
MNZ))'IQKLMWM[X# J+"%NT_$T#OIU/EF-3$H9;+9KIL*'B Y+'---MNMVC59
M.77RKW_IMZS6ZT-R3[ZQ8WODV]'!*)75-3R7Y,OU^SM0TU)A4W>?B*'=[)BM
MFAAJ8J!,F-/6#A0XU<2PK8J65L?L[ ]R]L1#>=2RGK=">GM;?1]&B7A814MU
M#;@E0RD[5IUH='C6_!*EK-?< 0V])H;M*&7-71@.6!/#MOQ\G9[9WA_D[(F?
M[ZAU6#F(Y_ $;V<&AAR<B\]J[H R66%3<9]HX:1YL@/Z0TT,VR$&JU_W0#P\
M8EB2@0B<X8'CDJN(FCWQ[UG/6QR]S>3#R<#V']B:NKJ&V[*ZTGH^\.$9\4L"
M\)UZ/D1-#%DVAK4#,=>:&+93?= [6;M=3851LS?.O<Y!.??>34:P@&16N_>>
MG4TL"1:W.SL@,RIL*NX3,5B@35;?M*B)83O:Y,E)G<YY>,10CI5VKU57&%=.
MF^P^LB/U(_U[V]8EHX&7I-\/1I6LKL6Y1)7L6[4OZO#<#TLJC'L[$!RL:6%+
M3NI=J!*KB6$[.DN[MW8E2(51LR=^R=8A.27_[VP:B>^'TZJFNL;FD@#W+O1-
MKK!UNU^TT*Q=DC4QJ&#%+A0SU<2P%:QTFB!U]P<U>^*2[#VK1W)[^_PZNYDE
M\W2WXP9;.=.=ZSM46;9;82-QG\BA8]5])&MBJ(GAD(EA28RXV:\S#BNGD+4?
MV85ZMUQ[7R/[#X#\COGVCKJ'--:DW]H!F5%A2W&?:*%UVMR!.'%-#-OQ]9[4
M/0,/D!B6Z2W]VKU7.6VR<R#NO2_)6$3&- K=U$GB@_#S=3LG.Z"75=A@W"=B
M..DWZUS.FAA4I[AV:Q<:_]3DL!6L #ETFFMW>ZDP<O;$TW?TV&;.=ZC/5LML
M=2NIJ5V)&Q&D8ET;81!&KHB.><&PU<2(0]]S#;5,^3OZ\*R%'^\]JEN'33GC
M?OE\4*FD'.LU^M8.3='=&#:V9 1O9+WS7+H^R/5!7CC(5J/;/-D=QW%]D.N#
M7!_DLO!/O]'>I3:B]4$^O(-<3C\'>Y"7U(]U&MWVJ=D_C&-U*-$>JR1WZ*?$
M'OA"):IL*KVG?]]Z6KB>S^ED(*+8F-@S(P@3 T!HN*DPDM @$ ,\S6(BS9;7
M]\DX-C[#PB;"#F QP]1?6(Y:B,3_,?*SGT\5 7B!"\C_^?B4Z&H#"^^:K166
MOBQ[J67V[\I>.K)>&1L4W:L!^9=T8OOAR(C8\6-X@>.GKHCACSB%RPW?BZ=1
MN$@(>P7YUC- _OS+[Q=OCZU3PPX2;Q"Z'@&=H&_$M@^?AF%D#.R)#]1_XTWL
M 9S0B1=X,; SX1J MD 8=FS<"M_'_RZ[*7 -D8A8E#PC"4>"8K-XT2U\!<P
M7C]-HSB%92$K>/?;66S ,V,/-FY'0"BC%$ ;1C/#3I-Q&'D_;(1XO.<DDH^1
MV1J%&+_:D>O9@2,6C^<'?_;=G@R\#2[J2>%7++O>&@@;QO4L^ / N,F>F?L)
M*&0!7R.O!M8*!_/?5WO.[3K/(!"_^.G$0ZFSP.QTR19Y#FPH\ 8-^B*)A)U,
M +1PM3$.XZF7P&9^@&S+Y.L4]@T7Q TC&=O)<C%72[E_''6? >^JRF 1[[_B
MUV"2)&'-D.X$X>.I\A__/8A^^L?2QTSL:.0%Y#/H;8J2[S>;6UI(V@B'()[
M)('C/P-II9U\X@.SJ3!:!JA+ U1V29JA(2O<%-0GT'&-R(N_X4,F]A]PO>T"
M#F-A.*ABA3=V[*1X[O%=">KA<$'J)QGO,&Z]9%SZ$A&C">_%8V Y<P]SO5@
M92!?F<##O*F_\#Y:U-!V@-, ?P+"C_ .UVCUC:F(',G7</F_F==FPW CH,3
M&,RT:UTQ@8681@:H-(D]5V1WZ8_MJ<>6/^HF!!XL<%\-A)YM -\%M!E ,W0/
M/G)HWX01>BT,;S*%E2-, 0. L@"N<\9V, )@VP"?!H /SHGM^S.X:!B+!-_F
MA\"! 3&234^!H8L[V*JD/.G- N)[70U:E(8SZDT P#^$0YX<8PQ?!YGQ; =D
M7!.! NARDH4'*"H"3 @%?\LJ1SL "78-N]"P5@Y'M:Z_Q>47Z,_%OUO-EL4B
M,7_R&'8,=SH C@@0#/=&8F K@@>J=L(4SP1^RFDG33Q?2DE\\ 1(@I[DSX[Y
M=M<8A7#H @) +$83%LK+:63NB;CL=J?Y1MU[!\5K$"TC^/SG^PB^%(;P-9"@
M**QXO9-A&A<LXURUL6B!L@J8LB/<962$M\&<9R;33Q"^(@"Z=N#Q_QI[N P@
MHQ@0-AQZ#G(SV"&P*R"EA&$5PTLC8*?X5OR<+UOI07/O4BG<!OE40:[0;4":
MWP0 ZQ:(*"17HO@^A0-!!#*V;T3V703,U$'?!8!AZKET 2U"($[PO.&N)2R
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M=E@H5!1"J^B@8(H=P!9)\G<1GRDKME/CSI'K]=*+DHHX]GE.C#/=OUT.W.R
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MOD.)3%"/ Z#'/$!(>*YD>GI"O"7[)Q_N]Y73>?,$$D*XL1Y8HBV@E"I@B#*
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ML4(L0 S&!XN%$UGBVRCQ/SRL-V 4'C.\RK+??MF?=R@(CBVUW@ 18!_0 .I
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M40%]')- J@ ^04=C5,H<I,I T/X2IPP)=X2$>=.,&*>AE P@+@2@5F)@$%'
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M1KLFM%9%?7LY&([!V VO.MW^WVXTOKJ_?OJT2]E;H]JEI3L/*W<\7;@,5FN
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M@['N=6S%4:#O39>Q";/S1CZ)-@)U:W2ZDE\B _2F:Q>7-*W&C K-%0$H&*"
M:JJ!M!H#Y)@B+JR4]'KO.9+[E.%=#,FM)8</Y,_Z]F"^&\AIC6Z8(6=[D#/'
MD8X@+6P1V^4BJ@"5L1@ <0T*;P1B@A@N>8 <L4\YWEC!]'8!8*=)H+X9[<LU
MT[NC.KT:]-\O%$IF--L4FBWVO54:.1M0*^A.B /*E -2$@:(,TX5E'+DBNC3
MQPAG;UA&BO9H/!DIMHT4\WJ/80)ZY8$0E@%JH &*"1]]8X7D 4*8)]$9ICA?
M4N;1,F?8D_ 8_3H8%)^ZO5ZEV<B<Q]1BS:9>K Q2FP.IQ4:'FALNH-3 6!=T
M&L8L,(P08+&%S(M8JZU2$I/".8DIPT-[U)D,#UN!ASD=ADN-H3$JX(%3(*R7
M!XI*!Z @1'*A*+.)ZU,$'>;> ;WV93"U4(<IB\VZ_;'NO^_&TH22$^9>&LW3
MML!:H]$<3Q:M]#Z?NO'+SU5ON QGFX>SDP5MAQ(?EHUH($R! <64 !E^@B*H
M.EX8! E)C=^X0DN8+5JO[63GS5/5=C)T/#ATS&E"%GIKA*% $1-+\+D"6G,,
MN"+:8U[$.%:$#LK@QGI&9F_.;6)XY+P;#EW1&>O/5?I/I08AFCT[+=:#ZH4K
MV^2>Z\\33,L0MCD(^VTQ]\>K0C#C@?4( >JE!(I!!!Q7UGH""QP#\7B?2K6D
M'*7UVD_V]3Q5[2<#Q@,!QIS.4V!DL" 0("**H/-(#C3D!B@15E43K*5+$2Q)
MX))<P>S]V4;-VN!C&,275*L6^V]]C('<I@M(91=0BU6?>OU>]W1_?-@O7M9+
MF+%LHUCV^X+RXY%4D'(.F)<84*444))Q8(7'2#EC3:S6E_OAE[D70H:,]B@_
M&3(>##+FU1_K"EE !I13!-#80$5+A0%BEA84&0TMB9#!Y3)O<<M</FVN4<O5
M;'5<+SQKNPK:6HC,K5'FTI*5INA)=V1=+R"T&UR/3B>+F/%Y<_AL%U0Z"#G#
MPD-0""\!118%RY05P"F#+>182F[VGM-]*/$2WKC6JW39G_545;H,' \,''.*
M'150$R8-4 @C0(65("RH PXJ(C3E&*O$W$8%:[]?J\WJVA85NYUQV94T!??0
MYKYA9W_K>_>H#W[P&;RIV=B:1M2*CYS5V$8I=#YQ-G?B_+7H?63(8PTQX%([
M0*7WP)!" D&)E=SI&&8)JJK<EW GR4+7$KP'<DRN3[OPE*!T^;(^32AMC6*?
MH70+4#JGO$O&"F8] D**H+Q3(8&B5 .*G586%98P&J"4[W-"[D\G\2# ]A2\
MFLO5F5==;;J][KA;T:O&X,7XRU:=FNL1\N"9U;SM<-CQ&^RT@96N\ZP;#*FN
M70'Y*UJ?3F/W;34I8M>O\7TTLDA-Y<'8#:\Z07R&@T]AZ"4JU2&7<&9?#TNP
M&OA.;]!_7WZ\<*9.KT%H*ZG%]_:FM@3O5]<OESU8-LBK=$>3NRIN7)7\L*3X
MO4 8:@\!-$0"RH)];H2D "+"PC))PSF+C8<8D3DA^ON$N?N:T>V#N=88RS,P
MEY%L/22;,XJAY 7%H@"$>!NKTPPPCC'@I)>>4(T%"4:QO'_[M/9E:;=<ZZQ[
M)G<^ZB^QE6#.SFZOXE6OU>MRJ;(.MG'D6BS)=X(;1&/6#HLE^1+)@%Q0 J>M
M*2"BHO BZF!<Y.XB&2Q:I+YDL'@ L)C/R-;,(>HH8$H&@\TX R03"D@#&=6,
M.H.*!!:0YTZQ#RZ$+Z\^]@9?G N/>!5;[N@XZSF!N;WZ3KU@;UQ/CUW1<)=G
MN^PN@+58<F\<,M@C!DCLN4%=X8 Q0H/"2J4A,U3(8)<I)G>QYJQ]_J4=!X;6
MZ#89&#8.#//DT(0++ T!1)"8$.:"V8.Q!BB@N#",6H==  8E#G!VV3QTH##L
M[%%GZ$S8^V6 L.B.2F4_>V_:I\WTPI#3DKTI5^RP7QS5ZY7-L<V!V)*:>J<D
MM$&=406G@&JL@-). 4<5H<(SZ'S0;OB^I&P)PWWK]9OLNWEJ^DV&B@>#BOF2
M*\R1M0$@2((*9(,A9+$%SA3!"G(DK&6Q]YSM2T:>(GUBRS6>H^[?W<+UB_M%
MJ9ZV<?;H>LXD;EXOUKSG.4/4&A!UL>BKH9H&$TR!L!X!HKSQ0"'$ :1.(NH0
M=L;N/9>2+6&Z;[TNDWTU3TV7R7"P83B8TU@4@X)[1P#61@/JN ":40,8MLX(
M!'U @KWG8FE8.GMHMBMF)1%H)'YV$Y7EGMS/3]OR:HWR<AZ7+"/5/9!JD0>'
M62>TLQPX: R@UB$@+2N "D@%B2"P<+&G.^:YIT6&@O8H+AD*-@ %<TJ+0Y(Z
M52" +?& 2FB!L0$4@K9B"UL8!6-8B:IE'*?9R;)=$2L9_NI:L]X]:Q.?MG75
M&GTE+=JR^'=V%F\*Q=XO*#0<.>=P80&2B &*!022X )PS)GFA&AB$S\7Q"+[
M8C):M$>ER6CQ$&@QI_,P1@J"HF<&60VH)PPH1#%@C&$IA"T\T;%+A6!P215G
MRUPU;>;HRVQ^-9O?II2X#5J:]^"F^H[5NXS56\3JKX>+U5Z(24J% $P2&ANP
M(J IXP!C+1$MA'4P:':([4.VDYS-#T(7M74>O">+.ZU1%#/N;!EWYH-YA$DN
MD0=&J&!1TE1E2C7PW'AM%;32T>@BWZ<2W3^>]R HL-.D<6L2>I6NL_O2>6V0
M0:[5U_@^8L"O-DG/];1#/NU1M\.:G8<EB]0ON=G!-HZ^19(KS[#$VGG@8>R2
MPI %RDH$"@8U=)!X5;BD<A/*EW0[V!65.P>(GYZ2G-%B^V@QIRAK');(:!PP
M @I  SP 8R &%FIC!%;*P8@6?#_HTQM3E%ND#K=<Z3FT=GCMBL[0C;M#%[M
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MBVENV8?T5'6AC!H/B1K=)FK8/[U2ECF& -+41+LIJ$/4^?!#8ZJ1H,SZ6,D
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M($0PTOO$I,K)2>O!<<DLMYG+:*R2]KX1HOI<EP<?TWG;)@B;DJ;$ )).-#&
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MC=>B1R]?XW/M*QR7'IX<GASM_75\]/<S?!Z\]OLG.">''PY_M<TS'KY\]_D
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MS3>LI.:AS*3I8]+,2,9PV0CGJ5A'-! O01&5<>&"8Y(%55G->@CQ(L5/;BG
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M/RB@'HCUS)5L9 Y)X9I14[*1Q1RB7DMKW8V4/8G_.6N/<I'(:;\72RFM/@S
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MS=ZK+Z]?'I2_'1_]=B .^6$'K?7AP8NK5:$!I% 6+$DI 9':4A*,ED0[AN]
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MF!F9E]?-S8X\>?#+PVE7RQ9IWCBX5+DXJ)_9Q=FD/@^^OV[D"+Q0@ZJ\'&K
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MJ(/@W<JB2)/-0*51Y'UU="2#ALT\3Q*A,7]%EP(6MMF1%;6DCS#0^C'XQ,=
M19<Q\3$HB;6U0RDPJL#:VO$OE+(AW;O7-@?MV$.+C:@'')OIQ@17D6)UBNUW
M^Q&F6C\&G_88%.U2 :6$,UH)T#D*Y+T263M5DW?:U[2IT38%]$[.4TO%#%D7
MUGOO,N#N-<KA,_.NK:^3NDOK_V2(&WZS%(7;8Y-H[#6:%WTL9B+<FC?PP4,.
MYL3*K\J<^+V9'5.&;\YX?'96\LEH@L3"EO.8)VVV]7)._H8O?K!UYF=F3'/,
M8W\?-GCAR8<^_C*%X5K&^(%L<2C$'"O8Q\J;FX*?5R_*>-'SYF.\G+.V#G5
MJ_=Y*RO]ASH!/4CYKB#ES8221874PEYN]-ZM(.3E]>7LFA9%#+.573I99 X&
MZWE- GTX[ZV092PIX<.9;HO/U!JQF%4R;XJH)U?#T)-;,Q5:-I,EY8\C0>72
MG=\S":%'M;=Q8'Z8*I-JF7MD+;EQ\7*J/E[,E;DU3^;VYOQ6EC9G=L)?H16
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MK,Q4>;WB*LY%;E9NKGOWN\T\O&*]<S4G;VCM'Z=OE=.AW'H1.FM>4./"GYB
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M2M7LXIGB!"GGA95&2>-,U8ZA1QU9ZQ]BBW8'NVYG?0(["QS;5XYD3M9!M3Y
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MU(9.];MW<KF%$5:)OZ.5S:I")0S*17 R%Z5MKM2Y^'<HERMA])0UI5A)9*5
M@ RL+Y'%U+C0JFJ]S-3D4JE>7]^18 M5O&  )%%0DG_4!M&:"LI8]M-2U= M
MY]TAP9TPNO24$Z(6CC*TWE3)MG.MP@1MO7/%@&O<M:J;SE^>8!HRY&.21A8
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ML 5ZE X#7S8,J$@NR&3(R03LO$;/ZJS&F&NE7%/N?0X[E/0[?0Y%VV#0"&O
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M;W9S1=N+J-4)C726(>;MV[^!Y)6A@"##)3QT[4GV_68+P@F<3^7<YFD!56$
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ML*4VEZK&R'JCD63)"N92,()LO-&47]&Q\UX,=4V@;B1P:P-P]#X =_W:O&"
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M?C!2:\_6QOS/KC/_UPKXZA@*+Q*41I^=U8A[*\3]-F\EI,9%XB@":IJU;LN
MKDJ+L"*<8"L\I6SCC10+ZE[56O?2X_B*$]L(BRL9W/9XNZJZ_XN*_UOB?*PB
MJ#\E%7Y1!4\>.>;OM.P/4J+U(=D]__SC*]><6*H,8@KG4@.$(1LL1M0(Z5V0
M*4IW6964N[537<*>66YOD+I/QN5UVZ;KDC;&(6&]7#(KYX@TSXKR5<JN)65J
MY'Q.\!I,,'V""<Z9-Z,*QU.Y-56R:*,WE1%3U=P%Y"RSXW-R2\[!R:$))X,N
MO'7.,E['F6=/,/-_Q5CDKB2%&A:"&]8W+E.3JFRE837LB9XO4[KHH@3=R:K0
MJY';E0M!YP+&[3(9"C9HKK;0"%65B\7EM--$5>.9HL:CHA1DW#=G=-N)7*[^
M$8CBY W+].C>P/4 .H9I]@ C\;!;9NS CYTRA[T9#ZT_&Y?G7\G" G]V.U69
M&1AV56XFBT>N7)YWYG2U\7(J9K9P:(3RFV5Q<EODG*4\J*+1.H$3-4O>7('R
MB;+DEZ_3;/7IB84J*TY3O#JE0I=6:G/8<*(NM?G8I3:GVHI<56MSM$(+:VW>
MJP:5-89P':GA@7-MF=.84J>L$UP;Q?RPS#4=EKF&#\VM#4J7U=,C=:FI2TK6
MX+WM3U^M!N+/%$.16X6X= )9;PDBG/.HC>36YIKGW"PJ5'-EU<6M8EC8Y09%
M79H@HXUOC?-!R[K-7&"E\STV-P&=RXY%A[8J0+>9Z^%T?+.LFY=/)]<)9\,J
M*#';H.VH<4Q93"874BG+F,"S6YU2-")L0MA*W\MN%K ?&Q[$K#P8^@W@8W],
M#*/L2W#3,B&_;K_=*N;:.'QPW?CCW#ZN'?P*:G>-'1S40\5_7N)H;XA1Q4^'
MS3/?.3GK=COMQJ#UJH E[A]E.<A=(:K>$>6?AE6XJEHWPWF_6.^\G" 84^M>
M:3UGA?T!HII_.#J#,_FH$;HP1;WBIT$[ U6WTVS"3:N6*;D04'ENV6ZKZ)WF
M:CSMPU=;Q?:@6V;<7T.V2L$&0E"U:BJ5W%[F7$-AV"K&9%942'M1"G*"I3P5
MGWJ,XAJK00X/CJ:[_$PH=)6"/.XQ>:NZ";-:X(A?CA7'6]8GMC$98;GPDG+N
MC#*8V.0(HXY&'4-5Y>T&)^9%(D9]&BZL*?(#WN6K$@%CX@G"N5X;#T!('#$"
M21J#"#9*FE-J]:(DBXO#L%,&^D[:7AYGS=439Q?>1+#,2Q2LX\]?O08*I1U%
MB>4"-28$I(76*!=MTHDF(B+;>$.VZ((*L:X2K#D+7@E0T\PIC%)@ '<ZK3B;
M"?-4X/,8B2(UK"V6OOV#;U\MIH)9*Q 6,H#TX9RXBB4*0A!LL#1*V8TW?%%7
M\>FN-D"]#U$F]+#<KO\<Q&FOT_8#D*>+< +X[ ]XS0-XRVUXR5JR+I&LL]WC
M3U]3E);E!CF618&XHBDW>Q0(-$IOI>>@/H)D,26N$*VMXFU93'>FIM2PZUIV
MAM]*RC#($G$,8Z$=ES@"[/)<W$X:DQCU\M8]M3[&8?74WGZJ)>,FDK%WO//5
M,LM,-!QYGD.@*0B%"1PCE83%C <7'=YX0Y7<HE=7KLXH,X,[(\8-&OJ)[98X
ME"VQ,Q7+AO:LE31-CYK:SUKF9W6-82VVD6EN6=;IVSL1<&7?6+YW L_-P?AE
ME^>=F/>T+9:!2?_T\: 'Y\C9RGHL+MIC/K';XJ)7]3-T6Y2ML5^*S^+I/13#
M9JN7>"C*Q;C,/7$;CJ QME93Y61D7,3,%*PUD9#(3=2:#CLNTF''1:"D^M:J
M]CT=$B]04Q;[!V^_^D!2KG5<%33C0-] 4W8)$1>3X,8Z()D;;^26F:<-(TWY
M,G]$5=3=QV:LCHO2N9!KL@\E*[9.FIVS&(O<@;M_5MA3VPV]TA$P81W,Q]+%
MEAJU*Y[J6UV>XB7>-KJ5LP,$N-\=^'YI0ZYTJ<I,E-M#9G >M1 .-[$R$U/\
MU!N;D5]MS<<VW*+X^(,7!1]=,AO[=7.8>>AJX6H]JX5?6_U[IN*QL5XSQJ2,
M&':28)IQ&PDV7$C'!76750N_MOKW;&5E)[7Q(;?@BMPG; 5),6@5E$S$B+0R
MM91OUWD"#IW&2>DKRU^<\4U6KJI\!FP.H2!OXUYL I?RV874<,5/?^S_9Q]1
M0U]E!"C*_@4?WQ_ ]X\:KM'O="M@*+_%L+CXTB\'_[[XTE:Q4RD%O9B;]13_
M"T=G5I]A3)6'?^08&SO+9D;Q,?;C]U:G=DM>+1RO*B]@T2@=7!>GQJ@'SJ@[
MT+BGQ7@33'0:LMD_/=E%KNRI]#V/*#LV\Q:KFH7T?+=Q,M)<Q\TX7&S'U"@[
M*L$]4B/3AMR-J)]?#]2:MU77ES[@XSA"XWMVE%<-ZYMP$)4UY4O&?QN"%*0@
M3"1GM!?<,>J,41XS#9I[M(Z6F3_ BR3#M0MBY8G5+MT_\%^%]-1989"*22.N
M!$'6$H*(Y$H+R9/0*3>IN[23V,@/<>'9&A*=S,@78\RK*D2B 1LI-7*7+]1L
M?*\4]:E;E![R:[Z1]XD#O;Z=Z]L#5IR7  M4+._9HH+E[\/]&L<EQD%#3H,F
M?)SB<_:I+SRWK^UPL+IQ:T_5Y:#4 ^[?XF!F]@A9KQX'6FPI39??XX!N8:+O
MWN- KG^/@[&I@XA*D;MGM8_R?Y=GX2Q(Q%G5-/-G6!][:<OV/'(P;_W6:YYI
MF=5PQ32Q<-3RR+0V&)3F0&BD6,+Y.^30E(B5*A+^G)V:P_3-UI?CHV/@S$<P
M/OZE!<_ZY_/9Y];GTR_;G\G^/Y_%[OE18^\?>(=WL^F;7UK[O^V> M<^W3TX
M@OM\^/'E^/?&E^-?ONT=?Q)?CK^=[_^V0S[_\YY/MFS8/?]\NG]P^%4(X:52
M#N6&:]DIZI%EF"*?;'*>6TE%#L38E HO*,AYVZX-MS\<UB(;_Y$/IE\7JR6]
MM3F>KJUN_IRJ0CT;?'XVM8\?"6QWYL'6!@WKZ)''TB+.DT!6"86P521($Y/'
M9..-T4N VB>M)E7!_.K7-MF>#TZ]8W'V!:^\TJ!TFYI+JXA*+S'F]G'1:W<.
MO0+QR1GED;#&9',M1]90^"D0+; 6S BQ\89L8D879"/<HBS30OA8"R*X&K7;
M"W3GXNWK1JX>!\?JXNUK 5D?YB"+8Z(5%AZYP"0 E6#(6:914C' 7T@R7&Z\
MH7)!::(U*=RY+E3KH-// 9\3&Z,,B:H [#Z4ZWXFRU7!L36G8R56U=QK64#V
M:5YSC-0)E0PRWH#FF'+N @X*)2FM=!%[2G@VTPF#%W"OVDQ7-QU\Z*K#Z\8<
MGP!Q:X_&\J'R\QQ46FU#%,(B0[Q"N5H,<L1AI&+D0FE08%4 SK?)@/;-5P^N
MS6P/Q?TN[\^#[E=9>/JX6E@5%%]5&/0E^+:7,"LUB#]L@Z/Z3%C6F> 7G F.
MA]S 0Z7@$ \^(,VE@'^L4"+P2$DN)[]IB-I2RZ7/]]]YRZU5/!.PAC*PY82/
MZN8Y+K;=?XW,LJ(KGU]5X]L$K4N,$P>@2<9H;A*U021*C33&>D^XN01TZJ#U
M50Q:_W *[_-5*\:L<@&)Y"GBU$;D@@1-7"=CG3)6$W-)T/JX;LYD+.]T?>RJ
MCDX9?'Y9IL[E0>//8DL_11WMW,$E+Q+*XY@*J2D#N/]NP*??OC=*/XLM_BRS
M?'>*5J<9_: 9B].CAC^J"@$,$P&J2DB^TRMI;<^6);?:<.TH.P"5V0'PN$:O
MRA$ >6AT%V4)?(^5?Z>\?4[M],,Z2\-D^NK%<E@YW,8>QLG\@OD:J?\S565Z
MAB&IH(BT)''!.)'"2.J)3DHF9>%O?I2"3 2Z0*UIG!HW("LCE/[( 4JS<///
M<+QOJ^%^*D?[!PQV"G9@(?WK,.CFC-.7!S3GN06.4T%K%LN6"O /UP TDG/$
M8HQ*.(FCQ!MO")VM'#ZLC#"N!#J;,3#.UDN=0;=_-).M1W*B5I4G'*N"D1-Y
M+Z/:"[,[X*8E)"\O>O$LH.O"?K;J&8QKT*I@J@;+1:&YG)4UZ _*JB\C;Q+<
M!C#N&)"Q@DKX);<XJ'X9U<MLN5Q0];33_0;RZ"M9KG)KX$LW:(UP74;[8^</
M+TX<+S%VLCI(;RXKZS+XIS1$'5,*)&*N6+0F2D>C2R99'E(8M>&IJE21JDK5
M-/S_Y8]@!IMQ/WV,/4 A?P0,=#M^C\W.2<Y>GF:G8^)Y< 3ZT^'1 I)[ */[
MI=GQWU[<&?"M+#UA*)>1!(^,XS8'VH#*&E-$P8BHHLS5\MA<KCMCDE@@J51I
MCJ,Q25#E>;(Z.FER[Z0(%/XDES_H#A9GW*U*?EW>FFW;[9; =I%M5Y76*B5]
M C3&E2JJFL=5YOF-ZP!=O/+:Y,11L\7PY7EO=\V)HWH+2[G\5#NX4(H[W?;J
MSX1:_AP0LJ7PS?("5V"P;$O=,(EQL6MA),MP,L3;?_,ZO\64&>SJEER3!BX/
MYT7L/GW>Y+N<TQN[N:K?V:5Q*L_I=5LGV9CY4^_5)D!RUYZ<;1; A<JC^]'?
M'U#Y,5]^@C<5N_#MHV6]\%1#^.5.W"+'5#5MBPL=51/]F+-::8ME^<LQ$URB
M_C&OTRT:QMTMS-?$1*R.)*S.%IJV:;ZOZI'=8"\][$$T[ZC1^?\W[QAYW;9K
M-4)HQD=U@/X)JG2C[#KW2Z/3\XW8]KG>TT[;3QA;KA"U9SDGG7XL2['FBAK?
M&]_+GAEPD#6&YMS#V([]W&>GT2O?\O+PTX>:J,4[]0FFZG?;'C7B(@\["S?!
MO><YQ[!%T:A\UN/.\7+F]<;A, \ZMXM/FUN$P]SJE:_UM#_!N]["[6R,P(E'
M8S$3W-%D)55,\^18#,H(/6/*P^2Z@O-S';5GO3K/)4*EL??/WM%G^OYL]^!+
M<^]\!W\Y_L8^'W\6GP^^_=C_YSW=^^=+8_^W#WS_K]D(E1WRF?YZ_/E@Y\=>
MZQ/;/?[8VC\(C;WC)CSS/5S_F7QIP7BW#T6NP[#7F(Y0,5RI0(E$7C*+N*<.
MZ10PBH09ZHA2FKN--P2K!>'=CUJ)L)3%VT;$W!+';QCN,MZ$JT,IISN4+Y$^
M/7+L^F[L#GK%WM;?<VV*;W-R/=AL/-Y$O-MF*+8/[6&V+!\@'TOW%0J @;XL
MU>P:9<'D!(1RV !RQ#.SY^EDS$6GF@!Z"SR]>R<V<)\Y71E.=&_>>>-9N!/O
M?!9S?&_>>?\YOD&^R#TXZ!H2,RH5#CA9JQ+CVD>GO<-P\D?J7%#1U\3LB8G9
MSAPQD\"CI?0,$6\DXK!<R+!$4"YRSFQ(TN>J!UPN:">U\KSLMCBWOKSL&9BU
MWO;L4:/XM^W%1@[ RBUYWG6Z)\,.,2_5V/?VWT1I/"Y,WSP#0M:QWVVC6;KQ
M_Z3_43G<*)[T<U@:@.-AI]WH]:\E:$>Y\[,O3FQ5Z#S,!-.\."M6;2E\!,96
MA54^T?1>66OAW@;#-21K0>50N""LH(%+39P-D1JAG;"66%Z3M:<F:[MS9$TG
M'@E+$1D;+>+$6.1D-"! *CKGN(F,;KRAB^KKK3Q9JXUH:T1+/C8.8W-(TWP<
ME*.YEU_V.<R)$!2(VIB.H=PGL]Q^95^B+ESPK_Y1-P+Q@DM/NL#,@'Q]:[3S
MJ4B*GS[N_/EO\FJR-]$U),X.^IU&JS5H5Y&DC79JVM:P7PT(:H3[WHW1/0O[
MT&Z.SZXM<"O*YVKCV]+YG$PQ!,<,YM%S*92.(6E.M5..:F/%D,^Q$9]C-9][
M7#[W88[/,8Y9Y(D@0WG.VU<>.>TH\I(3&RQ\G LF$RK6D=#5UK<U(B^[C;VW
M11407=*Y7O%'H]7(>;<OU?(VZ5\J^KE7;&Z:=F3[, .#9BB:T99YRA?DK!U/
M+YI2/OZ\K0POV+6U'6VE/9^U,6WYGD\LA4R<)JDB=\Q;AA6E6%N#)>;&#,F7
M&)$O49.OQR5?G^;(5U 1!Q\$TK!>B+.HD*48(^%Y"A$+KXC;>+.>W.NE&M,6
M)Y6L-PWIP!O%;G$0_5$;'G68XZ^696A[?O/U6W/@.[T(E[=[V?#6:/<&\*U<
M-.&P:UNK-6<K0RE^'S27%JUVU_E9@B'M.2[-DN/<EKXZ-[?#W6=UG@M/C)Y'
MYZ)46'">O:W4>J:9!\8HC!WS1#7BB:KFB8_+$S_/1\AAH0R)L N%28CS8)!U
M-"*K"0.JZ(4/?N.-4%ML_7CB4N%SM4CD=&70F2)B"PH<75GR:#C'/-<\F<^T
M'I<Z^?^FT]*'\XDO+K$.IF_0G[_DQC)RT&@!_]N+I\7'3LNVKY66\HZO&WV8
M>W\UE)5E:J2>R8>8^/>H.QK?B3V,R'6C_89L@F/RM6V>VK/>QK^F2\\TVFAR
MXBZ;IHD2-1>5T-[\C^O^Z\VBP5Q5W&9F#2O ,]9KQIB4H-1Q(P!NN8T$&RZD
MXX*ZV0I#UG/F783OP/XV4NH@G*2@'V(20_+RLN=@)[7Q04J7(O<)6T%2#%H%
M)1,Q(LT^ARAOHTI<..'RJ6 ]=CSP1),TA(9PZ7.NK8 T\SXV2(:C)TXJ+JV%
M+S'*A4U6*268J(L"U46!ZJ) RS13K$4AG%O5_5F+-[I?:9^U*#URR^H]M]"M
MZQH\:U"#9SGKN3KB7%?2>2S%\-^#UO\"B9RLHU-:D6OWOFT6O99M-L?EGH=N
M_ERK?)#+U1?]0:O31>,\Z&',93?V3CH@KB_9U7\_NW'MZZ]]_6MHPR5),LUT
MX$1%'@2UFK,8F ]>&4(8KVVX3VS#]7,V7"Q#(IICI%S B&NND1,6(TF(,D(Z
M1PS9>"-J7_\:^?K7DG;\<>8;=BK0<O/N-.P9S,=?,?=):4Y$4;8ZP58-G0KK
MNYU>+[>5R6UANH/6L+/0:.X*VXVV:H-0Y[N\'1P.>OTZX665R5B=];+\6H I
MBB@LQ<8$[N$_DEM/L!!:DX0C'I(Q/2)CNB9CCTO&#L=D;&][A^YM?_L*M-E;
MCAERF.:L%QJ0#B(@PXW*'C>;1-AXP]:2C-5)+VM$/O[L=CY\G,YZF2X)^))M
M8G=(>5E8?3I7J<Y)S+G57[=J>1.[WSN#7M$[Z_7CW2(RGX5MYZ]X N_O8%9J
M"]H*D[;:@K;\5&4J//5&,F(Y]Y'#*V*3@F3!.:SCR()F1J3-,%R3MJ<A;2,+
M6O2."6H8H@GGTC/4(J.L!0%*TB5CF$EIXPV5"_J+KSQIJRUH:T12/NS\\:GX
M& ^!:TPQMY=L15L&<6O%OG7PTO=M'/(L+#W;T=^3F=7FM-J<MH;,3#LG+8["
MB&"XY,Q%+Y2$3>"U<IC3BID1.M4EMV9FC]A:X_2/@\_]W;\R.SLDN^>'XFN4
MQ''I#)**:\29M"C'>"/!G">:PR(9N_&&K655P-J>MD8TY-?.X5&GVUX2+WL&
M$W(W7M9IYU$=GET0M)=K([L_$:M-9+6); V)F&5">V$PG'Z,4XJ=(HHE12T<
M[Y$*4A.QIR9B/^:(&!9.*9S[FQG.$(\R(ALT1A*8-+96*N,H$#$BM^3Z,;':
M2+9&Q.-]N]_IS=9GKDUDMZ9B[8%OQAQHYAL!Y92=,-%LM[I++C*3_9OY-,^1
M;-G#>0)C/#DJ ]N6X.Q\%L:>VJ*V#D2NMJ@MG<AQ#@=_(MJK:+F.UHB@:0+B
MQA5W)N&:R*T0D?O,=X\/?WS%,CD,6PQ108'(^<20"X0@$G+36I&\E;5%[8EX
MW.@KPSFH*H;<75&E4R__ /8 ^J#6AOKN*[*PMWS DZLTEX]^=3G\7XU^]^S'
MPC+E2V([ZS@KRW#^3[2267(FS:UF=&6(]+AY#'[P:5B2MK*>\_P "LL=9OIV
M.LO5,[TB:LOBZ;Y-07/G9/+2<B(UUPGTEL"P25YCPYS0E=J"1]UD<-U-YBD#
M 7;I[O8W_C5Z9G04"3&9C=#,4F2"=HAH@CVWA@N>LYSI@DJ5]U8BKL6?5=,C
M5L 1?9NZC\O($'7O8K,)W"D7@<F%Q(?>^>*G\2<WKT3T+/WU>T JN_#T\VS4
MM4"67"<TAA0IVW@OVN^55MYN_)X9%0!I)Q7O]O_>V4;$K%:LP\,7Z+HSHUK"
ML^66N,'#+ZO+Q;865*N<J,M%'V4WU&$'#Q9V<&_R=YL'/"?RAS%0/Z%BLDKS
M1)33,;%<SS9:;940-?E[:O+W8X[\6>K*FL"(V> 0UX(BG3!&RB:FDS4QI7!)
M.YLE1P(\*_+W#%S??QW!5CNRC>+W0;MWU)@J ?BNL[59_-$/0 +G/WWU4H,%
MGHP'/@LO]+#_W[),9[67O_;RKSQCBIIR:P+'E <>K'#,&2$I33AIBLF(,8D1
M8ZK[_STV8SJ;8TPT8&%T#$B)7(?&\H2<Y %9117A!OBNQ\"8%GGY7YC/?04,
M&8\(KQ'._F'L)/"C[DFG6S7?^*G\Y&ZDZ+G8$'<'@$)P26Q&GRTIQ9\[[-^W
MM.B\@U=PW<9E R$WC'HQ7/S\^-$V1:-]U'"-?LD$;^AC?2*CZLH0EGL1PMJ0
M]O2&M)>7OW-O0BB#]LH2K)-6''-G@Z(R6<R<)8D[5A/"IR:$YQ>$\,/9WL$G
M_#7$2!05#@5!$N+8$:2)3L@R:XWEQ#C%-MX0Q;?T0]O0G@\C? ;FH/??.P\:
M=;9V$[(PY&QD'+O@0!=FLDX"0C3H5EYG^*0N,?/F]QQL5YO)5I@5U6:RI;.B
MY*P**7CLI.5.*F.U48YZ3VUDELDA*Y(C5B3KPG^/S(KP#"MB7Z/V4DBFD-/<
M ROB&!EC&!(^8>EH2%1EQR*MS60K8 YZO%V_TVYWLMOK(IAL<QA--OIDQ2QE
MCYFG /RG"9CEBD;[.)9[8;. IV=7(OIS&Y&BU6EW?+/3+A.&2__B6=57K(/F
MRK]L%L/*RIU#8*!'V1'9&?1[C5!V/'QWU&C;EUL@9M_W.\.TXMJ^]%!,JNRN
MN;.S4QN75H-&.:(5$\)Q9QGW6AE&B9,<,R*9EL94- IN6]$H@FOCTB/3*#)-
MHSZ??DTJ /75%GF:(N*4<I3[M2,CI(@",ZP5S][&);@;:^/2&I&%[4;/=EL+
M6H+=K0W%\YB1G(&(6IW02&?#^BH7MK>3;N9!K9(3G=A^(^-6<=KH'Q7V1TFH
M0LQ-*"JG[<NU+]V;&-4FIMK$M(;<"!//@K/.6^*YM]H1+JFWBC/%<UG<FAL]
M-3>B,]SH_"O3EH0D#"+>9A.3ID@K1U P KN E?%<;KPA5#Y$YN)SY4;/P)#R
M:\<?P6Z?J6-7!:R_5./2E.]MU+)^HA9=<11;MC_VM+7*@=JV;[SD,L)[G>_C
MZG.UF6A5V5!M*5HZ&R)<$.X)39%;;E6T7FDC&0V:2"J'O>HQ(2,V1&J'V].%
M(0WCTADGP1B9D_AX0EQY@ZQR$F$<A7+*!Z: #?':4'2_6G#33-!U^OU.:T$9
MB\<JXE,/H![ \Q_ $K;]O_H6#ILW)?;ELZ[1'MAAZ<V;_*6,P9\HBS'$#IYK
M0<P7BCAMA/[1Z-B=N&HX4?CB$NM@4@;]RR^91<V;4X:#1BOVBKUX6GSLM&S[
M6O)0WO%UHP\/\U-T8JZ8+<V#E&8F06'BWZ,QQI[8PXA<-]IOR"8@G*]M\]2>
M]3;^-?62K48;3<[H99/1 GT%OIKEJ4+M:@"N^Z\WBP8SLXP5L;">,^^BC21W
M#9=2!^$D95%A$D/RLJ)"<$T,;_MEJWB:2#*Y,WS@VA@K,S<2.K&(DS%FXY+G
M$.5M5(D+)QR/#O80=CQPN)LTA(8P^YQ@G#8V6<62YRX%$^')-/$8J,1)\\N>
M8VV0#$=/G%1<VFRL8I2+?">E!!.7SJ"LSKV\+2[DL]RO(%1->]*+KT<__#S:
M5HUV*0CE13\/[S44Z@5544K9K3Z^6-(M7"WKT"@Q?/+PXZWRHQD&4GU&S1;#
MY-*/\=;EGUUY6[V%I5SZ;0E<*,6=;GOU9T(M?PX(V5)8K\M@V98B-Q[L8QO4
M;JUQ5]MC.8J@OE$5\G=PD,- 3FRW?W8#A7LMWJAUDMG)3[U7FY5']&RSZ'2+
M4K5\B%<$^'S,]RMUYHHP%+OP[:-;O-,-V-4MK9?5RS]\B;";S4T59=1)Q7;\
M'IN=DVQF6&)^I]BB-QC&9;7"Z):^LE88N7FML.6LY^J(<S>&8N?/C_]M6R<_
M;Q?O?YS$=B_>0*Z?W!VRCL6>W[XK=JHZS7^]79*-=1VGX< ."GMXV(V'0_X\
M3LKNM6SSPB]R;5;2V^8YW+@5N_^W-ZI\7=;TZ>20DRIGZ2*<Y/L]JV,_Y-RO
M3*''WRTH-=V<\$U,48)"\5<\Z8_<+Q>%D98PI(>M_\B66__Q"1L2O#"OT9)+
M@-]VII^+[RAXS$5(D2B%N;7$)6EY5#)Y177"0]\1'OF.L*E]1T\793ST'3F)
M(^'$H!@M1YP0AVRB"4E&J=!)2)=LCJ116V3YSJ-G7 /\NK"A]:!-F3KNP:@V
M'ZX5Y'I,1(X':0X3KEJQ;QV,O]<:1M$\Q;RLS'$\JM/]0 4LE^RO6M]Y?O#0
MX7O3GMO.]'.A/5(P0KS7S##&10K68..L4"$(*8Q.F?80,RQ^G7^H XB?+H!X
M2'N42<I0RS+CH2A7ZD&:*(X2I0H[:[3C:3DA,W? G_5E/<\@7/;M]T9H],\F
MRUK?@_T\@PGY\Y(V<(WVD ^5N><7-K"JU"-\#%\LC6TO.(SX[4FWT;P[.:IC
MB)\^AO@!K$$O@Q8%R;&27L@H,-?$.:!(Q.%$E&%$$C:D17Q$BWAM#7ID6L3F
M:)&@.K@H!1+>$\2MC$@;G)# 1E*F:9 YJJCN"7(O8]!-8B;7CB6\@YW9C3\R
M)DP5/IRHA[T$K?5Y3MW>P7\0I@9O%K;(E9":FS->27B?G*+5Z\,\MHMN]/&D
MK"=]=A(+7MC#3KO16X85:KG3NS(<X?=!\VQ9%JI[3-$CA5NOX0(-ZP6MZ/+<
MW.9US^5Y+LQ/!\&5Q=%SK[B3SGAO',6*FQQV+>20^:D1\U.U0>R1F1^?8WXD
M6.N(D"@DKA!GE"%-&(9?$Z8Z.1JTVWC#U998KD'L_HBV+K3P?C>OOWG[?)_9
MS)VAX*#,^W(6224SC78 ;'F-+M)*EAXX.H>H]#Z!H\42 Z)FPS87C73CS4&.
MAQM%VX:+:-O<R:Z7240H&KW"]O+'.78NV'X<_6R[78#J.&Y^UXW#BWI5F-VB
MVPXO;0'C+6SX;ML>GF STA=V&$&Z69R"F@&W/SEIPD3!@F]-!U\]MW6_:"[\
M.'%P5PSUFCBXQY?/?V)6BCJ';;@DC$5D(L@X5D'&6;#^ZS9$1L:@C0 &DQ3G
M2EJ@,Z"G2>,)LUKIA^C)D3I=T/7@X3_ZK]N#%@J=/AK><NU9SI?_'&'?^KMM
M_S&#_>/?6U\.=NCGUL[YWODWLKO]\=O>;^_%'CQS[]S#LSZV]K9W!8SUVW_.
M/Y'=\V]?.6-<^1!0SG!#W F&+/<"E&</'(5;00F^TCP% M>LPG^+48^A8G "
M?_!-$/7VX0AY^H!9O>K*B;)ZSQ)7V!.<)S?=K[W;;E@B4G+),5 Z(D^&."JU
M-,1[02F3D0XU#S+2/$B]81]JPU(8[U<AHU0YG!"6PR*N24 FRH2"HX2I'!TA
MTL8;([?,W(8MAGOUEL)YV]3G*^7T\7<& --4/'P)3J69)J-3H]WO%+8 PE.>
M9O:P&R^(U6WV222)8$JQHY9QK;P-0ADB@N588RW]<)^8T3Y91J1NO4\6[Y/]
M@T]?@\9*NQR)HH4#[9L(9 &VD B>*1,Y98%OO&%XB];[9+1/II-$%NZ4=@%"
MV@[E%H'?\\D^MW=FU(;Y A!7I= _BOF-5MT3\@YN5[T!JNJU\#J]*?VJMUET
M!KG&;;??CMU>T0**XV*>E$:_&<M^DVG0'X#6U.V<V68_-P8 Y/A7IPOW;K5B
MU^<H#QAR[/4[.<0CTX10P/-Z-J=&]8[*WI4GW4X8>-#?7*E^=3O?X4MIZB:-
M\RK-:GCW1;?,B]$;>!][O31H5D5ZX>=\XOMA4F_6$+N=P>%1I51.Z9V=?.'E
M*M]T@0)8K)\?9>T6U\O8!C+6@S6 F;].V&XB?H_]4HL%<G%)BKN6S+B^! 9L
M@(L*Q<2 _A]+06G&;'ZPDY0]T_O3HX8_RM_I=4!DL_R45L$R;*GL@%%*[*5'
MYBC,:;8=$8S1\V@MZ(2<<Z]C3,%Z+)D'@D-U=6X.:\7F'Z;YY<[>KZ.#LPG+
ML#?(\+6?=D<Q51_+(1YT_H(Q3QV8L$@^'YJGG6[HQ?;XO,0O[KS\?+:WO?.5
M.9 L%SPRPN7SDD5D)?PCJ24>UB%0"Z+6/^W,'Y?->&C]6=5$I=$!I>@BI&TS
MF[!.8[.9_VL!/MN#!)<-RA,%?FHT<V!@/GH&YP"%FT-! EA]7RJ")[GL:';B
MEG]'%=3U3F)&1+CP9*HJ:2F\MGVV52R&]A)S2RG/_MY&QMAV[!?>]HXJ^(OA
MUNK1/<5W >T;#N37;J<U@7+[Z9=!+\\HJ'![L;^?WL&HJ\]CJ)G@)9*-]PYV
MOWJ7J/"8(F)T0MPHCG1( @4KDY9)114P,$&QJ*7HB K>6AW05@1)%//8!YZ4
M=8RI)!T3- FKN?^Z<[4X9##;;O1..B"SO\&)?;+7Z</OXRI'^R?#ZOI#->&@
M\TO\.)3J6APN%8?CMR .V%GX/X+#4(,X)! 'RBGR% Y*&;!-@91QZO-UKL?2
MD&!S3B)41K"2,F<QR2:P38"8#%/9:-0$0/H'>)WW9:V8,,Z'GSQ?;6^,4!F"
M;.&&V[V\=M*T4QQ:>-HM8<JRI",&E+(24(H32X7@CFDJI,)4Q5F8HM?!U(UD
M\S<8Z1^=7F^_/?IZ+9J7B";9/_CP51L1HY<<1:H9XLY*9&&5$$V2"2<MX4)G
MG=5<A519.'+4^'__'TT)_1E.N,WBIT8;SL;X:FRUSU\:9/6B77J!;1;+' L5
M1\ZBSF@->T6H3NLLGF?1=D'Y"?#M;0";4E5D9+.4_:V;<.\%EM^JOIO5@F/"
M"?.)4^V<EH'"62HS;EIAOA*2:Z_=3BE9FKGXADH);(-8&<7YZZ$'OUHD8*5P
M1S^])2D-4<<$:!,Q5RQ: V]+HTLF61Y2*#TA9)3:3:HM.;T)W^6*<JY3U<5X
M>Z&UYLW8[/2 -AS XWYI=ORW)]]1GT8[BGX^V&M^@>?L_;8+N^D#WFWM")#^
M\[U_WN,OQV]/]_[9%;OGAV>[9[,[ZLO1+OW[V^[!!_SY'';3]H>SS\??!.PB
M\OG@8VMW^RWY?/[M?'][YSP7]87QDJ_&8A&--H@E&1&WF"'G541,,.*($5:1
MN2*%*O*4M(]8$\ZCIR",.K* M9"P)R-@802@.LEE/KJ#F"MFC9<A[Y=\!NR7
M>1L32](;;=BA+,R46%RHP5T_CNEQ4\8=B<9RFQ*7RKD@@Z:!&XPMU\I=4[SP
M\13=?_(9UX]#XU)E6?*3LCR9^]* QP+J3!IELGXPM%V4WYRTDL0B= >'0.K;
MH<0U.$#?3=\Z'\J-TE*3K3F C,U!R$=L+Y9YM_F&$X:13?A6]UM5US]_U -E
M)O_\4W5A_A%TAU8G+UON)'EQ]_SMDZ.S'FA",+$A]FTC7_EJ<UH-VJR>V.CU
MNPTWJ/QC!W-VJ.&$=6-I"KXP_TSJ5Y4)ZBP7:X,AI08L"I"36)P,+<F;0WDY
MS!A?&O<RIG>\'W2[.2NK-!3%;C_SBZ%5*WXO'P[C_E99NR9L3.-PA#**H-&>
MGK6)<8T.G6YLM-R@VQN^44FBR@929^-5S??SD]MI9'K;*OZ*L<@(6]"20-E6
M9E-#X];D!1>BT\VC'TRQI_*9E94OA_J6ET].\[7FKZ?8+D,^!9(V=N)5ML%>
M:7PIEP]$#69V8,=FV5GYR8+0C2>=;AE:4BY]HSO!4L>KE)]?-( ););:<9Z@
M]MG%(@684'A"ISN[G/F#:DE+8K%@#4$ 2U4<Y.=H]FH7\_M-\MQ^Q9$;K5A%
MM>0*B_"US&-@V5RS<5BR%A@+C&VK>&_AIM./;?0R)?[?04EWVC8+=+79\@A;
M'9B07@.>EAH^3]O<;,&6](->-C@X$.O3-;&,_M*)1QE60/YWX-]F+JU5;#>L
MBX"%Q=11M8JR_D^%_0O?XLAF^"X.FQV7D7;LJ@,1..[ (=(\N^)4L$66_01L
MMU/&1HUF9&P9AW.BQ,%\F^&A,-HHLP@#PK%H@/\7Y+*;F]^-[CTRZ[\N?K==
M^"M@[&;Q6_/LAVVYQF;QUUG[&/Y^MED<=!OE3\5_/N9?[#$,PU:R^GO^$?96
MOS.%J5F$G06-"H;8&\ \;A:_P*^'<%1N+7Q$OM?$8\J7F'W-\2A'(R^JE=V:
M&$7>5;/7C48\=]DM'$$/7@-\54I]*SPS*VM2ZOM:=CG#1BTF4CMA*!:.<\,=
M#Z#6"N8TP88Q>X,1/J4?$,ZBPP%(7Z=[-G3)V69)%R:V\ECN2\@:;K_1IOBT
M]==F\7[0!4VZVL@6WFAS@KF-C]26!?Z93_2+_5?MUN'=3W-4)B@<I8B59V/>
M@J-@@(I_570S;^KJ) 5ZU.V77RZY=:\\R$N?8P4%"X8Q-HKGH8S?IGQX/I>[
MH7IR7N5L= "B8%VVWX^X[J4/OY*=C<CNA$-SX8TNW);3M 7V1@N.^1"["Y"Z
M=%EMPJD U*:DZCDN+?/&[EG%8 [+MO  :4#/X48@&V':G]K,*D1YQ)0\.<_B
M3_85G"8AIO+;[=+CE/^>C2.9F36!+.1G->V@#9PD*R&;Q4_N57D_8%F-X>"&
M]'ET .5&JB5SAH']Y%^5K*LW.#EIEH=<#E\!(>P/I333])*XY&,&+@ U'\A;
MJ7[FR06<WBH>V/CPES^*8=",^^DR,T3O;3OL==K^DH\/+LR?O8,<;ORRC16?
M^%>2G,14&D245(A3PI"342/J;(J&Y: 5.PNS<$EBRE$KF>#)NMR!@6"J0E!)
M2A)FC14Y\+QJ4U"R6A"Q%F O[+'* )TI_\16G$2=GT#D8U8U7F5R/F'_&QNT
M+Z(,IAE"HS>]+U\7=["&7/^BTQ.#*;8^!L%\5%QY99VR(1D1"&<1QW#I^4/X
M$_1R,&*+$GF75@[";$FEEM\90&\)\@ -!_)MZ8UN>\/F )<F&<J[UF0?U]Q?
ME;+L>[ I=R\VY;O)3;D]VI1K5*=]5B]8QFI/)+0N+W'W\;LOY-/V)DF[:_Z.
MTPU ;U\4J_S?4BM@+G,:;ERF>TCW;U[BXY;OO3#]^='??K$4_-?#O?6UF:M/
M\+JW<-9[G6RRS 6.!5<Q6",23P);F9NJ"Y)C1T:<_++8D<LX>14/!\1\O[*@
M9O)=_6WB#RODB+\;$Q_F?A]_/GY[_N6?O:/]?S[S_=_>X_V#SS^ <9_MP>^[
MQ[\T]__YV-@]_G3V92[W>Z^QNPWCI>_%E^-#_OG@@]@[?@_7[!#X_6SWMT_B
MRV]PGX/?F_\YWQGF?;_O[QW#NQW[KSA9*W'@R O,$#=:(RNX1(QZS(CDTKM<
M IK)!26@EWB.WQ"';EMGZ/;@>\.$\O&V?*9 N'CZGRT0WKOJA5+112H]U\%P
MS[$U3C >K(B!11UT"82X!L(5 L)&!82[YY]/]P\.OS)N*,9.(AIRMIK4"EEG
M0:"]<M*Q!'_! (1"+DC#65%8NFNILM7GHR.#\Z7ZQPW*]MRM^,YJ\S$M6%"*
M&^8IYT8Z8X*@C$6)A:7P3\W'5@N&=J?YV,&'KX;H&)(B*#II<W*#1D80@F1D
M.7Y?$ROHQANM%Y3B67DZMAA>[LJXUGROWYMR..,E;.6<\<XX#\9XH93#";9^
MROI833E6;J\/*<?>]@[;V_[PE41-J)$".9^=*(%[I(%&(FJ2YS8'%LM,.0C?
MDDNJN_4DK&)(=U:?58P\R7=B%0O><D609C&K^.DV.1G6Q(133AK3W"5IA,_!
M%('DP IG[.6T(H>MP4\UYCP-YGR8YA?GG[X:!N2"8XJDMX YUE&4BS4B[GQP
M5%D9RY9?W"Q(*GIU6PWG,4_ZU=U_B\'F-OLO!J,9%I%*8;D)Q@6OC<#2.^#W
M/LC+C_IZ_ZW(F3\R,V!*+9?"(<,D13QBAJR2\$_07,*)GY13L/^D7E#&ZDGV
MW]55%2>#$7(XY',HBO4T118;O=GJB*.\@?Z1[5<1Q2[&]F6!+J-\@9P<UQU6
M49R-9IDJJ1%S?%L:!A#FB.,R001&WPD7\?3E$"Z"V]:D7LK!\#7G,O\V1R&/
M977)R9CZ*G6F5^;<7QK672:IA"+^[\ "DE8Y*>W#3IZXR0(E9;K#YH***,,/
MRA#$'!,>JMP6V+N]'%N9YZO*&&F?C0.402(&S7)MQBL\M:;CK-LRZK$L 9,7
MZR)J;^KNMM?KP(AR.D(9/GI)</BXRHN=E: %49&SSZ_JQ<#3QY&999Y'HQO*
MU(@R"+-72MC%.U;I+^.(UNF 4[A\X7(,@[D:5[_R=$3H1'CI5O%KGNMF<R(:
M;!2>.;MS1K48+IWER?6?#>F?6/PR^>F2_*UQ7DL9]3I*Y=H<Y7$-Y2:T&KG@
M_S!%;'C);!+W,,6DK#%1G.;$IHDR0!?-S6&WETG.91S].&UF,@1UE.G=NRC+
M.NJ5WNA7 ;8Y%2PN3HD:1<PN?$Y.:2M1K9+PBQC]SFF["E.=?!Y\*V=[E:&V
ML+[1YG2\*FELE-QUV8XJ/[=C:=LJ_AJXX]RE*E>)\D>-^'V8-)Q3K8Y@-$>=
M9NB54 &/@AEMCV$Q+_PX-6DDM5D,I^*K+X*CQ^]8(C=@QR 7LW5GU0Y?-"NG
ML9+Y\L@:)[+UQGD.(+5_57F&S;/-*VXQGMMAI/3$_<;;,J8T$IGQV"X!A*F9
MGIS=S6&QG='U54K5Y"Y;Q=R=]Z,W'Q?<*P^(7 WA*OQO=0 =VL,H[YBAHUSF
M"DBN2DNYP;%R[:ER%:I<>ZKEB\<(MOKX]<]8<F$+CI-%V^6A<7&\7'-V73,I
MPX+4PS2^B@<-GW234V_A2C;NA[13KW>5//U<Q<[#+>,5H#2-0R[. =#5PRMQ
MY-L,%#5Z<ZE3OT38QB4R3V\F^'=R4L=0!$\?]&8 [M(W+8<.ZFPGC[_1]H#\
M9<Y#-RNZPU^FYO'T*)8+=3&7%4V8&SC(7BY?E&^5,@FH@LQ'6<47!T$IC3 I
ME]*02R1T*C?E(M-F@B\MBRV-'G\SUG0Y'[I!:/NUH>JSJ54R4I5($"9A'I)V
M0@F%24[@X,*KRT/;'U]EB!,),<.(^HN$@_E,X2N3M\NE&4+:O(1/I4R5[]"H
M1.""=K?#PB6_XA$C\7E]D_.6D*=('#!;FHN[) Y(O$7EY1_?.<*?P&WYG6Y[
M]6="W2QOX'D/5C]*[L3\5U<[GOPF,?//[J7Q"WSIF8YS2V^G_6PS!Y;1,G?]
M,@=N^]:KZ%.^3;,&)J.A6B@;&6=8Y9J_(3I'#"4X.K(PK?>J,G\?*XJT-K7F
M[^6^:NX>_][:.]X]W3_XO;7[VTZN]=>$\<(S=LCG\^;1Y_.W9U\.OOWX?#;K
MOOITMMOZ3'?/WPKX[^GGXUSK[Q/?R^]S_/?Q_C^_'N]N_][</_CU>#)=8.R^
M@@51U@<4K<:(1V&0 [E%.%?_LB;@%/7&&[+)#5Y0^6_E(]0>KC'QY4[MA^I/
M_LP ]MX9">L%L/<.#V3&!)VXI,EC+@0V%D>&#=&Y)0O%?MB^:@BP5\0)U@#[
MH ![-@VP5G-&N8S(P"(!P%J&C%0:66:=P4EI:G-\P"81; ' UG!7P]W+A+MD
MO)1,>AFUX^3_9^];F]I*DFW_BL+GQHGN"!=3[T?/#4>XC=V'.0.TW;A]\1>B
MGB 0$B.!,?[U-ZNVWA(@@<"2O<?3&.NQ=U7MS%6969DKN;$<_B&\2A(,3 #"
MJ>9?R\!=C6A+(=K>E,G(@L")4Y#,Q!/B-$;D+.9(4H:E41(';5Z\,IROH+#J
MF?#LQRVL>E0*]/H66SS:7>5:*DH)_%\*3J37@L=D-+$R,Q\;]0AWM8:7)>!E
MK&!J>X?M;[\]BO \DB 4,6XUXH*!Z>2X0@J,VTBY3YX!O&A#ZXJIAT#5K='8
MS02"Q]L9CHC@F*,T*"ZDM29P)7R*3'(1*:W=JO5 B9NQ4JMOQT<"AV0HI4@;
M%L (20X9D"1D#!/:$!^]$<6MHGR+KU&Q5:VU*]%: S8FPRQ2S3FH:^[?[;1,
ME!L239]$\H'>0:VUJ]/:O8F]_?V1S#60EA'D'):()R&15L8C)U44Q@$(RQ)M
M!GMKPTLD*\=E_?V#1Q$OS)GEF@#,H_V#'+;C8'9R&SQ7A!HNDM5@*X#'8+&D
MM7_PW/[!(/R0' U!1H>B\ )Q%@ ^HI;(.F4D$9X8F5Z\8FHC_8/YN/$<,=I'
M61KK"P2//W;AGB1%1&2&<$6C\9P:X9U7+"3OQ2/\@QH('N0"#(! .J4 >"VB
MFC#$ _-($TD0-\$":H< #RPWUYQ'K5*KY8:K)4^>P&YL.>&",Z6-Y5PP:1Q)
MQ#-BZN.!Y[;Q!VH)< F.&?9(\$ 1%QI\=-BRX3<I N8F@7?^XI4P^/$6_@K5
M<DY5])+]W)^\B\P</O RL<55]*G;RY"I:N(-:2]S;[N8J1H(3D". W@#X*UR
MJYA-R6">P+75X#:H=.L(^3,WY-IO79TW;?MR'2OV/L5!4ZWK3K<5X/GF_F]^
M6&\V59PQ[+A5RB1VVO[F,C;>=+H7@T_\4KWVZZ!^,;?-@6OV<FG28O5P19E*
MW6L3_LJE3_"/FVXG-T-NG#7;%D;VR[]>_^^OC6;[I.F:EZ417E5H_++1[EPW
MSN!'Z:<\6/C&+\YVFQX4N]UTOU8%<\,VAZ4X!95"O'ZU\LNQ_LS17@X:XC;;
MJ67/S_L-@7+-W=5EIWE^?M4NG>)RS51O:[ F)_UVSF4V>3*#NKO+9NQ&&&CH
M7.4BD= \;E[.5AKE@JOA\QC5/E7%*:7E2^87R24U5Q?YZK=NV55SFFG>$X&U
MRWQX240>N+%>!!L=BYS'J *[QZNF#Z4]^1.>-+RU6' /T0W=^1_>!.;PZ]ZW
MUT>!"2>"U$AAKL&S]@II3BS"."EK62":TYP(/]L ^J):WU(>/J:KL)ZMJFYN
M*%]5K2 (3E]<I_D+!MHQT="SW_435>V11MVQ*H4J$MI_;]0_)BM$OP+X<F)0
MN7H>A*ATDLZZWF_".J-U;_;_WME&F6)B''(Z;E"U/E?) #VS,=+OR#JLE)Q0
MF=+;"=#B,@+8W:9P<X%@,*2J_+U?[F@;N62LF9KY]V.89FY..?>:PQ+(Z>YX
MZ[$C+-D,;8BQ8Z68@ZYG+\?;GHVU+JS8 8:=QNU\V9G;*6W)KO<Z62U(I@/*
MY]G..N,<I\IKKR/'.CP#<>N/?)#Q<*A[_PV<E.N][4.R^^WLZ^ZI/Z*41$9C
M0I$3A7C""3D,KHM)VB<JK$H!3#HJ\1P&IRPIK4'UZ#+R ::FP8YA2;'G&OZE
M/=B@F2XJ<@/&Z#.0?=;R,7<K9+NGQT>">\I=,,BZ&#*KGD 6&X(D9LP9YAWW
M$62"W"D3"S9/+-@RQ6Q$29&H:O\:IU)XN7"SQ0ENJ-*J<-CU;XK199:IRE^=
M7[7Z/<OO)ZUZ*%-5M(5G9)*J:BWI15Y//*,J2L&&I A]TR!S18!ZE6<[9A)4
MF_XRV! 8V%HVQY<5Y1I\TZB94$PK)K4.^CF:L-38, \;_/7^]O$1Q2SAH#%*
ML4H]L<B!#X.L3M$J@F'7R*DG>!XV5*(S (AL@HRLQ:&I4?3IJM>/.AQG8Z60
M( ULX]O,X2GK=R"4A6QC-9(IP1/@((U!2/#8J-?).1J%5]JE( 6N)?-[2>;-
M[NG[(_"E::2)("M4ZO?^,00L&<UM[I8<170+2^:(3.86!VL=@?H6*I:!K_"R
M[^[E[6;XYEB(IMKERKY=*%<NKKJ]*UOU>8<IO/WX.K/+]"J^K@G/Y.KRI-/M
M1Y)Z+U=(^=+7XSM([VX):MY'U#(5U'26FD@,<2(:#D:PLX+AO.EX,$Z%C0LQ
MJBQ)<3)X++_-B[4O1GHR2Q7PXI8H[[T3G%J0(+AR-M#,Z0Z?YQJ 3U#"F'%4
M2,MKNI7-8S#9J,'6="LUW4I-M_*3TZW,'.']F-6Q-=O*DNT)4[+>><$%SE%+
MG;-5P301G&)C;0PUV\J=N3%[VS"^3W^?[)V>G.P=Y.\<WNQ_^GBS?]!J??[C
M/=W_=(CW3CW9:\[DQN#=3V_%YT]OZ?X?;TEVRCZ?[HC/!W#/3W^??=X^%#!7
MNO?M(_U_W][.Y*[2@'' R2*98XL\48V<\QX1S[PA&EM*3)7_+C:R/6M-/["N
M %O3#RQ)9^6<XCAI^..XH5Q'3"*U3N,@;32A3OM]-@R=)E3AABA!,!(L8L0Q
MCTA3[1&S+D9N$L%&O7@EF=XRFT(_4.-9C6=/C&>4FWRL)"R6EF--K3":FFB$
MCM($J^I\Z>?"L^E\::44%48YI"*-B'L<D&-&H&B8I<SD-%/ZXA6G<G/P;#*9
M>C:T>TM,MQ\,E2#[WS%I=IAD!5YWTW5",_;6\:1CF-UVG<_3+W-N9TXNZ#PL
MH?:U>Q-;K=BU51H!ZJ??E:X$]B)>P;,>6X]A=MI8PX$2[A\2J=^223<Z?7'V
MO&7;S2^ +ZY\PT5W";<L+U1YL%4>+TPOIZPMG+^[-3:7>W)A%\Y^+8=$=XRW
M6L-^$J0]'DN2';2L: 94I?O!(,H_KO-BY=.;#[<=_(RFD;,][CK_V2SI7%@F
M_W75[ITT&[\W.SW?C&U?]21Z#N&,E[$7'RV)C<[592\+$MSEW#;;K?SA-R?-
M=M54* _QKYRY"0-\/=E$Y4,\SL>(^8O_TX'Q_&_^D;^S:[V]JE* 1N.:LT[^
MJMN%X95N&SGCJ-GNE;Y8_8&!5*YR0%OSAG"K[LTHW8R.Y//GJ^ZD_HT>R=R[
ME1R'$QOFWW*II.+[<HKORU&=. F>''KCE](,;FQM!Q<9AY=?[\A8G3^NO(15
M*M+C$U>YMCX)YA/WA!MG,S&6(4%&JZG#XH[6P'6*QY.F>.06X\=L+R>M;GNQ
M>WIXA!T+(5*.%&$4+,>@D'9@/G(ML&&>,FK9BU?$B'O3/1;,5%PT\[#S)580
M#+((3RTG]U_U8KIJ ?BG.*W.VU?=03[]3<Q=S$IJ_G1")!YV[.LG$RPCU(E8
MS7P [R81SF%=-/QM@K0X2DR37CJ:\V=?NPXZK_U_KIK=N#-<K==EL6HI7D2*
M][9WCICE28N461P"0YP0@XPP'/%DL*$R!)O2BU=BH9RE^SJ9372I&G]_S=.:
M_AS+0WK[,6>C+I2%]'"%\<8R3:BWG"E.07VB4>"..D8LSI0H]YTOJ5O"!>^Z
MG?,W<*,\A$^P\;VY@E4'Z^GMU[[ME;4'_A\.[-?%5,C\="KTENYMG]WLG7J\
M=[J+]P]VCW!@WJ;(D8TY6]TY@^!9::1YL,9B')EW+U[1+3K+A-9P#RQ@B(D*
MC8GF+!HNE3*&*N) 6VDTQ@7ST #YZB7DYP/9"0F!WP^/:-!,@U$ !@)+"#28
M($<U0RYIBT/@QCORXI56Y%;.WC&4G9?E-UW'-Y%^F?\Q)ZS2"),[?V]JZY_,
ML[^E(&+:__V^-?IK4XI/-[,4_\&E]4^W(\]?X+_ /&ZVBE.WTSZM_,%UM!Q&
M9?;W%-2W.SE$D@V,TTZSA X&89;I&$<$TV,X^>9@\MD'+;&$7("?W8GF92X^
M<.#\E;!5B;O8$$NSUN)@'-Q\N;GLE^F6,MLJ)C0<BHO'-KO;:/SF&2_*%X?W
M&ROTO1[4YY8;Y@+9UE4O!P &,:=4[*8Y@R\E%\,[YX\=Q\YQUUZ<E$Z.HT#.
M\);51_O%P9-KVZ_?>%EB(*G9ZG<7!J>_1*/ 8!MY_]EGNF4U1T6M_6:_%RV8
M5.Y"FZW!Y:]7-;<<;Y:;0T+5J[TKUXO_N<J3'[]<[[;KE::G1;!&B[Q('*R_
M?.NH*7-".W9>\7'5'GQ"!$?QE^LI-WHV(+-L/$9$3G*]311!\\2XT=Q(ICQ.
M1NG 716/P9+A.A[SO"4W,*Y#OGOZD>X>G%WOG;X]4@GL<(T5TBG[K\H$Y+#6
MR'C*M"!,B,R?P._W9'/<KST3@.F'>S.HKJCT<QW5\+Y2RSY$KZS8DD=.)19$
M.DXYN%$.*P'/2CL")G&D=4G;=W-BKG>_O25'A.A@>5"(2:P1ES:KEZ*(:BE9
MM,%BKL!SH?."G,-*[/LV]+(;+B\[1EKN3!"")4!EL%"#]L(3APG7X(J+6G:^
MH^P<?CUBU%%!?&&APXAK!@ZO-Q*)8**G-":?_&T!\J'LC&_R#SPS&F'6K;6X
M_1/I.>1,15ZG^]#?;9VN(Z[?4IE9&5(+EDOVK>TY-9)CAGLF[RJ4 I4UG+>]
MXVZGES^=)]\G')A[DE[&F-^MWKN[.WR>QEWW&9F)U63+8-W-A*LU,>G;*CGO
M+42<*EPDR8=$DV%>))Y[LEK!O;/6>YU(<GZA2LXYU9M#19@NXRRS_*WQ'$6<
M]\_MF8LR2S%U%0I9MBJ3J2W)'E:1>&?MH-D"2^8I+DO5$]20YLLN5D!95SIN
MZDR6*5]<ZYD\NB:1YS^;7I-8\'[QI-,EY[P>^>6/+DA<=M8;7I"HC8V8@"M$
M(\GMW\'8D<2"S>(CUZ1JU_DS]\OHX-T_/IP<GN^2W6^>[Q^<P??>G1R>?F[N
MG>_>[&X?W^S#./:W=_'^7U/YY:?OKS__\:YY^.WCM[UOQW"?#V>[G][!]W;H
MX;>=:_!X.,R9[WY[+\;;=8)G=)W[Z7GKN53@_V!A'>(LM\I0(<(/'J(R0AJ6
M7KSB1&]DQ>'R@/K0"IT?#. >74"S60#WZ (:IZ,G)!$6/>?1:PV>5\#:1&D$
MY_V&H3]Q0> S MS-),#EYT*4)"CF,D .3B'2(D4DJ!;$*O 1*7[QBF&]I1Y=
M0+,!</,38LT/!30A!4U%I%Q(Q8F7SG"C8^YKE1@F\3&M#6N@60)H1I7'>Z?'
M#,9T)#@5WF"%$HX4<9K[&$I&D<"$"R4M88F^>$48O_6 [VDD?BW*])X[ >??
MT76;9\UO5^?6K6.\^W6OI _TKEJ7@Q0XFU/%JPRRZHRS>][LVI(T<'LKC,D\
MG7=;C?_II'1NVVWT;]OXT/$GL?'ORRJ_YH_8SI$2?U(H:;<:O^1HYR!/KOKL
MK>TQ1G=>IE%&:^PA;/5'\Y"BNW1U>=6=3UH_5DDW7F!7<FQ.X!8Y/>5X<&12
M!E5>K2J)FE5<?G",T.P-3G#250N69"*K*6PU[CY[KJ:WNH-GZIV5W#+,)%<&
M@X'I2'341BF]B#7+[W<[/(1-Y./UD<*2!6T5,C+3_'JAD2$Q(AYYQ%1'JD0$
MM-=W4H!G'M7[:'U+>XJI,J_[&7Y?/O#,FH-9S!+W*@7/L4O&4F89\R(DPRC6
MMXB=>F:Q^PG3^F_@GN3(6NJU(A%92Q+B+ :DF80?P@OJD_ R$1"[+<QNS^4'
MK+2-O&]59ZSS#Z9?SA7$$20.A#!?80+G?YC=]I8]]G4K?[#5>MGX:^LU[**#
M?\/>"19:')3=#EX>7&:L]K0W5EXT)WUV?#7G-7KICA<LP]#AGKGY4ZMS? ./
M-H ]UZ_O&58LOVRXJ\M&NW,)@SEO5O5- !#P))J^_W58B%(G6C5(&>5O/G"K
M'FW0PVO>N57GAC?CR0V5^9"[X/0KX5>[5^=<8ACEO)UZ'N/ZDCF9WB;JHDE"
MX\0Y^&O1",!5Z1R3425:;]W?#4/WM]]^!0P-$MPP@5C ,1<2>N18,,A0:X)/
MP:H07KS2=Z>,9:D=ZOAJ]NP';MDT*@I#IL)I"UNV,9%JA[&)@D<AN:FW[.\G
M;@>OQ5$B4EKA),+.P99-%48ZXH2,"C)$IUE@V5+<HK-]B)]IR[X3+<<*JWR_
M\ ZV$0LC:Q9@+L7A>6_)E=QYJYXHV0;\;@&JGL,W3Q8NX!I3B3XLAWE\(#,Y
M5^-<\K.CNL\P68_ Q9\1EG@S;:@R].'FVHVE\KVDGY_;LSB/? +>*E]J]$[@
M*YD^)7;G>T =7Y&6^)+(.&R265D;Q1KJ@52VSZK[E6Y#(V$O_"%7ES;/./9#
M'HT_=]C_+GF ^7NG<]9X#8/[SY5]W&+^]W\9+O[YK.>GY;ZCWJ1;C7UX@N>=
M;J[7 J5)8+;D@J5VYE@H10$3!")5%T0[ORJ^=*K)]2]?"YT#F&-+E0HK%Z21
M24B&>;3:<"RX9DKG&C_K;^N%)VMSZ<G3I/</SLCNP5NZ=P#SRBU G?=2.IPI
M&'(O/$[ #XT.1:T$4XQY&G/?,SR[DTU6L%0%471&TZN:M0&>9#?@SY/<5W<'
M_)^\@96J--#Z;H'])Y!%%5,TEC AH^%:&,UB=!(SSS )1+!:%M=!%F&<NT?4
MYCH*$U'2*B#.L$<ZLX,DC3F3S("ED>EMY"RIP3Q99#.R6-GOV8[Q@*/YE"0[
MGWGG2_FS/EY<;JU3;?G@*^O;_YW=7G2>QU]E<&=&*7BP)%-,@1_CM Q4QR@=
M8\H*DPM^7JQ9J?I]WWP>PW&O<QDKR1:_]8\3*[G?NP+[O^FGG$8:HHXI!1(Q
M5RQ: TM,HTLF61[2_ X!TP?'O<ONE;\LQO[.^85M=C/,98#+\/PZFUG%1=AN
M]GRKTP-+[0#N_WNKX\^^.WX=]_'K C[S]GKWX)#N??IPLO_I(]X[?\_A7B=[
MVQ\!NSZ?[I6(_]N;P[^F\.O\7\W= [C?Z2'Y_,=;\?G@/=SKF!^> Q8>O":?
MSW?9[L$.7/M?)QF_<@OMA+TPQ"K$++:(&W *#>,:,:$CB<$ DJ7I>@VO5+(N
M2O#L);?$Y8HR#KK@'2<4GMR+1H1=X2)K?O<J9CL]%X..GL?+QL2#J@X&RA,:
MTOF] >O[./.83@C,E*S/+;BX?W"3D\$IJ[7EW.<>J4Y9PZ0DWG"N+2R,'Z9"
M/)70_N5/8KAJQ?TTL2H@M!\JZJ<WG=YE[Z>6T]/W1\SQ* BEB' 05FZ%1Y8E
M!KML4!('Z:U-TW*W)F[J017R@!U\$+HM09!*P@>.3*E6JJJFFV.*TIU5E#[_
M05]11I<I_B\(9\FY*+PVO4OX:Q@O[ES$ 4="=H8#K%6WZ6(FAFUUKG];J :/
M5-S&=1NY#>O,ME&#K=O(U6WDZC9R/WD;N;\BC,&"3UOWD?N1VH(\NFSK00;W
M7<G&0T$K9C99HX#6PPSM?LXQSY_=W?Z[N7?Z+[CJ&89[?SW\M OW_=#:/VB=
M[7U[3_?^V+G^_&8ZY_@X&^5PW1VZ>[[[;?\ [IGSE;_!'/_X*/8_O6=[VX?X
M\/3WLWD=XW2,5N1J!B>D0YQ8@TRT&-% <<18Y2A8SCF><Y2]_L5;=7NE=<71
MNKW2<CAJ/+=$>*4$%EP::9EU5C(C.67>DN4)QFL<?22.3G>-D\&YX"(BA@O$
MX8$C X\+,1$5I9(*$B3@J+B= +>&M1K6?C98(UQP#):@Q2GP:))6FMI$20X"
MQZ#UTK5H-:P]#M:FF\<EAJU46",BK$<\B(!<M X%;3@-AC",]8M72FWI34&U
M>QST01049A+O!L)-_N3248I4_K<!@8C74S'YQB_'MMG^]?90_*TA*[K<<LS=
M@'YFCSUGLI2G,3I)[!\3?H@^=_!IQM[@J+=_CMA_OT;MI5![=\:IEX(%IX-'
M"9N(N& 8.2\Y\@8+C[WGR?#,6, VD9)E/A0]J84[=<M;0]>;"1GSG\HOS^N=
MYA12^*T&C^<'CRE/UFF9J!,,.0/N++>1(2-#0F"G2TU<U)JQ?/ Q)R+X:ZW$
MZZ7$W\,5JU7WV51WVEMS 2L"_T=><(YX9!&4F#.DG%686'B8.%.QF16X:RM4
MX(<>F:Z_,W+0N<PYYP].$WJ@\]S/UJ$S_O.&1=-6>]BZ@E6I7;L[$GC_BI>7
MK=A/X!UA_Y^9"*9752;4\+X$O+^?<>L,]9+&8!$6.B=5\G)6"UY>XLPXESRG
M$MPZ(C?1K5NULC[OJ<?CQOO 4Y$?!>=7>VJR\3B_?H?%-<X_+<Y/>> IL"0T
MER@%;7)AFD/: >*GY!PS06)E<,[)6?E9<HVZ->K6J/N] R@UZCX+ZDX'3Z@)
MF LF$$N.(/"//* NL<ACDJ2G-EC%7KP22FS)'P5U)PE:AR7(XQ5\\PN+^#/7
M9 W3.DI'K=XX3\L]/;X;?788W&>'(:9B=FFV"QU(Z=(USDI2/=!>X]*>Q?88
M86@A^ I7/O;KMGKP//K:&=>/&6;^*FY/+M4M*U6QFXVM\%)44JL.,8R@;C_M
M#!N6EOAR[UUF>XBMS.ZS*:P'SUZ-^77OX#W>W_9PK3,8YR$]4IC#YN0)LK#\
MB%.=R3@L0=$1XVF0)+A, $GU/;RC,^UCQY(NII0J2UQ^%GFCRBWJ?K<W(&^O
M_R@TALW>H,*W_[D1)T?6QR&!QWFG%?U5*XMFJ;/-7[9#1JD^E]7,H K-VARJ
MH7]WOG:V&J^'7'VMFXT1^QU0VS02_;=?^R2-?W0Z@%6M5JT+B^G">W+$'8XA
M4(8B=1)Q+BW25$BD@]<,8Y%B2* +>%[OFD5UH4A@X9."=1]HPXC&\[WKQJ_?
M[,NL,]>QU2JZ,R:K>=N"R\?C/FE9M0'"73J^6=2@<(I6?(&39%K=^,4V9VC+
M[N08F=RNS/?=KN83!MQ/ #"3 G9[&?;M=L3\S1&LAPK5X*V+;C,WM&S=5$]X
M*9(@&16Q43N!<TR&.N&3CIAQ;(,QA#W+66L-$O- XO#;[O61E=*(2!0*R3'$
MA=+(2M@QX;7 "6'.,)T;K>,Y'5_&8>$VH1ON7W/4-F],+QN]*]?+='/-O#,U
M,D,HO#7LSSY?^WUL9<H >/$+>(Y9F/N7:\3SBU;G)L9&9M2[A.M=VV[H;<UB
MP1Q#=D%2'4I>W&[^?E\V&_D\;#8[[4PBV.G>K"%;3;Y/I4:GG[=?@PJTFI^W
MWYWM?OL([O7[:U G4*4=MGL.H_KT5AR>?\39O9Y4H[VSW>U6:__3O\YV/[W_
MM@?N]5ZY%JC2J;_Y?.IA3'#=@P_@7A]>[[X_DL)B2PELK(J#I:E\0$ZZ3+7%
M&$Y$625FF@L'[UQ(T3 1<I/SI!UF1&FG0LR!%#I-&C)8]>:#V&?NO]ODZ*RA
MPC"2A*4 UI(X!2_HY+$(6D3+UH;$Y+ED_<].J^EO?F8YWW]]E'C2DD6!9/ 6
M\9PL5\CUA7="8$,E)FQ:;C_%QE6O\GA:MG>)FNV7C=3LPF^=J\O&+__>>;?_
M:^,\7IYTPI#"_=R>@J #?O?94YLCV6_ ZA?H;PXX>[/89H;T5N/CUE];?;ZF
M\6]D5IDOMG65*65NRI>J^T^-Y-W82+8:^5]5]&.,(K'7J*A5<Q_UBY;U%65U
M_M36M$XVQO05+FHS2@98B;Q;Y3DWSJ_@VFXX,GM9+5'G&D9?>/-ZA< >5.LL
M7F[==;EW2UPNL\UW8^E DVWX\NEIP_FY:*6&NO6F6M2#/*2?6,.^[ET?<6.Q
MM(PAL,MHSGS0R'F*D=688F7 C6-V3>FDQB44Q&^:NKI00#5[677[KF'JM$ ^
M<VAWT?;VWX/B21KR$(HGQ;:86(PQ:%DB(LV>A#7I85>]=["R9DVJ69/FL2;]
MI 1".9;?.REAE=*?Y:&YKYMR^EX3"2UWNAZE%AAV>8RMY\Y$K:,5\,>&'/1+
M\KZ6.#.>RT#@<M1\C0[/'VA?58?G%V=PK:^[?^QD.TKL'WS$>W_ ^ [.ONYF
M[NM/.]\^__$Y7^OKWLW4X?GY!QCWV^M#&-O>MS.1(^4P/KC&VZ]PG:^'IWMG
MG\^SK?:6S:,1LE9)C#E&RBB,P)4&V\QH^$U@XCD\&*/DBU=*DBVSZ:FIZY8$
M51-N_#PP^N@D)6]QDI$(1S3FAC@#J)EB"DHS9TV_.^,"&:$UC*X&1J<R/TW0
MTHEDD*G 4S"DK0_Y]$%@[;W1/M-M"#T'1M<4U'Y<JHE/G>Y9Z478[>0^0361
MQ!-;;'F]=]I_5JN](>>7&X%#.S/F'&4BL$04BDE)Q".6R"CF$ FP@1!MJ8H)
M?->73-$Y1Z!K;]#5U><_O%U2@\73@<6TT<)BH$H31#!UB'.7>WHYB1R/D2FE
M) \^@X5@8NNV7DIUW?DJ%>^#O1ZVK:R:PO:N+BY:S0>R7<V9]YK@SOH9*;#T
MNX.5KY%E*629Y;'*B1;)1)-SDP68(9HCYQ1'\' BH\9&6=PAHN84PJV]$3(?
M39XC</0H(V1]P6#]C) :#!X#!E-F1M 8[ N9V6RH11QT#1F:+)(>'KPF4FL,
M9H9<(<-R'?ZXG]SFEXD\H.G\GQE"L&7\G,>%HFMCI'OS1[=3.S^K1*593A:&
MN31)$"1"SDQRPB&7&QISB;D%-XC)X%Z\8B\UX-(LZ=;:&RG+JN(SA5$>=/3U
M(V//^MD^-?:L'GNF+")J63+<*92PS]5K7"(;-45)2"M\$":1D+''<+%U6T/U
MM4."'S<JL]/VW9AK62\[5:YSMI#J@,RJ;* I!N$90,I+_B'"#+[$&GF60IZ/
ML^D^QEBIE04/3(3<-0PC9U)$D4H3M+.YLA&0A]=QF3HN\SUMDQH3GA 3IJP1
M%:-GEE"$F8J(QT@0X !&B3/O<^X*3KI@PJI:Q=3AF;NMC;'"R ?9>#\*T=EC
M4ZU7OBH_K8EV"PKOQ<O:45P=-!_.F&L*=DXBC4*>,##78.]$UOF(M(M!*<9A
M2RV.HM9R$_N\KEI!GS>(]4PDEC\FMC\V__L'P_;U"P/6V+YJ;)]N/!NXPL$S
MI*S7B,ML=G/#D>8<WI#41U4% 37>8JL- FX8<>5\$L;GIK(<KP?OLQ+  L>*
MX:&B0*A8'WSG_*+;["W)1/= XTQ-*W >R5")7Y^#$"RHQV9#]?CA# 4?O^V_
M/HJ6"$N%182D? Z(,;*2>)1$U$:F& (&-21;;)8\MN'ZC%$Y46^99_U L*Z?
M]2.>-=Y[?Y1I?X*@#&DO$^+!8?@M1F1TU)X2%V#9\[.F<T@#W8@=[+(D4#3O
MYH>H*%G[Y+44E]Y!%Q$N]B6V;K9^+&J_>]F5IMB86-($O!= O& YZ)@SS,/6
MES"LF/#4%I:=,8H_6WA>!@M^,TX16'&SC5.S98*=-_M_[VPC8AJ9B<UU0GY&
M\."^+S/H,,.]V[R,VYWK]H]M7SU<5R?X/K_M'KS&1\PG(C,/68BPX-P:AJR1
M!L5((K?>Q"1!<QDS<ZI:*HT<L/LM1!<)BMML]TF&4N'_[.47*@;I=C&+BKCU
M+N&O+(=%O#H7L>+Z[&TU7O<:%[9[.6!\RLH/K\<!=^!00$%S0SQO^JJ96)_F
MJ!O_<Q5[0P;>P@,UH!/MMFU%?-LXSCR1[7+W0H&;]:/7IY)J9:U 18(:Y[9]
ME6R?CCY?<YYVP)W!9CE[6:;9+69-!]8F\S(UNO8"S,#,4]@KS*<7,((R9UML
MS#+&0KA=ICUW>HWXI=/Z,F+K'-)5C^B\[]7Q$6]GN!HN)!A;KEDM2>&%.K'M
M3-4([PZHK?+"@9Y%;\OBP'#**YGZ<X&%G8/-MT=5*,E_G@ET[P?1O+@5P_#X
MNA1.Y>-NK)+]AC2492U&,Z_DL0T:@F!ISAOQZT43GDHHV8+S96@Q6LK^BO4G
MR#-MT46G8M'\K: X;)!]MJ*^$SSVK?XFB$=?L0ZT\>IR]BL+[XH'S7.8TEZ\
M;GSH@&C<^ZC*%7]K@@G0] O062H^M=>/_5R&II,/:3I/NB.:'%!RUXWV#-D$
MC^DWV[JV-[T7_Y@T(,!6&%_NVQ9W+N?GJ__KNO]X-6\*Z\86JIZ'+?0=H-+?
MV?T;L87VUH?D[?U@JSXYI+MT_X_W;/?;6[%'W^//G_Z&>^<MMG4"V_;70_JY
MN7_@\>'-]%;][O3PVR'_O.UAZSUCG[<_M#Y_>LMAZX;M^QULV^]./Y_OB+UO
M'TYAJX9Y''X[HH$;(ZA"5JN .%C6R%#8K;DRFD9/3))AAC!4<T^QQS&*P+D5
MV@D6!.?4)Q\33].T<.\ YMN%CW>GG3LX%'Q^"'7HO?>=,E:UXDS@(!T&G/58
M>P!<K%V"OZQD?FT(ZYY8\-]TVIE[J[)P/H"M\ :V;3"?X;>?4NQWKX]4""X0
M;U!0+/=UQ(#&PDIDI+>"&^M($+>+<7,DQK #@P%V 5@V8([N7;E3\!8;5Y4M
M4Y:Z6&@#WL%L#L%U+LJGLZ'8M:$X3;'Y)8?7>B/#!JQ"Y& GSX9 9226FVXU
M/IUTX(/91@QPQ6[378'I5;;W5C-E\Q',/!^'S%[9!,PQAL)K:L>IKF'HW8$)
MENV+F<'\LU&X#&$P>>*]QG%LYU]AZ.W.9;%WFS!%&%%L]&(\RW,^APW^&+[1
MI]V'F<^R9\.5_+A8PDM@DAZ?E$%TVL>=8ON4Q4/=^*4)FWPA?0@9M?L+! B>
M&]2 [5I9S=-S ;NQ<'>?Q%8A7+6-%*\K2M=&FGB8S<NKROJO-B*8RWD''$SX
M7+X.6%#5;C&TN7IQXFME/*%35@0^G)^^;=_TG8#IS\(")=MLE86*L;@-3;B/
M:^4UJUR0G79Y8-U0^N^4FX:.+P(7<Y2R"Q/-ZYO7%H'E \9$,0DO,C4PV'/%
M/A_,H#"5EPA3,;,K>1Q,J73TR$-MQ_E+DJE:1S=L]GI7L5L>=N:R+5>I?/?A
MHZJ\>=A>>Y7GE6\?O_1;BP#(@:=5?.<\,W@F12QC-WM<S<K*G9[4N+*!F,]9
MY]EKW+W C6.P5-O]UT\ AX=::C.'>V^&0O<Y66EWAFJ^;D3/WP6JV1&7W"0L
M(K)<,\03\V"A<(J\2RPXHH1*9DV):#_%"O.S4YX;"F19 ^!L-0$TPSB@5SIN
M<P7YU8!N&@ Q%BV^/.EE+6QE'W[8V22[<_E3%U==?]+/<':Q@KR,R5]@;R@[
MQ<%)'(9#!F@TNN]$*1EH3;=/Q+P(#^YSK^9^AN*JF\+$%+IQL+W%BKB[(J.N
MUB\T4XHEFE"=\?0:(5[$=G&M.Q4Z7=Y<E*6<N?9";,#Y;*M_OH;R6?QO3 X.
MZ)OMD*^"B'[FE?KO_]*4RG\^:Q8)W'AR'0C?$GG>.V//JH3FSF$X):S[!=2B
M:K !V]6)_1)+\F@S-;TMN)] $LLV :B?(;_?>@K,D<H>J@RD.P1@V'VC>O8O
M*S7+6WKO)'\K/W3;;6?,+QI6;5K=F.V(*AI7VHF@=KQ\V?@%C+;.>?RU[#SM
MW@(MZ&KQ6$ \WG7F:G4QJ_M;?1&-;K2A1!!CCFJ!J9+9MT>(U;=Y*C[Z>4!7
M5<>^K& T6PVC,.7+QD7KJD@ 7!=^&83<JKY#692JEF8N9RV7^X(%GQLC]C\W
M"+S"Z,":;?<&#0T'302:^3GG@_5\BUX3EM-VQP8W"!;WP X86EBOLUU3KI\O
MGT]4NCG:7>::;=KA*[60/H.0YJWGX@HL2'_;#C3LA)!= 6^[W6;5^V!L3YUZ
MIJ-W!L^S?V:VHB?ZW)9.WTN;LSY53R;0Z/8=BYB5!80-U*12GMSB;:J?V&WZ
ME\_QX?;'5UFOG 4?>\XI[;@Y_[06_#9<]4N)AO=J$W[WX#4_BI@D6$2)+,T)
M4\$+I+%CR&F/G6/"&S73]T=:KZ551(C$>=#24.*5-)%9:K%D,]U=UD01,E*$
MH0"4WK9?FI>#YB^YA>0H#-+WCH_!&8CY2D7HEW+TJZ/'<N'+ZC@T'Q.EE+OQ
M]:V9_(ECVVSW!N9NZ98(VV6K:5VS5<96'1E-[%TNYGWO)(;C'-S9'=VZ4O->
M_PBO6QW\]#-I0&^J/(EVWF3[49C1:O0U]3]7X*B7W7*>KJ['8\Q6R=ACG GX
MY34/,9NKY6GFR<.T6LUTDYM)CD%[64%8X*K/ZIP+9O OK77*LZN:[%1V:O74
M\J6'ANEPC^@?D;8RAC:J'6+LT5<GT8.DE5E)&+M07RA*/ESK)C_S06AHJ_&X
M12BN:&IUKH=K,#.A?(&AM5T:V&;OH-,>-*+UH I754"IVD-*@EX\@7UP,*]R
M.9A/"\0:/(>J'VUG9-;W=:S85A<PETYUZ%T)]KC(-VP1WM[PJS/S+\>JG39Z
M^)(,SLG[=M^X;.1S;OA6_\'ZOB79UZV^_@X]E/XI>N^B4V)6\.U6;HO=WSE7
ML*I;C=$F-NSW.S;%;)6/3[-7YE)Y9:,5J0;2MU,G;*'1X76>VF!F4T;0\!F.
M)7[T'^$P7^">C7X]P&3^:=;]&]SDANBMLS(0*V7NOA2XCE0E3')ZC92!RF*$
MG=N;1FFS4JG!C%3!"[D195[QSD6_N>WPZ0[[K1?/N:A#7NFA<.6(_.!"\6O?
MDNV6T-$OXV<:Y>M7W<[+QN]=V%\ !BYRMDFUR_S+PKIG[^PFMG\M.C8YPO'M
MXJK7=^@'TI4EZN+JLE! 9]:C,4^_:'@6I.99'%QML$." /4WJ=YM:%>I>UF;
M8FM.+TZY\]@<KWH#P,X[X]@1@86]>N@RYH.69FC:[DW_8*4"OVP(VYO16<_X
MV0^X6YWLWO8#$%-/,"=KY)!>+TZ-[1%Z5D @NUN$_/,6EV,)R9J_>NTP^F3O
MVE[TYFZ31=K XL^(=-[LGW7-R4T9/*G1#4:G4B58T(^CYN=?G17X&$O([XE-
M_]=?8!3'\4,\A^6&^^WVX[G[J2_G;_J+,.8CD(ED0L 8_QO(:XG[_G3^POL;
MN.>1=8PY["UBD8"[ $X"<B$I)+ * 5ZW7O(7KPB=Z718!<O!T;XMJ?=E%6D$
M";VZS">@129N%>4Q*2S)<X-0^Q*YJ)@GQI-7PAK,N2#& MQCJSD!737&+5H;
M,)*7?_?-]IN]3I7TMEG9X\\N43D+]<A8[A2E$G%"#>*<V4R>(1"-B2E-(]>&
MO'C%M_ALN<XP?;RDV85\%M[M$_SFUO&WR@)L@$\N"Z4/>2T'"\K!MX]'B5JN
M-8LH2&L1CQR012J/*--">>6]*,G(6V:61&4H!]FR^>?RV# K#YYJ&RC&,CK"
M \BATE8:D0B/B@GJ:VQX<IG8.ST^TEAQ:;%%-@7 !D((<IE30^BHC)/8D4+I
MM:5O(U(?%XP%@&%.4='*!:$&AB6$ .9S)#5X5X(I)+4$DT-AB<#L,"@ ,A"5
MO(\IY V"W5:D,&^7> !*S*EFP327Y5@&:,5C!&-4:N5A6,Q;2458E/IA12CQ
M_6M:GEU 8#R'1U@*@7.Y+Q.,(&XH6!#,)F24D)$QE5\!FU286ZF0SQ]F1YQ>
MW*Q&(FJX6(TT[!V\/5)".VT".((J)I &AI'&7B%KHU21"6*#!FG06_2.VM/Q
M2$@5&UD:+H[=Q91PR!2Q]$P291(G(NG<WDS*!.BFA)"XAHLG%Y#]@\,C387"
M,6!DP(! '.-\XJ44 B5UD7+E978X*&5SR%\: Z28B)XM@A6SN\?JQ>'!6/$3
MB@+9/=T]XD(*(X5$QED0!6<Y<H&(S!NKL]^G138MJ)G' ]28MVF\["=-E8S"
MDC45+R];U>E<5>75/UQ\XF#7KOW:/+\Z7T&P*]B;GU X]D[?'RGJG#4NH6AI
MMCNS14%"R&?D\&B23DGG4)?&,[$N6+-Y:0ZW%J,_>=G>X"O3M"*+'[4\=3V?
MN+V>;TTJ\^:7B]Y7QC1U4$2I2%A0#IBCN(_867!OH^,Q>,^C#&N3*S%S]C,Z
M5,I%(TW8\EJ]P1%+&%:(E!.<7LG>G G=ANBJ9"&?N=#1\/5ALF@Y+BTG$%N-
MG*LQ?04T?O[2[F0TS?'BG-%5SHNJ2HJE.0DL@WU?^FRG>X#;9"S/O;M9(D8Y
M2]+"'#&=]O%![)YOPSQK$_T69&5[!V='PBA/8E(H$\'D]N@1:9DXHBP$S(-+
M1"C A"TS9]?M6^A+YAXN"U]WZD;CN1,?7[P"M?G)9KR,!@/<&H]I (O-<^R)
M$8"S8$09ZA45+"[,_%-K\"(:?'IX%#VX*BE%I' ^!G2"(D<%;,[&<2VMP3B
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M.4*GVZ\]F*!$SQ,8$4W"S=[DVQ?ZI1CZ.@O?'%XJT_],4O!,5<X7EHVJ:G\
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MB9C::G!Y'G"9<MV49=9X4KJ[&'#=6$+.<XFL,\;@!/L)SN""5=V@:?VU?)G
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MFKLI_.0FQL]0H+-_>1*[=5G.K>SB6@<>%29>8'#/G6'.8*RBDAK6,]1!VK4
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MYH_7*&^U*[+9!@+S*HIDX'N9Z-=QG>T"AZE-6AFCGRY5K#80EC 0WE[_>]I
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M%#;&N+ZQ-29"W3*S3DZ$,V>=AP6>.Y2WXN55"Y*;J.?23RP&[:W"%E")J@[
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MGUU%U3Q0;U0.2@A:*QM+CLV+1?9V?K;X+A2F?[E>\^%$D?3;F\IS9"V)CC3
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M&NRYNW(/9$Z"S*T8.(+EP%VKUTW=2[0J-T?*0TFQ)&,+P+T'SER],<L YLR
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MARBVBL]\#^*$IE6%:!1HJ(K$<5-1&#[YVGI@9X1U!E=,QA7:98Z6FM/D>ZP
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MK19_Y>>\NS";^3[^O5TT6J[DS>P>R;ME6A^M7L^NK+F312B/\#O+JGCV;'5
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M&W],JO/>Q>'V8:N^W6@>GGPY;YR .F\UFO#>8WB/:)Q\I(U+#VI>Q_^Y_$)
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M)4Z(4QRBT$1;PPH?2LFG7Z94V+#*V/ 0C^8%P*'R:%X +J8N<+1C*G*"I+(
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M!CQE4#YEO78,"-GM9?LQ'U4^+P9,NM\$6;6]*^,K'Q6V=0'G5=9"/RA/@O(
M*?^EV,T D BG^Z 7.Z$<\[VKDF<!J]<!).I[L* 'I6B5: %3AN&66YJEY*C
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M+?GC'! H+'WPZP:%W>J;/7_6[@_R$^ ??#:R"W,M-U<9VJZ3=D)ID8/[-#2
MX)"U1X5U,&BV8VD%#P_EPKXO/@0G?+?X6SFN\HO%],=MNF8>76'HAW(24[1Q
M3]J/:>O_RGK(Y_L"7S0=V;\9R;^3PN_9>_Z,OC)Y\S2_1_'<S8#$BC8#>F2H
M<H[0XW-'U8?'RY+1&;Y&.'WGN_**ZR@Q<EIJQ"G6R!+X"1MA>'#$@_2L#)WA
MWV>GIZTK5W$\^'##.1SKZ#3A115]G #=9T/?$/,H?FC'IR4B0(3MW, E(#RX
M"93<T'AN+K[Y^;_FY][C&X8OGBPQ/W9.2K\GLI4]BH9N?M:TU2"L>PA+WW+/
M9)Z^2H^0C;?:C.A;\9<8D(6Q9#.Z-[H,&PL_/7))%[62=RWCDF5SS[2/'I*^
M?9?[/=JK#^5635];DK=V;SG*\#O</SX^^/;QU\&E)W6:V\S6^<&WSZWZMX_@
M:M?/#[<^DGKFBY[*\/O<VMW^!._\=-*X_')YF-O,7AX?'VY_@?%[^/GW'_5]
M^+F]AXL>%1,9?LS%7#AND> :(VZY0%H%@7*?S>"=)42IM4TU^][S*84D*Z(+
M=R:^SM2%AV2Z5KKPJKHPT:^%!\ND%01%817B COD;-*(1(<%L409$9^B"T\P
MV%;H>(59%M7SQ579 L[5U:Q^?6!%5.<L^WT+*8IB#X*5K>%N?8;-^BOVLIE[
M%>)&M *2.8!D9^I0E5110ZU#03$.0)(4@AVDB#ON900L >E8VV3OMTS^Y33N
MOVY%H-7$E0<6XLS$E<?5XE2X\O*X,FF@$&8"51A10B7B/E' %6]02#9%(WQ0
ME&9<F2ZU?#-:/EO^;]?R.:RO.4M])L.HKQED]K9_7$NM[OG< >8G7;:]S\"S
MP!L&S]T@YGD"S^!R/$O@^77CV564NHI2K\Q,B'E(JYNW&D6_3NZ].GOZ90;P
MY%'S>)?_]B5T^?_F#!DN!W_ DPEB'C3E9?2\EB>5]Z]A%MC*Y^Z-_(_ZR8?S
MW:V<<?%GNP'C/-PZ.@?_H]G8WB-%,]=O>[_JVWMX=ZKYZ]Y%?>L#;WS[>E)O
M'^ &O&-WZW?P/W;@&5\NZB=' GP7\%_VQ*S+ FL%QH9$9%2F V :(XT3_-5Q
M:[30W*:44S[E#&:OI8]L/$CCGL#DLIB+D>5 N>?N;;U,*/=D"I1GSEZO4.ZQ
M*#<190F<*LFX0,EXBKB1"AF04B2L4MX;*9TF@'(2+XRDN<*<"G.>!W.>N5RB
MPIQ'8LZ(2:]Q\J7 ')^"#\9XA!U-B%LED#;8H\B52#$2HXOZ<[& ;C<O@CDK
M?ZW]>4:E=]=EKJ&RY"+^*HL]BJ+(3CR_J\)VH9?@2W@GM7S^7[%[N^E+/Q8L
M<;O#C=OI?!QNVZ=N[R:2_7NX71<5E#T(RJ8OOX-(W&,24,H$&O C1M:!#65Y
M=-)%#>9NAC+)-L2R.XG/Q]VY.CENK^+95/K[@OH[X?X(3[%4@B-)F$1<YW"/
M5Q@)XG-9KR.*PA$%O[LCR/-N)'_A]G4E^2\G^6-&^*_ZUMYWG&0"ZX,BZ9T#
MQ]\9I%5.!\WTUC2Y$(5=V]1D!M7I]!71S:R"20ZWEV?PNQ*3NAV<]>!_JSK$
MK1_?+5&$4J&12QZVW,F ;$P!"2ISJJ67CKL'U2&^:$[(_G$N2N^<V58M4\JT
MS]I3W#@E_<V=9%%WE1X6Y>$/S_P@]&;JAUBMS \E-["<NS1O[L=2LJ'X@S(D
M)NK5"2_7\:E9$S,_^DXOMD',Z<)B)^\S8OK6@J:+:D9RYS$\"IUNG<4&O'G_
M/+9^QGHWT]V]$4/N]&1W_P,^N/Q\LKNU\ZO^;0_&> CC/6[O;K5:]3:<SEMU
M4M^'$WDR3[9=%_6MSR>-[3JOGWS\!0;;KT;[(]_=/@#C[\O%X=;7'_5+,-K:
M!^?%#<[?-UV8:+2S06EDDU>(DTB093Z@)(QRE F'I<YLGGH&,]6"HZDO%%"=
M-X5W"7$(=(F][R3]UT>@@VA[^^?="G@>!#P[4\##P'^T.G'$"/@4'/8-&1X\
MLL%;%[G$+.7F=T0]_1KGN5O?/: 7W%)C"W\4MKSAWN&O@BW'O1@K='D0NM2G
MT<5YPD54R*5 $%?!(<? P-&P>]+R8"SC:YM&+,RJJ0R7>\!%5(;+ZX/+I^Y9
MK\*6!V'+WA2V:,F=(,0B801'G">/G*<6816#P%XF'L7:IC++W[/WK1@NLC)<
ME@!;FC\KN^5AV/)E"EORC;\#447&,X5XPA1I11WB+#CO!.:4 ;9(/B,AI+);
M%J]R'PKFX4<C3&6]+ QABIVH8.91,',P!3,DZL Y50A+YQ&7RB!'!<TMG72*
MR3E' &:HPD]O55K9,',HWGXW4Q7<O)!^BDWSM%NW"H[NA:,*@1Z$0'[ZWLE;
MS8/"*.<_@A,5*'(8:R2<\B2JR(1+X$0I,:,?0G7O],**F+4BMW\Z&Q09_7 2
MQ_Z@LHA> 8*^=$:<@3%\_.7AHQ_:^6\5'CT(CXZF\"AXI8U(%ODH(N+!!N0B
MQR@!-)$H*'<BMV_'&Z0RB%Y"[\9?E?E:4?,7.FZ&$#N_5;)]IVS_&-3_F#AK
MDS,L6H^D$&#M4V*092DB3(.URDM5=!\K;- K*7[4V3K,.:13Q^N[S@);P*I4
M1^.,BMJWELW_@@ Q:8P'FFCT$BD&)CAWF<TY*8\(P5H1*BWF9FT3-O'I5QJ+
M5HTG'9UW%Q[<FK)M7K>'SJ=FT6[MJA_.1 ?CTUY.81]<3';&[E]W&[OJT5JV
MG!TU,VZ7Y0XYTSUW5[WJI1RB&ZQ/]%?._S97B^,9H[W1VBPS,$X^(Q7?R;_M
M#^ ?RO:NC^MB5N !L5IP3#AA/G&JG=,R4!VC=(PI*\QWPLS:[9GZ-[MP/7M)
M<+')C>X@U@CY[;FZWH\@=0OV,1/0MKJYV?CRU+C\& )I%T!S[Z)^\OD8OLOK
M] MN[!^='YQD$#W^4=\_P+O[_G)WZP WFA,U+KF>96OGHK$-8]PZNCS<WR.[
M6[_GTBBVNPT >;(G&I< T"=[]#^7>^>-RR\@!S@$I3DB(2>E.1:039F<.C%K
M F415KH\VT#*8OB0^PG /SOF*#6)1*[A>!,%,[!@Q%M,K)JLB?G]2OFF$.>&
MA,_NS7;ORVX.3IJ8N.)>$'!DC%46,RZUIHY(98V-=_=G6(!\_>V/8SAKQ=V4
M)6W)"JE>7LAVMSY^-SII2N%XM8P1Q+VQR"0.AZ\U5# !:QSI'(54KW'TY#W,
M_;HG2Z *^&[V,W;GSIO'<5@%E4_I^^J@BC.>OT+5DS$;TI!'%3VQ#2;TXFEA
MR0;5[%&/O?MW0CWNJ?<.=C[*W\5QV*X$"^J#F&G?S*3Q=%WO@R)3]U *SK#[
MES!$\.\K^QAL7+!V%\:HN)QQDN=F;EVR.,B3R7L6%0?)SD'_+WN13[Y5:<'^
M.%MKR'/ #RX_B,;^#CO<.CQI[-=AC'6VN]7($1,&W^?UDU:[ ;97XV*2Y^#X
MI+[U@]1/PH]&NT[JEWLP%@_OS1$3#[;:T<7NMP.8QQ<VJTI%&Z.C# 1AH<%6
M<P8< D<4F&Y&>$%5THEFAIYUQ>_B.E@2DIZ%P.X"J7V>-I[)H_.-@>N3@]"K
M!:Y/#C(_KE5/!:XO"*X3]$F*&!4)#8CR7*2# T9&>8\4\8EA"5O)2W!E7"\@
M\OQ"4/=VTT!VP;'O3<2 WU@6R-*8>,5:WX2B"FT>@#;3)8&4.6FI88@%+1$@
M#D'&"H8$YSKR&)*3F6P1ST@X6WHS;H$Y)8]$K5OC&*N) TMCC50X\&0<F.2L
MER%(YBTRWGJP.G3FC_81*<6U-D0;:G!F/'EZXNFK9GJ5UL[R&Q5?0-Z[,(C+
M&(:7ROW^67%C[+O]QV;!3T]^27!EMGWQCU<P,,;6/=_J[ Q7_>.OT]CI5RCS
M,)29+A)V6# C%4?Y/B^GU(!O8T) 3ODHC9:*6K V-)\1-/KG0UV:5PC0/.G8
M7U[UG U1#U'/19W[E7HN5CTGC(#(!&,Z6615=(A''!%H*T&1!N85)B&: .II
M9J1[OXIZOMV@PB?;[-5^VM99K-EP<M8?Y&RO&BC9<0Q'<3SEK+A2J^(-BS4'
M6C#D?&NY#RN<@29OQ]>\&Q^N-J,"FP>!S711OXL8:YHD\LYJQ!7X'I;AA (F
M/G$A*6%N;9,2.:-+5A5ZJ$(/+QQZJ"#A&2!APO[@WE,!M@<X!3@@GD)$6L3<
M2 (+34%<87O6-AE=0..\*@HQ=P'^HR\T%G+#_ ZMC_$L] PYV<[[T E_YU*%
M_/,?W;;+/3U&1:[5;>RB(&F:$T0X1@@F#$FF+>(LI[HP"J:*X";90'.Q8'$;
MJS5_BTV+5RG5Y2V#TJO;/Q4HO2(H3<9I) ]84H88RVW4%6?(2)J0Y<G IF*N
MC"I 21BQP:H4D==6TX(I9%1/>)H#F-W.NPC9O,853@:H/\JUKE!H<2@T35:$
M/='*@H]&F0'3*'".C-8)"<DU30PKR7.;\W7!] P0FC]@7,52WNQ]S@U=K=3Q
M8>HX8108@TV4*B!IB4 <&X*T50EYXIVQ"O:%\+7-62FCKZ**;S=J\N\[4T'G
M-+/>"FG,8HNA5IXT9FEB2^.A[$:WXRN#:=$(/<VF%C$X;HE@)$4"A-:,(",$
M1TQ&Z70FL28YEB36&9<S6G"L6"SI]5AL'A=K>MIX'UEV]59@?K%E62L/\TL3
MK:M@_@5@?L(0I\E2&Y1%FF"%N(T&.>\YDICQ9+A/1IHR.J?ET]NX+0OHSD$=
M-IN+:IKWA%_QMVS^C^O]:X(!Z#XFJGN^,]1(GLE03KO]9A[(;[W8@A']C->=
MG__K)KO,<%WQ]5>L@S4\&TQ_96Y$V6^V8[_6B.>US]VV[=R++<43?VL.8/7]
M'%Q96MY<@_$_CZ\:0Y_:HXA<+]H?R.9F K_9UKF]Z*_]Z^9"PRJ/+]QMRS3W
MAMQ!YG0O.=,$F9-S,9I$ K98<T6-5CA$1G!.6'0A\1<F<]KI] >]LX*<[3U3
M.C7V#[Y[8;11S""6XQ"<!(FTH6#O4N>HYUYK%^:D='H^HKG9E$[[XV1-M2$#
MTUD;1@0/Z4^F7XZ3/]48F8O<R:Q61WNI-K1^'-/2G7Q)?$/.V=%^ME4_6AK0
M[_C( 1!E%CR ]T+M1,3\U$ZW;-3*SAD_<LX+YX!Z=$3T(;;*TR"U6+-;O1_P
M/P W)QP@%N'PY4Q&3B0/-&FLJ,"26"ZLY^*6.-=.X].L*X;K,WEGV*;ALQW$
MOS.+:O@K]K)4@1ETY?@@NJ(']LCS:;2_MN!SX.5\^'70/LB,R>V#_?IY_:31
M/K@,)PWZ9^LP']A3G@^,Y]L7.-@]J6]]:L)G?C7:A\?URP\7=0I>%(4YM;^V
M&UL_P//Y.$FI_C-L?^7A_X-GT]9/=]+E]?;>Y>')#CW</S[.+,Z-S+R\_>6\
M<>+I[OZ/7S"/5OU;G=<_:?R=XBB-<1PEI2.X31@CIQ1'/C%)DV0R)0R:M\&F
MF[S]U_ 8#F<QMR6C$[;F4Q,<EC#>\MP<8\L43'ERS/QQ6#+[MO(:2OZPO=X%
M+-'2M1I9$>R8[$VMB)<62\0PM8@GJ9&EDJ((;IU4.%(10?V5  MVU2/C]Y_A
M"PQ[WVT@SQAJ\=]*@>&3@\\/FO**1Y:M2SCXH$@0C'M!C24V6?#350@<I_20
MU(T*#!<%AI,)GHXIZHA!7&.'N'>96S$&9'G06@@CB+X5#!\*30\1_N>'II=.
M EUJ)XA[;*Q55G-+N.)*XQ@9\]0G&KR.M'*"7EUW=^YQ@DZ;N_N??M3I 3N$
ML<-:X-WM [K[[=./@\O?V[O;#9C#%PP_M^I?P0DR'G.G+4:&*8RX<PSI:"-*
MSC@6A!4J@JJP#3RM]_,Y02N>NC@['/. X^]Q*E4=?\^K0A.^  \JVIPHXT0^
M_K0P"(X]BZB2V$EA2/)A;=.8U^86+H1OV2K#[PNTKJ;B/]GN)3P*Q0*X_=QS
MAX--T7D!\I1(-%KXRNY]#<6?L'N%5LY'$Y 6/"*.&4=64(\X8Y%$(<%U(;<H
M_BJHX4OG/"^U<4N%P,%H[[DF'.P51[0CEACG+"<$B\JX?74%K=\7X2>'WSX=
M-[[!YR^_L,/M'3!D/UP<G!0Y4KA^^;5YN/7Q_'#[\_%A"XS;E%,R/*&(>B\0
MY]XC[7)F0,0F@5$&VZ[7-LELXS:>];H@!YUNN]DIVN$MS-I=7N*U)UN[C].Q
MZM![7IV:C'S;F-O7*:1BHHA;G9#1$70#<^.B%4(XNK8IE5Y%<_?9R1B?8NXN
MK^8_\("=UGQ%94Q"$\7!X V)@/X3+Z4GG%LF;&7NOHKF3YB[+A!FI$](DZ#@
M&!3P$Z<61>IA;X)G4KFU3<74T_F.7D4/JV#NF$:&%+R(RD4C+==>&T%--#!3
MY[4-*E;V[JMKZ-Z]P=S#DUP/<)"_<WRX_1$??FO\V-WZ#.OQ!<:=U\#S>OLC
M;1"P=S&SDGH#QWGAS2HBD).2(I\QF8,_JT18V\0;9%9&R]_GS7Z_EGJVXV\W
M>WD5Y)UU^#U.U:K#[WE5:\+L-5J88'%"7L@ WJ#*-."&(!F)B]XH8R4<)%*\
M.JU6%>5=';/7T$@-)S;E-EG!2!.)B2&$HH:$:5F9O:^A^1-F+S.,1!,,4CP9
MQ'U.]1(L("J]Q4P0[U+(#J]Y>GNS*LS[VF8OH'A.MX0_".&*>>,]\RD%;%6,
M(>G*['UU#?UR7Y@7-[8/?S3HP<7AR4=QL/\C_[VUN_\IKPTYH)];]:T=TJ"'
MK8,<YE5&QEP^AV@ S>:9C<82,'M5HA)'I4)4H-YJ@]![,[E%%=:=F</W*)VJ
M3KGGU:%)YE@1\[T&0<K"4<<CC<AB&7,]@\!@C?@@<CT#41O3:K#T]FT5UGT=
M^Q8@5!H=,36,<4Z]9L$(1WPP,4;PHRK[]C4T?\*^M2[B2()'CC"!>"(&6:<T
M<L:!WJ?$HI6@^70!]FT5UGUM^Y8('J*,@DK.N*+1>AE\2!2$( 8>0V7?OKJ&
M'MP7UFWM?CNXS%0Q]?U6NWX"Z_7MS^/=[<_-QN6?QP?[GAY<[OTZ^+;SJY$+
M%2,XJ,(;\%>%5(A+*Y%322&,.281YZBNSH6*ZEG-V^4-XCS9O'V<2E6'W/.J
MT(1YZX.,2KB<H^LLXO ?<M%K)+Q@E!NOHF=KFT+B&11'2V_>5N';US%OL0J6
MP7^**@?FK;8V*)=B\M[)P)2JS-O7T/S)\*TCQ#DB$>$B(DX#1; [X.<:9F&3
MP-2U_#;-7P4]K,*W8QHI52BXL8R2E'O)M=:2A@SQ#!M+767>OKJ&^GO-V\;)
M$9BO7X\/3SS+3(B-_3];NUL[F1TQLQCR^N7>^>'6'CO()6A)&!^8,)G,GR(>
MC43:.8D"*+=F*7"J>,[2E3/#MW>GZ4Y2TKV-J,Z3#=['*5EU[#VO4DT8O,I@
MHHBAB!$5$-?4(6.\1=(E+15W%N?FA)JK5<Q7J.*YKY2OP!3#445-@^>:48U9
M9 I\W!1UM(%6!N]K:/XD&T/PP5.ED74,3D0)FN\"#0@'$C@C,G)LUC8-I3-(
MVU=!#ZMX[GCBO @QA"0D\9@;!FK(I9-813![C,6V,GA?74./[LM7@'E^O,QK
ML;OUX>+@\@/>_?;GC]W]'^S@Y!.LT8_+@V\?BQ3>>D[3!2F)43.-<,HM/F/
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M"WS7[44O"-\WI]*&)+F05)*8RYX;5G;?Z!PPF;0Z.:\B2Q2)E/J@X3V7F%[
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ML68^CW#@$L95Z[4Q*D/FF&*'[)W.RGB77!!U.'@+KS_'<^_@+0_@7"+4E75
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MX>D 43<=_G0 4EJMFQUIN<. [XBA66+PUXQ8[R)1.B?("I,U$9<^'I\.2)G
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M=OKX;OPLDNM"AGC[/)S-DGQR,M@LO"5)*TH 39\@=Q!$4YU,QE1>^E!+/BV
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MY>,T_-7U3MW9:.F7Z_$.@]W5&W?;;9JYD>CC__CA+Q]GG<SLJ9T.;8%IL"$
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MSC?H4QU/:#7;S4Y.J-@:52"K4,I=WOH<C*73K3J;]^'VO2H /<@5%:K:62-
MR]'I\X$=#_+MGW\-T1# -0ZND7 $>_G(3K[E>7]X4B%#,0SNNL?X-/#"E_OQ
M'MA=[-C/4I.-=7V3C?EJDHUW.B )\<!^K6-^\9=Q-CS<8Y?OO@E-0(2KHS>
M(.VWXO"@U=RE.U> */F>>/_3A^;>)**<A&- FXL]N@/WVSO=O7I_"=\[WO\$
MWSO9 T3)XW\OCM[M4$ 4L/C>?L8@,9%+#F37Y'Y7$4SW) T"4<+*)&]L"),)
MQD"+N5<R"&!0W%AM,(V:2B8HYE2 @3B18#R<]@;,>YPJ4_: Q.+O/^[N\+03
MED3!25*Y[XS0A$L@\@%8B5)>VNN][\G%[,]NJ^DO7[*(P4;Y6<6<79?]WDD
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M@H+=NU"0;0NN/$6>)X,X<0$Y;26* !'$1*Z)R2>;&5_(U"A0L,Y04(<,JP(
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M8O&P3G&@S.E R0=TBJMD5>=O\FP7/)D/3Z9;0!+M4B*:(16P1]S*A$P2$LG
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M'%Z!G4 _G.X=O+\X.MGANQ2>>W5TLGMP2(_:?[?V3MZS63D!C@E- H\(3-&
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M>R>OKW;?[>!9?1V\,\R:P)!(.:=?*H.,5@HY8.62".M-H ".FT*0&2?WURS
M6C<7?JE1_G)@=F$7N[=6)%!+%7WD'$QP)8WDT@7K@U219YA]B&>]P.PJ8':R
M-WPPU!KED!:YR+@P%%G#X _,N75.:1)TAME<=&&Z?4X!O0)Z+Q/T*)$D.>\)
MD!1N$[.$*RF\ESXJ)4+5S9KH GJU +VIS@HN.I'QSN-<$LJ1A#3!$@EL/0N
M?$S;#'J8\?4!O6?=6:$*>?4;.;(8&J"952/Z422LWYCH*SYN6G\9[<LX>_DC
MTXOO ;"=CL^MW&/_0^R?MW*,ZK=>M_WK<&7^A-?LYD__.5[" FES0=K.=$5*
M(F-0&B.)<]*$-P(9G C2C#HEJ)2>Q(UM1O",]EJU-Y;+<;*ZT9^E)[46&/DQ
M,#)9+--@KW+U>RH#1EP2BQRL'?*PK+!O6.^U!V9$Q>*\J"AUW91ZZ;F21:E_
MB%)/FCLA$">L(8@9 TJ=(D9@LTID5 C)&**XIQO;1,]J:?'CE/KYGAZ]L6?
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M4X($]\D%GVOX(["PVC.%A=O#PNWI&%I8>.,LW'22X#Q5/ _VM89[Q*F0R.)
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M>Z05^[^?V]DY3W)0V>ZCWC#T?.>7F:G^*^S'>/+D.L2UUK3Z\H#R@/* K7_
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MX3G$W2H/L$#<'2"NV0&=R< L#8@IFA"G+B%M3$"")1T3=DD+!Q!'Q4.<SUX
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M\PQ$: 1,.(5-GXRF.<\&CGE.EB=V]*$WJ*B+5S)P([A*,ZX>'<=.&O;[PR]
MQ)U1A$,>YYS #AQZQ];$ !^?]XOM#3K#3 ] @@L$ 1]GBNC\DJO#?\WIA-7U
M9]&.QITX"'#AL^CCB8NCVK_'R&XG$^,-(^5'O9,X[G3CE\ZKX8D=W.W5=SL;
MC=-7S\R:_6['#D(G2YXGYS!5\?QJBB"U6E2APSF.U7 $:^W;TW%\,O_+;_-<
MKMZ@>G9UT6^SF\W 39PNH5&%5O77OWWIA<EQ%KI[N/;8S[+ 9D^>?;U7?=5
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MVVCSE"23UMD\:PB(W"+)I #,!@&FX5,A7-.82$"*^5PDQQ(R0 !(16=(3%J
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MC?.C!VL;-FSHX5,PMQ.8N./YT=3D -_$#\-1A8(O!N?6_/D!VODOSD <=J9
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M=E+O:R4;LB]_-]<"G@Q#]07<[+QS(AS/)\"@DV&&9WO:"_UJ_?TX'N<'U?&
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M#57;;NK>.UY'+K64,3,6G8C*$YNZ&$3*K$%#C$5JXE^!E6=E]-UC&'KFN??
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M]\PY(^V'I03F)(N05K=*=FQT!6@_'("G=DW1YCVMX='Y9@_XAJ+SLMJDF71
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M,ZAUZWU+.'X\#E_-"7T$@16;AM&N@QIP(E==I ;MG>H!,_N+8Y=#U<I7DMH
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M<H*3LV$KYI;1XN<S*E-^9W*,+VAR.E]-$M'I),]PN9S6Z9"@=FCZVO..I[3
M13Z^.+S:Q,-V:!N]T=KT]!R'G?Z6#;*UY7\W$0]S^F0^8;N>6D.3U8(;JK18
M\CA7+]M0_T8O:#91#S:_Z <3GK;U[V8RS_E\T6:\G"\N)_F"<#$AWLIE\I R
MG22><,/?;Q1].'G*GVBS^V*ZNKB<N\O6KB_J>S8X><DKUI;E<@2C.;\YPQN&
M:*"[-N?N=Y[S1Z>M^SR9+VG89'DU6<W7*8ZGZ7S%<W1VMIC_/&W#FEU,_G +
M81FCL5H&28@.4D"T-F$"EI08I=7KD$]U0UBZ=PO+KX>.4OGS^8IA]O7)V6Q^
M08NO+CO-_5H^X6[\>=K$YP^\:OOM,_KW_QW+?/+/4_Q7//_FIT?RFX=/9D]^
M^N?)DZ>SZ9.?OIO^\/1/QX^?9OOXY+OC'Y[^[^R'D^_-$_WOZ?_]\O7%XZ>/
M7O[(>DS*F66C"VR%@ 0IDHM:%(FIL+YC2KM& 3<MD0GOPUG;!KQGYN<+7L9A
MJ1BSPUHQQYTNV]MGO&C+]J$E$\ZR7O#W3J<GYR=#O;H&KT7CO@6M(<=K=86W
MP\F_:%+F [0&B)^N>!N^VJDG^)Q>L4;A%5]0ZQHN+E[MXK8A&L;;3K\-%VZ0
M JWNWTW9]'):5L>7.N2U;VV +5]]!1.+>0;3C:^\-]*?3D]H.7E"+R??S4_P
M])V8'UK\8KIB69E?8P'_1A;@'HVFY=K/-K0!%PJ#!:E F5Q!AY2"*SH0N62,
M1QM_5!8.+K]UO+@<UAD^(Y$6A,\%5EZH+W#V$B^6!__].BLR 5[.MUZ76GS;
M!+]11!W]3UIPBV\8Q5NIU_U>U/OF27\R9WI5[HO)AE.?G)]P0_EU$M6Z4*!:
MBR()WA!&GFY-J<:*4&KY\6$C4<E_Q"LV?9T_OYJ?G$S7TNS+T_+5L-F?T6F>
MTO(AXV4V;[K*4W[BGV;S_/S>.?#OEQRHGCS]WOSPRY].'C/O/7GXF*V&QH'M
M^U^:Q[]\QSSX3W[6WR]^N!ASX/?\W?+3X[_\\#/SGN3/SAXS!S[AOCY^F']Y
M\I?OCO_]KT>_/'GXOS^UM&Z/N1\_:I*J%FN%9Z-. ,^Z")2&((^BO,HJU[@6
M<$P55+YLLB0B:JVE3%$1:.0UB1 ,,&OJY"R$@PFQ:#GCM5@MSEE3?6WN+\ET
ML^RCK3NBI?6BO/MYK_</8RZ82P(,!#R"EO8KLRC6RCOC*;X55K^W%L(<WQ1A
MUKOFLQ=K7?8%+J;S\^5DAB^7YZP=/VBZ[O2$_WTV9U/@M.WGC:(V?89KBL?3
M,IFWBZV3&3UC<<":2R9J N9*.9\NZ5+;8T-LNI$3YXOE4/ A-16=ELM!/>27
MUH]LBN;UIC*>7G;UJINKBS,F:&[B#-E,(>[F]#3/S@?A]JK#;13SDS.64*OY
MHOWG?,E$1.W7Y?G9V6RZ_I46+Z:9VC-?3,OP$M,XBU)J[=):W6F_SC<6Q/%\
MMOX8GLSY><,47(V!A>.JZ=$G>''5ZS,6F,/TU:;<#F*7O\Q;9ZAXT7K LG:Z
M'L<9;T[^$+_(2M)ZCGFG/*>VDR\ME*%?IR^FB_DP3)P-X^2!Y>GZ]W7%C'->
MD\&"O1I1:V.>9I<K^&!R3#A;'0]/66(EULTW_1]:63:L3.H"S\OE1 S[X.HS
M/&7EG#6#V133=-94^];2]=H=O!0LC]XP5:R##%*ZH:W5_GAM\N8LN$Y9O6'[
M8'[&_^56V#Z;M2;8CIO.R_ 5%M+#\];JR693MMV2CY&G>6W4\6/.9ZOV^5,6
MYZPO#9OJP61Q/EO_PAHW3\*PZY:T6LV&Y>&MN\#-4G%___:V_4V3)5O';!'R
M8U>309'BUUFY3VPM<_?;9I\U!8W7Y\9GK_2HUDYA[F+M:=#F9O.7AY-W&33W
M1!R7 VN0O@E[QOK+XVD^;E/01M5$8VD+P:HJFW+8],WV^LOIZGA^SCN)^[$:
M%G'SA?7GVC[%9VSP+U?M02>3%]-G\P4#?W9Q.'G$2%H;?ZSQ+:=I1DTS+<23
MR5K-NF>\SMPS?L(P[^/]]>#RB;P2K1U6EI:LPZ:FZC*_M7496CG!GP>U^6S>
M\#M=.P8&^3W9Z,S#)AEXZ+(K+-^'::"?&:8#1?'6/Q_&G3.+I3+HVWAZ<:-7
M?YP<SU_RU"X>7-] PX9:W< +SF;,83S1EY!YR:;!,"F#QP*O;:["3?)36*MI
M2GS[.IL.#=W-%\:?*L-LG3;NF%SJT&U\LRD;"85!_8")>K79R9MQ7G#_KGD/
MYC?;7.-NF( Y8Q:OK()AZ*?-&Y#;O$RO,/U.$_X^=OS]*8O?\E3FBT]9462C
MW#SYY?G/3WYY]//CA]__:$TK<%2-<%)G :I8$6R1PMAD;09=P>BQ3J8J:7"V
MND@%JAD*)A69 [9L1CK7L<[XM^FE?K/&*TN&D:R]$G:#N&Y$LD;G;-CVE_QQ
M70HN:"T'TR#0%^V%.AL\*@V-.'FV:)R1<,FTQE1YK?VA>1P.)QXT1#4YQ[;P
MC"'Y)APGG T/7!X3-;'U+V;9RZ\UD+:.WA39&ZWKE;G?'KAH[5U2\/ERH*0U
MLUQCL=:!5P.^Y,;EY:-XZS91RK]>#,-F._"X/3^UF1B&=H-XVQO-U3S,3&N#
M=:;!E30LR N<SG##]^?+P5>Q[L[0F[SQ$;]UA*PBKKV6C<X:5=;IC/_W>F_7
M4F%P8)VW)1U4B$TOZ95X6)/WM"W <K7NRG71L5R[]UB'7&[&PWH=TQC34AO9
M\905T<7@:M[TK7UZ,:6V>FUB>#W;<Y_AHJSUOO60SI>L3%VJ(X.H;%ISZ\%&
M"5H/)]&KL?*$\!XYI;7_L,G=U]20FY,U"+!\G8F&Q;M<]Y?'K)F]WTH>_KK-
MM3L$?]/T>R=M'/V),IXO+S<"T_IJ4 M8$V 3X00SG:^/$C83W"R406]YI;-L
M-,77-<3S]-,&K#.>$V[WO/F]UWI$*8-L?M7H2.^^Y*"K[;Y6A0:O[>'DX?F
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MXTQ+IL&\8VSG =47@D!5(UUYIR6!-AJ"3W(\M+FH>1;KZJZJ!*,B%*W5BAW
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MK\[]U%T2=?W8_X5M./7OSBZ0M::(O55,>K<$[5')@7RHXAFPO_-W[C@V]4B
M6\W^S)^M56[1$J%5QW7^A7.$9'?UQ.VN'W'0K7/)1^17.YD "CW*4[S.%B4[
MEX;?Y>5=B4B6.&4=DBS<-'%V;+?#P:M?>9QN<3#N;;Y_O?/5?J]WTFXS!@!'
ML4'8>9PUB\/:63%UG=GY0M15'[NMBB?PK>))\>MG$QOBHJD5K9.XPEE<<1O-
M$Z\U,I<B^%S^?V$>MIOQV.O(8 G$KH]C+6J8%]7*K:#P;IFP]1[,].-91:.\
MY*8>U>T_3>UUI6&F39GRHLBA+E=NQ:4/,W.-'^8>KRVMP^D4N#VJ>P+WAW"7
MW<%3N#LX7%>&M1?/"I3]ZY'-VG?R[E\UCK42+ID'9%(*1A8:>[X[Z]+T\->8
M^^9#3>=53:^X]+&9TP4\+ 33\%SC]W-2U+KG;DF 5C)+^9.5K=%.'%QR3,W:
MRCZ_4IU>7Z49$Y;/9S=1N#R79^4%6UG -3NU8I54DW@N4^M2<AVP:$V?8L.C
M.(GSGKN*7?!X6/GAK2%MG57YS"ML:V]C1V;V<\\G_/_)R? "8_'>TL=^N7]E
MF<HCNG*#T[]6I&NWE:7Z5Q&O!OQ_'1Z'!BAWEQ[XT9O<#)/K(CH&5<M^7D7S
MJTK;7,@^E":I^A1]:8%;3+I<V:Y?UERF5 64,SPW[)LFM15AW;:Y4QL792Q7
MNKZH)^AL2='KI:=H-9-_IHO)1?/Y9OE%F@E6*V.R*N&<ML[N\B"N4%JR6Y?]
MVT[?P/[.L@SD6^S'CT,_WJT+#^%];1B??YON\*VF,+(8)O4@KG4V154PTESE
MO)E?V8=='.[=UK,.'N\] JOT$1P+\.O+V(]:M6=/YH,=-GYJ?)_'DA2(7[!M
M#H^K8/BPF:5YI3?X.S:4O?6F%7;7R?AU+FH?UGNP;@;5XJDO@-=)?&TGI:,@
MW[W-T])0YX!DHFR@EF[QZN$R:,99NP,USW#)[UTHRJK!J+8B_5EFEEW5X?MP
M"3@UQVM&L0U'2SIXL"CBJ=H1%NU3<_*#BENFKETME;1S5IG:V2CS3N>LHZN6
M^_QY'C7P_?O"&"_5L/N/?F_&9+=C&!<3,"SZ9//7*R+8V&:!R[N=QYU4HS$[
MCU[NE6V8:3T1I?G"K##L+='3'"ZW5BR91R5"^,.TU7>V=)_=^0(VEET54LR?
MR@2I%\[<JX6MN<5B8?**KUV2*K(T;7I:MM)L69HYF'GUF/FIEO#E.?#$+"3O
MU_'IM$CTGS'')ZJQWN_SJ-H<.1J"SBL<5<\SM4:^5]G?/_-8U:/Y,<H&?)Q4
MDVM:.)(_Z?(X@ASVR*;C)*S,D&RP)5,R=^ $=O@HVP?UJ-4RI7D-Q-1OV,+O
M%S%3% Z>EG$ZL?4>3<"T_L#2"S:#,9_ O>L*SD)75@G/[_%XNF@4F=.#K]Z[
M6LZE*S\!B'A]5FN/LE M2NW\TZ/A<?67HQ)]FN[5>W=8^,+F]YA64Z'::%PM
MS3G+OX#+@B8_3-< ]LITW@O7#_8N][ 7[N%8^GJK9O.%#*9A$8\YQ?8J'56;
MV(5<^P2N7T> E)Q3G#]N:[_R4U?CL!?/VFS><++\O-.*BZL]2KP]Q&G-D=U6
M6%@[3A% NE8DTY7.NV'':)PN&XW#QFC<MH3K'2 %4W<W$[M%F=4;:P[\$TY_
M294]&N<ZSNIU#Z-_<PR/^+KTS93$R#9*=JLI@,@RZ/7"8=.M&$1EK[JSP65?
M_]Z?CP[O;]HR5M>Y[PW@RX5_I-/-D[^3#[DOF:F&..S\P,/XN.B QD6IK(B:
MUC,W!TVKG[2H5!:$%'.C8@'@->=$N79-.[$W^#G7438<*U7P8AVK2OE2PTS5
ML'75+"RS\?A=KFTIJ?K%V(_:K5AES>K0^J_<:MYN7&NL$O_/=&1%:<+2PJ^:
M]ZS,I/9;KC*TU2/=P70:GX'1<]9YZ>ILM"EE%F&_VC*JB:]A?8LD 33M#7Z?
M.RK-]I[8LS)K8-'NTNZ/&::J+3SS1-?#6ZIY@/,Y*+OU8!97J)UC8;')4=)"
MGS*>M8BF,[4.'#0'?\QJZRC?=F_PL"93*]6E.;2:OU15<,?9I317@3UBM>"8
M<,)\XE0[IV6@.D;I&%-6F%=$9NB["!C,%P.&]5KF /9B0-2/2[,+#[*'./3+
M%7>4AJAC2@&0G2L6K8'WHM$EDRP/*=05=Z2NN*MX)Y:))L!* [OM3;:0W\=G
MF1PPYOL?PCU^'HW]N]NNH'O[L*F@$R^/_GSSS^-_AL]_^<^;_4_/\/[1$_[\
M\,_1/[_\\?'EV[_$/V_?X>=_PW\?=2OH1L-_?GGZ[N H7__)IWUX1G@&<?#+
M?][]\_CI\.!P=/3\\ _QS^'HW?]^RM=\]RI8C3G\@T3P 7'I/#(\)D28"L$2
M[ 4GW=JE8$'%>L>PI)9'[8S3Q'!!G:9"8L-VX'A[>Y(-G,DI**_GQ?Y?VH!!
MM0.#>YG_XWY3CU?O?4?7K]7RGW^&Y6?V%HX/8<DPY[B+PC)+G?)<D:@TC6'G
MP1<^?R]J5JOGZ:'W&<:S9B@KL^9DYE4YS/#P71_/Q\]>>9RIOFE 42F#.&PU
M<D)()(-+V)%(N;?=K5;1,B:,-\%@[JC5P2GX-O'48VJPZ![/+3&3<J@GC><3
MK8I.:AS76&>I,MU)=AU;AD6Q2W)H"#RBBCQJ[FZWQ&U8B]LHB]N/E[$2"2_O
M7S]'X^+DD1,(UF%D3Z;QQ^8//V5=/;)G/PZ/RWN5+_U47ZSVB[+97\I;O!W5
M/D^Q=ZM?UQZ!,7N:B^P4S";P3VAN7/L+>\5?^-<LK/Z.JCW&]+F_QGODW-]=
M=%F"]R275[KLQ;\3BM[XPYH]*L0=>59"]A2]VGY]_8?5>Y*I._*L9H^3\W^[
M7<\*AX#3RTG7OPH@5*  L)/QZ__; 2T_CT2$[$;\B >DP%9SO?E'*5GY+#WY
MF#_]4RL*XV/.!'5QJH*HFU$&ZG.6,:XJVXI"RXJ@[ED"SV:.VMUWVV 9;N6C
ME]R[-?LQBFE%:WS]W;CW\"C7*TP'=> 7%.]QK,8:V8\QFZ^?W9A:<Q;%>C(;
ME.Z10?.X=^! /AU/X*_'@T?%F?5G@\,)7*P>__Q+SCE53ERQYV]P22YQY.[Z
MTOYUG$=^P>=STGM6+>:@6<=!,\3]135,KET!T2_MYY;V<4S#G"?XN4S"G#7Y
ML3HUDSGO8[6Z=2/]_',C>RFX[=>Y6N<G*55,C(/?%Y/0'MGIFVIUGX)/,_@U
MAM>7.KQ7T#9;O#2/A].Y=_K%=?D6KT,KZ#%8%P_*>+>T*)\Q&C+W<Z;-. ZH
M?NZ@\_]^NJHL76AJ;-(D>;U00%FLGW/AXW&V_IP=E>RVG<TSX&7^.#$W6-$O
M]\0E'FM-*C0O,F)[:UQ[9Z>QRES=(_<[,>QE4__Z&XD'MV Y7G(G_[LKZ#?W
MUC]UL\=;\+KWSNVC/YV&3A<]]=I1K4WT,G(CF5,TNF!%]"QB2F6FD":Z2R&-
M!$  O!W\:27".AO[=V_&(UB_Z9/_=SJ<G3UKTDNU6GHXJV8CE,CJ^""/"#J>
M3<9Y'L/K9QDGXW1V1V;?7C$>^_+O?T__.1R+_4__O/OG[3X]^/2:'_P"S_CV
M#_P\/^=CS_;_?O+I'WB&_<=_T/T7]7?^]]]OW%$8/7_[[M/!T9]'^Y]>LN>/
M7^.7AW^<'3S^0\"5WAU\\O .!^_V#_<_'#Q^^?%_/SV;[;_ 'W\[?#*#SW]X
M?OCZE39!1,L=LE)AQ#T7R'$?D=&44I6)Q!W>>4!VA31[:J5-?\6MN$EE,-A0
MJBZRYZ[U/%V%WP/E]PV4"C,0&V)U\)$SQ9PU2N$L+50$R?FM 66/A9MAX=DR
M%K*@)9P&@Z0@@(6PI<AJ(9$2U#+B8'-='F)+]T@/A#T0]D X5#%%DHBF+BGN
M%3?.A\ABQ$Q8#:9D;S%^ RAYT+$8E0L4*\&08#&/^C8:@:? 41ZPSB3E01JV
M\X#M:D%[B[$'RAXHLVM-DL+))\% 4J+USM*0DF8Z,*QQ8KW%>$>PL&,Q6IM4
M8BPB[:D#+$P*F10PPE(&YHC65'FP&)G>,ST2]DC8(^%0$!^4XXIY2WCP2JM<
MO<F%$XKCI%V/A'<#"9]WK,*@HC31.R23H(@3*I&1G",JH[56TJ!(W'D@Y)[N
M@; 'PAX(AP%S):+@WFG#X=\NR036(+',J,Q=W/O.WP!*[F>$+$BY3_<?O^.O
M<(J$<ND19R+"OP)!-@B%8J Q)<Z)-@%@<A>4X1Z] TCYF:* I@P=7B)>#*[]
M)^_F)S>N"DGE_]8>/E7U(F^?&GO^N0:.@<N\ H5'(P]S&::A_TQ9$=ULB=8J
M^;NH]GS2P1GJ7+"!$Z%-!*_98$.P\88SFANWB*D;MXC90/]=U+KU<]F>/[N[
M<Q!GS].A_=CKM8WTVA\K502<@3JC3J+(HT3<!X.T2@)AB0G/*=(D[<X#+J^E
MTRY CB]EX'=N>7XSPS<DS1L(LW-.&G#\A'>!&QJMEI9C8Z(5E+*D+R',O0S?
MF@QW8IG*,FZB,8@+Q4&&O4+&6XRD]=Q@%ZW$>.<!71?*7*8M[P5Y.P1Y$[4<
M8;N5-TH;[SDWVA"MP%$!P78A4(%[M7P71+J;JO782$&L1UHXD.ODP=OTTB"K
MM5"> '8[NO/ 2+4G>[V\[>*\@31;SC6QF88A6&XL=SQPSYVS!LRTI"\CS;T0
MWYH0=_1RSB]2;@02.5 $V.R039JCZ(@P ANL;:[0Y7NBU\MW0I WTLN8T^"5
M]4(X[KPU8*2!- M%:1*@J7N]?!=$NILL$Y(J3(5&@I*$.(D*::X#4E0HAS6-
M+!HPM57O+G];TDRXX#A9;G$*/)JDE:8V46*"X#'HR_C+O33?NC2O)'54#$(J
M89&E6B(N54!&:X,2==KI$!+% <QLLS5F]E5;.>]4T#[W[MO"$]$*RV=:QDS;
M:UO=K^OHF4;=[M?+PM>:E?IFX.L&8O?+J-7%I*>P-9<@8ZLX+V:_PQN/0P]C
M5X*QOU8[ 2,AW#*!0C0:@9X2R$H2$!8$2TJ\\8'L/) WTOUR"T4ZUS)*OF6I
MOO$@?B_5MRG5G>@!QA0LD  G&1.*>- 6.<(E\DQ9+03FTKB=!^0FZI-[H=Z:
M ."7"^?WPGV+PMV-[VN=;##$(A,(!\?#2F2QI8C(8**6/'"5A5N3-8U8&\8&
M>QG?-AF_@2!_+^-;*.,=!1X"HU@HBP0 .N(T.*0Q<R@F;@E5TC).0<;I]</_
MO8AOFXA_N>A_+^*W*.(KO3-!$A>41ECCW%'-&-**:01[SEF2(2K/=QYHOH=[
M$?_61/S+I01Z$;]--WPE1\"4UD(+Q)A+8*HGB[0Q"0D?@Q34@UZ/.P\HX6MR
M?K<GY-]%=7].%'QV1,-U"OFOU\JW+:"V_57^/5I=":U>KJ0"6!("LQ21U$GF
M>F")+',,4=B[:#!34H0\DU#OL>LG-+>FFW>3Y[E.:<.W 0?;VB;0@\!50: 3
M>' X1A9]1*$4#RNCD!,X%RE%. %<>5FX3=3UO9(>".XR$&Q_FT$/"5>$A&Z^
M06K-D[ 2^40U.#$B(LTH0=H23:5VL+'@Q"@MKI5.[.'@+L/!MK8I]"!P51#H
MLN1B(KWE%%&:.<^HTT@;QI#"UI@@L-.2]'9!#P1?-\_1 \$7!X)NVL((8CS6
M'HE(,I>-) BP7"&<=-(1LQ"5/(?RJP>"[P@(MK]#HH>$J\8,NFD.9H3VSD2D
ME/'@(7B.C)88L9BG>AL1@\?90V![_ YX"#V[U7?^R?X ?.>?[ _ =_[)&VJ5
MV\*T]\^+28:/HX]'+DX&K#/+\"I5.M^?T9J'Y$D1*?<\<LRPT\Q&#6ZLT EC
MG0J5ZR:V:D_ENFVF[I,/OW5-71\B-X; \>>8(ZX<1D;1@)S-$QZT3UKP/#E/
M*KTF%+9]5*Y?@_3Z^\.1#6#$Z$ 4P3[&7&>AG>/$\$0CHY@QJ\SY,-(SXF\%
M0.PO X01^1Q3AR2+%G%M,=*,:Z2$HI)SZ2*E.P_X]?GT>H2XRPBQT< USJ@E
MC%B<'#<I:0.+8WF@#"<MI>\MC6\"2/[J!-6PE800B;R/ G$G+'(^*I24<LXR
M$QG+0+(KF;X6PTB/(]\+CAB, 24L"Q$KGI(Q05I.63+:2A?X[>%(#Q4;0H5?
MA@HB&=$R6.1!02#NDT):9:B0.9U" ],LY#:#&VGX[X'B3@+%1NFX7-(5%*72
M<$^T9<E3A:7CWFJ:R-=V2=IF1AI^C %]BI-Q#QL;P\:[9=B(B8*/(@V*@6,$
M3B<#"T,*Y(@07D;EB<,[X)9H2NA/O;OR/:/'1ME\R8G& !W6*JZ\,B0I&H-U
MAME(ZAE7O;MRU\'DR<<Z./H)GED\?_B*,">E-!01L#L0#U@CX[E"03H+OJI4
M,;"=!W)74'8G')8^"_B=?[(_ -_Y)[^+1NA^S-E-^4T^%\'Y1 R5E/-,ZATT
MQY318$C 0N4R1HKK,D:P@?H!#-MCT'Q:R?1REZ@)P2!#G4(\.H9LC [1E"N?
MX1_#U<X#*G _@N';$V49(T@Q-D&XP)6@1AO*B:,V8D8=<;TH;[4H=W*R(0@"
MJ&P0,9:!9^((,D11)$S2(@2IK0!1OKF6A5Z0MR<:X8AGQC@KC8P\$F\(B\Y)
MKP)G.')\"4GNIR]L@4AWLJ/>PRYRY1&U!H-VQAY93#UR27)O*0BV%#L/F#)K
M2%#[:2IW6)ZMY4HI1JC3DCN%-<7,*09_5)SE8HA>GN^$/'=2F(P)*4(>/* H
M6-LX*.0LMHAYZ0V-RCJ2R8<86Z.D>WG>,GG>Q- F,41FL%7,<T>2E2HF(4'$
MD_/8I:]K:/>9QAN2[G?=JNF@K?4*X6@EXEH)I$D22*1<C<*$IH;?6*:Q%_*M
M4]K&<TN$5TI@P<$2M\R"1<Z,Y)1Y2W2OM.^&6*_D_)S1EL6@D>>Y2)%JCHQP
M$AQM%5(BF"8O<I!,;LM0PWX(6C\$;0LB^S=+T]R;+3>!;W@E!: )CLXPC2(K
M*0!%D0/O,P<91 PN<4W]31=(]2SM6R/U-Y $Z%G:MU',][N=%E@$13 2 ;:2
M^RB1-80@P@/QD5I*/=EYP-:,0.Q%_(Z+^)?+#O0B?JLBWDD72$<39H8@'YG/
MPU8PLM0SA!D))E BA<D=$E*MX3;OA?R."_F72QGT0GZK0M[)(4AF%1=@J9/
MP%RWBB!-4T0J6(NE28)PG7,(_42E;T_&;SR/T'OH6RGRG<2"Y))'Z2R2BD;$
MI0E@NGN#'-;2L-QX8G3OH7^S4O_E\@J]9K_=0%PWT2 LQE%SBUQ@ GQTCI&6
MRJ'DM/=@O!L;,1CP:RE&^TEJ_22UVU^F;6TDZ%'J:BA%5M(%+BA#)&,H@@V*
M.+4.N93 '1$2ZV0B,=[>;,? UG13]]SHVYN#Z*'@*T!!)Z5@"5;**H^$<1AQ
M+2PREB9D <(!(P@.%/P2<WT6N!X([C(0;'\C0P\)5X:$3@HBAZ:24A')I!E
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M-A3(2.SA3X(:F4>;"[/S@.X2J>YPM6&/3=\\-GW-MJW>0+DR_'024BHQX62
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MF8**>S"^)!AW"G<(DU''3.\GO$*<XSS 4"E$98@L19VB%7>X<*?7 KT6Z+7
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M[[KZ\HVM\>KH\Y^CX_/C,:[S9'\$_X4U_+S$1H7FT;>#?PUK.!@8YE#U=<-
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MY"YZS*-W@>Y=SB)#$B6YA4]RM8\[N)9= UR(5UP%(P+"VJ-TBJ^8$:YAX,=
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M2TSV<BP5HI6SP_R[_H@E+N3\OTW-$'I##WYA*@EW@8EU_:* ]B^,LR5I %C
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M5T57/!/9F%<D2;!*3-0$X%?2;<XXM?O-N:IM>VHQ<Y#QJ$;?6>85F!^,+P!
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MJ_IO/5>SS754AXF[NSB[RUN]WH72S*_E1PN"@O_ $FWXCT6Z+?^U2+FYK=L
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MX>T,2,C)F%2L_V(L[[ #0JZ@K'R0"E:@.H5>&+!/K8S'A]? /3E5;T$4M&8
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MM JQ3EA6IW!PJZ 36TM#ON!1#XH@I7=@(N#= ^:7JGM#9P_V8OQ[5J=P7*N
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M:WTXW'0<ZAI_%?1BJZ_7+9X QV.D992BTEB+;[M[:T^P50S$$^.9=58X&Y0
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M5*%\.)[3*F=S^C\(?X> 5*OK[@QW-WX<JOMO9OT,%HOH ;XRI]<',<QE)36
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MNCLH%M9 C)O%TL,K"%7OKE27UT 8VSR/L]S@DF-U^>5")6(-Q+PAU/R,7B5
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M)40:B/4 (Y(>>$J"&DI*ZB  ?N:-H?O<RY(G*&2!&DK$?ZF8/YY2*0.Z)UR
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M8_/)\\4*=<2[.(/5V23,/_SRY1/,5[!Z-B^OUR>P1#4RB:9(0:XEQA81G3T
M'"<'9G)T7F9(Z'L^D&'8X74[JF[V7XHTO<363-?CBR_G;*(J%\Y[RZQ5"7$0
MFTT.C#MPM2KM2ZQ=%- U&/WM%WYC=DHIV3>+Y4#5]7HY3:?KF&;P?G&'_+.S
M"2-WQ3"24N0$6I9XS2Q&<*"J#H:71S)=^XQG3+I^?Q;N[MEWE_VC!  3[V+)
M%EW# LIO0I1@'<;ZX&544J6JU:/[_&-R\WMQKJ&<CNC1[[4JE!(RQRQ9\4DS
M+35Y0#A].4GAG /C'RTE?;A&'%?<E)6*57'/<*91 0EAF#>E,AZ-1$=4.*N.
M$=)WC)O&'FUT7R&[F[+CT*FQ%D*@9][OSS"'.D7'5U:0E%U+$ S31:#N58*,
MJW;5Z!",CAVY_0V@)Q;1/!(Q#Y/C40/BHI1U/&<F=2AH<PW:W(0VUQ?O4@%?
M=+IAI]H%Q+LOD\UK?ETL"CWU'2P_3S.LWBUF98+> C<"70:CD-"ZZ,IB29DY
M'VTR-GGT*;JLE+LQC4&)]^+"3>(WDDPSA?H65H"/.4$P+^ SS!:?J$CC;-03
MKGAQMFJ&BQ)U?(V5><D-,[GZJ(U0V?11J_?"&D,(<"R^M)-/,\J\@\$._(HJ
M>QEG".Q9^3B=3U=KFH'/<(%-<F5\Y4Q'[AB"<2QZ\A1J3DIESXOMPYWM\&U#
M(O6=D*B#Q)H8WV?Y/TZG2RBOYF^6"U2#J]O9/BDB0+5<L6C1W="*4B?2(\18
MK(8<BBIB"^.[Y>NV889^XLSH-?LM[=)Z>9K7ITL<]3M8KV=#]2!">_7Q4YPN
MZ1>$_7E*1;*K24Z^)E!4"I,LVDZ'/T4%3$;%79459P5Z&:H=<&Y#+?/$J74$
M";;;NEC,%^?CWX0DY[JP>&%LJ9$%%RK50 -+N6"8$Z2JQ7$I8Y]DR9V0MN&.
M[1U2'HL\;01S@R?_^M/-J?L-?V]:D_U\\?'3$DX0*=K5*]M1UP =5*!]UQNZ
M56MO-:1&I=L#=^YXX2931?EO5RQ:'71,2G""*EI05<CH6$TB<ELC]Z%/"+L5
MO$-UTETO>8F/GWZ8/S]=+F&>O[Y?QODJYD$!S,OPVT;DO\;I_!+06\BSN%I-
MZW1SMH&^BU,HJ@DAJL*$JX;\O<(B5X+9Z)*+(GEA^Z3=CS&Z,>03^C'ZIJH<
M'5^:6>?[YN[9YSB=47H2ATFFZ!UD=#364S1!Y?^>KM:DO"[G-RBI"R^"F:@3
MPH^11:/0,N&\V\AY"?JX=-]Y"&/(>3P^I_M*_BC$?4,?#.MJ^-8;=*:6L,8X
M;(-[2(._F>'JO&TTVJF0=2JL!D/I<9S.6!UGJBJ%#(Q%V'QT'A\RHAVS,'WW
M21Z7UT<CQE%H_CRN3E[.%G_^.Y0/<&YBGM4U+&]:F,M!9"M*H?ID)VEF54W,
M0TC,B5!Q$$96T:>PM_% QI! &@>G>[/@*%2^J+O1@4,LQ3#KM63:<,N\CYZ!
M,@XDI*!RGQ-MVZ#K.0.7PA$<;29J$Z9\P9@^),U\0IMJ5)(Z*BZLTV,)O<;K
M^._%J%W6W7X".\IJ&D!E2P7NDLE4/ X;)>ZA.F91\ZAHJTCB^"S:W<E^/&^D
M.X%VE5(SZMR"YWRP>Q6IN%K!HLE@8 'YGU-E0>(L)1>RXCQS*_OD<1L/I&V1
MOA'2 "Y]EG@"U K 61 NXC"@1L]30-_QV$7ZCZNN'Y-WWR2_]Y;5<?TAET (
MP&#:<(/*)P;#DO:9T5G&P+VR/O0YZK&[/_2X"9,QD:NY9(^SR?)SG%&[GG<G
M .M#MU.N/ZOIQLD],!MMD3Q;K?#1FZSN>I*XUT8!R0A]/)VX8;Y8S5PRBJ14
MM.ZS%7(-QL$512=(_O>P_/AJ_ADVJ8W5!)U3[;W%F%38C"1W@/Q&SU4!5_BQ
M]:+V.2MU&YHQF:K]&?!-7="A\][,WCS+>7&*;W\+&::?2?FA+CH?HK7.HIDK
MK%A!&0'4>3A,8$HG&SRJO-3IC,A]J,9D7]HQHID<&E;\?\9W+Y9?J:2 1S1+
MP4?FI*C(S5J95^ 8OIIGPU6,G5IX744QALK!]I+?>YZ;2?K-$C[%:3DK]#@?
MD]+5:\Z1:JE&))WTJ(YTHGR&U#($Q4.?Q7\KG#&E=MO)_O"9;QMX7&J?%26P
MM+/6,Y4JFJ-B)0N)\M-<TB'WFI+I6.QQ!<D8:O?:B_Z@^6Z7]8DKJCJE__WR
M'Z<(94:NR+/U\[A<?L7(YW_'V2E,B@P>:@[,!8U:R5C42A:'#5Z47)72PO7)
MOV\%;\?ZO"?"C_:2:7<.8;W(_SQ9S'!F5X1M_76O8#H87P"T9T+2D;.4"@O6
M5.8*C]*($(7O=$ZA"?X&"=>/B_F 92-+I9V.449F0T99>J]9]%*S'"H/5OI@
M5)_<X$TD8XJY'H%KWYX<.T!0[0*U4J8TW#A[@Q[#J_GS^&FZCK,KX";)"9=%
M'DYN!J9=L"QFT"QI+8$[9W#(?<*U![&-*6@; :4:"[/AX8]UG,ZAG+?1PZCT
M]"-)"LH+J-,\19M6>#4!(5D,3!CUUD#R0V4Y*9T];7KR/B1[&-N8XL,1D*RQ
M,%ON-)ZS?&B4N/IWF.$:^.7CI]GB*\#[Y>GFC+O)W CF +T;C?$0QD#9,A>-
MQ1@8/1W=IYW>-NAV#$;[;E>/@&G-)=HRO7G.^:WV7X2(JF0,N$/B'+6N 9:H
MX;(  U:7%$KMTXEI1Z!CBHE'0,">8F[&Q?=+B*O3Y=<KGB02/_I0*<BGQ*Z,
M&"#ZX-'(6U^<BH#A8Q>Z?8ME%*?<1D2I Z75C#6_3^>+Y3 !9X/R.@*'Z)DR
MB5+$43(OE6?9NNI,DL;'/C5<-Y%LPQCW7T<''22H9G3Y;1K3=+8YE3$OWT[+
M1.@HDG6926\H8Q2 !9,BTZ(@V*IY+POW$+*&(S_/OTF.ZU4HR0ROA?I^)Q:U
MM"R(Q&M")[?X/G7MWV(94TZE*4=N+H,#Q=!C(=!B/X.2@\/UC$.QJ6J$$B/S
M0E6JR@U%X9I,O,^FUJUPQI05.18I]A3&V)+7/@=5##+9!#J7F0 M!1D.':VP
MWH/4T*E(ID/R^G%3)5V9]PCB;IHHF6Z*@V@G:&@?^ 'F>4H-[*%F%Y1B(#3U
M++.&I<%QB=%&F;41LL^!Q'M C6F/OBNI6@FF79ICV':<*&L!3,H,4L$Q\0S,
M9X4#T]$45:IVN=,&P/#^-J.X\!J\L8'SS#BGXVC&#RWU+2O9<($K$$.O/AKV
MG@K+,=0?[B3E;Q(E>T]Q.\=L,?]PL_31NI1X5A;]PHI#*@F=PV 3<[E4H367
M.75RU+\%,R:GK('$#YWN9G*GUIM_3F>SB0\I"J4R#J18IK4*+%H,#, GIX*-
MWID^INL<P9B<GP82WFMB&Y:)KN/\PQ2=I\U0_H#U+U_./*P+9%4$K@6/K%J!
M3A,R#I'YQ "2!9-YXK;7]1L/HQN3V]* #LT%THPJ+Z#"<NA[>-:#^@+@1'$3
M@U6.F<$;*Q:IFQ.ZVQ5T@. YQH)="'(WIC%ML32@1:/);UAT3'WFUE^ILP;U
M)B2W?&A[28B@E )T0Y^D4W?:@&&A!,NJ,-RC8TZE$9UJC^]&-;XZPX,(T4P
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M5M'[(+HQ1;1]F7;+%F5;V;7<[;XY#SF??B3!0!EB<>H3M(03-"?3S[ Q!G_
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M7!/K8L3E"2U(9SA.VN9LLLS)6UZ)]S7#GPSG747[D&];C>^7^.7;R<?FM_%
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M6TUS^O4:":07U^\APP3&$3["E]D+_/ _!EE1HV/RA'J!%F*4B3BT&DDT.;+
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MQ^=GI4KK/)KS83'$_ Z3"=IQ2BDQPN/R*@(GWAI)J ,C1>09U+::BA4493O
M0U__K*$"F[2I(A4]Q(674-: 7&9(M,'7ZZ70QQ ^\171FO3>5Z$^N'D*'0J!
M<YK!D90$)1)8.9?V0()S66<90NSI1N'3Z$[;JZ5/J3J[4-*?RKS$;7 XOD*
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MM5RXMM)*E[E0-'=<MS:-?3J:<1#I5RPFUQ+O[&HRGBX=T)^_?!HN-/XGG,7
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M1KV%2*B/.%/E<<Y9 .$F,A5E\DRW.978-L9ATR$J4=#T(+\>\M\?1)I?7+^
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MI;&>I<[Q' Z4M_C45LH3Z,<NPN]#+Y9YNP\@KC(75*3),8>3!4>D\4!\U)J
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MMQVEUL=1^B_-!(;GXY=S1%^S9;R)62NTZE/I#"&E*A4P<B!>XL^C9]FG5A=
M-@]QS/S5E-[&<_9ZT=RS^#]7P^G\&5,_3C\-/\-T-IQ=3>"-GY3ZZI]A_P#N
M#@_O&K/==Q[WPK329*V%$(YZ)TU0 :V7#(8*H42 & 8[C-,M?/7B:CH<PW1Z
M:\"O 1JAE$JY5%]P7* U)2.Q/%@2C&$<-9/QU*K=^<[AJVVHN@;LWOGK\AY.
M/S;SIT_@U7CFQ^?#,(*SZ11FTX&)-!N3(HG.E/M5V1,G2T:N<TD:)Q@UMI=I
M/PKM\#'<:OIQ/X!7EX8> KMK9O[APD_@W6088>!59C%Q-'&2!R(URVCV2$:B
M"$(&7+*5[.<$<BNL$]*/>N+OH47+ ^5=H87I&YB]S2_]]&+YFS1@P0IKI"9.
M1-S>?8C$\>Q(4D%K*Z1+O)]#@%U0GI#F]$9.Y6S?%:R7S648CN<A[I>XW0_Q
MR?-O/D[\>)IA@C#?7!59(O1FWD<-9_<W/[J"]\/S"UPH-7"6F=5$18CES@&0
MP*@E -'Y#"R(V.9212T\)Z!*3T9/9?]JC6#683Q+:?X[/YJOKN]@,E]J!QX@
M6%Q,"0JJB$XG?#D,(T8()JC/F:4VI?^ZH3@Q=3H %17SIN^+Y.[+L$1_Y[4X
M0_<$?SI?@=^7K][FMU<S=*!@.I_EGW&6 ]R]4[3*$2ILN?^)7X7@*6$JH),D
MG$BJ7\>BSCQ.0#6? <&5*RFU?-'>P_G5J#SF^NS3ITGSV8]^@I&__A4_>C&Z
M?@_ES@+^Z<!QKY)3DFC)54DOR:5?J2992J.M13^$MBF351?5"2C>$U-5L1C4
M]E=HK<' !D;@OQ2EI31'NS/Z^5U 7PJ#:,ZC S03#K@"KD=Y FK6.SD5Z_FN
ML/ZI:=)OP]%HX&QFBB8@MCBX,EM*K!6&.' F1"MPV^\G*W*%X(048"^A/B37
M]K!*O(?8G(^'_X3T*N'"-\Q#?Q,%6SFJ9^/T&G\\'*%(8(J_N[K$C]\+F<T/
M!#Y>^/'-9(4P5@4/!&(Y!@ 3<$F4Y<X=9,$9IS2*0RTS_4WSA-3T^:K'PW?!
M/:=WX2=8K-X?_9=;OQQ$)3EU0A$3C$;G6T?BE==$B.B$#:F4WWKV+\#ZN?VN
M]7TIPIJ(<;7CA!I3?-.,XQ7.<3R[];O7S?C\(TPN?X(P&Z12QS$*29BA2$8I
MM!HTE((D,2>T:CP"?/9J_^@T?W\##J >:UZ&SN<G[^'3,DC_-M\!IH-3"O#=
MI)27>KZI)$502CP5D+,&1F4_@:%-B$Y(Q:H(?8TV=#H$687.?X4TC&7>BZ#Y
MQ^9#,TH#!\:7%N[E)B(GT@M*G BBW!5A0B66>:M*-5L'.0&&ZPIR#<5['T+<
MG,E-F@B0IK^@,&XEL[S-:\[F%K^'-)"62G32<,OVI76B*G>\C$+'+5O0!I]G
MX[9TO@X'IWN@/0$U.AA9:S2L4Y&RGX;33\W4C_XT::X^O6EF^'V<QQ&O(+W]
MM(SP+(^%/S8O '=60-QI0&4,.FE)E/.^%#= >5E1NC>%X$WRPNDVY1_W'?\$
M=.9@XE^C,WL?$]RZ7_8X\#^A7%\WT^G;\>KC XO[HG/6$A=%(E*[1"P(3JC/
M@0H4E-IZ2Z/3M<Y] )^ GAV2LC6JUOEPX$.\@'0UNK6(WD[Q?'%]Z[O%]487
M7<I!<G1052R );&6 5%&>(/[-TNLGP2S79$>ZCIQ;RK5*S5/?;UX[7OS<N2G
M4_0GX^) =]Y>7BD:(RI$9I$1F2AZA#DSDE"LFD?'<77N?TE[".RIKA[WJQ3;
M%K6.Y/20[;@%WO(&0QN NUQ2KJE%3W%QN1=BVRM-!U:>1'VX%M:!=231X$IE
M*5R]C0SS)AL^>X-F8JNKS<>B-ANN.S\/K=F%C+ZU9?$-6G;YQ?4'/X)-!M_J
MUA/E,BI?KDYQ9U R-I$@DB'..U!!1FY[.N[L@OI)"O/45()M*M8G@SU<^G@U
M+HEL-S4'7OA1:7+_X0)@=C9.7Y,SRQS0>KN: -H"=R8\Q4>,KM)P?+Y^GHNB
MBCPDQ64J72]*BT[&B=.0B3 ,-#61Q_O]SROIZ6'F]TT8;<]052I>4%C[,C\&
M^(V_A%61UQ:P#V<1M@?^-';B<]2E;:MZSXK0MUFQ _SHDXXZ9$)#Q!4B03DI
MQ14BLJ!XUN!,:E72X[CU]Q&#]835=Q?^*_?L> WG/E[/NX@,F]DPWISL%9G^
MZL=7V<?9U01G\8N/Y93_^M7XP]4_+YJKEQ?#\:J-4V#2T*0"B5FB055* O@T
MOU0+CD;FN-7WXHAKCSBJ@'EB2[<OVINGY.PP-Y_G[Y\.)IH8 G$9T"D(AJ/?
M:2)A6GGOA&9H21WJSO,W8V;6(*/BK<)ML!8Y2:M7J W 7BW 1R$^C:U7A= 6
M2M*=C1[,L,>!9HM[>H"2B.Q#R=/,Q%/C298V^B@ROBS])NP>6%T>,:V>1EMV
M(:&RU?-N I_]</3Q G?E3W"%>VC9ME?]DXU-CO% -.C208UR1%C2>;6)2H2$
MVV.;!I#;QG@69^5=Z&AZD&5%(V.>, *3R^'$(Y8?EF!<D$J:HL2T].WUR1.;
M8^DXBIH=4+TE:W/+\L&#3XG-;E*K[9PT7YJWZ/:5YN:W$#&:6=)"$W 1B*0\
MDP 4T$_S/*IDP+7B<?W33XG,"O*KW!QKV:?M[639S'2^S3 J/0?T?@2X1*0H
MGD@T@=!D@?/LN856-Q!;531=A^"D;?PJ8J_<)6]S5]LVH*I7(M\(Y_"5R+LS
M]9#V2F*N7(1\,SAIO3>@%=%2E8Q-GD@(@I)(%0_!,!5S.%;NMQ0A/Q#UNTBW
M\G[^ 49E=?0S%&5X_?8_WW+'5]&HX%F,U!*<+UH9KA@8"(2(9"V-N-JQ5D;W
MYA&>2]ONG<3?5)==Y<KD\XJP,/GD)[/K$MF<ZRPU*F5+%9&YU&B.0$E@($C*
M)0.6<JUDJX/G5N_O.@0GOY]W%GO%<C@%SWOX=#6)%WX*9^=HME[.R_G<A;CJ
M6M\"9/7]O36\P^_WW9EL#D5#Y?V_/=C@LTF:.:)$R+B^,8]+9N DZZ!]"$Z9
M=F5LCD%7MM@'3Z0JNTB_LKWP<RKG:)\N_.1RE;GE: @)(22#^YU4BA,G*"5,
M6T93RMS*T,),>/#@PUH'/0F_J26YC4;"(6JUOUN*9EZ:\&PTUY"2,]A#Y?9'
MANJOCOLN<[Q7U5V#B<RA?9 #2*NE-QR$3%HDY6TV;$M5]T=&[;'&.Z5"*Z4<
M25R72LIH^3H1,^$BN6 MKF#L8.<M-ZB>4[&->;G@<?H9/_+9C\KU^4%2^-XS
M+] BM++(3.'*GG!EMQ%\E&!HZ"=]L]]Y/8OXZGZ:V6<YC8X*T&."QF&*1"45
M50RFM&(*A8<02\&T1(PK/A+3R?=T.^-;KB'V7)2_KGKTF%%0=[+3@0C1>UXZ
M"@/:>#(E1:SDG##%I+#2Y7 $%91N3>AW_:Y*>0^I]C=O5-;,4"[0 9 .O4<5
M++&)HJ,1E<PJT"CT-U7VLXNN["74'O/E>JQP1YUCV40@WK%BE,A,?(R:4.53
MI"X*Y_I-S_QF2AT^E\6K@B)4/#W>T#1C[]G-38W%YV[]\@W,!B8*(Y/5Q /U
M1-*("[7F@H"!S(32U$&;$ZF#@#T!U7V>Q%8\)^GX;J[VF/7%&'%:"D+('@(!
MD8J=+ *Q)?,NN:2\-"R'GBX1]32A$]#IYT3Y87H1[%].%*?CJ:=B?B-;I(3V
M<3G+D&A,@48K.<FLM6Z5]_&DML7OFEN+XAZ:'MSNRE8*#]Z2%[Y,"AAD2<"A
MADBI-0G&6T*=9DFBCZ;O9Y56TKXMH$Y(DVJ)_IEW2_C:6F;UN^M!:;RL7:;H
MZ(-&ES];$DH%,0K6B%*U,L/S+P^_9F(GI)W/205ZZ(&P4[?*E&4,7'&BDN9$
M<A2ALVA5..YRR2U@!OH)2AYQ*]$NNM<;.7UT&+A9PHN\X76IL'H_>O]W*$6A
M\>7X#!-_#G^=0KX:O1YF&*CL!<W)%+'@.A]*#?#R;4R*NLRD3KF?X%$7U">D
M:0<CKX]R_CLG5Z)%D8T,@L1<&GJS4I=5ZTBBA"0%:!=\/P?H1UG<M(M>]4K-
M4Q<WW9B:GXSS/FI&(I34.ZX$\0'G9!T3*AC-:?2_7UO:F>['KBWM(O:#75EI
M ^J;N[:T$U.M[J[L(^:#Z8!@'"(/D<A,,Y$F1A*80I@FZ)B2,52ULFZ>(_>[
M7ENJ3_TNTCW<M24M*:4Q2")X*+?:LR;>Y42\!JDT9$UYF]X.S__:TD[B;W=M
M:1?9]9#?ML4(?G']J__O9C(O6KK(LD\2K5R>"4L2;=_BR+N,MA*+ 3U[C[^[
MWY^YDBFY \B3M@;Z)JV'3)LM4+\"O7TEIP7<7DL9[0CX:0H;]:8 [16M&GL]
M)"KN"COG0&D.I4^Q";BV*TJ"=YR $4J9C"^HZ^?0^%DHVR-ED9ZKKNU"6@\Z
M5N+;$Q]G+_QT#>#%WLY3CE%G0/O *B)MQC4>]W3B/$@T?;3+LI^N:BW '3Z@
MURO!]\_9*K-SP-*/TD9#A2XYD[(<DHAY79I,1.9<N<AE9OW> 3C6TH]=+*H:
M9#Q)Z<<V '\O_;@GH3L7\]N'C2<I_>@]I3:6LK<)<.V3UA$GO2%&4NZ-<QP!
MGY*Z[%GZL5]MV86$0Y9^-$)X"3S@=ELV7O!HQ25EB*-&4X7_=>%>IL9)E'[<
MB8ZVI1]WD67ETH\;ZMY9R-3DDK(>M2A)&(QXR2CQ6K*L,Z,H@A;L'D_=P'UY
MK2"_C6_M(4H(S(W=V[_NHWC QD'Z*QO0;E[W"@8$'G ZQD>J9<FZM! D#XH&
M%W!I9WY+P8"-X_58*D (&T7DBB@+Z*!XASJKC2(B^L04!"M,OU<B^R@5\"#%
MY[YC-@C*6F?!$&K*:FF9(<&(6!)C,VZV7B??3VO,1Z$]BX5M/_UX--.J$PT]
M>,8[>W[*.I:$TL3.2[]!8B2([(E)00MJ@U/I]P:^572G5VJ>.L?E)D'LWH(_
M=P4XCX([JDC4#B=BBBO \!^9E<@QNZA,/]<RUJ$YFIC,3O3?S]/K2D,/GO5]
M3*L>CBU0]1J%68_K:4(OW7E[1!$Z"/UP*B$#:$]#(ADAE&@D)2&Y0)CEG@H;
M@LWTZ%7AD;#*H31A%UG7#Z3$81'&BV$SC4,81[CM_5,&DN/RIZ/BI6L &E(T
M!J)E!"FLH-FT28S9.LCA+=,:+#1]B+!R .57F%Q-W_SMIHF'SR:#(CF;>;\
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ML4S !5QZ;'1H3O]^K^G)]:P;<3VD2#_>%- [:ZE0:"#R $0R;DA@'K_BDEH
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MC#+<. %1%0-*)@_16@<E6$/.$OTTM[D#>@C53Q[UH*T&(=J-V%:(KJ-0LO@
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M57I72@OK:+L0WF,58PVG?:E%&?]OD9SR)TY'$]KK%7/!"\G &DY\E\Q S,:
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MVLK=D@_CLA7@):=3N3@7N3HO CT26#@%_NRBE :\^>5J=)GOQM$7FZ1)RH+
M7$ YAA"BDB!23I;,MQ1+&VOZ1QPG9#COJZI);W)N8"3?KNX&#D\6,Q*KT06"
M4Z*$4)2NO;BYT)*H[MKL#&M SD_OATBZ17']=?J;S$PXHALM0Y(Y7V@MV7&(
M@HB8''$2.T6<GUHOC :VYOZ"[;$H8[V&N0N,<^V$L9,*MO10V$=^#3MA!$^'
M@M 1%C>Y*F#EI>1U"TDV<6MYMT/Y--38J1-&'UK<16Q-.V'0UA%B$@$LK^/W
MC)%UF!)"80H-CRX)AKWI[T0Z8>PD_*V=,':17--.&":Q+ P6((.?CNT4(QW;
M(4#.D<>$P8EN1=A/J1/&WBK<6W(#=,+8=&=SUQ+A-YQ\FH:OGT?IS;A,IE^N
MAW+V>L_5\64M;K_V6>?ZG9B-7HA@L@RT.Z,-)9L4I=%6\2(#;KP3Z_C>YC=E
M5@M37*K#5 6K/?(\1$O,9-I++U%Q*=L4HK:_*7L[&:?%E*SY]?4U':"Z".84
MQ%B+2 TF^IE*8++%&+S0);6Y[E]'<D(NW7Y,V#!@=W]1'_/"*PDN2W2%3L]L
MR?7DK-I4!G(TO"1,2KA.9LASN/ ZA"!-%'+L"Z]ZL'^8A_GB:7?;>+B>3V.U
MB3H5"TPF 2HK$IR.&J2)*2/RHGVGG;63>;05QLD'&'92^*1OP??LXWRX)M0J
MI)MX61=0O8<?ML(9/AC1D[HFK60]&!$,JU405@%39/8K\@# !5:[)26R(%%P
MWZ/C.S !'@AC#*G_743<H][)U[CXZ^V;CZ]^_?#QQ<=7'VBO^_.O5^\_OGO_
MYN6[92YC]#ZRXB"BR+5#30;G#&U^!DU.C(MHXB,.5(?7#.L?]Z2(21LI]FA=
MILG5>#[]?O'FU85F7@L5"SCAD4XM1QY\[4F*TAEG0^06'\I?F6'ZCT^3;__K
MYHG7'_+-+Q;:7FCZ[GU/6:%[2JWG#W-1+WPS$_?E M%B5NK-1*Z8K?46-*OC
M!)$ ^DB<HF^.O/E@F;.YPT?YP"N>LO[ZE-X @ZI^F4RGD[]'XT^S#U=?OH3I
M]TGY?3+^-,?IE[>3.<[VCUQU??*A8:J]5K 6D]).V^(U3T9J11ND<RAD%$J@
MLCE[>='U)8<VVHCS-^,9.6%KKB3/F'S)D$J=@<>9@)!B H].,]K=2Q!M*AJW
M #J\H<CJ8]^LS&1?V#WY3W*<Z _")[S07!NEK(7$&"T=68&0@R>@6I/'$[P5
M;5+3NV,\QA3TPWEROYU($YTTB%;]B/1EF$Z_7\^JH8WVH@:4D3$/)C )*@0#
MWG /7#+N!.%&WR9"]1"J<V3( 7)OTJ)H%=M?XW#=#A7SKZ/9PJ*ZP!R<H@5#
MEJ7.+8H<8M(>/+>U W:4G+?)U7\4VCFRXU --&@W6L_KCW1>5Z 726AZOY"$
M(/.:IT-&74D&C!11<,.T*FU:&J^B. _%[RW7^SJ6_6X#UQ%3@;0EY=JC+=8)
M1<P7B!H3Y!PD.;[&HV_5G>P>F*&N)]I_X+O+]MC7#ZM\G=_P]39%FWPOSJQT
MD$1)Y.EI 9X< 3"(Q9!P4DIM^DEM0G.L2XB#-;QA9SA(T@T,A75,R['4'5 U
M+9#9C.LX-3&'Z^T1(AP@].$H88M(060#5HHZJ3S;ROP,K @1M,\FV#9U#$-2
MX9'JEJ&8L(NL&S#@ XY'D^DBD+-,.9,J>+0.K+<(*B$=E)(L&HPE&):0W)DV
MN2_WH QO)/:AH_5\AH,$W#R&L*!UB,F+G 1$Y*4.L?1DNKH,B#J5[&@;BFUZ
MZ-S'<BX&P(%2;N $_HAHI2]+%UQ-#8!MR(YC ARJN0>)<*#8FX>/5O#1+N4*
MIQW*TZX'*IA:/X!TUEETV7*1HFAS#@Q+AT?,@*'8L(NT>[[P?"&DOK[)N4)2
MB5@.M/51F!@89&_(UHGHP"<MP;B8M38AHU@[%#;>=6Y^^K'C/_M*?M*KV'H\
MW1>()-L R$G+<^9DK>@4R=P@XR60A0$.,42>B+KRL?O,K0\_!S4>++2^/T?.
M7EU-)[_B>/)E-*[W3QOP!54T0\_(("&K1!E7P*D0P6OR3UC!(-8MMLU*[?"N
M<]!QWR+MT3Q;X&-<?_A[-)N]GH9QV@Q3W>XO-35#62B9MA9EF26$"2&6(K)V
MFF=NNFB^^RO/@0"-!-QC''\!DY:P>J;H9>),,DI&1Y:2+KIF0PD2@,H@E&:Y
MCK(3UG;1^>;'GX-^>Q#<?5VJPZPJNPF1(R">''T@(U'6FDP/7A'%7,K!&/HW
MWKI.5M6FIY^#)@\7VWU%ZL/.8R/T]N/#+%M3J&1\E@3.U?NE;&C'8%%!DL*Z
MS%'B>D.\+2=RE[>=@Z+[%^M]Q9N#%*]7F6AO 'FG,=4;7A&8J^V1:Q(Z[3"8
M$\&,R++D7?2\Z>'GH-:#A79?B_8PIXAO ,15B9G1^5YJ3;9BV8#/1@#J3.9>
MB86O=Q7<XA1M>/@Y:/%@H=W7HCO,0E:/&G!N"5/Z1$N51+':B*;VP8C.2J"_
MXZRJ>:Y)=K*0.[_R'#3>2,#W>> /^YKE#_:!7[:ZD$9:BQ)L\*YV!'/@B*40
MZ_15Y3RY=)TLY,V//P?]]B"X#8&.P^)52OPWCC=S;8F/Y1"#Y RXU$B&GTJT
M<A\A8T;-BHC)B2Z*??Q5YZ#DG@6Z0>$'1IKY S:?9$M.,N><MQJDUQF4+@11
M,P/%NR"4CTX9W\E'ZO*V<U![_V+=H/G#(ERWQOYD$T2^M!--]N07D 1B):<L
M",ZR2+*0QM@2D\F=@EN=WG8.FN]?K!LT?UA,2S.V$F&7<EF9&8+44M8K$J=!
M>13@@TO F"[.V,B8ZZ3JS8\_!]WV(+@-RCPLJ*7-M@-&+N.G.IMH:XZ4\IS6
M6XRBE4<+G/DD//W%O#[A=HMB'WW562BY7X%N4/AAP2]C[0JD950FRYAT#<@(
MI%U%.1/ :5J]R5EP)Y0-JI..-S[]'-1ZN-@V:/+0:-:*_2]O?7H>,]:)FYS7
MRA3KR*LC0[ :!99L?YT+Z[8-;WKZ.6CR<+%MT.1A$2WM-T(J#(VBHUW;7+/5
M8H)HBH=DJZ6/UH1N88^-3S\+31XLM@V:/"RJ)=VJ4RZ7/II.0B>5D<[T6'NB
MR4A+C+65<JSIQJ2NTBTZN?'QYZ#+'@2W09F'A:;JA<8=)G5KKSE38@@:8A:F
MEH<&\,YX"(HSI>DX**Q3:&KSX\]!F3T(;D-"QH&A*;,*:6F*U;MD0>8W\,@E
M;188:=O/&1AWG-GL;/&L4S1JT]//096'BVV#)@^+.<D52TPM[Y.MKSU,= ;A
MM:EA3[*IN7)0,LO&I:2<[I84M^'AYZ#'@X6V08V'!9#DZNFMEJ=WY#H&\G_
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M+/A 0HS96:E*88ZW:7>Y,]2?;&VDUD%L^ Z2^W4TJTV>KZ9X4VNM6"!/6&9
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MI[KAF[Y.:9G_/@IQ=#FJPRHODHLN9EZ HZU3C[0 $A,#C\4Q52NEE&GI&QV
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M!123"%$$"<5+M,Y'+QNET#^E;(5==+AKML(N"CB%; 53,FIC,W A:Q%V)*]
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M1;U<'A\+4QHXJ3>0KS;EE8-R5LTUKK%VH:RMU)A34,M_ 5$[]-KE4-IXEAL
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M0UX[K>XBPAZU62W"]^/1;_5%@(ZP^L*"D\OK$5*1.TO>"6@=:TX>9^!]L$!
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M+\B;LB"!,??__+B)JG2VJ$>NBED4GSV_^7E[7K ]4Q,)J>>S%+J(**;69@Y
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M.-SGK8*0[J]XJ1)[_.QR:E)JV#Q_*1G?FJE!5TUDGG@,C;?M[6_+*_R\]\;
M<$ENX,9@GY(+?BIE=<CZ-[-OK*]8XCZ#377P\.Q*(75"*SC4AA[T6K*#I&FE
MU,T#S9::IX=!)6AXW*+/-&G;_$:3HT7E)MSBHI2$F^\V(OUO(:9/QT)\; 4D
M6W0W!W@8@.N"92C0!PV-(FGOX%HOM[.4"Y= #D"L@V>R;9I[84:#C/P[<QX
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M<NFWZ*4Z*(!Q'FL%6[,L790HFTBH<(ZF$=NV,K8Y6 =046)!Q_:=$]C&6_#
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M'+4$<,;3&"XX:(74$,QUDZ [88C8]MYP&PW=7!H]C(YAJWEF(OMRZ[M+F1Y
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M^LXX@;9XU\B(7?;FY6PY^^Z7$WCGRTV:MT1+*0BB&EMQ6D+$^!O)Z_0]@L=
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MK&YIV%/ES1$V#9N31-Q-YH_9J]X]FS*9'X/8Q#,D@-HS'"4[3VXZ+@"_GB/
M^#&<QK1K;]+OXX0J]-P1J;I0#5<8/N>IVC6Q+S,O(2A 7\8A1C1K>MOK'#[
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MCFK-26UW62*76Z&,4QNX2R8\:F-K@E9&/6O-4?EU>E-/!7]"=Q9WEP_X&R1
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MWU^<-C^ED(Z4"9A:S_B<1^^10>ZH)A2..83C+E-OR1OFA8>F7U(XR-%=LZ
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MGPGZ#Q4<\C^]W9A.4.$#06E(&JL*$6^A&>[WC#)AZ%"?*?#M%/;+SLOSYLL
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M14(AU- ZM)7K1@MR=B^]MUZH;-S6O6.!)E7H7A]\0,#6_5YRQW9R[D'C[T.
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M?JN@[#U6R'F0_;W?M8/1/9BXB-J8BGY^D1JZD\8:I$!JS=%3JF\%B:5H3M[
MT];=AXH@<]#_U$=M0T/&BU'-]IG:_?2/NY;.,P.L++P<$,1;>EA5&K0BGS8V
M1[Z+7SM+6WU=.,\D.6H+,&^;MP^3>LIN^&$ACC6PB(I\J/F:,- _/9$,2AU$
M3"6,K+[#BX^O>CA\[\"&B_2VY=?TAE)V"9*,\3F5;20&,DG]Y\D!:^@"]6.0
MCE\:X5![T+YB@*%*O_R@+A7=W@A4NV# %P]VEO0_#6RV>A?J'MQX8'1S].ZQ
MID$A*.EG\P"&+^L(BYX$Y1K)_?A) 5@L'JDSW.7IHG[K9/'=N&>IN=KUZ'=.
MG>57X%H,Z'/YQC<'6O4**(MG"L6MK'<AE%2[J'3L/%-R+R.;E6#R(]WN"R"*
M8Y.Q:S/RD5&C\M<$VQ4^$AKTDL.)S@H4!RO895VC&G$XAGM_J.Y24#8R O^M
M%4KV\]3X$H)4[-[#%O8*;.N*6+.A/>BCTR6RD-/<Y2M[J'< 5MXBJLAZLHUG
M@>B9PA)?:$M$#"SO64CIP70M1%0SY>P9S0!M NM^N;]7U<7ET\S#/3,$W@N:
M]2 TC4A0*TY0(N8F[9SO*H+92AN5Q)H^W!UPV\01!VG$Q@_:(/,S9!$ELH_O
M*<C%BA#7@<@<G]S?KQ6QB.HA;95OHK"R,!&C@<\;U-VX=1E>\1\BS6(\EX=V
M(89?%861-4 GD_;PS3SYOCL?TKK"+!7L=>T""];[?VQY<N]['-9'2.S]>IFA
M4\?W87S@3T6+J'PM.@*H/>S X4D@.+W/4RIF;Z/V>&5@T(LUTM=]/W[R.'UL
M^&G]MR?NM!LX]D,:JVS@$(&(J+H5'9#_A3.X]C[^^I;)H4\;A 8+KW4='KSO
M&O>5_X54N8A2Q+$MB%?SX*^E/V:= 1]*EL]EC>#D^9,8*_+=E/IF?-?#I2BL
M+Q&1%S+ZB&<P\35#'S<\<+PTN0SXGEX;BE5N70+T%6?*I"Y99SL"%2=Q%Q1]
M%E&!>!L.-=S9W;TVZ*&<9D$)\?U 4EL[S@L/:0[?OJHL**6QDF^4:)WZ6M![
M0W;0XT'AH_BXO@_4#[-+'O >$WHO7">8N9VW'#$SG'35WIE%E*:.8Q(PX<K;
MY&EO!$Q0P:&MF-HRL7>]G;C@^D84Z<HE#&CK"VF8W[X:T"Q+JC"::K(G!-.Q
M*@>^75,Z7Z1&'>UX6X"!M#+YTI3*/?+#$W2>R7@/E@-.5PLL#%@7)F<T>EZR
M;B@5+.1E$E$0.MV5I\:BW/;V:YN %0J.^J>TQ,V59$*FE3?,<+FE6ID. YG=
M$VG([^5!J>A/)GMA27M!Z6_AUI"J;'(_MJ(4QRDX+Y'0?IUQCG4-FYD1L"#"
MW^C&<Q\[=.P9TIUJ4/I^DVN^&RN(?FUWS^P\-K4;XMF-S2$&5?8SH"($\/2:
ME7@%5(C0+L6%OFOA:VOMJZ@Z&^[$FIWC9B%]41$":YTQ<^#!JX[SO):)',:N
MM=C6_!6?^9$4BS!,XHU%%']C1K^SR%;DC5'><?N;MYYZE!L$?E.ZW2]2:RU3
MZX4! UXD9)28OT;J,BY3N7CDHWMGMMX6\3A)6]U6,[2+UUQ?-(KO38$EOT)Z
M0Y%ZWKA*DER@]S-C\TS"@^BBHQAURW'FJ*.#.7]C PLC=W:$5@!,-&?X-.&*
M-/FG2_SHN!'/N7F9A:F1>YOC#JY^LZN^:A/Y2'D'5HJHSA%5PT,>;-[$ .YR
M2VJBX>C\;U]$AE*06;VB\E9-M1#R]Z#@;O[S84Q)28><+V9V5JK(>+Z_^*,<
M++8?<S?P)QYTQG7+67GJ3\8QS[09N+U':3:VW@L>R"%0"P(H747</9QU#S@B
MB#AL@G95B3<+C?X8]##\^<SD9XZ=P[^F^M4Q-G\_S@2/,6\FWNW)G<>(Y@=>
M+CJQON>"U-B>5#0E'XC#[N3<BT#T(XL%A)T[8Z'^; 3>\'[%?L:5QL##"]RM
MQ8T8Q.BMIJS?A8="G(SBW7>8A6>.7!F\>4\D4?WLY/!<3I8]TI8:4*$24*L9
MC(SY$'3@]EO<"$FTH&CC:J!!%=] <QB<(T,&R?"JCSG;'9F0VOPM&QEA@60_
ME_FLF9_[%, *M@F_;L.=:XZ$=T1,KOM;BF+-L56G9$/D' I"S\YNJHV]&T=Y
MBGQ4Q$5&GS\5_H8("EN8-'N5;Z6^86%'^6ZZ2-(/36M8(AJA17'LJN 5<'Y5
MMMH)ASV(J(W$;@ZMI3\MWYJZTMQGUXXBOND>A,RLMP.5+FL@<JI090Z9 SCM
M2_OB^\%'I[DCU"095G0$=X[#IHLH.9+FI6X>DX%;ZY,<U.G3]RUD&T+$(5*U
M'/X'!K2.#+@LF)[$*%RR*ADO#)BDMY9ZP)M;! D:P.!)P1N<YZ3(EQ%$]/BV
MB7SX^;5X/@W>*/'"DV9P&V"]Q1<=B[.;.N3-VZ]3E=(3/]'$$EG?B I^^'0I
MG>E2$$E/ B*%>MV[1KFQ0<>7I%!&1://*!.T(G>96]*[:6[3XOI&(<];7DQ3
M?EZDZ\U$\/?LY<:T&H)DOMQ>;OYM] =!7O^XE2GJ6A,OH-DDQ%P:J,K$L3*,
M[)00E!@F(+K<ED0T!#K?:^96Y_1DLPG:Y[X0R.3+:"$#'H:5A7MA(U"MBBS6
M=3%)+X*+[YK]J-U]+DQQP3F=7"!W,S'0=<P^9>[G$@;?!8TNHE:I54)8J8M!
MR0$X:8_)9(6AZ!IT\^R,@NC4\_WX9[BB"/[:-%C\(%:;T#EPC,I# ']EP#/[
M40[^$GY-0?,J@M<1RQBOX%6EW1="^[;?/'>8H1T86ZF(6,!)? Q4P3&O04:C
M-"A@ +T!2K%R&;RY7"[784O9B-3FW>N([P:)->:!QBGY0EP:7PHWD,E7 \2'
M(:L<%Y]VOA;YW;1ODJ,<3JVSX7)F[J.:D*^\9:3.150>9B*6YT/0Z0<F-W/R
M]H,I,>GTUR:"IK2@QRKHC-[:1W=VM7[8.9*ZXYZE4!]-@K0!>JXE2FAJL&D/
ML#K1:?7P6L09F%X6?/U[_LX7IU:7I7J(A.VCCE!A47%D#$T[L*O@=HPD</%I
M,/<HV-L<IIKWOKVS>GZA[_&;J/[W;1[Z1:+)4>EG?UB*JRMS?OLF])O0W$F@
M(IA.+S0"^%)[8=%F3M7 ^)&N7,YA$)%T*DIRR;@@>&O2;PHZG1*K!I*L(3L
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MU$7-5_:P;'V_.J5W%>;#3D?QHJ'>L/>;Y%'\$ 2:L!XOH@K-\GA'QK!:@B2
M]0JW 8$8Y.V\[02O_I41 R;F=/&=B?V:QX9/M]/Z3X&?7FA-1-B?,A66VNB[
M/;YHNQNU@,:B+H6?F8SG:0$5\MG&01XOST#FW-L<IS)9\&MIRH:G.S<5<"1Z
M>]^7.)Z.M]?6-@^4VO3;^H!:KP'?:!QXU#J. EI/]_CW(ZP29@[WD':!:OQ-
MF#QG<ISNM!AA: BWQM.NP]7N*V(*%E0.,9IE&U7=;K_);=Z\TV :GV'L[<M#
M.BX$QTIFY@['(OW'D(.E!=-W^<Z>_8IJ5?):49/7QBEKQCLD_%Q-GD8PHA[7
MSC]-^Q%T),R^Z]X^5>&3Y13P*!K:8<W? NK1^1OQ_9-71CK!LH+GIB#UZ):P
M]^YA5D7A:=^$G.)_D_1S7$2!)[08IMQ,",%P*U9"2R& H@1W83TKL)977291
MPFFN :*,W)_*=*2E0Z0-*7T*7EON2\=Y#L?^]LELD"DE'%M1YH%\ZF>@ K%!
M+E"A+9@)?P.^=#,L2DV[A!$IV\['=.H&)YM86G!,!-6DS84?VKW??,\MC1N[
MOGR,>7%&P?C3V@?SZAMO%%60I?K&,*!_+XU,],C0?ZQ5C>XZ43]S*/_)$[JZ
MEWYNP[*$KPF?*"HYTBFS0@7@=+_=Y,TE'UVD]4?$[8)8W$4J8[@:KX!%PU\Z
MY#.H843S@09+OQR"1_7IM:J-OIJ?5SWO[PNXIVM3ON:'Q+/E/A<$VY<<(C7O
MZ=.0C]_RMYSC*F8_YSRQ>R[)/S?%:''W&EX>_$ $KFU>+E"??;V4]T +RN9M
M(>I!-?W#G,QHA+ND'7M+147)%IR-'5\F]X<&;JX-L;Z!^O[GD-%VM;1\N8E@
ML*$"+P7+$8(/<]1BE-!KH1>.ZMP2CL:/8O-!'7=M^KPWI7]CYTN@JK@,F<-?
M>@=H?/7A5/2-YZ5RL.)7$ ??F59<1+'Q)AAP:BET[*P!81H!WS]'A/M>4E<L
MHB("B(BD?E9"!R"[9G/^WBP6()#HVXM8AV4W4/.OU2L =B\>T18C/APF+#.#
M:!W),0BSB#(-BD-8@9H2:C(6#>*A(#M$_B\HE 8A<)\X^T]J_@(UOV)/^A]K
M['Q(L.8:0AZOX4ZL)G0\H)\J%ZMU!,P.G\Q2BWHAM<$M4.+#0BZG?'(?QKW%
M1?S/[9/_U+30]"D[Q,K\ P%I?^P)5/!7&1;M3]WQIY[8IS1WB*#UQ^[ _8'N
M+R(?C_^3G/^ G%^LP5+\']NX@BE0F[ $L]B)$S_[:4J0;PU)VVM2ZXCGY,/I
M&BG+M6?KL6[&NX8S4"&_YH>;B;A)8U&8*_5HRT<6&H=CB%>VEK1F#]TW[^_^
M&F1\B2[\MF[4X<^4_U\\Z?Y/HZ:K] _A&,JT(1YO(U$'5*MFAL,*+<:V_=PB
MCE9T>FZ[57/4B_CJ \L&&M2F],V/NV3^W]%!_TVI^8,=51KTQV:O>TQ$+7$!
M] YLL.&H11-M^^?>WZIQ>'!/7$O*:MUUFZ;CVB*GZ2?[0K&-_]?VX']#:KI*
M_^!A485C473Z+$$#F^@9F_<?]&&=KZEQEH^3S%<EKCCE]H$E-F_T]XW>S[C+
MS&X%UB)JLH>G32CA'H>F,YV<"!ZU\E<*2X.W'PR2S4V/T9#;]6ZYQCNKC5>W
M;\H9%'IP_P&6<@A%TE?CK[6$Q1+[?1F.CH(D8U\$$.MWND.V0:"<!9B2R='N
M83\M=<BALD?F3/8A763 O;5W1?'A0=<M?6?ZU&^O?F.@'I+!.P%4K,>Y4\FT
M=W95M*YY=A/M#=\P@?6U,7P15;&(4H"N5R<EWIE3.%0==.9\V?7 G]]7W/\$
M7:D?>X.M>!Z*VUM@#:E$3,;RSA"**HV"^#)VL)@930Y6@-0<;MD50-YL\IV'
M98KY'(E9S-B+KZK1=CJU>\M?2T\9JB=0EB+:1"TYZ^4LHB[[RO-Q@G2L,/Q%
M/K$2'4L3\]FI@ S36MU&9<T#N#RGG3TQXCT6&TZ/,?;'Y[_M^0B=G<J><W8G
MT&O+)* @=@EE W$?Q^?Q,T_9_59#66_P="]OE,>JDN_Q#^PTZM-4+[Q5M$(1
M0WA;@ H-DC;!CDN+@<66?!&7":C, ;L:1;FJMHND97%5E<<OWC"X/3&TW$FO
MX,U5+"_*]JF#^X[ PV.FQ Q2.U7OG2"/YMI[;&JOA &7"GGY&6<7;CO+Z4B9
M&OXBI&]UXZ".J;^8DV-]KKGR'7.S3V>O+U_;;B/\$AGMF>F[P,H 7%29"2@2
M,Q'P4M,5#(K$'_]PYV)70>6CZ,LGC#8^F7&Y];?E:K?,.&,YM;M,=C5)J[6G
M^KAGS,N&U-@#.C<>>F^.]3FJ4!1Y-]K&(C;CYH9/-:A+QVT#/OH? COB_:@0
MV;Z@;4*C7[NWK^^;ADW%^L&2DC6OTSZHR3P Y_MIE<R8&T[%S$I*E(-(U$1J
M8GW*=!7CL]P[,ZBI@W F]'*@FJX0[1\N+US%K,5=U JEK=+;INL;@U,HW<P.
M;GAI/.YEO9;PL*/^S/-O=C?>M&YW^Z2RR753M&\H<!$(Q<@4;&TIDR/Z@T%1
MOC*6>B]N]GM9UAVX>>](E<I&= 8J4'=I67"X;R.D\VJ$DI\8A35LR-['31J.
M>#,[\N:T_KJ#7]YMJ1O9WWA#XE_7],^X2'(ZPTC*!'=F+0W-=\WP*M;K?,QU
M=C1K5RXN2&X(C.5:*FCK=YJ?O%6U7>0W+SE87HJ%$<BAD<G.MO1:1-&W"5.?
MYQIOYXB4N^R5*KK)]TWW4N[T91Q[\.J0W^!44V^?H^('1E>S$^9(YS]8=E)O
M]*5=7D1US1S]F&S53KNTB+KS<%[_1[Z=[ PT;6T>U<Y^<+_QP::P5<9AVX1;
M7[ZABA#&*S!K=6TY6E6+J/6C#E-/)FSU)!1LHL=6GFL7B7UL,1@T[9"/LE/D
M[2?JE$$-(+X:+S[;>$Q=/=;WF-?%G,P#=1M4-_ZV1R5ZXF+JZD64Z,56R+\R
MR2,B\_&%8 FL0E#\2N'[L:?B)_P<_I:2.+&?NI&@55[(#2(9<$B):8=>CMEX
M,HA).<\4BWM=CO9L+KS[J=PXUZ ^_FZ>$FIKP3;4\P]X<7X I#( R#H31"J
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MIK*:,D&=<KNR-5\#7FH-%G,DN,_S'&OK7^?5.VU%7Y&4^)>9YK^(6@-K$G=
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MCA=MC^L?<+W[&_9\.'EKV8ZE[;OO%W$,+;BQIXJR8-0::DR'Q;YR@KE^@F<
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ML(LBX2P^-B*4>HTUC^8X14J=?C6C*9G_QNG44:2A[J5'".__2?"3!DF0K;[
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M3;51Q9Y^SHHR%V6BW"*1EON)5=M$.IUUQI4D4OA!$$,9T1"BT$6ZU)H/PS!
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M($+<@S12@X[Z'7,<[&'J&%=$[6UI::-$!18\0VL;S]C/;;_8C\K8Q!+=0]:
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MT.#J85[@_B+S)6/Y1NC5Y^Q.7)/OHE S^RK:5X98J&FU#X-8*.<O="3$011
M@K!T0Q02&EHY?Q9M+TU$:X2@U!#!?8WQCS_$GNO]^<"^IIUW:-,E9D[A1$1/
M+, '-OGT!G%#?04:-*C'<PH'4#6J+VC3_JPNX !BGGM^0QXQ3-6^"+8F19'(
MA%5CW=6FO)*JL<W=9JT3+%3GK/6:9BYN]>'K!]%">))55GW #HFPJWQ#I 0O
M9D2?_2,P=&+&J)"$<:OZ(>/ 6IH6'DL)7.=UUI]LG7#BB6'@8U98AG2,U*EF
MDCE_5TV]TOG,()!MRJK'=C8=[*=&;J?,&#PNUZ/*\4C09E7J<>E\+N(C/WU(
MPHJBT/F.D_1&IR=ZLR;)7?%5E.5:\,N4OTV*NZ0H!/^8W"6E'EN4LTS6M0/]
M+BWSQZ^;^_OUHUZ"6*%8(.;S&(9(.!"Y 8:4(01E+!'G/G6"R"++Q6BXEJ;P
M#60EY15F<%>!!D*CO@!%A=LB7>78O7AZP>&%^F;RQ=*B !VS+D!M&&@L \HT
ML+7M K3=V)@':OO N[H;:Q/[\U].VHTVR4!>I#MGRR R=[=:IA\9G?S>G"7C
MM39CHI/1*7J:'67\QP],@MK&>?RGX#<*3KNPCETW#D.AIDRNFCPQ#T/"(P>J
MX=3%U*64A7893@\VL[11LHK5>JABM=2$Z,;VE.@1+LVF*^<S-/%8U0ED:R".
MN"!LQL*XR4$/-S5OYL]><_?2>O9?/4P .H[_L[2AE_S_;HI2#Y?;N.7/65[%
MCY5EGM!-M9I]G7U2MNKJ)=E:-7/S(55?JBC*5DA"3\C(B:'4J3P1$1[$04!@
M% >.$W#'#:E5T/"T<!<G2#WYE,%?2)(6?_S!#9T_O](#BO5IT(F[WDSWEM.A
M$^MG=YEFKU]WMG8.P336@JZYNBSG4X-!:_$$<CQ/YXPJZQ-#GG5XF(?^Y\/,
M3*T./.BRH87X^T9!>/>@_G.MGO(VTY4!5L3COH,B EF(?8A"'L$X="/(J53_
M)SG"V&IO\VA+2QLD=D!!A11HJ."W&JQM8JFC])JI^2BD32S$ _FR/W]QBHMQ
M3TT<;6W>LPZGC-X[H7#RAF%"\7I3)*G0T^P[FJ25Q[3;TOK 55.)3+1<557V
MBDOV]TV25[/O3E;FZO"#X&^%%$H!^37Y_C17/9&.<#W5&X$#D>-R&+, P4@@
M2AP62"2HC>),#WEITM6BU$?)FVB,;C9[0&IC[#1LAIYW?=71G"+(@P!#Q$,.
MJ2\QI+&>[(@P\@(\H"SB0EZ ^8LJ'G@/;!=?9NAULR%P(9TXSUC:&@LZUEYT
M8P>Z!M?E;0O0FEPE"^C8!1JKJ[H*]?N@##<J0VP].,_72Z..\C/ GM5=F*\;
MGOL=,[8\<&'N3D^M_E%OT4LUB5+?7;+%LW*D9+ZD&(;$4<X'"@)(]+$>'OB.
M#"CE-+!;6.MM;FF.0Q<M$-_UR=;C(81#Z#5<O!J-M*D7G[I\91+LH#:B/.*:
MD1$GXZ[Y]#<Y[YJ-D?E[:RYF=[W\5.@YM"I8Z/J6I'_),OXM6:]78>B% 48<
MNHA3Y1L[!%)!)8R=B$B)$!*157K96=$O3N=:5^G#YR]_)'?W?W[[<E[QZ:Z?
MWT$>M4/_.7WE/2F_:*) 2T4#:'E8IN=LW'V+=:)/6_!/ZT\;=\Z4KK4YB*';
MWW7C[W5DI/B8/.PW^:P0\:^%D)OUQT2*E1KE6,Q#"7U$ N6#ZU'.$PR&48P%
M(I();)7D^!PP2QNYMF6ZV^+HFPHJ6"NLMMO49W21Z2;T/,1/OL7<#!:U'7"M
M#3DT0.S54*_- 1_[.F? [O'YK(Z\-WP&H)EW?L^G;G]?=X1G#MRU+3/V^Q=Q
MKU[T6U*(SWEVDY.[;4GWRTUYF^5Z=-A=4Y]#<E>Z5@5U0@Q='G"(J.]"HC07
M\B#$?NP@ZF%IM:T[&,K2%':+&9 M:)!O40-2P;;<_QW>488;Q+/0/_4.LC8"
M[!""Q@SMS;=]LK.D>^%E?Y_8[S&?3>>XF]##X<R[2WTV;7O;V.<_<9BT_IKF
M6]_ZFGQO2LP5[4E=G;-VL]:!YN\5"Y_S),OKW+3JVL]9D52)_5;,8PZC7,!(
M$*D<68P@]AB%-.;81YXNYF'ER(X!:FER>\EY#:RJPJ!WJN];J'I%]5Y; 1X%
MR2TW+D?I0#/QG;M;)I;AKCG53F%KT,4NO?C6)*!5 %1&M3G(]2U;N\;3Y#%9
M'E6=1P$VJTZ/2>5SQ1[UV8/K&;?[AK7_W5G_^"3*%6$1I;[G0!D1I'S?((;$
M83$,'.E&).2.@SR;DA4GVK-2W!EJ3&RC +38DF;JF@I+E_84R6;2.2)U$ZOB
MD]B)=L+_J8>U(>6$3;@8NWIP;YMS%PLV(>! ;6"CVX:)R=6]FK-KO?JHY>O9
M3/YM4C#M;>J$S4K&F$C+%?5%Y)(001$I5P]1P6#,"(>"".4 <C\,:&SC]-D"
M6)J#UR*&[8HE;S"#O"\O^SB=8:9"4U(\L2QMH8,*^X$UR!9_E0:_*A2C31A/
MMH:2-ZJ.68.85=B&4O1<Z08_Y]PJZ!]2'42>Y8_UD97R6>8@WQ<D#CT!)281
M1)'JHAA%(0QCGU'F^W'D.<.*G/<WO#2IZR9\VB(?6H+\!.>&ZX(3,#GU*N A
M$B^:,WWEI/F6;-F:J/3WB<9?J+*W&27'"W<;WC_2E$]/0<) N6$"(>CY(88H
M$!C&V./0$TX4^-R)98C/FN<M<')WK=L ?'^*=^;L[HPIW3_'/$[+C<X"T!0B
M6J^S;T1](1-.[V:;T[W\1,YF]G;^E.U H,QERJNG5YNU]2K3)2W*G!B7J+1[
MZ()>^$/Q<5786X4==,"#WUKX(XZIPWB;.C"M#\)+1Y89T&,0&F;RE/,^K^Z3
MOR?%BKI12'WL01E(75A*,$A]'\' %:Y/N(R)8Y7<Z$@[2W/ZM]_7TR])(;4\
M)'Z,5SM].H.MN83(@JC!<G.$ADETY7E;+R(@1PP^IA3'+C^_9%*S]D!NQ&M!
M\B2]^:OZK_;UVX0555E,&@<<\9A ["IB41QQ&$>A UD<Q=(GKAMBJU52:P1+
MDY$6XX!547OVS21E4DXG%INJ7E*YJY>TPP\: \"6\=:$)U>-6S1T,)63U5,R
M0_%BQ92L2.JKI&3WH&'RIZM4OU<3QJ<)"D.7!9ZK_*% " %1%+J0L% I'O-%
M&,0!<8E1%:7>5I8F8U5E>JE0#DKU>)A(,[4ZFYZ)%:EB1@.<,,]C+P>C2LGA
MEF:O9W_4V$-EYX]??&:2U\Z&\R^"%)M<\"M]-F>3:\%Y38JDV"W<$R_@L1.'
MT!%(R8*(U#1)N3[:\_$C)&DHB5%J];-0+$TV=EE0+YX<QVL- 6JJL#4%5+8,
M3")KU5=FRC-Y#TRL3 /(GW0;YBP^ITEF:X7D97+=#B'K:"K<00\[?Y>9"WG\
M%,VS#5!7.%+G X.<N00B'TD8<^) Z4DG=,*8N=3N!,LP'$M3TJ?;IZTAQ\ZL
M@<SB3/.HW6>_?SU1I\RZG;WMCX]'^F.N[>T!9$ZVVVV#Y<4VOP<0UK<7/N1Q
M _7UEN1"*;;@NOB02(MZ>R#/59.B*BS\^G%WS>>ZV/#E-Y+SZC\Z<^1ERC^K
ME_J3>LV;M*4<^VZ$' (C'S.('"XAE1A#)+GTJ8.Y$]EEA9T Y-*4N4)Z5A;9
M*7K24(=?N'\F%FF;KK&7W0FY&U>3IP ZKV!/2/6>FD_9UL %B>-#ROM-J9SX
M;CZL=W5ZMVT81$2=2&(WAEX@E*1CCB$1<0 1X3%B OL46?G3YX!9FG2_*\KD
MKBHQ0,[.D'=6)QDN2,Q$_=3K$KVN<A6U=0&>I.!K;+D [Y."D37X'T%R\ LI
M=6'PQTG"6\:@>MPEBW, S;MR,0)U>PL88SS33GRY2%8?U7NR_GR;I>+3IMJR
M\+D@+O4\Z'O(UU62 X@][$-&6.P(3-4+;Q0+<^CA2Q/'"A^H ((:H9D@'B2N
M7^#.I6/R36=C)HR%IL_D \)1"/;33?;PL[JMTHR_(_U/6/^S$HJ##YSEP^\S
MI?V0>Z\9'!N>I((W)Y&UP_4T+6A5\*FN]+22GD\E=3PHN8?4O#;B$"O'"'+F
M1,(+'<(=-B #O04$H]=Y_E3RG7R*2BHW>@]]#5[=*-P_@K5UQ7*;+C%S><9F
M>+9@=(T:-+"!QOW,I<ED59$,5+7(CE<B&Q*.;DO8V%'JQNW/';QN2\R!F';K
M1YQ[.EF7/B5Y_BBS7$\OBX\*P8=2W!6K, [\D,8(QCSR((IX &,GC"'R'<EB
MET8.LUJK,VAS:2Y*YY1L54.X"QK\IF&#"K?E@IP)^V;R-3*G$\O6^72><<KX
M)$$3'2P^WNX+G24^2<3QX\.G;QTF1^T6XF6Z-_WZG*T3]KC;__/"6#!7N- -
M!8&((A?B0'C0Q0%W?>3%D@H;53)O>FGBU"*O#N685Q XMP/,A&D:6B?6IWY&
M+T"-'/S6_.\DFZWVQ(VJ6Q;-SRI?]K0\5[$!3Q@F9IVBP+L*G>^S_),H]5GF
M^F<=3RC4;Z[D-?F^BB@E01P[,(CTJ0:/1A S0J$?N;XKD""!;U6ZSA["TL2M
M+<G+FEJGD(LTN]-GU-2T)\U*H3Y'+@IU2;V\7M1QPW:J-Z"GS-1O6OXGGUSF
MR8/"KG#J+.&Z"EQUT'F'O(I$%MOCSPK^>/HWG+I1=7  C%GU<#A-SW7QC"?9
MZ>-Z_:AFN.TG^VNZ*72X2A.KC_S0\6,6P4CJ,C4HD)#Z.(0XCJGGT%A-1HU2
MGO8ULC2-V^$$+5 S_>IELE^AQN)G<@W:H^;TL0=SCGC&-OJUKM[ZR;EZTMIT
MG%W?9H4 V7:.K9=7?]:)/%@N>%("UIVY_5S]1 G[O=!5/M<;KK-^W)(2W)('
M :@0:7=\+3/U*[!INT+[QSH 5*C'J7$@*8#<*+: ,D?D#X+_=/YX8$)^K?CJ
MRDK%7:_1\-Y;9U%I$_"M#AM=:Z^T_WN3%K?)ZR0K6*(<*!V/7;WZ;HP#QET"
MB8@"B%SE95(D/1@%@>?$#E=S:Z,#M#UM+$UGO]ZJGVY) FJ\H ,8O,E^N@ ?
M2_X3>+7_U^/+YL9TGU;C$4B<6(P/T&:OQ<<(,I?B$8B:28GW"1M'#T\PT".'
MQ^Z<30U/0.^*X:E+SSTN\D4-4NKVV\N4OQ4/8IW=5Q%V3XI?;>M:7=_FV>;F
M]D"BE-V*6!0[D4]]!AT4JMD[\V*(O9A )W")1SQ/_=TJ)\%T4!>GS)U##JVM
ME7/1L7:O]%ZGG%YC,CB4JVCH<9317P^S)8-E=/K$(\F4_3W3$9BI>F>B4S*C
MPWVA@S13T7[\K,UD+0Z-1JH+(7Q(CU5**+ZHOV>I^@@>/ZNIGU[>7GEJ6 I#
MX4$<.A%$'I&0>CY2KXP,9."X)'2MRI(/0K&T4:<U0B]L;KI%2_1DF3:&Z$EM
MOC5%%Y>I;+&-5QK2:68#QN1=,?D2SZX7CI:.T;VPLP)\/M4+ \*9SF!QY,"F
M(4AF#G$Z@ZS]8*=S'F:_(-)-[K,]K[Y;\5X%C!#'TWMP?LAUZ#6%<:R<>A%C
M$7&D7'S/2"H-VEJ:(%:)'!XT1D"V('7VAFI/C8/U-BE6M?-F/ND_Q?GIU9$1
MF9Q8SYYG#MMEQP [O.-19[YN,B*%,ZV?''X?RZQ>PM9KV_4?U2Q"OYJ@8ITK
M\_0UZI+D0=VH?] YK>7V82.M2AORV;,:<^H)LZW*&)K279TQO<5>H-\]9-^O
ME3]-[L6F3%B[0"C<V,.N%T$>XE"YL"&%E" &62R)*Q%#+N*FNGRXB:7)L48)
MNC#!Q^0N*04W5X\C7)[6V_,9FEAF]\FQ7XL^PHZYI)[/TDQ*NL?6.!+8;W^/
M\AVY<3;!ZP?>U;D35PZ0M[O[=?8HQ,>D3&ZJ;F]>NYB%/A8RA($3.1#A,%1S
M](C!V*&8J+_Y)#3>D3O6R.(DKL$)=D M/M]C3!K(VPC\3"UP^]0,D;AC'%F(
MW A<S25S0SBS4[P39/1IWK%;YU.]$^"?Z-ZI:X=F^M:KHJD.3-'AG&_)';D1
M19710O#*AUPY+&">1 BZ7'AJ A[HQ&R"0S]$Q*,!#X*(V:7V/M7DTE2Q@0A(
MC?&BGK;8)O4^2;39^N*X]$T^^:XV@[9H+T#+Y67+Y5][N1R0F=N4GI%3<9]L
M=N;<VZ8T["?;-KYSF.1\$271QRG?D3Q5C;1>?HA=/V1A! 7U)40,$TB5JP4#
MPBB-8I_XU"J]]N%FEB8M+4K0PK13E2-<FBG)^0Q-K!Y[Y$R08KN?A%$UXDA3
ML^I"O[G/M>#$U0-=C@_OK[;% R_O=(W3E8M]+D(<P##2N?6)XT$2L4 Y&HZ'
MB/28RZR2:!]H8VE?OH:X*X@):I"6/L4!)@V=B//XF=IKL*+&WD4X;ORX/L&!
M=N9U HX;NC?J]UQJ]YE718OSQ]6;3ROD41IR*6 0NYX^/L?J* >J"Z@[@8@Y
M\4V^ZMTCE_81O[E-4F+VT79XZ?]&AUD[\2?YYC\_?+H\_Q/<MZTGYU%S<?W!
M-3]4WUKUE74>-<M'M0^]_88._.7LJK>=A.VZ.+@:?+N9*%<H#F*/8!>JH1&I
M\1(S-5[&##+?"9'/D>/$=%A>(S, 1F_F_%F-=HDLUE4(RYFE<D]T@ME0.RZG
M+U!4MX/Z C2X01?X)#5US;B:JM#NB=9?JOJN&2D])7D-'V"_B[+=<MZ=32W>
MI675TO4M*=^0-=NLE0Y\$G6L9G7Q9Y%7*75_3>4FY57FW;NDOKE)L*NN2#*^
MPEA&'O%]B%Q=9,=U!,12)V%$W(N%0XCC&&47F1[JTCR4%B]@.\ Z'".IC-=!
M?MKIV^0",'*?5($9ZGKUI1-%"4ONJV.&][6%X+XRT7RW8^*WXO2^TG+Z>F+%
M[M;\Z=AZ 5IK@387;.VM<@34%:/K6"AE$:B,O@#;5Z9C]P5H+ >?E_4.F.^;
M+>==F#-<:PGOA-6.WCS=U+,O.#& V787YR&RNT<Y4XO#)E>_)&FFTX:W=4*O
MOJ5J^+U-[CL511\_*QQIN0II3'DD,<0^8LK=$ 0J+X-#3,*0L$@&KA^L'D1.
M,].9E47K-DK2Q3#A=" I[K.FP'<F0=9B5]Y#;8W=#,NF)\SF6!.Q._&8_4E]
MPUE:JJ;6>DJU*UN\A=\M8$P?06W!>-.M ;2-.N&R:7_6*=< 8IY/NH8\8LQ5
MH_:W35+\-[5SKX]R;)=YWV1%6:P\'B,/!0BZ2&N=^G^0Q#Y1_W(9]0/A1@YN
MEY+.644R!31@:6EB^6OQ);;EC\_LF7/6ET9E^Z47G;:0IUYILF5MAN4G8T@+
M6).RI<]LH<KZJ?:K5Q_2--./>IUDZ^PF8<6'E+5Y>1B-?<^)H/3T\;. 2(AE
M2"'VW(A(#]&(&B= .][,TE:-6J1@"U5_A>PG\*K]BT4.GAYV3Z_@C,/9Q-)U
ME"[[ .$>LLR7.L8A;:9EBF/DC;.<<)J*GJ6 GIMGF\:?-J [!3>XVEX>OPCU
MR&JB+K/\CBC(5W3=1"%_)6M1?!'E)D^+G6M[)=44O[EM162 0QZJ,8\Z2/F5
M?@RICS",F7 ("B46OE%PS_E0EB:S#:P+O;#>V@.RK4$7H- F@;RVJ;JLG0ZJ
M>7@J2O6GZ@G@U5JG7=')6"R$^<Q^/2W>\_76Q *_[:B.*>"JTU&5->!+VU&=
M>?N5K-95FR?,UCGF@\5\G333@#)]9UF-0./PVS-*G=G ;"/9.$1T1[N1GF@_
M(G[*U&PDR;L'N +DX% G28X#WU$3!2%TIF0,94!%B'V/JW^8CG+[CU_:R/4I
M SN(YJ)V@+?3H\AY;$R^B-LA8H"_?X 1<^D^CYE_POS':::+]#86CS1#.$YB
MC^8>N&DV'3T.N*N-/5<-76=NZP]\2(LRKUZ=XC+E.@>]#B1BZD_U@DU2,-7)
MNCIK6^<8Q4AR+ABDG&"(A,,@9A&&$?%#2J,((69UAO ,+$M3TITIH&-+E7VQ
ML0;LS $[>TS*'X_>CZ9+TK/TSN3KT=-US(#UZK,I'7FQ>CB>F5>JSR9N?YGZ
M_$<.D^#/N1Y&RT==@K)4+;[[^R:ITE]^W-8GQ)($84A5ASG25TH;$1@C%$(U
M>#'.>21";G6,\G232Q/4%O%%57ZUK#[8+>HSJD,:D&\FC^-2.K$*CL"FM=B9
M$S2JIADT.ZMTF=/P7*$L[K03(EW.NXKH>OR;6*__*\V^I5^K9)""?RB*C3[&
M'<G(=9D/?8YUND;B*/VA$LK09U'(7(YCH_VRDRTM379JL$"CA;]KN*#%"VK
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M7M787$XLK$-I')ZWQH"7:7+1]#7\,OEE#*@XFC/&Y-X!R\^;(DE%472"$G0
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MB8.G[(U11Z])@,XZ5$U)]?-Q:=*V[!,=OU/#6OGXUVR]24N2/[Y/UDIL5U'
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M!"$!B1L3B#"EON]XR"?&=8Y[6UJ:&&S!=E.A7E@FW.WGME\11F5L8E'H(6M
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M,M3W%2IC(IG DL(,(V5,QXF$F.08RHC@D! A@]RH]^,%,DSM([)50W\[]HJ
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M1*B$**,84A+&4'$;(0%"68:M,H0[9YL:V;6B)[6TL%B 1E[+L(=.B,W,)F_
M#<R%YS'S>"QE!8K?V(#.&<<][S=1_N@,W^@F7[V&/OYX$DSY.I\VZ\U*;/_0
MV&DZ+F"_+U7J\@>BBCZ944Y#'*<)#"(:091B!#$7 61)+M6R<);F^:6MA]Q$
MLWG1QNE$I)[33#VL<7AI<R''M3)CKY^!_]#;UR=;#VW5 K5>^[_6FAW$5U5M
MK.5R!;[HX'N?3:V'@GW@_D2.POWD=D670=K?O>C"\=VX_/-R<:_SY'5DUYT:
MHFD7G0J4TIAED#&LF!E%4M<M#F"8X%S]@#EB5@&RIZ>9FAVHI:RK!F@YKX"6
MU++Q=@^N9BQZ.5H#<Z(;4-:TUHV#5Y(Z,]6HE-.M[FL"Z;G:I>?#7)3KY4)L
M.4>WKBP6]^K'?SXM%S<+95!66P9?Y:W><;ZY6Q4[YX9BY3,B+& 6DQ0BFG&(
M!=8[9&&,)4-1C(U+[ETBR-0H9:?+UC(HK\!>':#U 7N%P%<)*I7 #:B4LNF1
M<,'J]>_-C;4F Q/7A<OAU+OB@G6Q:6TQSOJ,UOEBF-?&LC_&Y9AVML^X8/@1
MNVM<#L)A\PT/XSDT@@O3*#G58N[#1JB529L73HJ(YP@KNY<$&40RS2 54L)4
M"J(^9UG""3+N"6<TY=0^6.%;)?6?@5!R@W8CQ$6[7UQJT?;,#/C^+Y!_. ?^
MUC1(GNG9^:%!TJ63G!FD%DWEO$,[TF?"#&)/K>6L0.KJ,F<VT'@-YZP4.^@]
M9W?G!97;OBP7RVUQR[J,C]XM691B%M$LC4/"H20)@2@+,,2,<T@I33.:R!2;
M=?$TFVYJ;%U)>P468@W>U!70?@&B%M6A!MIYE'.>R1C1!"(1J/_P/((D2&*(
M,QRK'Q3@66P7:N4!YU'CK.IPH$%!-ML<\O> #OS]JQ%K2[JK_]8(>[Y.GUOY
MMEY4_)=B.S_E^&75>M4_62*M_Z[+XC<_+5?M"I^M8"TUX;4N!UDE$\_B($QX
MP&)(I-1;SF$ <:I^"@,N&<XQ2VG@%LUI*,%4.:?8B@K(3M:*\MWB.DW7PXR-
MAL!XY)A/?3+WYJ".\"\'P9\:^;T&_J- +:$;)";45(:?$B%J"="Y>%';87P%
M1Y37"UY-=KLLURNQ+E95H=OV%:\+?,TB1F64!S'D6&!E;R&N3"T10!%)*E$>
MI9A9U1;V(M74C-]3)_-UE?7Z]3W4[-5EQ[7Q+$_X_"RT:UC%P,OW$V(J!EDY
M#Y$4%R ]<!B%BV0_.8;B C#[ R@N&=Q_57GUN1'%_>)]E8_#7NY6:GIMP-75
MA/5O\[JV,/_O39VX4-<>UN7# \XRH8QA2+@,("*!<K>33$!.,,]H3I7;;91O
M,+"<4_L@-*H UNBBO'3VH"X00+DW M0_USQ3E9#W5R;^DL6V</M_[A*.LE_0
M63!^N\!;34%+U;HD_%Y9L-=V5T9^M(KQ'E9DM++QE\@ZF=KQ'@"W*2#O8SJ[
M3TZY6L]^)3^*Q\UC<[[#& \)R3C,22PA"G (*<MBR!!%<:;^P .CD)NCD:=&
MZXUP9FQ]C%,WOUZD_=#1*K5<'A,JSFK;Q3;JIA;3J-]>L\SQJ*/PPEEEMF_R
M^0L<??N=]?A5:F)0K%"]Y=_$7.\&OE=F9UG5LZ*D%'R[[["KV9 RB@.BNS B
MC"#*)8$X9CD4-,!Q)C(>2#NG_B)QIO:65Y+"2M1MT ^X7JVTR791+8T+%\W0
M01]M*0:F' ^K8.]S>P'/K[-]F4CC>ME>X#MRK_V,ZIJ54.[CPMC+%UUR=AM"
MGV<\20(A8819J,V> -)<><E1'"(J%<7&S*@0K,%<4Z/(NO?J7M8K4$OKG*-P
M'F4SVO.$W<"<Y@Z;0\9"+R">TQ;.SS=R[D*OXL<)#/VW. 1Z;HM7R]?%JTE=
MHVC]LO^G3[]]N?DFR%PW%M0=P&9"AEAPY4[A*(Z4B<8I)%DJ(4GC) Q%DF6!
M<:&/BR29&O5L90/W*_TVW2L12[!<U)UM+4(7+UJ=;E(:%?.!*6NG1W4Z7;6U
MW<N]*XVV?CEH$/#I-_CEY@KLEDKK--;26 2;CK5$(\6@#K]4=F&J/N#MBEZ]
M:/SQ@EI]P' 0Z^IEP$O[=+U?SM4?ECI:ZUFT_#)]]/5%H7+FSZW]R=>=\Z*$
M\"Q&#*8"$8A"(B$-0PE3G&<13J.,A%:;$@/*.K5O8KL!WX&R;8_9LOK>D$MM
M9M-/9 $'_L">7:^*L=N_U\=2ZP>R>+7(0W14''$1!NIKYE_>G]0*;3#@SW=/
M&VY*UXX7:S5'H4:\+DNQUFV3/_Y@\PU7+MO?EDO^1S&?[S9*8Q)3@9B.VL4Z
M9@&',$\E@U$4,)G3,$A#;M?NPGSRJ7T9]K*#6OBZU_F;G0)@J\$OSOO:5HMC
M1OU#03XPEWM&VZ&[A3ULGEM;6 @P<E\+>VB.FUHXC&&_<?2A*)^6)9G_;;7<
M/'U9KO4&>+4[M1'\:YT@L5PT^]QWRW>Z1[Q0/,QG&".1"XD@%X)!Q% $:48C
M&#),L,Y"2U+CG&%7(:9&@%L]]';1YNE*9P\#WM(%++?*7(&GYIAIO014@%6C
MD?G&A?/"]6\GC;$< Y/C;B7^5J^$T@*TU0!?]RNQ/?"[6X)W GP;;R7,=X_&
M6)&1-HX&7!FK':-+(>W8+'(>>K1]HDN5;V\173R6PVE'$";?_RC*\I/R =CI
M-&RT+=&$$H%%B*"(\A@BR0.8AYF.+.8\B2(A0FK4Q-URWJE]FH*W8?)G4 D/
MI);^?)D+9+%[;K$0!L<8P\ [\*>FC6PE^/F:#,BE[(4%Q!;'$<- /=(WQ 9R
M3^<+]GAUG298C#;>V8&]B@<G!0ZWVS$_6VX6Z]7+[!^WLR!17D<:89C0)(>(
M!SE43PJ&$4(AYT&8I7%@5D)Y/ZC-<SY.\>-_D"=B>)39PJ:;9]WT'9A"_W%]
M>_WE\A?U6+>.+GC-Q?5V0_-+]:96;VEKJ%%>P&/1M^_6B;\X=D+0O2]UR<SK
M'T4YHREC 9(9C#!79A%A$<0)QI @+ 4C08Q2HS#ZDZ-/S?BIA&O*M6KY+/<<
M#Y$SVU1TQF/@5\T<"OMV!:=4]MN>X&"&<=L1G%+NJ/W R8O<7M<O8OV>E ^W
MJ^5SP05_]_+/4O";Q2?U45VP@]3]W78WXRFF>8I@1!()4<(32*E4K@ZC$48H
MH#0RVI)S%V%J+[X6'WR:+_^H*UR G>@FI2U\+8L980P+]L"LH@\>*JRWX@/Z
M MYH#4"Q^.4D[(.<2;B#Z)6G',08E<S<87K->!>,Y!@C+\I2B*_;TDV?=;_O
M?<<H'4RK_O\J B2)<TRISD#* J9LG22">4X$##,9$X:2B,295>R\O0Q3(\9V
M$$\C<5$WT]RI!2J]=GW,K)G29:7,J')@_ ?FREKZJ]= 7^T[QEUME^1ET&B;
M"V#T&\WO(,>X4?[N0!U%_U\PE&,4Y5J-\;"<JSO*.F!S1B,1YH*ED*4YA2A,
M,<PII;K-9TXE3W"<L-EZN29S,SX\GL**[G83#??.W>DYP,=YH5ZR^?REBG;3
MZ5UD\0)*G<[52/\?0%3R6T8O'D-L1F27 3<P3[6%^X]M-/?U>KTJZ&9=L=)Z
M"6Z);KOL,0+P+")^ _>.IQDWWNZLFD=A<N>OM.,#+HK9>W7[]4J0]TLN9H1P
M$K!<0AQP E&4,D@2G,)<TDB1 *5!*$RLHM<#3\W4>5\]MTHXH*4S>[./P.I^
MGR^!8."WV%![XQ?UG*H=.ZWJENK-_!^D?X3UC]7K>#38*"_A.16VK][9O[N&
MD[*5_LQ_$/7_;Q;7K-K4+6_)B^;1ZP57_[+:"-ZRM6=,9 E*=<7I.-()OWD,
M"0[5ZXF9>DM)G(9F/1DN$V-J+_-69AT^57V#=E6MP'PO]5_^A*,P^FO1J S>
M\$;I\Z67?2Z=V<=_^ 49F%IN=O!N5?@%% NP6Z+;UA(UBAAYDPZ1J)<@Z3DF
MU4F4D:-3+X'K.$[UHM$<@G_4JWV^_4(<[%I[YR&1$8.,TTR9-SR .$,A3$A.
M2,C"C"3F<3]&4TZ-*Z.W86]/FSBPB$0Q [Z;_8:!<V"F:Y#L;+@2!R[!/6:0
M6L3U>(=VI) >,X@]!?-8@=05QV,VT'@A/%:*'43OV-WI6B2\+.ZKH:_+OPM^
M7[5>*->KZOEJ'O4@I9RA&$.:58UM.((XCR1D(9;*3PU"Q(UHVV+.J?'V7F1
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M><R!.*(>BUO=N.?=IBP6HBROF1JZ++3U7O5)NU5VEIAA0=,HEQA*F@B(HBR
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MKFQEAU''2U-V5_D@/_F"81P/;>K R#I*\H[\^/CC22Q*\4XLA"S6,Y8+E+"
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M/36FV$IG[CZ^@JK?\W8'8.A3Z48PA[.C5R"8>\KN8(R5V-/W0%BYAJ?5[7
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M0U7:VSBFM]C'TS9!+R]A1.\*Q=XS9<I3S%D,PSB6NL*+[LFIOFY4TI0@)(*
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MU&BCE1;4XH*]O ZIK/W@7O9Z_4$6F##.HS4D [@?-H<<8&_PC94%? 6,;FG
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MO2:=+.G8@%#]!G[7*( .#+MK]PJ9@^H:"6,&5'?58-R _1?I^+:0]2#'G,?
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M,6L&:8I3&.<9I0*CC FGJ-O3PTR-I2LI04=,\%LMJ"657 #5SJJ['JK %#P
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M4?6\WL439%E.421-=#$A$*4B@3C7_(D)3UC"&2I(ZG2JX"S"U'SJ3AR"^8J
MG>A@+[OCH8/[M%B>200%._21A=S4,1^M^( ]@5=& U N?CH)>Y# D.$@^CWB
M<!=CW!.0P3 ='9 ,?]+ VHY2R=5*.\CTCWI3\H,Q7;EV9;_(M=2/^ZZ-U[?R
MAYPO:X^228%9P6/#ATK_0S!DM#!E2?*"97&N"NP4S>8JP/0H\;'<T'GY/_K=
M7#425VZCV,OL6/?1=4KL"#$DT('IL!6]RDMOSTC*!6CD!U^ZN+^UP-V]3N1
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MN7%U=O:[/WC5E^Y.*?W]I1%!BJ$(QAF-(4J*"-(,(Q@C5:215IVHU+JPB</
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M=Q^98 ?PZLU*BG+STPTPVK6Y>,:X,_WF]SJ&#%EQ SEP,(NE,"\<YN(&V>4
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M-W2'L:>VD.QE;:W']>! !Y<IL%L9 @$;/.!A$*9# M!=T?$=@6X]_M@AZ*[
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M3.O^^T<SIZW4Z)K0=C<,-9O99G^V7I6)3=.,("453%5N-FV+#!(92\A5QH7
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M!&(>,QB36"02<947RKK2YLDAID9/K915!\T;8 1U*#MY&L7+.\[78Q.8;$[
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M8IA"FJ "JICF<<&9_MBIQ>1 .:9&FJT:YL3S1"VG*DQ[<&[-T+FRLRA'F('
MS.P(?E!'_4HT_38$&"C+N/7]KP/LJ%S_E8\+F!>TRX;+$I+%6)IS:8XAHA$V
M-64Q9)(D2*6"H<PI==EI]*DQIWTRR\!V96YS8\>9P1 /S)0^P0Z3-Q0TM=%-
M@NEE#5U*?1SV$&_-(G?MO+Z9'NB;VWGUG3"-P7;%NV>QR@@KI(!%GF80"5)
MC#0!LECF,I&%)-(JK^@Z,:9&@E5[/MJ4_=Q48@.ZD_OJ]HPV$V-'?.'A#LR
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M,OO)P2;E\',N/V?KLY\?JGOP9)_VBUP)0_IFF[:L-VT7!'/,LYA"D6&A0]%
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M:/,GM <  E%[ %[E*[ MA5$=!Z5QQW%/S'W"[$*[4:=A9#*O;6\[.U?3L'<
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MJ.W(R2> 8^\J/T/M73]J[N*8EE#XU<$\-^BTDI>6$!RH6]I>YV,?]6U>-ON
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M<1L,P\@/G#4"3@_=46\'/W9/[S;9@W?4B>ZC=_P#[BH#K9+Z6ET+417FFA;
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M;'WA<F:O@)\O</8[G'M@_'G]O3J'BH*0_+=<O96K]8/IT21%M]6]BE60!C*
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M,HH2$L $"P91$"E((DYAG-%0T2C!F*2+E;PS&V5VX<N14:R^=:3^UG7'&O'
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M:@U(ADF"%!0X22#BW!R4I1QRE45"8!2$J:-2_?[F<R.:KFW#XI,GT-DQR%!
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MK1WH?G>.!D(W,F/UV_#"%&8%T'E.L[N-+Y(S_U=K_[Q?%S*_,Y1:R!7_56V
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M+$0X#6)J)53>-\C<>'-O)S"&-I+\M:V6/-"+:3]U^D)J9-9\#M)9?*R?;QL
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MFT>U>(WWW]4LZ*AF3,'.=8UZ@='O*FCF]\-V?FLE/3+N&-C[Y66O$D[+WF.
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M@?N&J)EEXMN]$.M?5N7F43')>[4D+%E!%MMAWY)'<U"S>XLC+J%@J01YBF,
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M<Q!O PR-)*;K#\MJO3*^1OT-)S+-0DX)("S7#;>R%.01YH!!DN<XQXR0W"V
M^&",N9%KUXSY6"[O@!KTH39H=I)7P\CU&,1V-'DA<!.:?A=@-B"8^"0JGF.(
M#\>9.'3XI**'$<.G+_5YC/"CJ&XS$B>YI QD60@!3" %5,0"A"D7))0LYPF[
M_!!!C30WDCBQ*Q[\KH5U)(73\%YRCN (VLN<(IS#R],A0@>+"8X0]&@S.$#H
M*&UW?-"]81A1_+<H[N[7@E]_%RMR)SYM]+;49VGB-:K/FW6U5C9P8[*PVY@G
M*8Y@!B)E1.A"IP+DF9! \)Q0E&(2V84<#QI];H1BA I>%<N@,O*^=N,0-^3M
M>&4T/$?FFE;NH!$\J"77MDDM>] 1_BHPXOMCH$&H>64E-PDF9:I!X.RSU["'
M#&.TG\EJJ0OEM5%G[XK%1@U]FU"$4X81B#/$ &0R!S3".0B5'80R&G&"0I?X
MKQ/CS"W8JQ4S>%3?DR&J  2\EM60UZ;BN[\Y<M@IK.W8R@."(_/2%KQ.R&PC
MI3_Z.0.#5Z(Y-=:DE')&X7WR.'>Y>]3$Q[*Z7MZ)A6A+\V8XDW'((X"1S "4
M" $<2P1$)'":9C%,B%7^P+&'S\UL4?(%C8#V9^\'B/5_X9?B,/)GW8%@0!S"
M 1;VP0:78#)11('-Z^$4,'!*YYZH@(-;)COZ/R5L]WS_Y#6^Z@]U"D_<"L2E
MB*4 "",(((\S0*)8 D*QQ%#"#,9.,9^]H\V-JMI*,#[*_71!#3.1"*J@3'&.
M (PC!@B*(4CS+,8D%W&20K?RTMY@G:;8]%C VFZ,>P)KY&7B>$VC;GFB,2L1
M'<%DY'I"W1%?N"K0$>7/U_8Y=M.T->%TE_1*U[(2U:Y$&!013S,F09@(95PB
MS &54H(XCB.4\ 3E"+:-S&[&KP=W3$:KC^YYZ[.;J6O!+<4Z(&R](:N"+()7
M=T2GT^B>9M,4@CLZM4/Y;N29FG/)M[U&:EK'[0]S*O'6!_XLZKH=%?!/4<RM
M#UI?%=QZQW#?,;A>% ]K\D4-NEQ_+-;%G?'"VMV#B&=A%.: XA #F$FH_I5)
M@ F".(VYSMNRW3WH&VANYGDM:U +&^RDM7>E>V$]O\7@"ZR1B?(43@/V'GH!
ML]^'\ 7<1'L2SB^:TP:%#1@]FQ6]MT^V<6&C1'<3P^KZP1T=MCW/1!A%+)$1
MR*A,E:>=9@ G,@=,I$CP/(<A<@I&ZSQ[;FRHC[$*+@+W'G)=P.PLRH$PC,QS
M2BHP2H.W(^KZ;K#P,BW:CBAVI'W"A4W6S.>.4)N0I##(6L.%$!RE4 +UC4(
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M0TV=P-VC[I%,Z[ZKA[KMCRO!:EI1_UX($T^UY-U2GK=,9"@2^J"#ZT[6G$E
M$@J!#)D4),OC"%IUJW49=&[,T)79E',D'6%=?60+S&W=7[](CN[9[L2]"K8"
M&SRO;? <X)O: ^39[;08>&*/TAZ*0V?1X=Z!I=5)L?HOLM@T%=9^%:3:K 3_
MO/RJ-RIUN4T=+5'M' A*(X2$("#)H/+]$D1 +D(!PI!PF.<9R25V*J?N*,#<
M&$K+'Q@%KMK=GE:'0'UC6RU,7)'C&8;SY-C1UYB0CTQE;FB/6R!]((I^BZ*[
M"C%M(?2!$!T4/Q_ZG,M*+#S/J]ZE15:W20SC.)088*[L,Y@KJRQG.F61PA#'
M H4L8ZX9T&?&= M#F2('^GVQ),H[)@K I2[/K!/0W+NTGD':^CS" WH35U@X
M**W0D==_B86ST(Q29.'TJ"]29N$L"*<*+9R_\>+"D:>ZG#81"S&C(1:I!#SG
M6'F#NKTT37) 0\ZR##$$D5/FG?7(<S.XSG4>_NC<*]I^$E*$(60B!6F2Z!:P
M. $TB@@@*$M@$F=238E;K.@HTS!-H.CUY[<?#F+@WKH$P%TX&]8[?/X1'GO3
M[QBT7XBI-#)JN4D[A,8J%7EF])<J\V@'2D^)1LL'#$Y"6"F#6+P3]7]_6'Y8
M?E<O2KE2*]4MQ@@AJ8#/4)XK2U4(0#E-@4 "QSAC2<B%FZ7:.][\K-2.<'_]
M2QY'\=]>%8T&KP/>Z. <2]V#N!TK78[B9-'21K[@52OI:QWFTA'6:WCS>4Q\
MQS/WC#AU /-YY8]$+%O<-&K;K^W>$\]QR$D"09PE(8"8QH 2E (<T2C&@DF:
M.QU7.(X_-S.U&WM0FZE-$+DRC+3D9O>]:==V%= G8\66R[Z#/2_39$=/(X(_
M,F'9=0 ;.[S#";67: CVTD$<3@ -; SF:3OPM^5J6]CUAOQHPO2JEG,K)<-F
MH;]KG36R5Z7G9D66U:(^6PQ9+M.8$I 1B0 4" %") $RD2F342H1C=U,,4^2
MS<]H>WNO?A)5L&H^7>7]* H-BH='W5U%,:IL*E&QMA+5>J>.&W_ZFET[7IUR
MQJ;AVZY&9DNSU4GO9S:VXU:K.MWNH(S8C<7D.9.Q9ZB]DK0OV28E;\^ [I.Z
M[\</)7M)OI<K;2-\%7?:?2]73]=,/[FM3TFX#"G*0,(9 S#-0T!0DH$P#^,D
M8YA$V*G[SMD1YV;9=@0.=A('M<BNY'L.;5M:]8CAZ(39 ]\(NWO6V'AFN'.C
M3LQ=EB <LI+MC</X1I?_NA&K!^VWURU;*L4P**110@&A.@A868: 8J:W\#C,
M8(0IE,R%88Z,,3=.Z8C6%/W('*M)' ,RB@A/8!Z#/.420!8)0!E3/T80DXSG
M-$292^_82X&<H%7LKDYS4.RDO!Q*.QZ^$*"1F7=7:N^#!33.1-NCO%=J/3;.
MI&3:H^@^??9=.HPPC:DG%24I;_^;6'TOF"[O)+?!*!]VL2@W:H3J^)^:LJJ2
MI'$HLPS0A.F:3)0!C+CNI,A#AK(DQ%*Z,*U/X>9&T;MPGXZH PO>>IU$.VIZ
MJ:D9F=,&SHHSN8T!GU=6]"K@I'0Z!K3[/#S*& -#GKZ38J'M:>7#?R,+L:N(
M8>J8DW7ST[54K/:^^"YN[E?EYN[^1BS_+LBJV@:#WO(<L0C"#,1)+G1%/0IH
M%N9 1BF%(<1(1&XA4;XDFQMUIR * R.B8RB.MZFRX^@7F8"1"7JO(L]5L%42
MR'(%M)I703>LO5'S25VY,+PLN#G&^J:^V(78_CEXI_YR%1 -A9G;  4-'$$4
M>@P.\CTG?H.'O$DW;7"1;U /@H^\#S PB$#<Z97C6"'69H,/D5!BB00@.%,F
M.(<04$HXX +#/$D3@HA3K;.S(\Z-G(^6(G:, 3B+LN6IOT_L1N;5H["-L'UJ
MC8G?4_RSHTY[;F\+PL%)O?6-0^LH5NO/\I>RY#O+5E3?R@57Q*(CY6.BZ$3H
MS;]8UT]D&4AA2*(D9"2C3N<TIX>:'Z-4YI"\4L3O7#7Q))YV%.('I=&YHP;(
MB%D;5XV@@9;49['$<VAXKI1X<KB)RR2>4_NP1N+9.]S;#2K/=:/^M$V@00D1
M5'F+"&, I<@!H3P&H41Q%L(,,F[=5_#9D^?V^3?"V3>W>XY3_W=^D?8C?]:-
M7 /:^SU'P+Z/WV D)FK8=^Y5<.K&=U39GK9[SZ^?K+_>43&[C?2.7^!.+YW<
MP#HON0E*T<6C!!?ZH$GWY].VSFT22B*ER("4D>YHQ1. (<2 HE"&>9+D68)L
MR<=AW+E14QOYI9NSK_9DM?]:78 _SV8CP3GZME(GB[B6^VH;6&=*VTT"KSU5
MC@3S1$3J#VXGRAT 6@\ANSQM,KH>H&*7S(?</LS5/!%JKF.!OM=[:6T-90X9
MB5"6@DRGV\$P1X! ' $U&S#+J(PCXI0)8SWRW.C^="[&3O;!-:_MY\/.<QT%
MY9%7 5\ .SNVSF!Y]7/M1Y_4[74&9=\+=G_ ,"K[LBJ9$+QI<Z(C<PHUIO@L
MVRZOHKK-99+B2/$7DXJ_8"0DP''"@(A0&*8P5,ZTT_:9Q9ASHZ^WI+I79BH3
M2ERN4T[,CIK>."++=4&+<EVP@+9]C)7C^?9>K35N+&8S%7;\Y1G@D9FKE;9M
MP+255\.[D]@?8SG XY6K;,:=E*4<@-CG)Y=;W9B)B^+V9_51K9_>*F-^I:-.
MN/CQ?\73K<R3-$IY"&B:0IU6# '%) ,B@Y0E!,LTM.*ADR/,C75J(8-&RL"(
M&2@Y[7CE-)#]+.(%GI$YPQD9:Y(XJ_T12J@$^^FN_/YOZE[#!O^$^I^@_J>A
M@--/G>2#/ZM4^WF?O_"2]JC?E&\NM(O^AJC99.+;O1!K7<24<]-&GBQTI[5%
MJ4OZ56^>U ^/I5IG?UF5F\=JVW3O>#>VCXIU/JBG5[<RA)#0D !!L:()R77V
MA")DPHDR8#AB(4[=NZM.(OO<"*CIC[#5_2IHM ^,^G79X"T 00<!7<:@Q2"H
M0>CV33S19C'X74,1&"P<?< IWS [*VRF[\WH)R]S?&4&]M><=/)&:,\YC?PO
MT-USTHDYWAQT6A$&QL34^5_OA;J%+(S$2L*/ZNU?W) ?3<F9)KUZNT<&891S
M&D*0",( %#@#-&,"I#@B D8LB8G5 =4E0LQM(6QT^'?'$)HA\-LM+F.#.O(J
MT8@?-/)?U>N%61R,#E?F)*51(WC5*/)ZE W,2Z#T&[,S1)!IHWDN@.H@SN>2
M9PT,05Z7[!_WY4+=4?W\SXWR<K8\W#3R[A;:O"F?=_%N:YANO]2,<QP*FH H
MCPF 3$8@QY2"E*8<$2DYSXA3O+)7\>9&H3\OBN!CL5@\F:]<ES@CRR=E%)*5
M:'3^UZ#6ND[[KH(H-I=&B6/^M^=IMB/DEYN\D:FZJU@[0UV[O-'NH$;M<P6W
M%8!'H?!QP/<;QNU7Q&ECOD>!]R! ?)Q1)JCT]F55E*LO0OVGOO9+615U2 S*
M<R(AA" 7* 40I0P0CB* " M9&$:(<#QBF;<38EEQRZ0UWKX*OF&U-Z^/UG1(
MV&,KK3X$>M2*!$_N68M>9M&._R>;F=G6<C-*!;56YI:M7B]4R>T,RB]7QNV4
M8/.MX78&RHL*N)U[MGLX[LW?_^OO-VVL/\JH1"$#"114<3#% &<) B+!4D 4
MIM2N0?7><^=F7=\\?7]:__4O40;_9A_>V<6IG^4NT'YDHC)2#8CS[^IN'[HZ
M$(.)0E.-='["38\HVA-.VKUZLG#1(R)VPT&/_7EH8;:JJM,6[\22%:)S$H2S
M%&4241!1S $D<0QRS!(0DC2+(10("J?XSM-#S8UPM*3!,U$O.+SK0=C.^O*#
MV\A4-12R >7'SJ'AN0K9R>$F+D9V3NW#FF1G[W"W/CYM-.=\EK\*KFOK*&NG
MN+M?5S>ER9V-\BQ&$8T568020*[^A1,N04)H*G-(LA!'MO9([TAS(XQ:6.W.
M+913R9ZZD9,/K0+!RF@05'VYMXZ(G[=LO.$X,H$T$'Z6P5;2JZ"6-;@IK_HS
MEAU1L[>)O*$WD95T$8I.1I05,CUF5?_]DQE:5FIT32^[&P8'K#^*U?KIBYI3
M?=RN=PH?]5NS.VWO=*@VP>EI CA/,P SF (,!0,YE9D0DG&8.G6H=AE\;OS;
MREYWFVD%=PY1MP??SG(;"]*1J;@5^RHP@C\'M1/5%/P^2GN9(:CYCF6W%V#J
MH'9G:(Y$M[L_P]U2?'X$?G#J_=NZ6!3_:U;#S_*36&^[1AFSE:Q63[)<_4%6
M_);%0J8LX2!.1 (@$SF@)$U!BD1"<)I*)*USRGT)-3?^:T-.9*V8.640;=.M
MS4XK;:$NQ3HHMSVZ%MIO8QW5[&TL;S-\WHA]B7D;F63WHH2.QP1=!1W5M%6G
ME.LT6*N=[I>=/'M;^B4F<2*S>]K)=++3?:/>8])[&VHRZ]\W.%U'P?NSW=?@
M+\0TSEP7[*V.XEU]7MW</ZW*@M<_MB<$-"580*K;YD8 PD0"S&4(<(Q$1!'*
MB;1R)*Q'G-OJN1,ZJ,54  >-W,UO[(G5#O/S2YYW),=V&@Y _+P/XH"3+,LW
MV'H-\H[J1 N,!;I^E@LG@'K6 KOG3$;T3FIU6=SMQF';/FU:\=OR@3957+YN
M0PP^</5V%;+0<6%UZ9=KICRVE> ZHEC]6BTCIF9"5:D7D>\:XW3^UK8GT461
M;P5E*-:]T;,T0@"F#((\)1+0'(8BI(B),'?9-YI4^KDM';M>.UP70">U&FX;
M3]-.O]W.U6PG=>15K-4[Z"A^%>Q4#[JZ-Q6R@E;[.L5CIV/0 ' 5=-I5=?Y^
M%>Q>'XV#ORVT%YD^KWMPTVHPZ2;>BTS._B[@RP@Q;'TT?>4[C]Z-=XLBO?V7
M9T!PTT,02I SH9N62I)$,DMQ[)0/?WJHN:T\1M)@N2.6Q4YJM_6G!UZ[Q<(/
M:",S>XW7,_;=R>F/><]CX94F>X:;E-/.J[U/0!9W>*A5^[94/^JZ8D+_BO_/
M9M<SDT4,0@Z@S*F.5X$ 2ZAX!%*1((P9%=:A*M:CSHU#C)RZG_1W88X,R$[4
M"^JHGL3\_*;'*$B.3"Q':Z;NY*Y_/2ZP%Y2G]0'P2Q:G'0#T9:5ISP'F4ICV
MY+->KBSM.?5ZB]*>O7EH:G-3C6*[1[XK%=ET7KG^46A.IRF5,0(I%RF -,D!
M260,9(:9C'3;4T[=<I:MQIT;J^^.E)Y51U62.D8NV^)N9R6.@.;8)N, ( >D
M]SK!XCEOUV[LB1-RG0 YS+1UNWT8)2GJ4^XS;\[R="A-\\_/=%'<U>LP1B@D
M.14 2:[LS%Q9EP2G N2$9HG + WS]/;1Y(8IH5=K.U*R&-GE$]H??\2MM5K,
MH-S*&9!U0,5=L5SJ;ZR4)@O6C:)LYH&)+,VB- <,2[4L\"0%6/?*BE&:ITDJ
M$YRU\_#STC)7>919:$>?>@[$DH^'OMWBX!G/\4U^+6W0PJGEO=K^M!/9WRKA
M@(_7%<)FW$E7!P<@]E<&EUL'&JKL7O#-0GR6>M>SVVQZ&SB<9#DG,96 $1H!
M2*(88&6?@A0C*D@HF&/4]ODAYV:>?ML\/)#5DV:<W?&'*8KC:)V>!]O2,/4*
MX<C4TPK['#[3?;DC>?#[C3F@&B4^VQXOO\;J^6&GM5.M83@P4>WO',9#-[H2
MP6;U9*K.F"I4VP.<6X:H3 G3M),DVBKE@"8H E)0'L4\AI(Y-2+N&6MNS/-%
M/>A>%_=0W\ZZ$3NHC,C!JV+9_-.Q(%<?UG;\XPG!D8FGE3(P8E[5Q<UTG_=&
M5'_\8H&'5V+I&V]21K%0?)]*;&X9ZN%VJ>GC-F==)&F2X#P"5,8Y@$D6@5RF
M6'E3,HE%F(<X=#)@3HPS-^[86V$OJ =P"E@>1UF<1A(@@22 @F.0APIB%.4B
M09!E69C<?A<K6DX(;7>\/S.XME[HQ8"-[GD.0&J M]F+@V</\_A8$WN5O0H?
M>I+]E[LWA;E9$5T+\-O3 RT7M[G .<90P45U'84XRP".:0*(2&*98,QSQFR;
MP3Q[\MQ8M1$NJ*6S;_WR'*[^C_LB$$8WJJST=VKP<E37P8U=GC]MLH8N1Y7H
M-G(Y?H%[Q,CG)2L7Y=U3DTE 4!22'#,02L&4=0,)R)7'!!B"4,(PPA&$MF$A
MSQ\]MT^OE<X^'F$/JOZO[C( QC[8:P0;D)"R!X)]Y,5P,"8*K_@JOHOEQI0W
MWBR)E,6B,"TVV:9:EP_JC;P*SKXS3J$5QQ'IB9_8NV&R((GC@G8C(4Y<,;2?
ME)H(!=O3+ZNRJFY#90W$C#& HXP"F&888"HA$"24$64<Q]KA*M=D8><5/'^\
M$RUM!QEQ1=1C!*_(X^.J_%$\$%TK?24>%^IJ8_"RLEH[[M#LX6GG"@Q':63N
MV@IV%1C1?+8%.J:RY\X]SX:8N+G.,?4.^]\<O<K=L/BU6 A%G$OQA3R9S=UO
M&\9$5;TAE>!?Q=UFH:?CZ7K)OQ%UI?EULZB$$$)E^&> AW&B$W(S9?GG!+ H
MDX)'<9K8Q3%=)L;<#):M)D&KRE70* .H%CO8J1,H?0*C4/TG^_7]@FD[;Q!-
M,QDC$] E\S# X+I@0NR-LVDF9B)#;I0/Q<FRNQS.'BOP@H=/9C%>#D#7NO3P
MM,&=34U-\[:V^8>ER=K81=:9J-_;)(29H(P"2C$&,$<<T PQ0'FNEK(\EC%Q
M; 5A-[#5MS=ILX<ZR8@8Z?[ZESR.XK^]*AI=7@>\T<:Y^:?-)-B:M=Z G:SE
M9MV0X54K\FO=@KX&NA.@:^3VVB+3 2??W2UMAIZZ,:4#'$=Z2KK</8RKKIE:
M7#43"OX+*99U%9WJ_OVB_.,_!+\3VWX[QUOK-"9#)N.(Y;GRKJ-(F=YI+  )
M4PZP9)"F D&8.K4]\R+5W"SQGZ5L4F[:_EBE#+1:?_U+E(9_T\H%1CO'B"X_
M4VA'A)-/S,@\V=$GT H%K[1*KZ_,O 2[*>EV-SO9Q>R<D>Y,IU[1]LJV?B2;
ME(R]@KG/U7X?[KYMTNF9^%]DL1'7N@1:U6Z,A#&A)** YYJ=,8>*G;,($,(8
M$AF7(K7>&.D;:&Z$VY$U,,(&M;3V7G0OK.<W+GR!-3()GL)IP+9#+V#V&PN^
M@)MHZ^ D@.K7P=V*+/7RLB[5>B\+IEY\4_'F@2S)7;T[KW_4ESZ2)Q-_O VJ
MU!8"*Q\>E*U0Z5 UG7:B;, V]80$2?"T"NHTF)_\;$+80-^SS=![^V0;"39*
M=+<*K*X?9F!OZT0W'P%.&4U('@/(H0!0Q!+@F.<@9HSF."8Z]<W%5-Y[_MPX
M>&!5^7W4[*S3"[ 8F6)W=>#]6XDGM/9J[^V/,:GE=D+!?1OLU&4#DY+$=^5G
M*_G>EM6ZBFY)Q).(T!#D"&;JN]59\B3F@!$4LPQQ2A*W#*3GSY_;=[L5SS&[
M: \UN^_V BS&-HU:R0(CFL=LH.,J^TW]V1MCVCR?XPH>)/6<N&Q AT_RX^U&
M=V;XSY)6UVQ]HUPLW3RTWOQ_IQ;UMGL[XHPD&<] #(E:@CE+09Y+"00*!1>Y
MC)2_9-W_TW;4N7W@<1AE=>T7M@ZTU/H'AUZ9UFB?=Y-&P7!D8M#(*:'-0: 6
M6\-XM<7QJCU#O J4^#;][2\ V*%5Z1A 3]7(U %P3_U.7='JZX9J_:SI>J6Z
MJO>LDZKSS<.LL*^"+4A5%<IOKFO^;]:?96>SS9R(O"T?'I7[)I95\5WOM)4/
MPN3QWH:4"H[C&""H>WT)D0 2*\,-\Q"3F,(TA5:-GKU(,[<%8%^9H%1?5RF#
M[I9X?5[X3*.@5JE)E7;,,[IL.NV,R<DF:>059N3Y<;98O>#JU;Z]3*))K6$O
MX.W;SGX>ZFYI7Z<_99DI/:&(_C_)<D-63U$<)FFS69-&.4.((X#"- 8PP1SD
M80Y!0AAC"+*$V)T&6XPU-U+5TOY+?9YKA ZX,O^TN/:&WSETS]O3'C$;F>,.
MX-+6<B-Q_>OHRL WX"CB'([V9K-'/"<RECWBZF0R6R+58RB?>\)DYK&E*EVC
MV/:68:9PMS)\I]8X1BEB6<R 1%D(H!0(T#SA0/T>2RHHQZ%389+CP\R-9_<:
MB+S2J =1Y)CB<@)2E,<H3=6J!3.J_H- !BA""! >J_]B"642NI44N!S4:2H*
M/(?5"YAV1OOE (V\4CTO&G45_/RC#0=JFQC^2M:;57\? 6>;NQ\6K\;TB:$F
MM9+[U=TW?\]</3 ><F%F17!S)&QBPK4%K<QGLV0WS0AO$Y9@D::IX@2" &0P
M5_]B#*28")E%G%*1.04\6@T[-Q8VY7.:Y C6$;=MHNL8QV@'O1VA^ =T[),F
M+6>#9;.-%ERO5NH24>]K_GP&4_?H0B>(_(8/V@T];7R@$QP' 8!N=U_0T>>(
M0Z_##=\72[+KC/I%_[E<7B]UEZ'FAR]EM5Z)=;$R+Y0NY*EC7<P-;X0L5[KZ
M_*URV[% ) $1ABF J5269!Y*0+#,:9HKSHL3Y\Y HXH\-U)4]L":% OS =^1
MXG0UVY>:8CL"G=?$C4R^/?NH;4#X\>+%W\1ZO=@%\77G_EDX.35*]QZQ#NN9
M-,D,^>^]-*[8T_=PFF0:CO:"FF;D:4_OWI4/ZN.YI1(G7.CHC#1G>FLC B3/
M(Q"%%'.:8!:%:(KCNUJ<N:TSEYX/U5I-=(#7S.BX)WCN\S3S([QS4S39&=YS
M9&=QB->(]*<XQ7L.GZ]CO+VG#J/H+ZM263-ZQ;CE.<)AS 5(<TX5W>(,Y$D<
M@C3)>2Q2F7!J5<3M\-%SH\Y/8AT4!D,W]NN E9,\$<I5 CD.H4[>CY7OGE 0
MBT2*!%+&.7+;(QX&US3[PG5YJ=7>BUH%RDPP^2AU!LI5L!2&W]:VD81'@+5;
M(H:!-3+=Z]=JSVO898VV.;_7Z_6JH)NU2?19EZ>R2?UQ_B%47OF[\_A)N?A0
MK7U>/7+%@%B''0^KZ6US.[4XS_([*^7]O5<V<W&WK,\#V-.ND=_V)6C>@>XK
ML"Y[L[(%9Y%($ -IEDM%,TS1#$P20)"45&9A$H;2.I3B1569VQI@5E5WQGIY
M(&T"0/XT,STR(W<-;<W.G3V90,.QG^9?9V8VF 0M*)WVJ,,)?4@$R\N^9PX!
M,G^:]VVB^)L_U7OG%N$SBZGN"R!Z60&GBT^:Q40\"W^:AT3#_."W)LO^K?9O
MKAO^BS(9AS*F@$AE^4*FK+ <I0G 41YG$8QERD,7?_APB+G91+6$=:NBX-6R
M#![)*OBN$^(= ZN.H&GGUUV&T<C61 ./D2ZX'B&3^[3V7EVV(\-,ZKJ=5G/?
MA>NYTE<#XG=%Q19EM5F)C[N>0HRD88PP2/.4 ZC6%T!HG@(1\CRG-.%QGKLU
M:[(8=6YD<.S ,]C)?5&W(9M)L",,[]".S"%>4/70![<'I9$[X1X;^85[X?:
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MFBQ5P3<XW80&[\\>FG%;LG_<EPMU1Z5/<-9/NHWB[MQF%^8%(T@XS0A(94P
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M8RRFD%JUU#@WT-RXK9$UZ JK(YM^LO?O>G$][SK[0FMDTCH)U( ZA;V(V7O
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MDNN")A#D:8:!2%#$(D)D)ITVH0^'F-O'N&VHKD5T+-QTB)_=>GT9*B-_G,\
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MP.[E.IFC7%ZOMREO1WJP-"X)A"P5)!8@QHEV#?,,4 0YD)SE* I%S)C5+MF
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MK@K\>0JV#)P:KS5;ALHPS @S[5?NRX6ZH])"K)\^E6NQ;>!,6(H8$1#$(J0
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M>LC+U\IXF/9R[NH[C'WY@OOM^2]OUH8F%[_4GK9:;>^KLN#;PXQ0BAG)5"(
M98PB?4"9PY1'&(HDB52>(,-<6.U&SAFZMA? SD]K_:2S2)J2\GA\O--JZ^(,
M-$Z"Q_9W+W-2?8@XIK,SQB8FI,LAGU)*S]</K%(T^O:WU4H4B^7):.J<4R&#
M..-JKZ#%/!,B(.-1!B,>Y(&D'&$BK2H5E^U=&T6T?EH6)WHP-2Q0N$/*=Y&B
M\12TKM:3\:VSX&/K[OFDV;Y480:,VW)%C\UI2Q9F )R4+0P?&RS0)-3GY^IS
MF\LRVEQGN6C.QE:KK:Q6_[!5OJ[U;FZ6^9U:ZG*>2X9HF,8*>J&R#T9SR/1U
MWSG# 4,(AP&++>6"!SER;=2SBZ-1%*DC 2O1M!RH#8K6$Q&U&G"UBZ_M9+"6
M=!JV;F8L-L5J>*:W_4)H7FN"F(%]&$#' 8X"F36*3O5T5AV,4P6G47"Z%G(:
MYLS4>DZC('M#UFG<YPWCUWO=;E MM8S4^EA9:G?B'U$69Y0H]LP1Q"0)(%,[
M.+6I8W%,XY0%Q.AR"U.#5\B7QSILC?^U'ILE)_9B;<9]+A'TS'%=L#S(XYHB
MX92>>HU.2D.F$+RF&^/GAJ9M[1C.@^!/RZJL%MOOQ>+I,*TD$8EC&4""LQ#B
M3'+(,$;Z!AU!L6!QGAA=2V9H[]I(Y6L]FZ18Y7E5Y2_<_K:%R^B:YE#.,/.>
M*NV&N@ZN@L97#ZQBB(OCG.>RS8E3&R, 3C,8L\<&BG#_8D6IR]AJH_F#E>*@
M\:U[Y[^R3?NWG\7FJ5A^6PHM<7'+BM6?K'P1<Z* 5QL_ I,T4823H "F!*50
M\!0)*5,A26HEV#W*G6OCHSNA-AL/3^HE'0Z0!AFY-&9L-1W@WLDLVW1N#9B!
M?610)?A0QS8#VG%0>SX#;6Q;]95ES5[ZNEJU!_RA]@:EV/\W^%RK1NJP@0K?
MH0JY$^3=*I:/<VE:=7,G\)THH;OYU,$]B%SH*19]Q/B]6/_UVU8EC_Q)CUS?
M_%NLYWD2H133$$8AR2'6W8@)D1B&*4*<\PSG%%LV(EXT>&U\>N0OT Z#O;_@
M47MLJ7G1B[AA\=\ACKZK_R,@'-*F:(2+ZU[%RT:G;E@T@N"-KD6SYP9JZ_ G
MD;^4^C(HE9XLQ/K+\N8P)'=?K3?B[^>RVNJ^^G8#^RTKBT73#O%0]SWLS]$S
M1A*<1$2M1$!5$AABR&B0P5!$) UDF ?,3HG'H7/71F&[V.K;X9KH=*=P)SYP
M'."^0M8)T5+8Q^5:FQ'B>ZV@9_)TLGC@L8[/3VN&#^#=RA*Y='!:$2,/T)Y(
M'OFP,;34F&V^U)WSVM@?ZL="M[[])QJM-RWD@# 32/>@J>=5-DI("#.*(QCP
M/(@XI5D8!O.E6&C7'VQJCCV&C0@A;0CAQ+P_<NAX6D\L-KJQ+\::2.; F]8A
M7> XX>;]X.P,=,'<^>NR%&D(C>-B9)_5B<N1AB"<%B1-'QR;F]X6RV(C[HI?
M6A9HH[YA"D5PS3%NS77S((@1I4$$8RP$Q A3F(6Q2C]3$B'*L PD&I9Y]IF^
MYKRR\1W6SH.#]VTW1)M_V*I#FB^*;8KH$NH)$\"1*(]([4P!\Y2X]9I_I[3,
M%);S29?Q)YPCMNYJWZD_??JP^Q?U2\;6XM.'_P%02P,$%     @ #EA75"*4
M $*W&0$ 108- !0   !L;'DM,C R,3$R,S%?<')E+GAM;.2]:7=;27(F_'U^
M1;T]7]^HRGWQL3U'2U5;GNJ2CB2[Q_,%)Y=("6X0D %0)?:OGT@L7$$*RTW<
MR[(7%DF!]\;R9&1$9&3$/_ZO;Q>3'[[B?#&>3?_I3_Q']J<?<)IF>3S]]$]_
M^K>/OX#[T__ZY__Q/_[Q_P/X/R_?__K#ZUFZO,#I\H=7<PQ+S#_\/EY^_N&O
M&1=_^Z',9Q<__'4V_]OX:P#XY]4?O9I]N9J//WU>_B"8$/?_=?X/OJ3$N'#@
M4N2@"E<0)!<0O M1H[""F?__TS]$IG40W$"**$&)DB#:F($7&:SF2B0F5@^=
MC*=_^X?Z)88%_D#,31>K'__I3Y^7RR__\--/O__^^X_?XGSRXVS^Z2?!F/QI
M^^D_;3[^[<'G?Y>K3W/O_4^K?[W^Z&*\ZX/T6/[3__G+KQ_29[P(,)XNEF&:
MZ@L6XW]8K'[YZRR%Y4KFWZ7KAT<_47^"[<>@_@I(=)+_^&V1__3/_^.''];B
MF,\F^![+#_6___;^S9U73L:3R=6/:7;Q4_W7GU[-" OOPJ=*Z^IOEU=?\)_^
MM!A??)E<_^[S',L__8G^CEXI.!?K%_[/F[_]Z>;=7^:X(+BL>/V5?K%Y1'W9
M$73@MR5.,ZZ9V[YB,DMW/C2IHIW-MW\Y"1$GJ]^.,HY'JR>_B(OE/*3E2 >E
MK906''*"G^$:@F (D7,G8E+)Y7R7[4KS@HA>:6*!Z<=/LZ\_T8-_JK+X+U6_
MA?6W*Z$\>.5:.,?1OEU\;Z9E-K]8R?1CB!,<96FQ<$1P,3%:139#*)&64K*)
MR:1T$OYD-AY[^UV.;BO\Q3S],)MGG)-EV;X^S-,#Y=]%]>83/WT)<WH0I,_C
MR;4.JHGI0I?+6<=27:N/2/_3#R2!@O,YYE_7VGN4T1672[*]N/KDL<BX7,"G
M$+Z,/I#0L3+R:A(6B[?EPW*6_O;BVW@Q$E)'6X@'4W($)9F'P+2#$@J3 I/,
M23\!CQ(6<47UYDTKC/R$D^5B^YL55(#QC>WYG]\EJ3_,=*/M60O1#P!#M^E_
M/;L(X^G(*&+<BP*%BP"*,P4>E0'TR+)))KBDFH#G(2W]H*9C)<\ZE?@0,#.[
MN)A-5WR\^ M>1)R/(J(/+B.84-TUGLA=2UZ"<U&**%,L1;3!S -:^L7,J=J]
M#Y;31-TC6,B[&[V@\(*QWV9+7+R^Q'^]G**H0<&&D< C+1J*!+*0!11&LL19
M6$B>R/!*R<3R=SS0[[YD+S"(@8.A6U'VC0G+W6TV.+&AM]!F B77$73(Q$8T
M$8*Q!82D'=J+S,B[VP<1C[]B+SS(YX"'CL38-QKXCT;H^[ V&T8R%J="#F"3
M$Z T*O+MT8/41D@18O19[F<A'G_)7HA0SP$1G8FR;TR('_E=1J1@DFT8,4SK
MDK,!XX(#Y4E&C@4)6A1B(Q&73NV#B:=>LA<F]'/ 1&>B[!L36VCG2R0.^(:#
M))F5QC)PJ1A023.(3B!D%I2W3!FAQ#Y@V/GTO5!@G@,*3A=>W^K7MYP?8D%N
MK9J5JNB4H427057J?06TBH*ED*U1EN^C_]V/WPL ]CD H /Q]8T \Z.UUX8L
M3"_#_(I\'KG=WX+1A:=2@(P6!Q5TANB-!L>Y+#87)<5>V\+3K]D+$>XY(*)#
M<?:-#'[+[1%,;<&-+"7GB 4K,8)2@N)DERPH&6(.TA:=]PHF=C]^+R3XYX"$
M#L37.P)^M!O[MMKAE-_PP*V64G@)AEFB'&T&GXH$9VAS2];E4O:#P.[G[Y=I
M8L\"!!U(L'<4\-M UELWAV>MC'$*2HJTM>7B($:R9QBX4P*UUQCW L'.Q^^'
M@:&G&[N27^\0D/86"V;+@HHZ)!T#B$@AK[*R0- J@D81M"NJ".[V@L#.Q^\'
M@>>19#Q=?CU"X)'3OE_'4WRSQ(O%B !N=+0<DHBTIX5HP;/$02@,)4EC(GOJ
M9.OH4_-K"OI)1W=^"MJIH <"F(_TV9'*R6CG!5A$5\,@ 0%Y@FPSHG4ZR>@Z
M TA]XZ".Q8_4WPY0'"S,@8#@Q90BH<E[_#*;+T<Q6L%<$A EA<CD &OPL89$
M69N2C>6Y0VMQ^\V#LA+=@>)HX0X$'.]P/I[EGZ?Y=5CBB&(CY^L)K%=*@7+9
M@[/< R+C@EN6*$3J#!UW7MW/&59S>!POWI[Q\>IR7@7WRWB1PN0_,,RO>>"%
M6\,"2,_)#8L6P7-/^ZN6)?ED8N;A]%K#1][>S[E6,Y1T(N2>@?+S=#E>7OTR
MGN!OERN_>A5%([.@>3VH1?*KO4X*8M$BD52,<O9D@-Q_:S^'6\V <9)0!P&(
M]_AI7"M:I\O?P@6.N*-(*U*HG;4E0>B8(&I'WQ%/.F,2*IR^L>QZ<S_G78V!
M<8)P!P&.-],TFY/'M!+*JB#QU>QRNIQ?O9IE'%D3"Y<Z0PZ* G,6)<10!!@7
M>5;TC^2#=X25)PGIYZ2L,72Z$_T@D/0Q?'N325+C,E[?1-G82S19QI(%%.$T
M>5J,@4?,P'6]<*,YJM+5)O0("?V<JC5&3Q?B'@1N7N1,&EEL_E/%PT=:*!6]
M,.!\2F1&R3OW5I"07"FVJ)*#>ZK<]Q#,['A]/V=OC?%RJIB'A)57].W;^<?9
M[].12C'PC!%XU :41V(A*TZ.N@_.,)06G[J)<@12;E[>T_G<>8!RI(R'!)/5
MGOIV_FX^^SJ>)APII@G41'CVOM[G"H:<=I8@N*R8#:;DW#%6[E'0TV'>>0!S
MBK2'A)IWL\4R3/[O^,O:#6.F!!L(^]F1B2Q"@M.\@"XNE\1X$LB[Q<R=]_=T
M]G<>Q!POZ;XS<I6'.885W4PF'J1F$*1,-1\0:X+(0K(^9:68B?;T,YW;;]P/
M$\\G07NT-'M&P:_TKY-WGV?3;69(UI,GPRU$QQFH3/ND"SQ"5,(I81T/]RM!
MCD#"_;?NAX;GDX@]2:H](^(#ILLYH9F+^'&\G."(&Y$25P)LB13$2R/ <6G
MT]<L+-?HV,F(N/_6_1#Q?#*P)TFU9T1\G(?:^>3#U46<34;"%HK'"<HJ!H(R
M44O&32A@H3#/2W$JGG[B>^>5^V'A^21=CY?G0$S#S]_2YS#]A*MLL>8NIZ(3
M:*N(?BD=635",T:O=$ 6,71G'FZ_>3]8/)^$ZLG2'40 \E><3/[WE"+N#Q@6
MM 'F-XO%)>V E@GI@F0@7%2$=8D042E(+F15+U(9>[K9>)*$_?#RW%*H7<A[
M$,#Y]]GDDO0Q7QU3SA<CC_5VMA1@LG>@7(K@&/E-*93@B$CEQ.F.Z,Y7[P>4
MYY8[/46^@P#(IKIA71M5]T_2R>5BA(E\ZJP-:)-D#;D1O,$(,F%BVCFTHJNC
MX-T4[%>)]MPRJ!U(>Q"H>3.EIX6T''_%UV$9-FR-BDJ%Q8P@.'U1M(^2>>09
M@K7%\%"D$UT=Z.VF8#_4/+<T:@?2'@1J5C;R55CBI]G\:A2U2-%2K%84>>?*
M.ELO^F5@*%2B7=5(UE4%P9T7[X>1YY8X/5ZV@X#&AXLPF;R\7) T%HM1(HI%
MMAZDK(54U1X&ZSQPIWT4O""SIB-HW'GQ?M!X/OG34V4["&C\?('S3[17_GD^
M^WWY^=7LXDN87HV2"9:89R224DO\O8%H?"1>8HPJ>%WNW[\_&B(["=@/*L\G
MN=J5K'N&S)M4YB\N\Y@^\6*YQ,5:);],PJ<1MU;E9!T$4R\3DRD$GU* PAWQ
MH9*+3IZ,F,??OQ]@GD_NM2-)#\+$?/A,\?X6[3*ZP@7%;"9S<L:SX>!*+&"U
MRSR@E-R>GGI[^-[]\/%\\K$G2G80N'AW&2?C],MD%I8CGE6.2G+ A)Q S041
MSQUX'111;DR(I_<]?O#:_5#Q?-*QI\EU$*!8-\9<77K^\)FDN'A[N:Q-U^OI
MPRB+D*2,]<)SU"27569921#".5=R<49U%0$_1<=^L'EN6=G.)#^0:WT?YV&Z
M&%<);:XFLJR0*U%O1#N*Z#D9R) UAQ)$*5B2%N'TXM;'WKX?9IY/@K83*?>,
ME!?$0*Y,K/PJBMN]9S5@RZ&6XEKZSB4%J)/B/O,D[S>5.0(>=UZYWX7/YY.%
M/5Z> S$9-[<0?Z'?+$:V6$1,"7+( I0("KPD/B1Z1(O)>WOZ?O/(R_<#Q_-)
MMG8AXT'!9'VO><T$TTJ94FLHC2:CY]"!4XEVRU)D9BE$QD^O<'[T]?M!Y?GD
M7+N1\S#<66)C'B9OIAF__6^\&IG:EC?4AGLJ!E#H2SV+(KF$K)2PA'E]>IID
MYZOW \ESR[Z>(M^!6)/%S7U$S"^OWE=*<)KP(WY;OJ0/_VU4-+,FY0 L2'*^
MD\K@R2&'9$OBL?;Y"]UUK_DN.?L!Z?GD9MOHH3-P_>-/#^1,//_MJ*%@JXSB
M+>'=)7:OV6 /'G'ZB+"GJ3IQ4MBJ_=F]%UP/FG(^9YE$ 5%+W564&9SQ!G2M
M&"@BZ.3W:C/]R/-/BDW6R=]505TLF) 5!$WA$[E(3( G(-*/4JJ )O .DF.W
M7MA/\ZK.-'4G)#E2C'U'IFNR?QG/+][DD18H.'.1?&(L0&&5!)\8 \L"5PI%
MMAVT)+KSRGXZ5;5$P!&B' 8&?MW,ER371A=6IW](5ELW>V00M.%0#(\L,%NT
M.SW&N/?2?EI2M<3!4>(<Y&;^:C9=S";C7-V5ZXEFBUEY^P77K2T61VSO>SRT
MBYF@AU%^H@NP;:A:_;L+O'[A-:*2+SZ:3#BRM:J4LPC!(P=&]D Z+5,(3Y5*
M'3_C[!&"3AWC]AZ_XO02%Z,<8S8F*. IU5;?M;( K0*5 TM%^IC#4W[#\8QM
M*>AW9%L7^KX_M^THV1YM/K[B/,XZ&^ZW6"Y>3///W[[@=(&+:W$$J7(*-H+F
M)9,AU!0W.1/(+<(LT-=CGZ<FYYXRXF\W1?W.=FN!FDYD/X@!D8OEV_+GV2Q7
M;C[@_.LXX>+#;))'F;9CC)(!C[;61$8#H7@&GEPLSS!'VJF;H6@W33T/C.Q$
MYSN U($"!@"E]Z0-(N SL?&:;.ID]J6NMHVP1D5:;@5/X%R0Q$R2$"W/@$)X
M$20/5K1!TY-D]3QTL@6@NE/# ##U 2>36EZ)4_(C)\32BWPQGJ[:!-;J_BU7
MF>DH2E'$E:@-4K*%R 7%@%)QKYW*W#]U2^N$(=I[T=?S*,L6*&N@F+XG4J3_
MNAS3*]],W\UG9((7NQ?2B"@+2=4+ D(%4-I(",EKD&$UU=<(K_<:7[7?ZWJ>
M>=DE=%H)>1"^./&QG%^FY>6\WE+#Y7*R]C6G^<W%ES">K]IFUWY.BQH,CTH*
M%%&0Z%R=Y:>TS^ MEY"X$;;6](G\5#7^2;OA 73V/%VST?;82E$#V"]_FTUG
MZY3+]-,Z[-E:8L\4BTISX&2(0$7G*;K5"DQ,Z+/'X-E35X2.1]RC)/4\M+,%
MN+H1_^$X\FL<3?%33<"=O!6N8Y(/88*+MUMVKN4TS6^7GW'^&RY'.8DZ>RA#
M*74JK6 *8@P!9#%<,6F\2&R/K7#/U_4\X[/KK;"%D(^W0+-EF'1B@=:P_W6V
M6/Q",GPUFQ)?E\3:32;X)9;9'->?^QB^X>+G;R1)TM]X&N97JY-_6D>)_I)(
MFZQ6$AE(,MOD%5BAC"/K*Q.O'<WJ+4VAP17EO#"2EE(;&]:0J7YC@Q:IL:$@
M8#"+@5C<+.R7%"Z5\7)D''/UTA>M9")>%:P!4JF5;U(') \WXU.%R:<"^0%!
M_489[4!XFN0'X,]]?RW1)R:7]4+'N]HA@Q2V7,['\7)9)\9]G#VRC**WT6CC
MP6(IH+)0X+..P!"=8$XB%VV.D=KPTV^8TH\-;:[WP9C/K11>CQ=I+0C,-W(@
M%^EMH74^TBE;Q76 D")M#3P*\#$+T *9S@I9B4^5U'2%Z:>I[#?F:8_4#G4T
M .M+=-^P-XI<)A^2!6:MH!".!R#9U/O]W&D1?/+JJ=YQ)T30M\GH-PIJ@:#C
MI3P $_5SF$_)PB[>X7QUQ?):(E%(GS-/D!#)T9"*@Q/$%B%?6JZR\T]V,#X>
M+8]1U,_HEI; Z43V S SW]_LB<.783%.*S9'C!A2+M 2<?7FKB$K&J00P$V,
MSB%&)MJ4=QQ(:+^G]=V@XV"_['A5#0Z)3V_F=QG5*(LV0= ZKB53F MYEO1=
M8;%8':P-H65$>P3)_1[]GP&=K=0W )S>E]Z*DU$H0I#S@)!3KCVL,5)8KSQ(
M3V&]%(R'1H=J.\GI-['7!%^GBWT 'MM>)OSU>')92YE7BR,+YWTR"(:OC+@J
M$ PS4#2:4A(7R9TCLMR#U'[S>/WMN$>K:P"V[$"C?8=5YSD:JSF(6*K9UAI(
MHA9,77C2)5I];8KJ3B"ZWV3=$/;=HU4X +3>E]^&EY'@13H5%&BG;)T?45N#
M2 TA9I?HI^A"FYCD$8+Z3;2=9?<]1O0#V'__BN-/GXGN%U]I:7S:C"9Z6QXT
MJ+J6F>5,^5@$6%;O:#/MP2?ZHC33SHJ,@;5QZPZEM)]AIRTS+$UU-0!KMB]_
M:T>7&UL$*@:)^P#*UX6FZ#O,3CMCBM>Q3?G!063VFW5IBY@CX7FX^H:+S=O.
MPYU^?M+Q$E3@$+,6H"B<A\@0(296!/>")W]6,_D8H?WF78: STY4^*PN,->&
MMG/\C-/%^"O>.LNZP\M)MYD?>T.[J\U[\=31/>?K][XMZS>]F.8=[[_9\Z56
M.6<+/(=,;B9]B9I^-%X5YE.H?87;W(<YC-"3KP=M7_>QECV,C*6(7W RZ9[5
MLT/!P&LEP 1F>'1UHF&;:]]WZ>AW!VZ)E0>W@(Z7_P!VV!M);>MO7]29,>/E
M&!<?\-/*B_XV7HQL-)[>7V\MK214#W&<5< \6E4;5Z!NO9J>)' @>#L" X_!
MJ4.%# %G:])W,/5Z=A'&TU&,0K""'G*6#!1R!"\"[?O>%U-4C*D\U<;XE.N+
M3U,V$&1U"8<']Q@[U,UPL+8K3_X77 V!UE%KHRR'(A*""N3:!C+SD%1Q,BDI
M,+2Z*_L=TGI&6Z=(V VSCM0R')SMSG5O6(JT^'1F"OBJE*L$#2&G M%%9,A,
ML*)-3< >Q/4;A9X#:YVI9@AHV^X$OU[W!HVQ*(_&04Y:ULH: TX1+TDQ[Y0T
MINA&9NP!+3UCJ8'_=9R8!P"4N[6DS//@6:[EQMK4T*:N(B? !N%TE,(;;'-P
M?WC%;GLGZDB=/EFL>XB !X".U9W*1_(VZSMIZP/:\2S3/\PQ+/ UKO]['2ZS
MHE6P48(36H$2&"%6$-2&]RZ;DI1J@ZD.B!^(H>H&B>=6YH#Q^PLQ._XT7<^Y
M35>K 2YU_"WI=9I7/TU66OXSN18WXGF/:1(6BW$9K_MGUL^N[FC4AD#>@ ^"
M-I"4-<1<&&A..T?A%D4CHWD.[OJUQ6>'[)Y+IC?\#'A-53Y?? WC2?6J2$#U
MHOX'3)?SE9O^(O_GY6)9C=FUWD8R,1MM\5 '$X#*-H)W40#%=2(:6Q3G3\U!
M;+,S',1"O_O#4%='6R0,? F\J[]8K>W5I][-2-"X',]QS?'J4O6["5F(77*P
M7&I'/(&LY4G**7(4 TDD&EYX1.59.?^*.(6C?FNZA[Q SH:37IOC[".)5V'Q
M^9?)[/=_P?P)MSOFBT++]?Z&>2, ,@KHG'(0$"F.$B94/UA#D3$83!1E-6K8
MVS$C_=:?#WE]M$;%P+>1&Z824]X:S."+SZ!B'=DAH@?R&F/(02>!YX?Z80!N
M5IP^9  ?I\$!U!L_Q51EIQC+N(T:3)TOI0KG$&K0$G3AGF5C"C]_0J=W7^.,
MR9I#E7"J!_ ;+IL#Z[KCA4=!<3 GAP8Y+1:5 RT6CV D+S;5:26R34G2/M3U
MNUV?$6)'J6, MFL'.UM6CNK_0SY#-,(8D&A2O:I)R\SS!%YA+-EQ'52;$]F.
M&>EWF^X8N'TJN3.,MZHB?ADH:$SXX3/B\M1ZX;O/ZK8R^ DZNZ\!_F4\I9>-
MPX3"[/&=45H\&,=#1F A!+)OAH.KDRTM:EX2>899M<FX[$/=J=;PQ6)!PKTI
M7%4R6148^,09*,\M1&4*9&Y]YCZ33]KF\NM=.@9RO-L5*NY;IQ.$/H"8=$W]
M^F#CYDJ<ET;S%#2HK"+%2(7\ 6D-<"0[Z;Q1.;>I'=E)3K\ .D6_.Z%RBK '
M@)B:J*D5\_2?G__K<OPU3.IUCQ?+5V$^OZ)M]M_#Y!)'JE[5<5K0'BM-O;6]
MFEJN*=3VZ)26235J";$7>4- U$DPN.\A=:Z3 0#MPV?RZ3[B_.+-]"NN,^*+
MD98VH;8(H?;F5+57?'1>@XO<2A:-<3&TV;]W4-/O<6#W,#I9X@- S8N49I=$
M]WM,2 N!X@"*%39"&O&LM"J6HI"B;1U6D8@7E<%:F0Q#QTIJ<X_@*:KZS6-U
MCZ+.-#  -*UR)C>,+$;<6LP8$EB6:QZ.XM@8,=>6)(9%X3)OA*#[E/2;FNH>
M-2=)>@!(J29S2A^YJB,I-+<\INQ !T^"<$90/(&!H$XR2#GKXELU^[NAHM\<
M4/<(.5K" T#'NSE^">/M;)2M,2S6:@S( 7EM;629A(@E$4]"%Q3<*].F8?).
M<OKM"-0]7DZ7^0" <T<L(Q:TES)8")7N>LL%O+0!DI>J<)>]:N6_W":CWP[;
M#1R6HV4\@!.07V?33_===LS*VGKVG') 4,DK\$PKT*CJ?-Q"OVB3Y-Q!S!!B
MI$Z2-Z<*>@#&I Y1_GT\F8P*TT+'H"!99NJ8 0Z!EP+(@K A,))#FXUG2\$0
M8IY.4'&42 < A3<D[NFG,7G::V&03_7SM\U9VC5/2"8U:61UKPQUOG:!P)P#
MR0CE/A=/)K:1&_M]ZH80 '4"H<Y5,0!XO=Z\]GK*U#5K(\Z"%SD+\ YK,P(M
M( :!X,C]BJ)$J4*;)G&/TS2$2*D3*'4D]@$ Z-V\S@E=7M62Z#I[MJ:U5Y./
M*R^2V6*"D,#UJI]%\L2&CE"L,IQ^;UUH4S/T%%5#")\Z 5%GHA\ C%99I;5L
M_C)>))P03SB[7$U/W/C[2I"C7S2#X#WY^XJ1O^\*Q1!*&N2\-AAN<Z+P?=J&
M$&AU JF.U3  8*V9&2'S,23R^ GX%'LFE. DCQ S:L<Y3[I1YZOU^_L=6=3Y
MR?A!XAQ"[#T.<3Q9WW*;Y@_+6?K;Y]F$A+ZH-G-Y=2T:&9D3(F@P@EPXDE.
M8!!!6^N%$$IEI9O 9%\*!W+QO56-3A-%#< *W>+K?D),VA*]CA&$L+24*#Z@
M=5EH94F&@6.L?6U:0VY0=3QM,/ XT$Y1R "@]1KC]:%MLLXDI\@81T%.'S$
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M<$(K;EN2^7%^6?M6(T_!T^HJG 2E=*T0IT<!+4(;D]?.IS;E(OM0UW>K_,&
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M+L)X.K(Y*,L2A1;,U<'I.8'WIHH'E5-"\ZS:U$;M)&<@R#E=W??[L)TL^P$
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M2Z95&2O!9T20/BLE*2XMC?+9!Q(ZD#SED;AX,*RVG9(&@,&[9]68+4/A(/M
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MK]3)%Q[NUXGNQ-NQ[]\/?,_Z..1LZAE*A')'>JNS1G):$S?)(:"K=_UI64%
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MXGBR\K-'*2=A5+9@9*X=[W6!(%T!PXMAT6')L<V1]W'T#JVU\IF=Q,Y4.0#
M[E]G.'(F6\VL B4=?3&T+P3%*!P,*:E0#Z1TFU/O_6GL=R\_?_UQ"]4=#\H9
M+;V6H%R?">P6I/*H8G &K$0D#DV$*)( 845$ERS/ILW,C<-I[3?4&<I-C*Z4
M.0 ;2OO!)M^V.598^=;$,*W$Y55M)K@DB5=IKP\5+%I1)#.0HXZUYH2#CTR
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M[UQQ^+@:YQUT*2I&#LG7VQ@Y"(A9%S"J!*<2TZVZAI^)P<%6[!V"V=TNQK#
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M(W3"6+YJ%4Y?E/<<G%81#'G8(CKC/;:Y+W4F>T3;=OCT:5YG@JZ:V]Z6_ W
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M1VIA"(#:5#P]8&E[DJ83RYY[$@Y2;&P#0JB#I=$S7:0-291&H'J:L($!ZU@
MW =6A]H8 K@>->J_7E\Y43)ZY1P'(Y( %0JYJ85YD"E[+Y4T4;<IN]B#N+U
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M6=,O)N.+9;B>;AFU\"J"=<'4#M0:G,((OC(CK=<EQSWT?/N9_47'I^ADUH&
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MHF&9H0'CR!DBW\A2A!HR>41%*!LC4XU&YSP@Y%@L\#8(>62!]Y#]Q&=$#RS
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MB!3@% W.6J0 Q],R-%(Q\?]7RC[)E*62 EBF.$^EXJ'VQP43#";)0L;09I[
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M*%A\5*'- <RVE'9M2T? SG9@W4^170#U42KB$4^W(2<)C5RE9&DO"K1G>/2
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MA=N!G7G:.]X9EJ/%!$$3V:I(A*A<AFSKY"J,VCSN8#EIH_YF"9H1P3..L#M
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MUH>A[?O5?)'F7\/%+XO?:+U^_!,OON$_EXO+S^L9-QY+0 &Q9 &JN#H"E7R
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M,(X!]03J/R-'X[>P6FUJZ\=V)9X\N)6S\#P'?;@#1B=426+U4I&"*HP00HC
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M4@JT*<I:BZU-!.166/IA]HU:<?XM+V#L!85G+V#LHY<.0-6DBHP5)U30"9Q
MDF;T")[7Z:(LYB22+5K\^P+&(1<P]@+7*2Y@[*/I'O+ZN^JN3;%.BEA :V%
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MNV_>\'I3=['IF(#Y<OG+@A8(KB_#(K_'1;BX[I<W:GW",20T*EX832JGJ&S
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M]2RYZ&+F!3C:3?]NV@>C8N"Q.*;J1675IJ/\\;3WYH:< M(GUG@7%;[[\OR
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M8PK"DET9;HC+Q!)$KQEHKXS4**TIQQKMN0V]O95 M3^=!]=BEUA]]^=W3!2
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M='=.!J(B"] V2^$$R2VW>9M_2,FXY;9MSJJ#I-T!6JX"MOL,1"&MX2Z =JI
MK0.$*(D5%H)TGOF MDWMZ2-2QBT:;8.7P^3= 6"N"U)GZWJJ&Q:4<[98!1@U
M72]3RA39*P%)6:T-';22MWD4VD#,5J!QIP6:0V7> 6PV3?H*TW=+4LW-,X%"
MYF+D$9)8I]U"AL!-!LMC<=XH+.Q8'5P/:=L*5/ZT0#6P1D8.EJ^XN<?,VF9N
M^"BJ%!(46*'HYICKK!"KZ<>$00ENO<IIBQCYN>_8+L'(3@,B@PJT ^?SQT_-
M\U_H7ZWS_%+)' .7X&+V=/)*#@%-@!*R,\HC*;]-*F<S/;V-?S[V.]T 6NH2
M:]>&**R1+!+A.EGBP^4(T40%!8E!M*8PW:9Y\BF*QGT3&4+;+P)H#]%W *'[
MBWA^-LMK]YN+1AVE!J8< U5,G6EI!6@*^TR20J-I,V+F)<IZ@]0^^G_XH#ND
M,CH UP,__Y-K_RL%@*NO;^<_<!'.;X) %EGRCB*&9+PFX16$&#&!<%+S(K@@
M[H\1EK](Z;@O;$W UU19_8'QL*&D(DK!%3%;=*TU0\?K:K$"0JCB,RO$_[%&
MTN_/16]+%<8OUCH2(KJTALV+]++C&I%5^0HR<E^K.8)3$**(QG)I+6N3;MN2
MP-XJO8Z%H!>A?+@Z#^C$7S5JP*]YR<GL'&=I@ONTU?_\[P]OEG^&GN%:X+]-
M;B<]_/1]&UJ.G3>)<!* ,V;K$IB:WT\*(G/*&*9T3&V60NY$YJ&^:ZLONS6P
M,V^=],HKX%H[PCQ9F&/<@O>\E-HL4W*;&\QN=([>V-X(9P]=54/M#7:N-O-9
M^T\$V?@Q WNPQK,\=@!8L9&I)!7(0G<8E7B J,G(>.&!CL'";7:G[\CJ8)V?
MON(JIA56*5^\A)!* F4Q0PR);OE%&4O!K:?_-F%^,SVGY)AVP<U#QS2 -D8,
M[)>+U=GG^IY61?47G)\OPO>ODQ2NNNA9$3[G7$><28HMDS$DER(AL2(SL\I(
MMM7S WW+/3C13P^A]"P9XR)I"/W.AQ;VV(C!\X<L7*>24EUFQ*(!3/5B'>J1
MJXTF/5MAF"E)V:V>$+9#S%-DC(.8 =4['UK6(P(FU>&FB\NS7_XX0X/.>N20
M<QTS)XH )[F"9+CCBOY)?'9HX!+3_SZ?__@_UY]X!9#K'];X6"/C[OM&A,$P
M2IL?),&1G<3OD]7D?"WMMV%Y]7067"K&V03HDP&E#0=/1-=QM<$GGQ7/6X4H
M6WF'Q]\_;OI]X(/D0/%V!8Y[;Q%%);H,$J*-$W5)0,QT9S.%%)RU8BP4)K?*
M1>P!D;'?G8?0ZI, V5/$(]=,O9E.OJW")SI39ZL[?JY?DC33P2+Y0O2UOC#*
M L$X#]F5A%QB= ]CC8TU4\]]1R] V%=[\P:B'!D2[[Z=A^ED=?D$)R8)B1KI
M;,PZT"^.@:O+_XKTG(REIJW5%J!X_EO&.4B:P&) <8X,#!+($DD5[U9OIO_X
M$OZ).7SZ&A;?0L*+58W /LP7JZ]OON&"?OAMENK?N^F(R)B-< 68YXQ<+!W$
M/JUGZ4?#M4_,1+L%:/:G8)S"NB: .I(:1@;;OW^]7.&:Q7?3R>\U.7J/C\*"
M52(SB-Y[BO%)?EYP <$Y9H(/*JN\!9R>^XYQ'N&; &8P48X-"9Q,<7$-^;=A
M%O(#>*<BI,\^0F1"DB_%2+ZT>!!>9E5RS+%L$Z^\]#WCM$"V@<:0(AT[;OG^
M_1E&3,&<LM50+!(C3M,Y*YP&6R6F!1(*MFFQ?O9+QFEN;!.U#";,L5'Q[?MT
M?HGX*/ 215L3,R=11')\15H(0FO(2@4=149=MCE#GOK\<1H7&T6P XAPY'3(
MI\4\7Z35QYL=:NN+?['!:L8R:,=<S1A'\"$9"$4CT[Y.>AHN6[:)@G';/0;.
MEQTLXCX@4I\SKSFXZ9_*0M5N-PN.:PM*! J;90@D$1^U#2HD.SA.'I,Q7JKD
M<,T^ALF!8AX[;996\]MN_V*"#22($ P=AL8(<JO9@94J6L9\5EIO<9#<^\C1
M-7VH<N:'2VID!?]RB:M5N+DCV>Q3+!8*B[I>F^O!:<EJD6&TR3&EW!8:OO^9
MXR6XAE?QWK(:.Y\U"=/)#3:]5M8PU'2]J3,[-,'2%96!.\\*R];)AY5-FS-4
M]SYSO)S3\#K>6U8CZ_C?PB)/PBS=-,=H942VGD'A%9XB% I9!87$R8C$5#1V
M*V?]X&/'2Q8-K^E#)+:WLG_@(LX'4/=?+[Z%Z?R<_G-!?TQ">3]?K'!^S8K+
M7&4"*6A16;%10*R3J)/R/J8L'/FG+93_[)>,EQP:'@K#27-D+_#;;%DYN"8<
MDRD^U!NKJQ><G"1XQ^HX!,)UT$P8M\THB)\^=+S4S_!JWU]:8P\ F7^;I,D4
M/Y:[5,7U-&=90I$*<DK$@Z*@)$:LSVTI%8NB2!ZVT/A3GS]NP]Z U_C!A-@A
M$&YFH7"F1.5"8*K=L2%"P(A0C.9!B:0DVQ<*8U[3A]/<"U#80XPC@X'LXPV9
MQA1OPE=7I/"ED"EX4Q= !@\^NDB6D9F41F<6M@D#'GYN7XK?1T_S@80VLL(_
MSR]JI^?LU\ERM9BDU<?REBXO9;Z83<)M4!M<"C9!(/B#*D&#M[& ,+:(8HE/
MNTWR_^5O&N>>WP@4 PMV9)C\(RPF\XOENJ#\1EBW:,^92VL""!<R*";HKLL)
M\M$4XPQ%/CQL<TH\\Q7C) <: 6,H48Z,B$]3$L)J4LJ;Z12O!'.U#<2S;")J
M!,-EJGV5=0B>LI"2JR,\I$M\F_*EISY_W)G* \>/@PBQ0R#</*+RJ"4W%G(.
M=*E"G8 NNQ[JN(OH'6?,;U-C\O0WC!=&#*.Y%Z"PAQC'!D.8I042]>EM38LM
M/BZ^?+U<S"?YZL>;]2J\J-HY NCKB)]@#3B3 F0IE2S$CGK8XK\9%]M\65\0
MV4>C\Y;B[04OJ]N$N67*$Z&>+F!*$O7UX2M97/^.Y\@#2WP7<*QV>F)H$EZV
M1,)^@AO[2?C;]XOI-"PN?\*MD&BM(J]IT-.%VQJZ-DFWG@QGI(W2\X=#+C8_
M#F_Z\/%"R ;*/UQ\'4QO>A1*_7+Y(:PN%A1KW_WOR_69J@(7?#V)EV[6H(17
M$$3)8#-B"IF[X-H,<-J>QG%W-0P8EC963W? N^;JVB*Y$TS6FETN K'"ZX.
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M&F#$)4N:I2(:C47M]RWMB/#8Z7%M%UUU +S-MTN;D265+4C/Z'8I%0.W'@3
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MO!:T/& YDV?29>U[E 0ZBQX.T4&JPCZET6LP0( P7MG]V%P87KSJ<&%(YNS
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MS_])F"N% J09CSU+:JS+"UWVI!Y!^[6F>#'H'XGJ4 A$B[!-=%W3V..=>#?
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MO0+JO-1GB&;78Y78H/%S6',NB6S5"835KETD#$SBS&[#O#_78O= 1F99+YJ
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M2;\NEY\(8[L8Q^J<IHU>>2)=>% ]T3476+M4)N-H=H;:/4]NK$FT]0(_\L3
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M78JYLSE(_!FRAS -(:J02S&7^$<T*)@Q69'OTC-M*FT]4-L*!_8531C^3T,
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MCPS6(X9PN7Z>4&S=QS/1:W,FKKLD[ ;I)(CE&J-E[+CU_4H[S(1+F76!#.Y
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MW@61]"/-:,\P=YV6DUG40EM2"T(?^[ZI[+K=DB*HP3-N+S?-C65DDHP(=-6
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M$[?O(\5_6[G.EBCQ<&92JN[)6O8=E WR6I<,U97/22EW-X();E6V 9=A=(#
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MK1!ORW 7&!9A"=H4?>[C5W+>/U7AU_%\\\R> A"=]#0$=T._"4'.\5(:Y>R
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M]W7L#_Q4= [;G7?B;S^==3O=#Z(_EN)C]#42GT)\_&C>$M>AVQ:_1F&6B+O
M"8M+7_9:K]\M_$X?<2J_I@=.X(_"]R[0I8S??,]5:Q!.WY_(1-S*F;B/)DZX
M@(2ZZY'0-Q#+;KSXGAP.I9OZCU+\MQ-F3CP7G19*G<[^PK7;DF$:L6!\'\O
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M_VAR()QC&*6*5^0S626=P[,&6:I[>>W9ID^TVVT?=NLDLHXCD,38N0/H-O\
M',TK 2/59853D.6(LS2X&,2G3O8<=X[WPGT=+%X;:T%B'1:02)+I;C'E5- P
M\/= CIU@6(Y(P]J1@:>.[ZF:D6!>LF47E/1L.U4=-9^JW,!)$G_H*\N TQ=
M&)B R!++Z)*NDP$5H+[E#RFPI7Z&!9;P:<3"/0$"1: C$0\E3V9^@NJZ'"R.
MY2A#B[YRPQVEA^/FT\.27!@0AX2/\"_.A2&*Q4#',?;(X,!J02W:XC45ND]/
MFI6!,TPGNT<H)PTG%/"S)G@.RJ[+SP>ATK&?<C$7%K1(<)(H-@T_0RTP4$5:
M[(P4PN4YN:%N4:KLS@K&?],QOT@P0G?;P0@-X\?3!O(C1@#)(W=!5(XB#GGD
M,G>9%%4 BQQ;4<4XPMU+909_*7Z[4?ZUUQS_^ON<ZXI777&GA2KTMRP _#9!
MI(V+7<T]M.L)+N#,XXAJ#EVJBBP:^78L"V_)F?_"?:E0#!1"F%*MHV5X$N(%
M>W,0FB=P9JCFV39,D:YQ$ A;I^!]3.".^!-CF187TA;PKRHDP4*S8;"K'&2"
MQ<1D?W 7A#"P=S%_4@WB5WB13"H[:E6XX]NK$N4D=Y9P 27\$$?5Y%02 ZCC
M=%,TH6,5"<QY/HS" [,NO96\_)=49]%I3!G<J@0?Q3@WG]2KQQ_L8.:W,55@
MJPC#@I<T@#Q "-4H#1;@EGV.A>NY?;Z#Y-.8 JXGD(^IT6L '>U=[ -Y8-B0
M8;HV!)U0Y^P48J\LC@MFL0:>8P6ZZD545^RJ?LD%N?@#HP;],L*LZ$(^2]K@
MY*A!=+KG-\<M.6Z?DK&J0WK%1&=$K38GLB62L3],L<AZXF<3NPL4&TB(YLX+
MI0O!9@,09X,1FW(@Y;A9'+--:==/8XHSP7Z8?C*69.]-8%EH24WCR)5 1$]J
M(]6T<V_0P7?:O!.)$V#:/8>SDP'K#W0?O&AAH[[CP\[>EWU&%T>QA3HV"JCT
M"QDHE%WQ$;F-K)$BJ?/UX#]@A+.;01%*$CL@*?PP91@<U0C*E"2%ZL#"G:KL
MY D_?WGR) >H:*,^<1ZI9%I!4^HS9]M!;\TAN,Y9^_"(.EC54X$*7KC.4%)O
MP^\X]D[W9.69L_ ">78 Q%:SE I1#&0HA[Z-,MY.DGAL$D6P[E%H:\PJP.&P
M.*@4-#P!<,9G6SY #313A@@05]E$J53@*0,:H3-3['8&]!=([!>%ZFZ02*P1
M45BC'"H4A5*,X27BO Y([.';DR#"/!PV9<2XS!/1:PVCI.80DHFM\L$'<H3Y
MJ -XAD=QU$(VTW3KTKSO:<V7, :QOBJ-SHQUY1,;RFU#G/S7_;_]U#D]_%#]
M_Q4EIA8>Z.CX0YU30U]4HFVO=OT/LNL%_Z]4<>Q307'@RXR2#W!4P!"/#@<B
MMUF[->@$M(&M'6EC8Z@6S*)DX>Z5Z[U[]]</%_LM(;^Z<DKEX-QQD[]U \)U
M@,..;]T"?03ZZ=54?593]<<8)FQ2_"CSA#I:@EG-,99A%@1617;%.ME.6FJ.
M:6)L7"T%2/9J2M*-2 UIU.%S:@O7M_=PFG,VQFRL8W.* V#W#&JCGLZGTGB
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M&_:*?I4(HF?#F-&7?@D;J*WAM$J78/4,_9B[);OE][/1%(MGF9A&%I69M"@
MN8S/[@G%0W$%BM!DJ)@ @^UFI-[$H:JM(,?&JG&]KDXBU@[?!2Z9282@)MRZ
MIF[8[NYQ3V.JU%=QSV\^' 4*8CB\G BOI)7JV#0G8?C,LQ=4$WE<FRLBNU>+
MC2*92"?)8MDRG!#(1QG07YC03P-.R8->*-#W@O'1?!MN.*,\:^7<HIU,?JKV
M/@5Y0'7QU**@8- P,%P<SPW:-+;"IKIXAZ6*CAL.\8!I-0.?"WR&*GIJPGMD
MM"'>#C^E]8(#S[5M"6%SX*Y^+/#_$@._H3Z2H)KAU1#-1=FEI*)E,;8:X_!N
MD&C@\R?P(V[\73A091&:]N&$DJ H*&QM%"?%6,-Z)[WT8"@*2E46=+5IF;K8
M$FEIFY?#KO:%?E*J@"]T7Z(W:N6O0L'E=.S'W@%Z1G/Q"(XOEDZ'(V>$(">[
MX2*V>N2*D.IC\]"QZJ[4'^M>3JY>%]=CY86U%&4I4IDQIBE*U\I!7^1SPZ\Q
M\$R%*=A!O1*VXPO(C J-\33%S4ASJ_W;VI%\3Y)T4UFT8SB'NXO[_O7E]1TE
MT<3UK>C_JR?N/E[L6D+M>'L2:O]40<#[;+-#WH Z/H5!C0O#_5;+;5U)4F%9
MC\Q]Y^_AJ!<-$CC90I! DYE_:[)FJ.HP\ZK!CW=V0'+CMNVB5I!J;-W"ODFZ
M^R.6(@GJY:C;+EDM#A&#&H!MDN1S4:AY093%10"3:G-86<NN>6;'VQ/7Z!?!
M9MM!M2Y.0%!QW2+I<D'/(@!=GMRQAT,Y!)S EO5<<Y+J6)S$IM5YQP=Z:J(?
M6[>XHM;DD*^NM;;&:#MFA6"[VJM/Q@Z[4Z4QDJ58!RCL6J^C9%7;5=YFYG?[
M=/?-XQ,@GJO>;]>WU_3GQ>V5N/QT<_>YS[;RI]_HSXO;/\6OGVX_/RPN@VS*
MB^$;7%Q=T>M<?!27%P__$A=_7-Q?[9C</-D>6Q]9,DN-C"ERZ+"N4_"F UPE
M(:(*\4B><M=A@1@O"@I0.SUX,8Z3N+KQ41X%0>F<\,BT\N@&N\EC:[W1[(D]
M4'HP%Q,.KLQ-J*GF%GQIWXE',L5K".M6TS;&!-I6QW(4Y \CX0YF\BIS+/+H
M3&$"FI@PH,6/">$MOV(:R42<YL()DDCX\'0WK8E<6Z'MEBBW[LC%]M&>N\^;
M6CY*-+MT&TV,UH$2,$NW=B319AV\>D@MRY1VX)ONG"39)L=A53BY/XYE,HX"
MAJY<2A^N'+%Y48VP746SD*R!*Q,^VV"*%CL']=<+FIO>] -I=1<Y;&,7OEB,
MP$1+-?*TVS[DT$5E2($0*SI-8==96 >9=]/89WQ ,?NUB N/VD?E/%H58,BQ
M:"^#]WLRTO!''\V:V8R]I16VCE7DPJU]\<CV>3@8.I<+8=2[)W2VQNVS565!
MFVS82-DQ<$S3(+C+2,*VJ#9,!;<H87)I?WXH/&<.9LXP5>[U0([\4(\XK($?
ML)@NV(@TFLQQQ[9-5$JW%6)@A0DZY:&W>HIP3"4D; '#S]#\4]-X""=<',P!
M'U"V-\GGXC'Z!]00AM>*OVY9-1DU:3^=DL:Q;+P8JB?$'!EUN8W,F"VET^RW
M^SNAY$"E8CXTST#C\LL5*"K7NG(K%P)!]%N 61QC2PXU9U!U-'5&LA!V*ECN
M!/^XDBX/$#[J+#AL(AB;7N SAIW44D9EY;1"G0&Q<Y]@,X =M:X7 LNXYD=B
MBV U]:S>_REO/I<K)787_/(V[LGVJ-TR8Q@1(A9'DX@IQ9/\KT*'TOW6>LZ3
M/B"X7\P>&'774('?PD^MPE;T,G CRZ^RI[!T[,S54=2^<<F*-,!HR;$*OY5X
M,9\%GM8_=_'6O9RY58W"W*_C\C!Q7>8>\(;U3L]TR%SIA:\7VB#>DMB@DPD^
MCM!2?@*02+/*2BY>]D,M45]GI#?3\KKP_ITEW#4%M>AU;F;8E*%HPI=<_YI+
MN8TRS9,+FG[T"I\\/0]]U4+<3,^HS3OI6(9@ =QG3BC1Y<-Z%%[AAM:=BE9E
M_<U8CRMXKQ4I+4FFP3[W[K5*G9&L;(6NK=VR@L4 9B5TZ=0!SE[!'C;8XW3;
MP1X;Y$O3J8_M/<P_+#3OKX>E-*]I T\S/(C#RO1;L7Z+=OXZC*<U-YBZ/O'-
M8?L03>S#]DFKGCURF.2UZDY$OD"KC)A8\#S-N>8C<V/%_0O-$L/\Z/AI$;'0
M("@8*77[B]N:K-[2]:R>M247;YN>_T1:;OUEZ26@M/9#-V:(P%KKI7%2]MPI
MM6(C-WGD> E6L.C>"X[9!@0/::YG\GR1CE)AAU4QG?_:TDZJADE2349%\&-G
M8?9'M4]O-S3BO@[)'#3+Q"YXBRIJ1>E <M?*2K#%GZB[+8YTU&UPDDUQC&I2
M.^MTM9#\T8)N15 @EV5&-(DY'.R!+#6@Y+UJ40C>3RQ<RC*PR/JV0[WLZ8#$
M2Z):M]R<!Q S$GN-#!C()PJ G4L(;$V%3@G/4(LOVK!W;NF&2H%,S9A)HJC6
M(A!T!605+L!4Y0+8@,>ZA]W#2H!..>"JL:<*F];?<CWL!787K8=>P$:H?A.+
MHA#USUT>C:B_YB^+1"S>'O-(2J6B)N)JPD,\=<S\XA.T?+&$BE,9,OJ7C\+>
MD%QYL# W1>N'MH5*O7A:^L R6$S7PHC<3ZRD8L%N',8D41'Z@DU."KP2CUZ3
M+_;S>JLAE:.QAN<1KNR-$J73&G05TD)FK&W;0&6P=8OI5(TELCK W8U]-]&F
M(K:Y8K6*.)IB=KLEX/ADDD:P<86)HJ5^XW;#JRD.MX=7=)$_\W\A*I-&",)*
MHT>5E0F]O_UT_.X#ILI='RL X50)31!$6"=H'95B&3@+'TP)C3*GLZD>K/9U
ML$29@!)B&OEHT4H*@>!>TNOQIB+*%2=4H'1X=(*L@FJS'TH;[&(]+[P5G.<C
M,-J4OK%VRI0/$D2,:9DM7)7VRF^H @W#VOR6A74J7%)^O47T8D3)0*8S*4-+
MAB0YN6L*_8OCHPTS31K3\GNU:1)ZJF<JD.6:6.@-VRIWQ;[UE45KKJ\G6ZRI
M5"&'4>: "@16\$ RQ=C2(L+LI(L(S#5<V\58<2WK=)J8P3P#KK!$8P/77ISB
M/'-&JON5&F$#?V0A0;6X(TOJ!X1#K)ELN+M\U)B>WZOXZ%Y/K.R9@HC&Y-N*
M:%33O=(J6VCE$S<'A1;+@3,CB)GM$EO0C;)*J0DKJ1)FDV,NZ7:5"0^PKLES
MY@L#,5@Y;R\"[UE;)F(ZE\,"JV%*O1IN!^#I?C1%OC9S,1:)D/)H,([/P$._
M+3O^KKN$YY[ N]7[O**SULH1?L2!? 2(N>")?)LNSBI/$&RMS2>K1@WF552_
MT>))N=Q(CPQ.VH=\1,7Y$5GH?HI-E?A.^>6?P:,&10;/>," (38'ZUFUB'#7
M>VD5A[WFMNS<UKMMSVV]ZVY,L-SCOQ.D4M(*Y'1:>+]:JC<!C:H]MD*%5+HH
M&ZF_MD.SD^)]:^!0?;#PDZ&,-RW20U/JI$?"UM2%VP9%H7]Y'6I1Q0+A.O6*
M"5<,:(&H^YO;YI:OJ\S'U,H=5JJI'V,KQ=X59CD<O\%5QW+B^&'RW=:<26!0
MW0E%%[EKF2E+PUL<P"T.HN%!^<65K6HP/8O8LY0FQF_6=>#T DV6<F$)G,[-
MK3@LWR[OSRG!J26#18U!5HGB;14FVX0GLX9&P\E? ?V.&^/H+:\0)0Z>+>@2
MD5<4K2MUN+M%HG+O+!=H<\BO&L=1-AJO0)]P$S5_.3B[7G<K<;%$5AQ49$4!
MX%%V@9^FZ+>;WQK5E'CM26J"YMTU;<A5G;OV/%PVHQ&LE@_E)W9O"U(=*DRO
MIL(/'3_ Q :VB<,Q;M*V!H91 #*!4A1BS7W]9MZKZNEOY[U^L28G5H AGIEB
M(K-%!%%>7&**RE>.\":+C$>&6=NJ(L4U6^:LVK1*VT9XF;\T=MLH&=.TUM7+
MQ,QM!)0A5>-ABFUNOERB -:KZO$D&TRHOR;&,]7BXWSQG-1?UIS'E&<O5]&V
M)"(P&B9 N6%5\8$HG&:1V.ONBYF47PCI1MD+[M8^SJ^J7_!>.<QL1Z0#9[9?
M)XP6^2$+Y8G*HUCO3!TW39&A6ML4CBW:N9[&)^W&#+-<E4[!1]JP_DTSX[!>
MG0] SX1+QF,HL[;:2D%/$5X.+ZQZK!6_M-8GY0'P!N8J\^6Z3KDAW?>_W4+4
MUH#[I]\X<]%IT4]:QE.H?:#R&JC12IVW4+MI"^ )O'MK>O=+/7M,%L7UKTB;
M9S<?^RNVD4M/^3B_>2_YMQB\7^2*_=C--06Q)GY"(M?4JFI,B?7"M$*K8EE]
M:N"S-C8\CV1YA9"*$ \^B BL86XM;F:OW[VF0]XX8M!BLO:!5H!2^6GNJ3U?
M!#=>L/O[3Q$#2VIW=VU:\TG[;%OTVXT?^I-L(BX(K;KYCA#E*C[=75_/CBOV
M4<=_3=0;I%&:%W54FK6M1.-,G;DN>:_KI^6,1K&:-X.V+@V,)O[)21DL8?YX
M#R] UZY[^*&XO_1AY\.^!B</_:]6C,JQ1GWJ]_PUPL5AAP1R"",>1\-02R6P
M+- #M[YG;?=:R%=.=IYM>[)S@R)M:>4>1D:*A*Z:G*H^7]PIBX9PZ?GK-=,-
MK/Y3<QWN6,P"A6Q/A1'R&-.JP"]FE$Q'UD5"8%D9(%D#=:,%"[-M\DQ0[DRG
M:VX;5:[-K?9CQ=E2J@^98X_36XT97"@(\77J-L1,\%BV&2TS7:].B):-DCI?
MQ,X#YK52Q5K&9S )GLNT^+:>N:\M]2O"^7P+A7-3.@?KELBG*(NO;WK8_/CN
MXL^;WFU_QRSKT^WI'=R@.2$:IUX: F6*0=%J5")Z3F/="MJS/@Q@PK8W3NR.
M1><$-1UAH.:U@--MI[NMZ33;SS-S.EK0&%S @F;UNHK3MXNHZ\(>QI99EE
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M9<;YVT'DS>$_XW02_/)_4$L#!!0    (  Y85U2B3<UJNCH  $J< 0 >
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M\^K1MQE<=Z'FO"11G.A8E(T79!KA53T:]O(S?T%CW.TQ"C?(7EF1W3XK5*G
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M%96PN)8BT ]AI&KC9N$NF521G64O5F2OIBR&T60+>A2+9N**IPR"6KH>CH^
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MV)F<"B)%,TSNH>0GL2IE3'M-5PLS?A2%WQ-!#5!%2C(VIV2W8K%TYYTS]0&
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M*+4CNM^+\%+=X[\;B;%LYE=2?_7:TJD!'WB$KB[AE;#;&1?8U20V"55 K2B
MLB7Y7=<:OUGQ0^=YF][6OC7?.!=^W?9CYS(+4 NZS1:L15'!^T/<K]1ANG@C
MBR-D$RI.XQ0M1_FQW2V+%B5J:I#"W ]\1?U.@8$FYY >./%%N0P>C$_4&=!Z
MY26(@-JS5#<LT5N2U05M.,?$.=W]E3<9O 58N;%J*LFU!MD+^0U/F9SH'"[:
MTP<7!R-;VT%<4VJ)L2+S%HQ& +2&' L,5Y2)/'<47:9%9I> S,@%A6J,SS<1
M:] T%>@HN6H"[Z'*&7#2+*T0>@/4TCZ7*@U'95<*@:!F$3$VTAT/F>HMUT:O
M]*P@TV*$,71L]H2S QXYD\0"\L>O]O!O)8[ZT7,H9FHY7 \8T_3SH;)]XW:V
M\0MZ],:\)),XD6BD:0+!/)2UV\ &K- 5:G7Q]':R,FH6:".)0>*;2 YE?5VP
M[QBA9!TCF P(209\]*+&B7]^BK5W-]?"I2I!4IK8-A:1B=)Z!L_%HPME1J86
M> -S+Q89$:^>;H'>(=\1-P$H#,\KQW 5.G %[*T$:86:1.K9-+C1'5^ZE 4*
ME#$3B$[9O2%,&TKWF(>2P*V"SN$I"#ES!@[DK&J%IF\]17_+HFQRVZ+L^<')
MX]72[&>R&/X0B^$/MAAN)_D31C1 (E&T(UEMU[2:D=?9-EB<C&4I*)ANVKP.
MD[)2^O6%%G(\!4$LHF*=H=PJSG%E:&DEK;&? ]]"</P6V':'C;A*;!.6VO1M
MU9<>W[?U)=WEA6$K5XQRU1-.T6;"?Q')5G512$X.M]1?H'-=; 7ZU3:-3TEE
M51$4ZEU;N&L[.@<^AB5?MMC2M[<5V>1 #K2]>T=8;]8IDZ:JAEJFM'5,=,9O
M<[F'(*2)D1VYPGY8D5U<IW6#_^ZX$')BHVCO>']EM:15]YY-'51Q>&4/L(Z@
M(O7DZK>F # 'E[PXL&C2GBB^"B-5%"+CV1Q[CX.G?X] 9VN>&P:>KR_0O%$@
MV96T$N/B*XQ3CH,(E\F;K'+;[U@*L@WJ?Y^"O.-0S(^WI9-NS:CH;U?I'3T1
MI>>A>Y(^L3-NCD-PT?D\6[(!96LZJ*HF++.8%0EY0N3Q7R=NV';Z,=O0=<;'
M6.2('M.F5AME5T8QB6[$,B1;9^M!%%@&#.NKT 9I9C,O.373Y84N1PQF@^BQ
M]&CJ2W'(.%VW5GQABW#J$#U/]^+]@.+V;)T0S;SE*(2MLMUILMJ&-K!6>SH=
MNG<03%-_I<3/AOFE734&"Y"2[PP=!P3*L;9)9&:X46(>@9'8-=18.FYAC58%
MX;A;PB)!<74@!I1RT\];D4<8E@F.R*<E\@_A>I@UY/&.MJUAW+I<?T8T97BJ
MR;'NK2IBMG>A?;1=*?!*.L9/6@BA(5_B9]XAC2BV;@+KQNE,;7=XZ_+]H+#]
MW)S'^P^_!Z#U^R:0VKG "8U.N:;8OIL01PLFO.UVF-Q;8AV0>EH6S<5TXP=H
MVRL8=@C>XUQ^O8*N5D6S1$!Z2$JZ\.'4<3*03E"# ,UK)A3QC.$/1Q84G9<
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M0?3FA6A#C.P+G&V5?D8 D=/#?2YH#XNN^A6& X=+_6&%N,XJF&09^L2@AT[
M)[[IB,-]0@J-GXT.ALZ%2I,M1MZ7.&:],'5]] D$N#'I^:;'AD$43LX.OML
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M=_555J?@^V.XSQ_^SDJ1+R2#9&[?AK1D7Z;86S,=&SK]PDF6#28K7-;>IYF
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M;,_3QC<SC25@ 6$2G' N8C3/<-PTI9VH&P.7XC]^K0$EPHJ-+JD40A^/8+]
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M-H6!0Z&<A!@79X*:1+7]:J9]K)18?D<3IYL\-E4A?$:!Y0O&$^,;K.0+?TJ
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MN4H)Q3>SFVO-_:VE@S=.R82HI/8\@B;S=#:G2+'8BP1<024KD0Q0[AU=KN(
M?QNO8\ LD?X2\1C0J8QFX4*B!%H#BM/&KBRPE@_(>JE=,%:P#&2]@5;B+G;@
M;:X-5J[?T$+85APQ2Q!;X1/!<?LC-H)0+4ZB D<TK:8AYR 2>2>29M[>7K4Z
M:MR53V:7_3'FU-NKDZ[J-:H/,X1\#%;Q>[ GWH19+U2 _MG2 ,_[IQ2>WQ#P
M&9.31RM,10-P[*:P,YB*:WT-FNMM4XUV';A)I9YD.A:K([2MOA#U_)OJZSW9
MDK[>7_"@J%$1MIHU[+1(&?SJ7QKLL\'-;P_A>7+[XA%C'S3DE K[,%-4EZ:-
MQ@O&.L#GGHB'Y;,+VADOWT[4SI1,R+3XQYL<;/!<C2+L83\[L-$!;CHCH _\
M&8L@$LNQ:JQ(EJ@T/ZD;<)V78#QC^6$EZ".3#/%K<!*S<![?C+(N_#.3C+,M
M/Y<<^Y:<?X#1:^*<*C>OT5,FF:7>?*PEUF?.&],P2[.N71RRK\"9(X,EQ3E1
MEHTQY#'&JGZ*95CD R.;@@7B]Y=(@\/;WLJZD -BEHQ0Z>8P$1RJH12R-6JR
MI9^/1,P[CNAXB#U6UH+;A.FT8'7PXU]A!VX(97.U%_WUG>ASS"X"4]F=%S"&
MB<:N[LSLH<%H"!"<[:<?@#6F2.JO4L%B:I]E7IAZ8[J?@_^QQ 7_(-P\!@$S
M.H^=R#DK7;V;P[(>;XG*^#6M8IV!1:B+IN)Y%M45X1V^O2CBMJ,]_%;4=MKU
M:S2LRB)/X^B5SE*RQ/#S "7T5I @SMQT8>983KFVDQ&4 $!#'?X5QK!HCGFT
MP,8%FEDD-K7<TUXC^64S.W2LX2'\*.H62:1<MIFSL4JH$]3#@ .K#*B.&>OY
M@=)VTOPDD0B3;W!7G5-(R I(M'PK^U?T^/3XV1-K)?C[0'DW,Z@0^=RV3+D7
MW>3%C"Y3G<H:3 3C;"Z&7$N8(AR&F_5@:N-3T9 O*2SA&GNS#IOI:9T8%4NU
M5B#IC? 81Y'X1U=Z3.<V7(OL7&&^&ARGD9E.BQ,_@Q&UP#98@TX#EVD'V)XI
MXH:]'(H8NEUQ/ML@@C2N3CM6H^8L'ZVQ+_'IF3L#8U3Z[MK%NC+J,'1"Q<+R
MT:2,(\FA6?NVX4,27TJX+.G0"J5F#_L%B_RAZ0[Q[E<MJUK/(M@$L&-3&JK+
M,-VI*?X.V\$I31=QFHX;S)7?,_[-P\1]T_FIMRJ_:&YJNN(FT/'#V>RIQ5]C
M %5,[U)1!Q/KZ_R"@CN9O $#^%2FG]M,2"3P,K!AX-O%M*!QP<U$;L68E]Y]
MY9[8\X4)$/1B$.^C':5RD(E<@&71L#R4V@$/M NL/565X>.DWVD-^LL-E[=%
M&O,N8L-E@NJ&J_=VQ_F#9N>H;)$7@X+(@TOU[@.2PY:RV6DO-J-L;B57C?H^
MY'0\=><7V6YS^PW-.+K.B49_*%0&-^-L#((\;D^Z&$7.@K; TU*V!W!-Y9W?
M)XV=LL*8$E'QDBW%7)/9J,ADX @%1JML$:@RBX!'W:<_)?WYY#[]>6=F'ZTD
MA]I#/?"053;E3PR/TI2'NL.J<B=FV&]5%VT66;JA\4:;ZZ(G!T=K=-$'K+$V
M(.;( "8:]@^M\$:W!&@YP>XDBB44I76W>PJ$!I,+,F*:DA7@LV8V*1K6^@ON
MC93?L.WD$AST([,Q]F<!X#L7RC("L5V=TT)R_X74#LI(%,K/@YSA[* XE<:4
M7;_HSI-<W"+'8ET*ZQ>I5"],BP6><3N[3(7\544E0>.EE#;G04TRUSW&IO"^
M[Q&R@$D*MGB@9$>NUMZ,<4;L."Q= !O4@M^C$TP=!?W'R9K::6[K$TR*RK3?
M4'7Y<+K);*L,'MVQ0N1*N'4JW#J(8(&=1!,N0;_4>>J-WT%W(I9XG<Q4=?4J
M<N:*8@<&ZOY"HV+4=J*]/6EE9F+XF4%[,BE]-ON&Q]QM)O5O:$37=4K]WXKH
M+"$HPO=VN PYP[<B[24:R\@C;EX6V?GJ\\@5M$S2' PR;(U4M'ILLRCQAR8\
M^<GU]6#,5^>)3!0)9^AL/,-N:,P%5?"P7>_#F."EWO 4+O=I!5G<0 <,D7"
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MXLN,'F@=^([(*BQ(/0$U'DXK_!;? S<2,TE@2=*2J(+<27BB4)[  "L/P+@
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MDID[DO0Q3] E/,\S8J3X:<FL9Q2UJ_ "?/(Y9U9,6I8:6"ZCRG)8 LX-,*
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M$AOAU8$!:@!"7'B\I3Q:%K(UV!:HSV%X!6"[W"N7&\7#<]&?(]6I<@+F#)A
MPH^+O["'O*+D#LS,EO:ZTEZ>?95S,&%,BUX!;#&MX*G\TH#"L#%CT5$VFL)'
MJU;'CO9/7[1]DZ+Y]$*%/V_[RUQ>(L+#9-K&;.!?>%YNJ87JC:)!UE")+6YX
M7]<3K;MKB]D&8#]C[/",?L\IV'-14^W2FR(C=!ET-*(P9@JB"P,;.6 "KA$
M9FRNJ4/4<PNB34$UD#L5"M8+<7]:M=6;"X5_>+@N:9)O5*VB3V5ZI>+I0Y<<
M-$Y7S_![S0*\T2QN!BU.FW4.K"QDA+S^>Z4N]>I?Q(+G>S7TL_6<,<^]Q^@
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M47 $M8!#Y[U@?/+?4E='2HL;P.ITS9/&)X6/EXZFY:&5V>OH1E;GE)_#F<_
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MDZYKZAL?:&P1,?\^-HZYHS*Z.^28?YEZ^MRX<,\]W$H4BN<L_*(W.D^9)/X
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M8QB2A7[ZSL]+OLNVN_V6]1#R[#)7$T9#U=Z+W/#-DALJ[W9R&X14QB.Q3&R
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M'C*=Z)A5C2I@R\D[, \-587N.RIT<EQ2S*SD$^-UU*5U12/BLMHGN"F9MAF
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M\Z9?.G2$SE>M0=IEU'#ND3_77QK<B]@R;>_;JCYQN?8.3;TR4Y<<Z9&NP/@
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M7(K;NS.,U%56P^F16>H&>:8EA.L8@F+B%1)9J @K1HM2"D^IGUVJ+HW]BKZ
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MT,U!5O'MY.Y9 ?>(,G5IQT[#L=.N-O6T*"F=YFY+M(L9Z20IT2LB]X9O(4_
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M>Q\VPXV"#&*#K9 W)PN(3ZT![3)+?C2?$<"LAO7$;L_CP5E@1PS$QQ0X!+[
M_AEY16Q%B(>FXZXOQ]^EW@O.]?4?_$J+,0:(8[2^K<7]LD$CC,J.TZ*I>'LY
MO&O^$H/_AO'*,T_0HU3KNE?B&\(M*]:B!JL%56LUG&QM:TLNOB#OSZKE1=@@
M9O1*R%%&!PTRE5]2:X^_55N;%!&"T2P8PY+[O[%D!.LLS:AUHPH8%_F*B# E
M4X:5AM^H(MTBD@E%/[M$%O#_**?KT>RU2U766X]84V_"!:_+3+Y4S&7JB6HH
M8">*E3?/F-=4:"7(O 8PNLD]FP^N;G*)M2J#*.G0XP/4K:'> :((EIVQ;W["
M^:G89UEKC\HA+FC5I<-L[K,48A,IZ'N_?CLF00</Q0I*$ Q4%8[?4$LP(M62
M.]I:9HHD54#*U$F%+TGPL;Q@UW&!!592&5:4*5 =R"^9YI%86'0RJ,V=\ ,;
MXE:([>F6"W?";@N$[#<#LZV,;9GK_LEQBV:X*M)E"Q*)M1LW8F9F]6WWU4./
MZ(58O!O)%,OBO7R*O0N\S4R=:]045Z[V8?-RSU9YD\T'7*G"ZUYARXBAWU&+
MZT1O$V";MTT5<%Z#3H"I[T/SLN->4.%D0U(RZ*Z[]"='+%.FE>GXY6+]&5<1
MTES=2XTKJKQL)%8>6D,1I0+^03*U(B=:3AOROB61JFL7D*A+.(W+E8JJJOTX
M)QLI RAR;TU]QNO6(W%KWN477+'I9U$,:#ZKJ1+A '.RE29-1JP\%GXC[N5N
M@]XU5]Z:&3;DEMNCU\/OX9R@F3X@[J.ENB5RA*1B1)-3<.-*4OM$Z&G^1\,V
MCQ_;ZY I]<:#,;^PTU@"P\*4TH*)F>J)@]GBNZ-XQ(P#SV49-M1X!1[V/&6R
M,+\9=?*;VU;@"X BD;$TA&$C?FT4+ZXA9^DKRS,:%O2/F0535)PW&Z'C4K@Q
M,-* ;YJ^\.:LQSB"CU_91,1UM+>_B8BO3T1\W>4;H_'+"!44\83FCZ8S_Y%K
M]Q('B>5T8"GEVV$5@[I0X%:3[^OK+FH@0%E&,3(47P0Z8"18>SC4E2IDO5IY
MUGX^_?):;S['^RGOME/'B6&MZ]9C(6%N60+"');P;$3/LC*ZUW5!=&BXJX88
M2HYHL5<G<@#;!)N];$"Z[96;\^08G%#D%76 LAHC[0DF!35V^T^046J!1R?3
MU"(['#4T:BW&5'MDJM?'%,Z>,MEG.XB/;=06A\J3"A-8U&;6!G!3*@$+K)7@
M&C'N2U5F>J]G/K>F*'"#>)B1L<(#N_KAS_74)NK=P86S(\, D!O+8VX%U,0:
M /-QY06>&GQ99!6_&J[&/ME**@X 8[D.>K5<.$=F"UA+WR2'GK_8>7[_HOV=
M(_H0R,_N3]"[G,[F% 45V4YX"%2J$<G$WMY9V6H<X#[C=8S#)-0HWOP CS-(
M@@OW$18*,+*-RUB\)A_#\$*[0*.TR,MZ R[AYFA0[EP2JUQ_D45]K#@:E&#+
M_CEAV)+4$546A"%Q_!$X66DU#2D9$; [42+S]O:JY1'1(3/%[+4_/9LZ^G32
M%0B&(3'_Q8=AQ9&'J>'-:?2<8?1!%@;VW#^K\!2'4+68J#R*85H:  ,W98W!
M;$EK'= X:9M(L^O K2KU)--CD86AQ&\#!M_\](TE%L7]-?@=K$F#W]_P[*AC
M"7:?+?!ID3+8TC\T*))O$J/[^SL']R]&,0) \P:I\ VS)75I.DR\@*3#4NWQ
M^RTGGM%&>?EFX@>F=0)]Q%_>Y6 [Y"J.L+?U=,?ZR-R/13@3^#46522^QZJQ
MHELBL_RD;M!Q7H+2Q_*\2L O)AG"I^#$4^%-OAEE'OAK)B%ENV$N./XK.>\
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M8$A8YXF,O B'O*P\9&UH#@/5 K$K[Z,<X*7>= \N'&K%8-S$ 0R@</C$&SN
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MH'5_JQ3_4@XE4.;NGCJ8;V467@=?$I$&6VF6[LCO,JS*^$;"2(,XE/EVRVD
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MX&6 3-MNISQO/='3RQWSV60P?9/Y#1XA"!V^:,E<@6-%2S^[_=:FLT-MGQ4
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MK250RLT1]/-,1.P,TCD)GHS\,^L;-BN6<SH+9L2RHG'O/,"U$[;1JHV ^1;
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MY9R)JLY]P8V_%R9L@O<4=N)6"4<^D3;=!&S I3;6&:M$J**!+ =2)@59NL[
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M79-HPIH>A8/Q:RR<2&"'HC+"&KV'F&E&;])ZDV6(,6BA83Q..#$$(=H3S')
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M0F+>K5%RT*(MS&_!P='>R:'1]-U]X":$HRK5&KAI,VP7NLC"M#ZJLE(]C_,
MZTD23JZ-F"*LK]_X)TKM,2' L8+CKAPBU/,P+4UJ)P;GT*G/0('3^L?8T4U0
M[_2:F6$X U<[=SKJZ1%VPU.PO+4FJQWJZQI)QIJF'6";) LK]EZ0'F=WQ?IB
MVCN"PNRD935*#7;S\N=5$LVBL<P;=38QL;EQN;*2W-0_[2!BG"NS6O\ED2LE
MM)^J?8;E,,^J*_0  1OM4*HCEFK9\8II4<J1UZF;*T&YJ,GMI5V/Z&#."W53
M=![:1%Z?;.3UHTBOJH>"B5S$_=T>$;*9MEQG,\!>=VFI*?U]>D5^WT2M@*S6
MH6J;6"4&ZY$RPSBB,QEF!+)<#=187!OA#*P&16A&"@MFB&N83>H>;)M:S\FW
M33D0;5D*,\6;0ZJC)BD0-;NM//A$+2/J I$Y']. $Y7 B[,WV^-ZA/3641"0
M)X-BS"FK<<8!N5.HYA06I\$4?NBAU%.=IC]R @HU7,B2C:QXRE&T/P3>0P]C
MU[3F@[;XR5;@*$.!-:$M<"[(P6+M.[7^ACD')E?"]C=VNEMF8TD:JR!M136Z
M*/-*ZI8P0D]"<2MVD/6%Q,*S<>"UZQ-3(_'TUN+(%_8&;43* V.P+ W5D[IT
MJQ0/O(ZT\^3ODE)(5A.6APLZ8YUYE-G^DWYL<WY\2:$E4[P*3)[$1,RK5,6I
M* BD4DU5YUV^/&V,B[ZD-\9\S:L,S1%@.N5J(S,[*TG4^!,%>*EP%RB1:S06
M'#16-HGM4'W;I&?>9,W>M,),4XSL9+&"=QAF$VZ<Z0>MQYAL4'"'B_Z4R[L]
M,:K3_$-*W6EYA9K ( 9ES!.4':\_,-E\-P@@C5W7\\Q4R:(-A1,IFX^3I:V5
MOD8I'&2$ \'[5<Z+..IM58!SBPD3=EJV!UR7(9<>/79;*,X>*LYF/;YIRW+.
M,H%]OY%I[."!H.X9*M>0PMVSJ"**/H3.$29[X I.5Z32 +D;JC -:-U LCG%
MF/XV/ZEXKBMZ7:^#!\((6IZ3-#B/"'+NJ\FF)#-I)=> \O)Q+;Q%ZR$E3GSO
MV#2H09R*E!+R!<V^0QU<X(O:[76MOX<)-2.@JT@E9OI)HPO#;[45RE/>E\YR
MRTW#%'QTIJ=VS?Z^)4<RFS@=&)S5(QOZRP=#^_[KZDM,S@I*NV.J3U6#L;N)
M R^-)>X2!][?Q($W<> G%P=>XDU[QRCPX:JCP+ ;7#M))/'-9IV>6Y>KSIH[
M-X@(3SA3\'-6XO5E>L+4[(H65=WM#DE.8EL[.+M/#G)$+=(VSF-.63H ^^?D
M;'<W^/(IV'K_[G([^.M?3GMG5"YR!/^<[I]U3*0&1YC(/MP[=&%[+1T\7&J+
MPT?],,8)N;=-%G:6SP$'=-;A+L#KNG;7Z>OOF;[UU+2'NO;4<+Y,8TZS!*?#
M[("L3+S["XR8>M!*W5FKZ<YF4.]D]63YX7/PQX?+S^^_?0O^^/O[K^__\8N.
MBU+4 K,]6_S_N@,HI<U3(+8QB-U!6E1H5F/R#@Y &9T#+[X, W/O9 VV]OW'
M#\''#Q\__C,X__PNN/C'IR_GG_^YE/DO;R>>VI[^/"4)$/Q/VW\;]7L5ZO?!
MTU>_7_>S: K_#,M1\O;_ %!+ P04    "  .6%=4047@7ST]  !BT $ '@
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MMK!\E':!ZV#P<;)* \F+Q\I!%6:E&89DIFP%G65GIC]MN/R6HP7ZN; U*6[
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M@3^*<9D8>3#;'J/;HR>C H-(08' YTS8082:%-;>][T9WE5XAJ6*%SLQ&5_
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M6SIQ=/+\0=/)1UU-B[P"4LG2>A8AN.YG]?6AV^=;&@EIY/1!TXCU4AR<GE&
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M;!X<DL']!O!8=[K4\8'D:'-XG8RU &";P3QF+I2/1Z?)T6F8#ZBMGDAP3'S
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MFE\GCK7P 1?A6E@O-\H:;&DJN1_A,>WCYFP*Y2ZZE$I.2M5S+D=:9Q79C-[
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M^S%'DV0<(CL9OK>C@L"*FPN=  >8R'PN]_EBYU#L[G,2$WGJ@V-FAZWZ!\8
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M"RX!]$%Z\V8R9*-$TNLZ)7Z=; ET7U <IY.K:X[ D>G]Y>=4]>< FD",G\2
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MYGMI'@^+9 ;_C.M)]NK_ U!+ P04    "  .6%=4Z!I\RR ,  "O^P  '0
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MC.';1S/4ZY]YJ-MON\9K'UJ'8<!AF216CKI.-=$-D02+(#+G1[?)A#">/,K
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M/#3YP2O8K?Y!=I\&\W\ 4$L#!!0    (  Y85U0Z58* ^@<   PH   >
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MZSW_A'#Q:.6+ %6V!*%YW\)-7&"BE7?4M 5\97T(8> (95PUY&6+I&R+"5
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MOD9@G[Q::C[KBRYWY7;P%U!+ P04    "  .6%=4[IM\4VLT  #/2@$ '0
M &QL>2TR,#(Q,3(S,7@Q,&ME>&AI8FET-#@N:'1M[7WID]M&LN?W_2OP//'F
M=4>@6]VZ+?DY0I;D&>_*,[.6'([W::,(%,D:@0 '1U.<OW[SJ@M'-UNR)#9-
M1]ANDD"A4)65YR\SO_N/5W]_^>Y__O$Z6;:K(OG'KS^\^>EE\LW9O7N_/7AY
M[]ZK=Z^2O[[[^4WR\/SB,GE7J[(QK:E*5=R[]_IOWR3?+-MV_>S>O<UF<[YY
M<%[5BWOO?KF'0SV\5U15H\_S-O_F^^_P&_BO5OGW_^N[_S@[2UY56;?299MD
MM5:MSI.N,>4B^2W7S?OD[$RN>EFMM[59+-OD_L7]^\EO5?W>7"G^O35MH;^W
MXWQWCS]_=X\>\MVLRK???Y>;J\3D__V-F7\[RY7.'FE]<?_AQ?SRZ;?9P^S1
MMQ?W=7[YY+YZ]/\N89+WX'*^IVFWA?[O;U:F/%MJ?/ZS)_?7[?.-R=OEL\N+
MB__\AJ[[_KMY5;;PL!INYC]YC.%(JE[ 8+.J;:O5LTL8[!N^V5Z05455/_O3
M!?WS''\YFZN5*;;/_NN=6>DF^9O>)+]4*U7^5]K +IPUNC9SOK Q_]8P*Y@@
M?=S(C&&<PI3:O@%/^_6'I9F9%O;S:?)*-UEMUKB?235/VJ6&!5^M5;G]\Y^>
MWK]\\KQ)+LX?P6U)6;4PA;S3L \/'J3)Y?GE_4?QUX\N$U7F\,N#)[U?'E_&
MB_.5EH5&?&9:59@L6JB'HPOU#E9C7A5%M4&Z;+H5S'6+R_2Z,,D;4Q1;>M_^
M@JE9=:636L]UK<L,Z#K7,W@;G74U'!R8L&F2F6K@!UAT'.!?'4QH;N"+V9:V
MP)0YT'-7ZS3)Z62H!A_[HY[5'4[A$I;_VV_AOS/=;K0NX>300*]TUS89#/"#
M*M_#4>V:ULXN>;&"9<E@H!/XM^FR3#=-52=ME;R$6<W@AC3YV_F+\],4G];B
MO1J>C\.VM [UBB8Q((>W>MWJU4S71!C)"5Z-:W'_XGEX+7UU^1R&QPL&U!..
M G04CA)>:T=Q\QH06SC0X_Y _MI41J*!@,0*G;7F2L.6;DR[I*&C-_7/\Y/A
M5Y'!H^F=)S_"VBH8>+4N=*N!! ;GK-6XHCCNNJZN3 ,_-?8W&9YH"+>H1Q1V
M0_#R:CXWF:X;(;\$_FZ!F#*@&Z"YMD72A6OEG?Q#W88&SU-%@=]LEB9;)JJ&
MAYB"J4\SSVCL9'[$IS\]>R%7N#5[ZZD<'_+Z0[94Y8*8RLHT#;U^&>S1Y<,4
M^?KE>?)N65?=8EEU+0QDW!-3?Y#HX;+:&^TV4+X)6%?_IZJKH^V6KSN[77Z=
M1P\V_0TKA!?@1U@A7(FFFS4F-ZHVN'1=6<"!2BJ81KTQ#6T7;4)^OA>L[UJ)
M\!==ZEH5^S31:8X<,Y5'3Y_?8MK/URK/X42<%7HN KW5']HS/EO/SAX\_FJO
M1K3XV+W,EY]"O#8/[I\_PK78P-D#@=5T<,H-BJM$+1:U7B![,26<=%4 _S)E
M9M;PEUI5'<P;3@B\SH/'#Y\_OKA(+^1?X2NU7BEX-$@_$%8MG"WD4"S@7NF,
MV<*#2V8++'_6P+1 7^F( =!<$IPJ*Z$QFVZ7JDU6:@N2T?*V1JV0$];$DYH1
MSMX(=YZA"@J$4%L&\6-7XW%.?L)'(JU]^UPXQI'D/B/)K11*N3$Y\> !;<)Q
M]3_CZL^TJN%D@Z*@07N$TZ22&@^[5_W@.,*Q++O5<3,^]V:@#M:59#KH_+C<
MGWNY:S2;-)ICU@X0C1@T2%;M_&Z09()/W:RJ820RTW!E9_!'":K@<;>^I&H"
M0ER!D%^KFNT>DO8LS'NV$R@QH+Z8!AE<#A9T5;T_@]_ JF:+JBRVQZW[$GRM
MAMW:JEFA4<C QB6DN;5H/AYWX OM0*Y!&<<MF&W)A]22@=O"PU&I9_>0W9-8
M49[IHMK$ZO+9W]>BDO\" Z_H0VAVP\G+JK)$1POH=L1>T5D!Q@",>P7CK=&+
MV\!U5U5QA5;!KV!@P+/>MHIT>_5!\9A'XOC\Q &"[9^P54@!N9YK!<_(M'C+
MKG2I8*;^>]H2_/&X+9]Y6] /%6P-'M?&E._)RP>G<:^<3=,^G-BE>_3A[+4/
MY]&G^7!V<.%$T8#=7#C1+4<7SIY1W+0+Y]'E47Q_11>.')NC"^?HPCG,Y3ZZ
M<.[2;AU=.'=VZXXNG/W8@0-TX81XNW7%:,-GM2X4(G0&"#Q[E]#2A;]%S9JJ
MZ-KI6X0*VVK][(&CKDDL'_]W6=N[UVJASV:U5N_/U!QXT3-5;-2V^>:+X0>/
M1^;HV#J8;3D4QY:'&!X=6WONV'KR!1Q; 3IU5\=6<,O1L;5G%#?MV'I\=&Q]
M7<<6'9NC8^OHV#K,Y0X=6Y]Y;K=,DTF^WE*!"G!T\>TWW1Y=?'=VZXXNOOW8
M@0-T\1V)X^C,.N!M.0QGEI/'+OM5TFPK>L'"H.<#O_:>E5"W8H?'1I//PY09
M:F=U[_H@*SITCXB^P/P.;D+-+LZW9!(OB2^553('W:[,T-]CZ9[N:V"*!0@M
MM!=K0RRM0>-]:E3](0.S?LSM@M/.U)I'$%;Z!A= M9+4^L;HL@DYZ>A5;U7!
MR_D&#J6>J>P]EU10/+GSVSMQOE+.Z$]BAN_33,=)^3<-8@PLA#61H3@/8"L\
M0:/'@  #/;\.4JA6V3+9:E6GF,T-LB_#4SR6Q'P_M=G1:UTW2"= FYMEU<!C
M%+Y/T\%0\D02[%;!19%.!%;@Q?#0&9;"H'SB,GG1+3"/_\%E<K)9:C)O@';Q
M "I_7:ZVIZ UP_R EEM,8U_7.M,Y%RZ Q[H7AU6@HAM86. .\*&?1C?,-)1:
MW[5<1 %_F*G&N'QV.$VPH4G9T?[ E[ ^M!VR.Z:B!'AQ^KJUP<(,&I<L4T76
M%5QZ05C?^)#SNEJ)VI05'2TW7ERHAE<89]=[R :XRUJ9/'ZC$Y@-#3;,C8=]
MG2./<R,L%<Y3E\-A3HD$9UV+G"R83PDB.\'*$'E7D 4\1@S).\R[MU\!<P5&
MBDS)^L;AQT:W4DQ UK*&\= XLPM/VU4JT3!?JC5Z$9*?5?T>[GS1-!7P:!X3
M1J.T>R1_%)%-\N+ENU]?O/GSGQX^><Y_)B<_O?SYQ>E=H-(YR?C1=4WFP%KH
M)"ND&99S\/;#$YRBL"16M5+O-:^O_E=GZK$M&U-[4)PL:I"M^9F\^9S^>?ZE
MUN&DK1;,HM@O@\43?#2$Q7Y#]*S6Z\)D:-6<?E7_D3T]>$#BO>"J#Y'$($YJ
M-X V2F59W5$QCHBU6*Y N(#K&'#REC648DNK0C&AEOB.,^B8C?#XN7B[01P5
M1M=D&[()E]KX409JA:A1:53>X_>A0SM[&-E%UE(4-BO3K7AG2UD\^\;VV[VD
MV#__Z?+QQ?,38&<DZ''UD(?>GHJ_)A&G24C&5-R'1?_GHFC\94"@GACIJS&*
MO .L7+3V'X*5LTK]2L.X1 ZTG.QJAF.$)^HMK@8>*UB(MT#.>,&).?6G3!NZ
M7"6%7@ 5+:O"X.4EU0FB&ZVF@+68</-,V;2F[=CD0(51=>VRJN%=<EYN.9)@
M)15JPU\M4&O!'0"1RMJD".J7N%-P:'&5_J>JW^/E;ZHR)\X!^WIB8+)N"G@'
MF25GK[NZ6L-[@QH*&T.<Z1>MBC/R/OVEKF"%WNJV+311T.L/P G@*[H7:^HT
M6]!P5UR%Z=V+7_[R^MU]^0Y4%7QUM(Q],2I8(=U6\ N0'7J3INGELV/$O@[U
M)??O!/+L:]F<3=.1@PN(&@ES_[G)3X)"@>.>@U'(+'86R%,XIVB76G8KY@U(
M(W@]/IF*35?VNI*+Q<:_J728D\'> G%7KU2NDVY-9>:V(7^.RW[925E/OSS^
M//EI3I(%SZEC^U8%H8"-W8]X//P3!T"^UY7J2H&&@^/"NW9<I,V6-%O9<TA*
MC2T6AGZ=NBK81T-<,S-UUJT0D(-EP&9Z"YR+W#=R*5XIZI-], BZHH+1:C'I
MNL;7UX-_R[,56UD-NZWE#1R[>PTC5RN3T2K_7)6ZQ<)[OY;$6Y&G+]450GVJ
M-;)$]V 6>08FUM58M(SD@=W<QC-*?%S@]L&)K;L9Z!(QU\>@)FLAPL9-9%]9
M28&.B0XH;4MK7\8D0Z&T9HVNR$@=M+M.1(+>_:H 111WK#5%M)1J@5ZV_CZB
M>ZVB947+T3GU+!$)T>6,Q>*Q["/)MJPY%HN>:WFR>$$H. @GCTL?RI;]>O[V
M//D1*+BFR 4<1UC^'RI5V^*(D_X37OD,*294AWSHA/7;0E^ILF>Y575JY:=&
M8_BFF:!ACNJTF[S'I_ K-Z2ICWDL5A6<:'39P%-PK<@,YH7Q!X,&\_O 1S-Z
MCX][45+5:KVN:EGQ'XJJPM.Q.$]>P";::Z=(J:D&5$1;C6L!\V&"1K>G+"-Z
M3_1<=44;>%=YJ*H7"MXKC7%<*HT$U/9ITN."Z47+< DQ'L5+S['&D)>S"[,@
M!=^@QZD&>RZ,0%J_%7U (L/_#X.0>[6/DTZ<C0VW,J2$]5-\9TOO8>6XD4JF
M0KT1AC,Z?MY@3/X!)_LE/N85GNH36K(Y84]IP4Z]%8X*@@K%-PP)0I? 0';@
M!=501L?D$7;\N2-\^(LEB#%XL>=FK'HP27E7=<]0/H9EOTA8M@F]^J)5_-^N
MDM#<BP4*IK%32&*U6_D-!Y$/EUZIHO-Z(^/&*=KBO.RATAZ02> 9LP01< 4!
M157S<0KBD&K5%3@_4J5![24G3O]&1BKG(X_H,9[8]84B.XYE,%U[UQX\H2LI
M\N M$?(9H3&3QL&'=(S>3Y/<-!D.RO;/R"4IJX\2F!--Z60J0' JE>.5&Y@U
MI8A!!EOXBZTHG+S2J@"F^<L4!UX7'19 OWP$!QXC-)>/9"[K"EZ^.64'H=6)
MY$FQC+@XOW\A=]^_V.'NN, TW'7[ :(4E%N!</:F]#HN_-?UJ,;'PE(XPTEC
MZK=N5,GRV.D,H&W]6;2-OKD^=>YWURYNDG:CW*?'MN@<7;>&Y/FKRCN@)?ZM
M:O'4N>2@EFNQZT5%>XWF.ZSQT%M3E6$:$+ISD7N3#R>TF*^)(0KN(#3Y5)^N
M!KX<2YSCPSKNZY (UE&U@U'M3$DP6RNP?IFN?W.A(T,&H&'W4,\!!4M0: R2
M7UYP(!V/#)G.L)3L4W]L?]%S_FYPB'#Z=$8'\X^U, R):T>,Y\G;&)F5ZX*0
M(:./(*]ZD]G:]6Y8>:WP\MC@01&635QJ&EH>1#;[68)V@EK#/(ZDR'YFU6J4
M8$99RXMXK64**PH!L=F'<K+6;/K-(A1A5=([TS:@*\&P(XK1))KT *<=2'<#
M61CL=E"O*Y*\@6\+.)V0(-G^EANR&C:Z.O3*=C5Y@^E^-QU<A%[X39R8Y,RC
M$S;ZJJ'_,GB@@,Z(#@CPA0XP>B09LR?^C8?4Z3GM^+O .5H8>/%3 K^7Y ]$
M'AR_$<=W&E!%&^H#@DX_!;?EI '0M;WYXEFI,L34(458^2/[S.0.5 O60-[W
M8(GQ/C$/<FOBX 0P\3,Z<5,25!Z,2O@Y] WX-3ZUFO5PF>E5)G_%Y6DJNP=$
M-"YV:(4,']3H1 9B#)MHY/"A-FVK'=4+AY-^)K$Q/N1L[::*?&<1]QF;-!(B
M.=CQ?)BUD+=]6C2Q<(\LXV)N=0>DGD1%(Q4B#HO^[PXXARW3[ES>L0;SLZKA
MI6TA,'=17,L-_>W!=8_#Z[RB<W?6K&=CQJLV:HXT&KO1V)-V=]ZT_R+#N#F&
M5RSF%P4O7G4"=LRAO#%9DM%KIP,;C0[^X$:*],5RF_C-;M[#\>,V>K;Z!XDO
M4[ ARQ6P\"P! 5"KA8OI_>$B\ ^.$?CIU?F7969-@G^R=H$BETPAB@O"$1XG
M<8O-%?I:F7S%N%#Q\FR-+O(HE\F9P1=(U7_1-<P_650P0$DVS QC7:@5"T;Z
M\A&)G\L=W#(?,>ZCBQL=-NZ$_5Y#A^>4HI'S/B-P[;$\7XVBWT$ABQ2S+R4C
MPE]LC0C55"6-^,\N7]@@-2DM0V8%\[ZD.,/%1:+.5^?)"6.)2&$^M89)NS3U
M(!89H=+[ILO^,_Z_EST8W,!SZ8'>J/UEF.9!EB;CZB+0MW7Y5/4 E3%A#IY(
MG[&-=A%4BVKWP,S>M,B?<WJ>_#!I2'LM.M?$EP7XB(.28Y6=XR)D1+L]!6NH
MU C?P@YTAHP+!K.,/3]^.>M.4O#BZ)*OK0,I-M43"[9P+K.YWCC,'2=]1X.&
MOBBTJ.+A0FN[]R#K-G&*"&CMZ$16@=%BM?H9^LM 5BZK//H>A[(#SY41F;Z&
MD6 %R,/,X#I)AP*3DL8JJO;4(@W(W/&3E 1<CCBP=A3:YXNBFJG"LH>9+C5N
M!'QC2;!AOYHIA^_7HRL8^66A5=VTP @8Z8FZ6E9PQ0VDWJK.">MC>_V9VK(K
M<Q5Q)'AA..-=K>7Q\"BRYRR&UD6;HT36#E3^^.UQV37" QP(HUIKM'Y):/"^
MP,I>$2AB46M"UJ11WIV?5*$V=T&O?!?#<]@03S /HRU\M(2WNK5^-8:;5'4,
M\:JCE,.@R>1>+<,XI.(?GIF]\,CK%XR\WJ?I7YMQ%M$BN6 HO9#]/; EA<L,
M##-KQ'M(;ODF!)Z/YZX1RQO"T^E>S$35B*U%[%I3,2^E6[5W!+LDRQZ['[C\
MB=J&P4O'3Y7DO246\ZS@M_*,\%+LZ$A%;N; 'CB_?&Y%H$15$4W24<IIJSX@
M+*F!V:_D%Z]&89[G$G;;B94X!YU?IBI@34",XBX E9A&C@6,3&_):.IV*\&'
M>6(1R ;3DQ":R"P7&1[.'V\:T])D(=/HR!:2 %L&,=0P>DM^-DGB<JC+47#5
M4A%J/YQ%%2XA#6+QI'MUMB<T*(0=S0JS<$!U(O4A!3=+)>N)?'Q[0+B6$W/*
M>2?#_TI,8D?JMR?-4JN 19=H2*%GMD!7<*8ZD:N!BE!M2CR/=%+F!FC) (](
M&:**RHB[M":/JX!EA3#[XUBS9/A]0Z _<LNGK"A1_ KT/OBY69JU3$$XAR5P
M/+VHZ.$K^Q'H@-(8*@?;VH9\2!]S[R"LYM.HY?+BZ3Z1R^4DN9B&8P5-R$%U
MN0 6SB41,123T\HY.TR4J0'+1/0J_2_G#8%Y$QH5UAZ.:[.T$-#!S0Q@.I3%
MOK_#8JLD V[U;UU*-,+DLO3^DI8 >5+SR%\R(JX^K5+*GJW>@YU6#PU1LZ#5
MRRMX//H=F05(KH0-+W(R(3",ID$KP]YGRBNX2?*4N4FW]%NG=  QG.E2&Y2T
MVL:0].>"Y08]!Z.LP'K1&D&&VJ1)M.?!4)(#0*B&;B6H,C"6$ /&VM!59?*;
MGQ31C'+VS!Q3(I55Y"733'TXTQ]0OX?O%JHT__X="NWL&?D\W(5\2IN,7]4,
M+Z\[-D+%*W]Y<0;$1%!ZT"%J;24"N^6Y4%R3)@'>RV Y!U:GGCZY/%F> AV[
MLXKZJ^2U(\;[2I<=MIK/N>[DMT\?TU!JI2G:2JEN,A&\2!Y[RDRRJ@]EIQ[M
M=- Q0X5CHU><TBBV@P=+A$O_]/(DPZ4_>>%6GY?P8$I)89KE#:J?(%C"]&S"
M+V*@?:!@6<!5RL:+M;N\-M37MA!G@]7SO$G:.EC N(JH^KJ@Z(BCME"@2A)#
MCO7&8"9B!N';>5.H[^<(?)JJ')H(I*J0_3N<=3!GI]4&BBR3)#PI!ZLI:V$]
M3-M$PQ!RI 4:[8BU$"/Q[T'S.BRZW!.;Q#K%6>:)73 GM!0E-2/F:.OKTAFX
MUU84P55TGSEA!:M%\D=.;V)4(MG*#-'+$*5%4IM-;DFMHUPZT=HR;<=NMR)R
MHO)X(\HTDXG%HM77G5LSYW<RG-C:1'G=:/9T:#K-MF%R]ZC3XQV&<#HXHJ^P
MP&9KMPBMHS+TA ;*QQ\NMOOP3L1VAWSB*W$%LF%(5/BR #'1D;1!<F-G)<7W
M'$P/P0X?K#^:DL085#?D(WS81[C)0;'8J\_%85M7B&*V#3R#EO.*/37EZ.7T
MO<,4:Y]MR:>%&D-A.6$7E-M";=* =[->).ZKFO@I?O//+@]"=W"*VL#,9/AO
MD^CYW$;;@G3\;5RVP[GUY2;$&K"1F7=4%H[0B&0?2V$OC4XVPI(V"=JQ]4$1
MP(UJC?5.FA).D:$2 VFR,',,):I"JD(:*@LD54TP@*D*D/Q5[;T6&.;5R ?%
MJN>:GPRVV(W(#FO9/T:=G!0#DAD3@A&$XG6]B@+J77.:K+JF=9S/EB[:AM9$
M%-2JZBBFA9>B;I:ZU#I7$@\9K!1,P.&KKN4+>EPV4%^#*1_8]OZNYL*8,=A4
MH]P6#5A7G(I]WLI"&$*E>T[A1\%&NJWGXF=87\(A^1\,D/QQX<:(!)#)CV5B
MC-UH[['AQ3\J"S8?;B*5R=CF&A:D4Z6DZGB4Q[C_Z/+AD\N36>0Z<EQE8QKM
MZ"D<5FYNZ&ZXKZZZ!6+/GSR,QCD1ENXE.:M2=D:"=>%R%OC0^7Q,H#>6&DZM
MC*#?HX/AWW*FVPT>A:'>S7!A9C+_[&K3Y,8'U+.*ZV>)#CY7F2F,9,;0(G 1
M&JMA,'7:%\128NX2!]2SB6GC$_UTY^9^4>R'TV32N1GGI>"*@9XU,V5DF:L9
MK%,"&[;:+[3-3:"CL*2\88@=OFEC4^4"-P*Q][EI,G:6,2D.Z]#=1ML]3UZ[
M^MOH521?3A%R3%LM!ECI4BOB%[:MP;60H; LMZ\XTQ_"UV])?J6B6<D[T.5>
M4]J:'0&!EY675(16?J\C_:+O%[V%, Q0)WA7@!N^':3E#A#=3V4 __0 5%S9
M"3Q(H)LE'A,9BO<9^><($[-4Q9R5@('O;;.L!B <6]>*HW9('--X&X=6LDY#
MEPA+4Z,='ZI_'(T/BXX-:HYQ=;$X1OE_8("\6NW5AHYC]JXY/?LT^<G:/UBM
M<Z-MKBVIG#[U5@!+OF#?..)NK&O QS$J00T@P-N*&>M28!<"AAM9O:P8UXP(
MURDUI>X*BDL#(UUUA;R(TU=.QQW*=JQ/ =+Y*I_739\,)JLPN9* V,BS]F5(
M6/1XUW[D)['8;UR$=.+M;1USF4DT"P(JE; %&9L;0Y?+1]1!A.NIK*H:KM3H
M@K<@26QXFU[J]H_L=0CHBZ+.Y1Q(NS0%JUX@.)U28E0K--<PM\+F&"TP-NZC
M6LW4#!5)*1UM.38&U6S*<5S4<@*:RK4UN!PN5]<8BR1*S6K2)A1U4\!,%DRD
M#>L^!KD8ZCT'=UP>RXKB(;BBO<J%CL_3!#T64:HG;N)<>5LBC7,%.-;/-=%2
M5[7 54;C;'57#". \E_;M(FS] /0*!BEI87YVWQS.(% KJHF<Q49Q>63YS)6
MG.PL-1Q2Z9"Y2V4/4P]J>_3+8$\6_>'2'?;A7*["?!CD&)PG?ZNBR01&&!\3
M4IJ%EKATJ4MV82PHR6L7NH55J=:FE../=L-:D_&08 V@1KO2/WR($TE]Q]-%
M1ZUDY.!N9_/W/!?$SH;RX_<3'G HXC7+=0%+5OO(NLU944$0%>BY,8N2U4_R
M5(0%IY$]$U&A[L),&5W3JN$T'3Y*O!VDS:$I$<;S^Z4%H_UG"D1GWA^PY/.C
M.Q&4_$I:9=SG>O\5R=]$>%C_,#D+0'H%X$];8B>6W(/>X=A(*^R/!0?9ZD+4
M-KSFXK]!PF%-9]@*E33F_#;[A[B#1 SQO-DJ_2Z'3@W3\KBDS,USX_0[&_3
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M;HT7^P]UW$]^K;9>/:.$?.JP4 ZBMF90Y(;9!ZL%G7C\I/KX 65[WHTM##H
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M+2;ORC5H(:^;-SUB#\SU"WVH@(NG1\#%IR;Y3Q)UV"$40\!(?E,L(>V5SBQ
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ME%"3'&7GZK+:$!EW=1OSK9B9"*6X*W9A:\+5#DS\FNLHIK50IMR@(8>[/0]
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M^@_@,GD;\B#)5S!+F"W0$HWO<\/_@#SN<IK'W4,<+?QOV:Z*[_\_4$L#!!0
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M-3M<<AB!+BB-H4JPV%Q@@?0QOP9A-;^-6B[N/STF<KF8)1?3LD>ZC3FHKE?
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M(7Q"!S3:$VLA1A+60?.Z771Y)#:)<W:SS!.[8$F8'$K)0V3+/I28XL+77!P
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M+IAF5'1A6!-VMFH)5U=P'^>* N;="*!_GOW=)I.)K"Z^%Z0E"_%P?4*? <)
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M+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  .6%=49CP/B WK  !T=0$
M$P              @ &FUP8 ;&QY+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0
M   (  Y85U2Q)O1(,ML! '9A$P 4              "  >3"!P!L;'DM,C R
M,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (  Y85U0BE !"MQD! $4&#0 4
M          "  4B>"0!L;'DM,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M  Y85U01"HSL_ST  "'C 0 ?              "  3&X"@!L;'DM,C R,3$R
M,S%X,3!K97AH:6)I=#$P,3 N:'1M4$L! A0#%     @ #EA75+XZ"B]+-@
MSHX! !\              ( !;?8* &QL>2TR,#(Q,3(S,7@Q,&ME>&AI8FET
M,3 Q,2YH=&U02P$"% ,4    "  .6%=4^7\YZEHL   Q5 $ 'P
M    @ 'U+ L ;&QY+3(P,C$Q,C,Q>#$P:V5X:&EB:70Q,#$W+FAT;5!+ 0(4
M Q0    (  Y85U2B3<UJNCH  $J< 0 >              "  8Q9"P!L;'DM
M,C R,3$R,S%X,3!K97AH:6)I=#$P,BYH=&U02P$"% ,4    "  .6%=4,@_D
M"$9%  #_T0$ '@              @ &"E L ;&QY+3(P,C$Q,C,Q>#$P:V5X
M:&EB:70Q,#,N:'1M4$L! A0#%     @ #EA75,W(;Y@Z-P  W),! !X
M         ( !!-H+ &QL>2TR,#(Q,3(S,7@Q,&ME>&AI8FET,3 T+FAT;5!+
M 0(4 Q0    (  Y85U2-Z\ZW6C<   66 0 >              "  7H1# !L
M;'DM,C R,3$R,S%X,3!K97AH:6)I=#$P-2YH=&U02P$"% ,4    "  .6%=4
M0K'-DLE!  "UR0$ '@              @ $020P ;&QY+3(P,C$Q,C,Q>#$P
M:V5X:&EB:70Q,#8N:'1M4$L! A0#%     @ #EA75,3C]9 K.   X[(! !X
M             ( !%8L, &QL>2TR,#(Q,3(S,7@Q,&ME>&AI8FET,3 W+FAT
M;5!+ 0(4 Q0    (  Y85U1!1>!?/3T  &+0 0 >              "  7S#
M# !L;'DM,C R,3$R,S%X,3!K97AH:6)I=#$P."YH=&U02P$"% ,4    "  .
M6%=4_Z"W5#U(  #+%0( '@              @ 'U  T ;&QY+3(P,C$Q,C,Q
M>#$P:V5X:&EB:70Q,#DN:'1M4$L! A0#%     @ #EA75.@:?,L@#   K_L
M !T              ( !;DD- &QL>2TR,#(Q,3(S,7@Q,&ME>&AI8FET,C$N
M:'1M4$L! A0#%     @ #EA75/,OFD$. P  =0@  !T              ( !
MR54- &QL>2TR,#(Q,3(S,7@Q,&ME>&AI8FET,C,N:'1M4$L! A0#%     @
M#EA75#I5@H#Z!P  #"@  !X              ( !$ED- &QL>2TR,#(Q,3(S
M,7@Q,&ME>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    (  Y85U1(:=8E] <  +@G
M   >              "  4AA#0!L;'DM,C R,3$R,S%X,3!K97AH:6)I=#,Q
M,BYH=&U02P$"% ,4    "  .6%=40#TDQ-($  #-&P  '0
M@ %X:0T ;&QY+3(P,C$Q,C,Q>#$P:V5X:&EB:70S,BYH=&U02P$"% ,4
M"  .6%=4[IM\4VLT  #/2@$ '0              @ &%;@T ;&QY+3(P,C$Q
M,C,Q>#$P:V5X:&EB:70T."YH=&U02P$"% ,4    "  .6%=4+A@5NS R  ##
M' $ '0              @ $KHPT ;&QY+3(P,C$Q,C,Q>#$P:V5X:&EB:70T
;.2YH=&U02P4&     !D &0 ;!P  EM4-

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
